<SEC-DOCUMENT>0001171843-26-004784.txt : 20260721
<SEC-HEADER>0001171843-26-004784.hdr.sgml : 20260721
<ACCEPTANCE-DATETIME>20260720180018
ACCESSION NUMBER:		0001171843-26-004784
CONFORMED SUBMISSION TYPE:	20-F/A
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260721
DATE AS OF CHANGE:		20260720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alpha Compute Corp
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	FINANCE SERVICES [6199]
		ORGANIZATION NAME:           	09 Crypto Assets
		EIN:				981611216
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		20-F/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40086
		FILM NUMBER:		261187748

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		PROVINCE COUNTRY:   	D8
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		PROVINCE COUNTRY:   	D8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AlphaTON Capital Corp
		DATE OF NAME CHANGE:	20250903

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PORTAGE BIOTECH INC.
		DATE OF NAME CHANGE:	20130822

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F/A
<SEQUENCE>1
<FILENAME>f20fa_071626.htm
<DESCRIPTION>FORM 20-F/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ptgef="http://portagebiotech.com/20260331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_022_IFRS%2D2025_gaap -->
<!-- Field: Set; Name: xdx; ID: xdx_032_ptgef_portagebiotech.com_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_043_20250401_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DDocumentFiscalYearFocus_2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001095435 -->
<!-- Field: Set; Name: xdx; ID: xdx_079_XDX_f20f__070826.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_061_EURPShares_0_EURPShares_xbrli%2D%2Dshares -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000004" name="dei:DocumentFiscalYearFocus">2026</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001095435</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0060" name="dei:AuditorFirmId">688</ix:nonNumeric>
  <ix:nonFraction name="ifrs-full:RestrictedCashAndCashEquivalents" contextRef="AsOf2025-03-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccountsReceivable" contextRef="AsOf2025-03-31" id="xdx2ixbrl0077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2025-03-31" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonCurrent" contextRef="AsOf2025-03-31" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonNetOfCurrentPortion" contextRef="AsOf2025-03-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-03-31" id="xdx2ixbrl0098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-03-31" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:EquipmentDeposits" contextRef="AsOf2025-03-31" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2025-03-31" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2025-03-31" id="xdx2ixbrl0110" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2025-03-31" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2025-03-31" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2025-03-31" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2025-03-31" id="xdx2ixbrl0140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TreasuryShares" contextRef="AsOf2025-03-31" id="xdx2ixbrl0167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssetReceivables" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssetReceivables" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossIoxIprd" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossIoxIprd" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossTarusIprd" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossTarusIprd" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossStimunity" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossStimunity" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossSaugatuck" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossSaugatuck" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossInvestmentInCompedica" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossInvestmentInCompedica" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfInvestmentInCompedica" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfInvestmentInCompedica" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnSettlementOfPutRightLiability" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnSettlementOfPutRightLiability" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnExtinguishmentOfDebt" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnExtinguishmentOfDebt" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOfLossesFromEquityMethodInvestment" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOffering" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0605" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0628" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0652" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrants" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0661" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0670" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0672" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0675" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsExercisedAndReturnOfShares" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0680" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="xdx2ixbrl0682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0683" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="xdx2ixbrl0692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0720" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0721" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0724" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2025-04-012026-03-31_custom_IOxIPRDMember" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2024-04-012025-03-31_custom_IOxIPRDMember" id="xdx2ixbrl0730" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2025-04-012026-03-31_custom_TarusIPRDMember" id="xdx2ixbrl0734" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2024-04-012025-03-31_custom_TarusIPRDMember" id="xdx2ixbrl0736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2025-04-012026-03-31_custom_StimunityMember" id="xdx2ixbrl0740" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2024-04-012025-03-31_custom_StimunityMember" id="xdx2ixbrl0742" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2025-04-012026-03-31_custom_SaugatuckMember" id="xdx2ixbrl0746" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2024-04-012025-03-31_custom_SaugatuckMember" id="xdx2ixbrl0748" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0753" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0757" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0760" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0761" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0765" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0769" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0770" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0774" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0778" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnImpairmentInvestmentInCompedica" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0785" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnImpairmentInvestmentInCompedica" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0786" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRemeasurementOfInvestmentInCompedica" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0789" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRemeasurementOfInvestmentInCompedica" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0797" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossFromEquityMethodInvestment" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0801" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossFromEquityMethodInvestment" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0802" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0806" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0809" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0810" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnExerciseOfPutRightLiability" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnExerciseOfPutRightLiability" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0814" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NoncashInterestExpense" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0825" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NoncashInterestExpense" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0826" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0830" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExpensesSettledUsingStablecoin" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0833" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExpensesSettledUsingStablecoin" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0834" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DividendsReceived" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DividendsReceived" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOfLossInAssociate" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0840" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOfLossInAssociate" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfSharesIssuedForServices" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfSharesIssuedForServices" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0845" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0872" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInvestmentProperty" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0884" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInvestmentProperty" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0885" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchasesOfStablecoin" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0889" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchasesOfStablecoin" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0890" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchasesOfDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0893" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchasesOfDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SalesOfStablecoin" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0897" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SalesOfStablecoin" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0898" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SalesOfDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0901" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SalesOfDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0905" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0906" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:EquipmentDeposit" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0909" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:EquipmentDeposit" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0910" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CashPaidForInvestmentInCompedica" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0913" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CashPaidForInvestmentInCompedica" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0914" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0917" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromExerciseOfPrefundedWarrants" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0924" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromExerciseOfPrefundedWarrants" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0926" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0930" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromRegisteredDirectOffering" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0933" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightIssuanceCosts" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0944" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightIssuanceCosts" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0945" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightIssuanceCosts" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0946" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PaymentsOnExternalDebt" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0953" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PaymentsOnExternalDebt" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0954" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredFinancingCosts" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredFinancingCosts" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0958" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LoanTerminationFee" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0961" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LoanTerminationFee" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesFromRSUDistribution" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0964" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesFromRSUDistribution" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0996" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0997" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CapitalExpendituresIncludedInAccountsPayable" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1001" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CapitalExpendituresIncludedInAccountsPayable" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1002" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RightToUseAssetAcquired" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1005" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LeaseLiabilityIncurred" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1009" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1013" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1014" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfStablecoin" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1017" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfStablecoin" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1018" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfDigitalAssetsReceivable" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1021" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfDigitalAssetsReceivable" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1022" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfStablecoinReceivable" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1025" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ContributionOfStablecoinReceivable" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1026" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ValueOfSharesUsedToPurchaseInterestInCompedica" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1029" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ValueOfSharesUsedToPurchaseInterestInCompedica" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1030" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1033" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1034" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsIssuedToInvestors" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1037" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightsIssuedToInvestors" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1038" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCostsSettledInCompanyStock" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1041" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCostsSettledInCompanyStock" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1042" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCostsSettledInWarrantsOnCompanysStock" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1045" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCostsSettledInWarrantsOnCompanysStock" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1046" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettlementOfPutRightLiabilityUsingStablecoinReceivable" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettlementOfPutRightLiabilityUsingStablecoinReceivable" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1050" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPutRights" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1053" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExerciseOfPutRights" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1057" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ReceiptOfDigitalAssetsReceivableTonTokens" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1061" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ReceiptOfDigitalAssetsReceivableTonTokens" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StablecoinUsedToPurchaseDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StablecoinUsedToPurchaseDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SaleOfDigitalAssetsSettledInStablecoin" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1069" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SaleOfDigitalAssetsSettledInStablecoin" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfBitcoinForTonTokens" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfBitcoinForTonTokens" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExternalDebtProceedsReceivedInStablecoin" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExternalDebtProceedsReceivedInStablecoin" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PaymentsOnExternalDebtUsingDigitalAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PaymentsOnExternalDebtUsingDigitalAssets" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1082" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesObtainedInExchangeForStablecoin" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesObtainedInExchangeForStablecoin" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl1090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentReceivablesFromSaleOfProperties" contextRef="AsOf2026-03-31" id="xdx2ixbrl1235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidInvestorRelations" contextRef="AsOf2025-03-31" id="xdx2ixbrl1245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidGpuInfrastructureCosts" contextRef="AsOf2026-03-31" id="xdx2ixbrl1250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidGpuInfrastructureCosts" contextRef="AsOf2025-03-31" id="xdx2ixbrl1251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidGpuLeasesShortterm" contextRef="AsOf2026-03-31" id="xdx2ixbrl1253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidGpuLeasesShortterm" contextRef="AsOf2025-03-31" id="xdx2ixbrl1254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoins" contextRef="AsOf2025-03-31_custom_USDCMember" id="xdx2ixbrl1272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoins" contextRef="AsOf2026-03-31_custom_USDCMember" id="xdx2ixbrl1274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoins" contextRef="AsOf2026-03-31_custom_UsdtMember" id="xdx2ixbrl1278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoins" contextRef="AsOf2026-03-31" id="xdx2ixbrl1282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="xdx2ixbrl1286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="xdx2ixbrl1287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="xdx2ixbrl1288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="xdx2ixbrl1294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StablecoinSold" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="xdx2ixbrl1303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromExternalDebtDrawdown" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="xdx2ixbrl1307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchasesOfStablecoin" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="xdx2ixbrl1310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StablecoinValueAsOfMarch31" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="xdx2ixbrl1318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ApproximateNumberOfTonTokensHeld" contextRef="AsOf2025-03-31" id="xdx2ixbrl1327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonTokensFairValueInThousands" contextRef="AsOf2025-03-31" id="xdx2ixbrl1330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsFairValueInThousands" contextRef="AsOf2025-03-31" id="xdx2ixbrl1333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_TONMember" id="xdx2ixbrl1343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="xdx2ixbrl1345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsSold" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PaymentsOnExternalDebtUsingDigitalAssets" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetPurchases" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ReceiptOfDigitalAssetsReceivable" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RevenueReceivedInDigitalAssets" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TokensUsedToSettlePutRights" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsExchanged" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="xdx2ixbrl1389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfMarch31" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="xdx2ixbrl1396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_USD1Member" id="xdx2ixbrl1422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_LockedTonMember" id="xdx2ixbrl1423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetValueAsOfApril1" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="xdx2ixbrl1424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDigitalAssetsReceivable" contextRef="From2025-04-012026-03-31_custom_USD1Member" id="xdx2ixbrl1430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TokensUsedToSettlePutRights" contextRef="From2025-04-012026-03-31_custom_LockedTonMember" id="xdx2ixbrl1439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StablecoinValueAsOfSeptember30" contextRef="From2025-04-012026-03-31_custom_USD1Member" id="xdx2ixbrl1442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StablecoinValueAsOfSeptember30" contextRef="From2025-04-012026-03-31_custom_LockedTonMember" id="xdx2ixbrl1443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StablecoinValueAsOfSeptember30" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="xdx2ixbrl1444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2024-03-31_custom_GPUsMember" id="xdx2ixbrl1450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2024-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2024-04-012025-03-31_custom_GPUsMember" id="xdx2ixbrl1455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember" id="xdx2ixbrl1457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2024-04-012025-03-31_custom_TotalMember" id="xdx2ixbrl1458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_GPUsMember" id="xdx2ixbrl1460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2025-03-31_custom_GPUsMember" id="xdx2ixbrl1465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2025-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2025-03-31_custom_RightOfUseAssetMember" id="xdx2ixbrl1467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2025-03-31_custom_TotalMember" id="xdx2ixbrl1468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_GPUsMember" id="xdx2ixbrl1475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember" id="xdx2ixbrl1477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_TotalMember371195968" id="xdx2ixbrl1478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2024-03-31_custom_GPUsMember" id="xdx2ixbrl1485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2024-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2024-04-012025-03-31_custom_GPUsMember" id="xdx2ixbrl1490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2024-04-012025-03-31_custom_GPUsMember" id="xdx2ixbrl1495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_GPUsMember" id="xdx2ixbrl1500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_RightOfUseAssetMember" id="xdx2ixbrl1502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_TotalMember" id="xdx2ixbrl1503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2025-04-012026-03-31_custom_GPUsMember" id="xdx2ixbrl1510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember" id="xdx2ixbrl1512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2025-04-012026-03-31_custom_TotalMember371195968" id="xdx2ixbrl1513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_GPUsMember" id="xdx2ixbrl1520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_GPUDepositsMember" id="xdx2ixbrl1522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_RightOfUseAssetMember" id="xdx2ixbrl1524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-03-31_custom_TotalMember" id="xdx2ixbrl1526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:BalanceAsOfApril1" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:InvestmentInCompedicaAsOfMarch31" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" id="xdx2ixbrl1650" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember" id="xdx2ixbrl1652" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember" id="xdx2ixbrl1654" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" id="xdx2ixbrl1694" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember" id="xdx2ixbrl1696" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember" id="xdx2ixbrl1698" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl1738" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl1740" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl1742" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl1770" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl1772" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2025-08-292025-09-02" id="xdx2ixbrl1802" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1804" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:BalanceOfPutRightLiability" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:BalanceOfTonPayable" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1852" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccruedOtherProfessionalFees" contextRef="AsOf2026-03-31" id="xdx2ixbrl1871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccruedCRO" contextRef="AsOf2026-03-31" id="xdx2ixbrl1880" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccruedClinicalAndRdServices" contextRef="AsOf2026-03-31" id="xdx2ixbrl1886" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherAccruedExpenses" contextRef="AsOf2026-03-31" id="xdx2ixbrl1892" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CurrentTaxOnProfitsForYear" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CurrentTaxOnProfitsForYear" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1942" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdjustmentsForCurrentTaxOfPriorPeriods" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1944" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1947" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DecreaseIncreaseInDeferredTaxAssets" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1953" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DecreaseIncreaseInDeferredTaxAssets" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1954" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProfitLossFromContinuingOperation" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1956" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TaxUsingBviTaxRate" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1964" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TaxUsingBviTaxRate" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1965" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NondeductibleExpenses" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NondeductibleExpenses" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1974" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1976" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ForeignCurrencyEffectAndOther" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1982" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IncomeTaxExpense" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1985" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ReservesAndAccruals" contextRef="AsOf2026-03-31" id="xdx2ixbrl2005" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetDeferredTaxAsset" contextRef="AsOf2026-03-31" id="xdx2ixbrl2014" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetDeferredTaxAsset" contextRef="AsOf2025-03-31" id="xdx2ixbrl2015" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl2085" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl2100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl2139" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember" id="xdx2ixbrl2174" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember" id="xdx2ixbrl2175" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_February152022Member" id="xdx2ixbrl2196" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_June82022Member" id="xdx2ixbrl2199" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_July272022Member" id="xdx2ixbrl2202" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember" id="xdx2ixbrl2365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember" id="xdx2ixbrl2367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember" id="xdx2ixbrl2369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember" id="xdx2ixbrl2371" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember" id="xdx2ixbrl2373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember" id="xdx2ixbrl2379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember" id="xdx2ixbrl2381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember" id="xdx2ixbrl2383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember" id="xdx2ixbrl2385" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember" id="xdx2ixbrl2387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2399" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2413" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2427" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="xdx2ixbrl2429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember" id="xdx2ixbrl2441" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember" id="xdx2ixbrl2455" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember" id="xdx2ixbrl2469" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="xdx2ixbrl2471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember" id="xdx2ixbrl2483" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember" id="xdx2ixbrl2497" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember" id="xdx2ixbrl2511" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="xdx2ixbrl2513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2525" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2539" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2553" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="xdx2ixbrl2557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2567" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2581" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember" id="xdx2ixbrl2595" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="xdx2ixbrl2599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2605" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember" id="xdx2ixbrl2609" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember" id="xdx2ixbrl2623" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2635" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember" id="xdx2ixbrl2637" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="xdx2ixbrl2639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember" id="xdx2ixbrl2651" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2661" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2663" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember" id="xdx2ixbrl2665" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2675" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember" id="xdx2ixbrl2679" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="xdx2ixbrl2681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember" id="xdx2ixbrl2687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2689" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember" id="xdx2ixbrl2693" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2695" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2699" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2705" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember" id="xdx2ixbrl2707" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2715" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2719" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember" id="xdx2ixbrl2721" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="xdx2ixbrl2723" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember" id="xdx2ixbrl2733" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember" id="xdx2ixbrl2747" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember" id="xdx2ixbrl2755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember" id="xdx2ixbrl2761" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember" id="xdx2ixbrl2763" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember" id="xdx2ixbrl2765" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember" id="xdx2ixbrl2771" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember" id="xdx2ixbrl2779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="xdx2ixbrl2787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="xdx2ixbrl2791" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="xdx2ixbrl2799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="xdx2ixbrl2801" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="xdx2ixbrl2805" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="xdx2ixbrl2807" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2815" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2817" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2819" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2829" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2831" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2833" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2843" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2845" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="xdx2ixbrl2847" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="xdx2ixbrl2857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="xdx2ixbrl2861" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="xdx2ixbrl2863" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="xdx2ixbrl2869" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="xdx2ixbrl2871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="xdx2ixbrl2875" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2881" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2883" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2885" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2887" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2889" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2891" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2893" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2897" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2899" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2901" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2903" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2905" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2911" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2913" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2915" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="xdx2ixbrl2917" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2923" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2925" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2927" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2929" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2931" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2933" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2935" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2939" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2945" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2953" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2955" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="xdx2ixbrl2959" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2967" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2969" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2971" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2973" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2975" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2981" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2983" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2985" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2987" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2995" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2997" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl2999" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="xdx2ixbrl3001" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3007" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3009" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3011" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3013" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3015" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3017" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3019" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3023" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3025" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3027" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3029" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3031" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3037" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3039" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3041" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="xdx2ixbrl3043" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember" id="xdx2ixbrl3061" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember" id="xdx2ixbrl3064" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember" id="xdx2ixbrl3065" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember" id="xdx2ixbrl3068" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember" id="xdx2ixbrl3071" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember" id="xdx2ixbrl3072" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember" id="xdx2ixbrl3075" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember" id="xdx2ixbrl3078" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember" id="xdx2ixbrl3079" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember" id="xdx2ixbrl3082" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember" id="xdx2ixbrl3085" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember" id="xdx2ixbrl3086" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember" id="xdx2ixbrl3089" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember" id="xdx2ixbrl3092" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember" id="xdx2ixbrl3093" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember" id="xdx2ixbrl3096" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember" id="xdx2ixbrl3099" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember" id="xdx2ixbrl3100" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember" id="xdx2ixbrl3103" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember" id="xdx2ixbrl3106" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember" id="xdx2ixbrl3107" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_AllanShawMember" id="xdx2ixbrl3110" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AllanShawMember" id="xdx2ixbrl3113" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AllanShawMember" id="xdx2ixbrl3114" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember" id="xdx2ixbrl3117" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember" id="xdx2ixbrl3120" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember" id="xdx2ixbrl3121" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember" id="xdx2ixbrl3124" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember" id="xdx2ixbrl3127" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember" id="xdx2ixbrl3128" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_RobertKramerMember" id="xdx2ixbrl3131" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_RobertKramerMember" id="xdx2ixbrl3134" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_RobertKramerMember" id="xdx2ixbrl3135" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember" id="xdx2ixbrl3138" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember" id="xdx2ixbrl3141" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember" id="xdx2ixbrl3142" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember" id="xdx2ixbrl3145" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember" id="xdx2ixbrl3148" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember" id="xdx2ixbrl3149" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_BrianWileyMember" id="xdx2ixbrl3152" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_BrianWileyMember" id="xdx2ixbrl3155" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_BrianWileyMember" id="xdx2ixbrl3156" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember" id="xdx2ixbrl3159" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember" id="xdx2ixbrl3162" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember" id="xdx2ixbrl3163" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember" id="xdx2ixbrl3166" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember" id="xdx2ixbrl3169" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember" id="xdx2ixbrl3170" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember" id="xdx2ixbrl3173" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember" id="xdx2ixbrl3176" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember" id="xdx2ixbrl3177" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" contextRef="From2025-04-012026-03-31_custom_YuryMitinMember" id="xdx2ixbrl3180" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_YuryMitinMember" id="xdx2ixbrl3183" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested" contextRef="From2025-04-012026-03-31_custom_YuryMitinMember" id="xdx2ixbrl3184" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl3208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl3211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl3215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl3218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl3222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl3225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LeaseLiabilityCurrentAndNoncurrent" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LeaseLiabilityCurrentAndNoncurrent" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="xdx2ixbrl3255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LeaseLiabilityCurrentAndNoncurrent" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl3256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLiquid" contextRef="AsOf2026-03-31_custom_Level2Member" id="xdx2ixbrl3268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLiquid" contextRef="AsOf2026-03-31_custom_Level3Member" id="xdx2ixbrl3269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLiquid" contextRef="AsOf2025-03-31_custom_Level1Member" id="xdx2ixbrl3270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLiquid" contextRef="AsOf2025-03-31_custom_Level2Member" id="xdx2ixbrl3271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLiquid" contextRef="AsOf2025-03-31_custom_Level3Member" id="xdx2ixbrl3272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLocked" contextRef="AsOf2026-03-31_custom_Level1Member" id="xdx2ixbrl3274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLocked" contextRef="AsOf2026-03-31_custom_Level2Member" id="xdx2ixbrl3275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLocked" contextRef="AsOf2025-03-31_custom_Level1Member" id="xdx2ixbrl3277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLocked" contextRef="AsOf2025-03-31_custom_Level2Member" id="xdx2ixbrl3278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLocked" contextRef="AsOf2025-03-31_custom_Level3Member" id="xdx2ixbrl3279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2026-03-31_custom_Level1Member" id="xdx2ixbrl3281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2026-03-31_custom_Level2Member" id="xdx2ixbrl3282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2025-03-31_custom_Level1Member" id="xdx2ixbrl3284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2025-03-31_custom_Level2Member" id="xdx2ixbrl3285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2025-03-31_custom_Level3Member" id="xdx2ixbrl3286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2026-03-31_custom_Level1Member" id="xdx2ixbrl3288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2026-03-31_custom_Level2Member" id="xdx2ixbrl3289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2025-03-31_custom_Level1Member" id="xdx2ixbrl3291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2025-03-31_custom_Level2Member" id="xdx2ixbrl3292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2025-03-31_custom_Level3Member" id="xdx2ixbrl3293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2026-03-31_custom_Level1Member" id="xdx2ixbrl3295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2026-03-31_custom_Level2Member" id="xdx2ixbrl3296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2025-03-31_custom_Level1Member" id="xdx2ixbrl3298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2025-03-31_custom_Level2Member" id="xdx2ixbrl3299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssets" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssets" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssetReceivables" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssetReceivables" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssetReceivables" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetReceivables" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetReceivables" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetReceivables" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossIoxIprd" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossIoxIprd" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossIoxIprd" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossTarusIprd" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossTarusIprd" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossTarusIprd" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossStimunity" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossStimunity" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossStimunity" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossSaugatuck" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossSaugatuck" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossSaugatuck" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossInvestmentInCompedica" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossInvestmentInCompedica" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ImpairmentLossInvestmentInCompedica" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfInvestmentInCompedica" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfInvestmentInCompedica" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnRevaluationOfInvestmentInCompedica" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnSettlementOfPutRightLiability" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnSettlementOfPutRightLiability" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnSettlementOfPutRightLiability" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnExtinguishmentOfDebt" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnExtinguishmentOfDebt" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:GainOnExtinguishmentOfDebt" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOfLossesFromEquityMethodInvestment" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareOfLossesFromEquityMethodInvestment" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IncomeTaxBenefit" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="xdx2ixbrl3482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IncomeTaxBenefit" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="xdx2ixbrl3483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ptgef-20260331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-04-01to2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_IOxIPRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:IOxIPRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_IOxIPRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:IOxIPRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_IOxIPRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:IOxIPRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TarusIPRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:TarusIPRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TarusIPRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:TarusIPRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_TarusIPRDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:TarusIPRDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_StimunityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:StimunityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_StimunityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:StimunityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_StimunityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:StimunityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_custom_IOXMember_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember_custom_IOXMember_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember_custom_IOXMember_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-012023-12-31_custom_IOXMember_custom_StimunityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:StimunityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-09-30_custom_CountryOfBritishVirginIslandsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ptgef:CountryOfBritishVirginIslandsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-09-30_custom_DelawareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ptgef:DelawareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-09-30_custom_SubsidiariesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_USDCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:USDCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_USDCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:USDCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_UsdtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:UsdtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_UsdtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:UsdtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_USDCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:USDCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_UsdtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:UsdtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TONMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">ptgef:TONMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BITCOINMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">ptgef:BITCOINMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TotalMember371194906">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">ptgef:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_USD1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:USD1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_LockedTonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LockedTonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_GPUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_GPUDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RightOfUseAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_GPUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_GPUDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_RightOfUseAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_GPUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_GPUDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_RightOfUseAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_GPUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_GPUDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_RightOfUseAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TotalMember371195968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_GPUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_GPUDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_RightOfUseAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-02-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ClassBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ClassCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeiesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeiesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SeiesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeiesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeiesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SeiesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-03_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-19_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PlacementAgentWarrants2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrants2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PlacementAgentsWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-02</xbrli:startDate>
        <xbrli:endDate>2026-01-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-292025-09-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-29</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-292025-09-02_custom_TonTokenVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:TonTokenVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-29</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TonTokenVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:TonTokenVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-02-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-02-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-022025-08-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-02</xbrli:startDate>
        <xbrli:endDate>2025-08-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-052025-10-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-05</xbrli:startDate>
        <xbrli:endDate>2025-10-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ATMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-01-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-01-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-112026-01-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-11</xbrli:startDate>
        <xbrli:endDate>2026-01-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsAndPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_ifrs-full_RestrictedShareUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_VestedStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:VestedStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_StockOptionGrantedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:StockOptionGrantedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_StockOptionGrantedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:StockOptionGrantedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_January132021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:January132021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_January192022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:January192022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_February152022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:February152022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_June82022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:June82022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_July272022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:July272022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_March302023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:March302023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_March72025Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:March72025Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_July272026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:July272026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_March112026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:March112026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-15_custom_CROMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:CROMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-30_custom_CROAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:CROAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_CROMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:CROMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MichaelTerpinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MichaelTerpinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:FDanielSicilianoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:FDanielSicilianoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_MarkSimonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrittanyKaiserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrittanyKaiserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:EnzoVillaniMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:EnzoVillaniMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WesLevittMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:YuryMitinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:YuryMitinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AlexanderPickettMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_IanBWaltersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanBWaltersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_IanBWaltersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanBWaltersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_IanBWaltersThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanBWaltersThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AndreaEParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaEParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AndreaEParkTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaEParkTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AllanShawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AllanShawTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AllanShawThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_RobertKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_RobertKramerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_RobertKramerThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BrianWileyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BrianWileyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BrittanyKaiserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrittanyKaiserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_EnzoVillaniMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:EnzoVillaniMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_YuryMitinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:YuryMitinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_Level1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_Level2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_Level3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_Level1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_Level2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_Level3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_DigitalComputeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:DigitalComputeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_ImmunoOncologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:ImmunoOncologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_ImmunoOncologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:ImmunoOncologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ImmunoOncologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:ImmunoOncologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_SaugatuckMember371226578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_SaugatuckMember371226609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SaugatuckMember371226609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EURPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>ptgef:EURPShares</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>UNITED STATES</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20250401__20260331_zHggSW2zIg4k"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000014" name="dei:DocumentType">20-F/A</ix:nonNumeric></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>(Amendment No. 1)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span id="xdx_90F_edei--DocumentRegistrationStatement_c20250401__20260331_zUAlsH0Vdv5a"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000015" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric></span>&#160;REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>OR</b>&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><span id="xdx_90D_edei--DocumentAnnualReport_c20250401__20260331_zomRCIqrfPle"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">For the fiscal year ended&#160;<b><span style="text-decoration: underline"><span id="xdx_90F_edei--DocumentPeriodEndDate_c20250401__20260331_zA56B7GiZGkk"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate"><span id="xdx_90D_edei--CurrentFiscalYearEndDate_c20250401__20260331_zAxvJkwCgzz" title="Current Fiscal Year End Date"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:datemonthdayen" id="Fact000019" name="dei:CurrentFiscalYearEndDate">March
31</ix:nonNumeric></span>, 2026</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">OR</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><span id="xdx_908_edei--DocumentTransitionReport_c20250401__20260331_z55ELlxyP0S1"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000020" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">OR</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><span id="xdx_904_edei--DocumentShellCompanyReport_c20250401__20260331_zbTiOcH5R04h"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000021" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric></span>&#160;SHELL
COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">Date of event requiring this shell company report ______________</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">For the transition period from ______________ to ______________</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">Commission File Number: <b><span id="xdx_904_edei--EntityFileNumber_c20250401__20260331_zfTEOkv2GLx3"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000022" name="dei:EntityFileNumber">001-40086</ix:nonNumeric></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityRegistrantName_c20250401__20260331_zmgNZ6cVFo6k"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000023" name="dei:EntityRegistrantName">Alpha
Compute Corp</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Exact name of Registrant as specified in its charter)</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline">N/A</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Translation of Registrant's name into English)</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250401__20260331_zHQ5cNsx7WCi"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:edgarprovcountryen" id="Fact000024" name="dei:EntityIncorporationStateCountryCode">British
Virgin Islands</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Jurisdiction of incorporation or organization)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20250401__20260331_zfChHZ7zPVMi"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000025" name="dei:EntityAddressAddressLine1">Clarence
Thomas Building</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20250401__20260331_zKUE71cEcWFg"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000026" name="dei:EntityAddressAddressLine2">P.O.
Box 4649</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressAddressLine3_c20250401__20260331_zWFQzlGoPkj5"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000027" name="dei:EntityAddressAddressLine3">Road
Town</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20250401__20260331_zA4KsXIBuPFk"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000028" name="dei:EntityAddressCityOrTown">Tortola</ix:nonNumeric></span>,
<span id="xdx_907_edei--EntityAddressCountry_c20250401__20260331_z4mSPf4aCQX8"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:countrynameen" id="Fact000029" name="dei:EntityAddressCountry">British
Virgin Islands</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20250401__20260331_zXFe9Ymgq024"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000030" name="dei:EntityAddressPostalZipCode">VG1110</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Address of principal executive office)</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span id="xdx_904_edei--ContactPersonnelName_c20250401__20260331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zUEJ6L8lBCo"><ix:nonNumeric contextRef="From2025-04-012026-03-31_dei_BusinessContactMember" id="Fact000031" name="dei:ContactPersonnelName">Wes
Levitt</ix:nonNumeric></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>c/o Alpha Compute Corp</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span id="xdx_901_edei--CityAreaCode_c20250401__20260331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zAzrdBr6cJJi" title="City Area Code"><ix:nonNumeric contextRef="From2025-04-012026-03-31_dei_BusinessContactMember" id="Fact000033" name="dei:CityAreaCode">(302)</ix:nonNumeric></span>
<span id="xdx_905_edei--LocalPhoneNumber_c20250401__20260331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zQ7xtRO2q7be" title="Local Phone Number"><ix:nonNumeric contextRef="From2025-04-012026-03-31_dei_BusinessContactMember" id="Fact000035" name="dei:LocalPhoneNumber">219-5556</ix:nonNumeric></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressAddressLine1_c20250401__20260331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zoqrqPmOPVqg" title="Entity Address, Address Line One"><ix:nonNumeric contextRef="From2025-04-012026-03-31_dei_BusinessContactMember" id="Fact000037" name="dei:EntityAddressAddressLine1">1111B
S Governors Ave STE 25907</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityAddressCityOrTown_c20250401__20260331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zS7x7fDAjBJa" title="Entity Address, City or Town"><ix:nonNumeric contextRef="From2025-04-012026-03-31_dei_BusinessContactMember" id="Fact000039" name="dei:EntityAddressCityOrTown">Dover</ix:nonNumeric></span>,&#160;<span id="xdx_90E_edei--EntityAddressStateOrProvince_c20250401__20260331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z72xPGDlGZH5" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2025-04-012026-03-31_dei_BusinessContactMember" format="ixt-sec:stateprovnameen" id="Fact000041" name="dei:EntityAddressStateOrProvince">Delaware</ix:nonNumeric></span>&#160;<span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250401__20260331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z6lrdM88Lnv9" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2025-04-012026-03-31_dei_BusinessContactMember" id="Fact000043" name="dei:EntityAddressPostalZipCode">19904</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline">w@alphacompute.ai</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Name, telephone, e-mail and/or facsimile number and Address of Company
Contact Person)</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Securities registered or to be registered pursuant to Section 12(b) of the Act:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border: black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; text-align: center"><span style="font-size: 10pt"><b>Trading
        Symbol</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Name
        of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20250401__20260331_zXTvRjvFL3jf"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000044" name="dei:Security12bTitle">Ordinary
        Shares, no par value</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20250401__20260331_zyAOQNy6Fil7"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000045" name="dei:TradingSymbol">ALP</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20250401__20260331_zakPb3wUCUjc"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:exchnameen" id="Fact000046" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>&#160;Capital
        Market</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Securities registered or to be registered pursuant to Section 12(g) of the Act:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline">Not applicable</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Title of Class)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline">Not applicable</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Title of Class)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate the number of outstanding shares of each of the Issuer's classes of capital or common
stock (ordinary shares) as of the close of the period covered by the annual report.&#160;<b>Ordinary shares without par value &#8211;
<span id="xdx_908_edei--EntityCommonStockSharesOutstanding_iI_c20260331_ziq6EGN9Ou"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-31" id="Fact000047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,470,877</ix:nonFraction></span>
as at March 31, 2026.</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule
405 of the Securities Act. Yes &#9744;&#160;<span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20250401__20260331_zVKQIzaT3uEh"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000048" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;&#9746;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">If this report is an annual or transition report, indicate by check mark if the registrant is
not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes &#9744;&#160;<span id="xdx_903_edei--EntityVoluntaryFilers_c20250401__20260331_z70Dt1npM3G3"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000049" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;&#9746;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;<span id="xdx_909_edei--EntityCurrentReportingStatus_c20250401__20260331_z21Hg9EMzSBh"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000050" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;
No &#9744;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark whether the registrant has submitted electronically every Interactive
Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit such files).&#160;<span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20250401__20260331_zRAjBJgq2lt5"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000051" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;
No &#9744;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or an emerging growth company. See the definitions of the "large accelerated filer,&#8221; &#8220;accelerated
filer," and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="width: 25%"><span style="font-size: 10pt">Large accelerated filer &#9744;</span></td>
    <td style="width: 25%"><span style="font-size: 10pt">Accelerated filer &#9744;</span></td>
    <td style="width: 25%"><span style="font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20250401__20260331_zqtNn6rWnJu8"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000052" name="dei:EntityFilerCategory">Non-accelerated
        filer</ix:nonNumeric></span>&#160;&#9746;</span></td>
    <td style="width: 25%"><span style="font-size: 10pt">Emerging growth company&#160;<span id="xdx_906_edei--EntityEmergingGrowthCompany_c20250401__20260331_z1s09TtSzBN2"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000053" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">If an emerging growth company that prepares its financial statements in accordance with U.S.
GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards<sup>&#8224;</sup>&#160;provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#8224;&#160;&#160; The term &#8220;new or revised financial accounting standard&#8221;
refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s
assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.
7262(b) by the registered public accounting firm that prepared or issued its audit report.&#160;<span id="xdx_90F_edei--IcfrAuditorAttestationFlag_c20250401__20260331_zCzjh3imegVf"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000054" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether
the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;<span id="xdx_901_edei--DocumentFinStmtErrorCorrectionFlag_c20250401__20260331_zKCedMYVNrhh" title="Document Financial Statement Error Correction [Flag]"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000056" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark whether any of those error corrections are restatements that required
a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery
period pursuant to &#167;240.10D-1(b). &#9744;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark which basis of accounting the registrant has used to prepare the financial
statements included in this filing:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 33%"><span style="font-size: 10pt">U.S. GAAP &#9744;</span></td>
    <td style="width: 34%"><span style="font-size: 10pt"><span id="xdx_900_edei--DocumentAccountingStandard_c20250401__20260331_zlRwr03c4TB9"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000057" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric></span>&#160;as issued by the International Accounting Standards Board &#9746;</span></td>
    <td style="width: 33%"><span style="font-size: 10pt">Other &#9744;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">If "Other" has been checked in response to the previous question, indicate by check
mark which financial statement item the registrant has elected to follow. Item 17 &#9744; Item 18 &#9744;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">If this is an annual report, indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;&#160;<span id="xdx_902_edei--EntityShellCompany_c20250401__20260331_zDtmD23eyfNc"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000058" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#9746;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>EXPLANATORY NOTE</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span id="xdx_901_edei--AmendmentDescription_c20250401__20260331_zor9WDeRE3wh"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000059" name="dei:AmendmentDescription">The
purpose of this Amendment No. 1 to Alpha Compute Corp's Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with
the Securities and Exchange Commission on July 16, 2026 (the "Form 20-F"), is to furnish Inline XBRL to the Form 20-F in accordance with
Rule 405 of Regulation S-T. There were also minor corrections made to the risk disclosure on page 5 titled "Our success depends on our
ability to attract, motivate, and retain executive officers and other key employees, and the loss of key personnel or an inability to
hire qualified employees could harm our business." Other than these stated changes, no other changes have been made to the Form 20-F.
This Amendment No. 1 to the Form 20-F speaks as of the original filing date of the Form 20-F, does not reflect events that may have occurred
subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 20-F</ix:nonNumeric></span>.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>Table of Contents</b>&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b></b></span></td>
    <td colspan="2" style="text-align: right"><b>Page No.</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 13%">&#160;</td>
    <td style="width: 73%">&#160;</td>
    <td style="width: 14%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2"><a href="#fwls"><span style="font-size: 10pt">Forward-Looking Statements</span></a></td>
    <td style="text-align: right"><a href="#fwls"><span style="font-size: 10pt">2</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2"><a href="#fpistatus"><span style="font-size: 10pt">Foreign Private Issuer Status and Reporting Currency</span></a></td>
    <td style="text-align: right"><a href="#fpistatus"><span style="font-size: 10pt">2</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Part I</b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i1"><span style="font-size: 10pt">Item 1.</span></a></td>
    <td><a href="#i1"><span style="font-size: 10pt">Identity of Directors, Senior Management and Advisors</span></a></td>
    <td style="text-align: right"><a href="#i1"><span style="font-size: 10pt">3</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i2"><span style="font-size: 10pt">Item 2.</span></a></td>
    <td><a href="#i2"><span style="font-size: 10pt">Offer Statistics and Expected Timetable</span></a></td>
    <td style="text-align: right"><a href="#i2"><span style="font-size: 10pt">3</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i3"><span style="font-size: 10pt">Item 3.</span></a></td>
    <td><a href="#i3"><span style="font-size: 10pt">Key Information</span></a></td>
    <td style="text-align: right"><a href="#i3"><span style="font-size: 10pt">3</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i4"><span style="font-size: 10pt">Item 4.</span></a></td>
    <td><a href="#i4"><span style="font-size: 10pt">Information on the Company</span></a></td>
    <td style="text-align: right"><a href="#i4"><span style="font-size: 10pt">11</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i4a"><span style="font-size: 10pt">Item 4A.</span></a></td>
    <td><a href="#i4a"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: right"><a href="#i4a"><span style="font-size: 10pt">15</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i5"><span style="font-size: 10pt">Item 5.</span></a></td>
    <td><a href="#i5"><span style="font-size: 10pt">Operating and Financial Review and Prospects</span></a></td>
    <td style="text-align: right"><a href="#i5"><span style="font-size: 10pt">15</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i6"><span style="font-size: 10pt">Item 6.</span></a></td>
    <td><a href="#i6"><span style="font-size: 10pt">Directors, Senior Management and Employees</span></a></td>
    <td style="text-align: right"><a href="#i6"><span style="font-size: 10pt">23</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i7"><span style="font-size: 10pt">Item 7.</span></a></td>
    <td><a href="#i7"><span style="font-size: 10pt">Major Shareholders and Related Party Transactions</span></a></td>
    <td style="text-align: right"><a href="#i7"><span style="font-size: 10pt">35</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i8"><span style="font-size: 10pt">Item 8.</span></a></td>
    <td><a href="#i8"><span style="font-size: 10pt">Financial Information</span></a></td>
    <td style="text-align: right"><a href="#i8"><span style="font-size: 10pt">37</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i9"><span style="font-size: 10pt">Item 9.</span></a></td>
    <td><a href="#i9"><span style="font-size: 10pt">The Offer and Listing</span></a></td>
    <td style="text-align: right"><a href="#i9"><span style="font-size: 10pt">37</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i10"><span style="font-size: 10pt">Item 10.</span></a></td>
    <td><a href="#i10"><span style="font-size: 10pt">Additional Information</span></a></td>
    <td style="text-align: right"><a href="#i10"><span style="font-size: 10pt">38</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#item11"><span style="font-size: 10pt">Item 11.</span></a></td>
    <td><a href="#item11"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures about Market Risk</span></a></td>
    <td style="text-align: right"><a href="#item11"><span style="font-size: 10pt">47</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i12"><span style="font-size: 10pt">Item 12.</span></a></td>
    <td><a href="#i12"><span style="font-size: 10pt">Description of Securities Other than Equity Securities</span></a></td>
    <td style="text-align: right"><a href="#i12"><span style="font-size: 10pt">48</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Part II</b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i13"><span style="font-size: 10pt">Item 13.</span></a></td>
    <td><a href="#i13"><span style="font-size: 10pt">Defaults, Dividend Arrearages and Delinquencies</span></a></td>
    <td style="text-align: right"><a href="#i13"><span style="font-size: 10pt">49</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i14"><span style="font-size: 10pt">Item 14.</span></a></td>
    <td><a href="#i14"><span style="font-size: 10pt">Material Modifications to the Rights of Security Holders and Use of Proceeds</span></a></td>
    <td style="text-align: right"><a href="#i14"><span style="font-size: 10pt">49</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i15"><span style="font-size: 10pt">Item 15.</span></a></td>
    <td><a href="#i15"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: right"><a href="#i15"><span style="font-size: 10pt">49</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16a"><span style="font-size: 10pt">Item 16A.</span></a></td>
    <td><a href="#i16a"><span style="font-size: 10pt">Audit Committee Financial Expert</span></a></td>
    <td style="text-align: right"><a href="#i16a"><span style="font-size: 10pt">50</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16b"><span style="font-size: 10pt">Item 16B.</span></a></td>
    <td><a href="#i16b"><span style="font-size: 10pt">Code of Ethics</span></a></td>
    <td style="text-align: right"><a href="#i16b"><span style="font-size: 10pt">50</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16c"><span style="font-size: 10pt">Item 16C.</span></a></td>
    <td><a href="#i16c"><span style="font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: right"><a href="#i16c"><span style="font-size: 10pt">50</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16d"><span style="font-size: 10pt">Item 16D.</span></a></td>
    <td><a href="#i16d"><span style="font-size: 10pt">Exemptions from the Listing Standards for Audit Committees</span></a></td>
    <td style="text-align: right"><a href="#i16d"><span style="font-size: 10pt">51</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16e"><span style="font-size: 10pt">Item 16E.</span></a></td>
    <td><a href="#i16e"><span style="font-size: 10pt">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></a></td>
    <td style="text-align: right"><a href="#i16e"><span style="font-size: 10pt">51</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16f"><span style="font-size: 10pt">Item 16F.</span></a></td>
    <td><a href="#i16f"><span style="font-size: 10pt">Change in Registrant&#8217;s Certifying Accountant</span></a></td>
    <td style="text-align: right"><a href="#i16f"><span style="font-size: 10pt">52</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16g"><span style="font-size: 10pt">Item 16G.</span></a></td>
    <td><a href="#i16g"><span style="font-size: 10pt">Corporate Governance</span></a></td>
    <td style="text-align: right"><a href="#i16g"><span style="font-size: 10pt">52</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16h"><span style="font-size: 10pt">Item 16H.</span></a></td>
    <td><a href="#i16h"><span style="font-size: 10pt">Mine Safety Disclosure</span></a></td>
    <td style="text-align: right"><a href="#i16h"><span style="font-size: 10pt">52</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16i"><span style="font-size: 10pt">Item 16I.</span></a></td>
    <td><a href="#i16i"><span style="font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="text-align: right"><a href="#i16i"><span style="font-size: 10pt">52</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16j"><span style="font-size: 10pt">Item 16J.</span></a></td>
    <td><a href="#i16j"><span style="font-size: 10pt">Insider Trading Policies</span></a></td>
    <td style="text-align: right"><a href="#i16j"><span style="font-size: 10pt">52</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i16k"><span style="font-size: 10pt">Item 16K.</span></a></td>
    <td><a href="#i16k"><span style="font-size: 10pt">Cybersecurity</span></a></td>
    <td style="text-align: right"><a href="#i16k"><span style="font-size: 10pt">52</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Part III</b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i17"><span style="font-size: 10pt">Item 17.</span></a></td>
    <td><a href="#i17"><span style="font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: right"><a href="#i17"><span style="font-size: 10pt">54</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i18"><span style="font-size: 10pt">Item 18.</span></a></td>
    <td><a href="#i18"><span style="font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: right"><a href="#i18"><span style="font-size: 10pt">54</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#i19"><span style="font-size: 10pt">Item 19.</span></a></td>
    <td><a href="#i19"><span style="font-size: 10pt">Exhibits</span></a></td>
    <td style="text-align: right"><a href="#i19"><span style="font-size: 10pt">106</span></a></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b><span id="fwls"></span>FORWARD-LOOKING STATEMENTS</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">This annual report on Form 20-F (this &#8220;Annual Report&#8221;) contains
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements contained in this
Annual Report other than statements of historical fact are forward-looking statements. These statements include, without limitation, statements
regarding our business strategy, plans and objectives of management for future operations. Forward-looking statements are generally identified
by the use of words such as &#8220;believe,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221;
&#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;targets,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221;
&#8220;plans,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; or similar expressions or variations on such expressions, although
not all forward-looking statements contain these identifying words. These statements are based on our current expectations and assumptions
and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or
implied by the forward-looking statements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-indent: 0.5in">Factors that could cause actual results to differ materially from
those contemplated by these forward-looking statements include, among others:&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>our future financial and operating results, including revenues, profitability, expenses, cash flows and liquidity;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>our ability to execute our growth, expansion and acquisition strategies and our ability to achieve our business objectives;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 18.05pt; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>current and future economic and geopolitical conditions;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>our ability to secure additional financing when needed and on acceptable terms;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>changes in laws, regulations and governmental policies applicable to our business;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>risks associated with the deployment, operation and maintenance of graphics processing units (&#8220;GPUs&#8221;) infrastructure;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>demand for AI compute services and the competitive landscape in which we operate;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>customer concentration and dependence on a limited number of counterparties;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>rapid technological developments that could render our GPU assets or infrastructure less competitive or obsolete;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>risks associated with our investment in TON and other digital assets, including price volatility and regulatory developments;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>risks associated with our legacy immune-oncology business and any future development activities;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>our ability to hire and retain qualified management personnel and key employees;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>risks related to Telegram&#8217;s platform and ecosystem;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>our ability to fully realize the anticipated benefits of our recent financing transactions;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>our ability to service and repay our debt obligations;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>risks from specific restrictions on our operations from our credit facility and other commercial agreements; and</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 18.05pt"/>
    <td style="width: 13.95pt">&#8226;</td>
    <td>the other risks and uncertainties described under &#8220;Item 3. Key Information&#8212;Risk Factors&#8221; and elsewhere in this Annual
        Report.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Historically, our business focused on pharmaceutical development, which
is subject to the risks inherent in the biotechnology industry. Although we have shifted our primary business focus, if we resume clinical
development activities, such activities would be subject to the risks associated with pharmaceutical development. We do not anticipate
directly engaging in the commercialization of any product candidates that may be developed.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The forward-looking statements contained in this Annual Report speak only
as of the date of this Annual Report. Except as required by applicable law, we undertake no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Unless the context indicates otherwise, references in this Annual Report
to &#8220;Alpha Compute Corp,&#8221; &#8220;Alpha Compute,&#8221; &#8220;the Company,&#8221; &#8220;our Company,&#8221; &#8220;we,&#8221;
&#8220;us&#8221; or &#8220;our&#8221; refer to Alpha Compute Corp and its subsidiaries.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="fpistatus"></span>FOREIGN PRIVATE ISSUER
STATUS AND REPORTING CURRENCY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Foreign Private Issuer Status</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Alpha Compute Corp is a British Virgin Islands (&#8220;BVI&#8221;) business
company continued under the laws of the BVI pursuant to a Certificate of Continuance issued by the Registrar of Corporate Affairs of the
BVI on July 5, 2013. As of the applicable determination date, more than 50% of our outstanding ordinary shares were held by non-United
States residents. &#160;&#160;As a result, we qualify as a &#8220;foreign private issuer&#8221; as defined under Rule 3b-4 of the Exchange
Act and may use this form as a registration statement under Section 12 of the Exchange Act or as an annual report filed under Section
13(a) or 15(d) of the Exchange Act.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Currency</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The financial information presented in this Annual Report is expressed in
U.S. (&#8220;US$&#8221; or &#8220;$&#8221;), except where otherwise indicated, and the financial data in this Annual Report is presented
in accordance with the International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards
Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i1"></span>ITEM 1 &#8211; IDENTITY OF
DIRECTORS, SENIOR MANAGEMENT AND ADVISORS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i2"></span>ITEM 2 &#8211; OFFER STATISTICS
AND EXPECTED TIMETABLE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i3"></span>ITEM 3 &#8211; KEY INFORMATION</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(A) SELECTED FINANCIAL DATA</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The selected financial data set forth below should be read in conjunction
with our consolidated financial statements and notes thereto appearing elsewhere in this Annual Report. The selected operations data for
each of the three fiscal years ended March 31, 2026, 2025, and 2024, and the consolidated balance sheet data as of March 31, 2026 and
2025 have been derived from our audited consolidated financial statements appearing elsewhere in this Annual Report. The selected operations
data for the years ended March 31, 2023 and 2022 and the consolidated balance sheet data as of March 31, 2024, 2023, and 2022 have been
derived from our audited consolidated financial statements for those periods, which are not included in this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>SUMMARY OF FINANCIAL INFORMATION IN THE COMPANY&#8217;S FINANCIAL STATEMENTS</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Operating Data (U.S. Dollars in thousands, except per share amounts)</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i></i></b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="19" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Net loss before non-controlling interests</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">(6,778</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">(75,382</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">(104,666</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">(19,169</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss attributable to owners of the Company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(38,626</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(6,767</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(75,339</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(104,611</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(16,870</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(6,778</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(75,420</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(109,949</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(19,169</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss attributable to the owners of the Company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(38,626</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(6,767</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(75,377</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(109,894</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(16,870</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Working capital</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(8,738</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">1,125</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">4,816</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">11,811</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">24,049</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">19,530</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">2,225</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">7,779</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">99,129</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">194,662</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Capital stock</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">266,053</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">221,800</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">219,499</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">218,782</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">158,324</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">192</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">1,952</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">1,564</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">0</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">33</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Share option reserves</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">25,275</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">23,530</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">23,841</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">21,204</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">16,928</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Equity attributable to owners of the Company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">7,229</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(123</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">4,022</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">76,045</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">121,205</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: normal">Weighted average number of shares outstanding - Basic <span style="font-size: 10pt; font-style: normal; font-weight: 700">(2)</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">9,248</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,183</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">968</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">806</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">653</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: normal">Weighted average number of shares outstanding - Diluted <span style="font-size: 10pt; font-style: normal; font-weight: 700">(1)(2)</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">9,248</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,183</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">968</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">806</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">653</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: normal">Net loss per share - Basic <span style="font-size: 10pt; font-style: normal; font-weight: 700">(2)</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(4.18</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(5.72</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(77.83</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(129.79</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(25.83</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: normal">Net loss per share - Diluted <span style="font-size: 10pt; font-style: normal; font-weight: 700">(1)(2)</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(4.18</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(5.72</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(77.83</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(129.79</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(25.83</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i></i></b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.5in">1.</td>
    <td>The effect of potential share issuances pursuant to the exercise of options and warrants would be anti-dilutive, and, therefore, basic
        and diluted loss per share are the same for the fiscal years presented.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.5in">2.</td>
    <td>The shares and per share data information have been adjusted to reflect the 1-for-20 reverse share split of the ordinary shares effective
        August 15, 2024.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has not declared or paid any dividends in any of the reporting
periods presented herein.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Exchange Rates</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Certain of our subsidiaries conduct operations and enter into transactions
in Canadian dollars (CDN$), British pound sterling (&#163;) (&#8220;GBP&#8221;), European Union (&#8220;EU&#8221;) euros (&#8364;), and
Swiss francs (&#8355;) (&#8220;CHF&#8221;). Exchange rate information included in this Annual Report has been derived from publicly available
sources, including the Bank of Canada and the Bank of England.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 13, 2026, the exchange rates for the conversion of one U.S. dollar
into Canadian dollars, British pound sterling, euros and Swiss francs were approximately &#160;CDN$1.42, &#163;0.75, &#8364;0.87, and
&#8355;0.81, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table sets forth the high and low exchange rates for each
of the Canadian dollar, British pound sterling, euro, and Swiss franc for one U.S. dollar for each of the last six months of the fiscal
year.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Year ended March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">October</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">November</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">December</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">January</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">February</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Canadian Dollar</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt">High</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.41</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.41</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.40</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.39</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.37</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.40</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Low</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.39</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.39</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.36</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.35</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.35</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.35</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">British Pounds</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">High</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.74</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.75</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.74</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.72</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.74</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Low</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.87</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.87</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.86</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.86</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.85</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.88</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">EU Euros</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">High</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.85</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.86</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.85</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.83</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.84</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.85</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Low</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.87</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.87</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.86</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.86</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.85</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.88</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Swiss Francs</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">High</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.79</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.79</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.79</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.76</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.76</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.77</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Low</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.81</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.81</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.81</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.80</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.78</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.80</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table sets forth the average exchange rates for each of the
Canadian dollar, British pound sterling, euro, and Swiss franc for one U.S. dollar for the five most recent financial years.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Years ended March 31,</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Average for the Fiscal Year</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 45%; font-size: 10pt; font-weight: bold; text-align: left">Canadian Dollar</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.38</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.39</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.35</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.32</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1.25</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">British Pounds</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.75</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.78</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.8</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.83</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">EU Euros</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.86</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.93</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.92</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.96</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.86</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Swiss Francs</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.80</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.89</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.89</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.95</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.92</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We operate in various jurisdictions and are subject to exchange rates for
the Canadian dollar, British pound sterling, the euro, and Swiss francs. Our exposure to foreign currency risk primarily relates to certain
monetary assets and liabilities denominated in foreign currencies, as well as accounts payable other obligations arising from transactions
settled in foreign currencies. Although exchange rates have fluctuated from period to period, foreign currency movements have not historically
had a material effect on our consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(B) CAPITALIZATION AND INDEBTEDNESS</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(C) REASONS FOR THE OFFER AND USE OF PROCEEDS</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(D) RISK FACTORS</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Investing in our securities involves a high degree of risk. You should carefully
consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report, before
making an investment decision. If any of the following risks occur, our business, financial condition, results of operations, cash flows
and prospects could be materially and adversely affected. In that event, the trading price of our securities could decline, and you could
lose all or part of your investment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The risks and uncertainties described below are not the only ones we face.
Additional risks and uncertainties that are not presently known to us or that we currently deem to be immaterial also may materially and
adversely affect our business, financial condition, results of operations, cash flows and prospects.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">This Annual Report contains forward-looking statements that involve risks
and uncertainties. Actual results may differ materially from those anticipated in such forward-looking statements as a result of various
factors, including the risks and uncertainties described below and elsewhere in this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Risks Related to Our Business</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>Our independent registered public accounting firm&#8217;s
report on our consolidated financial statements includes an explanatory paragraph regarding substantial doubt about our ability to continue
as a going concern.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our independent registered public accounting
firm&#8217;s report on our consolidated financial statements includes an explanatory paragraph expressing substantial doubt about our
ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that we will continue
as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The existence of substantial doubt regarding
our ability to continue as a going concern could adversely affect our ability to obtain additional financing, maintain relationships with
customers, suppliers and other counterparties, attract and retain employees and maintain confidence in our business. In addition, investors
may view the existence of a going concern qualification as an indication that we may be unable to continue operations, which could adversely
affect the market price of our ordinary shares.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Although management has developed plans intended
to address our liquidity needs and support our operations, there can be no assurance that such plans will be successful. If we are unable
to continue as a going concern, holders of our ordinary shares could suffer a complete loss of their investment.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>We may need to raise additional capital to fund our operations,
and we may not be able to obtain sufficient capital on acceptable terms or at all.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Historically, we have funded our operations
primarily using the proceeds from the sale of our equity securities and, to a lesser extent, debt securities. As of March 31, 2026, we
had a significant accumulated deficit and equity deficit attributable to owners, as reflected on our consolidated balance sheet. In addition,
a significant amount of our most recent fundings have been from related parties, none of whom have any obligation to further fund the
company.&#160;We expect that we will need to raise substantial additional capital from time to time, including in the near term, to support
our operations and execute our business strategy. There can be no assurance that additional financing will be available when needed, in
sufficient amounts, or on terms acceptable to us, if at all. If we are unable to obtain adequate financing, we may be required to delay,
reduce or discontinue certain aspects of our operations, scale back our growth plans, dispose of assets, seek strategic alternatives,
or otherwise take actions that could materially and adversely affect our business, financial condition, results of operations and prospects.
In addition, any future equity financing may be dilutive to existing shareholders, while debt financing, if available, could impose restrictive
covenants and increase our debt service obligations.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>We have a history of operating losses and may never achieve
profitability in the future.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Historically, we have generated only a limited
amount of business income. To date we have generated limited revenues, and it is currently not likely that we will generate significant
revenues in the near future. Our ability to generate revenue in the future or achieve profitable operations is largely dependent upon
our ability to attract and maintain experienced management and successful execution of our digital asset and compute strategies. We expect
to continue to incur substantial costs in connection with our AI computing infrastructure build-out, GPU procurement, data center operations,
and general corporate activities. We may never generate sufficient revenue to offset these costs and achieve profitability. Even if we
achieve profitability in any given period, we may not be able to sustain it in subsequent periods. If we fail to achieve or sustain profitability,
the market price of our securities may decline.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>Our success depends on our ability to attract, motivate,
and retain executive officers and other key employees, and the loss of key personnel or an inability to hire qualified employees could
harm our business.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our future success depends substantially on
the continued service and performance of our executive officers and other key employees, including personnel with specialized expertise
in compute infrastructure, AI/ML systems, and digital assets. Competition for such personnel is intense, and we compete with larger, more
established companies that may be able to offer greater compensation, equity, and career advancement opportunities. The loss of one or
more of our executive officers or key employees, or our inability to attract and retain qualified replacements, could disrupt our operations,
delay execution of our business strategy, and adversely affect our business, financial condition, and results of operations. We do not
maintain key person life insurance on our executive officers. In addition, our ability to retain employees may be affected by factors
outside our control, including volatility in our stock price or the value of our equity awards, industry-wide compensation trends, and
broader labor market conditions.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Risks Related to Our AI Infrastructure Strategy</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Our business model depends on the successful deployment and utilization
of GPUs in third-party data centers, which exposes us to operational, contractual and technology risks.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our business model involves deploying high-performance
GPUs in third-party data centers to process artificial intelligence (&#8220;AI&#8221;) compute workloads. Our ability to generate revenue
depends on the timely delivery, installation, configuration, and ongoing operation of these GPUs in facilities that we do not own or control.
Our deployment timelines may be affected by constraints affecting AI infrastructure generally, including shortages or delays in the availability
of GPUs, servers, high-bandwidth memory, networking equipment, transformers, switchgear, liquid cooling systems, fiber infrastructure
and other long-lead-time components. Any delay, disruption, or failure in deployment could materially and adversely affect our ability
to generate revenue.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In addition, this strategy subjects us to risks that
are outside our direct control, including data center operator performance, power availability, cooling capacity, physical security, network
connectivity, and compliance with service-level commitments. We generally do not own the data center facilities in which our hardware
operates, and we rely on contractual arrangements that may be subject to termination, renegotiation, or unfavorable renewal terms. Any
disruption in data center services, failure to scale capacity in line with demand, or inability to secure favorable data center arrangements
could materially and adversely affect our business, financial condition, and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Our revenue depends on demand for AI compute services, which may
fluctuate or decline.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our business depends on sustained demand for AI computing
services, including GPU-accelerated training and inference workloads. The market for AI compute is evolving rapidly and demand may fluctuate
due to changes in AI model architectures, algorithmic efficiency improvements that reduce compute requirements, customer budget constraints,
macroeconomic conditions, regulatory developments, or shifts in customer preferences toward more compute-efficient algorithms. If demand
for AI compute does not grow at the rate we anticipate, or if customers reduce their consumption of our services, our revenue, utilization
rates, and financial performance could be materially and adversely affected.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>We depend on a limited number of customers or workloads. and the
loss of any significant customer or a reduction in demand from our largest customers could materially harm our business.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A significant portion of our revenue is derived from
a limited number of customers. If any of these customers terminates its agreement with us, significantly reduces its usage of our services,
or fails to renew on comparable terms, our revenue could decline materially. In addition, our customer base may be concentrated in certain
industries or workloads, making us vulnerable to sector-specific downturns or shifts in technology priorities. We may also face pricing
pressure from large customers with significant negotiating leverage. The loss of, non-renewal, or significant reduction business from
any key customer could materially and adversely affect our business, financial condition and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Our business requires significant capital expenditures for GPU procurement
and infrastructure, and we may not achieve expected returns on invested capital.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our business model requires substantial upfront capital
expenditures to purchase GPUs and related equipment and to deploy such hardware in data centers. These expenditures must often be made
well in advance of generating corresponding revenue and may require us to commit capital based on anticipated customer demand and expected
utilization levels. We may finance these investments through equity issuances, debt financings, leases, vendor financing or other financing
arrangements. The markets for financing AI infrastructure and GPU fleets are evolving rapidly, and financing may become unavailable, more
costly or subject to restrictive covenants, collateral requirements or other terms that could limit our operational and financial flexibility.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">If customer demand does not develop as anticipated,
if we experience delays in procuring, deploying or commissioning hardware, or if utilization rates are lower than expected, we may be
unable to generate sufficient revenue to achieve acceptable returns on our capital investments. In addition, GPU and related hardware
prices may increase as a result of supply constraints, export controls, tariffs, geopolitical developments, technological transitions
or increased competition for limited supply, which could increase our capital requirements and adversely affect our returns. Rapid advancements
in AI hardware and architecture may also shorten the useful life of our existing equipment or render certain assets less competitive or
obsolete more quickly than expected, requiring additional capital expenditures or resulting in impairment charges. Any of these factors
could adversely affect our business, financial condition, results of operations and cash flows.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Rapid technological change may render our GPU assets obsolete and
require us to make significant additional investments to remain competitive.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The AI hardware market evolves rapidly. Newer, more powerful, or more energy-efficient
GPUs or alternative compute architectures (including ASICs, TPUs, custom accelerators and inference-optimized chips) may be introduced
that significantly outperform the hardware we deploy or materially reduce demand for our existing GPU assets. Changes in model architectures,
software optimization, memory requirements, interconnect technologies, liquid cooling requirements, rack density or customer workload
requirements may also reduce the competitiveness or useful life of our deployed assets. If our GPUs become technologically obsolete or
less competitive, we may be required to incur substantial capital expenditures to upgrade or replace them sooner than anticipated, accept
lower pricing or utilization or recognize impairment charges, any of which could negatively impact our financial condition.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>We depend on third-party data centers, cloud infrastructure, and
hardware vendors, and any failure or disruption in their services could materially affect our business.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our operations depend on third-party data center operators,
network providers, cloud services, and hardware vendors. We do not control the physical infrastructure in which much of our computing
hardware is deployed. If a data center operator experiences facility outages, power failures, network disruptions, natural disasters,
security breaches, or financial distress, our services could be interrupted, and we may be unable to meet customer obligations. We may
have limited redundancy or disaster recovery capabilities for certain deployments.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We rely on a limited number of hardware vendors, including
NVIDIA, for our GPU and accelerator supply. Sole-source or limited-source dependencies expose us to risks of supply shortages, price increases,
delayed deliveries, or changes in vendor terms and conditions. If any critical vendor discontinues a product line, experiences manufacturing
issues, or restricts access to its hardware, we may face significant delays or cost increases in scaling our infrastructure, which could
materially harm our business and financial results.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Our operations outside the United States, including GPU infrastructure
deployments in Canada and planned deployments in Sweden, subject us to additional legal, regulatory, economic, and operational risks.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We currently deploy computing infrastructure in Canada,
and we plan to expand deployments into Sweden and other foreign countries. Operating infrastructure outside the United States exposes
us to a variety of risks that could adversely affect our business, including:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">-</td>
    <td style="text-align: justify">compliance with local laws and regulations, including data protection and privacy laws (such as the EU General
        Data Protection Regulation as applicable to our Sweden deployment), import/export controls, tax regimes, and labor and employment laws
        that differ from those in the United States;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">-</td>
    <td style="text-align: justify">fluctuations in foreign currency exchange rates, including the Canadian dollar and the Swedish krona relative
        to the U.S. dollar, which could increase our costs or reduce the value of our foreign assets and revenues;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">-</td>
    <td style="text-align: justify">reliance on local utility infrastructure, including electricity availability, pricing, and grid stability,
        which may affect the cost and reliability of operating power-intensive GPU infrastructure;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">-</td>
    <td style="text-align: justify">potential export control or sanctions restrictions applicable to the transfer of advanced computing hardware
        across borders, which could delay or restrict our ability to deploy or service infrastructure internationally;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">-</td>
    <td style="text-align: justify">political, economic, or regulatory instability, changes in trade policy, or geopolitical developments affecting
        Canada, Sweden, or the broader EU/EEA regulatory environment;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">-</td>
    <td style="text-align: justify">difficulty enforcing contracts, protecting intellectual property, or resolving disputes in foreign jurisdictions;
        and</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">-</td>
    <td style="text-align: justify">the need to comply with local data residency or sovereignty requirements that could affect how we architect
        or operate our infrastructure.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As we expand our international footprint, these risks
may increase in scope and complexity, and our management team's limited experience operating in certain foreign jurisdictions may impair
our ability to manage these risks effectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Semiconductor supply chain constraints and export controls may limit
our ability to procure GPUs and other critical hardware, disrupt our operations, or increase our costs.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our business depends on the availability of advanced
GPUs, high-bandwidth memory, networking components, and related semiconductor hardware, substantially all of which are manufactured by
a limited number of suppliers. The global semiconductor supply chain is subject to capacity constraints, extended lead times, geopolitical
disruptions, natural disasters, and concentration risk in advanced fabrication and packaging facilities. If our suppliers are unable to
meet our demand, or if supply chain disruptions cause delays or cost increases, our ability to deploy and expand AI computing capacity
could be materially impaired.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In addition, GPUs and AI-related semiconductors are
increasingly subject to export control restrictions imposed by the United States and other governments. These controls may limit our ability
to procure certain hardware, restrict the jurisdictions in which we can deploy or offer services, or require us to obtain export licenses
that may be delayed or denied. Export controls may also encourage customers outside restricted regions to design out U.S.-origin semiconductors
to reduce their own compliance burden, may increase investment by foreign governments in competing semiconductor ecosystems, and may disrupt
supply chains and distribution channels. Any tightening or expansion of export controls could materially affect our hardware procurement
strategy, competitive position, and financial results.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Our AI computing operations require substantial energy, power, and
cooling resources, and environmental, permitting, or energy availability constraints could limit our growth.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">AI computing workloads, particularly GPU-intensive
training and inference operations, consume substantial amounts of electricity and generate significant heat requiring advanced cooling
systems. Securing adequate and reliable power supply at reasonable cost is a critical factor in our operations. Power availability at
data center locations is increasingly constrained due to competing demand from other AI companies, cryptocurrency operations, and general
electrification trends. Permitting delays, grid capacity limitations, or increases in energy costs could constrain our ability to expand
or operate our infrastructure.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Growing public and regulatory attention to the environmental
impact of data centers, including carbon emissions, water consumption for cooling, and electronic waste, may result in new regulations,
reporting requirements, or taxes that increase our operating costs. If we are unable to secure adequate energy supply at acceptable costs,
or if environmental regulations restrict our operations or expansion plans, our business growth and financial results could be materially
and adversely affected.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>We face intense competition from hyperscalers and large technology
companies that have substantially greater resources and may be our customers, suppliers, or partners.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The AI computing market is highly competitive. We compete
with hyperscale cloud providers such as Amazon Web Services, Microsoft Azure, and Google Cloud, as well as other large technology companies
that offer AI computing services. Many of these competitors have substantially greater financial, technical, and operational resources,
established customer relationships, brand recognition, and access to proprietary hardware and software. Some hyperscalers design and manufacture
their own AI accelerators, giving them potential cost and performance advantages.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In addition, some of our competitors may simultaneously
be our customers, suppliers, or partners, creating complex commercial relationships and potential conflicts of interest. Hyperscalers
and large cloud providers benefit from large fixed-cost economies of scale in data center operations, power procurement, and hardware
purchasing that may be difficult for us to replicate. If we cannot differentiate our offerings, maintain competitive pricing, or provide
specialized services that larger competitors do not, we may lose customers or fail to grow our market share, which could materially and
adversely affect our business and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>We are subject to evolving and increasingly complex AI regulations
and legal frameworks that could increase our compliance costs, limit our operations, or expose us to liability.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Governments worldwide are enacting or proposing legislation
and regulations specifically targeting AI. The European Union AI Act, which entered into force on August 1, 2024, will become generally
fully applicable on August 2, 2026, with certain obligations relating to prohibited AI practices and AI literacy already effective as
of February 2, 2025. The United States has issued executive orders on AI safety and security, and various U.S. federal agencies and state
legislatures are developing rules applicable to AI systems. Other jurisdictions, including the United Kingdom, China, and Canada, are
pursuing their own regulatory approaches.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">These regulations may classify certain AI systems or
computing services we provide as high-risk, impose transparency and documentation requirements, mandate risk assessments, or require human
oversight mechanisms. Compliance with multiple and potentially inconsistent regulatory frameworks across jurisdictions may be costly,
administratively burdensome, and technically challenging. Failure to comply with applicable AI regulations could result in fines, enforcement
actions, service restrictions, reputational harm, or litigation. Additionally, regulatory uncertainty may deter customers from adopting
AI computing services or delay their deployment decisions, which could adversely affect our revenue growth.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Data privacy, cybersecurity threats, and security vulnerabilities
in our AI computing infrastructure could expose us to liability, regulatory action, or reputational harm.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We process, store, and transmit customer data in connection
with our AI computing services, including potentially sensitive training data, model parameters, and inference outputs. We are subject
to various data protection and privacy laws, including the General Data Protection Regulation in the European Union, the California Consumer
Privacy Act, and similar laws in other jurisdictions. These laws impose requirements on data handling, breach notification, cross-border
data transfers, and individual rights.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our AI computing infrastructure faces cybersecurity
threats that are increasing in frequency, sophistication, and severity, including AI-enabled phishing attacks, prompt injection, data
extraction, model inversion attacks, adversarial manipulation of AI systems, malicious models introduced through supply-chain vulnerabilities,
ransomware, and unauthorized access to customer workloads. A cybersecurity incident affecting our infrastructure could disrupt operations,
compromise customer data or proprietary models, result in regulatory investigations and fines, trigger contractual liability, and damage
our reputation. We rely on third-party software, cloud services, and data center operators whose own security vulnerabilities could affect
us. Despite our security measures, no system is impenetrable, and we cannot guarantee that our defenses will prevent all breaches or attacks.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>We are subject to various operational risks associated with our TON and other digital
asset positions.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We hold significant positions in TON and may acquire additional digital
assets in the future. As a result, our business, financial condition and results of operations are exposed to risks associated with concentrated
holdings of digital assets, including market risk, liquidity risk, technological risk and regulatory risk. Investing in digital assets
is highly speculative and has historically experienced extreme price volatile.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The market value of our digital assets has fluctuated significantly in the
past and may continue to fluctuate substantially in the future. The value of TON and other digital assets may decline rapidly and without
warning as a result of changes in market sentiment, speculative trading activity, macroeconomic conditions, interest rates, technological
developments, cybersecurity incidents, regulatory actions, changes in the perceived utility or adoption of particular digital assets,
failures of exchanges, custodians or other market participants and other factors that are beyond our control. A substantial decline in
the value of our digital assets could materially and adversely affect our financial condition, results of operations and the market price
of our ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A substantial portion of our TON holdings is subject to vesting restrictions
and cannot be sold, which limits our liquidity and our ability to respond to price volatility. Tokens subject to these restrictions cannot
be sold, transferred, or otherwise monetized until they vest, regardless of changes in market price or our liquidity needs. As a result:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 5%">&#149;</td>
    <td style="width: 95%">we are unable to sell restricted TON to raise cash, even if we determine that doing so would be in our best interest
        or if we face unanticipated liquidity needs;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#149;</td>
    <td>we are unable to reduce our exposure to TON price declines during the vesting period, and declines in value during this period may result
        in losses that we cannot mitigate through sale;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#149;</td>
    <td>the illiquidity of these holdings may cause the value at which they are carried on our balance sheet to differ materially from the price
        we would realize in an actual sale, even after restrictions lapse, due to factors such as market depth and timing of any sale; and</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#149;</td>
    <td>our restricted TON should not be considered a source of near-term liquidity in evaluating our financial condition or capital resources.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Because the value of our digital assets is reflected in our financial statements,
fluctuations in the fair value of such assets may cause significant volatility in our reported earnings and financial condition and may
make period-to-period comparisons less meaningful. As a result, our historical financial results may not be indicative of future performance,
and investors may have difficulty evaluating our business and prospects.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our digital assets are subject to risks associated with custody and cybersecurity.
Cybersecurity incidents, including hacking, phishing, malware, insider misconduct and other malicious attacks, could result in the loss,
theft or misappropriation of our digital assets. If we, our custodians or our third-party service providers experience a security breach
or cyberattack and unauthorized parties obtain access to our private keys, or if our private keys are lost or destroyed, or other similar
circumstances or events occur, we could lose some or all of our digital assets. Digital asset transactions are generally irreversible,
and any stolen or improperly transferred digital assets may be unrecoverable.. In addition, there can be no assurance that our custodians
will maintain adequate insurance coverage or that any available insurance will fully cover losses relating to our digital assets.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Holders of our ordinary shares do not have any direct ownership interest
in, or specific rights to, any of our digital assets. In the event of our insolvency or liquidation, our assets, including our digital
assets, may be insufficient to satisfy claims of shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>The regulatory classification and treatment of our digital asset holdings is uncertain
and evolving, and we could be subject to investment company regulation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Digital assets are subject to an evolving and uncertain regulatory landscape.
The U.S. Securities and Exchange Commission, the Commodity Futures Trading Commission, and other regulators have asserted, or may in the
future assert, jurisdiction over certain digital assets, and the classification of specific digital assets as securities, commodities,
or other regulated instruments remains unsettled. Changes in regulatory classification could subject us to new registration, disclosure,
or compliance requirements, restrict our ability to hold or transact in certain digital assets, or expose us to enforcement actions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If our digital asset holdings are deemed to constitute a significant portion
of our total assets, or if the nature of our digital asset activities is determined to constitute an investment company under the Investment
Company Act of 1940, we could be required to register as an investment company, which would impose substantial operational restrictions
and compliance costs. We structure our operations to avoid investment company status, but there can be no assurance that we will not be
required to register or that regulatory interpretations will not change in a manner adverse to us.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>We may make early-stage investments in cryptocurrency and blockchain-related ventures,
which are highly speculative and could result in substantial or complete losses.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We may make early-stage investments in cryptocurrency, blockchain, and digital
asset-related businesses and projects. Such investments are inherently speculative and involve a high degree of risk. In many cases, these
investments may entitle us to receive digital assets over time, including through vesting arrangements lock-up periods, staking mechanisms
or other contractual restrictions that may limit our ability to sell or otherwise monetize such assets when we deem appropriate. As a
result, we may be unable to dispose of these investments during periods of market volatility or declining asset values.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Early-stage digital asset and blockchain ventures often have limited operating
histories, unproven business models, incomplete technologies, evolving governance structures and management teams with limited experience
in building or operating successful businesses. Many such projects may fail to achieve technological milestones, user adoption, commercial
viability or sufficient network effects. In addition, these investments are frequently illiquid, and there may be little or no active
trading market for the associated tokens or other interests, which could limit our ability to realize value from our investments.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The valuation of early-stage investments and related digital assets is inherently
uncertain and may be highly subjective. Such valuations may be adversely affected by changes in market conditions, technological developments,
competitive pressures, cybersecurity incidents, the failure of a project or network, adverse publicity, regulatory developments or changes
in the legal treatment of digital assets, including determinations that certain tokens constitute securities or are otherwise subject
to additional regulatory requirements. In addition, vesting schedules or concentrated token unlock events may create significant selling
pressure that negatively impacts the value of our investments.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Because of the speculative nature of these investments, we may experience
substantial declines in value or lose the entirety of amounts invested. Any such losses could materially and adversely affect our business,
financial condition and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><span style="text-decoration: underline">Risks Related to Ownership
of Our Shares</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>We may not be able to maintain compliance with the continued
listing requirements of The Nasdaq Capital Market and delisting could materially and adversely affect the liquidity and market price of
our securities.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 18.8pt">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our ordinary shares are listed on The Nasdaq
Capital Market and we are therefore subject to its continued listing requirements, including, among others, a minimum bid price of $1.00
per share and a minimum shareholders&#8217; equity requirement of $2.5 million. If we fail to satisfy one or more of the continued listing
requirements, we may be delisted from The Nasdaq Capital Market.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On March 2, 2026, we received a deficiency
letter from the Nasdaq Listing Qualifications Department notifying us that because the closing bid price for our ordinary shares was below
$1.00 per share for the last 30 consecutive business days, we did not meet the $1.00 per share minimum bid price requirement for continued
inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
we have an initial compliance period until August 31, 2026, during which we must achieve a closing bid price of at least $1.00 per share
for a minimum of 10 consecutive business days to regain compliance. If we do not regain compliance by August 31, 2026, we may be eligible
for an additional 180 calendar day period to regain compliance. To qualify, we must meet the continued listing requirement for market
value of publicly held shares and all other initial listing standards of The Nasdaq Capital Market, with the exception of the bid price
requirement.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As of March 31, 2026, our shareholders&#8217;
equity was approximately $6.5 million, which exceeds the $2.5 million threshold. However, there can be no assurance that we will maintain
this level of shareholders&#8217; equity in future periods. If we fail to satisfy any of Nasdaq&#8217;s continued listing requirements
and are unable to regain compliance within the applicable cure periods, our ordinary shares could be delisted. Such a delisting would
likely reduce the liquidity and market price of our securities, limit our ability to raise capital, and make it more difficult for our
shareholders to sell their shares.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>The issuance of additional ordinary shares, including upon
the exercise of our outstanding equity awards and warrants, will dilute the ownership interest of our existing shareholders and increase
the number of ordinary shares eligible for future resale.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As of March 31, 2026, we had 5,410 vested restricted
share units outstanding, which are subject to certain restrictions, and 2,246,507 share options outstanding. The exercise or settlement
of these equity awards, as well as the exercise of outstanding warrants and other convertible or equity-linked securities, would result
in the issuance of additional ordinary shares, which would dilute existing shareholders&#8217; ownership interests and may adversely affect
the market price of our ordinary shares.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">During the year ended March 31, 2026 (&#8220;Fiscal
2026&#8221;), we issued we issued and sold significant amounts of equity securities through private placements, at-the-market offerings
and registered direct offerings, and issued shares in connection with warrant exercises and strategic investments. We also issued shares
in connection with other transactions that were subsequently returned to us as treasury shares following the exercise of contractual rights
by certain investors. These issuances have increased, and may continue to increase, the number of ordinary shares outstanding and the
amount of freely tradable shares in the public market, which could contribute to ongoing selling pressure on our ordinary shares.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We expect to continue to require significant
capital to fund our operations, investments and growth strategy, and we may seek to raise additional capital through the issuance of equity
or equity-linked securities on an ongoing basis. We are not subject to any contractual restriction or limitation on the amount of equity
or equity-linked securities we may issue, and such issuances may occur at any time, in varying amounts, and at prices that may be below
the then-prevailing market price of our ordinary shares. As a result, existing shareholders may experience immediate and substantial dilution
from future issuances.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Any future issuances of equity or equity-linked
securities, including upon the exercise of outstanding awards or securities, could further dilute existing shareholders and increase the
supply of ordinary shares available for resale in the public market. The perception that additional issuances may occur, particularly
in connection with ongoing financing needs or market volatility, could also adversely affect the trading price of our ordinary shares,
regardless of whether such issuances actually occur.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>As a foreign private issuer, we are exempt from certain U.S.
securities regulations applicable to domestic issuers, which may limit the information available to our shareholders and provide fewer
protections than are available to shareholders of U.S. domestic reporting companies</i>.</b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We are a foreign private issuer within the
meaning of the rules promulgated under the Exchange Act. As a foreign private issuer, we are exempt from certain provisions of U.S. securities
law applicable to domestic issuers, including the requirement to file annual reports on Form 10-K, quarterly reports on Form 10-Q and
current reports on Form 8-K, the proxy solicitation rules under the Exchange Act and certain requirements of Regulation FD concerning
selective disclosure. As a result, our shareholders may not receive the same type or frequency of information and may not benefit from
the same protections that are available to shareholders of U.S. domestic reporting companies. Accordingly, there may be less publicly
available information concerning us than there is for U.S. domestic issuers listed on U.S. exchanges. If we cease to qualify as a foreign
private issuer, whether by operation of law or otherwise, we would become subject to the reporting and other requirements applicable to
U.S. domestic issuers., Among other things, we would be required to file annual reports on Form 10-K, quarterly reports on Form 10-Q and
current reports on Form 8-K, comply with the U.S. proxy rules and Regulation FD and satisfy various additional disclosure, governance
and reporting requirements applicable to domestic issuers. Compliance with these additional requirements would increase our legal, accounting,
administrative and other compliance costs and could divert management's attention from the operation of our business.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>We may be classified as a passive foreign investment company,
which could result in adverse U.S. federal income tax consequences for U.S. investors.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A non-U.S. corporation generally will be classified
as a passive foreign investment company (a &#8220;PFIC&#8221;) for any taxable year if either (i) at least 75% of our gross income is
passive income or (ii) at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the
production of passive income. For purposes of these tests, passive income includes dividends, interest and gains from the sale or exchange
of investment property and rents and royalties other than certain rents and royalties which are received from unrelated parties in connection
with the active conduct of a trade or business. Our PFIC status depends on the composition and value of our assets and the nature of our
income, which may vary from year to year and may be affected by fluctuations in the value of our digital asset holdings and investment
activities. Accordingly, there can be no assurance that we will not be classified as a PFIC for the current taxable year or any future
taxable year. We believe that we were a PFIC for our fiscal year ended March 31, 2018 and March 31, 2025.&#160;&#160;&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">If we are classified as a PFIC for any taxable
year during which a U.S. shareholder owns our ordinary shares, such U.S. holder may be subject to adverse U.S. federal income tax consequences.
These consequences may include the imposition of additional taxes and interest charges on certain distributions and gains realized on
a sale, exchange or other disposition of our ordinary shares, as well as certain reporting obligations. In certain circumstances, these
adverse consequences may apply even if we cease to be classified as a PFIC in a subsequent taxable year.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Certain elections, including a mark-to-market
election or a qualified electing fund (&#8220;QEF&#8221;) election, may be available to mitigate some of the adverse U.S. federal income
tax consequences associated with PFIC status. However, such elections are subject to various requirements and limitations, may not be
available to all U.S. holders and may require information that we are not obligated to provide.. We made the information available for
the fiscal years 2018 and 2019 to those shareholders who requested it and may make this information available for our fiscal years 2021,
2022, 2023, 2024, 2025, and 2026, if requested. Although we have made information available in prior years to facilitate QEF elections
and may do so in the future, we are under no obligation to provide such information.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Prospective and current U.S. holders are strongly
urged to consult their own tax advisors about the application of the PFIC rules and the consequences of acquiring, holding and disposing
of our ordinary shares.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>U.S. shareholders may not be able to enforce civil liabilities
against us, our directors and executive officers</i>.</b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We are a company incorporated under the laws
of the British Virgin Islands. Many of our directors and executive officers are non-residents of the United States. Because a substantial
portion of their assets and currently most of our assets are located outside the United States, it may be difficult for U.S. investors
to effect service of process within the United States upon us or such persons or to enforce judgments obtained in U.S. courts against
us or them, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our corporate affairs are governed by our Memorandum
and Articles of Association, the BVI Business Companies Act (Revised Edition 2020, as amended) (the &#8220;BVI Act&#8221;), and the common
law of the British Virgin Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under British Virgin
Islands may differ from, and may be less favorable than, those applicable to companies incorporated in the United States.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The British Virgin Islands courts are also
unlikely:</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">to recognize or enforce against us judgments of U.S. courts based on certain civil liability
        provisions of U.S. securities laws; and</td></tr>
  </table>

<p style="margin: 0pt 4pt 0pt 0.5in; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">to impose liabilities against us, in original actions brought in the British Virgin Islands,
        based on certain civil liability provisions of U.S. securities laws that are penal in nature.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">There is no statutory recognition in the British
Virgin Islands of judgments obtained in the United States.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We have been advised by counsel as to British
Virgin Islands law, that: (i) they are unaware of any proceedings that have been brought in the British Virgin Islands to enforce judgments
of the U.S. courts or to impose liabilities based on the civil liability provisions of the U.S. federal or state securities laws; (ii)
a final and conclusive judgment in the federal or state courts of the United States under which a sum of money is payable, other than
a sum payable in respect of taxes, fines, penalties or similar charges, may be subject to enforcement proceedings as a debt in the courts
of the British Virgin Islands under the common law doctrine of obligation; and (iii) because it is uncertain whether a British Virgin
Islands court would determine that a judgment of a U.S. court based on the civil liability provisions of the U.S. federal or state securities
laws is in the nature of a penalty, it is uncertain whether such a liability judgment would be enforceable in the British Virgin Islands.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Accordingly, U.S. investors may have more difficulty
protecting their interests through actions against us, our directors or our executive officers than would shareholders of a corporation
incorporated in the United States.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>As a foreign private issuer, we are permitted to rely on
certain home country governance practices in lieu of certain Nasdaq governance requirements applicable to U.S. domestic issuers, which
may provide less protection to our shareholders.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We are a foreign private issuer, and in accordance
with Nasdaq Listing Rule 5615(a)(3), we are permitted to follow certain corporate governance of the British Virgin Islands in lieu of
certain Nasdaq corporate governance requirements applicable to U.S. domestic companies. Accordingly, we may rely on exemptions from certain
Nasdaq rules relating to, among other things, board and committee independence requirements, quorum requirements, shareholder approval
requirements for certain issuances of securities, equity compensation plans and change of control transactions, and the requirement to
hold annual meetings of shareholders. As a result, our shareholders may not be afforded the same protections as shareholders of companies
that are subject to all of Nasdaq&#8217;s corporate governance requirements.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In particular, we are not required to have
a majority of our board of directors consist of independent directors or that our board committees consist of entirely independent directors.
Our board of directors and board committees, therefore, may include fewer independent directors than would be required if we were subject
to Nasdaq Listing Rule 5605(b)(1). In addition, we will not be subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent
directors must regularly have scheduled meetings at which only independent directors are present.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We also are exempt from the Nasdaq listing
rules as to quorum, and instead follow the quorum rules for shareholder meetings under British Virgin Islands law. We also are exempt
from the Nasdaq listing rules so as to not be required to obtain shareholder approval for certain issuance of securities, shareholder
approval of share option plans and change of control transactions under Nasdaq Listing Rule 5635 and to hold annual shareholder meetings
under Nasdaq Listing Rule 5620(a).</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">If we cease to qualify as a foreign private
issuer, we would be required to fully comply with Nasdaq&#8217;s corporate governance requirements applicable to U.S. domestic issuers,
which could increase our legal, accounting and administrative costs, require changes to the composition of our board and committees, and
make it more difficult and time-consuming to raise capital or engage in certain transactions.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>We may lose our foreign private issuer status in the future,
which could cause us to incur significant legal, accounting and other expenses and subject us to additional regulatory requirements.</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We are a foreign private issuer under the rules
of the Exchange Act. Our foreign private issuer status is determined annually and depends on a number of factors, including the geographic
distribution of our shareholders, the location of our assets and the residence or citizenship of our directors and executive officers.
Accordingly, there can be no assurance that we will continue to qualify as a foreign private issuer in the future.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">If we cease to qualify as a foreign private
issuer, we would become subject to the reporting and other requirements applicable to U.S. domestic issuers. Among other things, we would
be required to file annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and comply with additional
SEC and Nasdaq corporate governance requirements applicable to domestic issuers. Compliance with these additional requirements would increase
our legal, financial and other compliance costs and could require significant attention from management.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In addition, the loss of foreign private issuer
status could require changes to the composition and practices of our board of directors and its committees, reduce our flexibility in
certain corporate governance and capital-raising matters and make it more difficult and expensive for us to obtain director and officer
liability insurance. Increased regulatory requirements and associated costs could also make it more difficult for us to attract and retain
qualified members of our board of directors and executive officers. Any of these factors could materially and adversely affect our business,
financial condition and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Macroeconomic Risks Related to Our Business</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Macroeconomic conditions, including the effects of inflation, interest rates, capital
market volatility and economic uncertainty, may adversely affect our business, financial condition, and results of operations.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our business is sensitive to macroeconomic conditions, including inflation,
changes in interest rates, geopolitical events, tariffs and trade restrictions, and broader economic uncertainty. Adverse macroeconomic
conditions may reduce customer demand for our products and services, delay customer spending decisions and negatively affect the availability
and cost of capital.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Inflationary pressures and supply chain disruptions have increased and may
continue to increase, the cost of GPUs, servers, networking equipment, data center capacity, electricity, cooling systems, construction,
labor, transportation and other inputs necessary to operate and expand our business. In addition, changes in interest rates and tightening
credit conditions may increase our borrowing costs and reduce the availability of financing. Because our business requires substantial
capital expenditures and ongoing access to financing, any deterioration in capital market conditions could make it more difficult, costly
or dilutive for us to obtain the capital necessary to fund our operations, growth initiatives and strategic investments.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Broader economic weakness or uncertainty may also adversely affect the financial
condition of our customers, suppliers, service providers, financing counterparties and other business partners. The failure or financial
distress of one or more of these parties could disrupt our operations, increase our costs or impair our ability to execute our business
strategy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Any prolonged period of inflation, elevated interest rates, recessionary
pressures or other adverse macroeconomic conditions could materially and adversely affect our business, financial condition, results of
operations and the market price of our ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Changes to tariffs, trade policies, export controls and sanctions may have an adverse
effect on our business, financial condition and results of operations.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Governments around the world, including the United States, have imposed
and may continue to impose tariffs, export controls, sanctions and other trade restrictions, and trade relations between the United States
and certain foreign countries have become increasingly uncertain. Changes in trade policies or the expansion of existing tariffs, export
controls, sanctions or other restrictions could disrupt global supply chains, increase costs and limit the availability of products and
services necessary for our operations..</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In particular, tariffs, export controls, sanctions and other trade restrictions
may increase the cost of, delay the delivery of or limit access to GPUs, servers, networking equipment, power infrastructure, cooling
systems and other components critical to the deployment and operation of AI infrastructure. Such measures could also adversely affect
the operations of our subsidiaries, suppliers, manufacturers, data center partners, customers and other counterparties, resulting in delays,
increased costs, reduced demand or disruptions to our business.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In addition, changes in trade policies or heightened geopolitical tensions
could adversely affect global economic conditions and financial markets, resulting in reduced access to capital, lower customer spending
and increased volatility in our operating environment. The implementation of new tariffs, export controls, sanctions or other trade restrictions,
or the perception that such measures may be adopted, could have a material adverse effect on our business, financial condition and results
of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i4"></span>ITEM 4 &#8211; INFORMATION
ON THE COMPANY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(A) &#8239;HISTORY AND DEVELOPMENT OF THE COMPANY</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We were originally incorporated in Ontario, Canada in 1973. We were inactive
until 1985. Between 1986 and 2009, we were engaged in a variety of businesses and went through several name changes ending with Bontan
Corporation Inc.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In December 2012, we decided to change the focus of our business activities
from oil and gas to biotechnology. On June 4, 2013, we acquired Portage Pharma Ltd., a biotech private limited company formed under the
laws of the British Virgin Islands, through an exchange of shares. On July 5, 2013, we changed our name to Portage Biotech Inc. and moved
our jurisdiction to the British Virgin Islands under a certificate of continuance issued by the Registrar of Corporate Affairs of the
BVI.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 4, 2025, in connection with the change in the legal name of
the Company to AlphaTON Capital Corp effective on August 11, 2025, the Nasdaq ticker symbol of the Company&#8217;s ordinary shares was
changed to &#8220;ATON.&#8221; On April 21, 2026, in connection with the change in the legal name of the Company to Alpha Compute Corp
effective on April 14, 2026, the Nasdaq ticker symbol of the Company&#8217;s ordinary shares was changed to &#8220;ALP.&#8221;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are a BVI business company redomiciled and continued under the BVI Act
with our registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110. Our
U.S. agent, Portage Development Services Inc. (&#8220;PDS&#8221;), is located at 1111B S Governors Ave, Ste 25907, Dover, DE 19904. Our
telephone number is (302) 219-5556. Our website address is www.alphacompute.ai. The inclusion of our website address is intended to be
an inactive textual reference only and not an active hyperlink to our website. Information contained on, or accessible through, our website
is not a part of, and is not incorporated by reference into, this annual report. The SEC also maintains an internet website located at
www.sec.gov that contains the information we file or furnish electronically with the SEC.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are a foreign private issuer under the SEC rules. We had also been a
reporting issuer under the securities legislation of the provinces of Ontario and British Columbia. Our ordinary shares were listed on
the Canadian Securities Exchange (&#8220;CSE&#8221;) under the symbol &#8220;PBT.U.&#8221; On February 25, 2021, our ordinary shares began
trading on The Nasdaq Capital Market under the symbol &#8220;PRTG.&#8221; As the principal market for our ordinary shares is Nasdaq, we
voluntarily delisted from the CSE on April 23, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During August 2018, we reached a definitive agreement to acquire 100% of
SalvaRx Limited (&#8220;SalvaRx&#8221;) in exchange for 402,536 of our ordinary shares. The selling shareholders were SalvaRx Group plc
(94.2%), James Mellon (2.9%) and Gregory Bailey (2.9%), the latter two persons being directors of our company until the second quarter
of Fiscal 2026. The acquisition of SalvaRx was a &#8220;related party transaction&#8221; within the meaning of Multilateral Instrument
61-101&#160;<i>Protection of Minority Security Holders in Special Transactions&#160;</i>(&#8220;MI 61-101&#8221;). As a consequence, MI
61-101 required us to seek the approval of a majority of the disinterested shareholders to make this acquisition. On January 8, 2019,
the majority of our minority shareholders approved the SalvaRx acquisition on the terms as set out in the signed definitive agreement.
At the same time, the SalvaRx Group plc shareholders approved the definitive agreement, all required regulatory approvals were also obtained.
The SalvaRx acquisition was completed on January 8, 2019, and we acquired 100% of the equity of SalvaRx, which has full or partial ownership
of four immune-oncology companies that are developing nine product candidates.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 1, 2022, we, our wholly owned subsidiary, Portage Merger Sub I,
Inc., our wholly owned subsidiary, Portage Merger Sub II, LLC, and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine
receptor antagonists for the treatment of solid tumors, entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger
Agreement&#8221;). Under the structure of the Merger Agreement, Tarus Therapeutics, Inc. was ultimately merged into Portage Merger Sub
II, LLC, with the surviving entity renamed Tarus Therapeutics, LLC (&#8220;Tarus&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As consideration for Tarus, we issued to the former Tarus shareholders an
aggregate of 121,300 ordinary shares, calculated on the basis of $18 million divided by the 60-day volume weighted average price per share
of ordinary shares. Such ordinary shares have not been registered with the SEC and were subject to lock-up agreements for terms ranging
from six to twelve months, which expired on February 1, 2023 and July 1, 2023, respectively. Additionally, the ordinary shares that were
subject to a twelve month lock-up period, are also subject to a three month dribble-out period which commenced July 1, 2023. During the
dribble out period, each holder could not sell more than 10% of the average trading volume of our ordinary shares for the rolling three
month period prior to the date on which the holder executes a trade of our ordinary shares without our prior written consent (which we
were permitted to withhold at our sole discretion). Additionally, in the event that we resume further development of our adenosine program,
payments of up to $32 million in cash or our ordinary shares (at our discretion) would be triggered upon achievement of future development
and sales milestones, as described below. As a result of the transaction:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>We also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations ($1 million plus interest), for
        an aggregate of $3 million in liabilities. We repaid the short-term debt in July 2022.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Upon enrolling the first patient in a Phase 2 clinical trial utilizing Tarus&#8217; adenosine receptor antagonists, we would be required
        to pay an additional one-time payment of $15 million to the former Tarus shareholders. Payment may be in the form of cash or our ordinary
        shares (at our discretion). The remaining $17 million milestone is based on target commercial sales.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 18, 2022, we and our wholly owned subsidiary, SalvaRx, entered into
a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) with each of the minority shareholders of iOx (the &#8220;Sellers&#8221;)
resulting in the acquisition of the remaining 21.68% of the outstanding non-controlling ownership interest of iOx, which had been developing
our iNKT engager platform until we decided to pause further development in Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 1, 2023, we, through Tarus, entered into a clinical service agreement
with a third-party service provider. The term of the agreement has been extended to the earlier of February 20, 2026 or the completion
of provision of services and the payment of contractual obligations. The budgeted costs for the services to be provided are approximately
$6.9 million (previously $12.1 million).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In March 2025, we resumed patient enrollment into the final cohort arm of
TT-10 (PORT-6) as part of the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following a prior pause due to funding constraints. This
decision reflects the favorable safety and preliminary activity signals observed in earlier dose cohorts. In April 2025, we announced
confirmatory preclinical results in mesothelioma with our TT-4 (PORT-7) compound, supporting advancement of this indication in its first-inhuman
trial of TT-4 (PORT-7) which is expected to commence in the fourth quarter of fiscal 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On November 12, 2025, the Company and Cyncado Therapeutics (&#8220;Cyncado&#8221;)
announced a non-binding Letter of Intent with Australia&#8217;s Asbestos and Dust Diseases Research Institute (&#8220;ADDRI&#8221;) to
conduct an ADDRI-sponsored investigator-initiated clinical trial of TT-4 in mesothelioma in Australia. The planned trial is expected to
enroll approximately 50 patients, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado&#8217;s
planned U.S. mesothelioma activities, subject to execution of a definitive agreement and customary regulatory approvals. Under the contemplated
arrangement, Cyncado will supply TT-4 and limited support as part of an international mesothelioma program designed to accelerate decision-quality
clinical data generation.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 25, 2025, in connection with a closing of private financing
arrangement raising a mix of cash and digital assets (the &#8220;September 2025 PIPE&#8221;), the Company transitioned to being primarily
a digital asset treasury focused on scaling the Telegram super app. Telegram has an addressable market of one billion monthly active users.
The Company implemented a comprehensive M&amp;A and treasury strategy that combines direct token acquisition, validator operations, and
strategic ecosystem investments. Through our operations, the Company provided public market investors with institutional-grade exposure
to the Telegram ecosystem, including The Open Network (TON) token, while maintaining the governance standards and reporting transparency
of a Nasdaq-listed company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In November 2025, the Company began deploying NVIDIA GPUs to Telegram&#8217;s
proprietary AI protocol, Cocoon. Cocoon is Telegram&#8217;s Confidential Compute Open Network &#8212; a decentralized AI infrastructure
project built around the TON ecosystem. In early 2026, the Company completed a strategic pivot and rebranded as Alpha Compute Corp. to
reflect that its primary focus had shifted to AI compute infrastructure. This transition included the establishment of GPU procurement
and data center deployment capabilities, and the development of a proprietary confidential computing software stack.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#8220;SPA&#8221;) with Animoca Brands Limited (&#8220;Animoca Brands&#8221;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#8220;GaMee Global&#8221;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#8220;GaMee Transaction&#8221;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. Animoca
Brands, prior to closing, will conduct a reorganization to transfer 100% of the equity of Gamee Limited, a company incorporated in the
United Kingdom (the &#8220;UK Company&#8221;) to GaMee Global. The UK Company owns the entire equity in Gamee Mobile s.r.o., a company
incorporated under the laws of the Czech Republic (the &#8220;Czech Company&#8221; and together with GaMee Global and the UK Company,
&#8220;GaMee&#8221;). Under the terms of the SPA, at the closing of the GaMee Transaction (&#8220;Completion&#8221;), the Company has
agreed to pay total upfront consideration of $3.5 million (the &#8220;Completion Consideration&#8221;), comprised of: (i) $1.5 million
in cash, and (ii) $2.0 million in equity consideration in the Company, valued at $1.00 per share. The equity portion of the Completion
Consideration under subparagraph (ii) is structured as a combination of ordinary shares of the Company (&#8220;Ordinary Shares&#8221;)
and pre-funded warrants exercisable for Ordinary Shares (&#8220;Pre-Funded Warrants&#8221;). Specifically, at Completion, Animoca Brands
will receive: (i) 99,800 Ordinary Shares, and (ii) Pre-Funded Warrants exercisable for 1,900,200 Ordinary Shares, representing the balance
of the equity portion of the Completion Consideration. The GaMee Transaction closed on May 27, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On April 21, 2026, in connection with the change in the legal name of the
Company to Alpha Compute Corp effective on April 14, 2026, the Nasdaq ticker symbol of the Company&#8217;s ordinary shares was changed
to &#8220;ALP.&#8221; This name change reflects the Company&#8217;s strategic pivot to AI compute infrastructure.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(B) BUSINESS OVERVIEW</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Nature of Operations and Overview</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>The Company</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Alpha Compute Corp. (&#8220;Alpha Compute,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our,&#8221; or the &#8220;Company&#8221;) is a technology company focused on the acquisition, deployment, and leasing of high-performance
GPUs in data center facilities to power AI workloads, with a particular emphasis on confidential compute. The Company operates GPU infrastructure
in North America and Europe and provides GPU-as-a-Service (&#8220;GPUaaS&#8221;) and AI confidential compute solutions to enterprise customers,
technology companies, AI research laboratories, and decentralized AI ecosystems.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Beginning in late 2025, the Company commenced the acquisition and installation
of NVIDIA GPU hardware, including H200, B200, and B300 processors, in third-party data center facilities. In April 2026, the Company formally
rebranded to Alpha Compute Corp. and changed its Nasdaq ticker from &#8220;ATON&#8221; to &#8220;ALP&#8221; to reflect the completion
of this strategic transition. The Company retains a residual position in TON digital assets from its previous focus as a digital asset
treasury company, but this legacy segment is no longer the primary focus of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>GPU-as-a-Service (GPUaaS)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s primary revenue model consists of acquiring and leasing
NVIDIA GPU hardware and leasing compute capacity to enterprise customers under multi-year off-take agreements. Customers pay for dedicated
access to GPU clusters to run large-scale AI training, inference, and research workloads. The Company earns revenue based on contracted
lease rates and capacity utilization, providing a recurring, predictable revenue stream.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s first large-scale deployment, designated ALPHA-01, consists
of 504 NVIDIA B200 GPUs co-located in a hydroelectric-powered Canadian data center. ALPHA-01 became fully operational in May 2026 and
is subject to a two-year, $32.2 million compute off-take lease with a leading frontier AI research laboratory, representing $16.1 million
in annual contracted revenue. A second cluster, ALPHA-02, comprising 576 NVIDIA B300 GPUs, is planned for deployment in a hydroelectric-powered
Swedish data center and is targeted for commercial launch in the third quarter of calendar year 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>AI Confidential Computing</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Confidential computing is a hardware-level security paradigm that enables
computation on sensitive data within a protected, hardware-enforced trusted execution environment (&#8220;TEE&#8221;), such that the data
and the AI model remain encrypted and inaccessible even to the infrastructure operator. The Company and its partners have together developed
and deployed a proprietary software stack that enables confidential AI workloads to be processed on Telegram&#8217;s Cocoon AI protocol
via NVIDIA Blackwell-generation GPU hardware.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company believes confidential computing represents the highest-growth,
highest-value segment within the AI infrastructure market, driven by stringent data privacy requirements across healthcare, financial
services, government, defense, and decentralized AI applications. We believe the convergence of the EU AI Act (effective 2026), updated
FedRAMP 20x requirements, and various national data sovereignty mandates is creating a structural and mandatory procurement cycle for
privacy-preserving AI infrastructure.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Sovereign AI Infrastructure</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company targets enterprise clients, government entities, and regulated
industries seeking AI compute capacity that does not require surrendering data sovereignty to hyperscale cloud providers. The Company
offers co-location and dedicated GPU deployment arrangements designed to satisfy data residency requirements and regulatory mandates,
including in jurisdictions with strict cross-border data transfer restrictions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In conjunction with its infrastructure buildout, the Company has announced
plans to establish a U.S. government contracting entity, projected to launch in the third quarter of calendar year 2026, to pursue federal
government AI compute procurement opportunities, including those arising from FedRAMP compliance requirements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Digital Asset Business</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company launched a digital asset treasury business in September 2025
focused on TON blockchain and the Telegram ecosystem. In November 2025, the Company began deploying NVIDIA GPUs to Telegram&#8217;s proprietary
AI protocol, Cocoon. Cocoon is Telegram&#8217;s Confidential Compute Open Network &#8212; a decentralized AI infrastructure project built
around the TON ecosystem. In response to market trends in the digital asset space and opportunities in AI infrastructure, the Company
completed a strategic pivot and rebranded as Alpha Compute Corp in early 2026 to reflect that its primary focus had shifted to AI compute
infrastructure. This transition included the establishment of GPU procurement and data center deployment capabilities, and the development
of a proprietary confidential computing software stack.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">While investing in digital assets, staking digital assets, and operating
blockchain infrastructure is no longer a core focus of the Company, it will continue to maintain some exposure to TON and other digital
assets. By deploying GPU hardware to Telegram&#8217;s Cocoon protocol, the Company will continue to earn TON tokens, and through its May
2026 acquisition of GaMee, the Company has exposure to the broader Telegram ecosystem and large userbase. However, TON tokens earned from
Cocoon will generally be used for operating and capital expenditures for the AI infrastructure business line, rather than held for long-term
investment. The remaining locked TON tokens on the Company&#8217;s balance sheet are mostly in the process of being returned to investors
per their put rights granted as part of the September 2025 PIPE transaction, with two additional outstanding put rights exercised on June
22, 2026. One remaining investor has not exercised his put right on 235,000 locked TON contributed.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Legacy Immuno-oncology Business&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Prior to September 2025, Alpha Compute (under the name Portage Biotech)
primarily operated as a clinical-stage immuno-oncology company advancing treatments the Company believes will be first-in class therapies
that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive
cancers. The Company&#8217;s access to next-generation technologies, coupled with a deep understanding of biological mechanisms, enables
the identification of clinical therapies and product development strategies that accelerate these medicines through the translational
pipeline. After a review of the Company&#8217;s future funding needs for clinical development of its programs, as well as the capital
raising market for biotechnology companies, the Company discontinued the Company-sponsored trial for the invariant natural killer T-cell
(&#8220;iNKT&#8221;) program and paused further patient accrual to the Company sponsored adenosine trial for both PORT-6 and PORT-7.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In March 2025, the Company resumed patient enrollment into the final cohort
arm of TT-10 (PORT-6) as part of the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following a prior pause due to funding constraints.
This decision reflects the favorable safety and preliminary activity signals observed in earlier dose cohorts. In April 2025, the Company
announced confirmatory preclinical results in mesothelioma with its TT-4 (PORT-7) compound, supporting advancement of this indication
in its first-inhuman trial of TT-4 (PORT-7), which is expected to commence in the fourth quarter of fiscal 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On November 12, 2025, the Company and Cyncado announced a non-binding Letter
of Intent with Australia&#8217;s Asbestos and Dust Diseases Research Institute ("ADDRI") to conduct an ADDRI-sponsored, investigator-initiated
clinical trial of TT-4, Cyncado's selective A2B receptor antagonist, in mesothelioma in Australia. On May 31, 2026, Cyncado and ADDRI
executed a definitive Clinical Trial Research Agreement establishing the terms of the study. The trial is expected to enroll approximately
50 patients across multiple clinical sites, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with
Cyncado's planned U.S. mesothelioma activities. Under the agreement, Cyncado will supply TT-4 and provide limited support as part of an
international mesothelioma program. The trial remains subject to customary regulatory and ethics approvals and site activation before
enrollment begins.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(C) &#8239;ORGANIZATIONAL STRUCTURE</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our significant subsidiaries include as of March 31, 2026:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(a)</td>
    <td>SalvaRx, a wholly owned subsidiary, incorporated in the British Virgin Islands;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(b)</td>
    <td>iOx, a wholly owned subsidiary incorporated in the U.K.;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(c)</td>
    <td>Saugatuck, a 70% owned subsidiary through SalvaRx, incorporated in the British Virgin Islands. &#8220;Saugatuck and subsidiary&#8221;
        refers to Saugatuck and Saugatuck Rx LLC;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(d)</td>
    <td>PDS, a wholly owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary
        via a shared services agreement;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(e)</td>
    <td>SalvaRx LLC, a wholly owned subsidiary through SalvaRx incorporated in Delaware;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(f)</td>
    <td>Saugatuck Rx LLC, a wholly owned subsidiary of Saugatuck incorporated in Delaware; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(g)</td>
    <td>Tarus, a wholly owned subsidiary incorporated in Delaware.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(D) &#8239;PROPERTY, PLANT AND EQUIPMENT</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Alpha Compute purchased and made significant deposits on multiple graphic
processing units (&#8220;GPUs&#8221;) during the year ended March 31, 2026 to facilitate the increasing demand for AI compute processing.
As of March 31, 2026 the Company owned one Nvidia H200 server and one Nvidia B300 server with a combined carrying value of approximately
$1.3 million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 11, 2025 the Company signed an enterprise colocation service
agreement (the &#8220;Colo Agreement&#8221;) with atNorth AB (&#8220;atNorth&#8221;) to deploy the Company&#8217;s GPU hardware to atNorth&#8217;s
data center located in Kista, Sweden. The Colo Agreement consists of two data halls with a Phase I deployment of 1,213 kW of power and
a Phase II of 1,017 kW of power, with Phase II being structured as a Right of First Refusal (the &#8220;ROFR&#8221;). The agreement&#8217;s
commencement date was April 1, 2026, and extends for 60 months after which it automatically extends for successive 12 month periods unless
6 months&#8217; notice is provided by either party. On April 10, 2026, the Company paid a 982,368 EUR deposit to secure Phase I of the
agreement&#160;&#160;. As of the date of the issuance of these consolidated financial statements, the ROFR for Phase II of the deployment
has expired, although atNorth is still being considered for a further deployment once ready. The monthly colocation fee for Phase I that
has commenced is 163,728 EUR plus variable electricity costs estimated at 0.126 EUR/kWh.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has also made $8.6 million in deposits toward a purchase order
with Vertical Data, Inc. for 72 Nvidia B300 servers (576 GPUs) to be manufactured by Dell. The remaining cost of the acquisition will
be funded via a GPU equipment financing lender. The anticipated asset-backed loan will be non-recourse to the Company. The servers are
projected to be delivered and installed in atNorth&#8217;s Kista, Sweden data center in August 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 1, 2026, the Company entered into an office space lease in Lisbon,
Portugal with an initial term of 24 months, with options to purchase the property in the 12<sup>th</sup> and 24<sup>th</sup> months. As
part of executing the lease, the Company paid the first 12 months&#8217; rent and a non-refundable option fee in the amounts of 84,000
and 50,000 EUR, respectively. In the event the Company elects to purchase the property, the option fee and a portion of the rent payments
will be deducted from the purchase price.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i4a"></span>ITEM 4A &#8211; UNRESOLVED
STAFF COMMENTS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">None.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i5"></span>ITEM 5 &#8211; OPERATING AND
FINANCIAL REVIEW AND PROSPECTS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(A) &#8239;OPERATING RESULTS (All Amounts in 000&#8217;$)</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following discussion should be read in conjunction with our audited
consolidated financial statements and notes thereto for the fiscal year ended March 31, 2026, contained elsewhere in this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Revenues</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">97</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Operating expenses</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">23,193</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,418</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,253</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,801&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,129&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12,535&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">General and administrative expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">20,392&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4,289&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5,718&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(23,096</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(7,418</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(18,253</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,883</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(388</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,868</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11,305</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of put rights, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(5,959</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,411</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,349</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,700</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on novation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(676</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement with Parexel - iOx CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">946</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on Registered Direct Offering</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(2,432</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Offering costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(662</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - iOx IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(57,890</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Tarus IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(23,615</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Stimunity</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(1,002</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Saugatuck</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(178</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Commitment fee under Committed Purchase Agreement</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(839</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on dissolution of investment in associate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">27</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain from sale of investment in public company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">725</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(4,804</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(182</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">51</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">336</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on settlement of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(916</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange transaction (loss) gain</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(7</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Interest (expense) income, net</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,014</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">86</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">242</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on extinguishment of debt</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(582</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on forgiveness of loan interest</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">837</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Share of losses from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(44</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(233</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left">Loss before benefit for income taxes</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(38,626</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(6,781</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(85,930</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,548</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Net loss</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(6,778</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(75,382</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive loss</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Net unrealized loss on investments</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(38</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,778</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(75,420</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss attributable to:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(38,626</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(6,767</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(75,339</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(1</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,778</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(75,382</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss attributable to:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(38,626</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(6,767</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(75,377</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(1</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,778</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(75,420</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Results of Operations for Fiscal 2026 Compared to Fiscal 2025</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We incurred a net loss of approximately $38.6 million during the fiscal
year ended March 31, 2026 ( &#8220;Fiscal 2026&#8221;), compared to net loss of $6.8 million during the fiscal year ended March 31, 2025
(&#8220;Fiscal 2025&#8221;) and total comprehensive loss of approximately $38.6 million and $6.8 million during Fiscal 2026 and Fiscal
2025, respectively, an increase in net loss of $31.8 million and an increase in comprehensive loss of $31.8 million, year-over-year.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The components of the change in net loss and total comprehensive loss are
as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Revenues were $0.1 million for Fiscal 2026 compared to $0.0 million for Fiscal 2025, an increase of $0.1 million attributable to the 	launch
of compute processing revenues in March of Fiscal 2026. No revenues were generated during Fiscal 2025.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Operating expenses, which include research and development (&#8220;R&amp;D&#8221;), general and administrative (&#8220;G&amp;A&#8221;),
and depreciation 	expense, were $23.2 million in Fiscal 2026, compared to $7.4 million in Fiscal 2025, an increase of $15.8 million,
which is discussed 	more fully below.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A net gain of $0.9 million from the settlement and release of obligations and liabilities under the Master Services Agreement between
	iOx and Parexel during Fiscal 2025. See &#8220;iOx &#8211; Parexel Master Services Agreement&#8221; section of Note 19 &#8220;Commitments
and Contingent 	Liabilities&#8221; for additional discussion regarding this matter included elsewhere in this Report. No such gain
occurred during Fiscal 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in"><span style="font-size: 10pt">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A $2.9 million gain from the change in the fair value of certain warrants accounted for as liabilities issued in connection with the 2023</span>	<span style="font-size: 10pt">and
2026 Private Placement (defined below) in October 2023 and the January 2026 registered direct offering for Fiscal 2026, relative to </span>	<span style="font-size: 10pt">a
$0.4 million non-cash gain from the change in fair value during Fiscal 2025.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A loss of $4.8 million in Fiscal 2026 on the impairment of the Company&#8217;s investment in Compedica as a result of discontinuing the
	equity method of accounting for the investment in September 2025. Loss recognized under the equity method of accounting for the 	investment
in Compedica was less than $0.1 million for Fiscal 2026. No such losses occurred during Fiscal 2025.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A loss of $0.2 million in Fiscal 2026 on the change in fair value in the Company&#8217;s investment in Compedica since initial impairment.	No
such loss occurred during Fiscal 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A $8.6 million loss from the change in the fair value of certain put rights, net of redemptions, issued to investors in the Company 	accounted
for as liabilities issued in connection with the September 2025 Private Placement for Fiscal 2026. No such loss occurred 	during Fiscal
2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A $0.9 million loss from the settlement of a portion of the aforementioned put rights, recognized as the difference between the fair value
of the TON contributed by the respective investors at the time of put exercise and the carrying value of the put right. No such loss occurred
during Fiscal 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A $0.3 million gain from the settlement of a portion of the TON payable, recognized as the difference between the carrying value of the
	TON contributed by the respective investors at the time the TON was returned to the investors and the fair value of the TON payable.
	No such gain occurred during Fiscal 2025.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A loss of $3.8 million in Fiscal 2026 from the revaluation of digital assets and digital asset receivables received during the year from
	initial contribution in September 2025. No such loss occurred during Fiscal 2025.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A realized loss of $2.4 million in Fiscal 2026 on the sale of digital assets and the novation of digital asset receivables to the respective
	investors from initial purchase or contribution in September 2025. No such loss occurred during Fiscal 2025.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Interest expense, net was $1.0 million in Fiscal 2026, compared to $0.1 million in interest income in Fiscal 2025, an increase in expense
	of $1.1 million attributable to interest expense incurred on the BitGo credit facility entered into during Fiscal 2026 prior to its
	termination. There was no material change in interest income earned from Fiscal 2025 to Fiscal 2026.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A net gain on debt extinguishment of $0.3 million in Fiscal 2026 from the termination of the BitGo credit facility, consisting of $0.9
	million in interest forgiven as part of the termination, partially offset by the loan termination fee of $0.5 million and the derecognition
	of unamortized deferred financing costs of $0.1 million. No such gain occurred during Fiscal 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Other comprehensive loss was $0.0 million for Fiscal 2026 and Fiscal 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify"><b><i>Results of Operations for Fiscal 2025 Compared to Fiscal
2024</i></b></p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 40.5pt">We incurred a net loss of approximately $6.8
million during Fiscal 2025 compared to a net loss of approximately $75.4 million during Fiscal 2024, a decrease in net loss of $68.6 million,
year-over-year. Fiscal 2025 and 2024 include approximately ($0.2) million net non-cash gain and $60.9 million of net non-cash expenses,
respectively.</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 40.5pt">The components of the change in net loss and
total comprehensive loss are:</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 9pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">A net gain of $0.9 million from the settlement and release of obligations and liabilities
        under the Master Services Agreement between iOx and Parexel International (IRL) Limited (&#8220;Parexel&#8221;). See &#8220;iOx &#8211;
        Parexel Master Services Agreement&#8221; section of Note 13, &#8220;Commitments and Contingent Liabilities&#8221; for additional discussion
        regarding this matter included elsewhere in this Report.</td></tr>
  </table>

<p style="margin: 0pt 4pt 0pt 45pt; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 9pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">A $0.4 million non-cash loss from the change in the fair value of certain warrants accounted
        for as liabilities issued in connection with such equity offering in October 2023.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 9pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">Operating expenses, which include R&amp;D and G&amp;A expenses, were $7.4 million in Fiscal
        2025, compared to $18.2 million in Fiscal 2024, a decrease of $10.8 million, which is discussed more fully below. Operating expenses include
        $0.3 million and $2.6 million of non-cash share-based compensation expense in Fiscal 2025 and Fiscal 2024, respectively.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 9pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">A non-cash loss on impairment of $82.5 million comprised of 1) $57.9 million with respect
        to iOx in-process research and development (&#8220;IPR&amp;D&#8221;) , 2) $23.6 million with respect to the Tarus IPR&amp;D and 3) $1.0
        million with respect to our investment in Stimunity in Fiscal 2024. This represents a full impairment of the iOx and Tarus IPR&amp;D and
        our investment in Stimunity.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 9pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">A $0.8 million commitment fee expense related to the decision not to utilize the Committed
        Purchase Agreement in Fiscal 2024. There was no such fee in Fiscal 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 9pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">A $0.7 million gain recognized on the sale of Intensity Therapeutics, Inc. (&#8220;Intensity&#8221;)
        shares during Fiscal 2024. There was no such sale in Fiscal 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 9pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; padding-right: 4pt">Additionally, we reflected a non-cash net deferred income tax benefit of $3,000 in Fiscal
        2025, compared to a non-cash net deferred income tax benefit of $10.5 million in Fiscal 2024, a year-over-year change of $10.5 million
        reflecting the reduction of deferred tax liability due to the full impairment of the IPR&amp;D for iOx in Fiscal 2024.</td></tr>
  </table>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 4pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 40.5pt">Total comprehensive loss in Fiscal 2025 was
$6.8 million, compared to $75.4 million in Fiscal 2024, a decrease in total comprehensive loss of $68.6 million. There was no difference
between net loss and total comprehensive loss in Fiscal 2025. The difference between net loss and total comprehensive loss in Fiscal 2024
was entirely due to the recognition of the net change in fair value of an investment of $0.038 million originally in OCI during the fiscal
year.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Operating Expenses</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Total operating expenses for the last three completed fiscal years are as
follows (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 55%; font-size: 10pt; text-align: left">Research and development</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,801</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">3,129</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">12,535</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">General and administrative expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">20,199</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4,254</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5,664</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Depreciation expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">193</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">35</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">54</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total operating expenses</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">23,193</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,418</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">18,253</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Research and Development Expenses</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">R&amp;D costs decreased by approximately $0.3 million, or approximately
10%, from approximately $3.1 million in Fiscal 2025 to approximately $2.8 million in Fiscal 2026. The decrease was primarily attributable
to the decrease in clinical research and development expense, which decreased by approximately $0.7 million, from $1.8 million in Fiscal
2025 to $1.1 million in Fiscal 2026, as the Company continued its winddown of its research activities. R&amp;D non-cash share-based compensation
expense increased from $0 in Fiscal 2025 to $0.2 million in Fiscal 2026. Payroll-related expenses decreased by $0.2 million, from $0.7
million in Fiscal 2025 to $0.5 million in Fiscal 2026, due to the resignation of certain research employees during Fiscal 2026. Research
and development services and storage fees increased by approximately $0.7 million in Fiscal 2026 compared to Fiscal 2025 due to costs
incurred to conclude certain of the Company&#8217;s wound down clinical trials. Finally, consulting and manufacturing fees decreased by
approximately less than $0.1 million and less than $0.1 million, respectively, in Fiscal 2026 relative to Fiscal 2025 as the Company continued
its winddown of its research activities.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2025</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">R&amp;D expenses decreased by approximately $9.4 million, or approximately
75%, from approximately $12.5 million in Fiscal 2024, to approximately $3.1 million in Fiscal 2025. The decrease was primarily attributable
to clinical trial costs (principally CRO-related), which decreased by approximately $3.4 million, from $5.2 million in Fiscal 2024 to
$1.8 million in Fiscal 2025, due to the decision to pause enrollment in our sponsored clinical trials in the third and fourth quarters
of Fiscal 2024. Manufacturing-related costs decreased by $1.6 million from $1.8 million in Fiscal 2024, compared to $0.2 million in Fiscal
2025, related to the iNKT and adenosine clinical trials. During Fiscal 2024, we deprioritized development of the iNKT program and closed
the related clinical trial. In August 2024, we temporarily paused enrollment in the PORT-6 arm of the study. Enrollment resumed in March
2025 with the initiation of the final dose escalation cohort. Non-cash share-based compensation expense allocable to R&amp;D decreased
by $1.4 million, from $1.4 million in Fiscal 2024, compared to nil in Fiscal 2025, as the relevant share options fully vested by Fiscal
2024 and no new share option awards were allocable to R&amp;D during Fiscal 2025. Payroll-related expenses decreased by $0.9 million from
$1.6 million in Fiscal 2024 to $0.7 million in Fiscal 2025; the decrease in salaries was primarily due to reduced headcount. R&amp;D services
decreased by $0.5 million due to the pause of medical writing, analysis, and clinical studies at the beginning of Fiscal 2025. Scientific
consulting fees decreased by approximately $0.6 million from $0.8 million in Fiscal 2024 to $0.2 million in Fiscal 2025 to reflect the
decrease in activity year-over-year. Additionally, in Fiscal 2024, we incurred a one-time milestone payment of $0.5 million for dosing
our first adenosine patients, and finally, $0.5 million in fees paid with respect to the transition of the iNKT study prior to discontinuing
the study in Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2024</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">R&amp;D costs increased by approximately $3.8 million, or approximately
44%, from approximately $8.7 million in Fiscal 2023, to approximately $12.5 million in Fiscal 2024. The increase was primarily attributable
to clinical trial costs (principally CRO-related), which increased by approximately $2.5 million, from $2.7 million in Fiscal 2023 to
$5.2 million in Fiscal 2024, as activities ramped up throughout the period until we made the decision to pause enrollment in our sponsored
clinical trials in the third and fourth quarters of Fiscal 2024. Manufacturing-related costs increased by $1.0 million from $0.8 million
in Fiscal 2023, compared to $1.8 million in Fiscal 2024, related to the iNKT and adenosine clinical trials. Payroll-related expenses decreased
by $0.3 million from $1.9 million in Fiscal 2023 to $1.6 million in Fiscal 2024; the increases in salaries effective January 2023 were
more than offset by the fact that no annual bonuses were incurred in Fiscal 2024. R&amp;D non-cash share-based compensation expense decreased
by $0.8 million, from $2.2 million in Fiscal 2023, compared to $1.4 million in Fiscal 2024. This decrease was due to the continued vesting
of options granted in prior years, as well as recent grants having a lower grant date fair value. Additionally, in Fiscal 2024, we incurred
a milestone payment of $0.5 million for dosing our first adenosine patients, an increase in consulting fees of approximately $0.4 million
from $0.4 million in Fiscal 2023 to $0.8 million in Fiscal 2024 to reflect the increase in activity year-over-year, and, finally, $0.5
million in fees paid with respect to the transition of the iNKT study prior to discontinuing the study in Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>General and Administrative Expenses</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">G&amp;A expenses increased by approximately $15.9 million, or approximately
375%, from approximately $4.3 million in Fiscal 2025 to approximately $20.2 million in Fiscal 2026. Professional fees increased by $8.3
million, from $1.6 million in Fiscal 2025 to $9.9 million in Fiscal 2026, primarily related to $6.0 million and $2.3 million in legal
and marketing fees, respectively, in Fiscal 2026 associated with the Company&#8217;s capital raising efforts not incurred in Fiscal 2025.
Payroll-related expenses increased by $1.0 million from $1.3 million in Fiscal 2025 to $2.2 million in Fiscal 2026 primarily as a result
of increased headcount beginning in September 2025 as the Company executed on its strategic shift into the cryptocurrency industry and
roles and responsibilities shifting from the previous management team to the current management team, partially offset by lower headcount
in the first quarter of Fiscal 2026 as much of the Company&#8217;s operations had wound down. Additionally, G&amp;A non-cash share-based
compensation expense increased by $1.2 million due to share grants issued in Fiscal 2026 which became fully vested once granted. Office
and general expenses and consulting fees increased by $2.9 million and $2.4 million in Fiscal 2026, compared to Fiscal 2025, as spend
on consulting, corporate communications, and travel increased associated with the Company&#8217;s capital raising efforts. Additionally,
directors&#8217; fees increased by less than $0.1 million in Fiscal 2026, compared to Fiscal 2025, as all directors, except for two directors
who resigned in April 2024, waived their fees in Fiscal 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2025</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">G&amp;A expenses decreased by approximately $1.4 million, or approximately
24.9%, from approximately $5.7 million in Fiscal 2024, to approximately $4.3 million in Fiscal 2025. The decreases are attributable to
decreases in: non-cash share-based compensation expense allocable to G&amp;A expenses by $0.9 million, from $1.2 million in Fiscal 2024
to $0.3 million in Fiscal 2025, primarily due to the vesting of certain share options granted in prior years fully vesting by Fiscal 2024
and lower fair value associated with more recent grants; professional fees by $0.7 million, from $2.3 million in Fiscal 2024, compared
to $1.6 million in Fiscal 2025, primarily due to decline in public relations and accounting services related expenses; directors&#8217;
fees by $0.1 million, from $0.3 million in Fiscal 2024, compared to $0.2 million Fiscal 2025 due to the adoption of a new director compensation
policy in March 2025; and general office related supplies and expenses by $0.1 million, from $0.2 million in Fiscal 2024, compared to
$0.1 million in Fiscal 2025. These decreases were offset to some extent by an increase in payroll-related and consulting expenses by $0.4
million from $0.9 million in Fiscal 2024 to $1.3 million in Fiscal 2025 primarily attributable to $0.2 million in retention payments to
an employee and a consultant included in payroll expenses allocable to general and administrative expenses.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2024</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">G&amp;A expenses decreased by approximately $2.2 million, or approximately
28%, from approximately $7.9 million in Fiscal 2023, to approximately $5.7 million in Fiscal 2024. Professional fees decreased by $0.7
million, to $2.3 million in Fiscal 2024, compared to $3.0 million in Fiscal 2023, primarily attributable to legal fees associated with
the Tarus acquisition and other regulatory filings in Fiscal 2023. Additionally, G&amp;A non-cash share-based compensation expense decreased
by $0.8 million, from $2.0 million in Fiscal 2023 to $1.2 million in Fiscal 2024. This decrease of $0.8 million in G&amp;A non-cash share-based
compensation expense was attributable to the vesting of certain share options granted in prior years and lower fair value associated with
more recent grants. Insurance expense decreased by $0.5 million from $1.2 million in Fiscal 2023 to $0.7 million in Fiscal 2024, due to
the decrease in the D&amp;O premium year-over-year resulting from changes in the insurance markets. Directors&#8217; fees decreased by
$0.1 million in Fiscal 2024, compared to Fiscal 2023 as certain directors waived their fees in the quarter ended March 31, 2024. Finally,
payroll-related expenses decreased by $0.1 million from $1.0 million in Fiscal 2023 to $0.9 million in Fiscal 2024; the increase in annual
salaries effectuated in January 2023 was slightly more than offset by the fact that there were no annual bonuses incurred in Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Depreciation Expense</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Depreciation expense increased by approximately $0.2 million, or approximately
451%, from less than $0.1 million in Fiscal 2025, to approximately $0.2 million in Fiscal 2026 primarily due to depreciation expense on
GPUs purchased in Fiscal 2026. During Fiscal 2025, the Company did not own GPUs.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2025</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Depreciation expense decreased by less than $0.1 million, or approximately
35%, from $0.1 million in Fiscal 2024, to less than $0.1 million in Fiscal 2025 primarily due to the exit of the Company&#8217;s office
space lease during Fiscal 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2024</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Depreciation expense increased by $0.1 million, or approximately 540%, from
$0.0 million in Fiscal 2023, to $0.1 million in Fiscal 2024 primarily due to depreciation on the Company&#8217;s office space lease entered
into during Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(B)&#8239; LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Capital Resources</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 29, 2025, the Company completed the sale of 524,390 ordinary
shares for aggregate proceeds of $2,150,000, at a per share price of $4.10, the closing price of a share on Nasdaq on the date preceding
the date of the securities purchase agreement. The shares were sold to two directors of the Company, Messrs. Gregory Bailey and James
Mellon. The shares were sold in a private placement transaction pursuant to Regulation S, and were issued as restricted shares. The proceeds
are being used for general corporate purposes and working capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On May 5, 2025 we filed a shelf registration statement with the SEC in order
to sell ordinary shares, warrants and units in one or more offerings from time to time, which became effective on May 14, 2025 (&#8220;May
2025 Registration Statement&#8221;). In connection with the May 2025 Registration Statement, we have filed with the SEC:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>a base prospectus, which covered the offering, issuance and sale by us of up to $40 million in the aggregate of the securities identified
        above from time to time in one or more offerings; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>a prospectus supplement, which covered the offer, issuance and sale by us in our ATM offering of up to a maximum aggregate offering price
        of $3,377,250 of our ordinary shares that may be issued and sold from time to time under the At the Market Offering Agreement, dated June
        27, 2025 (the &#8220;June 2025 Sales Agreement&#8221;), with Rodman &amp; Renshaw LLC the sales agent (&#8220;Rodman&#8221;).</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>a prospectus supplement, which covered the offer, issuance and sale by us in our ATM offering of up to a maximum aggregate offering price
        of $2,841,450 of our ordinary shares that may be issued and sold from time to time under the At the Market Offering Agreement, dated September
        3, 2025 (the &#8220;September 2025 Sales Agreement&#8221;), with Chardan Capital Markets, LLC the sales agent (&#8220;Chardan&#8221;).</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>a prospectus supplement, which covered the offer, issuance and sale by us in our ATM offering of up to a maximum aggregate offering price
        of $18,473,482 of our ordinary shares that may be issued and sold from time to time under the At the Market Offering Agreement, dated
        October 8, 2025 (the &#8220;October 2025 Sales Agreement&#8221;), with Chardan the sales agent.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>a prospectus supplement, which covered the offer, issuance and sale by us in our ATM offering of up to a maximum aggregate offering price
        of $15,307,818 of our ordinary shares that may be issued and sold from time to time under the At the Market Offering Agreement, dated
        November 25, 2025 (the &#8220;November 2025 Sales Agreement&#8221;), with Chardan the sales agent.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 25, 2025, the Company completed the sale of 3,415,780 ordinary
shares at a per share price of $5.73&#160;&#160;, and pre-funded warrants to purchase 3,258,466 ordinary shares at a purchase price of
$5.73 per ordinary shares (less $0.001 per pre-funded warrant) for aggregate proceeds of approximately $34.5 million, consisting of cash
of $3.3 million and digital assets of $32.9 million. Each pre-funded warrant is exercisable for one ordinary share at an exercise price
of $0.001 per pre-funded warrant, is immediately exercisable and will expire once exercised in full. The shares and pre-funded warrants
were sold in a private placement transaction in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule
506 promulgated under the Securities Act, and the proceeds are being used for the establishment of the Company&#8217;s digital asset treasury.
160,000 ordinary shares were issued to the Company&#8217;s third-party asset manager as consideration for continued services to be provided
to the Company. The shares had a three-year vesting term and are subject to forfeiture in the event the agreement with the asset manager
is terminated under certain circumstances&#160;&#160;. The asset management agreement was subsequently terminated in December 2025 and
the shares granted, which had not vested, were forfeited. The shares were sold in a private placement transaction in reliance on the exemptions
provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated under the Securities Act, and were issued as restricted shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During the fiscal year ended March 31, 2026, the Company sold 4,062,632
ordinary shares under the ATM program, generating net proceeds of approximately $12.0 million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 3, 2025, the Company filed a shelf registration statement with
the SEC in order to sell up to $420,690,000 of ordinary shares, debt securities, warrants and units in one or more offerings from time
to time, which became effective on December 11, 2025 ( the &#8220;December 2025 Registration Statement&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 13, 2026, the Company entered into a securities purchase agreement
with certain purchasers, pursuant to which the Company offered for sale to the Purchasers in a registered direct offering an aggregate
of 5,230,000 ordinary shares and, in lieu thereof, pre-funded warrants to purchase up to 9,770,000 ordinary shares. The net proceeds from
the Offering were approximately $12.5 million. &#160;&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of July 13, 2026, the Company had approximately $10.3 million of cash
and cash equivalents on hand, which the Company expects may not be sufficient to fund its operating needs through FYE in March 2027. The
Company projects cash flow needs of approximately $25.0 million between now and FYE 2027, exceeding cash and cash equivalents on hand.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Contractual Obligations and Commitments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><i>iOx &#8211; Parexel Master Services Agreement</i></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Effective March 15, 2022, iOx, a wholly-owned subsidiary of the Company,
entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Parexel under which Parexel agreed to act as a clinical service
provider (&#8220;CRO&#8221;) pursuant to a work order (&#8220;Work Order&#8221;) effective June 1, 2022. Under such Work Order, Parexel
planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer. The MSA provided for a five-year
term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided for service fees
and pass-through expenses and clinical sites totaling $11.5 million. During the year ended March 31, 2023 (&#8220;Fiscal 2023&#8221;),
the Company executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs. As a result of the
Company&#8217;s decision to discontinue the development with respect to this program, on December 20, 2023, the Company provided Parexel
notice of termination of the contract, with a planned termination date of April 18, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As the ongoing CRO services were wound down, the Company noticed that expenses
incurred under the CRO agreement were higher than originally budgeted. Parexel agreed to refund the Company $0.552 million and release
the liability for amounts invoiced and unbilled services totaling $1.486 million, and the Company forfeited advanced payments of $1.091
million. As a result, the Company recognized a net gain of $0.946 million as of September 30, 2024. The Company received the refund from
Parexel on October 3, 2024. As of March 31, 2024, the Company reflected $1.414 million of payables to Parexel in accounts payable and
accrued liabilities and $1.277 million in prepaid expenses and other receivables in the consolidated statement of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>Vertical Data Server Purchase Agreement</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On January 5, 2026, the Company signed an agreement
with Vertical Data Inc. to acquire 72 Dell XE9780-B300 Servers containing a total of 576 GPUs along with associated required networking
equipment, at a total cost of $40.9 million. On the same day a deposit of $2.0 million was made, with additional deposits made in January
and February 2026 of $6.0 million for a total of $8.6 million in deposits made in order to hold the allocation of servers. The remaining
cost of the acquisition will be funded via a GPU equipment financing lender. The anticipated asset-backed loan will be non-recourse to
the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>Buzz HPC GPU Lease</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026 he Company entered into a GPU infrastructure services
agreement with Buzz Performance Cloud Inc. pursuant to which the Company secured rights to access 504 NVIDIA B200 GPUs for a 24-month
term. The arrangement contemplates aggregate contractual payments of approximately $29.6 million over the contract term and requires a
security deposit of $2.6 million, which was paid on February 13, 2026. As of March 31, 2026, no liability was yet recorded as the services
did not commence until early June.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>atNorth Colocation Lease Payments</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 11, 2025 the Company signed an enterprise colocation service
agreement (the &#8220;Colo Agreement&#8221;) with atNorth AB (&#8220;atNorth&#8221;) to deploy the Company&#8217;s GPU hardware to atNorth&#8217;s
data center located in Kista, Sweden. The Colo Agreement consists of two data halls with a Phase I deployment of 1,213 kW of power and
a Phase II of 1,017 kW of power, with Phase II being structured as a Right of First Refusal (the &#8220;ROFR&#8221;). The agreement&#8217;s
commencement date was April 1, 2026, and extends for 60 months after which it automatically extends for successive 12 month periods unless
6 months&#8217; notice is provided by either party. On April 10, 2026, the Company paid a 982,368 EUR deposit to secure Phase I of the
agreement. As of the date of the issuance of these consolidated financial statements, the ROFR for Phase II of the deployment has expired,
although atNorth is still being considered for a further deployment once ready.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The monthly colocation fee for Phase I that has commenced is 163,728 EUR
plus variable electricity costs estimated at 0.126 EUR/kWh.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><i>GaMee Acquisition Token Buyback</i></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#8220;SPA&#8221;) with Animoca Brands Limited (&#8220;Animoca Brands&#8221;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#8220;GaMee Global&#8221;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#8220;GaMee Transaction&#8221;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. The SPA
contains a post-closing item requiring the Company to, within ninety (90) days after close, acquire from the open market $2 million worth
of GMEE tokens. GMEE is the native utility token of the GaMee gaming platform and ecosystem. The GaMee Transaction closed on May 27, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><i>Tarus &#8211; Fortrea Clinical Service Agreement</i></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 1, 2023, Tarus entered into a clinical service agreement with Fortrea
Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier of August 14, 2025
or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services to be provided
are approximately $12.1 million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In March 2025, the Company resumed patient enrollment
into the final cohort arm of TT-10 (PORT-6) as part of the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following a prior pause due
to funding constraints. This decision reflects the favorable safety and preliminary activity signals observed in earlier dose cohorts.
In April 2025, we announced confirmatory preclinical results in mesothelioma with our TT-4 (PORT-7) compound, supporting advancement of
this indication in its first-inhuman trial of TT-4 (PORT-7) which is expected to commence in the quarter ending March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On May 31, 2026, Cyncado and ADDRI executed a definitive Clinical Trial
Research Agreement establishing the terms of the study. The trial is expected to enroll approximately 50 patients across multiple clinical
sites, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado's planned U.S. mesothelioma
activities. Under the agreement, Cyncado will supply TT-4 and provide limited support as part of an international mesothelioma program.
The trial remains subject to customary regulatory and ethics approvals and site activation before enrollment begins.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Going Concern </i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The accompanying consolidated financial statements for the fiscal year ended
March 31, 2026 have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity
of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly,
the accompanying consolidated financial statements for the fiscal year ended March 31, 2026 do not include any adjustments relating to
the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, the Company had cash, cash equivalents, and restricted
cash of approximately $0.7 million and total current liabilities of approximately $12.7 million. For the year ended March 31, 2026, the
Company reported a net loss of approximately $38.6 million and cash used in operating activities of approximately $18.5 million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In late Fiscal 2024, due to continued liquidity constraints, the Company
discontinued further clinical development of its sponsored iNKT trial and paused further patient accrual to its sponsored adenosine program
for both PORT-6 and PORT-7. During the Fiscal 2026, the Company transitioned its operating strategy away from biotechnology and toward
AI infrastructure, digital assets and the Telegram ecosystem. In connection with this strategy transition, the Company received funding
via a private placement in the form of both cash and digital assets. While this and subsequent equity raises, including a registered direct
offering on January 13, 2026, are a positive factor, the Company is continuing to explore financing options, including its ATM equity
program and other financings.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Despite the Company successfully raising capital via a private placement
of shares and a registered direct offering in September 2025 and January 2026 and successfully raising additional funds through its ATM
program, the Company&#8217;s cash and cash equivalents balance is decreasing, and the Company did not generate positive cash flows from
operations for Fiscal 2025 and 2026. Additionally, a portion of the Company&#8217;s digital asset holdings is subject to significant price
fluctuations and certain restrictions and therefore may not be relied upon to fund current obligations as they come due. These factors
raise significant doubt about the Company&#8217;s ability to continue as a going concern within one year after the date issuance of the
Company&#8217;s audited consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has incurred significant operating losses since inception and
expects to continue to incur significant operating losses for the foreseeable future as it invests in the buildout of its AI infrastructure
business. Historically, the Company has funded its operations primarily using the proceeds from the sale of its equity and debt securities.
The Company expects that it will require significant additional capital to fund its operations and execute its business strategy, beyond
the potential proceeds that could be reasonably generated from its ATM program. The Company&#8217;s ability to successfully raise sufficient
capital on acceptable terms, or at all, is subject to numerous risks and uncertainties. Future equity financings may be dilutive to existing
shareholders and any future debt financings may contain restrictive covenants that limit the Company&#8217;s operations or ability to
enter into certain transactions. See Note 17, &#8220;Capital Stock and Reserves,&#8221; for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of July 13, 2026, the Company had approximately $10.3 million of cash
and cash equivalents. Based on its current operating plan, the Company believes that its existing cash resources may not be sufficient
to fund its operations for at least the next 12 months from the date of issuance of its audited consolidated financial statements. Accordingly,
these conditions and events raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after
the date of the issuance of its audited consolidated financial statements. The accompanying consolidated financial statements have been
prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome
of this uncertainty.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Operating Cash Flow</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2026, we used cash of $20.5 million to fund operating activities,
compared to $5.5 million used during Fiscal 2025. The increase in cash used of $15.0 million year over year is primarily due to an increase
in general and administrative spend in the amount of $15.9 million during Fiscal 2026 as the Company works to fundraise and grow its operations,
partially offset by our decision to discontinue and pause further patient accrual in the respective clinical programs in the latter half
of Fiscal 2025, which resulted in a decrease in research and development costs of $0.3 million for Fiscal 2026 relative to Fiscal 2025.
Further, the Company generated $0.1 million in cash from GPU revenues for Fiscal 2026, relative to nil for Fiscal 2026, with the remaining
fluctuation attributable to changes in working capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2025</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2025, we used cash of $5.5 million to fund operating activities,
which was consistent with the decision to pause running clinical programs in the last half of Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2024</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2024, we used cash of $14.3 million to fund operating activities,
which was consistent with running both clinical programs until the decisions were made in the last half of Fiscal 2024 to discontinue
and pause further accrual in the respective clinical programs.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Investing Cash Flows</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2026, we used $6.3 million in investing activities, primarily
consisting of purchases of GPUs and deposits for GPUs totaling $10.3 million. Additionally, the Company purchased $0.9 million of stablecoin
and digital assets, partially offset by proceeds from sales of stablecoin and digital assets of $5.0 million. Further, the Company paid
$0.1 million in legal fees to facilitate its investment in Compedica.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2025</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2025, we had no investing activities.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2024</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2024, we generated cash of $2.8 million from investing activities,
which reflected the proceeds from the sales of Intensity shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Financing Cash Flows</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2026, we generated net cash of $25.9 million from financing
activities, consisting of cash received of $3.3 million, $12.6 million, and $15.0 million through a private placement of shares, issuance
of shares under the ATM program, and an issuance of shares under a registered direct offering, respectively, reduced by share issuance
fees of $3.6 million. During Fiscal 2026, we had financing cash outflows of $0.4 million, $0.3 million, $0.3 million, and $0.5 million
attributable to the repayment of our lease liability for the Lisbon office space and a GPU lease, payment of deferred financing costs
to secure the Company&#8217;s credit facility with BitGo, cash repayments of the BitGo credit facility, and payment of the BitGo loan
termination fee, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2025</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2025, we generated $2.1 million in cash from financing activities,
which was primarily attributable to $2.15 million in proceeds from the sale of 524,390 ordinary shares to two of our directors in a private
placement transaction.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Fiscal 2024</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2024, we generated $6.0 million in cash from financing activities,
of which $5.3 million net proceeds related to the Registered Direct Offering and $0.7 million related to net proceeds from sales under
the ATM program.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(C) RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">From May 23, 2012 to date, we, through our operating subsidiaries, have
been engaged in general research and development and clinical and pre-clinical studies as detailed under Item 4 (B) &#8220;Business Overview&#8221;
of this Annual Report. Research and development expenses analysis and details are provided under Item 5 (A) &#8220;Operating Results&#8221;
of this Annual Report. All research and development expenses are expensed as they are incurred.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>iOx (iNKT) License</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 1, 2015, iOx entered into a licensing agreement with Ludwig Institute
for Cancer Research Ltd. (&#8220;LICR&#8221;), which covers certain technology, intellectual property and know-how and development with
respect to iNKT cell agonists to treat human diseases. Under the terms of the licensing agreement (&#8220;LICR License&#8221;), LICR granted
to iOx an exclusive worldwide license, with the right to grant sublicenses, under the Licensed Patent and Licensed Technology, each as
defined in the LICR License, in each case, to develop, make, have made, use, sell, offer for sale and import Licensed Products, as defined
in the LICR License, subject to certain rights retained by LICR for academic and research purposes. The LICR License provides for a royalty
term of ten years after the first commercial sale, on a Licensed Product by Licensed Product, country by country basis. Upon the expiration
of the applicable royalty term, the license with respect to such Licensed Product in such country will convert to a non-exclusive, fully
paid-up license.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">LICR is entitled to 15,000 GBP as an annual license fee on each annual anniversary
of the effective date of the LICR License until royalties become duly payable and 15,000 GBP as a patent reimbursement fee until LICR
has been fully reimbursed for all patent costs incurred prior to the LICR License.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Additionally, LICR is entitled to milestone payments totaling up to 20.45
million GBP based upon the first Licensed Product achieving specific clinical, regulatory and sales-based milestones. LICR is also entitled
to milestone payment totaling up to 10.25 million GBP based upon a second Licensed Product achieving specific clinical, regulatory and
sales-based milestones.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Finally, LICR is entitled to a low-single digit royalty on net sales of
Licensed Products that marginally escalates upon sales levels all determined by territory. LICR is also entitled to a percentage of any
sublicensing income that gradually decreases based on the stage of development of the most advanced Licensed Product that is the subject
of the applicable sublicense agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Pursuant to the terms and conditions of the LICR License, LICR is responsible
for managing the preparation, filing, prosecution and maintenance of all Licensed Patent Rights, as defined in the LICR License. iOx will
reimburse LICR for all reasonable patent costs it incurs after the effective date of the LICR License. Further, the LICR License provides
that both parties have the right to termination for material breach or default in the performance of obligations under the LICR License
by the other party and in the event of insolvency of the other party.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Tarus (adenosine) License</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 1, 2022, we acquired Tarus Therapeutics, Inc. Pursuant to the license
agreement entered into by Tarus Therapeutics, Inc. and Impetis Biosciences Limited (&#8220;Impetis&#8221;) dated October 29, 2019 (&#8220;Impetis
License&#8221;), Impetis granted to Tarus an exclusive sublicensable worldwide license to develop and commercialize the adenosine receptor
antagonists for all indications and certain other assets which were granted upon exercise of a call option on November 5, 2020.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the terms of the Impetis License, Impetis is eligible to receive payments
totaling up to $38 million on an Impetis Compound (as defined in the Impetis License) based upon achievement of certain clinical and commercial
milestones. Milestone payments due in the amount of $1 million for achievement of certain regulatory milestones were paid in July 2022
and a $0.5 million milestone was paid upon dosing the first patient in September 2023.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Additionally, commencing upon the First Commercial Sale (as defined in the
Impetis License) of a Licensed Product (as defined in the Impetis License), Impetis is entitled to royalties on worldwide net sales that
begin in the mid-single digits and escalate through multiple tiers, with net sales over $1 billion receiving low double digit royalties.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Pursuant to the terms and conditions of the Impetis License, Tarus has exclusive
and full authority to manage all intellectual property (whether licensed or not) underlying the assets covered by the Impetis License
and any other aspects related to exploitation, development and commercialization thereof at its own cost, and Impetis must provide Tarus
reasonable assistance as requested at Tarus&#8217; cost and expense. Further, the Impetis License provides that both parties have the
right to termination for material breach by the other party and in the event that the other party undergoes certain events such as a voluntary
winding-up, a liquidation or entry into receivership.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(D) &#8239;TREND INFORMATION</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There are no other trends, commitments, events or uncertainties presently
known to management that are reasonably expected to have a material effect on the Company's business, financial condition or results of
operation other than as disclosed elsewhere in this Annual Report (refer to the heading entitled "Risk Factors" under Item 3 (D)
and Item 4 (B) &#8220;Business Overview&#8221; and elsewhere in this Item 5).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(E) &#8239;&#8239;CRITICAL ACCOUNTING ESTIMATES</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions
to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Significant areas where estimates are made include valuation of certain
assets, liabilities, and expenses (including warrant liabilities, put right liabilities, digital assets including discounts for lack of
marketability and collectability, and measurement of share-based compensation). Significant areas where critical judgments are applied
include warrant liabilities, put right liabilities, and digital assets including discounts for lack of marketability.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following methods and assumptions were used to estimate the fair values
of the respective assets, liabilities, and expenses:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Put Right Liability</b>: The fair value is estimated using a Black-Scholes
model and in certain cases, a Monte Carlo simulation (Level 3) (see Note 12, &#8220;Put Right Liability and TON Payable&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Warrant Liability</b>: The Series B Warrants, the Series C Warrants and
the 2023 and 2026 Placement Agent Warrants include the obligation, in the event of a Fundamental Transaction, as defined in the Series
B Warrants, the Series C Warrants and the 2023 and 2026 Placement Agent Warrants, for the Company or the successor entity to purchase
the warrants from the holder at the discretion of the holder and at the Black-Scholes value, as defined in the warrant agreements. As
a result, management concluded that, in line with IFRS 9 and paragraphs16A and 16B of IAS 32, such warrants will be accounted for as financial
liabilities on the consolidated statement of financial position with the changes in fair value recognized in the consolidated statement
of operations and other comprehensive loss. See Note 11, &#8220;Warrant Liability&#8221; for further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Digital Assets and Discounts for Lack of Marketability</b>: The Company
values liquid digital assets using the quoted prices per liquid token in the Company&#8217;s primary market, which are Level 1 inputs.
The fair value of locked tokens is computed by taking the number of locked tokens and discounting the month-end spot price by an average
of 14.8%. The discount used by management is based on the historical purchases of locked TON management has made on behalf of the Company
and Monte Carlo simulation based on estimated volatility during the lockup period (Level 3 inputs). Management monitors this discount
percentage and adjusts when appropriate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Share-Based Compensation</b>: The Company determines the fair value of
share-based payments granted to directors, officers, employees and consultants using the Black-Scholes option-pricing model at the grant
date. Assumptions for the Black-Scholes model are expected volatility, expected term, the risk-free interest rate, and expected dividend
yield.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i6"></span>ITEM 6 &#8211; DIRECTORS, SENIOR
MANAGEMENT AND EMPLOYEES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(A) &#8239;DIRECTORS AND SENIOR MANAGEMENT</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following tables set forth certain information relating to our directors
and executive officers as of the date of this annual report.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Non-Employee Directors</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; background-color: white">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; background-color: white">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; background-color: white">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; background-color: white; text-align: center"><span style="font-size: 10pt"><b>Committee
        Membership</b></span></td></tr>
  <tr style="background-color: white">
    <td style="border-bottom: Black 1pt solid; width: 16%; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>State and Country of Residence</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 7%; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 14%; text-align: center"><span style="font-size: 10pt"><b>Director Since</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Audit</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 13%; text-align: center"><span style="font-size: 10pt"><b>Compensation</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Nominating</b></span></td></tr>
  <tr style="background-color: #CCECFF">
    <td><span style="font-size: 10pt">Michael Terpin</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">San Juan, Puerto Rico</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">September 25, 2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;Member</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Chair</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member</span></td></tr>
  <tr>
    <td><span style="font-size: 10pt">F. Daniel Siciliano</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">San Francisco, USA</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">February 5, 2026</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;Chair</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;Member</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Executive Officers</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td rowspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 16%; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td rowspan="2" style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center"><span style="font-size: 10pt"><b></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td rowspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td rowspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td rowspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Officer
        Since</b></span></td></tr>
  <tr style="background-color: white">
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>State and Country of Residence</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="background-color: #CCEEFF"><span style="font-size: 10pt">Brittany Kaiser</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-size: 10pt">San Juan, Puerto Rico, USA</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td style="white-space: nowrap; background-color: #CCEEFF; text-align: center"><span style="font-size: 10pt">38</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF">&#160;</td>
    <td style="white-space: nowrap; background-color: #CCECFF"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td style="white-space: nowrap; background-color: #CCECFF">&#160;</td>
    <td style="background-color: #CCECFF"><span style="font-size: 10pt">August 4, 2025</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-size: 10pt">Enzo Villani</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">San Francisco, USA</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">56</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Chief Investment Officer and Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">September 25, 2025</span></td></tr>
  <tr>
    <td style="background-color: #CCEEFF"><span style="font-size: 10pt">Liza Horowitz</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-size: 10pt">Toronto, Canada</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td style="white-space: nowrap; background-color: #CCEEFF; text-align: center"><span style="font-size: 10pt">57</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF">&#160;</td>
    <td style="white-space: nowrap; background-color: #CCECFF"><span style="font-size: 10pt">Chief Operating Officer</span></td>
    <td style="white-space: nowrap; background-color: #CCECFF">&#160;</td>
    <td style="background-color: #CCECFF"><span style="font-size: 10pt">June 1, 2026</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-size: 10pt">Wes Levitt</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Amsterdam, Netherlands</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">39</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">October 24, 2025</span></td></tr>
  <tr style="background-color: #CCECFF">
    <td><span style="font-size: 10pt">Yury Mitin</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Toronto, Canada</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; text-align: center">40</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Chief Business Development Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">September 25, 2025</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Biographical Information</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Brittany Kaiser</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Brittany Kaiser was previously Chair of the Board of Gryphon Digital Mining.
She is an entrepreneur, activist, and globally recognized expert in data protection and privacy. As Co-Founder of the Own Your Data Foundation,
she teaches digital literacy education and training to governments, corporates, and families. She is also a Co-Founder of the Digital
Asset Trade Association (DATA) for legal advocacy where she does legislative drafting and lobbying on privacy and blockchain laws. Ms.
Kaiser sits on the board of many companies across industries, working on data ethics, compliance, and privacy protocols. She is also the
primary subject of the Netflix Original documentary &#8220;The Great Hack&#8221; and the author of &#8220;Targeted,&#8221; published by
HarperCollins.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Enzo Villani</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Enzo Villani is a serial entrepreneur with twenty-year expertise as a chief
strategist to Fortune 500 companies, private equity firms, and venture capital. Enzo was co-founder of Nasdaq Corporate Solutions, co-founder
and Chief Strategy Officer of two strategic M&amp;A consolidations in the areas of investor relations, proxy solicitation, corporate governance
and financial technology. Mr. Villani was key in consolidating over ten service companies across 4 continents representing over 5,000
public companies and raising in excess of $500 million. In the blockchain industry, Mr. Villani was Chief Strategy Officer of Transform
Group. Transform Group represented the launch of over 37% of the alt-coin market capitalization by 2019. He is the co-founder of Blockchain
Wire and was the head of international strategy and innovation at OKEx. Mr. Villani holds an MBA from Cornell University Johnson School.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Michael Terpin</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Michael Terpin is founder and CEO of Transform Ventures, a leading blockchain
advisory and venture studio since 2013, working with hundreds of crypto projects in their earliest stages, including Augur, Bancor, Ethereum,
Gnosis, Mastercoin, Neo, Tether and WAX. CNBC called Terpin &#8220;the godfather of crypto&#8221; for his long history of launching and
advising iconic crypto projects. His first book, Bitcoin Supercycle, was published by Skyhorse Publishing and distributed by Simon &amp;
Schuster in November 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Mr. Terpin also co-founded BitAngels, the world&#8217;s first angel network
for digital currency startups, in May, 2013, which has expanded to 25 city chapters. His venture studio incubated Blockchain Wire and
blockchain-based sustainability platform, OpenCarbon. A prolific angel investor, he is also a general partner at digital asset fund managers
Alpha Transform Holdings and Tradecraft Capital; senior advisor and LP at Alphabit Fund and LP at four other crypto funds. He also co-founded
and profitably exited the Dapps Fund, one of the first cryptocurrency venture funds, in March 2014.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>F. Daniel Siciliano</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">F. Daniel Siciliano is a successful technology entrepreneur, an independent
director on the board of the Federal Home Loan Bank of San Francisco, and a recognized expert in corporate strategy and governance, capital
financial markets, technological disruption (including fintech, AI and cybersecurity), and executive compensation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">From 2000 to 2015, Mr. Siciliano was co-founder, CEO and ultimately Executive
Chairman of LawLogix Group, Inc., a global software technology company. Mr. Siciliano is a Fellow at Stanford Law School (CodeX), Emeritus
Co-Director of Stanford&#8217;s Directors&#8217; College, prior Co-Chair of the We Robot Conference on AI/Robotics, Law, and Policy, and
is a past faculty director of the Rock Center for Corporate Governance at Stanford University.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Liza Horowitz</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt">Liza Horowitz is the Chief Operating Officer of Alpha Compute Corp. Ms. Horowitz has more than
25 years of leadership experience in wealth management, sustainability, and digital infrastructure. Ms. Horowitz spent nearly a decade
at ScotiaMcLeod, the wealth management division of Scotiabank, where she oversaw branch operations, regulatory compliance, and growth
of the wealth management practice. She subsequently spent nearly a decade in the sustainability sector, working with public and private
organizations on ESG strategy, sustainability reporting, carbon disclosure, and sustainable infrastructure initiatives.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Ms. Horowitz was a Director at Input Output Global (IOG), the core developer of the Cardano
blockchain, supporting marketing and finance initiatives across research and engineering teams. Ms. Horowitz received a Master of Science
in Environmental Studies from Green Mountain College.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Wes Levitt</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Wes Levitt previously served as Chief Investment Officer of Alpha Sigma
Capital, overseeing portfolio management and new investments in digital assets and blockchain startups. Mr. Levitt also served as Head
of Strategy at Theta Labs, a blockchain software development company, and as CFO of Blockchain Moon Acquisition Corp. Mr. Levitt spent
8 years in investment roles in real estate, first at Redwood Trust as an originator of commercial real estate loans for CMBS securitization,
then more recently at Mosser Capital as an asset manager of institutional real estate portfolios. He holds a BS in Economics from the
University of Oregon and an MBA from UC Berkeley Haas School of Business, and is a CFA Charterholder.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Yury Mitin</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Yury Mitin serves as Chief Business Development Officer (CBDO) at Alpha
Compute. He is also the Managing Partner at RSV Capital, a Canadian-based global investment firm specializing in late-stage investments
in high-growth technology enterprises. With over 18 years of institutional experience spanning venture capital and technology entrepreneurship,
Mr. Mitin focuses on identifying and scaling transformative businesses across high-growth verticals, including FinTech, Web3/Digital Assets,
EdTech, and Artificial Intelligence (AI).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Over the course of his career, Mr. Mitin has directed more than $200 million
in venture capital allocations and secondary market transactions, overseeing investments in category-defining companies such as Udemy,
eToro, Upgrade, Robinhood, MasterClass, and Groq. He holds a Ph.D. in Innovation and Entrepreneurship, an Executive MBA from the Skolkovo
Business School, and has completed executive education programs at Harvard Business School, the UC Berkeley Haas School of Business, and
the Ivey Business School.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b></b></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Family Relationships</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There are no family relationships between or among the directors and executive
officers.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Other Relationships</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There are no arrangements or understandings between or among any major shareholder,
customer, supplier or others, pursuant to which any of the above-named persons were selected as directors or as members of senior management.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(B) &#8239;COMPENSATION</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><b>1.</b></td>
    <td><b>General</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Board adopted and approved, effective as of March 6, 2026, a non-executive
director compensation policy (&#8220;Non-Executive Director Compensation Policy&#8221;), which replaced the previous plan approved in
March 2025. Under the new policy, each non-executive director of the Company is entitled to an annual cash retainer of $75,000, to be
paid in arrears, as well as an annual cash retainer of $10,000 for service as a member, or $20,000 for service as the Chair, of each of
the Audit, Compensation or Nominating and Corporate Governance Committees. Upon election to the Board, each non-executive director will
receive a grant of restricted share units (&#8220;RSUs&#8221;) equal to $150,000 in value based on the Company&#8217;s closing share price
on the grant date, and thereafter, on each anniversary of the director&#8217;s commencement of service, an annual RSU grant equal to $100,000
in value. The initial RSU award vests in equal quarterly installments over a four-year period from grant date, subject to a one-year cliff
and the director&#8217;s continued service through each applicable vesting date. Annual RSU awards likewise vest in equal quarterly installments
over a four-year period, subject to the director&#8217;s continued service through each applicable vesting date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company does not have any plans that provide for pensions, retirement
or similar benefits.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><b>2.</b></td>
    <td><b>Statement of Director and Executive Compensation</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following tables and accompanying notes set forth all compensation paid
or payable by the Company to its directors and senior management for the fiscal years ended March 31, 2026, 2025, and 2024. The share
information is adjusted to give effect to the 1-for-20 reverse share split completed on August 15, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>2. Statement of Director and Executive Compensation <i>(Cont&#8217;d)</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name &amp; Principal Position</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Year</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Fee and</p>
        <p style="margin-top: 0; margin-bottom: 0">Salary<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Transaction</p>
        <p style="margin-top: 0; margin-bottom: 0">Closing Bonus<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Securities Under</p>
        <p style="margin-top: 0; margin-bottom: 0">Options Granted</p></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Shares
        or Units<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(16)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Other<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total
        Compensation</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Michael Terpin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">61,250</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">61,250</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">F. Daniel Siciliano</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">17,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">17,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Gregory H. Bailey, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">55,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">49,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">49,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">James Mellon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">55,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">35,242</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">35,242</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Steven Mintz<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">77,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">54,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">157,296</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">113,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">143,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">45,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">45,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Jean-Christophe Renondin, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">54,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">109,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">96,992</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">126,992</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Justin Stebbing, M.D. PhD<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">64,760</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">119,760</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">121,240</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">151,240</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Linda Kozick<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">42,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">42,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Mark Simon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">55,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">55,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Robert Glassman<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">45,258</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">45,258</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>2. Statement of Director and Executive Compensation <i>(Cont&#8217;d)</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name &amp; Principal Position</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Year</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Fee and</p>
        <p style="margin-top: 0; margin-bottom: 0">Salary<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Transaction</p>
        <p style="margin-top: 0; margin-bottom: 0">Closing Bonus<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Securities Under</p>
        <p style="margin-top: 0; margin-bottom: 0">Options Granted</p></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Shares
        or Units<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(16)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Other<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total
        Compensation</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Executive Officers</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Brittany Kaiser</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Chief Executive Officer and Director</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">661,290</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">500,000</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">218,219</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">149,015</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">187,102</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">1,715,627</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Enzo Villani</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Investment Officer and Director</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">369,355</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">500,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">218,219</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">248,359</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,335,933</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Wes Levitt</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">219,086</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">219,086</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Yury Mitin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Business Development Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">369,355</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">500,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">218,219</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">99,344</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,186,918</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Alexander Pickett<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(10)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Executive Officer and Director</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">51,250</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">234,132</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">39.6</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">310,422</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">145,488</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">175,488</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Ian Walters<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(11)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Executive Officer and Chairman of the Board</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">152,383</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">152,383</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">453,186</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">54,716</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">507,902</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">642,700</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">75,185</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">717,885</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Andrea Park<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(12)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">218,429</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">50,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">39,857</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">308,286</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">163,790</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">113,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">28,659</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">305,607</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Allan Shaw<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(13)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer and Secretary</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">234,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">234,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">469,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">49,205</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">518,205</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Robert Kramer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Scientific Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">112,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">119,250</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">168,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">17,141</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">185,891</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Brian Wiley<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(14)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Business Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">114,844</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">8,627</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">123,471</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">153,125</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,297</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">155,422</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Justin Fairchild<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(15)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Vice President of Development</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">20,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">20,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">270,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">55,301</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">325,301</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>2. Statement of Director and Executive Compensation <i>(Cont&#8217;d)</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Notes</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(1)</td>
    <td>Represents base salary earned by executive officers in accordance with their respective contractor agreements and director&#8217;s fees
        earned by directors. For Brittany Kaiser, Enzo Villani, Yury Mitin, and Wes Levitt, their base salary is comprised of equal portions payable
        in USD and TON tokens. The figures in the table represent the sum of both. To date, these executives&#8217; USD portions of their salaries
        have been paid monthly, while the TON portions have been accrued by the Company.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(2)</td>
    <td>Dr. Bailey, Mr. Mellon, Mr. Mintz and Ms. Kozick waived their directors&#8217; fees with respect to the three months ended March 31, 2024.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(3)</td>
    <td>The contractor agreements for executives Brittany Kaiser, Enzo Villani, and Yury Mitin each provided for bonuses consisting of $250,000
        in cash and $250,000 worth of TON tokens, payable upon the Company raising at least $50 million in equity financing through private or
        public share offerings. This milestone was achieved on January 14, 2026, upon the closing of a $15 million registered direct share offering,
        which, together with prior equity financings, resulted in aggregate equity financing proceeds in excess of $50 million. During Fiscal
        2026, the Company paid the cash portion of the bonus to each executive and accrued the TON token portion of each executive&#8217;s bonus.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(4)</td>
    <td>Represents employee benefits paid by the Company.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(5)</td>
    <td>Represents the aggregate grant date fair value of 14,600 options to purchase ordinary shares granted on March 30, 2023, which vested on
        the first anniversary of the date of grant.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(6)</td>
    <td>Represents the aggregate grant date fair value of options to purchase ordinary shares granted on March 7, 2025, which one-quarter vested
        immediately, one-quarter vested on March 7, 2026, and the remaining balance to vest in equal parts on March 7, 2027 and March 7, 2028.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(7)</td>
    <td>Mr. Mellon and Dr. Bailey served as directors of the Company through September 25, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(8)</td>
    <td>Dr. Renondin and Dr. Stebbin served as directors of the Company through August 3, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(9)</td>
    <td>Mr. Mintz served as a director of the Company through February 6, 2026.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(10)</td>
    <td>Ms. Kozick and Dr. Glassman served as directors of the Company through April 25, 2024, and Mr. Simon served as a director of the Company
        through April 24, 2024.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(11)</td>
    <td>Mr. Pickett was appointed as our Chief Executive Officer under a consultancy agreement and joined our Board of Directors on December 15,
        2024. He resigned as Chief Executive Officer on August 2, 2025 and departed the Board of Directors on December 19, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(12)</td>
    <td>Dr. Walters served as our Chief Executive Officer and Chairman of our Board of Directors through December 14, 2024. In accordance with
        his employment agreement, all unvested share options at that time vested immediately.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(13)</td>
    <td>Ms. Park was appointed as our Chief Financial Officer on September 30, 2024 and left the Company in October 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(14)</td>
    <td>Mr. Shaw served as our Chief Financial Officer and Secretary through September 30, 2024. Other compensation in the amount of $127,250
        represent payments made to Mr. Shaw under a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) dated July 22,
        2024. Additional information concerning the Retention Agreement may be found in Note 14, Related Party Transactions to the consolidated
        financial statements included elsewhere in this Annual Report.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(15)</td>
    <td>Mr. Wiley served as our Chief Business Officer through November 15, 2024. In accordance with his employment agreement, all unvested share
        options at that time vested immediately.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(16)</td>
    <td>Mr. Fairchild resigned as our Vice President of Development in January 2024 but continued to provide his services as a consultant through
        May 31, 2024, his resignation date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(17)</td>
    <td>On March 11, 2026, the Board authorized the grant of 149,015 RSUs to Ms. Kaiser, 99,344 RSUs to Mr. Mitin, and 248,359RSUs to Mr. Villani,
        which were owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private
        or public share offerings. These RSUs were formally granted on April 29, 2026.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Outstanding Equity Awards at Fiscal Year-End</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table and related notes provide certain information regarding
all outstanding equity awards for our executive officers as of March 31, 2026, as adjusted to give effect to the 1-for-20 reverse share
split completed on August 15, 2024:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option
        Awards</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Stock
        Awards<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares or</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Market Value of Shares or</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Securities Underlying</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercised
        Options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Exercise</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Expiration</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Grant Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; font-style: normal">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Exercisable<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercisable</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Price</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; font-size: 10pt; font-style: normal">Alexander Pickett<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(2)</sup></span></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">3/7/2025</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">36,000</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">4.45</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">3/7/2035</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">45,937</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Ian B. Walters<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">15,085</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,285</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7,550</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Andrea E. Park<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(4)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/7/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">28,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4.45</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/7/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7,820</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Allan Shaw<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(5)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,761</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">840</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,550</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Robert Kramer<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,771</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2033</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,255</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2032</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,050</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2031</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Brian Wiley<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,386</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11/15/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11/15/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Brittany Kaiser<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Enzo Villani<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Yury Mitin<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Outstanding Equity Awards at Fiscal Year-End <i>(Cont&#8217;d)</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(1)</td>
    <td>Except as set forth below, vesting of all options is subject to continued service as an employee, director and/or consultant of Alpha
        Compute or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the
        date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(2)</td>
    <td>On December 15, 2024, Mr. Pickett was appointed as a director of the Company and our Chief Executive Officer under a consultancy agreement
        and served in such capacities through December 19, 2025, his resignation date. These options were awarded to Mr. Pickett for his services
        as a director. One fourth of the options vested immediately on grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(3)</td>
    <td>Dr. Walters served as our Chief Executive Officer and a director of the Company through December 14, 2024. Pursuant to the terms of his
        employment agreement, all unvested share options immediately vested on such date. Pursuant to the terms of his share option agreements,
        the vested share options are exercisable for two years from this date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(4)</td>
    <td>On September 30, 2024, Ms. Park was appointed as our Chief Financial Officer and departed the Company in October 2025. One fourth of the
        options vested immediately on the grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(5)</td>
    <td>Mr. Shaw served as our Chief Financial Officer through September 30, 2024. Pursuant to the terms of his share option agreements, the vested
        share options are exercisable for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(6)</td>
    <td>The above table excludes 4,550 RSUs to Mr. Kramer granted on January 13, 2021, with a grant date value of $1,615,250, which vested on
        the grant date but are subject to certain restrictions and 860 RSUs granted on January 19, 2022 with a grant date value of $175,784, which
        vested on the grant date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(7)</td>
    <td>Mr. Wiley served as our Chief Business Officer through November 15, 2024. Pursuant to the terms of his employment agreement, all unvested
        shares immediately vested on such date. Pursuant to the terms of his share option agreement, the vested share options are exercisable
        for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(8)</td>
    <td>On March 11, 2026, the Board authorized the grant of 545,315 share options each to Ms. Kaiser, Mr. Mitin, and Mr. Villani, which were
        owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private or public
        share offerings. These share options were formally granted on May 14, 2026.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Directors&#8217; and Officers&#8217; Liability Insurance</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We have purchased, at our expense, a directors&#8217; and officers&#8217;
liability insurance policy that provides insurance against possible liabilities incurred by our directors and officers in their capacity
as such.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">For the year ended March 31, 2026, our members of senior management were:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Alexander Pickett, Interim Chief Executive Officer and Director(1)</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Andrea Park, Chief Financial Officer(2)</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Brittany Kaiser, Chief Executive Officer and Director(3)</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Enzo Villani, Chief Investment Officer and Director(4)</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Wes Levitt, Chief Financial Officer (5)</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Yury Mitin, Chief Business Development Officer (6)</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(1)</td>
    <td>Mr. Pickett was appointed as our Chief Executive Officer and joined our Board of Directors effective December 15, 2024. He resigned as
        Chief Executive Officer effective August 2, 2025 and left the Board of Directors in December 2025.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(2)</td>
    <td>Ms. Park was appointed as our Chief Financial Officer effective September 30, 2024 and resigned in October 2025.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(3)</td>
    <td>Ms. Kaiser was appointed as our Chief Executive Officer and joined our Board of Directors effective August 2, 2025.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(4)</td>
    <td>Mr. Villani was appointed as our Chief Investment Officer and joined our Board of Directors effective September 25, 2025.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(5)</td>
    <td>Mr. Levitt was appointed as our Chief Financial Officer effective October 24, 2025.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(6)</td>
    <td>Mr. Mitin was appointed as our Chief Business Development Officer effective September 25, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Executive Compensation Overview</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During Fiscal 2026, we entered into contractor agreements with affiliates
of each Brittany Kaiser, Enzo Villani, and Yury Mitin, as well as a contractor agreement with Wes Levitt. The agreements provide for a
combination of base salary, bonuses, and long-term incentive compensation in the form of RSUs and options to purchase ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We expect to review executive compensation at least annually, with input
from a compensation consultant as needed. As part of this review process, the Board and the Compensation Committee will consider our compensation
values and philosophy, as well as the compensation levels necessary to ensure our executive compensation program remains competitive.
They will also review whether we are meeting our retention objectives and the potential cost of replacing a key employee.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Components of Executive Compensation</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Annual Base Salary</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our members of senior management each receive a base salary to compensate
them for services rendered to our company. The base salary payable to each member of senior management is intended to provide a fixed
component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. Base salaries are reviewed
annually, typically in connection with our annual performance review process, approved by our board of directors and the compensation
committee, and may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities,
performance, and experience.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Annual Bonus</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 27, 2025, the Board approved retention bonus payments of $25,000
to each then-current members of the Board and aggregate retention bonuses of $100,000 for members of our executive team and certain other
employees in connection with the completion of the Company&#8217;s transition to its digital asset treasury strategy.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Board did not approve any performance bonuses for Fiscal 2025 and Fiscal
2024.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Executive Equity Transaction Closing Bonus</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The contractor agreements for executives Brittany Kaiser, Enzo Villani,
and Yury Mitin each provided for bonuses consisting of $250,000 in cash and $250,000 worth of TON tokens, payable upon the Company raising
at least $50 million in equity financing through private or public share offerings. This milestone was achieved on January 14, 2026, upon
the closing of a $15 million registered direct share offering, which, together with prior equity financings, resulted in aggregate equity
financing proceeds in excess of $50 million. During Fiscal 2026, the Company paid the cash portion of the bonus to each executive and
accrued the TON token portion of each executive&#8217;s bonus.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Equity-Based Compensation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In Fiscal 2026, the Board of Directors authorized the grant of 1,930,396
options to purchase ordinary shares on March 11, 2026, with exercise prices ranging from $1.30 to $8.26 per share. The options have a
ten-year term and provide for accelerated vesting upon a change of control of the Company. The options had weighted-average grant date
fair value of $0.40 per share and vest as to one-quarter upon grant and the remainder in three equal installments on March 11, 2027, 2028,
and 2029. The grants were made to certain directors, officers, and advisors. The options were issued as discretionary options outside
the Company&#8217;s 2021 Equity Incentive Plan and were not part of any regularly established compensation arrangement. These options
were awarded pursuant to contractor agreements and advisory agreements and were contingent upon the Company raising at least $50 million
in equity financing through private or public share offerings, which milestone was achieved on January 14, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 11, 2026, the Board also authorized the grant of 1,235,924 RSUs,
which vested immediately upon grant. The grants were made to certain directors, officers, and employees and were issued as discretionary
awards outside the Company&#8217;s 2021 Equity Incentive Plan and not as part of any regularly established compensation arrangement. These
options were awarded pursuant to contractor agreements and were contingent upon the Company raising at least $50 million in equity financing
through private or public share offerings, which milestone was achieved on January 14, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 27, 2025, the Board authorized the grant of 97,739 fully vested
options under the terms of the Company&#8217;s 2021 Equity Incentive Plan to directors and certain employees.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In Fiscal 2025, the Board authorized the grant of 160,000 options to purchase
ordinary shares on March 7, 2025, with an exercise price of $4.45 per share. The options have a ten-year term and provide for accelerated
vesting upon a change of control of the Company. The options had grant date fair value of $4.04 per share and vest as to one-quarter upon
grant and the remainder in three equal installments on March 7, 2026, 2027, and 2028. The grants were made to certain directors, officers,
and employees. The options were issued as discretionary options under the Company&#8217;s 2021 Equity Incentive Plan and were not part
of any regularly established compensation arrangement.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In Fiscal 2024, the Compensation Committee did not approve any equity awards
to our directors or members of senior management.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Executive Contractor Agreements</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Brittany Kaiser:</i></b> The Company entered into an independent contractor
agreement with Own Your Data Technologies, LLC, an affiliate of Ms. Kaiser, setting forth the terms and conditions for Ms. Kaiser&#8217;s
services to the Company as its Chief Executive Officer, effective August 4, 2025. The agreement is for a term of five years and automatically
renews for successive one-year periods unless either party provides 180 days&#8217; notice of non-renewal. Pursuant to the agreement,
Ms. Kaiser is entitled an annual salary consisting of $500,000 in cash and $500,000 worth of TON tokens (totaling $1 million annually)
for her services. The agreement also provides for an annual equity grant of ALP shares worth $1.5 million and an annual long-term incentive
grant of ALP shares worth $2 million, in each case based on five-year company performance metrics. In addition, Ms. Kaiser is eligible
for a discretionary performance bonus of up to $2 million in cash, $2 million in TON tokens, and $6 million in ALP shares, in each case
subject to Board approval. Since the commencement of her engagement, the cash portion of Ms. Kaiser&#8217;s annual salary has been paid
in accordance with the agreement, while the TON token portion of her salary has accrued but has not yet been paid. In the event that Ms.
Kaiser is terminated without cause, she is entitled to compensation equal to two years of her annual base salary, two times her annual
target bonus, and the pro-rated portion of her current year bonus.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Enzo Villani:</i></b> The Company entered into an independent contractor
agreement with Alpha Sigma Capital Advisors, LLC, an affiliate of Mr. Villani, setting forth the terms and conditions for Mr. Villani&#8217;s
services to the Company as its Chief Investment Officer and Board Chairman, effective September 25, 2025. The agreement is for a term
of five years and automatically renews for successive one-year periods unless either party provides 180 days&#8217; notice of non-renewal.
Pursuant to the agreement, Mr. Villani is entitled to an annual salary consisting of $300,000 in cash and $300,000 worth of TON tokens
(totaling $600,000 annually) for his services. The agreement also provides for an annual equity grant of ALP shares worth $300,000 and
an annual long-term incentive grant of ALP shares worth $1.2 million, in each case based on five-year company performance metrics. In
addition, Mr. Villani is eligible for a discretionary performance bonus of up to $1.2 million in cash, $1.2 million in TON tokens, and
$1.2 million in ALP shares, in each case subject to Board approval. Since the commencement of his engagement, the cash portion of Mr.
Villani&#8217;s annual salary has been paid, while the TON token portion of his salary has accrued but has not yet been paid. In the event
that Mr. Villani is terminated without cause, he is entitled to compensation equal to two years of his annual base salary, two times his
annual target bonus, and the pro-rated portion of his current year bonus.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i></i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Yury Mitin:</i></b> The Company entered into an independent contractor
agreement with Red Shark Ventures Inc., an affiliate of Mr. Mitin, setting forth the terms and conditions for Mr. Mitin&#8217;s services
to the Company as its Chief Business Development Officer, effective September 25, 2025. The agreement is for a term of five years and
automatically renews for successive one-year periods unless either party provides 180 days&#8217; notice of non-renewal. Pursuant to the
agreement, Mr. Mitin is entitled to an annual salary consisting of $300,000 in cash and $300,000 worth of TON tokens (totaling $600,000
annually) for his services. The agreement also provides for an annual equity grant of ALP shares worth $300,000 and an annual long-term
incentive grant of ALP shares worth $1.2 million, in each case based on five-year company performance metrics. In addition, Mr. Mitin
is eligible for a discretionary performance bonus of up to $1.2 million in cash, $1.2 million in TON tokens, and $1.2 million in ALP shares,
in each case subject to Board approval. Since the commencement of his engagement, the cash portion of Mr. Mitin&#8217;s annual salary
has been paid, while the TON token portion of his salary has accrued but has not yet been paid. In the event that Mr. Mitin is terminated
without cause, he is entitled to compensation equal to two years of his annual base salary, two times his annual target bonus, and the
pro-rated portion of his current year bonus.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Wes Levitt:</i></b> The Company entered into an independent contractor
agreement with Wes Levitt setting forth the terms and conditions for his services to the Company as its Chief Financial Officer, effective
October 24, 2025. The agreement is for a term of five years and automatically renews for successive one-year periods unless either party
provides 180 days&#8217; notice of non-renewal. Pursuant to the agreement, Mr. Levitt is entitled to an annual salary of $250,000 in cash
and $250,000 worth of TON tokens (totaling $500,000 annually) for his services. Mr. Levitt&#8217;s agreement also provides for an annual
equity grant of ALP shares worth $250,000. In addition, Mr. Levitt is eligible for a discretionary performance bonus of up to $1 million
in cash, $1 million in TON tokens, and $1 million in ALP shares, in each case subject to Board approval. Since the commencement of his
engagement, the cash portion of Mr. Levitt&#8217;s annual salary has been paid, while the TON token portion of his salary has accrued
but has not yet been paid. In the event that Mr. Levitt is terminated without cause, he is entitled to compensation equal to two years
of his annual base salary, two times his annual target bonus, and the pro-rated portion of his current year bonus.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Liza Horowitz: </i></b>The Company entered into an independent contractor
agreement with Liza Horowitz setting forth the terms and conditions for her services to the Company as its Chief Operating Officer, effective
June 1, 2026. The agreement is for a term of four years and automatically renews for successive one-year periods unless either party provides
90 days&#8217; notice of non-renewal. Pursuant to the agreement, Ms. Horowitz is entitled to an annual salary of $250,000 in cash for
her services. Ms. Horowitz&#8217; agreement also provides for an annual equity grant of ALP shares worth $100,000. In addition, Ms. Horowitz
is eligible for a discretionary performance bonus of up to $250,000. In the event that Ms. Horowitz is terminated without cause, she is
entitled to compensation equal to 6 months of her annual base salary.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Alexander Pickett:</i></b> PDS entered into a consultant agreement
with Arctos Strategy, LLC setting forth the terms and conditions for Mr. Pickett&#8217;s services to the Company as its Interim Chief
Executive Officer, effective December 15, 2024 through March 15, 2025. Since that time, Mr. Pickett and the Board have extended the term
of the contract on a month-by-month basis. Pursuant to the agreement, the Company shall pay $1.00 per month for Mr. Pickett&#8217;s services.
Mr. Pickett will not be eligible to participate in any Company retirement, pension, life, health, accident and disability insurance, or
other employee benefit plans for the Company&#8217;s executive officers or employees other than the 2021 Equity Incentive Plan. Mr. Pickett
resigned as Chief Executive Officer on August 2, 2025 and departed the Board of Directors on December 19, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Ian Walters:</i></b> PDS entered into a Services Agreement with Dr.
Walters effective December 15, 2021 (the &#8220;CEO Services Agreement&#8221;). The directors resolved not to renew the CEO Services Agreement
and notification was duly provided to Dr. Walters on December 4, 2024. Dr. Walters served as our CEO through December 14, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b><i>Andrea Park:</i></b> PDS entered into an employment agreement with
our Chief Financial Officer Andrea Park, effective September 30, 2024 (the &#8220;Park Employment Agreement&#8221;). Pursuant to the Park
Employment Agreement, Ms. Park&#8217;s annual base salary was set at $325,000. Under the Park Employment Agreement, Ms. Park is eligible
to a $50,000 bonus upon consummation of a reverse merger transaction or similar transaction, if any. Ms. Park left the Company in October
2025.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The total executive and officer compensation earned which was paid or accrued
by the Company as of March 31, 2026 amounted to $5.8 million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Director Compensation</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><i>Non-Executive Director Compensation Policy</i></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 6 2026, the Board replaced the &#8220;Non-Executive Director Compensation
Policy&#8221; (the &#8220;Cancelled Policy&#8221;), which had been effective since March 7, 2025. In its place, the Board adopted and
approved, effective as of March 6, 2026, the Non-Executive Director Compensation Policy, pursuant to which each non-executive director
of the Company is entitled to an annual cash retainer of $75,000, to be paid in arrears, as well as an annual cash retainer of $10,000
for service as a member, or $20,000 for service as the Chair, of each of the Audit, Compensation or Nominating and Corporate Governance
Committees. Upon election to the Board, each non-executive director will receive a grant of RSUs equal to $150,000 in value based on the
Company&#8217;s closing share price on the grant date, and thereafter, on each anniversary of the director&#8217;s commencement of service,
an annual RSU grant equal to $100,000 in value. The initial RSU award vests in equal quarterly installments over a four-year period from
the grant date, subject to a one-year cliff and the director&#8217;s continued service through each applicable vesting date. Annual RSU
awards likewise vest in equal quarterly installments over a four-year period, subject to the director&#8217;s continued service through
each applicable vesting date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 7, 2025, the Board replaced the &#8220;Non-Executive Director Compensation
Policy&#8221; prior to the Cancelled Policy (the &#8220;Prior Policy&#8221;), which had been effective since January 1, 2022. Payments
under the Prior Policy had been suspended since April 2024, with directors waiving their entitlement to such fees during that period.
To replace the Prior Policy, the Board adopted and approved, effective as of March 7, 2025, the Cancelled Policy, pursuant to which each
person serving as a director of the Company, regardless of executive employment status, was entitled to an annual cash retainer of $30,000,
to be paid in arrears, upon confirmation by the Board that the Company has sufficient funds available for payment without adversely impacting
the then-available, necessary working capital. In addition, the policy also provided for a cash fee in the amount of $25,000 to each person
then serving as a director of the Company upon the consummation of a reverse merger transaction or similar transaction, if any.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company incurred Board fees totaling $232,500, $180,000, and $273,250
during the years ended March 31, 2026, 2025, and 2024, respectively. Dr. Bailey, Mr. Mellon, Mr. Mintz and Ms. Kozick waived their Board
fees for the three months ended March 31, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(C) BOARD PRACTICES</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Audit Committee</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, our Audit Committee consisted of F. Dan Siciliano
and Michael Terpin, who are both independent directors as determined by Nasdaq rules. Earlier in Fiscal 2026, our Audit Committee consisted
of Steven Mintz, Justin Stebbing, and Jean-Christophe Renondin, each of whom resigned during Fiscal 2026. Mr. Siciliano serves as the
Chair of the Audit Committee. The Board has determined that each member of our Audit Committee meets the financial literacy requirements
of the Nasdaq listing standards and satisfies the independence requirements of Exchange Act Rule 10A-3 and applicable Nasdaq audit committee
requirements, subject to any disclosed home-country exemptions. In addition, the Board has determined that Mr. Siciliano is an &#8220;audit
committee financial expert&#8221; within the meaning of Item 407(d) of Regulation S-K under the Exchange Act. Mr. Siciliano has more than
20 years of corporate, technology and governance experience, including services as CEO of a private market and startup equity exchange.
He has served on the boards of numerous private and public corporations, including serving as Chairman of the Federal Home Loan Bank of
San Francisco and was a professor at Stanford Law School and co-founder of Stanford&#8217;s Rock Center for Corporate Governance.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our Audit Committee will, among other things:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review our consolidated financial statements and our critical accounting policies and practices;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>select a qualified firm to serve as the independent registered public accounting firm to audit our consolidated financial statements;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>help to ensure the independence and performance of the independent registered public accounting firm;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>discuss the scope and results of the audit with the independent registered public accounting firm and review, with management and the
        independent registered public accounting firm, our interim and year-end results of operations;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>pre-approve all audit and all permissible non-audit services to be performed by the independent registered public accounting firm;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>oversee the performance of our internal audit function when established;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review the adequacy of our internal controls;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>develop procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review our policies on risk assessment and risk management; and</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review related party transactions.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Pre-Approval Policies and Procedures</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In the event that we plan to retain the services of the external auditors
to the Company for tax compliance, tax advice or tax planning, the CFO of the Company must consult with the Chairperson of the Audit Committee,
who has the authority to approve or disapprove on behalf of the committee, those non-audit services. All other permissible non-audit services
shall be approved or disapproved by the Audit Committee as a whole.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our external auditors are prohibited from performing for the Company non-audit
services of the following nature: (a) bookkeeping or other services related to the accounting records or consolidated financial statements;
(b) financial information systems design and implementation; (c) appraisal or valuation services, fairness opinions or contribution in-kind
reports; (d) actuarial services; (e) internal audit outsource services; (f) management functions; (g) human resources; (h) broker or dealer,
investment adviser or investment banking services; (i) legal services; (j) expert services unrelated to the audit; and (k) any other service
that the Canadian and the United States Public Company Accounting Oversight Board determines is impermissible.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Audit Committee Charter relating to compensation matters sets forth
the evaluation and review requirements for incentive and equity-based compensation plans for the executives based on their periodic performance
evaluation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Compensation Committee</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, our Compensation Committee consisted of F. Dan Siciliano
and Michael Terpin. Mr. Terpin serves as Chair of the committee. Earlier in Fiscal 2026, our Compensation Committee consisted of Jim Mellon,
Gregory Bailey, and Steven Mintz, each of whom resigned during Fiscal 2026. Each member of the Compensation Committee is also a non-employee
director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act. The purpose of our Compensation Committee is to discharge
the responsibilities of our board of directors relating to compensation of our executive officers. Our Compensation Committee will, among
other things:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review annually our compensation strategy, including base salary, incentive compensation and equity-based plans, including whether to
        adopt, amend and terminate compensation plans or arrangements;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review and approve, or recommend to the Board for review and approval, annually our corporate goals and objectives, including those applicable
        to the compensation of the CEO and to the extent applicable, other executive officers;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review, approve and determine, or make recommendations to our board of directors regarding, the compensation of our executive officers;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>administer our stock and equity incentive plans;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>review and approve, or make recommendations to our board of directors regarding, incentive compensation and equity plans;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>evaluate the efficacy of our compensation policy and strategy in achieving gender and minority pay parity, positive social impact and
        attracting a diverse workforce; and</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>establish and review general policies relating to compensation and benefits of our employees.</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Incentive Recovery Policy</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our Board has adopted a written policy to recover &#8220;excess&#8221; compensation
that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. The compensation includes
both cash-based and equity-based incentives. The compensation covered includes incentive awards awarded to any individuals (including
former employees) who served as an executive officer during the three most recently completed fiscal years preceding the date on which
the preparation of an accounting restatement is required, provided that the executive officers were awarded more incentive awards than
they would have received if the financial statements had been prepared correctly. The recovery will include an executive incentive award
even if the executive was not involved in preparing the financial statements or did not commit misconduct that led to the restatement.
Restatements attributable to an inadvertent error also will subject executive officers to the recovery of previously received incentive
awards.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Nominating Committee</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, our Nominating Committee consisted of F. Dan Siciliano
and Michael Terpin, who are both independent directors as determined by Nasdaq rules. Mr. Siciliano serves as Chair of the committee.
Earlier in Fiscal 2026, our Nominating Committee consisted of Jean-Christophe Renondin, Justin Stebbing, and Gregory Bailey, each of whom
resigned during Fiscal 2026. During Fiscal 2025, our Nominating Committee consisted of Jean-Christophe Renondin, Justin Stebbing, and
Gregory Bailey. Our Nominating Committee will, among other things:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
identify, evaluate and select, or make recommendations to our board of directors regarding, nominees for election to our board of 	directors
and its committees;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
evaluate the performance of our board of directors and of individual directors;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
consider and make recommendations to our board of directors regarding the size and composition of our board of directors and its 	committees;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
review developments in corporate governance practices;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
oversee environmental, social and governance (ESG) matters;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
evaluate the adequacy of our corporate governance practices and reporting; and</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
develop and make recommendations to our board of directors regarding corporate governance guidelines and matters.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Role of Board of Directors in Risk Oversight Process</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our board of directors has responsibility for the oversight of our risk
management processes and, either as a whole or through its committees, regularly discusses with management our major risk exposures, their
potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from
board committees and members of senior management to enable our board of directors to understand our risk identification, risk management
and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity,
strategic and reputational risk.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Code of Business Conduct</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has established a Code of Conduct applicable to our directors,
officers and employees. The Code of Conduct is accessible on our website at www.alphacompute.ai. If we make any substantive amendments
to the Code of Conduct or grant any waiver, including any implicit waiver, from a provision of the Code of Conduct to our officers, we
will disclose the nature of such amendment or waiver on that website or in a report on Form 6-K.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Compensation Committee Interlocks and Insider Participation</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">All compensation and related matters are reviewed by our Compensation Committee.
None of the members of our Compensation Committee is or has at any time during the past year been an officer or employee of ours. None
of our executive officers currently serves or in the past year has served as a member of the board of directors or Compensation Committee
of any entity that has one or more executive officers serving on our board of directors or on our Compensation Committee.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(D) EMPLOYEES</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We had two full-time employees as of March 31, 2026, as compared to three
employees as of March 31, 2025. The employees are located in the United States. The two employees oversee business operations and management
of clinical development. We also use the services of consultants and contractors.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(E) SHARE OWNERSHIP</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table sets forth information regarding the beneficial ownership
of our ordinary shares as of July 15, 2026, by (i) each of our executive officers, (ii) each of our directors, (iii) all of our directors
and executive officers as a group; and (iv) each person, or group of affiliated persons, who is known by us to beneficially own more than
5% of our ordinary shares. The table does not include holders of securities subject to a 4.99% or greater blocker provision.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Beneficial ownership is determined according to Rule 13d-3 of the SEC, which
generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment
power over that security, and includes shares underlying options, warrants and rights that are currently exercisable or exercisable within
60 days of July 15, 2026. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that
person or entity in the table below, all shares subject to options or warrants held by such person or entity were deemed outstanding if
such securities are currently exercisable, or exercisable within 60 days of July 15, 2026. These shares were not deemed outstanding, however,
for the purpose of computing the percentage ownership of any other person or entity.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Unless otherwise indicated, we believe that all persons named in the table
below have sole voting and investment power with respect to all ordinary shares beneficially owned by them. To our knowledge, no ordinary
shares beneficially owned by any executive officer, director or director nominee have been pledged as security.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary Shares</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Beneficially
        Owned</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">Directors and Executive Officers:</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Percentage</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Brittany Kaiser</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">370,777</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Enzo Villani</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">760,962</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Liza Horowitz</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Wes Levitt</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Yury Mitin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">247,185</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Michael Terpin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">F. Daniel Siciliano</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">All directors and executive officers as a group (7 individuals)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,378,924</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.89</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">5% Shareholders:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Not applicable</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">N/A</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">*</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">*Less than 1%</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">All shares held by the above persons carry the same rights as the other
holders of the ordinary shares of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(F) DISCLOSURE OF A REGISTRANT&#8217;S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION.</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">None.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i7"></span>ITEM 7 &#8211; MAJOR SHAREHOLDERS
AND RELATED PARTY TRANSACTIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(A)</b></td>
    <td><b>MAJOR SHAREHOLDERS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">See &#8220;Item 6. Directors, Senior Management and Employees&#8212;E. Share Ownership.&#8221;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(B)</b></td>
    <td><b>RELATED PARTY TRANSACTIONS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We have entered into related party transactions and certain services agreements
with our investees. Key management personnel of ours have also entered into related party transactions with investees. Key management
personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of us, including
directors and senior management of ours.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following subsidiaries and associates are considered related
parties:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 2%">(a)</td>
    <td><b>SalvaRx</b>, a wholly owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 2%">(b)</td>
    <td><b>iOx</b>. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Alpha Compute director resigned from the iOx board 		leaving
        two Alpha Compute insiders as directors. The management team of Alpha Compute comprises the management team of iOx.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 2%">(c)</td>
    <td><b>Saugatuck</b>. Saugatuck is 70% owned by the Company and is controlled by Alpha Compute.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 2%">(d)</td>
    <td style="padding-right: 1pt"><b>Portage Development Services Inc</b>. PDS provides human resources and other services to each operating
        subsidiary of Alpha Compute 	through shared services agreements.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 2%">(e)</td>
    <td style="padding-right: 1pt"><b>SalvaRx LLC</b>, a wholly owned subsidiary through SalvaRx incorporated in Delaware;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 2%">(f)</td>
    <td style="padding-right: 1pt"><b>Saugatuck Rx LLC</b>, a wholly owned subsidiary of Saugatuck incorporated in Delaware; and</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 36pt"/>
    <td style="width: 2%">(g)</td>
    <td><b>Tarus Therapeutics, LLC</b> (&#8220;Tarus&#8221;), a wholly owned subsidiary of Alpha Compute incorporated in Delaware.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Transactions between the parent company and its subsidiaries, which are
related parties, have been eliminated in consolidation and are not disclosed in this section.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following are related party balances and transactions other than those
disclosed elsewhere in the consolidated financial statements:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Board Resignations and Appointments</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On April 25, 2024, Mark Simon resigned all of his positions on the Board
of Directors, and on April 26, 2024, Linda Kozick and Dr. Robert Glassman resigned all of their positions on the Board of Directors. On
April 30, 2024, Dr. Jean -Christophe Renondin and Dr. Justin Stebbing were elected to the Board. On August 3, 2025, Justin Stebbing, and
Jean-Christophe Renondin resigned from the Board of Directors and Brittany Kaiser was appointed to the Board. On September 25, 2025, Gregory
Bailey and James Mellon resigned from the Board of Directors and Michael Terpin and Enzo Villani were appointed to the Board. On December
19, 2025, Alexander Pickett resigned from the board of directors of the Company. On February 6, 2026 Steven Mintz resigned from the board
of directors and was replaced with F. Dan Siciliano.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Advisory Agreement</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On August 20, 2025, the Company entered into an independent contractor agreement
with Ralph Matthew McKibbin (the &#8220;McKibbin Agreement&#8221;), pursuant to which Mr. McKibbin will provide development advisory services
to the Company. Mr. McKibbin is entitled to an equity grant in options at a strike price equal to the fair market value on the date of
the grant of 0.25% of the issued and outstanding ordinary shares of the Company after giving effect to the number of issued and outstanding
ordinary shares of the Company as of immediately after the Closing. 50% of the options will vest immediately and the remaining 50% shall
vest in equal installments over a 12-month period. Due to the relationship between Ms. Kaiser and Mr. McKibbin, the McKibbin Agreement
is a related party transaction for Ms. Kaiser.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Relationship with DecentraNet</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">DecentraNet is an early-stage venture investment fund and advisory firm.
They invest at the earliest stages (F&amp;F, Pre-Seed, and Seed), and have advisory clients ranging from startups to multi-billion dollar
public companies. In Fiscal 2026 the Company paid DecentraNet a total of $55,000 for advisory and fundraising services. Mr. McKibbin is
the founder of DecentraNet and a related party to the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Retention Agreements and General Releases</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 22, 2024, the Company and Portage Development Services, Inc. entered
into a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) with each of Allan Shaw, the Company&#8217;s former
Chief Financial Officer (&#8220;Employee&#8221;) and Joseph Ciavarella, the Company&#8217;s former controller (&#8220;Consultant&#8221;).
Under the terms of each of the Retention Agreements, Employee&#8217;s current employment agreement and Consultant&#8217;s current consulting
agreement both terminated on July 22, 2024, except with respect to certain provisions. In return for continuing to provide services to
the Company and its affiliates and completing certain tasks as described in the respective Retention Agreements, the Company paid an aggregate
$0.2 million (the &#8220;Retention Amount&#8221;) to Employee and Consultant, in addition to their monthly pay through September 30, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accrued the Retention Amount, as well as the monthly pay totaling
$0.2 million through September 30, 2024, in the consolidated financial statements for the three months ended June 30, 2024, as the material
terms of the Retention Agreements were known and agreed upon at June 30, 2024. In accordance with the terms of the Retention Agreements,
the Company paid in full the Retention Amount and issued 14,348 ordinary shares to the Employee and Consultant in lieu of cash bonuses
accrued in Fiscal 2023 totaling $0.1 million by September 30, 2024, the date on which the Employee&#8217;s employment and the Consultant&#8217;s
consulting relationship with the Company and its affiliates ended.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Relationship with Compedica</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As discussed in Note 10, the Company acquired an equity interest in Compedica,
a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes. The investment was made
in a share-for-share transaction whereby Compedica obtained a corresponding 27.4% interest in the Company, which was subsequently diluted
in connection with the private financing in September 2025. As of September 30, 2025, Compedica owned 11.9% of the Company&#8217;s ordinary
shares issued and outstanding. At the time of the Compedica investment, Jim Mellon was a director of both Compedica and the Company and
a greater than 5% owner of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#8217;s treasury and the investment being exited. The shares were returned to the Company treasury stock on May 21, 2026. As of
March 31, 2026, the Company no longer has any affiliation with Compedica, its employees, or directors, excepting the 625,000 Company shares
to be returned, which was completed on May 21, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Asset Management Agreement</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At the closing of the Company&#8217;s financing on September 25, 2025, the
Company entered into an Asset Management Agreement (the &#8220;Asset Management Agreement&#8221;) with Alpha Sigma Capital, LLC (the &#8220;Asset
Manager&#8221;). Pursuant to the Asset Management Agreement, the Asset Manager shall provide discretionary investment management services
with respect to, among other assets (including without limitation certain subsequently raised funds), certain of the Company&#8217;s net
proceeds from the Offering (the &#8220;Account Assets&#8221;) in accordance with the terms of the Asset Management Agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the Asset Management Agreement, the Company shall pay the Asset Manager
an asset-based fee equal to 1.0% per annum of the Account Assets. The Account Assets managed under the agreement are held in the name
of the Company and remain under Company control. The agreement term is one year, after which it renews automatically and can be terminated
by the Company with 90 days&#8217; notice, provided that the Company has decided to end the TON digital asset treasury strategy. The total
amount paid under this agreement in FY 2026 was $80,918.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Asset Manager is mandated to invest the Account Assets principally with
a long-only strategy primarily in TON, including staking (and restaking) TON to improve returns. The Asset Manager is not permitted to
invest in any OTC derivatives, futures contracts, or option contracts that would require the Asset Manager to register as a commodity
pool operator or commodity trading advisor.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Mr. Enzo Villani, Chief Investment Officer of the Company, is the Chief
Executive Officer and Chief Investment Officer of the Asset Manager. Alpha Sigma Capital was also an investor in the Company&#8217;s September
2025 financing.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Relationship with Content Syndicate</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt; text-indent: 0.5in; font-size: 10pt">Content Syndicate (dba Blockchain Wire) is a press release distribution service
focused on news from blockchain and crypto companies and projects. Their global reach includes distribution to broadcast and online media
outlets, social media sites, trade publications, leading blogs, industry executives, influencers and investors. They offer multiple distribution
options, ease-of-use, broad partnership integrations and a dedicated client services team. In Fiscal 2026 we paid Content Syndicate a
total of $167,462.50 for distribution and placement of press releases and media buys. Content Syndicate is a related party by virtue of
being owned by Enzo Villani and Michael Terpin.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Employment Agreements</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">For a description of compensation arrangements and employment agreements
between the Company and its members of senior management as well as director compensation arrangements, see Part I Item 6 (B) &#8220;Compensation&#8221;
of this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(C)</b></td>
    <td><b>INTERESTS OF EXPERTS AND COUNSEL</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.25in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i8"></span>ITEM 8 &#8211; FINANCIAL INFORMATION</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(A)</b></td>
    <td><b>CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Information regarding our consolidated financial statements is contained
under Item 18 of this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Dividend Policy</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Since its incorporation, the Company has not declared or paid, and has no
present intention to declare or to pay in the foreseeable future, any cash dividends with respect to its ordinary shares. Earnings will
be retained to finance further growth and development of the business of the Company. However, if the Board of Directors declares dividends;
all the ordinary shares will participate equally in the dividends, and, in the event of liquidation, in the net assets, of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In January 2018, the Company declared and distributed its then holdings
of common shares of Biohaven Pharmaceuticals Holding Company Ltd. as share dividend. Whether or not the Board of Directors will determine
to do any other distributions of property of the Company in the future is in their sole discretion and will depend on their determination
at the future time.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">All shares held by the above persons carry the same rights as the other
holders of the ordinary shares of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(B)</b></td>
    <td><b>SIGNIFICANT CHANGES</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#8220;SPA&#8221;) with Animoca Brands Limited (&#8220;Animoca Brands&#8221;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#8220;GaMee Global&#8221;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#8220;GaMee Transaction&#8221;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. Animoca
Brands, prior to closing, will conduct a reorganization to transfer 100% of the equity of Gamee Limited, a company incorporated in the
United Kingdom (the &#8220;UK Company&#8221;) to GaMee Global. The UK Company owns the entire equity in Gamee Mobile s.r.o., a company
incorporated under the laws of the Czech Republic (the &#8220;Czech Company&#8221; and together with GaMee Global and the UK Company,
&#8220;GaMee&#8221;). Under the terms of the SPA, at the closing of the GaMee Transaction (&#8220;Completion&#8221;), the Company has
agreed to pay total upfront consideration of $3.5 million (the &#8220;Completion Consideration&#8221;), comprised of: (i) $1.5 million
in cash, and (ii) $2.0 million in equity consideration in the Company, valued at $1.00 per share. The equity portion of the Completion
Consideration under subparagraph (ii) is structured as a combination of ordinary shares of the Company (&#8220;Ordinary Shares&#8221;)
and pre-funded warrants exercisable for Ordinary Shares (&#8220;Pre-Funded Warrants&#8221;). Specifically, at Completion, Animoca Brands
will receive: (i) 99,800 Ordinary Shares, and (ii) Pre-Funded Warrants exercisable for 1,900,200 Ordinary Shares, representing the balance
of the equity portion of the Completion Consideration. The GaMee Transaction closed on May 27, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i9"></span>ITEM 9 &#8211; THE OFFER AND
LISTING</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(A)</b></td>
    <td><b>OFFER AND LISTING DETAILS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our ordinary shares have been listed for trading on Nasdaq on the Nasdaq
Capital Market under the symbol &#8220;ALP&#8221; since April 21, 2026. Previously, our ordinary shares were listed for trading on Nasdaq
on the Nasdaq Capital Market under the symbol &#8220;PRTG&#8221; through August 10, 2025 and under the symbol &#8220;ATON&#8221; through
April 20, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table outlines the annual high and low market prices for an
ordinary share for the five most recent fiscal years. Except as noted, otherwise, data presented is adjusted for the 1-for-20 reverse
share split completed on August 15, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">High</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Low</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nasdaq</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nasdaq</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">Year ended March 31,</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">US$</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">US$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">2026</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">11.85</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">0.30</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11.06</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2.15</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">77.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">8.13</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">239.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">52.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">856.20</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">131.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table outlines the high and low market prices for an ordinary
share for each fiscal financial quarter for the two most recent fiscal periods and subsequent periods:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">High</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Low</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nasdaq</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nasdaq</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">Quarter ended:</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">US$</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">US$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">31-Mar-26</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">0.30</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">31-Dec-25</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">10.91</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.58</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">30-Sep-25</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9.97</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.09</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">30-Jun-25</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11.85</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4.90</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">31-Mar-25</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9.60</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3.96</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">31-Dec-24</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9.04</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">30-Sep-24</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">10.21</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2.15</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">30-Jun-24</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11.06</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4.24</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">31-Mar-24</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">37.80</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">8.13</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table outlines the high and low market prices for each of
the most recent six months:</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">High</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Low</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nasdaq</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nasdaq</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">Month</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">US$</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">US$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">June 2026</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">0.37</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">0.24</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">May 2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.45</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.24</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">April 2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.34</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.18</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">March 2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.42</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">February 2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.64</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">January 2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0.60</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(B)</b></td>
    <td><b>PLAN OF DISTRIBUTION</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(C)</b></td>
    <td><b>MARKETS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's ordinary shares currently trade in one place. Our ordinary
shares have been listed for trading on Nasdaq on the Nasdaq Capital Market under the symbol &#8220;ALP&#8221; since April 14, 2026. Previously,
our ordinary shares were listed for trading on Nasdaq on the Nasdaq Capital Market under the symbol &#8220;PRTG&#8221; through August
10, 2025 and under the symbol &#8220;ATON&#8221; through April 13, 2026. Before April 23, 2021, the Company&#8217;s ordinary shares were
traded in two places.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">1.</td>
    <td>Since February 25, 2021, the ordinary shares of the Company began trading on Nasdaq under the trading symbol &#8220;PRTG&#8221;. Before
        then, the ordinary shares had been traded in the OTC market since 2000 under the trading symbol "PTGEF&#8221;.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">2.</td>
    <td>Effective October 28, 2013, the Company's ordinary shares were also listed for trading in United States dollars on the Canadian Securities
        Exchange (formerly, Canadian National Stock Exchange) under the symbol "PBT.U". The Company voluntarily delisted its ordinary
        shares from the CSE at the market close on April 23, 2021, since the Company&#8217;s shares were trading on Nasdaq from February 2021.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(D)</b></td>
    <td><b>SELLING SHAREHOLDERS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Not applicable.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(E)</b></td>
    <td><b>DILUTION</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Not applicable.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(F)</b></td>
    <td><b>EXPENSES OF THE ISSUE</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i10"></span>ITEM 10 &#8211; ADDITIONAL
INFORMATION</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(A)</b></td>
    <td><b>SHARE CAPITAL</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">This Form 20-F is being filed as an Annual Report under the Exchange Act
and, as such, there is no requirement to provide any information under this section.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(B)</b></td>
    <td><b>MEMORANDUM AND ARTICLES OF ASSOCIATION</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>General</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We amended our Memorandum of Association and Articles of Association (&#8220;M&amp;A&#8221;)
on September 20, 2022 and filed an updated version thereof with the Registrar of Companies in the British Virgin Islands on September
20, 2022. Subsequently, we amended our M&amp;A on August 11, 2025 to reflect the Company&#8217;s name change to AlphaTON Capital Corp,
and on April 14, 2026 to reflect the Company&#8217;s name change to Alpha Compute Corp.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Pursuant to our M&amp;A, we are authorized to issue an unlimited number
of ordinary shares of no-par value.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following are summaries of material terms and provisions of our M&amp;A
and the BVI Act, insofar as they relate to the material terms applicable to our ordinary shares. Unless otherwise stated, the following
summaries are of the terms of our shares as of the date of this Annual Report. This summary is not intended to be complete, and you should
read the form of our Memorandum and Articles of Association, which has been filed as an exhibit to this report.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Meetings of shareholders</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If our shareholders want us to hold a meeting of shareholders of the company,
they may requisition the directors to hold one upon the written request of shareholders entitled to exercise at least 10% of the voting
rights in respect of the matter for which the meeting is requested. Under British Virgin Islands law, this 10% threshold may only be increased
to a maximum of 30% and any such increase would require an amendment to the M&amp;A.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The directors may decide whether a meeting of the shareholders will be held
as a Physical Meeting, a Virtual Meeting or a Hybrid Meeting as those terms are defined in the M&amp;A.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subject to our M&amp;A, a meeting of shareholders of the company will be
called by not less than ten days' written notice and no more than 60 days&#8217; notice. Notice of every meeting of shareholders may be
delivered electronically and will be given to all of our shareholders. However, the inadvertent failure of the convener or conveners of
a meeting of shareholders to give notice of the meeting to a shareholder, or the fact that a shareholder has not received the notice,
does not invalidate the meeting.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A meeting of shareholders is duly constituted if, at the commencement of
the meeting, there are present in person or by proxy two or more shareholders entitled to vote at the meeting.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Rights attaching to shares</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Voting rights</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Holders of our ordinary shares have identical rights, including dividend
and liquidation rights, provided that, except as otherwise expressly provided in our M&amp;A or required by applicable law, on any matter
that is submitted to a vote of our shareholders, holders of our ordinary shares are entitled to one vote per ordinary share.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the BVI Act, the ordinary shares are deemed to be issued when the
name of the shareholder is entered in our register of members. Our register of members is maintained by our transfer agent, TSX Trust
Company, which enters the names of our shareholders in our register of members. If (a) information that is required to be entered in the
register of shareholders is omitted from the register or is inaccurately entered in the register, or (b) there is unreasonable delay in
entering information in the register, a shareholder of the company, or any person who is aggrieved by the omission, inaccuracy or delay,
may apply to the British Virgin Islands courts for an order that the register be rectified, and the court may either refuse the application
or order the rectification of the register, and may direct us to pay all costs of the application and any damages the applicant may have
sustained.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subject to any rights or restrictions attached to any shares, at any general
meeting on a show of hands every shareholder of record who is present in person (or, in the case of a shareholder being a corporation,
by its duly authorized representative) or by proxy shall have one vote and on a poll every shareholder present in person (or, in the case
of a shareholder being a corporation, by its duly appointed representative) or by proxy shall have one vote for each share which such
shareholder is the holder. Voting at any meeting of the shareholders is by show of hands unless a poll is demanded. A poll may be demanded
by shareholders present in person or by proxy if the shareholder disputes the outcome of the vote on a proposed resolution and the chairman
shall cause a poll to be taken. In the case of a tie vote at a meeting of shareholders, the chairman shall be entitled to a second or
casting vote.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">No shareholder shall be entitled to vote or be reckoned in a quorum, in
respect of any share, unless such shareholder is registered as our shareholder at the applicable record date for that meeting. Shareholders
of record may also pass written resolutions without a meeting by a majority vote.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Protection of minority shareholders</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the laws of the British Virgin Islands, there is little statutory
law for the protection of minority shareholders other than the provisions of the BVI Act dealing with shareholder remedies. The principal
protection under statutory law is that shareholders may bring an action to enforce the BVI Act or the constituent documents of the Company,
our M&amp;A. Shareholders are entitled to have our affairs conducted in accordance with the BVI Act and the M&amp;A.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There are common law rights for the protection of shareholders that may
be invoked, largely dependent on English company law, since the common law of the British Virgin Islands is limited. Under the general
rule pursuant to English company law known as the rule in Foss v. Harbottle, a court will generally refuse to interfere with the management
of a company at the insistence of a minority of its shareholders who express dissatisfaction with the conduct of the company's affairs
by the majority or the board of directors. However, every shareholder is entitled to have the affairs of the company conducted properly
according to British Virgin Islands law and the constituent documents of the company. As such, if those who control the company have persistently
disregarded the requirements of the BVI Act or the provisions of the company's M&amp;A, then the courts may grant relief. Generally, the
areas in which the courts will intervene are the following: (1) an act complained of which is outside the scope of the authorized business
or is illegal or not capable of ratification by the majority; (2) acts that constitute fraud on the minority where the wrongdoers control
the company; (3) acts that infringe or are about to infringe on the personal rights of the shareholders, such as the right to vote; and
(4) where the company has not complied with provisions requiring approval of a special or extraordinary majority of shareholders, which
are more limited than the rights afforded minority shareholders under the laws of many states in the U.S.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Pre-emption rights</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">British Virgin Islands law does not make a distinction between public and
private companies and some of the protections and safeguards (such as statutory pre-emption rights) that investors may expect to find
in relation to a public company are not provided for under British Virgin Islands law, save to the extent they are expressly provided
for in the M&amp;A. There are no pre-emption rights applicable to the issuance of new shares by us under either British Virgin Islands
law generally or our M&amp;A more specifically.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Modification of rights</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As permitted by British Virgin Islands law, and our M&amp;A, we may vary
the rights attached to our ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Transfer of shares</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subject to any applicable restrictions set forth in our M&amp;A, any of
our shareholders may transfer all or any of his or her shares by a written instrument of transfer in the usual or common form or in a
form prescribed by the Designated Stock Exchange or by means of a Relevant System (as defined in our M&amp;A) or in any other form which
our directors may approve. Shares may be held electronically and transferred electronically.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Changes in authorized ordinary shares</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">By resolution of our directors, we may (i) consolidate and divide all or
any of our unissued authorized shares into shares of larger amount than our existing shares; (ii) sub-divide our existing ordinary shares,
or any of them into shares of smaller amount than is fixed by our memorandum of association, subject nevertheless to the provisions of
the BVI Act; or (iii) create new classes of shares with preferences to be determined by the board of directors at the time of authorization.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Dividends</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subject to the BVI Act and our M&amp;A, our directors may, by resolution,
authorize a distribution to shareholders at such time and of such an amount as they think fit, if they are satisfied, on reasonable grounds,
that, immediately after the distribution, we will satisfy the 'solvency test'. A company will satisfy the solvency test if (i) the value
of the company's assets exceeds its liabilities; and (ii) the company is able to pay its debts as they fall due. Where a distribution
is made to a shareholder at a time when the company did not, immediately after the distribution, satisfy the solvency test, it may be
recovered by the company from the shareholder unless (i) the shareholder received the distribution in good faith and without knowledge
of the company's failure to satisfy the solvency test; (ii) the shareholder has altered his position in reliance on the validity of the
distribution; and (iii) it would be unfair to require repayment in full or at all.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Share repurchases</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As permitted by the BVI Act and our M&amp;A, shares may be repurchased,
redeemed or otherwise acquired by us provided that, immediately following the repurchase or redemption, we are satisfied we will pass
the aforementioned solvency test.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We will require member consent before any share can be purchased, redeemed
or otherwise acquired by us, save where such redemption is pursuant to certain statutory provisions, such as pursuant to section 179 of
the BVI Act (redemption of minority shares) which allows for the holders of 90% or more of the votes to instruct the company to redeem
the shares of the company held by the remaining shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Liquidation rights</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As permitted by British Virgin Islands law and our M&amp;A, a voluntary
liquidator may be appointed under Part XII of the BVI Act if we satisfy the solvency test (as aforementioned save that it is satisfied
if assets equal or exceed liabilities).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Board of directors</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are managed by a board of directors, which consisted of four directors
at March 31, 2026. Our M&amp;A provide that the board of directors may be established by the board of directors up to a maximum of 15
members.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our shareholders may, pursuant to our M&amp;A, by resolution of shareholders
passed at a meeting of shareholders called for the purpose of removing the director or for purposes including the removal of the director
or by a written resolution of shareholders at any time remove any director before the expiration of his or her period of office with or
without cause, and may, pursuant to our M&amp;A, elect another person in his or her stead. Subject to our M&amp;A, the directors will
have power at any time and from time to time to appoint any person to be a director, either as an addition to the existing directors or
to fill a vacancy as long as the total number of directors does not at any time exceed the maximum number fixed by or in accordance with
our M&amp;A (if any).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The registration of transfers may be suspended at such times and for such
periods as the directors may from time to time determine.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our M&amp;A do not provide for alternate directors.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There are no share ownership qualifications for directors, unless otherwise
decided by a resolution of shareholders. Meetings of our board of directors may be convened at any time deemed necessary by any of our
directors.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Unless the quorum has been otherwise fixed by the board, a meeting of our
board of directors will be competent to make lawful and binding decisions if a majority of the directors are present or represented. At
any meeting of our directors, each director, whether by his or her presence or by his or her alternate, is entitled to one vote.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Questions arising at a meeting of our board of directors are required to
be decided by simple majority votes of the directors' present or represented at the meeting. In the case of a tie vote, the chairman of
the meeting shall not have a second or deciding vote. Our board of directors may also pass written resolutions without a meeting by a
majority vote.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The remuneration to be paid to the directors shall be such remuneration
as the directors or shareholders shall determine through a resolution.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Issuance of additional ordinary shares</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our M&amp;A authorize our board of directors to issue additional ordinary
shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our M&amp;A authorize our board of directors from time to time to issue
ordinary shares to the extent permitted by the BVI Act.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Changes in authorized shares</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are authorized to issue unlimited number of ordinary shares without par
value, which will be subject to the same provisions with reference to the payment of calls, liens, transfers, transmissions, forfeitures
and otherwise as the shares in issue. We may by resolution:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
consolidate and divide all or any of our unissued authorized shares into shares of a larger amount than our existing shares;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
sub-divide our existing ordinary shares, or any of them into shares of smaller amount than is fixed by our memorandum of association,
	subject nevertheless to the provisions of the BVI Act; or</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
create new classes of shares with preferences to be determined by the board of directors at the time of authorization.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Inspection of books and records</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under British Virgin Islands law holders of our ordinary shares will be
entitled, on giving written notice to us, to inspect and make copies or take extracts of our: (a) M&amp;A; (b) register of shareholders;
(c) register of directors; and (d) minutes of meetings and resolutions of shareholders and those classes of shareholders of which he is
a shareholder.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subject to our M&amp;A, our board of directors may, if they are satisfied
that it would be contrary to our interest to allow a shareholder to inspect any document, or part of a document as referenced above, refuse
to permit the shareholder to inspect the document or limit the inspection of the document, including limiting the making of copies or
the taking of extracts from the records. Where our directors exercise their powers in these circumstances, they shall notify the shareholder
as soon as reasonably practicable.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Conflicts of interest</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Pursuant to the BVI Act and the Company's M&amp;A, a director of the Company
who has an interest in a transaction and who has declared such interest to the other directors, may:</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
vote on a matter relating to the transaction;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
attend a meeting of directors at which a matter relating to the transaction arises and be included among the directors present at the
	meeting for the purposes of a quorum; and</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
sign a document on behalf of the company or do any other thing in his capacity as a director, which relates to the transaction.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Anti-money laundering laws</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In order to comply with legislation or regulations aimed at the prevention
of money laundering we are required to adopt and maintain anti-money laundering procedures and may require subscribers to provide evidence
to verify their identity. Where permitted, and subject to certain conditions, we may also delegate the maintenance of our anti-money laundering
procedures (including the acquisition of due diligence information) to a suitable person.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We reserve the right to request such information as is necessary to verify
the identity of a subscriber for our ordinary shares. In the event of delay or failure on the part of the subscriber in producing any
information required for verification purposes, we may refuse to accept the application, in which case any funds received will be returned
without interest to the account from which they were originally debited.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If any person resident in the British Virgin Islands knows or suspects that
another person is engaged in money laundering or terrorist financing and the information for that knowledge or suspicion came to their
attention in the course of their business, the person will be required to report his belief or suspicion to the Financial Investigation
Agency of the British Virgin Islands, pursuant to the Proceeds of Criminal Conduct Act (Revised Edition 2020, as amended). Such a report
shall not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Duties of directors</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">British Virgin Islands law provides that every director of the company in
exercising his powers or performing his duties shall act honestly and in good faith and in what the director believes to be in the best
interests of the company. Additionally, the director shall exercise the care, diligence, and skill that a reasonable director would exercise
in the same circumstances taking into account the nature of the company, the nature of the decision and the position of the director and
his responsibilities. In addition, British Virgin Islands law provides that a director shall exercise his powers as a director for a proper
purpose and shall not act, or agree to the company acting, in a manner that contravenes British Virgin Islands law or the memorandum and
articles of association of the company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Anti-takeover provisions</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The BVI Act does not prevent companies from adopting a wide range of defensive
measures, such as staggered boards, blank check preferred shares, removal of directors only for cause and provisions that restrict the
rights of shareholders to call meetings and submit shareholder proposals.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Voting rights and quorum requirements</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under British Virgin Islands law, the voting rights of shareholders are
regulated by the company's memorandum and articles of association and, in certain circumstances, the BVI Act. The memorandum and articles
of association will govern matters such as quorum for the transaction of business, rights of shares, and majority votes required to approve
any action or resolution at a meeting of the shareholders or board of directors. Unless the articles of association otherwise provide,
the requisite majority is usually a simple majority of votes cast. Under the M&amp;A, a resolution of shareholders requires a majority
vote of those persons voting at a meeting or in the case of a written resolution of shareholders, the vote of a majority of the shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Mergers and similar arrangements</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the BVI Act, two or more companies may merge or consolidate in accordance
with the statutory provisions. A merger means the merging of two or more constituent companies into one of the constituent companies,
and a consolidation means the uniting of two or more constituent companies into a new company. In order to merge or consolidate, the directors
of each constituent company must approve a written plan of merger or consolidation which must be authorized by a resolution approved,
at a duly convened and constituted meeting of the shareholders of the Company, by the affirmative vote of a majority of those persons
voting at a meeting or in the case of a written resolution of shareholders, the vote of a majority of the shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Shareholders not otherwise entitled to vote on the merger or consolidation
may still acquire the right to vote if the plan or merger or consolidation contains any provision which, if proposed as an amendment to
the memorandum of association and articles of association, would entitle them to vote as a class or series on the proposed amendment.
In any event, all shareholders must be given a copy of the plan of merger or consolidation irrespective of whether they are entitled to
vote at the meeting or consent to the written resolution to approve the plan of merger or consolidation.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Shareholder suits</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are not aware of any reported class action or derivative action having
been brought against the company in a British Virgin Islands court.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the BVI Act, if a company or a director of a company engages in, or
proposes to engage in, conduct that contravenes the BVI Act or the memorandum of association or articles of the company, the BVI Court
may, on the application of a shareholder or a director of the company, make an order directing the company or director to comply with,
or restraining the company or director from engaging in that conduct.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In addition, under the BVI Act, the BVI Court may, on the application of
a shareholder of a company, grant leave to that shareholder to bring proceedings in the name and on behalf of that company or to intervene
in proceedings to which the company is a party for the purpose of continuing, defending or discontinuing the proceedings on behalf of
the company. In determining whether to grant leave for such derivative actions, the Court must take into account certain matters, including
whether the shareholder is acting in good faith, whether the derivative action is in the interests of the company taking account of the
views of the company's directors on commercial matters and whether an alternative remedy to the derivative claim is available.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A shareholder of a company may bring an action against the company for breach
of a duty owed by the company to him as a shareholder. The BVI Act also includes provisions for actions based on oppression, and for representative
actions where the interests of the claimant are substantially the same as those of other shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Corporate governance </b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subject to the provisions of our M&amp;A, British Virgin Islands laws do
not restrict transactions between a company and its directors, requiring only that directors exercise a duty to act honestly, in good
faith and in what the directors believe to be in the best interests to the companies for which they serve.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Indemnification</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">British Virgin Islands law does not limit the extent to which a company's
memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision
may be held by the British Virgin Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud
or the consequences of committing a crime. Our M&amp;A provide for the indemnification of our directors against all losses or liabilities
incurred or sustained by a director as a director of our company in defending any proceedings, whether civil or criminal and this indemnity
only applies if he or she acted honestly and in good faith with a view to our best interests and, with respect to any criminal action,
he or she must have had no reasonable cause to believe his or her conduct was unlawful.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Insofar as indemnification for liabilities arising under the Securities
Act may be permitted for directors, officers or persons controlling us under the foregoing provisions, we have been advised that, in the
opinion of the U.S. SEC, such indemnification is against public policy as expressed in the Securities Act and therefore is unenforceable.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Staggered board of directors</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The BVI Act does not contain statutory provisions that require staggered
board arrangements for a British Virgin Islands company and our M&amp;A do not provide for a staggered board.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(C)</b></td>
    <td><b>MATERIAL CONTRACTS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We had no material contracts, other than contracts entered into in the ordinary
course of business, to which we or any of our subsidiaries is a party, for the two fiscal years immediately preceding the filing of this
report that are not otherwise disclosed in this Annual Report (including the Exhibits).</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(D)</b></td>
    <td><b>EXCHANGE CONTROLS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There is no income or other tax of the British Virgin Islands imposed by
withholding or otherwise on any payment to be made by us.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are free to acquire, hold and sell foreign currency and securities without
restriction. There is no exchange control legislation under British Virgin Islands law and accordingly there are no exchange control regulations
imposed under British Virgin Islands law that would prevent us from paying dividends to shareholders in United States dollars or any other
currencies, and all such dividends may be freely transferred out of the British Virgin Islands, clear of any income or other tax of the
British Virgin Islands imposed by withholding or otherwise without the necessity of obtaining any consent of any government or authority
of the British Virgin Islands.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(E)</b></td>
    <td><b>TAXATION</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>British Virgin Islands Tax Consequences</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the law of the British Virgin Islands as currently in effect, a holder
of our ordinary shares who is not a resident of the British Virgin Islands is not liable for British Virgin Islands income tax on dividends
paid with respect to our ordinary shares, and all holders of our ordinary shares are not liable to the British Virgin Islands for income
tax on gains realized on the sale or disposal of securities. The British Virgin Islands does not impose a withholding tax on dividends
paid by a company incorporated or continued under the BVI Act.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There are no capital gains, gift or inheritance taxes levied by the British
Virgin Islands on companies incorporated under the BVI Act. In addition, securities of companies incorporated under the BVI Act are not
subject to transfer taxes, stamp duties (unless such companies hold land in the BVI) or similar charges.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There is no income tax treaty or convention currently in effect between
(i) the United States and the British Virgin Islands or (ii) Canada and the British Virgin Islands, although a Tax Information Exchange
Agreement is in force between the United States and the BVI and Canada and the BVI.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>The BVI Economic Substance (Companies and Limited Partnership) Act (Revised Edition 2020)
(the &#8220;ESA&#8221;)</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The above legislation aimed at addressing concerns raised by the Council
of the European Union as to offshore structures engaged in certain activities, which attract profits without real economic activity provides
(among other things) that BVI companies that carry out certain defined activities, need to take steps to establish substance in the British
Virgin Islands. We have filed all our economic substance declarations when due in accordance with the requirements of the legislation.
We are not currently subject to any requirements to establish economic substance in the BVI and given the nature of our business and assets
at the current time the ESA has little material impact on us and our operations. However, the legislation is still in its early stages
and therefore remains subject to further clarification and interpretation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>U.S. Federal Income Tax Consequences</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The discussion below is for general information only and is not, and should
not be interpreted to be, tax advice to any holder of our ordinary shares. Each holder or a prospective holder of our ordinary shares
is urged to consult his, her or its own tax advisor.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>General</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">This section is a general summary of the material United States federal
income tax consequences of the ownership and disposition of our ordinary shares. This summary is based on the provisions of the Internal
Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the applicable Treasury regulations promulgated and proposed thereunder, judicial
decisions and current administrative rulings and practice, all of which are subject to change, possibly on a retroactive basis. The summary
applies to you only if you hold our ordinary shares as a capital asset within the meaning of Section 1221 of the Code. The United States
Internal Revenue Service (the &#8220;IRS&#8221;) may challenge the tax consequences described below, and we have not requested, nor will
we request, a ruling from the IRS or an opinion of counsel with respect to the United States federal income tax consequences of ownership
or disposition of our ordinary shares. This summary does not purport to be a comprehensive description of all the tax considerations that
may be relevant to the ownership of our ordinary shares. In particular, the discussion below does not cover tax consequences that depend
upon your particular tax circumstances nor does it cover any state, local or non-United States law, or the possible application of the
United States federal estate or gift tax. You are urged to consult your own tax advisors regarding the application of the United States
federal income tax laws to your particular situation as well as any state, local, non-United States and United States federal estate and
gift tax consequences of the ownership and disposition of our ordinary shares. In addition, this summary does not take into account any
special United States federal income tax rules that may apply to a particular holder of our ordinary shares, including, without limitation,
the following:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a dealer in securities;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a trader in securities that elects to use a mark-to-market method of accounting for its securities holdings;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a financial institution or a bank;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
an insurance company;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a tax-exempt organization;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a person that holds our ordinary shares in a hedging transaction or as part of a straddle or a conversion transaction;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a person whose functional currency for United States federal income tax purposes is not the U.S. dollar;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a person liable for alternative minimum tax;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a person that owns, or is treated as owning, 10% or more, by voting power or value, of our ordinary shares;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
certain former U.S. citizens and residents who have expatriated; or</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a person who receives our ordinary shares pursuant to the exercise of employee share options or otherwise as compensation.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>U.S. Holders</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">For purposes of the discussion below, you are a &#8220;U.S. Holder&#8221;
if you are a beneficial owner of our ordinary shares who or which is:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
an individual United States citizen or resident alien of the United States (as specifically defined for United States federal income tax
	purposes);</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a corporation, or other entity treated as a corporation for United States federal income tax purposes, created or organized in or under
the 	laws of the United States, any State or the District of Columbia;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
an estate whose income is subject to United States federal income tax regardless of its source; or</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
a trust (x) if a United States court can exercise primary supervision over the trust's administration and one or more United States 	persons
are authorized to control all substantial decisions of the trust or (y) if it was in existence on August 20, 1996, was treated as a 	United
States person prior to that date and has a valid election in effect under applicable Treasury regulations to be treated as a United 	States
person.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">If a partnership holds our ordinary shares, the tax treatment of a partner will generally depend
upon the status of the partner and upon the activities of the partnership. If you are a partner of a partnership holding our ordinary
shares, you should consult your tax advisor.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Distributions</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In general, subject to the PFIC rules discussed below, the gross amount
of any distribution received by a U.S. Holder with respect to our ordinary shares will be included in the gross income of the U.S. Holder
as a dividend to the extent attributable to our current and accumulated earnings and profits, as determined under U.S. federal income
tax principles. Unless we maintain calculations of our earnings and profits in accordance with U.S. federal income tax principles, U.S.
Holders should expect that any distribution will generally be treated as a dividend for U.S. federal income tax purposes. Any dividends
from us will not be eligible for the dividends-received deduction generally allowed to corporations in respect of dividends received from
U.S. corporations. For U.S. foreign tax credit purposes, dividends received on our ordinary shares by a U.S. Holder will generally be
treated as income from sources outside the United States and will generally constitute &#8220;passive category income.&#8221; A portion
of such dividends, however, will be treated as U.S. source income, subject to certain exceptions, in proportion to our U.S. source earnings
and profits if U.S. persons collectively own, directly or indirectly, 50% or more of the voting power or value of our ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">U.S. Holders that are individuals and certain other non-corporate U.S. Holders
will be subject to tax on dividend income from a &#8220;qualified foreign corporation&#8221; at preferential rates of taxation provided
that certain holding period and other requirements are met. For this purpose, a foreign corporation (other than a corporation that is
classified as a PFIC (as discussed below) for the taxable year in which the dividend is paid or the preceding taxable year) will generally
be considered to be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United
States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes
an exchange of information program, or (ii) with respect to any dividend it pays on stock which is readily tradable on an established
securities market in the United States. Our ordinary shares are listed on Nasdaq, which is an established securities market in the United
States, and are expected to be readily tradable. Thus, we expect that dividends paid on its ordinary shares will meet the conditions above
required for the preferential tax rates, provided we are not a PFIC in the year such dividend is paid or the preceding taxable year.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Sale, Exchange or Other Taxable Disposition</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subject to the PFIC rules discussed below, upon a sale, exchange or other
taxable disposition of our ordinary shares, a U.S. Holder will generally recognize a capital gain or loss equal to the difference between
the amount realized on such sale, exchange or other taxable disposition and the adjusted tax basis of such ordinary shares. As discussed
above, a U.S. Holder&#8217;s initial tax basis in our ordinary shares will generally equal the fair market value on the distribution date
of such shares. Such gain or loss will be a long-term capital gain or loss if our ordinary shares have been held for more than one year
and will be a short-term gain or loss if the holding period is equal to or less than one year. Such gain or loss will generally be considered
U.S. source gain or loss for U.S. foreign tax credit purposes. Long-term capital gains of certain non-corporate U.S. Holders are eligible
for reduced rates of taxation. For both corporate and non-corporate U.S. Holders, limitations apply to the deductibility of capital losses.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Passive Foreign Investment Company (PFIC)</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under the Code, we will be a PFIC for any taxable year in which, after the
application of certain "look-through" rules with respect to related companies, either (i) 75% or more of our gross income consists
of "passive income," or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce, or are held
for the production of, "passive income." Passive income generally includes interest, dividends, rents, rents and royalties other
than certain rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business,
and capital gains. Whether we will be a PFIC in any year depends on the composition of our income and assets, and the relative fair market
value of our assets from time to time, which we expect may vary substantially over time. We must make a separate determination each year
as to whether we are a PFIC. As a result, our PFIC status may change from year to year based on our income and assets. We believe that
we were a PFIC in the fiscal year ended in 2018 and that we were a PFIC for the fiscal years ended March 31, 2023 and 2024. We may have
been a PFIC in other years and we may be a PFIC in the future.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If we are a PFIC for any fiscal year during which a U.S. Holder holds our
ordinary shares, we generally will continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding fiscal years during
which the U.S. Holder holds our ordinary shares, unless we cease to meet the threshold requirements for PFIC status and that U.S. Holder
makes a qualifying "deemed sale" election with respect to the ordinary shares. If such an election is made, the U.S. Holder will
be deemed to have sold the ordinary shares it holds at their fair market value on the last day of the last fiscal year in which we qualified
as a PFIC, and any gain from such deemed sale will be subject to the consequences described below. After the deemed sale election, the
ordinary shares with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently
become a PFIC.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If we are a PFIC for any taxable year during which a U.S. Holder holds our
ordinary shares, the U.S. Holder may be subject to adverse tax consequences. Generally, gain recognized upon a disposition of our ordinary
shares by the U.S. Holder would be allocated ratably over the U.S. Holder's holding period for such ordinary shares. The amounts allocated
to the taxable year of disposition and to years before we became a PFIC would be taxed as ordinary income. The amount allocated to each
other taxable year would be subject to tax at the highest rate in effect for that taxable year for individuals or corporations, as appropriate,
and would be increased by an additional tax equal to interest on the resulting tax deemed deferred with respect to each such other taxable
year. Further, to the extent that any distribution received by a U.S. Holder on our ordinary shares exceeds 125% of the average of the
annual distributions on such ordinary shares received during the preceding three years or the U.S. Holder's holding period, whichever
is shorter, that distribution would be subject to taxation in the same manner described immediately above with respect to gain on disposition.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If we are a PFIC for any fiscal year during which any of our non-U.S. subsidiaries
is also a PFIC, a U.S. Holder of our ordinary shares during such year will be treated as owning a proportionate amount (by value) of the
shares of the lower-tier PFIC for purposes of the application of these rules to such subsidiary. U.S. Holders should consult their tax
advisers regarding the tax consequences if the PFIC rules apply to any of our subsidiaries. Alternatively, if we are a PFIC and if our
ordinary shares are "regularly traded" on a &#8220;qualified exchange,&#8221; a U.S. Holder may be eligible to make a mark-to-market
election that would result in tax treatment different from the general tax treatment described above. Our ordinary shares would be treated
as &#8220;regularly traded&#8221; in any calendar year in which more than a de minimis quantity of the ordinary shares are traded on a
qualified exchange on at least 15 days during each calendar quarter. Nasdaq is a qualified exchange for this purpose. However, because
a mark-to-market election cannot be made for equity interests in any lower-tier PFIC that we may own, a U.S. Holder that makes a mark-to-market
election with respect to us may continue to be subject to the PFIC rules with respect to any indirect investments held by us that are
treated as an equity interest in a PFIC for U.S. federal income tax purposes. If a U.S. Holder makes the mark-to-market election, the
U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ordinary shares at the end of each
taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of
the ordinary shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously
included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder's tax basis in the ordinary
shares will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of our ordinary
shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the
extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes a mark-to-market
election it will be effective for the taxable year for which the election is made and all subsequent taxable years unless our ordinary
shares are no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election. U.S. Holders are
urged to consult their tax advisers about the availability of the mark-to-market election, and whether making the election would be advisable
in their particular circumstances.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Alternatively, a U.S. Holder of stock in a PFIC may make a so-called &#8220;Qualified
Electing Fund&#8221; election to avoid the PFIC rules regarding distributions and gain described above. The PFIC taxation regime would
not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held our ordinary shares while we
are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made a valid and effective
QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our
ordinary earnings as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless
of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain
required information. U.S. Holders should be aware, however, that we are not required to make this information available but have agreed
to do so for prior fiscal years for those U.S. Holders who ask for it. The QEF election is made on a shareholder-by-shareholder basis
and generally may be revoked only with the consent of the IRS. U.S. Holders should consult with their own tax advisors regarding eligibility,
manner and advisability of making a QEF election if we are treated as a PFIC.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In addition, if we are a PFIC or, with respect to particular U.S. Holders,
are treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the preferential rates discussed
above with respect to dividends paid to certain non-corporate U.S. Holders would not apply.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If a U.S. Holder owns our ordinary shares during any year in which we are
a PFIC, the U.S. Holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign
Investment Company or Qualified Electing Fund) with respect to us, generally with the U.S. Holder&#8217;s federal income tax return for
that year. If we are a PFIC for a given taxable year, you should consult your tax advisor concerning your annual filing requirements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The U.S. federal income tax rules relating to PFICs are complex. U.S. Holders
are urged to consult their own tax advisers with respect to the ownership and disposition of our ordinary shares, the consequences if
we are or become a PFIC, any elections available with respect to our ordinary shares, and the IRS information reporting obligations with
respect to the ownership and disposition of our ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Foreign asset reporting</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Certain U.S. Holders, who are individuals, are required to report information
relating to an interest in ordinary shares, subject to certain exceptions (including an exception for ordinary shares held in accounts
maintained by U.S. financial institutions). U.S. Holders are urged to consult their tax advisors regarding their information reporting
obligations, if any, with respect to their ownership and disposition of ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Non-U.S. Holders </i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If you are not a U.S. Holder, you are a &#8220;Non-U.S. Holder.&#8221;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Distributions on Our Ordinary Shares</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">You generally will not be subject to U.S. federal income tax, including
withholding tax, on distributions made on our ordinary shares unless:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
you conduct a trade or business in the United States; and</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
the distributions are effectively connected with the conduct of that trade or business (and, if an applicable income tax treaty so requires
	as a condition for you to be subject to U.S. federal income tax on a net income basis in respect of income from our ordinary shares,
such 	distributions are attributable to a permanent establishment that you maintain in the United States).</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If you meet the two tests above, you generally will be subject to tax in
respect of such dividends in the same manner as a U.S. Holder, as described above. In addition, any effectively connected dividends received
by a non-U.S. corporation may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30
percent rate or such lower rate as may be specified by an applicable income tax treaty.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline">Sale, Exchange or Other Disposition of Our Ordinary
Shares</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Generally, you will not be subject to U.S. federal income tax, including
withholding tax, in respect of gain recognized on a sale or other taxable disposition of our ordinary shares unless:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
your gain is effectively connected with a trade or business that you conduct in the United States (and, if an applicable income tax treaty
	so requires as a condition for you to be subject to U.S. federal income tax on a net income basis in respect of gain from the sale
or other 	disposition of our ordinary shares, such gain is attributable to a permanent establishment maintained by you in the United
States); or</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
you are an individual Non-U.S. Holder and are present in the United States for at least 183 days in the taxable year of the sale or other
	disposition, and certain other conditions exist.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If you meet one of tests above, you generally will be subject to tax in
respect of any gain effectively connected with your conduct of a trade or business in the United States in the same manner as a U.S. Holder,
as described above. Effectively connected gains realized by a non-U.S. corporation may also, under certain circumstances, be subject to
an additional &#8220;branch profits tax&#8221; at a rate of 30 percent or such lower rate as may be specified by an applicable income
tax treaty.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Backup Withholding and Information Reporting</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Payments, including dividends and proceeds of sales, in respect of our ordinary
shares that are made in the United States or by a United States related financial intermediary may be subject to United States information
reporting rules. In addition, U.S. Holders may be subject to United States federal backup withholding tax. U.S. Holders will not be subject
to backup withholding provided that:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
you are a corporation or other exempt recipient; or</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
you provide your correct United States federal taxpayer identification number and certify, under penalties of perjury, that you are not
	subject to backup withholding.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Amounts withheld under the backup withholding rules may be credited against
your United States federal income tax, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by
filing the appropriate claim for refund with the IRS in a timely manner.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(F)</b></td>
    <td><b>DIVIDEND AND PAYING AGENTS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(G)</b></td>
    <td><b>STATEMENT BY EXPERTS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(H)</b></td>
    <td><b>&#8239;DOCUMENTS ON DISPLAY</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are currently subject to the informational requirements of the Exchange
Act applicable to foreign private issuers. To fulfill these requirements, we file with the SEC, within four months after the end of our
fiscal year an annual report on Form 20-F containing consolidated financial statements that will be examined and reported on, with an
opinion expressed, by an independent public accounting firm. We also file current reports on Form 6-K for significant corporate events
throughout the year. As a foreign private issuer, we are exempt from the rules under the Exchange Act relating to the furnishing of proxy
statements. Also, because we are a foreign private issuer our officers, directors and principal shareholders are exempt from the reporting
and short swing profit provisions contained in Section 16 of the Exchange Act.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">You may read and copy any document we file with the SEC without charge at
the SEC's public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of the documents
at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the
SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet site that contains reports
and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public
through this web site at http://www.sec.gov.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(I)</b></td>
    <td><b>SUBSIDIARY INFORMATION</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in"><b>(J)</b></td>
    <td><b>ANNUAL REPORT TO SECURITY HOLDERS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If we are required to provide an annual report to security holders in response
to the requirements of Form 6-K, we will submit the annual report to security holders in electronic format in accordance with the EDGAR
Filer Manual.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="text-decoration: underline"><b><span id="item11"></span>ITEM 11 &#8211; QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are exposed in varying degrees to a number of risks arising from financial
instruments. Management's close involvement in the operations allows for the identification of risks and variances from expectations.
We do not participate in the use of financial instruments to mitigate these risks and we have no designated hedging transactions. The
Board approves and monitors the risk management processes. The Board's main objectives for managing risks are to ensure liquidity, the
fulfilment of obligations, the continuation of our search for new business participation opportunities, and limited exposure to credit
and market risks while ensuring greater returns on the surplus funds on hand. There were no changes to the objectives or the process from
the prior year.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A summary of our risk exposures as it relates to financial instruments are
reflected below.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Fair value of Financial Instruments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our financial assets and liabilities are comprised of cash and cash equivalents,
receivables, stablecoin, digital assets receivable and investments in equities and public entities, accounts payable and accrued liabilities,
lease liability, put right liability, TON payable, warrant liability, deferred purchase price payable and deferred obligation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We classify the fair value of these transactions according to the following
fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Level 1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the
reporting 	date.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Level 2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
can be 	substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as
of the 	reporting date.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Level 3 &#8211; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
as 	Level 3 financial instrument.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Assessment of the significance of a particular input to the fair value measurement
requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our financial instruments are exposed to certain financial risks: Credit
Risk, Liquidity Risk, Digital Asset Risk, and Foreign Currency Risk.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Credit Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Credit risk is the risk of loss associated with a counterparty&#8217;s
inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#8217;s consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Cash and cash equivalents: </b>Cash and cash equivalents comprise cash
on hand and amounts invested in underlying treasury and money market funds that are readily convertible to a known amount of cash with
three months or less from date of acquisition and are subject to an insignificant risk of change in value. As of March 31, 2026 and 2025,
cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. Cash and cash equivalents
are held with major international financial institutions and therefore the risk of loss is minimal.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Liquidity Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Liquidity risk is the risk that the Company will encounter difficulty in
satisfying financial obligations as they become due.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s approach to managing liquidity
is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed
conditions without incurring unacceptable losses or risking harm to the Company&#8217;s reputation. The Company holds sufficient cash
and cash equivalents to satisfy current obligations under accounts payable and accruals.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company monitors its liquidity position regularly
to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects.&#160;&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Digital Asset Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company is subject to various risks including market risk, liquidity
risk and other risks related to its concentration in TON and other digital assets. Investing in digital assets is currently highly speculative
and volatile.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The price of our digital assets has been, and will likely continue to be,
highly volatile. Our financial results and the market price of our ordinary shares could be materially and adversely affected if the price
of our digital assets decreases substantially, as it has in the past, including as a result of shifts in market sentiment, speculative
trading, macroeconomic trends, technology-related disruptions and regulatory announcements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our historical financial statements do not reflect the potential variability
in earnings that we may experience in the future from holding or selling digital assets. Accordingly, volatility in our earnings may be
significantly more than what we experienced in prior periods, and it may be difficult to evaluate the Company&#8217;s business and future
prospects. We also may need to perform an analysis each quarter to identify whether events or changes in circumstances indicate that our
digital assets are impaired.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company will face risks relating to the custody of its digital assets.
Cybersecurity threats, including hacking, phishing and other malicious attacks, could result in the loss, theft or misappropriation of
our digital assets. If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain
access to our private keys, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose
some or all of our digital assets and our financial condition and results of operations could be materially and adversely affected.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There is a risk that some or all of the Company&#8217;s digital assets could
be lost or stolen. There can be no assurance that our custodians will maintain adequate insurance or that such coverage will cover any
losses with respect to the Company&#8217;s digital assets. Further, transactions in digital assets are irrevocable. Stolen or incorrectly
transferred digital assets may be irretrievable. As a result, any incorrectly executed transactions of the Company&#8217;s digital assets
could adversely affect an investment in the Company&#8217;s ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s shareholders have no specific rights to any specific
digital assets. In the event of the insolvency of the Company, its assets may be inadequate to satisfy a claim by its shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The SEC has stated that certain digital assets may be considered securities
under federal securities laws. The test for determining whether a particular digital asset is a security is complex and difficult to apply,
and the outcome is difficult to predict. Future developments could change the legal status of digital assets we hold. If our digital assets
are determined to be securities under federal or state securities laws or in a proceeding in a court of law, or otherwise, it may have
material adverse consequences for our digital assets, making them more difficult to be traded, cleared or custodied compared to other
digital assets that are not considered securities. In addition, if our digital assets are considered securities, the Company could be
considered an unregistered investment company under the Investment Company Act of 1940, which could necessitate the Company&#8217;s liquidation.
If the Company is required to comply with additional regulatory obligations, it could result in a significant increase in operating expenses
and make it difficult to continue our current operations, which would materially and adversely affect our business, financial condition
and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As a company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company. The current uncertainty in global capital markets could have an impact on the Company&#8217;s future
ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available
to the Company. See Note 17, &#8220;Capital Stock and Reserves,&#8221; for a discussion of the Company&#8217;s share offering and current
funding levels.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Foreign Currency Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">While the Company operates in various jurisdictions,
substantially all of the Company&#8217;s transactions are denominated in the U.S. Dollar.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i12"></span>ITEM 12 &#8211; DESCRIPTION
OF SECURITIES OTHER THAN EQUITY SECURITIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline">PART II</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i13"></span>ITEM 13 &#8211; DEFAULTS,
DIVIDEND ARREARAGES AND DELINQUENCIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">None.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i14"></span>ITEM 14 &#8211; MATERIAL MODIFICATIONS
TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">None.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i15"></span>ITEM 15 &#8211; CONTROLS AND
PROCEDURES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Disclosure Controls and Procedures</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our disclosure controls and procedures, as such term is defined in Rules
13(a)-15(e) and 15(d)-15(e) of the Exchange Act, are designed to provide reasonable assurance that all relevant information is communicated
to senior management, including the CEO and the CFO, to allow timely decisions regarding required disclosure. We carried out an evaluation,
under the supervision and with the participation of our management, including our CEO and CFO. Based on this evaluation, these officers
concluded that as of the end of the period covered by this Annual Report on Form 20-F, our disclosure controls and procedures were not
effective to ensure that the information required to be disclosed by our company in reports we file or submit under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission
(&#8220;SEC&#8221;). These disclosure controls and procedures include controls and procedures designed to ensure that such information
is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow
timely decisions regarding required disclosure. The conclusion that the disclosure controls and procedures were not effective was due
to the presence of material weaknesses in internal control over financial reporting as identified below under the heading " Management's
Annual Report on Internal Control over Financial Reporting". Management anticipates that such disclosure controls and procedures will
not be effective until the material weakness is remediated.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Management's Annual Report on Internal Control over Financial Reporting (ICFR)</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our management, including the CEO and CFO, is responsible for establishing
and maintaining adequate internal controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal
control system was designed to provide reasonable assurance to our management and our Board regarding the reliability of financial reporting
and preparation and fair presentation of published financial statements for external purposes in accordance with IFRS. Internal control
over financial reporting includes those policies and procedures that:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in">1.</td>
    <td>pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our
        assets;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in">2.</td>
    <td>provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
        IFRS, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in">3.</td>
    <td>provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
        have a material effect on the financial statements.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">All internal control systems, no matter how well designed, have inherent
limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial
statement preparation and presentation. Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Management assessed the effectiveness of our internal control over financial
reporting as of March 31, 2026. In making this assessment, it used the criteria established in Internal Control - Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the evaluation under these criteria, management
identified material weaknesses in our internal controls over financial reporting and, as a result, management concluded that our internal
control over financial reporting was not effective as of March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Management identified the following material weaknesses in our internal
control over financial reporting.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Ineffective implementation of Information Technology General Controls (&#8220;ITGCs&#8221;) including insufficient segregation of duties,
oversight of service organizations and lack of formal user access reviews;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A lack of segregation of duties in the accounting and finance functions result in inadequate controls relating to the documentation of
the review and approval of reconciliations and other schedules prepared internally to be included or disclosed in the financial statements;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Management lacks the number of skilled persons that it requires given the complexity of the Company's reporting requirements, including
the staff and expertise to apply complex accounting principles, specifically those relating to business combination accounting, income
taxes, warrant liabilities, equity transactions, digital assets and fair value estimates; and</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
The Company did not complete a Sarbanes-Oxley (SOX) Section 404A assessment.<b></b></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Attestation Report of the Registered Public Accounting Firm</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">This Annual Report does not include an attestation report of our registered
public accounting firm regarding internal control over financial reporting. Management's report is not subject to attestation by our registered
public accounting firm pursuant to rules of the SEC that permit us to provide only management's report in this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Changes in Internal Control over Financial Reporting and Planned Remediation Activities</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Management continues to improve its control over financial reporting and
leverages experienced personnel, including consultants to perform ongoing IFRS and SEC compliance requirements. In April 2026, we engaged
with an external consultant for a comprehensive review of internal controls and Sarbanes-Oxley compliance, with improvements to our processes
to be implemented throughout Fiscal 2027.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16a"></span>ITEM 16A &#8211; AUDIT COMMITTEE
FINANCIAL EXPERT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our Board has determined that Mr. Siciliano is an &#8220;audit committee
financial expert,&#8221; as such term is defined in Part II Item 16A.(b) of the General Instructions to Form 20-F, and is &#8220;independent,&#8221;
as such term is defined in Rule 10A-3(b)(1) under the Exchange Act.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16b"></span>ITEM 16B &#8211; CODE OF
ETHICS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We have adopted a Code of Ethics, which applies to all consultants, officers
and directors. A copy of our current code of ethics was included in the exhibits to the fiscal 2014 annual report on Form 20-F and is
incorporated by reference into the exhibit index to this Annual Report on Form 20-F.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During the most recently completed fiscal year, we neither: (a) amended
its Code of Ethics; nor (b) granted any waiver (including any implicit waiver) from any provision of its Code of Ethics.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16c"></span>ITEM 16C &#8211; PRINCIPAL
ACCOUNTANT FEES AND SERVICES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Marcum LLP (&#8220;Marcum&#8221;) served as our independent registered public
accountants until May 29, 2025, and audited our annual consolidated financial statements for the fiscal year ended March 31, 2024. On
November 1, 2024, CBIZ CPAs P.C. (&#8220;CBIZ CPAs&#8221;) acquired the attest business of Marcum. On May 29, 2025, Marcum resigned as
our auditors, and with the approval of our Audit Committee of our Board of Directors, CBIZ CPAs was engaged as our independent registered
public accounting firm.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Prior to engaging CBIZ CPAs, the Company did not consult with CBIZ CPAs
regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit
opinion that might be rendered on the Company&#8217;s consolidated financial statements, or (ii) any matter that was either the subject
of a disagreement (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described
in Item 304(a)(1)(v) of Regulation S-K and the related instructions).</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The reports of Marcum regarding the Company&#8217;s consolidated financial
statements for the fiscal years ended March 31, 2024, 2023 and 2022, did not contain any adverse opinion or disclaimer of opinion and
were not qualified or modified as to uncertainty, audit scope, or accounting principles except for the inclusion of an explanatory paragraph
in the audit report for the fiscal years ended March 31, 2024, 2023 and 2022 as to the Company&#8217;s ability to continue as a going
concern.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During the Company&#8217;s fiscal years ended March 31, 2024, 2023, and
2022, and the subsequent interim period through May 29, 2025, there were no (i) disagreements (as defined in Item 304(a)(1)(iv) of Regulation
S-K and the related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum
to make reference to the subject matter of the disagreements in their reports on the Company&#8217;s consolidated financial statements
for such years or (ii) &#8220;reportable events&#8221; (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions),
except for a material weakness related to a lack of design and maintenance of effective information technology general controls due to
certain privileged access rights, lack of formal processes for user provisioning, periodic user access review, change management for the
financial reporting system and lack of formal reviews of key third party service provider SOC reports, all of which could allow for inappropriate
financial transactions to be recorded that would not be detected by the Company's other manual controls, rendering them ineffective, as
disclosed in the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended March 31, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company provided Marcum with a copy of the Current Report on Form 6-K
reporting the change in the registered public accounting firms prior to its filing with the U.S. Securities and Exchange Commission (the
&#8220;SEC&#8221;) and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation
S-K, stating whether it agrees with the above statements and, if it does not agree, the aspects in which it did not agree. Marcum provided
its letter in which it did not object to the statements made by the Company, and a copy of the letter, dated May 29, 2025, was filed as
Exhibit 16 to the Current Report on Form 6-K.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following outlines the expenditures for accounting fees paid or accrued
to our independent public accountants, for the fiscal years ended March 31, 2026 and 2025 by CBIZ CPAs and Marcum:&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">CBIZ CPAs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Marcum</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; font-style: normal; text-align: left">Audit fees<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">638,600&#160;</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">128,750</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">-</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">201,253</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">638,600&#160;</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">330,003</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; text-align: left">Audit-related fees<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(2)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">16,995</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><b>$</b></td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">16,995</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(1)</td>
    <td>&#8220;Audit fees&#8221; means the aggregate fees incurred in connection with the audit of our annual consolidated financial statements
        included in our Annual Report on Form 20-F, review of the six month consolidated interim financial statements included in our Form 6-K,
        and services normally provided by our independent public accountants in connection with statutory and regulatory filings or engagements.</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(2)</td>
    <td>"Audit-related fees&#8221; relate to assurance and related services that are reasonably related to the performance of the audit or
        review of our consolidated financial statements and are not reported under &#8220;audit fees.&#8221; This category would include fees
        related to non-routine SEC filings.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our Audit Committee requires pre-approval of all audit and non-audit services.
Other than de minimis services incidental to audit services, non-audit services shall generally be limited to tax services such as advice
and planning and financial due diligence services. All fees for such non-audit services must be approved by the Audit Committee, except
to the extent otherwise permitted by applicable SEC regulations. The Audit Committee may delegate to one or more designated members of
the Audit Committee the authority to grant pre-approvals, provided such approvals are presented to the Audit Committee at a subsequent
meeting. During the years ended March 31, 2026 and 2025, 100% of the fees paid to our independent public accountants were approved by
the Audit Committee.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We did not have any engagement with our independent public accountants during
the Fiscal 2026 and Fiscal 2025 with respect to professional services for tax compliance, tax advice or tax planning or for any audit-related
services.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16d"></span>ITEM 16D &#8211; EXEMPTIONS
FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16e"></span>ITEM 16E &#8211; PURCHASES
OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 29, 2025, the Company completed the sale of 524,390 ordinary
shares for aggregate proceeds of $2,150,000, at a per share price of $4.10, the closing price of a share on the Nasdaq Stock Market on
the date preceding the date of the securities purchase agreement. The shares were sold to two directors of the Company, Messrs. Gregory
Bailey and James Mellon. The shares were sold in a private placement transaction pursuant to Regulation S, and are being issued as restricted
stock. The proceeds will be used for general corporate purposes and working capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In connection with the sale of the shares, the Company entered into a registration
rights agreement that provides for two demand registrations at any time on a Form F-1 or equivalent and once each year on a Form F-3,
provided the anticipated value of the shares being registered is at least $500,000. The registration rights agreement has a term of seven
years. The Company is obligated to pay the costs of the registration statement but not any broker or other selling commissions due to
a broker or dealer engaged by the selling shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On June 5, 2025, the Company and Compedica Holdings Limited, a company formed
under the laws of the Isle of Man (&#8220;Compedica&#8221;), entered a mutual Subscription Agreement (&#8220;Subscription Agreement&#8221;).
Pursuant to the Subscription Agreement, the Company issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501
shares of Compedica with a per share value of $4.29, in a transaction valued at $5,000,000. Compedica purchased 37.8% of Portage based
on the issued and outstanding ordinary shares of the Company immediately prior to the consummation of the Subscription Agreement, resulting
in a then ownership of 27.4% of the issued and outstanding ordinary shares of the Company immediately after the consummation of the Subscription
Agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s ordinary shares were sold pursuant to an exemption under
the Securities Act of 1933, as amended, under Regulation S, and were issued as &#8220;restricted stock.&#8221; Compedica was granted registration
rights on a resale basis, upon demand, while the shares are restricted stock and Compedica is not otherwise able to sell the shares in
the public market. The ordinary shares acquired by Compedica are not subject to any lock up arrangement. The Company reimbursed Compedica
for up to $50,000 of its legal fees in the transaction. Compedica was also granted the right to have an observer attend board meetings
and review written consents of the board of directors, subject to being restricted from access (including participation in the meeting)
to confidential or market sensitive information without a non-disclosure obligation with respect to such information. There are no broker
fees payable by either party to the Subscription Agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">If the Company enters into an equity funding arrangement, subject to the
monthly working capital requirements of the Company and unless agreed otherwise by the parties in writing, for a period of 12 months from
the date of the Subscription Agreement, the Company will use not less than 50% of the net funds to subscribe for new Compedica equity
at a price of $4.29 per share, the intended use of proceeds to be to support the continued development of the Compedica device and its
commercialization. To the extent less than 50% of the equity financing are invested in Compedica by the Company in any month (the &#8220;Shortfall&#8221;),
the Shortfall amount shall be added to the obligation of the Company to fund in the next following month (and the aggregate of Shortfalls
shall continue to accrue and be rolled forward for the duration of the 12 month term, with any outstanding Shortfall amount not advanced
as an equity investment at the end of the 12 month term immediately due and payable (unless agreed otherwise in writing by Compedica)).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#8217;s treasury and the investment being exited.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 25, 2025, the Company completed the sale of 3,415,780 &#160;&#160;ordinary
shares at a per share price of $5.73, and pre-funded warrants to purchase 3,258,466 ordinary shares at a purchase price of $5.73 per ordinary
share (less $0.001 per pre-funded warrant) for gross proceeds of approximately $34.5 million, consisting of cash of $3.3 million and digital
assets and stablecoin of $32.9 million. Each pre-funded warrant is exercisable for one ordinary share at an exercise price of $0.001 per
pre-funded warrant, is immediately exercisable and will expire once exercised in full. The shares and pre-funded warrants were sold in
a private placement transaction in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated
under the Securities Act, and the proceeds are being used for the establishment of the Company&#8217;s digital asset treasury.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During the fiscal year ended March 31, 2026, the Company sold 4,062,632
ordinary shares under the ATM program, generating net proceeds of approximately $12.0 million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 13, 2026, the Company entered into a securities purchase agreement
with certain purchasers, pursuant to which the Company offered for sale to the Purchasers in a registered direct offering an aggregate
of 5,230,000 ordinary shares and, in lieu thereof, pre-funded warrants to purchase up to 9,770,000 ordinary shares. The net proceeds from
the Offering were approximately $12.7 million.&#160;&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16f"></span>ITEM 16F &#8211; CHANGE IN
REGISTRANT'S CERTIFYING ACCOUNTANT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">See Item 16C.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16g"></span>ITEM 16G &#8211; CORPORATE
GOVERNANCE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are incorporated under the BVI Act. Our ordinary shares are registered
with the SEC and are listed on the Nasdaq Capital Market. As a result, our corporate governance framework is subject to laws of the British
Virgin Islands, or BVI, the securities laws and regulations of the United States and the listing requirements of the Nasdaq Marketplace
Rules.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under Rule 5615 of the Nasdaq Marketplace Rules, a foreign private issuer
may follow its home country practice in lieu of the requirements of the Nasdaq Marketplace Rules. We follow the exemptions provide under
the Nasdaq Marketplace Rules as described below.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">British Virgin Islands law does not require that a majority of our board
of directors consist of independent directors or that our board committees consist of entirely independent directors. Our board of directors
and board committees, therefore, may include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule
5605(b)(1). In addition, we will not be subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors must regularly
have scheduled meetings at which only independent directors are present.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We also are exempt from the Nasdaq listing rules as to quorum, and instead
to follow the quorum rules for shareholder meetings under British Virgin Islands law. We also are exempt from the Nasdaq listing rules
so as to not be required to obtain shareholder approval for certain issuance of securities, shareholder approval of share option plans
and change of control transactions under Nasdaq Listing Rule 5635 and to hold annual shareholder meetings under Nasdaq Listing Rule 5620(a).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As a foreign private issuer, we are exempt from the proxy rules set forth
in Sections 14(a), 14(b), 14(c) and 14(f) of the Securities Exchange Act of 1934. We solicit proxies in accordance with applicable rules
and regulations in the British Virgin Islands.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16h"></span>ITEM 16H &#8211; MINE SAFETY
DISCLOSURE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16i"></span>ITEM 16I &#8211; DISCLOSURE
REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Not applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16j"></span>ITEM 16J &#8211; INSIDER
TRADING POLICIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We have adopted an insider trading policy governing the purchase, sale,
and other dispositions of our securities by directors, senior management, and employees that are reasonably designed to promote compliance
with applicable insider trading laws, rules and regulations, and any applicable listing standards. A copy of our insider trading policy
is included in the exhibits to this Annual Report on Form 20-F.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<div>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i16k"></span>ITEM 16K &#8211; CYBERSECURITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We are increasingly dependent on software applications and computing infrastructure
to conduct key operations. We depend on both our own record retention and technology as well as the systems, networks and technology of
our contractors, consultants, vendors and other business partners.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Cybersecurity Program</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Given the importance of cybersecurity to our business, we maintain a cybersecurity
program to support both the effectiveness of our systems and our preparedness for information security risks. This program includes a
number of safeguards, such as: password protection; multi-factor authentication; continuous monitoring and alerting systems for internal
and external threats; regular evaluations of our cybersecurity program, including retention of outsourced experts.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We use a risk-based approach with respect to our use and oversight of third-party
service providers, tailoring processes according to the nature and sensitivity of the data accessed, processed, or stored by such third-party
service provider.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Process for Assessing, Identifying and Managing Material Risks from Cybersecurity Threats</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In the event of a cybersecurity incident, we maintain a regularly tested
incident response program. Pursuant to the program and its escalation protocols, designated personnel are responsible for assessing the
severity of an incident and associated threat, containing the threat, remediating the threat, including recovery of data and access to
systems, analyzing any reporting obligations associated with the incident, and performing post-incident analysis and program enhancements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We have relationships with a number of third-party service providers to
assist with cybersecurity containment and remediation efforts.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Governance</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We currently engage a qualified IT consultant who reports to our Chief Executive
Officer. This consultant has robust experience with cybersecurity, information technology development and deployment and information technology
risk assessment and management, including information security management.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our IT consultant regularly monitors our information technology systems
and monitors the prevention, detection, mitigation and remediation of cybersecurity incidents in consultation with our Chief Executive
Officer. To the extent necessary, our Chief Executive Officer reports such risks to our Board, which has overall responsibility for risk
oversight.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Over the last three years, we have not experienced any cybersecurity incidents
that have materially affected or are reasonably likely to materially affect is, including our business, results of operations, or financial
condition.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Board Oversight</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">While the Board of Directors has overall responsibility for risk oversight,
our Audit Committee oversees cybersecurity risk matters. The Audit Committee is responsible for reviewing, discussing with management,
and overseeing the Company&#8217;s data privacy, information technology and security and cybersecurity risk exposures, including: (i)
the potential impact of those exposures on the Company&#8217;s business, financial results, operations and reputation; (ii) the programs
and steps implemented by management to monitor and mitigate any exposures; (iii) the Company&#8217;s information governance and cybersecurity
policies and programs; and (iv) major legislative and regulatory developments that could materially impact the Company&#8217;s data privacy
and cybersecurity risk exposure.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In the event of a cybersecurity incident, the Chief Financial Officer would
apprise the full Board promptly with respect to any incident.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Cybersecurity Risks</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our cybersecurity risk management processes are integrated into our overall
Enterprise Risk Management (&#8220;ERM&#8221;) process. As part of our ERM process, we identify, assess and evaluate risks impacting our
operations across the Company, including those risks related to cybersecurity. We consider the severity and likelihood of certain risk
factors, drawing upon our industry experience and company knowledge. While we maintain a robust cybersecurity program, the techniques
used to infiltrate information technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate
and implement adequate security measures. For additional information, see Item 3 (D) &#8220;Risk Factors.&#8221;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We also maintain cybersecurity insurance providing coverage for certain
costs related to cybersecurity-related incidents that impact our own systems, networks, and technology or the systems, networks and technology
of our contractors, consultants, vendors and other business partners.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In the last three years, we did not experience any material cybersecurity
incidents or threats.</p> </div>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline">PART III</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i17"></span>ITEM 17 &#8211; FINANCIAL
STATEMENTS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The financial statements are provided pursuant to Item 18.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i18"></span>ITEM 18 &#8211; FINANCIAL
STATEMENTS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">See the Financial Statements beginning on page F-1 of this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Exhibits are listed in Item 19 hereof and filed as part of this Annual Report.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>ALPHA COMPUTE CORP</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="width: 88%"><a href="#auditreport"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB
        ID: 0199 and <span id="xdx_901_edei--AuditorFirmId_c20250401__20260331_zufmT72Vixr3"><span style="-sec-ix-hidden: xdx2ixbrl0060">0688</span></span>)</span></a></td>
    <td style="width: 12%; text-align: right"><a href="#auditreport"><span style="font-size: 10pt">F-1</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><a href="#financialposition"><span style="font-size: 10pt">Consolidated Statements of Financial Position</span></a></td>
    <td style="text-align: right"><a href="#financialposition"><span style="font-size: 10pt">F-4</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><a href="#comprehensiveincome"><span style="font-size: 10pt">Consolidated Statements of Operations and Other Comprehensive Income (Loss)</span></a></td>
    <td style="text-align: right"><a href="#comprehensiveincome"><span style="font-size: 10pt">F-5</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><a href="#changesinequity"><span style="font-size: 10pt">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit)</span></a></td>
    <td style="text-align: right"><a href="#changesinequity"><span style="font-size: 10pt">F-6</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><a href="#cashflows"><span style="font-size: 10pt">Consolidated Statements of Cash Flows</span></a></td>
    <td style="text-align: right"><a href="#cashflows"><span style="font-size: 10pt">F-7</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><a href="#financialnotes"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="text-align: right"><a href="#financialnotes"><span style="font-size: 10pt">F-8</span></a></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b><span id="auditreport"></span>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>Report of Independent Registered Public Accounting Firm</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">To the Shareholders and Board of Directors of</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">Alpha Compute Corp</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">We have audited the accompanying consolidated statements of financial position
of Alpha Compute Corp (the &#8220;Company&#8221;) as of March 31, 2026 and 2025, the related consolidated statements of operations and
other comprehensive income (loss), changes in shareholders&#8217; equity (deficit) and cash flows for each of the two years in the period
ended March 31, 2026, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, based
on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31,
2026 and 2025, and the results of its operations and its cash flows for each of the two years in the period ended March 31, 2026, in conformity
with International Financial Reporting Standards as issued by the International Accounting Standards Board.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Explanatory Paragraph &#8211; Going Concern</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As more fully described in Note 2, the Company has a significant working capital deficiency,
has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions
raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are
also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Basis for Opinion</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm
registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we express no such opinion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">Our audits included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Prior Period Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">The financial statements of the Company as of and for the year ended March
31, 2024, were audited by Marcum LLP, whose report dated August 14, 2024, included an explanatory paragraph expressing significant doubt
about the Company&#8217;s ability to continue as a going concern.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Critical Audit Matters</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">The critical audit matters communicated below are matters arising from
the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and
that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements,
taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit
matters or on the accounts or disclosures to which they relate.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">As discussed in Note 12 to the consolidated financial statements, the Company
issued put options to certain investors in connection with a financing transaction in which investors contributed digital assets in exchange
for ordinary shares and pre-funded warrants. The put options provide investors with the right, subject to specified terms and conditions,
to require the Company to repurchase the subscribed shares in exchange for the digital assets originally contributed in the financing
transaction. The Company accounted for the put options as financial liabilities and measured them at fair value.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">Auditing the valuation of the put option liabilities was especially challenging
and involved a high degree of auditor judgment due to the subjectivity associated with fair value measurements. The valuations required
management to apply complex valuation methodologies and utilize significant inputs and assumptions regarding the potential exercise of
the put rights, the expected timing of settlement, future market values of their own equity and the underlying digital assets, and other
transaction-specific contractual provisions. The fair value estimate was sensitive to changes in these assumptions, and the audit required
specialized skills and knowledge in evaluating the valuation methodology and significant inputs and assumptions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">Accordingly, we determined that the valuation of the put option liabilities
was a critical audit matter.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><i>How the Critical Audit Matter was addressed in the Audit</i></p>

<p style="margin: 0pt 0; font-size: 10pt"><i>&#160;</i></p>

<!-- Field: Page; Sequence: 58; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">Our audit procedures related to the valuation of the put option liabilities included, among
others:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Assessing the qualifications and competence of the third party specialist.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Reading the put option agreements and related transaction documents to evaluate the contractual terms and conditions affecting the valuation.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Utilizing our internal valuation specialist to assist in evaluating the valuation methodologies and significant inputs and assumptions
        applied by management.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Evaluating the adequacy of the related disclosures in the consolidated financial statements.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">/s/ <span style="font-variant: small-caps">CBIZ CPAs P.C.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-variant: small-caps">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>CBIZ CPAs P.C.</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-variant: small-caps">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">We have served as the Company&#8217;s auditor since 2019. (such date takes
into account the acquisition of the attest business of Marcum <span style="font-variant: small-caps">llp</span> by CBIZ CPAs P.C. effective
November 1, 2024).</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 3pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">To the Shareholders and Board of Directors of</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">Alpha Compute Corp</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">We have audited the accompanying consolidated statements of operations
and other comprehensive income (loss), changes in shareholders&#8217; equity (deficit) and cash flows of Alpha Compute Corp (the &#8220;Company&#8221;)
for the year ended March 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our
opinion, the financial statements present fairly, in all material respects, the results of the operations and cash flows of the Company
for the year ended March 31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Explanatory Paragraph &#8211; Going Concern</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and
needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the
Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated
financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Basis for Opinion</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm
registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">We conducted our audit in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of
material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of
its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over
financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial
reporting. Accordingly, we express no such opinion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Critical Audit Matters</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">Critical audit matters are matters arising from the current period audit
of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts
or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.
We determined that there are no critical audit matters.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">/s/ Marcum <span style="font-variant: small-caps">llp</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-variant: small-caps">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span id="xdx_905_edei--AuditorName_c20250401__20260331_zI6cNGbRfJZc"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000061" name="dei:AuditorName">Marcum
LLP</ix:nonNumeric></span><span style="font-variant: small-caps"></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-variant: small-caps">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt">We served as the Company&#8217;s auditor from 2019 through 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><span id="xdx_907_edei--AuditorLocation_c20250401__20260331_zHhYhJBvHQh9"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000062" name="dei:AuditorLocation">New
York</ix:nonNumeric></span>, NY</p>

<p style="margin: 0pt 0; font-size: 10pt">August 14, 2024</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 3pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><br/> </b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span id="financialposition"></span>Consolidated Statements of Financial Position</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_111_pn3n3_zT3J7HVwhnBd" summary="xdx: Statement - Consolidated Statements of Financial Position" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49E_20260331_z3wkblOhxgcj" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331_ztkSnYmlGPJ3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b>March 31,</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"><b>Notes</b></td>
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b>2025</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--AssetsAbstract_iB_zDccbMbPqX2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentAssetsAbstract_i01B_znASdLgAior3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CashAndCashEquivalents_i02I_maCAzYZH_zbbDMr6jnAFk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 55%; font-size: 10pt; text-align: left">Cash and cash equivalents</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 12%; font-size: 10pt; font-weight: bold; text-align: center">4</td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2026-03-31" id="Fact000070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">486</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,670</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--RestrictedCashAndCashEquivalents_i02I_maCAzYZH_z4MJFht9xvuh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Restricted cash</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">4</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:RestrictedCashAndCashEquivalents" contextRef="AsOf2026-03-31" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0074">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccountsReceivable_i02I_maCAzYZH_zPRE1Uyjbhrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts receivable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">4</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsReceivable" contextRef="AsOf2026-03-31" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0077">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--Stablecoin_i02I_maCAzYZH_z92XC0g7ACkd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">6</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2026-03-31" id="Fact000079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0080">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DigitalAssetsAtFairValueTonCurrent_i02I_maCAzYZH_zKrgITggGosk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Digital assets at fair value, TON, current</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">7</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonCurrent" contextRef="AsOf2026-03-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,291</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TradeAndOtherCurrentReceivables_i02I_maCAzYZH_zvRr4xoS6N8a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other receivables</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">5</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2026-03-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,984</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-03-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">555</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--CurrentAssets_i02TI_mtCAzYZH_maAzgCm_zTnHVwBUpmea" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current assets</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2026-03-31" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,003</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2025-03-31" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,225</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--NoncurrentAssetsAbstract_i02B_z2kUcUovcuKg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-current assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DigitalAssetsAtFairValueTonNetOfCurrentPortion_i02I_maNAz8SL_zjNXVb6nPGN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Digital assets at fair value, TON, net of current portion</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">7</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonNetOfCurrentPortion" contextRef="AsOf2026-03-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,201</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--RightofuseAssets_i02I_pn3n3_maNAz8SL_zGhdPAc04Bl8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Right-of-use asset</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">9</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2026-03-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">413</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--PropertyPlantAndEquipment_i02I_pn3n3_maNAz8SL_zviIUHM3n3n1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Property, plant, and equipment, net</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">9</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2026-03-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,283</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0101">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EquipmentDeposits_i02I_pn3n3_maNAz8SL_z9VoZhKCPjae" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Equipment deposits</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">9</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:EquipmentDeposits" contextRef="AsOf2026-03-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,308</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0104">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--OtherAssets_i02I_maNAz8SL_zPJyJiJ9JVh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">5</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2026-03-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,322</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--NoncurrentAssets_i02TI_mtNAz8SL_maAzgCm_zpr5MJGZ79lg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total non-current assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2026-03-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,527</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0110">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Assets_i01TI_mtAzgCm_zzavpmq31Iwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2026-03-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,530</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2025-03-31" id="Fact000113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,225</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--EquityAndLiabilitiesAbstract_iB_zqV9KQMPhg14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Equity</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentLiabilitiesAbstract_i01B_zibk6t7DQt8i" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--TradeAndOtherCurrentPayables_i02I_maCLzQi4_zTaWB7dducJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">13</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2026-03-31" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,146</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2025-03-31" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,100</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--TonPayableToSettlePutRightsExercised_i02I_maCLzQi4_zjnbHzLIx7He" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">12</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2026-03-31" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,425</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0125">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentLeaseLiabilities_i02I_maCLzQi4_zxu9VgiP3hng" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Lease liability - current</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">14</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2026-03-31" id="Fact000127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PutRightLiability_i02I_maCLzQi4_zRr7M1tLzLce" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Put right liability</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">12</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2026-03-31" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,105</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0131">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CurrentLiabilities_i02TI_mtCLzQi4_maLzHn2_zCRqXDWNNIDe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current liabilities</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2026-03-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,741</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2025-03-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,100</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--NoncurrentLiabilitiesAbstract_i01B_z3fkMUhlEQlc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-current liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--NoncurrentLeaseLiabilities_i02I_maNLz4nK_zfCdcpBzlzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Lease liability - non-current</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">14</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2026-03-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0140">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentWarrantLiability_i02I_maNLz4nK_zPE4KAmfEIAf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">11</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentWarrantLiability" contextRef="AsOf2026-03-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentWarrantLiability" contextRef="AsOf2025-03-31" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,952</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--NoncurrentLiabilities_i02TI_mtNLz4nK_maLzHn2_zyLDU3TB7zN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total non-current liabilities</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2026-03-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2025-03-31" id="Fact000146" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,952</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--Liabilities_i02TI_mtLzHn2_maEALznL4_z8f3IksPJ0L6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2026-03-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,006</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2025-03-31" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,052</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CommitmentsAndContingentLiabilities_iI_zZTC2hI6MR0j" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Commitments and Contingent Liabilities (Note 20)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--EquityAbstract_iB_zskRoCxzB6h7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shareholders&#8217; Equity</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--IssuedCapital_iI_maEATOOzwP3_zRyBtX4Kiseb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Capital stock</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">17</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2026-03-31" id="Fact000157" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">266,053</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2025-03-31" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221,800</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--OtherReserves_iI_maEATOOzwP3_zNDSJHpsA8f3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Stock option reserve</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">18</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2026-03-31" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,275</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2025-03-31" id="Fact000161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,530</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--RetainedEarnings_iI_maEATOOzwP3_z48iRKwfkxC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accumulated deficit</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2026-03-31" id="Fact000163" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">284,079</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2025-03-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">245,453</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--TreasuryShares_iNI_di_msEATOOzwP3_zhMo4mZ7pUc9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Treasury stock</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">17</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:TreasuryShares" contextRef="AsOf2026-03-31" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0167">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--EquityAttributableToOwnersOfParent_iTI_mtEATOOzwP3_maEzTVt_zgO9VXJsYuvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total equity attributable to owners of the Company</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2026-03-31" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,229</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2025-03-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">123</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--NoncontrollingInterests_iI_maEzTVt_zCvywAt334mc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">25</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2026-03-31" id="Fact000172" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">705</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2025-03-31" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">704</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--Equity_iTI_mtEzTVt_maEALznL4_z84evDnCN31f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total equity</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,524</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">827</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--EquityAndLiabilities_iTI_mtEALznL4_znSR1d4RuWN" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2026-03-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,530</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2025-03-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,225</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these consolidated financial
statements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span id="comprehensiveincome"></span>Consolidated Statements of Operations and Other Comprehensive
Income (Loss)</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(U.S. Dollars in thousands, except per share amounts)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_pn3n3_zuUztR3UUI5a" summary="xdx: Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_490_20250401__20260331_zH6ANOJ4JqX7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49A_20240401__20250331_zUXcGdiOuYec" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49B_20230401__20240331_zHw1s8VNDSFi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Notes</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_409_eifrs-full--Revenue_maPLFOAzGDt_zk7eAdyt3vmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; font-weight: bold">Revenues</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; font-size: 10pt; font-weight: bold; text-align: center">4</td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2025-04-01to2026-03-31" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ProfitLossAbstract_iB_zkLeQJ9obcO6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ResearchAndDevelopmentExpense_i01_msPLFOAzGDt_z1GhQ2RDWxbe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000189" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,801</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2024-04-012025-03-31" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,129</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2023-04-012024-03-31" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,535</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--GeneralAndAdministrativeExpense_i01_msPLFOAzGDt_zq4ttwJ1Cvd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">General and administrative expenses</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,199</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2024-04-012025-03-31" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,254</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2023-04-012024-03-31" id="Fact000195" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,664</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DepreciationExpense_i01_msPLFOAzGDt_zF5HRd1pC0Wh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Depreciation and amortization expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">9</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationExpense" contextRef="From2024-04-012025-03-31" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationExpense" contextRef="From2023-04-012024-03-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLossFromOperatingActivities_i01T_mtPLFOAzGDt_maPLBTz2MH_zqM2axPujhC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,096</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2024-04-012025-03-31" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,418</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2023-04-012024-03-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,253</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--GainsLossesOnChangeInFairValueOfWarrants_i01_maPLBTz2MH_zoMv7d83NE88" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">11</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2025-04-01to2026-03-31" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,883</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2024-04-012025-03-31" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">388</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2023-04-012024-03-31" id="Fact000207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,868</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_i01_maPLBTz2MH_ziiC3el5hYoh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0209">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2023-04-012024-03-31" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,305</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ChangeInFairValueOfPutRightsNetOfRedemptions_i01N_di_msPLBTz2MH_zqskQbO8DgN8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of put rights, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">12</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2025-04-01to2026-03-31" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,959</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossOnRevaluationOfDigitalAssets_i01N_di_msPLBTz2MH_z8T7yZ5b54Vk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">7</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,411</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LossOnRevaluationOfDigitalAssetReceivables_i01N_di_msPLBTz2MH_z7wfsXvJQZe3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">8</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssetReceivables" contextRef="From2025-04-01to2026-03-31" id="Fact000221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,497</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RealizedLossOnSaleOfDigitalAssets_i01N_di_msPLBTz2MH_zQ5fDgIaLGQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">7</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--RealizedLossOnNovationOfDigitalAssetsToInvestor_i01N_di_msPLBTz2MH_z9xoRx25rVBd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on novation of digital assets to investor</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">7</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor" contextRef="From2025-04-01to2026-03-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">676</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--GainOnSettlementWithParexelIoxCro_i01N_di_msPLBTz2MH_zh0XsbQ2xosf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement with Parexel - iOx CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">19</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2024-04-012025-03-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">946</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--LossOnRegisteredDirectOffering_i01N_di_msPLBTz2MH_zYb4S5LnAOm2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on Registered Direct Offering</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2023-04-012024-03-31" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,432</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--OfferingCosts_i01N_di_msPLBTz2MH_zjY6ADLK43Uh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Offering costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2023-04-012024-03-31" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">662</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ImpairmentLossIoxIprd_i01_maPLBTz2MH_zBGh1YrEZSBi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - iOx IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossIoxIprd" contextRef="From2023-04-012024-03-31" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,890</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ImpairmentLossTarusIprd_i01_maPLBTz2MH_zH3JnpnwaTfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Tarus IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossTarusIprd" contextRef="From2023-04-012024-03-31" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,615</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--ImpairmentLossStimunity_i01_maPLBTz2MH_zeTslkTdPUCa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Stimunity</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossStimunity" contextRef="From2023-04-012024-03-31" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,002</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--ImpairmentLossSaugatuck_i01_maPLBTz2MH_ze2N2zHIt6Jk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Saugatuck</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossSaugatuck" contextRef="From2023-04-012024-03-31" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">178</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--CommitmentFeeUnderCommittedPurchaseAgreement_i01N_di_msPLBTz2MH_zpvHokF856N2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Commitment fee under Committed Purchase Agreement</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2023-04-012024-03-31" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">839</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--GainOnDissolutionOfInvestmentInAssociate_i01_maPLBTz2MH_zIGn6wU4CKFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on dissolution of investment in associate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2023-04-012024-03-31" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainFromSaleOfInvestmentInPublicCompany_i01_maPLBTz2MH_zqfGYPge8TI3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain from sale of investment in public company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">725</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ImpairmentLossInvestmentInCompedica_i01N_di_msPLBTz2MH_zLHHczuur9Hh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">10</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossInvestmentInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,804</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LossOnRevaluationOfInvestmentInCompedica_i01N_di_msPLBTz2MH_zUGgH4qyHcc7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">10</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnRevaluationOfInvestmentInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_i01_maPLBTz2MH_z9iXCbgTPpNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">12</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2025-04-01to2026-03-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--GainOnSettlementOfTonPayable_i01_maPLBTz2MH_zLCv9QgIANF3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">12</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2025-04-01to2026-03-31" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">336</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LossOnSettlementOfPutRightLiability_i01N_di_msPLBTz2MH_z61AC5rUFLB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on settlement of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">12</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnSettlementOfPutRightLiability" contextRef="From2025-04-01to2026-03-31" id="Fact000289" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">916</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_i01_pn3n3_maPLBTz2MH_zXzKyCRMnBp5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange transaction (loss) gain</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2024-04-012025-03-31" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2023-04-012024-03-31" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--DepreciationAndAmortisationExpense_i01N_di_msPLBTz2MH_z35JoNqywS2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Interest (expense) income, net</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,014</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2024-04-012025-03-31" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">86</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2023-04-012024-03-31" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">242</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GainOnExtinguishmentOfDebt_i01_maPLBTz2MH_z3M6IKasbxKl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on extinguishment of debt</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">15</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainOnExtinguishmentOfDebt" contextRef="From2025-04-01to2026-03-31" id="Fact000301" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">255</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShareOfLossesFromEquityMethodInvestment_i01N_di_msPLBTz2MH_zjbHrKq34gn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Share of losses from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">10</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ShareOfLossesFromEquityMethodInvestment" contextRef="From2025-04-01to2026-03-31" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ShareOfLossesFromEquityMethodInvestment" contextRef="From2023-04-012024-03-31" id="Fact000307" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">233</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--ProfitLossBeforeTax_i01T_mtPLBTz2MH_maPLz3cx_zz0cCXkzlG0e" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before benefit for income taxes</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2025-04-01to2026-03-31" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-04-012025-03-31" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,781</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2023-04-012024-03-31" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">85,930</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_i01N_di_msPLz3cx_zy2Go81IJPf2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">16</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-04-012025-03-31" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2023-04-012024-03-31" id="Fact000315" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,548</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ProfitLoss_i01T_pn3n3_mtPLz3cx_maCIz3ji_zsw8gcLC08r1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Net loss</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012025-03-31" id="Fact000318" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,778</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012024-03-31" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,382</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--OtherComprehensiveIncomeAbstract_iB_z5YNgpz3cjr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive loss</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--NetUnrealizedLossOnInvestments_i01_maCIz3ji_zhtL6dWpznd2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Net unrealized loss on investments</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31" id="Fact000327" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--ComprehensiveIncome_i01T_mtCIz3ji_zBqPz0beAOB4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2025-04-01to2026-03-31" id="Fact000329" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2024-04-012025-03-31" id="Fact000330" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,778</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2023-04-012024-03-31" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,420</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ProfitLossAttributableToAbstract_iB_znwtZKx6bDN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss attributable to:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_maPLzCxb_zgNKNt5kT803" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2025-04-01to2026-03-31" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,626</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2024-04-012025-03-31" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,767</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2023-04-012024-03-31" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,339</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--ProfitLossAttributableToNoncontrollingInterests_i01_maPLzCxb_zORYMDlWV6Fg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">25</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2025-04-01to2026-03-31" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2024-04-012025-03-31" id="Fact000342" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2023-04-012024-03-31" id="Fact000343" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--ProfitLoss_i01T_mtPLzCxb_z5YGXNDzY207" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000345" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012025-03-31" id="Fact000346" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,778</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012024-03-31" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,382</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--ComprehensiveIncomeAttributableToAbstract_iB_zPsNpxZ05UU1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss attributable to:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ComprehensiveIncomeAttributableToOwnersOfParent_i01_maCIzrN4_zn5jBh2XzXpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2025-04-01to2026-03-31" id="Fact000353" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,626</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2024-04-012025-03-31" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,767</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2023-04-012024-03-31" id="Fact000355" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,377</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--ComprehensiveIncomeAttributableToNoncontrollingInterests_i01_maCIzrN4_zUGlMhcVPL8i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">25</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2025-04-01to2026-03-31" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2024-04-012025-03-31" id="Fact000358" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2023-04-012024-03-31" id="Fact000359" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--ComprehensiveIncome_i01T_mtCIzrN4_zFTlZN6xzV26" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2025-04-01to2026-03-31" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2024-04-012025-03-31" id="Fact000362" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,778</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2023-04-012024-03-31" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,420</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--EarningsPerShareAbstract_iB_zNxngxo9qaej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: center">19</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_eifrs-full--BasicEarningsLossPerShare_pip0_c20250401__20260331_zYX2tqPUj633" title="Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><span id="xdx_901_eifrs-full--DilutedEarningsLossPerShare_pip0_c20250401__20260331_zTGThQsnVmLg" title="Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2025-04-01to2026-03-31" id="Fact000369" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2025-04-01to2026-03-31" id="Fact000371" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">4</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eifrs-full--BasicEarningsLossPerShare_pip0_c20240401__20250331_zTRhpwXa77b2" title="Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><span id="xdx_907_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240401__20250331_zVPnsxNEJfk1" title="Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2024-04-012025-03-31" id="Fact000373" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2024-04-012025-03-31" id="Fact000375" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">5.72</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eifrs-full--BasicEarningsLossPerShare_pip0_c20230401__20240331_zWXW72lrBhx4" title="Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><span id="xdx_90E_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230401__20240331_zowZXpSVwTQk" title="Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2023-04-012024-03-31" id="Fact000377" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2023-04-012024-03-31" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">77.83</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_iB_zzuTIsz0ojVk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Weighted average shares outstanding</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: center">19</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_eifrs-full--WeightedAverageShares_pn3n3_c20250401__20260331_zcNAra9VFi8b" title="Weighted average shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20250401__20260331_zzQGWfCUjlD8" title="Weighted average shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2025-04-01to2026-03-31" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-01to2026-03-31" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,248</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90C_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20250331_zsc1hHO5FR1f" title="Weighted average shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><span id="xdx_905_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240401__20250331_ze6qjLKfRcF4" title="Weighted average shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-04-012025-03-31" id="Fact000389" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2024-04-012025-03-31" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,183</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eifrs-full--WeightedAverageShares_pn3n3_c20230401__20240331_zCQ7p0U9pzie" title="Weighted average shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><span id="xdx_906_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20240331_zPeHKsTyixKk" title="Weighted average shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpAA__"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2023-04-012024-03-31" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2023-04-012024-03-31" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">968</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these consolidated financial
statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 251pt 0pt 0; font-size: 10pt"><b><span id="changesinequity"></span>Consolidated Statements of Changes in Shareholders&#8217;
Equity (Deficit)</b></p>

<p style="margin: 0pt 251pt 0pt 0; font-size: 10pt"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 251pt 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"><b></b></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_pn3n3_zaee68yRW4z" summary="xdx: Statement - Consolidated Statements of Changes in Equity (Deficit)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_zLBnS1rhsx71" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4BA_ifrs-full--ComponentsOfEquityAxis_custom--StockOptionReserveMember_zX2NVKp5vyk4" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B2_ifrs-full--ComponentsOfEquityAxis_custom--TreasuryStockMember_zaV5T0uRiiCk" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B7_ifrs-full--ComponentsOfEquityAxis_custom--AccumulatedOtherComprehensiveIncomeLossMember_zXvdBJIHtyX4" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4BD_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_zgnGyN9mosC" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ComponentsOfEquityAxis_ifrs-full--EquityAttributableToOwnersOfParentMember_zMIg9su29eD5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B6_ifrs-full--ComponentsOfEquityAxis_ifrs-full--NoncontrollingInterestsMember_zLYf0zh8PFn6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4BA_zZjwchacx7fg" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Equity</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Number</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Stock</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Other</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Attributable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Non-</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">of</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Capital</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Treasury</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Comprehensive</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">(Accumulated</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">to Owners</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Controlling</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares*</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Reserve</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Deficit)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">of Company</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Equity</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%; font-size: 10pt; text-align: left">Balance, April 1, 2023 (Pre-Split)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--BalanceApril12022PresplitShares_pn3n3_c20230401__20240331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zLScxSzH0LC9" title="Balance, April 1, 2022 (Pre-Split), shares" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:BalanceApril12022PresplitShares" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000397" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">17,606</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230401__20240331_eifrs-full--Equity_iS_zrEQD8KPl65k" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Balance, April 1, 2023 (After 1-for-20 reverse share split)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--NumberOfSharesOutstanding_iS_pn3n3_c20230401__20240331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zBjVDwxFOJMd" title="Begnning balance, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2023-03-31_ifrs-full_IssuedCapitalMember" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">880</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31_ifrs-full_IssuedCapitalMember" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,782</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31_custom_StockOptionReserveMember" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,204</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,325</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31_ifrs-full_RetainedEarningsMember" id="Fact000403" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">159,616</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76,045</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">650</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-03-31" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75,395</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_zJ7tXWDoTD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Share-based compensation expense</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,637</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,637</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012024-03-31" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,637</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--SharesIssuedUnderRegisteredDirectOffering_zKDVzbNc7X6l" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shares issued under Registered Direct Offering</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SharesIssuedUnderRegisteredDirectOfferingShares_pn3n3_c20230401__20240331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zYZ5T0Zrbbl6" title="Shares issued under Registered Direct Offering, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingShares" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">98</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts_zE0rxG8XosCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Shares issued related to the ATM agreement, net of share issuance costs</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares_pn3n3_c20230401__20240331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zhL3Yqc68d1g" title="Shares issued related to the ATM agreement, net of share issuance costs, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">662</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">662</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2023-04-012024-03-31" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">662</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--SharesIssuedOrAccruedForServices_zJEkPFpLe0Ih" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shares issued or accrued for services</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SharesIssuedOrAccruedForServicesShares_pn3n3_c20230401__20240331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zCFoxJwRC0O5" title="Shares issued or accrued for services, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServicesShares" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000450" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012024-03-31" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--SharesIssuedPursuantToDistributionOfRestrictedStockUnits_zCnUpubjcZsh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Shares issued pursuant to distribution of restricted stock units</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares_pn3n3_c20230401__20240331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z0MPpoClNzja" title="Shares issued pursuant to distribution of restricted stock units, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2023-04-012024-03-31" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DerecognitionOfInvestmentInPublicCompany_z6EZ2AvDtaWb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Derecognition of investment in public company</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,363</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:DerecognitionOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,363</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--NetUnrealizedLossOnInvestments_zyssbSOvZYS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net unrealized loss on investments</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember" id="Fact000475" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2023-04-012024-03-31" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossFromContinuingOperations_zFKof2teg5pe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for the year</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,339</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,339</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2023-04-012024-03-31" id="Fact000488" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,382</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20240401__20250331_eifrs-full--Equity_iS_znCaf7bMi6yl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Balance, March 31, 2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--NumberOfSharesOutstanding_iS_pn3n3_c20240401__20250331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zRqhActYXFKi" title="Begnning balance, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000499" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">989</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,499</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31_custom_StockOptionReserveMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,841</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31_ifrs-full_RetainedEarningsMember" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">239,318</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,022</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember" id="Fact000496" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">693</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,329</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_zGzOD1rzjMzd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Share-based compensation expense</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="Fact000502" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000506" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012025-03-31" id="Fact000508" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense_zNNjo13C9zH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Correction of prior period overstated share-based compensation expense</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">632</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="Fact000514" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">632</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0516">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts_zOILdLBNP3B9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shares issued under private placement, net of share issuance costs</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares_pn3n3_c20240401__20250331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z9roPEgd4Fqi" title="Shares issued under private placement, net of share issuance costs, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">524</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000524" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" contextRef="From2024-04-012025-03-31" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PrefundedWarrantsExercised_zl17QaIRKFch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Pre-Funded warrants exercised</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--PrefundedWarrantsExercisedShares_pn3n3_c20240401__20250331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zT7ET6CHhFCe" title="Pre-Funded warrants exercised, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercisedShares" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000539" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">60</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000530" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012025-03-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_zUZDGnRVWJf2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse
        share split</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_pn3n3_c20240401__20250331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zSZpBMfP0GUa" title="Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">52</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SharesIssuedForAccruedBonuses_zmIEVWEGbNbk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Shares issued for accrued bonuses</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SharesIssuedAccruedForBonusesShares_pn3n3_c20240401__20250331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zXCXP9PFzxlc" title="Shares issued accrued for bonuses, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedAccruedForBonusesShares" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">19</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000557" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012025-03-31" id="Fact000559" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--SharesIssuedPursuantToDistributionOfRestrictedStockUnits_zFcXsZWUe2w8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shares issued pursuant to distribution of restricted stock units</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares_pn3n3_c20240401__20250331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z9K2T1odTHVd" title="Shares issued pursuant to distribution of restricted stock units, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000572" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000563" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000568" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits" contextRef="From2024-04-012025-03-31" id="Fact000570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossFromContinuingOperations_zYbJTEPsBQA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for the year</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember" id="Fact000578" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,767</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000579" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,767</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember" id="Fact000580" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2024-04-012025-03-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,778</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20250401__20260331_eifrs-full--Equity_iS_zg2UZfAOcDod" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Balance, March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iS_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zbQ5NR3SJmJ7" title="Begnning balance, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,653</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31_ifrs-full_IssuedCapitalMember" id="Fact000583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221,800</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31_custom_StockOptionReserveMember" id="Fact000584" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,530</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31_ifrs-full_RetainedEarningsMember" id="Fact000587" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">245,453</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000588" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">123</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31_ifrs-full_NoncontrollingInterestsMember" id="Fact000589" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">704</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-03-31" id="Fact000590" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">827</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_zE7aUQGAXFk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember" id="Fact000595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,745</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,745</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0600">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2025-04-01to2026-03-31" id="Fact000601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,745</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights_zSqMnwNWBeu5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shares issued under private placement, net of share issuance costs and put
        rights</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z22XHKBWMbI7" title="Shares issued under private placement, net of share issuance costs and put rights , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000612" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,416</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,535</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0605">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000608" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,535</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" contextRef="From2025-04-01to2026-03-31" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,535</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedRelatingToAcquisitionOfCompedica_zoAVJ2ez2xpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shares issued relating to the acquisition of Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--SharesIssuedRelatingToAcquisitionOfCompedicaShares_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zsTOkkAsMxcf" title="Shares issued relating to the acquisition of Compedica, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedicaShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">625</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatingToAcquisitionOfCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact000621" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts_zmWH6ixlGTT7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shares issued related to the ATM agreement, net of share issuance costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zuSHg4iOsAS4" title="Shares issued related to the ATM agreement, net of share issuance costs , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000634" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,063</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,030</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,030</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" contextRef="From2025-04-01to2026-03-31" id="Fact000632" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,030</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts_zUwgcvQhncwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shares issued under registered direct offering, net of share issuance costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zMrP3QuxhMM8" title="Shares issued under registered direct offering, net of share issuance costs , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,230</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,688</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,688</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2025-04-01to2026-03-31" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,688</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ExerciseOfPrefundedWarrants_zKC3INHJ94m2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Exercise of pre-funded warrants</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--ExerciseOfPrefundedWarrantsShares_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zneT3zoWiuai" title="Exercise of pre-funded warrants , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExerciseOfPrefundedWarrantsShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,231</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0652">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_zGj5K1ehqe45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Treasury stock obtained in exchange for return of investment interest to
        Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zAgTHPRl9Ra9" title="Treasury stock obtained in exchange for return of investment interest to Compedica , shares" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">625</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember" id="Fact000660" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0661">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000663" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact000665" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--PutRightsExercisedAndReturnOfShares_zb0VfCGKRIZ4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Put rights exercised and return of shares</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--PutRightsExercisedAndReturnShares_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z9eBSOFzrNWl" title="Put rights exercised and return, shares" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PutRightsExercisedAndReturnShares" contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000678" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">123</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0672">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0673">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0675">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossFromContinuingOperations_ziF0R60S6vS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss for the year</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0682">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember" id="Fact000684" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,626</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000685" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,626</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember" id="Fact000686" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2025-04-01to2026-03-31" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_439_c20250401__20260331_eifrs-full--Equity_iE_zDJBJJXI3PRh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance, March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesOutstanding_iE_pn3n3_c20250401__20260331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zcvwXR3dDAW5" title="Ending Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000698" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">23,470</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31_ifrs-full_IssuedCapitalMember" id="Fact000689" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">266,053</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31_custom_StockOptionReserveMember" id="Fact000690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,275</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31_custom_TreasuryStockMember" id="Fact000691" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31_ifrs-full_RetainedEarningsMember" id="Fact000693" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">284,079</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000694" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,229</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31_ifrs-full_NoncontrollingInterestsMember" id="Fact000695" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">705</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2026-03-31" id="Fact000696" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,524</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">*Giving retroactive effect to the 1-for-20 reverse share split effected on August 15, 2024.</p>

<p style="margin: 0pt 0 0pt 2in; font-size: 10pt; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of these
consolidated financial statements.</p>

<p style="margin: 0pt 0 0pt 2in; font-size: 10pt; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 2in; font-size: 10pt; text-align: center; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0 0pt 2in; font-size: 10pt; text-align: center; text-indent: 0.5in"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span id="cashflows"></span>Consolidated Statements of Cash Flows</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_112_pn3n3_zGxPOxurawpj" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_zoRnEaSowfDe" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_492_20240401__20250331_zDzbOkYnlLrg" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_498_20230401__20240331_z8GPvICVWcM9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_40D_eifrs-full--CashFlowsFromUsedInOperatingActivitiesAbstract_iB_z8rO1k8FfIyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from operating activities:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ProfitLoss_i01_maAFIDIzGff_zf6hkSDeE7f3" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; text-align: left; padding-left: 10pt">Net loss for the period</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000704" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012025-03-31" id="Fact000705" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,778</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012024-03-31" id="Fact000706" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,382</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eifrs-full--AdjustmentsForReconcileProfitLossAbstract_i01B_ze1pCV7I5sY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Adjustments for non-cash items:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--AdjustmentsForSharebasedPayments_i02_maAFIDIzGff_zBaZeIPTufSg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Share-based compensation expense</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2025-04-01to2026-03-31" id="Fact000712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,745</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2024-04-012025-03-31" id="Fact000713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2023-04-012024-03-31" id="Fact000714" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,637</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_i02N_di_msAFIDIzGff_z8lkSuA7M32d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2023-04-012024-03-31" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,305</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--LossOnRegisteredDirectOffering_i02_maAFIDIzGff_zO5STu5D87Sb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on Registered Direct Offering</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2023-04-012024-03-31" id="Fact000722" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,432</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OfferingCosts_i02_maAFIDIzGff_zhROyzxnSykh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Offering costs</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0724">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2023-04-012024-03-31" id="Fact000726" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">662</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment loss - iOx IPR&amp;D</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20250401__20260331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--IOxIPRDMember_zfoUEpBqih4h" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20240401__20250331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--IOxIPRDMember_zXDoSXLL3LG" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20230401__20240331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--IOxIPRDMember_zAyB8O2FiTJ" title="Impairment loss" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2023-04-012024-03-31_custom_IOxIPRDMember" id="Fact000732" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,890</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment loss - Tarus IPR&amp;D</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20250401__20260331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--TarusIPRDMember_zQfpwiHwSJkb" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20240401__20250331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--TarusIPRDMember_zdxUVq37DFf3" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20230401__20240331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--TarusIPRDMember_z1B2I4TakeR3" title="Impairment loss" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2023-04-012024-03-31_custom_TarusIPRDMember" id="Fact000738" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,615</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment loss - Stimunity</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20250401__20260331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--StimunityMember_zgI39sezkvci" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20240401__20250331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--StimunityMember_zH0cike89yRe" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20230401__20240331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--StimunityMember_zViZcpSfcwG1" title="Impairment loss" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2023-04-012024-03-31_custom_StimunityMember" id="Fact000744" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,002</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment loss - Saugatuck</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20250401__20260331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--SaugatuckMember_zPnrCaqJHe58" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0746">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20240401__20250331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--SaugatuckMember_zZFxTd7CtCI1" title="Impairment loss" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--ImpairmentLoss_i02_maAFIDIzGff_c20230401__20240331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--SaugatuckMember_z7UaLFC0Vfce" title="Impairment loss" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2023-04-012024-03-31_custom_SaugatuckMember" id="Fact000750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CommitmentFeeUnderCommittedPurchaseAgreement_i01_maAFIDIzGff_zd0G7LDSGYrj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Commitment fee under Committed Purchase Agreement</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0753">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2023-04-012024-03-31" id="Fact000754" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">839</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--GainOnDissolutionOfInvestmentInAssociate_i01N_di_msAFIDIzGff_zZ0GciPDeueg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Gain on dissolution of investment in associate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2023-04-012024-03-31" id="Fact000758" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--GainFromSaleOfInvestmentInPublicCompany_i01N_di_msAFIDIzGff_zHZqzm9D7UN9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Gain from sale of investment in public company</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0760">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0761">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31" id="Fact000762" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">725</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--IncreaseDecreaseInDeferredTaxLiabilityAsset_i01N_di_msAFIDIzGff_zfUPRvtar5r4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Decrease in deferred tax liability</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2023-04-012024-03-31" id="Fact000766" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,564</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--UnrealizedLossOnChangeInFairValueOfDigitalAssets_i01_maAFIDIzGff_zNsqNUy8SyC9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Unrealized loss on change in fair value of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000768" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,411</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables_i01_maAFIDIzGff_zR0gIIoKRHd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Unrealized loss on change in fair value of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" contextRef="From2025-04-01to2026-03-31" id="Fact000772" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,349</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RealizedLossOnSaleOfDigitalAssets_i01_maAFIDIzGff_zdRDjXkOaiPc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Realized loss on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000776" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--RealizedLossOnNovationOfDigitalAssetReceivables_i01_maAFIDIzGff_zdFzIZsOFhj3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Realized loss on novation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetReceivables" contextRef="From2025-04-01to2026-03-31" id="Fact000780" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">676</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LossOnImpairmentInvestmentInCompedica_i01_maAFIDIzGff_zE3vuIAZSoad" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on impairment - investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossOnImpairmentInvestmentInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact000784" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,804</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0785">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LossOnRemeasurementOfInvestmentInCompedica_i01_maAFIDIzGff_zej9lO3SJgBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on remeasurement of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossOnRemeasurementOfInvestmentInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact000788" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0789">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfWarrantLiability_i01_maAFIDIzGff_zjCcW4wyaaH4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiability" contextRef="From2025-04-01to2026-03-31" id="Fact000792" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,883</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiability" contextRef="From2024-04-012025-03-31" id="Fact000793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">388</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiability" contextRef="From2023-04-012024-03-31" id="Fact000794" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,868</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ChangeInFairValueOfPutRightsNetOfRedemptions_i01_maAFIDIzGff_zLPaJqfrT5Gi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of put rights, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2025-04-01to2026-03-31" id="Fact000796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,959</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossFromEquityMethodInvestment_i01_maAFIDIzGff_zhixOi56II5d" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossFromEquityMethodInvestment" contextRef="From2025-04-01to2026-03-31" id="Fact000800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0801">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_i01N_di_msAFIDIzGff_zRV93FdArgVb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2025-04-01to2026-03-31" id="Fact000804" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainOnSettlementOfTonPayable_i01N_di_msAFIDIzGff_zoZGVXwryYxh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2025-04-01to2026-03-31" id="Fact000808" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">336</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0809">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0810">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LossOnExerciseOfPutRightLiability_i01_maAFIDIzGff_zXK0r7BIb07i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on exercise of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossOnExerciseOfPutRightLiability" contextRef="From2025-04-01to2026-03-31" id="Fact000812" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">916</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0814">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LossOnExtinguishmentOfDebt_i01_maAFIDIzGff_zxjLjQrs4ifi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on extinguishment of debt</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossOnExtinguishmentOfDebt" contextRef="From2025-04-01to2026-03-31" id="Fact000816" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">582</ix:nonFraction>&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GainOnDebtExtinguishment_i01_maAFIDIzGff_zxsc4711sDi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Gain on forgiveness of loan interest</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(837</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--NoncashInterestExpense_i01_maAFIDIzGff_zZn1phoGhXTg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Noncash interest expense</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NoncashInterestExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000824" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0825">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--GainOnSettlementWithParexelIoxCro_i01_maAFIDIzGff_zoOYpMdSmP76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Gain on settlement with Parexel - iOx CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2024-04-012025-03-31" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">946</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ExpensesSettledUsingStablecoin_i01_maAFIDIzGff_znEdM3Qbmng" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Expenses settled using stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExpensesSettledUsingStablecoin" contextRef="From2025-04-01to2026-03-31" id="Fact000832" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,413</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0834">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DividendsReceived_i01N_di_maAFIDIzGff_z4dI0DkJNIzl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Revenues received in TON tokens</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DividendsReceived" contextRef="From2025-04-01to2026-03-31" id="Fact000836" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ShareOfLossInAssociate_i01_maAFIDIzGff_zcRRXtsgkhz" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Share of loss in associate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOfLossInAssociate" contextRef="From2023-04-012024-03-31" id="Fact000842" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">233</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--FairValueOfSharesIssuedForServices_i01_maAFIDIzGff_zGWR8Wd0M986" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Fair value of shares issued for services</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfSharesIssuedForServices" contextRef="From2023-04-012024-03-31" id="Fact000846" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DepreciationAndAmortizations_i01_maAFIDIzGff_zADCLX2T0idh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation and amortization</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DepreciationAndAmortizations" contextRef="From2025-04-01to2026-03-31" id="Fact000848" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DepreciationAndAmortizations" contextRef="From2024-04-012025-03-31" id="Fact000849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DepreciationAndAmortizations" contextRef="From2023-04-012024-03-31" id="Fact000850" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NetChangeInWorkingCapitalComponentsAbstract_i01B_z9rfbMO69d5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Changes in operating working capital:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_i02_maAFIDIzGff_za8CbL2f1Uda" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="From2025-04-01to2026-03-31" id="Fact000856" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AdjustmentsForDecreaseIncreaseInPrepaidExpenses_i02_maAFIDIzGff_z1xLjeyiEmwk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Prepaid expenses and other receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" contextRef="From2025-04-01to2026-03-31" id="Fact000860" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">96</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" contextRef="From2024-04-012025-03-31" id="Fact000861" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,574</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" contextRef="From2023-04-012024-03-31" id="Fact000862" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">32</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--AdjustmentsForDecreaseIncreaseInOtherAssets_i02_maAFIDIzGff_zRI3ZntCn0W6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Other assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000864" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,322</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2024-04-012025-03-31" id="Fact000865" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2023-04-012024-03-31" id="Fact000866" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_i02_maAFIDIzGff_zLJqTHMbuCnl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued liabilities</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2025-04-01to2026-03-31" id="Fact000868" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,549</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2024-04-012025-03-31" id="Fact000869" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">99</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2023-04-012024-03-31" id="Fact000870" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">972</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--AdjustmentsForIncreaseDecreaseInOtherLiabilities_i02_maAFIDIzGff_zR84VCbmkjsg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other current liabilities</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="From2024-04-012025-03-31" id="Fact000873" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="From2023-04-012024-03-31" id="Fact000874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CashFlowsFromUsedInOperatingActivities_iT_mtAFIDIzGff_maIDICAzufs_zmnGr3YsDaG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net cash used in operating activities</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000876" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,548</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2024-04-012025-03-31" id="Fact000877" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,462</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2023-04-012024-03-31" id="Fact000878" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,297</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--CashFlowsFromUsedInInvestingActivitiesAbstract_iB_znYDIc2hEe4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from investing activities:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ProceedsFromSalesOfInvestmentProperty_i01_maCFFUIzM7u_zINFY81KysD9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from sale of investment in public company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0884">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0885">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInvestmentProperty" contextRef="From2023-04-012024-03-31" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,812</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PurchasesOfStablecoin_i01N_di_msCFFUIzM7u_zIhtVF4RmyVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Purchases of stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PurchasesOfStablecoin" contextRef="From2025-04-01to2026-03-31" id="Fact000888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">311</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PurchasesOfDigitalAssets_i01N_di_msCFFUIzM7u_zcghunU0qZa4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Purchases of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PurchasesOfDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000892" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">609</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SalesOfStablecoin_i01_maCFFUIzM7u_ztgIPEXEjxek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Sales of stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SalesOfStablecoin" contextRef="From2025-04-01to2026-03-31" id="Fact000896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,100</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SalesOfDigitalAssets_i01_maCFFUIzM7u_zj5E4H8ayQAe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Sales of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SalesOfDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000900" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,900</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_i01N_di_msCFFUIzM7u_zIqoaIFlJ4Bc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Purchases of fixed assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000904" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,040</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EquipmentDeposit_i01N_di_msCFFUIzM7u_zS2rAxXZpsu5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Equipment deposits</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:EquipmentDeposit" contextRef="From2025-04-01to2026-03-31" id="Fact000908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,308</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidForInvestmentInCompedica_i01N_di_msCFFUIzM7u_zvq8NXiZRnEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Cash paid for investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:CashPaidForInvestmentInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact000912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CashFlowsFromUsedInInvestingActivities_iT_mtCFFUIzM7u_maIDICAzufs_znyLFfF0vMD8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net cash (used in) provided by investing
        activities</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000916" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,318</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2023-04-012024-03-31" id="Fact000918" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,812</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CashFlowsFromUsedInFinancingActivitiesAbstract_iB_zS3TL8nYwaSd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from financing activities:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromExerciseOfPrefundedWarrants_i01_maCFFUIzhAG_zqpD6WD33Ulh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from exercise of Pre-Funded Warrants</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromExerciseOfPrefundedWarrants" contextRef="From2024-04-012025-03-31" id="Fact000925" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ProceedsFromSharesIssuedUnderPrivatePlacement_i01_maCFFUIzhAG_z78L2jU6J2M1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from shares issued under private placement</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement" contextRef="From2025-04-01to2026-03-31" id="Fact000928" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,272</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement" contextRef="From2024-04-012025-03-31" id="Fact000929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0930">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromRegisteredDirectOffering_i01_maCFFUIzhAG_zpiVGwcFzspk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from Registered Direct Offering</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromRegisteredDirectOffering" contextRef="From2025-04-01to2026-03-31" id="Fact000932" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromRegisteredDirectOffering" contextRef="From2023-04-012024-03-31" id="Fact000934" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,338</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_i01_maCFFUIzhAG_zTmJjtLYorIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from shares issued under ATM and Committed Purchase Agreement</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" contextRef="From2025-04-01to2026-03-31" id="Fact000936" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,631</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" contextRef="From2023-04-012024-03-31" id="Fact000938" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">682</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--PaymentsForShareIssueCosts_i01N_di_msCFFUIzhAG_zaD0eqP0W7Ja" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Share issuance costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2025-04-01to2026-03-31" id="Fact000940" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,615</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2023-04-012024-03-31" id="Fact000942" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--PutRightIssuanceCosts_i01N_di_msCFFUIzhAG_zPd0t8rLKSB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Put right issuance costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"/>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_i01N_di_msCFFUIzhAG_zm5pQHGxzoYb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Repayment of lease liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000948" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">381</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2024-04-012025-03-31" id="Fact000949" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2023-04-012024-03-31" id="Fact000950" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--PaymentsOnExternalDebt_i01N_di_msCFFUIzhAG_zha1gX5v1gyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Payments on external debt</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PaymentsOnExternalDebt" contextRef="From2025-04-01to2026-03-31" id="Fact000952" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0954">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredFinancingCosts_i01N_di_msCFFUIzhAG_zsqJwoo2sogh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred financing costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DeferredFinancingCosts" contextRef="From2025-04-01to2026-03-31" id="Fact000956" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LoanTerminationFee_i01N_di_msCFFUIzhAG_ziwvfJLeQHO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loan termination fee</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LoanTerminationFee" contextRef="From2025-04-01to2026-03-31" id="Fact000960" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--SharesFromRSUDistribution_i01_maCFFUIzhAG_zOuqmgwmUbLf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Shares from RSU distribution</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesFromRSUDistribution" contextRef="From2023-04-012024-03-31" id="Fact000966" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CashFlowsFromUsedInFinancingActivities_iT_mtCFFUIzhAG_maIDICAzufs_zCOlkrof4bEa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net cash provided by financing activities</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000968" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,882</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2024-04-012025-03-31" id="Fact000969" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,104</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2023-04-012024-03-31" id="Fact000970" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,968</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--IncreaseDecreaseInCashAndCashEquivalents_iT_mtIDICAzufs_zSZxHCkMUARk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Decrease in cash, cash equivalents, restricted during
        period</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2025-04-01to2026-03-31" id="Fact000972" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">984</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2024-04-012025-03-31" id="Fact000973" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,358</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2023-04-012024-03-31" id="Fact000974" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,517</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentRestrictedCashAndCashEquivalents_iS_zTZqa2VW5au5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Cash and cash equivalents at beginning
        of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000976" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,670</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000977" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,028</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" contextRef="AsOf2023-03-31" id="Fact000978" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,545</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentRestrictedCashAndCashEquivalents_iE_zxQNGLgpeG7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Cash, cash equivalents, and restricted
        cash at end of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" contextRef="AsOf2026-03-31" id="Fact000980" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">686</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000981" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,670</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000982" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,028</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these consolidated financial
statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Consolidated Statements of Cash Flows <i>(Cont&#8217;d)</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_40D_ecustom--SupplementalCashFlowInformationsAbstract_iB_zIUwwixDJ9wa" style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidForInterest_i01_zjzwmJktdkE1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2025-04-01to2026-03-31" id="Fact000988" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2024-04-012025-03-31" id="Fact000989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2023-04-012024-03-31" id="Fact000990" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NoncashInvestingItemsAbstract_iB_zhMRUw9WGdDb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue_i01_zwBl51Tv4OJe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Exchange of Stimunity Convertible Note for Stimunity shares at fair value</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0997">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" contextRef="From2023-04-012024-03-31" id="Fact000998" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CapitalExpendituresIncludedInAccountsPayable_i01_zYTtElkg2kn8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Capital expenditures included in accounts payable</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CapitalExpendituresIncludedInAccountsPayable" contextRef="From2025-04-01to2026-03-31" id="Fact001000" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">333</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--RightToUseAssetAcquired_i01_zNPh0jSCgVna" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Right-of-use asset acquired</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:RightToUseAssetAcquired" contextRef="From2025-04-01to2026-03-31" id="Fact001004" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1005">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:RightToUseAssetAcquired" contextRef="From2023-04-012024-03-31" id="Fact001006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LeaseLiabilityIncurred_i01_zNbEMkt5EBv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Lease liability incurred</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityIncurred" contextRef="From2025-04-01to2026-03-31" id="Fact001008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityIncurred" contextRef="From2023-04-012024-03-31" id="Fact001010" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ContributionOfDigitalAssets_i01_z4fFMYXeIm6g" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Contribution of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact001012" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,802</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ContributionOfStablecoin_i01_z5PqqyIAWc8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Contribution of stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfStablecoin" contextRef="From2025-04-01to2026-03-31" id="Fact001016" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,421</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ContributionOfDigitalAssetsReceivable_i01_zD67G3425u5g" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Contribution of digital assets receivable</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssetsReceivable" contextRef="From2025-04-01to2026-03-31" id="Fact001020" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,016</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ContributionOfStablecoinReceivable_i01_zy0I4q1WQEs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Contribution of stablecoin receivable</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfStablecoinReceivable" contextRef="From2025-04-01to2026-03-31" id="Fact001024" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1025">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1026">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ValueOfSharesUsedToPurchaseInterestInCompedica_i01_zch68zDU8us8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Value of shares used to purchase interest in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ValueOfSharesUsedToPurchaseInterestInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact001028" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1029">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_i01N_di_z2zjW5UjIlNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Treasury stock obtained in exchange for return of investment interest
        to Compedica</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact001032" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1034">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PutRightsIssuedToInvestors_i01_zX6URMF8Eykd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Put rights issued to investors</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PutRightsIssuedToInvestors" contextRef="From2025-04-01to2026-03-31" id="Fact001036" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,150</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ShareIssuanceCostsSettledInCompanyStock_i01_zPWWqOV8PGb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Share issuance costs settled in Company stock</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ShareIssuanceCostsSettledInCompanyStock" contextRef="From2025-04-01to2026-03-31" id="Fact001040" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,087</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1041">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ShareIssuanceCostsSettledInWarrantsOnCompanysStock_i01_zQNYXvZSSbU9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Share issuance costs settled in warrants on the Company's stock</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ShareIssuanceCostsSettledInWarrantsOnCompanysStock" contextRef="From2025-04-01to2026-03-31" id="Fact001044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,123</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SettlementOfPutRightLiabilityUsingStablecoinReceivable_i01_znL6LND2Dqdi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Settlement of put right liability using stablecoin receivable</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SettlementOfPutRightLiabilityUsingStablecoinReceivable" contextRef="From2025-04-01to2026-03-31" id="Fact001048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ExerciseOfPutRights_i01_zu0NF5V5ZfUh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Exercise of put rights</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExerciseOfPutRights" contextRef="From2025-04-01to2026-03-31" id="Fact001052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,920</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SettlementOfPutRightLiabilityUsingDigitalAssetReceivables_i01_zS4DvL5Ha3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Settlement of put right liability using digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" contextRef="From2025-04-01to2026-03-31" id="Fact001056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,130</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ReceiptOfDigitalAssetsReceivableTonTokens_i01_zICTvymEaiQ6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Receipt of digital assets receivable, TON tokens</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReceiptOfDigitalAssetsReceivableTonTokens" contextRef="From2025-04-01to2026-03-31" id="Fact001060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,667</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StablecoinUsedToPurchaseDigitalAssets_i01_zS82YVFmMOs2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Stablecoin used to purchase digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StablecoinUsedToPurchaseDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact001064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,008</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SaleOfDigitalAssetsSettledInStablecoin_i01_zQ1Uc22p7jqk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Sale of digital assets settled in stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SaleOfDigitalAssetsSettledInStablecoin" contextRef="From2025-04-01to2026-03-31" id="Fact001068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ExchangeOfBitcoinForTonTokens_i01_zQyGACA9f9mb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Exchange of Bitcoin for TON tokens</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExchangeOfBitcoinForTonTokens" contextRef="From2025-04-01to2026-03-31" id="Fact001072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">425</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ExternalDebtProceedsReceivedInStablecoin_i01_zOjQbF98xHs8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">External debt proceeds received in stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExternalDebtProceedsReceivedInStablecoin" contextRef="From2025-04-01to2026-03-31" id="Fact001076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,100</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1077">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--PaymentsOnExternalDebtUsingDigitalAssets_i01_zPxftjR94VUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Payments on external debt using digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PaymentsOnExternalDebtUsingDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact001080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,825</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NoncashOperatingActivitiesAbstract_iB_ziQDNPdupOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-cash operating activities:</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidExpensesObtainedInExchangeForStablecoin_i01_zGSRKEGL9uQ2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Prepaid expenses obtained in exchange for stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrepaidExpensesObtainedInExchangeForStablecoin" contextRef="From2025-04-01to2026-03-31" id="Fact001088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,311</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these consolidated financial
statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 6 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001092" name="ptgef:NatureOfOperationsExplanatory"><p id="xdx_800_ecustom--NatureOfOperationsExplanatory_z0qgQAkOagd2" style="margin: 0pt 0; font-size: 10pt"><b><span id="financialnotes"></span>NOTE
1. <span id="xdx_82B_zH1KqvgCfDy1">NATURE OF OPERATIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Alpha Compute Corp (the &#8220;Company&#8221;
or &#8220;Alpha Compute&#8221;, formerly known as Portage Biotech, Inc. and AlphaTON Capital Corp) is incorporated in the British Virgin
Islands (&#8220;BVI&#8221;) with its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its
USA agent, Portage Development Services Inc. (&#8220;PDS&#8221;), is located at 59 Wilton Road, Westport, CT, 06880, USA.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company is a foreign private issuer under the Securities
and Exchange Commission (the &#8220;SEC&#8221;) rules. It is also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#8220;CSE&#8221;) under the symbol
&#8220;PBT.U&#8221;. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
under the symbol &#8220;PRTG&#8221;. As the principal market for the Company&#8217;s ordinary shares is Nasdaq, the Company voluntarily
delisted from the CSE on April 23, 2021. On September 4, 2025, in connection with the change in the legal name of the Company to AlphaTON
Capital Corp effective on August 11, 2025, the Nasdaq ticker symbol of the Company&#8217;s ordinary shares was changed to &#8220;ATON&#8221;.
On April 21, 2026, in connection with the change in the legal name of the Company to Alpha Compute Corp effective on April 14, 2026, the
Nasdaq ticker symbol of the Company&#8217;s ordinary shares was changed to &#8220;ALP&#8221;.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>The Company</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Alpha Compute Corp. ("Alpha Compute," "we," "us,"
"our," or the "Company") is a technology company focused on the acquisition, deployment, and leasing of high-performance
graphics processing units ("GPUs") in data center facilities to power artificial intelligence ("AI") workloads, with a
particular emphasis on confidential compute. The Company operates GPU infrastructure in North America and Europe and provides GPU-as-a-Service
("GPUaaS") and AI Confidential Compute solutions to enterprise customers, technology companies, AI research laboratories, and
decentralized AI ecosystems.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Beginning in late 2025, the Company commenced acquisition and installation
of NVIDIA GPU hardware, including H200, B200, and B300 processors, in third-party data center facilities. In April 2026, the Company formally
rebranded to Alpha Compute Corp. and changed its Nasdaq ticker from ATON to ALP to reflect the completion of this strategic transition.
The Company retains a residual position in TON digital assets from its previous focus as a digital asset treasury company, but this legacy
segment is no longer the primary focus of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>GPU-as-a-Service (GPUaaS)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's primary revenue model consists of acquiring and leasing NVIDIA
GPU hardware and leasing compute capacity to enterprise customers under multi-year off-take agreements. The Company earns revenue based
on contracted lease rates and capacity utilization.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's first large-scale deployment, designated ALPHA-01, consists
of 504 NVIDIA B200 GPUs co-located in a hydroelectric-powered Canadian data center. ALPHA-01 became fully operational in May 2026 and
is subject to a two-year, $32.2 million compute off-take lease with a leading frontier AI research laboratory, representing $16.1 million
in annual contracted revenue. A second cluster, ALPHA-02, comprising 576 NVIDIA B300 GPUs, is planned for deployment in a hydroelectric-powered
Swedish data center and is targeted for commercial launch in the third quarter of calendar year 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>AI Confidential Computing</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Confidential computing is a hardware-level security paradigm that enables
computation on sensitive data within a protected, hardware-enforced trusted execution environment ("TEE"), such that the data
and the AI model remain encrypted and inaccessible even to the infrastructure operator. The Company and its partners have together developed
and deployed a proprietary software stack that enables confidential AI workloads to be processed on Telegram&#8217;s Cocoon AI protocol
via NVIDIA Blackwell-generation GPU hardware.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company believes confidential computing represents the highest-growth,
highest-value segment within the AI infrastructure market, driven by stringent data privacy requirements across healthcare, financial
services, government, defense, and decentralized AI applications. The convergence of the EU AI Act (effective 2026), updated FedRAMP 20x
requirements, and various national data sovereignty mandates is creating a structural and mandatory procurement cycle for privacy-preserving
AI infrastructure.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Sovereign AI Infrastructure</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company targets enterprise clients, government entities, and regulated
industries seeking AI compute capacity that does not require surrendering data sovereignty to hyperscale cloud providers. The Company
offers co-location and dedicated GPU deployment arrangements designed to satisfy data residency requirements and regulatory mandates,
including in jurisdictions with strict cross-border data transfer restrictions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In conjunction with its infrastructure buildout, the Company has announced
plans to establish a U.S. Government Contracting entity, projected to launch in the third quarter of calendar year 2026, to pursue federal
government AI compute procurement opportunities including those arising from FedRAMP compliance requirements.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<ix:exclude><!-- Field: Page; Sequence: 66; Value: 6 -->
    <div id="xdx_23C_z1puLbxI1KSf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zFQWB7kXRH2g" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_239_zjbgRrHXHGF3" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zX7Shd9Vdte4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 1. NATURE OF OPERATIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_237_z2A4dpcChSI9" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b>Alpha Compute Capital</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has announced the launch of "Alpha Compute Capital,"
a financing division designed to structure and fund AI GPU Special Purpose Vehicles ("SPVs") and related financial products. Alpha
Compute Capital is intended to enable the Company to expand GPU deployment capacity using non-recourse, asset-backed financing facilities,
thereby reducing dilution to existing shareholders and accelerating infrastructure growth.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Digital Asset Business </b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company launched a digital asset treasury business in September 2025
focused on TON blockchain and the Telegram ecosystem. In November 2025, the Company began deploying Nvidia GPUs to Telegram&#8217;s proprietary
AI protocol, Cocoon. Cocoon is Telegram's Confidential Compute Open Network &#8212; a decentralized AI infrastructure project built around
the TON ecosystem. In response to market trends in the digital asset space and opportunities in AI infrastructure, in early 2026 the Company
completed a strategic pivot and rebranded as Alpha Compute Corp. to reflect that its primary focus had shifted to AI compute infrastructure.
This transition included the establishment of GPU procurement and data center deployment capabilities, and the development of a proprietary
confidential computing software stack.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">While investing in digital assets, staking digital assets, and operating
blockchain infrastructure is no longer a core focus of the Company, it will continue to maintain some exposure to TON and other digital
assets. By deploying GPU hardware to Telegram&#8217;s Cocoon protocol, the Company will continue to earn TON tokens, and through its May
2026 acquisition of GaMee, the Company has exposure to the broader Telegram ecosystem and large userbase. However, TON tokens earned from
Cocoon will generally be used for operating and capital expenditures for the AI infrastructure business line, rather than held for long-term
investment.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The remaining locked TON tokens on the Company&#8217;s balance sheet are
mostly in the process of being returned to investors per their put rights granted as part of the September 2025 PIPE transaction, with
two additional outstanding put rights exercised on June 22, 2026. One remaining investor has not exercised his put right on $0.2 million
locked TON contributed.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Legacy Immuno-oncology Business</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Prior to September 2025, Alpha Compute (under the name
Portage Biotech) primarily operated as a clinical-stage immuno-oncology company advancing treatments the Company believes will be first-in
class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients
with invasive cancers. Alpha Compute&#8217;s access to next-generation technologies coupled with a deep understanding of biological mechanisms
enables the identification of clinical therapies and product development strategies that accelerate these medicines through the translational
pipeline. After a review of the Company&#8217;s future funding needs for clinical development of its programs as well as the capital raising
market for biotechnology companies, the Company discontinued the Company sponsored trial for the invariant natural killer T-cell (&#8220;iNKT&#8221;)
program and pause further patient accrual to the Company sponsored adenosine trial for both PORT-6 and PORT-7.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In March 2025, we resumed patient enrollment into the
final dose-escalation cohort of TT-10 (PORT-6) under the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following an earlier pause related
to funding constraints. That decision reflected the favorable safety and preliminary activity signals seen in earlier dose cohorts. Dosing
in that final cohort is now underway, with the last dose-escalation patient currently being treated. In April 2025, we reported confirmatory
preclinical results for our TT-4 (PORT-7) compound in mesothelioma, supporting advancement of that indication. Under the trial protocol,
TT-4 dosing follows completion of the TT-10 dose-escalation cohort, and we are now preparing to enroll patients onto TT-4.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On November 12, 2025, Alpha Compute and Cyncado announced
a non-binding Letter of Intent with Australia&#8217;s Asbestos and Dust Diseases Research Institute (&#8220;ADDRI&#8221;) to conduct an
ADDRI-sponsored investigator-initiated clinical trial of TT-4 in mesothelioma in Australia. The planned trial is expected to enroll approximately
50 patients, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado&#8217;s planned U.S.
mesothelioma activities, subject to execution of a definitive agreement and customary regulatory approvals. Under the contemplated arrangement,
Cyncado will supply TT-4 and limited support as part of an international mesothelioma program designed to accelerate decision-quality
clinical data generation.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Reverse Stock Split</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;)
approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024,
the Company&#8217;s ordinary shares began trading on Nasdaq on a split-adjusted basis.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The reverse stock split was implemented to increase
the per share trading price of the Company&#8217;s ordinary shares for the purpose of ensuring a share price high enough to comply with
the minimum $1.00 bid price requirement for continued listing on Nasdaq. The Company received notice from Nasdaq on August 30, 2024 informing
the Company that it had regained compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 67; Value: 6 -->
    <div id="xdx_23E_zNMvZzliCVy4" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zcrfrkqnn0Q9" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_237_zI8YFWN7d4S3" style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_237_zsOtRAl3wCKh" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 1. NATURE OF OPERATIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_236_zEMwi34OlrFh" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As a result of the reverse stock split, every twenty
(20) pre-split ordinary shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from the reverse
stock split were rounded up to the nearest whole post-split ordinary share. The reverse stock split affected all shareholders uniformly
and did not alter any shareholder&#8217;s percentage interest in the Company&#8217;s ordinary shares, except for adjustments that may
result from the treatment of fractional shares. All outstanding options and warrants entitling their holders to purchase the Company&#8217;s
ordinary shares were adjusted as a result of the reverse stock split, in accordance with the terms of each such security. In addition,
the number of ordinary shares reserved for future issuance pursuant to the Company&#8217;s equity incentive plans were also appropriately
adjusted. The number of authorized ordinary shares was not proportionately reduced because the Company has an unlimited number of authorized
ordinary shares available for issuance, as permitted under the laws of the British Virgin Islands.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">All share and per share information included in the
consolidated financial statements have been retroactively adjusted to reflect the impact of the reverse stock split as if the stock split
occurred at the beginning of the periods presented. The shares of ordinary shares authorized remained at an unlimited number of ordinary
shares without par value.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001100" name="ifrs-full:DisclosureOfGoingConcernExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfGoingConcernExplanatory_zYG7tTV8Pu62" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. <span id="xdx_820_zPB9FXidVlub">GOING
CONCERN</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The accompanying consolidated financial statements for the fiscal year ended
March 31, 2026 have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity
of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly,
the accompanying consolidated financial statements for the fiscal year ended March 31, 2026 do not include any adjustments relating to
the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, the Company had cash, cash equivalents, and restricted
cash of approximately $<span id="xdx_902_eifrs-full--Cash_iI_pn3n3_dm_c20260331_z7UjVGJM0jv8"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2026-03-31" id="Fact001101" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million and total current liabilities of approximately $<span id="xdx_905_ecustom--TotalCurrentLiabilities_iI_pn5n6_c20260331_zLJBD86ckS6e"><ix:nonFraction name="ptgef:TotalCurrentLiabilities" contextRef="AsOf2026-03-31" id="Fact001102" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.7</ix:nonFraction></span>
million. For the year ended March 31, 2026, the Company is reporting a net loss of approximately $<span id="xdx_90F_ecustom--NetLossIncome_pn3n3_dm_c20250401__20260331_z1CiYsvAmf21"><ix:nonFraction name="ptgef:NetLossIncome" contextRef="From2025-04-01to2026-03-31" id="Fact001103" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">38.6</ix:nonFraction></span>
million, and cash used in operating activities of approximately $<span id="xdx_90C_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20250401__20260331_zppeVO2ZVsOl"><ix:nonFraction name="ptgef:CashUsedInOperatingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact001104" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">20.5</ix:nonFraction></span>
million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In late Fiscal 2024, because of continued liquidity constraints, the Company
discontinued further clinical development of its iNKT sponsored trial and pause further patient accrual to its sponsored adenosine program
for both PORT-6 and PORT-7. During the fiscal year ended March 31, 2026, the Company changed its operating strategy to focus on developing
the Telegram ecosystem and managing a strategic reserve of digital assets, primarily the TON token, and received funding via a private
placement in the form of both cash and digital assets. While this and subsequent equity raises including a registered direct offering
on January 13, 2026 are a positive factor the Company is continuing to explore financing options including its at-the-market (&#8220;ATM&#8221;)
equity program and other financings.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Despite the Company successfully raising capital via a private placement
of shares and a registered direct offering in September 2025 and January 2026, respectively, and successfully raising additional funds
through its ATM program, the Company&#8217;s cash and cash equivalents balance is decreasing, and the Company did not generate positive
cash flows from operations for the fiscal years ended March 31, 2026 and 2025. Additionally, a portion of the Company&#8217;s digital
asset balance may be subject to significant price fluctuations, is restricted for immediate use, or both and therefore may not be relied
upon to fund current obligations as they come due. These factors raise significant doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date issuance of these consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has incurred significant operating losses since inception and
expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of research and development activities and operating expenses. As previously discussed, the Company has discontinued
its iNKT sponsored trial and paused further patient accrual to the Company sponsored adenosine program in order to preserve cash resources.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities. The Company will require significant additional capital to make the investments it needs
to execute its new Telegram ecosystem and new digital asset strategies, beyond the potential proceeds that could be reasonably generated
from its ATM program. The Company&#8217;s ability to successfully raise sufficient funds through the sale of debt or equity securities
when needed is subject to many risks and uncertainties and, future equity issuances would result in dilution to existing shareholders
and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.
See Note 16, &#8220;Capital Stock and Reserves,&#8221; for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of July 13, 2026, the Company had approximately $<span id="xdx_905_ecustom--CashCashEquivalents_iI_pn3n3_dm_c20260331_zjJRM80f9lv5" title="cash, cash equivalents"><ix:nonFraction name="ptgef:CashCashEquivalents" contextRef="AsOf2026-03-31" id="Fact001106" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">10.3</ix:nonFraction></span>
million of cash, cash equivalents, and restricted cash on hand, which the Company expects may not be sufficient to fund its operating
needs through FYE in March 2027. The Company projects cash flow needs of approximately $<span id="xdx_905_ecustom--RestrictedCashOnHand_iI_c20260331_zkGjj8VtcHI6" title="Restricted cash on hand"><ix:nonFraction name="ptgef:RestrictedCashOnHand" contextRef="AsOf2026-03-31" id="Fact001108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25.0</ix:nonFraction></span>
million between now and FYE 2027, exceeding cash, cash equivalents, and restricted cash on hand. These factors raise substantial doubt
about the Company&#8217;s ability to continue as a going concern within one year after the date of the issuance of these consolidated
financial statements. There were no adjustments made to reflect the effect of this doubt.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001110" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zS59ac2GGlpi" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 3.
<span id="xdx_82C_z2CuiX4AkXYj">BASIS OF PRESENTATION</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Statement of Compliance and Basis of Presentation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">These consolidated financial statements have been prepared
in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) issued by the International Accounting Standards
Board (&#8220;IASB&#8221;), and interpretations of the International Financial Reporting Interpretations Committee (&#8220;IFRIC&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 68; Value: 6 -->
    <div id="xdx_234_zluEsRel3L44" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zUIy6LO1dNT" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_238_zdTGgXv0Tv9f" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><p id="xdx_23D_zQpxgLlPIhCa" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_z3SquufyXKO6" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 3. BASIS OF PRESENTATION <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_230_zAXyCbZHZ6M6" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">These consolidated financial statements have been prepared
on an historical cost basis except for items disclosed herein at fair value (see Note 21, &#8220;Financial Instruments and Risk Management&#8221;).
In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The Company has two reportable operating segments, Digital &amp;
Compute and Immuno-Oncology.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">These consolidated financial statements were
approved and authorized for issuance by the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board on July 15, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Consolidation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The consolidated financial statements include the accounts of the
Company and:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged
certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_90A_eifrs-full--ProportionOfVotingPowerHeldInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zpyCKxETZbEd" title="Percentage of outstanding shares"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" contextRef="From2021-09-012021-09-30_custom_IOXMember_custom_SalvaRxMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17.83</ix:nonFraction></span>%
of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from <span id="xdx_903_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zf1p7WpDmnj2" title="Percentage of ownership"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember_custom_IOXMember_custom_SalvaRxMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.49</ix:nonFraction></span>%
to <span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zWiVNXrgnHq5" title="Percentage of ownership"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember_custom_IOXMember_custom_SalvaRxMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">78.32</ix:nonFraction></span>%.
On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. The Company&#8217;s <span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20231201__20231231__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--StimunityMember_z06LXpMuyjxb" title="Non-controlling interest"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="From2023-12-012023-12-31_custom_IOXMember_custom_StimunityMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44</ix:nonFraction></span>%
interest in Stimunity S.A. (&#8220;Stimunity&#8221;) was transferred from Alpha Compute to iOx in December 2023 and was increased to <span id="xdx_90D_ecustom--NoncontrollingInterestIncreasedUponConversion_pip0_dp_c20231201__20231231__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--StimunityMember_z9f6BCDCglFg" title="Non-controlling interest increased upon conversion"><ix:nonFraction name="ptgef:NoncontrollingInterestIncreasedUponConversion" contextRef="From2023-12-012023-12-31_custom_IOXMember_custom_StimunityMember" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">48.9</ix:nonFraction></span>%
upon the conversion of the convertible note to equity. On December 3, 2025, the Company agreed to sell back our 48.9% interest back to
Stimunity for a token consideration of 1 EUR in order to facilitate an orderly wind-down of Stimunity;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Saugatuck, a <span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20250401__20250930__ifrs-full--GeographicalAreasAxis__custom--CountryOfBritishVirginIslandsMember_z8ylDweMC7Vj" title="Percentage of ownership subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2025-04-012025-09-30_custom_CountryOfBritishVirginIslandsMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>%
owned subsidiary incorporated in the British Virgin Islands;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Tarus Therapeutic Holdings Ltd., a wholly-owned subsidiary incorporated in the British Virgin Islands;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
PDS, a <span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20250401__20250930__ifrs-full--GeographicalAreasAxis__custom--DelawareMember_zuCrLVYfhLu4" title="Percentage of ownership subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2025-04-012025-09-30_custom_DelawareMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%
owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary via a shared
services agreement;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SalvaRx LLC, a wholly-owned subsidiary through SalvaRx incorporated in Delaware;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck incorporated in Delaware; and</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Tarus Therapeutics, LLC (&#8220;Tarus&#8221;), a wholly-owned subsidiary of Alpha Compute incorporated in Delaware.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">All inter-company balances and transactions have been eliminated
in consolidation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of shareholders&#8217; equity. As of March 31, 2026, non-controlling interest represents
the <span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20250401__20250930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z8AH8lfRHkIj" title="Non-controlling interest"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="From2025-04-012025-09-30_custom_SubsidiariesTwoMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>%
shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Functional and Presentation Currency</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The Company&#8217;s functional and presentation currency is the
U.S. Dollar.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Use of Estimates and Judgments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The preparation of the consolidated financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Estimates and underlying assumptions are reviewed on
an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future
periods affected.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Significant areas where estimates are made include
valuation of financial instruments, deferred tax assets and liabilities, warrant liabilities, digital assets, put right liabilities, and
measurement of share-based compensation. Significant areas where critical judgments are applied include warrant liabilities, put right
liabilities, and digital asset valuation with respect to discounts for lack of marketability.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Transactions with Non-controlling Interests</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Changes in the Company&#8217;s ownership interest in
a subsidiary corporation that do not result in a loss of control over the subsidiary corporation are accounted for as transactions with
equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest and the fair value
of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 69; Value: 6 -->
    <div id="xdx_232_zTcO1QJNfRgf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zVoEHUYDeTAb" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23E_zrkSgo8GpSl9" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>



<ix:exclude><p id="xdx_23D_zjLJTCynGUsc" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001134" name="ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p id="xdx_80B_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zjTMvWnc6BSi" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
4. <span id="xdx_826_zL81KC5bV0nh">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The accounting policies set out below have been applied consistently to
all periods presented in these consolidated financial statements, which have, in management's opinion, been properly prepared within reasonable
limits of materiality and within the framework of the significant accounting policies summarized below:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001136" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"><p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zq6bXFBJNhRl" style="margin: 0pt 0; font-size: 10pt"><b><i><span id="xdx_869_zrokjMcMtN3f">Financial
Instruments</span></i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>i) Financial Assets</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Classification</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Upon the initial recognition of financial assets, the financial assets are
classified as one of the following measurement methodologies: (a) amortized cost, (b) fair value through other comprehensive income (&#8220;FVTOCI&#8221;),
or (c) fair value through profit or loss (&#8220;FVTPL&#8221;). Subsequent measurement will be based on the initial classification of
the financial assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The classification of a financial asset at initial recognition depends on
the Company's business model for managing the financial asset and the financial asset's contractual cash flow characteristics.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In order for a financial asset to be measured at amortized cost or fair
value through other comprehensive income (&#8220;OCI&#8221;), it needs to give rise to cash flows that are solely payments of principal
and interest (&#8220;SPPI&#8221;) on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed
at an instrument level.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's business model for managing financial assets refers to how
it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting
contractual cash flows, selling the financial assets, or both.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Measurement</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">For purposes of subsequent measurement, financial assets are classified
in three categories:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%">Financial assets at amortized cost (debt instruments);</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>Financial assets at FVTOCI (equity instruments); and</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>Financial assets at FVTPL.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets at Amortized Cost (Debt Instruments)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">The Company measures financial assets at amortized cost if both of the following conditions
are met:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%">The financial asset is held within a business model with the objective of holding the financial asset in order to collect
        contractual cash flows; and</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
        on the principal amount outstanding.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at amortized cost are subsequently measured using the effective
interest rate method and are subject to a period impairment review. Gains and losses are recognized in profit or loss when the asset is
derecognized, modified or impaired.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's financial assets classified at amortized cost includes accounts
receivable, stablecoin, and prepaid expenses and other receivables.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets designated at Fair Value through OCI (Equity Instruments)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Upon initial recognition, the Company can elect to classify irrevocably
its equity investments as equity instruments designated at FVTOCI when they meet the definition of equity under IAS 32, &#8220;<i>Financial
Instruments: Presentation</i>,&#8221; and are not held for trading. The classification is determined on an instrument-by-instrument basis.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_23A_zbgLXAofZW7d" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 70; Value: 6 -->
    <div id="xdx_23F_zjg2cdpw2qr9" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_z9h1Eb44EdD4" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_233_zkivjCHZOUX3" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23B_zl3yymivJUXc" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_zQXKje3zcNlh" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Gains and losses on these financial assets are never recycled to profit
or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except
when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded
in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company irrevocably elected to classify its investment in Intensity
as FVTOCI. During the year ended March 31, 2024, the Company sold 100% of its investment in Intensity for proceeds of $2.812 million and
recognized a gain of $0.725 million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets at Fair Value through Profit or Loss</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at FVTPL include financial assets held for trading, financial
assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured
at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in
the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated
as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified
and measured FVTPL, irrespective of the business model.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at fair value through profit or loss are carried in the
consolidated statements of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.
The investments in associate (Stimunity and Compedica) and the Stimunity Convertible Note receivable are accounted for as FVTPL.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>ii) Financial Liabilities</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s financial liabilities include accounts payable and accrued
liabilities, which approximate fair value due to their short maturity, lease liability, warrant liability, put right liability and TON
payable to settle put rights exercised.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Warrant Liability</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Warrant liabilities are initially measured at fair value on the date of
issuance. After initial recognition, the warrant liabilities are remeasured at fair value at each reporting period, with changes in fair
value recognized through the consolidated statement of operations and other comprehensive loss in accordance with IFRS 9 &#8220;Financial
Instruments.&#8221; When the Company issues equity instruments to extinguish all or part of the liability, a gain or loss is recognized
in the consolidated statement of operations and other comprehensive loss, which is measured as the difference between the carrying amount
of the financial liability and the fair value of the equity instruments issued. Liability classified warrants are accounted for in accordance
with IFRS 9 and IFRS 13 &#8220;<i>Fair Value Measurement</i>,&#8221; where the terms of the instruments do not meet the criteria for classification
as equity under IAS 32 &#8220;<i>Financial Instruments: Presentation</i>.&#8221; See Note 11, &#8220;Warrant Liability&#8221; for a further
discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001142" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zAGIzTm5czbj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zWLd1DvAegf">Impairment
of Financial Assets and Intangible Assets</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">IFRS 9, &#8220;<i>Financial Instruments</i>,&#8221; requires the Company
to recognize an allowance for expected credit losses ("ECLs") for all debt instruments and investments not held at fair value
through profit or loss and contract assets. For intangible assets, at the end of each reporting period and whenever there is an indication
that the intangible asset may be impaired, the Company reviews the carrying amounts of its intangible assets to determine whether there
is any indication that those assets have suffered an impairment loss.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At the end of each reporting period, the Company assesses whether there
was objective evidence that a financial asset was impaired. The Company recognizes an allowance for ECLs for all debt instruments not
held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with
the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest
rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral
to the contractual terms.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">ECLs are recognized in two stages. For credit exposures for which there
has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default
events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant
increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of
the exposure, irrespective of the timing of the default (a lifetime ECL).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 71; Value: 6 -->
    <div id="xdx_238_zKxTqXPuIsdb" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zzUjIaK1gXSd" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23A_zZ1kVOeV9XI2" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23D_zlWpkw16HMWb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23A_zMhcz2PiTpa8" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001147" name="ptgef:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_zpRmemeYFdJj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_865_zwlvM4mX0Vmk">Cash,
Cash Equivalents, and Restricted Cash</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Cash and cash equivalents comprise cash in readily available checking accounts
and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash within three
months or less from date of acquisition and are subject to an insignificant risk of change in value. The carrying amounts approximate
fair value due to the short maturities of these instruments. The Company maintains most of its bank accounts in the United States ("U.S.").
As of March 31, 2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date
of purchase. Interest income earned on such investments totaled $<span id="xdx_90F_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20260331_zrFeBE0oQpZb" title="Investments"><ix:nonFraction name="ifrs-full:InvestmentProperty" contextRef="AsOf2026-03-31" id="Fact001149" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million, $<span id="xdx_90C_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20250331_zMypTLAoGPX" title="Investments"><ix:nonFraction name="ifrs-full:InvestmentProperty" contextRef="AsOf2025-03-31" id="Fact001151" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million and $<span id="xdx_909_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20240331_zaClKDTedD82" title="Investments"><ix:nonFraction name="ifrs-full:InvestmentProperty" contextRef="AsOf2024-03-31" id="Fact001153" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million in the years ended March 31, 2026, 2025 and 2024, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, the Company had $<span id="xdx_900_ecustom--CashRestrictedForUse_iI_pn3n3_dm_c20260331_zAwpvCBHawgl" title="Cash restricted for use"><ix:nonFraction name="ptgef:CashRestrictedForUse" contextRef="AsOf2026-03-31" id="Fact001155" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million in cash considered restricted for use and is held as collateral for the Company&#8217;s credit card balance with Silicon Valley
Bank. No cash was restricted for use as of March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001157" name="ptgef:DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory"><p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory_zQ5bnXcLF6I1" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_865_z8Y29tRA5GIi">Impairment
of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At the end of each annual reporting period and whenever there is an indication
that its property, plant and equipment and indefinite life intangible assets may be impaired, the Company reviews the carrying amounts
of such tangible intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If
any such indication exists, the recoverable amount of the asset is estimated to determine the extent of impairment loss (if any). When
it is not possible to estimate the recoverable amount of any individual asset, the Company estimates the recoverable amount of the cash-generating
unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated
to individual cash-generating units ("CGU" or "CGUs"), or the smallest group of cash-generating units for which a reasonable
and consistent allocation basis can be identified.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Recoverable amount is the higher of fair value less costs of disposal and
value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001159" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"><p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_z6u69SbANulg" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_864_zZuOgTYrTSqf">Share-based
Payments</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company determines the fair value of share-based payments granted to
directors, officers, employees and consultants using the Black-Scholes option-pricing model at the grant date. Assumptions for the Black-Scholes
model are determined as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%"><b><i>Expected Volatility</i></b>. The expected volatility rate used to value share option grants is based on the Company&#8217;s
        historical volatility.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Expected Term</i></b>. The Company used historical experience.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Risk-free Interest Rate</i></b>. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that
        had terms 	consistent with the expected term of the Company's share option grants.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Expected Dividend Yield</i></b>. The Company has never declared or paid any cash dividends and does not presently plan to pay cash
        	dividends in the foreseeable future.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Share-based payments to employees, officers and directors are recorded and reflected
as an expense over the vesting period with a corresponding increase in the share option reserve. On exercise, the associated amounts previously
recorded in the share option reserve are transferred to common share capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001161" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zrw28pDv89Vb" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_867_z1ZKTjA18v84">Loss
Per Share</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Basic loss per share is calculated by dividing net loss (the numerator)
by the weighted average number of ordinary shares outstanding (the denominator) during the period. Diluted loss per share reflects the
dilution that would occur if outstanding share options and share purchase warrants were exercised into ordinary shares using the treasury
stock method and convertible debt instruments were converted into ordinary shares using the if-converted method. Diluted loss per share
is calculated by dividing net loss applicable to ordinary shares by the sum of the weighted average number of ordinary shares outstanding
and all additional ordinary shares that would have been outstanding if potentially dilutive ordinary shares had been issued. The share
and per share information has been retroactively adjusted to reflect the impact of the stock dividend.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 72; Value: 6 -->
    <div id="xdx_233_zJmqWwRizfvc" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zic0ry8E0rG9" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23B_zYQ15fJ7vYS9" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_239_zj4fD7WpmzVi" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_233_zLBd3wirjMsc" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The inclusion of the Company's share options, restricted stock units and
share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore
excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the years
ended March 31, 2026, 2025, and 2024. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share, and accordingly, were excluded from the calculation (see Note 19, &#8220;Loss Per Share&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001166" name="ifrs-full:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023"><table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_z8ftXIMzNIQa" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B7_zUdta2IpW0Zf" style="display: none">Schedule of anti-dilutive effect on loss
        per share</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zSgEDUtn4RO8" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2025-04-012026-03-31_ifrs-full_WarrantsMember" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,531,581</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zby4c4g4Bjth" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2024-04-012025-03-31_ifrs-full_WarrantsMember" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">481,581</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zGDYkRfspGq6" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2023-04-012024-03-31_ifrs-full_WarrantsMember" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">481,581</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Share options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zjFUSFChu8hb" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2025-04-012026-03-31_custom_StockOptionsMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,246,507</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zX5zMTcxbVNg" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2024-04-012025-03-31_custom_StockOptionsMember" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">225,117</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zfqvikszk0E4" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2023-04-012024-03-31_custom_StockOptionsMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">90,281</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zbSDlZbM3fF6" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2025-04-012026-03-31_custom_RestrictedStockUnitsMember" id="Fact001180" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,241,334</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zMk7FZpnUWTc" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2024-04-012025-03-31_custom_RestrictedStockUnitsMember" id="Fact001182" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,410</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zcOYTRxczUv5" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" contextRef="From2023-04-012024-03-31_custom_RestrictedStockUnitsMember" id="Fact001184" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">18,467</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A4_zrEmZO7sqO61" style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001186" name="ptgef:DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory_zY1ZfxAjJTm3" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86B_zawFxBcOWf8b">Investment
in Public Company</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The investment is comprised of shares of private/public companies that have
been acquired through a private placement. The investment is initially recorded at fair value. Following acquisition, the Company evaluates
whether control or significant influence is exerted by the Company over the affairs of the investee company. Based on the evaluation,
the Company accounts for the investment using either the consolidation, equity accounting or fair value method. The Company sold the entire
investment in Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001188" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates"><p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForInvestmentInAssociates_zJUoPXSpf5If" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_867_zDJqp4VzmMm2">Investment
in Associate</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">An associate is an entity over which the Company has significant influence.
Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or
joint control over those policies. The investment in associate was written down to nil as of March 31, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The results and assets and liabilities of associates are incorporated in
these consolidated financial statements using the equity method of accounting, except when the investment, or a portion thereof, is classified
as held for sale, in which case it is accounted for in accordance with IFRS 5, &#8220;Non-current Assets Held for Sale and Discontinued
Operations&#8221;. Under the equity method, an investment in an associate is initially recognized in the consolidated statement of financial
position at cost from the date the investee becomes an associate and adjusted thereafter to recognize the Company's share of the profit
or loss and other comprehensive income of the associate. When the Company's share of losses of an associate exceed the Company's interest
in that associate (which includes any long-term interests that, in substance, form part of the Company's net investment in the associate),
the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company
has incurred legal or constructive obligations or made payments on behalf of the associate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">After application of the equity method, the Company determines whether it
is necessary to recognize an impairment loss on its investment in its associate. At each reporting date, the Company determines whether
there is objective evidence that the investment in the associate is impaired. If there is such evidence, the Company calculates the amount
of impairment as the difference between the recoverable amount of the associate and its carrying value, and then recognizes the loss within
'share of (loss) income in associate' in the consolidated statements of operations. With respect to its investment in Compedica, the Company
recognized a loss on impairment of $4.8 million as of September 30, 2025 due to the Company&#8217;s loss of significant influence over
the operations of Compedica.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001190" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"><p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_zQcsmzLWZ4Kc" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_863_zEaAf6viREwi">Research
and Development Expenses</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>(i) Research and Development</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Expenditure on research activities, undertaken with the prospect of gaining
new scientific or technical knowledge and understanding, is expensed as incurred.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Development activities involve a plan or design for the production of new
or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably,
the product or process is technically, and commercially feasible, future economic benefits are probable, and the Company intends to and
has sufficient resources to complete development and to use or sell the asset. Following initial recognition of the development expenditure
as an asset, the asset is carried at cost less any accumulated amortization. Amortization of the asset begins when development is complete
and the asset is available for use. It is amortized over the period of expected future benefit. During the period of development, the
asset is tested for impairment annually.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Research and development expenses include all direct and indirect operating
expenses supporting the products in development.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_23D_zbL59SQFV6yk" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 73; Value: 6 -->
    <div id="xdx_23E_zq1dfdz5cPvj" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zaxEjcJrlUg5" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23D_zdS1BbRwtB5l" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_236_zVIRqIT3Uwoi" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_237_zz3knBLuMDt6" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>(ii) Subsequent Expenditure</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subsequent expenditure is capitalized only when it increases the future
economic benefits embodied in the specific asset to which it relates. All other expenditures are recognized in income or loss as incurred.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>(iii) Clinical Trial Expenses</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Clinical trial expenses are a component of the Company's research and development
costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct development
activities on the Company's behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements is based
on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrollment,
services provided, contractual terms, and prior experience with similar contracts.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001196" name="ptgef:DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory"><p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory_zkRtD8qg5a6e" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_868_zUR2A6MIwkdk">Contingent
Liability</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A provision in accordance with IAS 37 &#8220;<i>Provisions, Contingent Liabilities
and Contingent Assets</i>,&#8221; is recognized when the Company has a present (legal or constructive) obligation as a result of a past
event and it is probable that economic resources shall be required to settle the obligation and a reliable estimate can be made of the
amount of the obligation. When the Company expects that some or all of the expense will be reimbursed to it, such as in an insurance contract,
the repayment will be recognized as a separate asset, only when it is highly likely that the asset will be received. The expense will
be recognized in profit and loss net of the portion reimbursed.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001198" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zoevFRVGYk92" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zVqVJ2K4A0S4">Determination
of Fair Value</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A number of the Company's accounting policies and disclosures required the
determination of fair value, both for financial and non-financial assets and liabilities. Fair values have been determined for measurement
and/or disclosure purposes based on assumptions that market participants would use when pricing the asset or liability, assuming that
market participants act in their economic best interest. When applicable, further information about the assumptions made in determining
fair values is disclosed in Note 15, &#8220;Financial Instruments and Risk Management&#8221; and other footnotes that specifically relate
to assets or liabilities measured at fair value.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001200" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zf26Z2XGEyGj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86B_zD5CdCIX2YK3">Income
Tax</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company uses the asset and liability method to account for income taxes.
Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying
amounts of existing assets and liabilities for accounting purposes, and their respective tax bases.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Deferred income tax assets and liabilities are measured using tax rates
that have been enacted or substantively enacted and applied to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized
in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and
are reviewed at the end of each reporting period.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001202" name="ptgef:DescriptionOfAccountingPolicyFoStablecoinExplanatory"><p id="xdx_848_ecustom--DescriptionOfAccountingPolicyFoStablecoinExplanatory_zi9uQyzIlenl" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zOUWdk3B0UF9">Stablecoin</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its stablecoins, which are comprised of USDC and
USDT, as in accordance with IAS 9 &#8220;Financial Instruments&#8221;. The Company&#8217;s stablecoins are initially recorded at cost,
and are contractually redeemable for fiat currency on demand or pegged 1:1 to the value of one U.S. dollar. The Company determines the
fair value of its stablecoins, which is at par with the U.S. dollar, in accordance with IFRS 13 &#8220;Fair Value Measurement&#8221; based
on the quoted (unadjusted) prices on the active exchange that the Company has determined is its principal market for the stablecoins (Level
1 inputs). Our primary custodian of stablecoins is BitGo, and the associated costs are expensed as incurred. Stablecoins are held for
use in business operations and not for the purpose of potential asset appreciation and is therefore classified as a current asset within
the consolidated statements of financial position. When the Company does not have possession, control, or the right to derive substantially
all of the economic benefits of ownership of stablecoin the Company has title to, the stablecoin is classified as a stablecoin receivable
within the consolidated statements of financial position. Stablecoin and stablecoin receivables qualify as financial instruments due to
their high level of liquidity, rights to redeem directly with the issuer, and their backing by high quality reserve assets not subject
to significant price fluctuations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 74; Value: 6 -->
    <div id="xdx_231_z21X0OewXREf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zrxydS25jxhi" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_231_zTRVZ9Pworaj" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><p id="xdx_236_zlDRx5LMDZql" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_235_z0hsV3Mn4rkb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_230_zz0ZiyxRT7E6" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001208" name="ptgef:DescriptionOfAccountingPolicyForDigitalAssetsExplanatory"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_zlzyHdBCCbP" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_862_z2wZN8uiLec4">Digital
Assets</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its digital assets, which are comprised of TON,
as indefinite-lived intangible assets in accordance with IAS 38 &#8220;Intangible Assets&#8221;. The Company&#8217;s digital assets are
initially recorded at cost. Subsequently, digital assets are remeasured at fair value as of each reporting period, adjusted by discounts
for lack of marketability for tokens restricted for use. The Company determines the fair value of its liquid digital assets in accordance
with IFRS 13 &#8220;Fair Value Measurement&#8221;, based on quoted (unadjusted) prices on the active exchange that the Company has determined
is its principal market for the digital assets (Level 1 inputs). For locked digital assets which are not immediately tradable, the Company
applies a lack of marketability discount to quoted prices to calculate fair value (Level 3 input). Our primary custodian of digital assets
is BitGo, and the associated costs are expensed as incurred. When the Company does not have possession, control, or the right to derive
substantially all of the economic benefits of ownership of digital assets the Company has title to, the digital assets are classified
as digital assets receivable within the consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Increases in fair value, to the extent they do not constitute reversals
of previous decreases in fair value, are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss),
within &#8220;Unrealized gain on digital assets&#8221; within Other comprehensive income, with accumulated unrealized gains recognized
on the Consolidated Statements of Financial Position within Accumulated other comprehensive income. Decreases in fair value, to the extent
they do not constitute reversals of previous increases in fair value, are recognized as incurred in the Company's Consolidated Statements
of Operations and Comprehensive Income (Loss), within &#8220;Loss on revaluation of digital assets&#8221; within Other expenses. Any losses
on revaluation not in excess of previously recognized gains are recognized as decreases to Accumulated other comprehensive income until
cost basis exceeds fair value, at which point additional losses are recognized as Other expense. Any gains on revaluation not in excess
of previously recognized losses are recognized as Other income until fair value exceeds cost basis, at which point additional gains are
recognized as Other comprehensive income. Revaluation gains and losses are recorded by token.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Realized gains, to the extent recognized within Accumulated other comprehensive
income, and losses are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss) within other
income (expense).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Digital assets are classified as current or noncurrent assets based on the
Company&#8217;s intended holding period of the token. If the Company has the intent and ability to hold the token for a period of one
year beyond the balance sheet date or if the token is not expected to become liquid within one year of the balance sheet date, the holding
is classified as noncurrent. Otherwise, the holding is classified as a current asset.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001210" name="ptgef:DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory"><p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_zZ4fAEFPxvHg" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_869_z7TbxQoibEG8">Revenue
from Contracts with Customers</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company recognizes revenue in accordance with IFRS 15, &#8220;<i>Revenue
from Contracts with Customers</i>,&#8221; which establishes a comprehensive framework for determining whether, how much, and when revenue
is recognized. Revenue is recognized to depict the transfer of promised services to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those services.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s primary source of revenue is derived from compute offtake
agreements, under which customers obtain access to dedicated or shared compute capacity (including processing power, memory, and related
infrastructure) for a specified contractual term.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.5in"><b><i>i)</i></b></td>
    <td><b><i>Identification of performance obligations</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Compute offtake agreements typically provide customers with a stand-ready obligation
to make compute capacity continuously available throughout the contract term. The Company has determined that such arrangements generally
contain a single performance obligation, being the provision of continuous access to compute services over time.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">To the extent that a contract includes multiple services (for example, initial configuration,
integration, or distinct ancillary services), the Company assesses whether such services are distinct and should be accounted for as separate
performance obligations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.5in"><b><i>ii)</i></b></td>
    <td><b><i>Determination of the transaction price</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">The transaction price reflects the amount of consideration the Company expects to receive
in exchange for transferring promised services to the customer. Consideration under compute offtake agreements is typically fixed based
on contracted capacity and term, and is frequently settled in digital assets.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">In arrangements where consideration is received in digital assets, such consideration
represents non-cash consideration and is measured at fair value at contract inception.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_233_zY0joJrUYUOa" style="margin: 0pt 0 0pt 1in; font-size: 10pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 75; Value: 6 -->
    <div id="xdx_23E_zMP9MUDPUYtl" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zSv2gzhYLZM3" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23B_zXbuRyLy4v9j" style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_238_zcWmzpP3u0Me" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_234_z3Z7uHHufha6" style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Any variability in consideration (such as pricing adjustments, service level credits,
or penalties) is estimated using either the expected value or most likely amount method, and included in the transaction price only to
the extent that it is highly probable that a significant reversal of revenue will not occur.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.5in"><b><i>iii)</i></b></td>
    <td><b><i>Allocation of the transaction price</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">If a contract contains more than one performance obligation, the transaction price is
allocated to each performance obligation based on the relative standalone selling prices of the distinct services at contract inception.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.5in"><b><i>iv)</i></b></td>
    <td><b><i>Timing of revenue recognition</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Revenue from compute offtake agreements is recognized over time, as the customer simultaneously
receives and consumes the benefits of the compute services as they are provided. Progress toward complete satisfaction of the performance
obligation is measured on a time-elapsed basis, or another systematic measure that faithfully depicts the pattern of transfer of services
to the customer.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Revenue is recognized only when:</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"/>
    <td style="width: 0.25in">1.</td>
    <td>A valid contract exists;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"/>
    <td style="width: 0.25in">2.</td>
    <td>The Company has transferred control of compute services to the customer; and</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"/>
    <td style="width: 0.25in">3.</td>
    <td>Collection of consideration is considered probable.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Digital assets received from customers is non-cash consideration and is
initially measured at fair value at contract inception. Any subsequent changes in the fair value of digital assets held by the Company
are accounted for in accordance with the Company&#8217;s accounting policy for digital assets, and do not affect the amount of revenue
recognized.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001216" name="ptgef:DescriptionOfAccountingPolicyForAccountsReceivableExplanatory"><p id="xdx_846_ecustom--DescriptionOfAccountingPolicyForAccountsReceivableExplanatory_zu3ay1vP4sj2" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zLn2ovINO1J3">Accounts
Receivable</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are recognized when the Company has an unconditional right
to consideration, which generally arises upon the invoicing of compute services or when contractual billing milestones are met. Trade
receivables are initially measured at fair value, which is typically equal to the invoiced amount or the fair value of digital assets
consideration to be received.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are subsequently measured at amortized cost, as they are
held solely for the collection of contractual cash flows (or cash-equivalent consideration). Trade receivables are presented net of any
allowance for expected credit losses. To the extent that invoices are settled directly in digital assets prior to the end of the reporting
period, no trade receivable is recognized, and the digital asset is recognized in accordance with the applicable accounting policy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001218" name="ptgef:DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory_zepWZP7ECA94" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_864_zjiJsipzIskk">Expected
Credit Losses</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company applies the simplified expected credit loss (ECL) model under
IFRS 9, &#8220;<i>Financial Instruments</i>.&#8221; Under this approach, lifetime expected credit losses are recognized at initial recognition
and updated at each reporting date. Expected credit losses are estimated based on:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Historical credit loss experience;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Current customer payment behavior, including digital asset settlement history; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Forward-looking information that is relevant to customer credit risk.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are written off when there is no reasonable expectation
of recovery.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001220" name="ptgef:DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory"><p id="xdx_842_ecustom--DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory_z4OVvBWBvuW3" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zV9xTkm552P5">Property,
Plant, and Equipment</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for property, plant and equipment in accordance with
IAS 16, &#8220;<i>Property, Plant and Equipment</i>.&#8221; The Company&#8217;s property, plant and equipment consist solely of GPUs used
in the provision of compute services under compute offtake agreements. GPUs are recognized as property, plant and equipment when:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>It is probable that future economic benefits associated with the asset will flow to the Company; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 76; Value: 6 -->
    <div id="xdx_234_z1JQ9Lnmc1qc" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zk7rEbEbt3ba" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_233_zOq4fea4rX94" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>



<ix:exclude><p id="xdx_238_znTfAHQjOE89" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_234_z9DSVpSBZsSg" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_znJI2woL3uTa" style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>The cost of the asset can be measured reliably.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">GPUs are initially measured at cost, which includes:</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>The purchase price, net of discounts or rebates;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Non-refundable taxes and duties;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Directly attributable costs necessary to bring the GPUs to the location and condition necessary for them to be capable of operating as
        intended by management (including transportation, installation, testing, and configuration costs); and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Any other expenditures directly attributable to preparing the GPUs for their intended use.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Costs incurred after GPUs are capable of operating as intended are expensed as incurred,
unless they meet the criteria for capitalization under IAS 16.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Following initial recognition, GPUs are carried at cost less accumulated
depreciation and accumulated impairment losses. The Company applies the cost model to all classes of property, plant and equipment. GPUs
are depreciated on a straight-line basis over their estimated useful lives, beginning when the assets are available for use, which is
when they are installed and ready for their intended operating condition. Management estimates the useful lives and residual values of
GPUs based on expected technological obsolescence, performance degradation, and expected usage patterns. Useful lives and residual values
are reviewed at least annually and adjusted prospectively when warranted.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">GPUs are derecognized upon disposal or when no future economic benefits
are expected from their use or disposal. Any gain or loss arising on derecognition is recognized in profit or loss and represents the
difference between the proceeds received and the carrying amount of the asset.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Deposits paid to suppliers for the future purchase of GPUs are recognized
as prepayments or other non-current assets, depending on the expected delivery date, and are not depreciated. Such deposits are initially
measured at the amount paid and reassessed at each reporting date to determine whether there is objective evidence that the deposit may
be impaired, including supplier non-performance or changes in expected delivery terms. Upon delivery and acceptance of the GPUs, deposits
are reclassified to property, plant and equipment as part of the cost of the related GPUs. If a purchase contract is terminated or delivery
becomes improbable, the deposit is written down to its recoverable amount, with any impairment recognized in profit or loss.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001226" name="ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory"><p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zzoCCzFQ5kDc" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86F_zK6NvyGkmJvk">Recent
Accounting Pronouncements</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(a)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21: The Effects of
Changes in Foreign Exchange Rates</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In August 2023, the IASB amended IAS 21, &#8220;The
Effects of Changes in Foreign Exchange Rates&#8221; (&#8220;IAS 21&#8221;) to clarify when a currency is exchangeable into another currency
and how a company estimates a spot rate when a currency lacks exchangeability, requiring consistent assessment and disclosure practices
for companies. The amendments are effective for annual reporting periods beginning on or after January 1, 2025, with early adoption permitted.
However, an entity cannot restate comparative information. The adoption of these amendments did not have a material effect on the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(b)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21 &#8211; Lack of
Exchangeability</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">An entity is impacted by the amendments to IAS 21, &#8220;<i>The Effects
of Changes in Foreign Exchange Rates</i>,&#8221; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The adoption of these amendments did not have a material effect on the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>New IFRS Accounting Standards not yet effective</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Standards issued but not yet effective up to the date
of issuance of the Company&#8217;s consolidated financial statements are listed below. This is of standards and interpretations issued,
which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes effective.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 77; Value: 6 -->
    <div id="xdx_239_ziHcxSt7iUU1" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zB6tLgUcgix9" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_233_zGw3wmZVyk3h" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_234_zul5B9yJ1Pyd" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_zDco1inhmreb" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(a)&#160;&#160;&#160;&#160;&#160; IAS 18: Presentation and Disclosure in
Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In April 2024, IFRS 18, &#8220;<i>Presentation and
Disclosure in Financial Statements</i>&#8221; (&#8220;IFRS 18&#8221;) was issued. IFRS 18 replaces IAS 1 and introduces significant changes
to the presentation of financial statements to enhance comparability across entities. The key requirements of the standard include:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Separate reporting of operating, investing, and financing activities in the statement of earnings, with prescribed
        subtotals for each category.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Disclosure of management-defined performance measures in a dedicated note within the financial statements.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The standard is effective for annual reporting periods
beginning on or after January 1, 2027, with retrospective application required. The Company intends to assess the impact of IFRS 18 on
its consolidated financial statements closer to the effective date. The effect of the new standard, however it may be, will only affect
matters of presentation and disclosure.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(b) Amendments to IFRS 9 and IFRS 7</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On May 30, 2024, the International Accounting Standards
Board (the IASB or the Board) issued Amendments to IFRS 9 and IFRS 7, <i>Amendments to the Classification and Measurement of Financial
Instruments</i>. The amendments:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify that a financial liability is derecognized on the &#8220;settlement date&#8221;, i.e., when the related
        obligation is discharged or cancelled or expires or the liability otherwise qualifies for derecognition. They also introduce an accounting
        policy option to derecognize financial liabilities that are settled through an electronic payment system before settlement date if certain
        conditions are met.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental,
        social and governance (ESG)-linked features and other similar contingent features.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify the treatment of non-recourse assets and contractually linked instruments (CLI).&#8217;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that
        reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive
        income (FVTOCI).</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The standard is effective for annual reporting periods
beginning on or after January 1, 2026, with retrospective application required. The Company intends to assess the impact of the Amendments
to IFRS 9 and IFRS 7 on its consolidated financial statements closer to the effective date.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001231" name="ifrs-full:DisclosureOfOtherAssetsExplanatory"><p id="xdx_802_eifrs-full--DisclosureOfOtherAssetsExplanatory_z8cxegF9nPB3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 5. <span id="xdx_82C_zUyHCb0h4r91">PREPAID
EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">At March 31, 2026 and 2025, prepaid expenses and other receivables
were comprised of the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001233" name="ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z7PSXYzVUWh4" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B3_zBTiNLsL1tF3" style="display: none">Schedule
        of prepaid expenses and other receivables</span></td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20260331_z9Ua6NdEC7Q3" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20250331_zQAmhQj4bWBb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_zIRNVvM77ce7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td>
    <td style="width: 1%; font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentReceivablesFromSaleOfProperties" contextRef="AsOf2025-03-31" id="Fact001236" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentAdvancesToSuppliers_iI_zQv0n1zLtdE5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2026-03-31" id="Fact001238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">595</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2025-03-31" id="Fact001239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">241</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentPrepaidExpenses_iI_zjZfbtSMhbb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2026-03-31" id="Fact001241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">567</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2025-03-31" id="Fact001242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidInvestorRelations_iI_zRbsssHADf6g" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid investor relations</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrepaidInvestorRelations" contextRef="AsOf2026-03-31" id="Fact001244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">534</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TaxDeposits_iI_zjx42jxiEREi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TaxDeposits" contextRef="AsOf2026-03-31" id="Fact001247" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TaxDeposits" contextRef="AsOf2025-03-31" id="Fact001248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PrepaidGpuInfrastructureCosts_iI_zUSNVdDOcRWb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid GPU infrastructure costs</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PrepaidGpuLeasesShortterm_iI_zg8pSOSwroF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid GPU leases, short-term</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--OtherCurrentReceivables_iI_zmSrzmJLGY4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Other receivables</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2026-03-31" id="Fact001256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">220</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2025-03-31" id="Fact001257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalPrepaidExpensesAndOtherReceivables_iI_zW8WIRSq50ma" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;&#160;Total prepaid expenses and other receivables</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TotalPrepaidExpensesAndOtherReceivables" contextRef="AsOf2026-03-31" id="Fact001259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,984</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TotalPrepaidExpensesAndOtherReceivables" contextRef="AsOf2025-03-31" id="Fact001260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">555</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, other assets consists of the long-term portion of
the prepaid investor relations contract in the amount of $<span id="xdx_90F_ecustom--OtherAssetsLongTermPortion_iI_pn3n3_dm_c20260331_zURFV8E1uB5f" title="Other assets long term portion"><ix:nonFraction name="ptgef:OtherAssetsLongTermPortion" contextRef="AsOf2026-03-31" id="Fact001262" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million and security deposits of $<span id="xdx_90D_ecustom--SecurityDeposits_iI_pn3n3_dm_c20260331_zZ5uTCLcU4xg" title="Security deposits"><ix:nonFraction name="ptgef:SecurityDeposits" contextRef="AsOf2026-03-31" id="Fact001264" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction></span>
million.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<ix:exclude><!-- Field: Page; Sequence: 78; Value: 6 -->
    <div id="xdx_23F_ztoX1Av8TRhc" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zaSxuLQ4H2Xl" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23B_ziVpyBB0s8q6" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zS5EJPOdMrB7" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001268" name="ptgef:DisclosureOfStablecoinExplanatory"><p id="xdx_80B_ecustom--DisclosureOfStablecoinExplanatory_zwM9XzBhgUe2" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 6. <span id="xdx_823_zVN9tj7Zfm8l">STABLECOIN
</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At March 31, 2026 and 2025, the Company&#8217;s stablecoin holdings were
comprised of the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001270" name="ptgef:DisclosureOfStablecoinTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--DisclosureOfStablecoinTableTextBlock_pn3n3_zDroblQh1KVb" summary="xdx: Disclosure - STABLECOIN (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BF_z0l09Yg7OyE8" style="display: none">Schedule of stablecoin</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49B_20260331_zIL509oZDWob" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_494_20250331_zxkMAHWSWtca" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">USDC</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zMbx5Il6jge3" title=" stablecoins" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1272">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zPwhDNdhBP7l" title=" stablecoins" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">USDT</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zOhsY8Mw4WGc" title=" stablecoins" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:Stablecoins" contextRef="AsOf2025-03-31_custom_UsdtMember" id="Fact001276" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zql3bii6Mp6" title=" stablecoins" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_ecustom--Stablecoins_iI_c20250331_z4TOuebvc49" title=" stablecoins" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:Stablecoins" contextRef="AsOf2025-03-31" id="Fact001280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_ecustom--Stablecoins_iI_c20260331_zDVgP5X5jJU5" title=" stablecoins" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1282">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AE_zCITyjbP5dRj" style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table summarizes the Company&#8217;s stablecoin purchases,
contributions, uses in the course of business, and sales for the fiscal year ended March 31, 2026 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001284" name="ptgef:DisclosureOfStablecoinPurchasesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfStablecoinPurchasesTableTextBlock_pn3n3_zCPT68n3dJUe" summary="xdx: Disclosure - STABLECOIN (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_z01UQdLF6AW3" style="display: none">Schedule of stablecoin purchases</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdcMember_zszXBmIapAeh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_494_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdtMember_zTifHJG5VV15" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49D_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zkhECywZeAF2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USDC</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USDT</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_408_ecustom--DigitalAssetValueAsOfApril1_zdaHJ180F3W7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1286">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1287">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ContributionOfStablecoin_zQ1NKlxvcxtj" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Contribution of Stablecoin</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfStablecoin" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="Fact001290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,411</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfStablecoin" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="Fact001291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfStablecoin" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,421</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromSaleOfDigitalAssets_zWpUAQ0gLn3d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Proceeds from sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="Fact001295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StablecoinUsedToSettleOperatingCosts_zMMPbm9i27Pg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin used to settle operating costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinUsedToSettleOperatingCosts" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="Fact001298" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,413</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinUsedToSettleOperatingCosts" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="Fact001299" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">311</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinUsedToSettleOperatingCosts" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001300" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,724</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--StablecoinSold_zYbNqw9JvaN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin sold</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinSold" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="Fact001302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,100</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinSold" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001304" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,100</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromExternalDebtDrawdown_zkNJPjYqrzgf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Proceeds from external debt drawdown</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromExternalDebtDrawdown" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="Fact001306" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,100</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1307">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromExternalDebtDrawdown" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,100</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PurchasesOfStablecoin_zzRBfZerqzD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Purchases of stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchasesOfStablecoin" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="Fact001311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">311</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchasesOfStablecoin" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">311</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StablecoinUsedToPurchaseDigitalAssets_zR02CfRYYGVk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Stablecoin used to purchase digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinUsedToPurchaseDigitalAssets" contextRef="From2025-04-012026-03-31_custom_USDCMember" id="Fact001314" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,998</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinUsedToPurchaseDigitalAssets" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="Fact001315" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:StablecoinUsedToPurchaseDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001316" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,008</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--StablecoinValueAsOfMarch31_zeHxYBKMY9vi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Stablecoin value as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StablecoinValueAsOfMarch31" contextRef="From2025-04-012026-03-31_custom_UsdtMember" id="Fact001319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StablecoinValueAsOfMarch31" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AA_zsS0c3ZQVmC3" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company did not hold or transact stablecoins during
the fiscal year ended March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s stablecoins are a digital asset intended to maintain
a stable value by tracking the U.S. dollar on a 1:1 basis. Stablecoins are held for use in business operations and not for the purpose
of potential asset appreciation and is therefore classified as a current asset within the consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001322" name="ptgef:DisclosureOfDigitalAssetsExplanatory"><p id="xdx_801_ecustom--DisclosureOfDigitalAssetsExplanatory_zrqYrphGTdd9" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 7. <span id="xdx_825_zkbTVcyO6Jf">DIGITAL
ASSETS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">At March 31, 2026 and 2025, digital assets were comprised of the
following (in thousands, except for number of tokens held):</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001324" name="ptgef:ScheduleOfDigitalAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfDigitalAssetsTableTextBlock_pn3n3_z3pEYyiac4Jh" summary="xdx: Disclosure - DIGITAL ASSETS (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BC_zuVJO3TDndrg" style="display: none">Schedule of Digital
        assets</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49B_20260331_zAXsHqW0ntgh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20250331_zxA7HCg3cAi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_407_ecustom--ApproximateNumberOfTonTokensHeld_iI_zzFNPsubLrA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Approximate number of TON Tokens held</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ApproximateNumberOfTonTokensHeld" contextRef="AsOf2026-03-31" id="Fact001326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,379,165</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TonTokensFairValueInThousands_iI_zvYPqCKZZ2f8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">TON Tokens, fair value (in thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TonTokensFairValueInThousands" contextRef="AsOf2026-03-31" id="Fact001329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,492</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetsFairValueInThousands_iI_zuaZyf59SBQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Digital assets, fair value (in thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetsFairValueInThousands" contextRef="AsOf2026-03-31" id="Fact001332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,492</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AB_z1q1HbI3nHh6" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At March 31, 2026, digital assets totaling $<span id="xdx_906_ecustom--DigitalAssets_iI_pn3n3_dm_c20260331_zpdsVS7oEZQg" title="Digital assets"><ix:nonFraction name="ptgef:DigitalAssets" contextRef="AsOf2026-03-31" id="Fact001335" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction></span>
million were managed under the Alpha Sigma Capital asset management agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<ix:exclude><p id="xdx_237_z6Mpc5E3gAG7" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 79; Value: 6 -->
    <div id="xdx_231_z66DGaufA9vf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zUkp4ygue6U1" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_231_zobMA7fQuWQi" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23B_zo1EYdNp999" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 7. DIGITAL ASSETS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_233_zZLshD8FK2W8" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table summarizes the Company&#8217;s digital asset purchases,
contributions, unrealized gains (losses) on digital assets, sales of digital assets, and other movements for the fiscal year ended March
31, 2026:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001341" name="ptgef:ScheduleOfDigitalAssetsPurchasesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfDigitalAssetsPurchasesTableTextBlock_pn3n3_zKfnHMmBCzlf" summary="xdx: Disclosure - DIGITAL ASSETS (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zkP3GrCNTvCi" style="display: none">Schedule of digital
        assets purchases</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TONMember_zd8TfTnhN7ji" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49F_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--BITCOINMember_zM2OwWS2qjU6" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_493_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TotalMember_zQOXlnavBZh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">TON</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Bitcoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetValueAsOfApril1_zUMU1tikAXeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ContributionOfDigitalAssets_zgXE3BDzJB12" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left">Contribution of digital assets</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,382</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="Fact001348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,802</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_zTL2wJuiwzLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Unrealized losses on digital assets recognized in Statement of Operations</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001351" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,411</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001353" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,411</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetsSold_zcpSrncvI5Ki" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets sold</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DigitalAssetsSold" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001355" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,921</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DigitalAssetsSold" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001357" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,921</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--PaymentsOnExternalDebtUsingDigitalAssets_zC2H8lfm4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Payments on external debt using digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PaymentsOnExternalDebtUsingDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001359" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,825</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PaymentsOnExternalDebtUsingDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001361" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,825</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DigitalAssetPurchases_zpNiTxlPdBb3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital asset purchases</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetPurchases" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,617</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetPurchases" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001365" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,617</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ReceiptOfDigitalAssetsReceivable_z7DwOCQZ5Xw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Receipt of digital assets receivable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReceiptOfDigitalAssetsReceivable" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001367" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,667</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReceiptOfDigitalAssetsReceivable" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001369" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,667</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RealizedLossGainOnSaleOfDigitalAssets_zK1izA3o06m3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Realized (loss) gain on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RealizedLossGainOnSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001371" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,705</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:RealizedLossGainOnSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="Fact001372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RealizedLossGainOnSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001373" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,700</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--RealizedLossOnNovationOfDigitalAssetsToInvestor_zxXJjlqha4Dj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Realized loss on novation of digital assets to investor</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001375" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">676</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001377" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">676</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--RevenueReceivedInDigitalAssets_zknQslf53Sja" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Revenue received in digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:RevenueReceivedInDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001379" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1380">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:RevenueReceivedInDigitalAssets" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TokensUsedToSettlePutRights_zgQX1EHZysVe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tokens used to settle put rights</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TokensUsedToSettlePutRights" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001383" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,130</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1384">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TokensUsedToSettlePutRights" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001385" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,130</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--DigitalAssetsExchanged_z4PcFalkmFIb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets exchanged</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetsExchanged" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">425</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DigitalAssetsExchanged" contextRef="From2025-04-012026-03-31_custom_BITCOINMember" id="Fact001388" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">425</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DigitalAssetsTransacted_zqOOtx4zbm52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Digital assets transacted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"/>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"/></tr>
  <tr id="xdx_401_ecustom--DigitalAssetValueAsOfMarch31_ztI6Q7YPWhS5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Digital asset value as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetValueAsOfMarch31" contextRef="From2025-04-012026-03-31_custom_TONMember" id="Fact001395" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,492</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1396">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetValueAsOfMarch31" contextRef="From2025-04-012026-03-31_custom_TotalMember371194906" id="Fact001397" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,492</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AA_z60UO6ChWQjb" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company did not hold or transact Digital assets during the fiscal year
ended March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company valued the TON treasury at $<span id="xdx_904_ecustom--TonTokensReceivable_iI_pn3n3_dm_c20260331_zAJSUyfVuhei" title="TON tokens receivable"><ix:nonFraction name="ptgef:TonTokensReceivable" contextRef="AsOf2026-03-31" id="Fact001399" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.22</ix:nonFraction></span>
per liquid token as of March 31, 2026. The Company did not hold digital assets as of March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has 2,277,108 TON tokens that are locked under vesting contracts
at March 31, 2026. The following table summarizes the unlocking schedule of TON tokens currently locked as of March 31, 2026:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001401" name="ptgef:SeheduleOfTonTokensTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--SeheduleOfTonTokensTableTextBlock_pn3n3_zaUme3yub7E5" summary="xdx: Disclosure - DIGITAL ASSETS (Details 2)" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20260331_zA4T0ZBkQ7Z8" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CapitalFutureMinimumPaymentsRemainderOfFiscalYear_iI_zcdYkOvwbux" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Fiscal 2027</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CapitalFutureMinimumPaymentsRemainderOfFiscalYear" contextRef="AsOf2026-03-31" id="Fact001403" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,121,493</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CapitalFutureMinimumPaymentsRemainderOfSecondYear_iI_zysjIrexSmR5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fiscal 2028</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CapitalFutureMinimumPaymentsRemainderOfSecondYear" contextRef="AsOf2026-03-31" id="Fact001405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">986,077</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CapitalFutureMinimumPaymentsRemainderOfThirdYear_iI_zwr72ctBdXM5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fiscal 2029</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CapitalFutureMinimumPaymentsRemainderOfThirdYear" contextRef="AsOf2026-03-31" id="Fact001407" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169,538</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CapitalFutureMinimumPaymentsRemainderOfTotalYear_iI_z30jfsuDEpy9" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">total&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CapitalFutureMinimumPaymentsRemainderOfTotalYear" contextRef="AsOf2026-03-31" id="Fact001409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,277,108</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A4_zz0zQdlPZnEf" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Of the <span id="xdx_90E_ecustom--TonTokensReceivableShares_iI_c20260331_znhLoPheLGtk" title="TON tokens receivable shares"><ix:nonFraction name="ptgef:TonTokensReceivableShares" contextRef="AsOf2026-03-31" id="Fact001411" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,277,108</ix:nonFraction></span>
locked TON tokens as of March 31, 2026, <span id="xdx_90C_ecustom--TokensArePayable_iI_c20260331_zRNPwJbK48Se" title="Tokens are payable"><ix:nonFraction name="ptgef:TokensArePayable" contextRef="AsOf2026-03-31" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,665</ix:nonFraction></span>
tokens are payable to investors following the exercise the investors&#8217; respective put rights.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company valued the TON tokens at $1.04 on average per locked token as
of March 31, 2026. The Company did not hold digital assets as of March 31, 2025. The aggregate fair value of locked tokens is computed
by taking the number of locked tokens and discounting the month-end spot price by an average of 14.8%. The discount used by management
is based on the historical purchases of locked TON management has made on behalf of the Company and Monte Carlo simulation based on estimated
volatility during the lockup period (Level 3 inputs). Management monitors this discount percentage and adjusts when appropriate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s liquid digital assets are routinely transacted with
in the ordinary course of business and are therefore classified as current assets within the consolidated statements of financial position.
Locked tokens are classified as current or noncurrent assets within the consolidated statements of financial position based on when the
locked tokens vest and become available for use by the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><p id="xdx_800_ecustom--DisclosureOfReceivablesDigitalAssetsExplanatory_zhLkuYZ4miXi" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 8.
<span id="xdx_82F_zJldj3i7fQB2">RECEIVABLES &#8211; STABLECOIN AND DIGITAL ASSETS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At March 31, 2026 and 2025, the Company had no Receivables &#8211; stablecoin
and digital assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<!-- Field: Page; Sequence: 80; Value: 6 -->
    <div id="xdx_236_zGZeEo65Ffnb" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zTPObKU3Ggdi" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page -->

<p id="xdx_238_zltqRb0PiMYf" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p id="xdx_23F_zxElPLJLmooj" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 8. RECEIVABLES &#8211; STABLECOIN AND DIGITAL ASSETS <i>(Cont&#8217;d)</i></b></p>

<p id="xdx_23D_zosLuJdCRFac" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table summarizes the Company&#8217;s movements in Receivables
&#8211; stablecoin and digital assets for the fiscal year ended March 31, 2026:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001420" name="ptgef:ScheduleOfReceivablesDigitalAssetsTableXextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfReceivablesDigitalAssetsTableXextBlock_pn3n3_zcPbiJLjvDeg" summary="xdx: Disclosure - RECEIVABLES DIGITAL ASSETS (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zPxHMxuyE3B" style="display: none">Schedule of movements
        in Receivables &#8211; digital assets</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--USD1Member_zvAQ4nDTUpIi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LockedTonMember_z6DEuMEBjGO2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zdVGRpuUFLv9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USD1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Locked TON</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_40F_ecustom--DigitalAssetValueAsOfApril1_zyN7eYCb5KJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1422">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1423">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1424">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ContributionOfDigitalAssetAndStablecoinReceivables_zRL4hMRNAhBi" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left">Contribution of digital asset and stablecoin receivables</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssetAndStablecoinReceivables" contextRef="From2025-04-012026-03-31_custom_USD1Member" id="Fact001426" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssetAndStablecoinReceivables" contextRef="From2025-04-012026-03-31_custom_LockedTonMember" id="Fact001427" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,016</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ContributionOfDigitalAssetAndStablecoinReceivables" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,016</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ChangeInFairValueOfDigitalAssetsReceivable_zmi3jzm6lcL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of digital assets receivable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1430">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfDigitalAssetsReceivable" contextRef="From2025-04-012026-03-31_custom_LockedTonMember" id="Fact001431" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,349</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfDigitalAssetsReceivable" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001432" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,349</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ReceiptOfDigitalAssetReceivables_zK2cqYByvCn" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Receipt of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ReceiptOfDigitalAssetReceivables" contextRef="From2025-04-012026-03-31_custom_LockedTonMember" id="Fact001435" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,667</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ReceiptOfDigitalAssetReceivables" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001436" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,667</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--TokensUsedToSettlePutRights_zsrqvgIgtnP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Tokens used to settle put rights</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TokensUsedToSettlePutRights" contextRef="From2025-04-012026-03-31_custom_USD1Member" id="Fact001438" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,000</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1439">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TokensUsedToSettlePutRights" contextRef="From2025-04-012026-03-31_custom_TotalMember" id="Fact001440" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,000</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--StablecoinValueAsOfSeptember30_zMXCskuZKWL8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">Stablecoin value as of September 30</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1442">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1443">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1444">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A6_zv4pWlcnsUk4" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company did not hold or transact digital asset
or stablecoin receivables during the fiscal year ended March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001446" name="ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock"><p id="xdx_809_ecustom--PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock_z7O8ztP9O2v1" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
9. <span id="xdx_826_zBhRRpIPV172">PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The table below presents the carrying value of property, plant, and equipment,
equipment deposits, and right-of-use assets (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>





<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001448" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89C_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_pn3n3_ztWFvZBQHXNa" summary="xdx: Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zUEvq8NNxXGl" style="display: none">Schedule of property, plant, and equipment,
        equipment deposits, and right-of-use assets</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_zpW4srsOHWL1" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zOnbMazTo1Z6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zPP5zmGgsKJ7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_z0jwmooRmGTl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">COST</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_438_c20240401__20250331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_zCTFEcOZ6IM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt">As of March 31, 2024</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1450">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1451">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2024-03-31_custom_RightOfUseAssetMember" id="Fact001452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2024-03-31_custom_TotalMember" id="Fact001453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zg68a3YI6A85" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fixed asset additions</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1455">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1456">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1457">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_zWY57ySxhiGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1460">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember" id="Fact001462" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">84</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_TotalMember" id="Fact001463" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">84</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_z8Lok5wLuKvi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1465">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1466">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1468">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zPXQ9xd60kh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fixed asset additions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2025-04-012026-03-31_custom_GPUsMember" id="Fact001470" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,373</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember" id="Fact001471" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,308</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember" id="Fact001472" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2025-04-012026-03-31_custom_TotalMember371195968" id="Fact001473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,197</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_ziH7HqU6haxg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1475">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1476">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1477">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1478">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iE_zEwPtn0uZyJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">As of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2026-03-31_custom_GPUsMember" id="Fact001480" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,373</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2026-03-31_custom_GPUDepositsMember" id="Fact001481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,308</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2026-03-31_custom_RightOfUseAssetMember" id="Fact001482" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" contextRef="AsOf2026-03-31_custom_TotalMember" id="Fact001483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,197</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z3vBMaS9FRxi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zfy107r1kwd9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zqFkM2sQsBIl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_zkDXC4qinAA6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">ACCUMULATED DEPRECIATION</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_43A_c20240401__20250331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_z0e0RyH1FQq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt">As of March 31, 2024</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1485">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1486">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2024-03-31_custom_RightOfUseAssetMember" id="Fact001487" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">40</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2024-03-31_custom_TotalMember" id="Fact001488" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">40</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetDepreciation_zIGD6dCaVfU3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fixed asset depreciation</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1490">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1491">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember" id="Fact001492" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2024-04-012025-03-31_custom_TotalMember" id="Fact001493" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--FixedAssetDisposals_z0MSpfjD5gR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1496">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember" id="Fact001497" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FixedAssetDisposals" contextRef="From2024-04-012025-03-31_custom_TotalMember" id="Fact001498" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_zEzZGIh1qSoe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1500">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1501">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetDepreciation_zTXbCosnHwS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fixed asset depreciation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2025-04-012026-03-31_custom_GPUsMember" id="Fact001505" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember" id="Fact001507" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">103</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:FixedAssetDepreciation" contextRef="From2025-04-012026-03-31_custom_TotalMember371195968" id="Fact001508" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--FixedAssetDisposals_zwFuT7n1Ixyg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1510">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1511">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_zGybfrJU1RL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">As of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_GPUsMember" id="Fact001515" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1516">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_RightOfUseAssetMember" id="Fact001517" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">103</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:AccumulatedDepreciationPropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_TotalMember" id="Fact001518" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z6WN0UwAJsDe" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_znNzd4DstTl9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zbSlImS7E54" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_ztw4gyvKNWk2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">CARRYING AMOUNT</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_z7Cw7T0yUl3a" title="Property plant equipment carrying amount" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1520">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zhkTwUokACy2" title="Property plant equipment carrying amount" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1522">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zmwSDbI5sjb4" title="Property plant equipment carrying amount" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1524">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zRVR3abWyjxb" title="Property plant equipment carrying amount" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">As of March 31, 2026</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_zc5BNZvguBda" title="Property plant equipment carrying amount" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_GPUsMember" id="Fact001528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,283</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zVOZIVXCuQZ6" title="Property plant equipment carrying amount" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_GPUDepositsMember" id="Fact001530" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,308</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zxmNqs7SUpI7" title="Property plant equipment carrying amount" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_RightOfUseAssetMember" id="Fact001532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">413</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zEHjO1yjB92k" title="Property plant equipment carrying amount" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2026-03-31_custom_TotalMember" id="Fact001534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,004</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A0_zfrjX2YHNj1j" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">* Refer to Note 13 for additional information on the Company&#8217;s office
lease.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001536" name="ifrs-full:DisclosureOfInvestmentPropertyExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_zZ04UqplP3V7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10.
<span id="xdx_82A_zKzSf8mpwIzf">INVESTMENT IN COMPEDICA</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On June 5, 2025, the Company acquired an equity interest in Compedica, Ltd.
("Compedica"), a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby the Company acquired a 6.0% interest in Compedica, valued at $5.0 million
plus $<span id="xdx_906_eifrs-full--ExpectedReimbursementOtherProvisions_iI_pn3n3_dm_c20250605_zoDQP8rxrp75" title="reimbursement of expenses"><ix:nonFraction name="ifrs-full:ExpectedReimbursementOtherProvisions" contextRef="AsOf2025-06-05" id="Fact001538" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million for reimbursement of expenses to Compedica to close the transaction, and Compedica obtained a corresponding 27.4% interest in
the Company and is accounted for under the equity method as it was determined that the Company has significant influence over Compedica
due to the interconnected nature of the ownership of the respective entities. Compedica&#8217;s interest in the Company was subsequently
diluted to 11.9% as a result of the shares issued under the private placement occurring in September 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company records its share of earnings and losses in Share of losses
from equity method investment within the consolidated statements of operations and other comprehensive income (loss). The Company recorded
a loss of less than $0.1 million for the fiscal year ended March 31, 2026, based on its share of Compedica's losses through the date significant
influence was lost as explained further below. The equity method investment is presented within "Investment in Compedica" on the
consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 81; Value: 6 -->
    <div id="xdx_233_z69p0TZZ9eqe" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_z0dv1dLdC8a2" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_232_zbOTJ61jGEId" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23C_zJsBH1XDAqtb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10. INVESTMENT IN COMPEDICA <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23F_zajUjqRYqPeg" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 25, 2025, in connection with the transition of the Company
to being primarily a digital asset treasury, Alpha Compute lost significant influence over Compedica and discontinued its use of the equity
method to account for its investment. Commencing on the date that significant influence was lost, the Company began accounting for its
investment as a financial instrument within the scope of IFRS 9 with changes in the fair value of its investment reflected as other income
(loss) within the consolidated statements of operations and other comprehensive income (loss). Subsequent to the discontinuing of the
equity method of accounting for Compedica, the fair value of the investment used by management is based on multiples analysis of publicly
traded comparable companies as Compedica is pre-revenue, as well as its holdings in the Company&#8217;s own ordinary shares (Level 3 inputs).
A loss on impairment of $<span id="xdx_902_eifrs-full--ImpairmentLoss_pn5n6_c20250401__20260331_zcvyWJaYfmxk" title="Loss on impairment"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2025-04-01to2026-03-31" id="Fact001543" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction>
</span>million was recognized as a result of the loss of significant influence.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#8217;s treasury and the investment being exited. As a result, the Company recognized less than $0.1 million in treasury stock
at the time the return of shares was agreed upon, the fair value of the investment as of February 6, 2026. Following the loss of control
through the exit of the investment, the Company recognized a loss on the change in fair value on the investment in Compedica of $<span id="xdx_90E_ecustom--ChangeInFairValueOnInvestmentInCompedica_iI_pn3n3_dm_c20260206_z0aQaLApZEug" title="Change in fair value on the investment in Compedica"><ix:nonFraction name="ptgef:ChangeInFairValueOnInvestmentInCompedica" contextRef="AsOf2026-02-06" id="Fact001545" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million. The 625,000 shares of the Company were returned to our treasury on May 21, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Movements in the investment balance during the fiscal year ended March 31,
2026 were as follows (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001547" name="ptgef:ScheduleOfInvestmentBalanceTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfInvestmentBalanceTableTextBlock_pn3n3_zlJhjYcJHsR4" summary="xdx: Disclosure - INVESTMENT IN COMPEDICA (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BC_zby3KgmHFTqi" style="display: none">Schedule of investment
        balance</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49C_20250401__20260331_zlOCaXX9QW9g" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_405_ecustom--BalanceAsOfApril1_zzHazQlxorCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--InitialInvestmentInCompedica_zYkc03g0jWq" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Initial investment in Compedica</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InitialInvestmentInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact001551" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,050</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LossFromEquityMethodInvestment_iN_di_zahSCSUDA4B6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossFromEquityMethodInvestment" contextRef="From2025-04-01to2026-03-31" id="Fact001553" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LossOnImpairment_zkQbgSipdHD3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss on impairment</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnImpairment" contextRef="From2025-04-01to2026-03-31" id="Fact001555" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,804</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfInvestmentInCompedica_z19ccBbFNYO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfInvestmentInCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact001557" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">182</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ReturnOfInvestmentInterestToCompedica_zdzWDw93edO" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Return of investment interest to Compedica</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ReturnOfInvestmentInterestToCompedica" contextRef="From2025-04-01to2026-03-31" id="Fact001559" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--InvestmentInCompedicaAsOfMarch31_zn3p4WeVfAn8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Investment in Compedica as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1561">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A6_zpwusgx72k89" style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001563" name="ptgef:DisclosureOfWarrantLiabilityExplanatory"><p id="xdx_808_ecustom--DisclosureOfWarrantLiabilityExplanatory_zPnG3vE8Xcj4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 11. <span id="xdx_82E_zvjKfFiDvhNl">WARRANT
LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The number of warrants and exercise price information herein have been retroactively
adjusted to reflect the impact of the reverse stock split. See Note 1 &#8220;Nature of Operations&#8221; and Note 17, &#8220;Capital Stock
and Reserves&#8221; for further discussion on the reverse stock split.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following table summarizes the changes in the warrant liability
during the fiscal years ended March 31, 2026, 2025, and 2024:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001565" name="ptgef:ScheduleOfWarrantLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zSJ5yKM1rq49" summary="xdx: Disclosure - WARRANT LIABILITY (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;<span id="xdx_8B4_zOtX7osxSNha" style="display: none">Schedule of changes in the warrant
        liability</span> </td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise
        Price</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fair Value
        Balance</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt">Fair value of warrants at issuance on October 3, 2023:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Class B Warrants</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_z14U3yUSXJNh" title="Fair value of warrants at issuance exercise price" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsAtIssuanceExercisePrice" contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember" id="Fact001567" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zK7pB4o7jgcf" title="Fair value of warrants shares" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsShares" contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember" id="Fact001569" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">157,895</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_fKDEp_zllTebPXe23f" title="Fair value of warrants amount"><ix:nonFraction name="ptgef:FairValueOfWarrantsAmount" contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember" id="Fact001571" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,537</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Class C Warrants</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98F_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zZqwBvXW4Ou1" title="Fair value of warrants at issuance exercise price" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsAtIssuanceExercisePrice" contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember" id="Fact001573" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zF0SOg9UzJKb" title="Fair value of warrants shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsShares" contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember" id="Fact001575" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">157,895</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_fKDEp_zfxB5j3Xzxyi" title="Fair value of warrants amount"><ix:nonFraction name="ptgef:FairValueOfWarrantsAmount" contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember" id="Fact001577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,663</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Placement Agent Warrants</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98A_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziFZ91lO4No4" title="Fair value of warrants at issuance exercise price" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsAtIssuanceExercisePrice" contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember" id="Fact001579" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">47.50</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqB6XUDfY1ib" title="Fair value of warrants shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsShares" contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember" id="Fact001581" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">7,896</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zKQVysaZxH3e" title="Fair value of warrants amount"><ix:nonFraction name="ptgef:FairValueOfWarrantsAmount" contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember" id="Fact001583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_zqtHTdLnVvM9" title="Change in fair value of warrant liability, amount" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilityAmount" contextRef="From2023-04-012024-03-31" id="Fact001585" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,868</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrant liability as of April 1, 2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20250331_zhCdCZ7VkcPa" title="Warrants outstanding, shares at ending" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityShares" contextRef="AsOf2024-03-31" id="Fact001587" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">323,686</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_985_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20250331_z6bRcsRO5bu1" title="Warrants outstanding, fair value at ending" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityFairValue" contextRef="AsOf2024-03-31" id="Fact001589" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,564</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20250331_zvb4yxb3qUW" title="Change in fair value of warrant liability, amount" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilityAmount" contextRef="From2024-04-012025-03-31" id="Fact001591" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">388</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrant liability as of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20250401__20260331_zAn9IrmUx4c" title="Warrants outstanding, shares at ending" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityShares" contextRef="AsOf2025-03-31" id="Fact001593" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">323,686</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_987_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20250401__20260331_zXKrm1Z1oqRl" title="Warrants outstanding, fair value at ending" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityFairValue" contextRef="AsOf2025-03-31" id="Fact001595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,952</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold">Fair value of warrants at issuance on January 27, 2026:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Placement Agent Warrants</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqGukfYAhsNa" title="Fair value of warrants at issuance exercise price" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsAtIssuanceExercisePrice" contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001597" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.25</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zExFn0kJ4wUc" title="Fair value of warrants shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsShares" contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001599" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,050,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zcGJf8jsozm4" title="Fair value of warrants amount"><ix:nonFraction name="ptgef:FairValueOfWarrantsAmount" contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,123</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20250401__20260331_ztiBIMoimCGd" title="Change in fair value of warrant liability, amount" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilityAmount" contextRef="From2025-04-01to2026-03-31" id="Fact001603" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,883</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrant liability as of March 31, 2026</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--WarrantsLiabilityShares_iE_pip0_c20250401__20260331_zP0o7uHf3ANj" title="Warrants outstanding, shares at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityShares" contextRef="AsOf2026-03-31" id="Fact001605" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,373,686</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_981_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20250401__20260331_zoyisK1hdM8b" title="Warrants outstanding, fair value at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityFairValue" contextRef="AsOf2026-03-31" id="Fact001607" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A0_zYmtGb15ZT0l" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series B Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-indent: 0.5in">A fair value of $<span id="xdx_908_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zdWGdTOdKe33" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2023-10-03_custom_SeiesBWarrantsMember" id="Fact001609" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.40</ix:nonFraction></span>
per each Series B Warrant was estimated at the issue date of October 3, 2023. A fair value of $<span id="xdx_90C_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zML2kunHQvE4" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2026-03-31_custom_SeiesBWarrantsMember" id="Fact001611" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></span>
and $<span id="xdx_905_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zLXUTsdR3qqh" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2025-03-31_custom_SeiesBWarrantsMember" id="Fact001613" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.65</ix:nonFraction></span>
per each warrant has been identified as of March 31, 2026 and 2025, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 82; Value: 6 -->
    <div id="xdx_232_zF50or3tMBik" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zftfKLplAoYh" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_234_zSiw796RUayg" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23C_zJsBH1XDdAqtb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10. INVESTMENT IN COMPEDICA <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23D_zHc65wfDlLVg" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001618" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_894_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zbBkvky6ahpb" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B0_z7H6GUTire6" style="display: none">&#160;Schedule of inputs
        associated with calculating the fair value</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcNWdnKA7t1h" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember" id="Fact001620" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcMANoGEFI6" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2025-03-31_custom_SeriesBWarrantsMember" id="Fact001622" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zvyaleOiJoij" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember" id="Fact001624" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrFeYkgCqag3" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember" id="Fact001626" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBI4iPKaOJHg" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2025-03-31_custom_SeriesBWarrantsMember" id="Fact001628" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.25</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zOrTS1j4RgTl" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember" id="Fact001630" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.32</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zmUJEZZIZuc" title="Expected life"><ix:nonNumeric contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" format="ixt-sec:duryear" id="Fact001632" name="ptgef:OptionLifeShareOptions">3.01</ix:nonNumeric></span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zbsUkU7mGR4a" title="Expected life"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember" format="ixt-sec:duryear" id="Fact001634" name="ptgef:OptionLifeShareOptions">1.51</ix:nonNumeric></span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zv2etxEPHTLc" title="Expected life"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember" format="ixt-sec:duryear" id="Fact001636" name="ptgef:OptionLifeShareOptions">0.51</ix:nonNumeric></span></b></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zRNSZr9Bsyke" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" id="Fact001638" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.4</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBLER54ju4x2" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember" id="Fact001640" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">207.73</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zGmE7X8gkY7h" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember" id="Fact001642" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zVHBmmT4Tp8h" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" id="Fact001644" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.95</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zM5h9A2Z0Qd3" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember" id="Fact001646" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.96</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zFFewYVR6R3a" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember" id="Fact001648" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.65</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zm1zYIyIC7N4" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1650">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEIaEviJaoxi" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1652">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z0PrTeT67bw9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AE_zlDGzZ3JoRZ2" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series C Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A fair value of $<span id="xdx_90A_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_z5lV7XrevEIc" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2023-10-03_custom_SeiesCWarrantsMember" id="Fact001656" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.60</ix:nonFraction></span>
per each Series C Warrant was estimated at the issue date of October 3, 2023. A fair value of $<span id="xdx_902_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_zGuWmpHCDq37" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2026-03-31_custom_SeiesCWarrantsMember" id="Fact001658" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></span>
and $<span id="xdx_900_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_zw3h8fUfUFC2" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2025-03-31_custom_SeiesCWarrantsMember" id="Fact001660" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.40</ix:nonFraction></span>
per each warrant has been identified as of March 31, 2026 and 2025, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001662" name="ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_zHEeq0KcG7Nh" summary="xdx: Disclosure - WARRANT LIABILITY (Details 2)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BA_zNeBUyzvjDYi" style="display: none">Schedule of fair value</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7CNQyvZbpx1" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember" id="Fact001664" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7Hzf0fZPJHk" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2025-03-31_custom_SeriesCWarrantsMember" id="Fact001666" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zjwJkg7CCLv2" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2026-03-31_custom_SeriesCWarrantsMember" id="Fact001668" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zviTyKgs47jj" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember" id="Fact001670" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHQ1bHUhjjFh" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2025-03-31_custom_SeriesCWarrantsMember" id="Fact001672" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.25</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zcltZ3A3DHUg" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2026-03-31_custom_SeriesCWarrantsMember" id="Fact001674" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.32</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zS3YhwfRInCc" title="Expected life"><ix:nonNumeric contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" id="Fact001676" name="ptgef:OptionLifeShareOptions">5.00</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zwfYlASTWvZk" title="Expected life"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" id="Fact001678" name="ptgef:OptionLifeShareOptions">3.51</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zMOMU1FAanz3" title="Expected life"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" id="Fact001680" name="ptgef:OptionLifeShareOptions">2.51</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zmtNXmZHp5Yg" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" id="Fact001682" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.7</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zVoQrwL8D1wi" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember" id="Fact001684" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">152.01</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z0oIs26uJvz4" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember" id="Fact001686" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zh1OWyqxbWui" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" id="Fact001688" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.80</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4scHsvnC34f" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember" id="Fact001690" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.91</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7jZajot0X8f" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember" id="Fact001692" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.73</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zlJFTptLrip9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zztiSm7DHUbh" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1696">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zQlFOIhDXNG1" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1698">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AC_zNvEScPOlZli" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>2023 Placement Agent Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A fair value of $<span id="xdx_907_ecustom--FairValueOfWarrantPerShare_iI_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zp4vbltIl7P" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2024-10-03_custom_PlacementAgentWarrantsMember" id="Fact001700" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.40</ix:nonFraction></span>
per each 2023 Placement Agent Warrant was estimated at the issue date of October 3, 2023. A fair value of $<span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zzwBi5irKrEd" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001702" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></span>
and $<span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7vpi84hlblg" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember" id="Fact001704" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.34</ix:nonFraction></span>
per each warrant has been identified as of March 31, 2026 and 2025, respectively.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001706" name="ptgef:DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory_z0WMoHkN2ua8" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B7_zdxKP3McVBCi" style="display: none">Schedule of Placement agent warrants</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsGPaZikPNz5" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember" id="Fact001708" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">47.60</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zZIC6pi2wQ0i" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember" id="Fact001710" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">47.50</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcJncvXobtOc" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001712" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">47.50</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGPqkcKIacvc" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember" id="Fact001714" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zbKildqYSvU9" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember" id="Fact001716" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.25</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zTZfbXr7F0O8" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001718" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.32</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKrk0SpAaIth" title="Expected life"><ix:nonNumeric contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact001720" name="ptgef:OptionLifeShareOptions">4.99</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zilGNvCPG75l" title="Expected life"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact001722" name="ptgef:OptionLifeShareOptions">3.51</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWOGkooFnHW7" title="Expected life"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact001724" name="ptgef:OptionLifeShareOptions">2.51</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z3WsBb78muC1" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" id="Fact001726" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.7</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zUSXXPL9Rkdf" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember" id="Fact001728" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">152.01</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z1axsY3Lm7h5" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001730" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsQkgNMI2bc" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" id="Fact001732" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.80</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zEzRqFTHCrCe" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember" id="Fact001734" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.91</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8OQj2rILoJd" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember" id="Fact001736" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.73</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zk25m7D81mwh" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zVbfQKyutFzi" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMWBmMUg5oN9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A7_zMovU1XiikA" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>2026 Placement Agent Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A fair value of $<span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zrPVyWvLZLn2" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2026-01-19_custom_PlacementAgentWarrantsMember" id="Fact001744" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></span>
per each 2026 Placement Agent Warrant was estimated at the issue date of January 19, 2026. A fair value of $<span id="xdx_908_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrants2026Member_zbAbw8GA52f2" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2026-03-31_custom_PlacementAgentWarrants2026Member" id="Fact001746" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.18</ix:nonFraction></span>
per each warrant has been identified as of March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001748" name="ptgef:DisclosureOfFairValueMeasurementPlacementAgentExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementPlacementAgentExplanatory_z8nF7hZ9QcQ7" summary="xdx: Disclosure - WARRANT LIABILITY (Details 4)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_z1jn5tB36Ll8" style="display: none">Schedule of 2026 placement
        agent warrants</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">January
        19, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--ExercisePriceFairValue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw8zpZbvkl1e" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2026-01-19_custom_PlacementAgentWarrantsMember" id="Fact001750" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.25</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zyrEA4PyGcIi" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2026-03-31_custom_PlacementAgentsWarrantsMember" id="Fact001752" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.25</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_ecustom--SharePriceFairvalue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zCQwB50xVWX8" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2026-01-19_custom_PlacementAgentWarrantsMember" id="Fact001754" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.30</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zNeHaoLISPfj" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2026-03-31_custom_PlacementAgentsWarrantsMember" id="Fact001756" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.32</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9hgK6z2usf" title="Expected life"><ix:nonNumeric contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact001758" name="ptgef:OptionLifeShareOptions">5.0</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zoTZ4ibQOFdk" title="Expected life"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember" format="ixt-sec:duryear" id="Fact001760" name="ptgef:OptionLifeShareOptions">4.79</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zq6YJfRZVQy4" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember" id="Fact001762" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">115.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zfwXAkArfdR9" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember" id="Fact001764" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8O8MSDk6kic" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember" id="Fact001766" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.68</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zrNAFmyLNYC7" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember" id="Fact001768" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.83</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zaPQDYAdUsOk" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1770">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_za1yL1zZIOEk" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1772">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AE_zBa8c1qZbeed" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<ix:exclude><!-- Field: Page; Sequence: 83; Value: 6 -->
    <div id="xdx_239_znzZkJn6Xiud" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zXbsFIN8mZSb" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_232_zBms3ArZmgd8" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>



<ix:exclude><p id="xdx_237_zu2lOB3zMIq9" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001776" name="ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory"><p id="xdx_803_ecustom--DisclosureOPutRightLiabilityAndTonPayableExplanatory_z07eYSeNTsjj" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
12. <span id="xdx_82A_zuEEucpkJCY2">PUT RIGHT LIABILITY AND TON PAYABLE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 2, 2025, the Company entered into five Side Letter Agreements
(&#8220;Side Letters&#8221;) with certain investors to repurchase its outstanding ordinary shares, as well as pre-funded warrants to purchase
ordinary shares held by these investors at the option of the holders and on August 25, 2025, the Company entered into a Treasury Management
Agreement with DWF MaaS Limited (&#8220;DWF&#8221;) whereby DWF is entitled to convert the Ordinary Shares it subscribed for in the September
2025 private placement into an equivalent value of TON from the amount of TON held by DWF on behalf of the Company up to a maximum value
of $15.0 million (collectively, the &#8220;Contingent Put Options&#8221;). <span id="xdx_90B_ecustom--TreasuryManagementAgreementDescription_c20250401__20260331_zZ9hVwnMMisa" title="Treasury Management Agreement description"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact001778" name="ptgef:TreasuryManagementAgreementDescription">A
total of 2,266,890 and 265,000 ordinary shares and an additional 745,226 and 2,513,240 pre-funded warrants to purchase ordinary shares
were subject to repurchase as defined within the Side Letters and Treasury Management Agreement, respectively, with various right expiration
dates between March 2026 and September 2026. In the event the holders exercise their Contingent Put Options, the Company is obligated
to settle the contract by transferring the same amount of USDC, Liquid TON, or Locked TON based on the Original Consideration within each
Side Letter or Treasury Management Agreement with no adjustment for value. As of September 30, 2025, a total of 2,531,890 ordinary shares
and an additional 3,258,466 pre-funded warrants to purchase ordinary shares were still subject to repurchase on various settlement dates
through September 2026.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The fair value of the put right liability is estimated
using a Black-Scholes model and in certain cases, a Monte Carlo simulation. The weighted average assumptions used to value the Side Letter
put rights at inception and as of March 31, 2026 are as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001780" name="ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock_pn3n3_zIddunfGqcRc" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zrXKzoyKcZp8" style="display: none">Schedule of fair value
        of the put right liability estimated using a Black-Scholes model</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">September
        2, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">ALP shares and TON correlation factor</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20250902_zrhsWfzkS2cg" title="Alp shares and ton correlation factor" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2025-09-02" id="Fact001782" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.60</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20260331_zsboCpXxXzli" title="Alp shares and ton correlation factor" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2026-03-31" id="Fact001784" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.10</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20250902_z195kcmK5ewe" title="Share price" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2025-09-02" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.96</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20260331_zjtJL9O38m4" title="Share price" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2026-03-31" id="Fact001788" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.32</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Remaining term (in years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250829__20250902_zgpKwqXliCyj" title="Remaining term (in years)"><ix:nonNumeric contextRef="From2025-08-292025-09-02" format="ixt-sec:duryear" id="Fact001790" name="ptgef:PutRightLiabilityemainingTermInYears">0.75</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250401__20260331_zr7gRSLEwfG9" title="Remaining term (in years)"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:duryear" id="Fact001792" name="ptgef:PutRightLiabilityemainingTermInYears">0.25</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected ALP volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902_zHgZF7d9rVxf" title="Expected ALP volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-08-292025-09-02" id="Fact001794" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.90</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331_z9MBYxO8IvT1" title="Expected ALP volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-04-01to2026-03-31" id="Fact001796" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250829__20250902_z18yGKKVtm09" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2025-08-292025-09-02" id="Fact001798" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.91</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331_zuDUQO9pypXi" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2025-04-01to2026-03-31" id="Fact001800" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.63</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">ALP dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250829__20250902_z2bPoYPz0Jyf" title="ALP dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331_z16FwPms4IIg" title="ALP dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1804">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON token price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_987_ecustom--TonTokenPrice_iI_pip0_c20250902_zAN6Q8YbDBn9" title="TON token price" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TonTokenPrice" contextRef="AsOf2025-09-02" id="Fact001806" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.11</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_ecustom--TonTokenPrice_iI_pip0_c20260331_z5jWLgPHY1Ma" title="TON token price" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TonTokenPrice" contextRef="AsOf2026-03-31" id="Fact001808" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.22</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON token volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zc1NOWV4TEr8" title="Expected ALP volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-08-292025-09-02_custom_TonTokenVolatilityMember" id="Fact001810" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zvd0uikAd9Ji" title="Expected ALP volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_TonTokenVolatilityMember" id="Fact001812" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">53.90</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Locked TON token discount for lack of marketability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250829__20250902_zCBHvDMCKXYg" title="Locked TON token discount for lack of marketability rate"><ix:nonFraction name="ptgef:LockedTonTokenDiscountForLackOfMarketabilityRate" contextRef="From2025-08-292025-09-02" id="Fact001814" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.30</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250401__20260331_zEN42IfWuxrj" title="Locked TON token discount for lack of marketability rate"><ix:nonFraction name="ptgef:LockedTonTokenDiscountForLackOfMarketabilityRate" contextRef="From2025-04-01to2026-03-31" id="Fact001816" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.80</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The fair value of the put right liability is most sensitive
to expected share price volatility, the value of the underlying digital assets, expected term and discount rate. An increase in expected
volatility, expected term or underlying digital asset values would result in a higher fair value measurement. An increase in the discount
rate would result in a lower fair value measurement. Management considered the interrelationship of these assumptions when determining
the fair value measurement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The DWF put right was capped at $<span id="xdx_900_eifrs-full--CurrentInterestReceivable_iI_pn3n3_dm_c20260331_zKAyaNILcu4" title="Fair value of stablecoin receivable"><ix:nonFraction name="ifrs-full:CurrentInterestReceivable" contextRef="AsOf2026-03-31" id="Fact001818" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">15.0</ix:nonFraction>
</span>million, the fair value of the stablecoin receivable contributed, which corresponded to the aggregate fair value of the ordinary
shares and pre-funded warrants issued to DWF. Therefore, at inception, the DWF put right was determined to have a fair value of $15.0
million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At inception, the outstanding Contingent Put Options
were determined to have a fair value of $16.1 million, net of issuance costs of $2.0 million, which was included within Put right liability
within the Company&#8217;s consolidated balance sheet.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 8, 2025 and December 30, 2025, one Side
Letter put right and the DWF put right were exercised, respectively, and on March 24, 2026 and December 30, 2025, the contributed locked
TON tokens receivable in the amount of 1,114,130, with a fair value of $<span id="xdx_902_ecustom--FairValueOfContribution_iI_pn3n3_dm_c20251208_zi9zyN3RICOg" title="Fair value of contribution"><ix:nonFraction name="ptgef:FairValueOfContribution" contextRef="AsOf2025-12-08" id="Fact001820" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction></span>
at contribution, and $<span id="xdx_90B_ecustom--Usd1Receivable_iI_pn3n3_dm_c20251208_zFn8D3KFL3v3" title="USD1 receivable"><ix:nonFraction name="ptgef:Usd1Receivable" contextRef="AsOf2025-12-08" id="Fact001822" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">15.0</ix:nonFraction></span>
million USD1 receivable were returned to the investor and DWF, respectively. In connection with the exercise of the Side Letter put right
on December 8, 2025, the Company recognized a loss on the exercise of $1.1 million, recognized as the difference between the fair value
of the TON contributed by the respective investor at the time of put exercise and the carrying value of the put right. When the locked
TON receivables were returned to the investor on March 24, 2026, the Company recognized a $0.4 million gain from the settlement of a portion
of the TON payable, recognized as the difference between the carrying value of the TON contributed by the respective investors at the
time the TON was returned to the investors and the fair value of the TON payable. As of March 31, 2026, the Company owes the investor
420,434 liquid TON tokens with a fair value of $0.5 million. When the USD1 receivable was returned to DWF on December 30, 2025, no such
gains or losses were recognized as USD1 is pegged to the U.S. dollar. Additionally, the Company terminated its Treasury Management Agreement
with DWF in connection with the return of DWF&#8217;s initial investment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On January 27, 2026 and March 19, 2026, one Side Letter
put right was partially exercised and a second Side Letter put right was fully exercised, respectively. In connection with the exercises
of the Side Letter put rights, the Company recognized a loss on the exercise of $<span id="xdx_907_ecustom--LossOnExercise_iI_pn3n3_dm_c20260127_znSdY4n71Gdb" title="loss on the exercise"><ix:nonFraction name="ptgef:LossOnExercise" contextRef="AsOf2026-01-27" id="Fact001824" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.4</ix:nonFraction>
</span>million, recognized as the difference between the fair value of the TON contributed by the respective investor at the time of put
exercise and the carrying value of the put right. The put rights were not settled during the fiscal year ended March 31, 2026 and as of
March 31, 2026, the Company owes the investors 369,278 liquid TON tokens and 453,125 locked Ton tokens receivable with fair values of
$0.5 million and $0.3 million, respectively, which corresponds to the fair value of the liquid and locked tokens to be returned to the
respective investors at March 31, 2026. The outstanding TON balances payable were settled and the TON tokens returned to the respective
investors in separate transfers on April 15, April 24, and April 28, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>



<ix:exclude><p id="xdx_237_zcnCeawjutO7" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 84; Value: 6 -->
    <div id="xdx_232_z6FLepy22tv2" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zAWROXoSJtw1" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_236_zr9Ztbwh3Me7" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_238_zX9Rn4d184Hg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 12. PUT RIGHT LIABILITY AND TON PAYABLE
<i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zreXqQrC9qd6" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As of March 31, 2026, the outstanding Contingent Put
Options were remeasured to fair value of $<span id="xdx_90A_ecustom--OutstandingContingentPutOptionsFairValue_iI_pn3n3_dm_c20260331_zNmujS1Hj00d" title="Outstanding Contingent Put Options fair value"><ix:nonFraction name="ptgef:OutstandingContingentPutOptionsFairValue" contextRef="AsOf2026-03-31" id="Fact001830" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.1</ix:nonFraction></span>
million, with the remeasurement change in fair value of $<span id="xdx_90E_ecustom--RemeasurementChangeInFairValue_iI_pn3n3_dm_c20260331_zwOU7OuzWywk" title="Remeasurement change in fair value"><ix:nonFraction name="ptgef:RemeasurementChangeInFairValue" contextRef="AsOf2026-03-31" id="Fact001832" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">6.0</ix:nonFraction></span>
million recorded within other losses in the Consolidated Statements of Operations and Comprehensive Income (Loss).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The following table summarizes the changes in the put
right liability during the fiscal year ended March 31, 2026 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001834" name="ptgef:ScheduleOfPutRightLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)" id="xdx_894_ecustom--ScheduleOfPutRightLiabilityTableTextBlock_pn3n3_zDV6kJn48r9d" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;<span id="xdx_8BA_zrd7CcyH9Nqh" style="display: none">Schedule of put
        right liability</span> </td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_zI5dL0OGoDy6" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_401_ecustom--BalanceOfPutRightLiability_zaWkEXp0qrEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_zaoCRQMYme17" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Put right recognition at contract inception</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets" contextRef="From2025-04-01to2026-03-31" id="Fact001838" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,150</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--GainsLossesOnChangeInFairValueOfDerivatives_zyPmsHzo3NEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of put right liability, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="From2025-04-01to2026-03-31" id="Fact001840" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,959</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProceedsFromExerciseOfOptions_zFTV2D5OOMT" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Exercise of side letter put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfOptions" contextRef="From2025-04-01to2026-03-31" id="Fact001842" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,920</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--SettlementOfDwfMaasLimitedPutRight_zR6kRtNdRtWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Settlement of DWF Maas Limited put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SettlementOfDwfMaasLimitedPutRight" contextRef="From2025-04-01to2026-03-31" id="Fact001844" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LossOnExerciseOfPutRightLiability_zoxN7NLCVRZf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss on exercise of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossOnExerciseOfPutRightLiability" contextRef="From2025-04-01to2026-03-31" id="Fact001846" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">916</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--PutRightLiabilityEndingBalance_zHmCFY1nPVij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Put right liability as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PutRightLiabilityEndingBalance" contextRef="From2025-04-01to2026-03-31" id="Fact001848" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,105</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>








</ix:nonNumeric></ix:nonNumeric><p id="xdx_8AB_zGtOGLFdxRA7" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The following table summarizes the changes in TON payable
during the fiscal year ended March 31, 2026 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>






<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001850" name="ptgef:ScheduleOfTonPayableTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)" id="xdx_89B_ecustom--ScheduleOfTonPayableTableTextBlock_pn3n3_zdAZZDIkciB5" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B7_zMjtOO9WIA6c" style="display: none">Schedule of TON payable</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_z5nOEyLqwnp5" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_407_ecustom--BalanceOfTonPayable_zZXYzpeNQcA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1852">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ExerciseOfSideLetterPutRightPayable_zt7S9e2GJCjb" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Exercise of side letter put right</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExerciseOfSideLetterPutRightPayable" contextRef="From2025-04-01to2026-03-31" id="Fact001854" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,920</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_iN_di_zn3xJzVG1Lnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2025-04-01to2026-03-31" id="Fact001856" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--GainOnSettlementOfTonPayable_iN_di_z0cqKFLVZR3f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2025-04-01to2026-03-31" id="Fact001858" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">336</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--SettlementOfPutRightLiabilityUsingDigitalAssets_iN_di_zvFzBjEs7nWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Settlement of put right liability using digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SettlementOfPutRightLiabilityUsingDigitalAssets" contextRef="From2025-04-01to2026-03-31" id="Fact001860" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,108</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--TonPayableEndingBalanceAsOfMarch31_z5qhLQCmoKBh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">TON payable as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TonPayableEndingBalanceAsOfMarch31" contextRef="From2025-04-01to2026-03-31" id="Fact001862" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,425</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A9_z6rNMOcoI9K" style="margin-top: 0; margin-bottom: 0">&#160;</p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001864" name="ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock"><p id="xdx_803_ecustom--AccountsPayableAndAccruedLiabilitiesTextBlock_z59nQYgQ1B6h" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 13.
<span id="xdx_829_ztC318AGAszd">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">At March 31, 2026 and 2025, accounts payable and accrued liabilities
were comprised of the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001866" name="ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zuBiDBB0PrP4" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_zHYRDfycesC8" style="display: none">Schedule of accounts
        payable and accrued liabilities</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_492_20260331_z5S14yhvqA45" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331_zrj8TolvXpN6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccountsPayable_iI_zWeTCv2cvwGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsPayable" contextRef="AsOf2026-03-31" id="Fact001868" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,413</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccountsPayable" contextRef="AsOf2025-03-31" id="Fact001869" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">427</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedOtherProfessionalFees_iI_zokfs4wSvUad" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued other professional fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedOtherProfessionalFees" contextRef="AsOf2025-03-31" id="Fact001872" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">262</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zjeBhK6CLhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued accounting and auditing fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccruedAccountingAndAuditingFees" contextRef="AsOf2026-03-31" id="Fact001874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedAccountingAndAuditingFees" contextRef="AsOf2025-03-31" id="Fact001875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_z4sLGMmf6tN4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued bonuses and other payroll-related expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses" contextRef="AsOf2026-03-31" id="Fact001877" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">913</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses" contextRef="AsOf2025-03-31" id="Fact001878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">89</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedCRO_iI_zHNCOvDYDg2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1880">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedCRO" contextRef="AsOf2025-03-31" id="Fact001881" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProfessionalFeesExpenses_iI_zg7p3eGGJla9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued legal fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProfessionalFeesExpenses" contextRef="AsOf2026-03-31" id="Fact001883" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProfessionalFeesExpenses" contextRef="AsOf2025-03-31" id="Fact001884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedClinicalAndRdServices_iI_zjEWa0vnkMU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued clinical and R&amp;D services</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedClinicalAndRdServices" contextRef="AsOf2025-03-31" id="Fact001887" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CapitalExpenditures_iI_zsLMetrmU6T9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Capital expenditures</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CapitalExpenditures" contextRef="AsOf2026-03-31" id="Fact001889" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">333</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CapitalExpenditures" contextRef="AsOf2025-03-31" id="Fact001890" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherAccruedExpenses_iI_zGfBgATblded" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Other</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherAccruedExpenses" contextRef="AsOf2025-03-31" id="Fact001893" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_zDwF6E6m6JXd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilityNet" contextRef="AsOf2026-03-31" id="Fact001895" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,504</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilityNet" contextRef="AsOf2025-03-31" id="Fact001896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,100</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A9_zWulB43PTbTa" style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>



<ix:exclude><p id="xdx_23A_zy1FKGKy3td3" style="margin: 0pt 0; font-size: 10pt; text-align: center"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 85; Value: 6 -->
    <div id="xdx_234_zf8o0186h4J3" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zQu8YrN6GFH4" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23F_zeLFQymCuvae" style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001900" name="ptgef:DisclosureOfLeaseLiabilityExplanatory"><p id="xdx_801_ecustom--DisclosureOfLeaseLiabilityExplanatory_z9KmRbVR8QT3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 14. <span id="xdx_829_zvaoSzA5FLWd">LEASE
LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company entered into a lease of GPU equipment, which commenced on November
30, 2025 (the &#8220;GPU Lease&#8221;). The GPU Lease provided for an original term of one year, with the full balance paid at commencement
in the amount of $<span id="xdx_90B_ecustom--Commencement_iI_pn3n3_dm_c20251130_zI01nE8kweZi" title="Commencement"><ix:nonFraction name="ptgef:Commencement" contextRef="AsOf2025-11-30" id="Fact001902" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million, with a purchase option exercisable at any point during the lease, with the purchase option being the remaining portion of the
GPU&#8217;s purchase price of $<span id="xdx_908_ecustom--PurchasePriceLeaseLiability_iI_pn3n3_dm_c20251130_zoACPsApa8Di" title="Purchase price"><ix:nonFraction name="ptgef:PurchasePriceLeaseLiability" contextRef="AsOf2025-11-30" id="Fact001904" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million. On February 5, 2026, the Company exercised the purchase price for the GPU equipment with a payment of $<span id="xdx_902_ecustom--PurchaseEquipmentPayment_iI_pn3n3_dm_c20260205_zX9w3DdTcVzb" title="Purchase equipment payment"><ix:nonFraction name="ptgef:PurchaseEquipmentPayment" contextRef="AsOf2026-02-05" id="Fact001906" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million, however the validity of the purchase option was disputed by the GPU owner and the broker of the lease has not yet been able to
deliver the GPU in question. The Company is pursuing a refund for the purchase option price, and the amount due is included in prepaid
expenses and other receivables within the consolidated balance sheet as of March 31, 2026. As the full balance of the lease was paid at
commencement and the purchase option ultimately disputed, no interest expense was incurred on the lease. As of March 31, 2026, the Company
had no contractual commitments remaining on the GPU lease.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company entered into a lease of office space in Lisbon, Portugal, which
commenced on March 1, 2026 (the &#8220;Lisbon Lease&#8221;). The Lisbon Lease provided for an original term of two years with purchase
options at the end of the 12<sup>th</sup> and 24<sup>th</sup> months of the lease, with certain rent payments and option payments being
credited towards the purchase price if the option is exercised. The Company calculated the Lisbon Lease liability using its incremental
borrowing rate of 14.75%. The Company prepaid the first twelve months rent in the amount of EUR 84,000.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Lisbon Lease liability is payable as follows (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001908" name="ptgef:ScheduleOfLeaseLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfLeaseLiabilityTableTextBlock_pn3n3_zyHnYTCitGr9" summary="xdx: Disclosure - LEASE LIABILITY (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"><span id="xdx_8BF_ziAyf6haDmHi" style="display: none">Schedule
        of Lease liability</span></td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49F_20260331_zHueMHvmtzS" style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; color: #212529; font-weight: bold">Fiscal Year ended March 31,</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: center">Amount</td></tr>
  <tr id="xdx_40B_ecustom--LeaseLiabilityFutureMinimumPaymentsDue_iI_zTsB5kKZnvr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">2027</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityFutureMinimumPaymentsDue" contextRef="AsOf2026-03-31" id="Fact001910" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LeaseLiabilityFutureMinimumPaymentsYearTwoDue_iI_zhc2Ggde5K81" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">2028</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityFutureMinimumPaymentsYearTwoDue" contextRef="AsOf2026-03-31" id="Fact001912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LeaseLiabilityFutureMinimumPaymentsYearDue_iI_zZh0HG83xjWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold">Total</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityFutureMinimumPaymentsYearDue" contextRef="AsOf2026-03-31" id="Fact001914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--Interest_iI_zgG0B6A3tiCk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">Less: Interest</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:Interest" contextRef="AsOf2026-03-31" id="Fact001916" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--TotalLeaseLiability_iI_zY5T9jBgSXvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">Total lease liability</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TotalLeaseLiability" contextRef="AsOf2026-03-31" id="Fact001918" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LeaseLiabilityCurrent_iI_zzvimpsFkTI5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">Lease liability - current</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityCurrent" contextRef="AsOf2026-03-31" id="Fact001920" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LeaseLiabilityNoncurrent_iI_zGLcqpdlDgZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Lease liability - non-current</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityNoncurrent" contextRef="AsOf2026-03-31" id="Fact001922" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A6_zDMMI7S1wOL" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001924" name="ptgef:DisclosureOfBitgoPrimeLoanExplanatory"><p id="xdx_80E_ecustom--DisclosureOfBitgoPrimeLoanExplanatory_zGDH3das5ZEl" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. <span id="xdx_825_z1fcrPTvlYR5">BITGO
PRIME LOAN</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><span id="xdx_904_ecustom--MasterLoanAgreementDescription_c20250802__20250828_zJgY9dHZTQm2" title="Master Loan Agreement description"><ix:nonNumeric contextRef="From2025-08-022025-08-28" id="Fact001926" name="ptgef:MasterLoanAgreementDescription">On
August 28, 2025, the Company entered into a master loan agreement (the &#8220;Master Loan Agreement&#8221;) with BitGo Prime, LLC (&#8220;BitGo&#8221;).
Pursuant to the Master Loan Agreement, the Company may borrow up to $35.0 million at an interest rate of 14.75% per annum with a 2.00%
origination fee paid upfront in the amount of $0.3 million. The Loan shall only be used to purchase liquid TON that will be delivered
to BitGo and such purchased liquid TON will also be pledged as collateral for the Loan. The outstanding loan balance must be repaid within
six months of the origination of the Loan, unless provided for otherwise or amended.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><span id="xdx_907_ecustom--MasterLoanAgreementDescription_c20251005__20251007_zn4PWtC6iFC8" title="Master Loan Agreement description"><ix:nonNumeric contextRef="From2025-10-052025-10-07" id="Fact001928" name="ptgef:MasterLoanAgreementDescription">On
October 7, 2025, the Company received its initial draw on the Master Loan Agreement in the amount of $2.1 million. No further draws have
been made on the loan, and on November 25, 2025 the loan balance was paid down to $1.8 million. On January 9, 2026, the remaining balance
of the loan was paid down and the Master Loan Agreement was exited. In connection with the extinguishment of the Master Loan Agreement,
the Company derecognized $0.1 million of deferred financing, incurred $0.5 million in loan termination fees paid to BitGo, and had $0.8
million in accrued interest forgiven by BitGo for payment of the loan termination fees, resulting in a net gain on debt extinguishment
of $0.3 million being recognized within the Consolidated Statements of Operations and Comprehensive Income (Loss).</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001930" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p id="xdx_805_eifrs-full--DisclosureOfIncomeTaxExplanatory_zISa5cJIJr6f" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 16. <span id="xdx_820_z7MKXEC3mKok">INCOME
TAXES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company is a BVI business company. The
BVI government does not, under existing legislation, impose any income or corporate tax on corporations. PDS is a U.S. corporation and
is subject to U.S. federal, state and local income taxes, as applicable. iOx is subject to U.K. taxes.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>



<ix:exclude><p id="xdx_23A_zmxmLvS6xHy5" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 86; Value: 6 -->
    <div id="xdx_23B_zhQv5PhZxDtf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zDjkie0aatuj" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_235_zhZ7K7AGCFCk" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23F_zWFPpsKZigr7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 16. INCOME TAXES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zKdxQ14XoD91" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The benefit from income taxes consists of the
following for the years ended March 31, 2026 and 2025 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001936" name="ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zINoBiaRScub" summary="xdx: Disclosure - INCOME TAXES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B0_zMmAGq60eaq3" style="display: none">Schedule
        of income tax benefit</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_497_20250401__20260331_zk0uk8CvJz41" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20240401__20250331_zhkTLop2mpcb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current tax:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CurrentTaxOnProfitsForYear_ztkQYH3yFeJe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Current tax on profits for the year</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1941">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1942">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AdjustmentsForCurrentTaxOfPriorPeriods_zFIKDWyJbwXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Adjustments for current
        tax of prior periods</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1944">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:AdjustmentsForCurrentTaxOfPriorPeriods" contextRef="From2024-04-012025-03-31" id="Fact001945" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentTaxExpenseIncome_i01_pn3n3_zZ7mca4NHGn" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1947">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2024-04-012025-03-31" id="Fact001948" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred income tax:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DecreaseIncreaseInDeferredTaxAssets_zmt0QnBzqidh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Decrease (increase) in deferred
        tax assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1953">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProfitLossFromContinuingOperation_i01_pn3n3_zDKwrJAl1i4e" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1956">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ProfitLossFromContinuingOperation" contextRef="From2024-04-012025-03-31" id="Fact001957" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



</ix:nonNumeric><p id="xdx_8AE_zMohqScrQGC2" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Reconciliation of tax expense (benefit) at statutory tax rate and the income
tax benefit as reported in the Consolidated Statement of Operations and Comprehensive Income (Loss) for the years ended March 31, 2026
and 2026 is as follows (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001959" name="ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z0sT7P32qNd7" summary="xdx: Disclosure - INCOME TAXES (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;<span id="xdx_8BD_zp1uJytHxqO1" style="display: none">Schedule of reconciliation
        income tax rates</span> </td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20250401__20260331_zxB3RRPk4Na8" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_491_20240401__20250331_zhn17T8tMIra" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_407_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_zYZQnEKeSmKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss before income tax</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax" contextRef="From2025-04-01to2026-03-31" id="Fact001961" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax" contextRef="From2024-04-012025-03-31" id="Fact001962" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,781</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxUsingBviTaxRate_pip0_dp_ztfnfs4nFxSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax using BVI tax rate of 0%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1965">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EffectOfTaxRatesInOtherCountries_zMKOlGVADbk7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Effect of tax rates in other countries</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:EffectOfTaxRatesInOtherCountries" contextRef="From2025-04-01to2026-03-31" id="Fact001967" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">273</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:EffectOfTaxRatesInOtherCountries" contextRef="From2024-04-012025-03-31" id="Fact001968" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--DerecognitionOfDeferredTaxAssets_zpF3OA9h1TWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Derecognition of deferred tax assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DerecognitionOfDeferredTaxAssets" contextRef="From2025-04-01to2026-03-31" id="Fact001970" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">156</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DerecognitionOfDeferredTaxAssets" contextRef="From2024-04-012025-03-31" id="Fact001971" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--NondeductibleExpenses_zxYssXEsZbT4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Nondeductible expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1973">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_zUWhvh4QdqYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Utilization of losses not previously benefitted</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1976">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1977">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxEffectsRelatedToEquityCompensation_zA30sF2tpoGi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Income tax effects related to equity compensation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:IncomeTaxEffectsRelatedToEquityCompensation" contextRef="From2025-04-01to2026-03-31" id="Fact001979" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ForeignCurrencyEffectAndOther_zCrtam5qUHZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Foreign currency effect and other</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ForeignCurrencyEffectAndOther" contextRef="From2024-04-012025-03-31" id="Fact001983" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxExpense_zNYBWWsrZ7gh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax in the statement of loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1985">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:IncomeTaxExpense" contextRef="From2024-04-012025-03-31" id="Fact001986" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



</ix:nonNumeric><p id="xdx_8A2_zLsNXd7vgLCa" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026 and 2025, the Company had $<span id="xdx_90F_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_pn3n3_dm_c20250401__20260331_zHRWbVY9BNo9" title="U.S. federal net operating losses"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2025-04-01to2026-03-31" id="Fact001988" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million and $<span id="xdx_908_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_pn3n3_dm_c20240401__20250331_zHEO2BTTYCa9" title="U.S. federal net operating losses"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2024-04-012025-03-31" id="Fact001990" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million of U.S. federal net operating losses, respectively, which carryforward indefinitely but are limited to 80% of taxable income when
utilized. As of March 31, 2026 and 2025, the Company also had $<span id="xdx_908_ecustom--UkLossCarryForwards_pn3n3_dm_c20250401__20260331_z33l5WhHXCga" title="UK Loss carry forwards"><ix:nonFraction name="ptgef:UkLossCarryForwards" contextRef="From2025-04-01to2026-03-31" id="Fact001992" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">15.9</ix:nonFraction></span>
million in UK loss carryforwards, which carryforward indefinitely<b>.</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026 and 2025, the Company&#8217;s deferred tax assets and
liabilities consisted of the effects of temporary differences attributable to the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001994" name="ptgef:ScheduleOfDeferredTaxAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfDeferredTaxAssetsTableTextBlock_pn3n3_zcwaE4FrkEFa" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B3_znCPruTYwnwd" style="display: none">Schedule
        of deferred tax assets and liabilities</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20260331_z3hbdug8JZJh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_495_20250331_zwWuvRPMVKC9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsAbstract_iB_zroFL7nzjGM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">The balance comprises temporary differences attributable to:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzNDo_zYYvIBRwiBn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Tax loss</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxAssetsNetOperatingLossCarryforward" contextRef="AsOf2026-03-31" id="Fact001999" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,265</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxAssetsNetOperatingLossCarryforward" contextRef="AsOf2025-03-31" id="Fact002000" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,935</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockbasedCompensation_i01_pn3n3_maNDTAzNDo_zg5NkV192sbd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockbasedCompensation" contextRef="AsOf2026-03-31" id="Fact002002" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockbasedCompensation" contextRef="AsOf2025-03-31" id="Fact002003" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">397</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ReservesAndAccruals_i01I_pn3n3_maNDTAzNDo_zpF098fkMhS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Reserves and accruals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2005">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ReservesAndAccruals" contextRef="AsOf2025-03-31" id="Fact002006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--NetDeferredTaxAssets_i01TI_pn3n3_mtNDTAzNDo_zFqHYt7xYwP2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total deferred tax assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NetDeferredTaxAssets" contextRef="AsOf2026-03-31" id="Fact002008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,276</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NetDeferredTaxAssets" contextRef="AsOf2025-03-31" id="Fact002009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,349</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetNotRecognized_i01NI_pn3n3_di_zXXTsip0DILl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset not recognized</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DeferredTaxAssetNotRecognized" contextRef="AsOf2026-03-31" id="Fact002011" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,276</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:DeferredTaxAssetNotRecognized" contextRef="AsOf2025-03-31" id="Fact002012" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,349</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--NetDeferredTaxAsset_i01TI_pn3n3_zLCqto0u8Gba" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2014">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2015">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AD_zgZf5vpXNZSj" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 87; Value: 6 -->
    <div id="xdx_23D_z61467uZkija" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zgNakeEjnxM5" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_237_znPaQv1Czdxi" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_239_zp62lwUluk3j" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 16. INCOME TAXES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_232_zpGCLwLy4C5h" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company assesses its deferred tax assets for recognition by considering
both positive and negative evidence in order to ascertain whether it is probable that deferred tax assets will be realized. Realization
of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain.
Due to the history of losses the Company has generated in the past, the Company believes that it is not probable that all of the deferred
tax assets in the U.S. and U.K. can be realized as of March 31, 2026; accordingly, the Company has not recognized any of its deferred
tax assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s deferred tax assets not recognized decreased by $<span id="xdx_906_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20260331_zJA8QNH2SAH" title="deferred tax assets"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2026-03-31" id="Fact002020" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million for the year ended March 31, 2026. The change in the deferred tax assets not recognized was primarily due to the true-up adjustment
for stock compensation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has concluded that there are no uncertain tax treatments that
require disclosure or recognition.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 20, 2021, the OECD published the Global Anti-Base Erosion Model
Rules (the "GloBE Rules"), also known as Pillar II. The GloBE Rules aim to impose a global minimum tax of 15% on multinational
enterprises with a revenue in excess of &#8364;750 million. As the Company&#8217;s revenue is below this threshold, it is currently outside
the scope of the Pillar II rules.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company continues to monitor developments in jurisdictions where it
operates, including the U.K., U.S., and British Virgin Islands. As of the reporting date, Pillar II is not expected to have a material
impact on the Company&#8217;s financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 4th 2025, President Trump signed into law the One Big Beautiful
Bill Act ("OBBBA"). The OBBBA includes changes to U.S. tax law applicable to the Company beginning in 2025. The impact of the
OBBBA on the Company's consolidated financial statements have been reflected in its current and deferred taxes; however, the enactment
did not have a material impact to the Company's consolidated financial statements for the fiscal years ended March 31, 2026 and 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002022" name="ptgef:CapitalStockAndReservesTextBlock"><p id="xdx_809_ecustom--CapitalStockAndReservesTextBlock_zMaTHYdGT5ob" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 17. <span id="xdx_82A_z0M6mbPW7N6h">CAPITAL
STOCK AND RESERVES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">Authorized ordinary shares<b>:</b> Unlimited number of Alpha Compute
ordinary shares without par value.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Private Placement Financings</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 29, 2025, the Company completed the sale of <span id="xdx_90A_ecustom--SaleOfStock_iI_c20250129_zoNQuKM7BNgh" title="Sale of stock"><ix:nonFraction name="ptgef:SaleOfStock" contextRef="AsOf2025-01-29" id="Fact002024" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">524,390</ix:nonFraction></span>
ordinary shares for aggregate proceeds of $<span id="xdx_90D_ecustom--AggregateProceeds_iI_c20250129_zPzgMx1xEox4" title="aggregate proceeds"><ix:nonFraction name="ptgef:AggregateProceeds" contextRef="AsOf2025-01-29" id="Fact002026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,000</ix:nonFraction></span>,
at a per share price of $4.10, the closing price of a share on Nasdaq on the date preceding the date of the securities purchase agreement.
The shares were sold to two directors of the Company, Messrs. Gregory Bailey and James Mellon. The shares were sold in a private placement
transaction pursuant to Regulation S, and were issued as restricted stock. The proceeds are being used for general corporate purposes
and working capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 25, 2025, the Company completed the sale of<span id="xdx_90A_ecustom--SaleOfStock_iI_c20250925_zQ64BTqkhxr" title="Sale of stock">
<ix:nonFraction name="ptgef:SaleOfStock" contextRef="AsOf2025-09-25" id="Fact002028" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,415,780</ix:nonFraction></span>
ordinary shares at a per share price of $<span id="xdx_901_ecustom--SharesPrice_iI_c20250925_zhw2oogyDLXg" title="Share price"><ix:nonFraction name="ptgef:SharesPrice" contextRef="AsOf2025-09-25" id="Fact002030" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.73</ix:nonFraction></span>,
and pre-funded warrants to purchase <span id="xdx_90D_ecustom--WarrantsToPurchase_iI_c20250925_zvr30dZnfgEh" title="Warrants to purchase"><ix:nonFraction name="ptgef:WarrantsToPurchase" contextRef="AsOf2025-09-25" id="Fact002032" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,258,466</ix:nonFraction></span>
ordinary shares at a purchase price of $<span id="xdx_909_ecustom--PurchasePrice_iI_c20250925_zRxnoxvcSlE6" title="Purchase price"><ix:nonFraction name="ptgef:PurchasePrice" contextRef="AsOf2025-09-25" id="Fact002034" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.73</ix:nonFraction></span>
per ordinary share (less $0.001 per pre-funded warrant) for gross proceeds of approximately $<span id="xdx_904_ecustom--GrossProceeds_pn3n3_dm_c20250401__20260331_zrNM5Tyj8Etl" title="Gross proceeds"><ix:nonFraction name="ptgef:GrossProceeds" contextRef="From2025-04-01to2026-03-31" id="Fact002036" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">34.5</ix:nonFraction>
</span>million, consisting of cash of $<span id="xdx_90B_eifrs-full--Cash_iI_pn3n3_dm_c20250925_zNpp85JcpAG7" title="Cash"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2025-09-25" id="Fact002038" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.3</ix:nonFraction></span>
million and digital assets and stablecoin of $<span id="xdx_904_ecustom--DgitalAssets_iI_pn3n3_dm_c20250925_zGhJyOdnC5s7" title="Dgital assets"><ix:nonFraction name="ptgef:DgitalAssets" contextRef="AsOf2025-09-25" id="Fact002040" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">32.9</ix:nonFraction></span>
million. Each pre-funded warrant is exercisable for one ordinary share at an exercise price of $0.001 per pre-funded warrant, is immediately
exercisable and will expire once exercised in full. The shares and pre-funded warrants were sold in a private placement transaction in
reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated under the Securities Act, and the
proceeds are being used for the establishment of the Company&#8217;s digital asset treasury. During the fiscal year ended March 31, 2026,
111,295 pre-funded warrants issued under the private placement were exercised and 2,513,240 were forfeited by DWF in connection with the
return of DWF&#8217;s initial investment. The remaining 633,931 pre-funded warrants outstanding have no expiration date.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><span id="xdx_90B_ecustom--OrdinarySharesIssued_iI_c20250925_zMzEOzVAaOMj" title="Ordinary shares issued"><ix:nonFraction name="ptgef:OrdinarySharesIssued" contextRef="AsOf2025-09-25" id="Fact002042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span>
ordinary shares were issued to the Company&#8217;s third-party asset manager as consideration for continued services to be provided to
the Company pursuant to a Treasury Management Agreement. The shares have a three-year vesting term and are subject to forfeiture in the
event the agreement with the asset manager is terminated under certain circumstances. The shares were sold in a private placement transaction
in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated under the Securities Act, and
were issued as restricted stock.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 8, 2025 and December 30, 2025, one Side Letter put right issued
as part of the September 25, 2025 private placement financing and the DWF put right were exercised, respectively, and on March 24, 2026
and December 30, 2025, the contributed locked TON tokens receivable in the amount of 1,114,130, with a fair value of $2.5 million at contribution,
and $15.0 million USD1 receivable were returned to the investor and DWF, respectively. Additionally, the Company terminated its Treasury
Management Agreement with DWF in connection with the return of DWF&#8217;s initial investment. Upon return of the investor and DWF&#8217;s
shares to the Company, the Company recognized treasury stock in the amount of 17,452 and 105,000 shares, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Shares Issued Under the ATM Program</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During the fiscal year ended March 31, 2026, the Company sold <span id="xdx_90D_ecustom--NumberOfSharesSold_c20250401__20260331__ifrs-full--CounterpartiesAxis__custom--ATMMember_zdNaRIiNOalb" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2025-04-012026-03-31_custom_ATMMember" id="Fact002044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,062,632</ix:nonFraction></span>
ordinary shares under the ATM program, generating net proceeds of approximately $<span id="xdx_908_ecustom--NetProceeds_c20250401__20260331__ifrs-full--CounterpartiesAxis__custom--ATMMember_zDJgS01vnRkk" title="net proceeds"><ix:nonFraction name="ptgef:NetProceeds" contextRef="From2025-04-012026-03-31_custom_ATMMember" id="Fact002046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12.0</ix:nonFraction></span>
million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Shares Issued for Investment in Compedica</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On June 5, 2025, the Company acquired an equity interest in Compedica, Ltd.
("Compedica"), a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby the Company issued <span id="xdx_909_ecustom--OrdinarySharesIssued_iI_c20250605_z3YHUlvLdZLa" title="Ordinary shares issued"><ix:nonFraction name="ptgef:OrdinarySharesIssued" contextRef="AsOf2025-06-05" id="Fact002048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></span>
ordinary shares valued at $5,000,000, at a per share price of $8.00, in exchange for a minority equity interest in Compedica.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 88; Value: 6 -->
    <div id="xdx_23B_zMY36QDKcsEj" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zIQdhwhaM5m6" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23F_zQaPyjRq7bHe" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_231_zISIEtOijha" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 17. CAPITAL STOCK AND RESERVES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zWmY5zcDxWv2" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#8217;s treasury and the investment being exited. As a result, the Company recognized less than $<span id="xdx_902_ecustom--TreasuryStock_iI_pn3n3_dm_c20260206_zMSlAAoDUoai" title="Treasury stock"><ix:nonFraction name="ptgef:TreasuryStock" contextRef="AsOf2026-02-06" id="Fact002053" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million in treasury stock at the time the shares were returned, the fair value of the investment as of February 6, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Registered Direct Offering</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 13, 2026, the Company entered into a securities purchase agreement
with certain purchasers, pursuant to which the Company offered for sale to the Purchasers in a registered direct offering an aggregate
of <span id="xdx_901_ecustom--AggregateOfferingOrdinaryShares_iI_c20260113_zVZTy70PWhb5" title="Aggregate offering ordinary shares"><ix:nonFraction name="ptgef:AggregateOfferingOrdinaryShares" contextRef="AsOf2026-01-13" id="Fact002055" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,230,000</ix:nonFraction></span>
ordinary shares and, in lieu thereof, pre-funded warrants to purchase up to <span id="xdx_902_ecustom--Proceedsfromexerciseofwarrant_iI_c20260113_zFPuJ3It08D2" title="ProceedsFromExerciseOfWarrants"><ix:nonFraction name="ptgef:Proceedsfromexerciseofwarrant" contextRef="AsOf2026-01-13" id="Fact002057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,770,000</ix:nonFraction></span>
ordinary shares. The net proceeds from the Offering were approximately $<span id="xdx_902_eifrs-full--ProceedsFromExerciseOfWarrants_pn3n3_dm_c20260101__20260113_zFC7djCYkVFl" title="Net proceeds"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="From2026-01-012026-01-13" id="Fact002059" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">12.7</ix:nonFraction></span>
million. During the fiscal year ended March 31, 2026,<span id="xdx_90E_eifrs-full--NumberOfSharesIssued_iI_c20260113_znl1rWpAssDl" title="Pre-funded warrants issued">
<ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-01-13" id="Fact002061" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,120,000</ix:nonFraction></span>
pre-funded warrants issued under the registered direct offering were exercised. The remaining<span id="xdx_909_eifrs-full--IncreaseDecreaseInNumberOfSharesOutstanding_c20260111__20260113_znS3Grajme2c" title="pre-funded warrants outstanding shares">
<ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="From2026-01-112026-01-13" id="Fact002063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">650,000</ix:nonFraction></span>
pre-funded warrants outstanding have no expiration date.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Reverse Share Split</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The reverse stock split decreased the number of ordinary shares outstanding
as of September 30, 2023, from 17,808,225 to 890,412. All share and per share information included in the consolidated financial statements
and in the Notes to the consolidated financial statements have been retroactively adjusted to reflect the impact of the reverse stock
split unless otherwise noted. The number of ordinary shares authorized remained at an unlimited number of common shares without par value.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Any fractional shares resulting from the reverse stock
split were rounded up to the nearest whole post-split ordinary share. As a result of this round up provision, the Company issued an additional
<span id="xdx_907_ecustom--AdditionalSharesIssued_iI_c20250930_zm6jUddGOn86" title="Additional shares issued"><ix:nonFraction name="ptgef:AdditionalSharesIssued" contextRef="AsOf2025-09-30" id="Fact002065" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,254</ix:nonFraction></span>
shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series A Warrants and Pre-Funded Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 29, 2023, we entered into a securities purchase agreement (the
&#8220;2023 Purchase Agreement&#8221;) with an institutional and accredited investor in connection with a registered direct offering (the
&#8220;2023 Registered Direct Offering&#8221;) and a concurrent private placement (the &#8220;2023 Private Placement,&#8221; and together
with the Registered Direct Offering, the &#8220;2023 Offerings&#8221;). The 2023 Offerings closed on October 3, 2023.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Pursuant to the 2023 Purchase Agreement, in the 2023 Registered Direct Offering,
the Company sold (i) <span id="xdx_906_ecustom--NumberOfSharesSold_c20220401__20230930_zlx1w6YbxBBc" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-04-012023-09-30" id="Fact002067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">98,500</ix:nonFraction></span>
shares of the Company&#8217;s ordinary shares at a purchase price of $38.00 per share and (ii) pre-funded warrants to purchase up to 59,395
ordinary shares, at a purchase price of $37.98 per pre-funded warrant. All pre-funded warrants, which were exercisable for one ordinary
share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In the 2023 Private Placement, we issued to such institutional and accredited
investor unregistered Series A Warrants to purchase up to <span id="xdx_906_ecustom--WarrantsPurchase_c20230401__20230930_zcahS3lcc5q5" title="Warrants purchase"><ix:nonFraction name="ptgef:WarrantsPurchase" contextRef="From2023-04-012023-09-30" id="Fact002069" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">157,895</ix:nonFraction></span>
ordinary shares. Each Series A Warrant was immediately exercisable for one private warrant share at an exercise price of $38.00 per share
but expired on April 3, 2025, 18 months from the date of issuance.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Series A Warrants and the pre-funded warrants are classified as a component
of equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the ordinary
shares with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares,
and permit the holders to receive a fixed number of ordinary shares upon exercise. In addition, the Series A Warrants and the pre-funded
warrants do not provide any guarantee of value or return.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On the October 3, 2023 issue date, the calculated fair value of the Series
A Warrants and the pre-funded warrants was $<span id="xdx_90E_ecustom--WarrantsPerShare_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zLmUN36Qaprd" title="Fair value of warrants"><ix:nonFraction name="ptgef:WarrantsPerShare" contextRef="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember" id="Fact002071" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.968</ix:nonFraction></span>
million ($18.80 per such warrant). Because the fair value of the warrants accounted for as liabilities exceeded the net proceeds from
the 2023 Registered Direct Offering, the proceeds allocated to the ordinary shares, the pre-funded warrants and the Series A warrants
was zero. The Series A Warrants expired on April 3, 2025, 18 months from the date of issuance, and all pre-funded warrants were exercised
in full on May 9, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series A Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The inputs associated with calculating the fair value are reflected below.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002073" name="ptgef:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zJmEF76Kps05" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details )" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_zyf6XnpCBDcc" style="display: none">Schedule of inputs associated with calculating
        the fair value</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">October
        3, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw4EC71or03" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2024-10-03_custom_PlacementAgentWarrantsMember" id="Fact002075" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">38.00</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--SharePriceFairvalue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziV5CYcdG7K8" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2024-10-03_custom_PlacementAgentWarrantsMember" id="Fact002077" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_ecustom--OptionLifeShareOptions_dtY_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zXs0B3wo5NJ9" title="Expected life"><ix:nonNumeric contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact002079" name="ptgef:OptionLifeShareOptions">1.50</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zL9lmSzNwlMb" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember" id="Fact002081" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHOFaNy6c8ya" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember" id="Fact002083" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.32</ix:nonFraction></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQQ7PNDXngPa" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl2085">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A1_zre7Mydms1lg" style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 89; Value: 6 -->
    <div id="xdx_23B_ztWQVBvhysgl" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zCbUMioynd25" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_234_zRje0OsXIEDf" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_238_zVgrW565tVbl" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 17. CAPITAL STOCK AND RESERVES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_234_zVidimYOwJj9" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b>Nature and Purpose of Reserves</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Stock Option Reserve</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The stock option reserve reflects the reserve of compensation
expense recognized over the vesting period based upon the grant date fair value of the Company&#8217;s equity settled grants calculated
in accordance with IFRS 2, &#8220;Share-based Payment&#8221;. See Note 18, &#8220;Stock Option Reserve,&#8221; below for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002090" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_z0sTtvsAGwEl" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
18. <span id="xdx_82B_zJ120GyPr3xe">STOCK OPTION RESERVE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The share option reserve reflects the reserve of compensation expense recognized
over the vesting period based upon the grant date fair value of the Company&#8217;s equity settled grants calculated in accordance with
IFRS 2, &#8220;<i>Share-based Payment</i>&#8221;.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted
Stock Units</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The following table provides the activity for the Company&#8217;s
stock option reserve for the fiscal years ended March 31, 2026 and 2025 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002092" name="ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_pn3n3_zQlgUwnMFFc" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zg3911QQfmG5" style="display: none">Schedule of stock option
        reserve</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Balance, beginning of year</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20250401__20260331_zTttwvXdqSWk" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2025-03-31" id="Fact002093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,530</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_988_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20250331_zHIUt32fJSbd" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2024-03-31" id="Fact002094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,841</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20250401__20260331_zD8TjPMADUpa" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2025-04-01to2026-03-31" id="Fact002096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,745</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20240401__20250331_zRWWFpgQGmna" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2024-04-012025-03-31" id="Fact002098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left"><sup>(1)</sup></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Correction of prior period overstated share-based compensation
        expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20250401__20260331_zCMB8KtkMoDb" title="Correction of prior period overstated share-based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2100">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20240401__20250331_zqXZzU3nC9h" title="Correction of prior period overstated share-based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" contextRef="From2024-04-012025-03-31" id="Fact002102" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">632</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)<sup>(2)</sup></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance, end of year</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20250401__20260331_zQh7X8oL6xu5" title="Ending balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2026-03-31" id="Fact002104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,275</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_983_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20250331_ztoJWxIq1csi" title="Ending balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2025-03-31" id="Fact002106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,530</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 14%; font-size: 10pt; text-align: center">(1)</td>
    <td style="width: 86%; font-size: 10pt; text-align: left">Amount is net of $0.6 million reversal of share-based compensation expense for unvested
        share options forfeited during the fiscal year ended.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">(2)</td>
    <td style="font-size: 10pt; text-align: left">Amount represents the correction as of March 31, 2025 for the overstated share-based compensation
        expenses in Fiscal 2022 and Fiscal 2024.</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A6_zHajdFlhghO" style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. All share and per share information have been retroactively adjusted to reflect
the impact of the reverse stock split unless otherwise noted. See Note 1 &#8220;Nature of Operations&#8221; and Note 17, &#8220;Capital
Stock and Reserves&#8221; for further discussion on the reverse stock split.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The 2021 Equity Incentive Plan (the &#8220;Equity Incentive
Plan&#8221;), as amended on January 19, 2022, allows for the grant of equity awards up to 248,043 or 15% of shares currently issued and
outstanding, 3,616,999as of March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On March 7, 2025, the Board authorized the grant of
a total of <span id="xdx_90C_ecustom--AuthorizedGrantOptionPurchaseShares_iI_pip0_c20250307_zYUQYky0Uwoe" title=" Authorized grant option purchase shares"><ix:nonFraction name="ptgef:AuthorizedGrantOptionPurchaseShares" contextRef="AsOf2025-03-07" id="Fact002108" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">160,000</ix:nonFraction></span>
options to purchase ordinary shares at a per share exercise price of $4.45, with a term of 10 years. Vesting will accelerate on a change
of control of the Company. The options had a per share fair value of $4.04 and vest as to one-quarter immediately and the balance as to
one-third on each March 7, 2026, 2027 and 2028. The grants were made to certain directors, officers and employees. The options were issued
under the Company&#8217;s 2021 Equity Incentive Plan.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In Fiscal 2026, the Board of Directors authorized on March 11, 2026, the
grant of 1,930,396 share options to purchase ordinary shares at a per share rate ranging from $1.30 to $8.26. Once vested, the share options
are exercisable for a period ending 10 years after the date of grant. Vesting will accelerate on a change of control of the Company. The
options had a per share fair value of $0.40 and vest as to one-quarter immediately and the remaining balance as to one-third on each March
11, 2027, 2028, and 2029. The grants were made to certain directors, officers, and advisors. The options were issued as discretionary
options outside the 2021 Equity Incentive Plan, and not part of any regularly constituted compensation plan. These options were awarded
pursuant to contractor agreements and advisory agreements contingent on the Company raising at least $50 million in equity financing via
either private or public share offerings, which was achieved on January 14, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 11, 2026 the Board of Directors also authorized the grant of <span id="xdx_90B_ecustom--SharesIssuedGrantedRsu_iI_c20260311_z2gG3aMQcugk" title="Shares issued granted RSU"><ix:nonFraction name="ptgef:SharesIssuedGrantedRsu" contextRef="AsOf2026-03-11" id="Fact002110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,235,924</ix:nonFraction></span>
Restricted Stock Units which vested immediately upon the grant date. The grants were made to certain directors, officers, and employees.
The Restricted Stock Units were issued as discretionary awards outside the 2021 Equity Incentive Plan, and not part of any regularly constituted
compensation plan. These options were awarded pursuant to contractor agreements contingent on the Company raising at least $50 million
in equity financing via either private or public share offerings, which was achieved on January 14, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 27, 2025 the board authorized the grant of <span id="xdx_907_ecustom--AuthorizedGrantOptionPurchaseShares_iI_c20250727_zRYJavRTRrzg" title=" Authorized grant option purchase shares"><ix:nonFraction name="ptgef:AuthorizedGrantOptionPurchaseShares" contextRef="AsOf2025-07-27" id="Fact002112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,739</ix:nonFraction></span>
share options under the terms of the Company&#8217;s 2021 Equity Incentive Plan to board members and employees. These options were fully
vested at the time of grant.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 90; Value: 6 -->
    <div id="xdx_232_z0xKZIc48K58" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zrO8kwyPCQri" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23B_zAfXGwhzig19" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_231_zMwZIhSHBF3d" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 18. STOCK OPTION RESERVE <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_z4SzDX7TueKd" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As of March 31, 2026, no shares were reserved for awards
previously granted or available for future awards under the Amended and Restated 2021 Equity Incentive Plan.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 21pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The changes in the number of stock options issued and outstanding
for the fiscal years ended March 31, 2026 and 2025 were as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002117" name="ptgef:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zgeG60Y8aoWc" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B5_zRjZbyHo3iW8" style="display: none">&#160;Schedule of share options issued
        and outstanding</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20250401__20260331_zj7VJGh2zJ32" title="Beginning balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2025-03-31" id="Fact002119" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">225,117</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20250331_z65qTL5i5Q8k" title="Beginning balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2024-03-31" id="Fact002121" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">90,281</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Granted</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zUxYnHSiwRqh" title="Granted" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2025-04-01to2026-03-31" id="Fact002123" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,028,135</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_zg2B21mMxib6" title="Granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2024-04-012025-03-31" id="Fact002125" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">160,000</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zidYIcIDQuZ7" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2025-04-01to2026-03-31" id="Fact002127" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">6,745</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_z585SocDALW5" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2024-04-012025-03-31" id="Fact002129" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">25,164</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zyCIvbmNY4sh" title="Ending balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2026-03-31_custom_PBI2021EquityIncentivePlanMember" id="Fact002131" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,246,507</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlJ9nP6aePD6" title="Ending balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2025-03-31_custom_PBI2021EquityIncentivePlanMember" id="Fact002133" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">225,117</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zeqUc30cW8W5" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="From2025-04-012026-03-31_custom_PBI2021EquityIncentivePlanMember" id="Fact002135" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,246,507</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zWaEvFNwkmLb" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="From2024-04-012025-03-31_custom_PBI2021EquityIncentivePlanMember" id="Fact002137" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">102,855</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Available for future awards</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20250401__20260331_z3rVNZ5aGWHi" title="Available for future awards" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2139">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20240401__20250331_zv0t3DdU9vF" title="Available for future awards" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" contextRef="From2024-04-012025-03-31" id="Fact002141" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">17,516</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AA_zm4MJb9ShjZ8" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The table above does not include fully vested restricted
stock units (&#8220;RSUs&#8221;) granted to certain executives in January 2021 and January 2022. In January 2024, the Company issued<span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zb8BcihnZoZ6" title="Shares issued">
<ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember" id="Fact002143" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">308</ix:nonFraction></span>
shares for the exercise of <span id="xdx_908_ecustom--NumberOfSharesExercise_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zN0yyMBlMf8e" title="Shares issued"><ix:nonFraction name="ptgef:NumberOfSharesExercise" contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember" id="Fact002145" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">470</ix:nonFraction></span>
RSUs net of 162 shares withheld to pay for an employee&#8217;s payroll taxes. In September 2024, the Company issued <span id="xdx_905_eifrs-full--NumberOfSharesIssued_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_ziO9FWvsv2Le" title="Shares issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact002147" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">882</ix:nonFraction></span>
shares for the exercise of <span id="xdx_904_ecustom--NumberOfSharesExercise_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zHwswvtgSAoe" title="Shares issued"><ix:nonFraction name="ptgef:NumberOfSharesExercise" contextRef="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact002149" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,152</ix:nonFraction></span>
RSUs net of <span id="xdx_904_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zh1BHbPZ8Iaj" title="Shares repurchased into treasury employee payroll taxes"><ix:nonFraction name="ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" contextRef="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact002151" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">270</ix:nonFraction></span>
shares withheld to pay for an employee&#8217;s payroll taxes. In December 2024, the Company issued <span id="xdx_909_eifrs-full--NumberOfSharesIssued_iI_pip0_c20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_ztKMN6JLex9a" title="Shares issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_ifrs-full_RestrictedShareUnitsMember" id="Fact002153" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">8,173</ix:nonFraction></span>
shares for the exercise of <span id="xdx_90C_ecustom--NumberOfSharesExercise_iI_pip0_c20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z86xq60VrTzl" title="Shares issued"><ix:nonFraction name="ptgef:NumberOfSharesExercise" contextRef="AsOf2026-03-31_ifrs-full_RestrictedShareUnitsMember" id="Fact002155" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">11,905</ix:nonFraction></span>
RSUs net of 3,732 shares withheld to pay for an employee&#8217;s payroll taxes. As of March 31, 2026, there were 1,241,334 RSUs granted
and outstanding, of which 4,550, 860, and 1,235,924 RSUs expire on January 13, 2031, January 19, 2032, and March 11, 2036, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The weighted-average estimated fair value of share
options granted during the years ended March 31, 2026 and 2025 was $0.40 and $4.04 per share, respectively, using the Black-Scholes option
pricing model with the following weighted-average assumptions:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002157" name="ptgef:ScheduleOfWeightedAverageAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfWeightedAverageAssumptionsTableTextBlock_zTv9z2f1KcE" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zXqVQ5uzHeb5" style="display: none">Schedule of weighted-average estimated
        fair value of share options</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt">Grant Price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zBwUR57N7nIi" title="Grant price"><ix:nonFraction name="ptgef:DescriptionOfGrantPriceShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember" id="Fact002159" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="USDPShares">1.30</ix:nonFraction></span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zqgA2HDH1mYj" title="Grant price"><ix:nonFraction name="ptgef:DescriptionOfGrantPriceShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember" id="Fact002161" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="USDPShares">4.45</ix:nonFraction></span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life (in years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zIzdxsHkCVy4" title="Expected life"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember" format="ixt-sec:duryear" id="Fact002163" name="ptgef:OptionLifeShareOptionsGranted">10</ix:nonNumeric></span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_ecustom--OptionLifeShareOptionsGranted_dtY_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zRn0b9MkpPXf" title="Expected life"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember" format="ixt-sec:duryear" id="Fact002165" name="ptgef:OptionLifeShareOptionsGranted">5.75</ix:nonNumeric></span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Risk-free interest rates</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zbm327X5L0R4" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember" id="Fact002167" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.68</ix:nonFraction></span></td>
    <td style="font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zhUY2lomD35l" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember" id="Fact002169" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.14</ix:nonFraction></span></td>
    <td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zpkwI2rP4Ecj" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember" id="Fact002171" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">115.0</ix:nonFraction></span></td>
    <td style="font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zGasLKz8m0E5" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember" id="Fact002173" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">135.8</ix:nonFraction></span></td>
    <td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvUjY2opY4nb"><span style="-sec-ix-hidden: xdx2ixbrl2174">&#8212;</span></span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvfRB8UiCMCf"><span style="-sec-ix-hidden: xdx2ixbrl2175">&#8212;</span>&#160;</span>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A0_z4sCcna5E4V8" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following is the weighted average exercise price and the remaining
contractual life for outstanding options as of March 31, 2026 and 2025:</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002177" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_z3jO5UVi58zc" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"> <span id="xdx_8BA_zQerUm64wrF7" style="display: none">Schedule of weighted average exercise price and the remaining
        contractual life</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20250401__20260331_zaU7tofFXeW" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2025-04-01to2026-03-31" id="Fact002179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.84</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20250331_zrFiK1dgikvb" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2024-04-012025-03-31" id="Fact002181" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">62.51</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20250401__20260331_zLKzMSH9P2O4" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:duryear" id="Fact002183" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">9.9</ix:nonNumeric></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20250331_zFFZeaPhjGB3" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-04-012025-03-31" format="ixt-sec:duryear" id="Fact002185" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">9.1</ix:nonNumeric></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AE_znQ9iA2kaHl2" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Share options granted and outstanding at the
end of the year have the following expiration dates and exercise prices:</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002187" name="ptgef:ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z7wkIYWaRz39" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B1_zqijrz5Mknw7" style="display: none">Schedule of Share options granted and
        outstanding</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td id="xdx_488_ecustom--ExpirationDate_zKINvOlmRmS2" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_48C_ecustom--ExercisePrice_pip0_zC1MEnqFF5Z7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_ecustom--ShareOptions_zPB6RVYkEeRl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Share Options as of</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Grant Date</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Expiration Date</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price $</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2026</td></tr>
  <tr id="xdx_41F_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January132021Member_z23nODcb10eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-size: 10pt; text-align: left">January 13, 2021</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_January132021Member" id="Fact002188" name="ptgef:ExpirationDate">January
        13, 2031</ix:nonNumeric></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 22%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_January132021Member" id="Fact002189" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">355.00</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 22%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_January132021Member" id="Fact002190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">21,400</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January192022Member_z0QzW6haKfGf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">January 19, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_January192022Member" id="Fact002191" name="ptgef:ExpirationDate">January
        19, 2032</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_January192022Member" id="Fact002192" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">204.40</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_January192022Member" id="Fact002193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">12,475</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--February152022Member_zQ4F2fGDGb19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">February 15, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_February152022Member" id="Fact002194" name="ptgef:ExpirationDate">February
        15, 2032</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_February152022Member" id="Fact002195" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">171.80</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--June82022Member_zu6xZSM5Ptlf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">June 8, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_June82022Member" id="Fact002197" name="ptgef:ExpirationDate">June
        8, 2032</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_June82022Member" id="Fact002198" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">220.00</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272022Member_zVcBTLbtjKcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">July 27, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_July272022Member" id="Fact002200" name="ptgef:ExpirationDate">July
        27, 2032</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_July272022Member" id="Fact002201" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">201.20</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March302023Member_ztOORJsba2E9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">March 30, 2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_March302023Member" id="Fact002203" name="ptgef:ExpirationDate">March
        30, 2033</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_March302023Member" id="Fact002204" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">58.40</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_March302023Member" id="Fact002205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">24,497</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March72025Member_zsxlz6Wud1k9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">March 7, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_March72025Member" id="Fact002206" name="ptgef:ExpirationDate">March
        7, 2035</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_March72025Member" id="Fact002207" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.45</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_March72025Member" id="Fact002208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">160,000</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41C_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272026Member_zZNh6A3YOVMb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">July 27, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_July272026Member" id="Fact002209" name="ptgef:ExpirationDate">July
        27, 2025</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_July272026Member" id="Fact002210" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.73</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_July272026Member" id="Fact002211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">97,739</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March112026Member_zc8GVRMsAJa6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">March 11, 2026</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_March112026Member" id="Fact002212" name="ptgef:ExpirationDate">March
        11, 2036</ix:nonNumeric></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2025-04-012026-03-31_custom_March112026Member" id="Fact002213" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.30</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOptions" contextRef="From2025-04-012026-03-31_custom_March112026Member" id="Fact002214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,930,396</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20240401__20250331_zEdYJu7BN6y6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ShareOptions" contextRef="From2024-04-012025-03-31" id="Fact002217" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,246,507</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



</ix:nonNumeric><p id="xdx_8A8_zisDzzJYdgMb" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>



<ix:exclude><p id="xdx_237_zx6yvDjkEswg" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 91; Value: 6 -->
    <div id="xdx_23A_zr7A52i3wvx2" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zQ3DUhRu8Gt9" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23B_zO16lXyYyq43" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_231_zsmkMKwbY6b7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 18. STOCK OPTION RESERVE <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The vested options can be exercised at any
time in accordance with the applicable option agreement. The exercise price was greater than the market price for all options outstanding
as of March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company recorded approximately $<span id="xdx_904_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20250401__20260331_zMaeFDpBLSoj" title="Share based compensation expense"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2025-04-01to2026-03-31" id="Fact002222" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.3</ix:nonFraction></span>
million of share-based compensation expense in the year ended March 31, 2026. During Fiscal 2025, the Company recorded approximately $<span id="xdx_907_ecustom--SharebasedCompensationExpense_pn5n6_c20250401__20260331__ifrs-full--MeasurementAxis__custom--VestedStockOptionMember_zTYsBG74UNJe" title="Share based compensation expense"><ix:nonFraction name="ptgef:SharebasedCompensationExpense" contextRef="From2025-04-012026-03-31_custom_VestedStockOptionMember" id="Fact002224" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million of share-based compensation, which reflects an additional $<span id="xdx_90C_ecustom--ReversalOfSharebasedCompensation_pn3n3_dm_c20250401__20260331_zye4ucMdcJF3" title="Reversal of share-based compensation"><ix:nonFraction name="ptgef:ReversalOfSharebasedCompensation" contextRef="From2025-04-01to2026-03-31" id="Fact002226" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million in share-based compensation expense for the accelerated vesting of certain employee share options offset by $<span id="xdx_90D_ecustom--ShareBasedCompensationExpenseUnvestedShareOptions_pn3n3_dm_c20250401__20260331_zqJPuDgWjKbh" title="Share based compensation expense unvested share options"><ix:nonFraction name="ptgef:ShareBasedCompensationExpenseUnvestedShareOptions" contextRef="From2025-04-01to2026-03-31" id="Fact002228" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million reversal of share-based compensation for unvested share options forfeited during the year. The Company recorded approximately
$<span id="xdx_90E_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20230401__20240331_zQG8kckinny9" title="Share based compensation expense"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2023-04-012024-03-31" id="Fact002230" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction>
</span>million of share-based compensation expense in the year ended March 31, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002232" name="ifrs-full:EarningsPerShareExplanatory"><p id="xdx_80B_eifrs-full--EarningsPerShareExplanatory_zpRwY5iYljT4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. <span id="xdx_820_zDbbmKWLPfc5">LOSS
PER SHARE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Basic earnings per share (&#8220;EPS&#8221;) is calculated
by dividing the net loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Diluted EPS is calculated by dividing the net loss attributable to ordinary
equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted average
number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares. Shares
issuable under pre-funded warrants are considered outstanding for this purpose.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The calculation of Basic and Diluted EPS reflects the
pre-funded warrants as outstanding shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following table reflects the loss and share data used in the
basic and diluted EPS calculations (in thousands, except per share amounts):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002234" name="ptgef:ScheduleOfEarningsPerShareTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zsS4CoeES4S4" summary="xdx: Disclosure - LOSS PER SHARE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span id="xdx_8BA_zvvguM3k50j8" style="display: none">Schedule
        of loss and share data used in the basic and diluted EPS calculations</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Numerator</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the
        Company</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20250401__20260331_zcRKw8gluL3i" title="Weighted average shares outstanding, Diluted">(<ix:nonFraction name="ptgef:WeightedAverageSharesOutstandingDiluted" contextRef="From2025-04-01to2026-03-31" id="Fact002236" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,627</ix:nonFraction></span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20240401__20250331_z2CcesYCo3yk" title="Weighted average shares outstanding, Diluted">(<ix:nonFraction name="ptgef:WeightedAverageSharesOutstandingDiluted" contextRef="From2024-04-012025-03-31" id="Fact002238" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,767</ix:nonFraction></span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20230401__20240331_zt94WqBLzg82" title="Weighted average shares outstanding, Diluted">(<ix:nonFraction name="ptgef:WeightedAverageSharesOutstandingDiluted" contextRef="From2023-04-012024-03-31" id="Fact002240" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,339</ix:nonFraction></span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Denominator</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Weighted average number of shares &#8211; Basic and Diluted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20250401__20260331_zgFzVd15Ikal" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-01to2026-03-31" id="Fact002242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,248</ix:nonFraction></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240401__20250331_zRBOm79ICEl8" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2024-04-012025-03-31" id="Fact002244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,183</ix:nonFraction></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20240331_z0WLRcgGgh2k" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2023-04-012024-03-31" id="Fact002246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">968</ix:nonFraction></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_ecustom--LossPerShareBasic_pip0_c20250401__20260331_zmbXl2cSO4al" title="Loss per share, Basic"><span id="xdx_90E_ecustom--LossPerShareDiluted_pip0_c20250401__20260331_zZwh5dIZyVJ2" title="Loss per share, Diluted">(<ix:nonFraction name="ptgef:LossPerShareBasic" contextRef="From2025-04-01to2026-03-31" id="Fact002248" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ptgef:LossPerShareDiluted" contextRef="From2025-04-01to2026-03-31" id="Fact002250" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">4.18</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--LossPerShareBasic_pip0_c20240401__20250331_zyMCfFL2LpE1" title="Loss per share, Basic"><span id="xdx_907_ecustom--LossPerShareDiluted_pip0_c20240401__20250331_zkOoovScaKYj" title="Loss per share, Diluted">(<ix:nonFraction name="ptgef:LossPerShareBasic" contextRef="From2024-04-012025-03-31" id="Fact002252" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ptgef:LossPerShareDiluted" contextRef="From2024-04-012025-03-31" id="Fact002254" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">5.72</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--LossPerShareBasic_pip0_c20230401__20240331_zShoRiQyeKue" title="Loss per share, Basic"><span id="xdx_90C_ecustom--LossPerShareDiluted_pip0_c20230401__20240331_zRBuKRaCJxSg" title="Loss per share, Diluted">(<ix:nonFraction name="ptgef:LossPerShareBasic" contextRef="From2023-04-012024-03-31" id="Fact002256" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ptgef:LossPerShareDiluted" contextRef="From2023-04-012024-03-31" id="Fact002258" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">77.83</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A1_zE1HceF0FEjf" style="margin: 0pt 0; font-size: 10pt; text-align: justify; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The inclusion of the Company&#8217;s share purchase
warrants (other than pre-funded warrants, as described above), stock options and RSUs in the computation of diluted loss per share would
have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between
basic loss per share and diluted loss per share for the fiscal years ended March 31, 2026, 2025, and 2024. The following table reflects
the Company&#8217;s outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded
from the calculation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002260" name="ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_zJv9JThhJnb3" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_z71f9aNcXd96" style="display: none">Schedule of anti-dilutive
        effect on loss per share</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zXFaxJRIrlg5" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2026-03-31_ifrs-full_WarrantsMember" id="Fact002262" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,531,581</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_ztitv7YcRfn3" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2025-03-31_ifrs-full_WarrantsMember" id="Fact002264" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">481,581</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zmL6DkL2CZV" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2024-03-31_ifrs-full_WarrantsMember" id="Fact002266" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">481,581</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Share options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zPkX8p87qSch" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2026-03-31_custom_StockOptionsMember" id="Fact002268" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,246,507</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zHgwbhDxhbOj" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2025-03-31_custom_StockOptionsMember" id="Fact002270" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">225,117</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_za9b0O0g2D32" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2024-03-31_custom_StockOptionsMember" id="Fact002272" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">90,281</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_z2Qo9CmrTeW6" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2026-03-31_custom_RestrictedStockUnitsMember" id="Fact002274" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,241,334</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zxskHsRj6qbd" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2025-03-31_custom_RestrictedStockUnitsMember" id="Fact002276" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,410</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zp4ohqFmVDm8" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2024-03-31_custom_RestrictedStockUnitsMember" id="Fact002278" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">18,467</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AD_zeDx4wONh7Yj" style="margin: 0pt 0; font-size: 10pt; color: Red"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002280" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zZ9WIfMXZg8c" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
20. <span id="xdx_827_zLVV0F4PNx7j">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>iOx &#8211; Parexel Master Services Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Effective March 15, 2022, iOx, a wholly-owned subsidiary
of the Company, entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Parexel under which Parexel agreed to act as a clinical
service provider (&#8220;CRO&#8221;) pursuant to a work order (&#8220;Work Order&#8221;) effective June 1, 2022. Under such Work Order,
Parexel planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer. The MSA provided
for a five-year term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided
for service fees and pass-through expenses and clinical sites totaling $<span id="xdx_903_ecustom--ServiceFees_iI_pn3n3_dm_c20220315__ifrs-full--CounterpartiesAxis__custom--CROMember_zUwMMp0oBXU6" title="service fees"><ix:nonFraction name="ptgef:ServiceFees" contextRef="AsOf2022-03-15_custom_CROMember" id="Fact002282" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">11.5</ix:nonFraction></span>
million. During the year ended March 31, 2023 (&#8220;Fiscal 2023&#8221;), the Company executed two change orders resulting in a $<span id="xdx_90B_ecustom--BudgetCosts_pn3n3_dm_c20220401__20230331_zj1yncGY4Ava" title="Budget costs"><ix:nonFraction name="ptgef:BudgetCosts" contextRef="From2022-04-012023-03-31" id="Fact002284" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million increase in the overall estimated budgeted costs. As a result of the Company&#8217;s decision to discontinue the development with
respect to this program, on December 20, 2023, the Company provided Parexel notice of termination of the contract, with a planned termination
date of April 18, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 92; Value: 6 -->
    <div id="xdx_231_zYKlfyuSM4c8" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zsHTp26XBVoi" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23E_zObtXdMLHeo5" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_230_zUiMMrMkaWcd" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 20. COMMITMENTS AND CONTINGENT LIABILITIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23C_zCnyoDntZiy7" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As the ongoing CRO services were wound down, the Company
noticed that expenses incurred under the CRO agreement were higher than originally budgeted. Parexel agreed to refund the Company $<span id="xdx_90B_ecustom--GrossProceeds_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_ziyWSMhmr6qj" title="Gross proceeds"><ix:nonFraction name="ptgef:GrossProceeds" contextRef="From2024-09-012024-09-30_custom_CROAgreementMember" id="Fact002289" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.552</ix:nonFraction></span>
million and release the liability for amounts invoiced and unbilled services totaling $<span id="xdx_901_ecustom--UnbilledServices_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_zBD2mmbKfgR3" title="Unbilled services"><ix:nonFraction name="ptgef:UnbilledServices" contextRef="From2024-09-012024-09-30_custom_CROAgreementMember" id="Fact002291" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.486</ix:nonFraction>
</span>million, and the Company forfeited advanced payments of $<span id="xdx_90A_ecustom--ForfeitedAdvancedPayments_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_ziugDIR1fpp" title="Forfeited advanced payments"><ix:nonFraction name="ptgef:ForfeitedAdvancedPayments" contextRef="From2024-09-012024-09-30_custom_CROAgreementMember" id="Fact002293" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.091</ix:nonFraction></span>
million. As a result, the Company recognized a net gain of $<span id="xdx_903_ecustom--NetGain_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_zvGcqNBmp0Fb" title="Net gain"><ix:nonFraction name="ptgef:NetGain" contextRef="From2024-09-012024-09-30_custom_CROAgreementMember" id="Fact002295" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.946</ix:nonFraction></span>
million as of September 30, 2024. The Company received the refund from Parexel on October 3, 2024. As of March 31, 2024, the Company reflected
$<span id="xdx_908_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_pn3n3_dm_c20230401__20240331__ifrs-full--CounterpartiesAxis__custom--CROMember_zotmX1mpiIuj" title="Accounts payable and accrued liabilitie"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2023-04-012024-03-31_custom_CROMember" id="Fact002297" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.414</ix:nonFraction></span>
million of payables to Parexel in accounts payable and accrued liabilities and $<span id="xdx_903_ecustom--PrepaidExpensesAndOtherReceivables_pn3n3_dm_c20230401__20240331__ifrs-full--CounterpartiesAxis__custom--CROMember_zbLOmLQIMeTf" title="prepaid expenses and other receivables"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivables" contextRef="From2023-04-012024-03-31_custom_CROMember" id="Fact002299" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.277</ix:nonFraction></span>
million in prepaid expenses and other receivables in the consolidated statement of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Buzz HPC GPU Lease</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026 he Company entered into a GPU infrastructure services
agreement with Buzz Performance Cloud Inc. pursuant to which the Company secured rights to access 504 NVIDIA B200 GPUs for a 24-month
term. The arrangement contemplates aggregate contractual payments of approximately $<span id="xdx_901_ecustom--ContractualPayments_iI_pn3n3_dm_c20260206_zDTtexGSiN8i" title="Contractual payments"><ix:nonFraction name="ptgef:ContractualPayments" contextRef="AsOf2026-02-06" id="Fact002301" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">29.6</ix:nonFraction></span>
million over the contract term and requires a security deposit of $<span id="xdx_901_ecustom--SecurityDeposits_iI_pn3n3_dm_c20260206_zTPpUh86TuFg" title="Security deposit"><ix:nonFraction name="ptgef:SecurityDeposits" contextRef="AsOf2026-02-06" id="Fact002303" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction></span>
million, which was paid on February 13, 2026. As of March 31, 2026, no liability was yet recorded as the services did not commence until
early June.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>atNorth Colocation Lease Payments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 11, 2025 the Company signed an enterprise colocation service
agreement (the &#8220;Colo Agreement&#8221;) with atNorth AB (&#8220;atNorth&#8221;) to deploy the Company&#8217;s GPU hardware to atNorth&#8217;s
data center located in Kista, Sweden. The Colo Agreement consists of two data halls with a Phase I deployment of 1,213 kW of power and
a Phase II of 1,017 kW of power, with Phase II being structured as a Right of First Refusal (the &#8220;ROFR&#8221;). The agreement&#8217;s
commencement date was April 1, 2026, and extends for 60 months after which it automatically extends for successive 12 month periods unless
6 months&#8217; notice is provided by either party. On April 10, 2026, the Company paid a 982,368 EUR deposit to secure Phase I of the
agreement. As of the date of the issuance of these consolidated financial statements, the ROFR for Phase II of the deployment has expired,
although atNorth is still being considered for a further deployment once ready. The monthly colocation fee for Phase I that has commenced
is 163,728 EUR plus variable electricity costs estimated at 0.126 EUR/kWh.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>GaMee Acquisition Token Buyback</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#8220;SPA&#8221;) with Animoca Brands Limited (&#8220;Animoca Brands&#8221;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#8220;GaMee Global&#8221;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#8220;GaMee Transaction&#8221;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. The SPA
contains a post-closing item requiring the Company to, within ninety (90) days after close, acquire from the open market $2 million worth
of GMEE tokens. GMEE is the native utility token of the GaMee gaming platform and ecosystem. The GaMee Transaction closed on May 27, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Tarus &#8211; Fortrea Clinical Service Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On March 1, 2023, Tarus entered into a clinical service
agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier
of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services
to be provided is approximately $12.1 million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In March 2025, the Company resumed patient enrollment
into the final cohort arm of TT-10 (PORT-6) as part of the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following a prior pause due
to funding constraints. This decision reflects the favorable safety and preliminary activity signals observed in earlier dose cohorts.
In April 2025, we announced confirmatory preclinical results in mesothelioma with our TT-4 (PORT-7) compound, supporting advancement of
this indication in its first-inhuman trial of TT-4 (PORT-7) which is expected to commence in the quarter ending March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On May 31, 2026, Cyncado and ADDRI executed a definitive
Clinical Trial Research Agreement establishing the terms of the study. The trial is expected to enroll approximately 50 patients across
multiple clinical sites, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado's planned
U.S. mesothelioma activities. Under the agreement, Cyncado will supply TT-4 and provide limited support as part of an international mesothelioma
program. The trial remains subject to customary regulatory and ethics approvals and site activation before enrollment begins.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<ix:exclude><p id="xdx_232_zbxAx6oTiCaj" style="margin: 0pt 0; font-size: 10pt; text-align: justify"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 93; Value: 6 -->
    <div id="xdx_230_zyqwzJWZXCwe" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zEkrPPQEsRPc" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_238_zcDve7VMgtb4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_237_zIE51v5toNqa" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 20. COMMITMENTS AND CONTINGENT LIABILITIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_zAd0UcnZECK8" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Nasdaq Notifications</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 10, 2024, the Company received written
notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;) indicating that it was not in compliance with
the minimum shareholders&#8217; equity requirement for continued listing on The Nasdaq Capital Market (the &#8220;Capital Market&#8221;)
as set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Shareholders&#8217; Equity Requirement&#8221;), because the shareholders&#8217;
equity of $695,000 as of September 30, 2024, as reported in the Company&#8217;s Report on Form 6-K containing unaudited consolidated financial
statements for the three and six months ended September 30, 2024, filed with the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) on December 31, 2024, was below the required minimum of $2.5 million, and because as of the date of the Notice, the
Company did not meet either of the alternative continued listing standards for the Nasdaq Capital Market, relating to market value of
listed securities of at least $35 million or net income from continuing operations of at least $500,000 in the most recently completed
fiscal year or in two of the last three most recently completed fiscal years. The Company submitted a plan on January 24, 2025, to regain
compliance with the shareholders&#8217; equity requirement or achieve compliance with an alternative continued listing standard for the
Capital Market (the &#8220;Compliance Plan&#8221;) and on February 11, 2025, the Company received notification from Nasdaq that Nasdaq
accepted the Compliance Plan and granted the Company an extension to regain compliance with the continued listing standards by June 9,
2025. In keeping with the Compliance Plan, on June 5, 2025, the Company increased its shareholders&#8217; equity, and submitted documentation
to Nasdaq indicating compliance as of June 9, 2025, with the shareholders&#8217; equity requirement. The Nasdaq Stock Market, LLC indicated
by letter dated June 24, 2025, that the Company has regained compliance with the continued listing standards of the Nasdaq Capital Market.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On March 2, 2026, the Company received a deficiency
letter from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) notifying the Company that because the closing bid
price for the Company&#8217;s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet
the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule
5550(a)(2) (the &#8220;Bid Price Rule&#8221;). The deficiency letter does not result in the immediate delisting of the Company&#8217;s
common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial
period of 180 calendar days, or until August 31, 2026 (the &#8220;Compliance Period&#8221;), to regain compliance with the Bid Price Rule.
If, at any time during the Compliance Period, the closing bid price per share of the Company&#8217;s common stock is at least $1.00 for
a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it complies with the Bid Price
Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The Nasdaq
letter also provides that in the event the Company does not regain compliance by August 31, 2026, the Company may be eligible for an additional
180 calendar day period to regain compliance. To qualify, the Company must meet the continued listing requirement for market value of
publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the bid price requirement.
Notwithstanding the terms set forth in the Nasdaq letter, there can be no assurance that the Company will be eligible for an additional
180 calendar day period to regain compliance. If the Company meets the applicable requirements, Nasdaq will inform the Company that it
has been granted an additional 180 calendar days. If, however, it appears to Nasdaq that the Company will not be able to cure the deficiency,
or if the Company is otherwise not eligible, Nasdaq could provide notice that the Company&#8217;s common stock will become subject to
delisting. In such event, Nasdaq rules would permit the Company to appeal the delisting determination to a Nasdaq Hearings Panel.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Ground Tunnel Consulting Services Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On July 15, 2025, Alpha Transform Holdings, a related
party of the Company, entered into a consulting service agreement with Ground Tunnel Capital LLC, a third-party advisory and marketing
consultant. This consulting service agreement was assigned to the Company on October 25, 2025. The effective date of the agreement occurred
upon the closing of the subsequent private placement of ordinary shares, which occurred on September 25, 2025, with contractual services
to be provided through July 15, 2028. $1.0 million was paid upon execution of the contract, with subsequent milestone payments of $0.25
million due on each October 15, 2025, January 15, 2026, April 15, 2026 and July 15, 2026. On April 15, 2026, the Company submitted its
third milestone payment in the amount of $0.25 million.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Treasury Management Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At the closing of the Company&#8217;s financing on
September 25, 2025, the Company entered into a treasury management agreement (the &#8220;DWF TMA&#8221;) with DWF MaaS Limited (&#8220;DWF&#8221;),
pursuant to which the Company appointed DWF to manage $15.0 million that DWF contributed in the September 2025 financing and implement
the TON treasury strategy for the Company. Under the DWF TMA, DWF is entitled to retain 100% of all profits earned until the balance with
DWF reaches $150.0 million at which point the Company will earn a 3% yield on all DWF-managed TON holdings, and additionally 10% of any
profits from asset management will be shared with the Company. In consideration for the services to be provided, the Company issued 160,000
ordinary shares to DWF, which shares shall vest linearly over a period of three (3) years from the date of issue to DWF. The initial term
of the agreement is 3 years and will commence on the date that the aggregate transfers from the Company to DWF reach $150 million.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company has the right to terminate the agreement
with 90 days&#8217; notice provided that a) the termination notice is submitted more than 18 months following commencement of the contract
term, and b) the Company publicly announces it will cease its strategy of holding TON as a treasury asset. Pursuant to the DWF AMA, DWF
is entitled to convert the Ordinary Shares it subscribed for in the September 2025 private placement into an equivalent value of TON from
the amount of TON held by DWF on behalf of the Company up to a maximum value of $15,000,000. DWF was granted the right to exercise this
conversion option at any time within twelve months from August 25, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 94; Value: 6 -->
    <div id="xdx_23A_zwOedhglWAb8" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zBBIRphTuVsk" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23E_zp7peqn0OzTg" style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23A_zpFqizUZvaS3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 20. COMMITMENTS AND CONTINGENT LIABILITIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_237_zhTZAaKlSBI3" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The range of management and trading activities that
DWF is authorized to conduct under the DWF AMA is limited to market-making, buying and selling the TON tokens, and providing liquidity
on decentralized or centralized exchanges. DWF cannot use derivatives as part of their mandate. DWF is mandated to actively manage the
assets under management to provide market liquidity in TON trading pairs and generate a return. DWF is required to hold and secure the
assets using institutional-grade custody solutions, which may include qualified third-party custodians, centralized cryptocurrency exchanges,
multi-party computation (MPC) wallets, and other industry-standard security protocols designed to safeguard digital assets.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In addition to the initial $15.0 million that DWF contributed
in the September 2025 financing, the Company is required to make additional transfers of a) $5 million 15 days after the close of the
September 2025 financing, and b) $55.0 million within 3 months of the September 2025 financing, with no less than $20.0 million to be
transferred each month. The Company also agrees to transfer 50% of any subsequent treasury fundraising to DWF for asset management until
the total assets under management total $225.0 million. Through December 30, 2025, there had been no additional transfers to DWF, and
DWF was managing only the $15.0 million of their own funds that they contributed as part of the September 2025 financing.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 30, 2025, the Company entered into that
certain Settlement Agreement and Release (the &#8220;Settlement Agreement&#8221;), by and between the Company and DWF MaaS Limited (&#8220;DWF&#8221;).
The Settlement Agreement resolves certain disputes over the rights and obligations related to that certain Treasury Management Agreement,
dated as of August 25, 2025 (the &#8220;Treasury Management Agreement&#8221;), by and between the Company and DWF, pursuant to which the
Company appointed DWF to manage and implement a portion of the Company&#8217;s TON treasury strategy. On September 25, 2025, DWF subscribed
for (i) 105,000 ordinary shares (the &#8220;Shares&#8221;) of the Company, no par value per share (the &#8220;Ordinary Shares&#8221;),
and (ii) pre-funded warrants to purchase up to 2,513,240 Ordinary Shares (the &#8220;Pre-Funded Warrants&#8221; and together with the
Shares, the &#8220;Repurchase Securities&#8221;), in exchange for consideration of USD1 $15,000,000, in each case pursuant to that certain
Securities Purchase Agreement, dated as of September 2, 2025, by and between the Company and certain investors party thereto (including
DWF). Also on September 25, 2025, pursuant to the terms of the Treasury Management Agreement, the Company and DWF entered into that certain
Ordinary Share Issuance Agreement (the &#8220;Restricted Share Agreement&#8221;), pursuant to which the Company issued 160,000 Ordinary
Shares (the &#8220;Restricted Shares&#8221;) to DWF, with such Restricted Shares vesting linearly over a three (3) year period from the
date of issuance. Pursuant to the Settlement Agreement, the Company agreed to: (i) purchase the Repurchase Securities from DWF for an
aggregate amount of USD1 $15,000,000 (or whatever amount remains in the digital wallet used to fund the initial deposit pursuant to the
Treasury Management Agreement); (ii) remove the vesting restrictions applicable to the Restricted Shares; and (iii) pay DWF USD $35,000.
As part of the Settlement Agreement, the Company and DWF each agreed to a mutual full release of claims. Further, the Treasury Management
Agreement and the Restricted Share Agreement were terminated and no longer enforceable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Vertical Data Server Purchase Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On January 5, 2026, the Company signed an agreement
with Vertical Data Inc. to acquire 72 Dell XE9780-B300 Servers containing a total of 576 GPUs along with associated required networking
equipment, at a total cost of $<span id="xdx_907_ecustom--NetworkingEquipmentCost_iI_pn3n3_dm_c20260105_zCgH8B05Y3d5" title="Networking equipment cost"><ix:nonFraction name="ptgef:NetworkingEquipmentCost" contextRef="AsOf2026-01-05" id="Fact002312" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">40.9</ix:nonFraction></span>
million. On the same day a deposit of $<span id="xdx_90B_ecustom--Deposit_iI_pn3n3_dm_c20260105_zC8372JhHxyd" title="Deposit"><ix:nonFraction name="ptgef:Deposit" contextRef="AsOf2026-01-05" id="Fact002314" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.0</ix:nonFraction></span>
million was made, with additional deposits made in January and February 2026 of $6.0 million for a total of $8.6 million in deposits made
in order to hold the allocation of servers. The remaining cost of the acquisition will be funded via a GPU equipment financing lender.
The anticipated asset-backed loan will be non-recourse to the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002316" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p id="xdx_80E_eifrs-full--DisclosureOfRelatedPartyExplanatory_zMNWtSsQYAeg" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. <span id="xdx_82D_zH4lT6D4Duwf">RELATED
PARTY TRANSACTIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Private Placement Financing</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 29, 2025, the Company completed the sale of<span id="xdx_90C_ecustom--SaleOfStock_iI_c20250129_zniq1FZ66aA3" title="sale of stock">
<ix:nonFraction name="ptgef:SaleOfStock" contextRef="AsOf2025-01-29" id="Fact002318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">524,390</ix:nonFraction></span>
ordinary shares for aggregate proceeds of $<span id="xdx_901_ecustom--AggregateProceeds_iI_c20250129_z4e7wqaeITZe" title="aggregate proceeds"><ix:nonFraction name="ptgef:AggregateProceeds" contextRef="AsOf2025-01-29" id="Fact002320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,000</ix:nonFraction></span>,
at a per share price of $4.10, the closing price of a share on Nasdaq on the date preceding the date of the securities purchase agreement.
The shares were sold to two former directors of the Company, Messrs. Gregory Bailey and James Mellon. The shares were sold in a private
placement transaction pursuant to Regulation S, and were issued as restricted stock. The proceeds are being used for general corporate
purposes and working capital.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>SalvaRx Acquisition</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Two of the Company&#8217;s former directors, Messrs.
Gregory Bailey and James Mellon, are also directors of SalvaRx Group plc, a company which owned approximately 2.2% of the Company&#8217;s
issued and outstanding ordinary shares as of March 31, 2025. As of March 31, 2026, SalvaRx Group plc owns no issued and outstanding shares
of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_232_z4aTb69DxlQ7" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 95; Value: 6 -->
    <div id="xdx_23A_zZ49q6cGgHBj" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zMlp4eBn8OYf" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23B_zhYjOdxVca1k" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_238_z8CCBKsxIrGh" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_zJCzSRzxNXo5" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Investments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company has entered into related party transactions
and certain services agreements with certain of its shareholders. Key management personnel of the Company have also entered into related
party transactions with certain of its shareholders. Key management personnel are those people who have the authority and responsibility
for planning, directing and controlling the activities of the Company, including directors and senior management of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following subsidiaries and associates are considered related
parties:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b>iOx</b>. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Alpha Compute director resigned from the iOx board 	leaving
two Alpha Compute insiders as directors. The management team of Alpha Compute comprises the management team of iOx.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b>Saugatuck</b>. Saugatuck is 70% owned by the Company and is controlled by Alpha Compute.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0.5in; font-size: 10pt; text-indent: 0in">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b>Portage Development Services Inc</b>. PDS provides human resources and other services to each operating subsidiary of Alpha Compute
		through shared services agreements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Transactions between the parent company and its subsidiaries,
which are related parties, have been eliminated in consolidation and are not disclosed in this note.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Board Resignations and Appointments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On April 25, 2024, Mark Simon resigned all of his positions
on the Board of Directors, and on April 26, 2024, Linda Kozick and Dr. Robert Glassman resigned all of their positions on the Board of
Directors. On April 30, 2024, Dr. Jean -Christophe Renondin and Dr. Justin Stebbing were elected to the Board. On August 3, 2025, Justin
Stebbing, and Jean-Christophe Renondin resigned from the Board of Directors and Brittany Kaiser was appointed to the Board. On September
25, 2025, Gregory Bailey and James Mellon resigned from the Board of Directors and Michael Terpin and Enzo Villani were appointed to the
Board. On December 19, 2025, Alexander Pickett resigned from the board of directors of the Company. On February 6, 2026 Steven Mintz resigned
from the board of directors and was replaced with F. Dan Siciliano.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Advisory Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 20, 2025, the Company entered into an independent
contractor agreement with Ralph Matthew McKibbin (the &#8220;McKibbin Agreement&#8221;), pursuant to which Mr. McKibbin will provide development
advisory services to the Company. Mr. McKibbin is entitled to an equity grant in options at a strike price equal to the fair market value
on the date of the grant of 0.25% of the issued and outstanding ordinary shares of the Company after giving effect to the number of issued
and outstanding ordinary shares of the Company as of immediately after the Closing. 50% of the options will vest immediately and the remaining
50% shall vest in equal installments over a 12-month period. Due to the relationship between Ms. Kaiser and Mr. McKibbin, the McKibbin
Agreement is a related party transaction for Ms. Kaiser.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Relationship with DecentraNet</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">DecentraNet is an early-stage venture investment fund and advisory firm.
They invest at the earliest stages (F&amp;F, Pre-Seed, and Seed), and have advisory clients ranging from startups to multi-billion dollar
public companies. In Fiscal 2026 the Company paid DecentraNet a total of $<span id="xdx_903_ecustom--Decentranet_iI_pip0_c20260331_zgVeevC4nwF8" title="DecentraNet"><ix:nonFraction name="ptgef:Decentranet" contextRef="AsOf2026-03-31" id="Fact002326" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USD">55,000</ix:nonFraction></span>
for advisory and fundraising services. Mr. McKibbin is the founder of DecentraNet and a related party to the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Retention Agreements and General Releases</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On July 22, 2024, the Company and Portage Development
Services, Inc. entered into a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) with each of Allan Shaw, the
Company&#8217;s former Chief Financial Officer (&#8220;Employee&#8221;) and Joseph Ciavarella, the Company&#8217;s former controller (&#8220;Consultant&#8221;).
Under the terms of each of the Retention Agreements, Employee&#8217;s current employment agreement and Consultant&#8217;s current consulting
agreement both terminated on July 22, 2024, except with respect to certain provisions. In return for continuing to provide services to
the Company and its affiliates and completing certain tasks as described in the respective Retention Agreements, the Company paid an aggregate
$0.2 million (the &#8220;Retention Amount&#8221;) to Employee and Consultant, in addition to their monthly pay through September 30, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company accrued the Retention Amount, as well as
the monthly pay totaling $0.2 million through September 30, 2024, in the consolidated financial statements for the three months ended
June 30, 2024, as the material terms of the Retention Agreements were known and agreed upon at June 30, 2024. In accordance with the terms
of the Retention Agreements, the Company paid in full the Retention Amount and issued 14,348 ordinary shares to the Employee and Consultant
in lieu of cash bonuses accrued in Fiscal 2023 totaling $0.1 million by September 30, 2024, the date on which the Employee&#8217;s employment
and the Consultant&#8217;s consulting relationship with the Company and its affiliates ended.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<ix:exclude><p id="xdx_23A_zsYbvnCFLaIk" style="margin: 0pt 0; font-size: 10pt; text-align: justify"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 96; Value: 6 -->
    <div id="xdx_23E_z1rrirSfD9q4" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zkqydRPvPr2g" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_234_zvFYeCgtiote" style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23D_zUNOwr3cHXGa" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_234_zJKFkLf3SHec" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Relationship with Compedica</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As discussed in Note 10, the Company acquired an equity
interest in Compedica, a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby Compedica obtained a corresponding 27.4% interest in the Company, which
was subsequently diluted in connection with the private financing in September 2025. As of September 30, 2025, Compedica owned 11.9% of
the Company&#8217;s ordinary shares issued and outstanding. At the time of the Compedica investment, Jim Mellon was a director of both
Compedica and the Company and a greater than 5% owner of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed
to exchange their ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being
returned to the Company&#8217;s treasury and the investment being exited. As of March 31, 2026, the Company no longer has any affiliation
with Compedica, its employees, or directors, excepting the 625,000 Company shares to be returned, which was completed on May 21, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Asset Management Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At the closing of the Company&#8217;s financing on
September 25, 2025, the Company entered into an Asset Management Agreement (the &#8220;Asset Management Agreement&#8221;) with Alpha Sigma
Capital, LLC (the &#8220;Asset Manager&#8221;). Pursuant to the Asset Management Agreement, the Asset Manager shall provide discretionary
investment management services with respect to, among other assets (including without limitation certain subsequently raised funds), certain
of the Company&#8217;s net proceeds from the Offering (the &#8220;Account Assets&#8221;) in accordance with the terms of the Asset Management
Agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Under the Asset Management Agreement, the Company shall
pay the Asset Manager an asset-based fee equal to 1.0% per annum of the Account Assets. The Account Assets managed under the agreement
are held in the name of the Company and remain under Company control. The agreement term is one year, after which it renews automatically
and can be terminated by the Company with 90 days&#8217; notice, provided that the Company has decided to end the TON digital asset treasury
strategy.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Asset Manager is mandated to invest the Account
Assets principally with a long-only strategy primarily in TON, including staking (and restaking) TON to improve returns. The Asset Manager
is not permitted to invest in any OTC derivatives, futures contracts, or option contracts that would require the Asset Manager to register
as a commodity pool operator or commodity trading advisor.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Mr. Enzo Villani, Chief Investment Officer of the Company,
is the Chief Executive Officer and Chief Investment Officer of the Asset Manager. Alpha Sigma Capital was also an investor in the Company&#8217;s
September 2025 financing.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Alpha Transform Holdings</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Alpha Transform Holdings ("ATH") is a related
party of the Company because it is majority-owned by Enzo Villani, CIO and Chairman, and Michael Terpin, board member. On July 15, 2025,
ATH entered into a consulting service agreement with Ground Tunnel Capital LLC, a third-party advisory and marketing consultant. This
consulting service agreement was assigned to the Company on October 25, 2025, after Company board approval on October 20, 2025. The effective
date of the agreement occurred upon the closing of the subsequent private placement of ordinary shares, which occurred on September 25,
2025, with contractual services to be provided through July 15, 2028. $1.0 million was paid upon execution of the contract, with subsequent
milestone payments of $0.25 million due on each October 15, 2025, January 15, 2026, April 15, 2026 and July 15, 2026. On April 15, 2026,
the Company submitted its third milestone payment in the amount of $0.25 million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Blockchain Wire / Content Syndicate</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Content Syndicate (dba Blockchain Wire) is a press release distribution
service focused on news from blockchain and crypto companies and projects. Their global reach includes distribution to broadcast and online
media outlets, social media sites, trade publications, leading blogs, industry executives, influencers and investors. They offer multiple
distribution options, ease-of-use, broad partnership integrations and a dedicated client services team. In Fiscal 2026 we paid Content
Syndicate a total of $0.2 million for distribution and placement of press releases and media buys. Content Syndicate is a related party
by virtue of being owned by Enzo Villani and Michael Terpin.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Compensation Arrangements</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table summarizes all compensation paid or payable by the Company
to its directors and senior management for the fiscal years ended March 31, 2026, 2025, and 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002332" name="ptgef:ScheduleOfCompensationPayableTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfCompensationPayableTableTextBlock_pn3n3_zHXd7Jnzfrck" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BA_zixr8vFgcR02" style="display: none">Schedule of compensation payable</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_494_20250401__20260331_zsRoltRPBld9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49F_20240401__20250331_zsUMlGFMdxLi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_492_20230401__20240331_z3f7odmy8b53" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Years ended March 31,</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_405_eifrs-full--ShorttermEmployeeBenefitsExpense_z3Z4JOrwThD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; font-size: 10pt; text-align: left">Short-term employee benefits (salary, bonus, etc.)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="From2025-04-01to2026-03-31" id="Fact002334" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,052</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="From2024-04-012025-03-31" id="Fact002335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,787</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="From2023-04-012024-03-31" id="Fact002336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,127</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--PostemploymentBenefitExpenseInProfitOrLoss_zgWTLhldnN2k" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Post-employment benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--OtherLongtermBenefits_z3xdmb0zVY02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other long-term benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TerminationBenefitsExpense_zafHHyIajBx2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Termination benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="From2025-04-01to2026-03-31" id="Fact002346" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="From2023-04-012024-03-31" id="Fact002348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SharebasedPaymentCompensation_zOi8VtKNS8R6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Share-based payment compensation</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharebasedPaymentCompensation" contextRef="From2025-04-01to2026-03-31" id="Fact002350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,600</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharebasedPaymentCompensation" contextRef="From2024-04-012025-03-31" id="Fact002351" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">590</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--KeyManagementPersonnelCompensationPostemploymentBenefits_zCLlzQjclxc6" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt">&#160;Total</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="From2025-04-01to2026-03-31" id="Fact002354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,804</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="From2024-04-012025-03-31" id="Fact002355" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,968</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="From2023-04-012024-03-31" id="Fact002356" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,176</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A6_ztqJSmixiNEk" style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 97; Value: 6 -->
    <div id="xdx_234_zalQndLDYfBf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_z8kbk8IrnvQ9" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_230_zuDUnU4X4G14" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_237_zHtgiwtega04" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_232_zymRlzMPuS5" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Compensation Arrangements</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following tables and accompanying notes set forth all compensation paid
or payable by the Company to its directors and senior management for the fiscal years ended March 31, 2026, 2025, and 2024. The share
information is adjusted to give effect to the 1-for-20 reverse share split completed on August 15, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Director Compensation</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>




<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002361" name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_88A_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_pn3n3_zsSJyhx1c6Hc" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B3_zt4kH5O16nzc" style="display: none">Schedule of Compensation</span><b></b></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name &amp; Principal Position</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Year</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Fee and</p>
        <p style="margin-top: 0; margin-bottom: 0">Salary<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Transaction</p>
        <p style="margin-top: 0; margin-bottom: 0">Closing Bonus<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Securities Under</p>
        <p style="margin-top: 0; margin-bottom: 0">Options Granted</p></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Shares
        or Units<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(16)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Other<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total
        Compensation</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Michael Terpin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNonqqAnuxL6" title="Fee and salary" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember" id="Fact002363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,250</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoGAzHJAW9ha" title="Bonus compensation" style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2365">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBJ5jtH5VJxi" title="Transaction closing bonus" style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2367">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXUS9z2RFnKe" title=" Securities Under options Granted" style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zo5x151YrI08" title="Shares or units" style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2371">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zeGeIqzBlHHa" title="Other compensation" style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2373">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKAQnKIBVFl" title="Total compensation" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember" id="Fact002375" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,250</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">F. Daniel Siciliano</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAxjPVuOqAd1" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember" id="Fact002377" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0Ds2tWNJgJf" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2379">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zViTOGYOjUTb" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3EDhTZQUYtk" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2383">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKfKYHRU4df" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2385">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQAzgB6RPKmk" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2387">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxHSyyvchTo5" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember" id="Fact002389" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Gregory H. Bailey, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zKA2GK6DRIsb" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="Fact002391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zclrmtQoP3W8" title="Bonus compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="Fact002393" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3E62n2WJsch" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2395">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3Laoj6J7x6l" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2397">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zaQPMUPA12H9" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2399">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDEwTQWqSVWl" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2401">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zYYV6QOSnEii" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="Fact002403" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zQW0F083ILE8" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="Fact002405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzLkgMAohvck" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2407">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9zPiAillZth" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2409">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcxjFC5oiD82" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2411">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdpe9o9DRVRe" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2413">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zJVTE3UPEleg" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2415">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0EPcEey05sf" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="Fact002417" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zafYIIQiMnc6" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="Fact002419" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjHLde5nX3Ka" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2421">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV8qA7QLXBM" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2423">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zq29hiLqruh1" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2425">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zidJETtEIj0l" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2427">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zOKkHDjgv5kg" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2429">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr7iC3iWVabk" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember" id="Fact002431" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">James Mellon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zkYEtExNX3L8" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="Fact002433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTjiH2TcAZI7" title="Bonus compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="Fact002435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_znhHbc0cne87" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2437">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zawteqprpt8c" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2439">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHczKE0v7c61" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2441">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCpjNRF2mW7" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2443">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5rHhXnKidG6" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="Fact002445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zWig206U3G18" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="Fact002447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfu21gboJ1tk" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2449">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdxYO2zK8eqa" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUcKJJa0bhBf" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2453">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjf6JrncjUyb" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2455">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqKSY5CqTFQe" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2457">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTy5cU7HFV8f" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="Fact002459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zw2QCK6ec9pi" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="Fact002461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,242</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhtuMXozwUg2" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2463">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBDeiB7FkJYf" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2465">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zM1t9ctOZH3i" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2467">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyAu82T1XFni" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2469">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoebWFZWmLZj" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQlZs1WrdtE1" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember" id="Fact002473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,242</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Steven Mintz<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zK96CTLr4KUh" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002475" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZ3OGprqhqdc" title="Bonus compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPEXV0JcrOGk" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2479">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfvaAeHDuLK3" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,796</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztrvWOcSlcsb" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z4VfQDhLBvr4" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2485">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhjUsjqSYTi4" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157,296</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zESRkB16EQy" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbyRiuRbTuIe" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2491">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2Vmxgqk48k8" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2493">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMg9yIgKCJBg" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113,158</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zG3vzCuGNoxi" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z59r180DH0gd" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2499">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zmGKMJGieq5h" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002501" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143,158</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zVw44CDH5dJ7" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002503" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,750</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwiyV4Epblrb" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2505">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zObscOD9MX7h" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2507">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQYts612ziEc" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2509">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKS6PeaJLfE6" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2511">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlQzVcEdoni3" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2513">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zGWAWnEfDsil" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember" id="Fact002515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,750</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Jean-Christophe Renondin, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zlfHg9RK3Rq4" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="Fact002517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCwBzTB6Tehc" title="Bonus compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="Fact002519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjoDgQ1BiKXi" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2521">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqK9q24YXjn5" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="Fact002523" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,796</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyUIr0qWbKhk" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2525">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zv9U42HQIach" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2527">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zT9pNoVuuFN2" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="Fact002529" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109,796</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zPxvg4vmLqY2" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="Fact002531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNNyYB3ivBO1" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2533">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEsWlDotiEAd" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2535">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMJYowivhzb1" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="Fact002537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96,992</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zin1LxHAWUNj" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2539">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zVtfsIEfAri6" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2541">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ziu28NvBoHPk" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember" id="Fact002543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">126,992</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_z75HluNHcuTe" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2545">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIHqOh38LsRb" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2547">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHmEUgDNtzBe" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2549">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCKmV9NTn7w5" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2551">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdFx3W0dfNC3" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2553">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zANYBart5atk" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2555">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9sT2Ix8V7l8" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2557">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Justin Stebbing, M.D. PhD<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_z2XVSuy8aLk9" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="Fact002559" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEqzzTFqvfXb" title="Bonus compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="Fact002561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFDJzVGeF81e" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2563">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIEBADLsTBd9" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="Fact002565" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,760</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlqOVuJSjh34" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2567">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvtSbnsTGWWl" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2569">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zedrsawnoOL4" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="Fact002571" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119,760</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zf6HK6RHLWDh" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="Fact002573" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zA28749keNBk" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2575">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2RqB6D16r43" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2577">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyddtzDsyDzi" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="Fact002579" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,240</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDN79Ubqn1" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2581">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zm2UjAPrRcrf" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2583">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNXemAyLNf1" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember" id="Fact002585" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,240</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zykeYTyHgPE9" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2587">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsWWmglVHGT4" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2589">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgB2nUeblEPa" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2591">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcQYHpDiclT3" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2593">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqF6sXtREO3h" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2595">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztFzI9yvPxfj" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2597">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQzOCViYiew7" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2599">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Linda Kozick<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zovruTySfId" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2601">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zkjeS6ybUqid" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2603">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWnki9hi25J8" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2605">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBOPWIdToL4e" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2607">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxQqGNhqk2ul" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2609">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFUoJqbH15Ze" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2611">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgQvMyONcsPe" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2613">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zYn1MzZ5W86d" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2615">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCWtdzLwNGR2" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2617">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zERocssYs7ia" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2619">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAHFQeeI0HD3" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2621">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNVDfucmuhr6" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2623">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV0Wd7pQjWy6" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2625">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z7sbm2QsPH98" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2627">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zvdbgjx5V7W7" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="Fact002629" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcGa3Q6kgqsb" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2631">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPHe0cUYrxBg" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2633">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z1TiHjTnJaii" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2635">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZa3YuppNtv7" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2637">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsZPQcnLKMsb" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2639">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr9JH4Y9zCf5" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember" id="Fact002641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Mark Simon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z3o4vt2SH14h" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2643">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zy2icmNOfQ6c" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2645">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSWn5iEL3Pd6" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2647">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zpWBlry94uwk" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2649">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAEfHnsSJ9T3" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2651">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEKwVCuNjS2a" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2653">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV6hacfGlro6" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2655">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zPzxiVbd5jvj" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2657">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWu738896MJd" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2659">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUSHpXd20fGl" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2661">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3g5SeQqJbF8" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2663">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAV11Afrww21" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2665">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_za0HrOXyFQX3" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2667">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWRzANTguJke" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2669">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z9ajTWyVlY6d" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="Fact002671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2bSz4QeWlel" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2673">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z8cJcD5mYKm3" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2675">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zblyaUGazip8" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2677">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj5sjbH4qSDc" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2679">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMX6fWtOk2kd" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2681">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSME3co5fKs4" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember" id="Fact002683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Robert Glassman<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zQySdV047Tic" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2685">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTJWhurMpP02" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2687">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSfs9jdBhhri" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2689">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXFY3pmarW25" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2691">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZXTLYmgUsmc" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2693">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zrxZi6X6OiBl" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2695">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5wbwwQk5Bk6" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2697">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zs32GrJba2ra" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2699">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj6i0XkDl3w2" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2701">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z6C27MJSgYn7" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2703">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zF3eb7ynJui7" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2705">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKd32So0gR5f" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2707">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhCzgbRnYmIb" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2709">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbGNoa8KJwNa" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2711">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zgb4SR5eT5K2" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="Fact002713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,258</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zw9Fd80Mp8H3" title="Bonus compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2715">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zg9P2hh7j3l4" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2717">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlsZDtlIXCj6" title=" Securities Under options Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2719">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvzYssiMoRwg" title="Shares or units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2721">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zU85u4TYgDY5" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2723">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwbCohDoSo3f" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember" id="Fact002725" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,258</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 98; Value: 6 -->
    <div id="xdx_23A_zV7MQUaemH07" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zi5Gurv9eM43" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p id="xdx_23B_zxF5vZuWAHPh" style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_238_ztnem469nyEh" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zIm8W4uGLece" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_238_zMbQdJ2kh3Ue" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23A_zlTIKPkRTnxa" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b>Executive Officer Compensation</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="display: none">Schedule of Executive officer compansation</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name &amp; Principal Position</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Year</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Fee and</p>
        <p style="margin-top: 0; margin-bottom: 0">Salary<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Transaction</p>
        <p style="margin-top: 0; margin-bottom: 0">Closing Bonus<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Securities Under</p>
        <p style="margin-top: 0; margin-bottom: 0">Options Granted</p></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Shares
        or Units<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(16)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Other<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total
        Compensation</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Executive Officers</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Brittany Kaiser</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Chief Executive Officer and Director</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zsRSL83B4n5d" title="Fee and salary" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_MarkSimonMember" id="Fact002731" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">661,290</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zEPCzIssRzuh" title="Bonus" style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2733">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_z9WoVYJ9tcVc" title="Transaction closing bonus" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember" id="Fact002735" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zBtwdwmLfEhh" title="Securities under option granted" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember" id="Fact002737" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,219</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_z1m4vflnG5Eb" title="Shares ot units" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember" id="Fact002739" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">149,015</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zr1kX8GaJow9" title="Other compensation" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember" id="Fact002741" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187,102</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zypWIDBYVWrf" title="Total compensation" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember" id="Fact002743" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,715,627</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Enzo Villani</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Investment Officer and Director</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zuBZJQ4UkBle" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember" id="Fact002745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369,355</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zfgD9Ar5QVqf" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2747">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zg4LeBuAFIIe" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember" id="Fact002749" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zWanGbKiWGDj" title="Securities under option granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember" id="Fact002751" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,219</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zO5BLxUIsWd1" title="Shares ot units" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember" id="Fact002753" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">248,359</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zqTFCmUoSNrk" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2755">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zUJuSOMnWKud" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember" id="Fact002757" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,335,933</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Wes Levitt</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zDMGf2sJVGbk" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember" id="Fact002759" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,086</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zxNhK6nhvpDf" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2761">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_z3R8ngyshAf1" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2763">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zKV5oLx0hZUk" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2765">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zaFdFsTKgH79" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember" id="Fact002767" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,086</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Yury Mitin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Business Development Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zlKYXakmAHL6" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember" id="Fact002769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369,355</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zGd8isiJ1sg7" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2771">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z7yuUMs6AoV9" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:TransactionClosingBonus" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember" id="Fact002773" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z2wfnxTx7kg7" title="Securities under option granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember" id="Fact002775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,219</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z9zucdGqvRy5" title="Shares ot units" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember" id="Fact002777" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">99,344</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zMuFYiLuL7s6" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2779">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zlzrsBO89wOh" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember" id="Fact002781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,186,918</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Alexander Pickett<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(10)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Executive Officer and Director</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zoMNnwHrkis7" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,250</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zlzP7JEn326k" title="Bonus" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002785" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zmQX7tKOXXuc" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2787">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zIyXQtfMZB8b" title="Securities under option granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002789" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234,132</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zmfQD2Fqp8o" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2791">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zxxULj9kjEyb" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zphngo34IxSi" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002795" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">310,422</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z7JQI9mIRBO4" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002797" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zri8f7P16vp3" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2799">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z2cIt3P0KVP5" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2801">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z7vwdqupXKGk" title="Securities under option granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002803" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,488</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zZ6gqYXgH0y1" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2805">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z9hQDr1rk7Pb" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2807">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zy7HRIehI78a" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember" id="Fact002809" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">175,488</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Ian Walters<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(11)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Executive Officer and Chairman of the Board</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z2ntn3Utyoac" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2811">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zWpHmoUEhn4g" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2813">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zILmvAYvfjGd" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2815">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zCuFeibAUeOe" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2817">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zr7KsUmwyex" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2819">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zWnm3M0wFTwj" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002821" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152,383</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zVQy7Vsh067c" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002823" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152,383</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zZP4cl1iLIV8" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">453,186</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zumuaXLbdQc" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2827">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z6ls8nrnoZae" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2829">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zQHEZPMXgYf9" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2831">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z7D5qD7vSuo5" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2833">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zUWMSVTb3bC7" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,716</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zKRTAAcMFwcb" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">507,902</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zTzgKDKRCom4" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002839" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">642,700</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zaKJJnXEzbIe" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2841">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zts7mxcbz45f" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2843">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z2xJ4xMUomX4" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2845">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zuAxUZwjGMkl" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2847">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zvkRwFiVuEnj" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75,185</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zfLBZfrTGhFa" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember" id="Fact002851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">717,885</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Andrea Park<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(12)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zkFIM5fA7jme" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002853" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,429</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z9mNpC5oEbig" title="Bonus" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionIncome" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zlePMuqfP4ba" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2857">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zifOP4lRS4t6" title="Securities under option granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002859" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,857</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z7sO66XItMi5" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2861">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zA3W7uVaXwed" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2863">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zSaS1byRA9Ek" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002865" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">308,286</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z1jy5LrjM131" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">163,790</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zMpHN4gcxztc" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2869">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z6rgIlKruOy" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2871">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zKc5sRNqdGc3" title="Securities under option granted" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SecuritiesUnderOptionsGranted" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002873" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113,158</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zBGMsDFPQ8d6" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2875">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zoGOCLueFBL3" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002877" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,659</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zoF3oXg6sq64" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember" id="Fact002879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">305,607</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Allan Shaw<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(13)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zgHuSnsumjKf" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2881">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zwy0CgrPuZli" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2883">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zCS6zaIV38eb" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2885">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zEX4abnPhO16" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2887">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zhhURZ8lkuF1" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2889">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z3kfJRvUNAt9" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2891">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zP1b00oWqVv7" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2893">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer and Secretary</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z6X35sXeNlJd" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="Fact002895" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zrRLLPKPECX9" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2897">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z1CPirGeDu62" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2899">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z54qeNf02j9i" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2901">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z5VFfQMkHou8" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2903">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zK8VHsn7BFx2" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2905">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zFwhvvEOIZkg" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="Fact002907" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z128A2Qx5r2g" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="Fact002909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">469,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zRVtZdvGG0b" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2911">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zO5VyWod8IRi" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2913">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zZvYXgeGleDf" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2915">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zcKBy7zxDL68" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2917">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zkgEV3Rsqmmi" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="Fact002919" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,205</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zhAAJ03Vki78" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember" id="Fact002921" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">518,205</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Robert Kramer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Scientific Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zeKbjXkh9SAg" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2923">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zlMWWmBuKCbg" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2925">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zdKEptj4Ttvf" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2927">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zxVDrHOOSkJj" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2929">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zCM0ZLJrDV58" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2931">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zyWlCsnUIaFc" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2933">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zaI15fUmyoJ2" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2935">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zBrpjzORSNtg" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="Fact002937" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,500</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zvONFNFROw6" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2939">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_z8V1YvePObZ2" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2941">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zLJURtCSGyDk" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2943">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zqWbFcPd9nX3" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2945">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zGSCMGrHVHT2" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="Fact002947" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,750</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zGFjVTSYQkyc" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="Fact002949" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119,250</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_z2QfVJVQM7ai" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="Fact002951" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168,750</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zIHfSoC5oSB7" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2953">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zkda0TIEZEGi" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2955">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zpdX0MBauMFh" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2957">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_ztBrxvJWBszk" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2959">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zMOI2sHHiYQ3" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="Fact002961" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,141</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zlKvAEI42wSc" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember" id="Fact002963" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">185,891</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Brian Wiley<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(14)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Business Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z6HodCwr8EHb" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2965">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zCjtu4hrtYg2" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2967">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zCl12DUxoWVh" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2969">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zintvgYZfpY2" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2971">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zzbVPpIjLuyf" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2973">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zzbWtG8jsEv1" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2975">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z3NPcwpBXBig" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2977">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zP7mrsMruzlk" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="Fact002979" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">114,844</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zJD4rK71PVy9" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2981">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zxgXDDrTAOz7" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2983">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zOLKndqNBW3c" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2985">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zYw5JAKDM8T2" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2987">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zF1ljkUkl9K" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="Fact002989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,627</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zlvNGoBPCXNe" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="Fact002991" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123,471</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zjhBwpmoheL5" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="Fact002993" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">153,125</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zNmlvkqiUwSj" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2995">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zKv4L5Ya4Anb" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2997">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zZNZFXTdGWbl" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2999">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zArx74zd0d5g" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3001">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zEaYMv5dbTJe" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="Fact003003" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,297</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z2IpzrN0hMfg" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember" id="Fact003005" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155,422</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Justin Fairchild<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(15)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Vice President of Development</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJcX9OX6qix8" title="Fee and salary" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3007">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zxANUsRQQ4Y4" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3009">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zOPIyjs78oJ7" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3011">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zvYY00g2HBsa" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3013">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_z8GgjQWtVzt3" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3015">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zUaiROfbpGCi" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3017">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJ7dIehYUuRl" title="Total compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3019">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zg1aCPOJvQC6" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="Fact003021" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zTB1JqzFenLk" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3023">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_ztFNYUEEbQLb" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3025">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zDvqGPJR89El" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3027">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zbmVM01TE0Ck" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3029">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zcUWUNrEXErh" title="Other compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3031">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_ziG576A421Sf" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="Fact003033" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zOZ59H7Pa2V3" title="Fee and salary" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="Fact003035" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">270,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJ1fGE5mCRKa" title="Bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3037">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zSCh88irr74l" title="Transaction closing bonus" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3039">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zXvRYRzgl2dk" title="Securities under option granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3041">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zvzDFfhxtqB" title="Shares ot units" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3043">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zsor9CvvkZQ2" title="Other compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherCompensation" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="Fact003045" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,301</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zlXniLHAyag4" title="Total compensation" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember" id="Fact003047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325,301</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>




<ix:exclude><p id="xdx_23C_zWUjFGt6tGo4" style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"></span></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zwi4xA3dqBXa" style="margin: 0pt 0; font-size: 10pt; text-indent: 389.5pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 99; Value: 6 -->
    <div id="xdx_236_zq2CdZwQEtG5" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zLbyuu2Emh0f" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_238_zAo5jqDtN4pc" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zDafj2NIrOYg" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_238_zOtggOSt9gxh" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_238_z9POkuMx3zk8" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b>Notes</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(1)</td>
    <td>Represents base salary earned by executive officers in accordance with their respective contractor agreements and director&#8217;s fees
        earned by directors. For Brittany Kaiser, Enzo Villani, Yury Mitin, and Wes Levitt, their base salary is comprised of equal portions payable
        in USD and TON tokens. The figures in the table represent the sum of both. To date, these executives&#8217; USD portions of their salaries
        have been paid monthly, while the TON portions have been accrued by the Company.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(2)</td>
    <td>Dr. Bailey, Mr. Mellon, Mr. Mintz and Ms. Kozick waived their directors&#8217; fees with respect to the three months ended March 31, 2024.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(3)</td>
    <td>The contractor agreements for executives Brittany Kaiser, Enzo Villani, and Yury Mitin each provided for bonuses consisting of $250,000
        in cash and $250,000 worth of TON tokens, payable upon the Company raising at least $50 million in equity financing through private or
        public share offerings. This milestone was achieved on January 14, 2026, upon the closing of a $15 million registered direct share offering,
        which, together with prior equity financings, resulted in aggregate equity financing proceeds in excess of $50 million. During Fiscal
        2026, the Company paid the cash portion of the bonus to each executive and accrued the TON token portion of each executive&#8217;s bonus.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(4)</td>
    <td>Represents employee benefits paid by the Company.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(5)</td>
    <td>Represents the aggregate grant date fair value of 14,600 options to purchase ordinary shares granted on March 30, 2023, which vested on
        the first anniversary of the date of grant.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(6)</td>
    <td>Represents the aggregate grant date fair value of options to purchase ordinary shares granted on March 7, 2025, which one-quarter vested
        immediately, one-quarter vested on March 7, 2026, and the remaining balance to vest in equal parts on March 7, 2027 and March 7, 2028.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(7)</td>
    <td>Mr. Mellon and Dr. Bailey served as directors of the Company through September 25, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(8)</td>
    <td>Dr. Renondin and Dr. Stebbin served as directors of the Company through August 3, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(9)</td>
    <td>Mr. Mintz served as a director of the Company through February 6, 2026.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(10)</td>
    <td>Ms. Kozick and Dr. Glassman served as directors of the Company through April 25, 2024, and Mr. Simon served as a director of the Company
        through April 24, 2024.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(11)</td>
    <td>Mr. Pickett was appointed as our Chief Executive Officer under a consultancy agreement and joined our Board of Directors on December 15,
        2024. He resigned as Chief Executive Officer on August 2, 2025 and departed the Board of Directors on December 19, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(12)</td>
    <td>Dr. Walters served as our Chief Executive Officer and Chairman of our Board of Directors through December 14, 2024. In accordance with
        his employment agreement, all unvested share options at that time vested immediately.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(13)</td>
    <td>Ms. Park was appointed as our Chief Financial Officer on September 30, 2024 and left the Company in October 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(14)</td>
    <td>Mr. Shaw served as our Chief Financial Officer and Secretary through September 30, 2024. Other compensation in the amount of $127,250
        represent payments made to Mr. Shaw under a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) dated July 22,
        2024. Additional information concerning the Retention Agreement may be found in Note 14, Related Party Transactions to the consolidated
        financial statements included elsewhere in this Annual Report.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(15)</td>
    <td>Mr. Wiley served as our Chief Business Officer through November 15, 2024. In accordance with his employment agreement, all unvested share
        options at that time vested immediately.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(16)</td>
    <td>Mr. Fairchild resigned as our Vice President of Development in January 2024 but continued to provide his services as a consultant through
        May 31, 2024, his resignation date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(17)</td>
    <td>On March 11, 2026, the Board authorized the grant of 149,015 RSUs to Ms. Kaiser, 99,344 RSUs to Mr. Mitin, and 248,359RSUs to Mr. Villani,
        which were owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private
        or public share offerings. These RSUs were formally granted on April 29, 2026.</td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"></p>



<ix:exclude><!-- Field: Page; Sequence: 100; Value: 6 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zMITdrh2luI" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zbUYqEoBWqG" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_232_zNOZ1272F14c" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_239_zii1rnZHbj7d" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_237_zy9VoeDvHjG" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b>Outstanding Equity Awards at Fiscal Year-End</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table and related notes provide certain information regarding
all outstanding equity awards for our executive officers as of March 31, 2026, as adjusted to give effect to the 1-for-20 reverse share
split completed on August 15, 2024:</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003058" name="ptgef:ScheduleOfOutstandingEquityAwardsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfOutstandingEquityAwardsTableTextBlock_pn3n3_zUddgk7Gcfgb" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 3)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center"><span id="xdx_8BC_zds2qVV7hoNg" style="display: none">Schedule of outstanding equity awards</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td id="xdx_489_ecustom--GrantDate_zv5L3hacsjJi" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_eifrs-full--AdjustedWeightedAverageShares_zXG6jKTofL26" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_484_ecustom--NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_zdw0j2DqgZS7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_481_ecustom--ExercisePrices_zDsaBjP2lnfh" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_ecustom--OptionExpirationDate_zxMOuc8Am8T5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_485_ecustom--NumberofShareUnitsofStockThetHaveNotVested_zAWcL9PojHuk" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_481_ecustom--MarketValueNumberofShareUnitsofStockThetHaveNotVested_zVLiL1qWgK3l" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option
        Awards</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Stock
        Awards<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares or</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Market Value of Shares or</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Securities Underlying</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercised
        Options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Exercise</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Expiration</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Grant Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; font-style: normal">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Exercisable<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercisable</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Price</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td></tr>
  <tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zgOPBxjAs4Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; font-size: 10pt; font-style: normal">Alexander Pickett<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(2)</sup></span></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember" id="Fact003059" name="ptgef:GrantDate">3/7/2025</ix:nonNumeric></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember" id="Fact003060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">36,000</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3061">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember" id="Fact003062" name="ptgef:ExercisePrices">4.45</ix:nonNumeric></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember" id="Fact003063" name="ptgef:OptionExpirationDate">3/7/2035</ix:nonNumeric></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3065">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettTwoMember_zZvKOqSPCb94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember" id="Fact003066" name="ptgef:GrantDate">7/27/2025</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember" id="Fact003067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">45,937</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3068">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember" id="Fact003069" name="ptgef:ExercisePrices">5.73</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember" id="Fact003070" name="ptgef:OptionExpirationDate">7/27/2035</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3071">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3072">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersMember_z6dycgWI0aA1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Ian B. Walters<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember" id="Fact003073" name="ptgef:GrantDate">3/30/2023</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember" id="Fact003074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,085</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3075">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember" id="Fact003076" name="ptgef:ExercisePrices">58.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember" id="Fact003077" name="ptgef:OptionExpirationDate">12/14/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3078">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3079">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersTwoMember_zd9ZGUIjKT68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember" id="Fact003080" name="ptgef:GrantDate">1/19/2022</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember" id="Fact003081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,285</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3082">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember" id="Fact003083" name="ptgef:ExercisePrices">204.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember" id="Fact003084" name="ptgef:OptionExpirationDate">12/14/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3085">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3086">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersThreeMember_zJXquc5spit6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember" id="Fact003087" name="ptgef:GrantDate">1/13/2021</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember" id="Fact003088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7,550</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3089">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember" id="Fact003090" name="ptgef:ExercisePrices">355.00</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember" id="Fact003091" name="ptgef:OptionExpirationDate">12/14/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3092">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3093">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkMember_zBMSVdDCBMY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Andrea E. Park<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(4)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember" id="Fact003094" name="ptgef:GrantDate">3/7/2025</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember" id="Fact003095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">28,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3096">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember" id="Fact003097" name="ptgef:ExercisePrices">4.45</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember" id="Fact003098" name="ptgef:OptionExpirationDate">3/7/2035</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3099">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3100">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkTwoMember_zlaEd1lAoeMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember" id="Fact003101" name="ptgef:GrantDate">7/27/2025</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember" id="Fact003102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7,820</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3103">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember" id="Fact003104" name="ptgef:ExercisePrices">5.73</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember" id="Fact003105" name="ptgef:OptionExpirationDate">7/27/2035</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3106">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3107">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z8UjEeWV6QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Allan Shaw<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(5)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawMember" id="Fact003108" name="ptgef:GrantDate">3/30/2023</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_AllanShawMember" id="Fact003109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,761</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3110">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawMember" id="Fact003111" name="ptgef:ExercisePrices">58.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawMember" id="Fact003112" name="ptgef:OptionExpirationDate">9/30/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3113">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3114">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawTwoMember_zG4l5SHTmNF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember" id="Fact003115" name="ptgef:GrantDate">1/19/2022</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember" id="Fact003116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">840</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3117">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember" id="Fact003118" name="ptgef:ExercisePrices">204.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember" id="Fact003119" name="ptgef:OptionExpirationDate">9/30/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3120">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3121">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawThreeMember_z8RpUX7kiZui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember" id="Fact003122" name="ptgef:GrantDate">1/13/2021</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember" id="Fact003123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,550</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3124">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember" id="Fact003125" name="ptgef:ExercisePrices">355.00</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember" id="Fact003126" name="ptgef:OptionExpirationDate">9/30/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3127">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3128">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zNIBveNX6rz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Robert Kramer<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerMember" id="Fact003129" name="ptgef:GrantDate">3/30/2023</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_RobertKramerMember" id="Fact003130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,771</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3131">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerMember" id="Fact003132" name="ptgef:ExercisePrices">58.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerMember" id="Fact003133" name="ptgef:OptionExpirationDate">3/30/2033</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3134">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3135">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerTwoMember_zAm81wtqiGEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember" id="Fact003136" name="ptgef:GrantDate">1/19/2022</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember" id="Fact003137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,255</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3138">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember" id="Fact003139" name="ptgef:ExercisePrices">204.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember" id="Fact003140" name="ptgef:OptionExpirationDate">1/19/2032</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3141">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3142">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerThreeMember_zN2YlmYF5yYj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember" id="Fact003143" name="ptgef:GrantDate">1/13/2021</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember" id="Fact003144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,050</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3145">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember" id="Fact003146" name="ptgef:ExercisePrices">355.00</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember" id="Fact003147" name="ptgef:OptionExpirationDate">1/13/2031</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3148">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3149">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zDZU33gCl6p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Brian Wiley<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrianWileyMember" id="Fact003150" name="ptgef:GrantDate">3/30/2023</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_BrianWileyMember" id="Fact003151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,386</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3152">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrianWileyMember" id="Fact003153" name="ptgef:ExercisePrices">58.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrianWileyMember" id="Fact003154" name="ptgef:OptionExpirationDate">11/15/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3155">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3156">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyTwoMember_zLLro33yoEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember" id="Fact003157" name="ptgef:GrantDate">1/19/2022</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember" id="Fact003158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,000</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3159">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember" id="Fact003160" name="ptgef:ExercisePrices">204.40</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember" id="Fact003161" name="ptgef:OptionExpirationDate">11/15/2026</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3162">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3163">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zjRR9pOhLd0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Brittany Kaiser<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember" id="Fact003164" name="ptgef:GrantDate">3/11/2026</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember" id="Fact003165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">545,315</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3166">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember" id="Fact003167" name="ptgef:ExercisePrices">1.30</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember" id="Fact003168" name="ptgef:OptionExpirationDate">5/14/2036</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3169">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3170">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zgu2Ii9G1Ngk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Enzo Villani<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember" id="Fact003171" name="ptgef:GrantDate">3/11/2026</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember" id="Fact003172" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">545,315</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3173">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember" id="Fact003174" name="ptgef:ExercisePrices">1.30</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember" id="Fact003175" name="ptgef:OptionExpirationDate">5/14/2036</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3176">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3177">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zNOIQExz8De1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Yury Mitin<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_YuryMitinMember" id="Fact003178" name="ptgef:GrantDate">3/11/2026</ix:nonNumeric></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2025-04-012026-03-31_custom_YuryMitinMember" id="Fact003179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">545,315</ix:nonFraction></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3180">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_YuryMitinMember" id="Fact003181" name="ptgef:ExercisePrices">1.30</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_YuryMitinMember" id="Fact003182" name="ptgef:OptionExpirationDate">5/14/2036</ix:nonNumeric></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3183">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3184">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>




<ix:exclude><p id="xdx_236_zKZBk821KnR2" style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b></b></span></p></ix:exclude>


<ix:exclude><p id="xdx_23B_z2KT1Q4Ketk" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 101; Value: 6 -->
    <div id="xdx_232_zQ5r6rwHQG6i" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zCrzC15ryHJ1" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23C_zkmPH8a7Tqbb" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>



<ix:exclude><p id="xdx_234_zvhNIKx7Bgcl" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_239_zVYgZaA510Hd" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23C_zac9AbLWAtE8" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b>Notes</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(1)</td>
    <td>Except as set forth below, vesting of all options is subject to continued service as an employee, director and/or consultant of Alpha
        Compute or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the
        date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(2)</td>
    <td>On December 15, 2024, Mr. Pickett was appointed as a director of the Company and our Chief Executive Officer under a consultancy agreement
        and served in such capacities through December 19, 2025, his resignation date. These options were awarded to Mr. Pickett for his services
        as a director. One fourth of the options vested immediately on grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(3)</td>
    <td>Dr. Walters served as our Chief Executive Officer and a director of the Company through December 14, 2024. Pursuant to the terms of his
        employment agreement, all unvested share options immediately vested on such date. Pursuant to the terms of his share option agreements,
        the vested share options are exercisable for two years from this date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(4)</td>
    <td>On September 30, 2024, Ms. Park was appointed as our Chief Financial Officer and departed the Company in October 2025. One fourth of the
        options vested immediately on the grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(5)</td>
    <td>Mr. Shaw served as our Chief Financial Officer through September 30, 2024. Pursuant to the terms of his share option agreements, the vested
        share options are exercisable for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(6)</td>
    <td>The above table excludes 4,550 RSUs to Mr. Kramer granted on January 13, 2021, with a grant date value of $1,615,250, which vested on
        the grant date but are subject to certain restrictions and 860 RSUs granted on January 19, 2022 with a grant date value of $175,784, which
        vested on the grant date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(7)</td>
    <td>Mr. Wiley served as our Chief Business Officer through November 15, 2024. Pursuant to the terms of his employment agreement, all unvested
        shares immediately vested on such date. Pursuant to the terms of his share option agreement, the vested share options are exercisable
        for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in">(8)</td>
    <td>On March 11, 2026, the Board authorized the grant of 545,315 share options each to Ms. Kaiser, Mr. Mitin, and Mr. Villani, which were
        owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private or public
        share offerings. These share options were formally granted on May 14, 2026.</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_zE2OMNS89Pl9" style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003192" name="ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory"><p id="xdx_80F_ecustom--DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_z5MIA4iv3GT8" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
22. <span id="xdx_82B_z4CGRHbfWm3g">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s financial instruments recognized
in the Company&#8217;s consolidated statements of financial position consist of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Fair value estimates are made at a specific point in
time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties
and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could
significantly affect these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_231_zwEZX7FSYgq9" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 102; Value: 6 -->
    <div id="xdx_238_zaFCY9t1npdj" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zB1A5mI4HlP9" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_234_zLAwWz9pnQ8c" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23D_z8VOkNrG4rY7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 22. <span id="xdx_82B_z2gPu8kuxSLi">FINANCIAL INSTRUMENTS
AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></span></b></p></ix:exclude>



<ix:exclude><p id="xdx_23B_zm9sFCfpfIYj" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following table summarizes the Company&#8217;s financial instruments
as of March 31, 2026 and 2025 (in thousands):</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003198" name="ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_pn3n3_zopiDedCWlsj" summary="xdx: Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_495_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zP6ymNiXA3pj" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_499_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zrf25agWTCtl" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zqXWYoAPlBYb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_497_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zHT3SIfzSXld" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_496_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z67FiqFDONzi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zMq4F3VxRHq5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Amortized</p>
        <p style="margin-top: 0; margin-bottom: 0">Cost</p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Amortized</p>
        <p style="margin-top: 0; margin-bottom: 0">Cost</p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="Fact003207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">686</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3208">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3209">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="Fact003210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,670</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3211">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3212">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--Stablecoin_i01I_pn3n3_z4e3MwE56iRa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:Stablecoin" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="Fact003214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3215">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3216">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3217">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3218">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3219">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3_zhCqM31u9Eg9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other current assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="Fact003221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,984</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3222">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3223">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="Fact003224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">555</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3225">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3226">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 48%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; width: 1%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_498_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z4sBZhEDAyW7" style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_49E_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zwLMtx0mT413" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_49F_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zrTGko2d4Dwd" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_493_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zfFMkwFheHT" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>Amortized <br/>Cost</b></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>FVTPL</b></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><b>Amortized</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Cost</b></p></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>FVTPL</b></td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3_zxH3Lyhkpnfd" style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2026-03-31_custom_AmortizedCostMember" id="Fact003233" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,146</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3234">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2025-03-31_custom_AmortizedCostMember" id="Fact003235" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,100</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3236">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--TonPayableToSettlePutRightsExercised_i01I_pn3n3_zqvR3mXfUEmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3238">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="Fact003239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,425</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3240">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3241">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PutRightLiability_i01I_pn3n3_zQLRQYSyQa81" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3243">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="Fact003244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,105</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3245">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3246">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3248">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="Fact003249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3250">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember" id="Fact003251" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,952</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LeaseLiabilityCurrentAndNoncurrent_i01I_pn3n3_zjFhkn48tGci" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Lease liability - current and noncurrent</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3253">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityCurrentAndNoncurrent" contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember" id="Fact003254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3255">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3256">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A2_zfMYLKFaEllf" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">*FVTOCI refers to financial assets and liabilities with changes in fair
value recognized within other comprehensive income.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">**FVTPL refers to financial assets and liabilities with changes in fair
value recognized within the statement of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">A summary of the Company&#8217;s risk exposures as it relates to
financial instruments are reflected below.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 103; Value: 6 -->
    <div id="xdx_239_z3c0D9aqPWB8" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zUT1gi7s7VLb" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_230_zy8kKRzm851i" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>



<ix:exclude><p id="xdx_23E_zMln0NcPVX3a" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 22. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_23A_zBlS2UqrdHT3" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Fair value of Financial Instruments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s financial assets and liabilities are comprised of cash
and cash equivalents, receivables and investments in equities and private entities, current digital assets at fair value, stablecoins,
accounts payable and accrued liabilities, lease liability, and warrant liability.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company classifies the fair value of these transactions according to
the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"/>
    <td style="width: 16.35pt">&#183;</td>
    <td>Level 1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the
        reporting date.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"/>
    <td style="width: 16.35pt">&#183;</td>
    <td>Level 2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
        can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
        the reporting date.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"/>
    <td style="width: 16.35pt">&#183;</td>
    <td>Level 3 &#8211; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
        as Level 3 financial instrument.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Assessment of the significance of a particular input to the fair value measurement
requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-indent: 0.5in">Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following methods and assumptions were used to estimate their
fair values:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Investment in Compedica</b>: The fair value of the investment used by
management is based on multiples analysis of publicly traded comparable companies as the Company is pre-revenue, along with Compedica&#8217;s
holdings in the Company&#8217;s ordinary shares (Level 3 inputs) (see Note 10, &#8220;Investment in Compedica&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Put Option Liability</b>: The fair value is estimated using a Black-Scholes
model and in certain cases, a Monte Carlo simulation (Level 3) (see Note 12, &#8220;Put Right Liability and TON Payable&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>TON Payable</b>: The fair value corresponds to the valuation of the TON
owed to the respective investors based on the Level 3 inputs denoted above (see Note 12, &#8220;Put Right Liability and TON Payable&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Warrant Liability</b>: The Series B Warrants, the Series C Warrants and
the 2023 and 2026 Placement Agent Warrants include the obligation, in the event of a Fundamental Transaction, as defined in the Series
B Warrants, the Series C Warrants and the 2023 and 2026 Placement Agent Warrants, for the Company or the successor entity to purchase
the warrants from the holder at the discretion of the holder and at the Black-Scholes value, as defined in the warrant agreements. As
a result, management concluded that, in line with IFRS 9 and paragraphs16A and 16B of IAS 32, such warrants will be accounted for as financial
liabilities on the consolidated statement of financial position with the changes in fair value recognized in the consolidated statement
of operations and other comprehensive loss. See Note 11, &#8220;Warrant Liability&#8221; for further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The fair value is estimated using a Black-Scholes model and in certain cases,
a Monte Carlo simulation (Level 3) (see Note 11, &#8220;Warrant Liability&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_231_zXwkTUniJHS4" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 104; Value: 6 -->
    <div id="xdx_238_zoWAmTvLHO3j" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zmwQ2ZjY6I7d" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_231_zBjjCVedNHyj" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_238_z0YQDsPK1Gn4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 22. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_236_zlMy798TEkSa" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following tables present the Company&#8217;s assets, including digital
assets accounted for in accordance with IAS 38 &#8220;<i>Intangible Assets</i>&#8221; (Level 1 and Level 3) (see Note 7, &#8220;Digital
Assets&#8221;), and financial liabilities that are measured at fair value (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003265" name="ptgef:LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock_pn3n3_zVLrHZkHFJR2" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BB_zE0eYMntBHej" style="display: none">Schedule of liabilities
        measured at fair value on a recurring basis</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_z1rLN6TA4HHd" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49C_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z2qYM4LPUosi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zD5X6q9UAmW9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_494_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zBld36kkVgs4" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zoeTRhfaF2J1" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zM5QmpE2t1fb" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial and digital assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DigitalAssetsAtFairValueTonLiquid_iI_zOUS9oCBMjnk" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Digital assets at fair value, TON liquid</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLiquid" contextRef="AsOf2026-03-31_custom_Level1Member" id="Fact003267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">126</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3268">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3269">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3270">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3271">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3272">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DigitalAssetsAtFairValueTonLocked_iI_zOUaVSZgiZeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets at fair value, TON locked</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3274">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3275">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DigitalAssetsAtFairValueTonLocked" contextRef="AsOf2026-03-31_custom_Level3Member" id="Fact003276" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,366</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3277">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3278">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3279">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zVPTI8wLoSN7" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49E_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z0j5MCgowog9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zeKOfFQgFhQi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_496_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zZzGpxmA9f99" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49A_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zCicAgyZOiU6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zzktOzhiinp3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TonPayableToSettlePutRightsExercised_iI_zg7mekSAa8u3" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">TON payable to settle put rights exercised</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3281">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3282">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TonPayableToSettlePutRightsExercised" contextRef="AsOf2026-03-31_custom_Level3Member" id="Fact003283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,425</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3284">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3285">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3286">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PutRightLiability_iI_z4Hlvat2BdB1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3288">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3289">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PutRightLiability" contextRef="AsOf2026-03-31_custom_Level3Member" id="Fact003290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,105</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3291">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3292">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3293">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--WarrantLiability_iI_pn3n3_zteIRtenVdC9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3295">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3296">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2026-03-31_custom_Level3Member" id="Fact003297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3298">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3299">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2025-03-31_custom_Level3Member" id="Fact003300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,952</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"></p>



</ix:nonNumeric><p id="xdx_8A4_zLUt3EOmq79e" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Credit Risk, Liquidity Risk, Digital Asset Risk, and Foreign Currency Risk</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">Our financial instruments are exposed to certain financial risks:
Credit Risk, Liquidity Risk, Digital Asset Risk, and Foreign Currency Risk.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Credit Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Credit risk is the risk of loss associated with a counterparty&#8217;s
inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#8217;s consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><b>Cash and cash equivalents: </b>Cash and cash equivalents
comprise cash on hand and amounts invested in underlying treasury and money market funds that are readily convertible to a known amount
of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. As of March 31,
2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. Cash
and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Liquidity Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Liquidity risk is the risk that the Company will encounter
difficulty in satisfying financial obligations as they become due. The Company&#8217;s approach to managing liquidity is to ensure, as
far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&#8217;s reputation. The Company holds sufficient cash and cash equivalents
to satisfy current obligations under accounts payable and accruals. The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Digital Asset Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company is subject to various risks including market risk, liquidity
risk and other risks related to its concentration in TON and other digital assets. Investing in digital assets is currently highly speculative
and volatile.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The price of our digital assets has been, and will likely continue to be,
highly volatile. Our financial results and the market price of our common stock could be materially adversely affected if the price of
our digital assets decreases substantially, as it has in the past, including as a result of shifts in market sentiment, speculative trading,
macroeconomic trends, technology-related disruptions and regulatory announcements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_239_zC44mh8GdUed" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 105; Value: 6 -->
    <div id="xdx_230_zV6RJTevFZC2" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zGpfj1imIhb1" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_23A_ztr2Apmb2Uuh" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 22. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT
<i>(Cont&#8217;d)</i></b></p></ix:exclude>


<ix:exclude><p id="xdx_238_zhyDUogDmdQ5" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our historical financial statements do not reflect the potential variability
in earnings that we may experience in the future from holding or selling digital assets. Accordingly, volatility in our earnings may be
significantly more than what we experienced in prior periods, and it may be difficult to evaluate the Company&#8217;s business and future
prospects. We also may need to perform an analysis each quarter to identify whether events or changes in circumstances indicate that our
digital assets are impaired.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company will face risks relating to the custody of its digital assets.
Cybersecurity threats, including hacking, phishing and other malicious attacks, could result in the loss, theft or misappropriation of
our digital assets. If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain
access to our private keys, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose
some or all of our digital assets and our financial condition and results of operations could be materially adversely affected.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There is a risk that some or all of the Company&#8217;s digital assets could
be lost or stolen. There can be no assurance that our custodians will maintain adequate insurance or that such coverage will cover any
losses with respect to the Company&#8217;s digital assets. Further, transactions in digital assets are irrevocable. Stolen or incorrectly
transferred digital assets may be irretrievable. As a result, any incorrectly executed transactions of the Company&#8217;s digital assets
could adversely affect an investment in the Company&#8217;s common stock.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s shareholders have no specific rights to any specific
digital assets. In the event of the insolvency of the Company, its assets may be inadequate to satisfy a claim by its shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The SEC has stated that certain digital assets may be considered securities
under federal securities laws. The test for determining whether a particular digital asset is a security is complex and difficult to apply,
and the outcome is difficult to predict. Future developments could change the legal status of digital assets we hold. If our digital assets
are determined to be securities under federal or state securities laws or in a proceeding in a court of law, or otherwise, it may have
material adverse consequences for our digital assets, making them more difficult to be traded, cleared or custodied compared to other
digital assets that are not considered securities. In addition, if our digital assets are considered securities, the Company could be
considered an unregistered investment company under the Investment Company Act of 1940, which could necessitate the Company&#8217;s liquidation.
If the Company is required to comply with additional regulatory obligations, it could result in a significant increase in operating expenses
and make it difficult to continue our current operations, which would materially and adversely affect our business, financial condition
and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As a company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company. The current uncertainty in global capital markets could have an impact on the Company&#8217;s future
ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available
to the Company. See Note 17, &#8220;Capital Stock and Reserves,&#8221; for a discussion of the Company&#8217;s share offering and current
funding levels.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Foreign Currency Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">While the Company operates in various jurisdictions,
substantially all of the Company&#8217;s transactions are denominated in the U.S. Dollar.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003305" name="ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock"><p id="xdx_80B_ecustom--DisclosureOfSegmentReportingExplanatoryTextBlock_zYLhgw8IYnpk" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
23. <span id="xdx_822_z3o7VW2Q9lrg">SEGMENT REPORTING</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">While the Company operates in various jurisdictions,
substantially all of the Company&#8217;s transactions are denominated in the U.S. Dollar.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Prior to the fiscal year ended March 31, 2026,
the Company had one operating segment, Immuno-Oncology. In September 2025, in connection with the replacement of the previous leadership
team, the Company made a strategic shift to digital assets and compute processing. While the majority of the Company&#8217;s operations
following September 2025 are now focused on compute processing and digital assets, certain subsidiaries continue to operate in the immuno-oncology
space.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our management reporting system produces reports
that present information about our business activities in a variety of ways. Based on these reports, the Chief Executive Officer, who
is responsible for assessing the performance of our Company and for making resource allocation decisions as our Chief Operating Decision
Maker (&#8220;CODM&#8221;), evaluates business activities based on several different results. Operating results are reviewed by operating
segment, comprised of the Company&#8217;s two operating segments: Digital &amp; Compute and Immuno-Oncology.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We use an operating loss indicator to measure
the performance of our operating segments. Information about assets and liabilities is not regularly provided to our CODM.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 106; Value: 6 -->
    <div id="xdx_239_zLS1NP6OBTgd" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zZiIzLDijtY6" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_230_zKGUO9ylINw6" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_233_z9kd33Uuwx7j" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 23. SEGMENT REPORTING <i>(Cont&#8217;d)</i></b></p></ix:exclude>



<ix:exclude><p id="xdx_235_zfSr33ExBhGe" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Results by segment for the fiscal years ended
March 31, 2026, 2025, and 2024 is as follows:</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003310" name="ptgef:ScheduleOfSegmentReportingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSegmentReportingTableTextBlock_pn3n3_zISlVstkjR3k" summary="xdx: Disclosure - SEGMENT REPORTING (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zZgatWOTNhLg" style="display: none">Schedule of segment reporting</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DigitalComputeMember_zQQi4pef5xyh" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zxYOSbH0llda" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_490_20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zhorSaE3Ib7b" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_491_20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zNoGn4xBsSre" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Digital &amp; Compute</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Revenue_zzcc9PH4Xbo" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Segment revenues</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3313">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3314">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3315">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProfitLossAbstract_iB_z4pFFDeP9sG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment expenses</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ResearchAndDevelopmentExpense_zg3qCDmOqQQ3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3322">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003323" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,801</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,129</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,535</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--GeneralAndAdministrativeExpense_zBljTZEYD6Lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: justify">General and administrative expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003327" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,344</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,855</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,254</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,664</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAndAmortisationExpense_zZweoOSFcnG6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Depreciation and amortization expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3333">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003334" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLossFromOperatingActivities_zYBtJ9OJJg14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment loss from operations</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003337" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,440</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003338" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,656</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003339" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,418</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003340" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,253</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--GainsLossesOnChangeInFairValueOfWarrants_z9f3jskqymAl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003342" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,097</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003343" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,786</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003344" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">388</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,868</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_zMuQEE6EtH44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3347">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3348">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3349">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,305</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ChangeInFairValueOfPutRightsNetOfRedemptions_z5PYPZjGT4g3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of put rights, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003352" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,959</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3353">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3354">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3355">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LossOnRevaluationOfDigitalAssets_zrVzmHl7BkU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003357" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,411</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3358">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3359">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3360">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LossOnRevaluationOfDigitalAssetReceivables_zONRYqKAQWV4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnRevaluationOfDigitalAssetReceivables" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003362" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,349</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3363">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3364">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3365">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RealizedLossOnSaleOfDigitalAssets_zYMyFjnobtSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RealizedLossOnSaleOfDigitalAssets" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003367" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,700</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3368">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3369">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3370">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--RealizedLossOnNovationOfDigitalAssetReceivables_zjFyq3GlZbCk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on novation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:RealizedLossOnNovationOfDigitalAssetReceivables" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">676</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3373">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3374">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3375">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--GainOnSettlementWithParexelIoxCro_zlrftFnk0Qda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement with Parexel - iOx CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3377">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3378">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003379" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">946</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3380">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LossOnRegisteredDirectOffering_z3GRGfSxrWIj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on Registered Direct Offering</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3382">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3383">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3384">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:LossOnRegisteredDirectOffering" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003385" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,432</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--OfferingCosts_zrDU1QCJpZs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Offering costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3387">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3388">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3389">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:OfferingCosts" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003390" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">662</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ImpairmentLossIoxIprd_zc4PuDWSybLi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - iOx IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3392">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3393">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3394">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossIoxIprd" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003395" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,890</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--ImpairmentLossTarusIprd_zSdN1Vd63KFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Tarus IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3397">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3398">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3399">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossTarusIprd" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003400" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,615</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ImpairmentLossStimunity_zG0sZ3DAYpQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Stimunity</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3402">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3403">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3404">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossStimunity" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003405" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,002</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--ImpairmentLossSaugatuck_zKChggm43D9j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Saugatuck</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3407">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3408">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3409">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossSaugatuck" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003410" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">178</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--CommitmentFeeUnderCommittedPurchaseAgreement_zR6Fjac30Lp8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Commitment fee under Committed Purchase Agreement</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3412">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3413">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3414">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:CommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003415" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">839</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--GainOnDissolutionOfInvestmentInAssociate_zFpbZKRPfAK3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on dissolution of investment in associate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3417">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3418">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3419">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainOnDissolutionOfInvestmentInAssociate" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003420" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GainFromSaleOfInvestmentInPublicCompany_zcVdomIRFAg1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain from sale of investment in public company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3422">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3423">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3424">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainFromSaleOfInvestmentInPublicCompany" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">725</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ImpairmentLossInvestmentInCompedica_zSXzRwv8SsX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3427">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ImpairmentLossInvestmentInCompedica" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003428" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,804</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3429">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3430">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossOnRevaluationOfInvestmentInCompedica_zB6DUIoyVn3j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnRevaluationOfInvestmentInCompedica" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003432" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">182</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3433">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3434">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3435">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_z2SYs5jPLmgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3438">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3439">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3440">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--GainOnSettlementOfTonPayable_zWhbQpfNGVn4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainOnSettlementOfTonPayable" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">336</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3443">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3444">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3445">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LossOnSettlementOfPutRightLiability_zc6tV1Gj9iBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on settlement of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnSettlementOfPutRightLiability" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003447" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">916</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3448">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3449">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3450">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--NetForeignExchangeGain_iN_di_zCRqQGgWV2Ze" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange transaction (loss) gain</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003452" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003455" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--InterestExpenseIncomeDefinedBenefitPlans_zs5vJnEVBKN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Interest (expense) income, net</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003457" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,022</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003458" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">86</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">242</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnExtinguishmentOfDebt_z4wcapWYoUf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on extinguishment of debt</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossOnExtinguishmentOfDebt" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003462" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">582</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GainOnExtinguishmentOfDebt_zxJa9QeFlVa5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on forgiveness of loan interest</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainOnExtinguishmentOfDebt" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003467" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">837</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3468">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3469">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3470">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ShareOfLossesFromEquityMethodInvestment_zv6RnYQVW1F3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Share of losses from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3472">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ShareOfLossesFromEquityMethodInvestment" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003473" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3474">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ShareOfLossesFromEquityMethodInvestment" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003475" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">233</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--SegmentLossBeforeBenefitForIncomeTaxes_zybOlmQXZrD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left">Segment loss before benefit for income taxes</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SegmentLossBeforeBenefitForIncomeTaxes" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003477" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,912</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SegmentLossBeforeBenefitForIncomeTaxes" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003478" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,715</ix:nonFraction></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:SegmentLossBeforeBenefitForIncomeTaxes" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003479" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,781</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:SegmentLossBeforeBenefitForIncomeTaxes" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003480" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">85,930</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxBenefit_zH7StBEZswxj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3482">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3483">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IncomeTaxBenefit" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003484" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IncomeTaxBenefit" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,548</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentNetLoss_z7sEEjClSHjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment net loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SegmentNetLoss" contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember" id="Fact003487" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,912</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SegmentNetLoss" contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember" id="Fact003488" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,715</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:SegmentNetLoss" contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember" id="Fact003489" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,778</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:SegmentNetLoss" contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember" id="Fact003490" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,382</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8AC_zrgbPX9ps6q" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003492" name="ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock"><p id="xdx_80F_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zwQXyHqLpqGk" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
23. <span id="xdx_82F_zNp7jQKCHDr7">CAPITAL MANAGEMENT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company considers the items included in shareholders&#8217;
equity as capital. The Company had accounts payable and accrued liabilities of approximately $<span id="xdx_90C_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20260331_zZBBUNtoLlGj" title="Payables and accrued expenses"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2026-03-31" id="Fact003494" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.1</ix:nonFraction></span>
million as of March 31, 2026 (accounts payable and accrued liabilities of approximately $<span id="xdx_908_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20250331_zUqGwimzqy85" title="Payables and accrued expenses"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2025-03-31" id="Fact003496" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.1</ix:nonFraction>
</span>million as of March 31, 2025), put right liabilities of approximately $<span id="xdx_902_ecustom--PutRightLiabilities_iI_pn3n3_dm_c20260331_ziAVwt4tP7kg" title="Put right liabilities"><ix:nonFraction name="ptgef:PutRightLiabilities" contextRef="AsOf2026-03-31" id="Fact003498" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.1</ix:nonFraction></span>
million as of March 31, 2026 (nil as of March 31, 2025), and current assets of approximately $<span id="xdx_90B_ecustom--CurrentAsset_iI_pn3n3_dm_c20260331_zOziBbIgo0M3" title="Current assets"><ix:nonFraction name="ptgef:CurrentAsset" contextRef="AsOf2026-03-31" id="Fact003500" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.0</ix:nonFraction></span>
million as of March 31, 2026 (approximately $<span id="xdx_900_ecustom--CurrentAsset_iI_pn3n3_dm_c20250331_zgrBYQWg9aie" title="Current assets"><ix:nonFraction name="ptgef:CurrentAsset" contextRef="AsOf2025-03-31" id="Fact003502" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.2</ix:nonFraction></span>
million as of March 31, 2025). The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue
as a going concern in order to pursue new business opportunities and to maintain a flexible capital structure while developing the Telegram
ecosystem and managing a strategic reserve of digital assets, which optimizes the costs of capital at an acceptable risk.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company manages the capital structure and makes
adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company is not subject to any externally imposed
capital requirements and does not presently utilize any quantitative measures to monitor its capital. During fiscal year ended March 31,
2026, the Company shifted its capital management approach to focus primarily developing the Telegram ecosystem, managing a strategic reserve
of digital assets, and acquiring GPUs to generate revenues from compute demand. There were no other changes to the Company&#8217;s approach
to capital management during the fiscal year ended March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<ix:exclude><p id="xdx_23D_zoUYAA0e2Vsl" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>



<ix:exclude><!-- Field: Page; Sequence: 107; Value: 6 -->
    <div id="xdx_23B_zfF0UyQ0k3u6" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zGtEO4Khx3K5" style="border-bottom: Black 1pt solid; break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt 0; font-size: 10pt"><b>ALPHA COMPUTE CORP</b></p><p style="margin: 0pt 0; font-size: 10pt"></p><p style="margin: 0pt 0; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></p><p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"><b>(U.S. Dollars)</b></span></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23C_zR85Kz9ll9h2" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003506" name="ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zOQllwliGhTc" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
24. <span id="xdx_82D_z6qOlJGjKTEf">NON-CONTROLLING INTEREST</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The table below summarize the Company&#8217;s non-controlling interest as
of the periods presented (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003508" name="ptgef:ScheduleOfNoncontrollingInterestTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zasandL9FVq4" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_z878ccb405r7" style="display: none">Schedule of non-controlling
        interest</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="vertical-align: middle; font-size: 10pt; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><b>Saugatuck</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>and subsidary</b></p></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2023</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zKO3eXzggBki" title="Non-controlling interest, at beginning" style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2023-03-31_custom_SaugatuckMember" id="Fact003510" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">650</ix:nonFraction></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztXhWty3KIZk" title="Net (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2023-04-012024-03-31_custom_SaugatuckMember371226578" id="Fact003512" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-controlling interest as of March 31, 2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z60iZH9zo4r" title="Non-controlling interest, at beginning" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2024-03-31_custom_SaugatuckMember" id="Fact003514" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">693</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z94XkukyZVqe" title="Net (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2024-04-012025-03-31_custom_SaugatuckMember371226609" id="Fact003516" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-controlling interest as of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zpONoyrL8okk" title="Non-controlling interest, at beginning" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2025-03-31_custom_SaugatuckMember" id="Fact003518" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">704</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zUWl0fjhWlAk" title="Net (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2025-04-012026-03-31_custom_SaugatuckMember371226609" id="Fact003520" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znWEiQvoQnbk" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2026-03-31_custom_SaugatuckMember" id="Fact003522" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">705</ix:nonFraction></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



</ix:nonNumeric><p id="xdx_8A3_zejfsfDugYI9" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company held 70% interest in Saugatuck and subsidiary through SalvaRx.
Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact003524" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfEventsAfterReportingPeriodExplanatory_zhFykYXAexX3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
25. <span id="xdx_82F_zE0GY6Qb2dv">SUBSEQUENT EVENTS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has evaluated subsequent events through July 15, 2026 the date
on which the consolidated financial statements were available to be issued.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On April 14, 2026, pursuant to prior approvals by our board of directors,
we filed a Certificate of Change of Name and Amendment to our Memorandum and Articles of Association. The documents changed our corporate
name from AlphaTON Capital Corp to Alpha Compute Corp to better reflect the nature of our expanded current business operations in compute
and AI infrastructure.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On April 21, 2026, our shares of common stock will begin trading under the
new symbol ALP on the Nasdaq Capital Market. The Certificate of Change of Name and Amendment to our Memorandum and Articles of Association
are filed as Exhibit 99.1 and Exhibit 99.2 to this current report and are incorporated herein by reference.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On May 12, 2026, Alpha Compute Corp (the &#8220;Company&#8221;) issued a
press release announcing the execution of a compute off-take agreement related to a cluster of 504 NVIDIA B200 GPUs. A copy of the press
release is attached hereto as Exhibit 99.1.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As previously disclosed, in connection with Alpha Compute Corp&#8217;s (the
&#8220;Company&#8221;) September 2025 private placement financing (the &#8220;Sept. 2025 Private Placement Financing&#8221;), the Company
entered into certain Side Letter Agreements (each, a &#8220;Side Letter&#8221;) with certain investors in the Sept. 2025 Private Placement
Financing. The Side Letters granted an irrevocable right and option to these investors to require the Company to repurchase all the ordinary
shares of the Company (&#8220;Ordinary Shares&#8221;) received by the respective investor in exchange for the consideration initially
provided by the respective investor to the Company (the &#8220;Put Option&#8221;). The period in which the Put Option may be exercised
varies from six to twelve months, depending on the investor, after the September 25, 2025 closing of the Sept. 2025 Private Placement
Financing. On June 22, 2026 two of these investors exercised their Put Options, obligating the Company to transfer to the investors a
total of 2,114,583 TON tokens and 5,136,459 USDC tokens (which represents the consideration initially provided by these investors to the
Company), with no adjustment for value, in exchange for the repurchase by the Company of a total of 1,196,295 Ordinary Shares and 633,931
Pre-Funded Warrants received by these investors in the Sept. 2025 Private Placement Financing.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#8220;SPA&#8221;) with Animoca Brands Limited (&#8220;Animoca Brands&#8221;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#8220;GaMee Global&#8221;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#8220;GaMee Transaction&#8221;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. Animoca
Brands, prior to closing, will conduct a reorganization to transfer 100% of the equity of Gamee Limited, a company incorporated in the
United Kingdom (the &#8220;UK Company&#8221;) to GaMee Global. The UK Company owns the entire equity in Gamee Mobile s.r.o., a company
incorporated under the laws of the Czech Republic (the &#8220;Czech Company&#8221; and together with GaMee Global and the UK Company,
&#8220;GaMee&#8221;). Under the terms of the SPA, at the closing of the GaMee Transaction (&#8220;Completion&#8221;), the Company has
agreed to pay total upfront consideration of $3.5 million (the &#8220;Completion Consideration&#8221;), comprised of: (i) $1.5 million
in cash, and (ii) $2.0 million in equity consideration in the Company, valued at $1.00 per share. The equity portion of the Completion
Consideration under subparagraph (ii) is structured as a combination of ordinary shares of the Company (&#8220;Ordinary Shares&#8221;)
and pre-funded warrants exercisable for Ordinary Shares (&#8220;Pre-Funded Warrants&#8221;). Specifically, at Completion, Animoca Brands
will receive: (i) 99,800 Ordinary Shares, and (ii) Pre-Funded Warrants exercisable for 1,900,200 Ordinary Shares, representing the balance
of the equity portion of the Completion Consideration. The GaMee Transaction closed on May 27, 2026.</p>



</ix:nonNumeric><p id="xdx_81F_z2QEgUmoXvVf" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt"></p>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><span style="text-decoration: underline"><span id="i19"></span>ITEM 19 &#8211; EXHIBITS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><b>(a)</b></td>
    <td><b>EXHIBITS</b></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt">The following documents are filed as part of this Annual Report on Form 20-F.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 84%"><span style="font-size: 10pt"><b>Description of Exhibit</b></span></td>
        </tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td> </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322006193/exh_41.htm"><span style="font-size: 10pt">1.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322006193/exh_41.htm"><span style="font-size: 10pt">Amended
        and Restated Memorandum of Association and Articles of Association of Portage Biotech Inc. as filed in the British Virgin Island on September
        22, 2022 - Incorporated herein by reference to Exhibit 4.1 to Form 6-K filed on September 22, 2022.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004510/exh_991.htm">1.2</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">
        <p style="margin: 0pt 0; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004510/exh_991.htm">Amended
        and Restated Memorandum of Association and Articles of Association of AlphaTON Capital Corp as filed in the British Virgin Island on September
        4, 2025. - Incorporated herein by reference to Exhibit 99.1 to Form 6-K filed on June 23, 2022.</a></p></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322006193/exh_41.htm">1.3</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322006193/exh_41.htm">Amended
        and Restated Memorandum of Association and Articles of Association of Alpha Capital Corp as filed in the British Virgin Island on April
        21, 2026. - Incorporated herein by reference to Exhibit 4.1 to Form 6-K filed on September 22, 2022.</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_21.htm"><span style="font-size: 10pt">2.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_21.htm"><span style="font-size: 10pt">Description
        of Rights of Stock Registered under Section 12 of the Exchange Act &#8211;&#160;Incorporated herein by reference&#160;to Exhibit 2.1 to
        Form 20-F filed on August 1, 2022.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_41.htm"><span style="font-size: 10pt">2.2</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_41.htm"><span style="font-size: 10pt">Form
        of Pre-Funded Ordinary Share Purchase Warrant, dated September 29, 2023 -&#160;Incorporated herein by reference&#160;to Exhibit 4.1 to
        Form 6-K filed on October 3, 2023.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_42.htm"><span style="font-size: 10pt">2.3</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_42.htm"><span style="font-size: 10pt">Form
        of Series A Ordinary Share Purchase Warrant, dated September 29, 2023-&#160;Incorporated herein by reference&#160;to Exhibit 4.2 to Form
        6-K filed on October 3, 2023.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_43.htm"><span style="font-size: 10pt">2.4</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_43.htm"><span style="font-size: 10pt">Form
        of Series B Ordinary Share Purchase Warrant, dated September 29, 2023 -&#160;Incorporated herein by reference&#160;to Exhibit 4.3 to Form
        6-K filed on October 3, 2023.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_44.htm"><span style="font-size: 10pt">2.5</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_44.htm"><span style="font-size: 10pt">Form
        of Series C Ordinary Share Purchase Warrant, dated September 29, 2023 -&#160;Incorporated herein by reference&#160;to Exhibit 4.4 to Form
        6-K filed on October 3, 2023.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_45.htm"><span style="font-size: 10pt">2.6</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_45.htm"><span style="font-size: 10pt">Form
        of Placement Agent Ordinary Share Purchase Warrant, dated September 29, 2023 -&#160;Incorporated herein by reference&#160;to Exhibit 4.5
        to Form 6-K filed on October 3, 2023.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000293/exh_41.htm">2.7</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000293/exh_41.htm">Form of Pre-Funded
        Ordinary Share Purchase Warrant, dated January 14, 2026 - Incorporated herein by reference to Exhibit 4.1 to Form 6-K filed on January
        15, 2026.</a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000293/exh_42.htm">2.7</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000293/exh_42.htm">Form of Placement
        Agent Ordinary Share Purchase Warrant, dated January 14, 2026 - Incorporated herein by reference to Exhibit 4.2 to Form 6-K filed on January
        15, 2026.</a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000849/exh_11.htm"><span style="font-size: 10pt">4.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000849/exh_11.htm"><span style="font-size: 10pt">At
        The Market Offering Agreement by and between Alpha Compute Corp and H.C. Wainright &amp; Co., dated February 17, 2026 &#8211; Incorporated
        herein by reference to Exhibit 1.1 to Form 6-K filed on February 17, 2026.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000293/exh_101.htm"><span style="font-size: 10pt">4.2</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000293/exh_101.htm"><span style="font-size: 10pt">Form
        of Securities Purchase Agreement, dated January 14, 2026 - Incorporated herein by reference to Exhibit 10.1 to Form 6-K filed on January
        15, 2026.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325003779/exh_101.htm"><span style="font-size: 10pt">4.3</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325003779/exh_101.htm"><span style="font-size: 10pt">Subscription
        Agreement between Portage Biotech Inc. and Compedica Holdings, LLC, dated June 5, 2025 -&#160;Incorporated herein by reference&#160;to
        - Exhibit 10.1 to Form 6-K filed on June 9, 2025.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000733/exh_101.htm"><span style="font-size: 10pt">4.4</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326000733/exh_101.htm"><span style="font-size: 10pt">Termination,
        Recission and Transfer Agreement between AlphaTON Capital Corp and Compedica Holdings, LLC, dated February 6, 2026 - Incorporated herein
        by reference to - Exhibit 10.1 to Form 6-K filed on February 10, 2026.</span></a></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 109; Options: NewSection; Value: 104 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><span style="font-size: 10pt"><b>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXHIBITS (Cont&#8217;d)</b></span></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 84%"><span style="font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326003721/exh_101.htm">4.5</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326003721/exh_101.htm">Form of Shareholders
        Agreement, dated May 27, 2026, by and between Alpha Compute Corp, Animoca Brands Limited and Ga Mee Global Limited - Incorporated herein
        by reference to Exhibit 10.1 to Form 6-K filed on May 27, 2026.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184321005284/exh_44.htm">4.6</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184321005284/exh_44.htm">Portage Biotech
        Inc. 2021 Equity Incentive Plan dated as of January 13, 2021 -&#160;Incorporated herein by reference&#160;to Exhibit 4(c)(iv).4 to Form
        20-F filed on July 29, 2021.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 15%"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323007378/exh_42.htm"><span style="font-size: 10pt">4.7</span></a></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 84%"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323007378/exh_42.htm"><span style="font-size: 10pt">Portage
        Biotech Inc. Amended and Restated 2021 Equity Incentive Plan -&#160;Incorporated herein by reference&#160;to Exhibit 4.2 to Form S-8 filed
        on December 1, 2023.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004791/exh_103.htm"><span style="font-size: 10pt">4.8</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004791/exh_103.htm"><span style="font-size: 10pt">Purchase
        Agreement dated as of July 6, 2022, by and between Portage Biotech Inc. and Lincoln Park Capital Fund, LLC -&#160;Incorporated herein
        by reference&#160;to Exhibit 10.3 to Form 6-K filed on July 8, 2022.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004791/exh_104.htm"><span style="font-size: 10pt">4.9</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004791/exh_104.htm"><span style="font-size: 10pt">Registration
        Rights Agreement dated as of July 6, 2022, by and between Portage Biotech Inc. and Lincoln Park Capital Fund, LLC -&#160;Incorporated
        herein by reference&#160;to Exhibit 10.4 to Form 6-K filed on July 8, 2022.</span></a></td></tr>
  <tr>
    <td colspan="3">
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b></b></span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b></b></span></p> </td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325005698/exh_108.htm"><span style="font-size: 10pt">4.10</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325005698/exh_108.htm"><span style="font-size: 10pt">Agreement
        effective as of August 4, 2025, by and between AlphaTON Capital Corp and Own Your Data Technologies, LLC, an affiliate of Brittany Kaiser
        - Incorporated herein by reference to Exhibit 10.8 to Form 6-K filed on September 3, 2025.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325005698/exh_1012.htm"><span style="font-size: 10pt">4.11</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325005698/exh_1012.htm"><span style="font-size: 10pt">Services
        Agreement effective as of August 20, 2025, by and between AlphaTON Capital Corp and Alpha Sigma Capital Advisors, LLC, an affiliate of
        Enzo Villani -&#160;Incorporated herein by reference&#160;to Exhibit 10.12 to Form 6-K filed on September 3, 2025.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325005698/exh_1011.htm"><span style="font-size: 10pt">4.12</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325005698/exh_1011.htm"><span style="font-size: 10pt">Services
        Agreement effective as of August 20, 2025, by and between AlphaTON Capital Corp and Red Shark Ventures, LLC, an affiliate of Yuri Mitin
        -&#160;Incorporated herein by reference&#160;to Exhibit 10.11 to Form 6-K filed on September 3, 2025.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325006621/exh_101.htm"><span style="font-size: 10pt">4.13</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184325006621/exh_101.htm"><span style="font-size: 10pt">Services
        Agreement effective as of October 22, 2025, by and between AlphaTON Capital Corp and Wes Levitt &#8211;&#160;Incorporated herein by reference&#160;to
        Exhibit 10.1 to Form 6-K filed on October 23, 2025.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_412.htm" style="-sec-extract: exhibit">4.14</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_412.htm" style="-sec-extract: exhibit">Services Agreement effective as of September 30, 2024, by and between Alpha Compute Corp and Liza Horowitz &#8211; Incorporated by reference to Exhibit 4.14 to Form 20-F filed on July 16, 2026.</a></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_1015.htm"><span style="font-size: 10pt">4.15</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_1015.htm"><span style="font-size: 10pt">Form
        of Restricted Share Unit Award and Dividend Equivalent Rights Agreement dated as of January 19, 2022 -&#160;Incorporated herein by reference&#160;to
        Exhibit 10.15 to Form 20-F filed on August 1, 2022.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_1016.htm"><span style="font-size: 10pt">4.16</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_1016.htm"><span style="font-size: 10pt">Form
        of Share Option Agreement dated as of February 15, 2022 -&#160;Incorporated herein by reference&#160;to Exhibit 10.16 to Form 20-F filed
        on August 1, 2022.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323004814/exh_424.htm"><span style="font-size: 10pt">4.17</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184323004814/exh_424.htm"><span style="font-size: 10pt">Services
        Agreement effective as of June 1, 2022, by and between Portage Development Services Inc. and Justin Fairchild -&#160;Incorporated herein
        by reference&#160;to Exhibit 4.24 to Form 20-F filed on July 31, 2023.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_81.htm" style="-sec-extract: exhibit">8.1</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_81.htm" style="-sec-extract: exhibit">List of subsidiaries. &#8211; Incorporated by reference to Exhibit 8.1 to Form 20-F filed on July 16, 2026.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000109543514000064/codeconduct.htm" style="-sec-extract: exhibit">11.1</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000109543514000064/codeconduct.htm" style="-sec-extract: exhibit">Code of Conduct - Incorporated herein by reference to Exhibit 11.3 to Form F-20 filed on July 31, 2014. &#8211; Incorporated by reference to Exhibit 11.1 to Form 20-F filed on July 16, 2026.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004800/exh_115.htm" style="-sec-extract: exhibit">11.2</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004800/exh_115.htm" style="-sec-extract: exhibit">Insider Trading Policy &#8211; Incorporated herein by reference to Exhibit 11.5 to Form 20-F filed on August 14, 2024 &#8211; Incorporated by reference to Exhibit 11.2 to Form 20-F filed on July 16, 2026.</a></td></tr>
  <tr style="background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><a href="exh_121.htm">12.1*</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="exh_121.htm">Certifications of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended.</a></span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 110; Value: 104 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><span style="font-size: 10pt"><b>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXHIBITS (Cont&#8217;d)</b></span></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 84%"><span style="font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center; width: 15%"><a href="exh_122.htm"><span style="font-size: 10pt">12.2*</span></a></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 84%"><a href="exh_122.htm"><span style="font-size: 10pt">Certifications of Chief Financial Officer Pursuant to Rule 13a-14(a)
        or 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="exh_131.htm"><span style="font-size: 10pt">13.1*</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="exh_131.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley
        Act of 2002.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="exh_132.htm">13.2*</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="exh_132.htm">Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_151.htm" style="-sec-extract: exhibit">15.1</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_151.htm" style="-sec-extract: exhibit">Consent of CBIZ CPAs P.C. - Incorporated by reference to Exhibit 15.1 to Form 20-F filed on July 16, 2026.</a></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_152.htm" style="-sec-extract: exhibit">15.2</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184326004704/exh_152.htm" style="-sec-extract: exhibit">Consent of Marcum LLP. - Incorporated by reference to Exhibit 15.2 to Form 20-F filed on July 16, 2026.</a></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004800/exh_971.htm"><span style="font-size: 10pt">97.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004800/exh_971.htm"><span style="font-size: 10pt">Incentive
        Compensation Recovery Policy &#8211; Incorporated herein by reference to Exhibit 97.1 to Form 20-F filed on August 14, 2024.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>101</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">The following financial information from our Annual Report on Form 20-F for
        the year ended March 31, 2024 has been formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Statements of Financial
        Position, (ii) Consolidated Statements of Operations and Other Comprehensive Income, (iii) Consolidated Statements of Cash Flows, and
        (iv) Notes to Consolidated Financial Statements.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>101.INS*</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>101.SCH*</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>101.CAL*</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>101.DEF*</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>101.LAB*</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>101.PRE*</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b>104</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted in Inline XBRL and contained in
        Exhibit 101)</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>* Filed herewith</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 111; Value: 104 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>SIGNATURES</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">The registrant hereby certifies that it meets all of the requirements for
filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">DATED at Tortola, British Virgin Islands, this 15th day of July, 2026</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Alpha Compute Corp</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 22%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 78%"><span style="font-size: 10pt"><i>/s/ Brittany Kaiser</i></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt"><i>/s/ Wes Levitt</i></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">107</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>exh_121.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>EXHIBIT 12.1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Brittany Kaiser, Chief Executive Officer of Alpha Compute Corp, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">1. I have reviewed this Annual Report on Form 20-F/A of Alpha Compute Corp for the fiscal year
ended March 31, 2026.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.05pt; margin: 0pt 5pt 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.05pt; margin: 0pt 32pt 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">4. The company&#8217;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0">(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 20pt 0pt 0">(b) Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 11pt 0pt 0">(c) Evaluated the effectiveness of the company&#8217;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 13pt 0pt 0">(d) Disclosed in this report any change in the company&#8217;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or
is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.05pt; margin: 0pt 22pt 0pt 0">5. The company&#8217;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee
of the company&#8217;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 19pt 0pt 0">(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability
to record, process, summarize and report financial information; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 31pt 0pt 0">(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Date: July 20, 2026</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD ROWSPAN="2" STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>Brittany Kaiser</I></FONT></TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Brittany Kaiser</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>exh_122.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>EXHIBIT 12.2</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Wes Levitt, Chief Financial Officer of Alpha Compute Corp, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">1. I have reviewed this Annual Report on Form 20-F/A of Alpha Compute Corp for the fiscal year
ended March 31, 2026.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.05pt; margin: 0pt 5pt 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.05pt; margin: 0pt 32pt 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">4. The company&#8217;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0">(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 20pt 0pt 0">(b) Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 11pt 0pt 0">(c) Evaluated the effectiveness of the company&#8217;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 13pt 0pt 0">(d) Disclosed in this report any change in the company&#8217;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or
is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.05pt; margin: 0pt 22pt 0pt 0">5. The company&#8217;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee
of the company&#8217;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 19pt 0pt 0">(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability
to record, process, summarize and report financial information; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 31pt 0pt 0">(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Date: July 20, 2026</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD ROWSPAN="2" STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>Wes Levitt</I></FONT></TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Wes Levitt</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>exh_131.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>EXHIBIT 13.1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0">I, Brittany Kaiser, Chief Executive Officer of Alpha Compute Corp (the
&#8220;Company&#8221;), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0">(i)&nbsp; the Annual Report on Form 20-F/A of the Company for the fiscal
year ended March 31, 2026 (the &#8220;Annual Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0.25in 0pt 0">(ii) the information contained in the Annual Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0.25in 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0.25in 0pt 0">Date: July 20, 2026</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD ROWSPAN="2" STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>Brittany Kaiser</I></FONT></TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Brittany Kaiser</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>This written statement is being furnished to the Securities and Exchange Commission as an
exhibit to the Company&#8217;s Annual Report on Form 20-F/A. A signed original of this statement has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>This certification accompanies this Annual Report on Form 20-F/A pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;). Such certification will not be deemed
to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent
that the Company specifically incorporates it by reference.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>5
<FILENAME>exh_132.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>EXHIBIT 13.2</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20pt; margin: 0pt 0">I, Wes Levitt, Chief Financial Officer of Alpha Compute Corp (the &#8220;Company&#8221;),
hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the
best of my knowledge:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0">(i)&nbsp; the Annual Report on Form 20-F/A of the Company for the fiscal
year ended March 31, 2026 (the &#8220;Annual Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0.25in 0pt 0">(ii) the information contained in the Annual Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 20.2pt; margin: 0pt 0.25in 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Date: July 20, 2026</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD ROWSPAN="2" STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>Wes Levitt</I></FONT></TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Wes Levitt</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>This written statement is being furnished to the Securities and Exchange Commission as an
exhibit to the Company&#8217;s Annual Report on Form 20-F/A. A signed original of this statement has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>This certification accompanies this Annual Report on Form 20-F/A pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;). Such certification will not be deemed
to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent
that the Company specifically incorporates it by reference.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ptgef-20260331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOaeI6bPtxZ97eekhsmR9bXk6jyMthy0ahSJBv6KWQUsH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ptgef="http://portagebiotech.com/20260331" elementFormDefault="qualified" targetNamespace="http://portagebiotech.com/20260331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://portagebiotech.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StatementsOfFinancialPosition" id="StatementsOfFinancialPosition">
          <link:definition>00000002 - Statement - Consolidated Statements of Financial Position</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss" id="StatementsOfOperationsAndOtherComprehensiveIncomeLoss">
          <link:definition>00000003 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit" id="StatementsOfChangesInEquityDeficit">
          <link:definition>00000004 - Statement - Consolidated Statements of Changes in Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000005 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/NatureOfOperations" id="NatureOfOperations">
          <link:definition>999006 - Disclosure - NATURE OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/GoingConcern" id="GoingConcern">
          <link:definition>999007 - Disclosure - GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>999008 - Disclosure - BASIS OF PRESENTATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>999009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets" id="PrepaidExpensesOtherReceivablesAndOtherAssets">
          <link:definition>999010 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/Stablecoin" id="Stablecoin">
          <link:definition>999011 - Disclosure - STABLECOIN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/DigitalAssets" id="DigitalAssets">
          <link:definition>999012 - Disclosure - DIGITAL ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets" id="PropertyPlantAndEquipmentAndRight-of-useAssets">
          <link:definition>999013 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InvestmentInCompedica" id="InvestmentInCompedica">
          <link:definition>999014 - Disclosure - INVESTMENT IN COMPEDICA</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiability" id="WarrantLiability">
          <link:definition>999015 - Disclosure - WARRANT LIABILITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayable" id="PutRightLiabilityAndTonPayable">
          <link:definition>999016 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
          <link:definition>999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LeaseLiability" id="LeaseLiability">
          <link:definition>999018 - Disclosure - LEASE LIABILITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/BitgoPrimeLoan" id="BitgoPrimeLoan">
          <link:definition>999019 - Disclosure - BITGO PRIME LOAN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999020 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" id="CapitalStockAndReserves">
          <link:definition>999021 - Disclosure - CAPITAL STOCK AND RESERVES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserve" id="StockOptionReserve">
          <link:definition>999022 - Disclosure - STOCK OPTION RESERVE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShare" id="LossPerShare">
          <link:definition>999023 - Disclosure - LOSS PER SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
          <link:definition>999024 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999025 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" id="FinancialInstrumentsAndRiskManagement">
          <link:definition>999026 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999027 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalManagement" id="CapitalManagement">
          <link:definition>999028 - Disclosure - CAPITAL MANAGEMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterest" id="Non-controllingInterest">
          <link:definition>999029 - Disclosure - NON-CONTROLLING INTEREST</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999030 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
          <link:definition>999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables" id="PrepaidExpensesOtherReceivablesAndOtherAssetsTables">
          <link:definition>999033 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StablecoinTables" id="StablecoinTables">
          <link:definition>999034 - Disclosure - STABLECOIN (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/DigitalAssetsTables" id="DigitalAssetsTables">
          <link:definition>999035 - Disclosure - DIGITAL ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables" id="PropertyPlantAndEquipmentAndRight-of-useAssetsTables">
          <link:definition>999036 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InvestmentInCompedicaTables" id="InvestmentInCompedicaTables">
          <link:definition>999037 - Disclosure - INVESTMENT IN COMPEDICA (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
          <link:definition>999038 - Disclosure - WARRANT LIABILITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables" id="PutRightLiabilityAndTonPayableTables">
          <link:definition>999039 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
          <link:definition>999040 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LeaseLiabilityTables" id="LeaseLiabilityTables">
          <link:definition>999041 - Disclosure - LEASE LIABILITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999042 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" id="CapitalStockAndReservesTables">
          <link:definition>999043 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveTables" id="StockOptionReserveTables">
          <link:definition>999044 - Disclosure - STOCK OPTION RESERVE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShareTables" id="LossPerShareTables">
          <link:definition>999045 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>999046 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" id="FinancialInstrumentsAndRiskManagementTables">
          <link:definition>999047 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999048 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" id="Non-controllingInterestTables">
          <link:definition>999049 - Disclosure - NON-CONTROLLING INTEREST (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>999050 - Disclosure - GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
          <link:definition>999051 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
          <link:definition>999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" id="PrepaidExpensesAndOtherReceivablesDetails">
          <link:definition>999054 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" id="PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative">
          <link:definition>999055 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StablecoinDetails" id="StablecoinDetails">
          <link:definition>999056 - Disclosure - STABLECOIN (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StablecoinDetails1" id="StablecoinDetails1">
          <link:definition>999057 - Disclosure - STABLECOIN (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/DigitalAssetsDetails" id="DigitalAssetsDetails">
          <link:definition>999058 - Disclosure - DIGITAL ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/DigitalAssetsDetails1" id="DigitalAssetsDetails1">
          <link:definition>999059 - Disclosure - DIGITAL ASSETS (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/DigitalAssetsDetails2" id="DigitalAssetsDetails2">
          <link:definition>999060 - Disclosure - DIGITAL ASSETS (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails" id="ReceivablesDigitalAssetsDetails">
          <link:definition>999061 - Disclosure - RECEIVABLES DIGITAL ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/DigitalAssetsDetailsNarrative" id="DigitalAssetsDetailsNarrative">
          <link:definition>999062 - Disclosure - DIGITAL ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" id="PropertyPlantAndEquipmentAndRight-of-useAssetsDetails">
          <link:definition>999063 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetails" id="InvestmentInCompedicaDetails">
          <link:definition>999064 - Disclosure - INVESTMENT IN COMPEDICA (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative" id="InvestmentInCompedicaDetailsNarrative">
          <link:definition>999065 - Disclosure - INVESTMENT IN COMPEDICA (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" id="WarrantLiabilityDetails">
          <link:definition>999066 - Disclosure - WARRANT LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" id="WarrantLiabilityDetails1">
          <link:definition>999067 - Disclosure - WARRANT LIABILITY (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" id="WarrantLiabilityDetails2">
          <link:definition>999068 - Disclosure - WARRANT LIABILITY (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" id="WarrantLiabilityDetails3">
          <link:definition>999069 - Disclosure - WARRANT LIABILITY (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails4" id="WarrantLiabilityDetails4">
          <link:definition>999070 - Disclosure - WARRANT LIABILITY (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" id="WarrantLiabilityDetailsNarrative">
          <link:definition>999071 - Disclosure - WARRANT LIABILITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails" id="PutRightLiabilityAndTonPayableDetails">
          <link:definition>999072 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1" id="PutRightLiabilityAndTonPayableDetails1">
          <link:definition>999073 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2" id="PutRightLiabilityAndTonPayableDetails2">
          <link:definition>999074 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative" id="PutRightLiabilityAndTonPayableDetailsNarrative">
          <link:definition>999075 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" id="AccountsPayableAndAccruedLiabilitiesDetails">
          <link:definition>999076 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LeaseLiabilityDetails" id="LeaseLiabilityDetails">
          <link:definition>999077 - Disclosure - LEASE LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative" id="LeaseLiabilityDetailsNarrative">
          <link:definition>999078 - Disclosure - LEASE LIABILITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative" id="BitgoPrimeLoanDetailsNarrative">
          <link:definition>999079 - Disclosure - BITGO PRIME LOAN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>999080 - Disclosure - INCOME TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>999081 - Disclosure - INCOME TAXES (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
          <link:definition>999082 - Disclosure - INCOME TAXES (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999083 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails" id="CapitalStockAndReservesDetails">
          <link:definition>999084 - Disclosure - CAPITAL STOCK AND RESERVES (Details )</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" id="CapitalStockAndReservesDetailsNarrative">
          <link:definition>999085 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" id="StockOptionReserveDetails">
          <link:definition>999086 - Disclosure - STOCK OPTION RESERVE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" id="StockOptionReserveDetails1">
          <link:definition>999087 - Disclosure - STOCK OPTION RESERVE (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" id="StockOptionReserveDetails2">
          <link:definition>999088 - Disclosure - STOCK OPTION RESERVE (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" id="StockOptionReserveDetails3">
          <link:definition>999089 - Disclosure - STOCK OPTION RESERVE (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" id="StockOptionReserveDetails4">
          <link:definition>999090 - Disclosure - STOCK OPTION RESERVE (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" id="StockOptionReserveDetailsNarrative">
          <link:definition>999091 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails" id="LossPerShareDetails">
          <link:definition>999092 - Disclosure - LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails1" id="LossPerShareDetails1">
          <link:definition>999093 - Disclosure - LOSS PER SHARE (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" id="CommitmentsAndContingentLiabilitiesDetailsNarrative">
          <link:definition>999094 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
          <link:definition>999095 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails1" id="RelatedPartyTransactionsDetails1">
          <link:definition>999096 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails3" id="RelatedPartyTransactionsDetails3">
          <link:definition>999097 - Disclosure - RELATED PARTY TRANSACTIONS (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999098 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" id="FinancialInstrumentsAndRiskManagementDetails">
          <link:definition>999099 - Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1" id="FinancialInstrumentsAndRiskManagementDetails1">
          <link:definition>999100 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
          <link:definition>999101 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" id="CapitalManagementDetailsNarrative">
          <link:definition>999102 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" id="Non-controllingInterestDetails">
          <link:definition>999103 - Disclosure - NON-CONTROLLING INTEREST (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <element id="ptgef_StockOptionReserveMember" name="StockOptionReserveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TreasuryStockMember" name="TreasuryStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccumulatedOtherComprehensiveIncomeLossMember" name="AccumulatedOtherComprehensiveIncomeLossMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IOxIPRDMember" name="IOxIPRDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TarusIPRDMember" name="TarusIPRDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StimunityMember" name="StimunityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SaugatuckMember" name="SaugatuckMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IOXMember" name="IOXMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SalvaRxMember" name="SalvaRxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CountryOfBritishVirginIslandsMember" name="CountryOfBritishVirginIslandsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DelawareMember" name="DelawareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SubsidiariesTwoMember" name="SubsidiariesTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_USDCMember" name="USDCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UsdtMember" name="UsdtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TotalMember" name="TotalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TONMember" name="TONMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BITCOINMember" name="BITCOINMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_USD1Member" name="USD1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LockedTonMember" name="LockedTonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GPUsMember" name="GPUsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GPUDepositsMember" name="GPUDepositsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RightOfUseAssetMember" name="RightOfUseAssetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ClassBWarrantsMember" name="ClassBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ClassCWarrantsMember" name="ClassCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeiesBWarrantsMember" name="SeiesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeiesCWarrantsMember" name="SeiesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PlacementAgentWarrants2026Member" name="PlacementAgentWarrants2026Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PlacementAgentsWarrantsMember" name="PlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TonTokenVolatilityMember" name="TonTokenVolatilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ATMMember" name="ATMMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" name="SeriesAWarrantsAndPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_VestedStockOptionMember" name="VestedStockOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PBI2021EquityIncentivePlanMember" name="PBI2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionGrantedMember" name="StockOptionGrantedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_January132021Member" name="January132021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_January192022Member" name="January192022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_February152022Member" name="February152022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_June82022Member" name="June82022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_July272022Member" name="July272022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_March302023Member" name="March302023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_March72025Member" name="March72025Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_July272026Member" name="July272026Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_March112026Member" name="March112026Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CROMember" name="CROMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CROAgreementMember" name="CROAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MichaelTerpinMember" name="MichaelTerpinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DirectorCompensationMember" name="DirectorCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FDanielSicilianoMember" name="FDanielSicilianoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GregoryHBaileyMDMember" name="GregoryHBaileyMDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_JamesMellonMember" name="JamesMellonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StevenMintzMember" name="StevenMintzMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_JeanChristopheRenondinMDMember" name="JeanChristopheRenondinMDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_JustinStebbingMDPhDMember" name="JustinStebbingMDPhDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LindaKozickMember" name="LindaKozickMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MarkSimonMember" name="MarkSimonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RobertGlassmanMember" name="RobertGlassmanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExecutiveOfficerCompensationMember" name="ExecutiveOfficerCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BrittanyKaiserMember" name="BrittanyKaiserMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EnzoVillaniMember" name="EnzoVillaniMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WesLevittMember" name="WesLevittMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_YuryMitinMember" name="YuryMitinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AlexanderPickettMember" name="AlexanderPickettMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IanWaltersMember" name="IanWaltersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AndreaParkMember" name="AndreaParkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AllanShawMember" name="AllanShawMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RobertKramerMember" name="RobertKramerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BrianWileyMember" name="BrianWileyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_JustinFairchildMember" name="JustinFairchildMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AlexanderPickettTwoMember" name="AlexanderPickettTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IanBWaltersMember" name="IanBWaltersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IanBWaltersTwoMember" name="IanBWaltersTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IanBWaltersThreeMember" name="IanBWaltersThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AndreaEParkMember" name="AndreaEParkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AndreaEParkTwoMember" name="AndreaEParkTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AllanShawTwoMember" name="AllanShawTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AllanShawThreeMember" name="AllanShawThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RobertKramerTwoMember" name="RobertKramerTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RobertKramerThreeMember" name="RobertKramerThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BrianWileyTwoMember" name="BrianWileyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AmortizedCostMember" name="AmortizedCostMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueToOtherComprehensiveIncomeMember" name="FairValueToOtherComprehensiveIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueThroughProfitOrLossMember" name="FairValueThroughProfitOrLossMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Level1Member" name="Level1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Level2Member" name="Level2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Level3Member" name="Level3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalComputeMember" name="DigitalComputeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ImmunoOncologyMember" name="ImmunoOncologyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsReceivable" name="AccountsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Stablecoin" name="Stablecoin" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsAtFairValueTonCurrent" name="DigitalAssetsAtFairValueTonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion" name="DigitalAssetsAtFairValueTonNetOfCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EquipmentDeposits" name="EquipmentDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TonPayableToSettlePutRightsExercised" name="TonPayableToSettlePutRightsExercised" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightLiability" name="PutRightLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentsAndContingentLiabilities" name="CommitmentsAndContingentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainsLossesOnChangeInFairValueOfWarrants" name="GainsLossesOnChangeInFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" name="ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" name="ChangeInFairValueOfPutRightsNetOfRedemptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnRevaluationOfDigitalAssets" name="LossOnRevaluationOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnRevaluationOfDigitalAssetReceivables" name="LossOnRevaluationOfDigitalAssetReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RealizedLossOnSaleOfDigitalAssets" name="RealizedLossOnSaleOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" name="RealizedLossOnNovationOfDigitalAssetsToInvestor" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainOnSettlementWithParexelIoxCro" name="GainOnSettlementWithParexelIoxCro" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnRegisteredDirectOffering" name="LossOnRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OfferingCosts" name="OfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ImpairmentLossIoxIprd" name="ImpairmentLossIoxIprd" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ImpairmentLossTarusIprd" name="ImpairmentLossTarusIprd" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ImpairmentLossStimunity" name="ImpairmentLossStimunity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ImpairmentLossSaugatuck" name="ImpairmentLossSaugatuck" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" name="CommitmentFeeUnderCommittedPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainOnDissolutionOfInvestmentInAssociate" name="GainOnDissolutionOfInvestmentInAssociate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainFromSaleOfInvestmentInPublicCompany" name="GainFromSaleOfInvestmentInPublicCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ImpairmentLossInvestmentInCompedica" name="ImpairmentLossInvestmentInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnRevaluationOfInvestmentInCompedica" name="LossOnRevaluationOfInvestmentInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" name="ChangeInFairValueOfTonPayableToSettlePutRightsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainOnSettlementOfTonPayable" name="GainOnSettlementOfTonPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnSettlementOfPutRightLiability" name="LossOnSettlementOfPutRightLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainOnExtinguishmentOfDebt" name="GainOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareOfLossesFromEquityMethodInvestment" name="ShareOfLossesFromEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetUnrealizedLossOnInvestments" name="NetUnrealizedLossOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IfrsStatementLineItems" name="IfrsStatementLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BalanceApril12022PresplitShares" name="BalanceApril12022PresplitShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderRegisteredDirectOffering" name="SharesIssuedUnderRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderRegisteredDirectOfferingShares" name="SharesIssuedUnderRegisteredDirectOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" name="SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" name="SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServices" name="SharesIssuedOrAccruedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServicesShares" name="SharesIssuedOrAccruedForServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits" name="SharesIssuedPursuantToDistributionOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" name="SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DerecognitionOfInvestmentInPublicCompany" name="DerecognitionOfInvestmentInPublicCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" name="CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" name="SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" name="SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrefundedWarrantsExercised" name="PrefundedWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrefundedWarrantsExercisedShares" name="PrefundedWarrantsExercisedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" name="AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" name="AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedForAccruedBonuses" name="SharesIssuedForAccruedBonuses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedAccruedForBonusesShares" name="SharesIssuedAccruedForBonusesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" name="SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" name="SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedRelatingToAcquisitionOfCompedica" name="SharesIssuedRelatingToAcquisitionOfCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares" name="SharesIssuedRelatingToAcquisitionOfCompedicaShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" name="SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" name="SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExerciseOfPrefundedWarrants" name="ExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExerciseOfPrefundedWarrantsShares" name="ExerciseOfPrefundedWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" name="TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" name="TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightsExercisedAndReturnOfShares" name="PutRightsExercisedAndReturnOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightsExercisedAndReturnShares" name="PutRightsExercisedAndReturnShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets" name="UnrealizedLossOnChangeInFairValueOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" name="UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" name="RealizedLossOnNovationOfDigitalAssetReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnImpairmentInvestmentInCompedica" name="LossOnImpairmentInvestmentInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnRemeasurementOfInvestmentInCompedica" name="LossOnRemeasurementOfInvestmentInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfWarrantLiability" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossFromEquityMethodInvestment" name="LossFromEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnExerciseOfPutRightLiability" name="LossOnExerciseOfPutRightLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnExtinguishmentOfDebt" name="LossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExpensesSettledUsingStablecoin" name="ExpensesSettledUsingStablecoin" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareOfLossInAssociate" name="ShareOfLossInAssociate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfSharesIssuedForServices" name="FairValueOfSharesIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DepreciationAndAmortizations" name="DepreciationAndAmortizations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetChangeInWorkingCapitalComponentsAbstract" name="NetChangeInWorkingCapitalComponentsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchasesOfStablecoin" name="PurchasesOfStablecoin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchasesOfDigitalAssets" name="PurchasesOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SalesOfStablecoin" name="SalesOfStablecoin" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SalesOfDigitalAssets" name="SalesOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EquipmentDeposit" name="EquipmentDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashPaidForInvestmentInCompedica" name="CashPaidForInvestmentInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromExerciseOfPrefundedWarrants" name="ProceedsFromExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement" name="ProceedsFromSharesIssuedUnderPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromRegisteredDirectOffering" name="ProceedsFromRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" name="ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightIssuanceCosts" name="PutRightIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PaymentsOnExternalDebt" name="PaymentsOnExternalDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredFinancingCosts" name="DeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LoanTerminationFee" name="LoanTerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesFromRSUDistribution" name="SharesFromRSUDistribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SupplementalCashFlowInformationsAbstract" name="SupplementalCashFlowInformationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashPaidForInterest" name="CashPaidForInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NoncashInvestingItemsAbstract" name="NoncashInvestingItemsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" name="ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalExpendituresIncludedInAccountsPayable" name="CapitalExpendituresIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RightToUseAssetAcquired" name="RightToUseAssetAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityIncurred" name="LeaseLiabilityIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ContributionOfDigitalAssets" name="ContributionOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ContributionOfStablecoin" name="ContributionOfStablecoin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ContributionOfDigitalAssetsReceivable" name="ContributionOfDigitalAssetsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ContributionOfStablecoinReceivable" name="ContributionOfStablecoinReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica" name="ValueOfSharesUsedToPurchaseInterestInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightsIssuedToInvestors" name="PutRightsIssuedToInvestors" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareIssuanceCostsSettledInCompanyStock" name="ShareIssuanceCostsSettledInCompanyStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock" name="ShareIssuanceCostsSettledInWarrantsOnCompanysStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable" name="SettlementOfPutRightLiabilityUsingStablecoinReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExerciseOfPutRights" name="ExerciseOfPutRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" name="SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReceiptOfDigitalAssetsReceivableTonTokens" name="ReceiptOfDigitalAssetsReceivableTonTokens" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StablecoinUsedToPurchaseDigitalAssets" name="StablecoinUsedToPurchaseDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SaleOfDigitalAssetsSettledInStablecoin" name="SaleOfDigitalAssetsSettledInStablecoin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExchangeOfBitcoinForTonTokens" name="ExchangeOfBitcoinForTonTokens" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExternalDebtProceedsReceivedInStablecoin" name="ExternalDebtProceedsReceivedInStablecoin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PaymentsOnExternalDebtUsingDigitalAssets" name="PaymentsOnExternalDebtUsingDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NoncashOperatingActivitiesAbstract" name="NoncashOperatingActivitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesObtainedInExchangeForStablecoin" name="PrepaidExpensesObtainedInExchangeForStablecoin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureNatureOfOperationsAbstract" name="DisclosureNatureOfOperationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NatureOfOperationsExplanatory" name="NatureOfOperationsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureSignificantAccountingPoliciesAbstract" name="DisclosureSignificantAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" name="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureStablecoinAbstract" name="DisclosureStablecoinAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfStablecoinExplanatory" name="DisclosureOfStablecoinExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureDigitalAssetsAbstract" name="DisclosureDigitalAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfDigitalAssetsExplanatory" name="DisclosureOfDigitalAssetsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" name="DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" name="PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureWarrantLiabilityAbstract" name="DisclosureWarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfWarrantLiabilityExplanatory" name="DisclosureOfWarrantLiabilityExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" name="DisclosurePutRightLiabilityAndTonPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory" name="DisclosureOPutRightLiabilityAndTonPayableExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" name="DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" name="AccountsPayableAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureLeaseLiabilityAbstract" name="DisclosureLeaseLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfLeaseLiabilityExplanatory" name="DisclosureOfLeaseLiabilityExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureBitgoPrimeLoanAbstract" name="DisclosureBitgoPrimeLoanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfBitgoPrimeLoanExplanatory" name="DisclosureOfBitgoPrimeLoanExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureCapitalStockAndReservesAbstract" name="DisclosureCapitalStockAndReservesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalStockAndReservesTextBlock" name="CapitalStockAndReservesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" name="DisclosureFinancialInstrumentsAndRiskManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" name="DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureSegmentReportingAbstract" name="DisclosureSegmentReportingAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock" name="DisclosureOfSegmentReportingExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureCapitalManagementAbstract" name="DisclosureCapitalManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" name="DisclosureOfCapitalManagementExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" name="DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" name="DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" name="DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" name="DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory" name="DescriptionOfAccountingPolicyFoStablecoinExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory" name="DescriptionOfAccountingPolicyForDigitalAssetsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" name="DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory" name="DescriptionOfAccountingPolicyForAccountsReceivableExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" name="DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" name="DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" name="DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" name="DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfStablecoinTableTextBlock" name="DisclosureOfStablecoinTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfStablecoinPurchasesTableTextBlock" name="DisclosureOfStablecoinPurchasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfDigitalAssetsTableTextBlock" name="ScheduleOfDigitalAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock" name="ScheduleOfDigitalAssetsPurchasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeheduleOfTonTokensTableTextBlock" name="SeheduleOfTonTokensTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock" name="ScheduleOfReceivablesDigitalAssetsTableXextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfInvestmentBalanceTableTextBlock" name="ScheduleOfInvestmentBalanceTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" name="ScheduleOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" name="DisclosureOfFairValueMeasurementOfWarrantsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" name="DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory" name="DisclosureOfFairValueMeasurementPlacementAgentExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" name="ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfPutRightLiabilityTableTextBlock" name="ScheduleOfPutRightLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfTonPayableTableTextBlock" name="ScheduleOfTonPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" name="AccountsPayableAndAccruedLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfLeaseLiabilityTableTextBlock" name="ScheduleOfLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" name="ScheduleOfIncomeTaxesBenefitTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" name="ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock" name="ScheduleOfDeferredTaxAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" name="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" name="ScheduleOfTermsStockOptionReserveTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock" name="ScheduleOfWeightedAverageAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" name="ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfEarningsPerShareTableTextBlock" name="ScheduleOfEarningsPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" name="ScheduleOfAntiDilutiveEffectTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfCompensationPayableTableTextBlock" name="ScheduleOfCompensationPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock" name="ScheduleOfOutstandingEquityAwardsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" name="ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" name="LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfSegmentReportingTableTextBlock" name="ScheduleOfSegmentReportingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" name="ScheduleOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TotalCurrentLiabilities" name="TotalCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossIncome" name="NetLossIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashUsedInOperatingActivities" name="CashUsedInOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashCashEquivalents" name="CashCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RestrictedCashOnHand" name="RestrictedCashOnHand" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NoncontrollingInterestIncreasedUponConversion" name="NoncontrollingInterestIncreasedUponConversion" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashRestrictedForUse" name="CashRestrictedForUse" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidInvestorRelations" name="PrepaidInvestorRelations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TaxDeposits" name="TaxDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidGpuInfrastructureCosts" name="PrepaidGpuInfrastructureCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidGpuLeasesShortterm" name="PrepaidGpuLeasesShortterm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TotalPrepaidExpensesAndOtherReceivables" name="TotalPrepaidExpensesAndOtherReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OtherAssetsLongTermPortion" name="OtherAssetsLongTermPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SecurityDeposits" name="SecurityDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Stablecoins" name="Stablecoins" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetValueAsOfApril1" name="DigitalAssetValueAsOfApril1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromSaleOfDigitalAssets" name="ProceedsFromSaleOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StablecoinUsedToSettleOperatingCosts" name="StablecoinUsedToSettleOperatingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StablecoinSold" name="StablecoinSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromExternalDebtDrawdown" name="ProceedsFromExternalDebtDrawdown" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StablecoinValueAsOfMarch31" name="StablecoinValueAsOfMarch31" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ApproximateNumberOfTonTokensHeld" name="ApproximateNumberOfTonTokensHeld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TonTokensFairValueInThousands" name="TonTokensFairValueInThousands" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsFairValueInThousands" name="DigitalAssetsFairValueInThousands" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" name="UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsSold" name="DigitalAssetsSold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetPurchases" name="DigitalAssetPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReceiptOfDigitalAssetsReceivable" name="ReceiptOfDigitalAssetsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RealizedLossGainOnSaleOfDigitalAssets" name="RealizedLossGainOnSaleOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RevenueReceivedInDigitalAssets" name="RevenueReceivedInDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TokensUsedToSettlePutRights" name="TokensUsedToSettlePutRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsExchanged" name="DigitalAssetsExchanged" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsTransacted" name="DigitalAssetsTransacted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetValueAsOfMarch31" name="DigitalAssetValueAsOfMarch31" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear" name="CapitalFutureMinimumPaymentsRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear" name="CapitalFutureMinimumPaymentsRemainderOfSecondYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear" name="CapitalFutureMinimumPaymentsRemainderOfThirdYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear" name="CapitalFutureMinimumPaymentsRemainderOfTotalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ContributionOfDigitalAssetAndStablecoinReceivables" name="ContributionOfDigitalAssetAndStablecoinReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfDigitalAssetsReceivable" name="ChangeInFairValueOfDigitalAssetsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReceiptOfDigitalAssetReceivables" name="ReceiptOfDigitalAssetReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StablecoinValueAsOfSeptember30" name="StablecoinValueAsOfSeptember30" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssets" name="DigitalAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TonTokensReceivable" name="TonTokensReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TonTokensReceivableShares" name="TonTokensReceivableShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TokensArePayable" name="TokensArePayable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" name="AccumulatedDepreciationPropertyPlantAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FixedAssetDepreciation" name="FixedAssetDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FixedAssetDisposals" name="FixedAssetDisposals" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BalanceAsOfApril1" name="BalanceAsOfApril1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InitialInvestmentInCompedica" name="InitialInvestmentInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnImpairment" name="LossOnImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfInvestmentInCompedica" name="ChangeInFairValueOfInvestmentInCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReturnOfInvestmentInterestToCompedica" name="ReturnOfInvestmentInterestToCompedica" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentInCompedicaAsOfMarch31" name="InvestmentInCompedicaAsOfMarch31" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOnInvestmentInCompedica" name="ChangeInFairValueOnInvestmentInCompedica" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" name="FairValueOfWarrantsAtIssuanceExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantsShares" name="FairValueOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantsAmount" name="FairValueOfWarrantsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfWarrantLiabilityAmount" name="ChangeInFairValueOfWarrantLiabilityAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsLiabilityShares" name="WarrantsLiabilityShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsLiabilityFairValue" name="WarrantsLiabilityFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePriceFairValue" name="ExercisePriceFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharePriceFairvalue" name="SharePriceFairvalue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OptionLifeShareOptions" name="OptionLifeShareOptions" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantPerShare" name="FairValueOfWarrantPerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightLiabilityemainingTermInYears" name="PutRightLiabilityemainingTermInYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TonTokenPrice" name="TonTokenPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate" name="LockedTonTokenDiscountForLackOfMarketabilityRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BalanceOfPutRightLiability" name="BalanceOfPutRightLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SettlementOfDwfMaasLimitedPutRight" name="SettlementOfDwfMaasLimitedPutRight" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightLiabilityEndingBalance" name="PutRightLiabilityEndingBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BalanceOfTonPayable" name="BalanceOfTonPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExerciseOfSideLetterPutRightPayable" name="ExerciseOfSideLetterPutRightPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets" name="SettlementOfPutRightLiabilityUsingDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TonPayableEndingBalanceAsOfMarch31" name="TonPayableEndingBalanceAsOfMarch31" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TreasuryManagementAgreementDescription" name="TreasuryManagementAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfContribution" name="FairValueOfContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Usd1Receivable" name="Usd1Receivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnExercise" name="LossOnExercise" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OutstandingContingentPutOptionsFairValue" name="OutstandingContingentPutOptionsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RemeasurementChangeInFairValue" name="RemeasurementChangeInFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayable" name="AccountsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedOtherProfessionalFees" name="AccruedOtherProfessionalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedAccountingAndAuditingFees" name="AccruedAccountingAndAuditingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" name="AccruedBonusesAndOtherPayrollrelatedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedCRO" name="AccruedCRO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProfessionalFeesExpenses" name="ProfessionalFeesExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedClinicalAndRdServices" name="AccruedClinicalAndRdServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalExpenditures" name="CapitalExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OtherAccruedExpenses" name="OtherAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilityNet" name="AccountsPayableAndAccruedLiabilityNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityFutureMinimumPaymentsDue" name="LeaseLiabilityFutureMinimumPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue" name="LeaseLiabilityFutureMinimumPaymentsYearTwoDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue" name="LeaseLiabilityFutureMinimumPaymentsYearDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Interest" name="Interest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TotalLeaseLiability" name="TotalLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityCurrent" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityNoncurrent" name="LeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Commencement" name="Commencement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchasePriceLeaseLiability" name="PurchasePriceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseEquipmentPayment" name="PurchaseEquipmentPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MasterLoanAgreementDescription" name="MasterLoanAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentTaxOnProfitsForYear" name="CurrentTaxOnProfitsForYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdjustmentsForCurrentTaxOfPriorPeriods" name="AdjustmentsForCurrentTaxOfPriorPeriods" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DecreaseIncreaseInDeferredTaxAssets" name="DecreaseIncreaseInDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProfitLossFromContinuingOperation" name="ProfitLossFromContinuingOperation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" name="IncomeLossOnOrdinaryActivitiesBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TaxUsingBviTaxRate" name="TaxUsingBviTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EffectOfTaxRatesInOtherCountries" name="EffectOfTaxRatesInOtherCountries" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DerecognitionOfDeferredTaxAssets" name="DerecognitionOfDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NondeductibleExpenses" name="NondeductibleExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UtilizationOfLossesNotPreviouslyBenefitted" name="UtilizationOfLossesNotPreviouslyBenefitted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeTaxEffectsRelatedToEquityCompensation" name="IncomeTaxEffectsRelatedToEquityCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ForeignCurrencyEffectAndOther" name="ForeignCurrencyEffectAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeTaxExpense" name="IncomeTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxAssetsAbstract" name="DeferredTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" name="DeferredTaxAssetsNetOperatingLossCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockbasedCompensation" name="StockbasedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReservesAndAccruals" name="ReservesAndAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxAssetNotRecognized" name="DeferredTaxAssetNotRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetDeferredTaxAsset" name="NetDeferredTaxAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UkLossCarryForwards" name="UkLossCarryForwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SaleOfStock" name="SaleOfStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AggregateProceeds" name="AggregateProceeds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesPrice" name="SharesPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsToPurchase" name="WarrantsToPurchase" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchasePrice" name="PurchasePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GrossProceeds" name="GrossProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DgitalAssets" name="DgitalAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OrdinarySharesIssued" name="OrdinarySharesIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfSharesSold" name="NumberOfSharesSold" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetProceeds" name="NetProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TreasuryStock" name="TreasuryStock" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AggregateOfferingOrdinaryShares" name="AggregateOfferingOrdinaryShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Proceedsfromexerciseofwarrant" name="Proceedsfromexerciseofwarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalSharesIssued" name="AdditionalSharesIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsPurchase" name="WarrantsPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsPerShare" name="WarrantsPerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionReserve" name="StockOptionReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" name="CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfOutstandingShareOption" name="NumberOfOutstandingShareOption" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" name="NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" name="NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" name="NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" name="NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfGrantPriceShareOptionsGranted" name="DescriptionOfGrantPriceShareOptionsGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OptionLifeShareOptionsGranted" name="OptionLifeShareOptionsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareOptions" name="ShareOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AuthorizedGrantOptionPurchaseShares" name="AuthorizedGrantOptionPurchaseShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedGrantedRsu" name="SharesIssuedGrantedRsu" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfSharesExercise" name="NumberOfSharesExercise" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" name="SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharebasedCompensationExpense" name="SharebasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReversalOfSharebasedCompensation" name="ReversalOfSharebasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareBasedCompensationExpenseUnvestedShareOptions" name="ShareBasedCompensationExpenseUnvestedShareOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WeightedAverageSharesOutstandingDiluted" name="WeightedAverageSharesOutstandingDiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossPerShareBasic" name="LossPerShareBasic" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossPerShareDiluted" name="LossPerShareDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AntidilutiveEffectOnLossPerShare" name="AntidilutiveEffectOnLossPerShare" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ServiceFees" name="ServiceFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BudgetCosts" name="BudgetCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnbilledServices" name="UnbilledServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ForfeitedAdvancedPayments" name="ForfeitedAdvancedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetGain" name="NetGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivables" name="PrepaidExpensesAndOtherReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ContractualPayments" name="ContractualPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetworkingEquipmentCost" name="NetworkingEquipmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Deposit" name="Deposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharebasedPaymentCompensation" name="SharebasedPaymentCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TransactionClosingBonus" name="TransactionClosingBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SecuritiesUnderOptionsGranted" name="SecuritiesUnderOptionsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OtherCompensation" name="OtherCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GrantDate" name="GrantDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" name="NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePrices" name="ExercisePrices" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OptionExpirationDate" name="OptionExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberofShareUnitsofStockThetHaveNotVested" name="NumberofShareUnitsofStockThetHaveNotVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested" name="MarketValueNumberofShareUnitsofStockThetHaveNotVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Decentranet" name="Decentranet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivable" name="PrepaidExpensesAndOtherReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilities" name="AccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityCurrentAndNoncurrent" name="LeaseLiabilityCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsAtFairValueTonLiquid" name="DigitalAssetsAtFairValueTonLiquid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DigitalAssetsAtFairValueTonLocked" name="DigitalAssetsAtFairValueTonLocked" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SegmentLossBeforeBenefitForIncomeTaxes" name="SegmentLossBeforeBenefitForIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeTaxBenefit" name="IncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SegmentNetLoss" name="SegmentNetLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PayablesAndAccruedExpense" name="PayablesAndAccruedExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PutRightLiabilities" name="PutRightLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentAsset" name="CurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossAttributableToNoncontrollingInterest" name="NetLossAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ptgef-20260331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Cover" roleURI="http://portagebiotech.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfFinancialPosition" roleURI="http://portagebiotech.com/role/StatementsOfFinancialPosition" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfChangesInEquityDeficit" roleURI="http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfCashFlows" roleURI="http://portagebiotech.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#NatureOfOperations" roleURI="http://portagebiotech.com/role/NatureOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#GoingConcern" roleURI="http://portagebiotech.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BasisOfPresentation" roleURI="http://portagebiotech.com/role/BasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPolicies" roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssets" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Stablecoin" roleURI="http://portagebiotech.com/role/Stablecoin" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssets" roleURI="http://portagebiotech.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssets" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedica" roleURI="http://portagebiotech.com/role/InvestmentInCompedica" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiability" roleURI="http://portagebiotech.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayable" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayable" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilities" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiability" roleURI="http://portagebiotech.com/role/LeaseLiability" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BitgoPrimeLoan" roleURI="http://portagebiotech.com/role/BitgoPrimeLoan" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxes" roleURI="http://portagebiotech.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReserves" roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserve" roleURI="http://portagebiotech.com/role/StockOptionReserve" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShare" roleURI="http://portagebiotech.com/role/LossPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CommitmentsAndContingentLiabilities" roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactions" roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagement" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReporting" roleURI="http://portagebiotech.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalManagement" roleURI="http://portagebiotech.com/role/CapitalManagement" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterest" roleURI="http://portagebiotech.com/role/Non-controllingInterest" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SubsequentEvents" roleURI="http://portagebiotech.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesTables" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssetsTables" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinTables" roleURI="http://portagebiotech.com/role/StablecoinTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsTables" roleURI="http://portagebiotech.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssetsTables" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaTables" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityTables" roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableTables" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilitiesTables" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityTables" roleURI="http://portagebiotech.com/role/LeaseLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesTables" roleURI="http://portagebiotech.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesTables" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveTables" roleURI="http://portagebiotech.com/role/StockOptionReserveTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareTables" roleURI="http://portagebiotech.com/role/LossPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsTables" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementTables" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReportingTables" roleURI="http://portagebiotech.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterestTables" roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#GoingConcernDetailsNarrative" roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BasisOfPresentationDetailsNarrative" roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesDetails" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesAndOtherReceivablesDetails" roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinDetails" roleURI="http://portagebiotech.com/role/StablecoinDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinDetails1" roleURI="http://portagebiotech.com/role/StablecoinDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails1" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails2" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#ReceivablesDigitalAssetsDetails" roleURI="http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetailsNarrative" roleURI="http://portagebiotech.com/role/DigitalAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaDetails" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaDetailsNarrative" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails1" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails2" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails3" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails4" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails1" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails2" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetailsNarrative" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityDetails" roleURI="http://portagebiotech.com/role/LeaseLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityDetailsNarrative" roleURI="http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BitgoPrimeLoanDetailsNarrative" roleURI="http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails1" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails2" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesDetails" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesDetailsNarrative" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails1" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails2" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails3" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails4" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetailsNarrative" roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareDetails" roleURI="http://portagebiotech.com/role/LossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareDetails1" roleURI="http://portagebiotech.com/role/LossPerShareDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails1" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails3" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementDetails" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementDetails1" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReportingDetails" roleURI="http://portagebiotech.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalManagementDetailsNarrative" roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterestDetails" roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfFinancialPosition" xlink:title="00000002 - Statement - Consolidated Statements of Financial Position">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents" xlink:label="loc_ifrs-fullRestrictedCashAndCashEquivalents" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsReceivable" xlink:label="loc_ptgefAccountsReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ptgefAccountsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoin" xlink:label="loc_ptgefStablecoin" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ptgefStablecoin" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonCurrent" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonNetOfCurrentPortion" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonNetOfCurrentPortion" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EquipmentDeposits" xlink:label="loc_ptgefEquipmentDeposits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ptgefEquipmentDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefTonPayableToSettlePutRightsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ptgefTonPayableToSettlePutRightsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiability" xlink:label="loc_ptgefPutRightLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ptgefPutRightLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentWarrantLiability" xlink:label="loc_ifrs-fullNoncurrentWarrantLiability" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ifrs-fullNoncurrentWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="loc_ifrs-fullTreasuryShares" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullTreasuryShares" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="loc_ifrs-fullDepreciationExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullDepreciationExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssets" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssetReceivables" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossOnSaleOfDigitalAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefRealizedLossOnSaleOfDigitalAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="loc_ptgefLossOnRegisteredDirectOffering" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefLossOnRegisteredDirectOffering" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="loc_ptgefOfferingCosts" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossIoxIprd" xlink:label="loc_ptgefImpairmentLossIoxIprd" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefImpairmentLossIoxIprd" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossTarusIprd" xlink:label="loc_ptgefImpairmentLossTarusIprd" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefImpairmentLossTarusIprd" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossStimunity" xlink:label="loc_ptgefImpairmentLossStimunity" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefImpairmentLossStimunity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossSaugatuck" xlink:label="loc_ptgefImpairmentLossSaugatuck" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefImpairmentLossSaugatuck" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossInvestmentInCompedica" xlink:label="loc_ptgefImpairmentLossInvestmentInCompedica" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefImpairmentLossInvestmentInCompedica" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfInvestmentInCompedica" xlink:label="loc_ptgefLossOnRevaluationOfInvestmentInCompedica" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefLossOnRevaluationOfInvestmentInCompedica" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainOnSettlementOfTonPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnSettlementOfPutRightLiability" xlink:label="loc_ptgefLossOnSettlementOfPutRightLiability" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefLossOnSettlementOfPutRightLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnExtinguishmentOfDebt" xlink:label="loc_ptgefGainOnExtinguishmentOfDebt" />
      <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossesFromEquityMethodInvestment" xlink:label="loc_ptgefShareOfLossesFromEquityMethodInvestment" />
      <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefShareOfLossesFromEquityMethodInvestment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="loc_ptgefNetUnrealizedLossOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ptgefNetUnrealizedLossOnInvestments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit" xlink:title="00000004 - Statement - Consolidated Statements of Changes in Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="loc_ptgefLossOnRegisteredDirectOffering" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefLossOnRegisteredDirectOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="loc_ptgefOfferingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-fullImpairmentLoss" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets" xlink:label="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" xlink:label="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossOnSaleOfDigitalAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefRealizedLossOnSaleOfDigitalAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnImpairmentInvestmentInCompedica" xlink:label="loc_ptgefLossOnImpairmentInvestmentInCompedica" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefLossOnImpairmentInvestmentInCompedica" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRemeasurementOfInvestmentInCompedica" xlink:label="loc_ptgefLossOnRemeasurementOfInvestmentInCompedica" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefLossOnRemeasurementOfInvestmentInCompedica" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfWarrantLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiability" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossFromEquityMethodInvestment" xlink:label="loc_ptgefLossFromEquityMethodInvestment" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefLossFromEquityMethodInvestment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefGainOnSettlementOfTonPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExerciseOfPutRightLiability" xlink:label="loc_ptgefLossOnExerciseOfPutRightLiability" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefLossOnExerciseOfPutRightLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashInterestExpense" xlink:label="loc_ptgefNoncashInterestExpense" />
      <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefNoncashInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExpensesSettledUsingStablecoin" xlink:label="loc_ptgefExpensesSettledUsingStablecoin" />
      <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefExpensesSettledUsingStablecoin" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="loc_ifrs-fullDividendsReceived" />
      <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullDividendsReceived" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossInAssociate" xlink:label="loc_ptgefShareOfLossInAssociate" />
      <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefShareOfLossInAssociate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfSharesIssuedForServices" xlink:label="loc_ptgefFairValueOfSharesIssuedForServices" />
      <link:calculationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefFairValueOfSharesIssuedForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DepreciationAndAmortizations" xlink:label="loc_ptgefDepreciationAndAmortizations" />
      <link:calculationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefDepreciationAndAmortizations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
      <link:calculationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:calculationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:calculationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:calculationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:calculationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:label="loc_ifrs-fullProceedsFromSalesOfInvestmentProperty" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullProceedsFromSalesOfInvestmentProperty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfStablecoin" xlink:label="loc_ptgefPurchasesOfStablecoin" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ptgefPurchasesOfStablecoin" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfDigitalAssets" xlink:label="loc_ptgefPurchasesOfDigitalAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ptgefPurchasesOfDigitalAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfStablecoin" xlink:label="loc_ptgefSalesOfStablecoin" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ptgefSalesOfStablecoin" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfDigitalAssets" xlink:label="loc_ptgefSalesOfDigitalAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ptgefSalesOfDigitalAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EquipmentDeposit" xlink:label="loc_ptgefEquipmentDeposit" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ptgefEquipmentDeposit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashPaidForInvestmentInCompedica" xlink:label="loc_ptgefCashPaidForInvestmentInCompedica" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ptgefCashPaidForInvestmentInCompedica" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderPrivatePlacement" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromRegisteredDirectOffering" xlink:label="loc_ptgefProceedsFromRegisteredDirectOffering" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromRegisteredDirectOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightIssuanceCosts" xlink:label="loc_ptgefPutRightIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefPutRightIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebt" xlink:label="loc_ptgefPaymentsOnExternalDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefPaymentsOnExternalDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredFinancingCosts" xlink:label="loc_ptgefDeferredFinancingCosts" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefDeferredFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LoanTerminationFee" xlink:label="loc_ptgefLoanTerminationFee" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefLoanTerminationFee" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesFromRSUDistribution" xlink:label="loc_ptgefSharesFromRSUDistribution" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefSharesFromRSUDistribution" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="999006 - Disclosure - NATURE OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcern" xlink:title="999007 - Disclosure - GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="999008 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="999009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets" xlink:title="999010 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Stablecoin" xlink:title="999011 - Disclosure - STABLECOIN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssets" xlink:title="999012 - Disclosure - DIGITAL ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets" xlink:title="999013 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedica" xlink:title="999014 - Disclosure - INVESTMENT IN COMPEDICA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="999015 - Disclosure - WARRANT LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayable" xlink:title="999016 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiability" xlink:title="999018 - Disclosure - LEASE LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BitgoPrimeLoan" xlink:title="999019 - Disclosure - BITGO PRIME LOAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:title="999021 - Disclosure - CAPITAL STOCK AND RESERVES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="999022 - Disclosure - STOCK OPTION RESERVE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="999023 - Disclosure - LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="999026 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReporting" xlink:title="999027 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagement" xlink:title="999028 - Disclosure - CAPITAL MANAGEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="999029 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables" xlink:title="999033 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinTables" xlink:title="999034 - Disclosure - STABLECOIN (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsTables" xlink:title="999035 - Disclosure - DIGITAL ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables" xlink:title="999036 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaTables" xlink:title="999037 - Disclosure - INVESTMENT IN COMPEDICA (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="999038 - Disclosure - WARRANT LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables" xlink:title="999039 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="999040 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityTables" xlink:title="999041 - Disclosure - LEASE LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="999042 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:title="999043 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="999044 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="999045 - Disclosure - LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsTables" xlink:title="999046 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="999047 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReportingTables" xlink:title="999048 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="999049 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:title="999050 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999051 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesDetails" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="999054 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" xlink:title="999055 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinDetails" xlink:title="999056 - Disclosure - STABLECOIN (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinDetails1" xlink:title="999057 - Disclosure - STABLECOIN (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails" xlink:title="999058 - Disclosure - DIGITAL ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails1" xlink:title="999059 - Disclosure - DIGITAL ASSETS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails2" xlink:title="999060 - Disclosure - DIGITAL ASSETS (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails" xlink:title="999061 - Disclosure - RECEIVABLES DIGITAL ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetailsNarrative" xlink:title="999062 - Disclosure - DIGITAL ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" xlink:title="999063 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaDetails" xlink:title="999064 - Disclosure - INVESTMENT IN COMPEDICA (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative" xlink:title="999065 - Disclosure - INVESTMENT IN COMPEDICA (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="999066 - Disclosure - WARRANT LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:title="999067 - Disclosure - WARRANT LIABILITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:title="999068 - Disclosure - WARRANT LIABILITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:title="999069 - Disclosure - WARRANT LIABILITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails4" xlink:title="999070 - Disclosure - WARRANT LIABILITY (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999071 - Disclosure - WARRANT LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails" xlink:title="999072 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1" xlink:title="999073 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2" xlink:title="999074 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative" xlink:title="999075 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="999076 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityDetails" xlink:title="999077 - Disclosure - LEASE LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative" xlink:title="999078 - Disclosure - LEASE LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative" xlink:title="999079 - Disclosure - BITGO PRIME LOAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="999080 - Disclosure - INCOME TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:title="999081 - Disclosure - INCOME TAXES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:title="999082 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="loc_ifrs-fullNetDeferredTaxAssets" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:label="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNetDeferredTaxAssets" xlink:to="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockbasedCompensation" xlink:label="loc_ptgefStockbasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNetDeferredTaxAssets" xlink:to="loc_ptgefStockbasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReservesAndAccruals" xlink:label="loc_ptgefReservesAndAccruals" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNetDeferredTaxAssets" xlink:to="loc_ptgefReservesAndAccruals" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="999083 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetails" xlink:title="999084 - Disclosure - CAPITAL STOCK AND RESERVES (Details )" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:title="999085 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="999086 - Disclosure - STOCK OPTION RESERVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="999087 - Disclosure - STOCK OPTION RESERVE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="999088 - Disclosure - STOCK OPTION RESERVE (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:title="999089 - Disclosure - STOCK OPTION RESERVE (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:title="999090 - Disclosure - STOCK OPTION RESERVE (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="999091 - Disclosure - STOCK OPTION RESERVE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="999092 - Disclosure - LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="999093 - Disclosure - LOSS PER SHARE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="999094 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails" xlink:title="999095 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails1" xlink:title="999096 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails3" xlink:title="999097 - Disclosure - RELATED PARTY TRANSACTIONS (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999098 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="999099 - Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1" xlink:title="999100 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReportingDetails" xlink:title="999101 - Disclosure - SEGMENT REPORTING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:title="999102 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="999103 - Disclosure - NON-CONTROLLING INTEREST (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ptgef-20260331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Cover" roleURI="http://portagebiotech.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfFinancialPosition" roleURI="http://portagebiotech.com/role/StatementsOfFinancialPosition" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfChangesInEquityDeficit" roleURI="http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfCashFlows" roleURI="http://portagebiotech.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#NatureOfOperations" roleURI="http://portagebiotech.com/role/NatureOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#GoingConcern" roleURI="http://portagebiotech.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BasisOfPresentation" roleURI="http://portagebiotech.com/role/BasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPolicies" roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssets" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Stablecoin" roleURI="http://portagebiotech.com/role/Stablecoin" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssets" roleURI="http://portagebiotech.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssets" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedica" roleURI="http://portagebiotech.com/role/InvestmentInCompedica" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiability" roleURI="http://portagebiotech.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayable" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayable" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilities" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiability" roleURI="http://portagebiotech.com/role/LeaseLiability" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BitgoPrimeLoan" roleURI="http://portagebiotech.com/role/BitgoPrimeLoan" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxes" roleURI="http://portagebiotech.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReserves" roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserve" roleURI="http://portagebiotech.com/role/StockOptionReserve" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShare" roleURI="http://portagebiotech.com/role/LossPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CommitmentsAndContingentLiabilities" roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactions" roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagement" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReporting" roleURI="http://portagebiotech.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalManagement" roleURI="http://portagebiotech.com/role/CapitalManagement" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterest" roleURI="http://portagebiotech.com/role/Non-controllingInterest" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SubsequentEvents" roleURI="http://portagebiotech.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesTables" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssetsTables" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinTables" roleURI="http://portagebiotech.com/role/StablecoinTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsTables" roleURI="http://portagebiotech.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssetsTables" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaTables" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityTables" roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableTables" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilitiesTables" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityTables" roleURI="http://portagebiotech.com/role/LeaseLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesTables" roleURI="http://portagebiotech.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesTables" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveTables" roleURI="http://portagebiotech.com/role/StockOptionReserveTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareTables" roleURI="http://portagebiotech.com/role/LossPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsTables" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementTables" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReportingTables" roleURI="http://portagebiotech.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterestTables" roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#GoingConcernDetailsNarrative" roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BasisOfPresentationDetailsNarrative" roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesDetails" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesAndOtherReceivablesDetails" roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinDetails" roleURI="http://portagebiotech.com/role/StablecoinDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinDetails1" roleURI="http://portagebiotech.com/role/StablecoinDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails1" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails2" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#ReceivablesDigitalAssetsDetails" roleURI="http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetailsNarrative" roleURI="http://portagebiotech.com/role/DigitalAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaDetails" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaDetailsNarrative" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails1" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails2" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails3" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails4" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails1" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails2" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetailsNarrative" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityDetails" roleURI="http://portagebiotech.com/role/LeaseLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityDetailsNarrative" roleURI="http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BitgoPrimeLoanDetailsNarrative" roleURI="http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails1" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails2" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesDetails" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesDetailsNarrative" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails1" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails2" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails3" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails4" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetailsNarrative" roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareDetails" roleURI="http://portagebiotech.com/role/LossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareDetails1" roleURI="http://portagebiotech.com/role/LossPerShareDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails1" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails3" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementDetails" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementDetails1" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReportingDetails" roleURI="http://portagebiotech.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalManagementDetailsNarrative" roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterestDetails" roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_40" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_40" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_40" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId_40" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName_40" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation_40" xlink:type="arc" order="63" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfFinancialPosition" xlink:title="00000002 - Statement - Consolidated Statements of Financial Position" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit" xlink:title="00000004 - Statement - Consolidated Statements of Changes in Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullIssuedCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ptgefStockOptionReserveMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockMember" xlink:label="loc_ptgefTreasuryStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ptgefTreasuryStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccumulatedOtherComprehensiveIncomeLossMember" xlink:label="loc_ptgefAccumulatedOtherComprehensiveIncomeLossMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ptgefAccumulatedOtherComprehensiveIncomeLossMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceApril12022PresplitShares" xlink:label="loc_ptgefBalanceApril12022PresplitShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefBalanceApril12022PresplitShares_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOffering" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOffering_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOffering_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingShares" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingShares_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" xlink:label="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" xlink:label="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits" xlink:label="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnits_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnits_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" xlink:label="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DerecognitionOfInvestmentInPublicCompany" xlink:label="loc_ptgefDerecognitionOfInvestmentInPublicCompany_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDerecognitionOfInvestmentInPublicCompany_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="loc_ptgefNetUnrealizedLossOnInvestments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetUnrealizedLossOnInvestments_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-fullProfitLossFromContinuingOperations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossFromContinuingOperations_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" xlink:label="loc_ptgefCorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrefundedWarrantsExercised" xlink:label="loc_ptgefPrefundedWarrantsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercised_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrefundedWarrantsExercisedShares" xlink:label="loc_ptgefPrefundedWarrantsExercisedShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercisedShares_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedForAccruedBonuses" xlink:label="loc_ptgefSharesIssuedForAccruedBonuses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForAccruedBonuses_90" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedAccruedForBonusesShares" xlink:label="loc_ptgefSharesIssuedAccruedForBonusesShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedAccruedForBonusesShares_90" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights_90" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares_90" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatingToAcquisitionOfCompedica" xlink:label="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedica_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedica_90" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares" xlink:label="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedicaShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedicaShares_90" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts_90" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares_90" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPrefundedWarrants" xlink:label="loc_ptgefExerciseOfPrefundedWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExerciseOfPrefundedWarrants_90" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPrefundedWarrantsShares" xlink:label="loc_ptgefExerciseOfPrefundedWarrantsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExerciseOfPrefundedWarrantsShares_90" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:label="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_90" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" xlink:label="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares_90" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsExercisedAndReturnOfShares" xlink:label="loc_ptgefPutRightsExercisedAndReturnOfShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightsExercisedAndReturnOfShares_90" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsExercisedAndReturnShares" xlink:label="loc_ptgefPutRightsExercisedAndReturnShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightsExercisedAndReturnShares_90" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:label="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:label="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IOxIPRDMember" xlink:label="loc_ptgefIOxIPRDMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefIOxIPRDMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TarusIPRDMember" xlink:label="loc_ptgefTarusIPRDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefTarusIPRDMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StimunityMember" xlink:label="loc_ptgefStimunityMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefStimunityMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefSaugatuckMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-fullProfitLoss_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract_160" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract_160" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="loc_ptgefLossOnRegisteredDirectOffering_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract_160" xlink:to="loc_ptgefLossOnRegisteredDirectOffering_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="loc_ptgefOfferingCosts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract_160" xlink:to="loc_ptgefOfferingCosts_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-fullImpairmentLoss_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract_160" xlink:to="loc_ifrs-fullImpairmentLoss_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="loc_ptgefGainOnDissolutionOfInvestmentInAssociate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefGainOnDissolutionOfInvestmentInAssociate_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="loc_ptgefGainFromSaleOfInvestmentInPublicCompany_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefGainFromSaleOfInvestmentInPublicCompany_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets" xlink:label="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssets_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" xlink:label="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossOnSaleOfDigitalAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefRealizedLossOnSaleOfDigitalAssets_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnImpairmentInvestmentInCompedica" xlink:label="loc_ptgefLossOnImpairmentInvestmentInCompedica_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefLossOnImpairmentInvestmentInCompedica_160" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRemeasurementOfInvestmentInCompedica" xlink:label="loc_ptgefLossOnRemeasurementOfInvestmentInCompedica_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefLossOnRemeasurementOfInvestmentInCompedica_160" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfWarrantLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiability_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiability_160" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions_160" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossFromEquityMethodInvestment" xlink:label="loc_ptgefLossFromEquityMethodInvestment_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefLossFromEquityMethodInvestment_160" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised_160" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefGainOnSettlementOfTonPayable_160" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExerciseOfPutRightLiability" xlink:label="loc_ptgefLossOnExerciseOfPutRightLiability_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefLossOnExerciseOfPutRightLiability_160" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt_160" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashInterestExpense" xlink:label="loc_ptgefNoncashInterestExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefNoncashInterestExpense_160" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro_160" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExpensesSettledUsingStablecoin" xlink:label="loc_ptgefExpensesSettledUsingStablecoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefExpensesSettledUsingStablecoin_160" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="loc_ifrs-fullDividendsReceived_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-fullDividendsReceived_160" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossInAssociate" xlink:label="loc_ptgefShareOfLossInAssociate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefShareOfLossInAssociate_160" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfSharesIssuedForServices" xlink:label="loc_ptgefFairValueOfSharesIssuedForServices_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefFairValueOfSharesIssuedForServices_160" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DepreciationAndAmortizations" xlink:label="loc_ptgefDepreciationAndAmortizations_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefDepreciationAndAmortizations_160" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:label="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract_160" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract_160" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable_160" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract_160" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses_160" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract_160" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets_160" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract_160" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable_160" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract_160" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities_160" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities_160" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:label="loc_ifrs-fullProceedsFromSalesOfInvestmentProperty_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ifrs-fullProceedsFromSalesOfInvestmentProperty_160" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfStablecoin" xlink:label="loc_ptgefPurchasesOfStablecoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ptgefPurchasesOfStablecoin_160" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfDigitalAssets" xlink:label="loc_ptgefPurchasesOfDigitalAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ptgefPurchasesOfDigitalAssets_160" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfStablecoin" xlink:label="loc_ptgefSalesOfStablecoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ptgefSalesOfStablecoin_160" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfDigitalAssets" xlink:label="loc_ptgefSalesOfDigitalAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ptgefSalesOfDigitalAssets_160" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_160" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EquipmentDeposit" xlink:label="loc_ptgefEquipmentDeposit_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ptgefEquipmentDeposit_160" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashPaidForInvestmentInCompedica" xlink:label="loc_ptgefCashPaidForInvestmentInCompedica_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract_160" xlink:to="loc_ptgefCashPaidForInvestmentInCompedica_160" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities_160" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="loc_ptgefProceedsFromExerciseOfPrefundedWarrants_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefProceedsFromExerciseOfPrefundedWarrants_160" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderPrivatePlacement_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderPrivatePlacement_160" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromRegisteredDirectOffering" xlink:label="loc_ptgefProceedsFromRegisteredDirectOffering_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefProceedsFromRegisteredDirectOffering_160" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_160" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts_160" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightIssuanceCosts" xlink:label="loc_ptgefPutRightIssuanceCosts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefPutRightIssuanceCosts_160" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_160" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebt" xlink:label="loc_ptgefPaymentsOnExternalDebt_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefPaymentsOnExternalDebt_160" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredFinancingCosts" xlink:label="loc_ptgefDeferredFinancingCosts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefDeferredFinancingCosts_160" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LoanTerminationFee" xlink:label="loc_ptgefLoanTerminationFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefLoanTerminationFee_160" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesFromRSUDistribution" xlink:label="loc_ptgefSharesFromRSUDistribution_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract_160" xlink:to="loc_ptgefSharesFromRSUDistribution_160" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities_160" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents_160" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="loc_ifrs-fullCurrentRestrictedCashAndCashEquivalents_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentRestrictedCashAndCashEquivalents_160" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SupplementalCashFlowInformationsAbstract" xlink:label="loc_ptgefSupplementalCashFlowInformationsAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSupplementalCashFlowInformationsAbstract_160" xlink:type="arc" order="65" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashPaidForInterest" xlink:label="loc_ptgefCashPaidForInterest_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefSupplementalCashFlowInformationsAbstract_160" xlink:to="loc_ptgefCashPaidForInterest_160" xlink:type="arc" order="66" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashInvestingItemsAbstract" xlink:label="loc_ptgefNoncashInvestingItemsAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:type="arc" order="67" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" xlink:label="loc_ptgefExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue_160" xlink:type="arc" order="68" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalExpendituresIncludedInAccountsPayable" xlink:label="loc_ptgefCapitalExpendituresIncludedInAccountsPayable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefCapitalExpendituresIncludedInAccountsPayable_160" xlink:type="arc" order="69" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RightToUseAssetAcquired" xlink:label="loc_ptgefRightToUseAssetAcquired_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefRightToUseAssetAcquired_160" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityIncurred" xlink:label="loc_ptgefLeaseLiabilityIncurred_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefLeaseLiabilityIncurred_160" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssets" xlink:label="loc_ptgefContributionOfDigitalAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefContributionOfDigitalAssets_160" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoin" xlink:label="loc_ptgefContributionOfStablecoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefContributionOfStablecoin_160" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssetsReceivable" xlink:label="loc_ptgefContributionOfDigitalAssetsReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefContributionOfDigitalAssetsReceivable_160" xlink:type="arc" order="74" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoinReceivable" xlink:label="loc_ptgefContributionOfStablecoinReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefContributionOfStablecoinReceivable_160" xlink:type="arc" order="75" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica" xlink:label="loc_ptgefValueOfSharesUsedToPurchaseInterestInCompedica_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefValueOfSharesUsedToPurchaseInterestInCompedica_160" xlink:type="arc" order="76" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:label="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_160" xlink:type="arc" order="77" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsIssuedToInvestors" xlink:label="loc_ptgefPutRightsIssuedToInvestors_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefPutRightsIssuedToInvestors_160" xlink:type="arc" order="78" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareIssuanceCostsSettledInCompanyStock" xlink:label="loc_ptgefShareIssuanceCostsSettledInCompanyStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefShareIssuanceCostsSettledInCompanyStock_160" xlink:type="arc" order="79" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock" xlink:label="loc_ptgefShareIssuanceCostsSettledInWarrantsOnCompanysStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefShareIssuanceCostsSettledInWarrantsOnCompanysStock_160" xlink:type="arc" order="80" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable" xlink:label="loc_ptgefSettlementOfPutRightLiabilityUsingStablecoinReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefSettlementOfPutRightLiabilityUsingStablecoinReceivable_160" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPutRights" xlink:label="loc_ptgefExerciseOfPutRights_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefExerciseOfPutRights_160" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" xlink:label="loc_ptgefSettlementOfPutRightLiabilityUsingDigitalAssetReceivables_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefSettlementOfPutRightLiabilityUsingDigitalAssetReceivables_160" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetsReceivableTonTokens" xlink:label="loc_ptgefReceiptOfDigitalAssetsReceivableTonTokens_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefReceiptOfDigitalAssetsReceivableTonTokens_160" xlink:type="arc" order="84" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToPurchaseDigitalAssets" xlink:label="loc_ptgefStablecoinUsedToPurchaseDigitalAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefStablecoinUsedToPurchaseDigitalAssets_160" xlink:type="arc" order="85" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaleOfDigitalAssetsSettledInStablecoin" xlink:label="loc_ptgefSaleOfDigitalAssetsSettledInStablecoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefSaleOfDigitalAssetsSettledInStablecoin_160" xlink:type="arc" order="86" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExchangeOfBitcoinForTonTokens" xlink:label="loc_ptgefExchangeOfBitcoinForTonTokens_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefExchangeOfBitcoinForTonTokens_160" xlink:type="arc" order="87" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExternalDebtProceedsReceivedInStablecoin" xlink:label="loc_ptgefExternalDebtProceedsReceivedInStablecoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefExternalDebtProceedsReceivedInStablecoin_160" xlink:type="arc" order="88" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebtUsingDigitalAssets" xlink:label="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashInvestingItemsAbstract_160" xlink:to="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets_160" xlink:type="arc" order="89" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashOperatingActivitiesAbstract" xlink:label="loc_ptgefNoncashOperatingActivitiesAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNoncashOperatingActivitiesAbstract_160" xlink:type="arc" order="90" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesObtainedInExchangeForStablecoin" xlink:label="loc_ptgefPrepaidExpensesObtainedInExchangeForStablecoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefNoncashOperatingActivitiesAbstract_160" xlink:to="loc_ptgefPrepaidExpensesObtainedInExchangeForStablecoin_160" xlink:type="arc" order="91" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="999006 - Disclosure - NATURE OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcern" xlink:title="999007 - Disclosure - GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="999008 - Disclosure - BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="999009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets" xlink:title="999010 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Stablecoin" xlink:title="999011 - Disclosure - STABLECOIN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssets" xlink:title="999012 - Disclosure - DIGITAL ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets" xlink:title="999013 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedica" xlink:title="999014 - Disclosure - INVESTMENT IN COMPEDICA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="999015 - Disclosure - WARRANT LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayable" xlink:title="999016 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiability" xlink:title="999018 - Disclosure - LEASE LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BitgoPrimeLoan" xlink:title="999019 - Disclosure - BITGO PRIME LOAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:title="999021 - Disclosure - CAPITAL STOCK AND RESERVES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="999022 - Disclosure - STOCK OPTION RESERVE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="999023 - Disclosure - LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="999026 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReporting" xlink:title="999027 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagement" xlink:title="999028 - Disclosure - CAPITAL MANAGEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="999029 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables" xlink:title="999033 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinTables" xlink:title="999034 - Disclosure - STABLECOIN (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsTables" xlink:title="999035 - Disclosure - DIGITAL ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables" xlink:title="999036 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaTables" xlink:title="999037 - Disclosure - INVESTMENT IN COMPEDICA (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="999038 - Disclosure - WARRANT LIABILITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables" xlink:title="999039 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="999040 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityTables" xlink:title="999041 - Disclosure - LEASE LIABILITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="999042 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:title="999043 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="999044 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="999045 - Disclosure - LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsTables" xlink:title="999046 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="999047 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReportingTables" xlink:title="999048 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="999049 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:title="999050 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999051 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:to="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:to="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain" xlink:to="loc_ptgefIOXMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="loc_ifrs-fullConsolidatedStructuredEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullConsolidatedStructuredEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsolidatedStructuredEntitiesDomain" xlink:label="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullConsolidatedStructuredEntitiesAxis" xlink:to="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsolidatedStructuredEntitiesDomain" xlink:label="loc_ifrs-fullConsolidatedStructuredEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullConsolidatedStructuredEntitiesAxis" xlink:to="loc_ifrs-fullConsolidatedStructuredEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" xlink:to="loc_ptgefSalvaRxMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StimunityMember" xlink:label="loc_ptgefStimunityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" xlink:to="loc_ptgefStimunityMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullBottomOfRangeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullTopOfRangeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-fullGeographicalAreasAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullGeographicalAreasAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-fullGeographicalAreasDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullGeographicalAreasAxis" xlink:to="loc_ifrs-fullGeographicalAreasDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-fullGeographicalAreasDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullGeographicalAreasAxis" xlink:to="loc_ifrs-fullGeographicalAreasDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CountryOfBritishVirginIslandsMember" xlink:label="loc_ptgefCountryOfBritishVirginIslandsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullGeographicalAreasDomain" xlink:to="loc_ptgefCountryOfBritishVirginIslandsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DelawareMember" xlink:label="loc_ptgefDelawareMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullGeographicalAreasDomain" xlink:to="loc_ptgefDelawareMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SubsidiariesTwoMember" xlink:label="loc_ptgefSubsidiariesTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefSubsidiariesTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInSubsidiary_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInSubsidiary_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncontrollingInterestIncreasedUponConversion" xlink:label="loc_ptgefNoncontrollingInterestIncreasedUponConversion_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNoncontrollingInterestIncreasedUponConversion_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesDetails" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:label="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-fullWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ifrs-fullWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ptgefStockOptionsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ptgefRestrictedStockUnitsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:label="loc_ifrs-fullNumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="999054 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" xlink:title="999055 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinDetails" xlink:title="999056 - Disclosure - STABLECOIN (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USDCMember" xlink:label="loc_ptgefUSDCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_ptgefUSDCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UsdtMember" xlink:label="loc_ptgefUsdtMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_ptgefUsdtMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoins" xlink:label="loc_ptgefStablecoins_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoins_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinDetails1" xlink:title="999057 - Disclosure - STABLECOIN (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USDCMember" xlink:label="loc_ptgefUSDCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefUSDCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UsdtMember" xlink:label="loc_ptgefUsdtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefUsdtMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefTotalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfApril1" xlink:label="loc_ptgefDigitalAssetValueAsOfApril1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfApril1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoin" xlink:label="loc_ptgefContributionOfStablecoin_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContributionOfStablecoin_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSaleOfDigitalAssets" xlink:label="loc_ptgefProceedsFromSaleOfDigitalAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsFromSaleOfDigitalAssets_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToSettleOperatingCosts" xlink:label="loc_ptgefStablecoinUsedToSettleOperatingCosts_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinUsedToSettleOperatingCosts_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinSold" xlink:label="loc_ptgefStablecoinSold_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinSold_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromExternalDebtDrawdown" xlink:label="loc_ptgefProceedsFromExternalDebtDrawdown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsFromExternalDebtDrawdown_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfStablecoin" xlink:label="loc_ptgefPurchasesOfStablecoin_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchasesOfStablecoin_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToPurchaseDigitalAssets" xlink:label="loc_ptgefStablecoinUsedToPurchaseDigitalAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinUsedToPurchaseDigitalAssets_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinValueAsOfMarch31" xlink:label="loc_ptgefStablecoinValueAsOfMarch31_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinValueAsOfMarch31_40" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails" xlink:title="999058 - Disclosure - DIGITAL ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails1" xlink:title="999059 - Disclosure - DIGITAL ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:label="loc_ifrs-fullDisclosureOfIntangibleAssetsMaterialToEntityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:label="loc_ifrs-fullIntangibleAssetsMaterialToEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:to="loc_ifrs-fullIntangibleAssetsMaterialToEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsMaterialToEntityDomain" xlink:label="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityAxis" xlink:to="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsMaterialToEntityDomain" xlink:label="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityAxis" xlink:to="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TONMember" xlink:label="loc_ptgefTONMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" xlink:to="loc_ptgefTONMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BITCOINMember" xlink:label="loc_ptgefBITCOINMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" xlink:to="loc_ptgefBITCOINMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" xlink:to="loc_ptgefTotalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfApril1" xlink:label="loc_ptgefDigitalAssetValueAsOfApril1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfApril1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssets" xlink:label="loc_ptgefContributionOfDigitalAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContributionOfDigitalAssets_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" xlink:label="loc_ptgefUnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsSold" xlink:label="loc_ptgefDigitalAssetsSold_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsSold_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebtUsingDigitalAssets" xlink:label="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetPurchases" xlink:label="loc_ptgefDigitalAssetPurchases_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetPurchases_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetsReceivable" xlink:label="loc_ptgefReceiptOfDigitalAssetsReceivable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReceiptOfDigitalAssetsReceivable_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossGainOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossGainOnSaleOfDigitalAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossGainOnSaleOfDigitalAssets_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RevenueReceivedInDigitalAssets" xlink:label="loc_ptgefRevenueReceivedInDigitalAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRevenueReceivedInDigitalAssets_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TokensUsedToSettlePutRights" xlink:label="loc_ptgefTokensUsedToSettlePutRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTokensUsedToSettlePutRights_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsExchanged" xlink:label="loc_ptgefDigitalAssetsExchanged_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsExchanged_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsTransacted" xlink:label="loc_ptgefDigitalAssetsTransacted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsTransacted_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfMarch31" xlink:label="loc_ptgefDigitalAssetValueAsOfMarch31_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfMarch31_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails2" xlink:title="999060 - Disclosure - DIGITAL ASSETS (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails" xlink:title="999061 - Disclosure - RECEIVABLES DIGITAL ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USD1Member" xlink:label="loc_ptgefUSD1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefUSD1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LockedTonMember" xlink:label="loc_ptgefLockedTonMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefLockedTonMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefTotalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfApril1" xlink:label="loc_ptgefDigitalAssetValueAsOfApril1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfApril1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssetAndStablecoinReceivables" xlink:label="loc_ptgefContributionOfDigitalAssetAndStablecoinReceivables_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContributionOfDigitalAssetAndStablecoinReceivables_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDigitalAssetsReceivable" xlink:label="loc_ptgefChangeInFairValueOfDigitalAssetsReceivable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfDigitalAssetsReceivable_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetReceivables" xlink:label="loc_ptgefReceiptOfDigitalAssetReceivables_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReceiptOfDigitalAssetReceivables_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TokensUsedToSettlePutRights" xlink:label="loc_ptgefTokensUsedToSettlePutRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTokensUsedToSettlePutRights_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinValueAsOfSeptember30" xlink:label="loc_ptgefStablecoinValueAsOfSeptember30_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinValueAsOfSeptember30_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetailsNarrative" xlink:title="999062 - Disclosure - DIGITAL ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" xlink:title="999063 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GPUsMember" xlink:label="loc_ptgefGPUsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefGPUsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GPUDepositsMember" xlink:label="loc_ptgefGPUDepositsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefGPUDepositsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RightOfUseAssetMember" xlink:label="loc_ptgefRightOfUseAssetMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefRightOfUseAssetMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefTotalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-fullAdditionsToRightofuseAssets_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsToRightofuseAssets_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullDisposalsPropertyPlantAndEquipment_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisposalsPropertyPlantAndEquipment_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" xlink:label="loc_ptgefAccumulatedDepreciationPropertyPlantAndEquipment_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAccumulatedDepreciationPropertyPlantAndEquipment_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FixedAssetDepreciation" xlink:label="loc_ptgefFixedAssetDepreciation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFixedAssetDepreciation_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FixedAssetDisposals" xlink:label="loc_ptgefFixedAssetDisposals_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFixedAssetDisposals_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment_210" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaDetails" xlink:title="999064 - Disclosure - INVESTMENT IN COMPEDICA (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative" xlink:title="999065 - Disclosure - INVESTMENT IN COMPEDICA (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="999066 - Disclosure - WARRANT LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ClassBWarrantsMember" xlink:label="loc_ptgefClassBWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefClassBWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ClassCWarrantsMember" xlink:label="loc_ptgefClassCWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefClassCWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:label="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsShares" xlink:label="loc_ptgefFairValueOfWarrantsShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsShares_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsAmount" xlink:label="loc_ptgefFairValueOfWarrantsAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAmount_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityShares" xlink:label="loc_ptgefWarrantsLiabilityShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityShares_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="loc_ptgefWarrantsLiabilityFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityFairValue_110" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:title="999067 - Disclosure - WARRANT LIABILITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeriesBWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:title="999068 - Disclosure - WARRANT LIABILITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeriesCWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:title="999069 - Disclosure - WARRANT LIABILITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails4" xlink:title="999070 - Disclosure - WARRANT LIABILITY (Details 4)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentsWarrantsMember" xlink:label="loc_ptgefPlacementAgentsWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentsWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999071 - Disclosure - WARRANT LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeiesBWarrantsMember" xlink:label="loc_ptgefSeiesBWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeiesBWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeiesCWarrantsMember" xlink:label="loc_ptgefSeiesCWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeiesCWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrants2026Member" xlink:label="loc_ptgefPlacementAgentWarrants2026Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrants2026Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantPerShare" xlink:label="loc_ptgefFairValueOfWarrantPerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantPerShare_120" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails" xlink:title="999072 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokenVolatilityMember" xlink:label="loc_ptgefTonTokenVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefTonTokenVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiabilityemainingTermInYears" xlink:label="loc_ptgefPutRightLiabilityemainingTermInYears_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightLiabilityemainingTermInYears_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokenPrice" xlink:label="loc_ptgefTonTokenPrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTonTokenPrice_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate" xlink:label="loc_ptgefLockedTonTokenDiscountForLackOfMarketabilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLockedTonTokenDiscountForLackOfMarketabilityRate_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1" xlink:title="999073 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2" xlink:title="999074 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative" xlink:title="999075 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="999076 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityDetails" xlink:title="999077 - Disclosure - LEASE LIABILITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative" xlink:title="999078 - Disclosure - LEASE LIABILITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative" xlink:title="999079 - Disclosure - BITGO PRIME LOAN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="999080 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:title="999081 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:title="999082 - Disclosure - INCOME TAXES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="999083 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetails" xlink:title="999084 - Disclosure - CAPITAL STOCK AND RESERVES (Details )">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:title="999085 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_ptgefATMMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaleOfStock" xlink:label="loc_ptgefSaleOfStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSaleOfStock_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AggregateProceeds" xlink:label="loc_ptgefAggregateProceeds_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateProceeds_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesPrice" xlink:label="loc_ptgefSharesPrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesPrice_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsToPurchase" xlink:label="loc_ptgefWarrantsToPurchase_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsToPurchase_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasePrice" xlink:label="loc_ptgefPurchasePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchasePrice_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrossProceeds" xlink:label="loc_ptgefGrossProceeds_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceeds_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-fullCash_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCash_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DgitalAssets" xlink:label="loc_ptgefDgitalAssets_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDgitalAssets_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OrdinarySharesIssued" xlink:label="loc_ptgefOrdinarySharesIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOrdinarySharesIssued_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetProceeds" xlink:label="loc_ptgefNetProceeds_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceeds_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStock" xlink:label="loc_ptgefTreasuryStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTreasuryStock_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AggregateOfferingOrdinaryShares" xlink:label="loc_ptgefAggregateOfferingOrdinaryShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateOfferingOrdinaryShares_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Proceedsfromexerciseofwarrant" xlink:label="loc_ptgefProceedsfromexerciseofwarrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsfromexerciseofwarrant_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-fullProceedsFromExerciseOfWarrants_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromExerciseOfWarrants_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-fullIncreaseDecreaseInNumberOfSharesOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseInNumberOfSharesOutstanding_140" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalSharesIssued" xlink:label="loc_ptgefAdditionalSharesIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalSharesIssued_140" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsPurchase" xlink:label="loc_ptgefWarrantsPurchase_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsPurchase_140" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsPerShare" xlink:label="loc_ptgefWarrantsPerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsPerShare_140" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="999086 - Disclosure - STOCK OPTION RESERVE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="999087 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain" xlink:label="loc_ifrs-fullDefinedBenefitPlansDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain" xlink:label="loc_ifrs-fullDefinedBenefitPlansDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansDomain" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="999088 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullMeasurementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="loc_ifrs-fullMeasurementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullMeasurementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="loc_ifrs-fullMeasurementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullMeasurementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionGrantedMember" xlink:label="loc_ptgefStockOptionGrantedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullMeasurementDomain" xlink:to="loc_ptgefStockOptionGrantedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfGrantPriceShareOptionsGranted" xlink:label="loc_ptgefDescriptionOfGrantPriceShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfGrantPriceShareOptionsGranted_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="loc_ptgefOptionLifeShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptionsGranted_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:title="999089 - Disclosure - STOCK OPTION RESERVE (Details 3)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:title="999090 - Disclosure - STOCK OPTION RESERVE (Details 4)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:label="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateBenchmarksAxis" xlink:label="loc_ifrs-fullInterestRateBenchmarksAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:to="loc_ifrs-fullInterestRateBenchmarksAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateBenchmarksDomain" xlink:label="loc_ifrs-fullInterestRateBenchmarksDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullInterestRateBenchmarksAxis" xlink:to="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateBenchmarksDomain" xlink:label="loc_ifrs-fullInterestRateBenchmarksDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullInterestRateBenchmarksAxis" xlink:to="loc_ifrs-fullInterestRateBenchmarksDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_January132021Member" xlink:label="loc_ptgefJanuary132021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJanuary132021Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_January192022Member" xlink:label="loc_ptgefJanuary192022Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJanuary192022Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_February152022Member" xlink:label="loc_ptgefFebruary152022Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefFebruary152022Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_June82022Member" xlink:label="loc_ptgefJune82022Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJune82022Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_July272022Member" xlink:label="loc_ptgefJuly272022Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJuly272022Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March302023Member" xlink:label="loc_ptgefMarch302023Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefMarch302023Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March72025Member" xlink:label="loc_ptgefMarch72025Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefMarch72025Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_July272026Member" xlink:label="loc_ptgefJuly272026Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJuly272026Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March112026Member" xlink:label="loc_ptgefMarch112026Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefMarch112026Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExpirationDate" xlink:label="loc_ptgefExpirationDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExpirationDate_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePrice" xlink:label="loc_ptgefExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOptions" xlink:label="loc_ptgefShareOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareOptions_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="999091 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:label="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="loc_ifrs-fullRestrictedShareUnitsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ifrs-fullRestrictedShareUnitsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ifrs-fullMeasurementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="loc_ifrs-fullMeasurementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullMeasurementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="loc_ifrs-fullMeasurementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullMeasurementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_VestedStockOptionMember" xlink:label="loc_ptgefVestedStockOptionMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullMeasurementDomain" xlink:to="loc_ptgefVestedStockOptionMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AuthorizedGrantOptionPurchaseShares" xlink:label="loc_ptgefAuthorizedGrantOptionPurchaseShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAuthorizedGrantOptionPurchaseShares_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedGrantedRsu" xlink:label="loc_ptgefSharesIssuedGrantedRsu_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedGrantedRsu_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfSharesExercise" xlink:label="loc_ptgefNumberOfSharesExercise_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesExercise_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:label="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharebasedCompensationExpense" xlink:label="loc_ptgefSharebasedCompensationExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharebasedCompensationExpense_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReversalOfSharebasedCompensation" xlink:label="loc_ptgefReversalOfSharebasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReversalOfSharebasedCompensation_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareBasedCompensationExpenseUnvestedShareOptions" xlink:label="loc_ptgefShareBasedCompensationExpenseUnvestedShareOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareBasedCompensationExpenseUnvestedShareOptions_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="999092 - Disclosure - LOSS PER SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="999093 - Disclosure - LOSS PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-fullWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ifrs-fullWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefStockOptionsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRestrictedStockUnitsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShare_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="999094 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CROMember" xlink:label="loc_ptgefCROMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_ptgefCROMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CROAgreementMember" xlink:label="loc_ptgefCROAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_ptgefCROAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ServiceFees" xlink:label="loc_ptgefServiceFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefServiceFees_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BudgetCosts" xlink:label="loc_ptgefBudgetCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefBudgetCosts_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrossProceeds" xlink:label="loc_ptgefGrossProceeds_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceeds_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnbilledServices" xlink:label="loc_ptgefUnbilledServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnbilledServices_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ForfeitedAdvancedPayments" xlink:label="loc_ptgefForfeitedAdvancedPayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefForfeitedAdvancedPayments_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetGain" xlink:label="loc_ptgefNetGain_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetGain_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivables_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivables_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContractualPayments" xlink:label="loc_ptgefContractualPayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContractualPayments_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SecurityDeposits" xlink:label="loc_ptgefSecurityDeposits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSecurityDeposits_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetworkingEquipmentCost" xlink:label="loc_ptgefNetworkingEquipmentCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetworkingEquipmentCost_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Deposit" xlink:label="loc_ptgefDeposit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDeposit_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails" xlink:title="999095 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails1" xlink:title="999096 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MichaelTerpinMember" xlink:label="loc_ptgefMichaelTerpinMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefMichaelTerpinMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FDanielSicilianoMember" xlink:label="loc_ptgefFDanielSicilianoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefFDanielSicilianoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GregoryHBaileyMDMember" xlink:label="loc_ptgefGregoryHBaileyMDMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefGregoryHBaileyMDMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JamesMellonMember" xlink:label="loc_ptgefJamesMellonMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJamesMellonMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StevenMintzMember" xlink:label="loc_ptgefStevenMintzMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefStevenMintzMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JeanChristopheRenondinMDMember" xlink:label="loc_ptgefJeanChristopheRenondinMDMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJeanChristopheRenondinMDMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JustinStebbingMDPhDMember" xlink:label="loc_ptgefJustinStebbingMDPhDMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJustinStebbingMDPhDMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LindaKozickMember" xlink:label="loc_ptgefLindaKozickMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefLindaKozickMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MarkSimonMember" xlink:label="loc_ptgefMarkSimonMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefMarkSimonMember_400" xlink:type="arc" order="402" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertGlassmanMember" xlink:label="loc_ptgefRobertGlassmanMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertGlassmanMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrittanyKaiserMember" xlink:label="loc_ptgefBrittanyKaiserMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrittanyKaiserMember_540" xlink:type="arc" order="542" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EnzoVillaniMember" xlink:label="loc_ptgefEnzoVillaniMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefEnzoVillaniMember_560" xlink:type="arc" order="562" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WesLevittMember" xlink:label="loc_ptgefWesLevittMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefWesLevittMember_580" xlink:type="arc" order="582" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_YuryMitinMember" xlink:label="loc_ptgefYuryMitinMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefYuryMitinMember_590" xlink:type="arc" order="592" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettMember" xlink:label="loc_ptgefAlexanderPickettMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAlexanderPickettMember_610" xlink:type="arc" order="612" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanWaltersMember" xlink:label="loc_ptgefIanWaltersMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanWaltersMember_650" xlink:type="arc" order="652" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaParkMember" xlink:label="loc_ptgefAndreaParkMember_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAndreaParkMember_710" xlink:type="arc" order="712" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawMember" xlink:label="loc_ptgefAllanShawMember_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawMember_750" xlink:type="arc" order="752" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerMember" xlink:label="loc_ptgefRobertKramerMember_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerMember_810" xlink:type="arc" order="812" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyMember" xlink:label="loc_ptgefBrianWileyMember_870" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrianWileyMember_870" xlink:type="arc" order="872" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JustinFairchildMember" xlink:label="loc_ptgefJustinFairchildMember_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJustinFairchildMember_930" xlink:type="arc" order="932" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DirectorCompensationMember" xlink:label="loc_ptgefDirectorCompensationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" xlink:to="loc_ptgefDirectorCompensationMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExecutiveOfficerCompensationMember" xlink:label="loc_ptgefExecutiveOfficerCompensationMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" xlink:to="loc_ptgefExecutiveOfficerCompensationMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-fullFeeAndCommissionExpense_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFeeAndCommissionExpense_1000" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionIncome" xlink:label="loc_ifrs-fullFeeAndCommissionIncome_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFeeAndCommissionIncome_1000" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TransactionClosingBonus" xlink:label="loc_ptgefTransactionClosingBonus_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTransactionClosingBonus_1000" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SecuritiesUnderOptionsGranted" xlink:label="loc_ptgefSecuritiesUnderOptionsGranted_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSecuritiesUnderOptionsGranted_1000" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_1000" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OtherCompensation" xlink:label="loc_ptgefOtherCompensation_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOtherCompensation_1000" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullCompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_1000" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails3" xlink:title="999097 - Disclosure - RELATED PARTY TRANSACTIONS (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettMember" xlink:label="loc_ptgefAlexanderPickettMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAlexanderPickettMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettTwoMember" xlink:label="loc_ptgefAlexanderPickettTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAlexanderPickettTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersMember" xlink:label="loc_ptgefIanBWaltersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanBWaltersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersTwoMember" xlink:label="loc_ptgefIanBWaltersTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanBWaltersTwoMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersThreeMember" xlink:label="loc_ptgefIanBWaltersThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanBWaltersThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaEParkMember" xlink:label="loc_ptgefAndreaEParkMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAndreaEParkMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaEParkTwoMember" xlink:label="loc_ptgefAndreaEParkTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAndreaEParkTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawMember" xlink:label="loc_ptgefAllanShawMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawTwoMember" xlink:label="loc_ptgefAllanShawTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawThreeMember" xlink:label="loc_ptgefAllanShawThreeMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawThreeMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerMember" xlink:label="loc_ptgefRobertKramerMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerTwoMember" xlink:label="loc_ptgefRobertKramerTwoMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerTwoMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerThreeMember" xlink:label="loc_ptgefRobertKramerThreeMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerThreeMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyMember" xlink:label="loc_ptgefBrianWileyMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrianWileyMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyTwoMember" xlink:label="loc_ptgefBrianWileyTwoMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrianWileyTwoMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrittanyKaiserMember" xlink:label="loc_ptgefBrittanyKaiserMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrittanyKaiserMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EnzoVillaniMember" xlink:label="loc_ptgefEnzoVillaniMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefEnzoVillaniMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_YuryMitinMember" xlink:label="loc_ptgefYuryMitinMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefYuryMitinMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrantDate" xlink:label="loc_ptgefGrantDate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrantDate_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" xlink:label="loc_ptgefNumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePrices" xlink:label="loc_ptgefExercisePrices_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrices_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionExpirationDate" xlink:label="loc_ptgefOptionExpirationDate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionExpirationDate_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberofShareUnitsofStockThetHaveNotVested" xlink:label="loc_ptgefNumberofShareUnitsofStockThetHaveNotVested_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberofShareUnitsofStockThetHaveNotVested_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested" xlink:label="loc_ptgefMarketValueNumberofShareUnitsofStockThetHaveNotVested_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMarketValueNumberofShareUnitsofStockThetHaveNotVested_190" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999098 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="999099 - Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" xlink:to="loc_ptgefAmortizedCostMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueThroughProfitOrLossMember" xlink:label="loc_ptgefFairValueThroughProfitOrLossMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" xlink:to="loc_ptgefFairValueThroughProfitOrLossMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" xlink:to="loc_ifrs-fullCashAndCashEquivalents_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoin" xlink:label="loc_ptgefStablecoin_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" xlink:to="loc_ptgefStablecoin_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivable_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefTonPayableToSettlePutRightsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:to="loc_ptgefTonPayableToSettlePutRightsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiability" xlink:label="loc_ptgefPutRightLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:to="loc_ptgefPutRightLiability_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:to="loc_ifrs-fullWarrantLiability_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityCurrentAndNoncurrent" xlink:label="loc_ptgefLeaseLiabilityCurrentAndNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:to="loc_ptgefLeaseLiabilityCurrentAndNoncurrent_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1" xlink:title="999100 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:label="loc_ifrs-fullImpairmentOfFinancialAssetsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="loc_ifrs-fullImpairmentOfFinancialAssetsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentOfFinancialAssetsDomain" xlink:label="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsAxis" xlink:to="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentOfFinancialAssetsDomain" xlink:label="loc_ifrs-fullImpairmentOfFinancialAssetsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsAxis" xlink:to="loc_ifrs-fullImpairmentOfFinancialAssetsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level1Member" xlink:label="loc_ptgefLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" xlink:to="loc_ptgefLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level2Member" xlink:label="loc_ptgefLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" xlink:to="loc_ptgefLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level3Member" xlink:label="loc_ptgefLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" xlink:to="loc_ptgefLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonLiquid" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonLiquid_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonLiquid_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonLocked" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonLocked_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonLocked_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefTonPayableToSettlePutRightsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTonPayableToSettlePutRightsExercised_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiability" xlink:label="loc_ptgefPutRightLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightLiability_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWarrantLiability_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReportingDetails" xlink:title="999101 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalComputeMember" xlink:label="loc_ptgefDigitalComputeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefDigitalComputeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImmunoOncologyMember" xlink:label="loc_ptgefImmunoOncologyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefImmunoOncologyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullRevenue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-fullProfitLossAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssets" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssets_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssetReceivables" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossOnSaleOfDigitalAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossOnSaleOfDigitalAssets_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="loc_ptgefLossOnRegisteredDirectOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRegisteredDirectOffering_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="loc_ptgefOfferingCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingCosts_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossIoxIprd" xlink:label="loc_ptgefImpairmentLossIoxIprd_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossIoxIprd_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossTarusIprd" xlink:label="loc_ptgefImpairmentLossTarusIprd_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossTarusIprd_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossStimunity" xlink:label="loc_ptgefImpairmentLossStimunity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossStimunity_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossSaugatuck" xlink:label="loc_ptgefImpairmentLossSaugatuck_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossSaugatuck_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="loc_ptgefGainOnDissolutionOfInvestmentInAssociate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnDissolutionOfInvestmentInAssociate_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="loc_ptgefGainFromSaleOfInvestmentInPublicCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainFromSaleOfInvestmentInPublicCompany_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossInvestmentInCompedica" xlink:label="loc_ptgefImpairmentLossInvestmentInCompedica_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossInvestmentInCompedica_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfInvestmentInCompedica" xlink:label="loc_ptgefLossOnRevaluationOfInvestmentInCompedica_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRevaluationOfInvestmentInCompedica_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnSettlementOfTonPayable_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnSettlementOfPutRightLiability" xlink:label="loc_ptgefLossOnSettlementOfPutRightLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnSettlementOfPutRightLiability_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-fullNetForeignExchangeGain_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNetForeignExchangeGain_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:label="loc_ifrs-fullInterestExpenseIncomeDefinedBenefitPlans_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullInterestExpenseIncomeDefinedBenefitPlans_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnExtinguishmentOfDebt" xlink:label="loc_ptgefGainOnExtinguishmentOfDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnExtinguishmentOfDebt_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossesFromEquityMethodInvestment" xlink:label="loc_ptgefShareOfLossesFromEquityMethodInvestment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareOfLossesFromEquityMethodInvestment_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SegmentLossBeforeBenefitForIncomeTaxes" xlink:label="loc_ptgefSegmentLossBeforeBenefitForIncomeTaxes_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSegmentLossBeforeBenefitForIncomeTaxes_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeTaxBenefit" xlink:label="loc_ptgefIncomeTaxBenefit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIncomeTaxBenefit_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SegmentNetLoss" xlink:label="loc_ptgefSegmentNetLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSegmentNetLoss_50" xlink:type="arc" order="35" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:title="999102 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="999103 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefSaugatuckMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest_80" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ptgef-20260331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionReserveMember" xlink:label="ptgef_StockOptionReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserveMember" xlink:to="ptgef_StockOptionReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserveMember_lbl" xml:lang="en-US">Stock Option Reserve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockMember" xlink:label="ptgef_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TreasuryStockMember" xlink:to="ptgef_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccumulatedOtherComprehensiveIncomeLossMember" xlink:label="ptgef_AccumulatedOtherComprehensiveIncomeLossMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccumulatedOtherComprehensiveIncomeLossMember" xlink:to="ptgef_AccumulatedOtherComprehensiveIncomeLossMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccumulatedOtherComprehensiveIncomeLossMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income Loss [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IOxIPRDMember" xlink:label="ptgef_IOxIPRDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IOxIPRDMember" xlink:to="ptgef_IOxIPRDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IOxIPRDMember_lbl" xml:lang="en-US">iOx IPR&amp;D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TarusIPRDMember" xlink:label="ptgef_TarusIPRDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TarusIPRDMember" xlink:to="ptgef_TarusIPRDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TarusIPRDMember_lbl" xml:lang="en-US">Tarus IPR&amp;D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StimunityMember" xlink:label="ptgef_StimunityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StimunityMember" xlink:to="ptgef_StimunityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StimunityMember_lbl" xml:lang="en-US">Stimunity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaugatuckMember" xlink:label="ptgef_SaugatuckMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaugatuckMember" xlink:to="ptgef_SaugatuckMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SaugatuckMember_lbl" xml:lang="en-US">Saugatuck [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US">Subsidiaries [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IOXMember" xlink:label="ptgef_IOXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IOXMember" xlink:to="ptgef_IOXMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IOXMember_lbl" xml:lang="en-US">IOX [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="ifrs-full_ConsolidatedStructuredEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis_lbl" xml:lang="en-US">Consolidated structured entities [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalvaRxMember" xlink:label="ptgef_SalvaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SalvaRxMember" xlink:to="ptgef_SalvaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SalvaRxMember_lbl" xml:lang="en-US">Salva Rx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US">Geographical areas [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CountryOfBritishVirginIslandsMember" xlink:label="ptgef_CountryOfBritishVirginIslandsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CountryOfBritishVirginIslandsMember" xlink:to="ptgef_CountryOfBritishVirginIslandsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CountryOfBritishVirginIslandsMember_lbl" xml:lang="en-US">Country Of British Virgin Islands [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DelawareMember" xlink:label="ptgef_DelawareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DelawareMember" xlink:to="ptgef_DelawareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DelawareMember_lbl" xml:lang="en-US">Delaware [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SubsidiariesTwoMember" xlink:label="ptgef_SubsidiariesTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SubsidiariesTwoMember" xlink:to="ptgef_SubsidiariesTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SubsidiariesTwoMember_lbl" xml:lang="en-US">Subsidiaries Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="ifrs-full_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionsMember" xlink:label="ptgef_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionsMember" xlink:to="ptgef_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="ptgef_RestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RestrictedStockUnitsMember" xlink:to="ptgef_RestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RestrictedStockUnitsMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USDCMember" xlink:label="ptgef_USDCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_USDCMember" xlink:to="ptgef_USDCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_USDCMember_lbl" xml:lang="en-US">U S D C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UsdtMember" xlink:label="ptgef_UsdtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UsdtMember" xlink:to="ptgef_UsdtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UsdtMember_lbl" xml:lang="en-US">Usdt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="ptgef_TotalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalMember" xlink:to="ptgef_TotalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TotalMember_lbl" xml:lang="en-US">Total [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:label="ifrs-full_IntangibleAssetsMaterialToEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:to="ifrs-full_IntangibleAssetsMaterialToEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsMaterialToEntityAxis_lbl" xml:lang="en-US">Intangible assets material to entity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TONMember" xlink:label="ptgef_TONMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TONMember" xlink:to="ptgef_TONMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TONMember_lbl" xml:lang="en-US">T O N [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BITCOINMember" xlink:label="ptgef_BITCOINMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BITCOINMember" xlink:to="ptgef_BITCOINMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BITCOINMember_lbl" xml:lang="en-US">B I T C O I N [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USD1Member" xlink:label="ptgef_USD1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_USD1Member" xlink:to="ptgef_USD1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_USD1Member_lbl" xml:lang="en-US">U S D 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LockedTonMember" xlink:label="ptgef_LockedTonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LockedTonMember" xlink:to="ptgef_LockedTonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LockedTonMember_lbl" xml:lang="en-US">Locked Ton [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GPUsMember" xlink:label="ptgef_GPUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GPUsMember" xlink:to="ptgef_GPUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GPUsMember_lbl" xml:lang="en-US">G P Us [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GPUDepositsMember" xlink:label="ptgef_GPUDepositsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GPUDepositsMember" xlink:to="ptgef_GPUDepositsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GPUDepositsMember_lbl" xml:lang="en-US">G P U Deposits [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RightOfUseAssetMember" xlink:label="ptgef_RightOfUseAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RightOfUseAssetMember" xlink:to="ptgef_RightOfUseAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RightOfUseAssetMember_lbl" xml:lang="en-US">Right Of Use Asset [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ClassBWarrantsMember" xlink:label="ptgef_ClassBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ClassBWarrantsMember" xlink:to="ptgef_ClassBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ClassBWarrantsMember_lbl" xml:lang="en-US">Class B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ClassCWarrantsMember" xlink:label="ptgef_ClassCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ClassCWarrantsMember" xlink:to="ptgef_ClassCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ClassCWarrantsMember_lbl" xml:lang="en-US">Class C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="ptgef_PlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PlacementAgentWarrantsMember" xlink:to="ptgef_PlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeiesBWarrantsMember" xlink:label="ptgef_SeiesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeiesBWarrantsMember" xlink:to="ptgef_SeiesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeiesBWarrantsMember_lbl" xml:lang="en-US">Seies B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeiesCWarrantsMember" xlink:label="ptgef_SeiesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeiesCWarrantsMember" xlink:to="ptgef_SeiesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeiesCWarrantsMember_lbl" xml:lang="en-US">Seies C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrants2026Member" xlink:label="ptgef_PlacementAgentWarrants2026Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PlacementAgentWarrants2026Member" xlink:to="ptgef_PlacementAgentWarrants2026Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PlacementAgentWarrants2026Member_lbl" xml:lang="en-US">Placement Agent Warrants 2026 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesBWarrantsMember" xlink:label="ptgef_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesBWarrantsMember" xlink:to="ptgef_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesCWarrantsMember" xlink:label="ptgef_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesCWarrantsMember" xlink:to="ptgef_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentsWarrantsMember" xlink:label="ptgef_PlacementAgentsWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PlacementAgentsWarrantsMember" xlink:to="ptgef_PlacementAgentsWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PlacementAgentsWarrantsMember_lbl" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokenVolatilityMember" xlink:label="ptgef_TonTokenVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TonTokenVolatilityMember" xlink:to="ptgef_TonTokenVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TonTokenVolatilityMember_lbl" xml:lang="en-US">Ton Token Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US">Counterparties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ATMMember" xlink:label="ptgef_ATMMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ATMMember" xlink:to="ptgef_ATMMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ATMMember_lbl" xml:lang="en-US">ATM [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:label="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:to="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember_lbl" xml:lang="en-US">Series A Warrants And Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="ifrs-full_RestrictedShareUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl" xml:lang="en-US">Restricted share units [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MeasurementAxis_lbl" xml:lang="en-US">Measurement [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_VestedStockOptionMember" xlink:label="ptgef_VestedStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_VestedStockOptionMember" xlink:to="ptgef_VestedStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_VestedStockOptionMember_lbl" xml:lang="en-US">Vested Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="ifrs-full_DefinedBenefitPlansAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="ptgef_PBI2021EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PBI2021EquityIncentivePlanMember" xlink:to="ptgef_PBI2021EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PBI2021EquityIncentivePlanMember_lbl" xml:lang="en-US">PBI 2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionGrantedMember" xlink:label="ptgef_StockOptionGrantedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionGrantedMember" xlink:to="ptgef_StockOptionGrantedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionGrantedMember_lbl" xml:lang="en-US">Stock Option Granted [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateBenchmarksAxis" xlink:label="ifrs-full_InterestRateBenchmarksAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateBenchmarksAxis" xlink:to="ifrs-full_InterestRateBenchmarksAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRateBenchmarksAxis_lbl" xml:lang="en-US">Interest rate benchmarks [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_January132021Member" xlink:label="ptgef_January132021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_January132021Member" xlink:to="ptgef_January132021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_January132021Member_lbl" xml:lang="en-US">January 132021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_January192022Member" xlink:label="ptgef_January192022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_January192022Member" xlink:to="ptgef_January192022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_January192022Member_lbl" xml:lang="en-US">January 192022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_February152022Member" xlink:label="ptgef_February152022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_February152022Member" xlink:to="ptgef_February152022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_February152022Member_lbl" xml:lang="en-US">February 152022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_June82022Member" xlink:label="ptgef_June82022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_June82022Member" xlink:to="ptgef_June82022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_June82022Member_lbl" xml:lang="en-US">June 82022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_July272022Member" xlink:label="ptgef_July272022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_July272022Member" xlink:to="ptgef_July272022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_July272022Member_lbl" xml:lang="en-US">July 272022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March302023Member" xlink:label="ptgef_March302023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_March302023Member" xlink:to="ptgef_March302023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_March302023Member_lbl" xml:lang="en-US">March 302023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March72025Member" xlink:label="ptgef_March72025Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_March72025Member" xlink:to="ptgef_March72025Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_March72025Member_lbl" xml:lang="en-US">March 72025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_July272026Member" xlink:label="ptgef_July272026Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_July272026Member" xlink:to="ptgef_July272026Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_July272026Member_lbl" xml:lang="en-US">July 272026 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March112026Member" xlink:label="ptgef_March112026Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_March112026Member" xlink:to="ptgef_March112026Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_March112026Member_lbl" xml:lang="en-US">March 112026 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CROMember" xlink:label="ptgef_CROMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CROMember" xlink:to="ptgef_CROMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CROMember_lbl" xml:lang="en-US">C R O [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CROAgreementMember" xlink:label="ptgef_CROAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CROAgreementMember" xlink:to="ptgef_CROAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CROAgreementMember_lbl" xml:lang="en-US">C R O Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MichaelTerpinMember" xlink:label="ptgef_MichaelTerpinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MichaelTerpinMember" xlink:to="ptgef_MichaelTerpinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MichaelTerpinMember_lbl" xml:lang="en-US">Michael Terpin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xml:lang="en-US">Associates [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DirectorCompensationMember" xlink:label="ptgef_DirectorCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DirectorCompensationMember" xlink:to="ptgef_DirectorCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DirectorCompensationMember_lbl" xml:lang="en-US">Director Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FDanielSicilianoMember" xlink:label="ptgef_FDanielSicilianoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FDanielSicilianoMember" xlink:to="ptgef_FDanielSicilianoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FDanielSicilianoMember_lbl" xml:lang="en-US">F Daniel Siciliano [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GregoryHBaileyMDMember" xlink:label="ptgef_GregoryHBaileyMDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GregoryHBaileyMDMember" xlink:to="ptgef_GregoryHBaileyMDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GregoryHBaileyMDMember_lbl" xml:lang="en-US">Gregory H Bailey M D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JamesMellonMember" xlink:label="ptgef_JamesMellonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_JamesMellonMember" xlink:to="ptgef_JamesMellonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_JamesMellonMember_lbl" xml:lang="en-US">James Mellon [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StevenMintzMember" xlink:label="ptgef_StevenMintzMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StevenMintzMember" xlink:to="ptgef_StevenMintzMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StevenMintzMember_lbl" xml:lang="en-US">Steven Mintz [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JeanChristopheRenondinMDMember" xlink:label="ptgef_JeanChristopheRenondinMDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_JeanChristopheRenondinMDMember" xlink:to="ptgef_JeanChristopheRenondinMDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_JeanChristopheRenondinMDMember_lbl" xml:lang="en-US">Jean Christophe Renondin M D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JustinStebbingMDPhDMember" xlink:label="ptgef_JustinStebbingMDPhDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_JustinStebbingMDPhDMember" xlink:to="ptgef_JustinStebbingMDPhDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_JustinStebbingMDPhDMember_lbl" xml:lang="en-US">Justin Stebbing M D Ph D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LindaKozickMember" xlink:label="ptgef_LindaKozickMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LindaKozickMember" xlink:to="ptgef_LindaKozickMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LindaKozickMember_lbl" xml:lang="en-US">Linda Kozick [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MarkSimonMember" xlink:label="ptgef_MarkSimonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MarkSimonMember" xlink:to="ptgef_MarkSimonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MarkSimonMember_lbl" xml:lang="en-US">Mark Simon [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertGlassmanMember" xlink:label="ptgef_RobertGlassmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RobertGlassmanMember" xlink:to="ptgef_RobertGlassmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RobertGlassmanMember_lbl" xml:lang="en-US">Robert Glassman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExecutiveOfficerCompensationMember" xlink:label="ptgef_ExecutiveOfficerCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExecutiveOfficerCompensationMember" xlink:to="ptgef_ExecutiveOfficerCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExecutiveOfficerCompensationMember_lbl" xml:lang="en-US">Executive Officer Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrittanyKaiserMember" xlink:label="ptgef_BrittanyKaiserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BrittanyKaiserMember" xlink:to="ptgef_BrittanyKaiserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BrittanyKaiserMember_lbl" xml:lang="en-US">Brittany Kaiser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EnzoVillaniMember" xlink:label="ptgef_EnzoVillaniMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EnzoVillaniMember" xlink:to="ptgef_EnzoVillaniMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EnzoVillaniMember_lbl" xml:lang="en-US">Enzo Villani [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WesLevittMember" xlink:label="ptgef_WesLevittMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WesLevittMember" xlink:to="ptgef_WesLevittMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WesLevittMember_lbl" xml:lang="en-US">Wes Levitt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_YuryMitinMember" xlink:label="ptgef_YuryMitinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_YuryMitinMember" xlink:to="ptgef_YuryMitinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_YuryMitinMember_lbl" xml:lang="en-US">Yury Mitin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettMember" xlink:label="ptgef_AlexanderPickettMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AlexanderPickettMember" xlink:to="ptgef_AlexanderPickettMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AlexanderPickettMember_lbl" xml:lang="en-US">Alexander Pickett [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanWaltersMember" xlink:label="ptgef_IanWaltersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IanWaltersMember" xlink:to="ptgef_IanWaltersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IanWaltersMember_lbl" xml:lang="en-US">Ian Walters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaParkMember" xlink:label="ptgef_AndreaParkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AndreaParkMember" xlink:to="ptgef_AndreaParkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AndreaParkMember_lbl" xml:lang="en-US">Andrea Park [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawMember" xlink:label="ptgef_AllanShawMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AllanShawMember" xlink:to="ptgef_AllanShawMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AllanShawMember_lbl" xml:lang="en-US">Allan Shaw [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerMember" xlink:label="ptgef_RobertKramerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RobertKramerMember" xlink:to="ptgef_RobertKramerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RobertKramerMember_lbl" xml:lang="en-US">Robert Kramer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyMember" xlink:label="ptgef_BrianWileyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BrianWileyMember" xlink:to="ptgef_BrianWileyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BrianWileyMember_lbl" xml:lang="en-US">Brian Wiley [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JustinFairchildMember" xlink:label="ptgef_JustinFairchildMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_JustinFairchildMember" xlink:to="ptgef_JustinFairchildMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_JustinFairchildMember_lbl" xml:lang="en-US">Justin Fairchild [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettTwoMember" xlink:label="ptgef_AlexanderPickettTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AlexanderPickettTwoMember" xlink:to="ptgef_AlexanderPickettTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AlexanderPickettTwoMember_lbl" xml:lang="en-US">Alexander Pickett Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersMember" xlink:label="ptgef_IanBWaltersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IanBWaltersMember" xlink:to="ptgef_IanBWaltersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IanBWaltersMember_lbl" xml:lang="en-US">Ian B Walters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersTwoMember" xlink:label="ptgef_IanBWaltersTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IanBWaltersTwoMember" xlink:to="ptgef_IanBWaltersTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IanBWaltersTwoMember_lbl" xml:lang="en-US">Ian B Walters Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersThreeMember" xlink:label="ptgef_IanBWaltersThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IanBWaltersThreeMember" xlink:to="ptgef_IanBWaltersThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IanBWaltersThreeMember_lbl" xml:lang="en-US">Ian B Walters Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaEParkMember" xlink:label="ptgef_AndreaEParkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AndreaEParkMember" xlink:to="ptgef_AndreaEParkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AndreaEParkMember_lbl" xml:lang="en-US">Andrea E Park [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaEParkTwoMember" xlink:label="ptgef_AndreaEParkTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AndreaEParkTwoMember" xlink:to="ptgef_AndreaEParkTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AndreaEParkTwoMember_lbl" xml:lang="en-US">Andrea E Park Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawTwoMember" xlink:label="ptgef_AllanShawTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AllanShawTwoMember" xlink:to="ptgef_AllanShawTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AllanShawTwoMember_lbl" xml:lang="en-US">Allan Shaw Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawThreeMember" xlink:label="ptgef_AllanShawThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AllanShawThreeMember" xlink:to="ptgef_AllanShawThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AllanShawThreeMember_lbl" xml:lang="en-US">Allan Shaw Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerTwoMember" xlink:label="ptgef_RobertKramerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RobertKramerTwoMember" xlink:to="ptgef_RobertKramerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RobertKramerTwoMember_lbl" xml:lang="en-US">Robert Kramer Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerThreeMember" xlink:label="ptgef_RobertKramerThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RobertKramerThreeMember" xlink:to="ptgef_RobertKramerThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RobertKramerThreeMember_lbl" xml:lang="en-US">Robert Kramer Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyTwoMember" xlink:label="ptgef_BrianWileyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BrianWileyTwoMember" xlink:to="ptgef_BrianWileyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BrianWileyTwoMember_lbl" xml:lang="en-US">Brian Wiley Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AmortizedCostMember" xlink:label="ptgef_AmortizedCostMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AmortizedCostMember" xlink:to="ptgef_AmortizedCostMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AmortizedCostMember_lbl" xml:lang="en-US">Amortized Cost [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:to="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Fair Value To Other Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueThroughProfitOrLossMember" xlink:label="ptgef_FairValueThroughProfitOrLossMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueThroughProfitOrLossMember" xlink:to="ptgef_FairValueThroughProfitOrLossMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueThroughProfitOrLossMember_lbl" xml:lang="en-US">Fair Value Through Profit Or Loss [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:label="ifrs-full_ImpairmentOfFinancialAssetsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:to="ifrs-full_ImpairmentOfFinancialAssetsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentOfFinancialAssetsAxis_lbl" xml:lang="en-US">Impairment of financial assets [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level1Member" xlink:label="ptgef_Level1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Level1Member" xlink:to="ptgef_Level1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Level1Member_lbl" xml:lang="en-US">Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level2Member" xlink:label="ptgef_Level2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Level2Member" xlink:to="ptgef_Level2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Level2Member_lbl" xml:lang="en-US">Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level3Member" xlink:label="ptgef_Level3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Level3Member" xlink:to="ptgef_Level3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Level3Member_lbl" xml:lang="en-US">Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalComputeMember" xlink:label="ptgef_DigitalComputeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalComputeMember" xlink:to="ptgef_DigitalComputeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalComputeMember_lbl" xml:lang="en-US">Digital Compute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImmunoOncologyMember" xlink:label="ptgef_ImmunoOncologyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ImmunoOncologyMember" xlink:to="ptgef_ImmunoOncologyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ImmunoOncologyMember_lbl" xml:lang="en-US">Immuno Oncology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsReceivable" xlink:label="ptgef_AccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsReceivable" xlink:to="ptgef_AccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoin" xlink:label="ptgef_Stablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Stablecoin" xlink:to="ptgef_Stablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Stablecoin_lbl" xml:lang="en-US">Stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonCurrent" xlink:label="ptgef_DigitalAssetsAtFairValueTonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsAtFairValueTonCurrent" xlink:to="ptgef_DigitalAssetsAtFairValueTonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsAtFairValueTonCurrent_lbl" xml:lang="en-US">Digital assets at fair value, TON, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion" xlink:label="ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion" xlink:to="ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion_lbl" xml:lang="en-US">Digital assets at fair value, TON, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property, plant, and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EquipmentDeposits" xlink:label="ptgef_EquipmentDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquipmentDeposits" xlink:to="ptgef_EquipmentDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EquipmentDeposits_lbl" xml:lang="en-US">Equipment deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableToSettlePutRightsExercised" xlink:label="ptgef_TonPayableToSettlePutRightsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TonPayableToSettlePutRightsExercised" xlink:to="ptgef_TonPayableToSettlePutRightsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TonPayableToSettlePutRightsExercised_lbl" xml:lang="en-US">TON payable to settle put rights exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability - current</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiability" xlink:label="ptgef_PutRightLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightLiability" xlink:to="ptgef_PutRightLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightLiability_lbl" xml:lang="en-US">Put right liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability - non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentWarrantLiability" xlink:label="ifrs-full_NoncurrentWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentWarrantLiability" xlink:to="ifrs-full_NoncurrentWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentWarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentsAndContingentLiabilities" xlink:label="ptgef_CommitmentsAndContingentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentsAndContingentLiabilities" xlink:to="ptgef_CommitmentsAndContingentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentsAndContingentLiabilities_lbl" xml:lang="en-US">Commitments and Contingent Liabilities (Note 20)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Capital stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Stock option reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US">Treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total equity attributable to owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAbstract_lbl" xml:lang="en-US">Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="ptgef_GainsLossesOnChangeInFairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:to="ptgef_GainsLossesOnChangeInFairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainsLossesOnChangeInFairValueOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:to="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xml:lang="en-US">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:to="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions_lbl" xml:lang="en-US">Change in fair value of put rights, net of redemptions</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssets" xlink:label="ptgef_LossOnRevaluationOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRevaluationOfDigitalAssets" xlink:to="ptgef_LossOnRevaluationOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_LossOnRevaluationOfDigitalAssets_lbl" xml:lang="en-US">Loss on revaluation of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssetReceivables" xlink:label="ptgef_LossOnRevaluationOfDigitalAssetReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRevaluationOfDigitalAssetReceivables" xlink:to="ptgef_LossOnRevaluationOfDigitalAssetReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_LossOnRevaluationOfDigitalAssetReceivables_lbl" xml:lang="en-US">Loss on revaluation of digital asset receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="ptgef_RealizedLossOnSaleOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:to="ptgef_RealizedLossOnSaleOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_RealizedLossOnSaleOfDigitalAssets_lbl" xml:lang="en-US">Realized loss on sale of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:label="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:to="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor_lbl" xml:lang="en-US">Realized loss on novation of digital assets to investor</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="ptgef_GainOnSettlementWithParexelIoxCro" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnSettlementWithParexelIoxCro" xlink:to="ptgef_GainOnSettlementWithParexelIoxCro_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_GainOnSettlementWithParexelIoxCro_lbl" xml:lang="en-US">Gain on settlement with Parexel - iOx CRO</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="ptgef_LossOnRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRegisteredDirectOffering" xlink:to="ptgef_LossOnRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_LossOnRegisteredDirectOffering_lbl" xml:lang="en-US">Loss on Registered Direct Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="ptgef_OfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingCosts" xlink:to="ptgef_OfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_OfferingCosts_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossIoxIprd" xlink:label="ptgef_ImpairmentLossIoxIprd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ImpairmentLossIoxIprd" xlink:to="ptgef_ImpairmentLossIoxIprd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ImpairmentLossIoxIprd_lbl" xml:lang="en-US">Impairment loss - iOx IPR&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossTarusIprd" xlink:label="ptgef_ImpairmentLossTarusIprd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ImpairmentLossTarusIprd" xlink:to="ptgef_ImpairmentLossTarusIprd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ImpairmentLossTarusIprd_lbl" xml:lang="en-US">Impairment loss - Tarus IPR&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossStimunity" xlink:label="ptgef_ImpairmentLossStimunity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ImpairmentLossStimunity" xlink:to="ptgef_ImpairmentLossStimunity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ImpairmentLossStimunity_lbl" xml:lang="en-US">Impairment loss - Stimunity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossSaugatuck" xlink:label="ptgef_ImpairmentLossSaugatuck" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ImpairmentLossSaugatuck" xlink:to="ptgef_ImpairmentLossSaugatuck_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ImpairmentLossSaugatuck_lbl" xml:lang="en-US">Impairment loss - Saugatuck</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:to="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement_lbl" xml:lang="en-US">Commitment fee under Committed Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="ptgef_GainOnDissolutionOfInvestmentInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:to="ptgef_GainOnDissolutionOfInvestmentInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainOnDissolutionOfInvestmentInAssociate_lbl" xml:lang="en-US">Gain on dissolution of investment in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="ptgef_GainFromSaleOfInvestmentInPublicCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:to="ptgef_GainFromSaleOfInvestmentInPublicCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainFromSaleOfInvestmentInPublicCompany_lbl" xml:lang="en-US">Gain from sale of investment in public company</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossInvestmentInCompedica" xlink:label="ptgef_ImpairmentLossInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ImpairmentLossInvestmentInCompedica" xlink:to="ptgef_ImpairmentLossInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ImpairmentLossInvestmentInCompedica_lbl" xml:lang="en-US">Impairment loss - investment in Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfInvestmentInCompedica" xlink:label="ptgef_LossOnRevaluationOfInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRevaluationOfInvestmentInCompedica" xlink:to="ptgef_LossOnRevaluationOfInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_LossOnRevaluationOfInvestmentInCompedica_lbl" xml:lang="en-US">Loss on revaluation of investment in Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:to="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised_lbl" xml:lang="en-US">Change in fair value of TON payable to settle put rights exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="ptgef_GainOnSettlementOfTonPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnSettlementOfTonPayable" xlink:to="ptgef_GainOnSettlementOfTonPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainOnSettlementOfTonPayable_lbl" xml:lang="en-US">Gain on settlement of TON payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnSettlementOfPutRightLiability" xlink:label="ptgef_LossOnSettlementOfPutRightLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnSettlementOfPutRightLiability" xlink:to="ptgef_LossOnSettlementOfPutRightLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_LossOnSettlementOfPutRightLiability_lbl" xml:lang="en-US">Loss on settlement of put right liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Foreign exchange transaction (loss) gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Interest (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnExtinguishmentOfDebt" xlink:label="ptgef_GainOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnExtinguishmentOfDebt" xlink:to="ptgef_GainOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossesFromEquityMethodInvestment" xlink:label="ptgef_ShareOfLossesFromEquityMethodInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareOfLossesFromEquityMethodInvestment" xlink:to="ptgef_ShareOfLossesFromEquityMethodInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ShareOfLossesFromEquityMethodInvestment_lbl" xml:lang="en-US">Share of losses from equity method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before benefit for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="ptgef_NetUnrealizedLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetUnrealizedLossOnInvestments" xlink:to="ptgef_NetUnrealizedLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetUnrealizedLossOnInvestments_lbl" xml:lang="en-US">Net unrealized loss on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss for period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Net loss attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xml:lang="en-US">Comprehensive loss attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Weighted average shares outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="ptgef_IfrsStatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IfrsStatementLineItems" xlink:to="ptgef_IfrsStatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IfrsStatementLineItems_lbl" xml:lang="en-US">IfrsStatementLineItems [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Begnning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceApril12022PresplitShares" xlink:label="ptgef_BalanceApril12022PresplitShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BalanceApril12022PresplitShares" xlink:to="ptgef_BalanceApril12022PresplitShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BalanceApril12022PresplitShares_lbl" xml:lang="en-US">Balance, April 1, 2022 (Pre-Split), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOffering" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderRegisteredDirectOffering" xlink:to="ptgef_SharesIssuedUnderRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOffering_lbl" xml:lang="en-US">Shares issued under Registered Direct Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingShares" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderRegisteredDirectOfferingShares" xlink:to="ptgef_SharesIssuedUnderRegisteredDirectOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOfferingShares_lbl" xml:lang="en-US">Shares issued under Registered Direct Offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" xlink:label="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" xlink:to="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts_lbl" xml:lang="en-US">Shares issued related to the ATM agreement, net of share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" xlink:label="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" xlink:to="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares_lbl" xml:lang="en-US">Shares issued related to the ATM agreement, net of share issuance costs , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="ptgef_SharesIssuedOrAccruedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServices" xlink:to="ptgef_SharesIssuedOrAccruedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServices_lbl" xml:lang="en-US">Shares issued or accrued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServicesShares" xlink:to="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xml:lang="en-US">Shares issued or accrued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits" xlink:label="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits" xlink:to="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits_lbl" xml:lang="en-US">Shares issued pursuant to distribution of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" xlink:label="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" xlink:to="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Shares issued pursuant to distribution of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DerecognitionOfInvestmentInPublicCompany" xlink:label="ptgef_DerecognitionOfInvestmentInPublicCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DerecognitionOfInvestmentInPublicCompany" xlink:to="ptgef_DerecognitionOfInvestmentInPublicCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DerecognitionOfInvestmentInPublicCompany_lbl" xml:lang="en-US">Derecognition of investment in public company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" xlink:label="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" xlink:to="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense_lbl" xml:lang="en-US">Correction of prior period overstated share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" xlink:to="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts_lbl" xml:lang="en-US">Shares issued under private placement, net of share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" xlink:to="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares_lbl" xml:lang="en-US">Shares issued under private placement, net of share issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrefundedWarrantsExercised" xlink:label="ptgef_PrefundedWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrefundedWarrantsExercised" xlink:to="ptgef_PrefundedWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrefundedWarrantsExercised_lbl" xml:lang="en-US">Pre-Funded warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrefundedWarrantsExercisedShares" xlink:label="ptgef_PrefundedWarrantsExercisedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrefundedWarrantsExercisedShares" xlink:to="ptgef_PrefundedWarrantsExercisedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrefundedWarrantsExercisedShares_lbl" xml:lang="en-US">Pre-Funded warrants exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:to="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_lbl" xml:lang="en-US">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse share split</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:to="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_lbl" xml:lang="en-US">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedForAccruedBonuses" xlink:label="ptgef_SharesIssuedForAccruedBonuses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedForAccruedBonuses" xlink:to="ptgef_SharesIssuedForAccruedBonuses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedForAccruedBonuses_lbl" xml:lang="en-US">Shares issued for accrued bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedAccruedForBonusesShares" xlink:label="ptgef_SharesIssuedAccruedForBonusesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedAccruedForBonusesShares" xlink:to="ptgef_SharesIssuedAccruedForBonusesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedAccruedForBonusesShares_lbl" xml:lang="en-US">Shares issued accrued for bonuses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" xlink:to="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights_lbl" xml:lang="en-US">Shares issued under private placement, net of share issuance costs and put rights</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" xlink:to="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares_lbl" xml:lang="en-US">Shares issued under private placement, net of share issuance costs and put rights , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatingToAcquisitionOfCompedica" xlink:label="ptgef_SharesIssuedRelatingToAcquisitionOfCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedRelatingToAcquisitionOfCompedica" xlink:to="ptgef_SharesIssuedRelatingToAcquisitionOfCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedRelatingToAcquisitionOfCompedica_lbl" xml:lang="en-US">Shares issued relating to the acquisition of Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares" xlink:label="ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares" xlink:to="ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares_lbl" xml:lang="en-US">Shares issued relating to the acquisition of Compedica, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:to="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts_lbl" xml:lang="en-US">Shares issued under registered direct offering, net of share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:to="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares_lbl" xml:lang="en-US">Shares issued under registered direct offering, net of share issuance costs , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPrefundedWarrants" xlink:label="ptgef_ExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExerciseOfPrefundedWarrants" xlink:to="ptgef_ExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPrefundedWarrantsShares" xlink:label="ptgef_ExerciseOfPrefundedWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExerciseOfPrefundedWarrantsShares" xlink:to="ptgef_ExerciseOfPrefundedWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExerciseOfPrefundedWarrantsShares_lbl" xml:lang="en-US">Exercise of pre-funded warrants , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:label="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:to="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_lbl" xml:lang="en-US">Treasury stock obtained in exchange for return of investment interest to Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" xlink:label="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" xlink:to="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares_lbl" xml:lang="en-US">Treasury stock obtained in exchange for return of investment interest to Compedica , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsExercisedAndReturnOfShares" xlink:label="ptgef_PutRightsExercisedAndReturnOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightsExercisedAndReturnOfShares" xlink:to="ptgef_PutRightsExercisedAndReturnOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightsExercisedAndReturnOfShares_lbl" xml:lang="en-US">Put rights exercised and return of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsExercisedAndReturnShares" xlink:label="ptgef_PutRightsExercisedAndReturnShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightsExercisedAndReturnShares" xlink:to="ptgef_PutRightsExercisedAndReturnShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightsExercisedAndReturnShares_lbl" xml:lang="en-US">Put rights exercised and return, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_2_lbl" xml:lang="en-US">Ending Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_lbl" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_2_lbl" xml:lang="en-US">Net loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments for non-cash items:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:to="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_2_lbl" xml:lang="en-US">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRegisteredDirectOffering" xlink:to="ptgef_LossOnRegisteredDirectOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnRegisteredDirectOffering_2_lbl" xml:lang="en-US">Loss on Registered Direct Offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingCosts" xlink:to="ptgef_OfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OfferingCosts_2_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="ifrs-full_ImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:to="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentFeeUnderCommittedPurchaseAgreement_2_lbl" xml:lang="en-US">Commitment fee under Committed Purchase Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:to="ptgef_GainOnDissolutionOfInvestmentInAssociate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_GainOnDissolutionOfInvestmentInAssociate_2_lbl" xml:lang="en-US">Gain on dissolution of investment in associate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:to="ptgef_GainFromSaleOfInvestmentInPublicCompany_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_GainFromSaleOfInvestmentInPublicCompany_2_lbl" xml:lang="en-US">Gain from sale of investment in public company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xml:lang="en-US">Decrease in deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets" xlink:label="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets" xlink:to="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets_lbl" xml:lang="en-US">Unrealized loss on change in fair value of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" xlink:label="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" xlink:to="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables_lbl" xml:lang="en-US">Unrealized loss on change in fair value of digital asset receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:to="ptgef_RealizedLossOnSaleOfDigitalAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RealizedLossOnSaleOfDigitalAssets_2_lbl" xml:lang="en-US">Realized loss on sale of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" xlink:label="ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" xlink:to="ptgef_RealizedLossOnNovationOfDigitalAssetReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RealizedLossOnNovationOfDigitalAssetReceivables_lbl" xml:lang="en-US">Realized loss on novation of digital asset receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnImpairmentInvestmentInCompedica" xlink:label="ptgef_LossOnImpairmentInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnImpairmentInvestmentInCompedica" xlink:to="ptgef_LossOnImpairmentInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnImpairmentInvestmentInCompedica_lbl" xml:lang="en-US">Loss on impairment - investment in Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRemeasurementOfInvestmentInCompedica" xlink:label="ptgef_LossOnRemeasurementOfInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRemeasurementOfInvestmentInCompedica" xlink:to="ptgef_LossOnRemeasurementOfInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnRemeasurementOfInvestmentInCompedica_lbl" xml:lang="en-US">Loss on remeasurement of investment in Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfWarrantLiability" xlink:label="ptgef_ChangeInFairValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantLiability" xlink:to="ptgef_ChangeInFairValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:to="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions_2_lbl" xml:lang="en-US">Change in fair value of put rights, net of redemptions</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossFromEquityMethodInvestment" xlink:label="ptgef_LossFromEquityMethodInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossFromEquityMethodInvestment" xlink:to="ptgef_LossFromEquityMethodInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossFromEquityMethodInvestment_lbl" xml:lang="en-US">Loss from equity method investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:to="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised_2_lbl" xml:lang="en-US">Change in fair value of TON payable to settle put rights exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnSettlementOfTonPayable" xlink:to="ptgef_GainOnSettlementOfTonPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_GainOnSettlementOfTonPayable_2_lbl" xml:lang="en-US">Gain on settlement of TON payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExerciseOfPutRightLiability" xlink:label="ptgef_LossOnExerciseOfPutRightLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnExerciseOfPutRightLiability" xlink:to="ptgef_LossOnExerciseOfPutRightLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnExerciseOfPutRightLiability_lbl" xml:lang="en-US">Loss on exercise of put right liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="ptgef_LossOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnExtinguishmentOfDebt" xlink:to="ptgef_LossOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashInterestExpense" xlink:label="ptgef_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NoncashInterestExpense" xlink:to="ptgef_NoncashInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NoncashInterestExpense_lbl" xml:lang="en-US">Noncash interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnSettlementWithParexelIoxCro" xlink:to="ptgef_GainOnSettlementWithParexelIoxCro_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainOnSettlementWithParexelIoxCro_2_lbl" xml:lang="en-US">Gain on settlement with Parexel - iOx CRO</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExpensesSettledUsingStablecoin" xlink:label="ptgef_ExpensesSettledUsingStablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExpensesSettledUsingStablecoin" xlink:to="ptgef_ExpensesSettledUsingStablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExpensesSettledUsingStablecoin_lbl" xml:lang="en-US">Expenses settled using stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="ifrs-full_DividendsReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsReceived" xlink:to="ifrs-full_DividendsReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DividendsReceived_lbl" xml:lang="en-US">Revenues received in TON tokens</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossInAssociate" xlink:label="ptgef_ShareOfLossInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareOfLossInAssociate" xlink:to="ptgef_ShareOfLossInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareOfLossInAssociate_lbl" xml:lang="en-US">Share of loss in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfSharesIssuedForServices" xlink:label="ptgef_FairValueOfSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfSharesIssuedForServices" xlink:to="ptgef_FairValueOfSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfSharesIssuedForServices_lbl" xml:lang="en-US">Fair value of shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DepreciationAndAmortizations" xlink:label="ptgef_DepreciationAndAmortizations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DepreciationAndAmortizations" xlink:to="ptgef_DepreciationAndAmortizations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DepreciationAndAmortizations_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:label="ptgef_NetChangeInWorkingCapitalComponentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:to="ptgef_NetChangeInWorkingCapitalComponentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetChangeInWorkingCapitalComponentsAbstract_lbl" xml:lang="en-US">Changes in operating working capital:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentProperty_lbl" xml:lang="en-US">Proceeds from sale of investment in public company</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfStablecoin" xlink:label="ptgef_PurchasesOfStablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasesOfStablecoin" xlink:to="ptgef_PurchasesOfStablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_PurchasesOfStablecoin_lbl" xml:lang="en-US">Purchases of stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfDigitalAssets" xlink:label="ptgef_PurchasesOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasesOfDigitalAssets" xlink:to="ptgef_PurchasesOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_PurchasesOfDigitalAssets_lbl" xml:lang="en-US">Purchases of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfStablecoin" xlink:label="ptgef_SalesOfStablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SalesOfStablecoin" xlink:to="ptgef_SalesOfStablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SalesOfStablecoin_lbl" xml:lang="en-US">Sales of stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfDigitalAssets" xlink:label="ptgef_SalesOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SalesOfDigitalAssets" xlink:to="ptgef_SalesOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SalesOfDigitalAssets_lbl" xml:lang="en-US">Sales of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchases of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EquipmentDeposit" xlink:label="ptgef_EquipmentDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquipmentDeposit" xlink:to="ptgef_EquipmentDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_EquipmentDeposit_lbl" xml:lang="en-US">Equipment deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashPaidForInvestmentInCompedica" xlink:label="ptgef_CashPaidForInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashPaidForInvestmentInCompedica" xlink:to="ptgef_CashPaidForInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_CashPaidForInvestmentInCompedica_lbl" xml:lang="en-US">Cash paid for investment in Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="ptgef_ProceedsFromExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:to="ptgef_ProceedsFromExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Proceeds from exercise of Pre-Funded Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement" xlink:label="ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement" xlink:to="ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement_lbl" xml:lang="en-US">Proceeds from shares issued under private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromRegisteredDirectOffering" xlink:label="ptgef_ProceedsFromRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromRegisteredDirectOffering" xlink:to="ptgef_ProceedsFromRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromRegisteredDirectOffering_lbl" xml:lang="en-US">Proceeds from Registered Direct Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:label="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:to="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_lbl" xml:lang="en-US">Proceeds from shares issued under ATM and Committed Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US">Share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightIssuanceCosts" xlink:label="ptgef_PutRightIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightIssuanceCosts" xlink:to="ptgef_PutRightIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_PutRightIssuanceCosts_lbl" xml:lang="en-US">Put right issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebt" xlink:label="ptgef_PaymentsOnExternalDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PaymentsOnExternalDebt" xlink:to="ptgef_PaymentsOnExternalDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_PaymentsOnExternalDebt_lbl" xml:lang="en-US">Payments on external debt</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredFinancingCosts" xlink:label="ptgef_DeferredFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredFinancingCosts" xlink:to="ptgef_DeferredFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_DeferredFinancingCosts_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LoanTerminationFee" xlink:label="ptgef_LoanTerminationFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LoanTerminationFee" xlink:to="ptgef_LoanTerminationFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_LoanTerminationFee_lbl" xml:lang="en-US">Loan termination fee</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesFromRSUDistribution" xlink:label="ptgef_SharesFromRSUDistribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesFromRSUDistribution" xlink:to="ptgef_SharesFromRSUDistribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesFromRSUDistribution_lbl" xml:lang="en-US">Shares from RSU distribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Decrease in cash, cash equivalents, restricted during period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SupplementalCashFlowInformationsAbstract" xlink:label="ptgef_SupplementalCashFlowInformationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SupplementalCashFlowInformationsAbstract" xlink:to="ptgef_SupplementalCashFlowInformationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SupplementalCashFlowInformationsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashPaidForInterest" xlink:label="ptgef_CashPaidForInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashPaidForInterest" xlink:to="ptgef_CashPaidForInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashPaidForInterest_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashInvestingItemsAbstract" xlink:label="ptgef_NoncashInvestingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NoncashInvestingItemsAbstract" xlink:to="ptgef_NoncashInvestingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NoncashInvestingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" xlink:label="ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" xlink:to="ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue_lbl" xml:lang="en-US">Exchange of Stimunity Convertible Note for Stimunity shares at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalExpendituresIncludedInAccountsPayable" xlink:label="ptgef_CapitalExpendituresIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalExpendituresIncludedInAccountsPayable" xlink:to="ptgef_CapitalExpendituresIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalExpendituresIncludedInAccountsPayable_lbl" xml:lang="en-US">Capital expenditures included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RightToUseAssetAcquired" xlink:label="ptgef_RightToUseAssetAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RightToUseAssetAcquired" xlink:to="ptgef_RightToUseAssetAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RightToUseAssetAcquired_lbl" xml:lang="en-US">Right-of-use asset acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityIncurred" xlink:label="ptgef_LeaseLiabilityIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityIncurred" xlink:to="ptgef_LeaseLiabilityIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityIncurred_lbl" xml:lang="en-US">Lease liability incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssets" xlink:label="ptgef_ContributionOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContributionOfDigitalAssets" xlink:to="ptgef_ContributionOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ContributionOfDigitalAssets_lbl" xml:lang="en-US">Contribution of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoin" xlink:label="ptgef_ContributionOfStablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContributionOfStablecoin" xlink:to="ptgef_ContributionOfStablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ContributionOfStablecoin_lbl" xml:lang="en-US">Contribution of stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssetsReceivable" xlink:label="ptgef_ContributionOfDigitalAssetsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContributionOfDigitalAssetsReceivable" xlink:to="ptgef_ContributionOfDigitalAssetsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ContributionOfDigitalAssetsReceivable_lbl" xml:lang="en-US">Contribution of digital assets receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoinReceivable" xlink:label="ptgef_ContributionOfStablecoinReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContributionOfStablecoinReceivable" xlink:to="ptgef_ContributionOfStablecoinReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ContributionOfStablecoinReceivable_lbl" xml:lang="en-US">Contribution of stablecoin receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica" xlink:label="ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica" xlink:to="ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica_lbl" xml:lang="en-US">Value of shares used to purchase interest in Compedica</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:to="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica_2_lbl" xml:lang="en-US">Treasury stock obtained in exchange for return of investment interest to Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsIssuedToInvestors" xlink:label="ptgef_PutRightsIssuedToInvestors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightsIssuedToInvestors" xlink:to="ptgef_PutRightsIssuedToInvestors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightsIssuedToInvestors_lbl" xml:lang="en-US">Put rights issued to investors</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareIssuanceCostsSettledInCompanyStock" xlink:label="ptgef_ShareIssuanceCostsSettledInCompanyStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareIssuanceCostsSettledInCompanyStock" xlink:to="ptgef_ShareIssuanceCostsSettledInCompanyStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareIssuanceCostsSettledInCompanyStock_lbl" xml:lang="en-US">Share issuance costs settled in Company stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock" xlink:label="ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock" xlink:to="ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock_lbl" xml:lang="en-US">Share issuance costs settled in warrants on the Company's stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable" xlink:label="ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable" xlink:to="ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable_lbl" xml:lang="en-US">Settlement of put right liability using stablecoin receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPutRights" xlink:label="ptgef_ExerciseOfPutRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExerciseOfPutRights" xlink:to="ptgef_ExerciseOfPutRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExerciseOfPutRights_lbl" xml:lang="en-US">Exercise of put rights</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" xlink:label="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" xlink:to="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables_lbl" xml:lang="en-US">Settlement of put right liability using digital asset receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetsReceivableTonTokens" xlink:label="ptgef_ReceiptOfDigitalAssetsReceivableTonTokens" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReceiptOfDigitalAssetsReceivableTonTokens" xlink:to="ptgef_ReceiptOfDigitalAssetsReceivableTonTokens_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReceiptOfDigitalAssetsReceivableTonTokens_lbl" xml:lang="en-US">Receipt of digital assets receivable, TON tokens</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToPurchaseDigitalAssets" xlink:label="ptgef_StablecoinUsedToPurchaseDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StablecoinUsedToPurchaseDigitalAssets" xlink:to="ptgef_StablecoinUsedToPurchaseDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StablecoinUsedToPurchaseDigitalAssets_lbl" xml:lang="en-US">Stablecoin used to purchase digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaleOfDigitalAssetsSettledInStablecoin" xlink:label="ptgef_SaleOfDigitalAssetsSettledInStablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaleOfDigitalAssetsSettledInStablecoin" xlink:to="ptgef_SaleOfDigitalAssetsSettledInStablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SaleOfDigitalAssetsSettledInStablecoin_lbl" xml:lang="en-US">Sale of digital assets settled in stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExchangeOfBitcoinForTonTokens" xlink:label="ptgef_ExchangeOfBitcoinForTonTokens" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExchangeOfBitcoinForTonTokens" xlink:to="ptgef_ExchangeOfBitcoinForTonTokens_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExchangeOfBitcoinForTonTokens_lbl" xml:lang="en-US">Exchange of Bitcoin for TON tokens</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExternalDebtProceedsReceivedInStablecoin" xlink:label="ptgef_ExternalDebtProceedsReceivedInStablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExternalDebtProceedsReceivedInStablecoin" xlink:to="ptgef_ExternalDebtProceedsReceivedInStablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExternalDebtProceedsReceivedInStablecoin_lbl" xml:lang="en-US">External debt proceeds received in stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebtUsingDigitalAssets" xlink:label="ptgef_PaymentsOnExternalDebtUsingDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PaymentsOnExternalDebtUsingDigitalAssets" xlink:to="ptgef_PaymentsOnExternalDebtUsingDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PaymentsOnExternalDebtUsingDigitalAssets_lbl" xml:lang="en-US">Payments on external debt using digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashOperatingActivitiesAbstract" xlink:label="ptgef_NoncashOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NoncashOperatingActivitiesAbstract" xlink:to="ptgef_NoncashOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NoncashOperatingActivitiesAbstract_lbl" xml:lang="en-US">Non-cash operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesObtainedInExchangeForStablecoin" xlink:label="ptgef_PrepaidExpensesObtainedInExchangeForStablecoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesObtainedInExchangeForStablecoin" xlink:to="ptgef_PrepaidExpensesObtainedInExchangeForStablecoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesObtainedInExchangeForStablecoin_lbl" xml:lang="en-US">Prepaid expenses obtained in exchange for stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureNatureOfOperationsAbstract" xlink:label="ptgef_DisclosureNatureOfOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureNatureOfOperationsAbstract" xlink:to="ptgef_DisclosureNatureOfOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureNatureOfOperationsAbstract_lbl" xml:lang="en-US">Nature Of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NatureOfOperationsExplanatory" xlink:label="ptgef_NatureOfOperationsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NatureOfOperationsExplanatory" xlink:to="ptgef_NatureOfOperationsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NatureOfOperationsExplanatory_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Notes and other explanatory information [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:to="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="ptgef_DisclosureSignificantAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:to="ptgef_DisclosureSignificantAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xml:lang="en-US">PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureStablecoinAbstract" xlink:label="ptgef_DisclosureStablecoinAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureStablecoinAbstract" xlink:to="ptgef_DisclosureStablecoinAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DisclosureStablecoinAbstract_lbl" xml:lang="en-US">Stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfStablecoinExplanatory" xlink:label="ptgef_DisclosureOfStablecoinExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfStablecoinExplanatory" xlink:to="ptgef_DisclosureOfStablecoinExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfStablecoinExplanatory_lbl" xml:lang="en-US">STABLECOIN</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="ptgef_DisclosureDigitalAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureDigitalAssetsAbstract" xlink:to="ptgef_DisclosureDigitalAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureDigitalAssetsAbstract_lbl" xml:lang="en-US">Digital Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfDigitalAssetsExplanatory" xlink:label="ptgef_DisclosureOfDigitalAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfDigitalAssetsExplanatory" xlink:to="ptgef_DisclosureOfDigitalAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfDigitalAssetsExplanatory_lbl" xml:lang="en-US">DIGITAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:label="ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:to="ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract_lbl" xml:lang="en-US">Property Plant And Equipment And Right-of-use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" xlink:label="ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" xlink:to="ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl" xml:lang="en-US">INVESTMENT IN COMPEDICA</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="ptgef_DisclosureWarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureWarrantLiabilityAbstract" xlink:to="ptgef_DisclosureWarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureWarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfWarrantLiabilityExplanatory" xlink:label="ptgef_DisclosureOfWarrantLiabilityExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfWarrantLiabilityExplanatory" xlink:to="ptgef_DisclosureOfWarrantLiabilityExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfWarrantLiabilityExplanatory_lbl" xml:lang="en-US">WARRANT LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:label="ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract_lbl" xml:lang="en-US">Put Right Liability And Ton Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory" xlink:label="ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory" xlink:to="ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory_lbl" xml:lang="en-US">PUT RIGHT LIABILITY AND TON PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Accounts Payable And Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:to="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureLeaseLiabilityAbstract" xlink:label="ptgef_DisclosureLeaseLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureLeaseLiabilityAbstract" xlink:to="ptgef_DisclosureLeaseLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureLeaseLiabilityAbstract_lbl" xml:lang="en-US">Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfLeaseLiabilityExplanatory" xlink:label="ptgef_DisclosureOfLeaseLiabilityExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfLeaseLiabilityExplanatory" xlink:to="ptgef_DisclosureOfLeaseLiabilityExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfLeaseLiabilityExplanatory_lbl" xml:lang="en-US">LEASE LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureBitgoPrimeLoanAbstract" xlink:label="ptgef_DisclosureBitgoPrimeLoanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureBitgoPrimeLoanAbstract" xlink:to="ptgef_DisclosureBitgoPrimeLoanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureBitgoPrimeLoanAbstract_lbl" xml:lang="en-US">Bitgo Prime Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfBitgoPrimeLoanExplanatory" xlink:label="ptgef_DisclosureOfBitgoPrimeLoanExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfBitgoPrimeLoanExplanatory" xlink:to="ptgef_DisclosureOfBitgoPrimeLoanExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfBitgoPrimeLoanExplanatory_lbl" xml:lang="en-US">BITGO PRIME LOAN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="ptgef_DisclosureCapitalStockAndReservesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:to="ptgef_DisclosureCapitalStockAndReservesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureCapitalStockAndReservesAbstract_lbl" xml:lang="en-US">Capital Stock And Reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalStockAndReservesTextBlock" xlink:label="ptgef_CapitalStockAndReservesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalStockAndReservesTextBlock" xlink:to="ptgef_CapitalStockAndReservesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalStockAndReservesTextBlock_lbl" xml:lang="en-US">CAPITAL STOCK AND RESERVES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">STOCK OPTION RESERVE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US">Financial Instruments And Risk Management</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:label="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:to="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSegmentReportingAbstract" xlink:label="ptgef_DisclosureSegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureSegmentReportingAbstract" xlink:to="ptgef_DisclosureSegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureSegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock" xlink:label="ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock" xlink:to="ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalManagementAbstract" xlink:label="ptgef_DisclosureCapitalManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureCapitalManagementAbstract" xlink:to="ptgef_DisclosureCapitalManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureCapitalManagementAbstract_lbl" xml:lang="en-US">Capital Management</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:to="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xml:lang="en-US">CAPITAL MANAGEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xml:lang="en-US">NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of Financial Assets and Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xml:lang="en-US">Impairment of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory_lbl" xml:lang="en-US">Investment in Public Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xml:lang="en-US">Investment in Associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">Contingent Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Determination of Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Income Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory_lbl" xml:lang="en-US">Stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_lbl" xml:lang="en-US">Digital Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US">Revenue from Contracts with Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory_lbl" xml:lang="en-US">Expected Credit Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property, Plant, and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023" xlink:label="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023" xlink:to="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_lbl" xml:lang="en-US">Schedule of anti-dilutive effect on loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:to="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfStablecoinTableTextBlock" xlink:label="ptgef_DisclosureOfStablecoinTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfStablecoinTableTextBlock" xlink:to="ptgef_DisclosureOfStablecoinTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfStablecoinTableTextBlock_lbl" xml:lang="en-US">Schedule of stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfStablecoinPurchasesTableTextBlock" xlink:label="ptgef_DisclosureOfStablecoinPurchasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfStablecoinPurchasesTableTextBlock" xlink:to="ptgef_DisclosureOfStablecoinPurchasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfStablecoinPurchasesTableTextBlock_lbl" xml:lang="en-US">Schedule of stablecoin purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfDigitalAssetsTableTextBlock" xlink:label="ptgef_ScheduleOfDigitalAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfDigitalAssetsTableTextBlock" xlink:to="ptgef_ScheduleOfDigitalAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfDigitalAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock" xlink:label="ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock" xlink:to="ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock_lbl" xml:lang="en-US">Schedule of digital assets purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeheduleOfTonTokensTableTextBlock" xlink:label="ptgef_SeheduleOfTonTokensTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeheduleOfTonTokensTableTextBlock" xlink:to="ptgef_SeheduleOfTonTokensTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeheduleOfTonTokensTableTextBlock_lbl" xml:lang="en-US">[custom:SeheduleOfTonTokensTableTextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock" xlink:label="ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock" xlink:to="ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock_lbl" xml:lang="en-US">Schedule of movements in Receivables &#8211; digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of property, plant, and equipment, equipment deposits, and right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfInvestmentBalanceTableTextBlock" xlink:label="ptgef_ScheduleOfInvestmentBalanceTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfInvestmentBalanceTableTextBlock" xlink:to="ptgef_ScheduleOfInvestmentBalanceTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfInvestmentBalanceTableTextBlock_lbl" xml:lang="en-US">Schedule of investment balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:to="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in the warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Schedule of inputs associated with calculating the fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:label="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:to="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory_lbl" xml:lang="en-US">Schedule of fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" xlink:label="ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" xlink:to="ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory_lbl" xml:lang="en-US">Schedule of Placement agent warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory" xlink:label="ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory" xlink:to="ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory_lbl" xml:lang="en-US">Schedule of 2026 placement agent warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" xlink:label="ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" xlink:to="ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock_lbl" xml:lang="en-US">Schedule of put right liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfPutRightLiabilityTableTextBlock" xlink:label="ptgef_ScheduleOfPutRightLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfPutRightLiabilityTableTextBlock" xlink:to="ptgef_ScheduleOfPutRightLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ScheduleOfPutRightLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of put right liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfTonPayableTableTextBlock" xlink:label="ptgef_ScheduleOfTonPayableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfTonPayableTableTextBlock" xlink:to="ptgef_ScheduleOfTonPayableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfTonPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of TON payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfLeaseLiabilityTableTextBlock" xlink:label="ptgef_ScheduleOfLeaseLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfLeaseLiabilityTableTextBlock" xlink:to="ptgef_ScheduleOfLeaseLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:label="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:to="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:label="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:to="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation income tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:label="ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:to="ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US">Schedule of inputs associated with calculating the fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" xlink:label="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" xlink:to="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of share options issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock" xlink:label="ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock" xlink:to="ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average estimated fair value of share options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of weighted average exercise price and the remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share options granted and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfEarningsPerShareTableTextBlock" xlink:label="ptgef_ScheduleOfEarningsPerShareTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfEarningsPerShareTableTextBlock" xlink:to="ptgef_ScheduleOfEarningsPerShareTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfEarningsPerShareTableTextBlock_lbl" xml:lang="en-US">Schedule of loss and share data used in the basic and diluted EPS calculations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:to="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive effect on loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfCompensationPayableTableTextBlock" xlink:label="ptgef_ScheduleOfCompensationPayableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfCompensationPayableTableTextBlock" xlink:to="ptgef_ScheduleOfCompensationPayableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfCompensationPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of compensation payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl" xml:lang="en-US">Schedule of Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock" xlink:label="ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock" xlink:to="ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding equity awards</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US">[custom:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" xlink:label="ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" xlink:to="ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of liabilities measured at fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfSegmentReportingTableTextBlock" xlink:label="ptgef_ScheduleOfSegmentReportingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfSegmentReportingTableTextBlock" xlink:to="ptgef_ScheduleOfSegmentReportingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfSegmentReportingTableTextBlock_lbl" xml:lang="en-US">Schedule of segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:to="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xml:lang="en-US">Schedule of non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalCurrentLiabilities" xlink:label="ptgef_TotalCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalCurrentLiabilities" xlink:to="ptgef_TotalCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TotalCurrentLiabilities_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetLossIncome" xlink:label="ptgef_NetLossIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossIncome" xlink:to="ptgef_NetLossIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossIncome_lbl" xml:lang="en-US">Net Loss Income</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashUsedInOperatingActivities" xlink:label="ptgef_CashUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashUsedInOperatingActivities" xlink:to="ptgef_CashUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashUsedInOperatingActivities_lbl" xml:lang="en-US">Cash Used In Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashCashEquivalents" xlink:label="ptgef_CashCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashCashEquivalents" xlink:to="ptgef_CashCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashCashEquivalents_lbl" xml:lang="en-US">cash, cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RestrictedCashOnHand" xlink:label="ptgef_RestrictedCashOnHand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RestrictedCashOnHand" xlink:to="ptgef_RestrictedCashOnHand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RestrictedCashOnHand_lbl" xml:lang="en-US">Restricted cash on hand</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:to="ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_lbl" xml:lang="en-US">Percentage of outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Percentage of ownership subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncontrollingInterestIncreasedUponConversion" xlink:label="ptgef_NoncontrollingInterestIncreasedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NoncontrollingInterestIncreasedUponConversion" xlink:to="ptgef_NoncontrollingInterestIncreasedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NoncontrollingInterestIncreasedUponConversion_lbl" xml:lang="en-US">Non-controlling interest increased upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:label="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable_lbl" xml:lang="en-US">Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:label="ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:to="ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_lbl" xml:lang="en-US">Anti-dilutive effect on loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentProperty" xlink:label="ifrs-full_InvestmentProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentProperty" xlink:to="ifrs-full_InvestmentProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentProperty_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashRestrictedForUse" xlink:label="ptgef_CashRestrictedForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashRestrictedForUse" xlink:to="ptgef_CashRestrictedForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashRestrictedForUse_lbl" xml:lang="en-US">Cash restricted for use</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:label="ifrs-full_CurrentReceivablesFromSaleOfProperties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:to="ifrs-full_CurrentReceivablesFromSaleOfProperties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentReceivablesFromSaleOfProperties_lbl" xml:lang="en-US">Prepaid clinical research costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidInvestorRelations" xlink:label="ptgef_PrepaidInvestorRelations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidInvestorRelations" xlink:to="ptgef_PrepaidInvestorRelations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidInvestorRelations_lbl" xml:lang="en-US">Prepaid investor relations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TaxDeposits" xlink:label="ptgef_TaxDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TaxDeposits" xlink:to="ptgef_TaxDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TaxDeposits_lbl" xml:lang="en-US">Tax deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidGpuInfrastructureCosts" xlink:label="ptgef_PrepaidGpuInfrastructureCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidGpuInfrastructureCosts" xlink:to="ptgef_PrepaidGpuInfrastructureCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidGpuInfrastructureCosts_lbl" xml:lang="en-US">Prepaid GPU infrastructure costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidGpuLeasesShortterm" xlink:label="ptgef_PrepaidGpuLeasesShortterm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidGpuLeasesShortterm" xlink:to="ptgef_PrepaidGpuLeasesShortterm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidGpuLeasesShortterm_lbl" xml:lang="en-US">Prepaid GPU leases, short-term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalPrepaidExpensesAndOtherReceivables" xlink:label="ptgef_TotalPrepaidExpensesAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalPrepaidExpensesAndOtherReceivables" xlink:to="ptgef_TotalPrepaidExpensesAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TotalPrepaidExpensesAndOtherReceivables_lbl" xml:lang="en-US">&#160;&#160;Total prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OtherAssetsLongTermPortion" xlink:label="ptgef_OtherAssetsLongTermPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OtherAssetsLongTermPortion" xlink:to="ptgef_OtherAssetsLongTermPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OtherAssetsLongTermPortion_lbl" xml:lang="en-US">Other assets long term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SecurityDeposits" xlink:label="ptgef_SecurityDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SecurityDeposits" xlink:to="ptgef_SecurityDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SecurityDeposits_lbl" xml:lang="en-US">Security deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoins" xlink:label="ptgef_Stablecoins" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Stablecoins" xlink:to="ptgef_Stablecoins_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Stablecoins_lbl" xml:lang="en-US">stablecoins</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfApril1" xlink:label="ptgef_DigitalAssetValueAsOfApril1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetValueAsOfApril1" xlink:to="ptgef_DigitalAssetValueAsOfApril1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetValueAsOfApril1_lbl" xml:lang="en-US">Digital asset value as of April 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContributionOfStablecoin" xlink:to="ptgef_ContributionOfStablecoin_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ContributionOfStablecoin_2_lbl" xml:lang="en-US">Contribution of Stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSaleOfDigitalAssets" xlink:label="ptgef_ProceedsFromSaleOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromSaleOfDigitalAssets" xlink:to="ptgef_ProceedsFromSaleOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromSaleOfDigitalAssets_lbl" xml:lang="en-US">Proceeds from sale of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToSettleOperatingCosts" xlink:label="ptgef_StablecoinUsedToSettleOperatingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StablecoinUsedToSettleOperatingCosts" xlink:to="ptgef_StablecoinUsedToSettleOperatingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StablecoinUsedToSettleOperatingCosts_lbl" xml:lang="en-US">Stablecoin used to settle operating costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinSold" xlink:label="ptgef_StablecoinSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StablecoinSold" xlink:to="ptgef_StablecoinSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StablecoinSold_lbl" xml:lang="en-US">Stablecoin sold</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromExternalDebtDrawdown" xlink:label="ptgef_ProceedsFromExternalDebtDrawdown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromExternalDebtDrawdown" xlink:to="ptgef_ProceedsFromExternalDebtDrawdown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromExternalDebtDrawdown_lbl" xml:lang="en-US">Proceeds from external debt drawdown</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasesOfStablecoin" xlink:to="ptgef_PurchasesOfStablecoin_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchasesOfStablecoin_2_lbl" xml:lang="en-US">Purchases of stablecoin</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinValueAsOfMarch31" xlink:label="ptgef_StablecoinValueAsOfMarch31" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StablecoinValueAsOfMarch31" xlink:to="ptgef_StablecoinValueAsOfMarch31_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StablecoinValueAsOfMarch31_lbl" xml:lang="en-US">Stablecoin value as of March 31</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ApproximateNumberOfTonTokensHeld" xlink:label="ptgef_ApproximateNumberOfTonTokensHeld" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ApproximateNumberOfTonTokensHeld" xlink:to="ptgef_ApproximateNumberOfTonTokensHeld_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ApproximateNumberOfTonTokensHeld_lbl" xml:lang="en-US">Approximate number of TON Tokens held</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokensFairValueInThousands" xlink:label="ptgef_TonTokensFairValueInThousands" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TonTokensFairValueInThousands" xlink:to="ptgef_TonTokensFairValueInThousands_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TonTokensFairValueInThousands_lbl" xml:lang="en-US">TON Tokens, fair value (in thousands)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsFairValueInThousands" xlink:label="ptgef_DigitalAssetsFairValueInThousands" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsFairValueInThousands" xlink:to="ptgef_DigitalAssetsFairValueInThousands_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsFairValueInThousands_lbl" xml:lang="en-US">Digital assets, fair value (in thousands)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable_lbl" xml:lang="en-US">Disclosure of intangible assets material to entity [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" xlink:label="ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" xlink:to="ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_lbl" xml:lang="en-US">Unrealized losses on digital assets recognized in Statement of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsSold" xlink:label="ptgef_DigitalAssetsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsSold" xlink:to="ptgef_DigitalAssetsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsSold_lbl" xml:lang="en-US">Digital assets sold</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetPurchases" xlink:label="ptgef_DigitalAssetPurchases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetPurchases" xlink:to="ptgef_DigitalAssetPurchases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetPurchases_lbl" xml:lang="en-US">Digital asset purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetsReceivable" xlink:label="ptgef_ReceiptOfDigitalAssetsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReceiptOfDigitalAssetsReceivable" xlink:to="ptgef_ReceiptOfDigitalAssetsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReceiptOfDigitalAssetsReceivable_lbl" xml:lang="en-US">Receipt of digital assets receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossGainOnSaleOfDigitalAssets" xlink:label="ptgef_RealizedLossGainOnSaleOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RealizedLossGainOnSaleOfDigitalAssets" xlink:to="ptgef_RealizedLossGainOnSaleOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RealizedLossGainOnSaleOfDigitalAssets_lbl" xml:lang="en-US">Realized (loss) gain on sale of digital assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:to="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor_2_lbl" xml:lang="en-US">Realized loss on novation of digital assets to investor</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RevenueReceivedInDigitalAssets" xlink:label="ptgef_RevenueReceivedInDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RevenueReceivedInDigitalAssets" xlink:to="ptgef_RevenueReceivedInDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RevenueReceivedInDigitalAssets_lbl" xml:lang="en-US">Revenue received in digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TokensUsedToSettlePutRights" xlink:label="ptgef_TokensUsedToSettlePutRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TokensUsedToSettlePutRights" xlink:to="ptgef_TokensUsedToSettlePutRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TokensUsedToSettlePutRights_lbl" xml:lang="en-US">Tokens used to settle put rights</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsExchanged" xlink:label="ptgef_DigitalAssetsExchanged" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsExchanged" xlink:to="ptgef_DigitalAssetsExchanged_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsExchanged_lbl" xml:lang="en-US">Digital assets exchanged</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsTransacted" xlink:label="ptgef_DigitalAssetsTransacted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsTransacted" xlink:to="ptgef_DigitalAssetsTransacted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsTransacted_lbl" xml:lang="en-US">Digital assets transacted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfMarch31" xlink:label="ptgef_DigitalAssetValueAsOfMarch31" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetValueAsOfMarch31" xlink:to="ptgef_DigitalAssetValueAsOfMarch31_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetValueAsOfMarch31_lbl" xml:lang="en-US">Digital asset value as of March 31</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Fiscal 2027</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear" xlink:to="ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear_lbl" xml:lang="en-US">Fiscal 2028</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear" xlink:to="ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear_lbl" xml:lang="en-US">Fiscal 2029</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear" xlink:to="ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear_lbl" xml:lang="en-US">total&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssetAndStablecoinReceivables" xlink:label="ptgef_ContributionOfDigitalAssetAndStablecoinReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContributionOfDigitalAssetAndStablecoinReceivables" xlink:to="ptgef_ContributionOfDigitalAssetAndStablecoinReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ContributionOfDigitalAssetAndStablecoinReceivables_lbl" xml:lang="en-US">Contribution of digital asset and stablecoin receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDigitalAssetsReceivable" xlink:label="ptgef_ChangeInFairValueOfDigitalAssetsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDigitalAssetsReceivable" xlink:to="ptgef_ChangeInFairValueOfDigitalAssetsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfDigitalAssetsReceivable_lbl" xml:lang="en-US">Change in fair value of digital assets receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetReceivables" xlink:label="ptgef_ReceiptOfDigitalAssetReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReceiptOfDigitalAssetReceivables" xlink:to="ptgef_ReceiptOfDigitalAssetReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReceiptOfDigitalAssetReceivables_lbl" xml:lang="en-US">Receipt of digital asset receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinValueAsOfSeptember30" xlink:label="ptgef_StablecoinValueAsOfSeptember30" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StablecoinValueAsOfSeptember30" xlink:to="ptgef_StablecoinValueAsOfSeptember30_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StablecoinValueAsOfSeptember30_lbl" xml:lang="en-US">Stablecoin value as of September 30</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssets" xlink:label="ptgef_DigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssets" xlink:to="ptgef_DigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssets_lbl" xml:lang="en-US">Digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokensReceivable" xlink:label="ptgef_TonTokensReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TonTokensReceivable" xlink:to="ptgef_TonTokensReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TonTokensReceivable_lbl" xml:lang="en-US">TON tokens receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokensReceivableShares" xlink:label="ptgef_TonTokensReceivableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TonTokensReceivableShares" xlink:to="ptgef_TonTokensReceivableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TonTokensReceivableShares_lbl" xml:lang="en-US">TON tokens receivable shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TokensArePayable" xlink:label="ptgef_TokensArePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TokensArePayable" xlink:to="ptgef_TokensArePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TokensArePayable_lbl" xml:lang="en-US">Tokens are payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl" xml:lang="en-US">As of March 31, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US">Fixed asset additions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed asset disposals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_2_lbl" xml:lang="en-US">As of March 31, 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" xlink:label="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" xlink:to="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">As of March 31, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FixedAssetDepreciation" xlink:label="ptgef_FixedAssetDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FixedAssetDepreciation" xlink:to="ptgef_FixedAssetDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FixedAssetDepreciation_lbl" xml:lang="en-US">Fixed asset depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FixedAssetDisposals" xlink:label="ptgef_FixedAssetDisposals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FixedAssetDisposals" xlink:to="ptgef_FixedAssetDisposals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_FixedAssetDisposals_lbl" xml:lang="en-US">Fixed asset disposals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" xlink:to="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">As of March 31, 2026</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Property plant equipment carrying amount</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceAsOfApril1" xlink:label="ptgef_BalanceAsOfApril1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BalanceAsOfApril1" xlink:to="ptgef_BalanceAsOfApril1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BalanceAsOfApril1_lbl" xml:lang="en-US">Balance as of April 1</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_InitialInvestmentInCompedica" xlink:label="ptgef_InitialInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InitialInvestmentInCompedica" xlink:to="ptgef_InitialInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InitialInvestmentInCompedica_lbl" xml:lang="en-US">Initial investment in Compedica</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossFromEquityMethodInvestment" xlink:to="ptgef_LossFromEquityMethodInvestment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_LossFromEquityMethodInvestment_2_lbl" xml:lang="en-US">Loss from equity method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnImpairment" xlink:label="ptgef_LossOnImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnImpairment" xlink:to="ptgef_LossOnImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnImpairment_lbl" xml:lang="en-US">Loss on impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfInvestmentInCompedica" xlink:label="ptgef_ChangeInFairValueOfInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfInvestmentInCompedica" xlink:to="ptgef_ChangeInFairValueOfInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfInvestmentInCompedica_lbl" xml:lang="en-US">Change in fair value of investment in Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReturnOfInvestmentInterestToCompedica" xlink:label="ptgef_ReturnOfInvestmentInterestToCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReturnOfInvestmentInterestToCompedica" xlink:to="ptgef_ReturnOfInvestmentInterestToCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReturnOfInvestmentInterestToCompedica_lbl" xml:lang="en-US">Return of investment interest to Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_InvestmentInCompedicaAsOfMarch31" xlink:label="ptgef_InvestmentInCompedicaAsOfMarch31" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentInCompedicaAsOfMarch31" xlink:to="ptgef_InvestmentInCompedicaAsOfMarch31_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentInCompedicaAsOfMarch31_lbl" xml:lang="en-US">Investment in Compedica as of March 31</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedReimbursementOtherProvisions" xlink:label="ifrs-full_ExpectedReimbursementOtherProvisions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedReimbursementOtherProvisions" xlink:to="ifrs-full_ExpectedReimbursementOtherProvisions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedReimbursementOtherProvisions_lbl" xml:lang="en-US">reimbursement of expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ImpairmentLoss_2_lbl" xml:lang="en-US">Loss on impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOnInvestmentInCompedica" xlink:label="ptgef_ChangeInFairValueOnInvestmentInCompedica" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOnInvestmentInCompedica" xlink:to="ptgef_ChangeInFairValueOnInvestmentInCompedica_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOnInvestmentInCompedica_lbl" xml:lang="en-US">Change in fair value on the investment in Compedica</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:label="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:to="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice_lbl" xml:lang="en-US">Fair value of warrants at issuance exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsShares" xlink:label="ptgef_FairValueOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantsShares" xlink:to="ptgef_FairValueOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantsShares_lbl" xml:lang="en-US">Fair value of warrants shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsAmount" xlink:label="ptgef_FairValueOfWarrantsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantsAmount" xlink:to="ptgef_FairValueOfWarrantsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantsAmount_lbl" xml:lang="en-US">Fair value of warrants amount</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:label="ptgef_ChangeInFairValueOfWarrantLiabilityAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:to="ptgef_ChangeInFairValueOfWarrantLiabilityAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfWarrantLiabilityAmount_lbl" xml:lang="en-US">Change in fair value of warrant liability, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityShares" xlink:label="ptgef_WarrantsLiabilityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityShares" xlink:to="ptgef_WarrantsLiabilityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsLiabilityShares_lbl" xml:lang="en-US">Warrants outstanding, shares at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="ptgef_WarrantsLiabilityFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityFairValue" xlink:to="ptgef_WarrantsLiabilityFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsLiabilityFairValue_lbl" xml:lang="en-US">Warrants outstanding, fair value at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityShares" xlink:to="ptgef_WarrantsLiabilityShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsLiabilityShares_2_lbl" xml:lang="en-US">Warrants outstanding, shares at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityFairValue" xlink:to="ptgef_WarrantsLiabilityFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsLiabilityFairValue_2_lbl" xml:lang="en-US">Warrants outstanding, fair value at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="ptgef_ExercisePriceFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePriceFairValue" xlink:to="ptgef_ExercisePriceFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePriceFairValue_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="ptgef_SharePriceFairvalue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharePriceFairvalue" xlink:to="ptgef_SharePriceFairvalue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharePriceFairvalue_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="ptgef_OptionLifeShareOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OptionLifeShareOptions" xlink:to="ptgef_OptionLifeShareOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OptionLifeShareOptions_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Expected dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantPerShare" xlink:label="ptgef_FairValueOfWarrantPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantPerShare" xlink:to="ptgef_FairValueOfWarrantPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantPerShare_lbl" xml:lang="en-US">Fair value of warrant per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Alp shares and ton correlation factor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiabilityemainingTermInYears" xlink:label="ptgef_PutRightLiabilityemainingTermInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightLiabilityemainingTermInYears" xlink:to="ptgef_PutRightLiabilityemainingTermInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightLiabilityemainingTermInYears_lbl" xml:lang="en-US">Remaining term (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2_lbl" xml:lang="en-US">Expected ALP volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_2_lbl" xml:lang="en-US">ALP dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokenPrice" xlink:label="ptgef_TonTokenPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TonTokenPrice" xlink:to="ptgef_TonTokenPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TonTokenPrice_lbl" xml:lang="en-US">TON token price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate" xlink:label="ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate" xlink:to="ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate_lbl" xml:lang="en-US">Locked TON token discount for lack of marketability rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceOfPutRightLiability" xlink:label="ptgef_BalanceOfPutRightLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BalanceOfPutRightLiability" xlink:to="ptgef_BalanceOfPutRightLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_BalanceOfPutRightLiability_lbl" xml:lang="en-US">Balance as of April 1</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets" xlink:label="ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets" xlink:to="ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_lbl" xml:lang="en-US">Put right recognition at contract inception</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US">Change in fair value of put right liability, net of redemptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US">Exercise of side letter put right</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfDwfMaasLimitedPutRight" xlink:label="ptgef_SettlementOfDwfMaasLimitedPutRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SettlementOfDwfMaasLimitedPutRight" xlink:to="ptgef_SettlementOfDwfMaasLimitedPutRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SettlementOfDwfMaasLimitedPutRight_lbl" xml:lang="en-US">Settlement of DWF Maas Limited put right</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiabilityEndingBalance" xlink:label="ptgef_PutRightLiabilityEndingBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightLiabilityEndingBalance" xlink:to="ptgef_PutRightLiabilityEndingBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightLiabilityEndingBalance_lbl" xml:lang="en-US">Put right liability as of March 31</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceOfTonPayable" xlink:label="ptgef_BalanceOfTonPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BalanceOfTonPayable" xlink:to="ptgef_BalanceOfTonPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_BalanceOfTonPayable_lbl" xml:lang="en-US">Balance as of April 1</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfSideLetterPutRightPayable" xlink:label="ptgef_ExerciseOfSideLetterPutRightPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExerciseOfSideLetterPutRightPayable" xlink:to="ptgef_ExerciseOfSideLetterPutRightPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ExerciseOfSideLetterPutRightPayable_lbl" xml:lang="en-US">Exercise of side letter put right</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets" xlink:label="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets" xlink:to="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets_lbl" xml:lang="en-US">Settlement of put right liability using digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableEndingBalanceAsOfMarch31" xlink:label="ptgef_TonPayableEndingBalanceAsOfMarch31" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TonPayableEndingBalanceAsOfMarch31" xlink:to="ptgef_TonPayableEndingBalanceAsOfMarch31_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TonPayableEndingBalanceAsOfMarch31_lbl" xml:lang="en-US">TON payable as of March 31</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryManagementAgreementDescription" xlink:label="ptgef_TreasuryManagementAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TreasuryManagementAgreementDescription" xlink:to="ptgef_TreasuryManagementAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TreasuryManagementAgreementDescription_lbl" xml:lang="en-US">Treasury Management Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentInterestReceivable" xlink:label="ifrs-full_CurrentInterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInterestReceivable" xlink:to="ifrs-full_CurrentInterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInterestReceivable_lbl" xml:lang="en-US">Fair value of stablecoin receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfContribution" xlink:label="ptgef_FairValueOfContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfContribution" xlink:to="ptgef_FairValueOfContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfContribution_lbl" xml:lang="en-US">Fair value of contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Usd1Receivable" xlink:label="ptgef_Usd1Receivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Usd1Receivable" xlink:to="ptgef_Usd1Receivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Usd1Receivable_lbl" xml:lang="en-US">USD1 receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExercise" xlink:label="ptgef_LossOnExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnExercise" xlink:to="ptgef_LossOnExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnExercise_lbl" xml:lang="en-US">loss on the exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OutstandingContingentPutOptionsFairValue" xlink:label="ptgef_OutstandingContingentPutOptionsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OutstandingContingentPutOptionsFairValue" xlink:to="ptgef_OutstandingContingentPutOptionsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OutstandingContingentPutOptionsFairValue_lbl" xml:lang="en-US">Outstanding Contingent Put Options fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RemeasurementChangeInFairValue" xlink:label="ptgef_RemeasurementChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RemeasurementChangeInFairValue" xlink:to="ptgef_RemeasurementChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RemeasurementChangeInFairValue_lbl" xml:lang="en-US">Remeasurement change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayable" xlink:label="ptgef_AccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayable" xlink:to="ptgef_AccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedOtherProfessionalFees" xlink:label="ptgef_AccruedOtherProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedOtherProfessionalFees" xlink:to="ptgef_AccruedOtherProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedOtherProfessionalFees_lbl" xml:lang="en-US">Accrued other professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedAccountingAndAuditingFees" xlink:label="ptgef_AccruedAccountingAndAuditingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedAccountingAndAuditingFees" xlink:to="ptgef_AccruedAccountingAndAuditingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedAccountingAndAuditingFees_lbl" xml:lang="en-US">Accrued accounting and auditing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" xlink:label="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" xlink:to="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses_lbl" xml:lang="en-US">Accrued bonuses and other payroll-related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedCRO" xlink:label="ptgef_AccruedCRO" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedCRO" xlink:to="ptgef_AccruedCRO_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedCRO_lbl" xml:lang="en-US">Accrued CRO</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProfessionalFeesExpenses" xlink:label="ptgef_ProfessionalFeesExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProfessionalFeesExpenses" xlink:to="ptgef_ProfessionalFeesExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProfessionalFeesExpenses_lbl" xml:lang="en-US">Accrued legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedClinicalAndRdServices" xlink:label="ptgef_AccruedClinicalAndRdServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedClinicalAndRdServices" xlink:to="ptgef_AccruedClinicalAndRdServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedClinicalAndRdServices_lbl" xml:lang="en-US">Accrued clinical and R&amp;D services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalExpenditures" xlink:label="ptgef_CapitalExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalExpenditures" xlink:to="ptgef_CapitalExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalExpenditures_lbl" xml:lang="en-US">Capital expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OtherAccruedExpenses" xlink:label="ptgef_OtherAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OtherAccruedExpenses" xlink:to="ptgef_OtherAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OtherAccruedExpenses_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilityNet" xlink:label="ptgef_AccountsPayableAndAccruedLiabilityNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilityNet" xlink:to="ptgef_AccountsPayableAndAccruedLiabilityNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilityNet_lbl" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityFutureMinimumPaymentsDue" xlink:label="ptgef_LeaseLiabilityFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityFutureMinimumPaymentsDue" xlink:to="ptgef_LeaseLiabilityFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityFutureMinimumPaymentsDue_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue" xlink:label="ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue" xlink:to="ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue" xlink:label="ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue" xlink:to="ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Interest" xlink:label="ptgef_Interest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Interest" xlink:to="ptgef_Interest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Interest_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalLeaseLiability" xlink:label="ptgef_TotalLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalLeaseLiability" xlink:to="ptgef_TotalLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TotalLeaseLiability_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityCurrent" xlink:label="ptgef_LeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityCurrent" xlink:to="ptgef_LeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_LeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability - current</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityNoncurrent" xlink:label="ptgef_LeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityNoncurrent" xlink:to="ptgef_LeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_LeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability - non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Commencement" xlink:label="ptgef_Commencement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Commencement" xlink:to="ptgef_Commencement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Commencement_lbl" xml:lang="en-US">Commencement</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasePriceLeaseLiability" xlink:label="ptgef_PurchasePriceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasePriceLeaseLiability" xlink:to="ptgef_PurchasePriceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchasePriceLeaseLiability_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchaseEquipmentPayment" xlink:label="ptgef_PurchaseEquipmentPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseEquipmentPayment" xlink:to="ptgef_PurchaseEquipmentPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseEquipmentPayment_lbl" xml:lang="en-US">Purchase equipment payment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MasterLoanAgreementDescription" xlink:label="ptgef_MasterLoanAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MasterLoanAgreementDescription" xlink:to="ptgef_MasterLoanAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MasterLoanAgreementDescription_lbl" xml:lang="en-US">Master Loan Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xml:lang="en-US">Current tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CurrentTaxOnProfitsForYear" xlink:label="ptgef_CurrentTaxOnProfitsForYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentTaxOnProfitsForYear" xlink:to="ptgef_CurrentTaxOnProfitsForYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentTaxOnProfitsForYear_lbl" xml:lang="en-US">Current tax on profits for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ptgef_AdjustmentsForCurrentTaxOfPriorPeriods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ptgef_AdjustmentsForCurrentTaxOfPriorPeriods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US">Adjustments for current tax of prior periods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US">Total current tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Deferred income tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DecreaseIncreaseInDeferredTaxAssets" xlink:label="ptgef_DecreaseIncreaseInDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DecreaseIncreaseInDeferredTaxAssets" xlink:to="ptgef_DecreaseIncreaseInDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DecreaseIncreaseInDeferredTaxAssets_lbl" xml:lang="en-US">Decrease (increase) in deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProfitLossFromContinuingOperation" xlink:label="ptgef_ProfitLossFromContinuingOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProfitLossFromContinuingOperation" xlink:to="ptgef_ProfitLossFromContinuingOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProfitLossFromContinuingOperation_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" xlink:label="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" xlink:to="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax_lbl" xml:lang="en-US">Loss before income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TaxUsingBviTaxRate" xlink:label="ptgef_TaxUsingBviTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TaxUsingBviTaxRate" xlink:to="ptgef_TaxUsingBviTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TaxUsingBviTaxRate_lbl" xml:lang="en-US">Tax using BVI tax rate of 0%</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EffectOfTaxRatesInOtherCountries" xlink:label="ptgef_EffectOfTaxRatesInOtherCountries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EffectOfTaxRatesInOtherCountries" xlink:to="ptgef_EffectOfTaxRatesInOtherCountries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EffectOfTaxRatesInOtherCountries_lbl" xml:lang="en-US">Effect of tax rates in other countries</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DerecognitionOfDeferredTaxAssets" xlink:label="ptgef_DerecognitionOfDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DerecognitionOfDeferredTaxAssets" xlink:to="ptgef_DerecognitionOfDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DerecognitionOfDeferredTaxAssets_lbl" xml:lang="en-US">Derecognition of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NondeductibleExpenses" xlink:label="ptgef_NondeductibleExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NondeductibleExpenses" xlink:to="ptgef_NondeductibleExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NondeductibleExpenses_lbl" xml:lang="en-US">Nondeductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UtilizationOfLossesNotPreviouslyBenefitted" xlink:label="ptgef_UtilizationOfLossesNotPreviouslyBenefitted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UtilizationOfLossesNotPreviouslyBenefitted" xlink:to="ptgef_UtilizationOfLossesNotPreviouslyBenefitted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UtilizationOfLossesNotPreviouslyBenefitted_lbl" xml:lang="en-US">Utilization of losses not previously benefitted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeTaxEffectsRelatedToEquityCompensation" xlink:label="ptgef_IncomeTaxEffectsRelatedToEquityCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxEffectsRelatedToEquityCompensation" xlink:to="ptgef_IncomeTaxEffectsRelatedToEquityCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeTaxEffectsRelatedToEquityCompensation_lbl" xml:lang="en-US">Income tax effects related to equity compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ForeignCurrencyEffectAndOther" xlink:label="ptgef_ForeignCurrencyEffectAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ForeignCurrencyEffectAndOther" xlink:to="ptgef_ForeignCurrencyEffectAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ForeignCurrencyEffectAndOther_lbl" xml:lang="en-US">Foreign currency effect and other</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeTaxExpense" xlink:label="ptgef_IncomeTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxExpense" xlink:to="ptgef_IncomeTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeTaxExpense_lbl" xml:lang="en-US">Income tax in the statement of loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredTaxAssetsAbstract" xlink:label="ptgef_DeferredTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxAssetsAbstract" xlink:to="ptgef_DeferredTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:label="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:to="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward_lbl" xml:lang="en-US">Tax loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockbasedCompensation" xlink:label="ptgef_StockbasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockbasedCompensation" xlink:to="ptgef_StockbasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockbasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReservesAndAccruals" xlink:label="ptgef_ReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReservesAndAccruals" xlink:to="ptgef_ReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReservesAndAccruals_lbl" xml:lang="en-US">Reserves and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredTaxAssetNotRecognized" xlink:label="ptgef_DeferredTaxAssetNotRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxAssetNotRecognized" xlink:to="ptgef_DeferredTaxAssetNotRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_DeferredTaxAssetNotRecognized_lbl" xml:lang="en-US">Deferred tax asset not recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetDeferredTaxAsset" xlink:label="ptgef_NetDeferredTaxAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetDeferredTaxAsset" xlink:to="ptgef_NetDeferredTaxAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_NetDeferredTaxAsset_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US">U.S. federal net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UkLossCarryForwards" xlink:label="ptgef_UkLossCarryForwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UkLossCarryForwards" xlink:to="ptgef_UkLossCarryForwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UkLossCarryForwards_lbl" xml:lang="en-US">UK Loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US">deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xml:lang="en-US">Disclosure of offsetting of financial assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaleOfStock" xlink:label="ptgef_SaleOfStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaleOfStock" xlink:to="ptgef_SaleOfStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SaleOfStock_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AggregateProceeds" xlink:label="ptgef_AggregateProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AggregateProceeds" xlink:to="ptgef_AggregateProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AggregateProceeds_lbl" xml:lang="en-US">aggregate proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesPrice" xlink:label="ptgef_SharesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesPrice" xlink:to="ptgef_SharesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_SharesPrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsToPurchase" xlink:label="ptgef_WarrantsToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsToPurchase" xlink:to="ptgef_WarrantsToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsToPurchase_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasePrice" xlink:label="ptgef_PurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasePrice" xlink:to="ptgef_PurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_PurchasePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrossProceeds" xlink:label="ptgef_GrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GrossProceeds" xlink:to="ptgef_GrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DgitalAssets" xlink:label="ptgef_DgitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DgitalAssets" xlink:to="ptgef_DgitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DgitalAssets_lbl" xml:lang="en-US">Dgital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OrdinarySharesIssued" xlink:label="ptgef_OrdinarySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OrdinarySharesIssued" xlink:to="ptgef_OrdinarySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfSharesSold" xlink:label="ptgef_NumberOfSharesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesSold" xlink:to="ptgef_NumberOfSharesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfSharesSold_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetProceeds" xlink:label="ptgef_NetProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetProceeds" xlink:to="ptgef_NetProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetProceeds_lbl" xml:lang="en-US">net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStock" xlink:label="ptgef_TreasuryStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TreasuryStock" xlink:to="ptgef_TreasuryStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TreasuryStock_lbl" xml:lang="en-US">Treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AggregateOfferingOrdinaryShares" xlink:label="ptgef_AggregateOfferingOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AggregateOfferingOrdinaryShares" xlink:to="ptgef_AggregateOfferingOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AggregateOfferingOrdinaryShares_lbl" xml:lang="en-US">Aggregate offering ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Proceedsfromexerciseofwarrant" xlink:label="ptgef_Proceedsfromexerciseofwarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Proceedsfromexerciseofwarrant" xlink:to="ptgef_Proceedsfromexerciseofwarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Proceedsfromexerciseofwarrant_lbl" xml:lang="en-US">ProceedsFromExerciseOfWarrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Pre-funded warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US">pre-funded warrants outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalSharesIssued" xlink:label="ptgef_AdditionalSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalSharesIssued" xlink:to="ptgef_AdditionalSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalSharesIssued_lbl" xml:lang="en-US">Additional shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsPurchase" xlink:label="ptgef_WarrantsPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsPurchase" xlink:to="ptgef_WarrantsPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsPurchase_lbl" xml:lang="en-US">Warrants purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsPerShare" xlink:label="ptgef_WarrantsPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsPerShare" xlink:to="ptgef_WarrantsPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsPerShare_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionReserve" xlink:label="ptgef_StockOptionReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_StockOptionReserve_lbl" xml:lang="en-US">Stock Option Reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" xlink:label="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" xlink:to="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_lbl" xml:lang="en-US">Correction of prior period overstated share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_StockOptionReserve_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="ptgef_NumberOfOutstandingShareOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Expired or forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:to="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xml:lang="en-US">Exercisable as at end</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Available for future awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfGrantPriceShareOptionsGranted" xlink:label="ptgef_DescriptionOfGrantPriceShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfGrantPriceShareOptionsGranted" xlink:to="ptgef_DescriptionOfGrantPriceShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfGrantPriceShareOptionsGranted_lbl" xml:lang="en-US">Grant price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="ptgef_OptionLifeShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OptionLifeShareOptionsGranted" xlink:to="ptgef_OptionLifeShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_OptionLifeShareOptionsGranted_lbl" xml:lang="en-US">Expected life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_3_lbl" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable_lbl" xml:lang="en-US">Disclosure of quantitative information about financial instruments that have yet to transition to alternative benchmark rate [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExpirationDate" xlink:label="ptgef_ExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExpirationDate" xlink:to="ptgef_ExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePrice" xlink:label="ptgef_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePrice" xlink:to="ptgef_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOptions" xlink:label="ptgef_ShareOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareOptions" xlink:to="ptgef_ShareOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareOptions_lbl" xml:lang="en-US">Share Options</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AuthorizedGrantOptionPurchaseShares" xlink:label="ptgef_AuthorizedGrantOptionPurchaseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AuthorizedGrantOptionPurchaseShares" xlink:to="ptgef_AuthorizedGrantOptionPurchaseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AuthorizedGrantOptionPurchaseShares_lbl" xml:lang="en-US">Authorized grant option purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedGrantedRsu" xlink:label="ptgef_SharesIssuedGrantedRsu" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedGrantedRsu" xlink:to="ptgef_SharesIssuedGrantedRsu_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedGrantedRsu_lbl" xml:lang="en-US">Shares issued granted RSU</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfSharesExercise" xlink:label="ptgef_NumberOfSharesExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesExercise" xlink:to="ptgef_NumberOfSharesExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfSharesExercise_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:label="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:to="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_lbl" xml:lang="en-US">Shares repurchased into treasury employee payroll taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharebasedCompensationExpense" xlink:label="ptgef_SharebasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharebasedCompensationExpense" xlink:to="ptgef_SharebasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_SharebasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReversalOfSharebasedCompensation" xlink:label="ptgef_ReversalOfSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReversalOfSharebasedCompensation" xlink:to="ptgef_ReversalOfSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReversalOfSharebasedCompensation_lbl" xml:lang="en-US">Reversal of share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareBasedCompensationExpenseUnvestedShareOptions" xlink:label="ptgef_ShareBasedCompensationExpenseUnvestedShareOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareBasedCompensationExpenseUnvestedShareOptions" xlink:to="ptgef_ShareBasedCompensationExpenseUnvestedShareOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareBasedCompensationExpenseUnvestedShareOptions_lbl" xml:lang="en-US">Share based compensation expense unvested share options</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WeightedAverageSharesOutstandingDiluted" xlink:label="ptgef_WeightedAverageSharesOutstandingDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WeightedAverageSharesOutstandingDiluted" xlink:to="ptgef_WeightedAverageSharesOutstandingDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_WeightedAverageSharesOutstandingDiluted_lbl" xml:lang="en-US">Weighted average shares outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossPerShareBasic" xlink:label="ptgef_LossPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossPerShareBasic" xlink:to="ptgef_LossPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_LossPerShareBasic_lbl" xml:lang="en-US">Loss per share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossPerShareDiluted" xlink:label="ptgef_LossPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossPerShareDiluted" xlink:to="ptgef_LossPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_LossPerShareDiluted_lbl" xml:lang="en-US">Loss per share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="ptgef_AntidilutiveEffectOnLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AntidilutiveEffectOnLossPerShare" xlink:to="ptgef_AntidilutiveEffectOnLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_AntidilutiveEffectOnLossPerShare_lbl" xml:lang="en-US">Anti-dilutive effect on loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ServiceFees" xlink:label="ptgef_ServiceFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ServiceFees" xlink:to="ptgef_ServiceFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ServiceFees_lbl" xml:lang="en-US">service fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BudgetCosts" xlink:label="ptgef_BudgetCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BudgetCosts" xlink:to="ptgef_BudgetCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BudgetCosts_lbl" xml:lang="en-US">Budget costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnbilledServices" xlink:label="ptgef_UnbilledServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnbilledServices" xlink:to="ptgef_UnbilledServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnbilledServices_lbl" xml:lang="en-US">Unbilled services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ForfeitedAdvancedPayments" xlink:label="ptgef_ForfeitedAdvancedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ForfeitedAdvancedPayments" xlink:to="ptgef_ForfeitedAdvancedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ForfeitedAdvancedPayments_lbl" xml:lang="en-US">Forfeited advanced payments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetGain" xlink:label="ptgef_NetGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetGain" xlink:to="ptgef_NetGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetGain_lbl" xml:lang="en-US">Net gain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xml:lang="en-US">Accounts payable and accrued liabilitie</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="ptgef_PrepaidExpensesAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivables" xlink:to="ptgef_PrepaidExpensesAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivables_lbl" xml:lang="en-US">prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContractualPayments" xlink:label="ptgef_ContractualPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContractualPayments" xlink:to="ptgef_ContractualPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ContractualPayments_lbl" xml:lang="en-US">Contractual payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SecurityDeposits" xlink:to="ptgef_SecurityDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_SecurityDeposits_2_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetworkingEquipmentCost" xlink:label="ptgef_NetworkingEquipmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetworkingEquipmentCost" xlink:to="ptgef_NetworkingEquipmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetworkingEquipmentCost_lbl" xml:lang="en-US">Networking equipment cost</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Deposit" xlink:label="ptgef_Deposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Deposit" xlink:to="ptgef_Deposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Deposit_lbl" xml:lang="en-US">Deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US">Short-term employee benefits (salary, bonus, etc.)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl" xml:lang="en-US">Post-employment benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherLongtermBenefits" xlink:label="ifrs-full_OtherLongtermBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLongtermBenefits" xlink:to="ifrs-full_OtherLongtermBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLongtermBenefits_lbl" xml:lang="en-US">Other long-term benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="ifrs-full_TerminationBenefitsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TerminationBenefitsExpense" xlink:to="ifrs-full_TerminationBenefitsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TerminationBenefitsExpense_lbl" xml:lang="en-US">Termination benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharebasedPaymentCompensation" xlink:label="ptgef_SharebasedPaymentCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharebasedPaymentCompensation" xlink:to="ptgef_SharebasedPaymentCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharebasedPaymentCompensation_lbl" xml:lang="en-US">Share-based payment compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US">&#160;Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="ifrs-full_FeeAndCommissionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Fee and salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionIncome" xlink:label="ifrs-full_FeeAndCommissionIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionIncome" xlink:to="ifrs-full_FeeAndCommissionIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionIncome_lbl" xml:lang="en-US">Bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TransactionClosingBonus" xlink:label="ptgef_TransactionClosingBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TransactionClosingBonus" xlink:to="ptgef_TransactionClosingBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TransactionClosingBonus_lbl" xml:lang="en-US">Transaction closing bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SecuritiesUnderOptionsGranted" xlink:label="ptgef_SecuritiesUnderOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SecuritiesUnderOptionsGranted" xlink:to="ptgef_SecuritiesUnderOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SecuritiesUnderOptionsGranted_lbl" xml:lang="en-US">Securities under option granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_3_lbl" xml:lang="en-US">Shares ot units</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OtherCompensation" xlink:label="ptgef_OtherCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OtherCompensation" xlink:to="ptgef_OtherCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OtherCompensation_lbl" xml:lang="en-US">Other compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" xlink:to="ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Total compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrantDate" xlink:label="ptgef_GrantDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GrantDate" xlink:to="ptgef_GrantDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GrantDate_lbl" xml:lang="en-US">Grant Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_2_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" xlink:label="ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" xlink:to="ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_lbl" xml:lang="en-US">Number of Securities Underlying Unexercised Options Un Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePrices" xlink:label="ptgef_ExercisePrices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePrices" xlink:to="ptgef_ExercisePrices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePrices_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionExpirationDate" xlink:label="ptgef_OptionExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OptionExpirationDate" xlink:to="ptgef_OptionExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OptionExpirationDate_lbl" xml:lang="en-US">Option Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberofShareUnitsofStockThetHaveNotVested" xlink:label="ptgef_NumberofShareUnitsofStockThetHaveNotVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberofShareUnitsofStockThetHaveNotVested" xlink:to="ptgef_NumberofShareUnitsofStockThetHaveNotVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberofShareUnitsofStockThetHaveNotVested_lbl" xml:lang="en-US">Number of Share Units of Stock Thet Have Not Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested" xlink:label="ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested" xlink:to="ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested_lbl" xml:lang="en-US">Market Value Number of Share Units of Stock Thet Have Not Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaleOfStock" xlink:to="ptgef_SaleOfStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_SaleOfStock_2_lbl" xml:lang="en-US">sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Decentranet" xlink:label="ptgef_Decentranet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Decentranet" xlink:to="ptgef_Decentranet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Decentranet_lbl" xml:lang="en-US">DecentraNet</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivable" xlink:to="ptgef_PrepaidExpensesAndOtherReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantLiability" xlink:label="ifrs-full_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityCurrentAndNoncurrent" xlink:label="ptgef_LeaseLiabilityCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityCurrentAndNoncurrent" xlink:to="ptgef_LeaseLiabilityCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityCurrentAndNoncurrent_lbl" xml:lang="en-US">Lease liability - current and noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_lbl" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonLiquid" xlink:label="ptgef_DigitalAssetsAtFairValueTonLiquid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsAtFairValueTonLiquid" xlink:to="ptgef_DigitalAssetsAtFairValueTonLiquid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsAtFairValueTonLiquid_lbl" xml:lang="en-US">Digital assets at fair value, TON liquid</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonLocked" xlink:label="ptgef_DigitalAssetsAtFairValueTonLocked" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DigitalAssetsAtFairValueTonLocked" xlink:to="ptgef_DigitalAssetsAtFairValueTonLocked_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DigitalAssetsAtFairValueTonLocked_lbl" xml:lang="en-US">Digital assets at fair value, TON locked</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Revenue_2_lbl" xml:lang="en-US">Segment revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAbstract_2_lbl" xml:lang="en-US">Segment expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_2_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xml:lang="en-US">Segment loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRevaluationOfDigitalAssets" xlink:to="ptgef_LossOnRevaluationOfDigitalAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnRevaluationOfDigitalAssets_2_lbl" xml:lang="en-US">Loss on revaluation of digital assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRevaluationOfDigitalAssetReceivables" xlink:to="ptgef_LossOnRevaluationOfDigitalAssetReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnRevaluationOfDigitalAssetReceivables_2_lbl" xml:lang="en-US">Loss on revaluation of digital asset receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ImpairmentLossInvestmentInCompedica" xlink:to="ptgef_ImpairmentLossInvestmentInCompedica_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ImpairmentLossInvestmentInCompedica_2_lbl" xml:lang="en-US">Impairment loss - investment in Compedica</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnRevaluationOfInvestmentInCompedica" xlink:to="ptgef_LossOnRevaluationOfInvestmentInCompedica_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnRevaluationOfInvestmentInCompedica_2_lbl" xml:lang="en-US">Loss on revaluation of investment in Compedica</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnSettlementOfPutRightLiability" xlink:to="ptgef_LossOnSettlementOfPutRightLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnSettlementOfPutRightLiability_2_lbl" xml:lang="en-US">Loss on settlement of put right liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US">Foreign exchange transaction (loss) gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:label="ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:to="ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_lbl" xml:lang="en-US">Interest (expense) income, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnExtinguishmentOfDebt" xlink:to="ptgef_GainOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_GainOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on forgiveness of loan interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareOfLossesFromEquityMethodInvestment" xlink:to="ptgef_ShareOfLossesFromEquityMethodInvestment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareOfLossesFromEquityMethodInvestment_2_lbl" xml:lang="en-US">Share of losses from equity method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SegmentLossBeforeBenefitForIncomeTaxes" xlink:label="ptgef_SegmentLossBeforeBenefitForIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SegmentLossBeforeBenefitForIncomeTaxes" xlink:to="ptgef_SegmentLossBeforeBenefitForIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SegmentLossBeforeBenefitForIncomeTaxes_lbl" xml:lang="en-US">Segment loss before benefit for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeTaxBenefit" xlink:label="ptgef_IncomeTaxBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxBenefit" xlink:to="ptgef_IncomeTaxBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_IncomeTaxBenefit_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SegmentNetLoss" xlink:label="ptgef_SegmentNetLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SegmentNetLoss" xlink:to="ptgef_SegmentNetLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SegmentNetLoss_lbl" xml:lang="en-US">Segment net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="ptgef_PayablesAndAccruedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PayablesAndAccruedExpense" xlink:to="ptgef_PayablesAndAccruedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PayablesAndAccruedExpense_lbl" xml:lang="en-US">Payables and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiabilities" xlink:label="ptgef_PutRightLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightLiabilities" xlink:to="ptgef_PutRightLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightLiabilities_lbl" xml:lang="en-US">Put right liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CurrentAsset" xlink:label="ptgef_CurrentAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentAsset" xlink:to="ptgef_CurrentAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_CurrentAsset_lbl" xml:lang="en-US">Current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NoncontrollingInterests_2_lbl" xml:lang="en-US">Non-controlling interest, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossAttributableToNoncontrollingInterest" xlink:to="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net (loss) attributable to non-controlling interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NoncontrollingInterests_3_lbl" xml:lang="en-US">Non-controlling interest, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_2_lbl" xml:lang="en-US">Current assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_2_lbl" xml:lang="en-US">Non-current assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_2_lbl" xml:lang="en-US">Current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_2_lbl" xml:lang="en-US">Non-current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_2_lbl" xml:lang="en-US">Treasury shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_4_lbl" xml:lang="en-US">Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_2_lbl" xml:lang="en-US">Equity and liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_3_lbl" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_2_lbl" xml:lang="en-US">Profit (loss) before tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xml:lang="en-US">Tax expense (income)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_2_lbl" xml:lang="en-US">Comprehensive income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_3_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_2_lbl" xml:lang="en-US">Increase (decrease) in deferred tax liability (asset)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantLiability" xlink:to="ptgef_ChangeInFairValueOfWarrantLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfWarrantLiability_2_lbl" xml:lang="en-US">ChangeInFairValueOfWarrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsReceived" xlink:to="ifrs-full_DividendsReceived_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DividendsReceived_2_lbl" xml:lang="en-US">Dividends received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasesOfDigitalAssets" xlink:to="ptgef_PurchasesOfDigitalAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchasesOfDigitalAssets_2_lbl" xml:lang="en-US">PurchasesOfDigitalAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquipmentDeposit" xlink:to="ptgef_EquipmentDeposit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EquipmentDeposit_2_lbl" xml:lang="en-US">EquipmentDeposit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashPaidForInvestmentInCompedica" xlink:to="ptgef_CashPaidForInvestmentInCompedica_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashPaidForInvestmentInCompedica_2_lbl" xml:lang="en-US">CashPaidForInvestmentInCompedica</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xml:lang="en-US">Payments for share issue costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PutRightIssuanceCosts" xlink:to="ptgef_PutRightIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PutRightIssuanceCosts_2_lbl" xml:lang="en-US">PutRightIssuanceCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_2_lbl" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PaymentsOnExternalDebt" xlink:to="ptgef_PaymentsOnExternalDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PaymentsOnExternalDebt_2_lbl" xml:lang="en-US">PaymentsOnExternalDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredFinancingCosts" xlink:to="ptgef_DeferredFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredFinancingCosts_2_lbl" xml:lang="en-US">DeferredFinancingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LoanTerminationFee" xlink:to="ptgef_LoanTerminationFee_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LoanTerminationFee_2_lbl" xml:lang="en-US">LoanTerminationFee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_3_lbl" xml:lang="en-US">Current restricted cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory_2_lbl" xml:lang="en-US">DescriptionOfAccountingPolicyFoStablecoinExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_2_lbl" xml:lang="en-US">DescriptionOfAccountingPolicyForDigitalAssetsExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfPutRightLiabilityTableTextBlock" xlink:to="ptgef_ScheduleOfPutRightLiabilityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfPutRightLiabilityTableTextBlock_2_lbl" xml:lang="en-US">ScheduleOfPutRightLiabilityTableTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2_lbl" xml:lang="en-US">ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:to="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_2_lbl" xml:lang="en-US">ScheduleOfAntiDilutiveEffectTableTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_2_lbl" xml:lang="en-US">Proportion of ownership interests held by non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_3_lbl" xml:lang="en-US">Property, plant and equipment, revalued assets, at cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" xlink:to="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccumulatedDepreciationPropertyPlantAndEquipment_3_lbl" xml:lang="en-US">AccumulatedDepreciationPropertyPlantAndEquipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FixedAssetDisposals" xlink:to="ptgef_FixedAssetDisposals_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FixedAssetDisposals_2_lbl" xml:lang="en-US">FixedAssetDisposals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityShares" xlink:to="ptgef_WarrantsLiabilityShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsLiabilityShares_3_lbl" xml:lang="en-US">WarrantsLiabilityShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityFairValue" xlink:to="ptgef_WarrantsLiabilityFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsLiabilityFairValue_3_lbl" xml:lang="en-US">WarrantsLiabilityFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2_lbl" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BalanceOfPutRightLiability" xlink:to="ptgef_BalanceOfPutRightLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BalanceOfPutRightLiability_2_lbl" xml:lang="en-US">BalanceOfPutRightLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BalanceOfTonPayable" xlink:to="ptgef_BalanceOfTonPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BalanceOfTonPayable_2_lbl" xml:lang="en-US">BalanceOfTonPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExerciseOfSideLetterPutRightPayable" xlink:to="ptgef_ExerciseOfSideLetterPutRightPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExerciseOfSideLetterPutRightPayable_2_lbl" xml:lang="en-US">ExerciseOfSideLetterPutRightPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets" xlink:to="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets_2_lbl" xml:lang="en-US">SettlementOfPutRightLiabilityUsingDigitalAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityCurrent" xlink:to="ptgef_LeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityCurrent_2_lbl" xml:lang="en-US">LeaseLiabilityCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityNoncurrent" xlink:to="ptgef_LeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">LeaseLiabilityNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_2_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxAssetNotRecognized" xlink:to="ptgef_DeferredTaxAssetNotRecognized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxAssetNotRecognized_2_lbl" xml:lang="en-US">DeferredTaxAssetNotRecognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetDeferredTaxAsset" xlink:to="ptgef_NetDeferredTaxAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetDeferredTaxAsset_2_lbl" xml:lang="en-US">NetDeferredTaxAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesPrice" xlink:to="ptgef_SharesPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesPrice_2_lbl" xml:lang="en-US">SharesPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasePrice" xlink:to="ptgef_PurchasePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchasePrice_2_lbl" xml:lang="en-US">PurchasePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserve_3_lbl" xml:lang="en-US">Stock Option Reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" xlink:to="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_2_lbl" xml:lang="en-US">CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfOutstandingShareOption_3_lbl" xml:lang="en-US">NumberOfOutstandingShareOption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OptionLifeShareOptionsGranted" xlink:to="ptgef_OptionLifeShareOptionsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OptionLifeShareOptionsGranted_2_lbl" xml:lang="en-US">OptionLifeShareOptionsGranted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharebasedCompensationExpense" xlink:to="ptgef_SharebasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharebasedCompensationExpense_2_lbl" xml:lang="en-US">SharebasedCompensationExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WeightedAverageSharesOutstandingDiluted" xlink:to="ptgef_WeightedAverageSharesOutstandingDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WeightedAverageSharesOutstandingDiluted_2_lbl" xml:lang="en-US">WeightedAverageSharesOutstandingDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossPerShareBasic" xlink:to="ptgef_LossPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossPerShareBasic_2_lbl" xml:lang="en-US">LossPerShareBasic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossPerShareDiluted" xlink:to="ptgef_LossPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossPerShareDiluted_2_lbl" xml:lang="en-US">LossPerShareDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AntidilutiveEffectOnLossPerShare" xlink:to="ptgef_AntidilutiveEffectOnLossPerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AntidilutiveEffectOnLossPerShare_2_lbl" xml:lang="en-US">AntidilutiveEffectOnLossPerShare</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">AccountsPayableAndAccruedLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_2_lbl" xml:lang="en-US">Warrant liability [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeGain_2_lbl" xml:lang="en-US">Net foreign exchange gain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxBenefit" xlink:to="ptgef_IncomeTaxBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeTaxBenefit_2_lbl" xml:lang="en-US">IncomeTaxBenefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentAsset" xlink:to="ptgef_CurrentAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentAsset_2_lbl" xml:lang="en-US">CurrentAsset</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ptgef-20260331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Cover" roleURI="http://portagebiotech.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfFinancialPosition" roleURI="http://portagebiotech.com/role/StatementsOfFinancialPosition" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfChangesInEquityDeficit" roleURI="http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StatementsOfCashFlows" roleURI="http://portagebiotech.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#NatureOfOperations" roleURI="http://portagebiotech.com/role/NatureOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#GoingConcern" roleURI="http://portagebiotech.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BasisOfPresentation" roleURI="http://portagebiotech.com/role/BasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPolicies" roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssets" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Stablecoin" roleURI="http://portagebiotech.com/role/Stablecoin" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssets" roleURI="http://portagebiotech.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssets" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedica" roleURI="http://portagebiotech.com/role/InvestmentInCompedica" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiability" roleURI="http://portagebiotech.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayable" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayable" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilities" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiability" roleURI="http://portagebiotech.com/role/LeaseLiability" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BitgoPrimeLoan" roleURI="http://portagebiotech.com/role/BitgoPrimeLoan" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxes" roleURI="http://portagebiotech.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReserves" roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserve" roleURI="http://portagebiotech.com/role/StockOptionReserve" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShare" roleURI="http://portagebiotech.com/role/LossPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CommitmentsAndContingentLiabilities" roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactions" roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagement" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReporting" roleURI="http://portagebiotech.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalManagement" roleURI="http://portagebiotech.com/role/CapitalManagement" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterest" roleURI="http://portagebiotech.com/role/Non-controllingInterest" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SubsequentEvents" roleURI="http://portagebiotech.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesTables" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssetsTables" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinTables" roleURI="http://portagebiotech.com/role/StablecoinTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsTables" roleURI="http://portagebiotech.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssetsTables" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaTables" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityTables" roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableTables" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilitiesTables" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityTables" roleURI="http://portagebiotech.com/role/LeaseLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesTables" roleURI="http://portagebiotech.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesTables" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveTables" roleURI="http://portagebiotech.com/role/StockOptionReserveTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareTables" roleURI="http://portagebiotech.com/role/LossPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsTables" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementTables" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReportingTables" roleURI="http://portagebiotech.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterestTables" roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#GoingConcernDetailsNarrative" roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BasisOfPresentationDetailsNarrative" roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesDetails" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesAndOtherReceivablesDetails" roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" roleURI="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinDetails" roleURI="http://portagebiotech.com/role/StablecoinDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StablecoinDetails1" roleURI="http://portagebiotech.com/role/StablecoinDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails1" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetails2" roleURI="http://portagebiotech.com/role/DigitalAssetsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#ReceivablesDigitalAssetsDetails" roleURI="http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#DigitalAssetsDetailsNarrative" roleURI="http://portagebiotech.com/role/DigitalAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" roleURI="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaDetails" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#InvestmentInCompedicaDetailsNarrative" roleURI="http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails1" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails2" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails3" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetails4" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails1" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetails2" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#PutRightLiabilityAndTonPayableDetailsNarrative" roleURI="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityDetails" roleURI="http://portagebiotech.com/role/LeaseLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LeaseLiabilityDetailsNarrative" roleURI="http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#BitgoPrimeLoanDetailsNarrative" roleURI="http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails1" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetails2" roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesDetails" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalStockAndReservesDetailsNarrative" roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails1" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails2" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails3" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetails4" roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#StockOptionReserveDetailsNarrative" roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareDetails" roleURI="http://portagebiotech.com/role/LossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#LossPerShareDetails1" roleURI="http://portagebiotech.com/role/LossPerShareDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails1" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetails3" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementDetails" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#FinancialInstrumentsAndRiskManagementDetails1" roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#SegmentReportingDetails" roleURI="http://portagebiotech.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#CapitalManagementDetailsNarrative" roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="ptgef-20260331.xsd#Non-controllingInterestDetails" roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" />
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfFinancialPosition" xlink:title="00000002 - Statement - Consolidated Statements of Financial Position">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-fullStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-fullCurrentAssetsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents" xlink:label="loc_ifrs-fullRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullRestrictedCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsReceivable" xlink:label="loc_ptgefAccountsReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ptgefAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoin" xlink:label="loc_ptgefStablecoin" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ptgefStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonCurrent" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-fullNoncurrentAssetsAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonNetOfCurrentPortion" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonNetOfCurrentPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EquipmentDeposits" xlink:label="loc_ptgefEquipmentDeposits" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ptgefEquipmentDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-fullEquityAndLiabilitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullCurrentLiabilitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefTonPayableToSettlePutRightsExercised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ptgefTonPayableToSettlePutRightsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiability" xlink:label="loc_ptgefPutRightLiability" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ptgefPutRightLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullNoncurrentLiabilitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentWarrantLiability" xlink:label="loc_ifrs-fullNoncurrentWarrantLiability" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentsAndContingentLiabilities" xlink:label="loc_ptgefCommitmentsAndContingentLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ptgefCommitmentsAndContingentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-fullEquityAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="loc_ifrs-fullTreasuryShares" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullTreasuryShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-fullProfitLossAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="loc_ifrs-fullDepreciationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullDepreciationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssets" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssetReceivables" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossOnSaleOfDigitalAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefRealizedLossOnSaleOfDigitalAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="loc_ptgefLossOnRegisteredDirectOffering" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefLossOnRegisteredDirectOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="loc_ptgefOfferingCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossIoxIprd" xlink:label="loc_ptgefImpairmentLossIoxIprd" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefImpairmentLossIoxIprd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossTarusIprd" xlink:label="loc_ptgefImpairmentLossTarusIprd" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefImpairmentLossTarusIprd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossStimunity" xlink:label="loc_ptgefImpairmentLossStimunity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefImpairmentLossStimunity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossSaugatuck" xlink:label="loc_ptgefImpairmentLossSaugatuck" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefImpairmentLossSaugatuck" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossInvestmentInCompedica" xlink:label="loc_ptgefImpairmentLossInvestmentInCompedica" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefImpairmentLossInvestmentInCompedica" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfInvestmentInCompedica" xlink:label="loc_ptgefLossOnRevaluationOfInvestmentInCompedica" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefLossOnRevaluationOfInvestmentInCompedica" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainOnSettlementOfTonPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnSettlementOfPutRightLiability" xlink:label="loc_ptgefLossOnSettlementOfPutRightLiability" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefLossOnSettlementOfPutRightLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnExtinguishmentOfDebt" xlink:label="loc_ptgefGainOnExtinguishmentOfDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossesFromEquityMethodInvestment" xlink:label="loc_ptgefShareOfLossesFromEquityMethodInvestment" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefShareOfLossesFromEquityMethodInvestment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="loc_ptgefNetUnrealizedLossOnInvestments" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:to="loc_ptgefNetUnrealizedLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:to="loc_ifrs-fullComprehensiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-fullProfitLossAttributableToAbstract" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-fullEarningsPerShareAbstract" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-fullBasicEarningsLossPerShare" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullBasicEarningsLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-fullDilutedEarningsLossPerShare" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDilutedEarningsLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-fullWeightedAverageShares" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit" xlink:title="00000004 - Statement - Consolidated Statements of Changes in Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-fullStatementOfChangesInEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullIssuedCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ptgefStockOptionReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockMember" xlink:label="loc_ptgefTreasuryStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ptgefTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccumulatedOtherComprehensiveIncomeLossMember" xlink:label="loc_ptgefAccumulatedOtherComprehensiveIncomeLossMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ptgefAccumulatedOtherComprehensiveIncomeLossMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceApril12022PresplitShares" xlink:label="loc_ptgefBalanceApril12022PresplitShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefBalanceApril12022PresplitShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOffering" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingShares" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" xlink:label="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" xlink:label="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits" xlink:label="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" xlink:label="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DerecognitionOfInvestmentInPublicCompany" xlink:label="loc_ptgefDerecognitionOfInvestmentInPublicCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDerecognitionOfInvestmentInPublicCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="loc_ptgefNetUnrealizedLossOnInvestments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetUnrealizedLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-fullProfitLossFromContinuingOperations" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossFromContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" xlink:label="loc_ptgefCorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrefundedWarrantsExercised" xlink:label="loc_ptgefPrefundedWarrantsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrefundedWarrantsExercisedShares" xlink:label="loc_ptgefPrefundedWarrantsExercisedShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercisedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedForAccruedBonuses" xlink:label="loc_ptgefSharesIssuedForAccruedBonuses" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForAccruedBonuses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedAccruedForBonusesShares" xlink:label="loc_ptgefSharesIssuedAccruedForBonusesShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedAccruedForBonusesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" xlink:label="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatingToAcquisitionOfCompedica" xlink:label="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedica" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares" xlink:label="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedicaShares" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedRelatingToAcquisitionOfCompedicaShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:label="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPrefundedWarrants" xlink:label="loc_ptgefExerciseOfPrefundedWarrants" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExerciseOfPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPrefundedWarrantsShares" xlink:label="loc_ptgefExerciseOfPrefundedWarrantsShares" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExerciseOfPrefundedWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:label="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" xlink:label="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsExercisedAndReturnOfShares" xlink:label="loc_ptgefPutRightsExercisedAndReturnOfShares" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightsExercisedAndReturnOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsExercisedAndReturnShares" xlink:label="loc_ptgefPutRightsExercisedAndReturnShares" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightsExercisedAndReturnShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_2" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-fullStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:label="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IOxIPRDMember" xlink:label="loc_ptgefIOxIPRDMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefIOxIPRDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TarusIPRDMember" xlink:label="loc_ptgefTarusIPRDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefTarusIPRDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StimunityMember" xlink:label="loc_ptgefStimunityMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefStimunityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="loc_ptgefSaugatuckMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="loc_ptgefLossOnRegisteredDirectOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefLossOnRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="loc_ptgefOfferingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-fullImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets" xlink:label="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" xlink:label="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefUnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossOnSaleOfDigitalAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefRealizedLossOnSaleOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnImpairmentInvestmentInCompedica" xlink:label="loc_ptgefLossOnImpairmentInvestmentInCompedica" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefLossOnImpairmentInvestmentInCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRemeasurementOfInvestmentInCompedica" xlink:label="loc_ptgefLossOnRemeasurementOfInvestmentInCompedica" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefLossOnRemeasurementOfInvestmentInCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfWarrantLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossFromEquityMethodInvestment" xlink:label="loc_ptgefLossFromEquityMethodInvestment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefLossFromEquityMethodInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefGainOnSettlementOfTonPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExerciseOfPutRightLiability" xlink:label="loc_ptgefLossOnExerciseOfPutRightLiability" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefLossOnExerciseOfPutRightLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashInterestExpense" xlink:label="loc_ptgefNoncashInterestExpense" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefNoncashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExpensesSettledUsingStablecoin" xlink:label="loc_ptgefExpensesSettledUsingStablecoin" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefExpensesSettledUsingStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="loc_ifrs-fullDividendsReceived" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullDividendsReceived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossInAssociate" xlink:label="loc_ptgefShareOfLossInAssociate" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefShareOfLossInAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfSharesIssuedForServices" xlink:label="loc_ptgefFairValueOfSharesIssuedForServices" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefFairValueOfSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DepreciationAndAmortizations" xlink:label="loc_ptgefDepreciationAndAmortizations" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefDepreciationAndAmortizations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:label="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:label="loc_ifrs-fullProceedsFromSalesOfInvestmentProperty" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullProceedsFromSalesOfInvestmentProperty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfStablecoin" xlink:label="loc_ptgefPurchasesOfStablecoin" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefPurchasesOfStablecoin" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfDigitalAssets" xlink:label="loc_ptgefPurchasesOfDigitalAssets" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefPurchasesOfDigitalAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfStablecoin" xlink:label="loc_ptgefSalesOfStablecoin" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefSalesOfStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalesOfDigitalAssets" xlink:label="loc_ptgefSalesOfDigitalAssets" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefSalesOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EquipmentDeposit" xlink:label="loc_ptgefEquipmentDeposit" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefEquipmentDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashPaidForInvestmentInCompedica" xlink:label="loc_ptgefCashPaidForInvestmentInCompedica" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefCashPaidForInvestmentInCompedica" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderPrivatePlacement" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromRegisteredDirectOffering" xlink:label="loc_ptgefProceedsFromRegisteredDirectOffering" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightIssuanceCosts" xlink:label="loc_ptgefPutRightIssuanceCosts" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefPutRightIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebt" xlink:label="loc_ptgefPaymentsOnExternalDebt" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefPaymentsOnExternalDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredFinancingCosts" xlink:label="loc_ptgefDeferredFinancingCosts" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefDeferredFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LoanTerminationFee" xlink:label="loc_ptgefLoanTerminationFee" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefLoanTerminationFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesFromRSUDistribution" xlink:label="loc_ptgefSharesFromRSUDistribution" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefSharesFromRSUDistribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="loc_ifrs-fullCurrentRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="loc_ifrs-fullCurrentRestrictedCashAndCashEquivalents_2" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentRestrictedCashAndCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SupplementalCashFlowInformationsAbstract" xlink:label="loc_ptgefSupplementalCashFlowInformationsAbstract" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSupplementalCashFlowInformationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashPaidForInterest" xlink:label="loc_ptgefCashPaidForInterest" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalCashFlowInformationsAbstract" xlink:to="loc_ptgefCashPaidForInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashInvestingItemsAbstract" xlink:label="loc_ptgefNoncashInvestingItemsAbstract" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNoncashInvestingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" xlink:label="loc_ptgefExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalExpendituresIncludedInAccountsPayable" xlink:label="loc_ptgefCapitalExpendituresIncludedInAccountsPayable" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefCapitalExpendituresIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RightToUseAssetAcquired" xlink:label="loc_ptgefRightToUseAssetAcquired" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefRightToUseAssetAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityIncurred" xlink:label="loc_ptgefLeaseLiabilityIncurred" />
      <link:presentationArc order="710" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefLeaseLiabilityIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssets" xlink:label="loc_ptgefContributionOfDigitalAssets" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefContributionOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoin" xlink:label="loc_ptgefContributionOfStablecoin" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefContributionOfStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssetsReceivable" xlink:label="loc_ptgefContributionOfDigitalAssetsReceivable" />
      <link:presentationArc order="740" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefContributionOfDigitalAssetsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoinReceivable" xlink:label="loc_ptgefContributionOfStablecoinReceivable" />
      <link:presentationArc order="750" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefContributionOfStablecoinReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica" xlink:label="loc_ptgefValueOfSharesUsedToPurchaseInterestInCompedica" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefValueOfSharesUsedToPurchaseInterestInCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:label="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefTreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightsIssuedToInvestors" xlink:label="loc_ptgefPutRightsIssuedToInvestors" />
      <link:presentationArc order="780" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefPutRightsIssuedToInvestors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareIssuanceCostsSettledInCompanyStock" xlink:label="loc_ptgefShareIssuanceCostsSettledInCompanyStock" />
      <link:presentationArc order="790" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefShareIssuanceCostsSettledInCompanyStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock" xlink:label="loc_ptgefShareIssuanceCostsSettledInWarrantsOnCompanysStock" />
      <link:presentationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefShareIssuanceCostsSettledInWarrantsOnCompanysStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable" xlink:label="loc_ptgefSettlementOfPutRightLiabilityUsingStablecoinReceivable" />
      <link:presentationArc order="810" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefSettlementOfPutRightLiabilityUsingStablecoinReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfPutRights" xlink:label="loc_ptgefExerciseOfPutRights" />
      <link:presentationArc order="820" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefExerciseOfPutRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables" xlink:label="loc_ptgefSettlementOfPutRightLiabilityUsingDigitalAssetReceivables" />
      <link:presentationArc order="830" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefSettlementOfPutRightLiabilityUsingDigitalAssetReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetsReceivableTonTokens" xlink:label="loc_ptgefReceiptOfDigitalAssetsReceivableTonTokens" />
      <link:presentationArc order="840" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefReceiptOfDigitalAssetsReceivableTonTokens" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToPurchaseDigitalAssets" xlink:label="loc_ptgefStablecoinUsedToPurchaseDigitalAssets" />
      <link:presentationArc order="850" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefStablecoinUsedToPurchaseDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaleOfDigitalAssetsSettledInStablecoin" xlink:label="loc_ptgefSaleOfDigitalAssetsSettledInStablecoin" />
      <link:presentationArc order="860" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefSaleOfDigitalAssetsSettledInStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExchangeOfBitcoinForTonTokens" xlink:label="loc_ptgefExchangeOfBitcoinForTonTokens" />
      <link:presentationArc order="870" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefExchangeOfBitcoinForTonTokens" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExternalDebtProceedsReceivedInStablecoin" xlink:label="loc_ptgefExternalDebtProceedsReceivedInStablecoin" />
      <link:presentationArc order="880" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefExternalDebtProceedsReceivedInStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebtUsingDigitalAssets" xlink:label="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets" />
      <link:presentationArc order="890" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashInvestingItemsAbstract" xlink:to="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncashOperatingActivitiesAbstract" xlink:label="loc_ptgefNoncashOperatingActivitiesAbstract" />
      <link:presentationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNoncashOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesObtainedInExchangeForStablecoin" xlink:label="loc_ptgefPrepaidExpensesObtainedInExchangeForStablecoin" />
      <link:presentationArc order="910" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNoncashOperatingActivitiesAbstract" xlink:to="loc_ptgefPrepaidExpensesObtainedInExchangeForStablecoin" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="999006 - Disclosure - NATURE OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureNatureOfOperationsAbstract" xlink:label="loc_ptgefDisclosureNatureOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NatureOfOperationsExplanatory" xlink:label="loc_ptgefNatureOfOperationsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureNatureOfOperationsAbstract" xlink:to="loc_ptgefNatureOfOperationsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcern" xlink:title="999007 - Disclosure - GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="loc_ifrs-fullDisclosureOfGoingConcernExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfGoingConcernExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="999008 - Disclosure - BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="999009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ptgefDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets" xlink:title="999010 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfOtherAssetsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfOtherAssetsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Stablecoin" xlink:title="999011 - Disclosure - STABLECOIN">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureStablecoinAbstract" xlink:label="loc_ptgefDisclosureStablecoinAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfStablecoinExplanatory" xlink:label="loc_ptgefDisclosureOfStablecoinExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureStablecoinAbstract" xlink:to="loc_ptgefDisclosureOfStablecoinExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssets" xlink:title="999012 - Disclosure - DIGITAL ASSETS">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="loc_ptgefDisclosureDigitalAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfDigitalAssetsExplanatory" xlink:label="loc_ptgefDisclosureOfDigitalAssetsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefDisclosureOfDigitalAssetsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets" xlink:title="999013 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:label="loc_ptgefDisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" xlink:label="loc_ptgefPropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:to="loc_ptgefPropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedica" xlink:title="999014 - Disclosure - INVESTMENT IN COMPEDICA">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInvestmentPropertyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfInvestmentPropertyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="999015 - Disclosure - WARRANT LIABILITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfWarrantLiabilityExplanatory" xlink:label="loc_ptgefDisclosureOfWarrantLiabilityExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefDisclosureOfWarrantLiabilityExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayable" xlink:title="999016 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:label="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory" xlink:label="loc_ptgefDisclosureOPutRightLiabilityAndTonPayableExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefDisclosureOPutRightLiabilityAndTonPayableExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiability" xlink:title="999018 - Disclosure - LEASE LIABILITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureLeaseLiabilityAbstract" xlink:label="loc_ptgefDisclosureLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfLeaseLiabilityExplanatory" xlink:label="loc_ptgefDisclosureOfLeaseLiabilityExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefDisclosureOfLeaseLiabilityExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BitgoPrimeLoan" xlink:title="999019 - Disclosure - BITGO PRIME LOAN">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureBitgoPrimeLoanAbstract" xlink:label="loc_ptgefDisclosureBitgoPrimeLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfBitgoPrimeLoanExplanatory" xlink:label="loc_ptgefDisclosureOfBitgoPrimeLoanExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureBitgoPrimeLoanAbstract" xlink:to="loc_ptgefDisclosureOfBitgoPrimeLoanExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:title="999021 - Disclosure - CAPITAL STOCK AND RESERVES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalStockAndReservesTextBlock" xlink:label="loc_ptgefCapitalStockAndReservesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ptgefCapitalStockAndReservesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="999022 - Disclosure - STOCK OPTION RESERVE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="999023 - Disclosure - LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-fullEarningsPerShareExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEarningsPerShareExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="999026 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:label="loc_ptgefDisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefDisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReporting" xlink:title="999027 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSegmentReportingAbstract" xlink:label="loc_ptgefDisclosureSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock" xlink:label="loc_ptgefDisclosureOfSegmentReportingExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSegmentReportingAbstract" xlink:to="loc_ptgefDisclosureOfSegmentReportingExplanatoryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagement" xlink:title="999028 - Disclosure - CAPITAL MANAGEMENT">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalManagementAbstract" xlink:label="loc_ptgefDisclosureCapitalManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="999029 - Disclosure - NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-fullDisclosureOfEventsAfterReportingPeriodExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForInvestmentInAssociates" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyFoStablecoinExplanatory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyFoStablecoinExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForDigitalAssetsExplanatory" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForDigitalAssetsExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForAccountsReceivableExplanatory" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForAccountsReceivableExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ptgefDescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023" xlink:label="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables" xlink:title="999033 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinTables" xlink:title="999034 - Disclosure - STABLECOIN (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureStablecoinAbstract" xlink:label="loc_ptgefDisclosureStablecoinAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfStablecoinTableTextBlock" xlink:label="loc_ptgefDisclosureOfStablecoinTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureStablecoinAbstract" xlink:to="loc_ptgefDisclosureOfStablecoinTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfStablecoinPurchasesTableTextBlock" xlink:label="loc_ptgefDisclosureOfStablecoinPurchasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureStablecoinAbstract" xlink:to="loc_ptgefDisclosureOfStablecoinPurchasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsTables" xlink:title="999035 - Disclosure - DIGITAL ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="loc_ptgefDisclosureDigitalAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfDigitalAssetsTableTextBlock" xlink:label="loc_ptgefScheduleOfDigitalAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefScheduleOfDigitalAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock" xlink:label="loc_ptgefScheduleOfDigitalAssetsPurchasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefScheduleOfDigitalAssetsPurchasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeheduleOfTonTokensTableTextBlock" xlink:label="loc_ptgefSeheduleOfTonTokensTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefSeheduleOfTonTokensTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock" xlink:label="loc_ptgefScheduleOfReceivablesDigitalAssetsTableXextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefScheduleOfReceivablesDigitalAssetsTableXextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables" xlink:title="999036 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:label="loc_ptgefDisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaTables" xlink:title="999037 - Disclosure - INVESTMENT IN COMPEDICA (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfInvestmentBalanceTableTextBlock" xlink:label="loc_ptgefScheduleOfInvestmentBalanceTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfInvestmentBalanceTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="999038 - Disclosure - WARRANT LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:label="loc_ptgefDisclosureOfFairValueMeasurementOfWarrantsExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefDisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" xlink:label="loc_ptgefDisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefDisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory" xlink:label="loc_ptgefDisclosureOfFairValueMeasurementPlacementAgentExplanatory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefDisclosureOfFairValueMeasurementPlacementAgentExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables" xlink:title="999039 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:label="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" xlink:label="loc_ptgefScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfPutRightLiabilityTableTextBlock" xlink:label="loc_ptgefScheduleOfPutRightLiabilityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefScheduleOfPutRightLiabilityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfTonPayableTableTextBlock" xlink:label="loc_ptgefScheduleOfTonPayableTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefScheduleOfTonPayableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="999040 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityTables" xlink:title="999041 - Disclosure - LEASE LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureLeaseLiabilityAbstract" xlink:label="loc_ptgefDisclosureLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfLeaseLiabilityTableTextBlock" xlink:label="loc_ptgefScheduleOfLeaseLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefScheduleOfLeaseLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="999042 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:label="loc_ptgefScheduleOfIncomeTaxesBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:label="loc_ptgefScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:label="loc_ptgefScheduleOfDeferredTaxAssetsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfDeferredTaxAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:title="999043 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_ptgefScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ptgefScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="999044 - Disclosure - STOCK OPTION RESERVE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" xlink:label="loc_ptgefScheduleOfTermsStockOptionReserveTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfTermsStockOptionReserveTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_ptgefScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock" xlink:label="loc_ptgefScheduleOfWeightedAverageAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfWeightedAverageAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_ptgefScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="999045 - Disclosure - LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfEarningsPerShareTableTextBlock" xlink:label="loc_ptgefScheduleOfEarningsPerShareTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefScheduleOfEarningsPerShareTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:label="loc_ptgefScheduleOfAntiDilutiveEffectTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefScheduleOfAntiDilutiveEffectTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsTables" xlink:title="999046 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfCompensationPayableTableTextBlock" xlink:label="loc_ptgefScheduleOfCompensationPayableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfCompensationPayableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfAuditorsRemunerationExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfAuditorsRemunerationExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock" xlink:label="loc_ptgefScheduleOfOutstandingEquityAwardsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfOutstandingEquityAwardsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="999047 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="loc_ptgefScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" xlink:label="loc_ptgefLiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefLiabilitiesMeasuredFairValueRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReportingTables" xlink:title="999048 - Disclosure - SEGMENT REPORTING (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSegmentReportingAbstract" xlink:label="loc_ptgefDisclosureSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfSegmentReportingTableTextBlock" xlink:label="loc_ptgefScheduleOfSegmentReportingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSegmentReportingAbstract" xlink:to="loc_ptgefScheduleOfSegmentReportingTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="999049 - Disclosure - NON-CONTROLLING INTEREST (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:title="999050 - Disclosure - GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-fullCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalCurrentLiabilities" xlink:label="loc_ptgefTotalCurrentLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefTotalCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetLossIncome" xlink:label="loc_ptgefNetLossIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefNetLossIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashUsedInOperatingActivities" xlink:label="loc_ptgefCashUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefCashUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashCashEquivalents" xlink:label="loc_ptgefCashCashEquivalents" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefCashCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RestrictedCashOnHand" xlink:label="loc_ptgefRestrictedCashOnHand" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefRestrictedCashOnHand" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999051 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:to="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesDomain" xlink:to="loc_ptgefIOXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="loc_ifrs-fullConsolidatedStructuredEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullConsolidatedStructuredEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsolidatedStructuredEntitiesDomain" xlink:label="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullConsolidatedStructuredEntitiesAxis" xlink:to="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" xlink:to="loc_ptgefSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StimunityMember" xlink:label="loc_ptgefStimunityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullConsolidatedStructuredEntitiesDomain" xlink:to="loc_ptgefStimunityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullBottomOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullTopOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-fullGeographicalAreasAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullGeographicalAreasAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-fullGeographicalAreasDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullGeographicalAreasAxis" xlink:to="loc_ifrs-fullGeographicalAreasDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CountryOfBritishVirginIslandsMember" xlink:label="loc_ptgefCountryOfBritishVirginIslandsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullGeographicalAreasDomain" xlink:to="loc_ptgefCountryOfBritishVirginIslandsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DelawareMember" xlink:label="loc_ptgefDelawareMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullGeographicalAreasDomain" xlink:to="loc_ptgefDelawareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SubsidiariesTwoMember" xlink:label="loc_ptgefSubsidiariesTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefSubsidiariesTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInSubsidiary" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NoncontrollingInterestIncreasedUponConversion" xlink:label="loc_ptgefNoncontrollingInterestIncreasedUponConversion" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNoncontrollingInterestIncreasedUponConversion" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesDetails" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:label="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-fullWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ifrs-fullWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ptgefStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ptgefRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:label="loc_ifrs-fullNumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-fullInvestmentProperty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullInvestmentProperty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CashRestrictedForUse" xlink:label="loc_ptgefCashRestrictedForUse" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefCashRestrictedForUse" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="999054 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:label="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-fullCurrentAdvancesToSuppliers" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCurrentAdvancesToSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-fullCurrentPrepaidExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCurrentPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidInvestorRelations" xlink:label="loc_ptgefPrepaidInvestorRelations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefPrepaidInvestorRelations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TaxDeposits" xlink:label="loc_ptgefTaxDeposits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefTaxDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidGpuInfrastructureCosts" xlink:label="loc_ptgefPrepaidGpuInfrastructureCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefPrepaidGpuInfrastructureCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidGpuLeasesShortterm" xlink:label="loc_ptgefPrepaidGpuLeasesShortterm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefPrepaidGpuLeasesShortterm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalPrepaidExpensesAndOtherReceivables" xlink:label="loc_ptgefTotalPrepaidExpensesAndOtherReceivables" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefTotalPrepaidExpensesAndOtherReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative" xlink:title="999055 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OtherAssetsLongTermPortion" xlink:label="loc_ptgefOtherAssetsLongTermPortion" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefOtherAssetsLongTermPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SecurityDeposits" xlink:label="loc_ptgefSecurityDeposits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefSecurityDeposits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinDetails" xlink:title="999056 - Disclosure - STABLECOIN (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureStablecoinAbstract" xlink:label="loc_ptgefDisclosureStablecoinAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureStablecoinAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USDCMember" xlink:label="loc_ptgefUSDCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_ptgefUSDCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UsdtMember" xlink:label="loc_ptgefUsdtMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_ptgefUsdtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoins" xlink:label="loc_ptgefStablecoins" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoins" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StablecoinDetails1" xlink:title="999057 - Disclosure - STABLECOIN (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureStablecoinAbstract" xlink:label="loc_ptgefDisclosureStablecoinAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureStablecoinAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USDCMember" xlink:label="loc_ptgefUSDCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefUSDCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UsdtMember" xlink:label="loc_ptgefUsdtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefUsdtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfApril1" xlink:label="loc_ptgefDigitalAssetValueAsOfApril1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfApril1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfStablecoin" xlink:label="loc_ptgefContributionOfStablecoin" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContributionOfStablecoin" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromSaleOfDigitalAssets" xlink:label="loc_ptgefProceedsFromSaleOfDigitalAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsFromSaleOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToSettleOperatingCosts" xlink:label="loc_ptgefStablecoinUsedToSettleOperatingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinUsedToSettleOperatingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinSold" xlink:label="loc_ptgefStablecoinSold" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProceedsFromExternalDebtDrawdown" xlink:label="loc_ptgefProceedsFromExternalDebtDrawdown" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsFromExternalDebtDrawdown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasesOfStablecoin" xlink:label="loc_ptgefPurchasesOfStablecoin" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchasesOfStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinUsedToPurchaseDigitalAssets" xlink:label="loc_ptgefStablecoinUsedToPurchaseDigitalAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinUsedToPurchaseDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinValueAsOfMarch31" xlink:label="loc_ptgefStablecoinValueAsOfMarch31" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinValueAsOfMarch31" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails" xlink:title="999058 - Disclosure - DIGITAL ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="loc_ptgefDisclosureDigitalAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ApproximateNumberOfTonTokensHeld" xlink:label="loc_ptgefApproximateNumberOfTonTokensHeld" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefApproximateNumberOfTonTokensHeld" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokensFairValueInThousands" xlink:label="loc_ptgefTonTokensFairValueInThousands" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefTonTokensFairValueInThousands" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsFairValueInThousands" xlink:label="loc_ptgefDigitalAssetsFairValueInThousands" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefDigitalAssetsFairValueInThousands" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails1" xlink:title="999059 - Disclosure - DIGITAL ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="loc_ptgefDisclosureDigitalAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:label="loc_ifrs-fullDisclosureOfIntangibleAssetsMaterialToEntityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ifrs-fullDisclosureOfIntangibleAssetsMaterialToEntityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:label="loc_ifrs-fullIntangibleAssetsMaterialToEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfIntangibleAssetsMaterialToEntityTable" xlink:to="loc_ifrs-fullIntangibleAssetsMaterialToEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsMaterialToEntityDomain" xlink:label="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityAxis" xlink:to="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TONMember" xlink:label="loc_ptgefTONMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" xlink:to="loc_ptgefTONMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BITCOINMember" xlink:label="loc_ptgefBITCOINMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" xlink:to="loc_ptgefBITCOINMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIntangibleAssetsMaterialToEntityDomain" xlink:to="loc_ptgefTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfApril1" xlink:label="loc_ptgefDigitalAssetValueAsOfApril1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfApril1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssets" xlink:label="loc_ptgefContributionOfDigitalAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContributionOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" xlink:label="loc_ptgefUnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsSold" xlink:label="loc_ptgefDigitalAssetsSold" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PaymentsOnExternalDebtUsingDigitalAssets" xlink:label="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPaymentsOnExternalDebtUsingDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetPurchases" xlink:label="loc_ptgefDigitalAssetPurchases" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetPurchases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetsReceivable" xlink:label="loc_ptgefReceiptOfDigitalAssetsReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReceiptOfDigitalAssetsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossGainOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossGainOnSaleOfDigitalAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossGainOnSaleOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetsToInvestor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RevenueReceivedInDigitalAssets" xlink:label="loc_ptgefRevenueReceivedInDigitalAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRevenueReceivedInDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TokensUsedToSettlePutRights" xlink:label="loc_ptgefTokensUsedToSettlePutRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTokensUsedToSettlePutRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsExchanged" xlink:label="loc_ptgefDigitalAssetsExchanged" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsExchanged" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsTransacted" xlink:label="loc_ptgefDigitalAssetsTransacted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsTransacted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfMarch31" xlink:label="loc_ptgefDigitalAssetValueAsOfMarch31" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfMarch31" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetails2" xlink:title="999060 - Disclosure - DIGITAL ASSETS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="loc_ptgefDisclosureDigitalAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear" xlink:label="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfSecondYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfSecondYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear" xlink:label="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfThirdYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfThirdYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear" xlink:label="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfTotalYear" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefCapitalFutureMinimumPaymentsRemainderOfTotalYear" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails" xlink:title="999061 - Disclosure - RECEIVABLES DIGITAL ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="loc_ptgefDisclosureDigitalAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_USD1Member" xlink:label="loc_ptgefUSD1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefUSD1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LockedTonMember" xlink:label="loc_ptgefLockedTonMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefLockedTonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetValueAsOfApril1" xlink:label="loc_ptgefDigitalAssetValueAsOfApril1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetValueAsOfApril1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContributionOfDigitalAssetAndStablecoinReceivables" xlink:label="loc_ptgefContributionOfDigitalAssetAndStablecoinReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContributionOfDigitalAssetAndStablecoinReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDigitalAssetsReceivable" xlink:label="loc_ptgefChangeInFairValueOfDigitalAssetsReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfDigitalAssetsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReceiptOfDigitalAssetReceivables" xlink:label="loc_ptgefReceiptOfDigitalAssetReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReceiptOfDigitalAssetReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TokensUsedToSettlePutRights" xlink:label="loc_ptgefTokensUsedToSettlePutRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTokensUsedToSettlePutRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StablecoinValueAsOfSeptember30" xlink:label="loc_ptgefStablecoinValueAsOfSeptember30" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStablecoinValueAsOfSeptember30" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DigitalAssetsDetailsNarrative" xlink:title="999062 - Disclosure - DIGITAL ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureDigitalAssetsAbstract" xlink:label="loc_ptgefDisclosureDigitalAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssets" xlink:label="loc_ptgefDigitalAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokensReceivable" xlink:label="loc_ptgefTonTokensReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefTonTokensReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokensReceivableShares" xlink:label="loc_ptgefTonTokensReceivableShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefTonTokensReceivableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TokensArePayable" xlink:label="loc_ptgefTokensArePayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDigitalAssetsAbstract" xlink:to="loc_ptgefTokensArePayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails" xlink:title="999063 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:label="loc_ptgefDisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GPUsMember" xlink:label="loc_ptgefGPUsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefGPUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GPUDepositsMember" xlink:label="loc_ptgefGPUDepositsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefGPUDepositsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RightOfUseAssetMember" xlink:label="loc_ptgefRightOfUseAssetMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefRightOfUseAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalMember" xlink:label="loc_ptgefTotalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ptgefTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-fullAdditionsToRightofuseAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsToRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullDisposalsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisposalsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" xlink:label="loc_ptgefAccumulatedDepreciationPropertyPlantAndEquipment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAccumulatedDepreciationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FixedAssetDepreciation" xlink:label="loc_ptgefFixedAssetDepreciation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFixedAssetDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FixedAssetDisposals" xlink:label="loc_ptgefFixedAssetDisposals" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFixedAssetDisposals" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccumulatedDepreciationPropertyPlantAndEquipment" xlink:label="loc_ptgefAccumulatedDepreciationPropertyPlantAndEquipment_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAccumulatedDepreciationPropertyPlantAndEquipment_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaDetails" xlink:title="999064 - Disclosure - INVESTMENT IN COMPEDICA (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceAsOfApril1" xlink:label="loc_ptgefBalanceAsOfApril1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefBalanceAsOfApril1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_InitialInvestmentInCompedica" xlink:label="loc_ptgefInitialInvestmentInCompedica" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefInitialInvestmentInCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossFromEquityMethodInvestment" xlink:label="loc_ptgefLossFromEquityMethodInvestment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefLossFromEquityMethodInvestment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnImpairment" xlink:label="loc_ptgefLossOnImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefLossOnImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfInvestmentInCompedica" xlink:label="loc_ptgefChangeInFairValueOfInvestmentInCompedica" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefChangeInFairValueOfInvestmentInCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReturnOfInvestmentInterestToCompedica" xlink:label="loc_ptgefReturnOfInvestmentInterestToCompedica" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefReturnOfInvestmentInterestToCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_InvestmentInCompedicaAsOfMarch31" xlink:label="loc_ptgefInvestmentInCompedicaAsOfMarch31" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefInvestmentInCompedicaAsOfMarch31" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative" xlink:title="999065 - Disclosure - INVESTMENT IN COMPEDICA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedReimbursementOtherProvisions" xlink:label="loc_ifrs-fullExpectedReimbursementOtherProvisions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullExpectedReimbursementOtherProvisions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-fullImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOnInvestmentInCompedica" xlink:label="loc_ptgefChangeInFairValueOnInvestmentInCompedica" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefChangeInFairValueOnInvestmentInCompedica" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="999066 - Disclosure - WARRANT LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ClassBWarrantsMember" xlink:label="loc_ptgefClassBWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefClassBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ClassCWarrantsMember" xlink:label="loc_ptgefClassCWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefClassCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:label="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsShares" xlink:label="loc_ptgefFairValueOfWarrantsShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantsAmount" xlink:label="loc_ptgefFairValueOfWarrantsAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityShares" xlink:label="loc_ptgefWarrantsLiabilityShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="loc_ptgefWarrantsLiabilityFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityShares" xlink:label="loc_ptgefWarrantsLiabilityShares_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="loc_ptgefWarrantsLiabilityFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:title="999067 - Disclosure - WARRANT LIABILITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:title="999068 - Disclosure - WARRANT LIABILITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:title="999069 - Disclosure - WARRANT LIABILITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails4" xlink:title="999070 - Disclosure - WARRANT LIABILITY (Details 4)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentsWarrantsMember" xlink:label="loc_ptgefPlacementAgentsWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentsWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999071 - Disclosure - WARRANT LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeiesBWarrantsMember" xlink:label="loc_ptgefSeiesBWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeiesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeiesCWarrantsMember" xlink:label="loc_ptgefSeiesCWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeiesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrants2026Member" xlink:label="loc_ptgefPlacementAgentWarrants2026Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrants2026Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfWarrantPerShare" xlink:label="loc_ptgefFairValueOfWarrantPerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails" xlink:title="999072 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:label="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokenVolatilityMember" xlink:label="loc_ptgefTonTokenVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefTonTokenVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiabilityemainingTermInYears" xlink:label="loc_ptgefPutRightLiabilityemainingTermInYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightLiabilityemainingTermInYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonTokenPrice" xlink:label="loc_ptgefTonTokenPrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTonTokenPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate" xlink:label="loc_ptgefLockedTonTokenDiscountForLackOfMarketabilityRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLockedTonTokenDiscountForLackOfMarketabilityRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1" xlink:title="999073 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:label="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceOfPutRightLiability" xlink:label="loc_ptgefBalanceOfPutRightLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefBalanceOfPutRightLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets" xlink:label="loc_ifrs-fullDecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ifrs-fullDecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-fullGainsLossesOnChangeInFairValueOfDerivatives" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ifrs-fullGainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-fullProceedsFromExerciseOfOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ifrs-fullProceedsFromExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfDwfMaasLimitedPutRight" xlink:label="loc_ptgefSettlementOfDwfMaasLimitedPutRight" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefSettlementOfDwfMaasLimitedPutRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExerciseOfPutRightLiability" xlink:label="loc_ptgefLossOnExerciseOfPutRightLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefLossOnExerciseOfPutRightLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiabilityEndingBalance" xlink:label="loc_ptgefPutRightLiabilityEndingBalance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefPutRightLiabilityEndingBalance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2" xlink:title="999074 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:label="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BalanceOfTonPayable" xlink:label="loc_ptgefBalanceOfTonPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefBalanceOfTonPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExerciseOfSideLetterPutRightPayable" xlink:label="loc_ptgefExerciseOfSideLetterPutRightPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefExerciseOfSideLetterPutRightPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefGainOnSettlementOfTonPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets" xlink:label="loc_ptgefSettlementOfPutRightLiabilityUsingDigitalAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefSettlementOfPutRightLiabilityUsingDigitalAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableEndingBalanceAsOfMarch31" xlink:label="loc_ptgefTonPayableEndingBalanceAsOfMarch31" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefTonPayableEndingBalanceAsOfMarch31" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative" xlink:title="999075 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract" xlink:label="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryManagementAgreementDescription" xlink:label="loc_ptgefTreasuryManagementAgreementDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefTreasuryManagementAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentInterestReceivable" xlink:label="loc_ifrs-fullCurrentInterestReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ifrs-fullCurrentInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueOfContribution" xlink:label="loc_ptgefFairValueOfContribution" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefFairValueOfContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Usd1Receivable" xlink:label="loc_ptgefUsd1Receivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefUsd1Receivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExercise" xlink:label="loc_ptgefLossOnExercise" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefLossOnExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OutstandingContingentPutOptionsFairValue" xlink:label="loc_ptgefOutstandingContingentPutOptionsFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefOutstandingContingentPutOptionsFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RemeasurementChangeInFairValue" xlink:label="loc_ptgefRemeasurementChangeInFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePutRightLiabilityAndTonPayableAbstract" xlink:to="loc_ptgefRemeasurementChangeInFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="999076 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayable" xlink:label="loc_ptgefAccountsPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedOtherProfessionalFees" xlink:label="loc_ptgefAccruedOtherProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedOtherProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedAccountingAndAuditingFees" xlink:label="loc_ptgefAccruedAccountingAndAuditingFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedAccountingAndAuditingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" xlink:label="loc_ptgefAccruedBonusesAndOtherPayrollrelatedExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedBonusesAndOtherPayrollrelatedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedCRO" xlink:label="loc_ptgefAccruedCRO" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedCRO" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProfessionalFeesExpenses" xlink:label="loc_ptgefProfessionalFeesExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefProfessionalFeesExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccruedClinicalAndRdServices" xlink:label="loc_ptgefAccruedClinicalAndRdServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedClinicalAndRdServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CapitalExpenditures" xlink:label="loc_ptgefCapitalExpenditures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefCapitalExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OtherAccruedExpenses" xlink:label="loc_ptgefOtherAccruedExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefOtherAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilityNet" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilityNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilityNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityDetails" xlink:title="999077 - Disclosure - LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureLeaseLiabilityAbstract" xlink:label="loc_ptgefDisclosureLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityFutureMinimumPaymentsDue" xlink:label="loc_ptgefLeaseLiabilityFutureMinimumPaymentsDue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefLeaseLiabilityFutureMinimumPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue" xlink:label="loc_ptgefLeaseLiabilityFutureMinimumPaymentsYearTwoDue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefLeaseLiabilityFutureMinimumPaymentsYearTwoDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue" xlink:label="loc_ptgefLeaseLiabilityFutureMinimumPaymentsYearDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefLeaseLiabilityFutureMinimumPaymentsYearDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Interest" xlink:label="loc_ptgefInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TotalLeaseLiability" xlink:label="loc_ptgefTotalLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefTotalLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityCurrent" xlink:label="loc_ptgefLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityNoncurrent" xlink:label="loc_ptgefLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative" xlink:title="999078 - Disclosure - LEASE LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureLeaseLiabilityAbstract" xlink:label="loc_ptgefDisclosureLeaseLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Commencement" xlink:label="loc_ptgefCommencement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefCommencement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasePriceLeaseLiability" xlink:label="loc_ptgefPurchasePriceLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefPurchasePriceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchaseEquipmentPayment" xlink:label="loc_ptgefPurchaseEquipmentPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLeaseLiabilityAbstract" xlink:to="loc_ptgefPurchaseEquipmentPayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative" xlink:title="999079 - Disclosure - BITGO PRIME LOAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureBitgoPrimeLoanAbstract" xlink:label="loc_ptgefDisclosureBitgoPrimeLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MasterLoanAgreementDescription" xlink:label="loc_ptgefMasterLoanAgreementDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureBitgoPrimeLoanAbstract" xlink:to="loc_ptgefMasterLoanAgreementDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="999080 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CurrentTaxOnProfitsForYear" xlink:label="loc_ptgefCurrentTaxOnProfitsForYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefCurrentTaxOnProfitsForYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ptgefAdjustmentsForCurrentTaxOfPriorPeriods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncome" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DecreaseIncreaseInDeferredTaxAssets" xlink:label="loc_ptgefDecreaseIncreaseInDeferredTaxAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefDecreaseIncreaseInDeferredTaxAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ProfitLossFromContinuingOperation" xlink:label="loc_ptgefProfitLossFromContinuingOperation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefProfitLossFromContinuingOperation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:title="999081 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" xlink:label="loc_ptgefIncomeLossOnOrdinaryActivitiesBeforeTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefIncomeLossOnOrdinaryActivitiesBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TaxUsingBviTaxRate" xlink:label="loc_ptgefTaxUsingBviTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefTaxUsingBviTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EffectOfTaxRatesInOtherCountries" xlink:label="loc_ptgefEffectOfTaxRatesInOtherCountries" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefEffectOfTaxRatesInOtherCountries" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DerecognitionOfDeferredTaxAssets" xlink:label="loc_ptgefDerecognitionOfDeferredTaxAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefDerecognitionOfDeferredTaxAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NondeductibleExpenses" xlink:label="loc_ptgefNondeductibleExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefNondeductibleExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UtilizationOfLossesNotPreviouslyBenefitted" xlink:label="loc_ptgefUtilizationOfLossesNotPreviouslyBenefitted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefUtilizationOfLossesNotPreviouslyBenefitted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeTaxEffectsRelatedToEquityCompensation" xlink:label="loc_ptgefIncomeTaxEffectsRelatedToEquityCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefIncomeTaxEffectsRelatedToEquityCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ForeignCurrencyEffectAndOther" xlink:label="loc_ptgefForeignCurrencyEffectAndOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefForeignCurrencyEffectAndOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeTaxExpense" xlink:label="loc_ptgefIncomeTaxExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefIncomeTaxExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:title="999082 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredTaxAssetsAbstract" xlink:label="loc_ptgefDeferredTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefDeferredTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:label="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockbasedCompensation" xlink:label="loc_ptgefStockbasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ptgefStockbasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReservesAndAccruals" xlink:label="loc_ptgefReservesAndAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ptgefReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="loc_ifrs-fullNetDeferredTaxAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ifrs-fullNetDeferredTaxAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DeferredTaxAssetNotRecognized" xlink:label="loc_ptgefDeferredTaxAssetNotRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ptgefDeferredTaxAssetNotRecognized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetDeferredTaxAsset" xlink:label="loc_ptgefNetDeferredTaxAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ptgefNetDeferredTaxAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="999083 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-fullAdjustmentsForUnrealisedForeignExchangeLossesGains" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullAdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UkLossCarryForwards" xlink:label="loc_ptgefUkLossCarryForwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefUkLossCarryForwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-fullDeferredTaxAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDeferredTaxAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetails" xlink:title="999084 - Disclosure - CAPITAL STOCK AND RESERVES (Details )">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:title="999085 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_ptgefATMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-fullClassesOfShareCapitalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalDomain" xlink:to="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaleOfStock" xlink:label="loc_ptgefSaleOfStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSaleOfStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AggregateProceeds" xlink:label="loc_ptgefAggregateProceeds" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesPrice" xlink:label="loc_ptgefSharesPrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsToPurchase" xlink:label="loc_ptgefWarrantsToPurchase" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PurchasePrice" xlink:label="loc_ptgefPurchasePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchasePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrossProceeds" xlink:label="loc_ptgefGrossProceeds" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-fullCash" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DgitalAssets" xlink:label="loc_ptgefDgitalAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDgitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OrdinarySharesIssued" xlink:label="loc_ptgefOrdinarySharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOrdinarySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetProceeds" xlink:label="loc_ptgefNetProceeds" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TreasuryStock" xlink:label="loc_ptgefTreasuryStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTreasuryStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AggregateOfferingOrdinaryShares" xlink:label="loc_ptgefAggregateOfferingOrdinaryShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateOfferingOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Proceedsfromexerciseofwarrant" xlink:label="loc_ptgefProceedsfromexerciseofwarrant" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsfromexerciseofwarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-fullProceedsFromExerciseOfWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-fullIncreaseDecreaseInNumberOfSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AdditionalSharesIssued" xlink:label="loc_ptgefAdditionalSharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsPurchase" xlink:label="loc_ptgefWarrantsPurchase" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WarrantsPerShare" xlink:label="loc_ptgefWarrantsPerShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="999086 - Disclosure - STOCK OPTION RESERVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefStockOptionReserve" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" xlink:label="loc_ptgefCorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefCorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefStockOptionReserve_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="999087 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain" xlink:label="loc_ifrs-fullDefinedBenefitPlansDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansDomain" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="999088 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullMeasurementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="loc_ifrs-fullMeasurementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullMeasurementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionGrantedMember" xlink:label="loc_ptgefStockOptionGrantedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMeasurementDomain" xlink:to="loc_ptgefStockOptionGrantedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DescriptionOfGrantPriceShareOptionsGranted" xlink:label="loc_ptgefDescriptionOfGrantPriceShareOptionsGranted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfGrantPriceShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="loc_ptgefOptionLifeShareOptionsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptionsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:title="999089 - Disclosure - STOCK OPTION RESERVE (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:title="999090 - Disclosure - STOCK OPTION RESERVE (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:label="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateBenchmarksAxis" xlink:label="loc_ifrs-fullInterestRateBenchmarksAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable" xlink:to="loc_ifrs-fullInterestRateBenchmarksAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateBenchmarksDomain" xlink:label="loc_ifrs-fullInterestRateBenchmarksDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksAxis" xlink:to="loc_ifrs-fullInterestRateBenchmarksDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_January132021Member" xlink:label="loc_ptgefJanuary132021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJanuary132021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_January192022Member" xlink:label="loc_ptgefJanuary192022Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJanuary192022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_February152022Member" xlink:label="loc_ptgefFebruary152022Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefFebruary152022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_June82022Member" xlink:label="loc_ptgefJune82022Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJune82022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_July272022Member" xlink:label="loc_ptgefJuly272022Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJuly272022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March302023Member" xlink:label="loc_ptgefMarch302023Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefMarch302023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March72025Member" xlink:label="loc_ptgefMarch72025Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefMarch72025Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_July272026Member" xlink:label="loc_ptgefJuly272026Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefJuly272026Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_March112026Member" xlink:label="loc_ptgefMarch112026Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInterestRateBenchmarksDomain" xlink:to="loc_ptgefMarch112026Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExpirationDate" xlink:label="loc_ptgefExpirationDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePrice" xlink:label="loc_ptgefExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOptions" xlink:label="loc_ptgefShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="999091 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:label="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="loc_ifrs-fullRestrictedShareUnitsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsDomain" xlink:to="loc_ifrs-fullRestrictedShareUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable" xlink:to="loc_ifrs-fullMeasurementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="loc_ifrs-fullMeasurementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullMeasurementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_VestedStockOptionMember" xlink:label="loc_ptgefVestedStockOptionMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMeasurementDomain" xlink:to="loc_ptgefVestedStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AuthorizedGrantOptionPurchaseShares" xlink:label="loc_ptgefAuthorizedGrantOptionPurchaseShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAuthorizedGrantOptionPurchaseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesIssuedGrantedRsu" xlink:label="loc_ptgefSharesIssuedGrantedRsu" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedGrantedRsu" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberOfSharesExercise" xlink:label="loc_ptgefNumberOfSharesExercise" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:label="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharebasedCompensationExpense" xlink:label="loc_ptgefSharebasedCompensationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharebasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ReversalOfSharebasedCompensation" xlink:label="loc_ptgefReversalOfSharebasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReversalOfSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareBasedCompensationExpenseUnvestedShareOptions" xlink:label="loc_ptgefShareBasedCompensationExpenseUnvestedShareOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareBasedCompensationExpenseUnvestedShareOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="999092 - Disclosure - LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WeightedAverageSharesOutstandingDiluted" xlink:label="loc_ptgefWeightedAverageSharesOutstandingDiluted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefWeightedAverageSharesOutstandingDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossPerShareBasic" xlink:label="loc_ptgefLossPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefLossPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossPerShareDiluted" xlink:label="loc_ptgefLossPerShareDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefLossPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="999093 - Disclosure - LOSS PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-fullWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ifrs-fullWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="999094 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CROMember" xlink:label="loc_ptgefCROMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_ptgefCROMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CROAgreementMember" xlink:label="loc_ptgefCROAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_ptgefCROAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ServiceFees" xlink:label="loc_ptgefServiceFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefServiceFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BudgetCosts" xlink:label="loc_ptgefBudgetCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefBudgetCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrossProceeds" xlink:label="loc_ptgefGrossProceeds" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_UnbilledServices" xlink:label="loc_ptgefUnbilledServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnbilledServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ForfeitedAdvancedPayments" xlink:label="loc_ptgefForfeitedAdvancedPayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefForfeitedAdvancedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetGain" xlink:label="loc_ptgefNetGain" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ContractualPayments" xlink:label="loc_ptgefContractualPayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContractualPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SecurityDeposits" xlink:label="loc_ptgefSecurityDeposits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSecurityDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetworkingEquipmentCost" xlink:label="loc_ptgefNetworkingEquipmentCost" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetworkingEquipmentCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Deposit" xlink:label="loc_ptgefDeposit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDeposit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails" xlink:title="999095 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-fullShorttermEmployeeBenefitsExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullShorttermEmployeeBenefitsExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:label="loc_ifrs-fullPostemploymentBenefitExpenseInProfitOrLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullPostemploymentBenefitExpenseInProfitOrLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherLongtermBenefits" xlink:label="loc_ifrs-fullOtherLongtermBenefits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullOtherLongtermBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="loc_ifrs-fullTerminationBenefitsExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullTerminationBenefitsExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SharebasedPaymentCompensation" xlink:label="loc_ptgefSharebasedPaymentCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefSharebasedPaymentCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationPostemploymentBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails1" xlink:title="999096 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MichaelTerpinMember" xlink:label="loc_ptgefMichaelTerpinMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefMichaelTerpinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FDanielSicilianoMember" xlink:label="loc_ptgefFDanielSicilianoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefFDanielSicilianoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GregoryHBaileyMDMember" xlink:label="loc_ptgefGregoryHBaileyMDMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefGregoryHBaileyMDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JamesMellonMember" xlink:label="loc_ptgefJamesMellonMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJamesMellonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_StevenMintzMember" xlink:label="loc_ptgefStevenMintzMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefStevenMintzMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JeanChristopheRenondinMDMember" xlink:label="loc_ptgefJeanChristopheRenondinMDMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJeanChristopheRenondinMDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JustinStebbingMDPhDMember" xlink:label="loc_ptgefJustinStebbingMDPhDMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJustinStebbingMDPhDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LindaKozickMember" xlink:label="loc_ptgefLindaKozickMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefLindaKozickMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MarkSimonMember" xlink:label="loc_ptgefMarkSimonMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefMarkSimonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertGlassmanMember" xlink:label="loc_ptgefRobertGlassmanMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertGlassmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrittanyKaiserMember" xlink:label="loc_ptgefBrittanyKaiserMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrittanyKaiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EnzoVillaniMember" xlink:label="loc_ptgefEnzoVillaniMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefEnzoVillaniMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_WesLevittMember" xlink:label="loc_ptgefWesLevittMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefWesLevittMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_YuryMitinMember" xlink:label="loc_ptgefYuryMitinMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefYuryMitinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettMember" xlink:label="loc_ptgefAlexanderPickettMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAlexanderPickettMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanWaltersMember" xlink:label="loc_ptgefIanWaltersMember" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanWaltersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaParkMember" xlink:label="loc_ptgefAndreaParkMember" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAndreaParkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawMember" xlink:label="loc_ptgefAllanShawMember" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerMember" xlink:label="loc_ptgefRobertKramerMember" />
      <link:presentationArc order="820" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyMember" xlink:label="loc_ptgefBrianWileyMember" />
      <link:presentationArc order="880" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrianWileyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_JustinFairchildMember" xlink:label="loc_ptgefJustinFairchildMember" />
      <link:presentationArc order="940" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefJustinFairchildMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DirectorCompensationMember" xlink:label="loc_ptgefDirectorCompensationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" xlink:to="loc_ptgefDirectorCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExecutiveOfficerCompensationMember" xlink:label="loc_ptgefExecutiveOfficerCompensationMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesDomain" xlink:to="loc_ptgefExecutiveOfficerCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-fullFeeAndCommissionExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFeeAndCommissionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionIncome" xlink:label="loc_ifrs-fullFeeAndCommissionIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFeeAndCommissionIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TransactionClosingBonus" xlink:label="loc_ptgefTransactionClosingBonus" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTransactionClosingBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SecuritiesUnderOptionsGranted" xlink:label="loc_ptgefSecuritiesUnderOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSecuritiesUnderOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OtherCompensation" xlink:label="loc_ptgefOtherCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOtherCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullCompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetails3" xlink:title="999097 - Disclosure - RELATED PARTY TRANSACTIONS (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettMember" xlink:label="loc_ptgefAlexanderPickettMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAlexanderPickettMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AlexanderPickettTwoMember" xlink:label="loc_ptgefAlexanderPickettTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAlexanderPickettTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersMember" xlink:label="loc_ptgefIanBWaltersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanBWaltersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersTwoMember" xlink:label="loc_ptgefIanBWaltersTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanBWaltersTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IanBWaltersThreeMember" xlink:label="loc_ptgefIanBWaltersThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefIanBWaltersThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaEParkMember" xlink:label="loc_ptgefAndreaEParkMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAndreaEParkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AndreaEParkTwoMember" xlink:label="loc_ptgefAndreaEParkTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAndreaEParkTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawMember" xlink:label="loc_ptgefAllanShawMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawTwoMember" xlink:label="loc_ptgefAllanShawTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AllanShawThreeMember" xlink:label="loc_ptgefAllanShawThreeMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefAllanShawThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerMember" xlink:label="loc_ptgefRobertKramerMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerTwoMember" xlink:label="loc_ptgefRobertKramerTwoMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RobertKramerThreeMember" xlink:label="loc_ptgefRobertKramerThreeMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefRobertKramerThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyMember" xlink:label="loc_ptgefBrianWileyMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrianWileyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrianWileyTwoMember" xlink:label="loc_ptgefBrianWileyTwoMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrianWileyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_BrittanyKaiserMember" xlink:label="loc_ptgefBrittanyKaiserMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefBrittanyKaiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_EnzoVillaniMember" xlink:label="loc_ptgefEnzoVillaniMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefEnzoVillaniMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_YuryMitinMember" xlink:label="loc_ptgefYuryMitinMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefYuryMitinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GrantDate" xlink:label="loc_ptgefGrantDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrantDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" xlink:label="loc_ptgefNumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ExercisePrices" xlink:label="loc_ptgefExercisePrices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OptionExpirationDate" xlink:label="loc_ptgefOptionExpirationDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NumberofShareUnitsofStockThetHaveNotVested" xlink:label="loc_ptgefNumberofShareUnitsofStockThetHaveNotVested" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberofShareUnitsofStockThetHaveNotVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested" xlink:label="loc_ptgefMarketValueNumberofShareUnitsofStockThetHaveNotVested" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMarketValueNumberofShareUnitsofStockThetHaveNotVested" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999098 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaleOfStock" xlink:label="loc_ptgefSaleOfStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefSaleOfStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AggregateProceeds" xlink:label="loc_ptgefAggregateProceeds" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefAggregateProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Decentranet" xlink:label="loc_ptgefDecentranet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefDecentranet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="999099 - Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" xlink:to="loc_ptgefAmortizedCostMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_FairValueThroughProfitOrLossMember" xlink:label="loc_ptgefFairValueThroughProfitOrLossMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyDomain" xlink:to="loc_ptgefFairValueThroughProfitOrLossMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Stablecoin" xlink:label="loc_ptgefStablecoin" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ptgefStablecoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefTonPayableToSettlePutRightsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefTonPayableToSettlePutRightsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiability" xlink:label="loc_ptgefPutRightLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefPutRightLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ifrs-fullWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LeaseLiabilityCurrentAndNoncurrent" xlink:label="loc_ptgefLeaseLiabilityCurrentAndNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefLeaseLiabilityCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1" xlink:title="999100 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:label="loc_ifrs-fullImpairmentOfFinancialAssetsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="loc_ifrs-fullImpairmentOfFinancialAssetsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentOfFinancialAssetsDomain" xlink:label="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsAxis" xlink:to="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level1Member" xlink:label="loc_ptgefLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" xlink:to="loc_ptgefLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level2Member" xlink:label="loc_ptgefLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" xlink:to="loc_ptgefLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_Level3Member" xlink:label="loc_ptgefLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullImpairmentOfFinancialAssetsDomain" xlink:to="loc_ptgefLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonLiquid" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonLiquid" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonLiquid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalAssetsAtFairValueTonLocked" xlink:label="loc_ptgefDigitalAssetsAtFairValueTonLocked" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDigitalAssetsAtFairValueTonLocked" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_TonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefTonPayableToSettlePutRightsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTonPayableToSettlePutRightsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiability" xlink:label="loc_ptgefPutRightLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPutRightLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SegmentReportingDetails" xlink:title="999101 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureSegmentReportingAbstract" xlink:label="loc_ptgefDisclosureSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSegmentReportingAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DigitalComputeMember" xlink:label="loc_ptgefDigitalComputeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefDigitalComputeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImmunoOncologyMember" xlink:label="loc_ptgefImmunoOncologyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefImmunoOncologyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-fullProfitLossAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions" xlink:label="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfPutRightsNetOfRedemptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssets" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfDigitalAssetReceivables" xlink:label="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRevaluationOfDigitalAssetReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnSaleOfDigitalAssets" xlink:label="loc_ptgefRealizedLossOnSaleOfDigitalAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossOnSaleOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_RealizedLossOnNovationOfDigitalAssetReceivables" xlink:label="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRealizedLossOnNovationOfDigitalAssetReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRegisteredDirectOffering" xlink:label="loc_ptgefLossOnRegisteredDirectOffering" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_OfferingCosts" xlink:label="loc_ptgefOfferingCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossIoxIprd" xlink:label="loc_ptgefImpairmentLossIoxIprd" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossIoxIprd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossTarusIprd" xlink:label="loc_ptgefImpairmentLossTarusIprd" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossTarusIprd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossStimunity" xlink:label="loc_ptgefImpairmentLossStimunity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossStimunity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossSaugatuck" xlink:label="loc_ptgefImpairmentLossSaugatuck" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossSaugatuck" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCommitmentFeeUnderCommittedPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnDissolutionOfInvestmentInAssociate" xlink:label="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnDissolutionOfInvestmentInAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainFromSaleOfInvestmentInPublicCompany" xlink:label="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainFromSaleOfInvestmentInPublicCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ImpairmentLossInvestmentInCompedica" xlink:label="loc_ptgefImpairmentLossInvestmentInCompedica" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefImpairmentLossInvestmentInCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnRevaluationOfInvestmentInCompedica" xlink:label="loc_ptgefLossOnRevaluationOfInvestmentInCompedica" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnRevaluationOfInvestmentInCompedica" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:label="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfTonPayableToSettlePutRightsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnSettlementOfTonPayable" xlink:label="loc_ptgefGainOnSettlementOfTonPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnSettlementOfTonPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnSettlementOfPutRightLiability" xlink:label="loc_ptgefLossOnSettlementOfPutRightLiability" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnSettlementOfPutRightLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-fullNetForeignExchangeGain" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNetForeignExchangeGain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:label="loc_ifrs-fullInterestExpenseIncomeDefinedBenefitPlans" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullInterestExpenseIncomeDefinedBenefitPlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_GainOnExtinguishmentOfDebt" xlink:label="loc_ptgefGainOnExtinguishmentOfDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGainOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_ShareOfLossesFromEquityMethodInvestment" xlink:label="loc_ptgefShareOfLossesFromEquityMethodInvestment" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareOfLossesFromEquityMethodInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SegmentLossBeforeBenefitForIncomeTaxes" xlink:label="loc_ptgefSegmentLossBeforeBenefitForIncomeTaxes" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSegmentLossBeforeBenefitForIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IncomeTaxBenefit" xlink:label="loc_ptgefIncomeTaxBenefit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIncomeTaxBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SegmentNetLoss" xlink:label="loc_ptgefSegmentNetLoss" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSegmentNetLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:title="999102 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_DisclosureCapitalManagementAbstract" xlink:label="loc_ptgefDisclosureCapitalManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="loc_ptgefPayablesAndAccruedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefPayablesAndAccruedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_PutRightLiabilities" xlink:label="loc_ptgefPutRightLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefPutRightLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_CurrentAsset" xlink:label="loc_ptgefCurrentAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefCurrentAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="999103 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ptgefSaugatuckMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20260331.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The
purpose of this Amendment No. 1 to Alpha Compute Corp's Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with
the Securities and Exchange Commission on July 16, 2026 (the "Form 20-F"), is to furnish Inline XBRL to the Form 20-F in accordance with
Rule 405 of Regulation S-T. There were also minor corrections made to the risk disclosure on page 5 titled "Our success depends on our
ability to attract, motivate, and retain executive officers and other key employees, and the loss of key personnel or an inability to
hire qualified employees could harm our business." Other than these stated changes, no other changes have been made to the Form 20-F.
This Amendment No. 1 to the Form 20-F speaks as of the original filing date of the Form 20-F, does not reflect events that may have occurred
subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alpha
Compute Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Clarence
Thomas Building<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">P.O.
Box 4649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Road
Town<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tortola<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">VG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">VG1110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
        Shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">23,470,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum
LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1111B
S Governors Ave STE 25907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dover<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">219-5556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Wes
Levitt<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 1,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoin', window );">Stablecoin</a></td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonCurrent', window );">Digital assets at fair value, TON, current</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">4,003<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion', window );">Digital assets at fair value, TON, net of current portion</a></td>
<td class="nump">1,201<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset</a></td>
<td class="nump">413<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant, and equipment, net</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EquipmentDeposits', window );">Equipment deposits</a></td>
<td class="nump">9,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="nump">3,322<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">15,527<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">19,530<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">4,146<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability - current</a></td>
<td class="nump">65<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="nump">7,105<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">12,741<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability - non-current</a></td>
<td class="nump">73<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentWarrantLiability', window );">Warrant liability</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,006<span></span>
</td>
<td class="nump">3,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Capital stock</a></td>
<td class="nump">266,053<span></span>
</td>
<td class="nump">221,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Stock option reserve</a></td>
<td class="nump">25,275<span></span>
</td>
<td class="nump">23,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(284,079)<span></span>
</td>
<td class="num">(245,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury stock</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total equity attributable to owners of the Company</a></td>
<td class="nump">7,229<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(705)<span></span>
</td>
<td class="num">(704)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="num">(827)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 19,530<span></span>
</td>
<td class="nump">$ 2,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetsAtFairValueTonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetsAtFairValueTonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EquipmentDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EquipmentDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Stablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Stablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonPayableToSettlePutRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonPayableToSettlePutRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,801<span></span>
</td>
<td class="nump">3,129<span></span>
</td>
<td class="nump">12,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">20,199<span></span>
</td>
<td class="nump">4,254<span></span>
</td>
<td class="nump">5,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation and amortization expense</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operations</a></td>
<td class="num">(23,096)<span></span>
</td>
<td class="num">(7,418)<span></span>
</td>
<td class="num">(18,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="num">(388)<span></span>
</td>
<td class="nump">6,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions', window );">Change in fair value of put rights, net of redemptions</a></td>
<td class="num">(5,959)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssets', window );">Loss on revaluation of digital assets</a></td>
<td class="num">(1,411)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssetReceivables', window );">Loss on revaluation of digital asset receivables</a></td>
<td class="num">(1,497)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnSaleOfDigitalAssets', window );">Realized loss on sale of digital assets</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor', window );">Realized loss on novation of digital assets to investor</a></td>
<td class="num">(676)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementWithParexelIoxCro', window );">Gain on settlement with Parexel - iOx CRO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRegisteredDirectOffering', window );">Loss on Registered Direct Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingCosts', window );">Offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossIoxIprd', window );">Impairment loss - iOx IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossTarusIprd', window );">Impairment loss - Tarus IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossStimunity', window );">Impairment loss - Stimunity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossSaugatuck', window );">Impairment loss - Saugatuck</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement', window );">Commitment fee under Committed Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnDissolutionOfInvestmentInAssociate', window );">Gain on dissolution of investment in associate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainFromSaleOfInvestmentInPublicCompany', window );">Gain from sale of investment in public company</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossInvestmentInCompedica', window );">Impairment loss - investment in Compedica</a></td>
<td class="num">(4,804)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfInvestmentInCompedica', window );">Loss on revaluation of investment in Compedica</a></td>
<td class="num">(182)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised', window );">Change in fair value of TON payable to settle put rights exercised</a></td>
<td class="nump">51<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementOfTonPayable', window );">Gain on settlement of TON payable</a></td>
<td class="nump">336<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnSettlementOfPutRightLiability', window );">Loss on settlement of put right liability</a></td>
<td class="num">(916)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange transaction (loss) gain</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Interest (expense) income, net</a></td>
<td class="num">(1,014)<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOfLossesFromEquityMethodInvestment', window );">Share of losses from equity method investment</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before benefit for income taxes</a></td>
<td class="num">(38,627)<span></span>
</td>
<td class="num">(6,781)<span></span>
</td>
<td class="num">(85,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">10,548<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(38,627)<span></span>
</td>
<td class="num">(6,778)<span></span>
</td>
<td class="num">(75,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedLossOnInvestments', window );">Net unrealized loss on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for period</a></td>
<td class="num">(38,627)<span></span>
</td>
<td class="num">(6,778)<span></span>
</td>
<td class="num">(75,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Net loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(38,626)<span></span>
</td>
<td class="num">(6,767)<span></span>
</td>
<td class="num">(75,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Comprehensive loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(38,626)<span></span>
</td>
<td class="num">(6,767)<span></span>
</td>
<td class="num">(75,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Loss per share, Basic</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (5.72)<span></span>
</td>
<td class="num">$ (77.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Loss per share, Diluted</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (5.72)<span></span>
</td>
<td class="num">$ (77.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average shares outstanding, Basic</a></td>
<td class="nump">9,248<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average shares outstanding, Diluted</a></td>
<td class="nump">9,248<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentFeeUnderCommittedPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainFromSaleOfInvestmentInPublicCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainFromSaleOfInvestmentInPublicCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnDissolutionOfInvestmentInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnDissolutionOfInvestmentInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementOfTonPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementOfTonPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementWithParexelIoxCro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementWithParexelIoxCro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainsLossesOnChangeInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossIoxIprd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossIoxIprd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossSaugatuck">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossSaugatuck</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossStimunity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossStimunity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossTarusIprd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossTarusIprd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRevaluationOfDigitalAssetReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRevaluationOfDigitalAssetReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRevaluationOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRevaluationOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRevaluationOfInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRevaluationOfInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnSettlementOfPutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnSettlementOfPutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetUnrealizedLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetUnrealizedLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossOnSaleOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossOnSaleOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareOfLossesFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareOfLossesFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Deficit) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Issued capital [member]</div></th>
<th class="th"><div>Stock Option Reserve [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income Loss [Member]</div></th>
<th class="th"><div>Retained earnings [member]</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 218,782<span></span>
</td>
<td class="nump">$ 21,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (4,325)<span></span>
</td>
<td class="num">$ (159,616)<span></span>
</td>
<td class="nump">$ 76,045<span></span>
</td>
<td class="num">$ (650)<span></span>
</td>
<td class="nump">$ 75,395<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Begnning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BalanceApril12022PresplitShares', window );">Balance, April 1, 2022 (Pre-Split), shares</a></td>
<td class="nump">17,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderRegisteredDirectOffering', window );">Shares issued under Registered Direct Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderRegisteredDirectOfferingShares', window );">Shares issued under Registered Direct Offering, shares</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts', window );">Shares issued related to the ATM agreement, net of share issuance costs</a></td>
<td class="nump">$ 662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares', window );">Shares issued related to the ATM agreement, net of share issuance costs , shares</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServices', window );">Shares issued or accrued for services</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServicesShares', window );">Shares issued or accrued for services, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits', window );">Shares issued pursuant to distribution of restricted stock units</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares', window );">Shares issued pursuant to distribution of restricted stock units, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DerecognitionOfInvestmentInPublicCompany', window );">Derecognition of investment in public company</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,363<span></span>
</td>
<td class="num">(4,363)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedLossOnInvestments', window );">Net unrealized loss on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(75,339)<span></span>
</td>
<td class="num">(75,339)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">(75,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica', window );">Treasury stock obtained in exchange for return of investment interest to Compedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 219,499<span></span>
</td>
<td class="nump">23,841<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(239,318)<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="nump">3,329<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits', window );">Shares issued pursuant to distribution of restricted stock units</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares', window );">Shares issued pursuant to distribution of restricted stock units, shares</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedLossOnInvestments', window );">Net unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,767)<span></span>
</td>
<td class="num">(6,767)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(6,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense', window );">Correction of prior period overstated share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(632)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts', window );">Shares issued under private placement, net of share issuance costs</a></td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares', window );">Shares issued under private placement, net of share issuance costs, shares</a></td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrefundedWarrantsExercised', window );">Pre-Funded warrants exercised</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrefundedWarrantsExercisedShares', window );">Pre-Funded warrants exercised, shares</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit', window );">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse share split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares', window );">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedForAccruedBonuses', window );">Shares issued for accrued bonuses</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedAccruedForBonusesShares', window );">Shares issued accrued for bonuses, shares</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica', window );">Treasury stock obtained in exchange for return of investment interest to Compedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="nump">$ 221,800<span></span>
</td>
<td class="nump">23,530<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(245,453)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(704)<span></span>
</td>
<td class="num">(827)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">1,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,745<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,745<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts', window );">Shares issued related to the ATM agreement, net of share issuance costs</a></td>
<td class="nump">$ 12,030<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,030<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares', window );">Shares issued related to the ATM agreement, net of share issuance costs , shares</a></td>
<td class="nump">4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedLossOnInvestments', window );">Net unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38,626)<span></span>
</td>
<td class="num">(38,626)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(38,627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights', window );">Shares issued under private placement, net of share issuance costs and put rights</a></td>
<td class="nump">$ 14,535<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,535<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares', window );">Shares issued under private placement, net of share issuance costs and put rights , shares</a></td>
<td class="nump">3,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedRelatingToAcquisitionOfCompedica', window );">Shares issued relating to the acquisition of Compedica</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares', window );">Shares issued relating to the acquisition of Compedica, shares</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts', window );">Shares issued under registered direct offering, net of share issuance costs</a></td>
<td class="nump">$ 12,688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares', window );">Shares issued under registered direct offering, net of share issuance costs , shares</a></td>
<td class="nump">5,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExerciseOfPrefundedWarrantsShares', window );">Exercise of pre-funded warrants , shares</a></td>
<td class="nump">9,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica', window );">Treasury stock obtained in exchange for return of investment interest to Compedica</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares', window );">Treasury stock obtained in exchange for return of investment interest to Compedica , shares</a></td>
<td class="num">(625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightsExercisedAndReturnOfShares', window );">Put rights exercised and return of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightsExercisedAndReturnShares', window );">Put rights exercised and return, shares</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance, value at Mar. 31, 2026</a></td>
<td class="nump">$ 266,053<span></span>
</td>
<td class="nump">$ 25,275<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (284,079)<span></span>
</td>
<td class="nump">$ 7,229<span></span>
</td>
<td class="num">$ (705)<span></span>
</td>
<td class="nump">$ 6,524<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2026</a></td>
<td class="nump">23,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BalanceApril12022PresplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BalanceApril12022PresplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DerecognitionOfInvestmentInPublicCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DerecognitionOfInvestmentInPublicCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExerciseOfPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExerciseOfPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetUnrealizedLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetUnrealizedLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrefundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrefundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrefundedWarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrefundedWarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightsExercisedAndReturnOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightsExercisedAndReturnOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightsExercisedAndReturnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightsExercisedAndReturnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedAccruedForBonusesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedAccruedForBonusesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedForAccruedBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedForAccruedBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedRelatingToAcquisitionOfCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedRelatingToAcquisitionOfCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderRegisteredDirectOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderRegisteredDirectOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">$ (38,627)<span></span>
</td>
<td class="num">$ (6,778)<span></span>
</td>
<td class="num">$ (75,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRegisteredDirectOffering', window );">Loss on Registered Direct Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingCosts', window );">Offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement', window );">Commitment fee under Committed Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnDissolutionOfInvestmentInAssociate', window );">Gain on dissolution of investment in associate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainFromSaleOfInvestmentInPublicCompany', window );">Gain from sale of investment in public company</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Decrease in deferred tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets', window );">Unrealized loss on change in fair value of digital assets</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables', window );">Unrealized loss on change in fair value of digital asset receivables</a></td>
<td class="nump">2,349<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnSaleOfDigitalAssets', window );">Realized loss on sale of digital assets</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetReceivables', window );">Realized loss on novation of digital asset receivables</a></td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnImpairmentInvestmentInCompedica', window );">Loss on impairment - investment in Compedica</a></td>
<td class="nump">4,804<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRemeasurementOfInvestmentInCompedica', window );">Loss on remeasurement of investment in Compedica</a></td>
<td class="nump">182<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="num">(2,883)<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="num">(6,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions', window );">Change in fair value of put rights, net of redemptions</a></td>
<td class="nump">5,959<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossFromEquityMethodInvestment', window );">Loss from equity method investment</a></td>
<td class="nump">44<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised', window );">Change in fair value of TON payable to settle put rights exercised</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementOfTonPayable', window );">Gain on settlement of TON payable</a></td>
<td class="num">(336)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnExerciseOfPutRightLiability', window );">Loss on exercise of put right liability</a></td>
<td class="nump">916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NoncashInterestExpense', window );">Noncash interest expense</a></td>
<td class="nump">171<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementWithParexelIoxCro', window );">Gain on settlement with Parexel - iOx CRO</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(946)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpensesSettledUsingStablecoin', window );">Expenses settled using stablecoin</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsReceived', window );">Revenues received in TON tokens</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOfLossInAssociate', window );">Share of loss in associate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfSharesIssuedForServices', window );">Fair value of shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DepreciationAndAmortizations', window );">Depreciation and amortization</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetChangeInWorkingCapitalComponentsAbstract', window );"><strong>Changes in operating working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Accounts receivable</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses and other receivables</a></td>
<td class="num">(96)<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Other assets</a></td>
<td class="num">(3,322)<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,549<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">Other current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,548)<span></span>
</td>
<td class="num">(5,462)<span></span>
</td>
<td class="num">(14,297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentProperty', window );">Proceeds from sale of investment in public company</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasesOfStablecoin', window );">Purchases of stablecoin</a></td>
<td class="num">(311)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasesOfDigitalAssets', window );">Purchases of digital assets</a></td>
<td class="num">(609)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SalesOfStablecoin', window );">Sales of stablecoin</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SalesOfDigitalAssets', window );">Sales of digital assets</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchases of fixed assets</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EquipmentDeposit', window );">Equipment deposits</a></td>
<td class="num">(9,308)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashPaidForInvestmentInCompedica', window );">Cash paid for investment in Compedica</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(6,318)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromExerciseOfPrefundedWarrants', window );">Proceeds from exercise of Pre-Funded Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement', window );">Proceeds from shares issued under private placement</a></td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromRegisteredDirectOffering', window );">Proceeds from Registered Direct Offering</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement', window );">Proceeds from shares issued under ATM and Committed Purchase Agreement</a></td>
<td class="nump">12,631<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share issuance costs</a></td>
<td class="num">(3,615)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightIssuanceCosts', window );">Put right issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="num">(381)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PaymentsOnExternalDebt', window );">Payments on external debt</a></td>
<td class="num">(275)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="num">(250)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LoanTerminationFee', window );">Loan termination fee</a></td>
<td class="num">(500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesFromRSUDistribution', window );">Shares from RSU distribution</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">25,882<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">5,968<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Decrease in cash, cash equivalents, restricted during period</a></td>
<td class="num">(984)<span></span>
</td>
<td class="num">(3,358)<span></span>
</td>
<td class="num">(5,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">10,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SupplementalCashFlowInformationsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashPaidForInterest', window );">Cash paid for interest</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NoncashInvestingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue', window );">Exchange of Stimunity Convertible Note for Stimunity shares at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalExpendituresIncludedInAccountsPayable', window );">Capital expenditures included in accounts payable</a></td>
<td class="nump">333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RightToUseAssetAcquired', window );">Right-of-use asset acquired</a></td>
<td class="nump">516<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityIncurred', window );">Lease liability incurred</a></td>
<td class="nump">516<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssets', window );">Contribution of digital assets</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfStablecoin', window );">Contribution of stablecoin</a></td>
<td class="nump">5,421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssetsReceivable', window );">Contribution of digital assets receivable</a></td>
<td class="nump">9,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfStablecoinReceivable', window );">Contribution of stablecoin receivable</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica', window );">Value of shares used to purchase interest in Compedica</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica', window );">Treasury stock obtained in exchange for return of investment interest to Compedica</a></td>
<td class="nump">20<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightsIssuedToInvestors', window );">Put rights issued to investors</a></td>
<td class="nump">18,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareIssuanceCostsSettledInCompanyStock', window );">Share issuance costs settled in Company stock</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock', window );">Share issuance costs settled in warrants on the Company's stock</a></td>
<td class="nump">1,123<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable', window );">Settlement of put right liability using stablecoin receivable</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExerciseOfPutRights', window );">Exercise of put rights</a></td>
<td class="nump">2,920<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables', window );">Settlement of put right liability using digital asset receivables</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReceiptOfDigitalAssetsReceivableTonTokens', window );">Receipt of digital assets receivable, TON tokens</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToPurchaseDigitalAssets', window );">Stablecoin used to purchase digital assets</a></td>
<td class="nump">3,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SaleOfDigitalAssetsSettledInStablecoin', window );">Sale of digital assets settled in stablecoin</a></td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfBitcoinForTonTokens', window );">Exchange of Bitcoin for TON tokens</a></td>
<td class="nump">425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExternalDebtProceedsReceivedInStablecoin', window );">External debt proceeds received in stablecoin</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PaymentsOnExternalDebtUsingDigitalAssets', window );">Payments on external debt using digital assets</a></td>
<td class="nump">1,825<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NoncashOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesObtainedInExchangeForStablecoin', window );">Prepaid expenses obtained in exchange for stablecoin</a></td>
<td class="nump">1,311<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_IOxIPRDMember', window );">iOx IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">57,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_TarusIPRDMember', window );">Tarus IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_StimunityMember', window );">Stimunity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_SaugatuckMember', window );">Saugatuck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 130<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_130_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 130<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_130_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investment property. [Refer: Investment property]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalExpendituresIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalExpendituresIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashPaidForInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashPaidForInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashPaidForInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashPaidForInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentFeeUnderCommittedPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContributionOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContributionOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContributionOfDigitalAssetsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContributionOfDigitalAssetsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContributionOfStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContributionOfStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContributionOfStablecoinReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContributionOfStablecoinReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DepreciationAndAmortizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DepreciationAndAmortizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EquipmentDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EquipmentDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExchangeOfBitcoinForTonTokens">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExchangeOfBitcoinForTonTokens</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExerciseOfPutRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExerciseOfPutRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExpensesSettledUsingStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExpensesSettledUsingStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExternalDebtProceedsReceivedInStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExternalDebtProceedsReceivedInStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainFromSaleOfInvestmentInPublicCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainFromSaleOfInvestmentInPublicCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnDissolutionOfInvestmentInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnDissolutionOfInvestmentInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementOfTonPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementOfTonPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementWithParexelIoxCro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementWithParexelIoxCro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LoanTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LoanTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnExerciseOfPutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnExerciseOfPutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnImpairmentInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnImpairmentInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRemeasurementOfInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRemeasurementOfInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetChangeInWorkingCapitalComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetChangeInWorkingCapitalComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NoncashInvestingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NoncashInvestingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NoncashOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NoncashOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PaymentsOnExternalDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PaymentsOnExternalDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PaymentsOnExternalDebtUsingDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PaymentsOnExternalDebtUsingDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesObtainedInExchangeForStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesObtainedInExchangeForStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchasesOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchasesOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchasesOfStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchasesOfStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightsIssuedToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightsIssuedToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossOnNovationOfDigitalAssetReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossOnNovationOfDigitalAssetReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossOnSaleOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossOnSaleOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReceiptOfDigitalAssetsReceivableTonTokens">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReceiptOfDigitalAssetsReceivableTonTokens</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RightToUseAssetAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RightToUseAssetAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SaleOfDigitalAssetsSettledInStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SaleOfDigitalAssetsSettledInStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SalesOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SalesOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SalesOfStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SalesOfStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareIssuanceCostsSettledInCompanyStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareIssuanceCostsSettledInCompanyStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareOfLossInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareOfLossInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesFromRSUDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesFromRSUDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StablecoinUsedToPurchaseDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StablecoinUsedToPurchaseDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SupplementalCashFlowInformationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SupplementalCashFlowInformationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_IOxIPRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_IOxIPRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_TarusIPRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_TarusIPRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_StimunityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_StimunityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_SaugatuckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ptgef_SaugatuckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureNatureOfOperationsAbstract', window );"><strong>Nature Of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NatureOfOperationsExplanatory', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_800_ecustom--NatureOfOperationsExplanatory_z0qgQAkOagd2" style="margin: 0pt 0; font-size: 10pt"><b><span id="financialnotes"></span>NOTE
1. <span id="xdx_82B_zH1KqvgCfDy1">NATURE OF OPERATIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Alpha Compute Corp (the &#8220;Company&#8221;
or &#8220;Alpha Compute&#8221;, formerly known as Portage Biotech, Inc. and AlphaTON Capital Corp) is incorporated in the British Virgin
Islands (&#8220;BVI&#8221;) with its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its
USA agent, Portage Development Services Inc. (&#8220;PDS&#8221;), is located at 59 Wilton Road, Westport, CT, 06880, USA.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company is a foreign private issuer under the Securities
and Exchange Commission (the &#8220;SEC&#8221;) rules. It is also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#8220;CSE&#8221;) under the symbol
&#8220;PBT.U&#8221;. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
under the symbol &#8220;PRTG&#8221;. As the principal market for the Company&#8217;s ordinary shares is Nasdaq, the Company voluntarily
delisted from the CSE on April 23, 2021. On September 4, 2025, in connection with the change in the legal name of the Company to AlphaTON
Capital Corp effective on August 11, 2025, the Nasdaq ticker symbol of the Company&#8217;s ordinary shares was changed to &#8220;ATON&#8221;.
On April 21, 2026, in connection with the change in the legal name of the Company to Alpha Compute Corp effective on April 14, 2026, the
Nasdaq ticker symbol of the Company&#8217;s ordinary shares was changed to &#8220;ALP&#8221;.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>The Company</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Alpha Compute Corp. ("Alpha Compute," "we," "us,"
"our," or the "Company") is a technology company focused on the acquisition, deployment, and leasing of high-performance
graphics processing units ("GPUs") in data center facilities to power artificial intelligence ("AI") workloads, with a
particular emphasis on confidential compute. The Company operates GPU infrastructure in North America and Europe and provides GPU-as-a-Service
("GPUaaS") and AI Confidential Compute solutions to enterprise customers, technology companies, AI research laboratories, and
decentralized AI ecosystems.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Beginning in late 2025, the Company commenced acquisition and installation
of NVIDIA GPU hardware, including H200, B200, and B300 processors, in third-party data center facilities. In April 2026, the Company formally
rebranded to Alpha Compute Corp. and changed its Nasdaq ticker from ATON to ALP to reflect the completion of this strategic transition.
The Company retains a residual position in TON digital assets from its previous focus as a digital asset treasury company, but this legacy
segment is no longer the primary focus of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>GPU-as-a-Service (GPUaaS)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's primary revenue model consists of acquiring and leasing NVIDIA
GPU hardware and leasing compute capacity to enterprise customers under multi-year off-take agreements. The Company earns revenue based
on contracted lease rates and capacity utilization.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's first large-scale deployment, designated ALPHA-01, consists
of 504 NVIDIA B200 GPUs co-located in a hydroelectric-powered Canadian data center. ALPHA-01 became fully operational in May 2026 and
is subject to a two-year, $32.2 million compute off-take lease with a leading frontier AI research laboratory, representing $16.1 million
in annual contracted revenue. A second cluster, ALPHA-02, comprising 576 NVIDIA B300 GPUs, is planned for deployment in a hydroelectric-powered
Swedish data center and is targeted for commercial launch in the third quarter of calendar year 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>AI Confidential Computing</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Confidential computing is a hardware-level security paradigm that enables
computation on sensitive data within a protected, hardware-enforced trusted execution environment ("TEE"), such that the data
and the AI model remain encrypted and inaccessible even to the infrastructure operator. The Company and its partners have together developed
and deployed a proprietary software stack that enables confidential AI workloads to be processed on Telegram&#8217;s Cocoon AI protocol
via NVIDIA Blackwell-generation GPU hardware.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company believes confidential computing represents the highest-growth,
highest-value segment within the AI infrastructure market, driven by stringent data privacy requirements across healthcare, financial
services, government, defense, and decentralized AI applications. The convergence of the EU AI Act (effective 2026), updated FedRAMP 20x
requirements, and various national data sovereignty mandates is creating a structural and mandatory procurement cycle for privacy-preserving
AI infrastructure.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Sovereign AI Infrastructure</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company targets enterprise clients, government entities, and regulated
industries seeking AI compute capacity that does not require surrendering data sovereignty to hyperscale cloud providers. The Company
offers co-location and dedicated GPU deployment arrangements designed to satisfy data residency requirements and regulatory mandates,
including in jurisdictions with strict cross-border data transfer restrictions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In conjunction with its infrastructure buildout, the Company has announced
plans to establish a U.S. Government Contracting entity, projected to launch in the third quarter of calendar year 2026, to pursue federal
government AI compute procurement opportunities including those arising from FedRAMP compliance requirements.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

















<p style="margin: 0pt 0; font-size: 10pt"><b>Alpha Compute Capital</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has announced the launch of "Alpha Compute Capital,"
a financing division designed to structure and fund AI GPU Special Purpose Vehicles ("SPVs") and related financial products. Alpha
Compute Capital is intended to enable the Company to expand GPU deployment capacity using non-recourse, asset-backed financing facilities,
thereby reducing dilution to existing shareholders and accelerating infrastructure growth.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Digital Asset Business </b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company launched a digital asset treasury business in September 2025
focused on TON blockchain and the Telegram ecosystem. In November 2025, the Company began deploying Nvidia GPUs to Telegram&#8217;s proprietary
AI protocol, Cocoon. Cocoon is Telegram's Confidential Compute Open Network &#8212; a decentralized AI infrastructure project built around
the TON ecosystem. In response to market trends in the digital asset space and opportunities in AI infrastructure, in early 2026 the Company
completed a strategic pivot and rebranded as Alpha Compute Corp. to reflect that its primary focus had shifted to AI compute infrastructure.
This transition included the establishment of GPU procurement and data center deployment capabilities, and the development of a proprietary
confidential computing software stack.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">While investing in digital assets, staking digital assets, and operating
blockchain infrastructure is no longer a core focus of the Company, it will continue to maintain some exposure to TON and other digital
assets. By deploying GPU hardware to Telegram&#8217;s Cocoon protocol, the Company will continue to earn TON tokens, and through its May
2026 acquisition of GaMee, the Company has exposure to the broader Telegram ecosystem and large userbase. However, TON tokens earned from
Cocoon will generally be used for operating and capital expenditures for the AI infrastructure business line, rather than held for long-term
investment.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The remaining locked TON tokens on the Company&#8217;s balance sheet are
mostly in the process of being returned to investors per their put rights granted as part of the September 2025 PIPE transaction, with
two additional outstanding put rights exercised on June 22, 2026. One remaining investor has not exercised his put right on $0.2 million
locked TON contributed.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Legacy Immuno-oncology Business</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Prior to September 2025, Alpha Compute (under the name
Portage Biotech) primarily operated as a clinical-stage immuno-oncology company advancing treatments the Company believes will be first-in
class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients
with invasive cancers. Alpha Compute&#8217;s access to next-generation technologies coupled with a deep understanding of biological mechanisms
enables the identification of clinical therapies and product development strategies that accelerate these medicines through the translational
pipeline. After a review of the Company&#8217;s future funding needs for clinical development of its programs as well as the capital raising
market for biotechnology companies, the Company discontinued the Company sponsored trial for the invariant natural killer T-cell (&#8220;iNKT&#8221;)
program and pause further patient accrual to the Company sponsored adenosine trial for both PORT-6 and PORT-7.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In March 2025, we resumed patient enrollment into the
final dose-escalation cohort of TT-10 (PORT-6) under the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following an earlier pause related
to funding constraints. That decision reflected the favorable safety and preliminary activity signals seen in earlier dose cohorts. Dosing
in that final cohort is now underway, with the last dose-escalation patient currently being treated. In April 2025, we reported confirmatory
preclinical results for our TT-4 (PORT-7) compound in mesothelioma, supporting advancement of that indication. Under the trial protocol,
TT-4 dosing follows completion of the TT-10 dose-escalation cohort, and we are now preparing to enroll patients onto TT-4.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On November 12, 2025, Alpha Compute and Cyncado announced
a non-binding Letter of Intent with Australia&#8217;s Asbestos and Dust Diseases Research Institute (&#8220;ADDRI&#8221;) to conduct an
ADDRI-sponsored investigator-initiated clinical trial of TT-4 in mesothelioma in Australia. The planned trial is expected to enroll approximately
50 patients, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado&#8217;s planned U.S.
mesothelioma activities, subject to execution of a definitive agreement and customary regulatory approvals. Under the contemplated arrangement,
Cyncado will supply TT-4 and limited support as part of an international mesothelioma program designed to accelerate decision-quality
clinical data generation.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Reverse Stock Split</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;)
approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024,
the Company&#8217;s ordinary shares began trading on Nasdaq on a split-adjusted basis.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The reverse stock split was implemented to increase
the per share trading price of the Company&#8217;s ordinary shares for the purpose of ensuring a share price high enough to comply with
the minimum $1.00 bid price requirement for continued listing on Nasdaq. The Company received notice from Nasdaq on August 30, 2024 informing
the Company that it had regained compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As a result of the reverse stock split, every twenty
(20) pre-split ordinary shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from the reverse
stock split were rounded up to the nearest whole post-split ordinary share. The reverse stock split affected all shareholders uniformly
and did not alter any shareholder&#8217;s percentage interest in the Company&#8217;s ordinary shares, except for adjustments that may
result from the treatment of fractional shares. All outstanding options and warrants entitling their holders to purchase the Company&#8217;s
ordinary shares were adjusted as a result of the reverse stock split, in accordance with the terms of each such security. In addition,
the number of ordinary shares reserved for future issuance pursuant to the Company&#8217;s equity incentive plans were also appropriately
adjusted. The number of authorized ordinary shares was not proportionately reduced because the Company has an unlimited number of authorized
ordinary shares available for issuance, as permitted under the laws of the British Virgin Islands.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">All share and per share information included in the
consolidated financial statements have been retroactively adjusted to reflect the impact of the reverse stock split as if the stock split
occurred at the beginning of the periods presented. The shares of ordinary shares authorized remained at an unlimited number of ordinary
shares without par value.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureNatureOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureNatureOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NatureOfOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NatureOfOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoingConcernExplanatory', window );">GOING CONCERN</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfGoingConcernExplanatory_zYG7tTV8Pu62" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. <span id="xdx_820_zPB9FXidVlub">GOING
CONCERN</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The accompanying consolidated financial statements for the fiscal year ended
March 31, 2026 have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity
of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly,
the accompanying consolidated financial statements for the fiscal year ended March 31, 2026 do not include any adjustments relating to
the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, the Company had cash, cash equivalents, and restricted
cash of approximately $<span id="xdx_902_eifrs-full--Cash_iI_pn3n3_dm_c20260331_z7UjVGJM0jv8">0.7</span>
million and total current liabilities of approximately $<span id="xdx_905_ecustom--TotalCurrentLiabilities_iI_pn5n6_c20260331_zLJBD86ckS6e">12.7</span>
million. For the year ended March 31, 2026, the Company is reporting a net loss of approximately $<span id="xdx_90F_ecustom--NetLossIncome_pn3n3_dm_c20250401__20260331_z1CiYsvAmf21">38.6</span>
million, and cash used in operating activities of approximately $<span id="xdx_90C_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20250401__20260331_zppeVO2ZVsOl">20.5</span>
million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In late Fiscal 2024, because of continued liquidity constraints, the Company
discontinued further clinical development of its iNKT sponsored trial and pause further patient accrual to its sponsored adenosine program
for both PORT-6 and PORT-7. During the fiscal year ended March 31, 2026, the Company changed its operating strategy to focus on developing
the Telegram ecosystem and managing a strategic reserve of digital assets, primarily the TON token, and received funding via a private
placement in the form of both cash and digital assets. While this and subsequent equity raises including a registered direct offering
on January 13, 2026 are a positive factor the Company is continuing to explore financing options including its at-the-market (&#8220;ATM&#8221;)
equity program and other financings.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Despite the Company successfully raising capital via a private placement
of shares and a registered direct offering in September 2025 and January 2026, respectively, and successfully raising additional funds
through its ATM program, the Company&#8217;s cash and cash equivalents balance is decreasing, and the Company did not generate positive
cash flows from operations for the fiscal years ended March 31, 2026 and 2025. Additionally, a portion of the Company&#8217;s digital
asset balance may be subject to significant price fluctuations, is restricted for immediate use, or both and therefore may not be relied
upon to fund current obligations as they come due. These factors raise significant doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date issuance of these consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has incurred significant operating losses since inception and
expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of research and development activities and operating expenses. As previously discussed, the Company has discontinued
its iNKT sponsored trial and paused further patient accrual to the Company sponsored adenosine program in order to preserve cash resources.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities. The Company will require significant additional capital to make the investments it needs
to execute its new Telegram ecosystem and new digital asset strategies, beyond the potential proceeds that could be reasonably generated
from its ATM program. The Company&#8217;s ability to successfully raise sufficient funds through the sale of debt or equity securities
when needed is subject to many risks and uncertainties and, future equity issuances would result in dilution to existing shareholders
and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.
See Note 16, &#8220;Capital Stock and Reserves,&#8221; for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of July 13, 2026, the Company had approximately $<span id="xdx_905_ecustom--CashCashEquivalents_iI_pn3n3_dm_c20260331_zjJRM80f9lv5" title="cash, cash equivalents">10.3</span>
million of cash, cash equivalents, and restricted cash on hand, which the Company expects may not be sufficient to fund its operating
needs through FYE in March 2027. The Company projects cash flow needs of approximately $<span id="xdx_905_ecustom--RestrictedCashOnHand_iI_c20260331_zkGjj8VtcHI6" title="Restricted cash on hand">25.0</span>
million between now and FYE 2027, exceeding cash, cash equivalents, and restricted cash on hand. These factors raise substantial doubt
about the Company&#8217;s ability to continue as a going concern within one year after the date of the issuance of these consolidated
financial statements. There were no adjustments made to reflect the effect of this doubt.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoingConcernExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoingConcernExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zS59ac2GGlpi" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 3.
<span id="xdx_82C_z2CuiX4AkXYj">BASIS OF PRESENTATION</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Statement of Compliance and Basis of Presentation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">These consolidated financial statements have been prepared
in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) issued by the International Accounting Standards
Board (&#8220;IASB&#8221;), and interpretations of the International Financial Reporting Interpretations Committee (&#8220;IFRIC&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">These consolidated financial statements have been prepared
on an historical cost basis except for items disclosed herein at fair value (see Note 21, &#8220;Financial Instruments and Risk Management&#8221;).
In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The Company has two reportable operating segments, Digital &amp;
Compute and Immuno-Oncology.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">These consolidated financial statements were
approved and authorized for issuance by the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board on July 15, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Consolidation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The consolidated financial statements include the accounts of the
Company and:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged
certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_90A_eifrs-full--ProportionOfVotingPowerHeldInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zpyCKxETZbEd" title="Percentage of outstanding shares">17.83</span>%
of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from <span id="xdx_903_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zf1p7WpDmnj2" title="Percentage of ownership">60.49</span>%
to <span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zWiVNXrgnHq5" title="Percentage of ownership">78.32</span>%.
On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. The Company&#8217;s <span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20231201__20231231__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--StimunityMember_z06LXpMuyjxb" title="Non-controlling interest">44</span>%
interest in Stimunity S.A. (&#8220;Stimunity&#8221;) was transferred from Alpha Compute to iOx in December 2023 and was increased to <span id="xdx_90D_ecustom--NoncontrollingInterestIncreasedUponConversion_pip0_dp_c20231201__20231231__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--StimunityMember_z9f6BCDCglFg" title="Non-controlling interest increased upon conversion">48.9</span>%
upon the conversion of the convertible note to equity. On December 3, 2025, the Company agreed to sell back our 48.9% interest back to
Stimunity for a token consideration of 1 EUR in order to facilitate an orderly wind-down of Stimunity;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Saugatuck, a <span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20250401__20250930__ifrs-full--GeographicalAreasAxis__custom--CountryOfBritishVirginIslandsMember_z8ylDweMC7Vj" title="Percentage of ownership subsidiary">70</span>%
owned subsidiary incorporated in the British Virgin Islands;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Tarus Therapeutic Holdings Ltd., a wholly-owned subsidiary incorporated in the British Virgin Islands;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
PDS, a <span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20250401__20250930__ifrs-full--GeographicalAreasAxis__custom--DelawareMember_zuCrLVYfhLu4" title="Percentage of ownership subsidiary">100</span>%
owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary via a shared
services agreement;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SalvaRx LLC, a wholly-owned subsidiary through SalvaRx incorporated in Delaware;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck incorporated in Delaware; and</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Tarus Therapeutics, LLC (&#8220;Tarus&#8221;), a wholly-owned subsidiary of Alpha Compute incorporated in Delaware.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">All inter-company balances and transactions have been eliminated
in consolidation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of shareholders&#8217; equity. As of March 31, 2026, non-controlling interest represents
the <span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20250401__20250930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z8AH8lfRHkIj" title="Non-controlling interest">30</span>%
shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Functional and Presentation Currency</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The Company&#8217;s functional and presentation currency is the
U.S. Dollar.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Use of Estimates and Judgments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The preparation of the consolidated financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Estimates and underlying assumptions are reviewed on
an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future
periods affected.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Significant areas where estimates are made include
valuation of financial instruments, deferred tax assets and liabilities, warrant liabilities, digital assets, put right liabilities, and
measurement of share-based compensation. Significant areas where critical judgments are applied include warrant liabilities, put right
liabilities, and digital asset valuation with respect to discounts for lack of marketability.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Transactions with Non-controlling Interests</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Changes in the Company&#8217;s ownership interest in
a subsidiary corporation that do not result in a loss of control over the subsidiary corporation are accounted for as transactions with
equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest and the fair value
of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80B_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zjTMvWnc6BSi" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
4. <span id="xdx_826_zL81KC5bV0nh">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The accounting policies set out below have been applied consistently to
all periods presented in these consolidated financial statements, which have, in management's opinion, been properly prepared within reasonable
limits of materiality and within the framework of the significant accounting policies summarized below:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>



<p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zq6bXFBJNhRl" style="margin: 0pt 0; font-size: 10pt"><b><i><span id="xdx_869_zrokjMcMtN3f">Financial
Instruments</span></i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>i) Financial Assets</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Classification</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Upon the initial recognition of financial assets, the financial assets are
classified as one of the following measurement methodologies: (a) amortized cost, (b) fair value through other comprehensive income (&#8220;FVTOCI&#8221;),
or (c) fair value through profit or loss (&#8220;FVTPL&#8221;). Subsequent measurement will be based on the initial classification of
the financial assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The classification of a financial asset at initial recognition depends on
the Company's business model for managing the financial asset and the financial asset's contractual cash flow characteristics.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In order for a financial asset to be measured at amortized cost or fair
value through other comprehensive income (&#8220;OCI&#8221;), it needs to give rise to cash flows that are solely payments of principal
and interest (&#8220;SPPI&#8221;) on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed
at an instrument level.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's business model for managing financial assets refers to how
it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting
contractual cash flows, selling the financial assets, or both.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Measurement</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">For purposes of subsequent measurement, financial assets are classified
in three categories:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%">Financial assets at amortized cost (debt instruments);</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>Financial assets at FVTOCI (equity instruments); and</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>Financial assets at FVTPL.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets at Amortized Cost (Debt Instruments)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">The Company measures financial assets at amortized cost if both of the following conditions
are met:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%">The financial asset is held within a business model with the objective of holding the financial asset in order to collect
        contractual cash flows; and</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
        on the principal amount outstanding.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at amortized cost are subsequently measured using the effective
interest rate method and are subject to a period impairment review. Gains and losses are recognized in profit or loss when the asset is
derecognized, modified or impaired.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's financial assets classified at amortized cost includes accounts
receivable, stablecoin, and prepaid expenses and other receivables.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets designated at Fair Value through OCI (Equity Instruments)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Upon initial recognition, the Company can elect to classify irrevocably
its equity investments as equity instruments designated at FVTOCI when they meet the definition of equity under IAS 32, &#8220;<i>Financial
Instruments: Presentation</i>,&#8221; and are not held for trading. The classification is determined on an instrument-by-instrument basis.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Gains and losses on these financial assets are never recycled to profit
or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except
when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded
in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company irrevocably elected to classify its investment in Intensity
as FVTOCI. During the year ended March 31, 2024, the Company sold 100% of its investment in Intensity for proceeds of $2.812 million and
recognized a gain of $0.725 million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets at Fair Value through Profit or Loss</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at FVTPL include financial assets held for trading, financial
assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured
at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in
the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated
as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified
and measured FVTPL, irrespective of the business model.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at fair value through profit or loss are carried in the
consolidated statements of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.
The investments in associate (Stimunity and Compedica) and the Stimunity Convertible Note receivable are accounted for as FVTPL.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>ii) Financial Liabilities</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s financial liabilities include accounts payable and accrued
liabilities, which approximate fair value due to their short maturity, lease liability, warrant liability, put right liability and TON
payable to settle put rights exercised.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Warrant Liability</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Warrant liabilities are initially measured at fair value on the date of
issuance. After initial recognition, the warrant liabilities are remeasured at fair value at each reporting period, with changes in fair
value recognized through the consolidated statement of operations and other comprehensive loss in accordance with IFRS 9 &#8220;Financial
Instruments.&#8221; When the Company issues equity instruments to extinguish all or part of the liability, a gain or loss is recognized
in the consolidated statement of operations and other comprehensive loss, which is measured as the difference between the carrying amount
of the financial liability and the fair value of the equity instruments issued. Liability classified warrants are accounted for in accordance
with IFRS 9 and IFRS 13 &#8220;<i>Fair Value Measurement</i>,&#8221; where the terms of the instruments do not meet the criteria for classification
as equity under IAS 32 &#8220;<i>Financial Instruments: Presentation</i>.&#8221; See Note 11, &#8220;Warrant Liability&#8221; for a further
discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zAGIzTm5czbj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zWLd1DvAegf">Impairment
of Financial Assets and Intangible Assets</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">IFRS 9, &#8220;<i>Financial Instruments</i>,&#8221; requires the Company
to recognize an allowance for expected credit losses ("ECLs") for all debt instruments and investments not held at fair value
through profit or loss and contract assets. For intangible assets, at the end of each reporting period and whenever there is an indication
that the intangible asset may be impaired, the Company reviews the carrying amounts of its intangible assets to determine whether there
is any indication that those assets have suffered an impairment loss.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At the end of each reporting period, the Company assesses whether there
was objective evidence that a financial asset was impaired. The Company recognizes an allowance for ECLs for all debt instruments not
held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with
the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest
rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral
to the contractual terms.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">ECLs are recognized in two stages. For credit exposures for which there
has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default
events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant
increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of
the exposure, irrespective of the timing of the default (a lifetime ECL).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



















<p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_zpRmemeYFdJj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_865_zwlvM4mX0Vmk">Cash,
Cash Equivalents, and Restricted Cash</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Cash and cash equivalents comprise cash in readily available checking accounts
and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash within three
months or less from date of acquisition and are subject to an insignificant risk of change in value. The carrying amounts approximate
fair value due to the short maturities of these instruments. The Company maintains most of its bank accounts in the United States ("U.S.").
As of March 31, 2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date
of purchase. Interest income earned on such investments totaled $<span id="xdx_90F_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20260331_zrFeBE0oQpZb" title="Investments">0.1</span>
million, $<span id="xdx_90C_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20250331_zMypTLAoGPX" title="Investments">0.1</span>
million and $<span id="xdx_909_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20240331_zaClKDTedD82" title="Investments">0.2</span>
million in the years ended March 31, 2026, 2025 and 2024, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, the Company had $<span id="xdx_900_ecustom--CashRestrictedForUse_iI_pn3n3_dm_c20260331_zAwpvCBHawgl" title="Cash restricted for use">0.2</span>
million in cash considered restricted for use and is held as collateral for the Company&#8217;s credit card balance with Silicon Valley
Bank. No cash was restricted for use as of March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory_zQ5bnXcLF6I1" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_865_z8Y29tRA5GIi">Impairment
of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At the end of each annual reporting period and whenever there is an indication
that its property, plant and equipment and indefinite life intangible assets may be impaired, the Company reviews the carrying amounts
of such tangible intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If
any such indication exists, the recoverable amount of the asset is estimated to determine the extent of impairment loss (if any). When
it is not possible to estimate the recoverable amount of any individual asset, the Company estimates the recoverable amount of the cash-generating
unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated
to individual cash-generating units ("CGU" or "CGUs"), or the smallest group of cash-generating units for which a reasonable
and consistent allocation basis can be identified.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Recoverable amount is the higher of fair value less costs of disposal and
value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_z6u69SbANulg" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_864_zZuOgTYrTSqf">Share-based
Payments</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company determines the fair value of share-based payments granted to
directors, officers, employees and consultants using the Black-Scholes option-pricing model at the grant date. Assumptions for the Black-Scholes
model are determined as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%"><b><i>Expected Volatility</i></b>. The expected volatility rate used to value share option grants is based on the Company&#8217;s
        historical volatility.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Expected Term</i></b>. The Company used historical experience.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Risk-free Interest Rate</i></b>. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that
        had terms 	consistent with the expected term of the Company's share option grants.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Expected Dividend Yield</i></b>. The Company has never declared or paid any cash dividends and does not presently plan to pay cash
        	dividends in the foreseeable future.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Share-based payments to employees, officers and directors are recorded and reflected
as an expense over the vesting period with a corresponding increase in the share option reserve. On exercise, the associated amounts previously
recorded in the share option reserve are transferred to common share capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zrw28pDv89Vb" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_867_z1ZKTjA18v84">Loss
Per Share</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Basic loss per share is calculated by dividing net loss (the numerator)
by the weighted average number of ordinary shares outstanding (the denominator) during the period. Diluted loss per share reflects the
dilution that would occur if outstanding share options and share purchase warrants were exercised into ordinary shares using the treasury
stock method and convertible debt instruments were converted into ordinary shares using the if-converted method. Diluted loss per share
is calculated by dividing net loss applicable to ordinary shares by the sum of the weighted average number of ordinary shares outstanding
and all additional ordinary shares that would have been outstanding if potentially dilutive ordinary shares had been issued. The share
and per share information has been retroactively adjusted to reflect the impact of the stock dividend.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The inclusion of the Company's share options, restricted stock units and
share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore
excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the years
ended March 31, 2026, 2025, and 2024. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share, and accordingly, were excluded from the calculation (see Note 19, &#8220;Loss Per Share&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_z8ftXIMzNIQa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B7_zUdta2IpW0Zf" style="display: none">Schedule of anti-dilutive effect on loss
        per share</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zSgEDUtn4RO8" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,531,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zby4c4g4Bjth" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zGDYkRfspGq6" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Share options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zjFUSFChu8hb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zX5zMTcxbVNg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">225,117</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zfqvikszk0E4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">90,281</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zbSDlZbM3fF6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,241,334</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zMk7FZpnUWTc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">5,410</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zcOYTRxczUv5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">18,467</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A4_zrEmZO7sqO61" style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory_zY1ZfxAjJTm3" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86B_zawFxBcOWf8b">Investment
in Public Company</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The investment is comprised of shares of private/public companies that have
been acquired through a private placement. The investment is initially recorded at fair value. Following acquisition, the Company evaluates
whether control or significant influence is exerted by the Company over the affairs of the investee company. Based on the evaluation,
the Company accounts for the investment using either the consolidation, equity accounting or fair value method. The Company sold the entire
investment in Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForInvestmentInAssociates_zJUoPXSpf5If" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_867_zDJqp4VzmMm2">Investment
in Associate</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">An associate is an entity over which the Company has significant influence.
Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or
joint control over those policies. The investment in associate was written down to nil as of March 31, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The results and assets and liabilities of associates are incorporated in
these consolidated financial statements using the equity method of accounting, except when the investment, or a portion thereof, is classified
as held for sale, in which case it is accounted for in accordance with IFRS 5, &#8220;Non-current Assets Held for Sale and Discontinued
Operations&#8221;. Under the equity method, an investment in an associate is initially recognized in the consolidated statement of financial
position at cost from the date the investee becomes an associate and adjusted thereafter to recognize the Company's share of the profit
or loss and other comprehensive income of the associate. When the Company's share of losses of an associate exceed the Company's interest
in that associate (which includes any long-term interests that, in substance, form part of the Company's net investment in the associate),
the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company
has incurred legal or constructive obligations or made payments on behalf of the associate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">After application of the equity method, the Company determines whether it
is necessary to recognize an impairment loss on its investment in its associate. At each reporting date, the Company determines whether
there is objective evidence that the investment in the associate is impaired. If there is such evidence, the Company calculates the amount
of impairment as the difference between the recoverable amount of the associate and its carrying value, and then recognizes the loss within
'share of (loss) income in associate' in the consolidated statements of operations. With respect to its investment in Compedica, the Company
recognized a loss on impairment of $4.8 million as of September 30, 2025 due to the Company&#8217;s loss of significant influence over
the operations of Compedica.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_zQcsmzLWZ4Kc" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_863_zEaAf6viREwi">Research
and Development Expenses</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>(i) Research and Development</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Expenditure on research activities, undertaken with the prospect of gaining
new scientific or technical knowledge and understanding, is expensed as incurred.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Development activities involve a plan or design for the production of new
or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably,
the product or process is technically, and commercially feasible, future economic benefits are probable, and the Company intends to and
has sufficient resources to complete development and to use or sell the asset. Following initial recognition of the development expenditure
as an asset, the asset is carried at cost less any accumulated amortization. Amortization of the asset begins when development is complete
and the asset is available for use. It is amortized over the period of expected future benefit. During the period of development, the
asset is tested for impairment annually.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Research and development expenses include all direct and indirect operating
expenses supporting the products in development.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><b><i>(ii) Subsequent Expenditure</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subsequent expenditure is capitalized only when it increases the future
economic benefits embodied in the specific asset to which it relates. All other expenditures are recognized in income or loss as incurred.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>(iii) Clinical Trial Expenses</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Clinical trial expenses are a component of the Company's research and development
costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct development
activities on the Company's behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements is based
on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrollment,
services provided, contractual terms, and prior experience with similar contracts.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory_zkRtD8qg5a6e" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_868_zUR2A6MIwkdk">Contingent
Liability</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A provision in accordance with IAS 37 &#8220;<i>Provisions, Contingent Liabilities
and Contingent Assets</i>,&#8221; is recognized when the Company has a present (legal or constructive) obligation as a result of a past
event and it is probable that economic resources shall be required to settle the obligation and a reliable estimate can be made of the
amount of the obligation. When the Company expects that some or all of the expense will be reimbursed to it, such as in an insurance contract,
the repayment will be recognized as a separate asset, only when it is highly likely that the asset will be received. The expense will
be recognized in profit and loss net of the portion reimbursed.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zoevFRVGYk92" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zVqVJ2K4A0S4">Determination
of Fair Value</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A number of the Company's accounting policies and disclosures required the
determination of fair value, both for financial and non-financial assets and liabilities. Fair values have been determined for measurement
and/or disclosure purposes based on assumptions that market participants would use when pricing the asset or liability, assuming that
market participants act in their economic best interest. When applicable, further information about the assumptions made in determining
fair values is disclosed in Note 15, &#8220;Financial Instruments and Risk Management&#8221; and other footnotes that specifically relate
to assets or liabilities measured at fair value.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zf26Z2XGEyGj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86B_zD5CdCIX2YK3">Income
Tax</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company uses the asset and liability method to account for income taxes.
Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying
amounts of existing assets and liabilities for accounting purposes, and their respective tax bases.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Deferred income tax assets and liabilities are measured using tax rates
that have been enacted or substantively enacted and applied to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized
in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and
are reviewed at the end of each reporting period.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<p id="xdx_848_ecustom--DescriptionOfAccountingPolicyFoStablecoinExplanatory_zi9uQyzIlenl" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zOUWdk3B0UF9">Stablecoin</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its stablecoins, which are comprised of USDC and
USDT, as in accordance with IAS 9 &#8220;Financial Instruments&#8221;. The Company&#8217;s stablecoins are initially recorded at cost,
and are contractually redeemable for fiat currency on demand or pegged 1:1 to the value of one U.S. dollar. The Company determines the
fair value of its stablecoins, which is at par with the U.S. dollar, in accordance with IFRS 13 &#8220;Fair Value Measurement&#8221; based
on the quoted (unadjusted) prices on the active exchange that the Company has determined is its principal market for the stablecoins (Level
1 inputs). Our primary custodian of stablecoins is BitGo, and the associated costs are expensed as incurred. Stablecoins are held for
use in business operations and not for the purpose of potential asset appreciation and is therefore classified as a current asset within
the consolidated statements of financial position. When the Company does not have possession, control, or the right to derive substantially
all of the economic benefits of ownership of stablecoin the Company has title to, the stablecoin is classified as a stablecoin receivable
within the consolidated statements of financial position. Stablecoin and stablecoin receivables qualify as financial instruments due to
their high level of liquidity, rights to redeem directly with the issuer, and their backing by high quality reserve assets not subject
to significant price fluctuations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>























<p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_zlzyHdBCCbP" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_862_z2wZN8uiLec4">Digital
Assets</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its digital assets, which are comprised of TON,
as indefinite-lived intangible assets in accordance with IAS 38 &#8220;Intangible Assets&#8221;. The Company&#8217;s digital assets are
initially recorded at cost. Subsequently, digital assets are remeasured at fair value as of each reporting period, adjusted by discounts
for lack of marketability for tokens restricted for use. The Company determines the fair value of its liquid digital assets in accordance
with IFRS 13 &#8220;Fair Value Measurement&#8221;, based on quoted (unadjusted) prices on the active exchange that the Company has determined
is its principal market for the digital assets (Level 1 inputs). For locked digital assets which are not immediately tradable, the Company
applies a lack of marketability discount to quoted prices to calculate fair value (Level 3 input). Our primary custodian of digital assets
is BitGo, and the associated costs are expensed as incurred. When the Company does not have possession, control, or the right to derive
substantially all of the economic benefits of ownership of digital assets the Company has title to, the digital assets are classified
as digital assets receivable within the consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Increases in fair value, to the extent they do not constitute reversals
of previous decreases in fair value, are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss),
within &#8220;Unrealized gain on digital assets&#8221; within Other comprehensive income, with accumulated unrealized gains recognized
on the Consolidated Statements of Financial Position within Accumulated other comprehensive income. Decreases in fair value, to the extent
they do not constitute reversals of previous increases in fair value, are recognized as incurred in the Company's Consolidated Statements
of Operations and Comprehensive Income (Loss), within &#8220;Loss on revaluation of digital assets&#8221; within Other expenses. Any losses
on revaluation not in excess of previously recognized gains are recognized as decreases to Accumulated other comprehensive income until
cost basis exceeds fair value, at which point additional losses are recognized as Other expense. Any gains on revaluation not in excess
of previously recognized losses are recognized as Other income until fair value exceeds cost basis, at which point additional gains are
recognized as Other comprehensive income. Revaluation gains and losses are recorded by token.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Realized gains, to the extent recognized within Accumulated other comprehensive
income, and losses are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss) within other
income (expense).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Digital assets are classified as current or noncurrent assets based on the
Company&#8217;s intended holding period of the token. If the Company has the intent and ability to hold the token for a period of one
year beyond the balance sheet date or if the token is not expected to become liquid within one year of the balance sheet date, the holding
is classified as noncurrent. Otherwise, the holding is classified as a current asset.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_zZ4fAEFPxvHg" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_869_z7TbxQoibEG8">Revenue
from Contracts with Customers</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company recognizes revenue in accordance with IFRS 15, &#8220;<i>Revenue
from Contracts with Customers</i>,&#8221; which establishes a comprehensive framework for determining whether, how much, and when revenue
is recognized. Revenue is recognized to depict the transfer of promised services to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those services.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s primary source of revenue is derived from compute offtake
agreements, under which customers obtain access to dedicated or shared compute capacity (including processing power, memory, and related
infrastructure) for a specified contractual term.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>i)</i></b></td>
    <td><b><i>Identification of performance obligations</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Compute offtake agreements typically provide customers with a stand-ready obligation
to make compute capacity continuously available throughout the contract term. The Company has determined that such arrangements generally
contain a single performance obligation, being the provision of continuous access to compute services over time.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">To the extent that a contract includes multiple services (for example, initial configuration,
integration, or distinct ancillary services), the Company assesses whether such services are distinct and should be accounted for as separate
performance obligations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>ii)</i></b></td>
    <td><b><i>Determination of the transaction price</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">The transaction price reflects the amount of consideration the Company expects to receive
in exchange for transferring promised services to the customer. Consideration under compute offtake agreements is typically fixed based
on contracted capacity and term, and is frequently settled in digital assets.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">In arrangements where consideration is received in digital assets, such consideration
represents non-cash consideration and is measured at fair value at contract inception.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Any variability in consideration (such as pricing adjustments, service level credits,
or penalties) is estimated using either the expected value or most likely amount method, and included in the transaction price only to
the extent that it is highly probable that a significant reversal of revenue will not occur.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>iii)</i></b></td>
    <td><b><i>Allocation of the transaction price</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">If a contract contains more than one performance obligation, the transaction price is
allocated to each performance obligation based on the relative standalone selling prices of the distinct services at contract inception.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>iv)</i></b></td>
    <td><b><i>Timing of revenue recognition</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Revenue from compute offtake agreements is recognized over time, as the customer simultaneously
receives and consumes the benefits of the compute services as they are provided. Progress toward complete satisfaction of the performance
obligation is measured on a time-elapsed basis, or another systematic measure that faithfully depicts the pattern of transfer of services
to the customer.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Revenue is recognized only when:</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"></td>
    <td style="width: 0.25in">1.</td>
    <td>A valid contract exists;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"></td>
    <td style="width: 0.25in">2.</td>
    <td>The Company has transferred control of compute services to the customer; and</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"></td>
    <td style="width: 0.25in">3.</td>
    <td>Collection of consideration is considered probable.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Digital assets received from customers is non-cash consideration and is
initially measured at fair value at contract inception. Any subsequent changes in the fair value of digital assets held by the Company
are accounted for in accordance with the Company&#8217;s accounting policy for digital assets, and do not affect the amount of revenue
recognized.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_846_ecustom--DescriptionOfAccountingPolicyForAccountsReceivableExplanatory_zu3ay1vP4sj2" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zLn2ovINO1J3">Accounts
Receivable</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are recognized when the Company has an unconditional right
to consideration, which generally arises upon the invoicing of compute services or when contractual billing milestones are met. Trade
receivables are initially measured at fair value, which is typically equal to the invoiced amount or the fair value of digital assets
consideration to be received.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are subsequently measured at amortized cost, as they are
held solely for the collection of contractual cash flows (or cash-equivalent consideration). Trade receivables are presented net of any
allowance for expected credit losses. To the extent that invoices are settled directly in digital assets prior to the end of the reporting
period, no trade receivable is recognized, and the digital asset is recognized in accordance with the applicable accounting policy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory_zepWZP7ECA94" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_864_zjiJsipzIskk">Expected
Credit Losses</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company applies the simplified expected credit loss (ECL) model under
IFRS 9, &#8220;<i>Financial Instruments</i>.&#8221; Under this approach, lifetime expected credit losses are recognized at initial recognition
and updated at each reporting date. Expected credit losses are estimated based on:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Historical credit loss experience;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Current customer payment behavior, including digital asset settlement history; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Forward-looking information that is relevant to customer credit risk.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are written off when there is no reasonable expectation
of recovery.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_842_ecustom--DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory_z4OVvBWBvuW3" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zV9xTkm552P5">Property,
Plant, and Equipment</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for property, plant and equipment in accordance with
IAS 16, &#8220;<i>Property, Plant and Equipment</i>.&#8221; The Company&#8217;s property, plant and equipment consist solely of GPUs used
in the provision of compute services under compute offtake agreements. GPUs are recognized as property, plant and equipment when:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>It is probable that future economic benefits associated with the asset will flow to the Company; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>





















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>The cost of the asset can be measured reliably.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">GPUs are initially measured at cost, which includes:</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>The purchase price, net of discounts or rebates;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Non-refundable taxes and duties;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Directly attributable costs necessary to bring the GPUs to the location and condition necessary for them to be capable of operating as
        intended by management (including transportation, installation, testing, and configuration costs); and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Any other expenditures directly attributable to preparing the GPUs for their intended use.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Costs incurred after GPUs are capable of operating as intended are expensed as incurred,
unless they meet the criteria for capitalization under IAS 16.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Following initial recognition, GPUs are carried at cost less accumulated
depreciation and accumulated impairment losses. The Company applies the cost model to all classes of property, plant and equipment. GPUs
are depreciated on a straight-line basis over their estimated useful lives, beginning when the assets are available for use, which is
when they are installed and ready for their intended operating condition. Management estimates the useful lives and residual values of
GPUs based on expected technological obsolescence, performance degradation, and expected usage patterns. Useful lives and residual values
are reviewed at least annually and adjusted prospectively when warranted.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">GPUs are derecognized upon disposal or when no future economic benefits
are expected from their use or disposal. Any gain or loss arising on derecognition is recognized in profit or loss and represents the
difference between the proceeds received and the carrying amount of the asset.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Deposits paid to suppliers for the future purchase of GPUs are recognized
as prepayments or other non-current assets, depending on the expected delivery date, and are not depreciated. Such deposits are initially
measured at the amount paid and reassessed at each reporting date to determine whether there is objective evidence that the deposit may
be impaired, including supplier non-performance or changes in expected delivery terms. Upon delivery and acceptance of the GPUs, deposits
are reclassified to property, plant and equipment as part of the cost of the related GPUs. If a purchase contract is terminated or delivery
becomes improbable, the deposit is written down to its recoverable amount, with any impairment recognized in profit or loss.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zzoCCzFQ5kDc" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86F_zK6NvyGkmJvk">Recent
Accounting Pronouncements</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(a)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21: The Effects of
Changes in Foreign Exchange Rates</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In August 2023, the IASB amended IAS 21, &#8220;The
Effects of Changes in Foreign Exchange Rates&#8221; (&#8220;IAS 21&#8221;) to clarify when a currency is exchangeable into another currency
and how a company estimates a spot rate when a currency lacks exchangeability, requiring consistent assessment and disclosure practices
for companies. The amendments are effective for annual reporting periods beginning on or after January 1, 2025, with early adoption permitted.
However, an entity cannot restate comparative information. The adoption of these amendments did not have a material effect on the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(b)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21 &#8211; Lack of
Exchangeability</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">An entity is impacted by the amendments to IAS 21, &#8220;<i>The Effects
of Changes in Foreign Exchange Rates</i>,&#8221; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The adoption of these amendments did not have a material effect on the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>New IFRS Accounting Standards not yet effective</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Standards issued but not yet effective up to the date
of issuance of the Company&#8217;s consolidated financial statements are listed below. This is of standards and interpretations issued,
which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes effective.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(a)&#160;&#160;&#160;&#160;&#160; IAS 18: Presentation and Disclosure in
Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In April 2024, IFRS 18, &#8220;<i>Presentation and
Disclosure in Financial Statements</i>&#8221; (&#8220;IFRS 18&#8221;) was issued. IFRS 18 replaces IAS 1 and introduces significant changes
to the presentation of financial statements to enhance comparability across entities. The key requirements of the standard include:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Separate reporting of operating, investing, and financing activities in the statement of earnings, with prescribed
        subtotals for each category.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Disclosure of management-defined performance measures in a dedicated note within the financial statements.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The standard is effective for annual reporting periods
beginning on or after January 1, 2027, with retrospective application required. The Company intends to assess the impact of IFRS 18 on
its consolidated financial statements closer to the effective date. The effect of the new standard, however it may be, will only affect
matters of presentation and disclosure.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(b) Amendments to IFRS 9 and IFRS 7</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On May 30, 2024, the International Accounting Standards
Board (the IASB or the Board) issued Amendments to IFRS 9 and IFRS 7, <i>Amendments to the Classification and Measurement of Financial
Instruments</i>. The amendments:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify that a financial liability is derecognized on the &#8220;settlement date&#8221;, i.e., when the related
        obligation is discharged or cancelled or expires or the liability otherwise qualifies for derecognition. They also introduce an accounting
        policy option to derecognize financial liabilities that are settled through an electronic payment system before settlement date if certain
        conditions are met.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental,
        social and governance (ESG)-linked features and other similar contingent features.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify the treatment of non-recourse assets and contractually linked instruments (CLI).&#8217;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that
        reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive
        income (FVTOCI).</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The standard is effective for annual reporting periods
beginning on or after January 1, 2026, with retrospective application required. The Company intends to assess the impact of the Amendments
to IFRS 9 and IFRS 7 on its consolidated financial statements closer to the effective date.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS</a></td>
<td class="text"><p id="xdx_802_eifrs-full--DisclosureOfOtherAssetsExplanatory_z8cxegF9nPB3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 5. <span id="xdx_82C_zUyHCb0h4r91">PREPAID
EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">At March 31, 2026 and 2025, prepaid expenses and other receivables
were comprised of the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z7PSXYzVUWh4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B3_zBTiNLsL1tF3" style="display: none">Schedule
        of prepaid expenses and other receivables</span></td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20260331_z9Ua6NdEC7Q3" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20250331_zQAmhQj4bWBb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_zIRNVvM77ce7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td>
    <td style="width: 1%; font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">192</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentAdvancesToSuppliers_iI_zQv0n1zLtdE5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">595</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">241</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentPrepaidExpenses_iI_zjZfbtSMhbb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">567</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">42</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidInvestorRelations_iI_zRbsssHADf6g" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid investor relations</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">534</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TaxDeposits_iI_zjx42jxiEREi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">68</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">68</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PrepaidGpuInfrastructureCosts_iI_zUSNVdDOcRWb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid GPU infrastructure costs</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PrepaidGpuLeasesShortterm_iI_zg8pSOSwroF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid GPU leases, short-term</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--OtherCurrentReceivables_iI_zmSrzmJLGY4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Other receivables</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">220</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">12</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalPrepaidExpensesAndOtherReceivables_iI_zW8WIRSq50ma" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;&#160;Total prepaid expenses and other receivables</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,984</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">555</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, other assets consists of the long-term portion of
the prepaid investor relations contract in the amount of $<span id="xdx_90F_ecustom--OtherAssetsLongTermPortion_iI_pn3n3_dm_c20260331_zURFV8E1uB5f" title="Other assets long term portion">0.7</span>
million and security deposits of $<span id="xdx_90D_ecustom--SecurityDeposits_iI_pn3n3_dm_c20260331_zZ5uTCLcU4xg" title="Security deposits">2.6</span>
million.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STABLECOIN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureStablecoinAbstract', window );"><strong>Disclosure Stablecoin Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfStablecoinExplanatory', window );">STABLECOIN</a></td>
<td class="text"><p id="xdx_80B_ecustom--DisclosureOfStablecoinExplanatory_zwM9XzBhgUe2" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 6. <span id="xdx_823_zVN9tj7Zfm8l">STABLECOIN
</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At March 31, 2026 and 2025, the Company&#8217;s stablecoin holdings were
comprised of the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--DisclosureOfStablecoinTableTextBlock_pn3n3_zDroblQh1KVb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BF_z0l09Yg7OyE8" style="display: none">Schedule of stablecoin</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49B_20260331_zIL509oZDWob" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_494_20250331_zxkMAHWSWtca" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">USDC</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zMbx5Il6jge3" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1272">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zPwhDNdhBP7l" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1274">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">USDT</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zOhsY8Mw4WGc" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins">21</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zql3bii6Mp6" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1278">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_ecustom--Stablecoins_iI_c20250331_z4TOuebvc49" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins">21</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_ecustom--Stablecoins_iI_c20260331_zDVgP5X5jJU5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1282">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8AE_zCITyjbP5dRj" style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table summarizes the Company&#8217;s stablecoin purchases,
contributions, uses in the course of business, and sales for the fiscal year ended March 31, 2026 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfStablecoinPurchasesTableTextBlock_pn3n3_zCPT68n3dJUe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_z01UQdLF6AW3" style="display: none">Schedule of stablecoin purchases</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdcMember_zszXBmIapAeh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_494_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdtMember_zTifHJG5VV15" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49D_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zkhECywZeAF2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USDC</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USDT</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_408_ecustom--DigitalAssetValueAsOfApril1_zdaHJ180F3W7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1286">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1287">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ContributionOfStablecoin_zQ1NKlxvcxtj" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Contribution of Stablecoin</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">5,411</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">10</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">5,421</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromSaleOfDigitalAssets_zWpUAQ0gLn3d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Proceeds from sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StablecoinUsedToSettleOperatingCosts_zMMPbm9i27Pg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin used to settle operating costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,413</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(311</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,724</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--StablecoinSold_zYbNqw9JvaN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin sold</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromExternalDebtDrawdown_zkNJPjYqrzgf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Proceeds from external debt drawdown</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1307">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PurchasesOfStablecoin_zzRBfZerqzD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Purchases of stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">311</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">311</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StablecoinUsedToPurchaseDigitalAssets_zR02CfRYYGVk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Stablecoin used to purchase digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(2,998</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(10</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(3,008</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--StablecoinValueAsOfMarch31_zeHxYBKMY9vi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Stablecoin value as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8AA_zsS0c3ZQVmC3" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company did not hold or transact stablecoins during
the fiscal year ended March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s stablecoins are a digital asset intended to maintain
a stable value by tracking the U.S. dollar on a 1:1 basis. Stablecoins are held for use in business operations and not for the purpose
of potential asset appreciation and is therefore classified as a current asset within the consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfStablecoinExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfStablecoinExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureStablecoinAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureStablecoinAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DIGITAL ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureDigitalAssetsAbstract', window );"><strong>Digital Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfDigitalAssetsExplanatory', window );">DIGITAL ASSETS</a></td>
<td class="text"><p id="xdx_801_ecustom--DisclosureOfDigitalAssetsExplanatory_zrqYrphGTdd9" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 7. <span id="xdx_825_zkbTVcyO6Jf">DIGITAL
ASSETS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">At March 31, 2026 and 2025, digital assets were comprised of the
following (in thousands, except for number of tokens held):</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfDigitalAssetsTableTextBlock_pn3n3_z3pEYyiac4Jh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BC_zuVJO3TDndrg" style="display: none">Schedule of Digital
        assets</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49B_20260331_zAXsHqW0ntgh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20250331_zxA7HCg3cAi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_407_ecustom--ApproximateNumberOfTonTokensHeld_iI_zzFNPsubLrA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Approximate number of TON Tokens held</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,379,165</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TonTokensFairValueInThousands_iI_zvYPqCKZZ2f8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">TON Tokens, fair value (in thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetsFairValueInThousands_iI_zuaZyf59SBQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Digital assets, fair value (in thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8AB_z1q1HbI3nHh6" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At March 31, 2026, digital assets totaling $<span id="xdx_906_ecustom--DigitalAssets_iI_pn3n3_dm_c20260331_zpdsVS7oEZQg" title="Digital assets">2.5</span>
million were managed under the Alpha Sigma Capital asset management agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table summarizes the Company&#8217;s digital asset purchases,
contributions, unrealized gains (losses) on digital assets, sales of digital assets, and other movements for the fiscal year ended March
31, 2026:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>



<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfDigitalAssetsPurchasesTableTextBlock_pn3n3_zKfnHMmBCzlf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zkP3GrCNTvCi" style="display: none">Schedule of digital
        assets purchases</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TONMember_zd8TfTnhN7ji" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49F_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--BITCOINMember_zM2OwWS2qjU6" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_493_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TotalMember_zQOXlnavBZh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">TON</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Bitcoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetValueAsOfApril1_zUMU1tikAXeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ContributionOfDigitalAssets_zgXE3BDzJB12" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left">Contribution of digital assets</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,382</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">420</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,802</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_zTL2wJuiwzLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Unrealized losses on digital assets recognized in Statement of Operations</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,411</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,411</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetsSold_zcpSrncvI5Ki" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets sold</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,921</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,921</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--PaymentsOnExternalDebtUsingDigitalAssets_zC2H8lfm4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Payments on external debt using digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,825</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,825</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DigitalAssetPurchases_zpNiTxlPdBb3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital asset purchases</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">3,617</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">3,617</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ReceiptOfDigitalAssetsReceivable_z7DwOCQZ5Xw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Receipt of digital assets receivable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">6,667</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">6,667</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RealizedLossGainOnSaleOfDigitalAssets_zK1izA3o06m3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Realized (loss) gain on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,705</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">5</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,700</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--RealizedLossOnNovationOfDigitalAssetsToInvestor_zxXJjlqha4Dj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Realized loss on novation of digital assets to investor</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(676</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(676</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--RevenueReceivedInDigitalAssets_zknQslf53Sja" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Revenue received in digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">69</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1380">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">69</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TokensUsedToSettlePutRights_zgQX1EHZysVe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tokens used to settle put rights</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,130</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1384">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,130</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--DigitalAssetsExchanged_z4PcFalkmFIb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets exchanged</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">425</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(425</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DigitalAssetsTransacted_zqOOtx4zbm52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Digital assets transacted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"></td></tr>
  <tr id="xdx_401_ecustom--DigitalAssetValueAsOfMarch31_ztI6Q7YPWhS5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Digital asset value as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1396">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8AA_z60UO6ChWQjb" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company did not hold or transact Digital assets during the fiscal year
ended March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company valued the TON treasury at $<span id="xdx_904_ecustom--TonTokensReceivable_iI_pn3n3_dm_c20260331_zAJSUyfVuhei" title="TON tokens receivable">1.22</span>
per liquid token as of March 31, 2026. The Company did not hold digital assets as of March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has 2,277,108 TON tokens that are locked under vesting contracts
at March 31, 2026. The following table summarizes the unlocking schedule of TON tokens currently locked as of March 31, 2026:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--SeheduleOfTonTokensTableTextBlock_pn3n3_zaUme3yub7E5" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - DIGITAL ASSETS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20260331_zA4T0ZBkQ7Z8" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CapitalFutureMinimumPaymentsRemainderOfFiscalYear_iI_zcdYkOvwbux" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Fiscal 2027</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,121,493</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CapitalFutureMinimumPaymentsRemainderOfSecondYear_iI_zysjIrexSmR5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fiscal 2028</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">986,077</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CapitalFutureMinimumPaymentsRemainderOfThirdYear_iI_zwr72ctBdXM5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fiscal 2029</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">169,538</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CapitalFutureMinimumPaymentsRemainderOfTotalYear_iI_z30jfsuDEpy9" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">total&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,277,108</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A4_zz0zQdlPZnEf" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Of the <span id="xdx_90E_ecustom--TonTokensReceivableShares_iI_c20260331_znhLoPheLGtk" title="TON tokens receivable shares">2,277,108</span>
locked TON tokens as of March 31, 2026, <span id="xdx_90C_ecustom--TokensArePayable_iI_c20260331_zRNPwJbK48Se" title="Tokens are payable">336,665</span>
tokens are payable to investors following the exercise the investors&#8217; respective put rights.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company valued the TON tokens at $1.04 on average per locked token as
of March 31, 2026. The Company did not hold digital assets as of March 31, 2025. The aggregate fair value of locked tokens is computed
by taking the number of locked tokens and discounting the month-end spot price by an average of 14.8%. The discount used by management
is based on the historical purchases of locked TON management has made on behalf of the Company and Monte Carlo simulation based on estimated
volatility during the lockup period (Level 3 inputs). Management monitors this discount percentage and adjusts when appropriate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s liquid digital assets are routinely transacted with
in the ordinary course of business and are therefore classified as current assets within the consolidated statements of financial position.
Locked tokens are classified as current or noncurrent assets within the consolidated statements of financial position based on when the
locked tokens vest and become available for use by the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureDigitalAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureDigitalAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfDigitalAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfDigitalAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract', window );"><strong>Property Plant And Equipment And Right-of-use Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock', window );">PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS</a></td>
<td class="text"><p id="xdx_809_ecustom--PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock_z7O8ztP9O2v1" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
9. <span id="xdx_826_zBhRRpIPV172">PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The table below presents the carrying value of property, plant, and equipment,
equipment deposits, and right-of-use assets (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>





<table cellpadding="0" cellspacing="0" id="xdx_89C_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_pn3n3_ztWFvZBQHXNa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zUEvq8NNxXGl" style="display: none">Schedule of property, plant, and equipment,
        equipment deposits, and right-of-use assets</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_zpW4srsOHWL1" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zOnbMazTo1Z6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zPP5zmGgsKJ7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_z0jwmooRmGTl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">COST</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_438_c20240401__20250331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_zCTFEcOZ6IM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt">As of March 31, 2024</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1450">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1451">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">84</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">84</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zg68a3YI6A85" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fixed asset additions</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1455">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1456">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1457">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_zWY57ySxhiGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1460">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_z8Lok5wLuKvi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1465">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1466">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1468">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zPXQ9xd60kh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fixed asset additions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,373</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">9,308</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">516</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">11,197</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_ziH7HqU6haxg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1475">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1476">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1477">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1478">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iE_zEwPtn0uZyJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">As of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,373</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">9,308</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">516</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">11,197</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z3vBMaS9FRxi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zfy107r1kwd9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zqFkM2sQsBIl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_zkDXC4qinAA6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">ACCUMULATED DEPRECIATION</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_43A_c20240401__20250331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_z0e0RyH1FQq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt">As of March 31, 2024</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1485">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1486">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(40</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(40</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetDepreciation_zIGD6dCaVfU3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fixed asset depreciation</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1490">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1491">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(44</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(44</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--FixedAssetDisposals_z0MSpfjD5gR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1496">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_zEzZGIh1qSoe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1500">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1501">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetDepreciation_zTXbCosnHwS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fixed asset depreciation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(90</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(103</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(193</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--FixedAssetDisposals_zwFuT7n1Ixyg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1510">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1511">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_zGybfrJU1RL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">As of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(90</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1516">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(103</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(193</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z6WN0UwAJsDe" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_znNzd4DstTl9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zbSlImS7E54" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_ztw4gyvKNWk2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">CARRYING AMOUNT</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_z7Cw7T0yUl3a" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1520">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zhkTwUokACy2" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1522">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zmwSDbI5sjb4" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1524">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zRVR3abWyjxb" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1526">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">As of March 31, 2026</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_zc5BNZvguBda" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">1,283</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zVOZIVXCuQZ6" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">9,308</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zxmNqs7SUpI7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">413</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zEHjO1yjB92k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">11,004</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A0_zfrjX2YHNj1j" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">* Refer to Note 13 for additional information on the Company&#8217;s office
lease.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN COMPEDICA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentPropertyExplanatory', window );">INVESTMENT IN COMPEDICA</a></td>
<td class="text"><p id="xdx_80A_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_zZ04UqplP3V7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10.
<span id="xdx_82A_zKzSf8mpwIzf">INVESTMENT IN COMPEDICA</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On June 5, 2025, the Company acquired an equity interest in Compedica, Ltd.
("Compedica"), a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby the Company acquired a 6.0% interest in Compedica, valued at $5.0 million
plus $<span id="xdx_906_eifrs-full--ExpectedReimbursementOtherProvisions_iI_pn3n3_dm_c20250605_zoDQP8rxrp75" title="reimbursement of expenses">0.1</span>
million for reimbursement of expenses to Compedica to close the transaction, and Compedica obtained a corresponding 27.4% interest in
the Company and is accounted for under the equity method as it was determined that the Company has significant influence over Compedica
due to the interconnected nature of the ownership of the respective entities. Compedica&#8217;s interest in the Company was subsequently
diluted to 11.9% as a result of the shares issued under the private placement occurring in September 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company records its share of earnings and losses in Share of losses
from equity method investment within the consolidated statements of operations and other comprehensive income (loss). The Company recorded
a loss of less than $0.1 million for the fiscal year ended March 31, 2026, based on its share of Compedica's losses through the date significant
influence was lost as explained further below. The equity method investment is presented within "Investment in Compedica" on the
consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 25, 2025, in connection with the transition of the Company
to being primarily a digital asset treasury, Alpha Compute lost significant influence over Compedica and discontinued its use of the equity
method to account for its investment. Commencing on the date that significant influence was lost, the Company began accounting for its
investment as a financial instrument within the scope of IFRS 9 with changes in the fair value of its investment reflected as other income
(loss) within the consolidated statements of operations and other comprehensive income (loss). Subsequent to the discontinuing of the
equity method of accounting for Compedica, the fair value of the investment used by management is based on multiples analysis of publicly
traded comparable companies as Compedica is pre-revenue, as well as its holdings in the Company&#8217;s own ordinary shares (Level 3 inputs).
A loss on impairment of $<span id="xdx_902_eifrs-full--ImpairmentLoss_pn5n6_c20250401__20260331_zcvyWJaYfmxk" title="Loss on impairment">4.8
</span>million was recognized as a result of the loss of significant influence.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#8217;s treasury and the investment being exited. As a result, the Company recognized less than $0.1 million in treasury stock
at the time the return of shares was agreed upon, the fair value of the investment as of February 6, 2026. Following the loss of control
through the exit of the investment, the Company recognized a loss on the change in fair value on the investment in Compedica of $<span id="xdx_90E_ecustom--ChangeInFairValueOnInvestmentInCompedica_iI_pn3n3_dm_c20260206_z0aQaLApZEug" title="Change in fair value on the investment in Compedica">0.2</span>
million. The 625,000 shares of the Company were returned to our treasury on May 21, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Movements in the investment balance during the fiscal year ended March 31,
2026 were as follows (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfInvestmentBalanceTableTextBlock_pn3n3_zlJhjYcJHsR4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN COMPEDICA (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BC_zby3KgmHFTqi" style="display: none">Schedule of investment
        balance</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49C_20250401__20260331_zlOCaXX9QW9g" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_405_ecustom--BalanceAsOfApril1_zzHazQlxorCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--InitialInvestmentInCompedica_zYkc03g0jWq" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Initial investment in Compedica</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">5,050</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LossFromEquityMethodInvestment_iN_di_zahSCSUDA4B6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(44</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LossOnImpairment_zkQbgSipdHD3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss on impairment</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(4,804</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfInvestmentInCompedica_z19ccBbFNYO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(182</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ReturnOfInvestmentInterestToCompedica_zdzWDw93edO" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Return of investment interest to Compedica</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(20</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--InvestmentInCompedicaAsOfMarch31_zn3p4WeVfAn8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Investment in Compedica as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1561">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A6_zpwusgx72k89" style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentPropertyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS40_g74-79_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentPropertyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfWarrantLiabilityExplanatory', window );">WARRANT LIABILITY</a></td>
<td class="text"><p id="xdx_808_ecustom--DisclosureOfWarrantLiabilityExplanatory_zPnG3vE8Xcj4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 11. <span id="xdx_82E_zvjKfFiDvhNl">WARRANT
LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The number of warrants and exercise price information herein have been retroactively
adjusted to reflect the impact of the reverse stock split. See Note 1 &#8220;Nature of Operations&#8221; and Note 17, &#8220;Capital Stock
and Reserves&#8221; for further discussion on the reverse stock split.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following table summarizes the changes in the warrant liability
during the fiscal years ended March 31, 2026, 2025, and 2024:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zSJ5yKM1rq49" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;<span id="xdx_8B4_zOtX7osxSNha" style="display: none">Schedule of changes in the warrant
        liability</span> </td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise
        Price</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fair Value
        Balance</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt">Fair value of warrants at issuance on October 3, 2023:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Class B Warrants</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_z14U3yUSXJNh" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zK7pB4o7jgcf" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants shares">157,895</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_fKDEp_zllTebPXe23f" title="Fair value of warrants amount">3,537</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Class C Warrants</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98F_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zZqwBvXW4Ou1" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zF0SOg9UzJKb" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares">157,895</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_fKDEp_zfxB5j3Xzxyi" title="Fair value of warrants amount">4,663</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Placement Agent Warrants</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98A_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziFZ91lO4No4" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price">47.50</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqB6XUDfY1ib" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares">7,896</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zKQVysaZxH3e" title="Fair value of warrants amount">232</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_zqtHTdLnVvM9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount">(6,868</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrant liability as of April 1, 2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20250331_zhCdCZ7VkcPa" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending">323,686</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_985_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20250331_z6bRcsRO5bu1" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending">1,564</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20250331_zvb4yxb3qUW" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount">388</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrant liability as of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20250401__20260331_zAn9IrmUx4c" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending">323,686</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_987_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20250401__20260331_zXKrm1Z1oqRl" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending">1,952</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold">Fair value of warrants at issuance on January 27, 2026:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Placement Agent Warrants</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqGukfYAhsNa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">1.25</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zExFn0kJ4wUc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">1,050,000</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zcGJf8jsozm4" title="Fair value of warrants amount">1,123</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20250401__20260331_ztiBIMoimCGd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">(2,883</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrant liability as of March 31, 2026</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--WarrantsLiabilityShares_iE_pip0_c20250401__20260331_zP0o7uHf3ANj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending">1,373,686</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_981_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20250401__20260331_zoyisK1hdM8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, fair value at ending">192</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A0_zYmtGb15ZT0l" style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series B Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-indent: 0.5in">A fair value of $<span id="xdx_908_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zdWGdTOdKe33" title="Fair value of warrant per share">22.40</span>
per each Series B Warrant was estimated at the issue date of October 3, 2023. A fair value of $<span id="xdx_90C_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zML2kunHQvE4" title="Fair value of warrant per share">0.00</span>
and $<span id="xdx_905_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zLXUTsdR3qqh" title="Fair value of warrant per share">5.65</span>
per each warrant has been identified as of March 31, 2026 and 2025, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_894_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zbBkvky6ahpb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B0_z7H6GUTire6" style="display: none">&#160;Schedule of inputs
        associated with calculating the fair value</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcNWdnKA7t1h" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcMANoGEFI6" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zvyaleOiJoij" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrFeYkgCqag3" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBI4iPKaOJHg" title="Share price">9.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zOrTS1j4RgTl" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zmUJEZZIZuc" title="Expected life">3.01</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zbsUkU7mGR4a" title="Expected life">1.51</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zv2etxEPHTLc" title="Expected life">0.51</span></b></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zRNSZr9Bsyke" title="Expected volatility">90.4</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBLER54ju4x2" title="Expected volatility">207.73</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zGmE7X8gkY7h" title="Expected volatility">85.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zVHBmmT4Tp8h" title="Risk free interest rate">4.95</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zM5h9A2Z0Qd3" title="Risk free interest rate">3.96</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zFFewYVR6R3a" title="Risk free interest rate">3.65</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zm1zYIyIC7N4" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1650">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEIaEviJaoxi" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1652">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z0PrTeT67bw9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AE_zlDGzZ3JoRZ2" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series C Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A fair value of $<span id="xdx_90A_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_z5lV7XrevEIc" title="Fair value of warrant per share">29.60</span>
per each Series C Warrant was estimated at the issue date of October 3, 2023. A fair value of $<span id="xdx_902_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_zGuWmpHCDq37" title="Fair value of warrant per share">0.00</span>
and $<span id="xdx_900_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_zw3h8fUfUFC2" title="Fair value of warrant per share">6.40</span>
per each warrant has been identified as of March 31, 2026 and 2025, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_zHEeq0KcG7Nh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BA_zNeBUyzvjDYi" style="display: none">Schedule of fair value</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7CNQyvZbpx1" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7Hzf0fZPJHk" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zjwJkg7CCLv2" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zviTyKgs47jj" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHQ1bHUhjjFh" title="Share price">9.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zcltZ3A3DHUg" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zS3YhwfRInCc" title="Expected life">5.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zwfYlASTWvZk" title="Expected life">3.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zMOMU1FAanz3" title="Expected life">2.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zmtNXmZHp5Yg" title="Expected volatility">100.7</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zVoQrwL8D1wi" title="Expected volatility">152.01</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z0oIs26uJvz4" title="Expected volatility">95.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zh1OWyqxbWui" title="Risk free interest rate">4.80</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4scHsvnC34f" title="Risk free interest rate">3.91</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7jZajot0X8f" title="Risk free interest rate">3.73</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zlJFTptLrip9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zztiSm7DHUbh" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1696">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zQlFOIhDXNG1" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1698">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AC_zNvEScPOlZli" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>2023 Placement Agent Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A fair value of $<span id="xdx_907_ecustom--FairValueOfWarrantPerShare_iI_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zp4vbltIl7P" title="Fair value of warrant per share">29.40</span>
per each 2023 Placement Agent Warrant was estimated at the issue date of October 3, 2023. A fair value of $<span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zzwBi5irKrEd" title="Fair value of warrant per share">0.00</span>
and $<span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7vpi84hlblg" title="Fair value of warrant per share">6.34</span>
per each warrant has been identified as of March 31, 2026 and 2025, respectively.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory_z0WMoHkN2ua8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B7_zdxKP3McVBCi" style="display: none">Schedule of Placement agent warrants</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsGPaZikPNz5" title="Exercise price">47.60</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zZIC6pi2wQ0i" title="Exercise price">47.50</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcJncvXobtOc" title="Exercise price">47.50</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGPqkcKIacvc" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zbKildqYSvU9" title="Share price">9.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zTZfbXr7F0O8" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKrk0SpAaIth" title="Expected life">4.99</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zilGNvCPG75l" title="Expected life">3.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWOGkooFnHW7" title="Expected life">2.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z3WsBb78muC1" title="Expected volatility">100.7</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zUSXXPL9Rkdf" title="Expected volatility">152.01</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z1axsY3Lm7h5" title="Expected volatility">95.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsQkgNMI2bc" title="Risk free interest rate">4.80</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zEzRqFTHCrCe" title="Risk free interest rate">3.91</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8OQj2rILoJd" title="Risk free interest rate">3.73</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zk25m7D81mwh" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zVbfQKyutFzi" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMWBmMUg5oN9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A7_zMovU1XiikA" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>2026 Placement Agent Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A fair value of $<span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zrPVyWvLZLn2" title="Fair value of warrant per share">1.07</span>
per each 2026 Placement Agent Warrant was estimated at the issue date of January 19, 2026. A fair value of $<span id="xdx_908_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrants2026Member_zbAbw8GA52f2" title="Fair value of warrant per share">0.18</span>
per each warrant has been identified as of March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The inputs associated with calculating the fair value are reflected
below.</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementPlacementAgentExplanatory_z8nF7hZ9QcQ7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_z1jn5tB36Ll8" style="display: none">Schedule of 2026 placement
        agent warrants</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">January
        19, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--ExercisePriceFairValue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw8zpZbvkl1e" title="Exercise price">1.25</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zyrEA4PyGcIi" title="Exercise price">1.25</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_ecustom--SharePriceFairvalue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zCQwB50xVWX8" title="Share price">1.30</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zNeHaoLISPfj" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9hgK6z2usf" title="Expected life">5.0</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zoTZ4ibQOFdk" title="Expected life">4.79</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zq6YJfRZVQy4" title="Expected volatility">115.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zfwXAkArfdR9" title="Expected volatility">105.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8O8MSDk6kic" title="Risk free interest rate">3.68</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zrNAFmyLNYC7" title="Risk free interest rate">3.83</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zaPQDYAdUsOk" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1770">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_za1yL1zZIOEk" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1772">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AE_zBa8c1qZbeed" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfWarrantLiabilityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfWarrantLiabilityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PUT RIGHT LIABILITY AND TON PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract', window );"><strong>Put Right Liability And Ton Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory', window );">PUT RIGHT LIABILITY AND TON PAYABLE</a></td>
<td class="text"><p id="xdx_803_ecustom--DisclosureOPutRightLiabilityAndTonPayableExplanatory_z07eYSeNTsjj" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
12. <span id="xdx_82A_zuEEucpkJCY2">PUT RIGHT LIABILITY AND TON PAYABLE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 2, 2025, the Company entered into five Side Letter Agreements
(&#8220;Side Letters&#8221;) with certain investors to repurchase its outstanding ordinary shares, as well as pre-funded warrants to purchase
ordinary shares held by these investors at the option of the holders and on August 25, 2025, the Company entered into a Treasury Management
Agreement with DWF MaaS Limited (&#8220;DWF&#8221;) whereby DWF is entitled to convert the Ordinary Shares it subscribed for in the September
2025 private placement into an equivalent value of TON from the amount of TON held by DWF on behalf of the Company up to a maximum value
of $15.0 million (collectively, the &#8220;Contingent Put Options&#8221;). <span id="xdx_90B_ecustom--TreasuryManagementAgreementDescription_c20250401__20260331_zZ9hVwnMMisa" title="Treasury Management Agreement description">A
total of 2,266,890 and 265,000 ordinary shares and an additional 745,226 and 2,513,240 pre-funded warrants to purchase ordinary shares
were subject to repurchase as defined within the Side Letters and Treasury Management Agreement, respectively, with various right expiration
dates between March 2026 and September 2026. In the event the holders exercise their Contingent Put Options, the Company is obligated
to settle the contract by transferring the same amount of USDC, Liquid TON, or Locked TON based on the Original Consideration within each
Side Letter or Treasury Management Agreement with no adjustment for value. As of September 30, 2025, a total of 2,531,890 ordinary shares
and an additional 3,258,466 pre-funded warrants to purchase ordinary shares were still subject to repurchase on various settlement dates
through September 2026.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The fair value of the put right liability is estimated
using a Black-Scholes model and in certain cases, a Monte Carlo simulation. The weighted average assumptions used to value the Side Letter
put rights at inception and as of March 31, 2026 are as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock_pn3n3_zIddunfGqcRc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zrXKzoyKcZp8" style="display: none">Schedule of fair value
        of the put right liability estimated using a Black-Scholes model</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">September
        2, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">ALP shares and TON correlation factor</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20250902_zrhsWfzkS2cg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor">0.60</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20260331_zsboCpXxXzli" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor">0.10</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20250902_z195kcmK5ewe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price">6.96</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20260331_zjtJL9O38m4" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price">0.32</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Remaining term (in years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250829__20250902_zgpKwqXliCyj" title="Remaining term (in years)">0.75</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250401__20260331_zr7gRSLEwfG9" title="Remaining term (in years)">0.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected ALP volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902_zHgZF7d9rVxf" title="Expected ALP volatility">82.90</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331_z9MBYxO8IvT1" title="Expected ALP volatility">85.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250829__20250902_z18yGKKVtm09" title="Risk free interest rate">3.91</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331_zuDUQO9pypXi" title="Risk free interest rate">3.63</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">ALP dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250829__20250902_z2bPoYPz0Jyf" title="ALP dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331_z16FwPms4IIg" title="ALP dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1804">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON token price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_987_ecustom--TonTokenPrice_iI_pip0_c20250902_zAN6Q8YbDBn9" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price">3.11</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_ecustom--TonTokenPrice_iI_pip0_c20260331_z5jWLgPHY1Ma" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price">1.22</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON token volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zc1NOWV4TEr8" title="Expected ALP volatility">62.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zvd0uikAd9Ji" title="Expected ALP volatility">53.90</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Locked TON token discount for lack of marketability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250829__20250902_zCBHvDMCKXYg" title="Locked TON token discount for lack of marketability rate">19.30</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250401__20260331_zEN42IfWuxrj" title="Locked TON token discount for lack of marketability rate">14.80</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The fair value of the put right liability is most sensitive
to expected share price volatility, the value of the underlying digital assets, expected term and discount rate. An increase in expected
volatility, expected term or underlying digital asset values would result in a higher fair value measurement. An increase in the discount
rate would result in a lower fair value measurement. Management considered the interrelationship of these assumptions when determining
the fair value measurement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The DWF put right was capped at $<span id="xdx_900_eifrs-full--CurrentInterestReceivable_iI_pn3n3_dm_c20260331_zKAyaNILcu4" title="Fair value of stablecoin receivable">15.0
</span>million, the fair value of the stablecoin receivable contributed, which corresponded to the aggregate fair value of the ordinary
shares and pre-funded warrants issued to DWF. Therefore, at inception, the DWF put right was determined to have a fair value of $15.0
million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At inception, the outstanding Contingent Put Options
were determined to have a fair value of $16.1 million, net of issuance costs of $2.0 million, which was included within Put right liability
within the Company&#8217;s consolidated balance sheet.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 8, 2025 and December 30, 2025, one Side
Letter put right and the DWF put right were exercised, respectively, and on March 24, 2026 and December 30, 2025, the contributed locked
TON tokens receivable in the amount of 1,114,130, with a fair value of $<span id="xdx_902_ecustom--FairValueOfContribution_iI_pn3n3_dm_c20251208_zi9zyN3RICOg" title="Fair value of contribution">2.5</span>
at contribution, and $<span id="xdx_90B_ecustom--Usd1Receivable_iI_pn3n3_dm_c20251208_zFn8D3KFL3v3" title="USD1 receivable">15.0</span>
million USD1 receivable were returned to the investor and DWF, respectively. In connection with the exercise of the Side Letter put right
on December 8, 2025, the Company recognized a loss on the exercise of $1.1 million, recognized as the difference between the fair value
of the TON contributed by the respective investor at the time of put exercise and the carrying value of the put right. When the locked
TON receivables were returned to the investor on March 24, 2026, the Company recognized a $0.4 million gain from the settlement of a portion
of the TON payable, recognized as the difference between the carrying value of the TON contributed by the respective investors at the
time the TON was returned to the investors and the fair value of the TON payable. As of March 31, 2026, the Company owes the investor
420,434 liquid TON tokens with a fair value of $0.5 million. When the USD1 receivable was returned to DWF on December 30, 2025, no such
gains or losses were recognized as USD1 is pegged to the U.S. dollar. Additionally, the Company terminated its Treasury Management Agreement
with DWF in connection with the return of DWF&#8217;s initial investment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On January 27, 2026 and March 19, 2026, one Side Letter
put right was partially exercised and a second Side Letter put right was fully exercised, respectively. In connection with the exercises
of the Side Letter put rights, the Company recognized a loss on the exercise of $<span id="xdx_907_ecustom--LossOnExercise_iI_pn3n3_dm_c20260127_znSdY4n71Gdb" title="loss on the exercise">0.4
</span>million, recognized as the difference between the fair value of the TON contributed by the respective investor at the time of put
exercise and the carrying value of the put right. The put rights were not settled during the fiscal year ended March 31, 2026 and as of
March 31, 2026, the Company owes the investors 369,278 liquid TON tokens and 453,125 locked Ton tokens receivable with fair values of
$0.5 million and $0.3 million, respectively, which corresponds to the fair value of the liquid and locked tokens to be returned to the
respective investors at March 31, 2026. The outstanding TON balances payable were settled and the TON tokens returned to the respective
investors in separate transfers on April 15, April 24, and April 28, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As of March 31, 2026, the outstanding Contingent Put
Options were remeasured to fair value of $<span id="xdx_90A_ecustom--OutstandingContingentPutOptionsFairValue_iI_pn3n3_dm_c20260331_zNmujS1Hj00d" title="Outstanding Contingent Put Options fair value">7.1</span>
million, with the remeasurement change in fair value of $<span id="xdx_90E_ecustom--RemeasurementChangeInFairValue_iI_pn3n3_dm_c20260331_zwOU7OuzWywk" title="Remeasurement change in fair value">6.0</span>
million recorded within other losses in the Consolidated Statements of Operations and Comprehensive Income (Loss).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The following table summarizes the changes in the put
right liability during the fiscal year ended March 31, 2026 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfPutRightLiabilityTableTextBlock_pn3n3_zDV6kJn48r9d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;<span id="xdx_8BA_zrd7CcyH9Nqh" style="display: none">Schedule of put
        right liability</span> </td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_zI5dL0OGoDy6" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_401_ecustom--BalanceOfPutRightLiability_zaWkEXp0qrEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_zaoCRQMYme17" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Put right recognition at contract inception</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">18,150</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--GainsLossesOnChangeInFairValueOfDerivatives_zyPmsHzo3NEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of put right liability, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">5,959</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProceedsFromExerciseOfOptions_zFTV2D5OOMT" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Exercise of side letter put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,920</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--SettlementOfDwfMaasLimitedPutRight_zR6kRtNdRtWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Settlement of DWF Maas Limited put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(15,000</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LossOnExerciseOfPutRightLiability_zoxN7NLCVRZf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss on exercise of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">916</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--PutRightLiabilityEndingBalance_zHmCFY1nPVij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Put right liability as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">7,105</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>








<p id="xdx_8AB_zGtOGLFdxRA7" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The following table summarizes the changes in TON payable
during the fiscal year ended March 31, 2026 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>






<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfTonPayableTableTextBlock_pn3n3_zdAZZDIkciB5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B7_zMjtOO9WIA6c" style="display: none">Schedule of TON payable</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_z5nOEyLqwnp5" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_407_ecustom--BalanceOfTonPayable_zZXYzpeNQcA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1852">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ExerciseOfSideLetterPutRightPayable_zt7S9e2GJCjb" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Exercise of side letter put right</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,920</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_iN_di_zn3xJzVG1Lnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(51</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--GainOnSettlementOfTonPayable_iN_di_z0cqKFLVZR3f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(336</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--SettlementOfPutRightLiabilityUsingDigitalAssets_iN_di_zvFzBjEs7nWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Settlement of put right liability using digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(1,108</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--TonPayableEndingBalanceAsOfMarch31_z5qhLQCmoKBh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">TON payable as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,425</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A9_z6rNMOcoI9K" style="margin-top: 0; margin-bottom: 0">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Accounts Payable And Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_803_ecustom--AccountsPayableAndAccruedLiabilitiesTextBlock_z59nQYgQ1B6h" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 13.
<span id="xdx_829_ztC318AGAszd">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">At March 31, 2026 and 2025, accounts payable and accrued liabilities
were comprised of the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zuBiDBB0PrP4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_zHYRDfycesC8" style="display: none">Schedule of accounts
        payable and accrued liabilities</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_492_20260331_z5S14yhvqA45" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331_zrj8TolvXpN6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccountsPayable_iI_zWeTCv2cvwGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,413</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">427</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedOtherProfessionalFees_iI_zokfs4wSvUad" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued other professional fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">262</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zjeBhK6CLhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued accounting and auditing fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">73</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">155</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_z4sLGMmf6tN4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued bonuses and other payroll-related expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">913</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">89</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedCRO_iI_zHNCOvDYDg2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1880">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">80</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProfessionalFeesExpenses_iI_zg7p3eGGJla9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued legal fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">414</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">60</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedClinicalAndRdServices_iI_zjEWa0vnkMU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued clinical and R&amp;D services</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">14</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CapitalExpenditures_iI_zsLMetrmU6T9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Capital expenditures</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">333</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherAccruedExpenses_iI_zGfBgATblded" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Other</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_zDwF6E6m6JXd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">5,504</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,100</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A9_zWulB43PTbTa" style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE LIABILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureLeaseLiabilityAbstract', window );"><strong>Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfLeaseLiabilityExplanatory', window );">LEASE LIABILITY</a></td>
<td class="text"><p id="xdx_801_ecustom--DisclosureOfLeaseLiabilityExplanatory_z9KmRbVR8QT3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 14. <span id="xdx_829_zvaoSzA5FLWd">LEASE
LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company entered into a lease of GPU equipment, which commenced on November
30, 2025 (the &#8220;GPU Lease&#8221;). The GPU Lease provided for an original term of one year, with the full balance paid at commencement
in the amount of $<span id="xdx_90B_ecustom--Commencement_iI_pn3n3_dm_c20251130_zI01nE8kweZi" title="Commencement">0.3</span>
million, with a purchase option exercisable at any point during the lease, with the purchase option being the remaining portion of the
GPU&#8217;s purchase price of $<span id="xdx_908_ecustom--PurchasePriceLeaseLiability_iI_pn3n3_dm_c20251130_zoACPsApa8Di" title="Purchase price">0.2</span>
million. On February 5, 2026, the Company exercised the purchase price for the GPU equipment with a payment of $<span id="xdx_902_ecustom--PurchaseEquipmentPayment_iI_pn3n3_dm_c20260205_zX9w3DdTcVzb" title="Purchase equipment payment">0.2</span>
million, however the validity of the purchase option was disputed by the GPU owner and the broker of the lease has not yet been able to
deliver the GPU in question. The Company is pursuing a refund for the purchase option price, and the amount due is included in prepaid
expenses and other receivables within the consolidated balance sheet as of March 31, 2026. As the full balance of the lease was paid at
commencement and the purchase option ultimately disputed, no interest expense was incurred on the lease. As of March 31, 2026, the Company
had no contractual commitments remaining on the GPU lease.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company entered into a lease of office space in Lisbon, Portugal, which
commenced on March 1, 2026 (the &#8220;Lisbon Lease&#8221;). The Lisbon Lease provided for an original term of two years with purchase
options at the end of the 12<sup>th</sup> and 24<sup>th</sup> months of the lease, with certain rent payments and option payments being
credited towards the purchase price if the option is exercised. The Company calculated the Lisbon Lease liability using its incremental
borrowing rate of 14.75%. The Company prepaid the first twelve months rent in the amount of EUR 84,000.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Lisbon Lease liability is payable as follows (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfLeaseLiabilityTableTextBlock_pn3n3_zyHnYTCitGr9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASE LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"><span id="xdx_8BF_ziAyf6haDmHi" style="display: none">Schedule
        of Lease liability</span></td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49F_20260331_zHueMHvmtzS" style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; color: #212529; font-weight: bold">Fiscal Year ended March 31,</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: center">Amount</td></tr>
  <tr id="xdx_40B_ecustom--LeaseLiabilityFutureMinimumPaymentsDue_iI_zTsB5kKZnvr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">2027</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">68</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LeaseLiabilityFutureMinimumPaymentsYearTwoDue_iI_zhc2Ggde5K81" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">2028</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">92</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LeaseLiabilityFutureMinimumPaymentsYearDue_iI_zZh0HG83xjWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold">Total</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">160</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--Interest_iI_zgG0B6A3tiCk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">Less: Interest</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">(22</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--TotalLeaseLiability_iI_zY5T9jBgSXvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">Total lease liability</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">138</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LeaseLiabilityCurrent_iI_zzvimpsFkTI5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">Lease liability - current</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">65</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LeaseLiabilityNoncurrent_iI_zGLcqpdlDgZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Lease liability - non-current</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">73</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A6_zDMMI7S1wOL" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfLeaseLiabilityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfLeaseLiabilityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BITGO PRIME LOAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureBitgoPrimeLoanAbstract', window );"><strong>Bitgo Prime Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfBitgoPrimeLoanExplanatory', window );">BITGO PRIME LOAN</a></td>
<td class="text"><p id="xdx_80E_ecustom--DisclosureOfBitgoPrimeLoanExplanatory_zGDH3das5ZEl" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. <span id="xdx_825_z1fcrPTvlYR5">BITGO
PRIME LOAN</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><span id="xdx_904_ecustom--MasterLoanAgreementDescription_c20250802__20250828_zJgY9dHZTQm2" title="Master Loan Agreement description">On
August 28, 2025, the Company entered into a master loan agreement (the &#8220;Master Loan Agreement&#8221;) with BitGo Prime, LLC (&#8220;BitGo&#8221;).
Pursuant to the Master Loan Agreement, the Company may borrow up to $35.0 million at an interest rate of 14.75% per annum with a 2.00%
origination fee paid upfront in the amount of $0.3 million. The Loan shall only be used to purchase liquid TON that will be delivered
to BitGo and such purchased liquid TON will also be pledged as collateral for the Loan. The outstanding loan balance must be repaid within
six months of the origination of the Loan, unless provided for otherwise or amended.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><span id="xdx_907_ecustom--MasterLoanAgreementDescription_c20251005__20251007_zn4PWtC6iFC8" title="Master Loan Agreement description">On
October 7, 2025, the Company received its initial draw on the Master Loan Agreement in the amount of $2.1 million. No further draws have
been made on the loan, and on November 25, 2025 the loan balance was paid down to $1.8 million. On January 9, 2026, the remaining balance
of the loan was paid down and the Master Loan Agreement was exited. In connection with the extinguishment of the Master Loan Agreement,
the Company derecognized $0.1 million of deferred financing, incurred $0.5 million in loan termination fees paid to BitGo, and had $0.8
million in accrued interest forgiven by BitGo for payment of the loan termination fees, resulting in a net gain on debt extinguishment
of $0.3 million being recognized within the Consolidated Statements of Operations and Comprehensive Income (Loss).</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureBitgoPrimeLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureBitgoPrimeLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfBitgoPrimeLoanExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfBitgoPrimeLoanExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_805_eifrs-full--DisclosureOfIncomeTaxExplanatory_zISa5cJIJr6f" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 16. <span id="xdx_820_z7MKXEC3mKok">INCOME
TAXES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company is a BVI business company. The
BVI government does not, under existing legislation, impose any income or corporate tax on corporations. PDS is a U.S. corporation and
is subject to U.S. federal, state and local income taxes, as applicable. iOx is subject to U.K. taxes.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>





















<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The benefit from income taxes consists of the
following for the years ended March 31, 2026 and 2025 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zINoBiaRScub" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B0_zMmAGq60eaq3" style="display: none">Schedule
        of income tax benefit</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_497_20250401__20260331_zk0uk8CvJz41" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20240401__20250331_zhkTLop2mpcb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current tax:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CurrentTaxOnProfitsForYear_ztkQYH3yFeJe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Current tax on profits for the year</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1941">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1942">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AdjustmentsForCurrentTaxOfPriorPeriods_zFIKDWyJbwXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Adjustments for current
        tax of prior periods</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1944">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentTaxExpenseIncome_i01_pn3n3_zZ7mca4NHGn" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1947">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred income tax:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DecreaseIncreaseInDeferredTaxAssets_zmt0QnBzqidh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Decrease (increase) in deferred
        tax assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1953">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProfitLossFromContinuingOperation_i01_pn3n3_zDKwrJAl1i4e" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1956">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<p id="xdx_8AE_zMohqScrQGC2" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Reconciliation of tax expense (benefit) at statutory tax rate and the income
tax benefit as reported in the Consolidated Statement of Operations and Comprehensive Income (Loss) for the years ended March 31, 2026
and 2026 is as follows (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z0sT7P32qNd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;<span id="xdx_8BD_zp1uJytHxqO1" style="display: none">Schedule of reconciliation
        income tax rates</span> </td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20250401__20260331_zxB3RRPk4Na8" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_491_20240401__20250331_zhn17T8tMIra" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_407_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_zYZQnEKeSmKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss before income tax</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(6,781</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxUsingBviTaxRate_pip0_dp_ztfnfs4nFxSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax using BVI tax rate of 0%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1965">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EffectOfTaxRatesInOtherCountries_zMKOlGVADbk7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Effect of tax rates in other countries</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(273</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(24</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--DerecognitionOfDeferredTaxAssets_zpF3OA9h1TWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Derecognition of deferred tax assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(156</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">23</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--NondeductibleExpenses_zxYssXEsZbT4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Nondeductible expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1973">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_zUWhvh4QdqYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Utilization of losses not previously benefitted</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1976">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1977">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxEffectsRelatedToEquityCompensation_zA30sF2tpoGi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Income tax effects related to equity compensation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">429</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ForeignCurrencyEffectAndOther_zCrtam5qUHZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Foreign currency effect and other</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxExpense_zNYBWWsrZ7gh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax in the statement of loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1985">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<p id="xdx_8A2_zLsNXd7vgLCa" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026 and 2025, the Company had $<span id="xdx_90F_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_pn3n3_dm_c20250401__20260331_zHRWbVY9BNo9" title="U.S. federal net operating losses">1.4</span>
million and $<span id="xdx_908_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_pn3n3_dm_c20240401__20250331_zHEO2BTTYCa9" title="U.S. federal net operating losses">0.6</span>
million of U.S. federal net operating losses, respectively, which carryforward indefinitely but are limited to 80% of taxable income when
utilized. As of March 31, 2026 and 2025, the Company also had $<span id="xdx_908_ecustom--UkLossCarryForwards_pn3n3_dm_c20250401__20260331_z33l5WhHXCga" title="UK Loss carry forwards">15.9</span>
million in UK loss carryforwards, which carryforward indefinitely<b>.</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026 and 2025, the Company&#8217;s deferred tax assets and
liabilities consisted of the effects of temporary differences attributable to the following (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfDeferredTaxAssetsTableTextBlock_pn3n3_zcwaE4FrkEFa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B3_znCPruTYwnwd" style="display: none">Schedule
        of deferred tax assets and liabilities</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20260331_z3hbdug8JZJh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_495_20250331_zwWuvRPMVKC9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsAbstract_iB_zroFL7nzjGM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">The balance comprises temporary differences attributable to:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzNDo_zYYvIBRwiBn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Tax loss</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">4,265</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">3,935</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockbasedCompensation_i01_pn3n3_maNDTAzNDo_zg5NkV192sbd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">11</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">397</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ReservesAndAccruals_i01I_pn3n3_maNDTAzNDo_zpF098fkMhS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Reserves and accruals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2005">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--NetDeferredTaxAssets_i01TI_pn3n3_mtNDTAzNDo_zFqHYt7xYwP2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total deferred tax assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">4,276</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4,349</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetNotRecognized_i01NI_pn3n3_di_zXXTsip0DILl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset not recognized</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(4,276</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,349</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--NetDeferredTaxAsset_i01TI_pn3n3_zLCqto0u8Gba" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2014">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2015">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8AD_zgZf5vpXNZSj" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company assesses its deferred tax assets for recognition by considering
both positive and negative evidence in order to ascertain whether it is probable that deferred tax assets will be realized. Realization
of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain.
Due to the history of losses the Company has generated in the past, the Company believes that it is not probable that all of the deferred
tax assets in the U.S. and U.K. can be realized as of March 31, 2026; accordingly, the Company has not recognized any of its deferred
tax assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s deferred tax assets not recognized decreased by $<span id="xdx_906_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20260331_zJA8QNH2SAH" title="deferred tax assets">0.1</span>
million for the year ended March 31, 2026. The change in the deferred tax assets not recognized was primarily due to the true-up adjustment
for stock compensation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has concluded that there are no uncertain tax treatments that
require disclosure or recognition.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 20, 2021, the OECD published the Global Anti-Base Erosion Model
Rules (the "GloBE Rules"), also known as Pillar II. The GloBE Rules aim to impose a global minimum tax of 15% on multinational
enterprises with a revenue in excess of &#8364;750 million. As the Company&#8217;s revenue is below this threshold, it is currently outside
the scope of the Pillar II rules.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company continues to monitor developments in jurisdictions where it
operates, including the U.K., U.S., and British Virgin Islands. As of the reporting date, Pillar II is not expected to have a material
impact on the Company&#8217;s financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 4th 2025, President Trump signed into law the One Big Beautiful
Bill Act ("OBBBA"). The OBBBA includes changes to U.S. tax law applicable to the Company beginning in 2025. The impact of the
OBBBA on the Company's consolidated financial statements have been reflected in its current and deferred taxes; however, the enactment
did not have a material impact to the Company's consolidated financial statements for the fiscal years ended March 31, 2026 and 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalStockAndReservesAbstract', window );"><strong>Capital Stock And Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalStockAndReservesTextBlock', window );">CAPITAL STOCK AND RESERVES</a></td>
<td class="text"><p id="xdx_809_ecustom--CapitalStockAndReservesTextBlock_zMaTHYdGT5ob" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 17. <span id="xdx_82A_z0M6mbPW7N6h">CAPITAL
STOCK AND RESERVES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">Authorized ordinary shares<b>:</b> Unlimited number of Alpha Compute
ordinary shares without par value.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Private Placement Financings</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 29, 2025, the Company completed the sale of <span id="xdx_90A_ecustom--SaleOfStock_iI_c20250129_zoNQuKM7BNgh" title="Sale of stock">524,390</span>
ordinary shares for aggregate proceeds of $<span id="xdx_90D_ecustom--AggregateProceeds_iI_c20250129_zPzgMx1xEox4" title="aggregate proceeds">2,150,000</span>,
at a per share price of $4.10, the closing price of a share on Nasdaq on the date preceding the date of the securities purchase agreement.
The shares were sold to two directors of the Company, Messrs. Gregory Bailey and James Mellon. The shares were sold in a private placement
transaction pursuant to Regulation S, and were issued as restricted stock. The proceeds are being used for general corporate purposes
and working capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 25, 2025, the Company completed the sale of<span id="xdx_90A_ecustom--SaleOfStock_iI_c20250925_zQ64BTqkhxr" title="Sale of stock">
3,415,780</span>
ordinary shares at a per share price of $<span id="xdx_901_ecustom--SharesPrice_iI_c20250925_zhw2oogyDLXg" title="Share price">5.73</span>,
and pre-funded warrants to purchase <span id="xdx_90D_ecustom--WarrantsToPurchase_iI_c20250925_zvr30dZnfgEh" title="Warrants to purchase">3,258,466</span>
ordinary shares at a purchase price of $<span id="xdx_909_ecustom--PurchasePrice_iI_c20250925_zRxnoxvcSlE6" title="Purchase price">5.73</span>
per ordinary share (less $0.001 per pre-funded warrant) for gross proceeds of approximately $<span id="xdx_904_ecustom--GrossProceeds_pn3n3_dm_c20250401__20260331_zrNM5Tyj8Etl" title="Gross proceeds">34.5
</span>million, consisting of cash of $<span id="xdx_90B_eifrs-full--Cash_iI_pn3n3_dm_c20250925_zNpp85JcpAG7" title="Cash">3.3</span>
million and digital assets and stablecoin of $<span id="xdx_904_ecustom--DgitalAssets_iI_pn3n3_dm_c20250925_zGhJyOdnC5s7" title="Dgital assets">32.9</span>
million. Each pre-funded warrant is exercisable for one ordinary share at an exercise price of $0.001 per pre-funded warrant, is immediately
exercisable and will expire once exercised in full. The shares and pre-funded warrants were sold in a private placement transaction in
reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated under the Securities Act, and the
proceeds are being used for the establishment of the Company&#8217;s digital asset treasury. During the fiscal year ended March 31, 2026,
111,295 pre-funded warrants issued under the private placement were exercised and 2,513,240 were forfeited by DWF in connection with the
return of DWF&#8217;s initial investment. The remaining 633,931 pre-funded warrants outstanding have no expiration date.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><span id="xdx_90B_ecustom--OrdinarySharesIssued_iI_c20250925_zMzEOzVAaOMj" title="Ordinary shares issued">160,000</span>
ordinary shares were issued to the Company&#8217;s third-party asset manager as consideration for continued services to be provided to
the Company pursuant to a Treasury Management Agreement. The shares have a three-year vesting term and are subject to forfeiture in the
event the agreement with the asset manager is terminated under certain circumstances. The shares were sold in a private placement transaction
in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated under the Securities Act, and
were issued as restricted stock.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 8, 2025 and December 30, 2025, one Side Letter put right issued
as part of the September 25, 2025 private placement financing and the DWF put right were exercised, respectively, and on March 24, 2026
and December 30, 2025, the contributed locked TON tokens receivable in the amount of 1,114,130, with a fair value of $2.5 million at contribution,
and $15.0 million USD1 receivable were returned to the investor and DWF, respectively. Additionally, the Company terminated its Treasury
Management Agreement with DWF in connection with the return of DWF&#8217;s initial investment. Upon return of the investor and DWF&#8217;s
shares to the Company, the Company recognized treasury stock in the amount of 17,452 and 105,000 shares, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Shares Issued Under the ATM Program</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">During the fiscal year ended March 31, 2026, the Company sold <span id="xdx_90D_ecustom--NumberOfSharesSold_c20250401__20260331__ifrs-full--CounterpartiesAxis__custom--ATMMember_zdNaRIiNOalb" title="Number of shares sold">4,062,632</span>
ordinary shares under the ATM program, generating net proceeds of approximately $<span id="xdx_908_ecustom--NetProceeds_c20250401__20260331__ifrs-full--CounterpartiesAxis__custom--ATMMember_zDJgS01vnRkk" title="net proceeds">12.0</span>
million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Shares Issued for Investment in Compedica</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On June 5, 2025, the Company acquired an equity interest in Compedica, Ltd.
("Compedica"), a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby the Company issued <span id="xdx_909_ecustom--OrdinarySharesIssued_iI_c20250605_z3YHUlvLdZLa" title="Ordinary shares issued">625,000</span>
ordinary shares valued at $5,000,000, at a per share price of $8.00, in exchange for a minority equity interest in Compedica.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#8217;s treasury and the investment being exited. As a result, the Company recognized less than $<span id="xdx_902_ecustom--TreasuryStock_iI_pn3n3_dm_c20260206_zMSlAAoDUoai" title="Treasury stock">0.1</span>
million in treasury stock at the time the shares were returned, the fair value of the investment as of February 6, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Registered Direct Offering</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 13, 2026, the Company entered into a securities purchase agreement
with certain purchasers, pursuant to which the Company offered for sale to the Purchasers in a registered direct offering an aggregate
of <span id="xdx_901_ecustom--AggregateOfferingOrdinaryShares_iI_c20260113_zVZTy70PWhb5" title="Aggregate offering ordinary shares">5,230,000</span>
ordinary shares and, in lieu thereof, pre-funded warrants to purchase up to <span id="xdx_902_ecustom--Proceedsfromexerciseofwarrant_iI_c20260113_zFPuJ3It08D2" title="ProceedsFromExerciseOfWarrants">9,770,000</span>
ordinary shares. The net proceeds from the Offering were approximately $<span id="xdx_902_eifrs-full--ProceedsFromExerciseOfWarrants_pn3n3_dm_c20260101__20260113_zFC7djCYkVFl" title="Net proceeds">12.7</span>
million. During the fiscal year ended March 31, 2026,<span id="xdx_90E_eifrs-full--NumberOfSharesIssued_iI_c20260113_znl1rWpAssDl" title="Pre-funded warrants issued">
9,120,000</span>
pre-funded warrants issued under the registered direct offering were exercised. The remaining<span id="xdx_909_eifrs-full--IncreaseDecreaseInNumberOfSharesOutstanding_c20260111__20260113_znS3Grajme2c" title="pre-funded warrants outstanding shares">
650,000</span>
pre-funded warrants outstanding have no expiration date.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Reverse Share Split</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The reverse stock split decreased the number of ordinary shares outstanding
as of September 30, 2023, from 17,808,225 to 890,412. All share and per share information included in the consolidated financial statements
and in the Notes to the consolidated financial statements have been retroactively adjusted to reflect the impact of the reverse stock
split unless otherwise noted. The number of ordinary shares authorized remained at an unlimited number of common shares without par value.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Any fractional shares resulting from the reverse stock
split were rounded up to the nearest whole post-split ordinary share. As a result of this round up provision, the Company issued an additional
<span id="xdx_907_ecustom--AdditionalSharesIssued_iI_c20250930_zm6jUddGOn86" title="Additional shares issued">52,254</span>
shares.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series A Warrants and Pre-Funded Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On September 29, 2023, we entered into a securities purchase agreement (the
&#8220;2023 Purchase Agreement&#8221;) with an institutional and accredited investor in connection with a registered direct offering (the
&#8220;2023 Registered Direct Offering&#8221;) and a concurrent private placement (the &#8220;2023 Private Placement,&#8221; and together
with the Registered Direct Offering, the &#8220;2023 Offerings&#8221;). The 2023 Offerings closed on October 3, 2023.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Pursuant to the 2023 Purchase Agreement, in the 2023 Registered Direct Offering,
the Company sold (i) <span id="xdx_906_ecustom--NumberOfSharesSold_c20220401__20230930_zlx1w6YbxBBc" title="Number of shares sold">98,500</span>
shares of the Company&#8217;s ordinary shares at a purchase price of $38.00 per share and (ii) pre-funded warrants to purchase up to 59,395
ordinary shares, at a purchase price of $37.98 per pre-funded warrant. All pre-funded warrants, which were exercisable for one ordinary
share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In the 2023 Private Placement, we issued to such institutional and accredited
investor unregistered Series A Warrants to purchase up to <span id="xdx_906_ecustom--WarrantsPurchase_c20230401__20230930_zcahS3lcc5q5" title="Warrants purchase">157,895</span>
ordinary shares. Each Series A Warrant was immediately exercisable for one private warrant share at an exercise price of $38.00 per share
but expired on April 3, 2025, 18 months from the date of issuance.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Series A Warrants and the pre-funded warrants are classified as a component
of equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the ordinary
shares with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares,
and permit the holders to receive a fixed number of ordinary shares upon exercise. In addition, the Series A Warrants and the pre-funded
warrants do not provide any guarantee of value or return.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On the October 3, 2023 issue date, the calculated fair value of the Series
A Warrants and the pre-funded warrants was $<span id="xdx_90E_ecustom--WarrantsPerShare_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zLmUN36Qaprd" title="Fair value of warrants">2.968</span>
million ($18.80 per such warrant). Because the fair value of the warrants accounted for as liabilities exceeded the net proceeds from
the 2023 Registered Direct Offering, the proceeds allocated to the ordinary shares, the pre-funded warrants and the Series A warrants
was zero. The Series A Warrants expired on April 3, 2025, 18 months from the date of issuance, and all pre-funded warrants were exercised
in full on May 9, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Series A Warrants</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The inputs associated with calculating the fair value are reflected below.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>



<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zJmEF76Kps05" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details )">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_zyf6XnpCBDcc" style="display: none">Schedule of inputs associated with calculating
        the fair value</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">October
        3, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw4EC71or03" title="Exercise price">38.00</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--SharePriceFairvalue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziV5CYcdG7K8" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_ecustom--OptionLifeShareOptions_dtY_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zXs0B3wo5NJ9" title="Expected life">1.50</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zL9lmSzNwlMb" title="Expected volatility">96.0</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHOFaNy6c8ya" title="Risk free interest rate">5.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQQ7PNDXngPa" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl2085">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A1_zre7Mydms1lg" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt"><b>Nature and Purpose of Reserves</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Stock Option Reserve</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The stock option reserve reflects the reserve of compensation
expense recognized over the vesting period based upon the grant date fair value of the Company&#8217;s equity settled grants calculated
in accordance with IFRS 2, &#8220;Share-based Payment&#8221;. See Note 18, &#8220;Stock Option Reserve,&#8221; below for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalStockAndReservesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalStockAndReservesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalStockAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalStockAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">STOCK OPTION RESERVE</a></td>
<td class="text"><p id="xdx_80F_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_z0sTtvsAGwEl" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
18. <span id="xdx_82B_zJ120GyPr3xe">STOCK OPTION RESERVE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The share option reserve reflects the reserve of compensation expense recognized
over the vesting period based upon the grant date fair value of the Company&#8217;s equity settled grants calculated in accordance with
IFRS 2, &#8220;<i>Share-based Payment</i>&#8221;.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted
Stock Units</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The following table provides the activity for the Company&#8217;s
stock option reserve for the fiscal years ended March 31, 2026 and 2025 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_pn3n3_zQlgUwnMFFc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zg3911QQfmG5" style="display: none">Schedule of stock option
        reserve</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Balance, beginning of year</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20250401__20260331_zTttwvXdqSWk" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">23,530</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_988_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20250331_zHIUt32fJSbd" style="width: 12%; font-size: 10pt; text-align: right">23,841</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20250401__20260331_zD8TjPMADUpa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense">1,745</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20240401__20250331_zRWWFpgQGmna" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">321</td>
    <td style="font-size: 10pt; text-align: left"><sup>(1)</sup></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Correction of prior period overstated share-based compensation
        expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20250401__20260331_zCMB8KtkMoDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Correction of prior period overstated share-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl2100">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20240401__20250331_zqXZzU3nC9h" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Correction of prior period overstated share-based compensation expense">(632</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)<sup>(2)</sup></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance, end of year</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20250401__20260331_zQh7X8oL6xu5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">25,275</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_983_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20250331_ztoJWxIq1csi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">23,530</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 14%; font-size: 10pt; text-align: center">(1)</td>
    <td style="width: 86%; font-size: 10pt; text-align: left">Amount is net of $0.6 million reversal of share-based compensation expense for unvested
        share options forfeited during the fiscal year ended.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">(2)</td>
    <td style="font-size: 10pt; text-align: left">Amount represents the correction as of March 31, 2025 for the overstated share-based compensation
        expenses in Fiscal 2022 and Fiscal 2024.</td></tr>
  </table>




<p id="xdx_8A6_zHajdFlhghO" style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. All share and per share information have been retroactively adjusted to reflect
the impact of the reverse stock split unless otherwise noted. See Note 1 &#8220;Nature of Operations&#8221; and Note 17, &#8220;Capital
Stock and Reserves&#8221; for further discussion on the reverse stock split.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The 2021 Equity Incentive Plan (the &#8220;Equity Incentive
Plan&#8221;), as amended on January 19, 2022, allows for the grant of equity awards up to 248,043 or 15% of shares currently issued and
outstanding, 3,616,999as of March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On March 7, 2025, the Board authorized the grant of
a total of <span id="xdx_90C_ecustom--AuthorizedGrantOptionPurchaseShares_iI_pip0_c20250307_zYUQYky0Uwoe" title=" Authorized grant option purchase shares">160,000</span>
options to purchase ordinary shares at a per share exercise price of $4.45, with a term of 10 years. Vesting will accelerate on a change
of control of the Company. The options had a per share fair value of $4.04 and vest as to one-quarter immediately and the balance as to
one-third on each March 7, 2026, 2027 and 2028. The grants were made to certain directors, officers and employees. The options were issued
under the Company&#8217;s 2021 Equity Incentive Plan.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In Fiscal 2026, the Board of Directors authorized on March 11, 2026, the
grant of 1,930,396 share options to purchase ordinary shares at a per share rate ranging from $1.30 to $8.26. Once vested, the share options
are exercisable for a period ending 10 years after the date of grant. Vesting will accelerate on a change of control of the Company. The
options had a per share fair value of $0.40 and vest as to one-quarter immediately and the remaining balance as to one-third on each March
11, 2027, 2028, and 2029. The grants were made to certain directors, officers, and advisors. The options were issued as discretionary
options outside the 2021 Equity Incentive Plan, and not part of any regularly constituted compensation plan. These options were awarded
pursuant to contractor agreements and advisory agreements contingent on the Company raising at least $50 million in equity financing via
either private or public share offerings, which was achieved on January 14, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 11, 2026 the Board of Directors also authorized the grant of <span id="xdx_90B_ecustom--SharesIssuedGrantedRsu_iI_c20260311_z2gG3aMQcugk" title="Shares issued granted RSU">1,235,924</span>
Restricted Stock Units which vested immediately upon the grant date. The grants were made to certain directors, officers, and employees.
The Restricted Stock Units were issued as discretionary awards outside the 2021 Equity Incentive Plan, and not part of any regularly constituted
compensation plan. These options were awarded pursuant to contractor agreements contingent on the Company raising at least $50 million
in equity financing via either private or public share offerings, which was achieved on January 14, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On July 27, 2025 the board authorized the grant of <span id="xdx_907_ecustom--AuthorizedGrantOptionPurchaseShares_iI_c20250727_zRYJavRTRrzg" title=" Authorized grant option purchase shares">97,739</span>
share options under the terms of the Company&#8217;s 2021 Equity Incentive Plan to board members and employees. These options were fully
vested at the time of grant.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As of March 31, 2026, no shares were reserved for awards
previously granted or available for future awards under the Amended and Restated 2021 Equity Incentive Plan.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 21pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The changes in the number of stock options issued and outstanding
for the fiscal years ended March 31, 2026 and 2025 were as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zgeG60Y8aoWc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B5_zRjZbyHo3iW8" style="display: none">&#160;Schedule of share options issued
        and outstanding</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20250401__20260331_zj7VJGh2zJ32" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">225,117</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20250331_z65qTL5i5Q8k" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance">90,281</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Granted</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zUxYnHSiwRqh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted">2,028,135</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_zg2B21mMxib6" style="font-size: 10pt; text-align: right" title="Granted">160,000</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zidYIcIDQuZ7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited">(6,745</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_z585SocDALW5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited">(25,164</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zyCIvbmNY4sh" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlJ9nP6aePD6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">225,117</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zeqUc30cW8W5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zWaEvFNwkmLb" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">102,855</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Available for future awards</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20250401__20260331_z3rVNZ5aGWHi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Available for future awards"><span style="-sec-ix-hidden: xdx2ixbrl2139">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20240401__20250331_zv0t3DdU9vF" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available for future awards">17,516</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8AA_zm4MJb9ShjZ8" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The table above does not include fully vested restricted
stock units (&#8220;RSUs&#8221;) granted to certain executives in January 2021 and January 2022. In January 2024, the Company issued<span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zb8BcihnZoZ6" title="Shares issued">
308</span>
shares for the exercise of <span id="xdx_908_ecustom--NumberOfSharesExercise_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zN0yyMBlMf8e" title="Shares issued">470</span>
RSUs net of 162 shares withheld to pay for an employee&#8217;s payroll taxes. In September 2024, the Company issued <span id="xdx_905_eifrs-full--NumberOfSharesIssued_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_ziO9FWvsv2Le" title="Shares issued">882</span>
shares for the exercise of <span id="xdx_904_ecustom--NumberOfSharesExercise_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zHwswvtgSAoe" title="Shares issued">1,152</span>
RSUs net of <span id="xdx_904_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zh1BHbPZ8Iaj" title="Shares repurchased into treasury employee payroll taxes">270</span>
shares withheld to pay for an employee&#8217;s payroll taxes. In December 2024, the Company issued <span id="xdx_909_eifrs-full--NumberOfSharesIssued_iI_pip0_c20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_ztKMN6JLex9a" title="Shares issued">8,173</span>
shares for the exercise of <span id="xdx_90C_ecustom--NumberOfSharesExercise_iI_pip0_c20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z86xq60VrTzl" title="Shares issued">11,905</span>
RSUs net of 3,732 shares withheld to pay for an employee&#8217;s payroll taxes. As of March 31, 2026, there were 1,241,334 RSUs granted
and outstanding, of which 4,550, 860, and 1,235,924 RSUs expire on January 13, 2031, January 19, 2032, and March 11, 2036, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The weighted-average estimated fair value of share
options granted during the years ended March 31, 2026 and 2025 was $0.40 and $4.04 per share, respectively, using the Black-Scholes option
pricing model with the following weighted-average assumptions:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfWeightedAverageAssumptionsTableTextBlock_zTv9z2f1KcE" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zXqVQ5uzHeb5" style="display: none">Schedule of weighted-average estimated
        fair value of share options</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt">Grant Price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zBwUR57N7nIi" title="Grant price">1.30</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zqgA2HDH1mYj" title="Grant price">4.45</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life (in years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zIzdxsHkCVy4" title="Expected life">10</span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_ecustom--OptionLifeShareOptionsGranted_dtY_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zRn0b9MkpPXf" title="Expected life">5.75</span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Risk-free interest rates</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zbm327X5L0R4" title="Risk free interest rate">3.68</span></td>
    <td style="font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zhUY2lomD35l" title="Risk free interest rate">4.14</span></td>
    <td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zpkwI2rP4Ecj" title="Expected volatility">115.0</span></td>
    <td style="font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zGasLKz8m0E5" title="Expected volatility">135.8</span></td>
    <td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvUjY2opY4nb"><span style="-sec-ix-hidden: xdx2ixbrl2174">&#8212;</span></span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvfRB8UiCMCf"><span style="-sec-ix-hidden: xdx2ixbrl2175">&#8212;</span>&#160;</span>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A0_z4sCcna5E4V8" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following is the weighted average exercise price and the remaining
contractual life for outstanding options as of March 31, 2026 and 2025:</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_z3jO5UVi58zc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"> <span id="xdx_8BA_zQerUm64wrF7" style="display: none">Schedule of weighted average exercise price and the remaining
        contractual life</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20250401__20260331_zaU7tofFXeW" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">6.84</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20250331_zrFiK1dgikvb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price">62.51</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20250401__20260331_zLKzMSH9P2O4" title="Weighted average remaining contractual life (in years)">9.9</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20250331_zFFZeaPhjGB3" title="Weighted average remaining contractual life (in years)">9.1</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8AE_znQ9iA2kaHl2" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Share options granted and outstanding at the
end of the year have the following expiration dates and exercise prices:</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z7wkIYWaRz39" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B1_zqijrz5Mknw7" style="display: none">Schedule of Share options granted and
        outstanding</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td id="xdx_488_ecustom--ExpirationDate_zKINvOlmRmS2" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_48C_ecustom--ExercisePrice_pip0_zC1MEnqFF5Z7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_ecustom--ShareOptions_zPB6RVYkEeRl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Share Options as of</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Grant Date</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Expiration Date</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price $</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2026</td></tr>
  <tr id="xdx_41F_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January132021Member_z23nODcb10eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-size: 10pt; text-align: left">January 13, 2021</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">January
        13, 2031</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 22%; font-size: 10pt; text-align: right">355.00</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 22%; font-size: 10pt; text-align: right">21,400</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January192022Member_z0QzW6haKfGf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">January 19, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">January
        19, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12,475</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--February152022Member_zQ4F2fGDGb19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">February 15, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">February
        15, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">171.80</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--June82022Member_zu6xZSM5Ptlf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">June 8, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">June
        8, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">220.00</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272022Member_zVcBTLbtjKcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">July 27, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">July
        27, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">201.20</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March302023Member_ztOORJsba2E9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">March 30, 2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">March
        30, 2033</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">24,497</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March72025Member_zsxlz6Wud1k9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">March 7, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">March
        7, 2035</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4.45</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">160,000</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41C_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272026Member_zZNh6A3YOVMb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">July 27, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">July
        27, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">97,739</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March112026Member_zc8GVRMsAJa6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">March 11, 2026</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">March
        11, 2036</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">1.30</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,930,396</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20240401__20250331_zEdYJu7BN6y6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



<p id="xdx_8A8_zisDzzJYdgMb" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

















<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The vested options can be exercised at any
time in accordance with the applicable option agreement. The exercise price was greater than the market price for all options outstanding
as of March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company recorded approximately $<span id="xdx_904_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20250401__20260331_zMaeFDpBLSoj" title="Share based compensation expense">2.3</span>
million of share-based compensation expense in the year ended March 31, 2026. During Fiscal 2025, the Company recorded approximately $<span id="xdx_907_ecustom--SharebasedCompensationExpense_pn5n6_c20250401__20260331__ifrs-full--MeasurementAxis__custom--VestedStockOptionMember_zTYsBG74UNJe" title="Share based compensation expense">0.3</span>
million of share-based compensation, which reflects an additional $<span id="xdx_90C_ecustom--ReversalOfSharebasedCompensation_pn3n3_dm_c20250401__20260331_zye4ucMdcJF3" title="Reversal of share-based compensation">0.3</span>
million in share-based compensation expense for the accelerated vesting of certain employee share options offset by $<span id="xdx_90D_ecustom--ShareBasedCompensationExpenseUnvestedShareOptions_pn3n3_dm_c20250401__20260331_zqJPuDgWjKbh" title="Share based compensation expense unvested share options">0.6</span>
million reversal of share-based compensation for unvested share options forfeited during the year. The Company recorded approximately
$<span id="xdx_90E_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20230401__20240331_zQG8kckinny9" title="Share based compensation expense">2.6
</span>million of share-based compensation expense in the year ended March 31, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_80B_eifrs-full--EarningsPerShareExplanatory_zpRwY5iYljT4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. <span id="xdx_820_zDbbmKWLPfc5">LOSS
PER SHARE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Basic earnings per share (&#8220;EPS&#8221;) is calculated
by dividing the net loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Diluted EPS is calculated by dividing the net loss attributable to ordinary
equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted average
number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares. Shares
issuable under pre-funded warrants are considered outstanding for this purpose.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The calculation of Basic and Diluted EPS reflects the
pre-funded warrants as outstanding shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following table reflects the loss and share data used in the
basic and diluted EPS calculations (in thousands, except per share amounts):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zsS4CoeES4S4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span id="xdx_8BA_zvvguM3k50j8" style="display: none">Schedule
        of loss and share data used in the basic and diluted EPS calculations</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Numerator</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the
        Company</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20250401__20260331_zcRKw8gluL3i" title="Weighted average shares outstanding, Diluted">(38,627</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20240401__20250331_z2CcesYCo3yk" title="Weighted average shares outstanding, Diluted">(6,767</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20230401__20240331_zt94WqBLzg82" title="Weighted average shares outstanding, Diluted">(75,339</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Denominator</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Weighted average number of shares &#8211; Basic and Diluted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20250401__20260331_zgFzVd15Ikal" title="Weighted average shares outstanding, Diluted">9,248</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240401__20250331_zRBOm79ICEl8" title="Weighted average shares outstanding, Diluted">1,183</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20240331_z0WLRcgGgh2k" title="Weighted average shares outstanding, Diluted">968</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_ecustom--LossPerShareBasic_pip0_c20250401__20260331_zmbXl2cSO4al" title="Loss per share, Basic"><span id="xdx_90E_ecustom--LossPerShareDiluted_pip0_c20250401__20260331_zZwh5dIZyVJ2" title="Loss per share, Diluted">(4.18</span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--LossPerShareBasic_pip0_c20240401__20250331_zyMCfFL2LpE1" title="Loss per share, Basic"><span id="xdx_907_ecustom--LossPerShareDiluted_pip0_c20240401__20250331_zkOoovScaKYj" title="Loss per share, Diluted">(5.72</span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--LossPerShareBasic_pip0_c20230401__20240331_zShoRiQyeKue" title="Loss per share, Basic"><span id="xdx_90C_ecustom--LossPerShareDiluted_pip0_c20230401__20240331_zRBuKRaCJxSg" title="Loss per share, Diluted">(77.83</span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>




<p id="xdx_8A1_zE1HceF0FEjf" style="margin: 0pt 0; font-size: 10pt; text-align: justify; color: Red"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The inclusion of the Company&#8217;s share purchase
warrants (other than pre-funded warrants, as described above), stock options and RSUs in the computation of diluted loss per share would
have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between
basic loss per share and diluted loss per share for the fiscal years ended March 31, 2026, 2025, and 2024. The following table reflects
the Company&#8217;s outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded
from the calculation.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_zJv9JThhJnb3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_z71f9aNcXd96" style="display: none">Schedule of anti-dilutive
        effect on loss per share</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zXFaxJRIrlg5" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,531,581</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_ztitv7YcRfn3" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zmL6DkL2CZV" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Share options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zPkX8p87qSch" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zHgwbhDxhbOj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">225,117</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_za9b0O0g2D32" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">90,281</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_z2Qo9CmrTeW6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,241,334</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zxskHsRj6qbd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">5,410</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zp4ohqFmVDm8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">18,467</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AD_zeDx4wONh7Yj" style="margin: 0pt 0; font-size: 10pt; color: Red"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80B_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zZ9WIfMXZg8c" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
20. <span id="xdx_827_zLVV0F4PNx7j">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>iOx &#8211; Parexel Master Services Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Effective March 15, 2022, iOx, a wholly-owned subsidiary
of the Company, entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Parexel under which Parexel agreed to act as a clinical
service provider (&#8220;CRO&#8221;) pursuant to a work order (&#8220;Work Order&#8221;) effective June 1, 2022. Under such Work Order,
Parexel planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer. The MSA provided
for a five-year term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided
for service fees and pass-through expenses and clinical sites totaling $<span id="xdx_903_ecustom--ServiceFees_iI_pn3n3_dm_c20220315__ifrs-full--CounterpartiesAxis__custom--CROMember_zUwMMp0oBXU6" title="service fees">11.5</span>
million. During the year ended March 31, 2023 (&#8220;Fiscal 2023&#8221;), the Company executed two change orders resulting in a $<span id="xdx_90B_ecustom--BudgetCosts_pn3n3_dm_c20220401__20230331_zj1yncGY4Ava" title="Budget costs">0.6</span>
million increase in the overall estimated budgeted costs. As a result of the Company&#8217;s decision to discontinue the development with
respect to this program, on December 20, 2023, the Company provided Parexel notice of termination of the contract, with a planned termination
date of April 18, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As the ongoing CRO services were wound down, the Company
noticed that expenses incurred under the CRO agreement were higher than originally budgeted. Parexel agreed to refund the Company $<span id="xdx_90B_ecustom--GrossProceeds_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_ziyWSMhmr6qj" title="Gross proceeds">0.552</span>
million and release the liability for amounts invoiced and unbilled services totaling $<span id="xdx_901_ecustom--UnbilledServices_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_zBD2mmbKfgR3" title="Unbilled services">1.486
</span>million, and the Company forfeited advanced payments of $<span id="xdx_90A_ecustom--ForfeitedAdvancedPayments_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_ziugDIR1fpp" title="Forfeited advanced payments">1.091</span>
million. As a result, the Company recognized a net gain of $<span id="xdx_903_ecustom--NetGain_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_zvGcqNBmp0Fb" title="Net gain">0.946</span>
million as of September 30, 2024. The Company received the refund from Parexel on October 3, 2024. As of March 31, 2024, the Company reflected
$<span id="xdx_908_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_pn3n3_dm_c20230401__20240331__ifrs-full--CounterpartiesAxis__custom--CROMember_zotmX1mpiIuj" title="Accounts payable and accrued liabilitie">1.414</span>
million of payables to Parexel in accounts payable and accrued liabilities and $<span id="xdx_903_ecustom--PrepaidExpensesAndOtherReceivables_pn3n3_dm_c20230401__20240331__ifrs-full--CounterpartiesAxis__custom--CROMember_zbLOmLQIMeTf" title="prepaid expenses and other receivables">1.277</span>
million in prepaid expenses and other receivables in the consolidated statement of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Buzz HPC GPU Lease</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On February 6, 2026 he Company entered into a GPU infrastructure services
agreement with Buzz Performance Cloud Inc. pursuant to which the Company secured rights to access 504 NVIDIA B200 GPUs for a 24-month
term. The arrangement contemplates aggregate contractual payments of approximately $<span id="xdx_901_ecustom--ContractualPayments_iI_pn3n3_dm_c20260206_zDTtexGSiN8i" title="Contractual payments">29.6</span>
million over the contract term and requires a security deposit of $<span id="xdx_901_ecustom--SecurityDeposits_iI_pn3n3_dm_c20260206_zTPpUh86TuFg" title="Security deposit">2.6</span>
million, which was paid on February 13, 2026. As of March 31, 2026, no liability was yet recorded as the services did not commence until
early June.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>atNorth Colocation Lease Payments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On December 11, 2025 the Company signed an enterprise colocation service
agreement (the &#8220;Colo Agreement&#8221;) with atNorth AB (&#8220;atNorth&#8221;) to deploy the Company&#8217;s GPU hardware to atNorth&#8217;s
data center located in Kista, Sweden. The Colo Agreement consists of two data halls with a Phase I deployment of 1,213 kW of power and
a Phase II of 1,017 kW of power, with Phase II being structured as a Right of First Refusal (the &#8220;ROFR&#8221;). The agreement&#8217;s
commencement date was April 1, 2026, and extends for 60 months after which it automatically extends for successive 12 month periods unless
6 months&#8217; notice is provided by either party. On April 10, 2026, the Company paid a 982,368 EUR deposit to secure Phase I of the
agreement. As of the date of the issuance of these consolidated financial statements, the ROFR for Phase II of the deployment has expired,
although atNorth is still being considered for a further deployment once ready. The monthly colocation fee for Phase I that has commenced
is 163,728 EUR plus variable electricity costs estimated at 0.126 EUR/kWh.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>GaMee Acquisition Token Buyback</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#8220;SPA&#8221;) with Animoca Brands Limited (&#8220;Animoca Brands&#8221;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#8220;GaMee Global&#8221;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#8220;GaMee Transaction&#8221;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. The SPA
contains a post-closing item requiring the Company to, within ninety (90) days after close, acquire from the open market $2 million worth
of GMEE tokens. GMEE is the native utility token of the GaMee gaming platform and ecosystem. The GaMee Transaction closed on May 27, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Tarus &#8211; Fortrea Clinical Service Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On March 1, 2023, Tarus entered into a clinical service
agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier
of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services
to be provided is approximately $12.1 million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In March 2025, the Company resumed patient enrollment
into the final cohort arm of TT-10 (PORT-6) as part of the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following a prior pause due
to funding constraints. This decision reflects the favorable safety and preliminary activity signals observed in earlier dose cohorts.
In April 2025, we announced confirmatory preclinical results in mesothelioma with our TT-4 (PORT-7) compound, supporting advancement of
this indication in its first-inhuman trial of TT-4 (PORT-7) which is expected to commence in the quarter ending March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On May 31, 2026, Cyncado and ADDRI executed a definitive
Clinical Trial Research Agreement establishing the terms of the study. The trial is expected to enroll approximately 50 patients across
multiple clinical sites, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado's planned
U.S. mesothelioma activities. Under the agreement, Cyncado will supply TT-4 and provide limited support as part of an international mesothelioma
program. The trial remains subject to customary regulatory and ethics approvals and site activation before enrollment begins.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Nasdaq Notifications</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 10, 2024, the Company received written
notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;) indicating that it was not in compliance with
the minimum shareholders&#8217; equity requirement for continued listing on The Nasdaq Capital Market (the &#8220;Capital Market&#8221;)
as set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Shareholders&#8217; Equity Requirement&#8221;), because the shareholders&#8217;
equity of $695,000 as of September 30, 2024, as reported in the Company&#8217;s Report on Form 6-K containing unaudited consolidated financial
statements for the three and six months ended September 30, 2024, filed with the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) on December 31, 2024, was below the required minimum of $2.5 million, and because as of the date of the Notice, the
Company did not meet either of the alternative continued listing standards for the Nasdaq Capital Market, relating to market value of
listed securities of at least $35 million or net income from continuing operations of at least $500,000 in the most recently completed
fiscal year or in two of the last three most recently completed fiscal years. The Company submitted a plan on January 24, 2025, to regain
compliance with the shareholders&#8217; equity requirement or achieve compliance with an alternative continued listing standard for the
Capital Market (the &#8220;Compliance Plan&#8221;) and on February 11, 2025, the Company received notification from Nasdaq that Nasdaq
accepted the Compliance Plan and granted the Company an extension to regain compliance with the continued listing standards by June 9,
2025. In keeping with the Compliance Plan, on June 5, 2025, the Company increased its shareholders&#8217; equity, and submitted documentation
to Nasdaq indicating compliance as of June 9, 2025, with the shareholders&#8217; equity requirement. The Nasdaq Stock Market, LLC indicated
by letter dated June 24, 2025, that the Company has regained compliance with the continued listing standards of the Nasdaq Capital Market.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On March 2, 2026, the Company received a deficiency
letter from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) notifying the Company that because the closing bid
price for the Company&#8217;s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet
the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule
5550(a)(2) (the &#8220;Bid Price Rule&#8221;). The deficiency letter does not result in the immediate delisting of the Company&#8217;s
common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial
period of 180 calendar days, or until August 31, 2026 (the &#8220;Compliance Period&#8221;), to regain compliance with the Bid Price Rule.
If, at any time during the Compliance Period, the closing bid price per share of the Company&#8217;s common stock is at least $1.00 for
a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it complies with the Bid Price
Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The Nasdaq
letter also provides that in the event the Company does not regain compliance by August 31, 2026, the Company may be eligible for an additional
180 calendar day period to regain compliance. To qualify, the Company must meet the continued listing requirement for market value of
publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the bid price requirement.
Notwithstanding the terms set forth in the Nasdaq letter, there can be no assurance that the Company will be eligible for an additional
180 calendar day period to regain compliance. If the Company meets the applicable requirements, Nasdaq will inform the Company that it
has been granted an additional 180 calendar days. If, however, it appears to Nasdaq that the Company will not be able to cure the deficiency,
or if the Company is otherwise not eligible, Nasdaq could provide notice that the Company&#8217;s common stock will become subject to
delisting. In such event, Nasdaq rules would permit the Company to appeal the delisting determination to a Nasdaq Hearings Panel.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Ground Tunnel Consulting Services Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On July 15, 2025, Alpha Transform Holdings, a related
party of the Company, entered into a consulting service agreement with Ground Tunnel Capital LLC, a third-party advisory and marketing
consultant. This consulting service agreement was assigned to the Company on October 25, 2025. The effective date of the agreement occurred
upon the closing of the subsequent private placement of ordinary shares, which occurred on September 25, 2025, with contractual services
to be provided through July 15, 2028. $1.0 million was paid upon execution of the contract, with subsequent milestone payments of $0.25
million due on each October 15, 2025, January 15, 2026, April 15, 2026 and July 15, 2026. On April 15, 2026, the Company submitted its
third milestone payment in the amount of $0.25 million.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Treasury Management Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At the closing of the Company&#8217;s financing on
September 25, 2025, the Company entered into a treasury management agreement (the &#8220;DWF TMA&#8221;) with DWF MaaS Limited (&#8220;DWF&#8221;),
pursuant to which the Company appointed DWF to manage $15.0 million that DWF contributed in the September 2025 financing and implement
the TON treasury strategy for the Company. Under the DWF TMA, DWF is entitled to retain 100% of all profits earned until the balance with
DWF reaches $150.0 million at which point the Company will earn a 3% yield on all DWF-managed TON holdings, and additionally 10% of any
profits from asset management will be shared with the Company. In consideration for the services to be provided, the Company issued 160,000
ordinary shares to DWF, which shares shall vest linearly over a period of three (3) years from the date of issue to DWF. The initial term
of the agreement is 3 years and will commence on the date that the aggregate transfers from the Company to DWF reach $150 million.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company has the right to terminate the agreement
with 90 days&#8217; notice provided that a) the termination notice is submitted more than 18 months following commencement of the contract
term, and b) the Company publicly announces it will cease its strategy of holding TON as a treasury asset. Pursuant to the DWF AMA, DWF
is entitled to convert the Ordinary Shares it subscribed for in the September 2025 private placement into an equivalent value of TON from
the amount of TON held by DWF on behalf of the Company up to a maximum value of $15,000,000. DWF was granted the right to exercise this
conversion option at any time within twelve months from August 25, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The range of management and trading activities that
DWF is authorized to conduct under the DWF AMA is limited to market-making, buying and selling the TON tokens, and providing liquidity
on decentralized or centralized exchanges. DWF cannot use derivatives as part of their mandate. DWF is mandated to actively manage the
assets under management to provide market liquidity in TON trading pairs and generate a return. DWF is required to hold and secure the
assets using institutional-grade custody solutions, which may include qualified third-party custodians, centralized cryptocurrency exchanges,
multi-party computation (MPC) wallets, and other industry-standard security protocols designed to safeguard digital assets.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In addition to the initial $15.0 million that DWF contributed
in the September 2025 financing, the Company is required to make additional transfers of a) $5 million 15 days after the close of the
September 2025 financing, and b) $55.0 million within 3 months of the September 2025 financing, with no less than $20.0 million to be
transferred each month. The Company also agrees to transfer 50% of any subsequent treasury fundraising to DWF for asset management until
the total assets under management total $225.0 million. Through December 30, 2025, there had been no additional transfers to DWF, and
DWF was managing only the $15.0 million of their own funds that they contributed as part of the September 2025 financing.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 30, 2025, the Company entered into that
certain Settlement Agreement and Release (the &#8220;Settlement Agreement&#8221;), by and between the Company and DWF MaaS Limited (&#8220;DWF&#8221;).
The Settlement Agreement resolves certain disputes over the rights and obligations related to that certain Treasury Management Agreement,
dated as of August 25, 2025 (the &#8220;Treasury Management Agreement&#8221;), by and between the Company and DWF, pursuant to which the
Company appointed DWF to manage and implement a portion of the Company&#8217;s TON treasury strategy. On September 25, 2025, DWF subscribed
for (i) 105,000 ordinary shares (the &#8220;Shares&#8221;) of the Company, no par value per share (the &#8220;Ordinary Shares&#8221;),
and (ii) pre-funded warrants to purchase up to 2,513,240 Ordinary Shares (the &#8220;Pre-Funded Warrants&#8221; and together with the
Shares, the &#8220;Repurchase Securities&#8221;), in exchange for consideration of USD1 $15,000,000, in each case pursuant to that certain
Securities Purchase Agreement, dated as of September 2, 2025, by and between the Company and certain investors party thereto (including
DWF). Also on September 25, 2025, pursuant to the terms of the Treasury Management Agreement, the Company and DWF entered into that certain
Ordinary Share Issuance Agreement (the &#8220;Restricted Share Agreement&#8221;), pursuant to which the Company issued 160,000 Ordinary
Shares (the &#8220;Restricted Shares&#8221;) to DWF, with such Restricted Shares vesting linearly over a three (3) year period from the
date of issuance. Pursuant to the Settlement Agreement, the Company agreed to: (i) purchase the Repurchase Securities from DWF for an
aggregate amount of USD1 $15,000,000 (or whatever amount remains in the digital wallet used to fund the initial deposit pursuant to the
Treasury Management Agreement); (ii) remove the vesting restrictions applicable to the Restricted Shares; and (iii) pay DWF USD $35,000.
As part of the Settlement Agreement, the Company and DWF each agreed to a mutual full release of claims. Further, the Treasury Management
Agreement and the Restricted Share Agreement were terminated and no longer enforceable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Vertical Data Server Purchase Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On January 5, 2026, the Company signed an agreement
with Vertical Data Inc. to acquire 72 Dell XE9780-B300 Servers containing a total of 576 GPUs along with associated required networking
equipment, at a total cost of $<span id="xdx_907_ecustom--NetworkingEquipmentCost_iI_pn3n3_dm_c20260105_zCgH8B05Y3d5" title="Networking equipment cost">40.9</span>
million. On the same day a deposit of $<span id="xdx_90B_ecustom--Deposit_iI_pn3n3_dm_c20260105_zC8372JhHxyd" title="Deposit">2.0</span>
million was made, with additional deposits made in January and February 2026 of $6.0 million for a total of $8.6 million in deposits made
in order to hold the allocation of servers. The remaining cost of the acquisition will be funded via a GPU equipment financing lender.
The anticipated asset-backed loan will be non-recourse to the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80E_eifrs-full--DisclosureOfRelatedPartyExplanatory_zMNWtSsQYAeg" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. <span id="xdx_82D_zH4lT6D4Duwf">RELATED
PARTY TRANSACTIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Private Placement Financing</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On January 29, 2025, the Company completed the sale of<span id="xdx_90C_ecustom--SaleOfStock_iI_c20250129_zniq1FZ66aA3" title="sale of stock">
524,390</span>
ordinary shares for aggregate proceeds of $<span id="xdx_901_ecustom--AggregateProceeds_iI_c20250129_z4e7wqaeITZe" title="aggregate proceeds">2,150,000</span>,
at a per share price of $4.10, the closing price of a share on Nasdaq on the date preceding the date of the securities purchase agreement.
The shares were sold to two former directors of the Company, Messrs. Gregory Bailey and James Mellon. The shares were sold in a private
placement transaction pursuant to Regulation S, and were issued as restricted stock. The proceeds are being used for general corporate
purposes and working capital.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>SalvaRx Acquisition</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Two of the Company&#8217;s former directors, Messrs.
Gregory Bailey and James Mellon, are also directors of SalvaRx Group plc, a company which owned approximately 2.2% of the Company&#8217;s
issued and outstanding ordinary shares as of March 31, 2025. As of March 31, 2026, SalvaRx Group plc owns no issued and outstanding shares
of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><b><i>Investments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company has entered into related party transactions
and certain services agreements with certain of its shareholders. Key management personnel of the Company have also entered into related
party transactions with certain of its shareholders. Key management personnel are those people who have the authority and responsibility
for planning, directing and controlling the activities of the Company, including directors and senior management of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following subsidiaries and associates are considered related
parties:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b>iOx</b>. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Alpha Compute director resigned from the iOx board 	leaving
two Alpha Compute insiders as directors. The management team of Alpha Compute comprises the management team of iOx.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b>Saugatuck</b>. Saugatuck is 70% owned by the Company and is controlled by Alpha Compute.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0.5in; font-size: 10pt; text-indent: 0in">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b>Portage Development Services Inc</b>. PDS provides human resources and other services to each operating subsidiary of Alpha Compute
		through shared services agreements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Transactions between the parent company and its subsidiaries,
which are related parties, have been eliminated in consolidation and are not disclosed in this note.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Board Resignations and Appointments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On April 25, 2024, Mark Simon resigned all of his positions
on the Board of Directors, and on April 26, 2024, Linda Kozick and Dr. Robert Glassman resigned all of their positions on the Board of
Directors. On April 30, 2024, Dr. Jean -Christophe Renondin and Dr. Justin Stebbing were elected to the Board. On August 3, 2025, Justin
Stebbing, and Jean-Christophe Renondin resigned from the Board of Directors and Brittany Kaiser was appointed to the Board. On September
25, 2025, Gregory Bailey and James Mellon resigned from the Board of Directors and Michael Terpin and Enzo Villani were appointed to the
Board. On December 19, 2025, Alexander Pickett resigned from the board of directors of the Company. On February 6, 2026 Steven Mintz resigned
from the board of directors and was replaced with F. Dan Siciliano.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Advisory Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On August 20, 2025, the Company entered into an independent
contractor agreement with Ralph Matthew McKibbin (the &#8220;McKibbin Agreement&#8221;), pursuant to which Mr. McKibbin will provide development
advisory services to the Company. Mr. McKibbin is entitled to an equity grant in options at a strike price equal to the fair market value
on the date of the grant of 0.25% of the issued and outstanding ordinary shares of the Company after giving effect to the number of issued
and outstanding ordinary shares of the Company as of immediately after the Closing. 50% of the options will vest immediately and the remaining
50% shall vest in equal installments over a 12-month period. Due to the relationship between Ms. Kaiser and Mr. McKibbin, the McKibbin
Agreement is a related party transaction for Ms. Kaiser.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Relationship with DecentraNet</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">DecentraNet is an early-stage venture investment fund and advisory firm.
They invest at the earliest stages (F&amp;F, Pre-Seed, and Seed), and have advisory clients ranging from startups to multi-billion dollar
public companies. In Fiscal 2026 the Company paid DecentraNet a total of $<span id="xdx_903_ecustom--Decentranet_iI_pip0_c20260331_zgVeevC4nwF8" title="DecentraNet">55,000</span>
for advisory and fundraising services. Mr. McKibbin is the founder of DecentraNet and a related party to the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Retention Agreements and General Releases</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On July 22, 2024, the Company and Portage Development
Services, Inc. entered into a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) with each of Allan Shaw, the
Company&#8217;s former Chief Financial Officer (&#8220;Employee&#8221;) and Joseph Ciavarella, the Company&#8217;s former controller (&#8220;Consultant&#8221;).
Under the terms of each of the Retention Agreements, Employee&#8217;s current employment agreement and Consultant&#8217;s current consulting
agreement both terminated on July 22, 2024, except with respect to certain provisions. In return for continuing to provide services to
the Company and its affiliates and completing certain tasks as described in the respective Retention Agreements, the Company paid an aggregate
$0.2 million (the &#8220;Retention Amount&#8221;) to Employee and Consultant, in addition to their monthly pay through September 30, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company accrued the Retention Amount, as well as
the monthly pay totaling $0.2 million through September 30, 2024, in the consolidated financial statements for the three months ended
June 30, 2024, as the material terms of the Retention Agreements were known and agreed upon at June 30, 2024. In accordance with the terms
of the Retention Agreements, the Company paid in full the Retention Amount and issued 14,348 ordinary shares to the Employee and Consultant
in lieu of cash bonuses accrued in Fiscal 2023 totaling $0.1 million by September 30, 2024, the date on which the Employee&#8217;s employment
and the Consultant&#8217;s consulting relationship with the Company and its affiliates ended.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><b><i>Relationship with Compedica</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As discussed in Note 10, the Company acquired an equity
interest in Compedica, a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby Compedica obtained a corresponding 27.4% interest in the Company, which
was subsequently diluted in connection with the private financing in September 2025. As of September 30, 2025, Compedica owned 11.9% of
the Company&#8217;s ordinary shares issued and outstanding. At the time of the Compedica investment, Jim Mellon was a director of both
Compedica and the Company and a greater than 5% owner of the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On February 6, 2026, the Company and Compedica agreed
to exchange their ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being
returned to the Company&#8217;s treasury and the investment being exited. As of March 31, 2026, the Company no longer has any affiliation
with Compedica, its employees, or directors, excepting the 625,000 Company shares to be returned, which was completed on May 21, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Asset Management Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At the closing of the Company&#8217;s financing on
September 25, 2025, the Company entered into an Asset Management Agreement (the &#8220;Asset Management Agreement&#8221;) with Alpha Sigma
Capital, LLC (the &#8220;Asset Manager&#8221;). Pursuant to the Asset Management Agreement, the Asset Manager shall provide discretionary
investment management services with respect to, among other assets (including without limitation certain subsequently raised funds), certain
of the Company&#8217;s net proceeds from the Offering (the &#8220;Account Assets&#8221;) in accordance with the terms of the Asset Management
Agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Under the Asset Management Agreement, the Company shall
pay the Asset Manager an asset-based fee equal to 1.0% per annum of the Account Assets. The Account Assets managed under the agreement
are held in the name of the Company and remain under Company control. The agreement term is one year, after which it renews automatically
and can be terminated by the Company with 90 days&#8217; notice, provided that the Company has decided to end the TON digital asset treasury
strategy.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Asset Manager is mandated to invest the Account
Assets principally with a long-only strategy primarily in TON, including staking (and restaking) TON to improve returns. The Asset Manager
is not permitted to invest in any OTC derivatives, futures contracts, or option contracts that would require the Asset Manager to register
as a commodity pool operator or commodity trading advisor.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Mr. Enzo Villani, Chief Investment Officer of the Company,
is the Chief Executive Officer and Chief Investment Officer of the Asset Manager. Alpha Sigma Capital was also an investor in the Company&#8217;s
September 2025 financing.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Alpha Transform Holdings</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Alpha Transform Holdings ("ATH") is a related
party of the Company because it is majority-owned by Enzo Villani, CIO and Chairman, and Michael Terpin, board member. On July 15, 2025,
ATH entered into a consulting service agreement with Ground Tunnel Capital LLC, a third-party advisory and marketing consultant. This
consulting service agreement was assigned to the Company on October 25, 2025, after Company board approval on October 20, 2025. The effective
date of the agreement occurred upon the closing of the subsequent private placement of ordinary shares, which occurred on September 25,
2025, with contractual services to be provided through July 15, 2028. $1.0 million was paid upon execution of the contract, with subsequent
milestone payments of $0.25 million due on each October 15, 2025, January 15, 2026, April 15, 2026 and July 15, 2026. On April 15, 2026,
the Company submitted its third milestone payment in the amount of $0.25 million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Blockchain Wire / Content Syndicate</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Content Syndicate (dba Blockchain Wire) is a press release distribution
service focused on news from blockchain and crypto companies and projects. Their global reach includes distribution to broadcast and online
media outlets, social media sites, trade publications, leading blogs, industry executives, influencers and investors. They offer multiple
distribution options, ease-of-use, broad partnership integrations and a dedicated client services team. In Fiscal 2026 we paid Content
Syndicate a total of $0.2 million for distribution and placement of press releases and media buys. Content Syndicate is a related party
by virtue of being owned by Enzo Villani and Michael Terpin.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Compensation Arrangements</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table summarizes all compensation paid or payable by the Company
to its directors and senior management for the fiscal years ended March 31, 2026, 2025, and 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfCompensationPayableTableTextBlock_pn3n3_zHXd7Jnzfrck" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BA_zixr8vFgcR02" style="display: none">Schedule of compensation payable</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_494_20250401__20260331_zsRoltRPBld9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49F_20240401__20250331_zsUMlGFMdxLi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_492_20230401__20240331_z3f7odmy8b53" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Years ended March 31,</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_405_eifrs-full--ShorttermEmployeeBenefitsExpense_z3Z4JOrwThD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; font-size: 10pt; text-align: left">Short-term employee benefits (salary, bonus, etc.)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right">4,052</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right">13,787</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right">2,127</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--PostemploymentBenefitExpenseInProfitOrLoss_zgWTLhldnN2k" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Post-employment benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--OtherLongtermBenefits_z3xdmb0zVY02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other long-term benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TerminationBenefitsExpense_zafHHyIajBx2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Termination benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">152</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">49</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SharebasedPaymentCompensation_zOi8VtKNS8R6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Share-based payment compensation</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,600</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">590</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--KeyManagementPersonnelCompensationPostemploymentBenefits_zCLlzQjclxc6" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt">&#160;Total</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,804</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,968</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,176</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A6_ztqJSmixiNEk" style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt"><b><i>Compensation Arrangements</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following tables and accompanying notes set forth all compensation paid
or payable by the Company to its directors and senior management for the fiscal years ended March 31, 2026, 2025, and 2024. The share
information is adjusted to give effect to the 1-for-20 reverse share split completed on August 15, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Director Compensation</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt"></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>




<table cellpadding="0" cellspacing="0" id="xdx_88A_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_pn3n3_zsSJyhx1c6Hc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B3_zt4kH5O16nzc" style="display: none">Schedule of Compensation</span><b></b></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name &amp; Principal Position</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Year</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Fee and</p>
        <p style="margin-top: 0; margin-bottom: 0">Salary<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Transaction</p>
        <p style="margin-top: 0; margin-bottom: 0">Closing Bonus<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Securities Under</p>
        <p style="margin-top: 0; margin-bottom: 0">Options Granted</p></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Shares
        or Units<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(16)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Other<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total
        Compensation</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Michael Terpin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNonqqAnuxL6" style="width: 6%; font-size: 10pt; text-align: right" title="Fee and salary">61,250</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoGAzHJAW9ha" style="width: 6%; font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2365">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBJ5jtH5VJxi" style="width: 6%; font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2367">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXUS9z2RFnKe" style="width: 6%; font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zo5x151YrI08" style="width: 6%; font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2371">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zeGeIqzBlHHa" style="width: 6%; font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2373">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKAQnKIBVFl" style="width: 6%; font-size: 10pt; text-align: right" title="Total compensation">61,250</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">F. Daniel Siciliano</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAxjPVuOqAd1" style="font-size: 10pt; text-align: right" title="Fee and salary">17,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0Ds2tWNJgJf" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2379">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zViTOGYOjUTb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3EDhTZQUYtk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2383">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKfKYHRU4df" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2385">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQAzgB6RPKmk" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2387">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxHSyyvchTo5" style="font-size: 10pt; text-align: right" title="Total compensation">17,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Gregory H. Bailey, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zKA2GK6DRIsb" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zclrmtQoP3W8" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3E62n2WJsch" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2395">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3Laoj6J7x6l" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2397">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zaQPMUPA12H9" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2399">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDEwTQWqSVWl" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2401">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zYYV6QOSnEii" style="font-size: 10pt; text-align: right" title="Total compensation">55,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zQW0F083ILE8" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzLkgMAohvck" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2407">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9zPiAillZth" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2409">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcxjFC5oiD82" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2411">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdpe9o9DRVRe" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2413">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zJVTE3UPEleg" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2415">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0EPcEey05sf" style="font-size: 10pt; text-align: right" title="Total compensation">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zafYIIQiMnc6" style="font-size: 10pt; text-align: right" title="Fee and salary">49,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjHLde5nX3Ka" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2421">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV8qA7QLXBM" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2423">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zq29hiLqruh1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2425">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zidJETtEIj0l" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2427">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zOKkHDjgv5kg" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2429">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr7iC3iWVabk" style="font-size: 10pt; text-align: right" title="Total compensation">49,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">James Mellon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zkYEtExNX3L8" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTjiH2TcAZI7" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_znhHbc0cne87" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2437">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zawteqprpt8c" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2439">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHczKE0v7c61" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2441">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCpjNRF2mW7" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2443">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5rHhXnKidG6" style="font-size: 10pt; text-align: right" title="Total compensation">55,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zWig206U3G18" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfu21gboJ1tk" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2449">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdxYO2zK8eqa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2451">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUcKJJa0bhBf" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2453">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjf6JrncjUyb" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2455">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqKSY5CqTFQe" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2457">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTy5cU7HFV8f" style="font-size: 10pt; text-align: right" title="Total compensation">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zw2QCK6ec9pi" style="font-size: 10pt; text-align: right" title="Fee and salary">35,242</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhtuMXozwUg2" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2463">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBDeiB7FkJYf" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2465">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zM1t9ctOZH3i" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2467">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyAu82T1XFni" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2469">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoebWFZWmLZj" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQlZs1WrdtE1" style="font-size: 10pt; text-align: right" title="Total compensation">35,242</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Steven Mintz<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zK96CTLr4KUh" style="font-size: 10pt; text-align: right" title="Fee and salary">77,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZ3OGprqhqdc" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPEXV0JcrOGk" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2479">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfvaAeHDuLK3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">54,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztrvWOcSlcsb" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z4VfQDhLBvr4" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2485">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhjUsjqSYTi4" style="font-size: 10pt; text-align: right" title="Total compensation">157,296</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zESRkB16EQy" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbyRiuRbTuIe" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2491">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2Vmxgqk48k8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2493">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMg9yIgKCJBg" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">113,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zG3vzCuGNoxi" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z59r180DH0gd" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2499">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zmGKMJGieq5h" style="font-size: 10pt; text-align: right" title="Total compensation">143,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zVw44CDH5dJ7" style="font-size: 10pt; text-align: right" title="Fee and salary">45,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwiyV4Epblrb" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2505">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zObscOD9MX7h" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2507">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQYts612ziEc" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2509">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKS6PeaJLfE6" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2511">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlQzVcEdoni3" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2513">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zGWAWnEfDsil" style="font-size: 10pt; text-align: right" title="Total compensation">45,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Jean-Christophe Renondin, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zlfHg9RK3Rq4" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCwBzTB6Tehc" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjoDgQ1BiKXi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2521">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqK9q24YXjn5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">54,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyUIr0qWbKhk" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2525">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zv9U42HQIach" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2527">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zT9pNoVuuFN2" style="font-size: 10pt; text-align: right" title="Total compensation">109,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zPxvg4vmLqY2" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNNyYB3ivBO1" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2533">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEsWlDotiEAd" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2535">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMJYowivhzb1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">96,992</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zin1LxHAWUNj" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2539">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zVtfsIEfAri6" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2541">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ziu28NvBoHPk" style="font-size: 10pt; text-align: right" title="Total compensation">126,992</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_z75HluNHcuTe" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2545">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIHqOh38LsRb" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2547">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHmEUgDNtzBe" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2549">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCKmV9NTn7w5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2551">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdFx3W0dfNC3" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2553">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zANYBart5atk" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2555">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9sT2Ix8V7l8" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2557">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Justin Stebbing, M.D. PhD<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_z2XVSuy8aLk9" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEqzzTFqvfXb" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFDJzVGeF81e" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2563">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIEBADLsTBd9" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">64,760</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlqOVuJSjh34" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2567">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvtSbnsTGWWl" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2569">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zedrsawnoOL4" style="font-size: 10pt; text-align: right" title="Total compensation">119,760</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zf6HK6RHLWDh" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zA28749keNBk" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2575">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2RqB6D16r43" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2577">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyddtzDsyDzi" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">121,240</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDN79Ubqn1" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2581">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zm2UjAPrRcrf" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2583">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNXemAyLNf1" style="font-size: 10pt; text-align: right" title="Total compensation">151,240</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zykeYTyHgPE9" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2587">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsWWmglVHGT4" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2589">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgB2nUeblEPa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2591">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcQYHpDiclT3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2593">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqF6sXtREO3h" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2595">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztFzI9yvPxfj" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2597">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQzOCViYiew7" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2599">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Linda Kozick<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zovruTySfId" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2601">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zkjeS6ybUqid" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2603">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWnki9hi25J8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2605">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBOPWIdToL4e" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2607">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxQqGNhqk2ul" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2609">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFUoJqbH15Ze" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2611">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgQvMyONcsPe" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2613">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zYn1MzZ5W86d" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2615">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCWtdzLwNGR2" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2617">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zERocssYs7ia" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2619">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAHFQeeI0HD3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2621">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNVDfucmuhr6" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2623">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV0Wd7pQjWy6" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2625">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z7sbm2QsPH98" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2627">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zvdbgjx5V7W7" style="font-size: 10pt; text-align: right" title="Fee and salary">42,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcGa3Q6kgqsb" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2631">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPHe0cUYrxBg" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2633">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z1TiHjTnJaii" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2635">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZa3YuppNtv7" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2637">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsZPQcnLKMsb" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2639">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr9JH4Y9zCf5" style="font-size: 10pt; text-align: right" title="Total compensation">42,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Mark Simon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z3o4vt2SH14h" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2643">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zy2icmNOfQ6c" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2645">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSWn5iEL3Pd6" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2647">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zpWBlry94uwk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2649">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAEfHnsSJ9T3" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2651">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEKwVCuNjS2a" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2653">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV6hacfGlro6" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2655">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zPzxiVbd5jvj" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2657">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWu738896MJd" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2659">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUSHpXd20fGl" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2661">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3g5SeQqJbF8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2663">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAV11Afrww21" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2665">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_za0HrOXyFQX3" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2667">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWRzANTguJke" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2669">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z9ajTWyVlY6d" style="font-size: 10pt; text-align: right" title="Fee and salary">55,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2bSz4QeWlel" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2673">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z8cJcD5mYKm3" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2675">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zblyaUGazip8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2677">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj5sjbH4qSDc" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2679">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMX6fWtOk2kd" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2681">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSME3co5fKs4" style="font-size: 10pt; text-align: right" title="Total compensation">55,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Robert Glassman<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zQySdV047Tic" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2685">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTJWhurMpP02" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2687">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSfs9jdBhhri" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2689">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXFY3pmarW25" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2691">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZXTLYmgUsmc" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2693">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zrxZi6X6OiBl" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2695">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5wbwwQk5Bk6" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2697">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zs32GrJba2ra" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2699">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj6i0XkDl3w2" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2701">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z6C27MJSgYn7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2703">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zF3eb7ynJui7" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2705">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKd32So0gR5f" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2707">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhCzgbRnYmIb" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2709">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbGNoa8KJwNa" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2711">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zgb4SR5eT5K2" style="font-size: 10pt; text-align: right" title="Fee and salary">45,258</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zw9Fd80Mp8H3" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2715">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zg9P2hh7j3l4" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2717">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlsZDtlIXCj6" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2719">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvzYssiMoRwg" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2721">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zU85u4TYgDY5" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2723">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwbCohDoSo3f" style="font-size: 10pt; text-align: right" title="Total compensation">45,258</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><b>Executive Officer Compensation</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="display: none">Schedule of Executive officer compansation</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name &amp; Principal Position</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Year</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Fee and</p>
        <p style="margin-top: 0; margin-bottom: 0">Salary<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Transaction</p>
        <p style="margin-top: 0; margin-bottom: 0">Closing Bonus<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Securities Under</p>
        <p style="margin-top: 0; margin-bottom: 0">Options Granted</p></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Shares
        or Units<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(16)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Other<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total
        Compensation</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Executive Officers</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Brittany Kaiser</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Chief Executive Officer and Director</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zsRSL83B4n5d" style="width: 6%; font-size: 10pt; text-align: right" title="Fee and salary">661,290</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zEPCzIssRzuh" style="width: 6%; font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2733">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_z9WoVYJ9tcVc" style="width: 6%; font-size: 10pt; text-align: right" title="Transaction closing bonus">500,000</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zBtwdwmLfEhh" style="width: 6%; font-size: 10pt; text-align: right" title="Securities under option granted">218,219</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_z1m4vflnG5Eb" style="width: 6%; font-size: 10pt; text-align: right" title="Shares ot units">149,015</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zr1kX8GaJow9" style="width: 6%; font-size: 10pt; text-align: right" title="Other compensation">187,102</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zypWIDBYVWrf" style="width: 6%; font-size: 10pt; text-align: right" title="Total compensation">1,715,627</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Enzo Villani</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Investment Officer and Director</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zuBZJQ4UkBle" style="font-size: 10pt; text-align: right" title="Fee and salary">369,355</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zfgD9Ar5QVqf" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2747">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zg4LeBuAFIIe" style="font-size: 10pt; text-align: right" title="Transaction closing bonus">500,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zWanGbKiWGDj" style="font-size: 10pt; text-align: right" title="Securities under option granted">218,219</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zO5BLxUIsWd1" style="font-size: 10pt; text-align: right" title="Shares ot units">248,359</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zqTFCmUoSNrk" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2755">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zUJuSOMnWKud" style="font-size: 10pt; text-align: right" title="Total compensation">1,335,933</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Wes Levitt</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zDMGf2sJVGbk" style="font-size: 10pt; text-align: right" title="Fee and salary">219,086</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zxNhK6nhvpDf" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2761">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_z3R8ngyshAf1" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2763">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zKV5oLx0hZUk" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2765">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zaFdFsTKgH79" style="font-size: 10pt; text-align: right" title="Total compensation">219,086</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Yury Mitin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Business Development Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zlKYXakmAHL6" style="font-size: 10pt; text-align: right" title="Fee and salary">369,355</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zGd8isiJ1sg7" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2771">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z7yuUMs6AoV9" style="font-size: 10pt; text-align: right" title="Transaction closing bonus">500,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z2wfnxTx7kg7" style="font-size: 10pt; text-align: right" title="Securities under option granted">218,219</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z9zucdGqvRy5" style="font-size: 10pt; text-align: right" title="Shares ot units">99,344</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zMuFYiLuL7s6" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2779">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zlzrsBO89wOh" style="font-size: 10pt; text-align: right" title="Total compensation">1,186,918</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Alexander Pickett<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(10)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Executive Officer and Director</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zoMNnwHrkis7" style="font-size: 10pt; text-align: right" title="Fee and salary">51,250</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zlzP7JEn326k" style="font-size: 10pt; text-align: right" title="Bonus">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zmQX7tKOXXuc" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2787">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zIyXQtfMZB8b" style="font-size: 10pt; text-align: right" title="Securities under option granted">234,132</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zmfQD2Fqp8o" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2791">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zxxULj9kjEyb" style="font-size: 10pt; text-align: right" title="Other compensation">39</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zphngo34IxSi" style="font-size: 10pt; text-align: right" title="Total compensation">310,422</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z7JQI9mIRBO4" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zri8f7P16vp3" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2799">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z2cIt3P0KVP5" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2801">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z7vwdqupXKGk" style="font-size: 10pt; text-align: right" title="Securities under option granted">145,488</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zZ6gqYXgH0y1" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2805">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z9hQDr1rk7Pb" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2807">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zy7HRIehI78a" style="font-size: 10pt; text-align: right" title="Total compensation">175,488</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Ian Walters<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(11)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Executive Officer and Chairman of the Board</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z2ntn3Utyoac" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2811">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zWpHmoUEhn4g" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2813">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zILmvAYvfjGd" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2815">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zCuFeibAUeOe" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2817">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zr7KsUmwyex" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2819">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zWnm3M0wFTwj" style="font-size: 10pt; text-align: right" title="Other compensation">152,383</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zVQy7Vsh067c" style="font-size: 10pt; text-align: right" title="Total compensation">152,383</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zZP4cl1iLIV8" style="font-size: 10pt; text-align: right" title="Fee and salary">453,186</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zumuaXLbdQc" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2827">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z6ls8nrnoZae" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2829">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zQHEZPMXgYf9" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2831">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z7D5qD7vSuo5" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2833">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zUWMSVTb3bC7" style="font-size: 10pt; text-align: right" title="Other compensation">54,716</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zKRTAAcMFwcb" style="font-size: 10pt; text-align: right" title="Total compensation">507,902</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zTzgKDKRCom4" style="font-size: 10pt; text-align: right" title="Fee and salary">642,700</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zaKJJnXEzbIe" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2841">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zts7mxcbz45f" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2843">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z2xJ4xMUomX4" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2845">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zuAxUZwjGMkl" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2847">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zvkRwFiVuEnj" style="font-size: 10pt; text-align: right" title="Other compensation">75,185</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zfLBZfrTGhFa" style="font-size: 10pt; text-align: right" title="Total compensation">717,885</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Andrea Park<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(12)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zkFIM5fA7jme" style="font-size: 10pt; text-align: right" title="Fee and salary">218,429</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z9mNpC5oEbig" style="font-size: 10pt; text-align: right" title="Bonus">50,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zlePMuqfP4ba" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2857">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zifOP4lRS4t6" style="font-size: 10pt; text-align: right" title="Securities under option granted">39,857</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z7sO66XItMi5" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2861">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zA3W7uVaXwed" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2863">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zSaS1byRA9Ek" style="font-size: 10pt; text-align: right" title="Total compensation">308,286</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z1jy5LrjM131" style="font-size: 10pt; text-align: right" title="Fee and salary">163,790</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zMpHN4gcxztc" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2869">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z6rgIlKruOy" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2871">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zKc5sRNqdGc3" style="font-size: 10pt; text-align: right" title="Securities under option granted">113,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zBGMsDFPQ8d6" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2875">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zoGOCLueFBL3" style="font-size: 10pt; text-align: right" title="Other compensation">28,659</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zoF3oXg6sq64" style="font-size: 10pt; text-align: right" title="Total compensation">305,607</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Allan Shaw<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(13)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zgHuSnsumjKf" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2881">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zwy0CgrPuZli" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2883">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zCS6zaIV38eb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2885">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zEX4abnPhO16" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2887">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zhhURZ8lkuF1" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2889">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z3kfJRvUNAt9" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2891">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zP1b00oWqVv7" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2893">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer and Secretary</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z6X35sXeNlJd" style="font-size: 10pt; text-align: right" title="Fee and salary">234,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zrRLLPKPECX9" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2897">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z1CPirGeDu62" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2899">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z54qeNf02j9i" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2901">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z5VFfQMkHou8" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2903">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zK8VHsn7BFx2" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2905">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zFwhvvEOIZkg" style="font-size: 10pt; text-align: right" title="Total compensation">234,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z128A2Qx5r2g" style="font-size: 10pt; text-align: right" title="Fee and salary">469,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zRVtZdvGG0b" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2911">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zO5VyWod8IRi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2913">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zZvYXgeGleDf" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2915">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zcKBy7zxDL68" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2917">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zkgEV3Rsqmmi" style="font-size: 10pt; text-align: right" title="Other compensation">49,205</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zhAAJ03Vki78" style="font-size: 10pt; text-align: right" title="Total compensation">518,205</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Robert Kramer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Scientific Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zeKbjXkh9SAg" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2923">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zlMWWmBuKCbg" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2925">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zdKEptj4Ttvf" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2927">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zxVDrHOOSkJj" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2929">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zCM0ZLJrDV58" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2931">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zyWlCsnUIaFc" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2933">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zaI15fUmyoJ2" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2935">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zBrpjzORSNtg" style="font-size: 10pt; text-align: right" title="Fee and salary">112,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zvONFNFROw6" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2939">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_z8V1YvePObZ2" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2941">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zLJURtCSGyDk" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2943">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zqWbFcPd9nX3" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2945">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zGSCMGrHVHT2" style="font-size: 10pt; text-align: right" title="Other compensation">6,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zGFjVTSYQkyc" style="font-size: 10pt; text-align: right" title="Total compensation">119,250</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_z2QfVJVQM7ai" style="font-size: 10pt; text-align: right" title="Fee and salary">168,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zIHfSoC5oSB7" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2953">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zkda0TIEZEGi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2955">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zpdX0MBauMFh" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2957">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_ztBrxvJWBszk" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2959">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zMOI2sHHiYQ3" style="font-size: 10pt; text-align: right" title="Other compensation">17,141</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zlKvAEI42wSc" style="font-size: 10pt; text-align: right" title="Total compensation">185,891</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Brian Wiley<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(14)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Chief Business Officer</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z6HodCwr8EHb" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2965">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zCjtu4hrtYg2" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2967">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zCl12DUxoWVh" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2969">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zintvgYZfpY2" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2971">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zzbVPpIjLuyf" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2973">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zzbWtG8jsEv1" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2975">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z3NPcwpBXBig" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2977">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zP7mrsMruzlk" style="font-size: 10pt; text-align: right" title="Fee and salary">114,844</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zJD4rK71PVy9" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2981">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zxgXDDrTAOz7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2983">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zOLKndqNBW3c" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2985">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zYw5JAKDM8T2" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl2987">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zF1ljkUkl9K" style="font-size: 10pt; text-align: right" title="Other compensation">8,627</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zlvNGoBPCXNe" style="font-size: 10pt; text-align: right" title="Total compensation">123,471</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zjhBwpmoheL5" style="font-size: 10pt; text-align: right" title="Fee and salary">153,125</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zNmlvkqiUwSj" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl2995">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zKv4L5Ya4Anb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2997">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zZNZFXTdGWbl" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl2999">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zArx74zd0d5g" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl3001">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zEaYMv5dbTJe" style="font-size: 10pt; text-align: right" title="Other compensation">2,297</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z2IpzrN0hMfg" style="font-size: 10pt; text-align: right" title="Other compensation">155,422</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Justin Fairchild<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(15)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Vice President of Development</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJcX9OX6qix8" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl3007">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zxANUsRQQ4Y4" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl3009">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zOPIyjs78oJ7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl3011">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zvYY00g2HBsa" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl3013">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_z8GgjQWtVzt3" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl3015">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zUaiROfbpGCi" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl3017">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJ7dIehYUuRl" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl3019">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zg1aCPOJvQC6" style="font-size: 10pt; text-align: right" title="Fee and salary">20,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zTB1JqzFenLk" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl3023">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_ztFNYUEEbQLb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl3025">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zDvqGPJR89El" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl3027">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zbmVM01TE0Ck" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl3029">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zcUWUNrEXErh" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl3031">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_ziG576A421Sf" style="font-size: 10pt; text-align: right" title="Total compensation">20,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zOZ59H7Pa2V3" style="font-size: 10pt; text-align: right" title="Fee and salary">270,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJ1fGE5mCRKa" style="font-size: 10pt; text-align: right" title="Bonus"><span style="-sec-ix-hidden: xdx2ixbrl3037">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zSCh88irr74l" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl3039">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zXvRYRzgl2dk" style="font-size: 10pt; text-align: right" title="Securities under option granted"><span style="-sec-ix-hidden: xdx2ixbrl3041">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zvzDFfhxtqB" style="font-size: 10pt; text-align: right" title="Shares ot units"><span style="-sec-ix-hidden: xdx2ixbrl3043">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zsor9CvvkZQ2" style="font-size: 10pt; text-align: right" title="Other compensation">55,301</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zlXniLHAyag4" style="font-size: 10pt; text-align: right" title="Total compensation">325,301</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>






























<p style="margin: 0pt 0; font-size: 10pt"><b>Notes</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(1)</td>
    <td>Represents base salary earned by executive officers in accordance with their respective contractor agreements and director&#8217;s fees
        earned by directors. For Brittany Kaiser, Enzo Villani, Yury Mitin, and Wes Levitt, their base salary is comprised of equal portions payable
        in USD and TON tokens. The figures in the table represent the sum of both. To date, these executives&#8217; USD portions of their salaries
        have been paid monthly, while the TON portions have been accrued by the Company.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(2)</td>
    <td>Dr. Bailey, Mr. Mellon, Mr. Mintz and Ms. Kozick waived their directors&#8217; fees with respect to the three months ended March 31, 2024.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(3)</td>
    <td>The contractor agreements for executives Brittany Kaiser, Enzo Villani, and Yury Mitin each provided for bonuses consisting of $250,000
        in cash and $250,000 worth of TON tokens, payable upon the Company raising at least $50 million in equity financing through private or
        public share offerings. This milestone was achieved on January 14, 2026, upon the closing of a $15 million registered direct share offering,
        which, together with prior equity financings, resulted in aggregate equity financing proceeds in excess of $50 million. During Fiscal
        2026, the Company paid the cash portion of the bonus to each executive and accrued the TON token portion of each executive&#8217;s bonus.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(4)</td>
    <td>Represents employee benefits paid by the Company.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(5)</td>
    <td>Represents the aggregate grant date fair value of 14,600 options to purchase ordinary shares granted on March 30, 2023, which vested on
        the first anniversary of the date of grant.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(6)</td>
    <td>Represents the aggregate grant date fair value of options to purchase ordinary shares granted on March 7, 2025, which one-quarter vested
        immediately, one-quarter vested on March 7, 2026, and the remaining balance to vest in equal parts on March 7, 2027 and March 7, 2028.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(7)</td>
    <td>Mr. Mellon and Dr. Bailey served as directors of the Company through September 25, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(8)</td>
    <td>Dr. Renondin and Dr. Stebbin served as directors of the Company through August 3, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(9)</td>
    <td>Mr. Mintz served as a director of the Company through February 6, 2026.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(10)</td>
    <td>Ms. Kozick and Dr. Glassman served as directors of the Company through April 25, 2024, and Mr. Simon served as a director of the Company
        through April 24, 2024.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(11)</td>
    <td>Mr. Pickett was appointed as our Chief Executive Officer under a consultancy agreement and joined our Board of Directors on December 15,
        2024. He resigned as Chief Executive Officer on August 2, 2025 and departed the Board of Directors on December 19, 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(12)</td>
    <td>Dr. Walters served as our Chief Executive Officer and Chairman of our Board of Directors through December 14, 2024. In accordance with
        his employment agreement, all unvested share options at that time vested immediately.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(13)</td>
    <td>Ms. Park was appointed as our Chief Financial Officer on September 30, 2024 and left the Company in October 2025.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(14)</td>
    <td>Mr. Shaw served as our Chief Financial Officer and Secretary through September 30, 2024. Other compensation in the amount of $127,250
        represent payments made to Mr. Shaw under a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) dated July 22,
        2024. Additional information concerning the Retention Agreement may be found in Note 14, Related Party Transactions to the consolidated
        financial statements included elsewhere in this Annual Report.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(15)</td>
    <td>Mr. Wiley served as our Chief Business Officer through November 15, 2024. In accordance with his employment agreement, all unvested share
        options at that time vested immediately.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(16)</td>
    <td>Mr. Fairchild resigned as our Vice President of Development in January 2024 but continued to provide his services as a consultant through
        May 31, 2024, his resignation date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(17)</td>
    <td>On March 11, 2026, the Board authorized the grant of 149,015 RSUs to Ms. Kaiser, 99,344 RSUs to Mr. Mitin, and 248,359RSUs to Mr. Villani,
        which were owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private
        or public share offerings. These RSUs were formally granted on April 29, 2026.</td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"></p>

















<p style="margin: 0pt 0; font-size: 10pt"><b>Outstanding Equity Awards at Fiscal Year-End</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following table and related notes provide certain information regarding
all outstanding equity awards for our executive officers as of March 31, 2026, as adjusted to give effect to the 1-for-20 reverse share
split completed on August 15, 2024:</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfOutstandingEquityAwardsTableTextBlock_pn3n3_zUddgk7Gcfgb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center"><span id="xdx_8BC_zds2qVV7hoNg" style="display: none">Schedule of outstanding equity awards</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td id="xdx_489_ecustom--GrantDate_zv5L3hacsjJi" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_eifrs-full--AdjustedWeightedAverageShares_zXG6jKTofL26" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_484_ecustom--NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_zdw0j2DqgZS7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_481_ecustom--ExercisePrices_zDsaBjP2lnfh" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_ecustom--OptionExpirationDate_zxMOuc8Am8T5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_485_ecustom--NumberofShareUnitsofStockThetHaveNotVested_zAWcL9PojHuk" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_481_ecustom--MarketValueNumberofShareUnitsofStockThetHaveNotVested_zVLiL1qWgK3l" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option
        Awards</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Stock
        Awards<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares or</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Market Value of Shares or</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Securities Underlying</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercised
        Options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Exercise</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Expiration</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Grant Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; font-style: normal">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Exercisable<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercisable</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Price</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td></tr>
  <tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zgOPBxjAs4Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; font-size: 10pt; font-style: normal">Alexander Pickett<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(2)</sup></span></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">3/7/2025</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">36,000</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3061">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">4.45</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">3/7/2035</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3065">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettTwoMember_zZvKOqSPCb94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">45,937</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3068">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3071">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3072">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersMember_z6dycgWI0aA1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Ian B. Walters<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">15,085</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3075">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3078">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3079">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersTwoMember_zd9ZGUIjKT68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,285</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3082">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3085">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3086">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersThreeMember_zJXquc5spit6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7,550</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3089">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3092">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3093">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkMember_zBMSVdDCBMY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Andrea E. Park<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(4)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/7/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">28,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3096">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4.45</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/7/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3099">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3100">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkTwoMember_zlaEd1lAoeMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7,820</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3103">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3106">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3107">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z8UjEeWV6QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Allan Shaw<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(5)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,761</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3110">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3113">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3114">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawTwoMember_zG4l5SHTmNF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">840</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3117">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3120">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3121">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawThreeMember_z8RpUX7kiZui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,550</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3124">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3127">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3128">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zNIBveNX6rz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Robert Kramer<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,771</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3131">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2033</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3134">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3135">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerTwoMember_zAm81wtqiGEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,255</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3138">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2032</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3141">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3142">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerThreeMember_zN2YlmYF5yYj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,050</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3145">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2031</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3148">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3149">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zDZU33gCl6p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Brian Wiley<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,386</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3152">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11/15/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3155">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3156">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyTwoMember_zLLro33yoEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3159">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11/15/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3162">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3163">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zjRR9pOhLd0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Brittany Kaiser<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3166">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3169">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3170">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zgu2Ii9G1Ngk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Enzo Villani<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3173">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3176">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3177">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zNOIQExz8De1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Yury Mitin<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3180">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3183">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3184">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>





























<p style="margin: 0pt 0; font-size: 10pt"><b>Notes</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(1)</td>
    <td>Except as set forth below, vesting of all options is subject to continued service as an employee, director and/or consultant of Alpha
        Compute or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the
        date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(2)</td>
    <td>On December 15, 2024, Mr. Pickett was appointed as a director of the Company and our Chief Executive Officer under a consultancy agreement
        and served in such capacities through December 19, 2025, his resignation date. These options were awarded to Mr. Pickett for his services
        as a director. One fourth of the options vested immediately on grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(3)</td>
    <td>Dr. Walters served as our Chief Executive Officer and a director of the Company through December 14, 2024. Pursuant to the terms of his
        employment agreement, all unvested share options immediately vested on such date. Pursuant to the terms of his share option agreements,
        the vested share options are exercisable for two years from this date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(4)</td>
    <td>On September 30, 2024, Ms. Park was appointed as our Chief Financial Officer and departed the Company in October 2025. One fourth of the
        options vested immediately on the grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(5)</td>
    <td>Mr. Shaw served as our Chief Financial Officer through September 30, 2024. Pursuant to the terms of his share option agreements, the vested
        share options are exercisable for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(6)</td>
    <td>The above table excludes 4,550 RSUs to Mr. Kramer granted on January 13, 2021, with a grant date value of $1,615,250, which vested on
        the grant date but are subject to certain restrictions and 860 RSUs granted on January 19, 2022 with a grant date value of $175,784, which
        vested on the grant date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(7)</td>
    <td>Mr. Wiley served as our Chief Business Officer through November 15, 2024. Pursuant to the terms of his employment agreement, all unvested
        shares immediately vested on such date. Pursuant to the terms of his share option agreement, the vested share options are exercisable
        for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(8)</td>
    <td>On March 11, 2026, the Board authorized the grant of 545,315 share options each to Ms. Kaiser, Mr. Mitin, and Mr. Villani, which were
        owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private or public
        share offerings. These share options were formally granted on May 14, 2026.</td></tr>
  </table>


<p id="xdx_8A2_zE2OMNS89Pl9" style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory', window );">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</a></td>
<td class="text"><p id="xdx_80F_ecustom--DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_z5MIA4iv3GT8" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
22. <span id="xdx_82B_z4CGRHbfWm3g">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s financial instruments recognized
in the Company&#8217;s consolidated statements of financial position consist of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Fair value estimates are made at a specific point in
time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties
and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could
significantly affect these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following table summarizes the Company&#8217;s financial instruments
as of March 31, 2026 and 2025 (in thousands):</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_pn3n3_zopiDedCWlsj" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_495_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zP6ymNiXA3pj" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_499_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zrf25agWTCtl" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zqXWYoAPlBYb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_497_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zHT3SIfzSXld" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_496_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z67FiqFDONzi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zMq4F3VxRHq5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Amortized</p>
        <p style="margin-top: 0; margin-bottom: 0">Cost</p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Amortized</p>
        <p style="margin-top: 0; margin-bottom: 0">Cost</p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">686</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3208">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3209">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1,670</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3211">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3212">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--Stablecoin_i01I_pn3n3_z4e3MwE56iRa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3215">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3216">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3217">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3218">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3219">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3_zhCqM31u9Eg9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other current assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,984</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3222">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3223">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">555</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3225">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3226">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 48%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; width: 1%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_498_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z4sBZhEDAyW7" style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_49E_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zwLMtx0mT413" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_49F_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zrTGko2d4Dwd" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_493_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zfFMkwFheHT" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>Amortized <br/>Cost</b></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>FVTPL</b></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><b>Amortized</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Cost</b></p></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>FVTPL</b></td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3_zxH3Lyhkpnfd" style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">4,146</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3234">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right">1,100</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3236">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--TonPayableToSettlePutRightsExercised_i01I_pn3n3_zqvR3mXfUEmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3238">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,425</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3240">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3241">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PutRightLiability_i01I_pn3n3_zQLRQYSyQa81" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3243">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">7,105</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3245">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3246">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3248">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">192</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3250">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">1,952</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LeaseLiabilityCurrentAndNoncurrent_i01I_pn3n3_zjFhkn48tGci" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Lease liability - current and noncurrent</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3253">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">138</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3255">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3256">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A2_zfMYLKFaEllf" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">*FVTOCI refers to financial assets and liabilities with changes in fair
value recognized within other comprehensive income.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">**FVTPL refers to financial assets and liabilities with changes in fair
value recognized within the statement of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">A summary of the Company&#8217;s risk exposures as it relates to
financial instruments are reflected below.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt"><b><i>Fair value of Financial Instruments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s financial assets and liabilities are comprised of cash
and cash equivalents, receivables and investments in equities and private entities, current digital assets at fair value, stablecoins,
accounts payable and accrued liabilities, lease liability, and warrant liability.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company classifies the fair value of these transactions according to
the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"></td>
    <td style="width: 16.35pt">&#183;</td>
    <td>Level 1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the
        reporting date.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"></td>
    <td style="width: 16.35pt">&#183;</td>
    <td>Level 2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
        can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
        the reporting date.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"></td>
    <td style="width: 16.35pt">&#183;</td>
    <td>Level 3 &#8211; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
        as Level 3 financial instrument.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Assessment of the significance of a particular input to the fair value measurement
requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-indent: 0.5in">Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">The following methods and assumptions were used to estimate their
fair values:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Investment in Compedica</b>: The fair value of the investment used by
management is based on multiples analysis of publicly traded comparable companies as the Company is pre-revenue, along with Compedica&#8217;s
holdings in the Company&#8217;s ordinary shares (Level 3 inputs) (see Note 10, &#8220;Investment in Compedica&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Put Option Liability</b>: The fair value is estimated using a Black-Scholes
model and in certain cases, a Monte Carlo simulation (Level 3) (see Note 12, &#8220;Put Right Liability and TON Payable&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>TON Payable</b>: The fair value corresponds to the valuation of the TON
owed to the respective investors based on the Level 3 inputs denoted above (see Note 12, &#8220;Put Right Liability and TON Payable&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><b>Warrant Liability</b>: The Series B Warrants, the Series C Warrants and
the 2023 and 2026 Placement Agent Warrants include the obligation, in the event of a Fundamental Transaction, as defined in the Series
B Warrants, the Series C Warrants and the 2023 and 2026 Placement Agent Warrants, for the Company or the successor entity to purchase
the warrants from the holder at the discretion of the holder and at the Black-Scholes value, as defined in the warrant agreements. As
a result, management concluded that, in line with IFRS 9 and paragraphs16A and 16B of IAS 32, such warrants will be accounted for as financial
liabilities on the consolidated statement of financial position with the changes in fair value recognized in the consolidated statement
of operations and other comprehensive loss. See Note 11, &#8220;Warrant Liability&#8221; for further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The fair value is estimated using a Black-Scholes model and in certain cases,
a Monte Carlo simulation (Level 3) (see Note 11, &#8220;Warrant Liability&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The following tables present the Company&#8217;s assets, including digital
assets accounted for in accordance with IAS 38 &#8220;<i>Intangible Assets</i>&#8221; (Level 1 and Level 3) (see Note 7, &#8220;Digital
Assets&#8221;), and financial liabilities that are measured at fair value (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock_pn3n3_zVLrHZkHFJR2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BB_zE0eYMntBHej" style="display: none">Schedule of liabilities
        measured at fair value on a recurring basis</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_z1rLN6TA4HHd" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49C_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z2qYM4LPUosi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zD5X6q9UAmW9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_494_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zBld36kkVgs4" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zoeTRhfaF2J1" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zM5QmpE2t1fb" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial and digital assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DigitalAssetsAtFairValueTonLiquid_iI_zOUS9oCBMjnk" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Digital assets at fair value, TON liquid</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">126</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3268">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3269">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3270">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3271">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3272">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DigitalAssetsAtFairValueTonLocked_iI_zOUaVSZgiZeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets at fair value, TON locked</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3274">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3275">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,366</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3277">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3278">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3279">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zVPTI8wLoSN7" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49E_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z0j5MCgowog9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zeKOfFQgFhQi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_496_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zZzGpxmA9f99" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49A_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zCicAgyZOiU6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zzktOzhiinp3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TonPayableToSettlePutRightsExercised_iI_zg7mekSAa8u3" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">TON payable to settle put rights exercised</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3281">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3282">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">1,425</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3284">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3285">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3286">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PutRightLiability_iI_z4Hlvat2BdB1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3288">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3289">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">7,105</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3291">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3292">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3293">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--WarrantLiability_iI_pn3n3_zteIRtenVdC9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3295">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3296">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">192</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3298">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3299">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">1,952</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"></p>



<p id="xdx_8A4_zLUt3EOmq79e" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Credit Risk, Liquidity Risk, Digital Asset Risk, and Foreign Currency Risk</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt">Our financial instruments are exposed to certain financial risks:
Credit Risk, Liquidity Risk, Digital Asset Risk, and Foreign Currency Risk.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Credit Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Credit risk is the risk of loss associated with a counterparty&#8217;s
inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#8217;s consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><b>Cash and cash equivalents: </b>Cash and cash equivalents
comprise cash on hand and amounts invested in underlying treasury and money market funds that are readily convertible to a known amount
of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. As of March 31,
2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. Cash
and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Liquidity Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Liquidity risk is the risk that the Company will encounter
difficulty in satisfying financial obligations as they become due. The Company&#8217;s approach to managing liquidity is to ensure, as
far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&#8217;s reputation. The Company holds sufficient cash and cash equivalents
to satisfy current obligations under accounts payable and accruals. The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Digital Asset Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company is subject to various risks including market risk, liquidity
risk and other risks related to its concentration in TON and other digital assets. Investing in digital assets is currently highly speculative
and volatile.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The price of our digital assets has been, and will likely continue to be,
highly volatile. Our financial results and the market price of our common stock could be materially adversely affected if the price of
our digital assets decreases substantially, as it has in the past, including as a result of shifts in market sentiment, speculative trading,
macroeconomic trends, technology-related disruptions and regulatory announcements.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>









<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>








<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our historical financial statements do not reflect the potential variability
in earnings that we may experience in the future from holding or selling digital assets. Accordingly, volatility in our earnings may be
significantly more than what we experienced in prior periods, and it may be difficult to evaluate the Company&#8217;s business and future
prospects. We also may need to perform an analysis each quarter to identify whether events or changes in circumstances indicate that our
digital assets are impaired.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company will face risks relating to the custody of its digital assets.
Cybersecurity threats, including hacking, phishing and other malicious attacks, could result in the loss, theft or misappropriation of
our digital assets. If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain
access to our private keys, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose
some or all of our digital assets and our financial condition and results of operations could be materially adversely affected.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">There is a risk that some or all of the Company&#8217;s digital assets could
be lost or stolen. There can be no assurance that our custodians will maintain adequate insurance or that such coverage will cover any
losses with respect to the Company&#8217;s digital assets. Further, transactions in digital assets are irrevocable. Stolen or incorrectly
transferred digital assets may be irretrievable. As a result, any incorrectly executed transactions of the Company&#8217;s digital assets
could adversely affect an investment in the Company&#8217;s common stock.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s shareholders have no specific rights to any specific
digital assets. In the event of the insolvency of the Company, its assets may be inadequate to satisfy a claim by its shareholders.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The SEC has stated that certain digital assets may be considered securities
under federal securities laws. The test for determining whether a particular digital asset is a security is complex and difficult to apply,
and the outcome is difficult to predict. Future developments could change the legal status of digital assets we hold. If our digital assets
are determined to be securities under federal or state securities laws or in a proceeding in a court of law, or otherwise, it may have
material adverse consequences for our digital assets, making them more difficult to be traded, cleared or custodied compared to other
digital assets that are not considered securities. In addition, if our digital assets are considered securities, the Company could be
considered an unregistered investment company under the Investment Company Act of 1940, which could necessitate the Company&#8217;s liquidation.
If the Company is required to comply with additional regulatory obligations, it could result in a significant increase in operating expenses
and make it difficult to continue our current operations, which would materially and adversely affect our business, financial condition
and results of operations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As a company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company. The current uncertainty in global capital markets could have an impact on the Company&#8217;s future
ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available
to the Company. See Note 17, &#8220;Capital Stock and Reserves,&#8221; for a discussion of the Company&#8217;s share offering and current
funding levels.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Foreign Currency Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">While the Company operates in various jurisdictions,
substantially all of the Company&#8217;s transactions are denominated in the U.S. Dollar.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_80B_ecustom--DisclosureOfSegmentReportingExplanatoryTextBlock_zYLhgw8IYnpk" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
23. <span id="xdx_822_z3o7VW2Q9lrg">SEGMENT REPORTING</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">While the Company operates in various jurisdictions,
substantially all of the Company&#8217;s transactions are denominated in the U.S. Dollar.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Prior to the fiscal year ended March 31, 2026,
the Company had one operating segment, Immuno-Oncology. In September 2025, in connection with the replacement of the previous leadership
team, the Company made a strategic shift to digital assets and compute processing. While the majority of the Company&#8217;s operations
following September 2025 are now focused on compute processing and digital assets, certain subsidiaries continue to operate in the immuno-oncology
space.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our management reporting system produces reports
that present information about our business activities in a variety of ways. Based on these reports, the Chief Executive Officer, who
is responsible for assessing the performance of our Company and for making resource allocation decisions as our Chief Operating Decision
Maker (&#8220;CODM&#8221;), evaluates business activities based on several different results. Operating results are reviewed by operating
segment, comprised of the Company&#8217;s two operating segments: Digital &amp; Compute and Immuno-Oncology.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We use an operating loss indicator to measure
the performance of our operating segments. Information about assets and liabilities is not regularly provided to our CODM.</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

















<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Results by segment for the fiscal years ended
March 31, 2026, 2025, and 2024 is as follows:</p>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSegmentReportingTableTextBlock_pn3n3_zISlVstkjR3k" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zZgatWOTNhLg" style="display: none">Schedule of segment reporting</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DigitalComputeMember_zQQi4pef5xyh" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zxYOSbH0llda" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_490_20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zhorSaE3Ib7b" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_491_20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zNoGn4xBsSre" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Digital &amp; Compute</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Revenue_zzcc9PH4Xbo" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Segment revenues</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">97</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3313">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3314">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3315">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProfitLossAbstract_iB_z4pFFDeP9sG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment expenses</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ResearchAndDevelopmentExpense_zg3qCDmOqQQ3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3322">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,801</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,129</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12,535</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--GeneralAndAdministrativeExpense_zBljTZEYD6Lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: justify">General and administrative expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">16,344</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">3,855</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4,254</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5,664</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAndAmortisationExpense_zZweoOSFcnG6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Depreciation and amortization expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">193</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3333">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">35</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">54</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLossFromOperatingActivities_zYBtJ9OJJg14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment loss from operations</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(16,440</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(6,656</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(7,418</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(18,253</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--GainsLossesOnChangeInFairValueOfWarrants_z9f3jskqymAl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,097</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,786</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(388</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,868</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_zMuQEE6EtH44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3347">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3348">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3349">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11,305</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ChangeInFairValueOfPutRightsNetOfRedemptions_z5PYPZjGT4g3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of put rights, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(5,959</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3353">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3354">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3355">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LossOnRevaluationOfDigitalAssets_zrVzmHl7BkU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,411</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3358">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3359">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3360">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LossOnRevaluationOfDigitalAssetReceivables_zONRYqKAQWV4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,349</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3363">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3364">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3365">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RealizedLossOnSaleOfDigitalAssets_zYMyFjnobtSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,700</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3368">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3369">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3370">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--RealizedLossOnNovationOfDigitalAssetReceivables_zjFyq3GlZbCk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on novation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">676</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3373">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3374">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3375">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--GainOnSettlementWithParexelIoxCro_zlrftFnk0Qda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement with Parexel - iOx CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3377">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3378">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">946</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3380">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LossOnRegisteredDirectOffering_z3GRGfSxrWIj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on Registered Direct Offering</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3382">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3383">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3384">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(2,432</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--OfferingCosts_zrDU1QCJpZs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Offering costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3387">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3388">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3389">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(662</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ImpairmentLossIoxIprd_zc4PuDWSybLi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - iOx IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3392">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3393">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3394">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(57,890</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--ImpairmentLossTarusIprd_zSdN1Vd63KFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Tarus IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3397">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3398">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3399">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(23,615</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ImpairmentLossStimunity_zG0sZ3DAYpQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Stimunity</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3402">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3403">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3404">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(1,002</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--ImpairmentLossSaugatuck_zKChggm43D9j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Saugatuck</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3407">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3408">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3409">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(178</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--CommitmentFeeUnderCommittedPurchaseAgreement_zR6Fjac30Lp8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Commitment fee under Committed Purchase Agreement</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3412">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3413">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3414">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(839</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--GainOnDissolutionOfInvestmentInAssociate_zFpbZKRPfAK3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on dissolution of investment in associate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3417">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3418">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3419">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">27</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GainFromSaleOfInvestmentInPublicCompany_zcVdomIRFAg1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain from sale of investment in public company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3422">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3423">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3424">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">725</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ImpairmentLossInvestmentInCompedica_zSXzRwv8SsX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3427">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(4,804</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3429">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3430">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossOnRevaluationOfInvestmentInCompedica_zB6DUIoyVn3j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(182</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3433">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3434">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3435">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_z2SYs5jPLmgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">51</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3438">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3439">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3440">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--GainOnSettlementOfTonPayable_zWhbQpfNGVn4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">336</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3443">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3444">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3445">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LossOnSettlementOfPutRightLiability_zc6tV1Gj9iBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on settlement of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(916</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3448">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3449">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3450">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--NetForeignExchangeGain_iN_di_zCRqQGgWV2Ze" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange transaction (loss) gain</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">4</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(5</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(7</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--InterestExpenseIncomeDefinedBenefitPlans_zs5vJnEVBKN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Interest (expense) income, net</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,022</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">8</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">86</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">242</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnExtinguishmentOfDebt_z4wcapWYoUf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on extinguishment of debt</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(582</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GainOnExtinguishmentOfDebt_zxJa9QeFlVa5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on forgiveness of loan interest</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">837</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3468">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3469">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3470">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ShareOfLossesFromEquityMethodInvestment_zv6RnYQVW1F3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Share of losses from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3472">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(44</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3474">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(233</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--SegmentLossBeforeBenefitForIncomeTaxes_zybOlmQXZrD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left">Segment loss before benefit for income taxes</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(28,912</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(9,715</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(6,781</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(85,930</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxBenefit_zH7StBEZswxj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3482">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3483">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,548</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentNetLoss_z7sEEjClSHjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment net loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(28,912</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(9,715</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,778</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(75,382</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>




<p id="xdx_8AC_zrgbPX9ps6q" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalManagementAbstract', window );"><strong>Capital Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock', window );">CAPITAL MANAGEMENT</a></td>
<td class="text"><p id="xdx_80F_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zwQXyHqLpqGk" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
23. <span id="xdx_82F_zNp7jQKCHDr7">CAPITAL MANAGEMENT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company considers the items included in shareholders&#8217;
equity as capital. The Company had accounts payable and accrued liabilities of approximately $<span id="xdx_90C_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20260331_zZBBUNtoLlGj" title="Payables and accrued expenses">4.1</span>
million as of March 31, 2026 (accounts payable and accrued liabilities of approximately $<span id="xdx_908_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20250331_zUqGwimzqy85" title="Payables and accrued expenses">1.1
</span>million as of March 31, 2025), put right liabilities of approximately $<span id="xdx_902_ecustom--PutRightLiabilities_iI_pn3n3_dm_c20260331_ziAVwt4tP7kg" title="Put right liabilities">7.1</span>
million as of March 31, 2026 (nil as of March 31, 2025), and current assets of approximately $<span id="xdx_90B_ecustom--CurrentAsset_iI_pn3n3_dm_c20260331_zOziBbIgo0M3" title="Current assets">4.0</span>
million as of March 31, 2026 (approximately $<span id="xdx_900_ecustom--CurrentAsset_iI_pn3n3_dm_c20250331_zgrBYQWg9aie" title="Current assets">2.2</span>
million as of March 31, 2025). The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue
as a going concern in order to pursue new business opportunities and to maintain a flexible capital structure while developing the Telegram
ecosystem and managing a strategic reserve of digital assets, which optimizes the costs of capital at an acceptable risk.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company manages the capital structure and makes
adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Company is not subject to any externally imposed
capital requirements and does not presently utilize any quantitative measures to monitor its capital. During fiscal year ended March 31,
2026, the Company shifted its capital management approach to focus primarily developing the Telegram ecosystem, managing a strategic reserve
of digital assets, and acquiring GPUs to generate revenues from compute demand. There were no other changes to the Company&#8217;s approach
to capital management during the fiscal year ended March 31, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_80F_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zOQllwliGhTc" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
24. <span id="xdx_82D_z6qOlJGjKTEf">NON-CONTROLLING INTEREST</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The table below summarize the Company&#8217;s non-controlling interest as
of the periods presented (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zasandL9FVq4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_z878ccb405r7" style="display: none">Schedule of non-controlling
        interest</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="vertical-align: middle; font-size: 10pt; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><b>Saugatuck</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>and subsidary</b></p></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2023</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zKO3eXzggBki" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(650</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztXhWty3KIZk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">(43</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-controlling interest as of March 31, 2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z60iZH9zo4r" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(693</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z94XkukyZVqe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">(11</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-controlling interest as of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zpONoyrL8okk" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(704</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zUWl0fjhWlAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest">(1</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znWEiQvoQnbk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(705</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



<p id="xdx_8A3_zejfsfDugYI9" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company held 70% interest in Saugatuck and subsidiary through SalvaRx.
Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interests in other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 1<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_1&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfEventsAfterReportingPeriodExplanatory_zhFykYXAexX3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE
25. <span id="xdx_82F_zE0GY6Qb2dv">SUBSEQUENT EVENTS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company has evaluated subsequent events through July 15, 2026 the date
on which the consolidated financial statements were available to be issued.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On April 14, 2026, pursuant to prior approvals by our board of directors,
we filed a Certificate of Change of Name and Amendment to our Memorandum and Articles of Association. The documents changed our corporate
name from AlphaTON Capital Corp to Alpha Compute Corp to better reflect the nature of our expanded current business operations in compute
and AI infrastructure.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On April 21, 2026, our shares of common stock will begin trading under the
new symbol ALP on the Nasdaq Capital Market. The Certificate of Change of Name and Amendment to our Memorandum and Articles of Association
are filed as Exhibit 99.1 and Exhibit 99.2 to this current report and are incorporated herein by reference.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On May 12, 2026, Alpha Compute Corp (the &#8220;Company&#8221;) issued a
press release announcing the execution of a compute off-take agreement related to a cluster of 504 NVIDIA B200 GPUs. A copy of the press
release is attached hereto as Exhibit 99.1.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As previously disclosed, in connection with Alpha Compute Corp&#8217;s (the
&#8220;Company&#8221;) September 2025 private placement financing (the &#8220;Sept. 2025 Private Placement Financing&#8221;), the Company
entered into certain Side Letter Agreements (each, a &#8220;Side Letter&#8221;) with certain investors in the Sept. 2025 Private Placement
Financing. The Side Letters granted an irrevocable right and option to these investors to require the Company to repurchase all the ordinary
shares of the Company (&#8220;Ordinary Shares&#8221;) received by the respective investor in exchange for the consideration initially
provided by the respective investor to the Company (the &#8220;Put Option&#8221;). The period in which the Put Option may be exercised
varies from six to twelve months, depending on the investor, after the September 25, 2025 closing of the Sept. 2025 Private Placement
Financing. On June 22, 2026 two of these investors exercised their Put Options, obligating the Company to transfer to the investors a
total of 2,114,583 TON tokens and 5,136,459 USDC tokens (which represents the consideration initially provided by these investors to the
Company), with no adjustment for value, in exchange for the repurchase by the Company of a total of 1,196,295 Ordinary Shares and 633,931
Pre-Funded Warrants received by these investors in the Sept. 2025 Private Placement Financing.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#8220;SPA&#8221;) with Animoca Brands Limited (&#8220;Animoca Brands&#8221;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#8220;GaMee Global&#8221;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#8220;GaMee Transaction&#8221;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. Animoca
Brands, prior to closing, will conduct a reorganization to transfer 100% of the equity of Gamee Limited, a company incorporated in the
United Kingdom (the &#8220;UK Company&#8221;) to GaMee Global. The UK Company owns the entire equity in Gamee Mobile s.r.o., a company
incorporated under the laws of the Czech Republic (the &#8220;Czech Company&#8221; and together with GaMee Global and the UK Company,
&#8220;GaMee&#8221;). Under the terms of the SPA, at the closing of the GaMee Transaction (&#8220;Completion&#8221;), the Company has
agreed to pay total upfront consideration of $3.5 million (the &#8220;Completion Consideration&#8221;), comprised of: (i) $1.5 million
in cash, and (ii) $2.0 million in equity consideration in the Company, valued at $1.00 per share. The equity portion of the Completion
Consideration under subparagraph (ii) is structured as a combination of ordinary shares of the Company (&#8220;Ordinary Shares&#8221;)
and pre-funded warrants exercisable for Ordinary Shares (&#8220;Pre-Funded Warrants&#8221;). Specifically, at Completion, Animoca Brands
will receive: (i) 99,800 Ordinary Shares, and (ii) Pre-Funded Warrants exercisable for 1,900,200 Ordinary Shares, representing the balance
of the equity portion of the Completion Consideration. The GaMee Transaction closed on May 27, 2026.</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zq6bXFBJNhRl" style="margin: 0pt 0; font-size: 10pt"><b><i><span id="xdx_869_zrokjMcMtN3f">Financial
Instruments</span></i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>i) Financial Assets</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Classification</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Upon the initial recognition of financial assets, the financial assets are
classified as one of the following measurement methodologies: (a) amortized cost, (b) fair value through other comprehensive income (&#8220;FVTOCI&#8221;),
or (c) fair value through profit or loss (&#8220;FVTPL&#8221;). Subsequent measurement will be based on the initial classification of
the financial assets.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The classification of a financial asset at initial recognition depends on
the Company's business model for managing the financial asset and the financial asset's contractual cash flow characteristics.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In order for a financial asset to be measured at amortized cost or fair
value through other comprehensive income (&#8220;OCI&#8221;), it needs to give rise to cash flows that are solely payments of principal
and interest (&#8220;SPPI&#8221;) on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed
at an instrument level.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's business model for managing financial assets refers to how
it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting
contractual cash flows, selling the financial assets, or both.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Measurement</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">For purposes of subsequent measurement, financial assets are classified
in three categories:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%">Financial assets at amortized cost (debt instruments);</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>Financial assets at FVTOCI (equity instruments); and</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>Financial assets at FVTPL.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets at Amortized Cost (Debt Instruments)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">The Company measures financial assets at amortized cost if both of the following conditions
are met:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%">The financial asset is held within a business model with the objective of holding the financial asset in order to collect
        contractual cash flows; and</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td>The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
        on the principal amount outstanding.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at amortized cost are subsequently measured using the effective
interest rate method and are subject to a period impairment review. Gains and losses are recognized in profit or loss when the asset is
derecognized, modified or impaired.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company's financial assets classified at amortized cost includes accounts
receivable, stablecoin, and prepaid expenses and other receivables.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets designated at Fair Value through OCI (Equity Instruments)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Upon initial recognition, the Company can elect to classify irrevocably
its equity investments as equity instruments designated at FVTOCI when they meet the definition of equity under IAS 32, &#8220;<i>Financial
Instruments: Presentation</i>,&#8221; and are not held for trading. The classification is determined on an instrument-by-instrument basis.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Gains and losses on these financial assets are never recycled to profit
or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except
when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded
in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company irrevocably elected to classify its investment in Intensity
as FVTOCI. During the year ended March 31, 2024, the Company sold 100% of its investment in Intensity for proceeds of $2.812 million and
recognized a gain of $0.725 million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Financial Assets at Fair Value through Profit or Loss</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at FVTPL include financial assets held for trading, financial
assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured
at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in
the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated
as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified
and measured FVTPL, irrespective of the business model.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial assets at fair value through profit or loss are carried in the
consolidated statements of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.
The investments in associate (Stimunity and Compedica) and the Stimunity Convertible Note receivable are accounted for as FVTPL.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>ii) Financial Liabilities</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s financial liabilities include accounts payable and accrued
liabilities, which approximate fair value due to their short maturity, lease liability, warrant liability, put right liability and TON
payable to settle put rights exercised.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Warrant Liability</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Warrant liabilities are initially measured at fair value on the date of
issuance. After initial recognition, the warrant liabilities are remeasured at fair value at each reporting period, with changes in fair
value recognized through the consolidated statement of operations and other comprehensive loss in accordance with IFRS 9 &#8220;Financial
Instruments.&#8221; When the Company issues equity instruments to extinguish all or part of the liability, a gain or loss is recognized
in the consolidated statement of operations and other comprehensive loss, which is measured as the difference between the carrying amount
of the financial liability and the fair value of the equity instruments issued. Liability classified warrants are accounted for in accordance
with IFRS 9 and IFRS 13 &#8220;<i>Fair Value Measurement</i>,&#8221; where the terms of the instruments do not meet the criteria for classification
as equity under IAS 32 &#8220;<i>Financial Instruments: Presentation</i>.&#8221; See Note 11, &#8220;Warrant Liability&#8221; for a further
discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment of Financial Assets and Intangible Assets</a></td>
<td class="text"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zAGIzTm5czbj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zWLd1DvAegf">Impairment
of Financial Assets and Intangible Assets</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">IFRS 9, &#8220;<i>Financial Instruments</i>,&#8221; requires the Company
to recognize an allowance for expected credit losses ("ECLs") for all debt instruments and investments not held at fair value
through profit or loss and contract assets. For intangible assets, at the end of each reporting period and whenever there is an indication
that the intangible asset may be impaired, the Company reviews the carrying amounts of its intangible assets to determine whether there
is any indication that those assets have suffered an impairment loss.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At the end of each reporting period, the Company assesses whether there
was objective evidence that a financial asset was impaired. The Company recognizes an allowance for ECLs for all debt instruments not
held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with
the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest
rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral
to the contractual terms.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">ECLs are recognized in two stages. For credit exposures for which there
has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default
events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant
increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of
the exposure, irrespective of the timing of the default (a lifetime ECL).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



















<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_zpRmemeYFdJj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_865_zwlvM4mX0Vmk">Cash,
Cash Equivalents, and Restricted Cash</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Cash and cash equivalents comprise cash in readily available checking accounts
and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash within three
months or less from date of acquisition and are subject to an insignificant risk of change in value. The carrying amounts approximate
fair value due to the short maturities of these instruments. The Company maintains most of its bank accounts in the United States ("U.S.").
As of March 31, 2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date
of purchase. Interest income earned on such investments totaled $<span id="xdx_90F_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20260331_zrFeBE0oQpZb" title="Investments">0.1</span>
million, $<span id="xdx_90C_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20250331_zMypTLAoGPX" title="Investments">0.1</span>
million and $<span id="xdx_909_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20240331_zaClKDTedD82" title="Investments">0.2</span>
million in the years ended March 31, 2026, 2025 and 2024, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">As of March 31, 2026, the Company had $<span id="xdx_900_ecustom--CashRestrictedForUse_iI_pn3n3_dm_c20260331_zAwpvCBHawgl" title="Cash restricted for use">0.2</span>
million in cash considered restricted for use and is held as collateral for the Company&#8217;s credit card balance with Silicon Valley
Bank. No cash was restricted for use as of March 31, 2025.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory', window );">Impairment of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill</a></td>
<td class="text"><p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory_zQ5bnXcLF6I1" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_865_z8Y29tRA5GIi">Impairment
of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">At the end of each annual reporting period and whenever there is an indication
that its property, plant and equipment and indefinite life intangible assets may be impaired, the Company reviews the carrying amounts
of such tangible intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If
any such indication exists, the recoverable amount of the asset is estimated to determine the extent of impairment loss (if any). When
it is not possible to estimate the recoverable amount of any individual asset, the Company estimates the recoverable amount of the cash-generating
unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated
to individual cash-generating units ("CGU" or "CGUs"), or the smallest group of cash-generating units for which a reasonable
and consistent allocation basis can be identified.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Recoverable amount is the higher of fair value less costs of disposal and
value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based Payments</a></td>
<td class="text"><p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_z6u69SbANulg" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_864_zZuOgTYrTSqf">Share-based
Payments</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company determines the fair value of share-based payments granted to
directors, officers, employees and consultants using the Black-Scholes option-pricing model at the grant date. Assumptions for the Black-Scholes
model are determined as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center; width: 11%">&#8226;</td>
    <td style="width: 89%"><b><i>Expected Volatility</i></b>. The expected volatility rate used to value share option grants is based on the Company&#8217;s
        historical volatility.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Expected Term</i></b>. The Company used historical experience.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Risk-free Interest Rate</i></b>. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that
        had terms 	consistent with the expected term of the Company's share option grants.</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: center">&#8226;</td>
    <td><b><i>Expected Dividend Yield</i></b>. The Company has never declared or paid any cash dividends and does not presently plan to pay cash
        	dividends in the foreseeable future.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Share-based payments to employees, officers and directors are recorded and reflected
as an expense over the vesting period with a corresponding increase in the share option reserve. On exercise, the associated amounts previously
recorded in the share option reserve are transferred to common share capital.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss Per Share</a></td>
<td class="text"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zrw28pDv89Vb" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_867_z1ZKTjA18v84">Loss
Per Share</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Basic loss per share is calculated by dividing net loss (the numerator)
by the weighted average number of ordinary shares outstanding (the denominator) during the period. Diluted loss per share reflects the
dilution that would occur if outstanding share options and share purchase warrants were exercised into ordinary shares using the treasury
stock method and convertible debt instruments were converted into ordinary shares using the if-converted method. Diluted loss per share
is calculated by dividing net loss applicable to ordinary shares by the sum of the weighted average number of ordinary shares outstanding
and all additional ordinary shares that would have been outstanding if potentially dilutive ordinary shares had been issued. The share
and per share information has been retroactively adjusted to reflect the impact of the stock dividend.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The inclusion of the Company's share options, restricted stock units and
share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore
excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the years
ended March 31, 2026, 2025, and 2024. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share, and accordingly, were excluded from the calculation (see Note 19, &#8220;Loss Per Share&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_z8ftXIMzNIQa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B7_zUdta2IpW0Zf" style="display: none">Schedule of anti-dilutive effect on loss
        per share</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zSgEDUtn4RO8" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,531,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zby4c4g4Bjth" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zGDYkRfspGq6" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Share options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zjFUSFChu8hb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zX5zMTcxbVNg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">225,117</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zfqvikszk0E4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">90,281</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zbSDlZbM3fF6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,241,334</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zMk7FZpnUWTc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">5,410</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zcOYTRxczUv5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">18,467</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A4_zrEmZO7sqO61" style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory', window );">Investment in Public Company</a></td>
<td class="text"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory_zY1ZfxAjJTm3" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86B_zawFxBcOWf8b">Investment
in Public Company</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The investment is comprised of shares of private/public companies that have
been acquired through a private placement. The investment is initially recorded at fair value. Following acquisition, the Company evaluates
whether control or significant influence is exerted by the Company over the affairs of the investee company. Based on the evaluation,
the Company accounts for the investment using either the consolidation, equity accounting or fair value method. The Company sold the entire
investment in Fiscal 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates', window );">Investment in Associate</a></td>
<td class="text"><p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForInvestmentInAssociates_zJUoPXSpf5If" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_867_zDJqp4VzmMm2">Investment
in Associate</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">An associate is an entity over which the Company has significant influence.
Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or
joint control over those policies. The investment in associate was written down to nil as of March 31, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The results and assets and liabilities of associates are incorporated in
these consolidated financial statements using the equity method of accounting, except when the investment, or a portion thereof, is classified
as held for sale, in which case it is accounted for in accordance with IFRS 5, &#8220;Non-current Assets Held for Sale and Discontinued
Operations&#8221;. Under the equity method, an investment in an associate is initially recognized in the consolidated statement of financial
position at cost from the date the investee becomes an associate and adjusted thereafter to recognize the Company's share of the profit
or loss and other comprehensive income of the associate. When the Company's share of losses of an associate exceed the Company's interest
in that associate (which includes any long-term interests that, in substance, form part of the Company's net investment in the associate),
the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company
has incurred legal or constructive obligations or made payments on behalf of the associate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">After application of the equity method, the Company determines whether it
is necessary to recognize an impairment loss on its investment in its associate. At each reporting date, the Company determines whether
there is objective evidence that the investment in the associate is impaired. If there is such evidence, the Company calculates the amount
of impairment as the difference between the recoverable amount of the associate and its carrying value, and then recognizes the loss within
'share of (loss) income in associate' in the consolidated statements of operations. With respect to its investment in Compedica, the Company
recognized a loss on impairment of $4.8 million as of September 30, 2025 due to the Company&#8217;s loss of significant influence over
the operations of Compedica.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_zQcsmzLWZ4Kc" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_863_zEaAf6viREwi">Research
and Development Expenses</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>(i) Research and Development</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Expenditure on research activities, undertaken with the prospect of gaining
new scientific or technical knowledge and understanding, is expensed as incurred.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Development activities involve a plan or design for the production of new
or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably,
the product or process is technically, and commercially feasible, future economic benefits are probable, and the Company intends to and
has sufficient resources to complete development and to use or sell the asset. Following initial recognition of the development expenditure
as an asset, the asset is carried at cost less any accumulated amortization. Amortization of the asset begins when development is complete
and the asset is available for use. It is amortized over the period of expected future benefit. During the period of development, the
asset is tested for impairment annually.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Research and development expenses include all direct and indirect operating
expenses supporting the products in development.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><b><i>(ii) Subsequent Expenditure</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Subsequent expenditure is capitalized only when it increases the future
economic benefits embodied in the specific asset to which it relates. All other expenditures are recognized in income or loss as incurred.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>(iii) Clinical Trial Expenses</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Clinical trial expenses are a component of the Company's research and development
costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct development
activities on the Company's behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements is based
on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrollment,
services provided, contractual terms, and prior experience with similar contracts.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory', window );">Contingent Liability</a></td>
<td class="text"><p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory_zkRtD8qg5a6e" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_868_zUR2A6MIwkdk">Contingent
Liability</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A provision in accordance with IAS 37 &#8220;<i>Provisions, Contingent Liabilities
and Contingent Assets</i>,&#8221; is recognized when the Company has a present (legal or constructive) obligation as a result of a past
event and it is probable that economic resources shall be required to settle the obligation and a reliable estimate can be made of the
amount of the obligation. When the Company expects that some or all of the expense will be reimbursed to it, such as in an insurance contract,
the repayment will be recognized as a separate asset, only when it is highly likely that the asset will be received. The expense will
be recognized in profit and loss net of the portion reimbursed.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Determination of Fair Value</a></td>
<td class="text"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zoevFRVGYk92" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zVqVJ2K4A0S4">Determination
of Fair Value</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">A number of the Company's accounting policies and disclosures required the
determination of fair value, both for financial and non-financial assets and liabilities. Fair values have been determined for measurement
and/or disclosure purposes based on assumptions that market participants would use when pricing the asset or liability, assuming that
market participants act in their economic best interest. When applicable, further information about the assumptions made in determining
fair values is disclosed in Note 15, &#8220;Financial Instruments and Risk Management&#8221; and other footnotes that specifically relate
to assets or liabilities measured at fair value.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income Tax</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zf26Z2XGEyGj" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86B_zD5CdCIX2YK3">Income
Tax</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company uses the asset and liability method to account for income taxes.
Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying
amounts of existing assets and liabilities for accounting purposes, and their respective tax bases.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Deferred income tax assets and liabilities are measured using tax rates
that have been enacted or substantively enacted and applied to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized
in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and
are reviewed at the end of each reporting period.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory', window );">Stablecoin</a></td>
<td class="text"><p id="xdx_848_ecustom--DescriptionOfAccountingPolicyFoStablecoinExplanatory_zi9uQyzIlenl" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zOUWdk3B0UF9">Stablecoin</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its stablecoins, which are comprised of USDC and
USDT, as in accordance with IAS 9 &#8220;Financial Instruments&#8221;. The Company&#8217;s stablecoins are initially recorded at cost,
and are contractually redeemable for fiat currency on demand or pegged 1:1 to the value of one U.S. dollar. The Company determines the
fair value of its stablecoins, which is at par with the U.S. dollar, in accordance with IFRS 13 &#8220;Fair Value Measurement&#8221; based
on the quoted (unadjusted) prices on the active exchange that the Company has determined is its principal market for the stablecoins (Level
1 inputs). Our primary custodian of stablecoins is BitGo, and the associated costs are expensed as incurred. Stablecoins are held for
use in business operations and not for the purpose of potential asset appreciation and is therefore classified as a current asset within
the consolidated statements of financial position. When the Company does not have possession, control, or the right to derive substantially
all of the economic benefits of ownership of stablecoin the Company has title to, the stablecoin is classified as a stablecoin receivable
within the consolidated statements of financial position. Stablecoin and stablecoin receivables qualify as financial instruments due to
their high level of liquidity, rights to redeem directly with the issuer, and their backing by high quality reserve assets not subject
to significant price fluctuations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>























<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory', window );">Digital Assets</a></td>
<td class="text"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_zlzyHdBCCbP" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_862_z2wZN8uiLec4">Digital
Assets</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its digital assets, which are comprised of TON,
as indefinite-lived intangible assets in accordance with IAS 38 &#8220;Intangible Assets&#8221;. The Company&#8217;s digital assets are
initially recorded at cost. Subsequently, digital assets are remeasured at fair value as of each reporting period, adjusted by discounts
for lack of marketability for tokens restricted for use. The Company determines the fair value of its liquid digital assets in accordance
with IFRS 13 &#8220;Fair Value Measurement&#8221;, based on quoted (unadjusted) prices on the active exchange that the Company has determined
is its principal market for the digital assets (Level 1 inputs). For locked digital assets which are not immediately tradable, the Company
applies a lack of marketability discount to quoted prices to calculate fair value (Level 3 input). Our primary custodian of digital assets
is BitGo, and the associated costs are expensed as incurred. When the Company does not have possession, control, or the right to derive
substantially all of the economic benefits of ownership of digital assets the Company has title to, the digital assets are classified
as digital assets receivable within the consolidated statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Increases in fair value, to the extent they do not constitute reversals
of previous decreases in fair value, are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss),
within &#8220;Unrealized gain on digital assets&#8221; within Other comprehensive income, with accumulated unrealized gains recognized
on the Consolidated Statements of Financial Position within Accumulated other comprehensive income. Decreases in fair value, to the extent
they do not constitute reversals of previous increases in fair value, are recognized as incurred in the Company's Consolidated Statements
of Operations and Comprehensive Income (Loss), within &#8220;Loss on revaluation of digital assets&#8221; within Other expenses. Any losses
on revaluation not in excess of previously recognized gains are recognized as decreases to Accumulated other comprehensive income until
cost basis exceeds fair value, at which point additional losses are recognized as Other expense. Any gains on revaluation not in excess
of previously recognized losses are recognized as Other income until fair value exceeds cost basis, at which point additional gains are
recognized as Other comprehensive income. Revaluation gains and losses are recorded by token.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Realized gains, to the extent recognized within Accumulated other comprehensive
income, and losses are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss) within other
income (expense).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Digital assets are classified as current or noncurrent assets based on the
Company&#8217;s intended holding period of the token. If the Company has the intent and ability to hold the token for a period of one
year beyond the balance sheet date or if the token is not expected to become liquid within one year of the balance sheet date, the holding
is classified as noncurrent. Otherwise, the holding is classified as a current asset.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory', window );">Revenue from Contracts with Customers</a></td>
<td class="text"><p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_zZ4fAEFPxvHg" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_869_z7TbxQoibEG8">Revenue
from Contracts with Customers</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company recognizes revenue in accordance with IFRS 15, &#8220;<i>Revenue
from Contracts with Customers</i>,&#8221; which establishes a comprehensive framework for determining whether, how much, and when revenue
is recognized. Revenue is recognized to depict the transfer of promised services to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those services.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company&#8217;s primary source of revenue is derived from compute offtake
agreements, under which customers obtain access to dedicated or shared compute capacity (including processing power, memory, and related
infrastructure) for a specified contractual term.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>i)</i></b></td>
    <td><b><i>Identification of performance obligations</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Compute offtake agreements typically provide customers with a stand-ready obligation
to make compute capacity continuously available throughout the contract term. The Company has determined that such arrangements generally
contain a single performance obligation, being the provision of continuous access to compute services over time.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">To the extent that a contract includes multiple services (for example, initial configuration,
integration, or distinct ancillary services), the Company assesses whether such services are distinct and should be accounted for as separate
performance obligations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>ii)</i></b></td>
    <td><b><i>Determination of the transaction price</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">The transaction price reflects the amount of consideration the Company expects to receive
in exchange for transferring promised services to the customer. Consideration under compute offtake agreements is typically fixed based
on contracted capacity and term, and is frequently settled in digital assets.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">In arrangements where consideration is received in digital assets, such consideration
represents non-cash consideration and is measured at fair value at contract inception.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Any variability in consideration (such as pricing adjustments, service level credits,
or penalties) is estimated using either the expected value or most likely amount method, and included in the transaction price only to
the extent that it is highly probable that a significant reversal of revenue will not occur.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>iii)</i></b></td>
    <td><b><i>Allocation of the transaction price</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">If a contract contains more than one performance obligation, the transaction price is
allocated to each performance obligation based on the relative standalone selling prices of the distinct services at contract inception.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in"><b><i>iv)</i></b></td>
    <td><b><i>Timing of revenue recognition</i></b></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Revenue from compute offtake agreements is recognized over time, as the customer simultaneously
receives and consumes the benefits of the compute services as they are provided. Progress toward complete satisfaction of the performance
obligation is measured on a time-elapsed basis, or another systematic measure that faithfully depicts the pattern of transfer of services
to the customer.</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">Revenue is recognized only when:</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"></td>
    <td style="width: 0.25in">1.</td>
    <td>A valid contract exists;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"></td>
    <td style="width: 0.25in">2.</td>
    <td>The Company has transferred control of compute services to the customer; and</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"></td>
    <td style="width: 0.25in">3.</td>
    <td>Collection of consideration is considered probable.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Digital assets received from customers is non-cash consideration and is
initially measured at fair value at contract inception. Any subsequent changes in the fair value of digital assets held by the Company
are accounted for in accordance with the Company&#8217;s accounting policy for digital assets, and do not affect the amount of revenue
recognized.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_846_ecustom--DescriptionOfAccountingPolicyForAccountsReceivableExplanatory_zu3ay1vP4sj2" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zLn2ovINO1J3">Accounts
Receivable</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are recognized when the Company has an unconditional right
to consideration, which generally arises upon the invoicing of compute services or when contractual billing milestones are met. Trade
receivables are initially measured at fair value, which is typically equal to the invoiced amount or the fair value of digital assets
consideration to be received.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are subsequently measured at amortized cost, as they are
held solely for the collection of contractual cash flows (or cash-equivalent consideration). Trade receivables are presented net of any
allowance for expected credit losses. To the extent that invoices are settled directly in digital assets prior to the end of the reporting
period, no trade receivable is recognized, and the digital asset is recognized in accordance with the applicable accounting policy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory', window );">Expected Credit Losses</a></td>
<td class="text"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory_zepWZP7ECA94" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_864_zjiJsipzIskk">Expected
Credit Losses</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company applies the simplified expected credit loss (ECL) model under
IFRS 9, &#8220;<i>Financial Instruments</i>.&#8221; Under this approach, lifetime expected credit losses are recognized at initial recognition
and updated at each reporting date. Expected credit losses are estimated based on:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Historical credit loss experience;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Current customer payment behavior, including digital asset settlement history; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Forward-looking information that is relevant to customer credit risk.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Trade receivables are written off when there is no reasonable expectation
of recovery.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, Plant, and Equipment</a></td>
<td class="text"><p id="xdx_842_ecustom--DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory_z4OVvBWBvuW3" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_866_zV9xTkm552P5">Property,
Plant, and Equipment</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for property, plant and equipment in accordance with
IAS 16, &#8220;<i>Property, Plant and Equipment</i>.&#8221; The Company&#8217;s property, plant and equipment consist solely of GPUs used
in the provision of compute services under compute offtake agreements. GPUs are recognized as property, plant and equipment when:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>It is probable that future economic benefits associated with the asset will flow to the Company; and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>





















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>The cost of the asset can be measured reliably.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">GPUs are initially measured at cost, which includes:</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>The purchase price, net of discounts or rebates;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Non-refundable taxes and duties;</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Directly attributable costs necessary to bring the GPUs to the location and condition necessary for them to be capable of operating as
        intended by management (including transportation, installation, testing, and configuration costs); and</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Any other expenditures directly attributable to preparing the GPUs for their intended use.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">Costs incurred after GPUs are capable of operating as intended are expensed as incurred,
unless they meet the criteria for capitalization under IAS 16.</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Following initial recognition, GPUs are carried at cost less accumulated
depreciation and accumulated impairment losses. The Company applies the cost model to all classes of property, plant and equipment. GPUs
are depreciated on a straight-line basis over their estimated useful lives, beginning when the assets are available for use, which is
when they are installed and ready for their intended operating condition. Management estimates the useful lives and residual values of
GPUs based on expected technological obsolescence, performance degradation, and expected usage patterns. Useful lives and residual values
are reviewed at least annually and adjusted prospectively when warranted.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">GPUs are derecognized upon disposal or when no future economic benefits
are expected from their use or disposal. Any gain or loss arising on derecognition is recognized in profit or loss and represents the
difference between the proceeds received and the carrying amount of the asset.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Deposits paid to suppliers for the future purchase of GPUs are recognized
as prepayments or other non-current assets, depending on the expected delivery date, and are not depreciated. Such deposits are initially
measured at the amount paid and reassessed at each reporting date to determine whether there is objective evidence that the deposit may
be impaired, including supplier non-performance or changes in expected delivery terms. Upon delivery and acceptance of the GPUs, deposits
are reclassified to property, plant and equipment as part of the cost of the related GPUs. If a purchase contract is terminated or delivery
becomes improbable, the deposit is written down to its recoverable amount, with any impairment recognized in profit or loss.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zzoCCzFQ5kDc" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86F_zK6NvyGkmJvk">Recent
Accounting Pronouncements</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2026</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(a)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21: The Effects of
Changes in Foreign Exchange Rates</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In August 2023, the IASB amended IAS 21, &#8220;The
Effects of Changes in Foreign Exchange Rates&#8221; (&#8220;IAS 21&#8221;) to clarify when a currency is exchangeable into another currency
and how a company estimates a spot rate when a currency lacks exchangeability, requiring consistent assessment and disclosure practices
for companies. The amendments are effective for annual reporting periods beginning on or after January 1, 2025, with early adoption permitted.
However, an entity cannot restate comparative information. The adoption of these amendments did not have a material effect on the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(b)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21 &#8211; Lack of
Exchangeability</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">An entity is impacted by the amendments to IAS 21, &#8220;<i>The Effects
of Changes in Foreign Exchange Rates</i>,&#8221; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The adoption of these amendments did not have a material effect on the Company.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>New IFRS Accounting Standards not yet effective</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Standards issued but not yet effective up to the date
of issuance of the Company&#8217;s consolidated financial statements are listed below. This is of standards and interpretations issued,
which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes effective.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"><b>(a)&#160;&#160;&#160;&#160;&#160; IAS 18: Presentation and Disclosure in
Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In April 2024, IFRS 18, &#8220;<i>Presentation and
Disclosure in Financial Statements</i>&#8221; (&#8220;IFRS 18&#8221;) was issued. IFRS 18 replaces IAS 1 and introduces significant changes
to the presentation of financial statements to enhance comparability across entities. The key requirements of the standard include:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Separate reporting of operating, investing, and financing activities in the statement of earnings, with prescribed
        subtotals for each category.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Disclosure of management-defined performance measures in a dedicated note within the financial statements.</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The standard is effective for annual reporting periods
beginning on or after January 1, 2027, with retrospective application required. The Company intends to assess the impact of IFRS 18 on
its consolidated financial statements closer to the effective date. The effect of the new standard, however it may be, will only affect
matters of presentation and disclosure.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(b) Amendments to IFRS 9 and IFRS 7</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On May 30, 2024, the International Accounting Standards
Board (the IASB or the Board) issued Amendments to IFRS 9 and IFRS 7, <i>Amendments to the Classification and Measurement of Financial
Instruments</i>. The amendments:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify that a financial liability is derecognized on the &#8220;settlement date&#8221;, i.e., when the related
        obligation is discharged or cancelled or expires or the liability otherwise qualifies for derecognition. They also introduce an accounting
        policy option to derecognize financial liabilities that are settled through an electronic payment system before settlement date if certain
        conditions are met.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental,
        social and governance (ESG)-linked features and other similar contingent features.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Clarify the treatment of non-recourse assets and contractually linked instruments (CLI).&#8217;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that
        reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive
        income (FVTOCI).</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The standard is effective for annual reporting periods
beginning on or after January 1, 2026, with retrospective application required. The Company intends to assess the impact of the Amendments
to IFRS 9 and IFRS 7 on its consolidated financial statements closer to the effective date.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investments in associates. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023', window );">Schedule of anti-dilutive effect on loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_z8ftXIMzNIQa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B7_zUdta2IpW0Zf" style="display: none">Schedule of anti-dilutive effect on loss
        per share</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zSgEDUtn4RO8" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,531,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zby4c4g4Bjth" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zGDYkRfspGq6" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Share options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zjFUSFChu8hb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zX5zMTcxbVNg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">225,117</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zfqvikszk0E4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">90,281</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zbSDlZbM3fF6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,241,334</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zMk7FZpnUWTc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">5,410</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zcOYTRxczUv5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">18,467</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of instruments (including contingently issuable shares) that could potentially dilute basic earnings per share in the future, but were not included in the calculation of diluted earnings per share because they are antidilutive for the period(s) presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock', window );">Schedule of prepaid expenses and other receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z7PSXYzVUWh4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B3_zBTiNLsL1tF3" style="display: none">Schedule
        of prepaid expenses and other receivables</span></td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20260331_z9Ua6NdEC7Q3" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20250331_zQAmhQj4bWBb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_zIRNVvM77ce7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td>
    <td style="width: 1%; font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">192</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentAdvancesToSuppliers_iI_zQv0n1zLtdE5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">595</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">241</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentPrepaidExpenses_iI_zjZfbtSMhbb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">567</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">42</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidInvestorRelations_iI_zRbsssHADf6g" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid investor relations</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">534</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TaxDeposits_iI_zjx42jxiEREi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">68</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">68</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PrepaidGpuInfrastructureCosts_iI_zUSNVdDOcRWb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid GPU infrastructure costs</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PrepaidGpuLeasesShortterm_iI_zg8pSOSwroF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid GPU leases, short-term</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--OtherCurrentReceivables_iI_zmSrzmJLGY4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Other receivables</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">220</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">12</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalPrepaidExpensesAndOtherReceivables_iI_zW8WIRSq50ma" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;&#160;Total prepaid expenses and other receivables</td>
    <td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,984</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">555</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STABLECOIN (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureStablecoinAbstract', window );"><strong>Disclosure Stablecoin Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfStablecoinTableTextBlock', window );">Schedule of stablecoin</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--DisclosureOfStablecoinTableTextBlock_pn3n3_zDroblQh1KVb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BF_z0l09Yg7OyE8" style="display: none">Schedule of stablecoin</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49B_20260331_zIL509oZDWob" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_494_20250331_zxkMAHWSWtca" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">USDC</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zMbx5Il6jge3" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1272">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zPwhDNdhBP7l" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1274">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">USDT</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zOhsY8Mw4WGc" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins">21</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zql3bii6Mp6" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1278">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_ecustom--Stablecoins_iI_c20250331_z4TOuebvc49" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins">21</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_ecustom--Stablecoins_iI_c20260331_zDVgP5X5jJU5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"><span style="-sec-ix-hidden: xdx2ixbrl1282">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfStablecoinPurchasesTableTextBlock', window );">Schedule of stablecoin purchases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfStablecoinPurchasesTableTextBlock_pn3n3_zCPT68n3dJUe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_z01UQdLF6AW3" style="display: none">Schedule of stablecoin purchases</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdcMember_zszXBmIapAeh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_494_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdtMember_zTifHJG5VV15" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49D_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zkhECywZeAF2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USDC</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USDT</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_408_ecustom--DigitalAssetValueAsOfApril1_zdaHJ180F3W7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1286">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1287">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ContributionOfStablecoin_zQ1NKlxvcxtj" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Contribution of Stablecoin</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">5,411</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">10</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">5,421</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromSaleOfDigitalAssets_zWpUAQ0gLn3d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Proceeds from sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StablecoinUsedToSettleOperatingCosts_zMMPbm9i27Pg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin used to settle operating costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,413</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(311</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,724</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--StablecoinSold_zYbNqw9JvaN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin sold</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromExternalDebtDrawdown_zkNJPjYqrzgf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Proceeds from external debt drawdown</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1307">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,100</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PurchasesOfStablecoin_zzRBfZerqzD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Purchases of stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">311</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">311</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StablecoinUsedToPurchaseDigitalAssets_zR02CfRYYGVk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Stablecoin used to purchase digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(2,998</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(10</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(3,008</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--StablecoinValueAsOfMarch31_zeHxYBKMY9vi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Stablecoin value as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfStablecoinPurchasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfStablecoinPurchasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfStablecoinTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfStablecoinTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureStablecoinAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureStablecoinAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DIGITAL ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureDigitalAssetsAbstract', window );"><strong>Digital Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfDigitalAssetsTableTextBlock', window );">Schedule of Digital assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfDigitalAssetsTableTextBlock_pn3n3_z3pEYyiac4Jh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BC_zuVJO3TDndrg" style="display: none">Schedule of Digital
        assets</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49B_20260331_zAXsHqW0ntgh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20250331_zxA7HCg3cAi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_407_ecustom--ApproximateNumberOfTonTokensHeld_iI_zzFNPsubLrA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Approximate number of TON Tokens held</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,379,165</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TonTokensFairValueInThousands_iI_zvYPqCKZZ2f8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">TON Tokens, fair value (in thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetsFairValueInThousands_iI_zuaZyf59SBQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Digital assets, fair value (in thousands)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock', window );">Schedule of digital assets purchases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfDigitalAssetsPurchasesTableTextBlock_pn3n3_zKfnHMmBCzlf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zkP3GrCNTvCi" style="display: none">Schedule of digital
        assets purchases</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TONMember_zd8TfTnhN7ji" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49F_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--BITCOINMember_zM2OwWS2qjU6" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_493_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TotalMember_zQOXlnavBZh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">TON</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Bitcoin</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetValueAsOfApril1_zUMU1tikAXeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ContributionOfDigitalAssets_zgXE3BDzJB12" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left">Contribution of digital assets</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,382</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">420</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,802</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_zTL2wJuiwzLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Unrealized losses on digital assets recognized in Statement of Operations</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,411</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,411</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--DigitalAssetsSold_zcpSrncvI5Ki" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets sold</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,921</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,921</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--PaymentsOnExternalDebtUsingDigitalAssets_zC2H8lfm4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Payments on external debt using digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,825</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,825</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DigitalAssetPurchases_zpNiTxlPdBb3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital asset purchases</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">3,617</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">3,617</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ReceiptOfDigitalAssetsReceivable_z7DwOCQZ5Xw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Receipt of digital assets receivable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">6,667</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">6,667</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RealizedLossGainOnSaleOfDigitalAssets_zK1izA3o06m3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Realized (loss) gain on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,705</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">5</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,700</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--RealizedLossOnNovationOfDigitalAssetsToInvestor_zxXJjlqha4Dj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Realized loss on novation of digital assets to investor</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(676</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(676</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--RevenueReceivedInDigitalAssets_zknQslf53Sja" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Revenue received in digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">69</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1380">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">69</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TokensUsedToSettlePutRights_zgQX1EHZysVe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tokens used to settle put rights</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,130</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1384">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,130</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--DigitalAssetsExchanged_z4PcFalkmFIb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets exchanged</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">425</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(425</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DigitalAssetsTransacted_zqOOtx4zbm52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Digital assets transacted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"></td></tr>
  <tr id="xdx_401_ecustom--DigitalAssetValueAsOfMarch31_ztI6Q7YPWhS5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Digital asset value as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1396">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,492</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SeheduleOfTonTokensTableTextBlock', window );">[custom:SeheduleOfTonTokensTableTextBlock]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--SeheduleOfTonTokensTableTextBlock_pn3n3_zaUme3yub7E5" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - DIGITAL ASSETS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20260331_zA4T0ZBkQ7Z8" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CapitalFutureMinimumPaymentsRemainderOfFiscalYear_iI_zcdYkOvwbux" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Fiscal 2027</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,121,493</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CapitalFutureMinimumPaymentsRemainderOfSecondYear_iI_zysjIrexSmR5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fiscal 2028</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">986,077</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CapitalFutureMinimumPaymentsRemainderOfThirdYear_iI_zwr72ctBdXM5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fiscal 2029</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">169,538</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CapitalFutureMinimumPaymentsRemainderOfTotalYear_iI_z30jfsuDEpy9" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">total&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,277,108</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock', window );">Schedule of movements in Receivables &#8211; digital assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfReceivablesDigitalAssetsTableXextBlock_pn3n3_zcPbiJLjvDeg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RECEIVABLES DIGITAL ASSETS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zPxHMxuyE3B" style="display: none">Schedule of movements
        in Receivables &#8211; digital assets</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--USD1Member_zvAQ4nDTUpIi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LockedTonMember_z6DEuMEBjGO2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zdVGRpuUFLv9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">For the year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">USD1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Locked TON</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_40F_ecustom--DigitalAssetValueAsOfApril1_zyN7eYCb5KJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Digital asset value as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1422">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1423">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1424">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ContributionOfDigitalAssetAndStablecoinReceivables_zRL4hMRNAhBi" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left">Contribution of digital asset and stablecoin receivables</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">15,000</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">9,016</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">24,016</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ChangeInFairValueOfDigitalAssetsReceivable_zmi3jzm6lcL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of digital assets receivable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1430">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,349</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,349</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ReceiptOfDigitalAssetReceivables_zK2cqYByvCn" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Receipt of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(6,667</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(6,667</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--TokensUsedToSettlePutRights_zsrqvgIgtnP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Tokens used to settle put rights</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(15,000</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1439">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(15,000</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--StablecoinValueAsOfSeptember30_zMXCskuZKWL8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">Stablecoin value as of September 30</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1442">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1443">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1444">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureDigitalAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureDigitalAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfDigitalAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfDigitalAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SeheduleOfTonTokensTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SeheduleOfTonTokensTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract', window );"><strong>Property Plant And Equipment And Right-of-use Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property, plant, and equipment, equipment deposits, and right-of-use assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_pn3n3_ztWFvZBQHXNa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zUEvq8NNxXGl" style="display: none">Schedule of property, plant, and equipment,
        equipment deposits, and right-of-use assets</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_zpW4srsOHWL1" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zOnbMazTo1Z6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zPP5zmGgsKJ7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_z0jwmooRmGTl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">COST</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_438_c20240401__20250331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_zCTFEcOZ6IM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt">As of March 31, 2024</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1450">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1451">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">84</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">84</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zg68a3YI6A85" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fixed asset additions</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1455">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1456">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1457">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_zWY57ySxhiGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1460">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_z8Lok5wLuKvi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1465">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1466">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1468">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zPXQ9xd60kh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fixed asset additions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,373</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">9,308</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">516</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">11,197</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_ziH7HqU6haxg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1475">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1476">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1477">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1478">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iE_zEwPtn0uZyJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">As of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,373</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">9,308</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">516</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">11,197</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z3vBMaS9FRxi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zfy107r1kwd9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zqFkM2sQsBIl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_zkDXC4qinAA6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">ACCUMULATED DEPRECIATION</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_43A_c20240401__20250331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_z0e0RyH1FQq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt">As of March 31, 2024</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1485">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1486">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(40</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(40</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetDepreciation_zIGD6dCaVfU3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fixed asset depreciation</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1490">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1491">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(44</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(44</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--FixedAssetDisposals_z0MSpfjD5gR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1496">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">84</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_zEzZGIh1qSoe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1500">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1501">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetDepreciation_zTXbCosnHwS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Fixed asset depreciation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(90</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(103</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(193</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--FixedAssetDisposals_zwFuT7n1Ixyg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Fixed asset disposals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1510">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1511">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_zGybfrJU1RL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">As of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(90</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1516">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(103</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(193</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z6WN0UwAJsDe" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_znNzd4DstTl9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zbSlImS7E54" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_ztw4gyvKNWk2" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">CARRYING AMOUNT</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPUs</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">GPU Deposits</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Right-of-Use Asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">As of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_z7Cw7T0yUl3a" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1520">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zhkTwUokACy2" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1522">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zmwSDbI5sjb4" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1524">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zRVR3abWyjxb" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"><span style="-sec-ix-hidden: xdx2ixbrl1526">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">As of March 31, 2026</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_zc5BNZvguBda" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">1,283</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zVOZIVXCuQZ6" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">9,308</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zxmNqs7SUpI7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">413</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zEHjO1yjB92k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount">11,004</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN COMPEDICA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfInvestmentBalanceTableTextBlock', window );">Schedule of investment balance</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfInvestmentBalanceTableTextBlock_pn3n3_zlJhjYcJHsR4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN COMPEDICA (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BC_zby3KgmHFTqi" style="display: none">Schedule of investment
        balance</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49C_20250401__20260331_zlOCaXX9QW9g" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_405_ecustom--BalanceAsOfApril1_zzHazQlxorCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--InitialInvestmentInCompedica_zYkc03g0jWq" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Initial investment in Compedica</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">5,050</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LossFromEquityMethodInvestment_iN_di_zahSCSUDA4B6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(44</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LossOnImpairment_zkQbgSipdHD3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss on impairment</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(4,804</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfInvestmentInCompedica_z19ccBbFNYO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(182</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ReturnOfInvestmentInterestToCompedica_zdzWDw93edO" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Return of investment interest to Compedica</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(20</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--InvestmentInCompedicaAsOfMarch31_zn3p4WeVfAn8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Investment in Compedica as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1561">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfInvestmentBalanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfInvestmentBalanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock', window );">Schedule of changes in the warrant liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zSJ5yKM1rq49" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;<span id="xdx_8B4_zOtX7osxSNha" style="display: none">Schedule of changes in the warrant
        liability</span> </td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise
        Price</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fair Value
        Balance</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt">Fair value of warrants at issuance on October 3, 2023:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Class B Warrants</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98B_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_z14U3yUSXJNh" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zK7pB4o7jgcf" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants shares">157,895</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_fKDEp_zllTebPXe23f" title="Fair value of warrants amount">3,537</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Class C Warrants</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98F_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zZqwBvXW4Ou1" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zF0SOg9UzJKb" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares">157,895</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_fKDEp_zfxB5j3Xzxyi" title="Fair value of warrants amount">4,663</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Placement Agent Warrants</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98A_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziFZ91lO4No4" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price">47.50</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqB6XUDfY1ib" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares">7,896</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zKQVysaZxH3e" title="Fair value of warrants amount">232</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_zqtHTdLnVvM9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount">(6,868</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrant liability as of April 1, 2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">-</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20250331_zhCdCZ7VkcPa" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending">323,686</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_985_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20250331_z6bRcsRO5bu1" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending">1,564</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20250331_zvb4yxb3qUW" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount">388</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrant liability as of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20250401__20260331_zAn9IrmUx4c" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending">323,686</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_987_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20250401__20260331_zXKrm1Z1oqRl" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending">1,952</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold">Fair value of warrants at issuance on January 27, 2026:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Placement Agent Warrants</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqGukfYAhsNa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">1.25</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zExFn0kJ4wUc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">1,050,000</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zcGJf8jsozm4" title="Fair value of warrants amount">1,123</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">-</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20250401__20260331_ztiBIMoimCGd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">(2,883</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrant liability as of March 31, 2026</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--WarrantsLiabilityShares_iE_pip0_c20250401__20260331_zP0o7uHf3ANj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending">1,373,686</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_981_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20250401__20260331_zoyisK1hdM8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, fair value at ending">192</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Schedule of inputs associated with calculating the fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zbBkvky6ahpb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B0_z7H6GUTire6" style="display: none">&#160;Schedule of inputs
        associated with calculating the fair value</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcNWdnKA7t1h" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcMANoGEFI6" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zvyaleOiJoij" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrFeYkgCqag3" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBI4iPKaOJHg" title="Share price">9.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zOrTS1j4RgTl" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zmUJEZZIZuc" title="Expected life">3.01</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zbsUkU7mGR4a" title="Expected life">1.51</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zv2etxEPHTLc" title="Expected life">0.51</span></b></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zRNSZr9Bsyke" title="Expected volatility">90.4</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBLER54ju4x2" title="Expected volatility">207.73</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zGmE7X8gkY7h" title="Expected volatility">85.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zVHBmmT4Tp8h" title="Risk free interest rate">4.95</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zM5h9A2Z0Qd3" title="Risk free interest rate">3.96</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zFFewYVR6R3a" title="Risk free interest rate">3.65</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zm1zYIyIC7N4" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1650">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEIaEviJaoxi" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1652">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z0PrTeT67bw9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory', window );">Schedule of fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_zHEeq0KcG7Nh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BA_zNeBUyzvjDYi" style="display: none">Schedule of fair value</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7CNQyvZbpx1" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7Hzf0fZPJHk" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zjwJkg7CCLv2" title="Exercise price">45.20</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zviTyKgs47jj" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHQ1bHUhjjFh" title="Share price">9.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zcltZ3A3DHUg" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zS3YhwfRInCc" title="Expected life">5.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zwfYlASTWvZk" title="Expected life">3.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zMOMU1FAanz3" title="Expected life">2.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zmtNXmZHp5Yg" title="Expected volatility">100.7</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zVoQrwL8D1wi" title="Expected volatility">152.01</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z0oIs26uJvz4" title="Expected volatility">95.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zh1OWyqxbWui" title="Risk free interest rate">4.80</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4scHsvnC34f" title="Risk free interest rate">3.91</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7jZajot0X8f" title="Risk free interest rate">3.73</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zlJFTptLrip9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zztiSm7DHUbh" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1696">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zQlFOIhDXNG1" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1698">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory', window );">Schedule of Placement agent warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory_z0WMoHkN2ua8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B7_zdxKP3McVBCi" style="display: none">Schedule of Placement agent warrants</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">October 3, 2023</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">March 31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsGPaZikPNz5" title="Exercise price">47.60</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zZIC6pi2wQ0i" title="Exercise price">47.50</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcJncvXobtOc" title="Exercise price">47.50</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGPqkcKIacvc" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zbKildqYSvU9" title="Share price">9.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zTZfbXr7F0O8" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKrk0SpAaIth" title="Expected life">4.99</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zilGNvCPG75l" title="Expected life">3.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWOGkooFnHW7" title="Expected life">2.51</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z3WsBb78muC1" title="Expected volatility">100.7</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zUSXXPL9Rkdf" title="Expected volatility">152.01</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z1axsY3Lm7h5" title="Expected volatility">95.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsQkgNMI2bc" title="Risk free interest rate">4.80</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zEzRqFTHCrCe" title="Risk free interest rate">3.91</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8OQj2rILoJd" title="Risk free interest rate">3.73</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zk25m7D81mwh" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zVbfQKyutFzi" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMWBmMUg5oN9" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory', window );">Schedule of 2026 placement agent warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementPlacementAgentExplanatory_z8nF7hZ9QcQ7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_z1jn5tB36Ll8" style="display: none">Schedule of 2026 placement
        agent warrants</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">January
        19, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--ExercisePriceFairValue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw8zpZbvkl1e" title="Exercise price">1.25</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zyrEA4PyGcIi" title="Exercise price">1.25</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_ecustom--SharePriceFairvalue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zCQwB50xVWX8" title="Share price">1.30</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zNeHaoLISPfj" title="Share price">0.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9hgK6z2usf" title="Expected life">5.0</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zoTZ4ibQOFdk" title="Expected life">4.79</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zq6YJfRZVQy4" title="Expected volatility">115.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zfwXAkArfdR9" title="Expected volatility">105.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8O8MSDk6kic" title="Risk free interest rate">3.68</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zrNAFmyLNYC7" title="Risk free interest rate">3.83</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zaPQDYAdUsOk" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1770">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_za1yL1zZIOEk" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1772">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PUT RIGHT LIABILITY AND TON PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract', window );"><strong>Put Right Liability And Ton Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock', window );">Schedule of put right liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock_pn3n3_zIddunfGqcRc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zrXKzoyKcZp8" style="display: none">Schedule of fair value
        of the put right liability estimated using a Black-Scholes model</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">September
        2, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March
        31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">ALP shares and TON correlation factor</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20250902_zrhsWfzkS2cg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor">0.60</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20260331_zsboCpXxXzli" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor">0.10</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20250902_z195kcmK5ewe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price">6.96</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20260331_zjtJL9O38m4" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price">0.32</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Remaining term (in years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250829__20250902_zgpKwqXliCyj" title="Remaining term (in years)">0.75</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250401__20260331_zr7gRSLEwfG9" title="Remaining term (in years)">0.25</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected ALP volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902_zHgZF7d9rVxf" title="Expected ALP volatility">82.90</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331_z9MBYxO8IvT1" title="Expected ALP volatility">85.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250829__20250902_z18yGKKVtm09" title="Risk free interest rate">3.91</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331_zuDUQO9pypXi" title="Risk free interest rate">3.63</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">ALP dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250829__20250902_z2bPoYPz0Jyf" title="ALP dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331_z16FwPms4IIg" title="ALP dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1804">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON token price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_987_ecustom--TonTokenPrice_iI_pip0_c20250902_zAN6Q8YbDBn9" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price">3.11</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_ecustom--TonTokenPrice_iI_pip0_c20260331_z5jWLgPHY1Ma" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price">1.22</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON token volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zc1NOWV4TEr8" title="Expected ALP volatility">62.00</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zvd0uikAd9Ji" title="Expected ALP volatility">53.90</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Locked TON token discount for lack of marketability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250829__20250902_zCBHvDMCKXYg" title="Locked TON token discount for lack of marketability rate">19.30</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250401__20260331_zEN42IfWuxrj" title="Locked TON token discount for lack of marketability rate">14.80</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The fair value of the put right liability is most sensitive
to expected share price volatility, the value of the underlying digital assets, expected term and discount rate. An increase in expected
volatility, expected term or underlying digital asset values would result in a higher fair value measurement. An increase in the discount
rate would result in a lower fair value measurement. Management considered the interrelationship of these assumptions when determining
the fair value measurement.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The DWF put right was capped at $<span id="xdx_900_eifrs-full--CurrentInterestReceivable_iI_pn3n3_dm_c20260331_zKAyaNILcu4" title="Fair value of stablecoin receivable">15.0
</span>million, the fair value of the stablecoin receivable contributed, which corresponded to the aggregate fair value of the ordinary
shares and pre-funded warrants issued to DWF. Therefore, at inception, the DWF put right was determined to have a fair value of $15.0
million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At inception, the outstanding Contingent Put Options
were determined to have a fair value of $16.1 million, net of issuance costs of $2.0 million, which was included within Put right liability
within the Company&#8217;s consolidated balance sheet.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 8, 2025 and December 30, 2025, one Side
Letter put right and the DWF put right were exercised, respectively, and on March 24, 2026 and December 30, 2025, the contributed locked
TON tokens receivable in the amount of 1,114,130, with a fair value of $<span id="xdx_902_ecustom--FairValueOfContribution_iI_pn3n3_dm_c20251208_zi9zyN3RICOg" title="Fair value of contribution">2.5</span>
at contribution, and $<span id="xdx_90B_ecustom--Usd1Receivable_iI_pn3n3_dm_c20251208_zFn8D3KFL3v3" title="USD1 receivable">15.0</span>
million USD1 receivable were returned to the investor and DWF, respectively. In connection with the exercise of the Side Letter put right
on December 8, 2025, the Company recognized a loss on the exercise of $1.1 million, recognized as the difference between the fair value
of the TON contributed by the respective investor at the time of put exercise and the carrying value of the put right. When the locked
TON receivables were returned to the investor on March 24, 2026, the Company recognized a $0.4 million gain from the settlement of a portion
of the TON payable, recognized as the difference between the carrying value of the TON contributed by the respective investors at the
time the TON was returned to the investors and the fair value of the TON payable. As of March 31, 2026, the Company owes the investor
420,434 liquid TON tokens with a fair value of $0.5 million. When the USD1 receivable was returned to DWF on December 30, 2025, no such
gains or losses were recognized as USD1 is pegged to the U.S. dollar. Additionally, the Company terminated its Treasury Management Agreement
with DWF in connection with the return of DWF&#8217;s initial investment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On January 27, 2026 and March 19, 2026, one Side Letter
put right was partially exercised and a second Side Letter put right was fully exercised, respectively. In connection with the exercises
of the Side Letter put rights, the Company recognized a loss on the exercise of $<span id="xdx_907_ecustom--LossOnExercise_iI_pn3n3_dm_c20260127_znSdY4n71Gdb" title="loss on the exercise">0.4
</span>million, recognized as the difference between the fair value of the TON contributed by the respective investor at the time of put
exercise and the carrying value of the put right. The put rights were not settled during the fiscal year ended March 31, 2026 and as of
March 31, 2026, the Company owes the investors 369,278 liquid TON tokens and 453,125 locked Ton tokens receivable with fair values of
$0.5 million and $0.3 million, respectively, which corresponds to the fair value of the liquid and locked tokens to be returned to the
respective investors at March 31, 2026. The outstanding TON balances payable were settled and the TON tokens returned to the respective
investors in separate transfers on April 15, April 24, and April 28, 2026.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As of March 31, 2026, the outstanding Contingent Put
Options were remeasured to fair value of $<span id="xdx_90A_ecustom--OutstandingContingentPutOptionsFairValue_iI_pn3n3_dm_c20260331_zNmujS1Hj00d" title="Outstanding Contingent Put Options fair value">7.1</span>
million, with the remeasurement change in fair value of $<span id="xdx_90E_ecustom--RemeasurementChangeInFairValue_iI_pn3n3_dm_c20260331_zwOU7OuzWywk" title="Remeasurement change in fair value">6.0</span>
million recorded within other losses in the Consolidated Statements of Operations and Comprehensive Income (Loss).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The following table summarizes the changes in the put
right liability during the fiscal year ended March 31, 2026 (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfPutRightLiabilityTableTextBlock_pn3n3_zDV6kJn48r9d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;<span id="xdx_8BA_zrd7CcyH9Nqh" style="display: none">Schedule of put
        right liability</span> </td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_zI5dL0OGoDy6" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_401_ecustom--BalanceOfPutRightLiability_zaWkEXp0qrEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_zaoCRQMYme17" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Put right recognition at contract inception</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">18,150</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--GainsLossesOnChangeInFairValueOfDerivatives_zyPmsHzo3NEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of put right liability, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">5,959</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProceedsFromExerciseOfOptions_zFTV2D5OOMT" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Exercise of side letter put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,920</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--SettlementOfDwfMaasLimitedPutRight_zR6kRtNdRtWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Settlement of DWF Maas Limited put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(15,000</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LossOnExerciseOfPutRightLiability_zoxN7NLCVRZf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss on exercise of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">916</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--PutRightLiabilityEndingBalance_zHmCFY1nPVij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Put right liability as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">7,105</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>








<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfPutRightLiabilityTableTextBlock', window );">Schedule of put right liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfPutRightLiabilityTableTextBlock_pn3n3_zDV6kJn48r9d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;<span id="xdx_8BA_zrd7CcyH9Nqh" style="display: none">Schedule of put
        right liability</span> </td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_zI5dL0OGoDy6" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_401_ecustom--BalanceOfPutRightLiability_zaWkEXp0qrEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_zaoCRQMYme17" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Put right recognition at contract inception</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">18,150</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--GainsLossesOnChangeInFairValueOfDerivatives_zyPmsHzo3NEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of put right liability, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">5,959</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProceedsFromExerciseOfOptions_zFTV2D5OOMT" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Exercise of side letter put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,920</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--SettlementOfDwfMaasLimitedPutRight_zR6kRtNdRtWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Settlement of DWF Maas Limited put right</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(15,000</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LossOnExerciseOfPutRightLiability_zoxN7NLCVRZf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss on exercise of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">916</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--PutRightLiabilityEndingBalance_zHmCFY1nPVij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Put right liability as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">7,105</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>








<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfTonPayableTableTextBlock', window );">Schedule of TON payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfTonPayableTableTextBlock_pn3n3_zdAZZDIkciB5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B7_zMjtOO9WIA6c" style="display: none">Schedule of TON payable</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331_z5nOEyLqwnp5" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Fiscal year ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td></tr>
  <tr id="xdx_407_ecustom--BalanceOfTonPayable_zZXYzpeNQcA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Balance as of April 1</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1852">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ExerciseOfSideLetterPutRightPayable_zt7S9e2GJCjb" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Exercise of side letter put right</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,920</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_iN_di_zn3xJzVG1Lnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(51</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--GainOnSettlementOfTonPayable_iN_di_z0cqKFLVZR3f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(336</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--SettlementOfPutRightLiabilityUsingDigitalAssets_iN_di_zvFzBjEs7nWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Settlement of put right liability using digital assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(1,108</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--TonPayableEndingBalanceAsOfMarch31_z5qhLQCmoKBh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">TON payable as of March 31</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,425</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfPutRightLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfPutRightLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfTonPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfTonPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Accounts Payable And Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zuBiDBB0PrP4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_zHYRDfycesC8" style="display: none">Schedule of accounts
        payable and accrued liabilities</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_492_20260331_z5S14yhvqA45" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331_zrj8TolvXpN6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccountsPayable_iI_zWeTCv2cvwGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,413</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">427</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedOtherProfessionalFees_iI_zokfs4wSvUad" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued other professional fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">262</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zjeBhK6CLhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued accounting and auditing fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">73</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">155</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_z4sLGMmf6tN4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued bonuses and other payroll-related expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">913</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">89</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedCRO_iI_zHNCOvDYDg2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1880">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">80</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProfessionalFeesExpenses_iI_zg7p3eGGJla9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued legal fees</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">414</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">60</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedClinicalAndRdServices_iI_zjEWa0vnkMU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued clinical and R&amp;D services</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">14</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CapitalExpenditures_iI_zsLMetrmU6T9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Capital expenditures</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">333</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">0</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherAccruedExpenses_iI_zGfBgATblded" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Other</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_zDwF6E6m6JXd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">5,504</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,100</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureLeaseLiabilityAbstract', window );"><strong>Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfLeaseLiabilityTableTextBlock', window );">Schedule of Lease liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfLeaseLiabilityTableTextBlock_pn3n3_zyHnYTCitGr9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASE LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"><span id="xdx_8BF_ziAyf6haDmHi" style="display: none">Schedule
        of Lease liability</span></td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49F_20260331_zHueMHvmtzS" style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; color: #212529; font-weight: bold">Fiscal Year ended March 31,</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: center">Amount</td></tr>
  <tr id="xdx_40B_ecustom--LeaseLiabilityFutureMinimumPaymentsDue_iI_zTsB5kKZnvr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">2027</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">68</td>
    <td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LeaseLiabilityFutureMinimumPaymentsYearTwoDue_iI_zhc2Ggde5K81" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">2028</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">92</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LeaseLiabilityFutureMinimumPaymentsYearDue_iI_zZh0HG83xjWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold">Total</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">160</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--Interest_iI_zgG0B6A3tiCk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">Less: Interest</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">(22</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--TotalLeaseLiability_iI_zY5T9jBgSXvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">Total lease liability</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right">138</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LeaseLiabilityCurrent_iI_zzvimpsFkTI5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt">Lease liability - current</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">65</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LeaseLiabilityNoncurrent_iI_zGLcqpdlDgZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Lease liability - non-current</td>
    <td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: right">73</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock', window );">Schedule of income tax benefit</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zINoBiaRScub" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B0_zMmAGq60eaq3" style="display: none">Schedule
        of income tax benefit</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_497_20250401__20260331_zk0uk8CvJz41" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_491_20240401__20250331_zhkTLop2mpcb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current tax:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CurrentTaxOnProfitsForYear_ztkQYH3yFeJe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Current tax on profits for the year</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1941">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1942">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AdjustmentsForCurrentTaxOfPriorPeriods_zFIKDWyJbwXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Adjustments for current
        tax of prior periods</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1944">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentTaxExpenseIncome_i01_pn3n3_zZ7mca4NHGn" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1947">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred income tax:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DecreaseIncreaseInDeferredTaxAssets_zmt0QnBzqidh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Decrease (increase) in deferred
        tax assets</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1953">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProfitLossFromContinuingOperation_i01_pn3n3_zDKwrJAl1i4e" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1956">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock', window );">Schedule of reconciliation income tax rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z0sT7P32qNd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;<span id="xdx_8BD_zp1uJytHxqO1" style="display: none">Schedule of reconciliation
        income tax rates</span> </td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20250401__20260331_zxB3RRPk4Na8" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_491_20240401__20250331_zhn17T8tMIra" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_407_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_zYZQnEKeSmKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss before income tax</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(38,627</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">(6,781</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxUsingBviTaxRate_pip0_dp_ztfnfs4nFxSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax using BVI tax rate of 0%</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1965">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EffectOfTaxRatesInOtherCountries_zMKOlGVADbk7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Effect of tax rates in other countries</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(273</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(24</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--DerecognitionOfDeferredTaxAssets_zpF3OA9h1TWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Derecognition of deferred tax assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(156</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">23</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--NondeductibleExpenses_zxYssXEsZbT4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Nondeductible expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1973">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_zUWhvh4QdqYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Utilization of losses not previously benefitted</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1976">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1977">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxEffectsRelatedToEquityCompensation_zA30sF2tpoGi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Income tax effects related to equity compensation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">429</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ForeignCurrencyEffectAndOther_zCrtam5qUHZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Foreign currency effect and other</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxExpense_zNYBWWsrZ7gh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax in the statement of loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1985">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b></b></p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfDeferredTaxAssetsTableTextBlock_pn3n3_zcwaE4FrkEFa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B3_znCPruTYwnwd" style="display: none">Schedule
        of deferred tax assets and liabilities</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20260331_z3hbdug8JZJh" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_495_20250331_zwWuvRPMVKC9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsAbstract_iB_zroFL7nzjGM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">The balance comprises temporary differences attributable to:</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzNDo_zYYvIBRwiBn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Tax loss</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">4,265</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">3,935</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockbasedCompensation_i01_pn3n3_maNDTAzNDo_zg5NkV192sbd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">11</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">397</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ReservesAndAccruals_i01I_pn3n3_maNDTAzNDo_zpF098fkMhS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Reserves and accruals</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2005">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--NetDeferredTaxAssets_i01TI_pn3n3_mtNDTAzNDo_zFqHYt7xYwP2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total deferred tax assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">4,276</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4,349</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetNotRecognized_i01NI_pn3n3_di_zXXTsip0DILl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset not recognized</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(4,276</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,349</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--NetDeferredTaxAsset_i01TI_pn3n3_zLCqto0u8Gba" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2014">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2015">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalStockAndReservesAbstract', window );"><strong>Capital Stock And Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of inputs associated with calculating the fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zJmEF76Kps05" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details )">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_zyf6XnpCBDcc" style="display: none">Schedule of inputs associated with calculating
        the fair value</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">October
        3, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold">Exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw4EC71or03" title="Exercise price">38.00</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--SharePriceFairvalue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziV5CYcdG7K8" title="Share price">39.40</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life (years)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_ecustom--OptionLifeShareOptions_dtY_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zXs0B3wo5NJ9" title="Expected life">1.50</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zL9lmSzNwlMb" title="Expected volatility">96.0</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHOFaNy6c8ya" title="Risk free interest rate">5.32</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_904_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQQ7PNDXngPa" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl2085">-</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalStockAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalStockAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock', window );">Schedule of stock option reserve</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_pn3n3_zQlgUwnMFFc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zg3911QQfmG5" style="display: none">Schedule of stock option
        reserve</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Balance, beginning of year</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20250401__20260331_zTttwvXdqSWk" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">23,530</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_988_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20250331_zHIUt32fJSbd" style="width: 12%; font-size: 10pt; text-align: right">23,841</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20250401__20260331_zD8TjPMADUpa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense">1,745</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20240401__20250331_zRWWFpgQGmna" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">321</td>
    <td style="font-size: 10pt; text-align: left"><sup>(1)</sup></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Correction of prior period overstated share-based compensation
        expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20250401__20260331_zCMB8KtkMoDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Correction of prior period overstated share-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl2100">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20240401__20250331_zqXZzU3nC9h" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Correction of prior period overstated share-based compensation expense">(632</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)<sup>(2)</sup></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance, end of year</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20250401__20260331_zQh7X8oL6xu5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">25,275</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_983_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20250331_ztoJWxIq1csi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">23,530</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 14%; font-size: 10pt; text-align: center">(1)</td>
    <td style="width: 86%; font-size: 10pt; text-align: left">Amount is net of $0.6 million reversal of share-based compensation expense for unvested
        share options forfeited during the fiscal year ended.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">(2)</td>
    <td style="font-size: 10pt; text-align: left">Amount represents the correction as of March 31, 2025 for the overstated share-based compensation
        expenses in Fiscal 2022 and Fiscal 2024.</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of share options issued and outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zgeG60Y8aoWc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B5_zRjZbyHo3iW8" style="display: none">&#160;Schedule of share options issued
        and outstanding</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20250401__20260331_zj7VJGh2zJ32" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">225,117</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20250331_z65qTL5i5Q8k" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance">90,281</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Granted</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zUxYnHSiwRqh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted">2,028,135</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_zg2B21mMxib6" style="font-size: 10pt; text-align: right" title="Granted">160,000</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zidYIcIDQuZ7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited">(6,745</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_z585SocDALW5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited">(25,164</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zyCIvbmNY4sh" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlJ9nP6aePD6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">225,117</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zeqUc30cW8W5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zWaEvFNwkmLb" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">102,855</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Available for future awards</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20250401__20260331_z3rVNZ5aGWHi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Available for future awards"><span style="-sec-ix-hidden: xdx2ixbrl2139">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20240401__20250331_zv0t3DdU9vF" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available for future awards">17,516</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock', window );">Schedule of weighted-average estimated fair value of share options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfWeightedAverageAssumptionsTableTextBlock_zTv9z2f1KcE" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zXqVQ5uzHeb5" style="display: none">Schedule of weighted-average estimated
        fair value of share options</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt">Grant Price</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zBwUR57N7nIi" title="Grant price">1.30</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zqgA2HDH1mYj" title="Grant price">4.45</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life (in years)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zIzdxsHkCVy4" title="Expected life">10</span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_ecustom--OptionLifeShareOptionsGranted_dtY_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zRn0b9MkpPXf" title="Expected life">5.75</span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Risk-free interest rates</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zbm327X5L0R4" title="Risk free interest rate">3.68</span></td>
    <td style="font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zhUY2lomD35l" title="Risk free interest rate">4.14</span></td>
    <td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Volatility</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zpkwI2rP4Ecj" title="Expected volatility">115.0</span></td>
    <td style="font-size: 10pt; text-align: left">%</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zGasLKz8m0E5" title="Expected volatility">135.8</span></td>
    <td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dividend yield</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvUjY2opY4nb"><span style="-sec-ix-hidden: xdx2ixbrl2174">&#8212;</span></span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvfRB8UiCMCf"><span style="-sec-ix-hidden: xdx2ixbrl2175">&#8212;</span>&#160;</span>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average exercise price and the remaining contractual life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_z3jO5UVi58zc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"> <span id="xdx_8BA_zQerUm64wrF7" style="display: none">Schedule of weighted average exercise price and the remaining
        contractual life</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20250401__20260331_zaU7tofFXeW" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">6.84</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20250331_zrFiK1dgikvb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price">62.51</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20250401__20260331_zLKzMSH9P2O4" title="Weighted average remaining contractual life (in years)">9.9</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20250331_zFFZeaPhjGB3" title="Weighted average remaining contractual life (in years)">9.1</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Share options granted and outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z7wkIYWaRz39" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B1_zqijrz5Mknw7" style="display: none">Schedule of Share options granted and
        outstanding</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td id="xdx_488_ecustom--ExpirationDate_zKINvOlmRmS2" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_48C_ecustom--ExercisePrice_pip0_zC1MEnqFF5Z7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_ecustom--ShareOptions_zPB6RVYkEeRl" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Share Options as of</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Grant Date</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Expiration Date</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price $</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2026</td></tr>
  <tr id="xdx_41F_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January132021Member_z23nODcb10eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-size: 10pt; text-align: left">January 13, 2021</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">January
        13, 2031</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 22%; font-size: 10pt; text-align: right">355.00</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 22%; font-size: 10pt; text-align: right">21,400</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January192022Member_z0QzW6haKfGf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">January 19, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">January
        19, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12,475</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--February152022Member_zQ4F2fGDGb19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">February 15, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">February
        15, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">171.80</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--June82022Member_zu6xZSM5Ptlf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">June 8, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">June
        8, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">220.00</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272022Member_zVcBTLbtjKcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">July 27, 2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">July
        27, 2032</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">201.20</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March302023Member_ztOORJsba2E9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">March 30, 2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">March
        30, 2033</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">24,497</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March72025Member_zsxlz6Wud1k9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">March 7, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">March
        7, 2035</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4.45</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">160,000</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41C_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272026Member_zZNh6A3YOVMb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">July 27, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">July
        27, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">97,739</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March112026Member_zc8GVRMsAJa6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">March 11, 2026</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">March
        11, 2036</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">1.30</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,930,396</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20240401__20250331_zEdYJu7BN6y6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfEarningsPerShareTableTextBlock', window );">Schedule of loss and share data used in the basic and diluted EPS calculations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zsS4CoeES4S4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span id="xdx_8BA_zvvguM3k50j8" style="display: none">Schedule
        of loss and share data used in the basic and diluted EPS calculations</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Numerator</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the
        Company</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20250401__20260331_zcRKw8gluL3i" title="Weighted average shares outstanding, Diluted">(38,627</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20240401__20250331_z2CcesYCo3yk" title="Weighted average shares outstanding, Diluted">(6,767</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20230401__20240331_zt94WqBLzg82" title="Weighted average shares outstanding, Diluted">(75,339</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Denominator</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Weighted average number of shares &#8211; Basic and Diluted</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20250401__20260331_zgFzVd15Ikal" title="Weighted average shares outstanding, Diluted">9,248</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240401__20250331_zRBOm79ICEl8" title="Weighted average shares outstanding, Diluted">1,183</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20240331_z0WLRcgGgh2k" title="Weighted average shares outstanding, Diluted">968</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_902_ecustom--LossPerShareBasic_pip0_c20250401__20260331_zmbXl2cSO4al" title="Loss per share, Basic"><span id="xdx_90E_ecustom--LossPerShareDiluted_pip0_c20250401__20260331_zZwh5dIZyVJ2" title="Loss per share, Diluted">(4.18</span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_ecustom--LossPerShareBasic_pip0_c20240401__20250331_zyMCfFL2LpE1" title="Loss per share, Basic"><span id="xdx_907_ecustom--LossPerShareDiluted_pip0_c20240401__20250331_zkOoovScaKYj" title="Loss per share, Diluted">(5.72</span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--LossPerShareBasic_pip0_c20230401__20240331_zShoRiQyeKue" title="Loss per share, Basic"><span id="xdx_90C_ecustom--LossPerShareDiluted_pip0_c20230401__20240331_zRBuKRaCJxSg" title="Loss per share, Diluted">(77.83</span></span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock', window );">Schedule of anti-dilutive effect on loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_zJv9JThhJnb3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_z71f9aNcXd96" style="display: none">Schedule of anti-dilutive
        effect on loss per share</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zXFaxJRIrlg5" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,531,581</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_ztitv7YcRfn3" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zmL6DkL2CZV" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Share options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zPkX8p87qSch" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">2,246,507</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zHgwbhDxhbOj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">225,117</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_za9b0O0g2D32" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">90,281</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_z2Qo9CmrTeW6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,241,334</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zxskHsRj6qbd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">5,410</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zp4ohqFmVDm8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">18,467</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfEarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfEarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfCompensationPayableTableTextBlock', window );">Schedule of compensation payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfCompensationPayableTableTextBlock_pn3n3_zHXd7Jnzfrck" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BA_zixr8vFgcR02" style="display: none">Schedule of compensation payable</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_494_20250401__20260331_zsRoltRPBld9" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49F_20240401__20250331_zsUMlGFMdxLi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_492_20230401__20240331_z3f7odmy8b53" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Years ended March 31,</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_405_eifrs-full--ShorttermEmployeeBenefitsExpense_z3Z4JOrwThD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; font-size: 10pt; text-align: left">Short-term employee benefits (salary, bonus, etc.)</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right">4,052</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right">13,787</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 11%; font-size: 10pt; text-align: right">2,127</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--PostemploymentBenefitExpenseInProfitOrLoss_zgWTLhldnN2k" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Post-employment benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--OtherLongtermBenefits_z3xdmb0zVY02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other long-term benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TerminationBenefitsExpense_zafHHyIajBx2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Termination benefits</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">152</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">49</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SharebasedPaymentCompensation_zOi8VtKNS8R6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Share-based payment compensation</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,600</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">590</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--KeyManagementPersonnelCompensationPostemploymentBenefits_zCLlzQjclxc6" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt">&#160;Total</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,804</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,968</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,176</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">Schedule of Compensation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_pn3n3_zsSJyhx1c6Hc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B3_zt4kH5O16nzc" style="display: none">Schedule of Compensation</span><b></b></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name &amp; Principal Position</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Year</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Fee and</p>
        <p style="margin-top: 0; margin-bottom: 0">Salary<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Transaction</p>
        <p style="margin-top: 0; margin-bottom: 0">Closing Bonus<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Securities Under</p>
        <p style="margin-top: 0; margin-bottom: 0">Options Granted</p></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Shares
        or Units<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(16)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Other<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total
        Compensation</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Michael Terpin</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 6%; font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNonqqAnuxL6" style="width: 6%; font-size: 10pt; text-align: right" title="Fee and salary">61,250</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoGAzHJAW9ha" style="width: 6%; font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2365">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBJ5jtH5VJxi" style="width: 6%; font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2367">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXUS9z2RFnKe" style="width: 6%; font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zo5x151YrI08" style="width: 6%; font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2371">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zeGeIqzBlHHa" style="width: 6%; font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2373">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKAQnKIBVFl" style="width: 6%; font-size: 10pt; text-align: right" title="Total compensation">61,250</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">F. Daniel Siciliano</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAxjPVuOqAd1" style="font-size: 10pt; text-align: right" title="Fee and salary">17,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0Ds2tWNJgJf" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2379">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zViTOGYOjUTb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3EDhTZQUYtk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2383">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKfKYHRU4df" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2385">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQAzgB6RPKmk" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2387">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxHSyyvchTo5" style="font-size: 10pt; text-align: right" title="Total compensation">17,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Gregory H. Bailey, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zKA2GK6DRIsb" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zclrmtQoP3W8" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3E62n2WJsch" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2395">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3Laoj6J7x6l" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2397">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zaQPMUPA12H9" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2399">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDEwTQWqSVWl" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2401">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zYYV6QOSnEii" style="font-size: 10pt; text-align: right" title="Total compensation">55,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zQW0F083ILE8" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzLkgMAohvck" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2407">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9zPiAillZth" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2409">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcxjFC5oiD82" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2411">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdpe9o9DRVRe" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2413">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zJVTE3UPEleg" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2415">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0EPcEey05sf" style="font-size: 10pt; text-align: right" title="Total compensation">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zafYIIQiMnc6" style="font-size: 10pt; text-align: right" title="Fee and salary">49,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjHLde5nX3Ka" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2421">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV8qA7QLXBM" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2423">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zq29hiLqruh1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2425">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zidJETtEIj0l" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2427">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zOKkHDjgv5kg" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2429">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr7iC3iWVabk" style="font-size: 10pt; text-align: right" title="Total compensation">49,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">James Mellon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zkYEtExNX3L8" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTjiH2TcAZI7" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_znhHbc0cne87" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2437">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zawteqprpt8c" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2439">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHczKE0v7c61" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2441">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCpjNRF2mW7" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2443">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5rHhXnKidG6" style="font-size: 10pt; text-align: right" title="Total compensation">55,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zWig206U3G18" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfu21gboJ1tk" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2449">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdxYO2zK8eqa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2451">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUcKJJa0bhBf" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2453">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjf6JrncjUyb" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2455">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqKSY5CqTFQe" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2457">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTy5cU7HFV8f" style="font-size: 10pt; text-align: right" title="Total compensation">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zw2QCK6ec9pi" style="font-size: 10pt; text-align: right" title="Fee and salary">35,242</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhtuMXozwUg2" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2463">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBDeiB7FkJYf" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2465">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zM1t9ctOZH3i" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2467">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyAu82T1XFni" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2469">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoebWFZWmLZj" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQlZs1WrdtE1" style="font-size: 10pt; text-align: right" title="Total compensation">35,242</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Steven Mintz<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zK96CTLr4KUh" style="font-size: 10pt; text-align: right" title="Fee and salary">77,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZ3OGprqhqdc" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPEXV0JcrOGk" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2479">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfvaAeHDuLK3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">54,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztrvWOcSlcsb" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z4VfQDhLBvr4" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2485">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhjUsjqSYTi4" style="font-size: 10pt; text-align: right" title="Total compensation">157,296</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zESRkB16EQy" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbyRiuRbTuIe" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2491">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2Vmxgqk48k8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2493">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMg9yIgKCJBg" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">113,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zG3vzCuGNoxi" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z59r180DH0gd" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2499">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zmGKMJGieq5h" style="font-size: 10pt; text-align: right" title="Total compensation">143,158</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zVw44CDH5dJ7" style="font-size: 10pt; text-align: right" title="Fee and salary">45,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwiyV4Epblrb" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2505">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zObscOD9MX7h" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2507">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQYts612ziEc" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2509">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKS6PeaJLfE6" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2511">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlQzVcEdoni3" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2513">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zGWAWnEfDsil" style="font-size: 10pt; text-align: right" title="Total compensation">45,750</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Jean-Christophe Renondin, M.D.<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zlfHg9RK3Rq4" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCwBzTB6Tehc" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjoDgQ1BiKXi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2521">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqK9q24YXjn5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">54,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyUIr0qWbKhk" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2525">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zv9U42HQIach" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2527">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zT9pNoVuuFN2" style="font-size: 10pt; text-align: right" title="Total compensation">109,796</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zPxvg4vmLqY2" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNNyYB3ivBO1" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2533">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEsWlDotiEAd" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2535">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMJYowivhzb1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">96,992</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zin1LxHAWUNj" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2539">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zVtfsIEfAri6" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2541">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ziu28NvBoHPk" style="font-size: 10pt; text-align: right" title="Total compensation">126,992</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_z75HluNHcuTe" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2545">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIHqOh38LsRb" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2547">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHmEUgDNtzBe" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2549">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCKmV9NTn7w5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2551">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdFx3W0dfNC3" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2553">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zANYBart5atk" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2555">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9sT2Ix8V7l8" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2557">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Justin Stebbing, M.D. PhD<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_z2XVSuy8aLk9" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEqzzTFqvfXb" style="font-size: 10pt; text-align: right" title="Bonus compensation">25,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFDJzVGeF81e" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2563">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIEBADLsTBd9" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">64,760</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlqOVuJSjh34" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2567">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvtSbnsTGWWl" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2569">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zedrsawnoOL4" style="font-size: 10pt; text-align: right" title="Total compensation">119,760</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zf6HK6RHLWDh" style="font-size: 10pt; text-align: right" title="Fee and salary">30,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zA28749keNBk" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2575">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2RqB6D16r43" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2577">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyddtzDsyDzi" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted">121,240</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">(5)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDN79Ubqn1" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2581">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zm2UjAPrRcrf" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2583">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNXemAyLNf1" style="font-size: 10pt; text-align: right" title="Total compensation">151,240</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zykeYTyHgPE9" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2587">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsWWmglVHGT4" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2589">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgB2nUeblEPa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2591">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcQYHpDiclT3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2593">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqF6sXtREO3h" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2595">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztFzI9yvPxfj" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2597">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQzOCViYiew7" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2599">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Linda Kozick<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zovruTySfId" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2601">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zkjeS6ybUqid" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2603">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWnki9hi25J8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2605">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBOPWIdToL4e" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2607">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxQqGNhqk2ul" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2609">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFUoJqbH15Ze" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2611">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgQvMyONcsPe" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2613">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zYn1MzZ5W86d" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2615">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCWtdzLwNGR2" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2617">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zERocssYs7ia" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2619">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAHFQeeI0HD3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2621">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNVDfucmuhr6" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2623">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV0Wd7pQjWy6" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2625">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z7sbm2QsPH98" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2627">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zvdbgjx5V7W7" style="font-size: 10pt; text-align: right" title="Fee and salary">42,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcGa3Q6kgqsb" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2631">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPHe0cUYrxBg" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2633">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z1TiHjTnJaii" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2635">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZa3YuppNtv7" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2637">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsZPQcnLKMsb" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2639">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr9JH4Y9zCf5" style="font-size: 10pt; text-align: right" title="Total compensation">42,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Mark Simon<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z3o4vt2SH14h" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2643">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zy2icmNOfQ6c" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2645">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSWn5iEL3Pd6" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2647">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zpWBlry94uwk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2649">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAEfHnsSJ9T3" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2651">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEKwVCuNjS2a" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2653">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV6hacfGlro6" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2655">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zPzxiVbd5jvj" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2657">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWu738896MJd" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2659">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUSHpXd20fGl" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2661">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3g5SeQqJbF8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2663">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAV11Afrww21" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2665">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_za0HrOXyFQX3" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2667">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWRzANTguJke" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2669">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z9ajTWyVlY6d" style="font-size: 10pt; text-align: right" title="Fee and salary">55,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2bSz4QeWlel" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2673">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z8cJcD5mYKm3" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2675">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zblyaUGazip8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2677">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj5sjbH4qSDc" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2679">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMX6fWtOk2kd" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2681">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSME3co5fKs4" style="font-size: 10pt; text-align: right" title="Total compensation">55,500</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal">Robert Glassman<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(9)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zQySdV047Tic" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2685">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTJWhurMpP02" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2687">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSfs9jdBhhri" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2689">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXFY3pmarW25" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2691">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZXTLYmgUsmc" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2693">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zrxZi6X6OiBl" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2695">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5wbwwQk5Bk6" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2697">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2025</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zs32GrJba2ra" style="font-size: 10pt; text-align: right" title="Fee and salary"><span style="-sec-ix-hidden: xdx2ixbrl2699">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj6i0XkDl3w2" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2701">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z6C27MJSgYn7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2703">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zF3eb7ynJui7" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2705">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKd32So0gR5f" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2707">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhCzgbRnYmIb" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2709">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbGNoa8KJwNa" style="font-size: 10pt; text-align: right" title="Total compensation"><span style="-sec-ix-hidden: xdx2ixbrl2711">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2024</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zgb4SR5eT5K2" style="font-size: 10pt; text-align: right" title="Fee and salary">45,258</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zw9Fd80Mp8H3" style="font-size: 10pt; text-align: right" title="Bonus compensation"><span style="-sec-ix-hidden: xdx2ixbrl2715">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zg9P2hh7j3l4" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"><span style="-sec-ix-hidden: xdx2ixbrl2717">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlsZDtlIXCj6" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"><span style="-sec-ix-hidden: xdx2ixbrl2719">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvzYssiMoRwg" style="font-size: 10pt; text-align: right" title="Shares or units"><span style="-sec-ix-hidden: xdx2ixbrl2721">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zU85u4TYgDY5" style="font-size: 10pt; text-align: right" title="Other compensation"><span style="-sec-ix-hidden: xdx2ixbrl2723">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwbCohDoSo3f" style="font-size: 10pt; text-align: right" title="Total compensation">45,258</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock', window );">Schedule of outstanding equity awards</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfOutstandingEquityAwardsTableTextBlock_pn3n3_zUddgk7Gcfgb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center"><span id="xdx_8BC_zds2qVV7hoNg" style="display: none">Schedule of outstanding equity awards</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td id="xdx_489_ecustom--GrantDate_zv5L3hacsjJi" style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_eifrs-full--AdjustedWeightedAverageShares_zXG6jKTofL26" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_484_ecustom--NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_zdw0j2DqgZS7" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_481_ecustom--ExercisePrices_zDsaBjP2lnfh" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_482_ecustom--OptionExpirationDate_zxMOuc8Am8T5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_485_ecustom--NumberofShareUnitsofStockThetHaveNotVested_zAWcL9PojHuk" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_481_ecustom--MarketValueNumberofShareUnitsofStockThetHaveNotVested_zVLiL1qWgK3l" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option
        Awards</td>
    <td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Stock
        Awards<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares or</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Market Value of Shares or</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Securities Underlying</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Units of Stock</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercised
        Options</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Exercise</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Expiration</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">That Have</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Grant Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; font-style: normal">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center">Exercisable<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(1)</sup></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unexercisable</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Price</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Date</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Not Vested</td></tr>
  <tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zgOPBxjAs4Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; font-size: 10pt; font-style: normal">Alexander Pickett<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(2)</sup></span></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">3/7/2025</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">36,000</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3061">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">4.45</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">3/7/2035</td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3065">-</span></td>
    <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettTwoMember_zZvKOqSPCb94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">45,937</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3068">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3071">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3072">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersMember_z6dycgWI0aA1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Ian B. Walters<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(3)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">15,085</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3075">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3078">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3079">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersTwoMember_zd9ZGUIjKT68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,285</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3082">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3085">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3086">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersThreeMember_zJXquc5spit6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7,550</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3089">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12/14/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3092">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3093">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkMember_zBMSVdDCBMY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal; text-align: left">Andrea E. Park<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(4)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/7/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">28,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3096">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4.45</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/7/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3099">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3100">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkTwoMember_zlaEd1lAoeMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7,820</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3103">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5.73</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7/27/2035</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3106">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3107">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z8UjEeWV6QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Allan Shaw<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(5)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,761</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3110">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3113">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3114">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawTwoMember_zG4l5SHTmNF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">840</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3117">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3120">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3121">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawThreeMember_z8RpUX7kiZui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,550</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3124">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">9/30/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3127">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3128">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zNIBveNX6rz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Robert Kramer<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(6)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,771</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3131">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2033</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3134">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3135">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerTwoMember_zAm81wtqiGEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,255</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3138">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2032</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3141">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3142">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerThreeMember_zN2YlmYF5yYj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2021</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,050</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3145">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">355.00</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/13/2031</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3148">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3149">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zDZU33gCl6p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: normal">Brian Wiley<span style="font-size: 10pt; font-style: normal; font-weight: 700"><sup>(7)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/30/2023</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,386</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3152">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">58.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11/15/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3155">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3156">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyTwoMember_zLLro33yoEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1/19/2022</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,000</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3159">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">204.40</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11/15/2026</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3162">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3163">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zjRR9pOhLd0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Brittany Kaiser<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3166">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3169">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3170">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zgu2Ii9G1Ngk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Enzo Villani<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3173">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3176">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3177">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zNOIQExz8De1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left">Yury Mitin<span style="font-size: 10pt; font-style: normal; font-weight: 400"><sup>(8)</sup></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3/11/2026</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">545,315</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3180">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1.30</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5/14/2036</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3183">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3184">-</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>





























<p style="margin: 0pt 0; font-size: 10pt"><b>Notes</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(1)</td>
    <td>Except as set forth below, vesting of all options is subject to continued service as an employee, director and/or consultant of Alpha
        Compute or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the
        date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(2)</td>
    <td>On December 15, 2024, Mr. Pickett was appointed as a director of the Company and our Chief Executive Officer under a consultancy agreement
        and served in such capacities through December 19, 2025, his resignation date. These options were awarded to Mr. Pickett for his services
        as a director. One fourth of the options vested immediately on grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(3)</td>
    <td>Dr. Walters served as our Chief Executive Officer and a director of the Company through December 14, 2024. Pursuant to the terms of his
        employment agreement, all unvested share options immediately vested on such date. Pursuant to the terms of his share option agreements,
        the vested share options are exercisable for two years from this date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(4)</td>
    <td>On September 30, 2024, Ms. Park was appointed as our Chief Financial Officer and departed the Company in October 2025. One fourth of the
        options vested immediately on the grant date, and the remaining vest in three equal annual installments thereafter.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(5)</td>
    <td>Mr. Shaw served as our Chief Financial Officer through September 30, 2024. Pursuant to the terms of his share option agreements, the vested
        share options are exercisable for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(6)</td>
    <td>The above table excludes 4,550 RSUs to Mr. Kramer granted on January 13, 2021, with a grant date value of $1,615,250, which vested on
        the grant date but are subject to certain restrictions and 860 RSUs granted on January 19, 2022 with a grant date value of $175,784, which
        vested on the grant date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(7)</td>
    <td>Mr. Wiley served as our Chief Business Officer through November 15, 2024. Pursuant to the terms of his employment agreement, all unvested
        shares immediately vested on such date. Pursuant to the terms of his share option agreement, the vested share options are exercisable
        for two years from such date.</td></tr>
  </table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in">(8)</td>
    <td>On March 11, 2026, the Board authorized the grant of 545,315 share options each to Ms. Kaiser, Mr. Mitin, and Mr. Villani, which were
        owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private or public
        share offerings. These share options were formally granted on May 14, 2026.</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfCompensationPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfCompensationPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock', window );">[custom:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_pn3n3_zopiDedCWlsj" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_495_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zP6ymNiXA3pj" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_499_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zrf25agWTCtl" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zqXWYoAPlBYb" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_497_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zHT3SIfzSXld" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_496_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z67FiqFDONzi" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zMq4F3VxRHq5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Amortized</p>
        <p style="margin-top: 0; margin-bottom: 0">Cost</p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">Amortized</p>
        <p style="margin-top: 0; margin-bottom: 0">Cost</p></td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">686</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3208">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3209">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">1,670</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3211">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3212">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--Stablecoin_i01I_pn3n3_z4e3MwE56iRa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Stablecoin</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">21</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3215">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3216">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3217">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3218">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3219">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3_zhCqM31u9Eg9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other current assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,984</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3222">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3223">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">555</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3225">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3226">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 48%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; width: 1%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_498_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z4sBZhEDAyW7" style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_49E_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zwLMtx0mT413" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_49F_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zrTGko2d4Dwd" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td>
    <td id="xdx_493_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zfFMkwFheHT" style="font-size: 10pt; text-align: right; width: 10%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">&#160;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>Amortized <br/>Cost</b></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>FVTPL</b></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><b>Amortized</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Cost</b></p></td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"><b>FVTPL</b></td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3_zxH3Lyhkpnfd" style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">4,146</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3234">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right">1,100</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3236">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--TonPayableToSettlePutRightsExercised_i01I_pn3n3_zqvR3mXfUEmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3238">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,425</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3240">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3241">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PutRightLiability_i01I_pn3n3_zQLRQYSyQa81" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3243">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">7,105</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3245">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3246">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3248">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">192</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3250">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">1,952</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LeaseLiabilityCurrentAndNoncurrent_i01I_pn3n3_zjFhkn48tGci" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Lease liability - current and noncurrent</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3253">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">138</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3255">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3256">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock', window );">Schedule of liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock_pn3n3_zVLrHZkHFJR2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BB_zE0eYMntBHej" style="display: none">Schedule of liabilities
        measured at fair value on a recurring basis</span></td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_490_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_z1rLN6TA4HHd" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49C_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z2qYM4LPUosi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_498_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zD5X6q9UAmW9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_494_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zBld36kkVgs4" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zoeTRhfaF2J1" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49E_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zM5QmpE2t1fb" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial and digital assets</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DigitalAssetsAtFairValueTonLiquid_iI_zOUS9oCBMjnk" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Digital assets at fair value, TON liquid</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">126</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3268">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3269">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3270">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3271">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3272">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DigitalAssetsAtFairValueTonLocked_iI_zOUaVSZgiZeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Digital assets at fair value, TON locked</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3274">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3275">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,366</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3277">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3278">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3279">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_496_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zVPTI8wLoSN7" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49E_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z0j5MCgowog9" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49A_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zeKOfFQgFhQi" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_496_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zZzGpxmA9f99" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49A_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zCicAgyZOiU6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zzktOzhiinp3" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TonPayableToSettlePutRightsExercised_iI_zg7mekSAa8u3" style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">TON payable to settle put rights exercised</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3281">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3282">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">1,425</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3284">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3285">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3286">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PutRightLiability_iI_z4Hlvat2BdB1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3288">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3289">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">7,105</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3291">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3292">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3293">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--WarrantLiability_iI_pn3n3_zteIRtenVdC9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3295">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3296">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">192</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3298">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3299">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td style="font-size: 10pt; text-align: right">1,952</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfSegmentReportingTableTextBlock', window );">Schedule of segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSegmentReportingTableTextBlock_pn3n3_zISlVstkjR3k" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zZgatWOTNhLg" style="display: none">Schedule of segment reporting</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_49C_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DigitalComputeMember_zQQi4pef5xyh" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zxYOSbH0llda" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_490_20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zhorSaE3Ib7b" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_491_20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zNoGn4xBsSre" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Digital &amp; Compute</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Immuno-Oncology</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Revenue_zzcc9PH4Xbo" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Segment revenues</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">97</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3313">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3314">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3315">&#8212;</span>&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProfitLossAbstract_iB_z4pFFDeP9sG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment expenses</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ResearchAndDevelopmentExpense_zg3qCDmOqQQ3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3322">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">2,801</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">3,129</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">12,535</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--GeneralAndAdministrativeExpense_zBljTZEYD6Lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: justify">General and administrative expenses</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">16,344</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">3,855</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">4,254</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">5,664</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAndAmortisationExpense_zZweoOSFcnG6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Depreciation and amortization expense</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">193</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3333">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">35</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">54</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLossFromOperatingActivities_zYBtJ9OJJg14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment loss from operations</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(16,440</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(6,656</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(7,418</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(18,253</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--GainsLossesOnChangeInFairValueOfWarrants_z9f3jskqymAl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,097</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">1,786</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(388</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">6,868</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_zMuQEE6EtH44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3347">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3348">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3349">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">11,305</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ChangeInFairValueOfPutRightsNetOfRedemptions_z5PYPZjGT4g3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of put rights, net of redemptions</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(5,959</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3353">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3354">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3355">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LossOnRevaluationOfDigitalAssets_zrVzmHl7BkU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,411</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3358">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3359">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3360">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LossOnRevaluationOfDigitalAssetReceivables_zONRYqKAQWV4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(2,349</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3363">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3364">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3365">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RealizedLossOnSaleOfDigitalAssets_zYMyFjnobtSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on sale of digital assets</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,700</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3368">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3369">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3370">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--RealizedLossOnNovationOfDigitalAssetReceivables_zjFyq3GlZbCk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Realized loss on novation of digital asset receivables</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">676</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3373">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3374">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3375">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--GainOnSettlementWithParexelIoxCro_zlrftFnk0Qda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement with Parexel - iOx CRO</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3377">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3378">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">946</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3380">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LossOnRegisteredDirectOffering_z3GRGfSxrWIj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on Registered Direct Offering</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3382">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3383">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3384">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(2,432</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--OfferingCosts_zrDU1QCJpZs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Offering costs</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3387">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3388">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3389">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(662</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ImpairmentLossIoxIprd_zc4PuDWSybLi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - iOx IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3392">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3393">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3394">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(57,890</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--ImpairmentLossTarusIprd_zSdN1Vd63KFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Tarus IPR&amp;D</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3397">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3398">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3399">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(23,615</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ImpairmentLossStimunity_zG0sZ3DAYpQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Stimunity</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3402">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3403">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3404">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(1,002</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--ImpairmentLossSaugatuck_zKChggm43D9j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - Saugatuck</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3407">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3408">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3409">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(178</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--CommitmentFeeUnderCommittedPurchaseAgreement_zR6Fjac30Lp8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Commitment fee under Committed Purchase Agreement</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3412">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3413">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3414">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(839</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--GainOnDissolutionOfInvestmentInAssociate_zFpbZKRPfAK3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on dissolution of investment in associate</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3417">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3418">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3419">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">27</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GainFromSaleOfInvestmentInPublicCompany_zcVdomIRFAg1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain from sale of investment in public company</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3422">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3423">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3424">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">725</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ImpairmentLossInvestmentInCompedica_zSXzRwv8SsX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Impairment loss - investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3427">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(4,804</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3429">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3430">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossOnRevaluationOfInvestmentInCompedica_zB6DUIoyVn3j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on revaluation of investment in Compedica</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(182</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3433">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3434">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3435">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_z2SYs5jPLmgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of TON payable to settle put rights exercised</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">51</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3438">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3439">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3440">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--GainOnSettlementOfTonPayable_zWhbQpfNGVn4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on settlement of TON payable</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">336</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3443">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3444">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3445">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LossOnSettlementOfPutRightLiability_zc6tV1Gj9iBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on settlement of put right liability</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(916</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3448">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3449">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3450">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--NetForeignExchangeGain_iN_di_zCRqQGgWV2Ze" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange transaction (loss) gain</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">4</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(5</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(7</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--InterestExpenseIncomeDefinedBenefitPlans_zs5vJnEVBKN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Interest (expense) income, net</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(1,022</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">8</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">86</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">242</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnExtinguishmentOfDebt_z4wcapWYoUf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on extinguishment of debt</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(582</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GainOnExtinguishmentOfDebt_zxJa9QeFlVa5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Gain on forgiveness of loan interest</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;$</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">837</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3468">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3469">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3470">&#8212;</span>&#160;&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ShareOfLossesFromEquityMethodInvestment_zv6RnYQVW1F3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Share of losses from equity method investment</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3472">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(44</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3474">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(233</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--SegmentLossBeforeBenefitForIncomeTaxes_zybOlmQXZrD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left">Segment loss before benefit for income taxes</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(28,912</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">(9,715</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(6,781</td>
    <td style="font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">(85,930</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxBenefit_zH7StBEZswxj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3482">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3483">&#8212;</span>&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,548</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentNetLoss_z7sEEjClSHjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment net loss</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(28,912</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(9,715</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,778</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(75,382</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfSegmentReportingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfSegmentReportingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock', window );">Schedule of non-controlling interest</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zasandL9FVq4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_z878ccb405r7" style="display: none">Schedule of non-controlling
        interest</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="vertical-align: middle; font-size: 10pt; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0"><b>Saugatuck</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>and subsidary</b></p></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2023</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zKO3eXzggBki" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(650</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztXhWty3KIZk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">(43</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-controlling interest as of March 31, 2024</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z60iZH9zo4r" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(693</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z94XkukyZVqe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">(11</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-controlling interest as of March 31, 2025</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td>
    <td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zpONoyrL8okk" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(704</td>
    <td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zUWl0fjhWlAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest">(1</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of March 31, 2026</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td id="xdx_985_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znWEiQvoQnbk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(705</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Sep. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TotalCurrentLiabilities', window );">Total Current Liabilities</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossIncome', window );">Net Loss Income</a></td>
<td class="nump">38,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashUsedInOperatingActivities', window );">Cash Used In Operating Activities</a></td>
<td class="nump">20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashCashEquivalents', window );">cash, cash equivalents</a></td>
<td class="nump">10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RestrictedCashOnHand', window );">Restricted cash on hand</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RestrictedCashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RestrictedCashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TotalCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TotalCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember', window );">Subsidiaries Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ptgef_CountryOfBritishVirginIslandsMember', window );">Country Of British Virgin Islands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ptgef_DelawareMember', window );">Delaware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_IOXMember', window );">IOX [Member] | Salva Rx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_IOXMember', window );">IOX [Member] | Salva Rx [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_IOXMember', window );">IOX [Member] | Salva Rx [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_IOXMember', window );">IOX [Member] | Stimunity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NoncontrollingInterestIncreasedUponConversion', window );">Non-controlling interest increased upon conversion</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in a subsidiary held by the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NoncontrollingInterestIncreasedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NoncontrollingInterestIncreasedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ptgef_CountryOfBritishVirginIslandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ptgef_CountryOfBritishVirginIslandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ptgef_DelawareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ptgef_DelawareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_IOXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_IOXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=ptgef_SalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=ptgef_SalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=ptgef_StimunityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=ptgef_StimunityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details ) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">1,531,581<span></span>
</td>
<td class="nump">481,581<span></span>
</td>
<td class="nump">481,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ptgef_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">2,246,507<span></span>
</td>
<td class="nump">225,117<span></span>
</td>
<td class="nump">90,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ptgef_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">1,241,334<span></span>
</td>
<td class="nump">5,410<span></span>
</td>
<td class="nump">18,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential ordinary shares that are antidilutive in the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ptgef_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ptgef_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ptgef_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ptgef_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentProperty', window );">Investments</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashRestrictedForUse', window );">Cash restricted for use</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2025-01-01<br> -Paragraph 76<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_76&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 269<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_269&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 271<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_271_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 269<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_269&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 271<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_271_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashRestrictedForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashRestrictedForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromSaleOfProperties', window );">Prepaid clinical research costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepaid insurance</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Other prepaid expenses</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidInvestorRelations', window );">Prepaid investor relations</a></td>
<td class="nump">534<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TaxDeposits', window );">Tax deposits</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidGpuInfrastructureCosts', window );">Prepaid GPU infrastructure costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidGpuLeasesShortterm', window );">Prepaid GPU leases, short-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TotalPrepaidExpensesAndOtherReceivables', window );">&#160;&#160;Total prepaid expenses and other receivables</a></td>
<td class="nump">$ 1,984<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromSaleOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromSaleOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidGpuInfrastructureCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidGpuInfrastructureCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidGpuLeasesShortterm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidGpuLeasesShortterm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidInvestorRelations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidInvestorRelations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TaxDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TaxDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TotalPrepaidExpensesAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TotalPrepaidExpensesAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Feb. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherAssetsLongTermPortion', window );">Other assets long term portion</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecurityDeposits', window );">Security deposits</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OtherAssetsLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OtherAssetsLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STABLECOIN (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoins', window );">stablecoins</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ptgef_USDCMember', window );">U S D C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoins', window );">stablecoins</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ptgef_UsdtMember', window );">Usdt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoins', window );">stablecoins</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Stablecoins">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Stablecoins</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ptgef_USDCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ptgef_USDCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ptgef_UsdtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ptgef_UsdtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STABLECOIN (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfStablecoin', window );">Contribution of Stablecoin</a></td>
<td class="nump">$ 5,421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasesOfStablecoin', window );">Purchases of stablecoin</a></td>
<td class="nump">311<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToPurchaseDigitalAssets', window );">Stablecoin used to purchase digital assets</a></td>
<td class="nump">3,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_USDCMember', window );">U S D C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfStablecoin', window );">Contribution of Stablecoin</a></td>
<td class="nump">5,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSaleOfDigitalAssets', window );">Proceeds from sale of digital assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToSettleOperatingCosts', window );">Stablecoin used to settle operating costs</a></td>
<td class="num">(2,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinSold', window );">Stablecoin sold</a></td>
<td class="num">(2,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromExternalDebtDrawdown', window );">Proceeds from external debt drawdown</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasesOfStablecoin', window );">Purchases of stablecoin</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToPurchaseDigitalAssets', window );">Stablecoin used to purchase digital assets</a></td>
<td class="num">(2,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinValueAsOfMarch31', window );">Stablecoin value as of March 31</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_UsdtMember', window );">Usdt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfStablecoin', window );">Contribution of Stablecoin</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSaleOfDigitalAssets', window );">Proceeds from sale of digital assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToSettleOperatingCosts', window );">Stablecoin used to settle operating costs</a></td>
<td class="num">(311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinSold', window );">Stablecoin sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromExternalDebtDrawdown', window );">Proceeds from external debt drawdown</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasesOfStablecoin', window );">Purchases of stablecoin</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToPurchaseDigitalAssets', window );">Stablecoin used to purchase digital assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinValueAsOfMarch31', window );">Stablecoin value as of March 31</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_TotalMember', window );">Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfStablecoin', window );">Contribution of Stablecoin</a></td>
<td class="nump">5,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSaleOfDigitalAssets', window );">Proceeds from sale of digital assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToSettleOperatingCosts', window );">Stablecoin used to settle operating costs</a></td>
<td class="num">(2,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinSold', window );">Stablecoin sold</a></td>
<td class="num">(2,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromExternalDebtDrawdown', window );">Proceeds from external debt drawdown</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasesOfStablecoin', window );">Purchases of stablecoin</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinUsedToPurchaseDigitalAssets', window );">Stablecoin used to purchase digital assets</a></td>
<td class="num">(3,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinValueAsOfMarch31', window );">Stablecoin value as of March 31</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContributionOfStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContributionOfStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetValueAsOfApril1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetValueAsOfApril1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromExternalDebtDrawdown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromExternalDebtDrawdown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromSaleOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromSaleOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchasesOfStablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchasesOfStablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StablecoinSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StablecoinSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StablecoinUsedToPurchaseDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StablecoinUsedToPurchaseDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StablecoinUsedToSettleOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StablecoinUsedToSettleOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StablecoinValueAsOfMarch31">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StablecoinValueAsOfMarch31</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_USDCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_USDCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_UsdtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_UsdtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DIGITAL ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureDigitalAssetsAbstract', window );"><strong>Digital Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ApproximateNumberOfTonTokensHeld', window );">Approximate number of TON Tokens held</a></td>
<td class="nump">$ 2,379,165<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonTokensFairValueInThousands', window );">TON Tokens, fair value (in thousands)</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsFairValueInThousands', window );">Digital assets, fair value (in thousands)</a></td>
<td class="nump">$ 2,492<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ApproximateNumberOfTonTokensHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ApproximateNumberOfTonTokensHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetsFairValueInThousands">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetsFairValueInThousands</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureDigitalAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureDigitalAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonTokensFairValueInThousands">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonTokensFairValueInThousands</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DIGITAL ASSETS (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssets', window );">Contribution of digital assets</a></td>
<td class="nump">$ 1,802<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PaymentsOnExternalDebtUsingDigitalAssets', window );">Payments on external debt using digital assets</a></td>
<td class="nump">1,825<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor', window );">Realized loss on novation of digital assets to investor</a></td>
<td class="nump">676<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_TONMember', window );">T O N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssets', window );">Contribution of digital assets</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations', window );">Unrealized losses on digital assets recognized in Statement of Operations</a></td>
<td class="num">(1,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsSold', window );">Digital assets sold</a></td>
<td class="num">(2,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PaymentsOnExternalDebtUsingDigitalAssets', window );">Payments on external debt using digital assets</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetPurchases', window );">Digital asset purchases</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReceiptOfDigitalAssetsReceivable', window );">Receipt of digital assets receivable</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossGainOnSaleOfDigitalAssets', window );">Realized (loss) gain on sale of digital assets</a></td>
<td class="num">(1,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor', window );">Realized loss on novation of digital assets to investor</a></td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RevenueReceivedInDigitalAssets', window );">Revenue received in digital assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TokensUsedToSettlePutRights', window );">Tokens used to settle put rights</a></td>
<td class="num">(1,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsExchanged', window );">Digital assets exchanged</a></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfMarch31', window );">Digital asset value as of March 31</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_BITCOINMember', window );">B I T C O I N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssets', window );">Contribution of digital assets</a></td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations', window );">Unrealized losses on digital assets recognized in Statement of Operations</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsSold', window );">Digital assets sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PaymentsOnExternalDebtUsingDigitalAssets', window );">Payments on external debt using digital assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetPurchases', window );">Digital asset purchases</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReceiptOfDigitalAssetsReceivable', window );">Receipt of digital assets receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossGainOnSaleOfDigitalAssets', window );">Realized (loss) gain on sale of digital assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor', window );">Realized loss on novation of digital assets to investor</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RevenueReceivedInDigitalAssets', window );">Revenue received in digital assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TokensUsedToSettlePutRights', window );">Tokens used to settle put rights</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsExchanged', window );">Digital assets exchanged</a></td>
<td class="num">(425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfMarch31', window );">Digital asset value as of March 31</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_TotalMember', window );">Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssets', window );">Contribution of digital assets</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations', window );">Unrealized losses on digital assets recognized in Statement of Operations</a></td>
<td class="num">(1,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsSold', window );">Digital assets sold</a></td>
<td class="num">(2,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PaymentsOnExternalDebtUsingDigitalAssets', window );">Payments on external debt using digital assets</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetPurchases', window );">Digital asset purchases</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReceiptOfDigitalAssetsReceivable', window );">Receipt of digital assets receivable</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossGainOnSaleOfDigitalAssets', window );">Realized (loss) gain on sale of digital assets</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor', window );">Realized loss on novation of digital assets to investor</a></td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RevenueReceivedInDigitalAssets', window );">Revenue received in digital assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TokensUsedToSettlePutRights', window );">Tokens used to settle put rights</a></td>
<td class="num">(1,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsExchanged', window );">Digital assets exchanged</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfMarch31', window );">Digital asset value as of March 31</a></td>
<td class="nump">$ 2,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContributionOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContributionOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetValueAsOfApril1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetValueAsOfApril1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetValueAsOfMarch31">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetValueAsOfMarch31</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PaymentsOnExternalDebtUsingDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PaymentsOnExternalDebtUsingDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossGainOnSaleOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossGainOnSaleOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReceiptOfDigitalAssetsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReceiptOfDigitalAssetsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RevenueReceivedInDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RevenueReceivedInDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TokensUsedToSettlePutRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TokensUsedToSettlePutRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_TONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_TONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_BITCOINMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_BITCOINMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=ptgef_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DIGITAL ASSETS (Details 2)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureDigitalAssetsAbstract', window );"><strong>Digital Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear', window );">Fiscal 2027</a></td>
<td class="nump">$ 1,121,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear', window );">Fiscal 2028</a></td>
<td class="nump">986,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear', window );">Fiscal 2029</a></td>
<td class="nump">169,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear', window );">total&#160;</a></td>
<td class="nump">$ 2,277,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureDigitalAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureDigitalAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES DIGITAL ASSETS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_USD1Member', window );">U S D 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssetAndStablecoinReceivables', window );">Contribution of digital asset and stablecoin receivables</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDigitalAssetsReceivable', window );">Change in fair value of digital assets receivable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TokensUsedToSettlePutRights', window );">Tokens used to settle put rights</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinValueAsOfSeptember30', window );">Stablecoin value as of September 30</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_LockedTonMember', window );">Locked Ton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssetAndStablecoinReceivables', window );">Contribution of digital asset and stablecoin receivables</a></td>
<td class="nump">9,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDigitalAssetsReceivable', window );">Change in fair value of digital assets receivable</a></td>
<td class="num">(2,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReceiptOfDigitalAssetReceivables', window );">Receipt of digital asset receivables</a></td>
<td class="num">(6,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TokensUsedToSettlePutRights', window );">Tokens used to settle put rights</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinValueAsOfSeptember30', window );">Stablecoin value as of September 30</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_TotalMember', window );">Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetValueAsOfApril1', window );">Digital asset value as of April 1</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContributionOfDigitalAssetAndStablecoinReceivables', window );">Contribution of digital asset and stablecoin receivables</a></td>
<td class="nump">24,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDigitalAssetsReceivable', window );">Change in fair value of digital assets receivable</a></td>
<td class="num">(2,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReceiptOfDigitalAssetReceivables', window );">Receipt of digital asset receivables</a></td>
<td class="num">(6,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TokensUsedToSettlePutRights', window );">Tokens used to settle put rights</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StablecoinValueAsOfSeptember30', window );">Stablecoin value as of September 30</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDigitalAssetsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDigitalAssetsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContributionOfDigitalAssetAndStablecoinReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContributionOfDigitalAssetAndStablecoinReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetValueAsOfApril1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetValueAsOfApril1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReceiptOfDigitalAssetReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReceiptOfDigitalAssetReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StablecoinValueAsOfSeptember30">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StablecoinValueAsOfSeptember30</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TokensUsedToSettlePutRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TokensUsedToSettlePutRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_USD1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_USD1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_LockedTonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_LockedTonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DIGITAL ASSETS (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureDigitalAssetsAbstract', window );"><strong>Digital Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssets', window );">Digital assets | $</a></td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonTokensReceivable', window );">TON tokens receivable | $</a></td>
<td class="nump">$ 1,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonTokensReceivableShares', window );">TON tokens receivable shares | shares</a></td>
<td class="nump">2,277,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TokensArePayable', window );">Tokens are payable | shares</a></td>
<td class="nump">336,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureDigitalAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureDigitalAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TokensArePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TokensArePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonTokensReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonTokensReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonTokensReceivableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonTokensReceivableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant equipment carrying amount</a></td>
<td class="nump">$ 1,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_GPUsMember', window );">G P Us [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Fixed asset additions</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2026</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDepreciation', window );">Fixed asset depreciation</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDisposals', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2026</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant equipment carrying amount</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_GPUDepositsMember', window );">G P U Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Fixed asset additions</a></td>
<td class="nump">9,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2026</a></td>
<td class="nump">9,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDepreciation', window );">Fixed asset depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDisposals', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2026</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant equipment carrying amount</a></td>
<td class="nump">9,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_RightOfUseAssetMember', window );">Right Of Use Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Fixed asset additions</a></td>
<td class="nump">516<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2026</a></td>
<td class="nump">516<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDepreciation', window );">Fixed asset depreciation</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDisposals', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2026</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant equipment carrying amount</a></td>
<td class="nump">413<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_TotalMember', window );">Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Fixed asset additions</a></td>
<td class="nump">11,197<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">As of March 31, 2026</a></td>
<td class="nump">11,197<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDepreciation', window );">Fixed asset depreciation</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FixedAssetDisposals', window );">Fixed asset disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment', window );">As of March 31, 2026</a></td>
<td class="num">(193)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant equipment carrying amount</a></td>
<td class="nump">$ 11,004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 77<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_77_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 202<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_202_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 202<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_202_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccumulatedDepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccumulatedDepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FixedAssetDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FixedAssetDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FixedAssetDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FixedAssetDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_GPUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_GPUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_GPUDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_GPUDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_RightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_RightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ptgef_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN COMPEDICA (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BalanceAsOfApril1', window );">Balance as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InitialInvestmentInCompedica', window );">Initial investment in Compedica</a></td>
<td class="nump">5,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossFromEquityMethodInvestment', window );">Loss from equity method investment</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnImpairment', window );">Loss on impairment</a></td>
<td class="num">(4,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfInvestmentInCompedica', window );">Change in fair value of investment in Compedica</a></td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReturnOfInvestmentInterestToCompedica', window );">Return of investment interest to Compedica</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InvestmentInCompedicaAsOfMarch31', window );">Investment in Compedica as of March 31</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BalanceAsOfApril1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BalanceAsOfApril1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InitialInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InitialInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInCompedicaAsOfMarch31">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInCompedicaAsOfMarch31</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReturnOfInvestmentInterestToCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReturnOfInvestmentInterestToCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN COMPEDICA (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Feb. 06, 2026</div></th>
<th class="th"><div>Jun. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedReimbursementOtherProvisions', window );">reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Loss on impairment</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOnInvestmentInCompedica', window );">Change in fair value on the investment in Compedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedReimbursementOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount expected to be reimbursed by another party on expenditures to settle other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_85_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 258<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_258_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 258<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_258_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedReimbursementOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 130<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_130_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 130<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_130_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOnInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOnInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfWarrantLiabilityAmount', window );">Change in fair value of warrant liability, amount</a></td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
<td class="num">$ (6,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityShares', window );">Warrants outstanding, shares at ending</a></td>
<td class="nump">323,686<span></span>
</td>
<td class="nump">323,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityFairValue', window );">Warrants outstanding, fair value at ending</a></td>
<td class="nump">$ 1,952<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityShares', window );">Warrants outstanding, shares at ending</a></td>
<td class="nump">1,373,686<span></span>
</td>
<td class="nump">323,686<span></span>
</td>
<td class="nump">323,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityFairValue', window );">Warrants outstanding, fair value at ending</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 1,952<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassBWarrantsMember', window );">Class B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice', window );">Fair value of warrants at issuance exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsShares', window );">Fair value of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAmount', window );">Fair value of warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassCWarrantsMember', window );">Class C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice', window );">Fair value of warrants at issuance exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsShares', window );">Fair value of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAmount', window );">Fair value of warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice', window );">Fair value of warrants at issuance exercise price</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsShares', window );">Fair value of warrants shares</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAmount', window );">Fair value of warrants amount</a></td>
<td class="nump">$ 1,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfWarrantLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfWarrantLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantsAtIssuanceExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 days<span></span>
</td>
<td class="text">6 months 3 days<span></span>
</td>
<td class="text">1 year 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.40%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">207.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="nump">3.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">2 years 6 months 3 days<span></span>
</td>
<td class="text">3 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.70%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">152.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">3.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Oct. 03, 2024</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jan. 19, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="nump">$ 47.60<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">2 years 6 months 3 days<span></span>
</td>
<td class="text">3 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">100.70%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">152.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.32%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.68%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">3.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details 4) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Oct. 03, 2024</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jan. 19, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="nump">$ 47.60<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">2 years 6 months 3 days<span></span>
</td>
<td class="text">3 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">100.70%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">152.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.32%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.68%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">3.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentsWarrantsMember', window );">Placement Agents Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jan. 19, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Oct. 03, 2024</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeiesBWarrantsMember', window );">Seies B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantPerShare', window );">Fair value of warrant per share</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeiesCWarrantsMember', window );">Seies C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantPerShare', window );">Fair value of warrant per share</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantPerShare', window );">Fair value of warrant per share</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 6.34<span></span>
</td>
<td class="nump">$ 29.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrants2026Member', window );">Placement Agent Warrants 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantPerShare', window );">Fair value of warrant per share</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeiesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeiesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeiesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeiesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrants2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrants2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PUT RIGHT LIABILITY AND TON PAYABLE (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Alp shares and ton correlation factor</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Share price</a></td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiabilityemainingTermInYears', window );">Remaining term (in years)</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected ALP volatility</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">ALP dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonTokenPrice', window );">TON token price</a></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate', window );">Locked TON token discount for lack of marketability rate</a></td>
<td class="nump">19.30%<span></span>
</td>
<td class="nump">14.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_TonTokenVolatilityMember', window );">Ton Token Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected ALP volatility</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">53.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightLiabilityemainingTermInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightLiabilityemainingTermInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonTokenPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonTokenPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_TonTokenVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_TonTokenVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PUT RIGHT LIABILITY AND TON PAYABLE (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract', window );"><strong>Put Right Liability And Ton Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BalanceOfPutRightLiability', window );">Balance as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets', window );">Put right recognition at contract inception</a></td>
<td class="nump">18,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of put right liability, net of redemptions</a></td>
<td class="nump">5,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Exercise of side letter put right</a></td>
<td class="num">(2,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SettlementOfDwfMaasLimitedPutRight', window );">Settlement of DWF Maas Limited put right</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnExerciseOfPutRightLiability', window );">Loss on exercise of put right liability</a></td>
<td class="nump">916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiabilityEndingBalance', window );">Put right liability as of March 31</a></td>
<td class="nump">$ 7,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract assets resulting from the right to consideration becoming unconditional. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BalanceOfPutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BalanceOfPutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnExerciseOfPutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnExerciseOfPutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightLiabilityEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightLiabilityEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SettlementOfDwfMaasLimitedPutRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SettlementOfDwfMaasLimitedPutRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PUT RIGHT LIABILITY AND TON PAYABLE (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract', window );"><strong>Put Right Liability And Ton Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BalanceOfTonPayable', window );">Balance as of April 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExerciseOfSideLetterPutRightPayable', window );">Exercise of side letter put right</a></td>
<td class="nump">2,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised', window );">Change in fair value of TON payable to settle put rights exercised</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementOfTonPayable', window );">Gain on settlement of TON payable</a></td>
<td class="num">(336)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets', window );">Settlement of put right liability using digital assets</a></td>
<td class="num">(1,108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableEndingBalanceAsOfMarch31', window );">TON payable as of March 31</a></td>
<td class="nump">$ 1,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BalanceOfTonPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BalanceOfTonPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExerciseOfSideLetterPutRightPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExerciseOfSideLetterPutRightPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementOfTonPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementOfTonPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonPayableEndingBalanceAsOfMarch31">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonPayableEndingBalanceAsOfMarch31</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jan. 27, 2026</div></th>
<th class="th"><div>Dec. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract', window );"><strong>Put Right Liability And Ton Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TreasuryManagementAgreementDescription', window );">Treasury Management Agreement description</a></td>
<td class="text">A
total of 2,266,890 and 265,000 ordinary shares and an additional 745,226 and 2,513,240 pre-funded warrants to purchase ordinary shares
were subject to repurchase as defined within the Side Letters and Treasury Management Agreement, respectively, with various right expiration
dates between March 2026 and September 2026. In the event the holders exercise their Contingent Put Options, the Company is obligated
to settle the contract by transferring the same amount of USDC, Liquid TON, or Locked TON based on the Original Consideration within each
Side Letter or Treasury Management Agreement with no adjustment for value. As of September 30, 2025, a total of 2,531,890 ordinary shares
and an additional 3,258,466 pre-funded warrants to purchase ordinary shares were still subject to repurchase on various settlement dates
through September 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInterestReceivable', window );">Fair value of stablecoin receivable</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfContribution', window );">Fair value of contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Usd1Receivable', window );">USD1 receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnExercise', window );">loss on the exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OutstandingContingentPutOptionsFairValue', window );">Outstanding Contingent Put Options fair value</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RemeasurementChangeInFairValue', window );">Remeasurement change in fair value</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current interest receivable. [Refer: Interest receivable]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OutstandingContingentPutOptionsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OutstandingContingentPutOptionsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RemeasurementChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RemeasurementChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TreasuryManagementAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TreasuryManagementAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Usd1Receivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Usd1Receivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Accounts Payable And Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayable', window );">Accounts payable</a></td>
<td class="nump">$ 2,413<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedOtherProfessionalFees', window );">Accrued other professional fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedAccountingAndAuditingFees', window );">Accrued accounting and auditing fees</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses', window );">Accrued bonuses and other payroll-related expenses</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedCRO', window );">Accrued CRO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProfessionalFeesExpenses', window );">Accrued legal fees</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedClinicalAndRdServices', window );">Accrued clinical and R&amp;D services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalExpenditures', window );">Capital expenditures</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherAccruedExpenses', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilityNet', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 5,504<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedAccountingAndAuditingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedAccountingAndAuditingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedCRO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedCRO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedClinicalAndRdServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedClinicalAndRdServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedOtherProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedOtherProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OtherAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OtherAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProfessionalFeesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProfessionalFeesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASE LIABILITY (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureLeaseLiabilityAbstract', window );"><strong>Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityFutureMinimumPaymentsDue', window );">2027</a></td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue', window );">2028</a></td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue', window );">Total</a></td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Interest', window );">Less: Interest</a></td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TotalLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityNoncurrent', window );">Lease liability - non-current</a></td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Interest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Interest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TotalLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TotalLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASE LIABILITY (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 05, 2026</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureLeaseLiabilityAbstract', window );"><strong>Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Commencement', window );">Commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasePriceLeaseLiability', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseEquipmentPayment', window );">Purchase equipment payment</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Commencement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Commencement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseEquipmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseEquipmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchasePriceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchasePriceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BITGO PRIME LOAN (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2025</div></th>
<th class="th"><div>Aug. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureBitgoPrimeLoanAbstract', window );"><strong>Bitgo Prime Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MasterLoanAgreementDescription', window );">Master Loan Agreement description</a></td>
<td class="text">On
October 7, 2025, the Company received its initial draw on the Master Loan Agreement in the amount of $2.1 million. No further draws have
been made on the loan, and on November 25, 2025 the loan balance was paid down to $1.8 million. On January 9, 2026, the remaining balance
of the loan was paid down and the Master Loan Agreement was exited. In connection with the extinguishment of the Master Loan Agreement,
the Company derecognized $0.1 million of deferred financing, incurred $0.5 million in loan termination fees paid to BitGo, and had $0.8
million in accrued interest forgiven by BitGo for payment of the loan termination fees, resulting in a net gain on debt extinguishment
of $0.3 million being recognized within the Consolidated Statements of Operations and Comprehensive Income (Loss).<span></span>
</td>
<td class="text">On
August 28, 2025, the Company entered into a master loan agreement (the &#8220;Master Loan Agreement&#8221;) with BitGo Prime, LLC (&#8220;BitGo&#8221;).
Pursuant to the Master Loan Agreement, the Company may borrow up to $35.0 million at an interest rate of 14.75% per annum with a 2.00%
origination fee paid upfront in the amount of $0.3 million. The Loan shall only be used to purchase liquid TON that will be delivered
to BitGo and such purchased liquid TON will also be pledged as collateral for the Loan. The outstanding loan balance must be repaid within
six months of the origination of the Loan, unless provided for otherwise or amended.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureBitgoPrimeLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureBitgoPrimeLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_MasterLoanAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_MasterLoanAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract', window );"><strong>Current tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentTaxOnProfitsForYear', window );">Current tax on profits for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdjustmentsForCurrentTaxOfPriorPeriods', window );">Adjustments for current tax of prior periods</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Total current tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DecreaseIncreaseInDeferredTaxAssets', window );">Decrease (increase) in deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProfitLossFromContinuingOperation', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 193<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_193_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 193<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_193_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentTaxOnProfitsForYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentTaxOnProfitsForYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DecreaseIncreaseInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DecreaseIncreaseInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProfitLossFromContinuingOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProfitLossFromContinuingOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax', window );">Loss before income tax</a></td>
<td class="num">$ (38,627)<span></span>
</td>
<td class="num">$ (6,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TaxUsingBviTaxRate', window );">Tax using BVI tax rate of 0%</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EffectOfTaxRatesInOtherCountries', window );">Effect of tax rates in other countries</a></td>
<td class="num">$ (273)<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DerecognitionOfDeferredTaxAssets', window );">Derecognition of deferred tax assets</a></td>
<td class="num">(156)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NondeductibleExpenses', window );">Nondeductible expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UtilizationOfLossesNotPreviouslyBenefitted', window );">Utilization of losses not previously benefitted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxEffectsRelatedToEquityCompensation', window );">Income tax effects related to equity compensation</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ForeignCurrencyEffectAndOther', window );">Foreign currency effect and other</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxExpense', window );">Income tax in the statement of loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DerecognitionOfDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DerecognitionOfDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EffectOfTaxRatesInOtherCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EffectOfTaxRatesInOtherCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ForeignCurrencyEffectAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ForeignCurrencyEffectAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxEffectsRelatedToEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxEffectsRelatedToEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NondeductibleExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NondeductibleExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TaxUsingBviTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TaxUsingBviTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UtilizationOfLossesNotPreviouslyBenefitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UtilizationOfLossesNotPreviouslyBenefitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxAssetsNetOperatingLossCarryforward', window );">Tax loss</a></td>
<td class="nump">$ 4,265<span></span>
</td>
<td class="nump">$ 3,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockbasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Total deferred tax assets</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">4,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxAssetNotRecognized', window );">Deferred tax asset not recognized</a></td>
<td class="num">(4,276)<span></span>
</td>
<td class="num">(4,349)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetDeferredTaxAsset', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxAssetNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxAssetNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxAssetsNetOperatingLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxAssetsNetOperatingLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">U.S. federal net operating losses</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UkLossCarryForwards', window );">UK Loss carry forwards</a></td>
<td class="nump">15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">deferred tax assets</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UkLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UkLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES (Details ) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Oct. 03, 2024</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jan. 19, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="nump">$ 47.60<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">2 years 6 months 3 days<span></span>
</td>
<td class="text">3 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">100.70%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">152.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.32%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.68%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">3.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 13, 2026</div></th>
<th class="th"><div>Jan. 13, 2026</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Feb. 06, 2026</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 25, 2025</div></th>
<th class="th"><div>Jun. 05, 2025</div></th>
<th class="th"><div>Jan. 29, 2025</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SaleOfStock', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,415,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AggregateProceeds', window );">aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesPrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsToPurchase', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,258,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DgitalAssets', window );">Dgital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TreasuryStock', window );">Treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AggregateOfferingOrdinaryShares', window );">Aggregate offering ordinary shares</a></td>
<td class="nump">5,230,000<span></span>
</td>
<td class="nump">5,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Proceedsfromexerciseofwarrant', window );">ProceedsFromExerciseOfWarrants</a></td>
<td class="nump">9,770,000<span></span>
</td>
<td class="nump">9,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Pre-funded warrants issued</a></td>
<td class="nump">9,120,000<span></span>
</td>
<td class="nump">9,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">pre-funded warrants outstanding shares</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdditionalSharesIssued', window );">Additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsPurchase', window );">Warrants purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsAndPreFundedWarrantsMember', window );">Series A Warrants And Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsPerShare', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,062,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetProceeds', window );">net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AggregateOfferingOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AggregateOfferingOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AggregateProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AggregateProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DgitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DgitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Proceedsfromexerciseofwarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Proceedsfromexerciseofwarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SaleOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SaleOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Stock Option Reserve</a></td>
<td class="nump">$ 23,530<span></span>
</td>
<td class="nump">$ 23,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock based compensation expense</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">$ 2,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense', window );">Correction of prior period overstated share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Ending balance</a></td>
<td class="nump">$ 25,275<span></span>
</td>
<td class="nump">$ 23,530<span></span>
</td>
<td class="nump">$ 23,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockOptionReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockOptionReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Beginning balance</a></td>
<td class="nump">225,117<span></span>
</td>
<td class="nump">90,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement', window );">Granted</a></td>
<td class="nump">2,028,135<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement', window );">Expired or forfeited</a></td>
<td class="num">(6,745)<span></span>
</td>
<td class="num">(25,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement', window );">Available for future awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember', window );">PBI 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Beginning balance</a></td>
<td class="nump">225,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Ending balance</a></td>
<td class="nump">2,246,507<span></span>
</td>
<td class="nump">225,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="nump">2,246,507<span></span>
</td>
<td class="nump">102,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend as percentage, share options granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ptgef_StockOptionGrantedMember', window );">Stock Option Granted [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfGrantPriceShareOptionsGranted', window );">Grant price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0130<span></span>
</td>
<td class="nump">$ 0.0445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptionsGranted', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.68%<span></span>
</td>
<td class="nump">4.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">135.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend as percentage, share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfGrantPriceShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfGrantPriceShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ptgef_StockOptionGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ptgef_StockOptionGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 62.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 4) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_January132021Member', window );">January 132021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">January
        13, 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 355.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="nump">21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_January192022Member', window );">January 192022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">January
        19, 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 204.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="nump">12,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_February152022Member', window );">February 152022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">February
        15, 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 171.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_June82022Member', window );">June 82022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">June
        8, 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 220.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_July272022Member', window );">July 272022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">July
        27, 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 201.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_March302023Member', window );">March 302023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">March
        30, 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 58.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="nump">24,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_March72025Member', window );">March 72025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">March
        7, 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_July272026Member', window );">July 272026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">July
        27, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="nump">97,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_March112026Member', window );">March 112026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">March
        11, 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOptions', window );">Share Options</a></td>
<td class="nump">1,930,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_January132021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_January132021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_January192022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_January192022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_February152022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_February152022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_June82022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_June82022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_July272022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_July272022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_March302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_March302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_March72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_March72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_July272026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_July272026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRateBenchmarksAxis=ptgef_March112026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRateBenchmarksAxis=ptgef_March112026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 11, 2026</div></th>
<th class="th"><div>Jan. 13, 2026</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jul. 27, 2025</div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AuthorizedGrantOptionPurchaseShares', window );">Authorized grant option purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,739<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedGrantedRsu', window );">Shares issued granted RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,235,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share based compensation expense</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReversalOfSharebasedCompensation', window );">Reversal of share-based compensation</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareBasedCompensationExpenseUnvestedShareOptions', window );">Share based compensation expense unvested share options</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ptgef_VestedStockOptionMember', window );">Vested Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharebasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="nump">8,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesExercise', window );">Shares issued</a></td>
<td class="nump">11,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes', window );">Shares repurchased into treasury employee payroll taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AuthorizedGrantOptionPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AuthorizedGrantOptionPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReversalOfSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReversalOfSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareBasedCompensationExpenseUnvestedShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareBasedCompensationExpenseUnvestedShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharebasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharebasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedGrantedRsu">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedGrantedRsu</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ptgef_VestedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ptgef_VestedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WeightedAverageSharesOutstandingDiluted', window );">Weighted average shares outstanding, Diluted</a></td>
<td class="num">$ (38,627)<span></span>
</td>
<td class="num">$ (6,767)<span></span>
</td>
<td class="num">$ (75,339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average shares outstanding, Diluted</a></td>
<td class="nump">9,248<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossPerShareBasic', window );">Loss per share, Basic</a></td>
<td class="num">$ (4.18)<span></span>
</td>
<td class="num">$ (5.72)<span></span>
</td>
<td class="num">$ (77.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossPerShareDiluted', window );">Loss per share, Diluted</a></td>
<td class="num">$ (4.18)<span></span>
</td>
<td class="num">$ (5.72)<span></span>
</td>
<td class="num">$ (77.83)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WeightedAverageSharesOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WeightedAverageSharesOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LOSS PER SHARE (Details 1) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">1,531,581<span></span>
</td>
<td class="nump">481,581<span></span>
</td>
<td class="nump">481,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">2,246,507<span></span>
</td>
<td class="nump">225,117<span></span>
</td>
<td class="nump">90,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">1,241,334<span></span>
</td>
<td class="nump">5,410<span></span>
</td>
<td class="nump">18,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AntidilutiveEffectOnLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AntidilutiveEffectOnLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 06, 2026</div></th>
<th class="th"><div>Jan. 05, 2026</div></th>
<th class="th"><div>Mar. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BudgetCosts', window );">Budget costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Accounts payable and accrued liabilitie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
<td class="num">$ (99)<span></span>
</td>
<td class="nump">$ 972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ContractualPayments', window );">Contractual payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecurityDeposits', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetworkingEquipmentCost', window );">Networking equipment cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Deposit', window );">Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_CROMember', window );">C R O [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ServiceFees', window );">service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Accounts payable and accrued liabilitie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivables', window );">prepaid expenses and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_CROAgreementMember', window );">C R O Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrossProceeds', window );">Gross proceeds</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnbilledServices', window );">Unbilled services</a></td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ForfeitedAdvancedPayments', window );">Forfeited advanced payments</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetGain', window );">Net gain</a></td>
<td class="nump">$ 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BudgetCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BudgetCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContractualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContractualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Deposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Deposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ForfeitedAdvancedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ForfeitedAdvancedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetworkingEquipmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetworkingEquipmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnbilledServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnbilledServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_CROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_CROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_CROAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_CROAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Short-term employee benefits (salary, bonus, etc.)</a></td>
<td class="nump">$ 4,052<span></span>
</td>
<td class="nump">$ 13,787<span></span>
</td>
<td class="nump">$ 2,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TerminationBenefitsExpense', window );">Termination benefits</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharebasedPaymentCompensation', window );">Share-based payment compensation</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">&#160;Total</a></td>
<td class="nump">$ 5,804<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">$ 2,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TerminationBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 171<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_171&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TerminationBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharebasedPaymentCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharebasedPaymentCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 13, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_DirectorCompensationMember', window );">Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_MichaelTerpinMember', window );">Michael Terpin [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">61,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">61,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_FDanielSicilianoMember', window );">F Daniel Siciliano [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_GregoryHBaileyMDMember', window );">Gregory H Bailey M D [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 49,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">49,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JamesMellonMember', window );">James Mellon [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">35,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">35,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StevenMintzMember', window );">Steven Mintz [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">77,500<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">45,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 54,796<span></span>
</td>
<td class="nump">$ 113,158<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">157,296<span></span>
</td>
<td class="nump">143,158<span></span>
</td>
<td class="nump">45,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JeanChristopheRenondinMDMember', window );">Jean Christophe Renondin M D [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 54,796<span></span>
</td>
<td class="nump">$ 96,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">109,796<span></span>
</td>
<td class="nump">126,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JustinStebbingMDPhDMember', window );">Justin Stebbing M D Ph D [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 64,760<span></span>
</td>
<td class="nump">$ 121,240<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">119,760<span></span>
</td>
<td class="nump">151,240<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_LindaKozickMember', window );">Linda Kozick [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_MarkSimonMember', window );">Mark Simon [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">55,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">55,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_MarkSimonMember', window );">Mark Simon [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">661,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertGlassmanMember', window );">Robert Glassman [Member] | Director Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrittanyKaiserMember', window );">Brittany Kaiser [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 218,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="nump">149,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="nump">$ 187,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">1,715,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_EnzoVillaniMember', window );">Enzo Villani [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">369,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 218,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="nump">248,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">1,335,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WesLevittMember', window );">Wes Levitt [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">219,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">219,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_YuryMitinMember', window );">Yury Mitin [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">369,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 218,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="nump">99,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">1,186,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettMember', window );">Alexander Pickett [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">51,250<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 234,132<span></span>
</td>
<td class="nump">$ 145,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">310,422<span></span>
</td>
<td class="nump">175,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanWaltersMember', window );">Ian Walters [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">453,186<span></span>
</td>
<td class="nump">642,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="nump">$ 152,383<span></span>
</td>
<td class="nump">$ 54,716<span></span>
</td>
<td class="nump">$ 75,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">152,383<span></span>
</td>
<td class="nump">507,902<span></span>
</td>
<td class="nump">717,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaParkMember', window );">Andrea Park [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="nump">218,429<span></span>
</td>
<td class="nump">163,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="nump">$ 39,857<span></span>
</td>
<td class="nump">$ 113,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 28,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="nump">308,286<span></span>
</td>
<td class="nump">305,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawMember', window );">Allan Shaw [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">234,500<span></span>
</td>
<td class="nump">469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 49,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">234,500<span></span>
</td>
<td class="nump">518,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerMember', window );">Robert Kramer [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="nump">168,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,750<span></span>
</td>
<td class="nump">$ 17,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">119,250<span></span>
</td>
<td class="nump">185,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyMember', window );">Brian Wiley [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">114,844<span></span>
</td>
<td class="nump">153,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,627<span></span>
</td>
<td class="nump">$ 2,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">123,471<span></span>
</td>
<td class="nump">155,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JustinFairchildMember', window );">Justin Fairchild [Member] | Executive Officer Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fee and salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionIncome', window );">Bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TransactionClosingBonus', window );">Transaction closing bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecuritiesUnderOptionsGranted', window );">Securities under option granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares ot units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherCompensation', window );">Other compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 55,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment', window );">Total compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 325,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 74A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_74A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OtherCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OtherCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SecuritiesUnderOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SecuritiesUnderOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TransactionClosingBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TransactionClosingBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_DirectorCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_DirectorCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_MichaelTerpinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_MichaelTerpinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_FDanielSicilianoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_FDanielSicilianoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_GregoryHBaileyMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_GregoryHBaileyMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JamesMellonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JamesMellonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StevenMintzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StevenMintzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JeanChristopheRenondinMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JeanChristopheRenondinMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JustinStebbingMDPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JustinStebbingMDPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_LindaKozickMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_LindaKozickMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_MarkSimonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_MarkSimonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_ExecutiveOfficerCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_ExecutiveOfficerCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertGlassmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertGlassmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrittanyKaiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrittanyKaiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_EnzoVillaniMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_EnzoVillaniMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WesLevittMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WesLevittMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_YuryMitinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_YuryMitinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanWaltersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanWaltersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JustinFairchildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_JustinFairchildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details 3) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">9,248<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettMember', window );">Alexander Pickett [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/7/2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">3/7/2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettTwoMember', window );">Alexander Pickett Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">7/27/2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">45,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">7/27/2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersMember', window );">Ian B Walters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/30/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">15,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">58.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">12/14/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersTwoMember', window );">Ian B Walters Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">1/19/2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">6,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">204.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">12/14/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersThreeMember', window );">Ian B Walters Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">1/13/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">7,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">355.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">12/14/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaEParkMember', window );">Andrea E Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/7/2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">3/7/2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaEParkTwoMember', window );">Andrea E Park Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">7/27/2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">7,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">7/27/2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawMember', window );">Allan Shaw [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/30/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">1,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">58.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">9/30/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawTwoMember', window );">Allan Shaw Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">1/19/2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">204.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">9/30/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawThreeMember', window );">Allan Shaw Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">1/13/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">6,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">355.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">9/30/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerMember', window );">Robert Kramer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/30/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">58.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">3/30/2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerTwoMember', window );">Robert Kramer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">1/19/2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">204.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">1/19/2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerThreeMember', window );">Robert Kramer Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">1/13/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">3,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">355.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">1/13/2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyMember', window );">Brian Wiley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/30/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">58.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">11/15/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyTwoMember', window );">Brian Wiley Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">1/19/2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">204.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">11/15/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrittanyKaiserMember', window );">Brittany Kaiser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/11/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">545,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">5/14/2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_EnzoVillaniMember', window );">Enzo Villani [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/11/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">545,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">5/14/2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_YuryMitinMember', window );">Yury Mitin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrantDate', window );">Grant Date</a></td>
<td class="text">3/11/2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">545,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable', window );">Number of Securities Underlying Unexercised Options Un Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrices', window );">Exercise Prices</a></td>
<td class="text">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionExpirationDate', window );">Option Expiration Date</a></td>
<td class="text">5/14/2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested', window );">Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested', window );">Market Value Number of Share Units of Stock Thet Have Not Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberofShareUnitsofStockThetHaveNotVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberofShareUnitsofStockThetHaveNotVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AlexanderPickettTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IanBWaltersThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaEParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaEParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaEParkTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AndreaEParkTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_AllanShawThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RobertKramerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrianWileyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrittanyKaiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_BrittanyKaiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_EnzoVillaniMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_EnzoVillaniMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_YuryMitinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_YuryMitinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Sep. 25, 2025</div></th>
<th class="th"><div>Jan. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SaleOfStock', window );">sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,415,780<span></span>
</td>
<td class="nump">524,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AggregateProceeds', window );">aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Decentranet', window );">DecentraNet</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AggregateProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AggregateProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Decentranet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Decentranet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SaleOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SaleOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>- FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 1,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoin', window );">Stablecoin</a></td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="nump">7,105<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember', window );">Amortized Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoin', window );">Stablecoin</a></td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">4,146<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityCurrentAndNoncurrent', window );">Lease liability - current and noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember', window );">Fair Value To Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoin', window );">Stablecoin</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueThroughProfitOrLossMember', window );">Fair Value Through Profit Or Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Stablecoin', window );">Stablecoin</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="nump">7,105<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityCurrentAndNoncurrent', window );">Lease liability - current and noncurrent</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Stablecoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Stablecoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonPayableToSettlePutRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonPayableToSettlePutRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="nump">$ 1,425<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="nump">7,105<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonLiquid', window );">Digital assets at fair value, TON liquid</a></td>
<td class="nump">126<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonLocked', window );">Digital assets at fair value, TON locked</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonLiquid', window );">Digital assets at fair value, TON liquid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonLocked', window );">Digital assets at fair value, TON locked</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonLiquid', window );">Digital assets at fair value, TON liquid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DigitalAssetsAtFairValueTonLocked', window );">Digital assets at fair value, TON locked</a></td>
<td class="nump">2,366<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TonPayableToSettlePutRightsExercised', window );">TON payable to settle put rights exercised</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiability', window );">Put right liability</a></td>
<td class="nump">7,105<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 1,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetsAtFairValueTonLiquid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetsAtFairValueTonLiquid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DigitalAssetsAtFairValueTonLocked">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DigitalAssetsAtFairValueTonLocked</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TonPayableToSettlePutRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TonPayableToSettlePutRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentOfFinancialAssetsAxis=ptgef_Level3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Segment revenues</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,801<span></span>
</td>
<td class="nump">3,129<span></span>
</td>
<td class="nump">12,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">20,199<span></span>
</td>
<td class="nump">4,254<span></span>
</td>
<td class="nump">5,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,014<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Segment loss from operations</a></td>
<td class="num">(23,096)<span></span>
</td>
<td class="num">(7,418)<span></span>
</td>
<td class="num">(18,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="num">(388)<span></span>
</td>
<td class="nump">6,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions', window );">Change in fair value of put rights, net of redemptions</a></td>
<td class="nump">5,959<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssets', window );">Loss on revaluation of digital assets</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssetReceivables', window );">Loss on revaluation of digital asset receivables</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnSaleOfDigitalAssets', window );">Realized loss on sale of digital assets</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetReceivables', window );">Realized loss on novation of digital asset receivables</a></td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementWithParexelIoxCro', window );">Gain on settlement with Parexel - iOx CRO</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(946)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRegisteredDirectOffering', window );">Loss on Registered Direct Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingCosts', window );">Offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossIoxIprd', window );">Impairment loss - iOx IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossTarusIprd', window );">Impairment loss - Tarus IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossStimunity', window );">Impairment loss - Stimunity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossSaugatuck', window );">Impairment loss - Saugatuck</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement', window );">Commitment fee under Committed Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnDissolutionOfInvestmentInAssociate', window );">Gain on dissolution of investment in associate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainFromSaleOfInvestmentInPublicCompany', window );">Gain from sale of investment in public company</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossInvestmentInCompedica', window );">Impairment loss - investment in Compedica</a></td>
<td class="nump">4,804<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfInvestmentInCompedica', window );">Loss on revaluation of investment in Compedica</a></td>
<td class="nump">182<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised', window );">Change in fair value of TON payable to settle put rights exercised</a></td>
<td class="nump">51<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementOfTonPayable', window );">Gain on settlement of TON payable</a></td>
<td class="nump">336<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnSettlementOfPutRightLiability', window );">Loss on settlement of put right liability</a></td>
<td class="nump">916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnExtinguishmentOfDebt', window );">Gain on forgiveness of loan interest</a></td>
<td class="nump">255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOfLossesFromEquityMethodInvestment', window );">Share of losses from equity method investment</a></td>
<td class="nump">44<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_DigitalComputeMember', window );">Digital Compute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Segment revenues</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">16,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization expense</a></td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Segment loss from operations</a></td>
<td class="num">(16,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions', window );">Change in fair value of put rights, net of redemptions</a></td>
<td class="num">(5,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssets', window );">Loss on revaluation of digital assets</a></td>
<td class="num">(1,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssetReceivables', window );">Loss on revaluation of digital asset receivables</a></td>
<td class="num">(2,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnSaleOfDigitalAssets', window );">Realized loss on sale of digital assets</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetReceivables', window );">Realized loss on novation of digital asset receivables</a></td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementWithParexelIoxCro', window );">Gain on settlement with Parexel - iOx CRO</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRegisteredDirectOffering', window );">Loss on Registered Direct Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingCosts', window );">Offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossIoxIprd', window );">Impairment loss - iOx IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossTarusIprd', window );">Impairment loss - Tarus IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossStimunity', window );">Impairment loss - Stimunity</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossSaugatuck', window );">Impairment loss - Saugatuck</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement', window );">Commitment fee under Committed Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnDissolutionOfInvestmentInAssociate', window );">Gain on dissolution of investment in associate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainFromSaleOfInvestmentInPublicCompany', window );">Gain from sale of investment in public company</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossInvestmentInCompedica', window );">Impairment loss - investment in Compedica</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfInvestmentInCompedica', window );">Loss on revaluation of investment in Compedica</a></td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised', window );">Change in fair value of TON payable to settle put rights exercised</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementOfTonPayable', window );">Gain on settlement of TON payable</a></td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnSettlementOfPutRightLiability', window );">Loss on settlement of put right liability</a></td>
<td class="num">(916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange transaction (loss) gain</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans', window );">Interest (expense) income, net</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnExtinguishmentOfDebt', window );">Gain on forgiveness of loan interest</a></td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOfLossesFromEquityMethodInvestment', window );">Share of losses from equity method investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SegmentLossBeforeBenefitForIncomeTaxes', window );">Segment loss before benefit for income taxes</a></td>
<td class="num">(28,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SegmentNetLoss', window );">Segment net loss</a></td>
<td class="num">(28,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_ImmunoOncologyMember', window );">Immuno Oncology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Segment revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,801<span></span>
</td>
<td class="nump">3,129<span></span>
</td>
<td class="nump">12,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,855<span></span>
</td>
<td class="nump">4,254<span></span>
</td>
<td class="nump">5,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Segment loss from operations</a></td>
<td class="num">(6,656)<span></span>
</td>
<td class="num">(7,418)<span></span>
</td>
<td class="num">(18,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,786<span></span>
</td>
<td class="num">(388)<span></span>
</td>
<td class="nump">6,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions', window );">Change in fair value of put rights, net of redemptions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssets', window );">Loss on revaluation of digital assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfDigitalAssetReceivables', window );">Loss on revaluation of digital asset receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnSaleOfDigitalAssets', window );">Realized loss on sale of digital assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RealizedLossOnNovationOfDigitalAssetReceivables', window );">Realized loss on novation of digital asset receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementWithParexelIoxCro', window );">Gain on settlement with Parexel - iOx CRO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRegisteredDirectOffering', window );">Loss on Registered Direct Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingCosts', window );">Offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossIoxIprd', window );">Impairment loss - iOx IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossTarusIprd', window );">Impairment loss - Tarus IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossStimunity', window );">Impairment loss - Stimunity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossSaugatuck', window );">Impairment loss - Saugatuck</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement', window );">Commitment fee under Committed Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnDissolutionOfInvestmentInAssociate', window );">Gain on dissolution of investment in associate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainFromSaleOfInvestmentInPublicCompany', window );">Gain from sale of investment in public company</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ImpairmentLossInvestmentInCompedica', window );">Impairment loss - investment in Compedica</a></td>
<td class="num">(4,804)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnRevaluationOfInvestmentInCompedica', window );">Loss on revaluation of investment in Compedica</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised', window );">Change in fair value of TON payable to settle put rights exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementOfTonPayable', window );">Gain on settlement of TON payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnSettlementOfPutRightLiability', window );">Loss on settlement of put right liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange transaction (loss) gain</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans', window );">Interest (expense) income, net</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnExtinguishmentOfDebt', window );">Gain on forgiveness of loan interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareOfLossesFromEquityMethodInvestment', window );">Share of losses from equity method investment</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SegmentLossBeforeBenefitForIncomeTaxes', window );">Segment loss before benefit for income taxes</a></td>
<td class="num">(9,715)<span></span>
</td>
<td class="num">(6,781)<span></span>
</td>
<td class="num">(85,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">10,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SegmentNetLoss', window );">Segment net loss</a></td>
<td class="num">$ (9,715)<span></span>
</td>
<td class="num">$ (6,778)<span></span>
</td>
<td class="num">$ (75,382)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentFeeUnderCommittedPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentFeeUnderCommittedPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainFromSaleOfInvestmentInPublicCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainFromSaleOfInvestmentInPublicCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnDissolutionOfInvestmentInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnDissolutionOfInvestmentInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementOfTonPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementOfTonPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementWithParexelIoxCro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementWithParexelIoxCro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainsLossesOnChangeInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossIoxIprd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossIoxIprd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossSaugatuck">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossSaugatuck</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossStimunity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossStimunity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ImpairmentLossTarusIprd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ImpairmentLossTarusIprd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRevaluationOfDigitalAssetReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRevaluationOfDigitalAssetReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRevaluationOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRevaluationOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnRevaluationOfInvestmentInCompedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnRevaluationOfInvestmentInCompedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnSettlementOfPutRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnSettlementOfPutRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossOnNovationOfDigitalAssetReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossOnNovationOfDigitalAssetReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RealizedLossOnSaleOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RealizedLossOnSaleOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SegmentLossBeforeBenefitForIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SegmentLossBeforeBenefitForIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SegmentNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SegmentNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareOfLossesFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareOfLossesFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_DigitalComputeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_DigitalComputeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_ImmunoOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_ImmunoOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalManagementAbstract', window );"><strong>Capital Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PayablesAndAccruedExpense', window );">Payables and accrued expenses</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PutRightLiabilities', window );">Put right liabilities</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentAsset', window );">Current assets</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PayablesAndAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PayablesAndAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PutRightLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PutRightLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at beginning</a></td>
<td class="num">$ (704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at ending</a></td>
<td class="num">(705)<span></span>
</td>
<td class="num">$ (704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember', window );">Saugatuck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at beginning</a></td>
<td class="num">(704)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="num">$ (650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net (loss) attributable to non-controlling interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at ending</a></td>
<td class="num">$ (705)<span></span>
</td>
<td class="num">$ (704)<span></span>
</td>
<td class="num">$ (693)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>349</ContextCount>
  <ElementCount>537</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>110</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Changes in Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>999006 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>999007 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoingConcern</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999008 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets</Role>
      <ShortName>PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - STABLECOIN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Stablecoin</Role>
      <ShortName>STABLECOIN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - DIGITAL ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DigitalAssets</Role>
      <ShortName>DIGITAL ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets</Role>
      <ShortName>PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - INVESTMENT IN COMPEDICA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInCompedica</Role>
      <ShortName>INVESTMENT IN COMPEDICA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - WARRANT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiability</Role>
      <ShortName>WARRANT LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PutRightLiabilityAndTonPayable</Role>
      <ShortName>PUT RIGHT LIABILITY AND TON PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - LEASE LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LeaseLiability</Role>
      <ShortName>LEASE LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - BITGO PRIME LOAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BitgoPrimeLoan</Role>
      <ShortName>BITGO PRIME LOAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - CAPITAL STOCK AND RESERVES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReserves</Role>
      <ShortName>CAPITAL STOCK AND RESERVES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - STOCK OPTION RESERVE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserve</Role>
      <ShortName>STOCK OPTION RESERVE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShare</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - CAPITAL MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalManagement</Role>
      <ShortName>CAPITAL MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterest</Role>
      <ShortName>NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables</Role>
      <ShortName>PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - STABLECOIN (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StablecoinTables</Role>
      <ShortName>STABLECOIN (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Stablecoin</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - DIGITAL ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DigitalAssetsTables</Role>
      <ShortName>DIGITAL ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/DigitalAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables</Role>
      <ShortName>PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - INVESTMENT IN COMPEDICA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInCompedicaTables</Role>
      <ShortName>INVESTMENT IN COMPEDICA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInCompedica</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - WARRANT LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityTables</Role>
      <ShortName>WARRANT LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiability</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables</Role>
      <ShortName>PUT RIGHT LIABILITY AND TON PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PutRightLiabilityAndTonPayable</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - LEASE LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LeaseLiabilityTables</Role>
      <ShortName>LEASE LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LeaseLiability</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReservesTables</Role>
      <ShortName>CAPITAL STOCK AND RESERVES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockAndReserves</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - STOCK OPTION RESERVE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveTables</Role>
      <ShortName>STOCK OPTION RESERVE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserve</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareTables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShare</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/SegmentReporting</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestTables</Role>
      <ShortName>NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterest</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/GoingConcern</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/BasisOfPresentation</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative</Role>
      <ShortName>PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - STABLECOIN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StablecoinDetails</Role>
      <ShortName>STABLECOIN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StablecoinTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - STABLECOIN (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StablecoinDetails1</Role>
      <ShortName>STABLECOIN (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StablecoinTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - DIGITAL ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DigitalAssetsDetails</Role>
      <ShortName>DIGITAL ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/DigitalAssetsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - DIGITAL ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DigitalAssetsDetails1</Role>
      <ShortName>DIGITAL ASSETS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/DigitalAssetsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999060 - Disclosure - DIGITAL ASSETS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DigitalAssetsDetails2</Role>
      <ShortName>DIGITAL ASSETS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/DigitalAssetsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999061 - Disclosure - RECEIVABLES DIGITAL ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails</Role>
      <ShortName>RECEIVABLES DIGITAL ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999062 - Disclosure - DIGITAL ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DigitalAssetsDetailsNarrative</Role>
      <ShortName>DIGITAL ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/DigitalAssetsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999063 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails</Role>
      <ShortName>PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999064 - Disclosure - INVESTMENT IN COMPEDICA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInCompedicaDetails</Role>
      <ShortName>INVESTMENT IN COMPEDICA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInCompedicaTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999065 - Disclosure - INVESTMENT IN COMPEDICA (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative</Role>
      <ShortName>INVESTMENT IN COMPEDICA (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInCompedicaTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999066 - Disclosure - WARRANT LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails</Role>
      <ShortName>WARRANT LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999067 - Disclosure - WARRANT LIABILITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails1</Role>
      <ShortName>WARRANT LIABILITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999068 - Disclosure - WARRANT LIABILITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails2</Role>
      <ShortName>WARRANT LIABILITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999069 - Disclosure - WARRANT LIABILITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails3</Role>
      <ShortName>WARRANT LIABILITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999070 - Disclosure - WARRANT LIABILITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails4</Role>
      <ShortName>WARRANT LIABILITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999071 - Disclosure - WARRANT LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative</Role>
      <ShortName>WARRANT LIABILITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999072 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails</Role>
      <ShortName>PUT RIGHT LIABILITY AND TON PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999073 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1</Role>
      <ShortName>PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999074 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2</Role>
      <ShortName>PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999075 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative</Role>
      <ShortName>PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999076 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999077 - Disclosure - LEASE LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LeaseLiabilityDetails</Role>
      <ShortName>LEASE LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LeaseLiabilityTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>999078 - Disclosure - LEASE LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative</Role>
      <ShortName>LEASE LIABILITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LeaseLiabilityTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>999079 - Disclosure - BITGO PRIME LOAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative</Role>
      <ShortName>BITGO PRIME LOAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/BitgoPrimeLoan</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>999080 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>999081 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>999082 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>999083 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>999084 - Disclosure - CAPITAL STOCK AND RESERVES (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReservesDetails</Role>
      <ShortName>CAPITAL STOCK AND RESERVES (Details )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockAndReservesTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>999085 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative</Role>
      <ShortName>CAPITAL STOCK AND RESERVES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockAndReservesTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>999086 - Disclosure - STOCK OPTION RESERVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails</Role>
      <ShortName>STOCK OPTION RESERVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>999087 - Disclosure - STOCK OPTION RESERVE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails1</Role>
      <ShortName>STOCK OPTION RESERVE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>999088 - Disclosure - STOCK OPTION RESERVE (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails2</Role>
      <ShortName>STOCK OPTION RESERVE (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>999089 - Disclosure - STOCK OPTION RESERVE (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails3</Role>
      <ShortName>STOCK OPTION RESERVE (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>999090 - Disclosure - STOCK OPTION RESERVE (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails4</Role>
      <ShortName>STOCK OPTION RESERVE (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>999091 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetailsNarrative</Role>
      <ShortName>STOCK OPTION RESERVE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>999092 - Disclosure - LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails</Role>
      <ShortName>LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>999093 - Disclosure - LOSS PER SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails1</Role>
      <ShortName>LOSS PER SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>999094 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>999095 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>999096 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsDetails1</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>999097 - Disclosure - RELATED PARTY TRANSACTIONS (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsDetails3</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>999098 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>999099 - Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails</Role>
      <ShortName>- FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>999100 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>999101 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SegmentReportingDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/SegmentReportingTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>999102 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalManagementDetailsNarrative</Role>
      <ShortName>CAPITAL MANAGEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalManagement</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="f20fa_071626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>999103 - Disclosure - NON-CONTROLLING INTEREST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestDetails</Role>
      <ShortName>NON-CONTROLLING INTEREST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterestTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F/A" isDefinitelyFs="true" isIfrs="true" original="f20fa_071626.htm">f20fa_071626.htm</File>
    <File>ptgef-20260331.xsd</File>
    <File>ptgef-20260331_cal.xml</File>
    <File>ptgef-20260331_def.xml</File>
    <File>ptgef-20260331_lab.xml</File>
    <File>ptgef-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="707">https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "f20fa_071626.htm": {
   "nsprefix": "ptgef",
   "nsuri": "http://portagebiotech.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "f20fa_071626.htm"
     ]
    },
    "schema": {
     "local": [
      "ptgef-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ptgef-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptgef-20260331_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ptgef-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgef-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 172,
   "keyCustom": 365,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 92,
   "hidden": {
    "total": 880,
    "http://portagebiotech.com/20260331": 645,
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 230,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 349,
   "entityCount": 1,
   "segmentCount": 110,
   "elementCount": 766,
   "unitCount": 4,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 707,
    "http://xbrl.sec.gov/dei/2025": 45
   },
   "report": {
    "R1": {
     "role": "http://portagebiotech.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://portagebiotech.com/role/StatementsOfFinancialPosition",
     "longName": "00000002 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss",
     "longName": "00000003 - Statement - Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit",
     "longName": "00000004 - Statement - Consolidated Statements of Changes in Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://portagebiotech.com/role/StatementsOfCashFlows",
     "longName": "00000005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-012024-03-31",
      "name": "ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://portagebiotech.com/role/NatureOfOperations",
     "longName": "999006 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:NatureOfOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:NatureOfOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://portagebiotech.com/role/GoingConcern",
     "longName": "999007 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfGoingConcernExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfGoingConcernExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://portagebiotech.com/role/BasisOfPresentation",
     "longName": "999008 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPolicies",
     "longName": "999009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets",
     "longName": "999010 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS",
     "shortName": "PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://portagebiotech.com/role/Stablecoin",
     "longName": "999011 - Disclosure - STABLECOIN",
     "shortName": "STABLECOIN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfStablecoinExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfStablecoinExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://portagebiotech.com/role/DigitalAssets",
     "longName": "999012 - Disclosure - DIGITAL ASSETS",
     "shortName": "DIGITAL ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfDigitalAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfDigitalAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets",
     "longName": "999013 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS",
     "shortName": "PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://portagebiotech.com/role/InvestmentInCompedica",
     "longName": "999014 - Disclosure - INVESTMENT IN COMPEDICA",
     "shortName": "INVESTMENT IN COMPEDICA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://portagebiotech.com/role/WarrantLiability",
     "longName": "999015 - Disclosure - WARRANT LIABILITY",
     "shortName": "WARRANT LIABILITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfWarrantLiabilityExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfWarrantLiabilityExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://portagebiotech.com/role/PutRightLiabilityAndTonPayable",
     "longName": "999016 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE",
     "shortName": "PUT RIGHT LIABILITY AND TON PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities",
     "longName": "999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://portagebiotech.com/role/LeaseLiability",
     "longName": "999018 - Disclosure - LEASE LIABILITY",
     "shortName": "LEASE LIABILITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfLeaseLiabilityExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfLeaseLiabilityExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://portagebiotech.com/role/BitgoPrimeLoan",
     "longName": "999019 - Disclosure - BITGO PRIME LOAN",
     "shortName": "BITGO PRIME LOAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfBitgoPrimeLoanExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfBitgoPrimeLoanExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://portagebiotech.com/role/IncomeTaxes",
     "longName": "999020 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReserves",
     "longName": "999021 - Disclosure - CAPITAL STOCK AND RESERVES",
     "shortName": "CAPITAL STOCK AND RESERVES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:CapitalStockAndReservesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:CapitalStockAndReservesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://portagebiotech.com/role/StockOptionReserve",
     "longName": "999022 - Disclosure - STOCK OPTION RESERVE",
     "shortName": "STOCK OPTION RESERVE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://portagebiotech.com/role/LossPerShare",
     "longName": "999023 - Disclosure - LOSS PER SHARE",
     "shortName": "LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities",
     "longName": "999024 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactions",
     "longName": "999025 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement",
     "longName": "999026 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://portagebiotech.com/role/SegmentReporting",
     "longName": "999027 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://portagebiotech.com/role/CapitalManagement",
     "longName": "999028 - Disclosure - CAPITAL MANAGEMENT",
     "shortName": "CAPITAL MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://portagebiotech.com/role/Non-controllingInterest",
     "longName": "999029 - Disclosure - NON-CONTROLLING INTEREST",
     "shortName": "NON-CONTROLLING INTEREST",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://portagebiotech.com/role/SubsequentEvents",
     "longName": "999030 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesTables",
     "longName": "999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables",
     "longName": "999033 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://portagebiotech.com/role/StablecoinTables",
     "longName": "999034 - Disclosure - STABLECOIN (Tables)",
     "shortName": "STABLECOIN (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfStablecoinTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfStablecoinExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:DisclosureOfStablecoinTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfStablecoinExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://portagebiotech.com/role/DigitalAssetsTables",
     "longName": "999035 - Disclosure - DIGITAL ASSETS (Tables)",
     "shortName": "DIGITAL ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfDigitalAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfDigitalAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables",
     "longName": "999036 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)",
     "shortName": "PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://portagebiotech.com/role/InvestmentInCompedicaTables",
     "longName": "999037 - Disclosure - INVESTMENT IN COMPEDICA (Tables)",
     "shortName": "INVESTMENT IN COMPEDICA (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfInvestmentBalanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfInvestmentBalanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityTables",
     "longName": "999038 - Disclosure - WARRANT LIABILITY (Tables)",
     "shortName": "WARRANT LIABILITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables",
     "longName": "999039 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Tables)",
     "shortName": "PUT RIGHT LIABILITY AND TON PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables",
     "longName": "999040 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://portagebiotech.com/role/LeaseLiabilityTables",
     "longName": "999041 - Disclosure - LEASE LIABILITY (Tables)",
     "shortName": "LEASE LIABILITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfLeaseLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfLeaseLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://portagebiotech.com/role/IncomeTaxesTables",
     "longName": "999042 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReservesTables",
     "longName": "999043 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)",
     "shortName": "CAPITAL STOCK AND RESERVES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://portagebiotech.com/role/StockOptionReserveTables",
     "longName": "999044 - Disclosure - STOCK OPTION RESERVE (Tables)",
     "shortName": "STOCK OPTION RESERVE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://portagebiotech.com/role/LossPerShareTables",
     "longName": "999045 - Disclosure - LOSS PER SHARE (Tables)",
     "shortName": "LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsTables",
     "longName": "999046 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfCompensationPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfCompensationPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables",
     "longName": "999047 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://portagebiotech.com/role/SegmentReportingTables",
     "longName": "999048 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfSegmentReportingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfSegmentReportingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://portagebiotech.com/role/Non-controllingInterestTables",
     "longName": "999049 - Disclosure - NON-CONTROLLING INTEREST (Tables)",
     "shortName": "NON-CONTROLLING INTEREST (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://portagebiotech.com/role/GoingConcernDetailsNarrative",
     "longName": "999050 - Disclosure - GOING CONCERN (Details Narrative)",
     "shortName": "GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ifrs-full:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:TotalCurrentLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "999051 - Disclosure - BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-09-30_custom_SubsidiariesTwoMember",
      "name": "ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-09-30_custom_SubsidiariesTwoMember",
      "name": "ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails",
     "longName": "999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2025-04-012026-03-31_ifrs-full_WarrantsMember",
      "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023",
       "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_ifrs-full_WarrantsMember",
      "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023",
       "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "999053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ifrs-full:InvestmentProperty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory",
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ifrs-full:InvestmentProperty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory",
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails",
     "longName": "999054 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative",
     "longName": "999055 - Disclosure - PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)",
     "shortName": "PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:OtherAssetsLongTermPortion",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:OtherAssetsLongTermPortion",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://portagebiotech.com/role/StablecoinDetails",
     "longName": "999056 - Disclosure - STABLECOIN (Details)",
     "shortName": "STABLECOIN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptgef:Stablecoins",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfStablecoinTableTextBlock",
       "ptgef:DisclosureOfStablecoinExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptgef:Stablecoins",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfStablecoinTableTextBlock",
       "ptgef:DisclosureOfStablecoinExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://portagebiotech.com/role/StablecoinDetails1",
     "longName": "999057 - Disclosure - STABLECOIN (Details 1)",
     "shortName": "STABLECOIN (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ContributionOfStablecoin",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_USDCMember",
      "name": "ptgef:ContributionOfStablecoin",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfStablecoinPurchasesTableTextBlock",
       "ptgef:DisclosureOfStablecoinExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://portagebiotech.com/role/DigitalAssetsDetails",
     "longName": "999058 - Disclosure - DIGITAL ASSETS (Details)",
     "shortName": "DIGITAL ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:ApproximateNumberOfTonTokensHeld",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfDigitalAssetsTableTextBlock",
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:ApproximateNumberOfTonTokensHeld",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfDigitalAssetsTableTextBlock",
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://portagebiotech.com/role/DigitalAssetsDetails1",
     "longName": "999059 - Disclosure - DIGITAL ASSETS (Details 1)",
     "shortName": "DIGITAL ASSETS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ContributionOfDigitalAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_TONMember",
      "name": "ptgef:ContributionOfDigitalAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfDigitalAssetsPurchasesTableTextBlock",
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://portagebiotech.com/role/DigitalAssetsDetails2",
     "longName": "999060 - Disclosure - DIGITAL ASSETS (Details 2)",
     "shortName": "DIGITAL ASSETS (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:CapitalFutureMinimumPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:SeheduleOfTonTokensTableTextBlock",
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:CapitalFutureMinimumPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:SeheduleOfTonTokensTableTextBlock",
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails",
     "longName": "999061 - Disclosure - RECEIVABLES DIGITAL ASSETS (Details)",
     "shortName": "RECEIVABLES DIGITAL ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_USD1Member",
      "name": "ptgef:ContributionOfDigitalAssetAndStablecoinReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReceivablesDigitalAssetsTableXextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_USD1Member",
      "name": "ptgef:ContributionOfDigitalAssetAndStablecoinReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReceivablesDigitalAssetsTableXextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://portagebiotech.com/role/DigitalAssetsDetailsNarrative",
     "longName": "999062 - Disclosure - DIGITAL ASSETS (Details Narrative)",
     "shortName": "DIGITAL ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:DigitalAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:DigitalAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfDigitalAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails",
     "longName": "999063 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)",
     "shortName": "PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_GPUsMember",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://portagebiotech.com/role/InvestmentInCompedicaDetails",
     "longName": "999064 - Disclosure - INVESTMENT IN COMPEDICA (Details)",
     "shortName": "INVESTMENT IN COMPEDICA (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:InitialInvestmentInCompedica",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfInvestmentBalanceTableTextBlock",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:InitialInvestmentInCompedica",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfInvestmentBalanceTableTextBlock",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative",
     "longName": "999065 - Disclosure - INVESTMENT IN COMPEDICA (Details Narrative)",
     "shortName": "INVESTMENT IN COMPEDICA (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-05",
      "name": "ifrs-full:ExpectedReimbursementOtherProvisions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-05",
      "name": "ifrs-full:ExpectedReimbursementOtherProvisions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails",
     "longName": "999066 - Disclosure - WARRANT LIABILITY (Details)",
     "shortName": "WARRANT LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ChangeInFairValueOfWarrantLiabilityAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ChangeInFairValueOfWarrantLiabilityAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails1",
     "longName": "999067 - Disclosure - WARRANT LIABILITY (Details 1)",
     "shortName": "WARRANT LIABILITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2025-08-292025-09-02",
      "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-10-03_custom_SeriesBWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails2",
     "longName": "999068 - Disclosure - WARRANT LIABILITY (Details 2)",
     "shortName": "WARRANT LIABILITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2025-08-292025-09-02",
      "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-10-03_custom_SeriesCWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails3",
     "longName": "999069 - Disclosure - WARRANT LIABILITY (Details 3)",
     "shortName": "WARRANT LIABILITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2025-08-292025-09-02",
      "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails4",
     "longName": "999070 - Disclosure - WARRANT LIABILITY (Details 4)",
     "shortName": "WARRANT LIABILITY (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2025-08-292025-09-02",
      "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_PlacementAgentsWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfFairValueMeasurementPlacementAgentExplanatory",
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
     "longName": "999071 - Disclosure - WARRANT LIABILITY (Details Narrative)",
     "shortName": "WARRANT LIABILITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_SeiesBWarrantsMember",
      "name": "ptgef:FairValueOfWarrantPerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_SeiesBWarrantsMember",
      "name": "ptgef:FairValueOfWarrantPerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfWarrantLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
     "longName": "999072 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)",
     "shortName": "PUT RIGHT LIABILITY AND TON PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-02",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-02",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1",
     "longName": "999073 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)",
     "shortName": "PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfPutRightLiabilityTableTextBlock",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfPutRightLiabilityTableTextBlock",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2",
     "longName": "999074 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)",
     "shortName": "PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ExerciseOfSideLetterPutRightPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfTonPayableTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:ExerciseOfSideLetterPutRightPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfTonPayableTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative",
     "longName": "999075 - Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)",
     "shortName": "PUT RIGHT LIABILITY AND TON PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:TreasuryManagementAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:TreasuryManagementAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails",
     "longName": "999076 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:AccountsPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:AccountsPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://portagebiotech.com/role/LeaseLiabilityDetails",
     "longName": "999077 - Disclosure - LEASE LIABILITY (Details)",
     "shortName": "LEASE LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:LeaseLiabilityFutureMinimumPaymentsDue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfLeaseLiabilityTableTextBlock",
       "ptgef:DisclosureOfLeaseLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:LeaseLiabilityFutureMinimumPaymentsDue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfLeaseLiabilityTableTextBlock",
       "ptgef:DisclosureOfLeaseLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative",
     "longName": "999078 - Disclosure - LEASE LIABILITY (Details Narrative)",
     "shortName": "LEASE LIABILITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-30",
      "name": "ptgef:Commencement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfLeaseLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-30",
      "name": "ptgef:Commencement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfLeaseLiabilityExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative",
     "longName": "999079 - Disclosure - BITGO PRIME LOAN (Details Narrative)",
     "shortName": "BITGO PRIME LOAN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "From2025-10-052025-10-07",
      "name": "ptgef:MasterLoanAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfBitgoPrimeLoanExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-052025-10-07",
      "name": "ptgef:MasterLoanAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfBitgoPrimeLoanExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails",
     "longName": "999080 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "From2024-04-012025-03-31",
      "name": "ptgef:AdjustmentsForCurrentTaxOfPriorPeriods",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31",
      "name": "ptgef:AdjustmentsForCurrentTaxOfPriorPeriods",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails1",
     "longName": "999081 - Disclosure - INCOME TAXES (Details 1)",
     "shortName": "INCOME TAXES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails2",
     "longName": "999082 - Disclosure - INCOME TAXES (Details 2)",
     "shortName": "INCOME TAXES (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfDeferredTaxAssetsTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfDeferredTaxAssetsTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999083 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
     "longName": "999084 - Disclosure - CAPITAL STOCK AND RESERVES (Details )",
     "shortName": "CAPITAL STOCK AND RESERVES (Details )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "From2025-08-292025-09-02",
      "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R85": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
     "longName": "999085 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)",
     "shortName": "CAPITAL STOCK AND RESERVES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-25",
      "name": "ptgef:SaleOfStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-25",
      "name": "ptgef:SharesPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails",
     "longName": "999086 - Disclosure - STOCK OPTION RESERVE (Details)",
     "shortName": "STOCK OPTION RESERVE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptgef:StockOptionReserve",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31",
      "name": "ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails1",
     "longName": "999087 - Disclosure - STOCK OPTION RESERVE (Details 1)",
     "shortName": "STOCK OPTION RESERVE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptgef:NumberOfOutstandingShareOption",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "ptgef:NumberOfOutstandingShareOption",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails2",
     "longName": "999088 - Disclosure - STOCK OPTION RESERVE (Details 2)",
     "shortName": "STOCK OPTION RESERVE (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "From2025-08-292025-09-02",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
       "ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_StockOptionGrantedMember",
      "name": "ptgef:DescriptionOfGrantPriceShareOptionsGranted",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWeightedAverageAssumptionsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails3",
     "longName": "999089 - Disclosure - STOCK OPTION RESERVE (Details 3)",
     "shortName": "STOCK OPTION RESERVE (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails4",
     "longName": "999090 - Disclosure - STOCK OPTION RESERVE (Details 4)",
     "shortName": "STOCK OPTION RESERVE (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "From2024-04-012025-03-31",
      "name": "ptgef:ShareOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31",
      "name": "ptgef:ShareOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
     "longName": "999091 - Disclosure - STOCK OPTION RESERVE (Details Narrative)",
     "shortName": "STOCK OPTION RESERVE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "AsOf2025-07-27",
      "name": "ptgef:AuthorizedGrantOptionPurchaseShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-07-27",
      "name": "ptgef:AuthorizedGrantOptionPurchaseShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://portagebiotech.com/role/LossPerShareDetails",
     "longName": "999092 - Disclosure - LOSS PER SHARE (Details)",
     "shortName": "LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:WeightedAverageSharesOutstandingDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfEarningsPerShareTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ptgef:WeightedAverageSharesOutstandingDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfEarningsPerShareTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://portagebiotech.com/role/LossPerShareDetails1",
     "longName": "999093 - Disclosure - LOSS PER SHARE (Details 1)",
     "shortName": "LOSS PER SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_ifrs-full_WarrantsMember",
      "name": "ptgef:AntidilutiveEffectOnLossPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_ifrs-full_WarrantsMember",
      "name": "ptgef:AntidilutiveEffectOnLossPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
     "longName": "999094 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "From2022-04-012023-03-31",
      "name": "ptgef:BudgetCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-012023-03-31",
      "name": "ptgef:BudgetCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetails",
     "longName": "999095 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfCompensationPayableTableTextBlock",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfCompensationPayableTableTextBlock",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
     "longName": "999096 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-13",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember",
      "name": "ifrs-full:FeeAndCommissionExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3",
     "longName": "999097 - Disclosure - RELATED PARTY TRANSACTIONS (Details 3)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:AdjustedWeightedAverageShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:WeightedAverageShares",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_AlexanderPickettMember",
      "name": "ptgef:GrantDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfOutstandingEquityAwardsTableTextBlock",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999098 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-25",
      "name": "ptgef:SaleOfStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:Decentranet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
     "longName": "999099 - Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "shortName": "- FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_AmortizedCostMember",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1",
     "longName": "999100 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:TonPayableToSettlePutRightsExercised",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_Level1Member",
      "name": "ptgef:DigitalAssetsAtFairValueTonLiquid",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock",
       "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://portagebiotech.com/role/SegmentReportingDetails",
     "longName": "999101 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_DigitalComputeMember",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfSegmentReportingTableTextBlock",
       "ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://portagebiotech.com/role/CapitalManagementDetailsNarrative",
     "longName": "999102 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)",
     "shortName": "CAPITAL MANAGEMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:PayablesAndAccruedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "ptgef:PayablesAndAccruedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://portagebiotech.com/role/Non-controllingInterestDetails",
     "longName": "999103 - Disclosure - NON-CONTROLLING INTEREST (Details)",
     "shortName": "NON-CONTROLLING INTEREST (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ifrs-full:NoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-03-31_custom_SaugatuckMember",
      "name": "ifrs-full:NoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f20fa_071626.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ptgef_ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ATMMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued liabilities",
        "label": "AccountsPayableAndAccruedLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccountsPayableAndAccruedLiabilitiesTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccountsPayableAndAccruedLiabilityNet",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccountsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedAccountingAndAuditingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccruedAccountingAndAuditingFees",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued accounting and auditing fees"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccruedBonusesAndOtherPayrollrelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued bonuses and other payroll-related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedCRO": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccruedCRO",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued CRO"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedClinicalAndRdServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccruedClinicalAndRdServices",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical and R&amp;D services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedOtherProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccruedOtherProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued other professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccumulatedDepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccumulatedDepreciationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "As of March 31, 2025",
        "periodEndLabel": "As of March 31, 2026",
        "label": "AccumulatedDepreciationPropertyPlantAndEquipment"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccumulatedOtherComprehensiveIncomeLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AccumulatedOtherComprehensiveIncomeLossMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income Loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional round up shares issued for fractional shares in connection with 1-for-20 reverse share split"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AdditionalSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AdditionalSharesIssued",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed asset additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r106"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, Diluted",
        "verboseLabel": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ptgef_AdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriods",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for current tax of prior periods"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Adjustments for decrease (increase) in other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other receivables",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts payable and accrued liabilitie"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for non-cash items:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "Stock based compensation expense"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. federal net operating losses"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r238"
     ]
    },
    "ptgef_AggregateOfferingOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AggregateOfferingOrdinaryShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate offering ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AggregateProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AggregateProceeds",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aggregate proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AlexanderPickettMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AlexanderPickettMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alexander Pickett [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AlexanderPickettTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AlexanderPickettTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alexander Pickett Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AllanShawMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AllanShawMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allan Shaw [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AllanShawThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AllanShawThreeMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allan Shaw Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AllanShawTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AllanShawTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allan Shaw Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AmortizedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AmortizedCostMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AndreaEParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AndreaEParkMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Andrea E Park [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AndreaEParkTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AndreaEParkTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Andrea E Park Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AndreaParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AndreaParkMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Andrea Park [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ptgef_AntidilutiveEffectOnLossPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AntidilutiveEffectOnLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Anti-dilutive effect on loss per share",
        "label": "AntidilutiveEffectOnLossPerShare"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ApproximateNumberOfTonTokensHeld": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ApproximateNumberOfTonTokensHeld",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate number of TON Tokens held"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r96",
      "r99",
      "r141",
      "r142",
      "r163"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "ptgef_AuthorizedGrantOptionPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "AuthorizedGrantOptionPurchaseShares",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized grant option purchase shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BITCOINMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BITCOINMember",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "B I T C O I N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BalanceApril12022PresplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BalanceApril12022PresplitShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, April 1, 2022 (Pre-Split), shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BalanceAsOfApril1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BalanceAsOfApril1",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance as of April 1"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BalanceOfPutRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BalanceOfPutRightLiability",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Balance as of April 1",
        "label": "BalanceOfPutRightLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BalanceOfTonPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BalanceOfTonPayable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Balance as of April 1",
        "label": "BalanceOfTonPayable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share, Basic"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r71",
      "r76",
      "r81",
      "r110",
      "r187",
      "r188",
      "r241"
     ]
    },
    "ptgef_BrianWileyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BrianWileyMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brian Wiley [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BrianWileyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BrianWileyTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brian Wiley Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BrittanyKaiserMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BrittanyKaiserMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brittany Kaiser [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BudgetCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "BudgetCosts",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Budget costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219"
     ]
    },
    "ptgef_CROAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CROAgreementMember",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "C R O Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CROMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CROMember",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "C R O [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CapitalExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalExpendituresIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CapitalExpendituresIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital expenditures included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalFutureMinimumPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CapitalFutureMinimumPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalFutureMinimumPaymentsRemainderOfSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CapitalFutureMinimumPaymentsRemainderOfSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal 2028"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalFutureMinimumPaymentsRemainderOfThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CapitalFutureMinimumPaymentsRemainderOfThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalFutureMinimumPaymentsRemainderOfTotalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CapitalFutureMinimumPaymentsRemainderOfTotalYear",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "total"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalStockAndReservesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CapitalStockAndReservesTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL STOCK AND RESERVES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r60",
      "r111",
      "r158"
     ]
    },
    "ptgef_CashCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CashCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cash, cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashPaidForInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CashPaidForInterest",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashPaidForInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CashPaidForInvestmentInCompedica",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for investment in Compedica",
        "label": "CashPaidForInvestmentInCompedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashRestrictedForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CashRestrictedForUse",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash restricted for use"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CashUsedInOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Used In Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3",
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r122"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3",
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r122"
     ]
    },
    "ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      },
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone",
        "negatedLabel": "Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfDigitalAssetsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOfDigitalAssetsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of digital assets receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOfInvestmentInCompedica",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of investment in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfPutRightsNetOfRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOfPutRightsNetOfRedemptions",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      },
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of put rights, net of redemptions",
        "label": "Change in fair value of put rights, net of redemptions"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfTonPayableToSettlePutRightsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOfTonPayableToSettlePutRightsExercised",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      },
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2",
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of TON payable to settle put rights exercised",
        "negatedLabel": "Change in fair value of TON payable to settle put rights exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liability",
        "label": "ChangeInFairValueOfWarrantLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfWarrantLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOfWarrantLiabilityAmount",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOnInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ChangeInFairValueOnInvestmentInCompedica",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value on the investment in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ClassBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ClassBWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ClassCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ClassCWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r137",
      "r138"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r137",
      "r138"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillDomain",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r118"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r118"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r145",
      "r170"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r145",
      "r170"
     ]
    },
    "ptgef_Commencement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Commencement",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commencement"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommitmentFeeUnderCommittedPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CommitmentFeeUnderCommittedPurchaseAgreement",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Commitment fee under Committed Purchase Agreement",
        "label": "Commitment fee under Committed Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommitmentsAndContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CommitmentsAndContingentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities (Note 20)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total compensation"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss for period",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r45",
      "r57",
      "r124",
      "r132",
      "r150",
      "r172",
      "r186"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r175"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Owners of the Company",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r176"
     ]
    },
    "ifrs-full_ConsolidatedStructuredEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ConsolidatedStructuredEntitiesAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated structured entities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ifrs-full_ConsolidatedStructuredEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ConsolidatedStructuredEntitiesDomain",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Consolidated structured entities' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ContractualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ContractualPayments",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual payments"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ContributionOfDigitalAssetAndStablecoinReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ContributionOfDigitalAssetAndStablecoinReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of digital asset and stablecoin receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ContributionOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ContributionOfDigitalAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ContributionOfDigitalAssetsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ContributionOfDigitalAssetsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of digital assets receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ContributionOfStablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ContributionOfStablecoin",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of stablecoin",
        "verboseLabel": "Contribution of Stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ContributionOfStablecoinReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ContributionOfStablecoinReceivable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of stablecoin receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Correction of prior period overstated share-based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Correction of prior period overstated share-based compensation expense",
        "label": "CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ptgef_CountryOfBritishVirginIslandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CountryOfBritishVirginIslandsMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Of British Virgin Islands [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ptgef_CurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CurrentAsset",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets",
        "label": "CurrentAsset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r53",
      "r165",
      "r186"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentInterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of stablecoin receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current interest receivable. [Refer: Interest receivable]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability - current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r166",
      "r186"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_CurrentReceivablesFromSaleOfProperties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentReceivablesFromSaleOfProperties",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical research costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "label": "Current restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current tax benefit"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r196"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CurrentTaxOnProfitsForYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "CurrentTaxOnProfitsForYear",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax on profits for the year"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Decentranet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Decentranet",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DecentraNet"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DecreaseIncreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DecreaseIncreaseInDeferredTaxAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease (increase) in deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put right recognition at contract inception"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in contract assets resulting from the right to consideration becoming unconditional. [Refer: Contract assets]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ptgef_DeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DeferredFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred financing costs",
        "label": "DeferredFinancingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredTaxAssetNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DeferredTaxAssetNotRecognized",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax asset not recognized",
        "label": "DeferredTaxAssetNotRecognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r115",
      "r160",
      "r164"
     ]
    },
    "ptgef_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredTaxAssetsNetOperatingLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DeferredTaxAssetsNetOperatingLossCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails2": {
       "parentTag": "ifrs-full_NetDeferredTaxAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeAbstract",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r120"
     ]
    },
    "ifrs-full_DefinedBenefitPlansDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansDomain",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r120"
     ]
    },
    "ptgef_DelawareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DelawareMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delaware [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Deposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Deposit",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest (expense) income, net",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r94",
      "r101",
      "r149",
      "r179",
      "r199"
     ]
    },
    "ptgef_DepreciationAndAmortizations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DepreciationAndAmortizations",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization expense"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ptgef_DerecognitionOfDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DerecognitionOfDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derecognition of deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DerecognitionOfInvestmentInPublicCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DerecognitionOfInvestmentInPublicCompany",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derecognition of investment in public company"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfAccountingPolicyFoStablecoinExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyFoStablecoinExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stablecoin",
        "label": "DescriptionOfAccountingPolicyFoStablecoinExplanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForAccountsReceivableExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForDigitalAssetsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Digital Assets",
        "label": "DescriptionOfAccountingPolicyForDigitalAssetsExplanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ptgef_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Determination of Fair Value"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Financial Assets and Intangible Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ptgef_DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investments in associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ptgef_DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Public Company"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ptgef_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contracts with Customers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "verboseLabel": "Expected ALP volatility"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ptgef_DescriptionOfGrantPriceShareOptionsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfGrantPriceShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ptgef_DgitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DgitalAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dgital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetPurchases",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset purchases"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetValueAsOfApril1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetValueAsOfApril1",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1",
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails",
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset value as of April 1"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetValueAsOfMarch31": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetValueAsOfMarch31",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset value as of March 31"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsAtFairValueTonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsAtFairValueTonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets at fair value, TON, current"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsAtFairValueTonLiquid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsAtFairValueTonLiquid",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets at fair value, TON liquid"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsAtFairValueTonLocked": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsAtFairValueTonLocked",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets at fair value, TON locked"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsAtFairValueTonNetOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsAtFairValueTonNetOfCurrentPortion",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets at fair value, TON, net of current portion"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsExchanged": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsExchanged",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets exchanged"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsFairValueInThousands": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsFairValueInThousands",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets, fair value (in thousands)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsSold",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalAssetsTransacted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalAssetsTransacted",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets transacted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DigitalComputeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DigitalComputeMember",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital Compute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share, Diluted"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25"
     ]
    },
    "ptgef_DirectorCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DirectorCompensationMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureAccountsPayableAndAccruedLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureBitgoPrimeLoanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureBitgoPrimeLoanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Bitgo Prime Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureCapitalManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureCapitalManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureCapitalStockAndReservesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureCapitalStockAndReservesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock And Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureDigitalAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureDigitalAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureFinancialInstrumentsAndRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments And Risk Management"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureLeaseLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureNatureOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureNatureOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOPutRightLiabilityAndTonPayableExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOPutRightLiabilityAndTonPayableExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PUT RIGHT LIABILITY AND TON PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAuditorsRemunerationExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of compensation to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ptgef_DisclosureOfBitgoPrimeLoanExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfBitgoPrimeLoanExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/BitgoPrimeLoan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BITGO PRIME LOAN"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfCapitalManagementExplanatoryTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL MANAGEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r120"
     ]
    },
    "ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property, plant, and equipment, equipment deposits, and right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r118"
     ]
    },
    "ptgef_DisclosureOfDigitalAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfDigitalAssetsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DIGITAL ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inputs associated with calculating the fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r143"
     ]
    },
    "ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfFairValueMeasurementPlacementAgentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfFairValueMeasurementPlacementAgentExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of 2026 placement agent warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Placement agent warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets that are either past due or impaired [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets that are either past due or impaired."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r91",
      "r136"
     ]
    },
    "ifrs-full_DisclosureOfGoingConcernExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGoingConcernExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive effect on loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of instruments (including contingently issuable shares) that could potentially dilute basic earnings per share in the future, but were not included in the calculation of diluted earnings per share because they are antidilutive for the period(s) presented."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing instruments with potential future dilutive effect not included in calculation of diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsMaterialToEntityTable",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets material to entity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to intangible assets that are material to the entity."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r126"
     ]
    },
    "ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInterestsInOtherEntitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CONTROLLING INTEREST"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for interests in other entities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfInvestmentPropertyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInvestmentPropertyExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedica"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENT IN COMPEDICA"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for investment property."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ptgef_DisclosureOfLeaseLiabilityExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfLeaseLiabilityExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE LIABILITY"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average exercise price and the remaining contractual life"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOffsettingOfFinancialAssetsTable",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the offsetting of financial assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r118"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutFinancialInstrumentsThatHaveYetToTransitionToAlternativeBenchmarkRateTable",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about financial instruments that have yet to transition to alternative benchmark rate [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the quantitative information about financial instruments that have yet to transition to alternative benchmark rate."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ptgef_DisclosureOfSegmentReportingExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfSegmentReportingExplanatoryTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTION RESERVE"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r63",
      "r139"
     ]
    },
    "ptgef_DisclosureOfStablecoinExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfStablecoinExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/Stablecoin"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STABLECOIN"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfStablecoinPurchasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfStablecoinPurchasesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stablecoin purchases"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfStablecoinTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfStablecoinTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3",
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r122"
     ]
    },
    "ptgef_DisclosureOfWarrantLiabilityExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureOfWarrantLiabilityExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANT LIABILITY"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosurePropertyPlantAndEquipmentAndRightofuseAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment And Right-of-use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosurePutRightLiabilityAndTonPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosurePutRightLiabilityAndTonPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Put Right Liability And Ton Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureSegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureSegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureStablecoinAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureStablecoinAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "DisclosureWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed asset disposals"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r116"
     ]
    },
    "ifrs-full_DividendsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DividendsReceived",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revenues received in TON tokens",
        "label": "Dividends received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends received."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219",
      "r221"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER SHARE"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ptgef_EffectOfTaxRatesInOtherCountries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "EffectOfTaxRatesInOtherCountries",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of tax rates in other countries"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ptgef_EnzoVillaniMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "EnzoVillaniMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Enzo Villani [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_EquipmentDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "EquipmentDeposit",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equipment deposits",
        "label": "EquipmentDeposit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_EquipmentDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "EquipmentDeposits",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit",
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r66",
      "r67",
      "r68",
      "r123",
      "r131",
      "r141",
      "r142",
      "r147",
      "r163",
      "r168"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity attributable to owners of the Company",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ptgef_ExchangeOfBitcoinForTonTokens": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExchangeOfBitcoinForTonTokens",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of Bitcoin for TON tokens"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of Stimunity Convertible Note for Stimunity shares at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExecutiveOfficerCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExecutiveOfficerCompensationMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExerciseOfPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExerciseOfPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExerciseOfPrefundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExerciseOfPrefundedWarrantsShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExerciseOfPutRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExerciseOfPutRights",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of put rights"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExerciseOfSideLetterPutRightPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExerciseOfSideLetterPutRightPayable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of side letter put right",
        "label": "ExerciseOfSideLetterPutRightPayable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExercisePrice",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExercisePriceFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExercisePriceFairValue",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alp shares and ton correlation factor"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ptgef_ExercisePrices": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExercisePrices",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend",
        "verboseLabel": "ALP dividend yield",
        "terseLabel": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_ExpectedReimbursementOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpectedReimbursementOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "reimbursement of expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount expected to be reimbursed by another party on expenditures to settle other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r125"
     ]
    },
    "ptgef_ExpensesSettledUsingStablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExpensesSettledUsingStablecoin",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses settled using stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExpirationDate",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExternalDebtProceedsReceivedInStablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ExternalDebtProceedsReceivedInStablecoin",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External debt proceeds received in stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FDanielSicilianoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FDanielSicilianoMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "F Daniel Siciliano [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueOfContribution",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of contribution"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfSharesIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueOfSharesIssuedForServices",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares issued for services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueOfWarrantPerShare",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant per share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueOfWarrantsAmount",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantsAtIssuanceExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueOfWarrantsAtIssuanceExercisePrice",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants at issuance exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueOfWarrantsShares",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueThroughProfitOrLossMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Through Profit Or Loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueToOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FairValueToOtherComprehensiveIncomeMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value To Other Comprehensive Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_February152022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "February152022Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 152022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee and salary"
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ifrs-full_FeeAndCommissionIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FeeAndCommissionIncome",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonus"
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ptgef_FixedAssetDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FixedAssetDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed asset depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FixedAssetDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "FixedAssetDisposals",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed asset disposals",
        "label": "FixedAssetDisposals"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ForeignCurrencyEffectAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ForeignCurrencyEffectAndOther",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency effect and other"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ForfeitedAdvancedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ForfeitedAdvancedPayments",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited advanced payments"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GPUDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GPUDepositsMember",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "G P U Deposits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GPUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GPUsMember",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "G P Us [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainFromSaleOfInvestmentInPublicCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GainFromSaleOfInvestmentInPublicCompany",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      },
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain from sale of investment in public company",
        "negatedLabel": "Gain from sale of investment in public company"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainOnDissolutionOfInvestmentInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GainOnDissolutionOfInvestmentInAssociate",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      },
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on dissolution of investment in associate",
        "negatedLabel": "Gain on dissolution of investment in associate"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GainOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on extinguishment of debt",
        "verboseLabel": "Gain on forgiveness of loan interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainOnSettlementOfTonPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GainOnSettlementOfTonPayable",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      },
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2",
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on settlement of TON payable",
        "negatedLabel": "Gain on settlement of TON payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainOnSettlementWithParexelIoxCro": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GainOnSettlementWithParexelIoxCro",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 9.0
      },
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on settlement with Parexel - iOx CRO",
        "label": "Gain on settlement with Parexel - iOx CRO"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of put right liability, net of redemptions"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ptgef_GainsLossesOnChangeInFairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GainsLossesOnChangeInFairValueOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange transaction (loss) gain"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r121",
      "r154"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r181",
      "r190",
      "r192",
      "r195"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r181",
      "r190",
      "r192",
      "r195"
     ]
    },
    "ptgef_GrantDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GrantDate",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GregoryHBaileyMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GregoryHBaileyMDMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gregory H Bailey M D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "GrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IOXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IOXMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IOX [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IOxIPRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IOxIPRDMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "iOx IPR&amp;D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IanBWaltersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IanBWaltersMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ian B Walters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IanBWaltersThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IanBWaltersThreeMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ian B Walters Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IanBWaltersTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IanBWaltersTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ian B Walters Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IanWaltersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IanWaltersMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ian Walters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "ptgef_IfrsStatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IfrsStatementLineItems",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/DigitalAssetsDetails1",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails",
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3",
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails",
      "http://portagebiotech.com/role/StablecoinDetails",
      "http://portagebiotech.com/role/StablecoinDetails1",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit",
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetails4",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ImmunoOncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ImmunoOncologyMember",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immuno Oncology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetailsNarrative",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss",
        "verboseLabel": "Loss on impairment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "ptgef_ImpairmentLossInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ImpairmentLossInvestmentInCompedica",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss - investment in Compedica",
        "label": "Impairment loss - investment in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ImpairmentLossIoxIprd": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ImpairmentLossIoxIprd",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss - iOx IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ImpairmentLossSaugatuck": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ImpairmentLossSaugatuck",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss - Saugatuck"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ImpairmentLossStimunity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ImpairmentLossStimunity",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss - Stimunity"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ImpairmentLossTarusIprd": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ImpairmentLossTarusIprd",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss - Tarus IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentOfFinancialAssetsAxis",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_ImpairmentOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentOfFinancialAssetsDomain",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Impairment of financial assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IncomeLossOnOrdinaryActivitiesBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before income tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncomeTaxBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IncomeTaxBenefit",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax benefit",
        "label": "IncomeTaxBenefit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncomeTaxEffectsRelatedToEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IncomeTaxEffectsRelatedToEquityCompensation",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax effects related to equity compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "IncomeTaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax in the statement of loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit",
        "label": "Tax expense (income)"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r18",
      "r62",
      "r95",
      "r112",
      "r113",
      "r114",
      "r178"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Decrease in cash, cash equivalents, restricted during period",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r111"
     ]
    },
    "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in deferred tax liability",
        "label": "Increase (decrease) in deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "pre-funded warrants outstanding shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r144",
      "r169"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ptgef_InitialInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "InitialInvestmentInCompedica",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial investment in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsMaterialToEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsMaterialToEntityAxis",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets material to entity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r126"
     ]
    },
    "ifrs-full_IntangibleAssetsMaterialToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsMaterialToEntityDomain",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets material to the entity. It also represents the standard value for the 'Intangible assets material to entity' axis if no other member is used. [Refer: Intangible assets material to entity]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r126"
     ]
    },
    "ptgef_Interest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Interest",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseIncomeDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseIncomeDefinedBenefitPlans",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest (expense) income, net"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_InterestRateBenchmarksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestRateBenchmarksAxis",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate benchmarks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_InterestRateBenchmarksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestRateBenchmarksDomain",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all interest rate benchmarks. It also represents the standard value for the 'Interest rate benchmarks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ptgef_InvestmentInCompedicaAsOfMarch31": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "InvestmentInCompedicaAsOfMarch31",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Compedica as of March 31"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentProperty",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r128",
      "r129",
      "r156"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r203"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ptgef_JamesMellonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "JamesMellonMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Mellon [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_January132021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "January132021Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 132021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_January192022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "January192022Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 192022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_JeanChristopheRenondinMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "JeanChristopheRenondinMDMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jean Christophe Renondin M D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_July272022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "July272022Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 272022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_July272026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "July272026Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 272026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_June82022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "June82022Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 82022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_JustinFairchildMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "JustinFairchildMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Justin Fairchild [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_JustinStebbingMDPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "JustinStebbingMDPhDMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Justin Stebbing M D Ph D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation expense"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ptgef_LeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LeaseLiabilityCurrent",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability - current",
        "label": "LeaseLiabilityCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LeaseLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LeaseLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability - current and noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LeaseLiabilityFutureMinimumPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LeaseLiabilityFutureMinimumPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LeaseLiabilityFutureMinimumPaymentsYearDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LeaseLiabilityFutureMinimumPaymentsYearDue",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LeaseLiabilityFutureMinimumPaymentsYearTwoDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LeaseLiabilityFutureMinimumPaymentsYearTwoDue",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LeaseLiabilityIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LeaseLiabilityIncurred",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability incurred"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LeaseLiabilityNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability - non-current",
        "label": "LeaseLiabilityNoncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Level1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Level1Member",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Level2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Level2Member",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Level3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Level3Member",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r67",
      "r142"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r67",
      "r142"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r96",
      "r100",
      "r141",
      "r142",
      "r163"
     ]
    },
    "ptgef_LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LindaKozickMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LindaKozickMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Linda Kozick [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LoanTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LoanTerminationFee",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loan termination fee",
        "label": "LoanTerminationFee"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LockedTonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LockedTonMember",
     "presentation": [
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Locked Ton [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LockedTonTokenDiscountForLackOfMarketabilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LockedTonTokenDiscountForLackOfMarketabilityRate",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Locked TON token discount for lack of marketability rate"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossFromEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossFromEquityMethodInvestment",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from equity method investment",
        "negatedLabel": "Loss from equity method investment"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnExercise",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "loss on the exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnExerciseOfPutRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnExerciseOfPutRightLiability",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on exercise of put right liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnExtinguishmentOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnImpairment",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on impairment"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnImpairmentInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnImpairmentInvestmentInCompedica",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on impairment - investment in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnRegisteredDirectOffering",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on Registered Direct Offering",
        "label": "Loss on Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnRemeasurementOfInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnRemeasurementOfInvestmentInCompedica",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on remeasurement of investment in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnRevaluationOfDigitalAssetReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnRevaluationOfDigitalAssetReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on revaluation of digital asset receivables",
        "label": "Loss on revaluation of digital asset receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnRevaluationOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnRevaluationOfDigitalAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on revaluation of digital assets",
        "label": "Loss on revaluation of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnRevaluationOfInvestmentInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnRevaluationOfInvestmentInCompedica",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on revaluation of investment in Compedica",
        "label": "Loss on revaluation of investment in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnSettlementOfPutRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossOnSettlementOfPutRightLiability",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on settlement of put right liability",
        "label": "Loss on settlement of put right liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossPerShareBasic",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss per share, Basic",
        "label": "LossPerShareBasic"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "LossPerShareDiluted",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss per share, Diluted",
        "label": "LossPerShareDiluted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_March112026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "March112026Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 112026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_March302023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "March302023Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 302023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_March72025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "March72025Member",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 72025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_MarkSimonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "MarkSimonMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mark Simon [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_MarketValueNumberofShareUnitsofStockThetHaveNotVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "MarketValueNumberofShareUnitsofStockThetHaveNotVested",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Value Number of Share Units of Stock Thet Have Not Vested"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_MasterLoanAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "MasterLoanAgreementDescription",
     "presentation": [
      "http://portagebiotech.com/role/BitgoPrimeLoanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Loan Agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r37",
      "r66",
      "r130",
      "r141"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r37",
      "r66",
      "r130",
      "r141"
     ]
    },
    "ptgef_MichaelTerpinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "MichaelTerpinMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael Terpin [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NatureOfOperationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NatureOfOperationsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetChangeInWorkingCapitalComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetChangeInWorkingCapitalComponentsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating working capital:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetDeferredTaxAsset",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "NetDeferredTaxAsset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Net deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_NetForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetForeignExchangeGain",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange transaction (loss) gain",
        "label": "Net foreign exchange gain"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r246"
     ]
    },
    "ptgef_NetGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetGain",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetLossAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (loss) attributable to non-controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetLossIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetLossIncome",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Income"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetProceeds",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "net proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetUnrealizedLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetUnrealizedLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net unrealized loss on investments"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetworkingEquipmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NetworkingEquipmentCost",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Networking equipment cost"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NoncashInvestingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NoncashInvestingItemsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NoncashOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NoncashOperatingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NoncontrollingInterestIncreasedUponConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NoncontrollingInterestIncreasedUponConversion",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest increased upon conversion"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest",
        "periodStartLabel": "Non-controlling interest, at beginning",
        "periodEndLabel": "Non-controlling interest, at ending"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r50",
      "r161"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r54",
      "r165",
      "r186"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability - non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r166",
      "r186"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ptgef_NondeductibleExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NondeductibleExpenses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nondeductible expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and other explanatory information [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfOutstandingShareOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberOfOutstandingShareOption",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "NumberOfOutstandingShareOption"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive effect on loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "Number of potential ordinary shares that are antidilutive in the period presented."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ptgef_NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available for future awards"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable as at end"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired or forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfSharesExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberOfSharesExercise",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants issued",
        "verboseLabel": "Shares issued",
        "terseLabel": "Shares ot units"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Begnning balance, shares",
        "periodEndLabel": "Ending Balance, shares",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r144",
      "r169"
     ]
    },
    "ptgef_NumberOfSharesSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberOfSharesSold",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Securities Underlying Unexercised Options Un Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberofShareUnitsofStockThetHaveNotVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "NumberofShareUnitsofStockThetHaveNotVested",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Share Units of Stock Thet Have Not Vested"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Offering costs",
        "label": "Offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OptionExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OptionExpirationDate",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OptionLifeShareOptions": {
     "xbrltype": "durationItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OptionLifeShareOptions",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OptionLifeShareOptionsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OptionLifeShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected life",
        "label": "OptionLifeShareOptionsGranted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OrdinarySharesIssued",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OtherAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OtherAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ptgef_OtherAssetsLongTermPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OtherAssetsLongTermPortion",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets long term portion"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OtherCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OtherCompensation",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r202"
     ]
    },
    "ifrs-full_OtherLongtermBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherLongtermBenefits",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term benefits"
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r203"
     ]
    },
    "ptgef_OutstandingContingentPutOptionsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "OutstandingContingentPutOptionsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Contingent Put Options fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PBI2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PBI2021EquityIncentivePlanMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PBI 2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PayablesAndAccruedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PayablesAndAccruedExpense",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share issuance costs",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ptgef_PaymentsOnExternalDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PaymentsOnExternalDebt",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on external debt",
        "label": "PaymentsOnExternalDebt"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PaymentsOnExternalDebtUsingDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PaymentsOnExternalDebtUsingDigitalAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments on external debt using digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PlacementAgentWarrants2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PlacementAgentWarrants2026Member",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PlacementAgentsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PlacementAgentsWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PostemploymentBenefitExpenseInProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-employment benefits"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ptgef_PrefundedWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrefundedWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrefundedWarrantsExercisedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrefundedWarrantsExercisedShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidExpensesAndOtherReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrepaidExpensesAndOtherReceivable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidExpensesAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrepaidExpensesAndOtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "prepaid expenses and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidExpensesObtainedInExchangeForStablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrepaidExpensesObtainedInExchangeForStablecoin",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses obtained in exchange for stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidGpuInfrastructureCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrepaidGpuInfrastructureCosts",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid GPU infrastructure costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidGpuLeasesShortterm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrepaidGpuLeasesShortterm",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid GPU leases, short-term"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidInvestorRelations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PrepaidInvestorRelations",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid investor relations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of side letter put right"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ptgef_ProceedsFromExerciseOfPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProceedsFromExerciseOfPrefundedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ptgef_ProceedsFromExternalDebtDrawdown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProceedsFromExternalDebtDrawdown",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from external debt drawdown"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ProceedsFromRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProceedsFromRegisteredDirectOffering",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ProceedsFromSaleOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProceedsFromSaleOfDigitalAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOfInvestmentProperty",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of investment in public company"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investment property. [Refer: Investment property]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from shares issued under ATM and Committed Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ProceedsFromSharesIssuedUnderPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProceedsFromSharesIssuedUnderPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from shares issued under private placement"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Proceedsfromexerciseofwarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Proceedsfromexerciseofwarrant",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsFromExerciseOfWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ProfessionalFeesExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProfessionalFeesExpenses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued legal fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r45",
      "r96",
      "r98",
      "r124",
      "r132",
      "r151",
      "r171",
      "r186",
      "r191"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAbstract",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses",
        "verboseLabel": "Segment expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r173"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before benefit for income taxes",
        "label": "Profit (loss) before tax"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r193",
      "r194",
      "r199",
      "r200"
     ]
    },
    "ptgef_ProfitLossFromContinuingOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ProfitLossFromContinuingOperation",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperations",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss for the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r96",
      "r98",
      "r171"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Segment loss from operations"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r249"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails",
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant, and equipment, net",
        "verboseLabel": "Property plant equipment carrying amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r117",
      "r155"
     ]
    },
    "ptgef_PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "As of March 31, 2025",
        "periodEndLabel": "As of March 31, 2026",
        "label": "Property, plant and equipment, revalued assets, at cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r119"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of ownership subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21",
      "r51"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Proportion of ownership interests held by non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_ProportionOfVotingPowerHeldInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfVotingPowerHeldInSubsidiary",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of outstanding shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in a subsidiary held by the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21",
      "r51"
     ]
    },
    "ptgef_PurchaseEquipmentPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PurchaseEquipmentPayment",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase equipment payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of fixed assets",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ptgef_PurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PurchasePrice",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchase price",
        "label": "PurchasePrice"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchasePriceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PurchasePriceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchasesOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PurchasesOfDigitalAssets",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of digital assets",
        "label": "PurchasesOfDigitalAssets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchasesOfStablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PurchasesOfStablecoin",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of stablecoin",
        "label": "Purchases of stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Put right issuance costs",
        "label": "PutRightIssuanceCosts"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put right liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightLiability",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put right liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightLiabilityEndingBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightLiabilityEndingBalance",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put right liability as of March 31"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightLiabilityemainingTermInYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightLiabilityemainingTermInYears",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining term (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightsExercisedAndReturnOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightsExercisedAndReturnOfShares",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put rights exercised and return of shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightsExercisedAndReturnShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightsExercisedAndReturnShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put rights exercised and return, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PutRightsIssuedToInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "PutRightsIssuedToInvestors",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put rights issued to investors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r71",
      "r76",
      "r81",
      "r110",
      "r187",
      "r188",
      "r241"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r71",
      "r76",
      "r81",
      "r110",
      "r187",
      "r188",
      "r241"
     ]
    },
    "ptgef_RealizedLossGainOnSaleOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RealizedLossGainOnSaleOfDigitalAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized (loss) gain on sale of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RealizedLossOnNovationOfDigitalAssetReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RealizedLossOnNovationOfDigitalAssetReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized loss on novation of digital asset receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RealizedLossOnNovationOfDigitalAssetsToInvestor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RealizedLossOnNovationOfDigitalAssetsToInvestor",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized loss on novation of digital assets to investor",
        "label": "Realized loss on novation of digital assets to investor"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RealizedLossOnSaleOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RealizedLossOnSaleOfDigitalAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 7.0
      },
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized loss on sale of digital assets",
        "label": "Realized loss on sale of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ReceiptOfDigitalAssetReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ReceiptOfDigitalAssetReceivables",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipt of digital asset receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ReceiptOfDigitalAssetsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ReceiptOfDigitalAssetsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipt of digital assets receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ReceiptOfDigitalAssetsReceivableTonTokens": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ReceiptOfDigitalAssetsReceivableTonTokens",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipt of digital assets receivable, TON tokens"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RemeasurementChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RemeasurementChangeInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remeasurement change in fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r127"
     ]
    },
    "ptgef_ReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails2": {
       "parentTag": "ifrs-full_NetDeferredTaxAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves and accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ptgef_RestrictedCashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RestrictedCashOnHand",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash on hand"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for restricted share units."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ptgef_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r203",
      "r204"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r201"
     ]
    },
    "ptgef_ReturnOfInvestmentInterestToCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ReturnOfInvestmentInterestToCompedica",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return of investment interest to Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Segment revenues"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r83",
      "r93",
      "r97",
      "r102",
      "r103",
      "r105",
      "r177",
      "r186",
      "r199",
      "r200"
     ]
    },
    "ptgef_RevenueReceivedInDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RevenueReceivedInDigitalAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue received in digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ReversalOfSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ReversalOfSharebasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reversal of share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RightOfUseAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RightOfUseAssetMember",
     "presentation": [
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right Of Use Asset [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RightToUseAssetAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RightToUseAssetAcquired",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset acquired"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r107"
     ]
    },
    "ptgef_RobertGlassmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RobertGlassmanMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert Glassman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RobertKramerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RobertKramerMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert Kramer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RobertKramerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RobertKramerThreeMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert Kramer Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RobertKramerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "RobertKramerTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert Kramer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SaleOfDigitalAssetsSettledInStablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SaleOfDigitalAssetsSettledInStablecoin",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of digital assets settled in stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SaleOfStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SaleOfStock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock",
        "verboseLabel": "sale of stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SalesOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SalesOfDigitalAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SalesOfStablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SalesOfStablecoin",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SalvaRxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SalvaRxMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salva Rx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SaugatuckMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SaugatuckMember",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Saugatuck [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of inputs associated with calculating the fair value",
        "label": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfAntiDilutiveEffectTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of anti-dilutive effect on loss per share",
        "label": "ScheduleOfAntiDilutiveEffectTableTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfCompensationPayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfCompensationPayableTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of compensation payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfDeferredTaxAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfDeferredTaxAssetsTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfDigitalAssetsPurchasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfDigitalAssetsPurchasesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of digital assets purchases"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfDigitalAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfDigitalAssetsTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfEarningsPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfEarningsPerShareTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of loss and share data used in the basic and diluted EPS calculations"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of put right liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfIncomeTaxesBenefitTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income tax benefit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfInvestmentBalanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfInvestmentBalanceTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInCompedicaTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of investment balance"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfLeaseLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfLeaseLiabilityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfNoncontrollingInterestTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfNoncontrollingInterestTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfOutstandingEquityAwardsTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outstanding equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfPutRightLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfPutRightLiabilityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of put right liability",
        "label": "ScheduleOfPutRightLiabilityTableTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfReceivablesDigitalAssetsTableXextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfReceivablesDigitalAssetsTableXextBlock",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of movements in Receivables \u2013 digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation income tax rates"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfSegmentReportingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfSegmentReportingTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment reporting"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share options issued and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share options granted and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfTermsStockOptionReserveTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfTonPayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfTonPayableTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of TON payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfWarrantLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfWarrantLiabilityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of changes in the warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfWeightedAverageAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ScheduleOfWeightedAverageAssumptionsTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted-average estimated fair value of share options"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SecuritiesUnderOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SecuritiesUnderOptionsGranted",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities under option granted"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ptgef_SecurityDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SecurityDeposits",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/PrepaidExpensesOtherReceivablesAndOtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposits",
        "verboseLabel": "Security deposit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ptgef_SegmentLossBeforeBenefitForIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SegmentLossBeforeBenefitForIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment loss before benefit for income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SegmentNetLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SegmentNetLoss",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment net loss"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeheduleOfTonTokensTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SeheduleOfTonTokensTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SeheduleOfTonTokensTableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeiesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SeiesBWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seies B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeiesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SeiesCWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seies C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeriesAWarrantsAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SeriesAWarrantsAndPreFundedWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants And Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ServiceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ServiceFees",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "service fees"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SettlementOfDwfMaasLimitedPutRight": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SettlementOfDwfMaasLimitedPutRight",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of DWF Maas Limited put right"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SettlementOfPutRightLiabilityUsingDigitalAssetReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SettlementOfPutRightLiabilityUsingDigitalAssetReceivables",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of put right liability using digital asset receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SettlementOfPutRightLiabilityUsingDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SettlementOfPutRightLiabilityUsingDigitalAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of put right liability using digital assets",
        "label": "SettlementOfPutRightLiabilityUsingDigitalAssets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SettlementOfPutRightLiabilityUsingStablecoinReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SettlementOfPutRightLiabilityUsingStablecoinReceivable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of put right liability using stablecoin receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareBasedCompensationExpenseUnvestedShareOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ShareBasedCompensationExpenseUnvestedShareOptions",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation expense unvested share options"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareIssuanceCostsSettledInCompanyStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ShareIssuanceCostsSettledInCompanyStock",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs settled in Company stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareIssuanceCostsSettledInWarrantsOnCompanysStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ShareIssuanceCostsSettledInWarrantsOnCompanysStock",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs settled in warrants on the Company's stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareOfLossInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ShareOfLossInAssociate",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of loss in associate"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareOfLossesFromEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ShareOfLossesFromEquityMethodInvestment",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/SegmentReportingDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of losses from equity method investment",
        "label": "Share of losses from equity method investment"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ShareOptions",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharePriceFairvalue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharePriceFairvalue",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharebasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharebasedCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation expense",
        "label": "SharebasedCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharebasedPaymentCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharebasedPaymentCompensation",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesFromRSUDistribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesFromRSUDistribution",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares from RSU distribution"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedAccruedForBonusesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedAccruedForBonusesShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued accrued for bonuses, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedForAccruedBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedForAccruedBonuses",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for accrued bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedGrantedRsu": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedGrantedRsu",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued granted RSU"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedOrAccruedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedOrAccruedForServices",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedOrAccruedForServicesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedOrAccruedForServicesShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedPursuantToDistributionOfRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to distribution of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to distribution of restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued related to the ATM agreement, net of share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued related to the ATM agreement, net of share issuance costs , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedRelatingToAcquisitionOfCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedRelatingToAcquisitionOfCompedica",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued relating to the acquisition of Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedRelatingToAcquisitionOfCompedicaShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedRelatingToAcquisitionOfCompedicaShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued relating to the acquisition of Compedica, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under private placement, net of share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under private placement, net of share issuance costs and put rights"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under private placement, net of share issuance costs and put rights , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under private placement, net of share issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under registered direct offering, net of share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under registered direct offering, net of share issuance costs , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderRegisteredDirectOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesIssuedUnderRegisteredDirectOfferingShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Registered Direct Offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesPrice",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "label": "SharesPrice"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SharesRepurchasedIntoTreasuryEmployeePayrollTaxes",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares repurchased into treasury employee payroll taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term employee benefits (salary, bonus, etc.)"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r64",
      "r140"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesDomain",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r64",
      "r140"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r63",
      "r139"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesDomain",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r63",
      "r139"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ptgef_Stablecoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Stablecoin",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stablecoin"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StablecoinSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StablecoinSold",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stablecoin sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StablecoinUsedToPurchaseDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StablecoinUsedToPurchaseDigitalAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stablecoin used to purchase digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StablecoinUsedToSettleOperatingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StablecoinUsedToSettleOperatingCosts",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stablecoin used to settle operating costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StablecoinValueAsOfMarch31": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StablecoinValueAsOfMarch31",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stablecoin value as of March 31"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StablecoinValueAsOfSeptember30": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StablecoinValueAsOfSeptember30",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stablecoin value as of September 30"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Stablecoins": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Stablecoins",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "stablecoins"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails",
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails",
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetails4",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StevenMintzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StevenMintzMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Steven Mintz [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StimunityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StimunityMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stimunity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StockOptionGrantedMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Granted [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StockOptionReserve",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Stock Option Reserve",
        "periodEndLabel": "Ending balance",
        "label": "Stock Option Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StockOptionReserveMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Reserve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockbasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "StockbasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails2": {
       "parentTag": "ifrs-full_NetDeferredTaxAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SubsidiariesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SubsidiariesTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SupplementalCashFlowInformationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "SupplementalCashFlowInformationsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TONMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TONMember",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "T O N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TarusIPRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TarusIPRDMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tarus IPR&amp;D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TaxDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TaxDeposits",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TaxUsingBviTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TaxUsingBviTaxRate",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax using BVI tax rate of 0%"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TerminationBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TerminationBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination benefits"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ptgef_TokensArePayable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TokensArePayable",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tokens are payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TokensUsedToSettlePutRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TokensUsedToSettlePutRights",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1",
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tokens used to settle put rights"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TonPayableEndingBalanceAsOfMarch31": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TonPayableEndingBalanceAsOfMarch31",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TON payable as of March 31"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TonPayableToSettlePutRightsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TonPayableToSettlePutRightsExercised",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TON payable to settle put rights exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TonTokenPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TonTokenPrice",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TON token price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TonTokenVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TonTokenVolatilityMember",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ton Token Volatility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TonTokensFairValueInThousands": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TonTokensFairValueInThousands",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TON Tokens, fair value (in thousands)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TonTokensReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TonTokensReceivable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TON tokens receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TonTokensReceivableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TonTokensReceivableShares",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TON tokens receivable shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r71",
      "r76",
      "r81",
      "r110",
      "r187",
      "r188",
      "r241"
     ]
    },
    "ptgef_TotalCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TotalCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TotalLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TotalLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TotalMember",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1",
      "http://portagebiotech.com/role/PropertyPlantAndEquipmentAndRight-of-useAssetsDetails",
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails",
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TotalPrepaidExpensesAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TotalPrepaidExpensesAndOtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total prepaid expenses and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r157",
      "r167"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TransactionClosingBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TransactionClosingBonus",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction closing bonus"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TreasuryManagementAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TreasuryManagementAgreementDescription",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Management Agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TreasuryShares",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock",
        "label": "Treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r198",
      "r203"
     ]
    },
    "ptgef_TreasuryStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TreasuryStock",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TreasuryStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TreasuryStockMember",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows",
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock obtained in exchange for return of investment interest to Compedica",
        "negatedLabel": "Treasury stock obtained in exchange for return of investment interest to Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfChangesInEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock obtained in exchange for return of investment interest to Compedica , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ptgef_USD1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "USD1Member",
     "presentation": [
      "http://portagebiotech.com/role/ReceivablesDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S D 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_USDCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "USDCMember",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails",
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S D C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UkLossCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "UkLossCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UK Loss carry forwards"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UnbilledServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "UnbilledServices",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss on change in fair value of digital asset receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UnrealizedLossOnChangeInFairValueOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "UnrealizedLossOnChangeInFairValueOfDigitalAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss on change in fair value of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/DigitalAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized losses on digital assets recognized in Statement of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Usd1Receivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "Usd1Receivable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD1 receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UsdtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "UsdtMember",
     "presentation": [
      "http://portagebiotech.com/role/StablecoinDetails",
      "http://portagebiotech.com/role/StablecoinDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Usdt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UtilizationOfLossesNotPreviouslyBenefitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "UtilizationOfLossesNotPreviouslyBenefitted",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Utilization of losses not previously benefitted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ValueOfSharesUsedToPurchaseInterestInCompedica": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "ValueOfSharesUsedToPurchaseInterestInCompedica",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares used to purchase interest in Compedica"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_VestedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "VestedStockOptionMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability",
        "label": "Warrant liability [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ptgef_WarrantsLiabilityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "WarrantsLiabilityFairValue",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, fair value at ending",
        "periodEndLabel": "Warrants outstanding, fair value at ending",
        "label": "WarrantsLiabilityFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsLiabilityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "WarrantsLiabilityShares",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, shares at ending",
        "periodEndLabel": "Warrants outstanding, shares at ending",
        "label": "WarrantsLiabilityShares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ptgef_WarrantsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "WarrantsPerShare",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "WarrantsPurchase",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsToPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "WarrantsToPurchase",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r134"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://portagebiotech.com/role/PutRightLiabilityAndTonPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r133",
      "r135"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, Basic"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WeightedAverageSharesOutstandingDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "WeightedAverageSharesOutstandingDiluted",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares outstanding, Diluted",
        "label": "WeightedAverageSharesOutstandingDiluted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WesLevittMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "WesLevittMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wes Levitt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ptgef_YuryMitinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20260331",
     "localname": "YuryMitinMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails1",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yury Mitin [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "74A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_74A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "77",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_77_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_85_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS40_g74-79_TI",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "1",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_1&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Section": "Nature of the risks associated with an entity's interests in consolidated structured entities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS12_g14-17_TI",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "13C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_13C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "24J",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24J_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "168",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "202",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_202_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "204",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "218",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "258",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_258_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "264",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_264_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "269",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "273",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "43",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_118_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "193",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "158",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_158&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "171",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_171&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0001171843-26-004784-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-26-004784-xbrl.zip
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MW+($  "'#@  "P   &5X:%\Q,S(N:'1MS5=M;]I($/Z.Q'\8<4H5)-ZYY-)
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M*G^Q,+W;?_3D-T=2 PR06# ,&Z'^1.+"K(<AKAW(@&B4B#L6T3WS=ACS288
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M+[XU"2O$_7!_OECE/SXBRR:/VDB]EJUQ6V=_=.AR*6N$0^MXA=:VU1MZSD(
M?1<$*3,=.\\2(T%6=.(&8.* 4'0>?_+H\Z@))Y MC!_;BF+,"!&/2$&$H&<-
MQ2/G I:<ODU)4 RLQR+CL@)+Q@T>85O6VI:%;*MMW\K8_"IK,S0P].N9:1*M
MQ2.OGAMY]\CN#5T:'XC30WX:B]16$XI4WP3 H[%M#&<6<BB.1] E/$$/IC%%
MICU_T&3=)A.23L;I)*96JY4JK%875-R@J6'A>'*J5L ,PU)./7N,S/@ZJU;
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M[9)-C*R^OKM@C'3Z-4N$V>YV3]+;P;9K!OJ"@]6L<^S%.8+87 X%<:;)$O(
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M;'-7&;(<]9>!Z?$31QD:C+&I/L@F1?"M879M-+'H8=TX]]?D*)%R5JK_3O[
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M70.. :D*RUX(S:_MYS/5Q-J175L/\KQ25>!%M,B(<VNSP(NH^.",+PYM,R&
MYX.*+X2^#RN^$/H^U/A":%[$%W'B"X$7$5_$B2\$7D1\L2V^$'N81=K#S"[:
MB/)&! YVCH,2^R8"/<5"3[$\%9[Z">N 06,58NW)/!)F!3J5FJBC*KKU<!45
MUV_U5U_M[!RML".[QT\AXY[F:;5V6ME1I\#426E&>Z9)Z>II[:*4PG%ISW2'
MID7,82F%X]*>W:).7G!Y6FN544SK-HOR$==C]@LWDS5O5;C+%FCZP/B!]*^&
M)MM8(RP?Q'(7QO8N5[I"HB:L<ZY 34%04TC_J'I:KY3'?*_Z1Y3V3/VC6ED;
M$[JT9^P"L+C>,8<E\K$WC7G,L-?E.$MC3G.ZS<7?2N2CKPF7\1%3N(SC+&T>
M#1U:Y1'IJF=?];D>&84]M7+:/)?V3&U>L(_5'MSMA5-ES C/YI3,4HPLOS>U
M8%"X3YM'@^NEG"TN[5EG_JME%%- 8CPV\OS"A?<0G!?LB7"K11&N?Q$L;53$
M:,]N6M<6BV"];&):05XMP8)27Q5NEEV'RRW<)$UYLQ/NMD,V;6_[K*VK#R:Z
MG>DJ4@]J.Y%;#GGZ?GF6QS46Y7&BR5>A2Q0:"<KC&IF5Q_F/<I4I0[-^[JF2
MX2XJB\"JU5(*QZ4]TUS+15GWWUW:LQ,.=1]HAF5AL[X_(LLVL6(CE1FM)WU/
M+G\;S*?4$K?)\"K69C9^05TB3G-&!W6S,,NGPZ6PH^79553&*<EZ12"AZ$C(
M+O1<JR462"@X$C*O*@[-Q'\EHB!BL WE1V]J$ZGN QKND&S-3,<=]_GH(;R*
M%/VV\P=77?)AE=ZU:,^[ND*9?4'T"L9] ,H-&F(=J5=()W^Q*5<KNSA1S.^=
MM0CIWRLP4#@,9->!(_(D@4!#,=!0X+4D\B2DP% !,52L\Y"1G1N6?MQGFFQ%
MZCY@)\1U#6-6V!N^KC "*\*N<-J5WV5])IOS:IT:Z7V 29?6J)'0]Y$(D*Q)
MRG@BFS]65J0 EH5AB046>OJH=EA@\;$LP,(%EEOT;#+1-0\'+4$\"[CPV9:9
MCBX/!REK[ J0<()$F]<N#@DEJ_P*F'#!Y$XVE7&]0JO##@,G&PP+H/ #A<ZO
MY@'AQ,>O@$F\96<OKG&+L>SLX-ZV$L.$S2[GU,UAX&2#80&4[05)>U4D3H0U
M,NCA@-[P$6GD7^J#_VCH\LE"G!/(K8Q :+L VL[APG>A[<)HNY'W!2W+/:>#
M4/?&3MN!F'*A[B*H.S=;+M1=!'7G;<Q]Y?%4!'MS2(!/[>'<'XAQ%^HOE/KS
M-O9"_852?^;&O\:.[38]]5\_]O9"VZ&MN18,[DBAKKPS4&A0PQF*G?(<F(9H
M.)-YB6G+ZWWA'+-=SIOVR$2L&G/O)] :ISM+<KO:B 611GX]B=965F%:,P=$
MDCY*C1QV/:HE[HM<S;HO<LC>(5;&,M(&!&G8/1GC?76#3:38AGEM3*8$G_*^
MG%OF<U$#!!,YW^+1T<<CG3"H$$UW]1?B$;-3]%V];5F&@@E9*_2$:T-L?F[)
ML@A\"WP7+2$46<%^(^L8:7W"JX9EW1"P]56Z!\I&(+=\EEF@7*"\G/8Y7!3>
M$Y]-JN3Y;U<RUM#\[F8?D)L;7+*84,$*$?9YBWT.%IFPSRG@5- )5U+['-J'
M0-AG89_3V>=B]5((+B 0]EG8YS3V.?/>9J$[-,(^"_N<SCX7<@.J(>RSL,]E
M*$E*G]_X79X@ZPYIVGZ MM2F>4,7(JNQ):NQ(2UAD).!J* S[/!R&<(6"UM<
MS@R&L,7"%N]7WD+88F&+RYFM$+98V.+]RE'T;?2"]#NLVS_W :^EML4;NA Y
MBJUM/M:D)6QQ,A 5=(8=7HY"V&)AB\N9HQ"V6-CB_<I1"%LL;'$Y<Q3"%@M;
MO%\YBM^1K%^/34S^,1VC1Z0;NHIU4>^V<\.\73$B>[&MPF*KZ(3)!H!702?B
MX>4UA/T6]GO?,A["?@O[?2BY$&&_A?W>MRR)L-_"?A],_H3\@?6^C9Z?L3ZZ
MNWD8"].]<],=IA.1-=F6-0F3FC#8Z4!5T)EW@+D28:N%K=Z/#(FPU<)6[W=>
M1-AJ8:OW(QLB;+6PU7N= _F"=57^P_B)E1_[@-M2V^@-78B<QY:<QX:TA$U.
M!J*"SK##RW$(6RQL<3ES&L(6"UN\7SD,88N%+2YGSD+88F&+]RM'<2>;/_IX
MLA]H+;4E7M.$R$]LNSMP55;""B<!4$'GUN'E)H0-%C:X?'D)88.%#8YG@XN<
MDQ V6-C@\N4CA T6-CB>#2YR+N+1(/^P/VNR94WDO0!LJ0UQD#I$5B(EU@6>
M!8PBDEM!\V[?@96A1=I_A)<DS266=[&\A]GE,B2\A%T6=GD?4U_"+@N['&:7
MRY $$W99V.7RI<,Z;TB9V?@%]89$?$AL303A)5I(![U%4:QL!ASBKTQLDWDX
M_T/&%C(%[ L"^R"U".QOR>0)Q O$ER:S!V"W._I/XRO6-%G' L(%@?"&3H3%
M!K'8 NL"ZV6VU=^0]06]D.5-H+<@Z%W3B+#3P(C_:V;.[["-11ZE*(A?TXA
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MDE."MM',?[T69N6)C2*<9=N^]:_HY [YZA6M5^',%I9Z66A#!O ^9 P%WSW
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M'VSZZ/)@DZ79H3WOW1B10Q.<%Y;SPUU-#Y?SP_4CBIE#RZT$S>FE<LO:U91
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MA"9:?S4TC8ED$T8LV1'>$7F_K86]YDQJ:_;8F(W&ZQ(=RR](&FHSQ9XQ*MG
M1%'84"FCSM].-F4SH9<,(THL&T$W;&F,+=LPJ:NAS8_&,M&E-"%CFK3Z"@V'
M5*.&+AE$Z@HAF!8+.&]<E&A9-OF #9JN3HM_SCQ_>G?U7KIN/W0'[2_=_VD/
MNKU[J7U_(W7O;SI7@\[-?:??__7#\PXGSCV1K#R=:D2N!!*Q!4-8]&B)SP65
MS_5[Z;'3[O?N^])M[U$:_-:1>K>WG4<FIJ<^_9?T\-B[[G1N$DDJ!8'%%-@-
M$5BW_X=TV[X>]!Z+(9.N_H(LFQH.[,Q "Y&9[-@HK+\8&OF:3-<Q61B)S1J9
M"-%B36K_SJ2_C)ED$=NAJ9)"K/-P1J<WG<%814YI"WW.L7TSW;6,KO6S%!/_
M_^Q]:7/;9I;NY^!7X.8Z,W(5I8A:O,0]J5)L)]%T;'ELI5-SOX'$2PEM$&!C
MD<S^]?>L[P*"M"1+LB1SJJ:3B"3P+F<_SSEG!#P^,GEY#M*X/#$DTLZSYC0&
M.2&04!%T60%B9DJ2#D4$/H<%6@.B)3XHBA:$Q'LS*ZMF (]$F11-DX^X+5 %
M&>T1Q0>\> QBLBRVXL,)?#37USC\*B^Y',,I#.A 1BW(55.#0';R"-:09KB:
M <C^NLU!V,&#6(VAS!W @8#.F< SZPBW/ZO*>@9RKH:?XGF-C)6 H#](O:7@
MCM4&_XLDHDEAC;C!I(G-&:R=519(=L1GH?(9TU5T[HP?#]M$A!+KMCE<$_TY
MRLO:\.%6H$FJ!G\_QP>X$[HD5_03U?5BBR](1&0@H+8ALBG@($$%HPJ-)V"N
M;44'*5\97-^R)])AZV-F<+.P%'C.1[#T"M1Y8)<09@N^!8]EC8=?2(V9XN=P
MJ]G4:K8DKTNXY7GGIJ/N35\+E<4!E=VF;%MV<5W&5,8E6^T\J=+-O"R)19UV
MY[,5N</7%"U<$Y@L:)/D]E#PC-,,SK+RCYH-H5,B>?C=.)NIL56WX]-5BT"#
M2QZ.!RXF:01D!%8,G'I6C/.6N/ 2,HZ^8?+:G(- ,_VRZ]954N :+$<Z?O_S
M>]KD>[)SR?Q#$_D7H5GK0MR@/MO#!ZRB/_&W_MF"-IO,>7?9ST<DW%(S,T2>
M<*LG&?H L(E9"];S6$UK,IVS:OH?__?9SO#IBSJJF&@O:I<*4:"R+-!WR,$/
M 6J9HYQ-3L!//,5W \$1K;4C^"6\%!Z1ENT(A,ZH;%D0L(LP)U^BQ'6U)B*"
M/"GQI_ W(+("*"7[[(%?^LP^+[<O^<A^V7"92XG\2XFO_U+@K\#I]6=N)>JY
ME;CG5F+45[CX*3#$7#[YS!K)2QH94Z#&@87!]\!G;*<L7UC5G&=YOHH<2+BD
M)>DMV3-9-TF*%^&)UBD&.%2VB80$;=DVL&3#QA ()2?(YBM%TK50PRT1'=Z,
M^81T5K#AM'C=ED&C)8S8<^5B</7J=.\)Y0B/,TZ<#2*T@*&(*9XT?DQQ!-3L
MI]FL)E,X&L.>X&I0[=0M^B[PKW3;;!@3FY@*C3F.&31@(,+K\1N5H8>:Z2PO
MY\;PS^R[8/T3L-/Q,,3R5Q.$[$Y=Z4!L0U!\$>K9L\R<<^S$/\ONH?P+=%HV
M 3^++/:D9BL\U3\H6>,#P69J"XII^ ?M&SGGIQGHZ\XY1W+.N!2@E8^F"4WB
M$B\2XR_U*;#4:H/H/I&QC=9,09:=D @!"8+6QAE8&3,4H2#E4/(U5*H5P:G"
M7:*,HW/)LW^U68I461B3,DT@89%8Q7/S#KXA2V4,=S="DYC$$D;(#%\@F5'\
M-I)/(XS/C<?P)O $R<&"*T9KFN\W6LU(@_BTS%.D[OX;% *H6[+SDAAE;&X:
M$X-34XL;EUW8D[FB.:&7'.C>_[.Y&?^:F3S]*7X'5_(B_F#^U2)G_!0_B3<W
M)8B<9F>ZD-XZF3U7)\,+W6S*&3P!5R1_T!\\(<OI!FH.^PRTY>E"6%]?K'L1
M"[B[^T,8 E_\QMX/_54^_N'JL;Z(C^<S6.!!!0)V_")^FTP-'_W;$L][S__1
MC_HK_&39VW=_Z$T#=*/V&K+_VX]PF3W76IGDXR9''WX"$P-)X6)7V4>BOD3Q
M7^CO#?=,%':]5/X72V84$"B4JR1#'\JIKG$RRQKX)T;&,:C>D1ODL8ET1X,$
MY(+*=U&#R,3@D*'LTF>AF@#9,6.JAKN?DJ^-_GB>WXRUNX*E;TY^_^Z%P@=X
M2AQF;ZFL-CS(R"48VEJ]37#QQR2XK?%6)[G5>D#K*-J]>!#<!4;70&#F()@-
MYC4:"B:E!BP>]T5PJDF*VLK>& M?<842L*]A;Z32X=+@IMIIR[Y@:O JV>*0
MU]L_@3&2C=K&WOYY089,@H;\)*<@5Z\M/TIR4C/UJ3%-:(Y$G95,T0#2[0?U
MW7"D<&B^?4U'5HD/:TVF DO&X0'GI_ I?9GB@C:UPF1>D;E%Y(Z5ZF+A;S'U
M_(7FT(S-$<]@#QG(MS=[F(GO,YO22>$__3@#10M !YND(MZ@*Q6U'854PQ?Q
M"2ZV,8%9!R2-B9V3.7DIJQ1[GY5J57QREF0YW>CY*9PI[M&DN-;(XVJ^%CA<
MJL@7=O;Y&V-I\*.),OB"M1 8S4!7F![T3&9G/%9(=!4?= IW.Q^ ZYZV: E6
M<9K5UN00EP8VRX%8-3,\@P?K, W!7^BCDZH\;\3$&>"S9AA,0G.7<GKP?6,^
MZK&BUYK#1L'#S, $&42X=22:<[S\)OF(CB'?$!TRFS.?"0)?.338"0=&@46/
M]#UI&TQN"L>Z:Y933;.\Q7UPIC7C# $98F*ED5D.AT5BQ+L8O%*ED(%L,IO2
MP<%"01Z,\;' /V<&?B.)42!TT)TUTZL(INJ,K'F7X;Q>>^[:S75/>;(0D:SG
MW+L8.$.T5JTKACKV#*W9\6D&_P("OYR ,!"W49B>;^K!J\ 34Q ((.78/>BK
M;)K!?T9.Q%M)!O0"/C'(,6!Y% R+SY ? \T!G;7D&2.=-7%6>W%[M$[R["/R
M6R"X]3F^JHGT48$PELNA<*CG[ML'R(_"NR3#AJ\\UBO/?9\75YG#L1O*+6B8
MK)V513<RX?O[UK5'751E:/2FOIO(KIXZ:*(C4,&))$RS$])$)-WHVZCE4(VH
MB$,SP>JZP)^#?X=+P524I^7&H([IN.!KA2'AQ_D]?-O!H3R>]=ND2N M"#:
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M.U!Z@1,-@T2!WK<JVL5%?>(EKPX308M*FP^+RZEI]X<39:E:S?F !?'LE<=
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MO51C_=1_DIL:?T ?WW\%HZU.C70F[QXR?!7M-* SO 60!CA%6=M_DVDWI;$
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MY<7!N!&-< 7RH0NLV4>4ZW#$%.7)^6>)*&PWZ<=2T>;(J-MNP7H:;Y=4_:]
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MYM*-EG0Q^T@W==AKR )D+TJP6EL2!JWW;"V2!P(61[QOO-1G!,IBUVX.2 5
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MB'+(CI"NFUPB'@YML[TNGYS(=<P'2[?&722]]]M56Z257)%>_0K?X/X!=Y8
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M>WNPT_<<,%MYW(8:N, ^-&DIE#Q+KS"D/[[V10Y!%F*'Z U0_<[3P5T,45T
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MKO?F++K9=N_7U.+.AR%Y=4Y_QXS4(,:B&V.+,?UE!J5YF&NE!YTF>5[KU7.
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M(]N\87OFRZ*L<=(T539J&RGG_FG-LVN>76_S;J=(CLX+4Q$2MCDUU%3E3K5
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M_THZ]/[@Z1_,K#%3H4>0S=3E%FBN/"DR;$_CA/]%GOV=>W@4+/T<60^G"#1
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M@?(+KR@\A:&-1I,>F/WVZP6>LW)Q=\<L;\84,3_/%/&2D4-Z?6E*Z,"_)"7
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MM_C\3'_!Y.0>)1!(Z:T>_HZ_.L-?Z7>,3DL8Y!%"M+7-OM$&:;IU_I:K]NJ
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MKBU7?X1R];8M5[^/F,6A'U&Y"R7AG^3IE.M*/%QI+V6?VH-NH3H1M;0G.6P
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M66-FSSW<J9N$HRJ;7DOGWYGSHE]<<R1G_%0P>$&] 472-/L2^V'?GP"KSSO
M550UW[SJ6R;QI??;G!3OCUY3]Z)O+]V+_I:@5G.4OT"HW1I*\0P^CQL!*1=L
M*.15&ZW"ANZ/5[XQ4N&;5?>P>RLE@].5N<7K%Q[HOM-%!?#5VR] N=MH8"5_
M-GGWJ@F, _]#E\A/JFOSGQ45'T9AEE@RO@L9&S,D;TO*1]*C(4YC;13=KB-%
MWXJ5R PEL(W(NWC;<SR3D] ^BGEL=T+XL[M;-  OT6@%I>X;^@;7R,!WRO1N
M42]03^&\>^0KSYVG?(VPK$91;M$+5-WW:?EF>-^KVP(OHX$OZ%AT[Z]76>QK
M7'#6<%ZJ!]0C[/M)X/&E1:%%H46A1:%%H46A16'-4'@G_32^[+UJ-3INJ[WG
MMKK=UTNHJK.;*7=UN1F/J^'\;B=V'XKG779D8;>P6]@M[!9V"_N3A?V>E0XU
M0FRO*MED$60RHKZVUU8\&+G0SDT+R3,2XQ*6/:%U[_*I8&FG"52R=*OW^N)I
MRZ+(HLBBR*+(HN@IH.C!Q)H-8-H IL6CQ:/%H\6CQ:/%H\6CQ>,3P^/CQS@K
MNYS7W EL8;>P6]@M[!9V"_MSA?UA-8\GA/;58I?/B>":NVZWL8+C]CG!OH)?
MWX)MP;9@6[ W'>S[9><V^/9LG% 6CQ:/%H\6CQ:/%H\6CQ:/=<'C0P??"OOK
M-'0_/GR\NA.*V/+'F ;IL-^WV:'G!WSJLM/M]]MW[(S2R3NCW*(#S;/VC5K8
M+>P6=@N[A=W"_EQA?VCEYPD?1'TC@FT:#%)/V%O=^L)>TXB)!=N"_>S![MXK
M7WM8M>()H1TGQM23X.JL1-24QUBP+=@6[.<)]OVR<ZL_S-<?.O4DN,Z^34NV
M8%NP+=@6[&< ]OVR\SOI#\NF)3]A[-N FH7=PFYAM[!;V"WLF^^A6"YK],6[
M_WACGK!3'@11:!-#+=U;V"WL%G8+NX7=PK[)^LT30KM- ZTC[#8-U()MP;9@
M/S>P;1KH8RD1-@VT=K#7E,=8L"W8%NSG";9- WTL_:&F::#MKMOJM.H)>TUY
MC 7;@FW!?IY@WR\[OY/^8-- GS7E6=@M[!9V"[N%W<+^5#P4RZ:!7J3\BH?L
MU _3?]:7!KIGTT MW5O8+>P6=@N[A;T6L-L(C$T#+4&^6^/Y@#8-M'9@=SON
M[GY-KWI-C[RF8#>[NV[K_DC=JA(V&=0F@]:=R=04[&:S[3:[>VL%_E7W]1.
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M!=N";<&V8%NPK=9@TSO7 7FG"X>Y5T_8+7NQ8%NP+=C/".S[9>=:?WB3>KV
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M[FVD"F(#+76C1PN[A=W";F&WL%O8GX[?HZ!_=!H-M5]\7$W^?O'N(. _O7#
M8_;%[__@:7K'X>$=8TI[8_7IX<^: BSL%G8+NX7=PFYA?ZZP;TITYQ8S=S;K
MF.H;W^DVX?#KZNKOUC?,45-O=ZO=<9OM%<:)/"?@:WKF[?WMFC+W=K/A=EKW
M1NV/KWX\F9, !:.F.13M&N<2U)3AUA3L9J?K=O;6&T=_U7W]!""OZ8'7%.SF
M[OKI_*'S19XP^JT[S<)N8;>P6]@M[!;VI^"WH%_<D!Q2M>43+V3?O2#E<;+&
M1)&F312Q-\'";F&WL%O8+>RU@/WQ(S6+$D6.1IX/2DO(HB%+1YP=1EX\> )G
M5M^LD9IZ/BW8%FP+]O,$N]EMN>V]>YOA5FO@'U;]>$)XKV]:2*?;QL+S>@)?
M4Q9KP;9@/WNPNQUWMUE3OM9M[+K[C6>2;_J$\ YJ1$V;]NQT6NZN32^U8%NP
M+=C/">S=+IA'-;4-=YN[[M[] 7\G-6*Y!-,GA&P;=+.P6]@M[!9V"[N%??/=
M$DOW&@L',??8%R_^L<;DT99-'K5T;V&WL%O8+>P6]EK _M#ZS;SDT0]^Z(5]
MWPOLX)BG 'ESS^VT:CI'HVN;GM0-[/:^N]?=K2?L-3WRFH+=;H HO[_4O<=7
M-Y[,2=0W?;2YTW9W]ZV$M6 _>[";S;;;[-JV8K4Y\-:>N].MJ>'4;G3=G<:]
MJ=%WTBUL;[%G37H6=@N[A=W";F&WL#\=[P7]8HG!<X$7LHN1=[W&7)#VD\L%
MJ6\TIJ:FE 7;@FW!MF!;L#=/<UDZS8-ZA%WP?LQ3+YX^@2.J;U@&QVMU;>*#
M!=N";<&V8#]YL.^9GS^LRO&4\%[;AAZ=G7V;.FG!MF!;L)\7V)U]M]6HJ5G8
M;>[=)_!W4B-L0X]G1&@6=@N[A=W";F&WL#\5MT359LZC'GR0_1%[XR=1YFII
MT<)N8;>P6]@M[!;VIZESB.R+B[[/P]0?^GW;9>,)0%Y39ZH%VX)MP;9@6[ W
M3;-X0ABO;YIFL]FR:9H6; NV!?MY@;WC[G9KRM::S7V0T#95\Q&TB)JF:C9W
M]NI[W6K*8"W8%NQG#W9SUVUVFC6%?:_K[NW?&_!W4B-LJN8S(C0+NX7=PFYA
MM[!;V)^*6V+9=EN'L>^%[+L?\.D:^VUUGER_+4OW%G8+NX7=PFYAM[ _!?UF
M7EKH89;X(4\2FQ3Z!""OJ=O6@FW!MF!;L"W8FZ97/"&,USDIM./N=6J:RV+Y
MBP7;@OT\P=YS=UHU'<S;;+7=SNYF9G,\<RVBIH*TV6V[S;JJ4#5EL!9L"_:S
M![OEMO;KJD5TNVZGU=I(+<+FA#XC0K.P6]@M[!9V"[N%_:EX)9;-"?U/EJ1^
MR#YX?MP?^<%@C8FA79L8:HG?PFYAM[!;V"WLM8#]H96<V<W\Z?<Y^Q+SQ!_P
M,&71D+WG5SR()F/X\0F<C\T/M6!;L"W8%FP+M@7;9G;8_-";(+>#62W8%FP+
MM@7[&8!]O^S<Z@\V,[0,^:Y5("S8%FP+]C,#N]MUVXV:M@MMM^X5>*U&O$F]
M7L#?.<YO$[7\V(LO?7@)5F&-F85?O/NM!Z_C_T\>Z#6U;_WR_VQML0\^#P:_
MLB_>)7_++OC?&0\1':U]MK4E,3;PK]17>E$\X/&64(U^98<!Z$:L Y],HL ?
MO&5B%UMI-/F5[2#VY"_4"SNT%<(5Z_,@F'B#@1]>_OM%XP7]C(>A?BY^$E2O
MP)LDL#7U7V_9M3](1PA@XY<JB.>K=K"_JH,U:4,LW6[_4CSOV2<ZOQ27ZO,P
MY3$L9F!7X?4M^SJ=P 8/8J_G]]^RS]Z8"]Q_CA#?K5WSK3?J-?S3O,^W?ZFD
M^S*-*@+][0V<9L6YQMS[L=7CPRB&#4V(&)8[RRH"S#\_*7S0A V!)A);FH8E
MG'Z(X3QX:+OKAT37K6UVD7HI'ZLPGQ_S?AK%S L'[/@G[V>I?\79432>\##Q
M4C\*V6_^NU='L/Z__G>OU=Q].WC]VQM_;??JK@!]CE*>K&LS*UVV13>J2!&-
M"HJ@/2PVJN#=66M)?E4@X,W\/[<(0:^:KPOL_-TYG\0\ 1PF8*LEG"5>X,53
MQKTXY /6@__2-!")[D )\T/F]?O 6CR\7]=^.F+IB/LQ@Y4F0#WX<!_@CSU!
M29<Q)_I*B*@&DL(D]21LR'E"^\'_Y1]6SR7;[ .L<AC[:>J%4_:'YR<\=MEQ
M^$_$_O2!GX6^R_[*8->G?NJ'+GWE.T_8)WX%[[AR<R9X?@(;'$]B6&F 5 ^\
MP@O8)(J1OA.XPU,\>+TI /C;Q7M:]^O99SB''W 7MMG7$6=#_S(#L/$1^ P3
M!!,KI-+ODFR,WX"#'L$[$1O =:--P7XT=A.)#OJ0W@B\)C9/^_8-/(T\0'*/
M\Q VZP_8&- ]"J8N [D,&\#/XD[U0OGC<')Q)C",3^'%!JQNKR:1Q3^W=X&F
M*FY2SL">Y15JE:[0^WB;'7K8#]1EI_#?IP!;%,K_]L/T'R*<4R"8/Z)_?)#Y
MUQX<^$">K"9S10!X'<2EDM<)-BUH:P3W2)QTPC@P/EC4B_LCUFZZ#%T/]A"7
M/\1VZ1#Q+E?S+!#KQC6]B0_A4>>\"-@9G,\DCJY\/"Y<JA>%6<*1_X2)CUG#
MEWC+7[:ZY$ Q64[?2T:TGOHCNX;K/,+'<R[D*F;%LDD4FE>:Q;!!7-Y+047S
MDI2][#;8&#:*,ASW]G?FIU/@8"'P<7P0""S*+G&__A7P*!;%>CN3K!?X?9:,
MO)@$ 8_A!6*!P$IA39ZD40BRP ,>WQ_Y'.D;OO(?+\R0WS8[1*$[;K[+?A E
M$GB/O6QV]<YB?@EXX3%7HJ+T55=O"GA=?P2<-+KDL&(L+@UL'@^L!!O@"6Y3
M%J2P*HJO2SC?2X1Q!@EP6'W.!\31^<\^ML7#\\E1M\W>9[@/T,82($J]&P&?
M>0#$F0E6/$G)BR5/%W2 5YM())>R>."*1RLV3D=M+E!\1TM26M-R@>6Y0&>^
M-L3'DR":<I2:(1_Z:2*.<QUBLY:H[LY'-2(TOY&7L0>*$RI);.B!@+SR@@QO
M/S*1'6""T42H-'!U)AF(/U3K0!>%"PR,AEA%(M80+$B*R 8QH+8KF 8#3B[^
MKJ]O2LI<#&S2"T.X5'&"Z\G+2KN!_Z9U[:$O?>@[=S[T6YWV+AUV5QTV2*8M
M4/!C$"KRX',Q.Q[S@0^?1=UY]KGRDCM"P./>8S[V_!#E0 ]T<S2$8(OXEA2M
M:$_ 4DEYB5VA#1J_V;,$M31![98(*M>W":VY*LY -T,E!!02K6&KVZSDL])W
M+O@DY>,>G#K2#%*./9&E3V2OPAHZYV$4#OS\3"Y2WNO!SRL<RD%VF<%E:ML#
M6?% ]JNN")FA.?8]C?]YZ/_ >S&I[CN"\=D#6-[%UBB?0&[ZJPOQ,?"29.RM
M=B/ M D4B^H(282'>^&/HW"9PS5TG<**G;NX#^IYQ&4W*I[#%SA@GJ;"")Y,
M(I^4$O@ARF(F.JWG#G79:IUEX0#^Z9$[ ,Q34"2FN?.!COB_L!!J(K#(8>3%
M ]-+3]K%>]X7TJO9S6UC.E#V.^HI"8 M-C)O$["(9+<MP6Z%HY:C B/-T)L^
MO6_Y]*HT5.5'_.X%*;K8\]N\B'CPE(Y&H"\C)T%EN9I&U'7/3TO=>'8RX\K/
M/<R^,H(%*2JB!,83!$"W4D.6SAFIIGOH\L9_^&.N=&A#Q[;DL3QYE#V4*$6^
M>/&/1?SE@W!C@>UA7.U<O956<(<(!\.V!3D#^MD9$ SIP?8JKW1693\2B>61
M=UUYCV</"8_C@O=CGJ+&-6N6J'/;9F?DZ.R;T5@9>?+&429"N"^;K5V<%J]O
M<AZ.FGA3X=0>>P,R6/5&E1PZYRD\@.L>%*301Q[R&+9\SM&7S-DK=#JV&F\K
MGJ>_--^^)G-^P/Z3!5/6:I5%TP$</;X':_KA$+M@T"H@!P$CH7!'\\KMC+TI
MZW$@!M@S0H\17V)IL#?Z(MR2=,J^QAZ@J*_=!ZGP\%.RA6?Z (;Z/!(5"4?O
M;S_(T&?/@X1? ]*Y0#0PQ8,PS @3Z)"UMV3Y6U)V 2+Q?2\9Z_DU*4^ET??B
M<W2E]9VY8FPE\:5)P8JQM1]ZV06(AZ[[Y!2T4SSZA77G> -51(G$6"]+*6CG
MAQ0MB52DC0X?:0I62X1)I/7K5-&1/O13X"<JA.K2JV)7@B$AK[#GO?QYESUT
M9\K]V6PJ%VIN3WA9.HIB@$(8&<(+3*[^?;?1[++SBV_$N\F"EO'6_7VWW>GD
M?R+WAL[[:'7VW'9WW_RKBLT6XX;L&GEZ= V?GF1QDA%E1#(H7QT)OGN$]<KW
M&/=)ALL@:\YZX@5!5DP5(9!HTR0M Y"JAN-;FO+[]^RM69#UV&[8K,='R'K<
MLUF/BY/ZSK(4]#IT1U^R8W$A#ZZ!^9"4%S%\]A?WXJWC<+ 128R45@84&UV3
M%DR4CZPMENIMB!F.6M2!9I1Z?EA0HC&HAC&R2P=UG<A @.1(GD  YJ.@U*W(
M\?/(#5G(+\+@%_QA\-^,]"%@EI?X"@=&E2<I-;=@T:U6 _: ,50N%:QD$O@I
MV2T!5QQ+>)R4$O?KJGB_O2!=CC_<)"T%45<(S"4RXU=+S:=?J-Z O2@ KBFA
MU#>K><.:RZ7KSWSHX?8)1X#]#?_]HMDMGU-1=#1ST7%+H*J9[QFI_EH<"Q9Q
M:[C%,_A\WN)Q=5SLWC\JJC9:A9Z+-.K_*&/G;ETN=_,NESL532Z7KC*]_RMX
MYZMUQWNT-)FL]49\SLC*CH:W1Y'>8GNE+=[];![@PZN?TVI[6?V<T).'^3#1
M4A-\-V;_H&3\X"G[4Z7\%*&P;."1V< %Z(8Q&-AP)-_021Q,08C=-X'-;N36
M,DZ)]B=U)Y[@EK^%F"2+]Q=5A:>^]7MF.TMO[6G8"8^[]X?4EZO)!PSHN(_%
M9%I#%A?X]@;$ZL"WEP9^K<SU6(*^D9"N]9B/?T[\V+L#7WY"L'[%Z-?OWE4-
MCK4(ZAWX_H/N&OW E6=STR[NZ/1Y4" _4CSHO9?>%ZA57HK'I])E?3*2]:+K
M<WVNF.82\T;NB\8>FQ5H04XHW7#(URK%O\1^?^,A7NM9WR-7V4R /T<I^Y-2
M6>H,]M+R_7:]"U7\J%N5HE$E:PX"_M.CW#N9/KX^3MY:@I.K_59%PQ>9B?*U
M5A6859VDWNR^F=]<^6Y[N&D+-[;"D@OM+PO+SFJ=#M>]SZ>"IQ4:QM4519WM
MS@K]QNN*)<$\VA93]LH]#13=LXYQ7Q&L9= '-W&!)%_;U];2OK+3=??;-9WJ
M7M=NK=N[[7I"+B_F*E+R.8%?4WK?S!%!W_'[*XX=7#UF>'OD/>2WGL"T20N[
MA=W";F&O ^P/:YK=',H3&SSQ0G:HFS^LSP/<7L(#O&X+L?VFW4 +L5H/WRQ:
M:W;=QI[5F.L$=G=ONU/3,47-UIMFYXV=C&W!?HJR]$'=G,TWS7V\*:TG<+X[
M;LO*L%J!#??&"C$KQ"S85HC=(,3:>%.J![AMUOGNNMUN33E:36]TN]O=KNO
M6"O$+-@;(\26B];=%YJ?T/%9K[R%W<)N8;>P/RVC:]DHW$$XB+G'CD6;[?5%
MX3J/$H5[,FF:K;W5ZBF>TS6KJ2*\6MW#<X)\]5J&YP1]3<E],^V^6\C1QSF#
M)UAZL.ONM:Q(JQ/8MO+ RC0+]F/+-.O+W C[WL)N8;>P6]CK /OC^S*QB4S@
MA33';7U>RZZM'5@<PW=W=ZHS:Y[]A:JIREOCTH%]>3%MOHH%^\G)S ?U4CZE
MRH&]NK*SFM[G.M<-6 EFP;82;$D)]F3*!G9LV4#-P*YSV8"581;L39%A-M*V
M$=YG"[N%W<)N8:\#[)L0:3N/>O!)]D?LC7E\O_./;;#-\%RYN[LVV%8GL&L<
M;),7LUW3?-*:$OQFFGD;[ZI\,L&V)N+/DG:-P*YSN$W>S';US7SVX->4XJT,
MN]5->3+AMK;;L.&V6H%=YW";O)EMZWBP8#^V#+/AMHUP05O8+>P6=@M['6#?
MA'#;8>Q[(?ON!WRZOF#;K@VVW1!L:^_9%+,Z@5WC8%L3K+RN3:JT8#])J6FC
M;?,]E75U6]7T1M<ZVF:%F 5[4X28=55NA/EN8;>P6]@M['6 _5%<E<JSV&DT
MEITP<!C[:>J%4_:'YR=WKA_HY"[-O4=Q:8+:.5?GW"SRZW:Z;KMITR_K!'9S
MNUU3<[ KILNUK35HP7YLZ6JMP8W0D"SL%G8+NX6]#K _%6OP./PG8G_ZV+O9
MMZ:@-06?LHZXV6!;4]":@A;LQQ:MUA3<"/7(PFYAM[!;V.L ^U,Q!?_*XBD[
M]5,_M(:@-02?LH:XV6!;0] :@A;L=0K6-ZG7"_@[Q_EMHI8?>_&E#R_!*JPQ
MLS"*I_DB+O^(%%H37/I_MK;8!Y\'@U_9%^^2OV47_.^,A[C]=I-M;4D(!_Z5
M6K87Q0,>;PGA_BL[#$"ZLPYL*(D"?_"6B3UNI='D5[:#T,I?J!=V:*,$&^OS
M()AX@X$?7O[[1>,%_8S(4S\7/PG*0^!-$MB:^J^W[-H?I",$L/%+%3[F*R>P
MOZJ#,,]2+-UN_U(\G]DG.K\4E^KS,.4Q+&9@5^'U+?LZG< &#V*OY_??LL_>
MF O<?XX0WZU]\ZTWZC7\T[S/MW^Y2?\CFE($]=L;.,V*<XVY]V.KQX=1#!N:
M$#$L=Y95Y)E_?E+XH D; DTDM@J%]]Z=96F2>B$2#3O^._/3*3NX]N)!PKP4
MUD[@D-E?W(NWCL,!^\U_]^H(%OG7_^ZUFKMO!Z"Y^;"AGJ+_I3^<@P-OK42]
MBTBTB.)&!8KIXXOU;'AW5H&67VUL=_WPQ9OY?V[AW]^]:KXN\+-WQS_['##A
M)2SA*>PZ3D>LQX/HVF57/$D1]]&0>4' HDGJ1V'"?'@TZ_V7]U/8$-S0$![*
M.'R0QU<^$# L!;R)CR=!-.7<90,_AF>C&'X[> /_@C>2+("#37'E@V R\F@W
M^+^C:#S)4L[P:?Q*X@]\#_3Z*&3I"):>3 ) ")Z)VMS 2_DV.PLY[#W#S<.:
M^*C:+3X'FX,%KWT  G]4JPW]&'[PPM '1"?T&7I7[P;7QM]=QK!9%_=/[\5\
M[/DA?KSG!1[>V26^Z8>LO</@D@/1C@%GHV *OP/Z#H(Q<)$$%X"+.01^LKV:
M>!#_W-Z%\ZT?.;=*Y'P6LO>\S\<]'K-FUV5@2'5<=AIOLR]^_P=/4W:-]#F9
M1'Z(9X0_Y!0JSQ&I$%-,\<"!J-C1R.=#=OR3][,4:(6=#8= Z#$#0Y<CH6J*
M[L,[ES'G>**:BG 5O!OP-2"").N/6-]#=*<^QV,'@_ER9.QZGW8->Q_!38MY
M KCRD*XDJ7\=\20GM6L@&N8A5X3EX3J:D,)EIC7DQ4SR'9E +W%Y_/&8PSU,
M>4 WD:X#[:;J3BAJ!\ XEP0/=PS_M59ZKR6YMTOD_AZ.[[L7 !(316-PN(MH
M%@]L/L7/4F-'W"&@JBQ.,CQXH#)\!;XY3O!](#%-68+KXP'G%\$EZ9&%DIB2
MD1?G%&:2EF*;\I((<E_TV<):^0<35^\'WZC\+OXW_\GCOI\0D>!=2:\C-@5]
M(F'#.!K#N_ %VH2ESV7ILS/+CB] O1"TU&YH?IS P7KQCUEFG)/N!S\$ANH#
MVS!)=\ G7HS/FE0+W.8,J!F_@9RS@J-I@EC,V7!1R]T>C7JZ)>I!8883V2M9
MVRQ]*.8U2W&W9",&^] $M#(;R7F9)81E"6&G1 A?4??O12#&!*S\9S_(!J ]
M=7!X(3N_^)8HY4>,%1&W6 B3_WAP/4&Y;[:)&)HN:.7 &#SCIK,K+\A(C7_9
M='= ;VQU@7*N1SX<G99*!:%BO-O+4J(#TR@"G ##0.TMC?V^I!5@)GL[<K=5
M^Q.*7VOQ]G:[[NY>1VY.;RD7G<7-69I;FN9V*Y@/=<VJY#Z'6>*'/$EFF,]G
MH-*"]7$#[[E98RJRGOM1F=RE-26]&\OJUD)V>[,:TZD7 QZ;3:*?'7$TAQ&8
M>,S+TE$4 Q #XY[#P<HX7.GDN ?+(%L$;4M42PI+F(*D0KG!'V7ZK.)W:%'F
MZM(U?&I2I">?7#AI[ FGCA:7+)M(_J/TLA@^BDJ3E[* >Z XO01F/8;/(>T!
M>^3"J3<4DARU*]]CW$?=B4UB_\H3GJ!)U@O\?ED"#X<\AG<291$782>[>$CA
M7;@F!K<]]:;*J-FY-S)=Q<OY7IIBB?1<TKE(KJ)_]\GW>GZ R#H)DRQ&I]-M
M?)OP.;7/55^6GF<_',!9*_)^]YVSD0=B&4BD/_(2/G#QL)%-\I\3'B:H0VMC
MLP!A5(30"32$OH*032(X=S1*8<U)'%WY*/+S/WN7'NK<\%B2^,@7U!H^/=;/
MXAC.O#>E_>A-%+XN5'DB:>&2F3KH"04^MOWHN/V #!9N$S)8QD-T\ C.T-:<
M 0$;D[@A_I[PT(>7QE[H7=*=I&OPJ_6 FQQW-G0V]( G37]E%]-Q+PH(_KWV
MVZJ<CW<' ?_ID==/.ME<N) @7_WQ0H>+NN/*^U[!<BR>"W@.!V ^DX_ G6?O
M*=^O1>8-R"RU3'"7(]6VQ>Y2V#5+D!1J3TAU)PY<B=N.Q>U2N/T.@OP3O_*1
MS\[S^BBOD47F#<C,$R3=LA'[GE_Q()H4"%8Y81Y5/7ZF.LA,%'YA@/*F<,Y_
MX5$N(I7"3 154%L5C(.AU*=W9@*CV^QW+B.,]*4\##_G:_E:!]EE!JIW2\0J
M:1N85V/8JH5-^$98EESTM;FR,Q'JV\4^<LS/>K<)^_H8R\&0^F"Z'!S-_1[W
M=Z>*]Z!&R"Y'^@Q/TB)LS]&,ED5W3ORM;NU07A4>$]K1;7F)9A2=VB&S'&+2
MCM%%N%RH,-V*2N^<TK6*?RIG=>BAY6$B\HK.KC!!B%_?.5OR3NZN]QFZ<U5>
MI_!O77-&&;8DUF2RX:S?6<3+X!0"C(HD#O .<GW/V+U%4PWYCJD3>^@U#@*1
M'57U)?&AW"8AS[.Y$>FCI-"(Y_2C<<^7J5NPI9Z'3FHO\.*IRWI1F"4\$9L(
MHO!R"X,TZ+2$A?" ^N8!^3)?,8)'8"4*()(74SJ[ 3/* <NB&*XGAA-%M&AE
M-^;Z#O0[)R>PB(C&'"D, TF2 @L Z@"!2*4(IC)&ZX>3+'4HMN05WS"22.&\
M0LX'?+#-#N ,O#@521^4/4=?A7/IPZTM1%+"/(5$+PH_C.%<.1=YF_@-'WU]
MR #,KSL4CQ5G,!GY091$D]&T0$&X=F'# 7(,W"GN!,\'D,+1E<VEN[P2,;#S
MR]@;RP241/PQ]?'!;0>H;RIVZ@6)1O'UB%, !>X.!D3&G(LD7OA(S%,D+Z1'
M"E7#*HG&Q"2B/WH(=T(HC/DD(.8.R/\!GU(IO0_I&J>7C=<6E3&T;!G#PY<Q
MM!NVC&$Q]2*+B4(2$)%I;IBLYX&#>>)6^>\.1.;:(0J."Q)-MZV:6'OTZ^RF
MT!:)>+ 0..+2,\6K*$N0R.4.,+<QB625!PUO80A')$PKW@YZ@I#GYD(3;TKW
M'GDU?DYLJ'H_/GHY4A&G0X$L=0&/#?V??(#:@* "?+O XV,^#) 9 Y]%/JPE
M@8R,)BSY@3P^X:E+ C7V\8*Y+(Y@9]+TGZ"H4K'/;7&@! .&0E$,".$ ^\@E
M;#J=((.A.@24=2&G1"4A>1$M,J\1ODB!=+S598$*>C+ F4=9>\IX*X9;R](0
ML2$DK=" QMZ4]0"8P7\SRD 1^;?^F#"O_@WW'?E%#A=M%&CK!T^5>*6,2Y9Z
M/Q";I#)Z_7Z4X?&$<*G] 0)4QI?K&""*#>5X?GAAEU]+5!(WYT*&[#\9$$MK
M5]4G&-J4(H-<PR -%R_06'&^E_!.H]%PU&6"U\,M"M+#\1A7O:BD>9>@7U]B
M)DAI;2X6!4F*J](%-Q8IZE0I!QT*5U.)>1&J2(Y2:)*J&Z!H-N!*@S=26_3=
M!",!*(F> +A\@'3@7_HI9@4G6%"5 M4F:&0D\&3*+Z<KTE/U6:Q/2?^JD3WP
M!RR,4G66# TG\^HKI".B<R--N'[%SP[YE!_AON0R598)?L53\<1A'H%ZCMS@
MKK<)OJ/V>9LUYJ._VJA%-&L"3FZP99VB+2ONEY1  UI*G1[9-+JL[R7FN>+M
M0?KWDA$=IO[E=203Z+^>?0;J_@'<V]4B<5ZRE[-TLI?*F)S)]*K*\ +I"FOQ
M) 49*CPT_9'/KTH9M!V5&(.[<^@&R]/'&D9@%EV](V J@ ?2 H2L*GU5IL,!
MEXLNI4&%7 $VBP=3@@7P D(%[%'A?\]YEGC0R8$FR<D'Q''X3Q2B= XYJK99
ME2/$1/3$\Z5$Q1.;P"$9_$FP7<5B<PX(!^N *(PSF3JHC]1<H/B.YG&TYJ/<
M:\+>%FHS@Y*ZO"%"\22</:<*!_:\O,VFN]]NN.W]'6<)5X[(7BRFAA)-RNQ<
MCL1)ZJT77B(%D1;U$OMUX+(O][9;.\C1Q7+_/WM?UM1&EJW[7/M79#BJ;L$-
MH6;PV#ZW(U08VU39X .XW?68DE*0[52F*@>PZM??->TI!S$:@>%$G"XC*7?N
M8>TUKV^QLJM?2TE\H0(!NT;I9N2-(O>&Z](:@;T;H1@;F_);8@-A !-.CR-6
M;8&;94E-7M;?-@X8;2<:K\&;<S2L;-*ZFH1Q[N2\K_>?KMN)T[2H#">D[0*&
ML/97A45!.<^&!_)+=]"+4ZO:\<IUZEO+.LY+9JSPKU>\ !I:DDNGX3AR<_V-
MQMLSV86L2X;CT[B S_T]H#'BHJC8QSP&*LI)TZ Z9/E15I7H@5)MF@>6,FAY
MMVO\AI] 'M!;:7R4Y]HA1CPZ.JY >08M#O8/V'A<G,#K?5=<CN1#0JA6:ZJ\
M6E,W*;A=@CEKG]<_IZ&X=/P8U;]+I0ZK:TD3G>=\<7%RQU2VQ1GBZ GL9C>;
M6\]ZKS:?D@NYI[P"%[>LP-ZC:]"]U:[-B7?0NPH9UD'(O571/H?<27,MKD_L
MJK6P^F+$?BVB;E.1U(,BZF[KLH.<7[WHO=AZ%4RJQ%3"F./CTGRO^N625 5'
M[3LQ-,$;NEYB;,73.RZT6?!F4NI;% W5J6B8P^ 06UI3-4@Z/^T_?;98K0@N
MK%:H:ZL53M%<38MXVE]_>G$M0EU+BWBA&3.K$J)$O+P:,U4>,[V"%F'OPG5T
M"'4UMGI'[LA3:T.UA/O:?!_"C%DT*?$46XZ0+79/WPA[O:X)Y<8:C- :&*%U
M)RPHMO1J[HU_:@./B%V+3R\5($2).8YF$0WG2&55B]?OGZ7!GWAV;\(R#(ZB
MT4F:)=DQ^GV##Q^V\7;:Y $\2[=<KHA*XD>,BV3%"<F#+!W'?,.0C=G']/52
M)N @A9@&5Z8@3V%'_EFOF5ZFTW/\A ,,.1 #9;X*4Y_@,UR02=IW56;3L&0O
MO\JC-#KC)XIJA*X'_#4R/N+-Z/#.QL@M$O1*Z#(\N/ES6WRU\7(=F.O<5'+!
MI1$YD&;I&KTA3)H5J+;.5#E)>5C]"ARG3)!YI3K<(*&7FJ/JV7J+HTI_V.*H
M"E;*#!@S/O[SAM&Q=/!C51$V3F1C0O6M)3W:+)MVV<Q0.(,1K8,/G[3DY)F
MS?W,>:>[NI9<#[5@H$T]3"_0;KT1N@:&Y!*!T?'$^?Q&VCWD^&RG$9:?P^*
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M;XROH,&.N-P5YO&0Q_<TUKE!F]=%&;ICWZ5&9@LEEOPU' K5N[7(GW_&>:S
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MCV^^I<0]BVY<V(_[(_KK'@,>-TI)U],X[EX\X1Y.^7Z$0/Y76#=%0?[YX]_
MQ^#'+04_FJ2VM;'V,<S7?I1PQ^VX\>_[-OU(T8Y6DGX3C=;N1WQCO?]JXV&Z
M2\ X>/FCN/!:B'!][3":W0\B?-5_]>)ATN"S_OJK.TF#U^!^ZVN_5^G](+Q+
M9B?\2)3WM/_JAPE@=&N5]X$(7_6?/]" Q5;_U7?+K5BR[G<?$@E>]=?;I_D
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M*<X2.0!%RC )7S7]=4#)H#I@MDV$?LX2'9U@HR4$UT"^"+[%KAL"LP%$<<3
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M@/!&CDWSO9)GK8\B;\G1<7-_0.>F++K;X:K=%7^Y5.R;%&GQU!D^4U3%C$N
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MQYS8\9WA"<Z%ZWD=F*Q000_2%)<B_;1,)I17A*8,JF];U3JBC= 8N2!(L7:
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M%09[W^DJA+&FLG"S8FW?$?(D$Q=O2:X62B;>9L-9/<VDU.)85J&#6<U8ED.
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MSOPN=?#<<1Y.>Z9\J WTRAY(B;715$-6E-GHJ_%D80G'..82YC$=#<W$EAS
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M4E?U\XA=<[9W5A#%)-?1/'KQS#/\47IYOD*2"$5)#:Z>: ^).#&>&/.BQ7T
M(B]'(@*IE,,R@,=Z#@0N,M;#"PYT)%W642U&?L]M2W-&:U96E\ZT>RN;].JS
MZC\)/GD?.!+.@-IK2.">Z\)!]5S_A]-=LGF8L'>>M3B"SY.];_N9K=WSO&=
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M[IU,F!@;'G@H0"*A(1$[<<3[XMQK/0'1Q9P).*M#T!KJ5>1YEV@:9LA:_$7
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M;_[7.*=V$NE*_K9*C9IC=3*0CJ=9/*Z+4*NW^D8;H;\R;&Y- 3O2 QBC"<9
MY_V9@?=T(+0\Q\5)9F[2_^Z\M9/37E&?U+G=-^KEGK,F%''>7ED9H^,M4I8K
M.3E36F5Q>K/K$D+TH5 #(-P)UTV* &3 ;D,P,$D_JZ_G1#O3=.$+;ISA <I;
M)B7(.8E>-*#''?0,':9:FM[*!'?+'*Z^*R81!M9*SB!=%5PS#VSF>SMKOMRX
MQ'W]= W$^6W-Y.@YM6:*8"M-X(5)N^:>L&E!9LX(I@<C$22<*:>H41+FM1@&
MK!$LS3MT1V\=E+-Y=TXR9+OIA\SE+.0..0:6V!Z61I",)=F4WB>M2FV:I9T
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M)1L/YZ&]L^+$/I]YD U)M&)2]*3B!'HG3S^\PN2&<R6Y%U)NI2LE@U$2QM.
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M\MEU?;U+5%ZN!%.[5.VU>IC/ +Q]ZHBD:D\=8"(\G0P\&;H_^#2@>AM>W_&
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MB2CI_,/IH?*Q0!'L-#^#4ZA]2N(Q^]Z[@JE5KV";H2C0B>#MD@=JA9/I]5O
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ME2K#F@[%HA"9 EH%W +S8^FE I$"?JC,1B[ M,P#:E^[ALG0'#C+W"=(TT9
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M"?DHT.QPAEXAU6).Y2L\,0F(=-U^2@<]I?&G)!M$S1:M*L$1CR'6*B*3P/6
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M?^,Y7\KJI78MRAB6T:"FMAM2E#Y+=:HW^<N6;=+"C5EY:F<'A=>V/>"BM<D
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M3:OP?E-#B*IJ;M+IPCZ?/_D?H!H/#7)//"QYOAB!T*^K+*TC=1'%X-QF!^D
MDZ:)W;F;S +<J"\F9D,F4 8$6M.80<V9W'3WL10W= MIW@J*NW7HJ8'O)R/M
M_+P)MP\O#7->,IVY.KF%VL1L03PO[P[VR_,,Q;$T%!6VJAY8- Y2,\:!+) .
M:2+L;)/P'-5 !X+^;@PTX((9(KM7MK6NF!C3-82%!&T9)B9 )HJ^&"AE/0/*
MP'V2'<,X8)/PE;"7+> .0N^QB7\HQ$SP*;.^K[D"RUXO6T>@CPY>^%%[G_W
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M](Q0HX*;V/3(ND-N3O0G"-0[PKY;;,U""S48_  /C D?$*O'1.^[_Q*D/=0
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MM32)>"81SS<:\=SNF'/<4OGE"M7-V,R;^>!07_>R:NM'W\^,2D>Z8D*H-B_
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M)!S\E@_9@B^&,POE9"?<% \W10O05*(A)1+^.CC^6F-::"5>H$9(E$;"4&^
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M@6AB+*55N70F<K.0A%W6,Q23P,7629X$+K9.\B1PL762)]B#=Z7ZH\6-\K$
M%!)[8&O7-I]-KNT;O;:+@TCY5U:$;/\6!D>1\DMJGFY(7[6PRY)RJIJD"]3K
M$5/5^PNC27?/_>[3UX'>?9;W%CK$RJ%,9VN20O<F&7QS[R*XM&!H<Y13W4J0
MZ<ILY;^.7P975Y6E56P1CVTW]6N1"!U__*#PROB!"#@5X6(F%L/>LL\&(I6E
M>%1<J1*RSWK"-J\T-),HR-9)GD1!MD[R) JR;9(7$NC#NS0!H@6@"K&T<DGL
M@NU=WUQR?=_X]5T<B"K$TEUBF[=Q92#J[(687=4B((1,TD//7_DNFZ:L8XSI
MWWJ^<?WY2[4PS.T:L236B6&'D4F.V%*E9[[6_;X'@6V/EE!^*W$@G=SFI\9W
M=2RK3AQH!96W$MM929?XO>_B*[UO$;:IIG/YD#/Q$J'_2CV;^-];)WGB?V^=
MY(G_O6V2%Q/_>^LD3Y+V6R=YXJ9NG>3YA.3;)GEA^R1?Z7'?8O?GL3EAPSXZ
M;*9=0S][Z0YDO4_.#?.&V&-3;_8:^A.Q;(33B %<MX:G><S%0_'?+!G\)H4H
M[8PWA0 1VX.GP/XD@V]04G'L$=LB^EJ223>)CJ;J;!/^RO8IV09=#?[OS368
MR<9^UEN)!]3ZMY];-UKU1JXZ\8"X#M,]Q-A"" NFI[$80JQTCS_>4(IK2N66
MNM>$&J3W[I5)XOYNG>2)^QL7R;<A+M<;=N9[::"4C'6<96ZC>+I$0L)U+25^
M_-9)GOCQ[U!"OA8U4HJ6ITXDY\ZN\0X"%>^4Y+N^QHO1(Z5HQ0$[O)7!L:R*
M&]]P^C^+I+U2TQ5!0AZUF'8RWWKUBW]O&K\*NT:1M-PQ2T2LF,Y?<@,8+#JQ
MWS?$C3450IW%5N)'57+2;IY/S>OOFA,_6D'OK<2"5M(E_OA..=JD@<7QG6QN
MH^UG$AV,.C@)-FR;Y.4DU[YUDB<^^M9)GOCH6R=YDFO?.LD3%W;K)$\:Y6^=
MY#OH-Q?LA=?OB<<C:YE&3[4O#<M"_Z4.;U#UL:KWFR-BRG24^/U4/<_<E#+M
MTE,[2C7'9O BGZ21K"BPT"/V9OCJ"'9_36Q)@\U0< $V.IT0V8Q,W<!7+#FQ
MCF$JQ'0^?J(!,?!+DF5HJL)?$2?3QOU"SM2<45=RZ-;WFQS:ZR5197W?*3GG
MMWC.ZSMLR3F_Q7->WTM,SODMGO/ZKFERSGMTS@MR#8XM_M=J4WSMA,,-89G*
M,]G4X4E64,ZA$JW7_8+L(ACYI5PI7,YA,R<;-2>1<.8V.3,:/J42:R8\X=6$
M5\/PZK6AXS=,0]/@00+6$2Q,HS4$6,"@(5L")+QY$+RY&"!4B:LLQ!6+Y=VS
M7F#X,E\-Q*%X0YI,M=RK9_?3TR\G7[[\:.1;-X/=(HCF+T7NN(C7XD36L+=0
M6KJ2S>Y RF?3$FXJMKO'7[/N9:!?DQ1C#(HYS@OH I#.?&=V/499*J!?S;%M
MV;*.&\%CW"S\J/OT_.,FKYS6OA?==C;TW9)S.#-HHPV0;&E_&U>"+*237W#4
M@ ;1$$C5: BD.>!1+I\NE$,B#;?*@6_S+OUG6Z\+R8?L@L7%=)4XIJSF2J5T
MIA@2[I:PW'MD.5X@QD#:(WS*#;&(^40")5T<(UIRQ72N'+*$-N&YO>.YE19[
M>*9;6958C=:1]94H_HT=57SNX0'Q6]A8?S6FG$XB7=ZZ=%DOEE^-MWZO4DAG
MRM5$T+P]UHN5\Z+%ZJNOG*%,6;"<SN5VS8") -P/ ;A&&+X::YZHG-FUA9_(
MP)W(P!FFBF/44BE=S!7V1Z Y,?8_J5S_)Y7Z>R3>[_UBE^!U"WCA4#;[JGYD
M&Z._).\/Q*KISW@\_88H<"H=>"G^_\CW,O8U^GDI,_<>=\WK?>O_NU"?,)!K
M$A ;2.LG(I%>#V?2V0;%!V>/X$B/<AGXR!,H-,)'TUDC3;7Y1XDB ??4QGUP
M]*1LD0;H"\=+ET+_FU/U ((%497^3-7!"X!3RQP757W1AD,]+L29?/CG%C8O
M=[O&$+R+"=)(-VQB2;AY<%&P!5O?E#60'R:=V >TLD@*K@I-[.#<3JFGZK+>
M5>%#E@T_P))W:T=DB?LM_/G_<W0DG:M$4_Z26G(?[EN;_!X3O0O/*^4_2=]D
M;8R/EHZ.^.55U*>EM[?@9L:\AU0*.*02'M(F#O[\R+LOL:-/TNUD! ^OF7)'
M[7Z2KD%8LEU?&[B_DO=+?XIOX6^05G__"3L/H(%)Y,>C#H$K!@\;41*NN6_/
MR7H/W_M"[\)PP?0X-L\<H8402+S:9>MS3:HWKUIWMV?PYTTKB@R,\&(6<$ M
MUI6M04\SGBU\#@TIU+V7N>U<8;SM=?BP=(Z?CK3.SC\?[X[;Q](IF&JR:6'7
M1WM@C"U95ZP_7BW]J::"$](T;MS\WX?,!_IOV%97_%MD&O.9PGTVF^-)Q.G%
M2ZOY,C;EY]$#*.GQ$-X\H1_\RR6!="2%HLUL/K"+VQU9L&KQMT_2LZK8 ]Q&
MYK\?1#)[8XGHQ5EG_-<L,5=;E.OY/NME@ O5TGU 1G=JW.AG<MMX[IV2Q=T=
M FM6XE[I+FB20TH4')H4&4U.IYWFXT]=NS3[!TB3"E(B[]"DP&A2N6@]->K?
MOG>OJKNAB1>>LO1&1T&0; ]E#2(&M<'_?<AFE^,;7H'J8=KTPS\_"6J#,SH:
MR,&[O$MBYC=.RUA10GNRH>)[VU!A21WNJ0\ A58%-2H0\W=G87,QC@K4^S5T
M7%5;)5:M8]D8,[A73T "FLWL8^6\UYCT]J8L]\,_U#RBAJ;4@ZU(AMB%)#O;
M^&M72N5 =&>RS:UH??<N%Q;4U-^K8+0,Y=IYX[0QO>CU[J>]TN"Q?4K.RKU\
M?(A4[F04B_]=X=8N=@KF"N?AVJJ&$D@QX=,$O6T]Y;O6D\+'E,5C<Q&>NSZ6
M.Q)FNYR)O^PJ)&;[U40/SD8L?FQD%HCEO#=PN 6G6*08>+2Q9I]*Z7(YY-37
M]6AY\,>8=XZQ$'B,L=;RE(OI?"6WN7,,5DQ%GV*J*0]CUIO6HAUK@29=52,N
MF5S[,I,%"Y-D1_5OY4;1^EG=(PO3LPNJK8"<1QC=E$ W#L/9EIMP$K?1;6B'
M2WPO!MR!;#-8'-27B -:N=&1P?5LR1/Z0Y ".;_U>B+_(HW6[;C7[F^PGBJ<
MQ4K7>T07+&$:D^@6K:&3R O^G;QG.;!*\:TZV6@F:S87QQ3[=+FPT9E3;^:N
M;^005YBFV6@ T1EG(Q=U5GER6FM9H-DX()2Y="D?TC.,0\5XAAC6Z6R$AGXN
MJR;%2C1[IZ1'3!.H,C:[ R!/RU2[!$A$0:6R.;9JNB(^T^S BZE(;Q@O5V"G
MPE-U@DKI^EY1[X>61S%5M,?VN%:^RN>4[5BJX704HP#FOWM  ^D)B8 Y9(5O
M41IQ.D@C) 0\@U)".I(H,6C'>_%9NB3\G^'0!3ZG-E^DH:#-6[A&X2H@RMD8
M^F6^96D3EDSE@R;3TOD-&Q$_D<3X*VNJF=V43>?#XI!?&33(N"(<@P)-_8;T
M50OAULJI:I*NW>P!B6AQ_JR#T"RV;\?%TTJYW=FY@X!K1^2FNWJ)+5\2ZW\#
M'!Y6$.1BF(CPA@5!:#+%,,7@+9-IB;A<?M6CR+U<'/YB+EW(APR;QF&^GKBR
M3VR];EA!L9#!37,R?=';D\<HO64V9G**5<-YP;+? D^&O;J%P[ZZ8<D40V__
MMTRF)1+.=Z$C";18*H!*&Q=G.S:\&L,1F-P424TA!<Q+;;1N_I\\''TZW36B
MM%HI^\+@[G(Y9,,OZ%?VG=)DRR(63GZTP>%0P96HP0]L]"4N#$-Y5C6-=:(2
MBJ71? %BG(H&5#WC[FQT\EL=% 9. ZH9$JZ%< TM*6*82[]ODL(]XY-USW@6
M=1WK&?\X-=H_+B_SEQ=;/>+\._0*W".NKGO$LR#R6(^X-CFI-'/GZNV7>(YX
M1;S9O]UPVDSTJO&MW*_B\G'8[,5RNE*-.F9V<UIN8S;WO,)CX=L]4GGYW:H\
M2@_O;?G:&SVKGY_;7QX[VY6([]"+V!NE-W?*RLO=M]_Y\NDYHEVW><KO,'O@
MGO+I;O7>W"EG3W*-PJW\2&YB.N4-JKZ9Q<\HOS@"];E\NI2-+U#_5ER\MJT.
MD1"3W=^/XFYUG4,)<3_ZC7S5(M/'IZZZ52E8>-?6?V&WNF[NE#]GNNHCJ50G
M-V2[IQS#E.#]/>6U+9IX==W<*7]3?W5'[5[W^2*[][IN9O%^75>( UN436<R
M^Q?-W**?UY;'?=D>=Q]W?U,J.]9Z@A+BIK1TLR[__O*9%"O;E8?OVO9?V[:)
M6>O-GO*O\Y=;I5RWZXV8Y&'84W[7P>NU[W+,6F_VE,MW\N5Y/?.MUXW)MMFD
MUO,OWJ_UBG$T?<^&K<>+ Y!0\^!IC>%0I1#C<T+N=(68[">V"VBK]4U"6Q7-
M5QXKF8ORY6G[XJ?YL'-HEKL3J4<(D!?V(CF;D<1N)&<[;R'S'%)R%=^AO;X)
M,JT_[O1=D6D9L'4-.1 %YE",PS6HY$/V;8Y#2)9<(7DAJWI3/U4MR]#&^%;4
M>T^$E68T=-!\1E>5;:PCR,[7$?S*7'35UBD9DR@%;AMS/'!3"&55W&UA&8'J
M; Q+#&2QM;? WF&EP#LTYC=!IJ0,8*&T#"L0(DG*6!(&\55G+4/U5_PR$C?8
MA@7YJ=$:=S2U6V==@8-%Y.=?OZ?#ZFGY[CI*4X!X[4@J%VF;*0NV,B\21W0[
M$N]R_ 8X.>R%+[W#T/XFR'38</^5<C&$$(@B%DMQ@(C*N>U4.\WDD?0N#O(B
MIX3]V=!%/=BM_'*IRAU5PUDH&#\)%H^]N];-DRV;1;.P3Q:DV ]*1:?ZU)9?
M)$WLZ0WP<^AK_PY!/IL@TV&7"JQL'[6&+(@D)>.H)LAFTL52R($BKQ245=>
MO-.!(!H\26%58T&EMFH?Q[VR2/-\-/+:^GU]-ZFT)_7=6Y'N;EA:#UBANZAP
MG^T*?6T2KKKJ?;688:;#NL<?K=U,*9:RZ70A&[5;2<R4?RM:H7K06B$LF<J;
M]L""A7 QLA"^(5VB/F&G@P!Q?)/I-QK&OS>?E2UU^MNL9)9,=[.)D%Z7/:*)
MZW(\U=[Y0M2\P6&*Z_*!Y\G"DFG3+N'*[/V-[S:RJ,L*(UFY.7WX\=B4U59W
MYT;RS:P@%A'7Q"1&:;OR=",*U5A\Q'0Y$[4:[T"%ZF'GTT*3:=,@O&"AFETD
M5*^-)YEE^$(;OLKYM/'+:IX/'J+,8]B8X3LG;76^M<3472E\5W)!-%%<B0,Z
M6"J7$D&\Q9>_EVT&"\+3V49]+F[6F\_#3!Y10*+-B[^S_-.X4?O5-N0H?5,W
MTZ]/=8'%1S/Y?&<GARKI0AUS1/D6!^JOD*YDHF8CWI>$"VM#50X["1>:3)L&
M H:4L#=D2&1K;%)PK1\VL43,DH>JULRWO_1/R#Y9F4+BFMY-S:.H$JD;^N@C
MBMY8,EUAIPLE@I=)E"3/%89,U=WDN9:/$?@NFZ:LVPX&8U[B/M2[WPO/$UG^
M' 6&%7.UTX*4U3/;Q7H0K+<J7]=MU3Y[Q-$D:S5:4FK!#+=<NE+);U+(!H_D
MVS/!L8%S7#&UIAK+U)K*1JHV]_NP-G+K5N#:JK%.-BVE*Z7X#F[%K,0E*J<U
MMF^0IM8U >/OABAD.,*E!,24+UORE]\]\[9XH>Z3M;](#8W&-F,7*RWIA-K_
MIKN]]ZR3UKP<"UD@HFZ*([=73%>+"6!B+8,VR>V%(M-N<GLG_H +WJ6SWV/:
MP\@>&(KK=,^+W8'ZTE2+I4:CN">Q;%J81NCJI2%=OB>P<JAR=?FI1I*DE4P<
MJ;E"$K=>0SY4,H==6A>:3)ON]K&R5B/ D+DU=#'TS&@3V]:(8]J<O1"SJUI$
M":YNN_E6S9\K-;/_+<I\KZV;MK?-:V>FHFU(%MVKQ^"5B-CN>Q;'ZSJ!8=@C
MHJ".(\=8W&@]QYL(P805/DEN,129=I-;K,PVK6%WC667W#L8+(B-7Q???CR;
MDY\O4::/;: + R*"G?7/R-Z#%:[+SC6B!(TC59C/;Q2%]JY$:)(E#$.F[&ZR
MA(59>(:P3]Q@W9(<X8]_,V;YI-')E/<J3BM0&<(V]<5H#R-9N!J,L>2@HPG6
M;!SE:]5L N]=2VPDQ6NAR+2;XK7BO'2U05B-56O C)E3T@F(P[X\7#Y\-:V"
MVHLB5C>#*2:^E=,B"EC[H8O0^=.,*#MCR60%X-=V2.?W4CEP(-M<"=_E;2"!
MQ_U\'R"_K&ZAG,U:I^I>]4(07C9<M+[Z1'2"DJTG:0:H$%7'D>W6NQ9H'ROY
M\H$YJ5SG'Y1-M)D]KW0?KPV]*UN#!K](9R\CHEMD7CC\TK.C@7$Q^'$;I4%T
MO,8-7[-S^\'*H:M^SU)@F5D3?(;13)I<+..1RDGKJ77\G%R2KPA%IMWD*[*+
M\Q7?57O0DDWR0K2&\5(WC7G!:31_CJZ4]K"%+2WVSZKRY"Z>83,2WPU6H#9?
MI/I-\UT+U;",%P,F['U)MK6R/W.W) (6OI*KQHFNKA:B!BS?ID4=EM/S.Z]Z
MXM:+Q=A'N;- <K5M3!QV#56?EZ_ZF7*5_]H9ZKNW2\72N5!5I#$N'AXJ5O^N
M9>D2@;#\3*,9JODX\A;8)76CA4UO1J"'%A!)YB(4F7:3N?#/3SQ5GU18F&*Q
M'D!>;*-7@A:41N;T\<MU8ZKMDX5Z0YZ(/@9I:O+5(\P1P36V\4C>=WW.R@[M
M<R<;48;&D;\H;;0,YUT95TD%3B@R[;P"IST ;Z79PW3AS.0\O^3LWMS\L*W^
MXV"Z<]N3+IGE12QK[:EX;U50AF6I0@QNS6':>X4#+W=9XM4$2XD(E>.50BPM
MQ/-1/9D(PC+O"DM/ 06EB-6PK#%1S@VS3<PGM1O4??3B^TWENY*YJE;V*BAZ
M[BNBL>AN))5N!\\'_'JVH42D L_&X.$<J$@]\&S/$I&Z6I9$$J^QP+2B=A*/
M(%W+KG0])2/P?U7:V+>F*[6A 5)R*B_HP%$[K5_^R-UF5&7WU3'>E4NRKDBR
M9^WO6H(N8?!EQQG-AR_$TD.OFD1!8S^Z%0FM0K2$UDQ%4WRS0@_SD%:HCF(<
M'1:*\<TI7">*<4UL4>3\W3 ?03[7Y1'VA<>NG89.=-NJ=2P;EX2:Y.1^6C5[
MG:MFJ:H4Y>V8Y2&DQ[+"=QKH,$;$E!'9*CVS74I=MLV_WK.2.5PS^T#,Y,U#
M0#V9HIKR,&:-:"RPM=VYK^+/6U-62*W;A>ON&2@!4B/GMS_E2KUSF>ME[Y0H
M B1>^Y,OU_(,"GG/ F%ESBC:&4<S2HO1/*Y%[4>3QA<A0PO%),,4BDR[R3#5
MUI*Y+9.,9%41V)EY89M]N7P@$_5L^/RX3T%4OFX!RK>H[V_8 V(>RLBF5XOB
MF:./)H-+T5R718#)I'/&%@YU1<B@E(T%\U8L;\0AW>_CV\JE7!%-*,7:E3T?
M=>[%HOL7K+5R:VFM)@IZ9Z[KC,:Z:>1_Z79=SWR/DO:+USV@"SV X:VOYGO/
MB4941+'V1<^G\[F-#GPY!%VTZDQ7Z:%B''UGXZO >#-*:-/GMDK_Q)$(+6PQ
M$7J^1/<(JKA4\D8PW":",SKH\LOOV\]7G7%=WRNTLQ.M$FU;:<:TVS41>R)Z
M7ZGOVV]:[W:$.O^(&BN69H/I8B&94!#!!(E^L*O45KPEA%$/]Q!,CNAGN$*%
ME>-(R%;+\;E.*W78Z5HZC&KX2U?>!SA1E<*W>F?X^&#MIN*1/1L^-UKJ677'
MIDD\0]ZBZZ[ 5R_EYXYA*L1T/GZB 1GP2Y)E:*K"7Q&GO(W[A6O&L\OK-]O?
M.HGF'KCQ0]WL"6Y"S\U>_BA*KAQM9MPB;SN<G(SA;$+IP/?(-5MAFE5:-8ZN
M/R%U:KPGLA %Y=&Y==D:G&O&,YV_<V<1!8@F0$,U6.D3U[2W]T/;5;1#&?Y6
MKTW'/>M^.M0OS/Q/ZU2^V%+!PEK(J"4J.4=5\C6Q)=HR:VRQ.EH7-"4[!$C4
M<]RAU7",%\U'+<<+L<B MQIRW.1FCN]@Y?\FN6B5K5".DX>*Z4)I>SH@X9<-
M\,LJ,R%:7&P!OV1!(5;+6V88K[VP,><Y[O#KFXC>)HCD=YZ\VC ZKK3*9F?3
M,GU"S*U?.+F?ZC]/&]W<X(P4MC36)!07XT:D'NZ$S455Q2X\EG=2J9#(A62;
M"^1"QB<76J;1)42A8J$-!H;5[+E3=.&78.@X(X_JY^=WC>E5>7P_;5R?_ZQD
M_YU8IU%ZV\>+/!);8/+ @DU@MP%W0C+ZYZ-Q1U.[8*(-1[+^OD<>A8QQ5PI)
MOX&(E$OZ#2QSET))E"C>4B4.M$TN7<EN,5E9=\M'6V.S.Y MI(>__RH?RNF5
MK@/[VWGA9CCYMJ6ZT9""5NR =G,YB"ZL2_LR!YYHM.AC)1:$3#8I[ HKPY-Q
MG&'(5-U-^^I:H-0\5?M8ANZ X0,$9[<_&.MWF=^_Y,+NS5*OM%38V@\7'S\G
M,7VG&4UH5N-H\U;*)/U6PTJ#I%=U*#+%X%E%$)J>GO_<[)YK\^^1E':_T3K[
M<?;P0O:JV)6N_'#,RZ7M,&</,:*0C,=KRF:BEBD<9I"@FG0."$6FW70.J,S)
MRCGCTB\N'XIGA<\5>?*U1G9N6#HR\G",RA!R\O7V9#43!Q8^EZXFHG(=&5#-
M''A+[+!D6A^4'H>H])=;" >NV1.1W)8FZW9-5\Y^C]41AGCK&L@CM:<2I68%
MI)@71#Q_&W+C7/M2..GNDSGJ\^%[Z@M1#D#8K@1$O9X)(LKG6&:IIC.1*VX/
MS>.O9@X\U1663+L9I.II:^U<O%,R,BS5#I:R[9Q9>_GQ:V2-BSNW8IT5P[VE
M2SY$F<K'^<T<7D3I&$<*J9K.9T+"UA/IF$F22&'(E-U-$BGC2D?$#+9D5:'U
M7@**T-"Q;S-10/@%2\NGWY7K'^JO&_VLMVN;=&6-,$5%TC:!.%?%CWURMAGY
M&B<%20%2>Q5319/BV3AR6F%G:R251[%6DH06B.OGT3:[^>1LW+-9/WFWC0+<
M3 0P/RO =16:KP!7GUR>]\XS3U>GE0VZ B'D192JVX^\[/8/:60:.+E5D3H3
MMQ* +@O_E]3B;K46-[9 3S;66MQ2.I]]"Z6X"?>M+ZW7S[+NOE%+<LZAL>2O
M$#++P>35;!S1DC7 Y!L_L;]?4XB[MK.:%."^Y\SM@02P-A* VI MG5RXY,(E
M%VZYDUQ=Y22?J[JL=Q=7O+?SMY<5_>>SW%;VN.*])W:15+PG<B&1"VOER;W%
MJ6<OQ.RJ#,9">G"1B?)=-DU9GP& #FH7]]/?H]/2]]-\_D[;_21H?\$[X=M
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MHLJV[H2]6H_% 3?)%M.9L%.W$T6V<S&9($[V_82V4^OS.G^,UD* **+E$3@
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MKJE 6RO(*T%F=60?"Z"@:T4L^ZAO&L_V()T2_W["7)TDK"G.D)QG9LZ?15Y
MT9@J,DD')[^B!8!?I.Q,HW)=M!K0-F!*&@P%T[" *XBLV8,N-:(]F4L>R4Q+
M?>.)F+K09#V$BC"[>L[]D$<C#=PG9M%15@0*P)>93\?# F=W^-$:Z)F/;G@!
M92!<E/&(YV>(<E.[:L&/7U+>);/W/F'(#BQ(7>@RND4+EXDA2+CQX*(JU)@
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M/5:TY:VVH*$6=!=+;"0%N9<:"K(1T8OO1%65)[$3=&$>"U>TFP]N.+_7S[)
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MQBS)WZ+B+F!HYT*7[9%]T9+V+0@Q>+[$BBAQ5A341HP21W)J_[C7'V/Q8P#
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M"&?M\*!"&%7TJYB(IS9MAV_1^%X>C5_EHIXK]S>^%5<?WT1/[K^)[AP-EB5
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M^=L_>GAVQ)\!H_Z_0G,R1$LL&6);Z?PK7"&!(R=TI<-9I!+\M_YA7X-?S5M
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MRVIQB=W)GO_%PG69W\@=61E:GFP>_NDK] :UIOG3<:U\_9C],]XC;X@N>[9
M!/)+=.F?51*6'6DTMU 4Y2"Y>"YWN(6V<PN%'X=S(/G.96_YA11%F<0VQ=#_
M0DKP%Y*37OLI*EI-:X@S_:NMZ>^D,BVE]41NL'//AZV8=%!_P^W4$*6#INF
M%8P?1#(6!@0"'6PD=U,^XA! /G$(RVU&64;.$0MJ$?-1@*%ME!$^_M6Y=06Q
M] +-1UP_D4\$+%:-/EQ8]K]$:]J5_BKZE&PV]:KV*J,O&*WIVY_S)_6E+V9.
MG_;*R^.J">%*U>A.?/P^2Q<4NIV#! 4[]F@NVTA+-7+YW.&JW; KF#\4:GP
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M<<*RVWUGA +(6":$ $;1K63'0-YS-#;3FDX3TVM)K3]JE6ZX:"Q=!1DL^J]
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MYZFHFBS#XV5,I :0E8E81%8G7$FG,%:L?DPA1XNN>D43C0GBP9%A8B9IP]
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ML]&Y$A\:4'\GW#'W+DNO-M-SMYSA?X=E^"E7/D.D7=[K[U3GY>%D\EK6=MT
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M9^.<37A?[' V:Y[-G#)65Z9WB8;TK6C-V!6MV=".7"[2]L>@9GT$9Q6P6O[
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MX$D@29X2D?!Z@<RY\)7V/?/ND)X^D]O&"!@IQYP:K^_/:<J>(1,?&%T46(7
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M78(0C'P!ZQ(JU+BQ=4P=C)R/OV]Z;^TG'G6D.X58*ND8M<_XA%7*[0#:^:#
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M")D4';H@,U<@OS$X/#FY'P)&!V2<2BPG(,D [**;[B&@'S3$Q U49D2=D07
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M'2R=O-@4LKPR1+V_L-$6=3Y((P@'\\:IVF7VWR3WE.E;8DKI7-O0R-22Y&M
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M]87,XO+($?^;Y$2KL"IJ[#?F<[35E;"A[CH"=D57KNXSTI8)GZBM25L/^,;
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M^W6MV+I^9+_]OF[6[IL9 ^%ZBYYY#XL5$5G< Q(=CH=GQ!6!V  (""\"D6&
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M)"U%3D8Y(/B3@2R]@7]JS\ J'3R%$"45:%05B"8G$AIR:(;E!%Y_/7P4T*#
M?U54Q$562\$C(57FJ$$""/5H+K(&HS@7BM@H:ZQ(T\?LG(./X47D74"C S[(
M046>T4N9+=7.,C?D^ 5<IX)83]/M0ZM?IQL#9<*!C=G1L3#7YXB:XC8>-MI
MJFK6)&.U)L;RG;N;"RHX?9435L9I9 %UH1$%QE11]<)L]&2PV[DL8YMIO!.M
MRK56FX1F)@P+'ZH/1YX#VPA7QZO(>[6H5>W!\/3PPS^%AR&-1E#5( @JR G7
MO#* \M %1F(^9@3-Z<C8G Y,+V/JBL7AP%_W\CFLO]GL=JA+";D=F.>,H\_@
MHU>@/81OY40#)HBD_E/FL]_J!(@V^!/C#Q7L/YL"JDT4&]MIMG,(XER(5BI;
ME)LF!9HHZ3]#%C4S!+1$LQ95:<G(K.*EOGG\&NT!O 4,V"[20&T-Y[B50'42
MR@G^R*N(E64D&8R0 2&FC,&19/  N#/@%9>+W^UOT,1;&Z(C ]%0EYRPX'2"
MH%V[G+;FPQU1*< 1A9%9>8MI0AX\[$,17K$"\F&8*.6P0:* ^^0WZ\?NS&P-
M#%7RFM$3] X=#&IU+C[WZKQZ)E<#P:!09&69'72XF$_:Q_\O15)%JAH3 PH$
M^WQM-2I-F,;TG-^$ 876!/\'Q,C!MI&@GC8N/5K./Q8E@J&-6A8HJ/,Y=W.^
MF*KK>W]PCHA+B %^M.TF0R.Y[)PG$Z7"GCCG+^"+>'A/H8Y,F]#T[#$!+S$B
MI#D::-M#,?"XD),24'9@R2_9C5YK#JO';H#+/IU/M7A4:<PQI$]/.2V^7;V(
M"SF=4NW &2^Q^!,HWW)DC)'M=,-63TX(%R:>M@@<6QR*2T+7%%3))(H.2R$1
MOA,_DBC=DB$H!_55;RGI8C894F=CEBM>P9:R0S*Q/LH/G'%E]^IU1RHU^8*Y
MO0BGR6(19#0)J)=J2*27G9^CM^ V(PNN+K4OD_SY687^>-W5*(T09@J5X7T>
MASCDJ+V]"5 TZ4FB:8^,W;67CGA8;K<NM#0R[A$^RY^6:K3*U]\^A<FZYA3E
M7T+?PM%XI6R\ H?*Z*<00;3BU18J8$G@9RXPLH.R4*%'Q #-[KY37C\7>]77
MT_']TV)'\P%C;1*7APO.S-_13FVP4QZG'D%JDH"<(>F0,=>.#%+=SU^KP^M,
M?(^_7B_XZ4QIO?4NBI_$.MEO<DZ((=[-T5 =3)2E\5=X\:,2R7AL,UMI]]&4
M;QJD+8E#BX">70_?9ZS0&+_LJ%TS$5G56D+<T@J.YR1MB4VG'R5!<[B#UT<6
M6I/M(LAM$EF0L)B@.SNSK1I=2OUUX^;FHGQ/+CO74>J2/7I:TJ[;I@K^==NG
MO#J6NC(_Y:XE1O2OVVYZUVW[?ATHM,8YS3)*\:4I1*_;+KKKMHO]-3D:RMW>
M0GB^*W[[?7K1.^MDNG<7-TWBNE-K'U+AMK/:TF($;A@%Q'J06K6QS*$BG08X
M.IE'-4"X$#9?R5-]/!"H0E7ZZ\OQ<Y4]?^G=3BFCXA(_AX /(HPG 5$T'O4M
M'"-53O*4_C>JXF <Q[RRX+5_^]T1,[7Y&&R4H"I9;;2;ZE]A-L5;$. 6&&,+
MUEHQSTWJ16.X+ MPX)E$(!;,$M?7=>*']EWT"Z/ +-.%)9$,>#YX-7R#YZ/M
MRYTR*P)73Q'S&?S>/W0QER>T@E!<<&V6$MJKJX@9JO,$FE*OQJ5R^?SWC%;&
MAI3TB-.*X^>SD2QYU5?]D\_1A%$JC J=X'J5"2,(A"0*8'T<,4>UP9)96R;P
M[W/P5#B.5)TPL!P8%E1RA%9!RK$9\&E,-UB^ILR'9OD<:_TV^B)0[!+\]DS@
MV#&$WU9PE0[8-@2@T^I*X;KP"J6YJJ@,&LN)CU8OY9Q"QAC ,G.T:5PIFE'X
M#T?1G95$VH_@T[/ G@B<HM@K U$%ZI*'E8J WE-TXYUS:52SMV=;R4ZN;,VI
M(\K1= 29SQ>QC@!_*_?78J'[J-9+? N.GTM61Y#YDWS1^%O9H2,JD75$9ZA*
M ["NLI>.P,7$4$F@.D9>A;U@K,PL]>I9[TVY18?*D:;HM"5B-)=1M3)\ED),
MF 670?754X;EC))?Q&>HIM/LFR&HHM8WHW_$8&FC()F5EB+2$&2N0EAK^R\9
M$97V5ZV%PV9%L/:@C%YO"A]N?ZA>VNR];?A9[@.6F>:("Q$>G\AA#]#H]P#'
M"=XTYY6)W@S@K_XRUI, 7A@WE,8BX&,6:B*#G/ 9+#?B4+'T"#?LB>.L64 -
M/EPT/@Q.!FT+UNU:-)^V1UT38:K#2FKPY4K&\F4=+,%0M$#LQX!#1%A7C[48
M5 269@>#DLY79@'E%5@3#LMDP9,)D5.),2SJ!1]@N8'J(%;&H8*U7AD+62SE
M[K8V1K-Y$2ZH XP!HU4E@UU" LO<A!,5L UP;$-IRA$_KB5%^9F,ZMJ7HTD;
M#8+\2%9.8"&_S=G$6^TQ'_Y^9K'/&=^UNYI>7^ZO+^Z9XO#RXE(NC:)[F26W
MEYGOK\LW5T_-.CV]DMZ^_;YHUSLWS4RO]I3R.%V8F0C3#_H*; 0_6FTNY^<!
MLQ&G?RZ( :P+AX9SB'^#S'0&_F8,-)PL8J,@<:CO!%I9(/A0J2A(3@1NS"L"
MXEX@X=.9I'"HSXS'; LD;RC),PEY/RKS 25)_P%D^!S1;=SCM:"66\OOH"QD
MP&^4^> 5*"VH"M!'1AP+78LLH!)\*)0808(U;=HKP5N@* /-Q\QF C^$$5N.
MX#L?A/-A5SG\X<#B].T(3^6!M^==%>Z'4S#]F%XO[DL?YZNB)\LFM*#M8 Q*
MFV$,3OOKR>VBV)V\?#34T1'&8&<P!N7]P1B (+SQ^L9S>891YZ]'&(._ \8
MG/KDI7Q5KIW56Y;JAE2U:"20A<=6=Z9<O?!CN1S+"\!6GD!6GOB/__T#'*:J
MM3RS@*[\;W_4!;]E ?5XQ7[<DH4GJ5$E4R":*R)UK"UE/V/ B=R(!^XX<!5M
MIADU?@+O00_H,[CO"HWHTK(%N&_/49Z.6P514QX"*4BN2RMBH&[3TD9R^8YC
M$=,XX8B2]:!+?LU?AOO+*:>8\ELW@)UZ-8!M>H_>!';1EDYYYNY^.!\$-H'9
M1.M@.L#TJR1HU&WX:9$!U9Q=8"" N)G6SMY+>8YYIZ-T@9DRI,M6I$:P+:M
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MX:@H05J"#_'PDS*G3$  G]44/<:-4@&/2W,5FMP,0E 92C-.5_?&E@D9[O-
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M1DC3J.;@HG5W3U!9O3,%>6 :*F&765E:>G+ #.&^1X*LF)_W.$*C1P;/G,6
M=:.Y#&M*T!#AN:)L"SJY@P&3U?PW=Z1G%+1HSBJBE$:H&G1*,6JQ KQ/@1$9
M.)C=,7BR98^28SRPO\XK/76AU,Z6S; :T%!V&;+BGD<)'+9+$'6>K;HR_0%K
M59 2['1[%YVVK@?3G409H81,FRX770P)MQAF]B&&A%L,,PXQU&%2[9((=:,N
MC?OK>J]-,8P% IGG4),S&AQ+$DV\\0L1NK&P'AQ$;7CRS)G6SC\BK I#,9Z!
M8>8S^)</(K^7<L6P=F $O"IIB4H542RBE9]CWD.MW9 *CKIZ$T_<RXI$G])+
M_$#-==)<@>.H?_Z[I3)-7'E2?B6./4Z>*NB@,1-H1F/KDL::5TECJ)=I4#;K
M6V'\L!1O6JUA8!VCEW(T*A@_00&C9_#J*&DL]==CNDJ2M[>CZ5DQ3$FCE:V-
MLB]9]^G^YJK%M)<8[>7;$6/+G:=5A[D#)M*4D)&$(/T(;Y1>ED,G0:)RB)XE
M>D9FHFDW$PG3<@^$"U^S&I=PT(9]M0T5]WCPH?>_[W?LIO:X[)%2#JGV3QD!
M=QL-.."^B=I 2^@/?K+*9.,.J6*9(>GVQ/K\O>9^>4XQ[:GJ<O'$OM\_OGUS
MKG2;8N>@>D;7&OT0;]P33ZLQ$'-IUUAV.ENDO4HLTCBU6!P1FY$B<$TE/-<4
M#*XI8JXYOWA0:6IT>3]@PW%-.BQ2\&21L&-W-K!(I>"%J[SU>1QDV9PU%>*5
MT#GLP,+DZ;PM]5=#V&\HN=>29%?R3PG2BXU*[[5[4VL\S,P+;YP\\:>2GX'<
M3FF:N=%-^XDW1+H:8XBT2U[(;+G@A<CQ1:(UD\-J<3G,I4/O'A];L_'MV51,
M@L-VQ4X% ]K%VS['F+;M8B::"JEY0YSF?\I\]OL'^?.__\&_'&IUHT_,4Y=D
M64-L S[J3.8E64^?P[2ZEAE6?)2WD23:3HE'B,=2BL'"R*5EWJ!)M<ZH"VG6
M123K&!0S6;UN(1>\ ()D"K(*]9O3RI7Z=B,US*KE[0[))=E)$\]6=[:Q,HO,
MY[^A&Q"2^J4E%3'=#^*X_7@V=0:-RHV5-+C194'>GU[6#[18KTX.AAD]..]'
MD*._)75BF"@R'W8,N-U$*6!/X&=.6^4]GS,=GON)C1F5F#%+,(9P"R&50[!-
M1KX%EO<&95KB6"+M'5%%'7V-8*7Y0. 2S\9LB*N;0?;E=E)^JDC7I8^Y"=#7
MQ AH TS'8-'<;F/)!>9>@0:93R0P+V:I<LA(([6SW\8VI<.R$?B3#L^?+HNC
M2I>/'Q?OY%#AT^#/W242R7P246^41&(RIQI8Q1ZO&D.'(M%LPAT"+7>61(*'
MIU 6GOC=O/[LPJ9<G'ZM@R)#_YQ>I10NJ5?#X^=Y!4&W8>C;$J%#QV$T?$8P
M()$#7"]4J#)'$+$<:T1PUHHL-)9XQ"%X;S9@"DYN=_Z!)V6ID(WMOM24N1DL
M;Q"UFK.AZ=KBD16VNIVB4>$3(S)&(\]:F( 09AK5 )G_+N1\!&Y3WTBIOSYG
M7MF6,!E/.MM54G^I\25AAH=$&.B1V3#0@P@>Z&%6W>K%@5H1-WA6!RP.1QQ6
M6'K\Z;)13*@U5&G5=5K)'2KXUK\%F=-=H$MHQ8\>JTT!2=5CW'1*]7L!M8K6
M 0#.3V3@)W2L_BR""M8J(27+Y$2,]4AE$<+E4C'D'E>0FH#"S)*1646#SJ8*
ME6R^0$.D6K+XW8)-KXTJ$"RS0MB,93Q.EJ"S);*4K5:K'EHGZJ3+70'>AA1Y
MO)>R#M()J7@J :I9I]A829MA "U5;,B<C8QURQ05X]NH*A5[:#I@N#GXT0#<
M <YEOMQ?/S_</K^M\@]+B3.<2\)\EKX*7-=IX">'F@&Y>4'^GF.^[/ <(XVS
M]T#+,7#,2QN&$&KFW@H$[SUFP%"@'ICDA5RAF-4'?@#+/$6J.(\K8'/$'ZTJ
M>PE\%5@SS0E0X7%0XA@"#Q7.H"IO$2AAP5&0C7%@]75.&-:V&'L=-UA(OH!T
M(_1MH'"#?4DB=_(.Q!JLRX:MK4/0:D$%_G0&?EJ=\#+2!VALL96!\>S9LEZ_
M6\&+&UO@8Z<,B\:=ZD-3\<P3"<Y,E48C0# 9UTMSTYD@K3A][J.^/PL:>,8<
M@^>L3??7?0>ITMVC#DR_IV15"> (&SJ]K/I!TM4(25I&VF8,;4QFJW0^2U=+
M#B<V E<CAH2-&L:,J7_(')V'C_BGD@-*F.A )L$^<]8<9ZR_*\-XS+%@]+PH
MA^-7720(9J1J1ZLC%(_QM(P0HD($BTHFI*CD<X5\5%$QYBO:A8;P$9J,=EQ8
M=BI976RJL<1&PVYF%[PBR?YB Y<$O1_@T<'1&/+*( BTN!!@7@WT'O!K$" ]
M( 0D%1X)/IX+C QH <?$H<$;SN *=O:@52F.=2$G <BS=68R.D &[M"<S*18
M-[BR_AQ^&E =#C>2[%/29897T+AD%<0U##C(?XIYPC*16_-3M-$&X(,+GLF
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M(=RO7 *NX-,(M*#K%JW/%RUAIHV%9?]V\_WL)Z"OSB_$5#EQGH%)_7^IQF2
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MN.O41(S^4!4T\!$(^IGCHR;13=RSYXKP=5F[T.0N;P59\H&<A\7L''X;QH)
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M%)_7?P3+P_U)0^B\T5OXMA^)9$2/.!9E=8 U-FCF!'K4 "QF]%DR/$=3NYJ
MM KZ?DEL819&;$'8Q<T2EI(QM:.B#D&68%E(X0 BGD.YP#* #$ER(PBV+K4_
MFX"!U_"%_$"39 K9I*%,.PLZIYY9/J<><>;+E=R9C.HW7"N[V*N(Y]3[5<VN
M.:>>W=V<^NSK5#]O#)CT<^%1E>(Y]=]C3GWY=7K7'#ZW;Z[/195?Q0MRNY7!
MWYA")HIT<Z/=O M/K?;*XPS![PKF5ZTTCW[!@HNOTZ(R44O*\(\TR01>L*V=
M/:_:@A^4)R/&5*6K@H&"K#+;RL6]EY^0MJ+:R ]R76X)<I>U2;.G9<^B^WJD
M@3M$'!G\!?1(:S ]>68/:1JST5=%:@?)!?*UK*O\U,?UT43H!G9=KXOLJ#,-
MXDF:VD)?]UA27"IG]?7G$$^M8"A;SIQI,4N3I_I-KZ^E/^P*!_QJN/OQNQ>;
M8:YESL/+R%F]]+D3M%[;?O8LQV.BY4(QT7C>#SG#;:2!$Z.),K;3\+PZ(V@R
M(=X5&2V'6&.L8HZ!CX\4] D9/&N3V>:[/8[JSP?C:Z9[O;V3+928?K]YU>G6
M[#+I!^^B%Q^N=['AGF^.#L-1.N6R2P?RV@ZT*7GVV&7+71^0P<)X%,C,"3K2
ML!7SJWGCF\9$XFT*Z:A;NJC1G<' .LG*_ TL/M.YRP_Y<-E0#C>5\RN.\+C!
M#H?)[;[ U.RN@BX51"4\K+4+@]?]SM<1F+@5AV?H8]L[S?%9Z^.VT!^D*DWK
M.&^-Q2T^.V-I(9\4'XJ:S7'+?6$!"U==' R)T\FFD@X !\>IB=)8) )KW)H8
M-L&\4]&3[EI#%3_!?$ >/]H]0MO+#!@/0FS/3DW/^L!L8IE PG)A^._(4\;_
M>Z$T-*$MYELM.'8D/.!:+)Z:OD8@2QWVG^G^0+H8.0H/R2MU$'3L1F+XCE9+
M@XF]LA7F#PK6N=(&@Z'D+(F,Y3+A*'S:KR#"S6F(%PPJ82?&Y!R(7@6C(@EL
M+M(354T<"%*[;!B.>:5]!X H-<R]^,VA<T7S^JY_?7]Q(S8Z%E<,R#+< 5D"
M0Z/92UFL5Y9O)9SS#\.@HT^9S-S)+8ZH&Q6,,#;*CL/-U4WG%OBH8_F\ U67
M-L9KV<@#,O-7A=%T2IU7B]19]8&Z!JE=+TFU@IL5WGSU.X6JB$UM!./!"99/
MFG*&H=WI*-BAI'0T01]JH]80,%U,XS7A<,H@X(BI4A4US&,0.BK*ZJA-(05W
MZLH@D>24\V[ $$#HG3B I)-$%7J!3O$ICKI]O"A=Y*D"DTK!:G0CXX*8OH^V
MVTM =)/<8+C/J$M6A.6E/X J",1Z7;32+D0^S1CI"/C)87$* ^1O?>&(L.SC
M&#H\B*+]!,OR]"90TBDFE7Z=EAJ(_F=UZ39KCT(K^BQ@L7;P>>&\<CGF))5V
MR3R;"L/(9W(! NT06'>%H4E.C+AV.-D%9J(!]C1!;\;B[&L-TLXT%?E\B7Q\
M+JD;U<%#+YMNC"HVM%[=\ZYEV2?WFU:@<1BV-K.<Q$E#<CX%N#V1:E4=DDP3
M4RSM:XHA,5=4AU<-3Y@@DQ<,= WR"X+N3D^V)4B9@A3U^S@*C.Y'24Z(@H:D
M _*Y*^M@HCA-+1::LC0?+ QO50WIH*(JJRV2%<%ZF3)%)M1WAJJ,K1P030Z+
M=ZM&]&8<\B"*>:!)NHBK;(Q=&D?FT,7.,@$@AUU!X*X8,$F6+U@Y2N-7UN<@
MO24.9'7BFP6#JZ$G:.U/C&&G4HYOP]\3>.XZ24I0>+UD ON5A.[W)%7_%!$E
M3-?#N4QL#* /D:F@GRH9X-X39%DW,UND(.#"6)UI*M!)AF:I]R=L?JJ?Z+5(
M^R2L3U^0SZ3HC/,S1K;,^DQ3Q*!TYFW7)O42-;B9X#L52=.'%)+;D8XTN)/6
MM;M*S:2<<1\Y"8])8LH37C%.Q8$H&KDX4U1!92)6$94VN>O2*0K?=&@=G:%5
MW(%TIS!".E+ ^25YXOJ*/L+W)U1?T SY-E3J22KZ^TA!=I>>2!L/-=9FIA9)
M@I)D'9OHH1*VV, RGIQ2B%N-M:;,Q;K2E:"4!"J799)L.DN5'VJ6FD?L02YY
MZ^B,B:\6C4S%A7.H1I(2_BWI8#BTS)]UCZUHFX>6U:B35<%Y8&(XCY]D:"VF
M07\! Q4J,9()01[V<'&%*1F(%DC@9=G@"<R6;6P<&64B(PU3Q\F%L%+DQ[4G
MA 4PC='A."2V(XK.99'X-RS$9(YV KV83K/)#$.(.)!'.C46- D[3"*XT9K4
M D6.4]:.7#9Z4NJ41@8=^MI_WI]Z*ZKI\$Q/4R^?"3=HN_D6,@"(\4XUU'=1
M0;;B!'I:UJWM"NTVF57'1C57SH_!/;8QT@#$?S612&V)3S@U0[WJ*=;**U(?
ML0-50/8JDLAKJ8]#B:8:=O_9J8V%%K:DT+O3J;^)I:7*..@-)A9B" FO$&DH
MI&C/A 00_TQ6FT@\O"\A)T/^:!>D"+AH"?8J*<@V&*B:J;;/5?26*_@OV#$I
M;J.\Q6VXLL"U>JS.$BU1&T+LKRUU8<H?V@IB MVE/LEZ&NA+.C%_;%UZEK\I
MET$:!:HK]"5C"?@PX*E8\,#2!R,,$QB]J8'$!,HL_B\2#R0E$QWIA@0^*Z+=
M=-?!DFNEW<8LBM;7EG0RIMK,3A![%&X4!RNK T2?(=AQ$+ P7DPT#%Q[&C(;
M(/:9OZ"@ND D&@$Q0P(.#BT<-H34X_ $JDAQ=0]:I&$MFX5%Y@J':M)\@R(I
M(CKJG[G4+Z0I)^:U  \1DQ:+6$BG*O*_(0O^C@R^O]!E8-CKGZ#BH!CQ#(A+
M#N24_" 1XD#%"+I $!&PT8@_8NI0<EK&:5BTQ\=B4IML=^98R3JQ\7HC3"@F
M8]BMT:L \QD-01O90^XJB"Y(@2/GU2BJ,[(O>U^0:NLNLY2(;,RCM.QBP1G+
M$4N!N7_LMO^$8Q7!Z+\6FJ /J)(VZB*3U:YQ@L]AQ8%X4VN?8$L!4K;D^+$/
M:/",_2+,8*20$?X ;H4D:L",^5$7[9&B.<,45DV?TEE)B478Q(>V?!8SQV1X
MU? WI[>O-A$-\0VL.XLNS;HO"_[8BFX@:C5%VQ@"]>,.$M#,*6V*TWH7[<)C
M95*G&3X"OKDP^8:@.KMC]OJHCU-;2,,ADHH*7#?X?L/<1."B06&VU![B&TH@
MI]UHG- IZF?UKM8X2?^BL+^J6=5TQ/"A!?(Q]'\T]3-?(A].T;]L#L7EODD'
MLC12E\B&!7-TA)[0'HEP2)"@,,TS=-IH8?B )4>9GHE%318LC-&M!I:4+G1
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MBZ:=C@U#80@1?<@&0-X-65K8Y95PY!NW$<$"D(,B]4=]TG#?4V5H#C/C]T8
MT,BU8BL$7%JS-PF*:W3\+HC!VJLM"@,<D2/K=2>/7'\REYU 2]1%_' (D2OF
M@ZZ-Q]=@R@G/\ZF?S5\_D3?G"H3ZK+M,UEVSUVU'(YMB"WMZV%2>_6["V#/D
MD-,Y/IE*I>;6N.'93YH(QB-QY/PR6C7\=YQ7A7!6^N2*,D)UL+.1(HS:$HD8
M^&4@$G8&PHHF#'O(SC6,QB\SC4.,:K\U=B0PU+%M#=\&4 +XY!!7,=3M04GP
MP/*7T22(6\]U[.@"L1,FL<M%B]6<K69V>1YP6U-$OK51ZD=:4BTN [(RISSE
MJN(UCT3P3=80T< BE3!%RLPE]T7$-48^R8P(R8;=/A9]&!5/B!*TMDU-7YY-
M0NFX(4:J&>@<@P$*'C$\#!=<6[0#EV%(0;'YD/J+M;8'H2:H486X=]\(GQIK
MPE*#FY'QA##7 _A4"O.=P5%]5<=I=3RBRPQ;04>O/50+7@2?_E1-,LCP),(I
M<[[O&LKE+M=$7DP?5%7;:/B#L[X4%%P4P'#FK"[<  $5K@F/7IDG6W[Z!))>
MK9XDCD6O=L(3N@(=IGF6B46*QWYX%>W(XF)<0>:L>:"3OD$K0X4KCFN*G*?!
M/UC;DG\GH-!H,!3M\G3'B_$+NX!=++K+UR$;#]E6LP>4D':&*&8US#RV;I):
M"BJ73, V3JD+A7H7Q0%\RGJ 9TVX;11_B_?;O-GNVL9QG_GG2H39YIVVVAK!
M&9,F4;0E@U2..\JQ.R+\QMK-F-=JS'2Z^,HTWHLD!Q$)B0#$G(BZQ6]U,#:<
MI9,"/:SGX3RPHE[M1$PUYJ=G#CNZA0.\?CE-2UQ(8*LE(8=PDC!(;B61/)?\
M_0B]V#(!T=T"P9B9ZA-T;W4ZEO1B<9S,Y+7@_)SWO)D+:TKMQ$##R &&]O?>
MUA";A H8S#SV7?87?8KT\>Q<0ZQEV12^O"&6!WJJ.4+O@D)#R*.YZ>*\MK#Q
MY7VN>4VBA5)DH?-M+\=$2V4^A[FJ)'W,J@0VJX1?/QFW655 *ZCB%<"GW#4H
M]IE:8J2*Q,@T>MR-FTOJ]\6V!'=Y6[1,1=_V]X2+\%X6\0@-Z#0RC]&60E^+
M,4NG?K9^_61__<Q[@!%Z^&A%Q<[%X) ?NLV1S46J6G!E3S8%4QU%$&7C/-$9
MX,(U,ZUD!GCGWC;X80YXAH6JW4WVT\1%)PF& >9JJ0_Y"5<6U_6.I)?7#1:R
MV6L.]("+]I"3LBP1S)Z([1*"TX*C%S*\<1(X]&J&6@W/QWU]&LD>E]1*0X,L
M1O+;390$$"5I5!OA/V%U (%TK27A5L^ACM$3--%\!2EA(C ):.%HC4;5TC+)
M<++/^2_GW6)J,D'656?N7[ 8'T+A[BO$(2'>PX<8NIN7W+S:1TMN0HV.U)4@
M"HD+A11':4'"RZ;F#OUX#6U$A90+TK43SWM@"=BB]K_2O*K(:Q8/1DU9:B$3
MLR?*;<)QQ*L ; Q2I6](V(JWI,,0$+_ M'( 5/AJRM,$<AK@.]9 6#M+XO(S
M':\D9VI.P&T)$(*'"E=!UT<:/J<9L\!,A(1V,A<=]X&@LR!L+@S09UK&#%QK
MFQYADQ1<,.$C4PE+W9F6IVN5LVH.EI*D>NHG8F1$$Z@+' SP\%Y;5OS) 2R.
M2(*7BI,@F@EA8MX9R00X*^Z=(MG$#/()E:CP").DU@Y;>'*OJ4^,"(IW"7.N
M<7),V 6S\S,)ZTK"]PD&C\)B:[U2&T$S"1D9/ "X$_=VH?(!B"(;^S-YNBTZ
M<51P?83QP'-$0?0)G:H*BBCOL#KE#,,^4XV1@M:!(\4&%%!82&D["\5=CI#^
MH2TW)B\/>@*I%,*R<8Y<"#B!).XNQ7"6"5)=L@1!K673R 2?\M2X>&AJ*##D
M=WCK6(3V6-+-7"#1H>BQ">,- G%C)'W)*Z&"6#<*N3T7J:.7DC$H06XO&S[-
M&5^Q'ZJV"$Y"PD8;,XP),[4\:AJSPD'GCN$A UFP2@4H/"$;O&BB_,WF O.Y
ML#([0L7P+C?/65<SKU[&+/!QGG+V%)LI=@V:V<F -T%2[/,!C1P[0@\0D<)0
M1'?;>.J4X:V&E#;<=%"P@79ETMCF-C-$8OP&7>-&9;/Q,SYQY]K3SO)GWN_N
MM[UI"8\]1VPTNU#S)B.@!M:JUZPC"K4,#@('(T22&T$1C"ZJC6O>MM3V,0>*
M9.@G"-[[QHC7XDAXPH_%%U3\#DT:]6T:^7=>E)XJ5./&4_<+O[P1A/I,,2[Z
M@^5U)!;WRJ%[3)6P70!/PQ%/6 H2+-XA6?BVA0]@&8)*5COJ[=@SE-C9],!E
M'Q!QQ!5>\-'&W:V]9ZBN&HK=B=<A=]9U&-M.XG](N/@0FK$,(PK7 $,^'<=0
MB<_1 3< 7;8*QGP!9PV;BH)LIS[@61K(,;KLT#93CGVB71(28:+,FCCP8'1N
M[-_4!%*8H!#@O>B))X1N;;S'GGW7@ UL65L@_L9JE4G"7"UV>9%&1]:I@P],
M"Q/KT[8[@(>I=*%8+01&3-)3<DBY5:@GLH=L6_18)$@0;TYXU#=\%6W*U.+&
M+W5HFJ'&4 \N([</=V_A/CV!LOUF$GA&GA.)+ML.O7GQX#<;+R"7D^D:@/&4
MF+F:T+&SQK-PJ3C0Q:HC,RXK_&S+)+3[,X?X^A>=RW#8<!8C8#;81&=Z@8FW
MH(V<0?J>T6"'BR>P#6"8G:*;=@G,-3GL^GH[<QPW*T09?EE^DFF^VAT\]DW4
M5[%-CUP(.FNFG^QZ2E<[DN?23=C0I\U?KH.P?$>SQE''J4M\S 1J$4+/IK)
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M+N;^F@&RZZK2\?FPHP1W8I1](G]2=%7-DM:Q !'-TT0#GY#/FI#3KLIPV]D
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MSIP641[H:4 N@<1_T7ZAGP!'<Q-YKWFR] Q,S@>UX!C81O5'.,T.0+461CY
M6\B"U$<>9(5@4"7G25K";0#X[<8A.WBX@I6;:!NCTRA91;H-FO[1<;=$H,PA
MV%5F]OG1"+)2)<"1@[(9M)=9A7IHU3-& 8-_*8*%&NA)+;EI@3%>'+!2&0;9
MG(C/GLNY3#9U4F"1U!)ZZ<Y&*,%P&1 ;\IDT 645@$>,7A!=5UL2YA_+PU/0
M+:1J$%K!35L#(@"0MC">!2 LOF"@&1<TO/&0LOD,&$#F@PF*+)G7:;%[GBVD
M^!>VS3N!WHU'4-8Z\+N7(K_[O7D>1BA]DN+=&*%T&%/IN-1I;CD<_QU1I;H
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M^.6J__&=LF;-Z)6&1$>]X?:@$ZNJW\.>%W<&:PF2UA>,X?'N&LZD40;9Q\R
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M=EB&_>Z,Y7:+G2<%?EL#!AD;O%)1M8NAV$<\5-74@:@-)U49<0)R#,H?(VD
MO'"0G#B]RM\K5Q>%QXILFVQX@FPHG+C$A=Z0XI&[VIDPH,!VYVK'I75Q:5U,
MQYB.,1UC.L9TC.D8TS&FXX'1<??5=Y53JB0HDBA3=:DER9*@J-^^/"'>>[SW
M>._QWN.]QWL_UKU':WD<$-E7JZK;>X8+6@9D%LT1G,^P8O\58EM:IN66P__Y
MK[?JX^CN(]^FEU7/A1'O#Z5D;@Z)5@WE9\*8ZI%)\D&GG!VZ-&2"%,4=M#"D
M2CHS?+J][%YV@E3'A9J*7:MPY("XIQA=Q5O$7/,H->[.7N[>'AK-%8K>PF2>
M[%H%(@?$/%S4A6P1LQ!;+O4:?^X?7H;O:]2RA<I*:Y6$'! K52*H3XN8>Z97
MG:N7\]H#U^XL+5$+E5?6*N,^(%[)15%V%C&SW.>GW4*Z5KWJOP>I/ N57]8J
MR#X@?BGO9359Q SV=5Z?3,:M7D/E@Q24A>%51EI%%H[WF<T=GO<95X\=318U
MIF-,QYB.,1UC.L9TC.D8T_&[T#'JZC'7^KB4-3D1/NX/,DV6?*:!:S>ASD^I
M@B#)XB1)W9R63C<$G>9LT.DUP+V/.KD?[SW>>[SW>._QWN.]'^O>HS9^#O@@
MCK:DC0X%!R[$?,$Z&0W#.CXGIO%-R4P]7.69LZMTJ7:A-P^FF&T!:8Q/^._6
MG4[(T2&D$]A4,O5=BMF8*!'>YO#KMC)P+5GK#^_5*ON4#:V,;451( 3<B22$
M 8;(\-]'$MCH"O,BE@.VG&84YNE2;_5V5)B7._8*F7S4A7E1L]"UH+ZE+S-?
M:7G'A7FY8R^>B:(P+V+N$>ZK-P_5/,V<YR(MS,L=>S%Y*HK"O(B9I53^;-P_
M?=0?G^2("_,0J8Z<7^B]+,R+F,%>7A[3]W=UI2Q)1UF8%XK_P*7"\!_X:/V'
M: -[NQ;KU<)X_%$J-"YP&(^S%!5_*&&\^Z=4)95E+Z[+V7T+XW&6\N&WHGS"
M@)>,PW@^8;Q%8K"G]_7T^KU[DU=[X]9[Q-VH7.K8G4T^6-#K +DF-ZU*>4F6
M_PQW%/3B4L?N?>96"7H=( NUOMXJ15Z52EEFMT$OCCYVQS07..AU,-S3'H@Y
M-5>J/=;$*(->''WLG<O994&O U0UEX^-,OM0+<MB-^J@%WWLN9E,Z$&O V2P
M5+G:*HN3%*]W#CGHM66_DPX#"REBOS,.>LT/>G%'J= *@8->K*6HN$,)>@F=
MEXN+>^E&:2T=8QIUT(NUE ^W%>431BL\E_L^0&SEH$&O16*PI_?UV_EU6^25
M9_8JT(#2, U"YMB=33I8T.L N>8Q^Y'/W%\_%VYV%/-BCMWY7 F![0 YZ(/)
M]:3K#VW4HW<<\V*.W2]E \>\#H9[I/9EN3$L7[REY$AC7LRQYVF893&O U0U
M=U?OYZ6W[IA_CSSFQ1Q[:H8)/>9U@ RF9:0B*ST]"LWW0XYY;=GM9,-HF8K8
M[=PHYA44@6W?I'MO^F?CO<=[C_<>[SW>>[SW8]U[M%FU8 !9/WY?(G-3IVY$
M65:5& ,KYOMX[_'>X[W'>X_W'N]]G^V; R+[T2)>%8\!\0H;P,3^-:.\[R_E
M8?GK]IF]WKLNN0U:=&<VZ@G:AM&=^YT:Y-@H<:YFN71;*8[&FW3.-%KY/Q>9
MXX*X6L;_832(?B=TJWQTZ%;1<;_2.V^V4BU%S&9V5._$'GOA 1LUL%5TW"-\
M#L6/@3889EL[+G5BC[T<@8X TRHZQCEO3:_*J7&FE:8CK7+BCKTPMQ@%G%5T
M?%(<O-W6*DS_*1-U?1-W[&6X_%X"647'6KQVWGM6KJ3V6?J02YNVYR!P83@(
M,7S5WL3DCA.^*G4,\%4^,;DGJ<NDT@_L&;UW,;D-.HB7J9P#;![>*??GH@2M
MBNYN[HP8NMM4+^EAY'A5W+$[DJ7H\*JB8YCVU\L=,[W*BA_"CL)8_+%[EBNU
M[1T6]SRTKBXOA52S5^CL.(S%'[O768P I2HZQGGKI"\UI?7V,&E&&L;BC[VQ
MDXL"H"HZ/OFXJK_PQ8]&Y5Z,.H[%'WMZI;"7V%01YJ\G?.LA<UYYS'Y76*HE
M3B4?!BA,C$BU-W&LXT2DJAP#(I5/'.N3N2]>I<56;B#M6QQK@Z[@)2HG'<H,
M13[)<,SWB&,%!E\/HX<^NKNY-QS=/*O3SX<N$W4<*WWLGF0N.@BJZ!BF4!*E
M0J;R?OG2V5$<*WWLKF4A:OBIZ+CGAA[F6L.[/^>LM.,X5OK8O<XHD*>B8YQ)
M?I1E&O1S19$BC6.ECSW9DHD"="HZ/E'%YE/ESU/_^L];U'&LS+'G5\+'6#\L
MWKJ7_^CTD]8>ENE#CF-MSZG,A-*P%*U3N5$<*T:9.CQ]%N\]WGN\]WCO\=[C
MO1\A"D-0E*GZ4!R+"G4C*<-I>"A3V1AE*N;[>._QWN.]QWN/]_XM]AY7 GTW
ME*G%,[D.!&6*&,#8_C4#O%>Y=+%QK7%7#[U]JP3:H(EV9J.>H&T83;29S/>9
M2!>XHRV,;O-9+MU6=N,/>W<VT#YZ'^W6<:%,+>/_,#HZOQ/*5#HZE*GHN+]:
M?GY,7;:TN[/W'94U98Z]TH"/&F4J.N[IC(6\>%X:75^QVRIK\E6E@V%7[/RS
MD)H1:]-L&'7%/)?,Y-+?0YMF(D#-BDX0AMKXZ:Y5EUMZM.V&V6.O)2Y$@9H5
M'9]PCYW[4N^Z,-:XJ,NTLL=>/ES<2]BLZ'BK]_:@OWW47QH2=\AE6EN\H\/P
M>&@^DV0BO*3C*.-WP\U:W'%U(+A9/E'&<KWV7J#3Y?O)O@49-^AP7J9R#K##
M>:?,OQ@T+F38K.CNYN:D)HUJS<;H0HRZW3!W[.7Y?'2P6=$Q#//8_^I^O'/9
M]^R.XG*Y8W<MBU'#9D7'/3?=W.2B>U6\+'0/(BZWO0LX%T:6CZ;9),UGMWL#
M_^1_[5XFF A P*(3@S-V/"V.SF[5KVB;)W/'WF/+1 $"%AV?\#F-SJ9*YZEN
M.^JH7.[8LU^5O00!BXZW^F=7-Y=GDOC!]PXY*K>U&YI/A9$YH[D(;N@X*A<H
M*G><*&#!HW)[C +F$Y5[_.2X8NF<;U]F]BTLMT'#]C*=$T;#-L<G,_PW"<NE
MHT0!B^YR_I0FCUQYT)2U9L1A.3YU[.G8@.5RA\4P=TV]=5?*W3QG>KL)R_&I
M8_<MTU&C@$7'/?<O0SU-,U.IO..AC'SJV-W.X$,9#X%QKNKIJBA<7G?*Z2@#
M63Q][+FCI8&LPU(P\OWTL55NJXK$1AS(XNEC3Q>5]A(%+,)@^E/^22EW2KHD
M'W(@:WM.)1U&JBEBIW*C.%:, G9X^BS>>[SW>._QWN.]QWL_0I2,8"A@?DN^
M% 7EI-C3)&3J#7HB51.1_=66E"1U<UHZ#0\I+!,CA<6R$>\]WGN\]WCO\=Z_
MQ=ZCMH$.^"!B[+!]Q@X#(]FVD4T3^:9DY1\ZY]U<[8JM?7#[5DRT05OQXEU[
M@L!A]!A_IX8_/DI4L27\NZW42?&S,&T4T@VQ=V008RM)1ABML-\);XR-#F]L
M1W+QII:Z]W1!NGJ6=E1-Q1Q[@0,=-?C8CECIXRKWP7 OSV\*?Q =CQ$I72:,
M0N?O!$O&10!+MB,1F3Q<:*F/I^95[SW2(C+FV"N=\U%@E.V(:<:Y!XXYO[\0
M6KVH*\J88Z]TWD_ LATQ6B,WN%4?1Z/*+7/(Y651W>MA.%-T*A?IQ1YM&'37
M<KY:T/,XH<P6MXT=")39LJ!G]6O<Y<;]ZX\79M^"GAMT;:^BC=@P6KB_4]!S
M<3-QR"AG.[K0;V\G+P56&A?NZ*A[*]EOT(L0%>39CKBGK#_))74HE?/M'84&
MV6-W6U=JM#Q@5KJY?%$_I7%OVJ0/(C08U:4=1J8RET[F<EL>6K\7P&C9"(#1
M=B0?DD)??YWGGQYNWR*-"[+'WH-<C (E;4=,\SCLZ!?E3EZ3TE''!;ECS]F5
M]Q(R;5?::<1D;\<%];SZ?LAQP8@N=2Z,?!_-1'"KQW'!0''!XP138X\!3&U9
M7###G\NCV_/6J"&&$A<,>CT>N]]:B!*+;$>WWL7YQUV/S5[KM<B!R;AC3[O2
MT0&3[8A[SOOEAV[I=C@MB#L*GG''[MNQ4:.4[:IT^:K_F+MM*)G/K=75!60I
M_MC=/C8"R+(=<5&[\L4^I=J=VR(;:8B)/_9$T-+QF >L>O*W+P6T'%X8OD<=
M8N*/W8;.[R68V8X8+:<WF(NO[&-&SH868@K*:!$8VQN%5V*,K\,3\WCO\=[C
MO<=[C_<>[_TH\2WP+];!^$+&H*10]:'8;$I*ET![4=5>*8;WBL4BWGN\]WCO
M\=[CO<=[WV_SYX /XFCAO5)' >^%[6/3/+XI(<O8FD?__%@?3;+"]7MNWYK<
M-FFYG;=A=U4='T:W[7?J;\M'"NHUEVNWUIST,9TV*A_CSG-XU3G[@><53![2
M8?1[?B<HKW*$4%Z12T.E=#E]/!,K67I7U4;I8T_S!V[5&RBLPAXP+UV4"_G2
MM=XHM','T:L7@:X-8ZI4FDMFTM]$UP:?_'A(@B%_W#V.+NMO/9:+M((J?>S5
MP$N;] Y3D8Z']::B-\Z>GN2HBZ?2WZ#V=Q]QNR+G,;&MZ<*GHMY=<X?<FK?]
M.SP3AK]$T[E(+_%HHYJ[EN[58IC'B=85/(:YSVA=\V.8G?3Y5;IV?OU4ZNU;
M#'.3]N" .BB,SN#O%,.L1(K1%?GEG6>R&2[W+MX6WJ/N,,Q\@^KZR."Y(F<<
MIO912)?HM,:Q.PKW98[=)V56#_<=)B]-VNWAM*1/2E/I(,)]$5S3H0#[,G02
M<<0W@.7*1P'+%;E8E&XSN8?FAT)'&NK+'GN#;382/*[(N:7//+SEJUJMI76B
M#O5ECSWQQNPG%%?D/';[+/;SD^O;#GW(D;[M7]_9,+)U-!_!]1U'^@)%^HX3
M?RLX+O\^XV_-C_1-WL67QN2\6RV'4ZT8]#H\=L=T,6Y;V-!;D=]R^M-3ORL_
MGI\UN*AC8MEC3YH&C(D=)N-T"XSR(#;E<E7844PL=^S.6VGUF-AA\E+K_N5\
M4)):<H/=,>)6[MB].SX*Q*W(&>BCDM:?A[7R'=N+-'Z4._:T#AL)V%;D_#*L
M3"]RDW'UJ_,6=?PH=^P&\Y[B;$7.8_?3N^*C]"*)GYFH(;9R$5C6&T50@D%L
M[9JG]Z;;-MY[O/=X[_'>X[W'>S_6O4>;D0D&J/7C][6DM 7J2IU*K??P$+-R
M,6)6S/?QWN.]QWN/]Q[O_5OL/:XX^6[X6)ECP,?"!C"Q?\W ICK61HU)O7/1
MCK#0))TZ]FPO$R6 U.RQ;BL,_OXFUM.3YL.'U(ZXP 11Y\A9AHL.8RDZAGE2
MWJ5<3V+XR^QN"DO2J6//ZF9V@ZT4'0\5[JI/%^V&>LV)NRTH2:>./=V;B0![
M*#K&^;K_.+OM?;PS(SG*0I)TZMAK(=-18 Y%QR>5!_7RHWE.\W_$B M(TO2Q
M&\+\7F(-1<=;W?OQS>3NMJ57Q8@+1])T!!9S' CY;B [P0,A>PRRXQ,(>5'H
MF^D?_BF;CC020A^[>\)'"4,3G5XO/@W;T^O/V[,:$W4DA#YV+X2)#GXF.H8I
MU]26KK_H&6E'+39I^MC=DC5:; Z+A_+GE7M1O$B=EW;<6I-FOI??LAU@EN@8
MY_:QU!FU^J.>EHXT$L(<>] ^%04D2W1\\IAZ:F<&]V]/DW34D1#FV WA[%Y"
ML43'6QF]V6?N]>IY+NHI]6EFWZ?4'WDDY#A!2!9[M@<"0N(3"1FWF]VW+_XQ
M\Y39-YAAU@) XE8%0)K9J OX*,V$@5O(,3&\\%:@5**[I5IG GN??N]^Z.&-
M1@MX2[''[E,5HX-0B8YAJN=BJO7PHGT5NCN*Z[#'[F3M"#HE.AZB&]+Y6T.Y
M%*2MP0@'Y:5C]\+2$4"F1,<X?P3V9308W ['F4CC.NRQIR"6QG4.2\'H?ZKW
M+>7ZZL9AU404UV&//>M0V$N(E.AX2\M=GG,ON6FQPQ\RMN[V7$LNC.E9$;N6
M&T6S8D"8?==>\=[CO<=[C_<>[SW>^Q$V3 <%A+D1M'>J+O55)8:#B;D^WGN\
M]WCO\=[CO<=[WV?KYH#(?K1P,,5C@(,!\Q=;OV8HEU6Y\9"IG]-<. /& Z8(
MN&-/8--1HL%X3W5KLV\9J=6_O>O<IUM15\IPQYZE3D6'!1,5N]2?%%XJ7[/5
M=GI'=3+<L2>M*[M!@HF*@P9/!5F;Y+C1Y_N.JV2X8\]ILQ'@P$3%-OERYUS1
MZY<YQSRJ*&ID^&,OYRQ'@0(3%9>4KSX?BZ/;MSHC1%TAPQ^[^5O92PR8J#CK
M,=T36ITS65/34?<]\1'8R7'LX[LAP"P>HGL@"# SL8_J]$MZ;+;YM_%;E+$/
M_MB=DER4^"]1Z?2G48;-9G/IF\O(<7#Y8_<]TM&AOT3%+@_U\\%SFTDA*V!'
ML8_TL3LCW&ZP7Z+B(+;+U\7[C\MF);OCV$?ZV+T5)@+DE\AB'X\TG>]HGY\,
M'6GL(WWL 7H^"MR7J+A$2)UK=\^3ROTS&W7L(WWLYB^SEZ@OD=G)M6G^MM$=
M7;Y'CGZ;WO>QR4<>^SA.S)?%J!<'@ODR$_O("6^-I\FC_!(2]NU^(+YXMNEN
MRLN$T93'\TG^N^"]9*/$>XGJ?F*:]2EW+S[)HAQU'"=S['Y4/CJTEZC8)=NZ
M;)7X_LM5G]U1'"=S[([5&M.,#HF#FO)$>#@3IM)@UW&<S+%[7KD(D%ZB8ILW
M7G]KGG,?]5(KTCA.YMB3#9'@O$3%)3?/Z<[3\.Z=>6]''<?)'GM^@=U+E)?(
MBG=ORFQ+Y3M7.O=-,5X6.I-9]O"<R8UB5S'"R[YKKGCO\=[CO<=[C_<>[_T(
M>Z"#(KS45&2L#:DS6=#UOA##O,2L'^\]WGN\]WCO\=[CO>^UB7- 9#]:F)?T
M,<"\$!O8-('-D.[]I-Y^3'&9AM2*LM\I>^P)[,#SKB/BF&GC\JDWTFX&U53D
MDZJSQYYC#CC1*(QV95\IWEJ^IZ/GWMJ%7D^3=E3HDCWVS/..P%HB9:/GR@L[
MZ O:$\/ON-HE=^SYZ4($B"V1\LZ?Y\;U2[_[H/>C+7G)'7M=9B4*V)9(647[
M^B.EG]-W4D&.NNXE=^SF;'HOL5LB92_^L_GY>?_.%]XC!W#)Q8.K=QK5.$X
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M_GDXK7<2V(0V!>Y4*C:*#@J.S:?2N<QA%,C2"6I!FY&$S^OV149K?_2.XVA
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M.C7?OCDV6*.3K4:7Z S+-TDO0>8CSPWN,:,-LF>WYZA]GLU)^YP;C,NJ1U'
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MGZ+!M78MX17!*K'%^B>*:QI")G\X,S=##YW=1TFX?;!>Y(_3TW1]\_FN/'L
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MSJV,X:DM 9+K"&EP6$5FNH#NMCI(,>!?PP'P:_%)_0>-/@Z4,VP'P_A3.'P
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MWD3-5S@6H\G4B(*8XEEZTV_)Z('N9]VH LDN3M:P/WF:JHF!#+DPN1KQ;U;
M7=<T5;.<"J'IWI"8RL8P3Y^F:O8_?*&P4]@I[!3V0X ].%43V5:3LC;4'Q0\
MY5WQ\C0MFSM7\J?L=:NSVWD:?';&/?S!)FEF"#CIV6=9FJ%9+T/S%8(YFI[9
M8L1 U[IN3G4(-#>S=1J(-#&S.>5!<[MA,17#'AJ:F-G_8(7"3F&GL%/8#P'V
MX,1,9-M5GFUC<*58BN:/":R<WY0_A[ECQ.YV6@:?G"%'/]BDS!3QIGSZ'$W)
MK)>268S>/$W(;"]2R-&5Z!M2&SF6IF.V3 &.)F,VISAH)C<LIH08DS%_6U)=
M1;^/CO[M>8_O2D9+@2_!4YCTS(.GX)B+8O?X/7@T_(=%%GTV5%M&O^%-GC_-
M\9G7X<5+L9/CV OMEOL6S1G^K<.;Z[_'#D%DU3O HO,47X?<Q1U[(UP@JS-U
MG!^6WB-'^L6X/W#\<?=G"RG00*"DC!%Z9H\T>:;_\^,'<Z(@5?Z'J8(7]8NI
MH7<;:0WR</87\R"I-OP]P_SXX?*'K'R,P<&]#F]$(V/TSVY.,XH/2%TW9&3X
MYRZJ$$@P B#9U%5%]N$B@&8" ,T0]!*> 9!4M2?)LJ*U_O=;^AOY-V9*[]^3
MKX0X195Z)IS9^]LOIJ_(5AL#E/YO$(WG)PKA?$$,/BXCSJ-Y_K^3?#_[">&_
MP90Z^3%.! _]OYB[00^.6#"DNM+XQ5R#O7!(=*UC6@C<^+?^]KZ&?S7O /Q_
MOXINB;1ZHOKOWT#I0)J77H<E8UAB16-P]H==3'-V1/.Z@:3.CSH"IQI Z1%N
M"\<'X55&_7?ALGI68$J5J^K]71G^O*TZ(MI;YC'+?;K^^UJWD G<PI1TC4"+
MPW$@CB9I#452F9H%/^@"P<T5#O.5"OI^_[/VDSG&W&Z8?\THI!$5QQD&<Y+#
M+(NT0V^2ZIUN]2PG9>_>Z_7P&M33D5]IHO%W":_#C_;U^<5GMMAJJ,N\R^/F
M9=^8?QT^/+=>I(+(IL_D9=YX70$^X]B?S&WYLG!7/F:JA=N[9^;NMG!=*Y3N
MSBO7->9?Y?=W8 WK?_XO&*#L+QFHI*R %B"!U,@7ZI>/!:N<BPPMR[.Z]Z E
MOSMY"OCR4@I^D1:?U"1S3.>W+\I"\-W9=);[UO1/4=&^_3W_UQS^_>_O[%\3
MKM3O\F<# 4(DDS&1A?,)5INI(U7OIY@/9$* T&+T)B.I*J.3*,!D%/BH77]#
M#0LK%!QT*)H-VL1$Q@=$:/A1H ]0MZ?J X12C*P8\%G=@)_*?\,?\ W35BU)
ML_"3"VJO+9'3X/]*>K=G6XC!G\9O,159D8P!HVN,U89']WHJ( 33Q#L<UF0_
MF8J&X.PV/CP\$W_4.RW^'!P.'MA7  C\3^]I3<6 ?TB:I@"B3?(:\EW_-/C9
M^&<MG+A*X?.3[QFH*RD:?GE=4B5LU$*\4]$8/L. %01MVP6<M=4!_,RT +-$
M[^('@/UI@LG]N9QGZOSOSRS0-X"K1WY6(MF9FV+GBL8<HP:):1E63#$0^0HI
MYLKXR5251@=9%M/'_-GKZ8J&:83_,>)0EXZ8"_&U2$QP8"JFU%90DRE_HH9M
M :\PE683&-U@; W\"?B^S]$-^$[+0,22^ER$GX)E ]X&3&#:C3;3D#"Z<2X<
MWF?H=JL]=NH\.36<O0V29B 3<$6B;I?5[]K('+%:'YB&D?H2>#8R%L=Q2$&8
MR3-<P31')QH'.H3P*-TN CFTD$HDD8@#.4V03'C<;N'-!R[#@XSA/R+E]X-D
M=WZ*W8^!?(^2"D@T/1X#XB[B64RP^1P_RXV"(T/ 5;9AVICPP&7X*_#.KHF_
M#RSF<Y:C]3&!1X*0(M;#UEQF,G':>61,QEC+4YNND#CLONBU$\\:O=!,^>?!
MWPA\+_X[<A*+A$FPK%A]G1D@\%&9IJ%WX;OP!G((RI]A^5.85<<U<"\<7N+3
MOCXV@;"2T9E5QB/6'04GXZPKHYYDX,^.<RUHFPIP,WX'UIP!&LUGB,6:#3^4
M:K>M<8\XQ3W8F-7:4C]0M<WRAZ>\9CEN134RICY\!EI:C8QT&66$L(R0F6*$
M.^S[UW4P8PZL;FAH,D)*%-/,;>W>])P?9^V2(\6.,?DC@7B"<\_RA!G8%'CE
MH!BD,4EG/G 6$;/#?]A4!OQ&3@3.Z;<5()UOE2:,RMAWZ[9%^& \* *<@,+
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MB@6@J*]J;2"OL1,7#8+0AX<M><:/^;=N_.W>'ZF'C&1W&3#WQL0N@N)%1J%
M(2\F+P]_"VB<KO[HQ]6>,V*(L)>*]H<I@FLAA:^OTHR-YMGG^S3J"(Q#ZFBG
M8%(P]P[,8%V5&=5M"XT&:!;+K$H#'((4-!E^8MA('E-6$Z7;SS/^<M#N]+2F
M'/GU#&&59F8'9@\.L",$$&>OCP/*EQIK7WJ]V<#![>O7><,P022E7IZ/H(0B
MI%AAIZ]NQ-5:&\P.:Y08>.&0.Y7#HW,3HK1L-9(7(^F:8-.'U^ ?O=PL7YJ+
MN"=]K!/K3M=<YKO3:\BR5%2UK5L,D%EVUI8@><*BOW_<\MVGYGVYV]JA;O6[
MRK5ORRT=+V,%2)B>;3G$,;T=+#A4/>@N$3Z"[DC:D[-(IX>1J##NT=<EBRD5
MGX]$Q0O<JBTGR6D>"BE+0IIVH7R!H>4OLT5AW])CG<:N['D.U6#"F-U<WMX\
MUP8W4H[=>F>Q9ZO\^'.05.49EGEVKZ%Q'[&]J!-R6C@V89>$*!HALQ!Z4+L4
M5G!H=^17&(JM.W+!0)M'R<"+]8(LTPY%5NXIJ57R6(<&4!NS2J-9%].RL1'#
M%$G E.>H60HG.>+AADM1<+NX'K>+$=V;$U?E]Q7L)3N*XRZ19"(?027GKF5!
MDZ]US;UX.1'8O9VT.YJ0LTX;RK8#.W+RD?ED?HQNBFHRH_GG3ZJF#ZL=:+2W
MX6CO:Q':A)45HPC_6#Y'K6Q(.:+!WU<8BO]J7(BEZ,VKY\N+$ZFLJLV5EJ(O
MN1MZ:@WT_W/&G#,&:N(=RI8^MKC1&6A K-58:XRS&KDQVH?<!,5PY&R2'BW3
M)I^"7[HC$L8W L%W\$J@)1<BSSG^_R--EQL[/MYLZ:_\QJLK]1YR>B776^@<
MS5++@K>8T=LV/KV$TU#,#AY9098U BH 8 MO[9:<=;1'P2O1\?9M0*B*&GA+
M;1VI>C_*[=4+5TKS7Z^4SK\.^4;Z."^]5Q^+.;I2VE,^LY^(>*6TL+V5TMG7
MX?T=VU*R9O;ALAZZHYNNE-[KE=+IU^$@U[FX'79S(JN$MHYP0(_#EEV_7'X=
M7JE:^KI1?7CBI67>>.UME@Z_#G?.YNAESUQX'1;5&G?_;LAG=_P*/D2XE='!
M8 ,,.#!@' ,*9FC$@><CDS(.6,0F,Z2C<+=P1?4<5P$;0N*ZX-8-#!P>ZGX4
M--T]A7T'=XJ(\QQ%^T"FY1A4<"3P9YUGPN_@@1\@G0S\DOPPY6<&9*6E6&,'
MLHA[XF WA3T1=SJEF3J20K8RI\""3"0B4N23_>GT?B3^V$8(QC14P(?25-Q5
MX\T)AH.? '06 &,Z :*)L0"&@:PJUX^LB=WE8]]M>S>&F;I$Z.NX>U(7HY7X
M>G43&82D0,&>#:BV\>= YSH/P)\>^4V+UY5_Q=Q+^1V+G(M) Y<.,'#DY8MO
M,\)WYW;?<^F?&>Q]_CVW63'SD_=VKN?XR;CJ-[FWS; ,$4+6=?8<2?.I8&N2
M_&:;V)Z]VSK^ P2F@3_U(2FJ2P\&$QN""0"N@T4%3#SH1"Q1C9'\P,\FY-ET
M&<:_KF:@'FZ@!<; ]O/GG"B.TC0$3;F%-'4$*(5C/S S&.$N:8%NH(I\$F,R
M@LKMZK*KO"REBUQYPVKK0X?@Q<FG-H$#= ,^TF\KC;9/T@:X+G6(VNPZJ$M@
M!TE5!ZXHXZ/@QQN&7L=7WA!6TT2,'2[J@?^(?C)5YRCP*P\R# I22"@K*Z#I
M+?Q(X#=M]*^1KB!<YA\'/YUR661<QB_D,I>)=$?%DS@=C$NCK2GO-C$>8%#Q
M%S3=&GUIC'0.&V J23_!?QE9<.()>%9(]HD+I/:.%11*1TSIM>PI7M!FFEX:
M@^0U@&  #LA+@QA2"3P)3$P;G'I'7K&IFS*X7? E;(,$%D<&=FIP7N'-EEM=
MK[#1E0:,U&R"6)#O$IDBOQQ+J019X0WD4W DN R.KB0-8A1RV+9D$B-B$HN/
M^6;RW*;G#@8N^TD=.7FO::=PUF?K]0S]4^EB;Q"^ 4]O@%\VP*K"\4-,!JC1
M0J!A9!MY]##;H$Y^0"C?!6Q;MN%8-]\7&LOE[$"2ZF["_^HBJZW++C9,T^[V
M')>MCT#"//<*Q&X,)4=C6%_2R9HZ$"B@K!@8(:XK7?# D;K E@.[KD@&X<)O
M^(>Y"W);QV($!_3ZX*@[8D'%'.FHKJU:2L]A(TD=F HA=\^NJTH#> .\7QG)
M)%:1#,<>$-?9=7K&4H/XJ3T#_3! ;6DXII!4'<A"DJ+^F;T(Z:BMJ]BBF)Z9
MG(Z@B)>-\X]F6\**X+NG#1US_Q?SW42(P:D*P%V*J&XN_6L.ILAOV5]_K1>(
M;)3&N%>W0CB6N1RU1040&+#L,;$,M"7R[*2G?M0:@%5D'H&+ ZAR0D4PUX8E
MX3^!X.#12,P5KL<Q)<E0=5#40'['F'D(GL LYV,6GX\T=HZ.1]Z ;\FX=Q.B
MP?(()9'C>.RL@:C%[ALR>[HFFYX^'!E[5[#@&4=ZWU$FC@-F]I 3+S@R!W[C
M9-0WR;@,'(IXIU)=A^]L%]<;Y6BORR^ G6L(#Z9@BHS[&>R,CWY<\G^,H291
M-I?F>(("7#QFJK[A+[3P__H?=T( )WS608&U".E2GH[!BLER_)$36Y,E_ CP
MJNY& 7X*ZS09@<<U<N"=4QV%.BP3_K I$I",ZT_WGZ;= $_3A'^1),X <UK/
M!C\&F(H@H^^]L&GH7?(5K$S!)W!="5DQ&P8:9UKO]]@R.I^94!A>$F@6=B^5
M([4,Y*1\?S(%\TC"; ]V(\6,&96&[F#?<6H(TO&X#\< G)_<UIB\DZ(".](R
MI%[;9#,%\A,V4\0G/2_4&!ZD !#0'@'95U051UVN@^/$=?BHOEM\-!Z(NT+7
M&$]=3Y391MYT3S<5@B5R0O*MR=H=,U.[4Q8]_6BBB#<^QGVB1JGJ)F"QYLL]
MZ\O]C,2X4DX@;MJ&&R6:#1NB!5W;P;3:4G:*66"GCI:S4U_C<%E-N;#..)XC
M9U^'3_W.W;VF_#FK">'S^E\FXA<6,X6OBYFYUZ'^6.C>?5R>5?@W6LR,K9@I
M;J^867@==OLWW,O;<^8\*]-BYF$4,T$%%=_>2@](OCX;O*U?IEOP*E JZ>>;
M8[-ZP9YJ2VB[;58Q,Z]#]6J0S>?NRIU:V,KK5]9RQ<KF M/I)S(L)ZL#+H.)
M?9:@Z-@I0HSGO-WRWI%7WIOPEDA- Q>N2$+.<<BPLY7SK"9@^AQ\8:VE8+5>
M<-?-*+\]!^2[5US!QCK  &=]^WOLGL-YAF=\G<)@,VB"VRAUZB8 Y<G:)/.=
M.%VZ;<(CS+_6JH4Y3#+JF)OH33T!;]KIB1=^I%E+'_6I?@-/IB'UX&668:/)
M7M2,^&VR(W8$V94+C]_>>HMP,1:H591,Q;PC]_GA[455;W1"VU2_PR_/C;6R
MK_A6K[?]X=(X>^F<G?RYY;YYG5_D-?\PQ^!OJJ3+B_FQA.Q^/T;@SJDFP_ZU
MC_/Y/>7N8[M8?!V6T^CY2K.*9VBD9,$=[ZG2X!_<=0_O!M<6R;9*\G!C3.ZG
M]>?P./BU.*9R"87S!XKIFXI=Z2I?/$T['3Q:_AP4EV)@ SLVA])1#I/CM(E6
M8;W!V:QQ>9VY*PAG9PO&F(?K7T]\M_]BNI2BH OGT85[?[X2+JOW$#I3NJQ%
MESG[,I:C"^_1Y5A\RKSG[PO=Q_P>TV430R]'&!>"Y_VOJ*&*JLQG.IV'EBG,
MQWC"!HA.:95U<>EK%1W=W;:;T@GWASU 7):CP*6O":[$FVZOS%ELL[X=7/Z[
MS[L,N/ SO9=5A@G<_,"R&\=6S*L?XH$HZMT/6R#]YN7$33DD$"8N@3#Q"82)
M\MY^P,0OITYW;Z$%3HY.WL_8EE=Z(,XW!9."2<&D8"Z>%70\*K"X92TW_+9&
M$TMT[5)YMQ7Y53E_'5;N:WF]5+QZTSJ1KR8A70JK&9KCA5?_<%>A2F (1.2^
MK"9997-+B DW7Q(^S(";\<SA5/DP&\4H&VZGMY$DAT]"3H/)+#_/D5(F'LKD
M]X0R*Y,A"IRO@>#L\@,9$[37)7)L+C_KGF)S/C:Y^+ 9[%"FPSF4>J.#/(=2
M>JB]M)075%_!H=S4_.80_B0!87=*\5L9/YD5Z/C)&+$=P9!"BNU50R$B[Z%#
M(3XH%,IF(@B%N!2?"1D,;9KZNS^U,INE<SV_P% $D_D3CJ'E(ZH5/:E8IYGL
M5:ORKEFDQ>U.F4@;A1^J=^>Y_J5>N\[N<>/C+M"E'&FC</I-O"JU]+[>VN>&
MU%V@2R'21F%T 1^_:9VT;_:Y@7NS#9F92!N%7X:GO<]N(=_,+Y"$A-7PIK@W
MLD;ADM(HM 8O%>4^<X"XC*3IVM<$PXY5&;851>OQM%&8-@IO%%NT47@W&H6#
M7T2;A_<(IN0V<"8+)LI[^P'3WC</CUTS/Z26/0HF!9."2<'<(IC!31XGHR:/
M.UUSYW7>Z35D62JJVA:9[&F6/Y'1P,L_2)]'*]M%G5I!RMFK[.G>6.,P;N7P
MYDE;.F,2$!@\OIN@TF20!P5M/%Q<)LM%V\FU;CJ54F9$F6B[PBAEUNHQ":,Q
MUVLSR?&1+*T6<&YF=WON][5',[=\SQSM>)V/S>5[XB@VYV-S^26_$?</%T:N
MI:<6_3G'Q(\4SM0/R>**<I'=H7[AJN<PCE;"[4[Q?2O-JKD(^LHB+JDG&=L1
M]*A1;"]RVV:TT7H^6CX=@8^63;'ID#[:IJF]^VV<^>7CTYU*"<6 H>7CQ$/#
M$!]7*_#TI:JQ9AAW_\.$6^0..;;0^:V%M >YE(\NR;::ZGB<7I&;5)L1EG7H
MY9TXL;U\($.Q'=(?\E71/].::$V7*))!$7F..D0A983>_/D*0YN^^;.[&(I"
M\L60DL^GHPB&V%1>7%7V5[Z>-=MT$Y &"[$9^A?C^F"W2/[VVU_E\??$+H_Q
MG2^Y@O ZO+RW^'*E^Y[-HV7VU'BP+;L'D7RY9"!9P<L;S4Z*<>8#X0U^SK^]
M:_.D-=O]&9[\=Z(;H%@UIF0;!M(:SL=7.<#$=;=(-NQ6;"-P_;2SMAI]]G1W
MKZZWO6WT80. ,/\YB@XCFU@X'$S%?Y5Q0HXO'8IIP;8K,V^@&I3F8(HR[LX@
M]X08S7C7'ME%BO^.%X_H)ED1I ,A\ H@LO!'8IR-0 9>Q>UO$CH">KD;1H&*
MH+V:>-VBXNR1=E8F^GLTS9]D>6=C\L6291E*W;:\)H$/R5!TVPQF&[)CTME_
M6D>JWA]_XI'W1%7I*M9HPZJ_MMI9E0(/,%!310UKM(]Q>CU2\'Y&,WC]8RQ\
MM01AL1J9M_W['P9SXMQ?'Y%-DXJ)G-^ :6J3G9_X_]V=W\Z26@=U3A,BP:UE
MD,4TSI[9KJZA@;>QOFF3=;C>DB;XG*RH XQB$CN[5)>8CJ;W-?<U1]X&<W>S
MIH$0?JC5QGN=P8:8[NY23""RC[4!,+C+.,EA#;P&M?Y&-KW#PS7,0XJW4][R
M&=W9UXE!(;R!=Y/B'_L7)X[(!E9W%:N8FL$7TY=,QL.9[&R&G0#>7:/EP#&V
M$)V  #C1F'P:H!B,[6+U8/)6MOYD,+F.@LA%X&PC5?:>_T9V=8&,:D3@@$DG
MI4BQ[-%N4;P-E&SLFY5]$**NHF&W(%:E.:G>=U1OC@XYHSH)DX]OY"6[9\$
M.8KS2%::P("V"M\%EC.!1F:32,^(2F/:TEV//@!-!RP&C($9]"YHF5NO9^@2
M<"RP.MFGBQ^I^L=4R/I"I.&]45A_'C4ELO\6])>)Q2_EG%NQG..VI0\L//BD
M"B(I)N]!^/$(642[CR]@Z[>1AD^7<A0"SH&U04F#Q^E,)@;M#>Q.EL!KLN+
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MK;9BR#](AA?8W?C +C \XP/(;)CCDB(Q/C382@)38(IC*)TSDN-#2&]#F&\
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MNQJX#N&BCG#[P"VXNZ@@J4X_>3=6E2!4G_8$07K&"IU@1DBBDL0B?KT ^W'
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MA^&XUR&O9Q\>N9N\:K2^_:Z53W$BE;DM5RNW=^?7IWYZ>:6FS' =G0?&TI&
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MC:K$;"J77[63:SF[E9YGM\@]=\=RU>1K]D'.\!<G[5T*L&:-F#/+A)JQ<<U
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MV6^SO+:. EF^TWJSP!\ ;38F]&NDA[.15L0YGM^0U,\3\2^3"#74\@;A%!%
MBMQD^XEN.#GX.^D3F:_#0;VB=F^>7HSC..9+!;M@H52;"Y S;JI.0((_"$R8
MDFXAG;$P6$F.+A=+4RBJ1YUVR$9:0^=RJ3Q+$]%[PQ\AE&VD0[+RJ>S*FQZ3
MWA&X-I77**%G5RNASZ%R)I7-K3IW@)(T(B\I%^FFH)R8RO/Q+!LOC$W9]-#C
M8NQU>):M6<7RB]G_W/:4L3G>_KGORG@>#DTT;"BAE*,)I<.@\_)WT[=/Y^2E
M A9.;YU2U%'[)[DH;B_$%^=31EF+4=;Q>J(8*LZF4Z(0LN<W6G)\Z1&YON0U
M(N[DZS!KELMO);5V]M;>2 IH%44YR]/<3[$WE@;2D),*BLQBNL]?EJ_)UQA9
MM^LJ6M4F!'>B;.!U2T0:+G=$G2K*;2U5M#'JK9I-HBRX"18,H=ZWE8W:-@?&
MPVZ;Y*T-,-(Z#F74":^PFY2C(0OEFM6Y9@WO,A]I3BTKIOBP7?M1LHWO9/YM
MX<%_OX_P?]XQKNTN,I3&[W][O@.:*Y1>A^ J5I_R/3/S[ON97<EH*=K_;^_:
MNA)7GOT[GZ*/Y[_/T;T0DW!19O:9M1#1<8^CCI>Y[!=7" WT&!(F"2)^^E/5
MW;E!@ 1183;SX"@D?:OZ55575U7S@T&B3/0/^X!FP&E-Z+3_(;&?V)\SU(5G
MAPICBU!8W3Z,P7,&=(Q&VE:,(XZ8:X"Q.<"3ZKK>1QOGLV[I'5XEJO'8-^$/
MSW9&-]#MH6D;]UNQN2O'H?&=N:F[I^&7[Z./O\[ZOT[NLZS;^<5-(Z<5"T3X
M2(+1:,=W3^?]_9]?/M4_'CG[6Q_JM<O3F]H9^5P[KYTT/C?.;Z2+)%QSF$W*
MCGUJ97DKSF8_8:58>R0_9%8+%@;>+)29M?7AIDN)O$L*Z>PRX&B7>/ I\VC/
MQ5-@<]"B&(Q'7 PMZ(+.A$>X[V?_?4Y&[.DN,<3B%TBTR:[>(KIAP/[&<X,*
MU[K%/P0N:05%TACE >YZO^_8CP!8CYHC\I_X2E>5>DAW62'3K5FMFFA+9L3=
ML=.[OE6TBG>MWIV!_*D409X\_7-X>'ONV6?FR<\MXC$/E]%O)#8DF4KNSMXT
M3^T_+M]J[D4[BI$8*A9PH%0FXJ,*2:<ZG-UR/6::.&Z=K^UGW3&ZI*CF"0Z(
M;"^1+@>+T*4LZ'+[ZV3(>D^_1N@F>&VZE!/I4ED"7=0$NN0D86;0I;R33R@A
MF(X*D<+YXW7VH(%IN&"UKT.OY%WNWW?"]4\:P9QUG^PQ Q(6V$),K/C^PDBP
MF#F-%LB QL!QT$6BNR[UTA BDGE:%^_6\-5I%+AX8H?-TXZM?"X&%*C'^IQ3
M&S_21^HU+RL+V$T)TB?I_#&5])F]A$K*)91"I.,<_OCRK5/5&7V9)4P2%&5E
M@6S1B274"DGFYMPE+._$-*W4Q_!<\R>%1AY 8@R[U"(]-(9@O^'K9X)A]WC'
MA-ZFG8'NM+BR'V]%5N?$!W$QF#6@.1B$3CHV;\NV#.I@*AKA-C ^UQ\X[H 2
MBPY)<^ RD;+6[]N.A_-E4IC#@SV=61[FM^FD;=)'AJK''YP+MJ/A@3$'@V?P
M>8L^4-/N8Y\XS!MJTHZC]W+4L-V1"Q8*;S28HXX- $=UP&IUJ$N=!YYBT!)N
M-,D)>6P;%M+N>ZP'-I,P=Z!!@>U@G8!S+%0^M,]-<A"([GUAA<TWO@K^;";6
M4ZS3/75S>@N;1//817(P?O&6R:4]3I\734+#C\ B6W9/; !:#!E3TK K%@.?
M18Z%30(,T>"KA]\-8(R..>($X2N^RJO&7&+9'G$''#>X(/@IO 3\K9L@FEBO
M;[NTE?.7U$&3UZ%B_7 Y6C85;?21Y2P/WAEX )\GRIOZ-= !0)Z.F"0]JN-6
MA2]\SP9<8*"E%S&>CP8.KEN;H;@@(ZH[A%IH?P?@SZ'\S$=1"X8Y:WMHHX<M
M26[@KGTN:G5X&SIMVR!68:0@F!P&(YT",!( +#\37;D$= F;#1<)7SJYO.6S
M[5"+XLMX_QL%<2(S?@SAVH9Q0#<M+M(0_/C#LHD-8W("EH16$F65G%X.A=7D
M[%MB1?'-&:O*M=*S^!3> RE.'_E^*;I=U8I'=T_V[8]:3:':5]=,O^>$=KEJ
M\!N=Z.2_=G?),:-FZQVYA/F^)]? G!1D,S:Q_Y[PFW+>D0K9W97>BQ9[B SL
M\.ZI?:S<CKXH]\5!96NF8Z,4GI^)@>]Z=A_:1N3)#_P7*GST0FH:U#2ER^O_
MML#DP+]!N1G^W_$N#=LT];X+8_9_>T^&K.5U<4+*'TF+Y#G3SMA@?$D.EX@'
M1S9=+/X1/_&;?*+T1[PI@V(6]M:'X]TH$?SE?T]N1GT88LT!16J\)^=@:@@2
MG=M(B])!]*T]_S7\:MH BG\D.M[&SRE]_]%?>T#I:30_\1H7I4_=Q^*G\FR:
M1\Y,FP[5[W=%G/@[V#(BMZ7C@]1H^JOYH79V^;%&ZA>?+V]O&O#_U:7O,\G0
M3+:GFQ_.;4](ESIH.)RMCL+TF%FZ93"0%]<@O(6\7V PT7B:I,ZW;PO7(/:1
MVQUW1W0@G47]&!6C#(.<))AEEG2(BJ#ZW=/50?G34]4TJUTMM0@*!=QD5R_L
M-"PKE:V)ZD=1;Y]?"<D]M2Y03S10S8*=&7'Z3;H-(]4/,[8%^[0OICDTV4GW
MQLCN-RQ-^@U!+51^79A_G_S\=--H;\&#Y[OUB_.;JXNSL]/S$W)Z?M.X:ER_
MD?<PP682$KT)!L,0#*8>FA!@Y"3I9&"$7>0 !_@:M:]?LP*,A)RT$OO )G;+
M]:TF0-PVV)Q>UQZX8 FX.^^>-=>E,^-!W(-];71I:V "ZYS#7BB<J<](-_Q>
MNHC[.ITV#)BCNA^)+\G4E]P?/^FXC&?5XZ^_\/(G3JT1;_P="3F?[))I7$>V
MCRALTTQW)Z.2WO*#9985"KS8(>X8V@YK=T\'^P>&T2PI96<_F%.+N0#QT3MD
M6>C;7VO<RXPQ,1\6_@L+L$A<KGPH_(L4*'@]\JY(*8GQF?98JS7WD,\W% /N
M&1=HPGQ2)HPGA2N/:WW0T;V!<1](_\7:P4T9['%=,&Z<46#&O#%#S ]UDV+E
MH#QI^B?RR?ETO8.(KL'&UR1BMU=,G+TOQY*V&C-88_IK*8[B Z_G02E^9T2B
MM'?OV+64\>@ +2HE1;V[PY-S[@J]BS10Q\VZ[8 =<]&^HB::M9>Z@W9-[9&Y
M=W>!@O&93)ROWSU]NBC2[T^=SN$]"]RITY8VCYZR)@66L^#CK?$5T>8M2>J2
M[,FKD>BM+<:#",;F%]?LZE+C!RKEE DYV3AF,C?G+97KE #I<QE""@SA.:PY
M\/S[C*=9@VL5C!VB-'*\(V-::I$)W]C)G/K2F/6^=[]YH^*GTW_N0\P"1>25
M+6EIDMHA\.RPH QKERUF:&QIBONJIE7*F#0;P_UR;U=YRX(%*Q)C/E?]QKRM
MI=>PYJ9JVEIV35L*4%M>'FHK"OOG8_7)+CF+*MI75ZZST38&LL5RA*8IUVI*
ME&TTZGIIU.IS->J+8+-:^GX_N!_]\_47_7=HU*FQVXD:M:)4Q\"^0-S4C*L_
M4E8KV&C4("3D335J/;M&+0>HK2P/M?V+<WODG!W8]_=KHU)GPVT,94M-M]E7
M%KT7<*-2U[:$P!(5[XM ^/:;J;1_=K^9M3?:RBXAY^ZYNGAJ0EXZ7:PMU:OU
M4JHX0S;>"FCG*9E;651TY3?,;0VE23F="=!X:?EA?6NP+P_V%ZN9T@2@5BNJ
M_U\]37<QJV&V8!B3!TOU=NTKJY&B.YDUMUBTJ#BD>T^DN+BBK:WIR7'1)+SB
MW1/]V7;;1X/.C]-JEJB0\2R\YT=G!#E7U&R1?>6/4! QBP3,0<*30*8[(^)U
M05)VNO" ^:!?/19R4Y^4J6#N6%L8=#KL K^.=NVA1:.OY"./7CV2L[-ZQ@C+
MY*/49ZS>&R5 EK72[%BFQ@.&E]7:,+\KBC'S /Y+'B S/9JI/C6:*55K=T_=
MX]']C^\U^OB]F#V>J9R8!]E03GY4OC2UUL/6A^O;P^O&E]O&^0UI?(6?URL3
MQQ1F)[J$/NCF@ ?\(=_R0$S0!P\B.EYBX^^!.2)J6::N8/ 2A@CF0'R+3 *1
M/Q")'6P'L8-N$#LH@IKU!YV9ON':I(2Y[H"V7C- ?FP]+BS_5+PDYI<7F1RZ
MQ8/AX2O;$2'6L% N:8Z(/7! +&/F" _^=J@![.3F<T,,L#9A]CJIHV76!MO,
MXX$T=1[ C;]A("R7&C58DQ:/SX9.L$506K8#WPQ$2D<-33M3I+W57->&Q40M
M(W)>6K8Q$&LJ0L-;O 7#=H#7D3"(-!%>7C/[7?WFXIS(U& @O=/'+OD71!96
M"3YM4@\P0QS:-GDR /0%8!F(BRJP#_H(C(.!XWY.6"35!</;>8X$B%L9UI[C
M4SF%3]J.'N1B+"8$Q^CV AR@J3X'X%1YMJ_(B+%[/1N#6&V0XT-FFL)E0CQ'
M1[-)Y'O@8N4P^<<=]4!ID]K9)5Y@A4MXKKLM_5=  C"([ZDGLY=>BE%RF.8D
MV=$EC<<N:S*/5*L%E;\5^4 3>07,#6CJ<)DI\AB@%2R$+3FK13 ] :8.,  F
M@=\M(RLYETRZSSJ()LTG7 );;R,),#!34]Y'PC0U]?V.E#Y$SV$0I@M3,JGN
MXKI;L'LR_+0)^DB- ;=6,?4Q2-FPV^U=3[^'QSL.%;D6CK#2>18- 6O!133!
M2V#ED_.OIT>G-7*H*0I/"BF0&C35'_E90WP(.7\(C#MH=(S&XVN.+<;IN&(H
MJO%(U@=F#UQ,JQ':F+;R0AI8%A7V_I!YW00J!8&S2*W<%&I=T[['37ON[$71
M_("X 8UNB.67:@?(%B4ZOE80KUS*5RZ#5X[]5_Q>8IE%.6YQ\>Q_3*X!L&+>
MWC5K47(F1&7-IST,G0*Y8#L5]!L^%DR!3]]O1]SO [J#,"$H9HTT%XQ42(Y(
MZR[I@$! OD-S!##\8!LR8P^3VA#'F.N'THAG$"%[!5W#1S*C*Y92Q3\&10@*
M!@$!,@^_A=T,C,(9Y4+A&'UI6\[\0CY&^&4,;C![4)64/< XFR.11$?=ODC6
M# ;$\^X>A5K##5M@6V!A!B[9X GF,4Q-RZ%29JW9[<63IF*,@5G>%WQA_!&*
MI161V3B2T+P)GR4]D#A-+A4<@V%FW(..>W2A<%WVR+L<4A/3W0 Y73</V\N^
MV&+[*L$?'K +6JD!]25["U.K3!!#_*UV)OX L?CWP*)$TWR3;6C+-F*T#Z:
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MYHJC/.%4OI;A':KFNS ;_J%JS?!\!XE8@WG0$$]%\*%Q? 3C"7;5(5!J@\[
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M12RMT1E#]MG50@!@C)U(AR87;6!:C+0+,BJ1E?&<K4F](:564FXO?OVQ4"\
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MKP$9CRA8(6Q#Q6E4/*L=K@$5S_0F-3<$3"+@Y55C#0AXZ5#T9VS$Z10ZEE:
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MS+0R*CD@>.;K!.^K<N^BKA]J.@A^8P7TVL',W6+?,VFG>B8(SM693/,9KB,
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MTS6DL$'5&+=%U;8@&%A1X#*\CST:%3/VRS5EX@Z$N-?&_R<L+X^.CXC95G>
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M-\T6!Z\?7A-J0C6U27,!>$+FOG--TM500A'+RE?,*&:GDE#$SC$J^U<U(=I
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M%I1P-W\:*F,9&"%!K7*R4*G@"ICUOSQ&G]8U2UE@^V2JLLS62^RA6R0N=Z7
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ME3_)NZ0\ .HZ: YV^D6@5-=M23.X"LXNPJ[CNVL_+3ZZQ3_O((Y>$Q3,T;Q
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MF)("24&_8:R@A:MX1Z%4N21V[HZK3,TR;YHSA2)69).7QTJ'=MMY[2\IOJ1
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ME)9>3 [JYGTO0B[V6K#KB:/(*D/$FP4,H<\,$ >, 5ID47RT%[(/A]-1>X.
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M#]KHWM9_4:32_K,&+8S,Y9&-BRG7C#A#9WX?8_RGZ7-];N@%/!E5S3*@#^T
M <%X<ASU1'U,Z!P%\SA+:#)=]&W3*CT8*$GS@E\14?J65ZG+$5" PAL-%(*A
M4:V8!SJD4(J_LF=AL_>S2>$UBIX]EW\R ID)+#TV-$:%\T:'I)AM\__B]F>F
MD\1S@-(Q-!J%\.,X#-%NP\.V:J7X<Q8Y<]1UW7 =E [?1-:J+D2@1I@7_!Y,
M^8^D+^,(/3G>O/#5#E$4"A100\R+PNN3_".I1OH,+K=,!<RC'3! E3"OXJ$>
MN<>K#G1=9'DWY">V.7P"@@.JAWG9HL/(_I'4)-5_X%/Q\K" "F)>RNH FH])
M.QC,R4Y>#^FI9T(PC?)Q%+H(S>.BL2 N5^3@?\0JPCQK*G>H0P 8V8DOD#&K
M$Q_.*!W!<M%LA1&I3MER!AO92 ^0BH@FC8>T)0Q Y='\\48VL-<01'L/R^5K
MLGHI, 8:V6D.Y3Z7<"T9[NSC(.UGCS6RU5R2]ZH[ %3:_WSMCA:%#1O[3I!T
M@SDI0WLBQJWG.W'L+3PT[\:27E$3T(WL;)?R'!ICL9:-=(-4'SV%L<<M9*''
M&=G6#EW*/++U/&& \1X[WCP-K21Z!ZKG&=FK#I4)E"U'TNK,X,2U%SB!>TB4
MR830L)M;"GU*=7=XTIK<UI?W _"]7NAT(V-$@81VG6 Y)FF)$,LA:^ET-[VT
M8QQYSTZ"L"ERA3>;2 (Q,J*L(T,PPW1+4O::+=A<(P/0.G(SX<HMH1YUDQ5V
M_>2O&#H0J)$Q;B,+$\K0(PG(\BL@BWLA4T)Y=[=M8PS!+",C;(#D0<1IS?9E
MC0;D\QAWKE#RG!ASL)'!+'@5BAAP)#YXH4NCQ2TYN"J=6)5C<$FW_ "@1L;,
M=19G;8;J6;L%EJ0_!46!XXMZ='BCC0RFP:M7R (M4BCNJ-J@+-Q">:.-O,0-
M*@4Q"S2U%CK!#$4KC $A]AIQ*])9(\V\.PW*?C[M>@ZI4M\U#5.F]WT<IT3>
M0WH)(_?,A#_!S O/H(*HY,1Q>.MT(0SA"0E'\!\DI?SL^%7WW<-AM)\@DZ67
M<A<DRY! 2J _QZ2"#7+G/F VJ$S9J&"#G*?8\M,Z0R=9D^XFQMM9V<,S5U=7
M9V?OK8Z%MSC7#\FU1_B'87=V/QE8HVMK-!Y,NC-[-)PJ?R?G)DR]#1RW10$+
MRP_[6-Z,[.&-U1L->X/)4#EZ7YS8B].$>8Q5QMDQ!24L/^YC^:4[M:>$E>/)
M8#H8SE)NJG]TR%L&.+1QR3EN5A6+F3L.?<\MZVL)[ZM]O*?VS="^MGO=X<SJ
M]GJC^^&,L'L\NK5[]D"].NSU *3UFZ5K[_ B9I6$;RDZ/]NG" M@W+7[UN"W
M\6 X'4S_9HUFOPPFUF30&]A?NU]NR:^ZPW[^Z^YT.IBIIY-1%U,BXIP2RXP@
MVL.JKQPS=M5(";F+?>3Z]HT]Z][J8AVW7 '_/4T$=<)%9QTC/@67M(Z0'6_V
M^]^L\2W6_$P?!O]S;X_O!F0AX)\F]LTOL\[HNG,_'>BB5'RZ7"+H[3Y!]O#K
M8#I+D;>'>+.\&P_Z>%$KQYA["5L)V7?[R/[:G4S(?G-K=[_8M_;L=_4JM'\Y
M"U8=QHTZ):0I8SF^GV4ZL44[U9/9:&B-N[^3Y:J<C'R/CW.\22^FZT9K-&=5
MO)>(H6QJOM-/"\Q32O O)_>#_H8^'=O_3K*.J3V4I;T==/&*U*<[7[QD&8XC
M;X5(U,Y"D3*J7^S9S0AO,O8=1G345;^';YY39<K_@K*1]A!O$0-KUOU-@XQ[
MSA,Q,-,D=+^1+1M[5M$S&U'*#O:ZX]343&>CWC^S?1F[5Y.O&M!.\1VE=Q+F
M*+,PIHQCANEH3/R_ EGURRB,XS'*CJ586%(&\'8TQ8L?NS_37[H3]?AM'VN)
MTS/2U$]%6[O!WK<N*#.'M?;.3LW<-%4&'!40=W50,B8Z=JT)\LE;G6,'>R4S
M;/]BQ^5%71>4]9L,;KLSO,V.N]@!L6;8$DZ[/3VQ5Q[4.CABCI-H7<ACXL7?
M[IP S]@YIRX105G#:WO8'?9LO#+MX70VN=^*9&)/_VG==8?=FP'YI?IEBI8$
MZPDB \H%%B7T*?LW'=RDOA(.%483HD&Z-D$QFRE;5VQ_&ODY#(..BQ<H_@%/
M6A:7=['0I>S><#3LD"4Y&=W>DBC2'LX&> O4H 3KAQC]N<9L'3SO9'JVV%Y2
M1G!Z_V6*?7ZB!X.O1'_;#=<%8?LE'1^*PW;KIP*:AH>/143-=B^O+Y%$&\XJ
MDC)8Z@F22DGP"60$G342$_K(WF8H^#11!GF;I]"'Z$["@H\K97AWTQ8Z]4DF
M?\$GB Y):V4Q]!'.3&?PZ:.L-">IH8^ _>P&'W?*<E,Y#HWZ)DQV\&F@S#D@
MY:&/*DCN@TO;6\KX0S,@^@C<387P2:%\@;V$B,[UO<DZ\-&E['PY]Z /5TX2
M@H\W9;[YJ0B=-GH_)\$G@&&KZ<R$1O4NI2CX2%-&>S=1H0]=7HC/1YTRS_Q
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MP<&;94;>4Y::C[@.2\)!G6E,($EVC?:$@_HE"W7*> M0OVP-];<,U#]0)ER
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ML=?'"V:,BIB*\T9KJXRQKQ'>MCH17KUBB=FVWTH9,U=.XF, AC%*,!2.W I
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M4)L8#@.?=W#3U(M'.PQ73I![(MDP%"DMT7Z)94CI[_4J_1\K)TY1'+R(Z/V
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MR=[3CI$##^TBA>GJ/605U*XFV_<V(G&?>10R/<R'5(9KF<HNJ&E=)BRYK)6
MB\3VSX;K=I]/2*FZDNN_QWZ*^2'U'E;AVK,$Q >II(8K&^895+PF,W2<U> G
MU\/O\(DT]IV KO4RG>$J!Q@&]:W)XAS&B(P"A _]60(=N?<9#Z93:,6&Z0W7
M/X=Q$ =-IN<!>[TD6:%8%HU2*[LPH;,/(J/)#!TC=X67RY?SB\<)N=4,K$<'
M5(9KGLHNJ&E-IF<_FL2.AU?(\<OB,0K@BT 40L/U#7$,JER3E;G'%5W9>R2&
MJ[G,*ZA@35;F9J)UG]VY$\X0G/]!HS1<W2#+H-8U69^[Y6TFM&;/[%JS9P)K
MMB;K<\/4MJK3X#'P9PY\NY#1P!+]0YQ#4-"DJ@.*_-Y7+YQ&\2+CZ@;_0 >!
M2FJX^F&>0<7KNEJ[\OP4>3F#V_)LVXN/@-^ U\IT.$38!Y'1&D_]CH+@]S#Z
M&8Z1DT0A\G)#@Q7/ )H8C@F?=Q 0K1'6;U&P"E,GSI)U8V8%G0-2*P"@\0PJ
M7FLP=9V4OMW!R'2%[CVP6E@! X-U$ VM0=:L0",IJOJ$KIW46?/+0H/>P@HT
M&*R#:&A-6LXF:P=O7[.(G6>P1VB%[LL<@RK7FJL\7CA!L*GWPU+Y'J$5*B]S
M#*I<:S9R=X'B&5X,O\;1SW2^OAC,4CVU@140P)R#4&C-.NX^[\H5Y#<DF3B4
MJ.T @<XVA, 'S==P=X]_X]-!Z#DQ@ %,;S@*',9!'#29SNLGO7<GM(PU(@PK
M;837RG!,A-@'D=%J.A?+1S WZ *=X=H'& ;UK=4R'JX> ]^]"2*':0<4R*S0
M]B&_H+*U6L-73O@C7BU3]V481RY")'24;.>E@#DFU($5 (E+ D*G]VIOM%B0
M*V61^R-[2"@9K-*$+*286Z8[@]'."J"X H#X:"YWE>PN_R'OZF6$IB@FB1X3
M])Q>X0_]8!^TN,T-1TM.#A T7;G0>:U=?$!/HC!$ 1REIE$:#@7(,JAU319Y
MSYW&61@EBMMIBO TSL):8-H+3&\X AS&01PT%\.Z\?'"NDB[<1S%G0AO>2X;
M#WX[PW$1% #"YZ.NP'8^=&[\>-$#[/,]$L.U7N855+#. '84PZM^@< .Y7+7
M^(^:S.@U/[>1R\B).2"R0\5[W()J+CYQ^/9 $/R1'YN_4?ZTUVFE)XEVV0B#
MZ39%81CEWL@MTWM/%5VTSEK;9ME;16$2!;Y'CF^[/R2M:-K:]MC:=?E6FSR#
M)<KK:I#'_S*/$O%FQ&A.;M$\H?QQ</+6*EW.2W$Y=U]J83NCE7VKM?>Q5OZU
MUK^1[_V[3BUTLKQ#?,CN_KG"X_<:?\KU4[K([\5%7G?;\L-6WG'KW]9=_WNE
M=ZLHC_YEOWKH3>-D^^G2I"NL$ADY1'W\0N;CGK.5(W6>HS!:O&3+V=F[R[.+
M3V^GJR!X(!2[G\ZP4?.P(\DDRGZ?46QY+ $$/6NU;<MMJG1=K/3.%1.*_=52
M7"QH :WQX2NUF),%(0KS69E+!CR.M6T"M5"*L-#36-(P'<++%IZ"J@WX@8\]
M,<0^T4M;HD#P<=/SZ):YT!GY:)=J>#6\WZ46X2R#T]N\20R]]+6EIY _:#8I
MQ*?8(6@ \ZJ74O!(EOG6!\O\$8D$Q4\(5'C6 *+7_KZ:M,KY[(-*5Z[U28R<
M9!6_9.RP%4XA?: MR^;I&N(<W&R4J[GMNJO%*B F#\MF9 ,@U<D#;3TU#QIY
MF<#]P\##W8@\ 1\BK^O$(8GL\K<0>@OMGJGJVPA#  @Y-?>%U"*W/N6D:>P_
MKE)BA$RBP<\0Q5@/0X=$Y?E8BO;Q0,N^,Q-=*9' ^)*!>/>CD!R+L?;P]V99
MTCQ*4H$)RVSX0 O5F(DL7XYZHR5U3%_^Y'SXHAF@*DZL JL6.3;RG,K!5"1/
M:#<*H496 ,7F'CQMJCYL7CF!$[JHO8S]X!S__6*(N5D&?IKS!1TO.<U,1D"8
M?_#P:-[\P8=?8K:@:Y3_=S*/H]5LG@GSB/_M#9V7[=N+C@M52MO9]Q7Z,QGS
MXP4#SZ/*71O9 ,P=+/>DRE+^= O>8;UKGV1]9%67Z$MC[BP0[<!DP"I( IX@
M3X80>PF5[.;UH"6PQ%;-@Q7";(0R%\(D:J>+]BQ&F6Q]E*[W8D)$]H9.E%#+
M0I2$E>G/*A2E!8/@K)HAJQQ.\1DIW^NKA59@OE9-QA4">!"W73?&/]Q$\1C%
M3[XK!B&MG54@@0) ,%3-Q:T,@_A\@EM;#XG _*C\<JT0,L-53*9K.HFNR2-_
MQ-N&%3>8CA#YEXOG>1;,N,<*%<)*IC^KT),63%]LK2J;XC-0OM=7BZW(C%7N
M:;G&)V$WFN6Z&TQ[X1/F+"NI&^97+^$KO%D'HNV-1TU*$!"?JEX8$!]\^KD/
M8^0$_E_((W'$0;AC#9QA[%;&8R' /HB DGO :OU@PSB:^BF1XP:KA%PJ\\,5
MJ0*Y38]F>;WXK4W&4U8,$%?E#I/==:7!=!C[49P7&1D\H9A<,\,K\];]1J8^
M"I.,S>XS^9&6B9QU>URO)B.I2CP0X5K=*YGO!W/\A)D<!HY[K'M%IC_C43U*
M,!#/6OTK,FQ*>CRE>GVUV(J<1I4[6(;XSRMRK>>[$Y-GX9/N,XI=/T&TRYM9
M$[B%\<AP6 >UKMR? C/"GCF\=A8C(##Z*^?SPRF6GI<IQ@E&$6;K?EF<NS=1
M?!/GL3\G6/\A[)"R!-GOOOOI_'P:Q1?O1HALQB@O]$&"QV R9CV?,Q[U.N4&
M!XOZ?-QZI&#/^%H_^J\Z<$36&N5^GP/6U_[CJRA<)6)'I5(CX^'C<P^J7[E;
MI\C+SG>_YD7\O HTM0H*E@P@(/4GN @>D]NA-URE(W\V5V\W%ONV"M*CA 0Q
MKS]EI@++]=B6Y2_\2^ O,O/K3\+QP]DD:KM_KOQD'0S(7%F>[SK".1J,/JQ"
M4D@8$*OZ,VP8K$EFU7![>E6XB<RT6M-GF+EXQ_IE)?NU"MG* H(XUYJ?4X5=
M11FJK\QO6UU,"/G*]0I Y#?^LT'9M0;!R6AB/$8\WD'%*_<&,3AASR9N0YM!
M$)D#RCTK>U?U!X_Y7>)>N'GI%-NY(Y2NXH,<D_RRXB3B'C45=6\\K"KE!,%7
M[M=1Q#5[SBK]R+_*0!!9"Y1[E;:6[3:PA,W=#;N<X!J_J?'0B<H  J+<Y</@
MJ#(<]H,A D7![W+:<JP=)YG?!-%/H#SI!XE:G;BG5MY54YJ3F\5X[2>DCN0J
M1B1]V8U"UP]\9^U7V)0\Q LO_LE_#% [25#FW?L:1=Y//PBX!3P5?<#.,I]*
MM6MS,=# (56DR68.RLHM#RK<QPD+AJH%O%2_4%*-5M3C$!%*H'ZE1"\G*T8J
M"U\5_*TL6*IY"!A>U%3?,*FG\"E\A!H\]X:C:W8UP3VB$U8+E)]K$5,*?6[#
MB1.O$KZB#\A.6!/L.%73Y("47;DF&!P62?W%"JOHA5<5=H],NUVI2MDT.2!E
M?U&O;&<U<](5KR+L =G#^>G*P1ZI;9H@X-FN<CIJG5O[QJXG]\/N$^+C6]\-
M"V=M-_6?, (H:3\F*4FS9&[O4CT]G.M>SJK8AU5D@N W\%RWNQW( G9'I1\T
M%4C =R+9@!DX6]O>?Z_6]W$S#WQNP**=1"(35;B3UP&WI+B@76;Z:-C= 5W7
MK6-.:E[;$V)?#3 V[)" X*%?^;WGS+G4"V\</_[F!"LTF%Z3MV7CK%J%.\>L
M#6/?19B]K#HR.3/C,\B&9O 8^+/,3]6+GN^P-I(T"N'KT'5\S-814;=&H"&D
M/*R9EV20+0');F4UJ"*B0>@HCW%N/LO,F=PCLEKW%$E F]Z\G;.W6.*%(+,!
M.(???4I;(6.* ^&F/(^\$RT6?B;"#4)9=F7^FW2W"&_K#X);FT0?5I]?*TH+
M@:D\K?PKUL,@O/:3) I6Y>I-;?Q[U\>&-@2D:'O[0923%'36U0$@$6SL!*A"
M"3+!YJ\#/F%!69D QFV"!_7/>^'FN#MQGF]]Y]$/R)LMQ!W*W"'%N[%Z,%07
M&!P4ROWOA_7;:&://R,/]>5>;FARR_9C-;!'2 R[^D^,+#X?(O^)F+*J,"[T
M^"^'=DEV$'?E?J/1'I_Y'B0TA;D-[4=14$00+.4>FGV&^M'3.K-,<F9*=O/:
M@!04&(15N6MG70MU:SH7SX#<FT-"C>V'4$),$#CE108V#L)%=I=E_5!\!?1$
M>G@M$(K+"N*HWG%4WI[7EPVWQVV)4,AA4_N1$Q82A$RY>XC"TO8J3'9W>H0\
MM%A"=9@AL< ^7B6('&E!-)7[BC8%I/,7)>]0.H^\W<K 6CSA5O8C)B(?F$Z@
M/'F7,GXF4;@):$9CE*8!*E]'DYA\(MW9C^I1@H-P*W?UY%[EG)M\J]YQR?:Y
MT]O8#QQ?.A =Y>Z:_"Q5*)*P'B_<\PJWH?TX"8H(@J7<Q[)AB,BQ\I-Y/GBN
MT2-S9Z.W>#WP0+*!N"AWIY"GQ;%,F[("G#<@Z-3VX\&2"\1"N0_D<'$EE76'
M3HR>4="+GCMQ)+KGE!K:CY"@B"!8ROT>ZS&2Y"QY]PEY:34E^Z ;4>_HK4OZ
ML%K9#Y.(?"!&57T:M98&>/(]%'I)[AJE'N4+%Y\/B*W&DR<6"&,]U14'V:8I
MD/1"I[8:"JY<(!;*O10%B^V@ZCCOJ5A^2_LQ$I41PDO]=>-KM(R1FY=?:(=>
M>Q'%J?\7^#9;UHC5QGZ,^-*!Z"AW,/11NG&%?(_B'R37UUF2<!P) T0A241E
MW#;*CZ[B7=B/G;2P()3&7S7:93YM_CN)'0^U73=:A85(+>M 4JW'$UT;K8HM
M^U*2G-#@<*GJ#SGA<!G&:.GXWN9$?LPX.>CJE0\0JK3@R##P55:>@(-TCF(P
MLTE83X5N7OF(*$D*CH:J/B%MHZ&<6%M<#^'8!J KH>Y>U>B0D!@<)0;>UN()
MF4V!3?3 E]E.^'V]\O%!%Q<<' 9ZP<1.[ZPA(=;#:RI8PD&YJI-,+\IYIH6*
M,C6,GJQ%G2L3B'Y5MUR]=6I<A+QD<PTK*>8EXC_B$4Z-J!=+OO [,,L%(0H@
MI;J-J*C0$'BOW-.WN:R*F>''H:C$5H/#$PL$0KE3K\"$T"T2B/Y5P2%Q9^2]
M\DRA]1SE3XL2H?T8 "*!RE?_(&S.@-!4H-&^&@ADIH"!7J7-9":O$>4[W#!P
MPK0=>B0W=TFVOJS2HS_UD==.*(IBGAZ.[MWJ<:)<#^#(4IZUM.7K&BVCQ <#
M58=T5N/%D C4O/(4)"+&T/&]S.L@<>&*U\Y^9,0D!)&RPP4CN<**]?":C'$.
MRG:X8&[\T E=%2X81D_6HLZ5"41?>694T2E0X;50P>9FK<VBZH^J"@K!]T&]
M^Z3HT^&]^"X"(K>3UP6EH+@@H.K=, 7F9 MZBK1]7?!5K/"IW%7#'%+M=($-
M(?F"AD=U^KIPKB@^.  ,3(S:5)_>E*3.A(5*QNX,;["5U0- 6#X0X=J>CMU[
MU!UVCE.(K4:$)Q8(A(&Y19M!-9C>DER'0I)#T4E%49#(3)3NU.IAH4I\</@H
M=S]M&24765$<.@'K.B^=VFK(N'*!6"BOWK.ICKF5@+FHTJGMQX(E%XB%\NMJ
MMY$33E"\P$P0M=T@\*I:F=)^#""90/TK=\3D1]S,J!G?7V.K)O8?LYK08-01
M:F _&AS1(%!H8I_ZK"&FD>-]HJ_)%\I!V<#7M\KILT128J'B_Y" VY,3\-Y=
M$NW##J3EI &Q-O#"6V>%-VMR"8LL2VZ*/'FH!;NP VDI84"@U2?PK);+O.B&
MLUUV>N$TBA?YI5G>#571]D:#5$$2$"'E*1A[X>Z\A(U0[#\G/9'>*RD3#/(7
M10$5K]P$WM8-6L>>LZ'#O;'-:F3^)!!@'P1 N=W;?7:S*SR#W:/,G0AS%J?D
MF>%^E"+B[]S\*3\-M]-MF08P5^FX;D]UH4D8F4BUK"#BZHO>YG>TLMNYGI^N
M2#0C=(.51X[ ZUMX":=&HTP?5F$I+Q@(G'*S//-W3R)LJV09L&T7GVABN#8J
M0&X5'$P9(,U_4I[:L.='?L$#@IPS0<73J:W2.TL$4.W*$Q#P*KIUMPCFOS.:
M6 4 5PX0!>4)!?NL\*^ 0/06ZU_T[L<G]2\RP^. 6<&&-XA.7ZQ&];00K43S
M27DX'AHKL@#16EJ,#BP."(URNWZOE!QQ\DZB37[.QN(52/>7Z\4JR*J(!L*G
MW#LPB;-77E[&:>3^&#RF6 GD'+XQN+(GAO$9_>"MTISM2<3%55'W5@&N5&9P
M)"AW4VR?,L@3[R91SET4<_.>RBVLPHLG!@A!/45D]]*MUC6*\P7""?,QQ8P1
M\YM;!8Z43"!2]<3OZ6QM+@<,-@PF54$#>GHM^#'%@Z#\K-SS4'PHI/0$Q4%Q
M</YYLUIO=D%ZA(@@K,H]&^5W1<!]C$)J%2 @_Z"VU5>OX(X)R;=/*W=H%7)'
M2@GB6\/SP_C3RQ1T"$RB<!+]0'"];N$.K,)/4BH0+^4.D]T*O&]QBE4X$6EL
M%4X2$H$8*?><4!ZJWIZ-Q,H \5O;A9*$2"!,-3RBLXD]7_DI80 ;\-SECMG(
M*E $) &QJ"&58G=]87-C<//BB\BD$6UO&4(R0H%@*?=FT&^=E$XUL'M)L+U5
M8,D)!8*EW*&QEH;QX 4G58S[5(8%^6*BSWV4\/A20ZF'O0+_5#>R0 E-J5Y.
M.Y&JO+5213X0PX(+XN]O#T3'P^?'YF^4/^UUBO#$)E5"-I_:T]0RBE-GAA[]
M*$7N_&]NM'B;*:KOD$RHP72MA<++1ZF?DO9?OGQY]^YCZZQU[2=N$"68&O^C
MWY[<C[JMP4UK,.R.VI/>H#\NB%$+JU^C[-9:Z.+EB\;DIT,FOPYZ_:^MSJ#?
MZ8[Z=7-WY21^DM5J24C:;O%.59')SX=,7K7'O3%1Y'#4'7?[DTR7=3,[]F>A
M/_5=4CTOSWS#JAU&@>\6K@D5V?YRR/:X][7?N^EUVOU)J]WI#.[[$Z+LX>"V
MU^EU:Q\+AQ.0E)$ON"G:H4=YR*,@T/F[0X&P^H?MWG6K^\]AMS_NCO^C-9C\
MUAVU1MU.M_>M?75+?M7N7Z]_W1Z/NY/:Q2ROM$49SDN@3 B?'3SLZV:,>I J
M\G9QR-MU[VMOTK[5I#BP0"3^.?-VG473L]4Z]Y JP&5Y@)"E;O+'?[2&MWC4
MYX.A^X_[WO"N2R8!_M>H]_6WR=G@YNQ^W-4D*+.X85&>]X?R]/K?NN-)QGNO
MCU?)NV'W&L_GNAE>1U]*#Y$7>?UPR.OW]FA$5IK;7ONJ=]N;_%'[^#ETBN)Q
M4W[?OLAS:8L<WD_R ;'C.ALDDT&_-6S_069JW5(<9#63%_U<-UXAC_)825&6
MTDZZ7N''&\8S0? O1_?=ZZUX&I;]_>15&NNE_?6VV\:34=O N?+3632,_04B
ME[UI'):VTJO>Y.L +R^].\SGH%W[VMT+\8]HXCQ3P;\H[8R]/EX<NJU)^Y_U
M [Q.TL\"LF2IQH>I^(G.9VGWZ[2'V0XSG@PZO^?K,3Y1C;[5SW6><;,D':XY
MIC%<VA)S1@=#<N+;\%K[#(J29(CR,D<T)DO;WNU@C*<]/O&,?VN/:F<OK[65
M>2JRREO9P13MM@OZ@G51VMSPB+WK99O;.!L)V @@Y]-N80_1L%R-4."0NF$.
M/HE,\*Z78)L2,+$N2GO>J'O;GN#E==C&AX[6!.]_XW9'BZ&UOBSO!+T0V\&K
M#1HC/_EQYX2X1;&>7%&&TAYXT^NW^YT>GI2]_G@RNM\!,NJ-?V_=M?OMKUWR
MR]IG*)HMLNO#A*!0W+#(?6G7&W>_9L<C;!D,1F3X:%K]V$HN[7";=4^?-OM1
M>.:2C. H"(@'\N!>;9';TF[7'_3/R&P<#6YOB<78ZT^Z>.VK?P2L'A/TYPHK
MM?M4O#E?8/:RM/6-[Z_&^(A/!D'W&QF[)S7,&0;Z9=D69!OHK7_;]/;O)Y5I
MLI>-492HO%WR),K[JET>*=\#+!_%P*S@@= F]<X5 8M4VH9W#@EM?.YY)F!6
M2]OMOG]"XV"2<53 \I3-STKN"FUR4_T6L'BEO1GP7FCC_]"- ;->VJ]+S@Q]
M@XWIU8!%*&WB KX-;4*).#E T=Z7MGQ15X<V^?9]'K DI1/ @>=#X]3>^A=@
M;DN[>]'+H(U5P-T LUW:M&&G@\:=^=#[ /-/V:'+/@A]0[O@C(!Y+FW5^RX)
M;=Q"UCS,>6E3AFUZ;5((&?>P2*6-6-C$US<?#FQ]6)C2UERR^+4Q#9C4,._"
MAK4V$8KQ^6N4.GZ0],DI*?6I_M /I:UW+U[?^K=U'ZUM)[5+0(GABPA2VGFI
M,7VJ0$IS=]B)1X<Y.A"U:940=YH=3 NNA)T!D?1"XMSQ/=^)-V<]BM#;'BMV
MJ#0_R0D"S"+^JY?^0J8]'J[=_$+&KV^2?/TZ*KOL6&&+@!>3E<[?[=C&W2+O
MUS=X$Z%HY]2C1D36]K//+* IWH?2L3''"HO=U2,ZP[]%85+()*(40SX.X,/A
M(JLVR@BQ<RQ<9PF#QXZ&32]J<QDWH^#,VV.2,ABDX:N"_[ZJRB/@PL "V;J'
MP,.Y\HS6W2A 4V<5I/+[QRF&2:8(:*1<*D]?[@W^>;>7\ULZ]6P('DY5O;["
M%(L@ 2Q:A+%AD$2![Q$3>HS/#"[)._:Z89IG7'.V8I'6KV83%E<59?&U#7G^
MJBO6_E1;K@18<CC;N,WJ@-KLK;7FX:!Y.QT[P9,S>F9OJ7M$)]M6I293Q&)?
M]=+*N"R_+AS-T>\^V0,-9L-53)$ ',0&[F C<J6+=T0I$+V:DTA)< I>AL+%
MWVSVR$YU?"AKF(J!C8<!>1C,WMJEH*IGHZX1K:LH3:/%8)K) &Y(6WH*>0WH
M"6Y,M"ERB W$,&A"&VA#3Z*E,$"'M ^T)<(8=*C<@HN=@=!\1=$L=I9SO-L&
M;5*(E7=< !J\FJ,#4R%E3*M6HM()*7\O YN<ZGC!1H&+F8W'#G6PF7T<40*M
M9G]"AV1JQB^#Z56,59C,O_GQS ][2>"$7L*V@@6:/KP_U1;'FSA1!4' E5)Y
MR=)K%#@_G1@^5&1D^U0/'VS0-85G2*T?##Q4=)P4S2*RU^+#T2[[4"1>PFGY
M:HX98BJBP&T3V@*.<V[;D\5'Q  2Q]7&,TF=T)I]2JD)?MUQD.)Z]#/B^.MI
MQ ^Z2YS)SZ1(2 9(Z28^F$XNUY$<</)FT;<HOW;Z$\6_H< K[#$OK-DGV,4#
M[7T 0RH-5I(%@MG Q;4HUN!GB.)D[B]W3QS)X\SLQ#JD^=* +E#+L$[(2+YZ
M(74=RS<IF,?E([JU?SP(R*<M)$YGHA>ZQ-!#WOTR"O,'F(M&!JTRK' G)N-7
M41J!4*W^0J/,*A#KFS%;U@N7:^3+0&RNV32W:R1OUQ1N!'[WT_D0(XA1<H*;
M%4GTN/:#%;FTU)U.D9OVHW3W>G;'"=Q5X&R>[L1TR.LZ<8@1WK_?R5J#=7-B
M_WT>?7A9?!%H@K^*+9\VUHRWUDCQYBO'CR;2VA!?FL;14(K>"NO8BD,F6QR^
MQT:L_:D<<A)@R>%LHV-.!]1F.^AJ'@[6Y4%M7H?D9]CL4YXL\5EJ4AY"6)9!
M]3K-R'[>EBWAA'[+E*?+@:ZB;980X-10KN\1MAICW\URMS$K]UA5'+W#+4[G
MS:ZL?XXP-KFU^RO"]F"Z/>(-8L\/G?@E?^M],G?2=HSV580/<G[DK2M;[$QW
MVKJFH'N\ZIOK55$OJ("SW$R'"[.L2:G6E;#G15_%EH-:G)O:FX5RG S74JD8
MUF$%SD*US4(1SJV<9E4:%8&T5$JK8LU1_4#ORH\R "W5VRK6']V"UG@%I;R"
MM()A4LX\1@?V^^"XVK'8==8)G(0L.U0AN1EH_,:&.,[X$):R4T058X6[BRF-
M0'Z22/.399\)(R6%L8VNKOIA-MO15>M0T)R/=C^^[K!M]QW%Z6[D2\R@"&1=
MFS_J/O%2CDZW%*>[3%=9J?N\@PM7#6Z^S<$=/!472!X^F>LWH/)JINE_:"R=
MTZRE\GLW96NI==[82Y+V4K$T]!5*?R(4[J?=2AE/HKW9;TG)Z<UFL^JUW^J1
M1%+5E1X33:OF2D]SI:>YTF/BE1X[3*@J=W=LL)].5BJFFD;W&0=5JERGDX@\
M!\E4:H'DA%9I%:T><J[/)BV^$??-"5:H35(*EK$?G$-J9C317G9 UF;E\2Y@
MPZHJ_Q"FL?^XRE--=U8JI'2(WGB-,QG7MB(/X\A%R$MNL!QC)T"#O9$ &MV<
M9L8K7X1_<*VIS_UUCTW2231&:8I9PJ:5DV;/Y=!OIAWXFN"VQJ,A+ 1X]*L/
MDG$4T#*A#O@F5!:I><LNI-"JI;:$UIGN<XKBT FNT6-Z'3L_O>@GN+SSVAFO
M="$!(!BJ5B"!85C%[MS)@@/\K95*;+["0:XA+7^L>T'?L"2TM0HU-AX%<2D@
M5#[5A\KV@'N'/SB_! _T< N+]$]E'5+ZYU.&I/;&!B.%K_0DX^&[W+IR+VD,
M4\-HI8<8 8Z;4%J%"\FI$\Y\\JIS!L,=9C_VG6 2947G7R3O% MU9G\@34IK
M%L?1>'+RHFEB[0V)J<F!>C@\9%1E16"-)Q _!B/:PZF";%*0R>)M8\!-%^1F
M!]\T# O-@;C)H,^)<&P(3A:&DYQ.$<2\-L_O56]"TKC8>MTC.EU$[@CEEB5H
M0G,JQVX3H/N7#M )N;0838S7.X]W;>OU?1@C)_#_0MYME*5WAWO,C) ;S4+R
MYUZX%6TP70=1(CBS^MA^C4=0B8#:@H%[O+&"3R5"XX&@<ZPMIC=T7K(;$(.P
M&(>Y3_QP)A;S%FQO/ Y2@FB+$!8_O8WAB S^+;'QBH>YUA8 S$H#+-.#G6Q7
M, !2.*^=\;H7$D!;A'!4V)&^8C$'H43RC5!C"P 1E4);A+#(TB#L1T\.Y=0W
MB?)G2"+0II/LQBJD1.41"#"JPNP)A2N43V1RAA.<0JQ6%B#"91\"X(MZ)\</
M%";%Q*WA*AWYLSFL?483XU7/XYT5,JO14N@^X]-$.*-6[2H?OK?4QJN;P;8^
M/][^0K>^N2:HZAVY7;H^X!M4=JT&L&BB#JN-56J72M8Y/VFQ?EKRRP4E^>7C
M.]'DEXO:$W:*-=_$DHT^GA]R7ZSR!B8>-4D\S7WXYCY\<Q^^N0]OU*7IYC[\
MJX76[)2<5W,?_IQ['_[<TOOPYR?(P;F-W!_$D1"RM7I 9MG->!KW^FQW6W)P
MFNOQUMGH9F7?M$-O=^FG8.C*)^5 /1F/4D61M"WWG<Q[V0MO'#_.1I%T&%:\
M!_/!DA,%7-JT1,@%YA.OG?& " D 'C:;L-)1RJ\:5E*>AD.Y.#I&RS03<_<8
MD<!-V4(KX[4OP#X$P ?3?/"LQST^EE[*A7SQ.I]GB98H3E^& 7F%)O2Z?Z[\
M)8$,_YQ-@+-H>K9*$-=37WJ+9C@:#+NCR1__T1K>MON3_)&2[C_N>\.[+GF>
M!O]KU/OZV^1L<'-V/^XV7OPCO?@@DE+>>UXO]GOMQ?1DL[=^4X <GMNB+X-P
M>C#$>R^(*/AH@)">[/#><T62>$:"V\?)GPP1 TX>=RN]^QJA-]S;KV=X:/;^
M?QW><QX#W5&<_D$1T:D5@?QK<POASUZC991P'ULM$9XP$G"DGBERZ(L)9&;%
M8'J_-BHX+]S2B UXW*6*XF%9]$4.) ,R)WO%^2A%'TH KM(&'N% >3M.'+_X
MX:R]("_%ME-2EY,$JYZ(S\0#$^ZW/1_5\<.%[K6NBIFG0$35H:0:1TK;\S+=
M)Y,H6UFBZ=9/PQH'C&9VH,P5P"*##9NQ>"=V@@0<NAS'#:>U'8B*RJ$M"M5V
MW=5BE:4!X*-2C%P_NW0E U+6D6P_1L-UA$3:XB<W_O-Z/2]R!\%#IS8?!!;?
M I$2Y:K>3%\!/6](K5+R/M.0AJM>4S[%8;+20=%HS$39A] [:>W=_/(N8;(7
M=J+%$GF^ZS"";>\/@VV]_K?N>)(%UGK]5F=P-^Q>]SIM?<5X61(P8Z(?9$71
M&!S]3KY$QISSZ >D$A>,R,=#,;ZW1Z,VEN&VU[[JW?8F?S2139F5JU +*$]5
M2GHAF<D")86Y3>V,80IJY#4$+L=S)T8=9YEE5XC&*LN-3AB>% 4+##Y *K#"
MJJ5*(1%^HC4[>; 11$0(0ZM#BLI@M"1PJ )JS>'!C).K]8&%$\BBT9X^9,B8
M+9$ \]KBA1D#'0E-'] :$#64436->WVQ0FS$N=G\;<_P_XDIG=7&@,BAH/*Y
M4NB+&1;N"&SX:*>])%DYH8NZS_A8Y"=H&/LN>'%"O(>'<X-]#)5D41U1DH$I
M&VNP6PYJ8"4(1=:U;0:TP9#%&&5F0M; 2IT76=<6G*%<73ITU+ Q$.[ ?$PD
M10'/HZHQV@R0+1?LE0@@-U__3,:U1;U*7&R'@[#"MRTLU/D![P(1,/T>?L"5
M3'NO[N,G<5]R\V1=XTUNO,F--UG"/=5XDQMO\NN L?$FU^5-'B-2"D?0G4PE
MML:?#'*OS8>PYS/BGMSIU ^?##^T,]C6YB#+1L26@2>6EBFDQJL8XEG;0!XL
M<WMIBC)6\G^"M@.=VG@M,]A6[0&K,^\<)6[L+_-23=WG)2*EQK]%@9/NO!AK
MT;Z2=9%:;GV7ORW=F\DP'RN6:B>;KF$P\I,?-S%"/2Q)C))TA!5US$ 0[,^^
MH2 CF&H?8(V#83/"K_TGWT.AUTZ&>,_&ZG%FLN- LBLKAD 5F6QR15)?#_@L
MX8J\:%R1C2NR<44VKLC&%=FX(AM79..*5.B*%,RWI!);YHJD<-^X(AM79..*
M;%R1C2NR<44VKLC&%=FX(AM7Y&MV15[27)%?)%R1EXTKLG%%-J[(QA79N"(;
M5V3CBFQ<D69>1K;%,<D3HO%/-O[)QC_9^"<;_V3CGVS\DXU_LO%/-O[)U^R?
M?$_Q3WYZ)^&??-_X)QO_9..?;/R3C7^R\4\V_LG&/]GX)U^%?W*?D:0*! >-
M[*D6RA<#A,%,/_%'<RTM'MNV^(E-5S'$LUU^8M.US&"[\1.+.U0-AOE8L1H_
ML9P[U;JA("-8XR<6\:G:, 2JR&23GYCU\-6G<PE_<>')J\9OW/B-&[]QXS=N
M_,:-W[CQ&S=^8Q5.'"13[-/J6I\G+O69,2!<RX!2#( &OKFJIG$/#FOSWX[2
M;5+5$P]A&5$?-8% "*L L6N'ETB[T3@4!3Z!:WBT")O=F3 0&G"+AW/=+ZK)
M>I=YO O$2O0[%(:K=.3/YH57?$)O$H5#YX68 / [U)\N#KT*P_M):]3[^EO1
MK]#N7[<F@WYKV/ZC?77;;5ZF;KP+C7>A\2XTWH7&N]!X%QKO@MK3)CZV3*(?
M*-Q%>=DG?XC^X;TM!WZF!&#TTL#5<B_#:# =K-(D=4+/#V?%Z-S%N_,O[,BE
M:"^67&Z1$D? O# %[N^(F!S(:S^A&!LE!X(6I2L(W0NS/SPZ^/B&S9/,SB56
MUBQ3)V]LU/1)*P92G;)K\VB6#%5$](09G:!XT0O_0$X,6GPB;4U&4DX(\'QE
MWD)P\E0V@T$_5BSPX&7X,&BN/#=7GILKS\I2V02O/*LUP;*C!<_NRHA,UCG
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MG2(:+S,0;&)(7B 7K?(],:8.K,A2I\C 3R)C-#I5)B /"P'L;,P"5 N?V1F
MRB#6773CJH=_>YX7]L$&)I;2?T*$'T[A#4Z[T[W PI\\D:P<$!R5WV'A1N_H
M+X7P(GGT5@]?##=.!-B'$% ^'_8\*OOW:"G/:22%]S2$PJQ2/5H#7$715)]$
MI$#M/B_]&'F#^":*I\A7BZ]TYU9"74U*\ 2C!_4LG$%.SAQ>X?#^<=U:BK2<
M?."&J0/C]I/C!X15/"QO5BDVG]H_G=A+E,WN2A^P$O?JDD(CX*3U)D#O'+4H
M<:GF-ML[=]%XYR2]<]OB:W=9TLRZV&B%JA("'=GOKQ/6EL6.NX)H/(==B=00
M1YTX3(=@ \);X:DK\,YW\5"(3^69@W3.P,9&3]QQ\)CM>:L,H>Y[MKO#Q]I&
MYERK!>A/5M86G@.1(-O:#/Z](GD9&]E=*+':<?DU">$>3"X95T44;:XV>OU2
M#B[,1L9#P>?>HCV_*=EYJI*=!A9N:<KX-F5\F\JM.BNWOC?2DW9)\Z25WGUC
M>](N3Y>F]Y["_I?2VV]L]M\WCD!)1^ _5GBX^VE6FK<73J-XX61S]C%:I=LB
M:+TP2>-5YFR>S)WT-^<)_8'2233!<R7)QL8D:@=X4PVS?JY0Z,X73OR#;+!2
MWD1=W-CODM2+F\5^S>)A;RL@-R>1U<H0;Z?F$5"^$</3JQ66%%T,OJ>.W>Y4
M/E4!4,1PM-'36@>49OM?%<.MV2O[7TZX<N*7\TN2!<AVR%)(3^:+%9HP$9]Y
M;1[9S?>_X+]=B.FY0%K##*A;T8?<@YI6KNH;]!AG+'S@ZYI&^W"R*IW2R@;9
M![<,]0-[%:+/ H-ZG^QTI<'E!S2%<W!]KD&]P<O%)Q'][M.=+O^\@H(IK(->
M'^4:OL/=SR_?X;]<LE5<(GSX8(V.Z;Q#2OY0CY()QA\$=%R@>_AHEXH/68<T
M_+&^A>*CX$*QIGOX9(V&J:Q#&OY4SQ@^/^>KN$3X\-D:'=-YAY3\N88G>)=^
MG/E0KC'+D(;WJ1[.=1^/9>/>-'XAG2HW\?8>_(4U6B"R0:$E=K69<B)/ZNZ]
M2&N\-LO<@O:#D4$WUDN)7\[EHE?-&XE5HU@%-_=W/YT/,7IAZCM!?G'BV@]6
M1*W=Z12Y:3]*>Z$;K#QR9ZKC!.XJ</*T@(P.>5TG#OUPMBW8(A7!TL&)_=$K
M?7A9'+F:X*\F@VD;:\9;:Z2@-UX$2Z2U(9$LC:/A<%"*Z]B*:!9;''XH1*S]
MJ:);$F#)X6QCM$L'U&9'OVH>#O5$PVH<$?A@FF*;!*^!V<)WCT&"GP_;-H-;
MG<Y1+C5;#['E"*3<?][<R3-T;Q>^U&=@3G=SJ<_HS;>YU'?Z2WW?\#J/U_B=
M8X;M&0?(3Q>#$+O3QV);7_RAO4KG4>S_A;PL/3[G9%,JF//$!;\I'CB&>RF%
MA=#F62]6P5Y?61@E*Z9/N$1MOMY9?%MDEJMY!<%@L 0X5WWX$JM+M"F?! :?
MZ-1&*YO+-[@'U[,(C=!RO1+B8WL:;=YAZBZ60?2"T-!YP0H()LXSO$E(=V0^
M0!5%@K S\&V7W]'+G1,Z>>4I;)(E41BBH!,MEO@LFAENI5I5K$6O0G=&CX+C
M!8/&0M5W8]CS./M^D2MR8S*$5TYF(Z.1$64?TK_R)UQ&Z D/"R<8 %Q!$/#:
MF8^"F 2@H5/+1+@"!L5]^)0;8Z))&#(=F0]519$@[ HOR.A/Y[@EKTJOG8CP
M"R=?+@[S-VX'XW%KV!VUQK^U1QK?-J'P2WO5Y,NE(,/->R;2*2;9C4G'S4;V
M%4I_(A2.4(!EP'MVG/I(KFRB:&_VIWK(Z<WB=(T.EFD6Q3Z)7.U+R(O=\%H:
M$LJ11++\A+R(?JSPY\"B\*,!_+:GBMT( B2.JXV1G3JA-3ON4Q/\UJ51;-[K
MXZ=.[%.>[$*R\ 0\A*[,O^HU6*0B)ZSHPZ*6)\]+D=4T2P!P2BC7=2$AAK#"
MS@M:6^50B]-=BJND>XX@H(-'?0"UD,J4)[L,PJ)1!T9/.>W,=QN(22 0-]7O
M)>A$BX6?YMF$H=?!.ZH?SC*!G4=2-9",/8%;(.\/C?+.X.ZN-[GK]B?C5KM_
MC?_=G_3Z7_&_6[>]]E7OMC?I=<?-O9#CC?;!=)J@E, VF&YK(E5XY8#?C_V&
MNJBN;#;1HQ6YE+H4-,LIU(:8XL)8E4[KH ;L,+SWV!>PR*CT)S.P8>6S<;+2
MD%8 E>$&\W%P:DZ7[(P&[$/_EN!TABQKT$<0J]IL5OS5]BQ&V?C@JO* \G2%
MG6242F,:7'/4^P10_.2[Z 8Q\H1V)-H3=Z7CI0>\"I@X:O1XM?)F*.U$"?R0
M8H'$>#T>\JIMOG^-B9D:1RY"'JC)/2+C=5GF%IS>JK5Y'V*;.4#>>EJ "CVD
M,UZG5(;!?5UYQ<'-^Z]M[PF; ;M7(2']@@V,5S2;<TCCZM\]1>E7^EDV3\S-
M_VR\-HM\0KJKFFA8HUG1]OY[E>0^.3P>>J%+,FK1-<K_VPLGL>.AMNN24P\>
M'SPG3X7N3$;V:+E C[CJ632,T=+QO77Z&/&O#M(YBD?(1?X380=<P/@M349(
M1@0(#.5IC\2U'3MNNG("WO9!(35>W1#/D'X_J[=LW%7LIR_7:!DE/JS<0SKC
M-4ME&%+KEQIVXI]1_,,/9]T_5_Z2L$O,!,;.3",W7LDLOEDN>;7*7D,,*7?]
M9^.56>035%[!E-0?=2P$MU^**7>,/.4/AQ'&4?>V/>E>MX;MT>2/UF34[H_;
M'5)T;JPO9YDC!S5_^6,%09I<YB:7N<EE;G*9FUQFXQ)>FUSF5PNMX:%9FW*9
MP8/(G>_.'11,4+ST.=5M**36Y".S!- 6[+FY=D(?!6/?]0/?"2/.VSU4ZA,&
M>:NHG"$$N,K5$&0CC+_\=H6/\NCE[IJM=SKUZ1Z<J:1WAA!@$$-Y..Z_G 5*
M[E 0\.IFE0CUIQP?IVY  /B,KES7XQ0]H? .2_T7[Z[# >'#N5WY]H  H*X_
MJA_7R D[\]A/TF@Y1R,41J&'-Q3.NL)N]7!AU\(N(@VXPE^HAV25I'Z(A\;C
MHQ_.[JZ'<QX:4(.'BY.]9E,-"+8@( :?E6-PZX>>\WOTE^_^8.N^1/AP:=?N
M"@@ GMK5;ZUW3OQC["]X&^L!&=[_K=(SE7WP_*)^4QU%^*OIU\!)DH7#436-
M]N&]75LK+ .H=/6[ZU7LIZD3OOSN^ F*V4JGT3Y\L&LQ@66 E/Y!_7K2#?^*
MOOE!@*TUML9+A \?[!KC@ "@KM4/\.\HN45/&'2VI@_('C[8=2ZAL@]J6?UI
MY(]5_'*'-<-9M@_('CY\L4K+5/9!+7]1KN5V@)Z=$/<^Q&<AQ!O2=.J'CR=[
M_KN2SEE20*K_>*Y<]3TG_.X$*8HY%^T/Z1X^GNQ=WTKJIO,/*OJ#^C$>>C%R
M,*,<L^:0[N&39>.:RC^DZ$_J1W2;[,KCN?.3MXKLD3U\LFL\4]D'M:Q^..>'
M_-]C9\$[79<I'S[;-:0A"2!U?U8_J/'Q'B]@F1>>9\KLT3U\/MFK$57-& K_
MH*(_U>0"O''\V)W[@2?B_CL@?OAB5]4?AA"0WK]<5M5[C3D$8W\6^E/?=<*T
ME]5XS=*G>V$[22+7Q[K@9@2)]O Z,H/D]*7NWMU)AP _G42\CU-E#$D")X^[
MC1E$.J$W.Z-(T_#0G&%T[<?(Q>3%BM[LS1EN<;)\(^FI%PG+HWJ5AGV\S\C-
M2J0-IE@2) $(O^7#AY,=G8Z"1E0RT*5FXI.>-PAEM>06"S])F(]L;-L 34@:
MB[F7;02YA[ S<"\\%*07NM%""KB\A:6X[3$/P:8\/;!P&N_@$[H?SJZB< 5>
MQ@'(S5:Y .?:]J'UA4YLYMP3+_JZ;.WZZ3TP;8W5R +=B_ /GLG,6ZA4O39H
M+FHBK$. *:\'DEW=%WFMJ41HMI*9/(-G+O.F0Y'[&ZR(R=R/-[X<4AN#R#Z8
M#N-HB>+T91C@68\WONU5:];,.;)KL_%7+"48%#3XKO7EENW"'>5/5>XH7S9W
ME)L[RLT=Y>:.<G-'V;"+K,T=Y5<+K=D1A==Q1UE)DJ%5D7U8!FU>L4,6)C\Y
M]Y7!!C5,$9VZWY<#U+]R 'I.>"6:X+E/:-D=<3K_X 93IZ*Y@YQ&:]E;8: (
MX()>J\8Q*1+7^8[:L@OY#"% +V(-+X21#-^N:"IS@?#!LAQ;*O^@0[%.1?/W
M30JM94_@@2* #KD:CBO5<L?MTC.%>TC%G^I3L<!1\)#RP:[+:X  D*X_UZAK
M_OY(HWVPZQH;* *D\2_J7S ]YEJ$9>5J( E@?VVMZN:N)U3BAW.[[$J&$+!1
M6:_>^6L+0/YP;I>)R10#U+YZ4[/R9:!SNVQ,.O^@HM5;F#L&N(L+A?3AW"[C
M$A0!U+AZV_+HLAWG=IF8L R@TM7;F4>4[;"LZAL@ *AK]19FQ8(2YW:9F%3V
M02VK-S*SC,AKS"NDWRW!P[EN&T<VL>V 54B+!D9,\Z>=D/<=^;,Y>0WM"<7.
M#.4ID*QP*;.AT8C)B #.!]6S(<\]C0ZSAX,7/YS=A^@9Q2[>?;QU-O%]V,U_
M V0M97T>T:71^*D1#HPZU7 9*^-E&+,>JMRG,E__-'[!L)+R).D,U>[STH^S
M/%+6+D*C-5^],-=@#*FV%8DLA_=8,0G^.8W<'Y,Y2G]SGE _2K^AA'&30[P'
M\P&1E06,0-51'Q2EWYQ@A8Y'K%)GYH-WA%A@7,O@1/.^$Y-5XVF7S5E(./]<
M)>%\VV/M[WS=^*$3NKX3],(DC5?9#=]VZ(W\Y,>=$^(6Y#>,Q\N^'(IWUKKI
M]=O]3J]]V^KUQY/1_5VW/QFWVOWKUJ@W_KUUU^ZWOW;)+PNOF37I]5+I]:0R
M33:][I!#?D-8'TS;28)2N<QZ@8[L3ZH7UI;%^?2WZ D%24'6WWQL7,7N_(67
M3\]K:4@^O3B(AT-!3#56I-+#HO#SK?EM3Y5*+PB0.*XVIM+7":W9J?0UP:\[
ME7Z!3UC^7\@CK_MRTDK*I"=+HA>>1!%? &W.NRVSDVA[Q3E&<S(BGU!>ZH*-
M@' 'I\NPKP2,G%P@7C4"-H^CU6P^Q!:AGP[BVRCAI.#S6YXN)_](B)@"@5N7
M@:>28CAL:T_F)[/V([8JL;7,VKT$FIO\,+FT'!9%JSI.,B=UA/!_2$6 )R<@
M_@$VF+069F0#"X!2QA041]MNAX<@-F_<B'H&S$AV%+8IFL:^MDC1,$9+Q_?6
M-<V(VRO;-$?(11AI1J2/V]!*&,2D4AUTTKTOW?K.HQ]D$<S*FQ.E#WMW*$@8
M;8&OMNM&*[RJ#IT7,LKPN,._B5?(*W &FE(";0V;C!Q]1U6DTQ;]FD3AFIE)
M-$9I&J#A*AV1=(YD$Z$&@UTB;>W%2E@Z@0B7HNUM_?V-$"_@=G9(:"\*=%$@
ME7\R;\_Z3B)_(1.S+?$AK96PL:6!D/NL>K+<(B=!VV]W5G&,LD)H_2AT\W]
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MU7SZ X!OXBV) .2-6$]W*S/Y _%C(@$D$O_^/U^W*7B!N$!Y]A_?O/_]=]\
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MQ'30P_ 99@5Z@?,LSK?P+B\*!3,L+;CCS$%-Z]ADI1X(SP[!/&9@SP9@1L#
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MWX$=-<!*#\#&Q-0AXL?E9]4B>/]G=VZ*!]5YJ.XW[U20 .)2%<$2?':POT&
M7,-=7JBW-0123CM6#''0OT.1<+I9B$O8VZ 1=;"KA3;/Y6+]N:BFJ*H-+;&D
MP[TL%=3>-I9(+! 6J+!QFU=4EJ:3$FG Q,\J+GE\CC"LZQ";A2*\AJ?H0P9=
M$G",Q;USS1RC(JPHJ$97'7KBY'CZW$ME,HU*T&'ZNP)H+]]=(.6=%5IH0C*
M2] EUTP]&+$G7IG2@!-T3 ,)T!$-KL*E@1B:F 97#FE )D(Q9!.@#?D? SJH
M%=S1P@1X1P^5=" T,8 XIDNK IB.0]H\0@2-!A&QH,/T/ 707H*>0"H06BB@
M<4EZ5-3I(,*>:#*(B 4=TT [B(BD0J*!V2!2T<#_($(%K0>2OI+OP81O@&Y
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M]]1!*MR24,Z=1U+ [)R10,@[)73(QCRH)4$E.OW8U"#[@?SVP:#_!W+N^U\
MD^__GE!@_<\CD_8_$YV^_V_A$V;0_J A@%C0'0-40#L*B*0"X8 "VI@$C2BH
M9!UX@7T&_ZSS &,9AU^_&%[ORQ\*!-+C8E3<%T^DP)]=]7/Z]N%/VHX>"[GL
M:3' ?E</)8+I:R$LOK/3-U#)3=_;G\B;>/[^._++]XKN%DBYZV\IQ*[#.9%
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M$;S!IE=?()"^%J,2;'A] 4S,0:WSG)@O/])ZIEOE>1NQH,-*YPJ@O4+G JE
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M[\DR>J.CX:JK]: \9W> ,>?G[@YN,'<.S]J2=\*?!+[P(/,%4V(YYC"K2C.
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MBU!X\!,_X>P^)=G(<%+S_UJ?E7+$.?W'-?T@U:[9MXFALRQI7H7BVS'2<YC
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M"G!M@_CJR@B[%F546'(R6K(LF%7^N8#L4/TL)E,DS%VEI)%U1S8-W(Y7$L%
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MFRP\S8/]91A/^2+E:<E3/-7[M^R\J29?/VB__E>(8U1 L,,HKO9KZ,0"-S!
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MQ3 PXYWEQV/7%:=H+#59/=O:%EW0@<S:Y)M'GS,,HQ3]"A-:UIO,8++!9_U
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M.OV.=NQ&93)+P^6=\I,Z19.X*A*#_(]W=+/I#P%_*[,D0>R(X"IG:93Y>E]
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M0_Y#QB0RY:NW7M1E7LR5'99_L&Q0KR"$H68@7+*$.V993QUT^H"N6]<6>EO
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MM7%^G"TW[#;S0J]AO)*=*32ZV5]Z)-K^1IS&PR3BRX^FL93NX&FXE5"#U*^
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MRPZ[9UKF0DGAC/2LH?;VND@,$M,]!_O4BI4L(H61"YOT>M<#R4$T!Q2@@,N
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MST8F[AM3!#U(%] NS# '%J$38;$%(S+-"C1WV)H)%6V\J[C& (&/"0(VDP2
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MZ3WHE]):2!7AWZKX=5]:!*U93/H@++.'B9 ?RA!,V!=:P''2'P*MXF6["VN
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M\=LP_-G(::&52<*W Y=;0>$VK>+R^#,"\][$X<>TEHP(ZO.64+A-:[8B/HU
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M6;_&]EPC)T(%UB'[9(D$*D3]UHXJ6R0' 6V+:C]=]M]D1<&E+1D-H4CKMU%
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MZ#N>*&J<UQHJY69-:,K[A1 +*\6W3Q9[8%6XV_-:0\77;*REJOC$6%@IOKO
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M4#T91+<9-+89%,5>8=5SR=_<\I8 9<TZSFL?.^1"0[A+]OO1'$=?[\F8,TV
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M\U9 G'^R V<VCQ:?- .BM6T"NN?2I*N'X&N(M4U":<L^5;.E3<)U8=FW1]0
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M%ED!C<:H=\; SAC8&0,[8V!G#.R,@9TQL#,&=L; SAC8A#'P!X8Q\.?W"L;
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M4_,* '1BG=[Z^6QKN_<?!K@,#GD;0O2$_ @_HRR[CZ2D'+P#\SI#);$H0]2
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M  "\%P  "P              @ $     97AH7S$R,2YH=&U02P$"% ,4
M"  'L/1<@AAB6;T&  "M%P  "P              @ 'M!@  97AH7S$R,BYH
M=&U02P$"% ,4    "  'L/1<$EQ&G<($  #;#@  "P              @ '3
M#0  97AH7S$S,2YH=&U02P$"% ,4    "  'L/1<9Y:2W+($  "'#@  "P
M            @ &^$@  97AH7S$S,BYH=&U02P$"% ,4    "  'L/1<EE).
M>[)E!  @2#  $               @ &9%P  9C(P9F%?,#<Q-C(V+FAT;5!+
M 0(4 Q0    (  >P]%PE_.;^["L  "55 @ 2              "  7E]! !P
M=&=E9BTR,#(V,#,S,2YX<V102P$"% ,4    "  'L/1< Z43.88:  #2;P$
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I968M,C R-C S,S%?<')E+GAM;%!+!08     "@ * '("  ! #08    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>f20fa_071626_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptgef="http://portagebiotech.com/20260331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ptgef-20260331.xsd" xlink:type="simple"/>
    <context id="From2025-04-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_IOxIPRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:IOxIPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_IOxIPRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:IOxIPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_IOxIPRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:IOxIPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TarusIPRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:TarusIPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TarusIPRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:TarusIPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_TarusIPRDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:TarusIPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_StimunityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:StimunityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_StimunityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:StimunityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_StimunityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:StimunityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_custom_IOXMember_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember_custom_IOXMember_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember_custom_IOXMember_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2023-12-012023-12-31_custom_IOXMember_custom_StimunityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">ptgef:StimunityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-09-30_custom_CountryOfBritishVirginIslandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ptgef:CountryOfBritishVirginIslandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-09-30_custom_DelawareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ptgef:DelawareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-09-30_custom_SubsidiariesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_USDCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:USDCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_USDCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:USDCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_UsdtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:UsdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_UsdtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ptgef:UsdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_USDCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:USDCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_UsdtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:UsdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TONMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">ptgef:TONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BITCOINMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">ptgef:BITCOINMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TotalMember371194906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">ptgef:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_USD1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:USD1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_LockedTonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LockedTonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_GPUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_GPUDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RightOfUseAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_GPUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_GPUDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_RightOfUseAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_GPUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_GPUDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_RightOfUseAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_GPUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_GPUDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_RightOfUseAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TotalMember371195968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_GPUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_GPUDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:GPUDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_RightOfUseAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ptgef:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-06-05</instant>
        </period>
    </context>
    <context id="AsOf2026-02-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2026-02-06</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ClassBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ClassCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeiesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeiesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SeiesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeiesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeiesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SeiesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeiesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-03_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-03</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-19_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-19</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PlacementAgentWarrants2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrants2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PlacementAgentsWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-02</startDate>
            <endDate>2026-01-19</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-12-08</instant>
        </period>
    </context>
    <context id="AsOf2026-01-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2026-01-27</instant>
        </period>
    </context>
    <context id="AsOf2025-09-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-09-02</instant>
        </period>
    </context>
    <context id="From2025-08-292025-09-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2025-08-29</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-08-292025-09-02_custom_TonTokenVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:TonTokenVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-29</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TonTokenVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:TonTokenVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="AsOf2026-02-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2026-02-05</instant>
        </period>
    </context>
    <context id="From2025-08-022025-08-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2025-08-02</startDate>
            <endDate>2025-08-28</endDate>
        </period>
    </context>
    <context id="From2025-10-052025-10-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2025-10-05</startDate>
            <endDate>2025-10-07</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="AsOf2025-09-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-09-25</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ATMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2026-01-13</instant>
        </period>
    </context>
    <context id="From2026-01-012026-01-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-13</endDate>
        </period>
    </context>
    <context id="From2026-01-112026-01-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2026-01-11</startDate>
            <endDate>2026-01-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2022-04-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsAndPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-03</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="AsOf2026-03-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2026-03-11</instant>
        </period>
    </context>
    <context id="AsOf2025-07-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2025-07-27</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_ifrs-full_RestrictedShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_VestedStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:VestedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_StockOptionGrantedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:StockOptionGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_StockOptionGrantedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:StockOptionGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_January132021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:January132021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_January192022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:January192022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_February152022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:February152022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_June82022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:June82022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_July272022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:July272022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_March302023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:March302023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_March72025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:March72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_July272026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:July272026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_March112026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InterestRateBenchmarksAxis">ptgef:March112026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-15_custom_CROMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:CROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-15</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-09-012024-09-30_custom_CROAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:CROAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_CROMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:CROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2026-01-05</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MichaelTerpinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MichaelTerpinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:FDanielSicilianoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:FDanielSicilianoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:GregoryHBaileyMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JamesMellonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StevenMintzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JeanChristopheRenondinMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinStebbingMDPhDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:LindaKozickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertGlassmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:DirectorCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_MarkSimonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:MarkSimonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrittanyKaiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrittanyKaiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:EnzoVillaniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:EnzoVillaniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WesLevittMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:YuryMitinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:YuryMitinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanWaltersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:JustinFairchildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:ExecutiveOfficerCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AlexanderPickettMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AlexanderPickettTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_IanBWaltersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanBWaltersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_IanBWaltersTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanBWaltersTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_IanBWaltersThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IanBWaltersThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AndreaEParkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaEParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AndreaEParkTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AndreaEParkTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AllanShawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AllanShawTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AllanShawThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:AllanShawThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_RobertKramerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_RobertKramerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_RobertKramerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RobertKramerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BrianWileyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BrianWileyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrianWileyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BrittanyKaiserMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:BrittanyKaiserMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_EnzoVillaniMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:EnzoVillaniMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_YuryMitinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:YuryMitinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_Level1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_Level2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_Level3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_Level1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_Level2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_Level3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ptgef:Level3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_DigitalComputeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:DigitalComputeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_ImmunoOncologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:ImmunoOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_ImmunoOncologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:ImmunoOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ImmunoOncologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:ImmunoOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_SaugatuckMember371226578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_SaugatuckMember371226609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SaugatuckMember371226609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-04-01to2026-03-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2025-04-01to2026-03-31" id="Fact000004">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-04-01to2026-03-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-04-01to2026-03-31" id="Fact000006">0001095435</dei:EntityCentralIndexKey>
    <dei:AuditorFirmId contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0060">688</dei:AuditorFirmId>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsReceivable
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoin
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonCurrent
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonNetOfCurrentPortion
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0098"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0101"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquipmentDeposits
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherAssets
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0110"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TreasuryShares
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0167"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssetReceivables
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssetReceivables
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OfferingCosts
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OfferingCosts
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossIoxIprd
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossIoxIprd
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossTarusIprd
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossTarusIprd
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossStimunity
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossStimunity
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossSaugatuck
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossSaugatuck
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossInvestmentInCompedica
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossInvestmentInCompedica
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfInvestmentInCompedica
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfInvestmentInCompedica
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnSettlementOfPutRightLiability
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnSettlementOfPutRightLiability
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnExtinguishmentOfDebt
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnExtinguishmentOfDebt
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareOfLossesFromEquityMethodInvestment
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPrefundedWarrants
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0664"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0669"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0670"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0672"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0675"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsExercisedAndReturnOfShares
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0680"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-012026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      id="xdx2ixbrl0692"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0721"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OfferingCosts
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0724"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OfferingCosts
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0725"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2025-04-012026-03-31_custom_IOxIPRDMember"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2024-04-012025-03-31_custom_IOxIPRDMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2025-04-012026-03-31_custom_TarusIPRDMember"
      id="xdx2ixbrl0734"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2024-04-012025-03-31_custom_TarusIPRDMember"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2025-04-012026-03-31_custom_StimunityMember"
      id="xdx2ixbrl0740"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2024-04-012025-03-31_custom_StimunityMember"
      id="xdx2ixbrl0742"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2025-04-012026-03-31_custom_SaugatuckMember"
      id="xdx2ixbrl0746"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="From2024-04-012025-03-31_custom_SaugatuckMember"
      id="xdx2ixbrl0748"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0753"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0757"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0760"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0761"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0765"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0769"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0774"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0778"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnImpairmentInvestmentInCompedica
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0785"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnImpairmentInvestmentInCompedica
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0786"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRemeasurementOfInvestmentInCompedica
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0789"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRemeasurementOfInvestmentInCompedica
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0797"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossFromEquityMethodInvestment
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0801"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossFromEquityMethodInvestment
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0802"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0805"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0806"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0809"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0810"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnExerciseOfPutRightLiability
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnExerciseOfPutRightLiability
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0814"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NoncashInterestExpense
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0825"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NoncashInterestExpense
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0826"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExpensesSettledUsingStablecoin
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0833"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExpensesSettledUsingStablecoin
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0834"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DividendsReceived
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DividendsReceived
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0838"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareOfLossInAssociate
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0840"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareOfLossInAssociate
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfSharesIssuedForServices
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfSharesIssuedForServices
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0845"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0858"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0872"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromSalesOfInvestmentProperty
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0884"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromSalesOfInvestmentProperty
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0885"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchasesOfStablecoin
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0889"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchasesOfStablecoin
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0890"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchasesOfDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0893"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchasesOfDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0894"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SalesOfStablecoin
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0897"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SalesOfStablecoin
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0898"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SalesOfDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0901"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SalesOfDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0905"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0906"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquipmentDeposit
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0909"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquipmentDeposit
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0910"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CashPaidForInvestmentInCompedica
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0913"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CashPaidForInvestmentInCompedica
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0914"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0917"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromExerciseOfPrefundedWarrants
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0924"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromExerciseOfPrefundedWarrants
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0926"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0930"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromRegisteredDirectOffering
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0933"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0941"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightIssuanceCosts
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0944"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightIssuanceCosts
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0945"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightIssuanceCosts
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0946"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PaymentsOnExternalDebt
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0953"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PaymentsOnExternalDebt
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0954"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredFinancingCosts
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0957"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredFinancingCosts
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0958"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LoanTerminationFee
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0961"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LoanTerminationFee
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesFromRSUDistribution
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0964"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesFromRSUDistribution
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0996"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0997"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CapitalExpendituresIncludedInAccountsPayable
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1001"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CapitalExpendituresIncludedInAccountsPayable
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1002"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RightToUseAssetAcquired
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1005"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LeaseLiabilityIncurred
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1009"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1013"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1014"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfStablecoin
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1017"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfStablecoin
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1018"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfDigitalAssetsReceivable
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1021"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfDigitalAssetsReceivable
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1022"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfStablecoinReceivable
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1025"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ContributionOfStablecoinReceivable
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1026"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ValueOfSharesUsedToPurchaseInterestInCompedica
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1029"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ValueOfSharesUsedToPurchaseInterestInCompedica
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1030"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1034"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsIssuedToInvestors
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1037"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightsIssuedToInvestors
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1038"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCostsSettledInCompanyStock
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1041"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCostsSettledInCompanyStock
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1042"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCostsSettledInWarrantsOnCompanysStock
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1045"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCostsSettledInWarrantsOnCompanysStock
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1046"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettlementOfPutRightLiabilityUsingStablecoinReceivable
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1049"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettlementOfPutRightLiabilityUsingStablecoinReceivable
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1050"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPutRights
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1053"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExerciseOfPutRights
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1054"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettlementOfPutRightLiabilityUsingDigitalAssetReceivables
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1057"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettlementOfPutRightLiabilityUsingDigitalAssetReceivables
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1058"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ReceiptOfDigitalAssetsReceivableTonTokens
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1061"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ReceiptOfDigitalAssetsReceivableTonTokens
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1062"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StablecoinUsedToPurchaseDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1065"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StablecoinUsedToPurchaseDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1066"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SaleOfDigitalAssetsSettledInStablecoin
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1069"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SaleOfDigitalAssetsSettledInStablecoin
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfBitcoinForTonTokens
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1073"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfBitcoinForTonTokens
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1074"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExternalDebtProceedsReceivedInStablecoin
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1077"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExternalDebtProceedsReceivedInStablecoin
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1078"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PaymentsOnExternalDebtUsingDigitalAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1081"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PaymentsOnExternalDebtUsingDigitalAssets
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1082"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesObtainedInExchangeForStablecoin
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1089"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesObtainedInExchangeForStablecoin
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl1090"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentReceivablesFromSaleOfProperties
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1235"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidInvestorRelations
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1245"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidGpuInfrastructureCosts
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1250"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidGpuInfrastructureCosts
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1251"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidGpuLeasesShortterm
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1253"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidGpuLeasesShortterm
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1254"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoins
      contextRef="AsOf2025-03-31_custom_USDCMember"
      id="xdx2ixbrl1272"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoins
      contextRef="AsOf2026-03-31_custom_USDCMember"
      id="xdx2ixbrl1274"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoins
      contextRef="AsOf2026-03-31_custom_UsdtMember"
      id="xdx2ixbrl1278"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoins
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1282"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      id="xdx2ixbrl1286"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      id="xdx2ixbrl1287"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      id="xdx2ixbrl1288"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      id="xdx2ixbrl1294"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StablecoinSold
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromExternalDebtDrawdown
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      id="xdx2ixbrl1307"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchasesOfStablecoin
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      id="xdx2ixbrl1310"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StablecoinValueAsOfMarch31
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      id="xdx2ixbrl1318"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ApproximateNumberOfTonTokensHeld
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1327"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonTokensFairValueInThousands
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1330"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsFairValueInThousands
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1333"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      id="xdx2ixbrl1343"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1344"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      id="xdx2ixbrl1345"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1352"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsSold
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1356"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PaymentsOnExternalDebtUsingDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1360"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetPurchases
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1364"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ReceiptOfDigitalAssetsReceivable
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1368"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1376"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RevenueReceivedInDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1380"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TokensUsedToSettlePutRights
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1384"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsExchanged
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      id="xdx2ixbrl1389"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfMarch31
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      id="xdx2ixbrl1396"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_USD1Member"
      id="xdx2ixbrl1422"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_LockedTonMember"
      id="xdx2ixbrl1423"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetValueAsOfApril1
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      id="xdx2ixbrl1424"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDigitalAssetsReceivable
      contextRef="From2025-04-012026-03-31_custom_USD1Member"
      id="xdx2ixbrl1430"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TokensUsedToSettlePutRights
      contextRef="From2025-04-012026-03-31_custom_LockedTonMember"
      id="xdx2ixbrl1439"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StablecoinValueAsOfSeptember30
      contextRef="From2025-04-012026-03-31_custom_USD1Member"
      id="xdx2ixbrl1442"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StablecoinValueAsOfSeptember30
      contextRef="From2025-04-012026-03-31_custom_LockedTonMember"
      id="xdx2ixbrl1443"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StablecoinValueAsOfSeptember30
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      id="xdx2ixbrl1444"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2024-03-31_custom_GPUsMember"
      id="xdx2ixbrl1450"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2024-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1451"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2024-04-012025-03-31_custom_GPUsMember"
      id="xdx2ixbrl1455"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1456"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember"
      id="xdx2ixbrl1457"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2024-04-012025-03-31_custom_TotalMember"
      id="xdx2ixbrl1458"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_GPUsMember"
      id="xdx2ixbrl1460"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1461"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2025-03-31_custom_GPUsMember"
      id="xdx2ixbrl1465"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2025-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1466"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2025-03-31_custom_RightOfUseAssetMember"
      id="xdx2ixbrl1467"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2025-03-31_custom_TotalMember"
      id="xdx2ixbrl1468"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_GPUsMember"
      id="xdx2ixbrl1475"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1476"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember"
      id="xdx2ixbrl1477"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_TotalMember371195968"
      id="xdx2ixbrl1478"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31_custom_GPUsMember"
      id="xdx2ixbrl1485"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1486"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDepreciation
      contextRef="From2024-04-012025-03-31_custom_GPUsMember"
      id="xdx2ixbrl1490"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDepreciation
      contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1491"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDisposals
      contextRef="From2024-04-012025-03-31_custom_GPUsMember"
      id="xdx2ixbrl1495"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDisposals
      contextRef="From2024-04-012025-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1496"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_GPUsMember"
      id="xdx2ixbrl1500"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1501"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_RightOfUseAssetMember"
      id="xdx2ixbrl1502"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_TotalMember"
      id="xdx2ixbrl1503"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDepreciation
      contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1506"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDisposals
      contextRef="From2025-04-012026-03-31_custom_GPUsMember"
      id="xdx2ixbrl1510"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDisposals
      contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1511"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDisposals
      contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember"
      id="xdx2ixbrl1512"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FixedAssetDisposals
      contextRef="From2025-04-012026-03-31_custom_TotalMember371195968"
      id="xdx2ixbrl1513"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1516"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_GPUsMember"
      id="xdx2ixbrl1520"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_GPUDepositsMember"
      id="xdx2ixbrl1522"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_RightOfUseAssetMember"
      id="xdx2ixbrl1524"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-03-31_custom_TotalMember"
      id="xdx2ixbrl1526"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:BalanceAsOfApril1
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1549"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:InvestmentInCompedicaAsOfMarch31
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1561"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      id="xdx2ixbrl1650"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember"
      id="xdx2ixbrl1652"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember"
      id="xdx2ixbrl1654"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1694"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1696"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1698"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl1738"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl1740"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl1742"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl1770"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl1772"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2025-08-292025-09-02"
      id="xdx2ixbrl1802"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1804"
      unitRef="Pure"
      xsi:nil="true"/>
    <ptgef:BalanceOfPutRightLiability
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1836"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:BalanceOfTonPayable
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1852"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccruedOtherProfessionalFees
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1871"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccruedCRO
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1880"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccruedClinicalAndRdServices
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1886"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OtherAccruedExpenses
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1892"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CurrentTaxOnProfitsForYear
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1941"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CurrentTaxOnProfitsForYear
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1942"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1944"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1947"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DecreaseIncreaseInDeferredTaxAssets
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1953"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DecreaseIncreaseInDeferredTaxAssets
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1954"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProfitLossFromContinuingOperation
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1956"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TaxUsingBviTaxRate
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1964"
      unitRef="Pure"
      xsi:nil="true"/>
    <ptgef:TaxUsingBviTaxRate
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1965"
      unitRef="Pure"
      xsi:nil="true"/>
    <ptgef:NondeductibleExpenses
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1973"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NondeductibleExpenses
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1974"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1976"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1977"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ForeignCurrencyEffectAndOther
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1982"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncomeTaxExpense
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1985"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ReservesAndAccruals
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl2005"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetDeferredTaxAsset
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl2014"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetDeferredTaxAsset
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl2015"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl2085"
      unitRef="Pure"
      xsi:nil="true"/>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl2100"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl2139"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember"
      id="xdx2ixbrl2174"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember"
      id="xdx2ixbrl2175"
      unitRef="Pure"
      xsi:nil="true"/>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_February152022Member"
      id="xdx2ixbrl2196"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_June82022Member"
      id="xdx2ixbrl2199"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_July272022Member"
      id="xdx2ixbrl2202"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2365"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2367"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2369"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2371"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2373"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2379"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2381"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2383"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2385"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2387"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2395"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2397"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2399"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2401"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2407"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2409"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2411"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2413"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2415"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2421"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2423"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2425"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_GregoryHBaileyMDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2427"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      id="xdx2ixbrl2429"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2437"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2439"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2441"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2443"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2449"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2451"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2453"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2455"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2457"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2463"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2465"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2467"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_JamesMellonMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2469"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      id="xdx2ixbrl2471"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2479"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2483"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2485"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2491"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2493"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2497"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2499"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2505"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2507"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2509"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_StevenMintzMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2511"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      id="xdx2ixbrl2513"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2521"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2525"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2527"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2533"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2535"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2539"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2541"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2545"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2547"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2549"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2551"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_JeanChristopheRenondinMDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2553"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2555"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      id="xdx2ixbrl2557"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2563"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2567"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2569"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2575"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2577"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2581"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2583"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2587"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2589"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2591"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2593"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_JustinStebbingMDPhDMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2595"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2597"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      id="xdx2ixbrl2599"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2601"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2603"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2605"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2607"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2609"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2611"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2613"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2615"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2617"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2619"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2621"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2623"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2625"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2627"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2631"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2633"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2635"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_LindaKozickMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2637"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      id="xdx2ixbrl2639"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2643"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2645"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2647"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2649"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2651"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2653"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2655"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2657"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2659"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2661"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2663"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2665"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2667"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2669"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2673"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2675"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2677"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_MarkSimonMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2679"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      id="xdx2ixbrl2681"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2685"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember"
      id="xdx2ixbrl2687"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2689"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2691"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2693"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2695"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2697"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2699"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2701"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2703"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2705"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2707"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2709"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2711"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2715"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2717"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2719"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_RobertGlassmanMember_custom_DirectorCompensationMember"
      id="xdx2ixbrl2721"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      id="xdx2ixbrl2723"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember"
      id="xdx2ixbrl2733"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember"
      id="xdx2ixbrl2747"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember"
      id="xdx2ixbrl2755"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember"
      id="xdx2ixbrl2761"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember"
      id="xdx2ixbrl2763"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember"
      id="xdx2ixbrl2765"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember"
      id="xdx2ixbrl2771"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember"
      id="xdx2ixbrl2779"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      id="xdx2ixbrl2787"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      id="xdx2ixbrl2791"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      id="xdx2ixbrl2799"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      id="xdx2ixbrl2801"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      id="xdx2ixbrl2805"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      id="xdx2ixbrl2807"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2811"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2813"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2815"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2817"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2819"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2827"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2829"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2831"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2833"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2841"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2843"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2845"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      id="xdx2ixbrl2847"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      id="xdx2ixbrl2857"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      id="xdx2ixbrl2861"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      id="xdx2ixbrl2863"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      id="xdx2ixbrl2869"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      id="xdx2ixbrl2871"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      id="xdx2ixbrl2875"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2881"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2883"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2885"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2887"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2889"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2891"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2893"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2897"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2899"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2901"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2903"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2905"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2911"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2913"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2915"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      id="xdx2ixbrl2917"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2923"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2925"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2927"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2929"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2931"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2933"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2935"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2939"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2941"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2943"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2945"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2953"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2955"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2957"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      id="xdx2ixbrl2959"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2965"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2967"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2969"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2971"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2973"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2975"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2977"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2981"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2983"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2985"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2987"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2995"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2997"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl2999"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      id="xdx2ixbrl3001"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3007"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3009"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3011"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3013"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3015"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3017"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3019"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3023"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3025"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3027"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3029"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3031"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3037"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TransactionClosingBonus
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3039"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3041"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      id="xdx2ixbrl3043"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember"
      id="xdx2ixbrl3061"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember"
      id="xdx2ixbrl3064"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember"
      id="xdx2ixbrl3065"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember"
      id="xdx2ixbrl3068"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember"
      id="xdx2ixbrl3071"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember"
      id="xdx2ixbrl3072"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember"
      id="xdx2ixbrl3075"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember"
      id="xdx2ixbrl3078"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember"
      id="xdx2ixbrl3079"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember"
      id="xdx2ixbrl3082"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember"
      id="xdx2ixbrl3085"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember"
      id="xdx2ixbrl3086"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember"
      id="xdx2ixbrl3089"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember"
      id="xdx2ixbrl3092"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember"
      id="xdx2ixbrl3093"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember"
      id="xdx2ixbrl3096"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember"
      id="xdx2ixbrl3099"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember"
      id="xdx2ixbrl3100"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember"
      id="xdx2ixbrl3103"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember"
      id="xdx2ixbrl3106"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember"
      id="xdx2ixbrl3107"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_AllanShawMember"
      id="xdx2ixbrl3110"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AllanShawMember"
      id="xdx2ixbrl3113"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AllanShawMember"
      id="xdx2ixbrl3114"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember"
      id="xdx2ixbrl3117"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember"
      id="xdx2ixbrl3120"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember"
      id="xdx2ixbrl3121"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember"
      id="xdx2ixbrl3124"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember"
      id="xdx2ixbrl3127"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember"
      id="xdx2ixbrl3128"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_RobertKramerMember"
      id="xdx2ixbrl3131"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_RobertKramerMember"
      id="xdx2ixbrl3134"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_RobertKramerMember"
      id="xdx2ixbrl3135"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember"
      id="xdx2ixbrl3138"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember"
      id="xdx2ixbrl3141"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember"
      id="xdx2ixbrl3142"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember"
      id="xdx2ixbrl3145"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember"
      id="xdx2ixbrl3148"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember"
      id="xdx2ixbrl3149"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_BrianWileyMember"
      id="xdx2ixbrl3152"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_BrianWileyMember"
      id="xdx2ixbrl3155"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_BrianWileyMember"
      id="xdx2ixbrl3156"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember"
      id="xdx2ixbrl3159"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember"
      id="xdx2ixbrl3162"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember"
      id="xdx2ixbrl3163"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember"
      id="xdx2ixbrl3166"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember"
      id="xdx2ixbrl3169"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember"
      id="xdx2ixbrl3170"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember"
      id="xdx2ixbrl3173"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember"
      id="xdx2ixbrl3176"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember"
      id="xdx2ixbrl3177"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable
      contextRef="From2025-04-012026-03-31_custom_YuryMitinMember"
      id="xdx2ixbrl3180"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_YuryMitinMember"
      id="xdx2ixbrl3183"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:MarketValueNumberofShareUnitsofStockThetHaveNotVested
      contextRef="From2025-04-012026-03-31_custom_YuryMitinMember"
      id="xdx2ixbrl3184"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl3208"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3209"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl3211"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3212"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoin
      contextRef="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl3215"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoin
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3216"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoin
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3217"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoin
      contextRef="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl3218"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:Stablecoin
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3219"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2026-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl3222"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3223"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2025-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl3225"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3226"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3234"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3236"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3238"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3240"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3241"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3243"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3245"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3246"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3248"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3250"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LeaseLiabilityCurrentAndNoncurrent
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3253"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LeaseLiabilityCurrentAndNoncurrent
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl3255"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LeaseLiabilityCurrentAndNoncurrent
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl3256"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLiquid
      contextRef="AsOf2026-03-31_custom_Level2Member"
      id="xdx2ixbrl3268"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLiquid
      contextRef="AsOf2026-03-31_custom_Level3Member"
      id="xdx2ixbrl3269"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLiquid
      contextRef="AsOf2025-03-31_custom_Level1Member"
      id="xdx2ixbrl3270"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLiquid
      contextRef="AsOf2025-03-31_custom_Level2Member"
      id="xdx2ixbrl3271"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLiquid
      contextRef="AsOf2025-03-31_custom_Level3Member"
      id="xdx2ixbrl3272"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLocked
      contextRef="AsOf2026-03-31_custom_Level1Member"
      id="xdx2ixbrl3274"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLocked
      contextRef="AsOf2026-03-31_custom_Level2Member"
      id="xdx2ixbrl3275"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLocked
      contextRef="AsOf2025-03-31_custom_Level1Member"
      id="xdx2ixbrl3277"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLocked
      contextRef="AsOf2025-03-31_custom_Level2Member"
      id="xdx2ixbrl3278"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DigitalAssetsAtFairValueTonLocked
      contextRef="AsOf2025-03-31_custom_Level3Member"
      id="xdx2ixbrl3279"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2026-03-31_custom_Level1Member"
      id="xdx2ixbrl3281"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2026-03-31_custom_Level2Member"
      id="xdx2ixbrl3282"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2025-03-31_custom_Level1Member"
      id="xdx2ixbrl3284"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2025-03-31_custom_Level2Member"
      id="xdx2ixbrl3285"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2025-03-31_custom_Level3Member"
      id="xdx2ixbrl3286"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2026-03-31_custom_Level1Member"
      id="xdx2ixbrl3288"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2026-03-31_custom_Level2Member"
      id="xdx2ixbrl3289"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2025-03-31_custom_Level1Member"
      id="xdx2ixbrl3291"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2025-03-31_custom_Level2Member"
      id="xdx2ixbrl3292"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PutRightLiability
      contextRef="AsOf2025-03-31_custom_Level3Member"
      id="xdx2ixbrl3293"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2026-03-31_custom_Level1Member"
      id="xdx2ixbrl3295"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2026-03-31_custom_Level2Member"
      id="xdx2ixbrl3296"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2025-03-31_custom_Level1Member"
      id="xdx2ixbrl3298"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2025-03-31_custom_Level2Member"
      id="xdx2ixbrl3299"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3313"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3314"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3315"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3322"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3333"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3347"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3348"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3349"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3353"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3354"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3355"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3358"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssets
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3359"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssets
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3360"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssetReceivables
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3363"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssetReceivables
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3364"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfDigitalAssetReceivables
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3365"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3368"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3369"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3370"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnNovationOfDigitalAssetReceivables
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3373"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnNovationOfDigitalAssetReceivables
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3374"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RealizedLossOnNovationOfDigitalAssetReceivables
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3375"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3377"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3378"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3380"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3382"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3383"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3384"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OfferingCosts
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3387"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OfferingCosts
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3388"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OfferingCosts
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3389"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossIoxIprd
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3392"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossIoxIprd
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3393"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossIoxIprd
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3394"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossTarusIprd
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3397"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossTarusIprd
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3398"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossTarusIprd
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3399"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossStimunity
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3402"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossStimunity
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3403"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossStimunity
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3404"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossSaugatuck
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3407"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossSaugatuck
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3408"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossSaugatuck
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3409"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3412"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3413"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3414"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3417"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3418"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3419"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3422"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3423"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3424"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossInvestmentInCompedica
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3427"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossInvestmentInCompedica
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3429"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ImpairmentLossInvestmentInCompedica
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3430"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfInvestmentInCompedica
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3433"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfInvestmentInCompedica
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3434"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnRevaluationOfInvestmentInCompedica
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3435"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3438"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3439"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3440"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3443"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3444"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3445"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnSettlementOfPutRightLiability
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3448"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnSettlementOfPutRightLiability
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3449"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnSettlementOfPutRightLiability
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3450"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnExtinguishmentOfDebt
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3468"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnExtinguishmentOfDebt
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3469"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnExtinguishmentOfDebt
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3470"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareOfLossesFromEquityMethodInvestment
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3472"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareOfLossesFromEquityMethodInvestment
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3474"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncomeTaxBenefit
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      id="xdx2ixbrl3482"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncomeTaxBenefit
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      id="xdx2ixbrl3483"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-04-01to2026-03-31" id="Fact000014">20-F/A</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="From2025-04-01to2026-03-31" id="Fact000015">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="From2025-04-01to2026-03-31" id="Fact000016">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-04-01to2026-03-31" id="Fact000017">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-04-01to2026-03-31" id="Fact000019">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-04-01to2026-03-31" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="From2025-04-01to2026-03-31" id="Fact000021">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="From2025-04-01to2026-03-31" id="Fact000022">001-40086</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-04-01to2026-03-31" id="Fact000023">Alpha Compute Corp</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-04-01to2026-03-31" id="Fact000024">D8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2025-04-01to2026-03-31" id="Fact000025">Clarence Thomas Building</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-04-01to2026-03-31" id="Fact000026">P.O. Box 4649</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2025-04-01to2026-03-31" id="Fact000027">Road Town</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2025-04-01to2026-03-31" id="Fact000028">Tortola</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2025-04-01to2026-03-31" id="Fact000029">VG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2025-04-01to2026-03-31" id="Fact000030">VG1110</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="From2025-04-012026-03-31_dei_BusinessContactMember"
      id="Fact000031">Wes Levitt</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="From2025-04-012026-03-31_dei_BusinessContactMember"
      id="Fact000033">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-04-012026-03-31_dei_BusinessContactMember"
      id="Fact000035">219-5556</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-04-012026-03-31_dei_BusinessContactMember"
      id="Fact000037">1111B S Governors Ave STE 25907</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-04-012026-03-31_dei_BusinessContactMember"
      id="Fact000039">Dover</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2025-04-012026-03-31_dei_BusinessContactMember"
      id="Fact000041">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-04-012026-03-31_dei_BusinessContactMember"
      id="Fact000043">19904</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="From2025-04-01to2026-03-31" id="Fact000044">Ordinary         Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-04-01to2026-03-31" id="Fact000045">ALP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-04-01to2026-03-31" id="Fact000046">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">23470877</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-04-01to2026-03-31" id="Fact000048">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-04-01to2026-03-31" id="Fact000049">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-04-01to2026-03-31" id="Fact000050">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-04-01to2026-03-31" id="Fact000051">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-04-01to2026-03-31" id="Fact000052">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-04-01to2026-03-31" id="Fact000053">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-04-01to2026-03-31" id="Fact000054">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-04-01to2026-03-31" id="Fact000056">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="From2025-04-01to2026-03-31" id="Fact000057">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="From2025-04-01to2026-03-31" id="Fact000058">false</dei:EntityShellCompany>
    <dei:AmendmentDescription contextRef="From2025-04-01to2026-03-31" id="Fact000059">The
purpose of this Amendment No. 1 to Alpha Compute Corp's Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with
the Securities and Exchange Commission on July 16, 2026 (the "Form 20-F"), is to furnish Inline XBRL to the Form 20-F in accordance with
Rule 405 of Regulation S-T. There were also minor corrections made to the risk disclosure on page 5 titled "Our success depends on our
ability to attract, motivate, and retain executive officers and other key employees, and the loss of key personnel or an inability to
hire qualified employees could harm our business." Other than these stated changes, no other changes have been made to the Form 20-F.
This Amendment No. 1 to the Form 20-F speaks as of the original filing date of the Form 20-F, does not reflect events that may have occurred
subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 20-F</dei:AmendmentDescription>
    <dei:AuditorName contextRef="From2025-04-01to2026-03-31" id="Fact000061">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-04-01to2026-03-31" id="Fact000062">New York</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">486000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">1670000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">200000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ptgef:AccountsReceivable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">21000</ptgef:AccountsReceivable>
    <ptgef:Stablecoin
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">21000</ptgef:Stablecoin>
    <ptgef:DigitalAssetsAtFairValueTonCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">1291000</ptgef:DigitalAssetsAtFairValueTonCurrent>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">1984000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">555000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">4003000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">2225000</ifrs-full:CurrentAssets>
    <ptgef:DigitalAssetsAtFairValueTonNetOfCurrentPortion
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">1201000</ptgef:DigitalAssetsAtFairValueTonNetOfCurrentPortion>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">413000</ifrs-full:RightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">1283000</ifrs-full:PropertyPlantAndEquipment>
    <ptgef:EquipmentDeposits
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">9308000</ptgef:EquipmentDeposits>
    <ifrs-full:OtherAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">3322000</ifrs-full:OtherAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">15527000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">19530000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">2225000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">4146000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">1100000</ifrs-full:TradeAndOtherCurrentPayables>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">1425000</ptgef:TonPayableToSettlePutRightsExercised>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">65000</ifrs-full:CurrentLeaseLiabilities>
    <ptgef:PutRightLiability
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">7105000</ptgef:PutRightLiability>
    <ifrs-full:CurrentLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">12741000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">1100000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">73000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentWarrantLiability
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">192000</ifrs-full:NoncurrentWarrantLiability>
    <ifrs-full:NoncurrentWarrantLiability
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">1952000</ifrs-full:NoncurrentWarrantLiability>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">265000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000146"
      unitRef="USD">1952000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">13006000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">3052000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000157"
      unitRef="USD">266053000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">221800000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">25275000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000161"
      unitRef="USD">23530000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000163"
      unitRef="USD">-284079000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">-245453000</ifrs-full:RetainedEarnings>
    <ifrs-full:TreasuryShares
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">20000</ifrs-full:TreasuryShares>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">7229000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">-123000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000172"
      unitRef="USD">-705000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">-704000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">6524000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">-827000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">19530000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">2225000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">97000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000189"
      unitRef="USD">2801000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000190"
      unitRef="USD">3129000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">12535000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000193"
      unitRef="USD">20199000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">4254000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000195"
      unitRef="USD">5664000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:DepreciationExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">193000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">35000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">54000</ifrs-full:DepreciationExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">-23096000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">-7418000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-18253000</ifrs-full:ProfitLossFromOperatingActivities>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">2883000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">-388000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000207"
      unitRef="USD">6868000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">11305000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">5959000</ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions>
    <ptgef:LossOnRevaluationOfDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">1411000</ptgef:LossOnRevaluationOfDigitalAssets>
    <ptgef:LossOnRevaluationOfDigitalAssetReceivables
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">1497000</ptgef:LossOnRevaluationOfDigitalAssetReceivables>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">1700000</ptgef:RealizedLossOnSaleOfDigitalAssets>
    <ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">676000</ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">-946000</ptgef:GainOnSettlementWithParexelIoxCro>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">2432000</ptgef:LossOnRegisteredDirectOffering>
    <ptgef:OfferingCosts
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">662000</ptgef:OfferingCosts>
    <ptgef:ImpairmentLossIoxIprd
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">-57890000</ptgef:ImpairmentLossIoxIprd>
    <ptgef:ImpairmentLossTarusIprd
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">-23615000</ptgef:ImpairmentLossTarusIprd>
    <ptgef:ImpairmentLossStimunity
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">-1002000</ptgef:ImpairmentLossStimunity>
    <ptgef:ImpairmentLossSaugatuck
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">-178000</ptgef:ImpairmentLossSaugatuck>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">839000</ptgef:CommitmentFeeUnderCommittedPurchaseAgreement>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">27000</ptgef:GainOnDissolutionOfInvestmentInAssociate>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">725000</ptgef:GainFromSaleOfInvestmentInPublicCompany>
    <ptgef:ImpairmentLossInvestmentInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">4804000</ptgef:ImpairmentLossInvestmentInCompedica>
    <ptgef:LossOnRevaluationOfInvestmentInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">182000</ptgef:LossOnRevaluationOfInvestmentInCompedica>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">51000</ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">336000</ptgef:GainOnSettlementOfTonPayable>
    <ptgef:LossOnSettlementOfPutRightLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000289"
      unitRef="USD">916000</ptgef:LossOnSettlementOfPutRightLiability>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">-1000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">-7000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">7000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">1014000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">-86000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">-242000</ifrs-full:DepreciationAndAmortisationExpense>
    <ptgef:GainOnExtinguishmentOfDebt
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">255000</ptgef:GainOnExtinguishmentOfDebt>
    <ptgef:ShareOfLossesFromEquityMethodInvestment
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">44000</ptgef:ShareOfLossesFromEquityMethodInvestment>
    <ptgef:ShareOfLossesFromEquityMethodInvestment
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000307"
      unitRef="USD">233000</ptgef:ShareOfLossesFromEquityMethodInvestment>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">-38627000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">-6781000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">-85930000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">-3000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000315"
      unitRef="USD">-10548000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">-38627000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000318"
      unitRef="USD">-6778000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">-75382000</ifrs-full:ProfitLoss>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000327"
      unitRef="USD">-38000</ptgef:NetUnrealizedLossOnInvestments>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000329"
      unitRef="USD">-38627000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000330"
      unitRef="USD">-6778000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">-75420000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">-38626000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">-6767000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">-75339000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">-1000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000342"
      unitRef="USD">-11000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">-43000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000345"
      unitRef="USD">-38627000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000346"
      unitRef="USD">-6778000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">-75382000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000353"
      unitRef="USD">-38626000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">-6767000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">-75377000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">-1000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000358"
      unitRef="USD">-11000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000359"
      unitRef="USD">-43000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">-38627000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000362"
      unitRef="USD">-6778000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">-75420000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000369"
      unitRef="USDPShares">-4</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000371"
      unitRef="USDPShares">-4</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact000373"
      unitRef="USDPShares">-5.72</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact000375"
      unitRef="USDPShares">-5.72</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000377"
      unitRef="USDPShares">-77.83</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000379"
      unitRef="USDPShares">-77.83</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000385"
      unitRef="Shares">9248000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000387"
      unitRef="Shares">9248000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000389"
      unitRef="Shares">1183000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000391"
      unitRef="Shares">1183000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000393"
      unitRef="Shares">968000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000395"
      unitRef="Shares">968000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:BalanceApril12022PresplitShares
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000397"
      unitRef="Shares">17606000</ptgef:BalanceApril12022PresplitShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2023-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000408"
      unitRef="Shares">880000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">218782000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">21204000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">-4325000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000403"
      unitRef="USD">-159616000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">76045000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">-650000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">75395000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">2637000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">2637000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">2637000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingShares
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000428"
      unitRef="Shares">98000</ptgef:SharesIssuedUnderRegisteredDirectOfferingShares>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000439"
      unitRef="Shares">9000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">662000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">662000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">662000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedOrAccruedForServicesShares
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000450"
      unitRef="Shares">1000</ptgef:SharesIssuedOrAccruedForServicesShares>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">50000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">50000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">50000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000461"
      unitRef="Shares">1000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">5000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">5000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">5000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">4363000</ptgef:DerecognitionOfInvestmentInPublicCompany>
    <ptgef:DerecognitionOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">-4363000</ptgef:DerecognitionOfInvestmentInPublicCompany>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31_custom_AccumulatedOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">-38000</ptgef:NetUnrealizedLossOnInvestments>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">-38000</ptgef:NetUnrealizedLossOnInvestments>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">-38000</ptgef:NetUnrealizedLossOnInvestments>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">-75339000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">-75339000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">-43000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000488"
      unitRef="USD">-75382000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000499"
      unitRef="Shares">989000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">219499000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">23841000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">-239318000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">4022000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000496"
      unitRef="USD">-693000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">3329000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000502"
      unitRef="USD">321000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000506"
      unitRef="USD">321000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000508"
      unitRef="USD">321000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">-632000</ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">632000</ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationExpense>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000528"
      unitRef="Shares">524000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsShares>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">2150000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000524"
      unitRef="USD">2150000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">2150000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCosts>
    <ptgef:PrefundedWarrantsExercisedShares
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000539"
      unitRef="Shares">60000</ptgef:PrefundedWarrantsExercisedShares>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000530"
      unitRef="USD">1000</ptgef:PrefundedWarrantsExercised>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">1000</ptgef:PrefundedWarrantsExercised>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">1000</ptgef:PrefundedWarrantsExercised>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000550"
      unitRef="Shares">52000</ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares>
    <ptgef:SharesIssuedAccruedForBonusesShares
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000561"
      unitRef="Shares">19000</ptgef:SharesIssuedAccruedForBonusesShares>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">120000</ptgef:SharesIssuedForAccruedBonuses>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000557"
      unitRef="USD">120000</ptgef:SharesIssuedForAccruedBonuses>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000559"
      unitRef="USD">120000</ptgef:SharesIssuedForAccruedBonuses>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000572"
      unitRef="Shares">9000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnitsShares>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000563"
      unitRef="USD">30000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000568"
      unitRef="USD">30000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits>
    <ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000570"
      unitRef="USD">30000</ptgef:SharesIssuedPursuantToDistributionOfRestrictedStockUnits>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000578"
      unitRef="USD">-6767000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">-6767000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000580"
      unitRef="USD">-11000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000581"
      unitRef="USD">-6778000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000592"
      unitRef="Shares">1653000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000583"
      unitRef="USD">221800000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000584"
      unitRef="USD">23530000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">-245453000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">-123000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">-704000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">-827000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-012026-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000595"
      unitRef="USD">1745000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">1745000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000601"
      unitRef="USD">1745000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000612"
      unitRef="Shares">3416000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRightsShares>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">14535000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000608"
      unitRef="USD">14535000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights>
    <ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">14535000</ptgef:SharesIssuedUnderPrivatePlacementNetOfShareIssuanceCostsAndPutRights>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedicaShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000623"
      unitRef="Shares">625000</ptgef:SharesIssuedRelatingToAcquisitionOfCompedicaShares>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000614"
      unitRef="USD">5000000</ptgef:SharesIssuedRelatingToAcquisitionOfCompedica>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">5000000</ptgef:SharesIssuedRelatingToAcquisitionOfCompedica>
    <ptgef:SharesIssuedRelatingToAcquisitionOfCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000621"
      unitRef="USD">5000000</ptgef:SharesIssuedRelatingToAcquisitionOfCompedica>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000634"
      unitRef="Shares">4063000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCostsShares>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">12030000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">12030000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000632"
      unitRef="USD">12030000</ptgef:SharesIssuedRelatedToAtmAgreementNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000645"
      unitRef="Shares">5230000</ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCostsShares>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">12688000</ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">12688000</ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">12688000</ptgef:SharesIssuedUnderRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <ptgef:ExerciseOfPrefundedWarrantsShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000656"
      unitRef="Shares">9231000</ptgef:ExerciseOfPrefundedWarrantsShares>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000667"
      unitRef="Shares">-625000</ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedicaShares>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-012026-03-31_custom_TreasuryStockMember"
      decimals="-3"
      id="Fact000660"
      unitRef="USD">-20000</ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000663"
      unitRef="USD">-20000</ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000665"
      unitRef="USD">-20000</ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica>
    <ptgef:PutRightsExercisedAndReturnShares
      contextRef="From2025-04-012026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000678"
      unitRef="Shares">-123000</ptgef:PutRightsExercisedAndReturnShares>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-012026-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">-38626000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-012026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">-38626000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-012026-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000686"
      unitRef="USD">-1000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">-38627000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000698"
      unitRef="Shares">23470000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000689"
      unitRef="USD">266053000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000690"
      unitRef="USD">25275000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31_custom_TreasuryStockMember"
      decimals="-3"
      id="Fact000691"
      unitRef="USD">-20000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000693"
      unitRef="USD">-284079000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000694"
      unitRef="USD">7229000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000695"
      unitRef="USD">-705000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000696"
      unitRef="USD">6524000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000704"
      unitRef="USD">-38627000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000705"
      unitRef="USD">-6778000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000706"
      unitRef="USD">-75382000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">1745000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000713"
      unitRef="USD">321000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000714"
      unitRef="USD">2637000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">11305000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000722"
      unitRef="USD">2432000</ptgef:LossOnRegisteredDirectOffering>
    <ptgef:OfferingCosts
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000726"
      unitRef="USD">662000</ptgef:OfferingCosts>
    <ifrs-full:ImpairmentLoss
      contextRef="From2023-04-012024-03-31_custom_IOxIPRDMember"
      decimals="-3"
      id="Fact000732"
      unitRef="USD">57890000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="From2023-04-012024-03-31_custom_TarusIPRDMember"
      decimals="-3"
      id="Fact000738"
      unitRef="USD">23615000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="From2023-04-012024-03-31_custom_StimunityMember"
      decimals="-3"
      id="Fact000744"
      unitRef="USD">1002000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="From2023-04-012024-03-31_custom_SaugatuckMember"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">178000</ifrs-full:ImpairmentLoss>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000754"
      unitRef="USD">839000</ptgef:CommitmentFeeUnderCommittedPurchaseAgreement>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000758"
      unitRef="USD">27000</ptgef:GainOnDissolutionOfInvestmentInAssociate>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000762"
      unitRef="USD">725000</ptgef:GainFromSaleOfInvestmentInPublicCompany>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000766"
      unitRef="USD">10564000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000768"
      unitRef="USD">1411000</ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssets>
    <ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000772"
      unitRef="USD">2349000</ptgef:UnrealizedLossOnChangeInFairValueOfDigitalAssetReceivables>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000776"
      unitRef="USD">1700000</ptgef:RealizedLossOnSaleOfDigitalAssets>
    <ptgef:RealizedLossOnNovationOfDigitalAssetReceivables
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000780"
      unitRef="USD">676000</ptgef:RealizedLossOnNovationOfDigitalAssetReceivables>
    <ptgef:LossOnImpairmentInvestmentInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000784"
      unitRef="USD">4804000</ptgef:LossOnImpairmentInvestmentInCompedica>
    <ptgef:LossOnRemeasurementOfInvestmentInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000788"
      unitRef="USD">182000</ptgef:LossOnRemeasurementOfInvestmentInCompedica>
    <ptgef:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000792"
      unitRef="USD">-2883000</ptgef:ChangeInFairValueOfWarrantLiability>
    <ptgef:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">388000</ptgef:ChangeInFairValueOfWarrantLiability>
    <ptgef:ChangeInFairValueOfWarrantLiability
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000794"
      unitRef="USD">-6868000</ptgef:ChangeInFairValueOfWarrantLiability>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000796"
      unitRef="USD">5959000</ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions>
    <ptgef:LossFromEquityMethodInvestment
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000800"
      unitRef="USD">44000</ptgef:LossFromEquityMethodInvestment>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000804"
      unitRef="USD">51000</ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000808"
      unitRef="USD">336000</ptgef:GainOnSettlementOfTonPayable>
    <ptgef:LossOnExerciseOfPutRightLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000812"
      unitRef="USD">916000</ptgef:LossOnExerciseOfPutRightLiability>
    <ptgef:LossOnExtinguishmentOfDebt
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000816"
      unitRef="USD">582000</ptgef:LossOnExtinguishmentOfDebt>
    <ptgef:NoncashInterestExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">171000</ptgef:NoncashInterestExpense>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">-946000</ptgef:GainOnSettlementWithParexelIoxCro>
    <ptgef:ExpensesSettledUsingStablecoin
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000832"
      unitRef="USD">1413000</ptgef:ExpensesSettledUsingStablecoin>
    <ifrs-full:DividendsReceived
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000836"
      unitRef="USD">69000</ifrs-full:DividendsReceived>
    <ptgef:ShareOfLossInAssociate
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">233000</ptgef:ShareOfLossInAssociate>
    <ptgef:FairValueOfSharesIssuedForServices
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000846"
      unitRef="USD">50000</ptgef:FairValueOfSharesIssuedForServices>
    <ptgef:DepreciationAndAmortizations
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000848"
      unitRef="USD">193000</ptgef:DepreciationAndAmortizations>
    <ptgef:DepreciationAndAmortizations
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000849"
      unitRef="USD">35000</ptgef:DepreciationAndAmortizations>
    <ptgef:DepreciationAndAmortizations
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000850"
      unitRef="USD">54000</ptgef:DepreciationAndAmortizations>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000856"
      unitRef="USD">-21000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000860"
      unitRef="USD">-96000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000861"
      unitRef="USD">1574000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000862"
      unitRef="USD">-32000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000864"
      unitRef="USD">-3322000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000865"
      unitRef="USD">46000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000866"
      unitRef="USD">40000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000868"
      unitRef="USD">3549000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000869"
      unitRef="USD">-99000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000870"
      unitRef="USD">972000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000873"
      unitRef="USD">-3000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000874"
      unitRef="USD">2000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000876"
      unitRef="USD">-20548000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000877"
      unitRef="USD">-5462000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000878"
      unitRef="USD">-14297000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:ProceedsFromSalesOfInvestmentProperty
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">2812000</ifrs-full:ProceedsFromSalesOfInvestmentProperty>
    <ptgef:PurchasesOfStablecoin
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">311000</ptgef:PurchasesOfStablecoin>
    <ptgef:PurchasesOfDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000892"
      unitRef="USD">609000</ptgef:PurchasesOfDigitalAssets>
    <ptgef:SalesOfStablecoin
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000896"
      unitRef="USD">2100000</ptgef:SalesOfStablecoin>
    <ptgef:SalesOfDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000900"
      unitRef="USD">2900000</ptgef:SalesOfDigitalAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000904"
      unitRef="USD">1040000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ptgef:EquipmentDeposit
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000908"
      unitRef="USD">9308000</ptgef:EquipmentDeposit>
    <ptgef:CashPaidForInvestmentInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000912"
      unitRef="USD">50000</ptgef:CashPaidForInvestmentInCompedica>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000916"
      unitRef="USD">-6318000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000918"
      unitRef="USD">2812000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ptgef:ProceedsFromExerciseOfPrefundedWarrants
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000925"
      unitRef="USD">1000</ptgef:ProceedsFromExerciseOfPrefundedWarrants>
    <ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000928"
      unitRef="USD">3272000</ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement>
    <ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000929"
      unitRef="USD">2150000</ptgef:ProceedsFromSharesIssuedUnderPrivatePlacement>
    <ptgef:ProceedsFromRegisteredDirectOffering
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000932"
      unitRef="USD">15000000</ptgef:ProceedsFromRegisteredDirectOffering>
    <ptgef:ProceedsFromRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000934"
      unitRef="USD">5338000</ptgef:ProceedsFromRegisteredDirectOffering>
    <ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000936"
      unitRef="USD">12631000</ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement>
    <ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000938"
      unitRef="USD">682000</ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000940"
      unitRef="USD">3615000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000942"
      unitRef="USD">20000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000948"
      unitRef="USD">381000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000949"
      unitRef="USD">47000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000950"
      unitRef="USD">40000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ptgef:PaymentsOnExternalDebt
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000952"
      unitRef="USD">275000</ptgef:PaymentsOnExternalDebt>
    <ptgef:DeferredFinancingCosts
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000956"
      unitRef="USD">250000</ptgef:DeferredFinancingCosts>
    <ptgef:LoanTerminationFee
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000960"
      unitRef="USD">500000</ptgef:LoanTerminationFee>
    <ptgef:SharesFromRSUDistribution
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000966"
      unitRef="USD">8000</ptgef:SharesFromRSUDistribution>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000968"
      unitRef="USD">25882000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000969"
      unitRef="USD">2104000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000970"
      unitRef="USD">5968000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000972"
      unitRef="USD">-984000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000973"
      unitRef="USD">-3358000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000974"
      unitRef="USD">-5517000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000976"
      unitRef="USD">1670000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000977"
      unitRef="USD">5028000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000978"
      unitRef="USD">10545000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000980"
      unitRef="USD">686000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000981"
      unitRef="USD">1670000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000982"
      unitRef="USD">5028000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ptgef:CashPaidForInterest
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000988"
      unitRef="USD">54000</ptgef:CashPaidForInterest>
    <ptgef:CashPaidForInterest
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000989"
      unitRef="USD">3000</ptgef:CashPaidForInterest>
    <ptgef:CashPaidForInterest
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000990"
      unitRef="USD">30000</ptgef:CashPaidForInterest>
    <ptgef:ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000998"
      unitRef="USD">429000</ptgef:ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue>
    <ptgef:CapitalExpendituresIncludedInAccountsPayable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001000"
      unitRef="USD">333000</ptgef:CapitalExpendituresIncludedInAccountsPayable>
    <ptgef:RightToUseAssetAcquired
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001004"
      unitRef="USD">516000</ptgef:RightToUseAssetAcquired>
    <ptgef:RightToUseAssetAcquired
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">87000</ptgef:RightToUseAssetAcquired>
    <ptgef:LeaseLiabilityIncurred
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001008"
      unitRef="USD">516000</ptgef:LeaseLiabilityIncurred>
    <ptgef:LeaseLiabilityIncurred
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001010"
      unitRef="USD">87000</ptgef:LeaseLiabilityIncurred>
    <ptgef:ContributionOfDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001012"
      unitRef="USD">1802000</ptgef:ContributionOfDigitalAssets>
    <ptgef:ContributionOfStablecoin
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001016"
      unitRef="USD">5421000</ptgef:ContributionOfStablecoin>
    <ptgef:ContributionOfDigitalAssetsReceivable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001020"
      unitRef="USD">9016000</ptgef:ContributionOfDigitalAssetsReceivable>
    <ptgef:ContributionOfStablecoinReceivable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001024"
      unitRef="USD">15000000</ptgef:ContributionOfStablecoinReceivable>
    <ptgef:ValueOfSharesUsedToPurchaseInterestInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001028"
      unitRef="USD">5000000</ptgef:ValueOfSharesUsedToPurchaseInterestInCompedica>
    <ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001032"
      unitRef="USD">-20000</ptgef:TreasuryStockObtainedInExchangeForReturnOfInvestmentInterestToCompedica>
    <ptgef:PutRightsIssuedToInvestors
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001036"
      unitRef="USD">18150000</ptgef:PutRightsIssuedToInvestors>
    <ptgef:ShareIssuanceCostsSettledInCompanyStock
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001040"
      unitRef="USD">1087000</ptgef:ShareIssuanceCostsSettledInCompanyStock>
    <ptgef:ShareIssuanceCostsSettledInWarrantsOnCompanysStock
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001044"
      unitRef="USD">1123000</ptgef:ShareIssuanceCostsSettledInWarrantsOnCompanysStock>
    <ptgef:SettlementOfPutRightLiabilityUsingStablecoinReceivable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001048"
      unitRef="USD">15000000</ptgef:SettlementOfPutRightLiabilityUsingStablecoinReceivable>
    <ptgef:ExerciseOfPutRights
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001052"
      unitRef="USD">2920000</ptgef:ExerciseOfPutRights>
    <ptgef:SettlementOfPutRightLiabilityUsingDigitalAssetReceivables
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001056"
      unitRef="USD">1130000</ptgef:SettlementOfPutRightLiabilityUsingDigitalAssetReceivables>
    <ptgef:ReceiptOfDigitalAssetsReceivableTonTokens
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001060"
      unitRef="USD">6667000</ptgef:ReceiptOfDigitalAssetsReceivableTonTokens>
    <ptgef:StablecoinUsedToPurchaseDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001064"
      unitRef="USD">3008000</ptgef:StablecoinUsedToPurchaseDigitalAssets>
    <ptgef:SaleOfDigitalAssetsSettledInStablecoin
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001068"
      unitRef="USD">21000</ptgef:SaleOfDigitalAssetsSettledInStablecoin>
    <ptgef:ExchangeOfBitcoinForTonTokens
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001072"
      unitRef="USD">425000</ptgef:ExchangeOfBitcoinForTonTokens>
    <ptgef:ExternalDebtProceedsReceivedInStablecoin
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001076"
      unitRef="USD">2100000</ptgef:ExternalDebtProceedsReceivedInStablecoin>
    <ptgef:PaymentsOnExternalDebtUsingDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001080"
      unitRef="USD">1825000</ptgef:PaymentsOnExternalDebtUsingDigitalAssets>
    <ptgef:PrepaidExpensesObtainedInExchangeForStablecoin
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001088"
      unitRef="USD">1311000</ptgef:PrepaidExpensesObtainedInExchangeForStablecoin>
    <ptgef:NatureOfOperationsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001092">&lt;p id="xdx_800_ecustom--NatureOfOperationsExplanatory_z0qgQAkOagd2" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="financialnotes"&gt;&lt;/span&gt;NOTE
1. &lt;span id="xdx_82B_zH1KqvgCfDy1"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Alpha Compute Corp (the &#x201c;Company&#x201d;
or &#x201c;Alpha Compute&#x201d;, formerly known as Portage Biotech, Inc. and AlphaTON Capital Corp) is incorporated in the British Virgin
Islands (&#x201c;BVI&#x201d;) with its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its
USA agent, Portage Development Services Inc. (&#x201c;PDS&#x201d;), is located at 59 Wilton Road, Westport, CT, 06880, USA.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company is a foreign private issuer under the Securities
and Exchange Commission (the &#x201c;SEC&#x201d;) rules. It is also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#x201c;CSE&#x201d;) under the symbol
&#x201c;PBT.U&#x201d;. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;)
under the symbol &#x201c;PRTG&#x201d;. As the principal market for the Company&#x2019;s ordinary shares is Nasdaq, the Company voluntarily
delisted from the CSE on April 23, 2021. On September 4, 2025, in connection with the change in the legal name of the Company to AlphaTON
Capital Corp effective on August 11, 2025, the Nasdaq ticker symbol of the Company&#x2019;s ordinary shares was changed to &#x201c;ATON&#x201d;.
On April 21, 2026, in connection with the change in the legal name of the Company to Alpha Compute Corp effective on April 14, 2026, the
Nasdaq ticker symbol of the Company&#x2019;s ordinary shares was changed to &#x201c;ALP&#x201d;.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;The Company&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Alpha Compute Corp. ("Alpha Compute," "we," "us,"
"our," or the "Company") is a technology company focused on the acquisition, deployment, and leasing of high-performance
graphics processing units ("GPUs") in data center facilities to power artificial intelligence ("AI") workloads, with a
particular emphasis on confidential compute. The Company operates GPU infrastructure in North America and Europe and provides GPU-as-a-Service
("GPUaaS") and AI Confidential Compute solutions to enterprise customers, technology companies, AI research laboratories, and
decentralized AI ecosystems.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Beginning in late 2025, the Company commenced acquisition and installation
of NVIDIA GPU hardware, including H200, B200, and B300 processors, in third-party data center facilities. In April 2026, the Company formally
rebranded to Alpha Compute Corp. and changed its Nasdaq ticker from ATON to ALP to reflect the completion of this strategic transition.
The Company retains a residual position in TON digital assets from its previous focus as a digital asset treasury company, but this legacy
segment is no longer the primary focus of operations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;GPU-as-a-Service (GPUaaS)&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company's primary revenue model consists of acquiring and leasing NVIDIA
GPU hardware and leasing compute capacity to enterprise customers under multi-year off-take agreements. The Company earns revenue based
on contracted lease rates and capacity utilization.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company's first large-scale deployment, designated ALPHA-01, consists
of 504 NVIDIA B200 GPUs co-located in a hydroelectric-powered Canadian data center. ALPHA-01 became fully operational in May 2026 and
is subject to a two-year, $32.2 million compute off-take lease with a leading frontier AI research laboratory, representing $16.1 million
in annual contracted revenue. A second cluster, ALPHA-02, comprising 576 NVIDIA B300 GPUs, is planned for deployment in a hydroelectric-powered
Swedish data center and is targeted for commercial launch in the third quarter of calendar year 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;AI Confidential Computing&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Confidential computing is a hardware-level security paradigm that enables
computation on sensitive data within a protected, hardware-enforced trusted execution environment ("TEE"), such that the data
and the AI model remain encrypted and inaccessible even to the infrastructure operator. The Company and its partners have together developed
and deployed a proprietary software stack that enables confidential AI workloads to be processed on Telegram&#x2019;s Cocoon AI protocol
via NVIDIA Blackwell-generation GPU hardware.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company believes confidential computing represents the highest-growth,
highest-value segment within the AI infrastructure market, driven by stringent data privacy requirements across healthcare, financial
services, government, defense, and decentralized AI applications. The convergence of the EU AI Act (effective 2026), updated FedRAMP 20x
requirements, and various national data sovereignty mandates is creating a structural and mandatory procurement cycle for privacy-preserving
AI infrastructure.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Sovereign AI Infrastructure&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company targets enterprise clients, government entities, and regulated
industries seeking AI compute capacity that does not require surrendering data sovereignty to hyperscale cloud providers. The Company
offers co-location and dedicated GPU deployment arrangements designed to satisfy data residency requirements and regulatory mandates,
including in jurisdictions with strict cross-border data transfer restrictions.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;In conjunction with its infrastructure buildout, the Company has announced
plans to establish a U.S. Government Contracting entity, projected to launch in the third quarter of calendar year 2026, to pursue federal
government AI compute procurement opportunities including those arising from FedRAMP compliance requirements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Alpha Compute Capital&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company has announced the launch of "Alpha Compute Capital,"
a financing division designed to structure and fund AI GPU Special Purpose Vehicles ("SPVs") and related financial products. Alpha
Compute Capital is intended to enable the Company to expand GPU deployment capacity using non-recourse, asset-backed financing facilities,
thereby reducing dilution to existing shareholders and accelerating infrastructure growth.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Digital Asset Business &lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company launched a digital asset treasury business in September 2025
focused on TON blockchain and the Telegram ecosystem. In November 2025, the Company began deploying Nvidia GPUs to Telegram&#x2019;s proprietary
AI protocol, Cocoon. Cocoon is Telegram's Confidential Compute Open Network &#x2014; a decentralized AI infrastructure project built around
the TON ecosystem. In response to market trends in the digital asset space and opportunities in AI infrastructure, in early 2026 the Company
completed a strategic pivot and rebranded as Alpha Compute Corp. to reflect that its primary focus had shifted to AI compute infrastructure.
This transition included the establishment of GPU procurement and data center deployment capabilities, and the development of a proprietary
confidential computing software stack.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;While investing in digital assets, staking digital assets, and operating
blockchain infrastructure is no longer a core focus of the Company, it will continue to maintain some exposure to TON and other digital
assets. By deploying GPU hardware to Telegram&#x2019;s Cocoon protocol, the Company will continue to earn TON tokens, and through its May
2026 acquisition of GaMee, the Company has exposure to the broader Telegram ecosystem and large userbase. However, TON tokens earned from
Cocoon will generally be used for operating and capital expenditures for the AI infrastructure business line, rather than held for long-term
investment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The remaining locked TON tokens on the Company&#x2019;s balance sheet are
mostly in the process of being returned to investors per their put rights granted as part of the September 2025 PIPE transaction, with
two additional outstanding put rights exercised on June 22, 2026. One remaining investor has not exercised his put right on $0.2 million
locked TON contributed.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legacy Immuno-oncology Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Prior to September 2025, Alpha Compute (under the name
Portage Biotech) primarily operated as a clinical-stage immuno-oncology company advancing treatments the Company believes will be first-in
class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients
with invasive cancers. Alpha Compute&#x2019;s access to next-generation technologies coupled with a deep understanding of biological mechanisms
enables the identification of clinical therapies and product development strategies that accelerate these medicines through the translational
pipeline. After a review of the Company&#x2019;s future funding needs for clinical development of its programs as well as the capital raising
market for biotechnology companies, the Company discontinued the Company sponsored trial for the invariant natural killer T-cell (&#x201c;iNKT&#x201d;)
program and pause further patient accrual to the Company sponsored adenosine trial for both PORT-6 and PORT-7.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;In March 2025, we resumed patient enrollment into the
final dose-escalation cohort of TT-10 (PORT-6) under the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following an earlier pause related
to funding constraints. That decision reflected the favorable safety and preliminary activity signals seen in earlier dose cohorts. Dosing
in that final cohort is now underway, with the last dose-escalation patient currently being treated. In April 2025, we reported confirmatory
preclinical results for our TT-4 (PORT-7) compound in mesothelioma, supporting advancement of that indication. Under the trial protocol,
TT-4 dosing follows completion of the TT-10 dose-escalation cohort, and we are now preparing to enroll patients onto TT-4.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On November 12, 2025, Alpha Compute and Cyncado announced
a non-binding Letter of Intent with Australia&#x2019;s Asbestos and Dust Diseases Research Institute (&#x201c;ADDRI&#x201d;) to conduct an
ADDRI-sponsored investigator-initiated clinical trial of TT-4 in mesothelioma in Australia. The planned trial is expected to enroll approximately
50 patients, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado&#x2019;s planned U.S.
mesothelioma activities, subject to execution of a definitive agreement and customary regulatory approvals. Under the contemplated arrangement,
Cyncado will supply TT-4 and limited support as part of an international mesothelioma program designed to accelerate decision-quality
clinical data generation.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;)
approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024,
the Company&#x2019;s ordinary shares began trading on Nasdaq on a split-adjusted basis.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The reverse stock split was implemented to increase
the per share trading price of the Company&#x2019;s ordinary shares for the purpose of ensuring a share price high enough to comply with
the minimum $1.00 bid price requirement for continued listing on Nasdaq. The Company received notice from Nasdaq on August 30, 2024 informing
the Company that it had regained compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;As a result of the reverse stock split, every twenty
(20) pre-split ordinary shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from the reverse
stock split were rounded up to the nearest whole post-split ordinary share. The reverse stock split affected all shareholders uniformly
and did not alter any shareholder&#x2019;s percentage interest in the Company&#x2019;s ordinary shares, except for adjustments that may
result from the treatment of fractional shares. All outstanding options and warrants entitling their holders to purchase the Company&#x2019;s
ordinary shares were adjusted as a result of the reverse stock split, in accordance with the terms of each such security. In addition,
the number of ordinary shares reserved for future issuance pursuant to the Company&#x2019;s equity incentive plans were also appropriately
adjusted. The number of authorized ordinary shares was not proportionately reduced because the Company has an unlimited number of authorized
ordinary shares available for issuance, as permitted under the laws of the British Virgin Islands.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;All share and per share information included in the
consolidated financial statements have been retroactively adjusted to reflect the impact of the reverse stock split as if the stock split
occurred at the beginning of the periods presented. The shares of ordinary shares authorized remained at an unlimited number of ordinary
shares without par value.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:NatureOfOperationsExplanatory>
    <ifrs-full:DisclosureOfGoingConcernExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001100">&lt;p id="xdx_801_eifrs-full--DisclosureOfGoingConcernExplanatory_zYG7tTV8Pu62" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 2. &lt;span id="xdx_820_zPB9FXidVlub"&gt;GOING
CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The accompanying consolidated financial statements for the fiscal year ended
March 31, 2026 have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity
of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly,
the accompanying consolidated financial statements for the fiscal year ended March 31, 2026 do not include any adjustments relating to
the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As of March 31, 2026, the Company had cash, cash equivalents, and restricted
cash of approximately $&lt;span id="xdx_902_eifrs-full--Cash_iI_pn3n3_dm_c20260331_z7UjVGJM0jv8"&gt;0.7&lt;/span&gt;
million and total current liabilities of approximately $&lt;span id="xdx_905_ecustom--TotalCurrentLiabilities_iI_pn5n6_c20260331_zLJBD86ckS6e"&gt;12.7&lt;/span&gt;
million. For the year ended March 31, 2026, the Company is reporting a net loss of approximately $&lt;span id="xdx_90F_ecustom--NetLossIncome_pn3n3_dm_c20250401__20260331_z1CiYsvAmf21"&gt;38.6&lt;/span&gt;
million, and cash used in operating activities of approximately $&lt;span id="xdx_90C_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20250401__20260331_zppeVO2ZVsOl"&gt;20.5&lt;/span&gt;
million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;In late Fiscal 2024, because of continued liquidity constraints, the Company
discontinued further clinical development of its iNKT sponsored trial and pause further patient accrual to its sponsored adenosine program
for both PORT-6 and PORT-7. During the fiscal year ended March 31, 2026, the Company changed its operating strategy to focus on developing
the Telegram ecosystem and managing a strategic reserve of digital assets, primarily the TON token, and received funding via a private
placement in the form of both cash and digital assets. While this and subsequent equity raises including a registered direct offering
on January 13, 2026 are a positive factor the Company is continuing to explore financing options including its at-the-market (&#x201c;ATM&#x201d;)
equity program and other financings.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Despite the Company successfully raising capital via a private placement
of shares and a registered direct offering in September 2025 and January 2026, respectively, and successfully raising additional funds
through its ATM program, the Company&#x2019;s cash and cash equivalents balance is decreasing, and the Company did not generate positive
cash flows from operations for the fiscal years ended March 31, 2026 and 2025. Additionally, a portion of the Company&#x2019;s digital
asset balance may be subject to significant price fluctuations, is restricted for immediate use, or both and therefore may not be relied
upon to fund current obligations as they come due. These factors raise significant doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date issuance of these consolidated financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company has incurred significant operating losses since inception and
expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of research and development activities and operating expenses. As previously discussed, the Company has discontinued
its iNKT sponsored trial and paused further patient accrual to the Company sponsored adenosine program in order to preserve cash resources.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities. The Company will require significant additional capital to make the investments it needs
to execute its new Telegram ecosystem and new digital asset strategies, beyond the potential proceeds that could be reasonably generated
from its ATM program. The Company&#x2019;s ability to successfully raise sufficient funds through the sale of debt or equity securities
when needed is subject to many risks and uncertainties and, future equity issuances would result in dilution to existing shareholders
and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.
See Note 16, &#x201c;Capital Stock and Reserves,&#x201d; for a further discussion.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As of July 13, 2026, the Company had approximately $&lt;span id="xdx_905_ecustom--CashCashEquivalents_iI_pn3n3_dm_c20260331_zjJRM80f9lv5" title="cash, cash equivalents"&gt;10.3&lt;/span&gt;
million of cash, cash equivalents, and restricted cash on hand, which the Company expects may not be sufficient to fund its operating
needs through FYE in March 2027. The Company projects cash flow needs of approximately $&lt;span id="xdx_905_ecustom--RestrictedCashOnHand_iI_c20260331_zkGjj8VtcHI6" title="Restricted cash on hand"&gt;25.0&lt;/span&gt;
million between now and FYE 2027, exceeding cash, cash equivalents, and restricted cash on hand. These factors raise substantial doubt
about the Company&#x2019;s ability to continue as a going concern within one year after the date of the issuance of these consolidated
financial statements. There were no adjustments made to reflect the effect of this doubt.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ifrs-full:DisclosureOfGoingConcernExplanatory>
    <ifrs-full:Cash
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001101"
      unitRef="USD">700000</ifrs-full:Cash>
    <ptgef:TotalCurrentLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact001102"
      unitRef="USD">12700000</ptgef:TotalCurrentLiabilities>
    <ptgef:NetLossIncome
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001103"
      unitRef="USD">38600000</ptgef:NetLossIncome>
    <ptgef:CashUsedInOperatingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001104"
      unitRef="USD">20500000</ptgef:CashUsedInOperatingActivities>
    <ptgef:CashCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001106"
      unitRef="USD">10300000</ptgef:CashCashEquivalents>
    <ptgef:RestrictedCashOnHand
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001108"
      unitRef="USD">25.0</ptgef:RestrictedCashOnHand>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001110">&lt;p id="xdx_809_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zS59ac2GGlpi" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 3.
&lt;span id="xdx_82C_z2CuiX4AkXYj"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Statement of Compliance and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;These consolidated financial statements have been prepared
in accordance with the International Financial Reporting Standards (&#x201c;IFRS&#x201d;) issued by the International Accounting Standards
Board (&#x201c;IASB&#x201d;), and interpretations of the International Financial Reporting Interpretations Committee (&#x201c;IFRIC&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;These consolidated financial statements have been prepared
on an historical cost basis except for items disclosed herein at fair value (see Note 21, &#x201c;Financial Instruments and Risk Management&#x201d;).
In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The Company has two reportable operating segments, Digital &amp;amp;
Compute and Immuno-Oncology.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;These consolidated financial statements were
approved and authorized for issuance by the Audit Committee (the &#x201c;Audit Committee&#x201d;) of the Board on July 15, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The consolidated financial statements include the accounts of the
Company and:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"&gt;(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged
certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing &lt;span id="xdx_90A_eifrs-full--ProportionOfVotingPowerHeldInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zpyCKxETZbEd" title="Percentage of outstanding shares"&gt;17.83&lt;/span&gt;%
of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from &lt;span id="xdx_903_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zf1p7WpDmnj2" title="Percentage of ownership"&gt;60.49&lt;/span&gt;%
to &lt;span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--SalvaRxMember_zWiVNXrgnHq5" title="Percentage of ownership"&gt;78.32&lt;/span&gt;%.
On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. The Company&#x2019;s &lt;span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20231201__20231231__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--StimunityMember_z06LXpMuyjxb" title="Non-controlling interest"&gt;44&lt;/span&gt;%
interest in Stimunity S.A. (&#x201c;Stimunity&#x201d;) was transferred from Alpha Compute to iOx in December 2023 and was increased to &lt;span id="xdx_90D_ecustom--NoncontrollingInterestIncreasedUponConversion_pip0_dp_c20231201__20231231__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--IOXMember__ifrs-full--ConsolidatedStructuredEntitiesAxis__custom--StimunityMember_z9f6BCDCglFg" title="Non-controlling interest increased upon conversion"&gt;48.9&lt;/span&gt;%
upon the conversion of the convertible note to equity. On December 3, 2025, the Company agreed to sell back our 48.9% interest back to
Stimunity for a token consideration of 1 EUR in order to facilitate an orderly wind-down of Stimunity;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Saugatuck, a &lt;span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20250401__20250930__ifrs-full--GeographicalAreasAxis__custom--CountryOfBritishVirginIslandsMember_z8ylDweMC7Vj" title="Percentage of ownership subsidiary"&gt;70&lt;/span&gt;%
owned subsidiary incorporated in the British Virgin Islands;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Tarus Therapeutic Holdings Ltd., a wholly-owned subsidiary incorporated in the British Virgin Islands;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
PDS, a &lt;span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20250401__20250930__ifrs-full--GeographicalAreasAxis__custom--DelawareMember_zuCrLVYfhLu4" title="Percentage of ownership subsidiary"&gt;100&lt;/span&gt;%
owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary via a shared
services agreement;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SalvaRx LLC, a wholly-owned subsidiary through SalvaRx incorporated in Delaware;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck incorporated in Delaware; and&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Tarus Therapeutics, LLC (&#x201c;Tarus&#x201d;), a wholly-owned subsidiary of Alpha Compute incorporated in Delaware.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;All inter-company balances and transactions have been eliminated
in consolidation.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of shareholders&#x2019; equity. As of March 31, 2026, non-controlling interest represents
the &lt;span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20250401__20250930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z8AH8lfRHkIj" title="Non-controlling interest"&gt;30&lt;/span&gt;%
shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Functional and Presentation Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The Company&#x2019;s functional and presentation currency is the
U.S. Dollar.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates and Judgments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The preparation of the consolidated financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Estimates and underlying assumptions are reviewed on
an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future
periods affected.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Significant areas where estimates are made include
valuation of financial instruments, deferred tax assets and liabilities, warrant liabilities, digital assets, put right liabilities, and
measurement of share-based compensation. Significant areas where critical judgments are applied include warrant liabilities, put right
liabilities, and digital asset valuation with respect to discounts for lack of marketability.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Transactions with Non-controlling Interests&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Changes in the Company&#x2019;s ownership interest in
a subsidiary corporation that do not result in a loss of control over the subsidiary corporation are accounted for as transactions with
equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest and the fair value
of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;















</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="From2021-09-012021-09-30_custom_IOXMember_custom_SalvaRxMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Pure">0.1783</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember_custom_IOXMember_custom_SalvaRxMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Pure">0.6049</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember_custom_IOXMember_custom_SalvaRxMember"
      decimals="INF"
      id="Fact001120"
      unitRef="Pure">0.7832</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="From2023-12-012023-12-31_custom_IOXMember_custom_StimunityMember"
      decimals="INF"
      id="Fact001122"
      unitRef="Pure">0.44</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <ptgef:NoncontrollingInterestIncreasedUponConversion
      contextRef="From2023-12-012023-12-31_custom_IOXMember_custom_StimunityMember"
      decimals="INF"
      id="Fact001124"
      unitRef="Pure">0.489</ptgef:NoncontrollingInterestIncreasedUponConversion>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2025-04-012025-09-30_custom_CountryOfBritishVirginIslandsMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Pure">0.70</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2025-04-012025-09-30_custom_DelawareMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="From2025-04-012025-09-30_custom_SubsidiariesTwoMember"
      decimals="INF"
      id="Fact001130"
      unitRef="Pure">0.30</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001134">&lt;p id="xdx_80B_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zjTMvWnc6BSi" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_826_zL81KC5bV0nh"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The accounting policies set out below have been applied consistently to
all periods presented in these consolidated financial statements, which have, in management's opinion, been properly prepared within reasonable
limits of materiality and within the framework of the significant accounting policies summarized below:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zq6bXFBJNhRl" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zrokjMcMtN3f"&gt;Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;i) Financial Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Upon the initial recognition of financial assets, the financial assets are
classified as one of the following measurement methodologies: (a) amortized cost, (b) fair value through other comprehensive income (&#x201c;FVTOCI&#x201d;),
or (c) fair value through profit or loss (&#x201c;FVTPL&#x201d;). Subsequent measurement will be based on the initial classification of
the financial assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The classification of a financial asset at initial recognition depends on
the Company's business model for managing the financial asset and the financial asset's contractual cash flow characteristics.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;In order for a financial asset to be measured at amortized cost or fair
value through other comprehensive income (&#x201c;OCI&#x201d;), it needs to give rise to cash flows that are solely payments of principal
and interest (&#x201c;SPPI&#x201d;) on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed
at an instrument level.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company's business model for managing financial assets refers to how
it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting
contractual cash flows, selling the financial assets, or both.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Measurement&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;For purposes of subsequent measurement, financial assets are classified
in three categories:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 89%"&gt;Financial assets at amortized cost (debt instruments);&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Financial assets at FVTOCI (equity instruments); and&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Financial assets at FVTPL.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Financial Assets at Amortized Cost (Debt Instruments)&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;The Company measures financial assets at amortized cost if both of the following conditions
are met:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 89%"&gt;The financial asset is held within a business model with the objective of holding the financial asset in order to collect
        contractual cash flows; and&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
        on the principal amount outstanding.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Financial assets at amortized cost are subsequently measured using the effective
interest rate method and are subject to a period impairment review. Gains and losses are recognized in profit or loss when the asset is
derecognized, modified or impaired.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company's financial assets classified at amortized cost includes accounts
receivable, stablecoin, and prepaid expenses and other receivables.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Financial Assets designated at Fair Value through OCI (Equity Instruments)&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Upon initial recognition, the Company can elect to classify irrevocably
its equity investments as equity instruments designated at FVTOCI when they meet the definition of equity under IAS 32, &#x201c;&lt;i&gt;Financial
Instruments: Presentation&lt;/i&gt;,&#x201d; and are not held for trading. The classification is determined on an instrument-by-instrument basis.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Gains and losses on these financial assets are never recycled to profit
or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except
when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded
in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company irrevocably elected to classify its investment in Intensity
as FVTOCI. During the year ended March 31, 2024, the Company sold 100% of its investment in Intensity for proceeds of $2.812 million and
recognized a gain of $0.725 million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Financial Assets at Fair Value through Profit or Loss&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Financial assets at FVTPL include financial assets held for trading, financial
assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured
at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in
the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated
as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified
and measured FVTPL, irrespective of the business model.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Financial assets at fair value through profit or loss are carried in the
consolidated statements of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.
The investments in associate (Stimunity and Compedica) and the Stimunity Convertible Note receivable are accounted for as FVTPL.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;ii) Financial Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s financial liabilities include accounts payable and accrued
liabilities, which approximate fair value due to their short maturity, lease liability, warrant liability, put right liability and TON
payable to settle put rights exercised.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Warrant Liability&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Warrant liabilities are initially measured at fair value on the date of
issuance. After initial recognition, the warrant liabilities are remeasured at fair value at each reporting period, with changes in fair
value recognized through the consolidated statement of operations and other comprehensive loss in accordance with IFRS 9 &#x201c;Financial
Instruments.&#x201d; When the Company issues equity instruments to extinguish all or part of the liability, a gain or loss is recognized
in the consolidated statement of operations and other comprehensive loss, which is measured as the difference between the carrying amount
of the financial liability and the fair value of the equity instruments issued. Liability classified warrants are accounted for in accordance
with IFRS 9 and IFRS 13 &#x201c;&lt;i&gt;Fair Value Measurement&lt;/i&gt;,&#x201d; where the terms of the instruments do not meet the criteria for classification
as equity under IAS 32 &#x201c;&lt;i&gt;Financial Instruments: Presentation&lt;/i&gt;.&#x201d; See Note 11, &#x201c;Warrant Liability&#x201d; for a further
discussion.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zAGIzTm5czbj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zWLd1DvAegf"&gt;Impairment
of Financial Assets and Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;IFRS 9, &#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;,&#x201d; requires the Company
to recognize an allowance for expected credit losses ("ECLs") for all debt instruments and investments not held at fair value
through profit or loss and contract assets. For intangible assets, at the end of each reporting period and whenever there is an indication
that the intangible asset may be impaired, the Company reviews the carrying amounts of its intangible assets to determine whether there
is any indication that those assets have suffered an impairment loss.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;At the end of each reporting period, the Company assesses whether there
was objective evidence that a financial asset was impaired. The Company recognizes an allowance for ECLs for all debt instruments not
held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with
the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest
rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral
to the contractual terms.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;ECLs are recognized in two stages. For credit exposures for which there
has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default
events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant
increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of
the exposure, irrespective of the timing of the default (a lifetime ECL).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



















&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_zpRmemeYFdJj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zwlvM4mX0Vmk"&gt;Cash,
Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Cash and cash equivalents comprise cash in readily available checking accounts
and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash within three
months or less from date of acquisition and are subject to an insignificant risk of change in value. The carrying amounts approximate
fair value due to the short maturities of these instruments. The Company maintains most of its bank accounts in the United States ("U.S.").
As of March 31, 2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date
of purchase. Interest income earned on such investments totaled $&lt;span id="xdx_90F_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20260331_zrFeBE0oQpZb" title="Investments"&gt;0.1&lt;/span&gt;
million, $&lt;span id="xdx_90C_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20250331_zMypTLAoGPX" title="Investments"&gt;0.1&lt;/span&gt;
million and $&lt;span id="xdx_909_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20240331_zaClKDTedD82" title="Investments"&gt;0.2&lt;/span&gt;
million in the years ended March 31, 2026, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As of March 31, 2026, the Company had $&lt;span id="xdx_900_ecustom--CashRestrictedForUse_iI_pn3n3_dm_c20260331_zAwpvCBHawgl" title="Cash restricted for use"&gt;0.2&lt;/span&gt;
million in cash considered restricted for use and is held as collateral for the Company&#x2019;s credit card balance with Silicon Valley
Bank. No cash was restricted for use as of March 31, 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory_zQ5bnXcLF6I1" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z8Y29tRA5GIi"&gt;Impairment
of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;At the end of each annual reporting period and whenever there is an indication
that its property, plant and equipment and indefinite life intangible assets may be impaired, the Company reviews the carrying amounts
of such tangible intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If
any such indication exists, the recoverable amount of the asset is estimated to determine the extent of impairment loss (if any). When
it is not possible to estimate the recoverable amount of any individual asset, the Company estimates the recoverable amount of the cash-generating
unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated
to individual cash-generating units ("CGU" or "CGUs"), or the smallest group of cash-generating units for which a reasonable
and consistent allocation basis can be identified.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Recoverable amount is the higher of fair value less costs of disposal and
value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_z6u69SbANulg" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zZuOgTYrTSqf"&gt;Share-based
Payments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company determines the fair value of share-based payments granted to
directors, officers, employees and consultants using the Black-Scholes option-pricing model at the grant date. Assumptions for the Black-Scholes
model are determined as follows:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 89%"&gt;&lt;b&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&lt;/b&gt;. The expected volatility rate used to value share option grants is based on the Company&#x2019;s
        historical volatility.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Expected Term&lt;/i&gt;&lt;/b&gt;. The Company used historical experience.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Risk-free Interest Rate&lt;/i&gt;&lt;/b&gt;. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that
        had terms 	consistent with the expected term of the Company's share option grants.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Expected Dividend Yield&lt;/i&gt;&lt;/b&gt;. The Company has never declared or paid any cash dividends and does not presently plan to pay cash
        	dividends in the foreseeable future.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;Share-based payments to employees, officers and directors are recorded and reflected
as an expense over the vesting period with a corresponding increase in the share option reserve. On exercise, the associated amounts previously
recorded in the share option reserve are transferred to common share capital.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zrw28pDv89Vb" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z1ZKTjA18v84"&gt;Loss
Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Basic loss per share is calculated by dividing net loss (the numerator)
by the weighted average number of ordinary shares outstanding (the denominator) during the period. Diluted loss per share reflects the
dilution that would occur if outstanding share options and share purchase warrants were exercised into ordinary shares using the treasury
stock method and convertible debt instruments were converted into ordinary shares using the if-converted method. Diluted loss per share
is calculated by dividing net loss applicable to ordinary shares by the sum of the weighted average number of ordinary shares outstanding
and all additional ordinary shares that would have been outstanding if potentially dilutive ordinary shares had been issued. The share
and per share information has been retroactively adjusted to reflect the impact of the stock dividend.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The inclusion of the Company's share options, restricted stock units and
share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore
excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the years
ended March 31, 2026, 2025, and 2024. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share, and accordingly, were excluded from the calculation (see Note 19, &#x201c;Loss Per Share&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_z8ftXIMzNIQa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B7_zUdta2IpW0Zf" style="display: none"&gt;Schedule of anti-dilutive effect on loss
        per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zSgEDUtn4RO8" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,531,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zby4c4g4Bjth" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zGDYkRfspGq6" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Share options&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zjFUSFChu8hb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zX5zMTcxbVNg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;225,117&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zfqvikszk0E4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;90,281&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock units&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zbSDlZbM3fF6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,241,334&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zMk7FZpnUWTc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;5,410&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zcOYTRxczUv5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;18,467&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A4_zrEmZO7sqO61" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory_zY1ZfxAjJTm3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zawFxBcOWf8b"&gt;Investment
in Public Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The investment is comprised of shares of private/public companies that have
been acquired through a private placement. The investment is initially recorded at fair value. Following acquisition, the Company evaluates
whether control or significant influence is exerted by the Company over the affairs of the investee company. Based on the evaluation,
the Company accounts for the investment using either the consolidation, equity accounting or fair value method. The Company sold the entire
investment in Fiscal 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForInvestmentInAssociates_zJUoPXSpf5If" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zDJqp4VzmMm2"&gt;Investment
in Associate&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;An associate is an entity over which the Company has significant influence.
Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or
joint control over those policies. The investment in associate was written down to nil as of March 31, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The results and assets and liabilities of associates are incorporated in
these consolidated financial statements using the equity method of accounting, except when the investment, or a portion thereof, is classified
as held for sale, in which case it is accounted for in accordance with IFRS 5, &#x201c;Non-current Assets Held for Sale and Discontinued
Operations&#x201d;. Under the equity method, an investment in an associate is initially recognized in the consolidated statement of financial
position at cost from the date the investee becomes an associate and adjusted thereafter to recognize the Company's share of the profit
or loss and other comprehensive income of the associate. When the Company's share of losses of an associate exceed the Company's interest
in that associate (which includes any long-term interests that, in substance, form part of the Company's net investment in the associate),
the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company
has incurred legal or constructive obligations or made payments on behalf of the associate.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;After application of the equity method, the Company determines whether it
is necessary to recognize an impairment loss on its investment in its associate. At each reporting date, the Company determines whether
there is objective evidence that the investment in the associate is impaired. If there is such evidence, the Company calculates the amount
of impairment as the difference between the recoverable amount of the associate and its carrying value, and then recognizes the loss within
'share of (loss) income in associate' in the consolidated statements of operations. With respect to its investment in Compedica, the Company
recognized a loss on impairment of $4.8 million as of September 30, 2025 due to the Company&#x2019;s loss of significant influence over
the operations of Compedica.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_zQcsmzLWZ4Kc" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zEaAf6viREwi"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(i) Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Expenditure on research activities, undertaken with the prospect of gaining
new scientific or technical knowledge and understanding, is expensed as incurred.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Development activities involve a plan or design for the production of new
or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably,
the product or process is technically, and commercially feasible, future economic benefits are probable, and the Company intends to and
has sufficient resources to complete development and to use or sell the asset. Following initial recognition of the development expenditure
as an asset, the asset is carried at cost less any accumulated amortization. Amortization of the asset begins when development is complete
and the asset is available for use. It is amortized over the period of expected future benefit. During the period of development, the
asset is tested for impairment annually.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Research and development expenses include all direct and indirect operating
expenses supporting the products in development.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(ii) Subsequent Expenditure&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Subsequent expenditure is capitalized only when it increases the future
economic benefits embodied in the specific asset to which it relates. All other expenditures are recognized in income or loss as incurred.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(iii) Clinical Trial Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Clinical trial expenses are a component of the Company's research and development
costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct development
activities on the Company's behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements is based
on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrollment,
services provided, contractual terms, and prior experience with similar contracts.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory_zkRtD8qg5a6e" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zUR2A6MIwkdk"&gt;Contingent
Liability&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;A provision in accordance with IAS 37 &#x201c;&lt;i&gt;Provisions, Contingent Liabilities
and Contingent Assets&lt;/i&gt;,&#x201d; is recognized when the Company has a present (legal or constructive) obligation as a result of a past
event and it is probable that economic resources shall be required to settle the obligation and a reliable estimate can be made of the
amount of the obligation. When the Company expects that some or all of the expense will be reimbursed to it, such as in an insurance contract,
the repayment will be recognized as a separate asset, only when it is highly likely that the asset will be received. The expense will
be recognized in profit and loss net of the portion reimbursed.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zoevFRVGYk92" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zVqVJ2K4A0S4"&gt;Determination
of Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;A number of the Company's accounting policies and disclosures required the
determination of fair value, both for financial and non-financial assets and liabilities. Fair values have been determined for measurement
and/or disclosure purposes based on assumptions that market participants would use when pricing the asset or liability, assuming that
market participants act in their economic best interest. When applicable, further information about the assumptions made in determining
fair values is disclosed in Note 15, &#x201c;Financial Instruments and Risk Management&#x201d; and other footnotes that specifically relate
to assets or liabilities measured at fair value.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zf26Z2XGEyGj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zD5CdCIX2YK3"&gt;Income
Tax&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company uses the asset and liability method to account for income taxes.
Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying
amounts of existing assets and liabilities for accounting purposes, and their respective tax bases.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Deferred income tax assets and liabilities are measured using tax rates
that have been enacted or substantively enacted and applied to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized
in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and
are reviewed at the end of each reporting period.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



&lt;p id="xdx_848_ecustom--DescriptionOfAccountingPolicyFoStablecoinExplanatory_zi9uQyzIlenl" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zOUWdk3B0UF9"&gt;Stablecoin&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company accounts for its stablecoins, which are comprised of USDC and
USDT, as in accordance with IAS 9 &#x201c;Financial Instruments&#x201d;. The Company&#x2019;s stablecoins are initially recorded at cost,
and are contractually redeemable for fiat currency on demand or pegged 1:1 to the value of one U.S. dollar. The Company determines the
fair value of its stablecoins, which is at par with the U.S. dollar, in accordance with IFRS 13 &#x201c;Fair Value Measurement&#x201d; based
on the quoted (unadjusted) prices on the active exchange that the Company has determined is its principal market for the stablecoins (Level
1 inputs). Our primary custodian of stablecoins is BitGo, and the associated costs are expensed as incurred. Stablecoins are held for
use in business operations and not for the purpose of potential asset appreciation and is therefore classified as a current asset within
the consolidated statements of financial position. When the Company does not have possession, control, or the right to derive substantially
all of the economic benefits of ownership of stablecoin the Company has title to, the stablecoin is classified as a stablecoin receivable
within the consolidated statements of financial position. Stablecoin and stablecoin receivables qualify as financial instruments due to
their high level of liquidity, rights to redeem directly with the issuer, and their backing by high quality reserve assets not subject
to significant price fluctuations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;























&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_zlzyHdBCCbP" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z2wZN8uiLec4"&gt;Digital
Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company accounts for its digital assets, which are comprised of TON,
as indefinite-lived intangible assets in accordance with IAS 38 &#x201c;Intangible Assets&#x201d;. The Company&#x2019;s digital assets are
initially recorded at cost. Subsequently, digital assets are remeasured at fair value as of each reporting period, adjusted by discounts
for lack of marketability for tokens restricted for use. The Company determines the fair value of its liquid digital assets in accordance
with IFRS 13 &#x201c;Fair Value Measurement&#x201d;, based on quoted (unadjusted) prices on the active exchange that the Company has determined
is its principal market for the digital assets (Level 1 inputs). For locked digital assets which are not immediately tradable, the Company
applies a lack of marketability discount to quoted prices to calculate fair value (Level 3 input). Our primary custodian of digital assets
is BitGo, and the associated costs are expensed as incurred. When the Company does not have possession, control, or the right to derive
substantially all of the economic benefits of ownership of digital assets the Company has title to, the digital assets are classified
as digital assets receivable within the consolidated statements of financial position.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Increases in fair value, to the extent they do not constitute reversals
of previous decreases in fair value, are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss),
within &#x201c;Unrealized gain on digital assets&#x201d; within Other comprehensive income, with accumulated unrealized gains recognized
on the Consolidated Statements of Financial Position within Accumulated other comprehensive income. Decreases in fair value, to the extent
they do not constitute reversals of previous increases in fair value, are recognized as incurred in the Company's Consolidated Statements
of Operations and Comprehensive Income (Loss), within &#x201c;Loss on revaluation of digital assets&#x201d; within Other expenses. Any losses
on revaluation not in excess of previously recognized gains are recognized as decreases to Accumulated other comprehensive income until
cost basis exceeds fair value, at which point additional losses are recognized as Other expense. Any gains on revaluation not in excess
of previously recognized losses are recognized as Other income until fair value exceeds cost basis, at which point additional gains are
recognized as Other comprehensive income. Revaluation gains and losses are recorded by token.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Realized gains, to the extent recognized within Accumulated other comprehensive
income, and losses are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss) within other
income (expense).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Digital assets are classified as current or noncurrent assets based on the
Company&#x2019;s intended holding period of the token. If the Company has the intent and ability to hold the token for a period of one
year beyond the balance sheet date or if the token is not expected to become liquid within one year of the balance sheet date, the holding
is classified as noncurrent. Otherwise, the holding is classified as a current asset.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_zZ4fAEFPxvHg" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z7TbxQoibEG8"&gt;Revenue
from Contracts with Customers&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company recognizes revenue in accordance with IFRS 15, &#x201c;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;,&#x201d; which establishes a comprehensive framework for determining whether, how much, and when revenue
is recognized. Revenue is recognized to depict the transfer of promised services to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those services.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s primary source of revenue is derived from compute offtake
agreements, under which customers obtain access to dedicated or shared compute capacity (including processing power, memory, and related
infrastructure) for a specified contractual term.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;i)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Identification of performance obligations&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Compute offtake agreements typically provide customers with a stand-ready obligation
to make compute capacity continuously available throughout the contract term. The Company has determined that such arrangements generally
contain a single performance obligation, being the provision of continuous access to compute services over time.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;To the extent that a contract includes multiple services (for example, initial configuration,
integration, or distinct ancillary services), the Company assesses whether such services are distinct and should be accounted for as separate
performance obligations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;ii)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Determination of the transaction price&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;The transaction price reflects the amount of consideration the Company expects to receive
in exchange for transferring promised services to the customer. Consideration under compute offtake agreements is typically fixed based
on contracted capacity and term, and is frequently settled in digital assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;In arrangements where consideration is received in digital assets, such consideration
represents non-cash consideration and is measured at fair value at contract inception.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Any variability in consideration (such as pricing adjustments, service level credits,
or penalties) is estimated using either the expected value or most likely amount method, and included in the transaction price only to
the extent that it is highly probable that a significant reversal of revenue will not occur.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;iii)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Allocation of the transaction price&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;If a contract contains more than one performance obligation, the transaction price is
allocated to each performance obligation based on the relative standalone selling prices of the distinct services at contract inception.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;iv)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Timing of revenue recognition&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Revenue from compute offtake agreements is recognized over time, as the customer simultaneously
receives and consumes the benefits of the compute services as they are provided. Progress toward complete satisfaction of the performance
obligation is measured on a time-elapsed basis, or another systematic measure that faithfully depicts the pattern of transfer of services
to the customer.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Revenue is recognized only when:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;
    &lt;td&gt;A valid contract exists;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;
    &lt;td&gt;The Company has transferred control of compute services to the customer; and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;3.&lt;/td&gt;
    &lt;td&gt;Collection of consideration is considered probable.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Digital assets received from customers is non-cash consideration and is
initially measured at fair value at contract inception. Any subsequent changes in the fair value of digital assets held by the Company
are accounted for in accordance with the Company&#x2019;s accounting policy for digital assets, and do not affect the amount of revenue
recognized.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_846_ecustom--DescriptionOfAccountingPolicyForAccountsReceivableExplanatory_zu3ay1vP4sj2" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zLn2ovINO1J3"&gt;Accounts
Receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Trade receivables are recognized when the Company has an unconditional right
to consideration, which generally arises upon the invoicing of compute services or when contractual billing milestones are met. Trade
receivables are initially measured at fair value, which is typically equal to the invoiced amount or the fair value of digital assets
consideration to be received.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Trade receivables are subsequently measured at amortized cost, as they are
held solely for the collection of contractual cash flows (or cash-equivalent consideration). Trade receivables are presented net of any
allowance for expected credit losses. To the extent that invoices are settled directly in digital assets prior to the end of the reporting
period, no trade receivable is recognized, and the digital asset is recognized in accordance with the applicable accounting policy.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory_zepWZP7ECA94" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zjiJsipzIskk"&gt;Expected
Credit Losses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company applies the simplified expected credit loss (ECL) model under
IFRS 9, &#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;.&#x201d; Under this approach, lifetime expected credit losses are recognized at initial recognition
and updated at each reporting date. Expected credit losses are estimated based on:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Historical credit loss experience;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Current customer payment behavior, including digital asset settlement history; and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Forward-looking information that is relevant to customer credit risk.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Trade receivables are written off when there is no reasonable expectation
of recovery.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_842_ecustom--DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory_z4OVvBWBvuW3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zV9xTkm552P5"&gt;Property,
Plant, and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company accounts for property, plant and equipment in accordance with
IAS 16, &#x201c;&lt;i&gt;Property, Plant and Equipment&lt;/i&gt;.&#x201d; The Company&#x2019;s property, plant and equipment consist solely of GPUs used
in the provision of compute services under compute offtake agreements. GPUs are recognized as property, plant and equipment when:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;It is probable that future economic benefits associated with the asset will flow to the Company; and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;The cost of the asset can be measured reliably.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;GPUs are initially measured at cost, which includes:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;The purchase price, net of discounts or rebates;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Non-refundable taxes and duties;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Directly attributable costs necessary to bring the GPUs to the location and condition necessary for them to be capable of operating as
        intended by management (including transportation, installation, testing, and configuration costs); and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Any other expenditures directly attributable to preparing the GPUs for their intended use.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;Costs incurred after GPUs are capable of operating as intended are expensed as incurred,
unless they meet the criteria for capitalization under IAS 16.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Following initial recognition, GPUs are carried at cost less accumulated
depreciation and accumulated impairment losses. The Company applies the cost model to all classes of property, plant and equipment. GPUs
are depreciated on a straight-line basis over their estimated useful lives, beginning when the assets are available for use, which is
when they are installed and ready for their intended operating condition. Management estimates the useful lives and residual values of
GPUs based on expected technological obsolescence, performance degradation, and expected usage patterns. Useful lives and residual values
are reviewed at least annually and adjusted prospectively when warranted.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;GPUs are derecognized upon disposal or when no future economic benefits
are expected from their use or disposal. Any gain or loss arising on derecognition is recognized in profit or loss and represents the
difference between the proceeds received and the carrying amount of the asset.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Deposits paid to suppliers for the future purchase of GPUs are recognized
as prepayments or other non-current assets, depending on the expected delivery date, and are not depreciated. Such deposits are initially
measured at the amount paid and reassessed at each reporting date to determine whether there is objective evidence that the deposit may
be impaired, including supplier non-performance or changes in expected delivery terms. Upon delivery and acceptance of the GPUs, deposits
are reclassified to property, plant and equipment as part of the cost of the related GPUs. If a purchase contract is terminated or delivery
becomes improbable, the deposit is written down to its recoverable amount, with any impairment recognized in profit or loss.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zzoCCzFQ5kDc" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zK6NvyGkmJvk"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements Issued&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Impact of Adoption of Significant New IFRS Standards in Fiscal 2026&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;&lt;b&gt;(a)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21: The Effects of
Changes in Foreign Exchange Rates&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;In August 2023, the IASB amended IAS 21, &#x201c;The
Effects of Changes in Foreign Exchange Rates&#x201d; (&#x201c;IAS 21&#x201d;) to clarify when a currency is exchangeable into another currency
and how a company estimates a spot rate when a currency lacks exchangeability, requiring consistent assessment and disclosure practices
for companies. The amendments are effective for annual reporting periods beginning on or after January 1, 2025, with early adoption permitted.
However, an entity cannot restate comparative information. The adoption of these amendments did not have a material effect on the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;&lt;b&gt;(b)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21 &#x2013; Lack of
Exchangeability&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;An entity is impacted by the amendments to IAS 21, &#x201c;&lt;i&gt;The Effects
of Changes in Foreign Exchange Rates&lt;/i&gt;,&#x201d; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The adoption of these amendments did not have a material effect on the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;New IFRS Accounting Standards not yet effective&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Standards issued but not yet effective up to the date
of issuance of the Company&#x2019;s consolidated financial statements are listed below. This is of standards and interpretations issued,
which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes effective.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;&lt;b&gt;(a)&#160;&#160;&#160;&#160;&#160; IAS 18: Presentation and Disclosure in
Financial Statements&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;In April 2024, IFRS 18, &#x201c;&lt;i&gt;Presentation and
Disclosure in Financial Statements&lt;/i&gt;&#x201d; (&#x201c;IFRS 18&#x201d;) was issued. IFRS 18 replaces IAS 1 and introduces significant changes
to the presentation of financial statements to enhance comparability across entities. The key requirements of the standard include:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Separate reporting of operating, investing, and financing activities in the statement of earnings, with prescribed
        subtotals for each category.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Disclosure of management-defined performance measures in a dedicated note within the financial statements.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The standard is effective for annual reporting periods
beginning on or after January 1, 2027, with retrospective application required. The Company intends to assess the impact of IFRS 18 on
its consolidated financial statements closer to the effective date. The effect of the new standard, however it may be, will only affect
matters of presentation and disclosure.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;(b) Amendments to IFRS 9 and IFRS 7&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On May 30, 2024, the International Accounting Standards
Board (the IASB or the Board) issued Amendments to IFRS 9 and IFRS 7, &lt;i&gt;Amendments to the Classification and Measurement of Financial
Instruments&lt;/i&gt;. The amendments:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Clarify that a financial liability is derecognized on the &#x201c;settlement date&#x201d;, i.e., when the related
        obligation is discharged or cancelled or expires or the liability otherwise qualifies for derecognition. They also introduce an accounting
        policy option to derecognize financial liabilities that are settled through an electronic payment system before settlement date if certain
        conditions are met.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental,
        social and governance (ESG)-linked features and other similar contingent features.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Clarify the treatment of non-recourse assets and contractually linked instruments (CLI).&#x2019;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that
        reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive
        income (FVTOCI).&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The standard is effective for annual reporting periods
beginning on or after January 1, 2026, with retrospective application required. The Company intends to assess the impact of the Amendments
to IFRS 9 and IFRS 7 on its consolidated financial statements closer to the effective date.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001136">&lt;p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zq6bXFBJNhRl" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zrokjMcMtN3f"&gt;Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;i) Financial Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Upon the initial recognition of financial assets, the financial assets are
classified as one of the following measurement methodologies: (a) amortized cost, (b) fair value through other comprehensive income (&#x201c;FVTOCI&#x201d;),
or (c) fair value through profit or loss (&#x201c;FVTPL&#x201d;). Subsequent measurement will be based on the initial classification of
the financial assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The classification of a financial asset at initial recognition depends on
the Company's business model for managing the financial asset and the financial asset's contractual cash flow characteristics.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;In order for a financial asset to be measured at amortized cost or fair
value through other comprehensive income (&#x201c;OCI&#x201d;), it needs to give rise to cash flows that are solely payments of principal
and interest (&#x201c;SPPI&#x201d;) on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed
at an instrument level.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company's business model for managing financial assets refers to how
it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting
contractual cash flows, selling the financial assets, or both.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Measurement&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;For purposes of subsequent measurement, financial assets are classified
in three categories:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 89%"&gt;Financial assets at amortized cost (debt instruments);&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Financial assets at FVTOCI (equity instruments); and&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Financial assets at FVTPL.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Financial Assets at Amortized Cost (Debt Instruments)&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;The Company measures financial assets at amortized cost if both of the following conditions
are met:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 89%"&gt;The financial asset is held within a business model with the objective of holding the financial asset in order to collect
        contractual cash flows; and&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
        on the principal amount outstanding.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Financial assets at amortized cost are subsequently measured using the effective
interest rate method and are subject to a period impairment review. Gains and losses are recognized in profit or loss when the asset is
derecognized, modified or impaired.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company's financial assets classified at amortized cost includes accounts
receivable, stablecoin, and prepaid expenses and other receivables.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Financial Assets designated at Fair Value through OCI (Equity Instruments)&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Upon initial recognition, the Company can elect to classify irrevocably
its equity investments as equity instruments designated at FVTOCI when they meet the definition of equity under IAS 32, &#x201c;&lt;i&gt;Financial
Instruments: Presentation&lt;/i&gt;,&#x201d; and are not held for trading. The classification is determined on an instrument-by-instrument basis.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Gains and losses on these financial assets are never recycled to profit
or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except
when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded
in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company irrevocably elected to classify its investment in Intensity
as FVTOCI. During the year ended March 31, 2024, the Company sold 100% of its investment in Intensity for proceeds of $2.812 million and
recognized a gain of $0.725 million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Financial Assets at Fair Value through Profit or Loss&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Financial assets at FVTPL include financial assets held for trading, financial
assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured
at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in
the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated
as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified
and measured FVTPL, irrespective of the business model.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Financial assets at fair value through profit or loss are carried in the
consolidated statements of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.
The investments in associate (Stimunity and Compedica) and the Stimunity Convertible Note receivable are accounted for as FVTPL.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;ii) Financial Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s financial liabilities include accounts payable and accrued
liabilities, which approximate fair value due to their short maturity, lease liability, warrant liability, put right liability and TON
payable to settle put rights exercised.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Warrant Liability&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Warrant liabilities are initially measured at fair value on the date of
issuance. After initial recognition, the warrant liabilities are remeasured at fair value at each reporting period, with changes in fair
value recognized through the consolidated statement of operations and other comprehensive loss in accordance with IFRS 9 &#x201c;Financial
Instruments.&#x201d; When the Company issues equity instruments to extinguish all or part of the liability, a gain or loss is recognized
in the consolidated statement of operations and other comprehensive loss, which is measured as the difference between the carrying amount
of the financial liability and the fair value of the equity instruments issued. Liability classified warrants are accounted for in accordance
with IFRS 9 and IFRS 13 &#x201c;&lt;i&gt;Fair Value Measurement&lt;/i&gt;,&#x201d; where the terms of the instruments do not meet the criteria for classification
as equity under IAS 32 &#x201c;&lt;i&gt;Financial Instruments: Presentation&lt;/i&gt;.&#x201d; See Note 11, &#x201c;Warrant Liability&#x201d; for a further
discussion.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001142">&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zAGIzTm5czbj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zWLd1DvAegf"&gt;Impairment
of Financial Assets and Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;IFRS 9, &#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;,&#x201d; requires the Company
to recognize an allowance for expected credit losses ("ECLs") for all debt instruments and investments not held at fair value
through profit or loss and contract assets. For intangible assets, at the end of each reporting period and whenever there is an indication
that the intangible asset may be impaired, the Company reviews the carrying amounts of its intangible assets to determine whether there
is any indication that those assets have suffered an impairment loss.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;At the end of each reporting period, the Company assesses whether there
was objective evidence that a financial asset was impaired. The Company recognizes an allowance for ECLs for all debt instruments not
held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with
the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest
rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral
to the contractual terms.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;ECLs are recognized in two stages. For credit exposures for which there
has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default
events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant
increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of
the exposure, irrespective of the timing of the default (a lifetime ECL).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



















</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001147">&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_zpRmemeYFdJj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zwlvM4mX0Vmk"&gt;Cash,
Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Cash and cash equivalents comprise cash in readily available checking accounts
and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash within three
months or less from date of acquisition and are subject to an insignificant risk of change in value. The carrying amounts approximate
fair value due to the short maturities of these instruments. The Company maintains most of its bank accounts in the United States ("U.S.").
As of March 31, 2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date
of purchase. Interest income earned on such investments totaled $&lt;span id="xdx_90F_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20260331_zrFeBE0oQpZb" title="Investments"&gt;0.1&lt;/span&gt;
million, $&lt;span id="xdx_90C_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20250331_zMypTLAoGPX" title="Investments"&gt;0.1&lt;/span&gt;
million and $&lt;span id="xdx_909_eifrs-full--InvestmentProperty_iI_pn3n3_dm_c20240331_zaClKDTedD82" title="Investments"&gt;0.2&lt;/span&gt;
million in the years ended March 31, 2026, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As of March 31, 2026, the Company had $&lt;span id="xdx_900_ecustom--CashRestrictedForUse_iI_pn3n3_dm_c20260331_zAwpvCBHawgl" title="Cash restricted for use"&gt;0.2&lt;/span&gt;
million in cash considered restricted for use and is held as collateral for the Company&#x2019;s credit card balance with Silicon Valley
Bank. No cash was restricted for use as of March 31, 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory>
    <ifrs-full:InvestmentProperty
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001149"
      unitRef="USD">100000</ifrs-full:InvestmentProperty>
    <ifrs-full:InvestmentProperty
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001151"
      unitRef="USD">100000</ifrs-full:InvestmentProperty>
    <ifrs-full:InvestmentProperty
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001153"
      unitRef="USD">200000</ifrs-full:InvestmentProperty>
    <ptgef:CashRestrictedForUse
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001155"
      unitRef="USD">200000</ptgef:CashRestrictedForUse>
    <ptgef:DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001157">&lt;p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory_zQ5bnXcLF6I1" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z8Y29tRA5GIi"&gt;Impairment
of Property, Plant, and Equipment and Indefinite Life Intangible Assets other than Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;At the end of each annual reporting period and whenever there is an indication
that its property, plant and equipment and indefinite life intangible assets may be impaired, the Company reviews the carrying amounts
of such tangible intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If
any such indication exists, the recoverable amount of the asset is estimated to determine the extent of impairment loss (if any). When
it is not possible to estimate the recoverable amount of any individual asset, the Company estimates the recoverable amount of the cash-generating
unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated
to individual cash-generating units ("CGU" or "CGUs"), or the smallest group of cash-generating units for which a reasonable
and consistent allocation basis can be identified.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Recoverable amount is the higher of fair value less costs of disposal and
value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForImpairmentOfIndefiniteLifeIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001159">&lt;p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_z6u69SbANulg" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zZuOgTYrTSqf"&gt;Share-based
Payments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company determines the fair value of share-based payments granted to
directors, officers, employees and consultants using the Black-Scholes option-pricing model at the grant date. Assumptions for the Black-Scholes
model are determined as follows:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 89%"&gt;&lt;b&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&lt;/b&gt;. The expected volatility rate used to value share option grants is based on the Company&#x2019;s
        historical volatility.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Expected Term&lt;/i&gt;&lt;/b&gt;. The Company used historical experience.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Risk-free Interest Rate&lt;/i&gt;&lt;/b&gt;. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that
        had terms 	consistent with the expected term of the Company's share option grants.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Expected Dividend Yield&lt;/i&gt;&lt;/b&gt;. The Company has never declared or paid any cash dividends and does not presently plan to pay cash
        	dividends in the foreseeable future.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;Share-based payments to employees, officers and directors are recorded and reflected
as an expense over the vesting period with a corresponding increase in the share option reserve. On exercise, the associated amounts previously
recorded in the share option reserve are transferred to common share capital.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001161">&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zrw28pDv89Vb" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z1ZKTjA18v84"&gt;Loss
Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Basic loss per share is calculated by dividing net loss (the numerator)
by the weighted average number of ordinary shares outstanding (the denominator) during the period. Diluted loss per share reflects the
dilution that would occur if outstanding share options and share purchase warrants were exercised into ordinary shares using the treasury
stock method and convertible debt instruments were converted into ordinary shares using the if-converted method. Diluted loss per share
is calculated by dividing net loss applicable to ordinary shares by the sum of the weighted average number of ordinary shares outstanding
and all additional ordinary shares that would have been outstanding if potentially dilutive ordinary shares had been issued. The share
and per share information has been retroactively adjusted to reflect the impact of the stock dividend.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The inclusion of the Company's share options, restricted stock units and
share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore
excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the years
ended March 31, 2026, 2025, and 2024. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share, and accordingly, were excluded from the calculation (see Note 19, &#x201c;Loss Per Share&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_z8ftXIMzNIQa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B7_zUdta2IpW0Zf" style="display: none"&gt;Schedule of anti-dilutive effect on loss
        per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zSgEDUtn4RO8" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,531,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zby4c4g4Bjth" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zGDYkRfspGq6" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Share options&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zjFUSFChu8hb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zX5zMTcxbVNg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;225,117&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zfqvikszk0E4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;90,281&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock units&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zbSDlZbM3fF6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,241,334&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zMk7FZpnUWTc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;5,410&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zcOYTRxczUv5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;18,467&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A4_zrEmZO7sqO61" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023 contextRef="From2025-04-01to2026-03-31" id="Fact001166">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023_z8ftXIMzNIQa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details )"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B7_zUdta2IpW0Zf" style="display: none"&gt;Schedule of anti-dilutive effect on loss
        per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zSgEDUtn4RO8" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,531,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zby4c4g4Bjth" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zGDYkRfspGq6" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Share options&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zjFUSFChu8hb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zX5zMTcxbVNg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;225,117&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsMember_zfqvikszk0E4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;90,281&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock units&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20250401__20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zbSDlZbM3fF6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,241,334&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20240401__20250331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zMk7FZpnUWTc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;5,410&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_pip0_c20230401__20240331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--RestrictedStockUnitsMember_zcOYTRxczUv5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;18,467&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ifrs-full:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareExplanatory2023>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2025-04-012026-03-31_ifrs-full_WarrantsMember"
      decimals="INF"
      id="Fact001168"
      unitRef="Shares">1531581</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2024-04-012025-03-31_ifrs-full_WarrantsMember"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">481581</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2023-04-012024-03-31_ifrs-full_WarrantsMember"
      decimals="INF"
      id="Fact001172"
      unitRef="Shares">481581</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2025-04-012026-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">2246507</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2024-04-012025-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001176"
      unitRef="Shares">225117</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2023-04-012024-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Shares">90281</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2025-04-012026-03-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact001180"
      unitRef="Shares">1241334</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2024-04-012025-03-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact001182"
      unitRef="Shares">5410</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented
      contextRef="From2023-04-012024-03-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact001184"
      unitRef="Shares">18467</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ptgef:DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001186">&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory_zY1ZfxAjJTm3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zawFxBcOWf8b"&gt;Investment
in Public Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The investment is comprised of shares of private/public companies that have
been acquired through a private placement. The investment is initially recorded at fair value. Following acquisition, the Company evaluates
whether control or significant influence is exerted by the Company over the affairs of the investee company. Based on the evaluation,
the Company accounts for the investment using either the consolidation, equity accounting or fair value method. The Company sold the entire
investment in Fiscal 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForInvestmentInPrivateCompaniesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates contextRef="From2025-04-01to2026-03-31" id="Fact001188">&lt;p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForInvestmentInAssociates_zJUoPXSpf5If" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zDJqp4VzmMm2"&gt;Investment
in Associate&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;An associate is an entity over which the Company has significant influence.
Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or
joint control over those policies. The investment in associate was written down to nil as of March 31, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The results and assets and liabilities of associates are incorporated in
these consolidated financial statements using the equity method of accounting, except when the investment, or a portion thereof, is classified
as held for sale, in which case it is accounted for in accordance with IFRS 5, &#x201c;Non-current Assets Held for Sale and Discontinued
Operations&#x201d;. Under the equity method, an investment in an associate is initially recognized in the consolidated statement of financial
position at cost from the date the investee becomes an associate and adjusted thereafter to recognize the Company's share of the profit
or loss and other comprehensive income of the associate. When the Company's share of losses of an associate exceed the Company's interest
in that associate (which includes any long-term interests that, in substance, form part of the Company's net investment in the associate),
the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company
has incurred legal or constructive obligations or made payments on behalf of the associate.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;After application of the equity method, the Company determines whether it
is necessary to recognize an impairment loss on its investment in its associate. At each reporting date, the Company determines whether
there is objective evidence that the investment in the associate is impaired. If there is such evidence, the Company calculates the amount
of impairment as the difference between the recoverable amount of the associate and its carrying value, and then recognizes the loss within
'share of (loss) income in associate' in the consolidated statements of operations. With respect to its investment in Compedica, the Company
recognized a loss on impairment of $4.8 million as of September 30, 2025 due to the Company&#x2019;s loss of significant influence over
the operations of Compedica.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001190">&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_zQcsmzLWZ4Kc" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zEaAf6viREwi"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(i) Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Expenditure on research activities, undertaken with the prospect of gaining
new scientific or technical knowledge and understanding, is expensed as incurred.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Development activities involve a plan or design for the production of new
or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably,
the product or process is technically, and commercially feasible, future economic benefits are probable, and the Company intends to and
has sufficient resources to complete development and to use or sell the asset. Following initial recognition of the development expenditure
as an asset, the asset is carried at cost less any accumulated amortization. Amortization of the asset begins when development is complete
and the asset is available for use. It is amortized over the period of expected future benefit. During the period of development, the
asset is tested for impairment annually.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Research and development expenses include all direct and indirect operating
expenses supporting the products in development.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(ii) Subsequent Expenditure&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Subsequent expenditure is capitalized only when it increases the future
economic benefits embodied in the specific asset to which it relates. All other expenditures are recognized in income or loss as incurred.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(iii) Clinical Trial Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Clinical trial expenses are a component of the Company's research and development
costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct development
activities on the Company's behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements is based
on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrollment,
services provided, contractual terms, and prior experience with similar contracts.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001196">&lt;p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory_zkRtD8qg5a6e" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zUR2A6MIwkdk"&gt;Contingent
Liability&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;A provision in accordance with IAS 37 &#x201c;&lt;i&gt;Provisions, Contingent Liabilities
and Contingent Assets&lt;/i&gt;,&#x201d; is recognized when the Company has a present (legal or constructive) obligation as a result of a past
event and it is probable that economic resources shall be required to settle the obligation and a reliable estimate can be made of the
amount of the obligation. When the Company expects that some or all of the expense will be reimbursed to it, such as in an insurance contract,
the repayment will be recognized as a separate asset, only when it is highly likely that the asset will be received. The expense will
be recognized in profit and loss net of the portion reimbursed.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForContingentLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001198">&lt;p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zoevFRVGYk92" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zVqVJ2K4A0S4"&gt;Determination
of Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;A number of the Company's accounting policies and disclosures required the
determination of fair value, both for financial and non-financial assets and liabilities. Fair values have been determined for measurement
and/or disclosure purposes based on assumptions that market participants would use when pricing the asset or liability, assuming that
market participants act in their economic best interest. When applicable, further information about the assumptions made in determining
fair values is disclosed in Note 15, &#x201c;Financial Instruments and Risk Management&#x201d; and other footnotes that specifically relate
to assets or liabilities measured at fair value.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001200">&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zf26Z2XGEyGj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zD5CdCIX2YK3"&gt;Income
Tax&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company uses the asset and liability method to account for income taxes.
Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying
amounts of existing assets and liabilities for accounting purposes, and their respective tax bases.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Deferred income tax assets and liabilities are measured using tax rates
that have been enacted or substantively enacted and applied to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized
in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and
are reviewed at the end of each reporting period.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ptgef:DescriptionOfAccountingPolicyFoStablecoinExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001202">&lt;p id="xdx_848_ecustom--DescriptionOfAccountingPolicyFoStablecoinExplanatory_zi9uQyzIlenl" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zOUWdk3B0UF9"&gt;Stablecoin&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company accounts for its stablecoins, which are comprised of USDC and
USDT, as in accordance with IAS 9 &#x201c;Financial Instruments&#x201d;. The Company&#x2019;s stablecoins are initially recorded at cost,
and are contractually redeemable for fiat currency on demand or pegged 1:1 to the value of one U.S. dollar. The Company determines the
fair value of its stablecoins, which is at par with the U.S. dollar, in accordance with IFRS 13 &#x201c;Fair Value Measurement&#x201d; based
on the quoted (unadjusted) prices on the active exchange that the Company has determined is its principal market for the stablecoins (Level
1 inputs). Our primary custodian of stablecoins is BitGo, and the associated costs are expensed as incurred. Stablecoins are held for
use in business operations and not for the purpose of potential asset appreciation and is therefore classified as a current asset within
the consolidated statements of financial position. When the Company does not have possession, control, or the right to derive substantially
all of the economic benefits of ownership of stablecoin the Company has title to, the stablecoin is classified as a stablecoin receivable
within the consolidated statements of financial position. Stablecoin and stablecoin receivables qualify as financial instruments due to
their high level of liquidity, rights to redeem directly with the issuer, and their backing by high quality reserve assets not subject
to significant price fluctuations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;























</ptgef:DescriptionOfAccountingPolicyFoStablecoinExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForDigitalAssetsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001208">&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDigitalAssetsExplanatory_zlzyHdBCCbP" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z2wZN8uiLec4"&gt;Digital
Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company accounts for its digital assets, which are comprised of TON,
as indefinite-lived intangible assets in accordance with IAS 38 &#x201c;Intangible Assets&#x201d;. The Company&#x2019;s digital assets are
initially recorded at cost. Subsequently, digital assets are remeasured at fair value as of each reporting period, adjusted by discounts
for lack of marketability for tokens restricted for use. The Company determines the fair value of its liquid digital assets in accordance
with IFRS 13 &#x201c;Fair Value Measurement&#x201d;, based on quoted (unadjusted) prices on the active exchange that the Company has determined
is its principal market for the digital assets (Level 1 inputs). For locked digital assets which are not immediately tradable, the Company
applies a lack of marketability discount to quoted prices to calculate fair value (Level 3 input). Our primary custodian of digital assets
is BitGo, and the associated costs are expensed as incurred. When the Company does not have possession, control, or the right to derive
substantially all of the economic benefits of ownership of digital assets the Company has title to, the digital assets are classified
as digital assets receivable within the consolidated statements of financial position.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Increases in fair value, to the extent they do not constitute reversals
of previous decreases in fair value, are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss),
within &#x201c;Unrealized gain on digital assets&#x201d; within Other comprehensive income, with accumulated unrealized gains recognized
on the Consolidated Statements of Financial Position within Accumulated other comprehensive income. Decreases in fair value, to the extent
they do not constitute reversals of previous increases in fair value, are recognized as incurred in the Company's Consolidated Statements
of Operations and Comprehensive Income (Loss), within &#x201c;Loss on revaluation of digital assets&#x201d; within Other expenses. Any losses
on revaluation not in excess of previously recognized gains are recognized as decreases to Accumulated other comprehensive income until
cost basis exceeds fair value, at which point additional losses are recognized as Other expense. Any gains on revaluation not in excess
of previously recognized losses are recognized as Other income until fair value exceeds cost basis, at which point additional gains are
recognized as Other comprehensive income. Revaluation gains and losses are recorded by token.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Realized gains, to the extent recognized within Accumulated other comprehensive
income, and losses are recognized in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss) within other
income (expense).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Digital assets are classified as current or noncurrent assets based on the
Company&#x2019;s intended holding period of the token. If the Company has the intent and ability to hold the token for a period of one
year beyond the balance sheet date or if the token is not expected to become liquid within one year of the balance sheet date, the holding
is classified as noncurrent. Otherwise, the holding is classified as a current asset.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForDigitalAssetsExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001210">&lt;p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_zZ4fAEFPxvHg" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z7TbxQoibEG8"&gt;Revenue
from Contracts with Customers&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company recognizes revenue in accordance with IFRS 15, &#x201c;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;,&#x201d; which establishes a comprehensive framework for determining whether, how much, and when revenue
is recognized. Revenue is recognized to depict the transfer of promised services to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those services.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s primary source of revenue is derived from compute offtake
agreements, under which customers obtain access to dedicated or shared compute capacity (including processing power, memory, and related
infrastructure) for a specified contractual term.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;i)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Identification of performance obligations&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Compute offtake agreements typically provide customers with a stand-ready obligation
to make compute capacity continuously available throughout the contract term. The Company has determined that such arrangements generally
contain a single performance obligation, being the provision of continuous access to compute services over time.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;To the extent that a contract includes multiple services (for example, initial configuration,
integration, or distinct ancillary services), the Company assesses whether such services are distinct and should be accounted for as separate
performance obligations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;ii)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Determination of the transaction price&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;The transaction price reflects the amount of consideration the Company expects to receive
in exchange for transferring promised services to the customer. Consideration under compute offtake agreements is typically fixed based
on contracted capacity and term, and is frequently settled in digital assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;In arrangements where consideration is received in digital assets, such consideration
represents non-cash consideration and is measured at fair value at contract inception.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Any variability in consideration (such as pricing adjustments, service level credits,
or penalties) is estimated using either the expected value or most likely amount method, and included in the transaction price only to
the extent that it is highly probable that a significant reversal of revenue will not occur.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;iii)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Allocation of the transaction price&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;If a contract contains more than one performance obligation, the transaction price is
allocated to each performance obligation based on the relative standalone selling prices of the distinct services at contract inception.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;b&gt;&lt;i&gt;iv)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&lt;i&gt;Timing of revenue recognition&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Revenue from compute offtake agreements is recognized over time, as the customer simultaneously
receives and consumes the benefits of the compute services as they are provided. Progress toward complete satisfaction of the performance
obligation is measured on a time-elapsed basis, or another systematic measure that faithfully depicts the pattern of transfer of services
to the customer.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;Revenue is recognized only when:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 1in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;
    &lt;td&gt;A valid contract exists;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;
    &lt;td&gt;The Company has transferred control of compute services to the customer; and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;3.&lt;/td&gt;
    &lt;td&gt;Collection of consideration is considered probable.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Digital assets received from customers is non-cash consideration and is
initially measured at fair value at contract inception. Any subsequent changes in the fair value of digital assets held by the Company
are accounted for in accordance with the Company&#x2019;s accounting policy for digital assets, and do not affect the amount of revenue
recognized.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForAccountsReceivableExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001216">&lt;p id="xdx_846_ecustom--DescriptionOfAccountingPolicyForAccountsReceivableExplanatory_zu3ay1vP4sj2" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zLn2ovINO1J3"&gt;Accounts
Receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Trade receivables are recognized when the Company has an unconditional right
to consideration, which generally arises upon the invoicing of compute services or when contractual billing milestones are met. Trade
receivables are initially measured at fair value, which is typically equal to the invoiced amount or the fair value of digital assets
consideration to be received.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Trade receivables are subsequently measured at amortized cost, as they are
held solely for the collection of contractual cash flows (or cash-equivalent consideration). Trade receivables are presented net of any
allowance for expected credit losses. To the extent that invoices are settled directly in digital assets prior to the end of the reporting
period, no trade receivable is recognized, and the digital asset is recognized in accordance with the applicable accounting policy.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForAccountsReceivableExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001218">&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory_zepWZP7ECA94" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zjiJsipzIskk"&gt;Expected
Credit Losses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company applies the simplified expected credit loss (ECL) model under
IFRS 9, &#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;.&#x201d; Under this approach, lifetime expected credit losses are recognized at initial recognition
and updated at each reporting date. Expected credit losses are estimated based on:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Historical credit loss experience;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Current customer payment behavior, including digital asset settlement history; and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Forward-looking information that is relevant to customer credit risk.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Trade receivables are written off when there is no reasonable expectation
of recovery.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory>
    <ptgef:DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001220">&lt;p id="xdx_842_ecustom--DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory_z4OVvBWBvuW3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zV9xTkm552P5"&gt;Property,
Plant, and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company accounts for property, plant and equipment in accordance with
IAS 16, &#x201c;&lt;i&gt;Property, Plant and Equipment&lt;/i&gt;.&#x201d; The Company&#x2019;s property, plant and equipment consist solely of GPUs used
in the provision of compute services under compute offtake agreements. GPUs are recognized as property, plant and equipment when:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;It is probable that future economic benefits associated with the asset will flow to the Company; and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;The cost of the asset can be measured reliably.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;GPUs are initially measured at cost, which includes:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;The purchase price, net of discounts or rebates;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Non-refundable taxes and duties;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Directly attributable costs necessary to bring the GPUs to the location and condition necessary for them to be capable of operating as
        intended by management (including transportation, installation, testing, and configuration costs); and&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;Any other expenditures directly attributable to preparing the GPUs for their intended use.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;Costs incurred after GPUs are capable of operating as intended are expensed as incurred,
unless they meet the criteria for capitalization under IAS 16.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Following initial recognition, GPUs are carried at cost less accumulated
depreciation and accumulated impairment losses. The Company applies the cost model to all classes of property, plant and equipment. GPUs
are depreciated on a straight-line basis over their estimated useful lives, beginning when the assets are available for use, which is
when they are installed and ready for their intended operating condition. Management estimates the useful lives and residual values of
GPUs based on expected technological obsolescence, performance degradation, and expected usage patterns. Useful lives and residual values
are reviewed at least annually and adjusted prospectively when warranted.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;GPUs are derecognized upon disposal or when no future economic benefits
are expected from their use or disposal. Any gain or loss arising on derecognition is recognized in profit or loss and represents the
difference between the proceeds received and the carrying amount of the asset.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Deposits paid to suppliers for the future purchase of GPUs are recognized
as prepayments or other non-current assets, depending on the expected delivery date, and are not depreciated. Such deposits are initially
measured at the amount paid and reassessed at each reporting date to determine whether there is objective evidence that the deposit may
be impaired, including supplier non-performance or changes in expected delivery terms. Upon delivery and acceptance of the GPUs, deposits
are reclassified to property, plant and equipment as part of the cost of the related GPUs. If a purchase contract is terminated or delivery
becomes improbable, the deposit is written down to its recoverable amount, with any impairment recognized in profit or loss.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfPolicyForPropertyPlantAndEquipmentExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001226">&lt;p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zzoCCzFQ5kDc" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zK6NvyGkmJvk"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements Issued&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Impact of Adoption of Significant New IFRS Standards in Fiscal 2026&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;&lt;b&gt;(a)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21: The Effects of
Changes in Foreign Exchange Rates&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;In August 2023, the IASB amended IAS 21, &#x201c;The
Effects of Changes in Foreign Exchange Rates&#x201d; (&#x201c;IAS 21&#x201d;) to clarify when a currency is exchangeable into another currency
and how a company estimates a spot rate when a currency lacks exchangeability, requiring consistent assessment and disclosure practices
for companies. The amendments are effective for annual reporting periods beginning on or after January 1, 2025, with early adoption permitted.
However, an entity cannot restate comparative information. The adoption of these amendments did not have a material effect on the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;&lt;b&gt;(b)&#160;&#160;&#160;&#160;&#160; Amendments to IAS 21 &#x2013; Lack of
Exchangeability&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;An entity is impacted by the amendments to IAS 21, &#x201c;&lt;i&gt;The Effects
of Changes in Foreign Exchange Rates&lt;/i&gt;,&#x201d; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The adoption of these amendments did not have a material effect on the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;New IFRS Accounting Standards not yet effective&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Standards issued but not yet effective up to the date
of issuance of the Company&#x2019;s consolidated financial statements are listed below. This is of standards and interpretations issued,
which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes effective.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0in"&gt;&lt;b&gt;(a)&#160;&#160;&#160;&#160;&#160; IAS 18: Presentation and Disclosure in
Financial Statements&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;In April 2024, IFRS 18, &#x201c;&lt;i&gt;Presentation and
Disclosure in Financial Statements&lt;/i&gt;&#x201d; (&#x201c;IFRS 18&#x201d;) was issued. IFRS 18 replaces IAS 1 and introduces significant changes
to the presentation of financial statements to enhance comparability across entities. The key requirements of the standard include:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Separate reporting of operating, investing, and financing activities in the statement of earnings, with prescribed
        subtotals for each category.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Disclosure of management-defined performance measures in a dedicated note within the financial statements.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The standard is effective for annual reporting periods
beginning on or after January 1, 2027, with retrospective application required. The Company intends to assess the impact of IFRS 18 on
its consolidated financial statements closer to the effective date. The effect of the new standard, however it may be, will only affect
matters of presentation and disclosure.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;(b) Amendments to IFRS 9 and IFRS 7&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On May 30, 2024, the International Accounting Standards
Board (the IASB or the Board) issued Amendments to IFRS 9 and IFRS 7, &lt;i&gt;Amendments to the Classification and Measurement of Financial
Instruments&lt;/i&gt;. The amendments:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Clarify that a financial liability is derecognized on the &#x201c;settlement date&#x201d;, i.e., when the related
        obligation is discharged or cancelled or expires or the liability otherwise qualifies for derecognition. They also introduce an accounting
        policy option to derecognize financial liabilities that are settled through an electronic payment system before settlement date if certain
        conditions are met.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental,
        social and governance (ESG)-linked features and other similar contingent features.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Clarify the treatment of non-recourse assets and contractually linked instruments (CLI).&#x2019;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that
        reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive
        income (FVTOCI).&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The standard is effective for annual reporting periods
beginning on or after January 1, 2026, with retrospective application required. The Company intends to assess the impact of the Amendments
to IFRS 9 and IFRS 7 on its consolidated financial statements closer to the effective date.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001231">&lt;p id="xdx_802_eifrs-full--DisclosureOfOtherAssetsExplanatory_z8cxegF9nPB3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 5. &lt;span id="xdx_82C_zUyHCb0h4r91"&gt;PREPAID
EXPENSES, OTHER RECEIVABLES, AND OTHER ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;At March 31, 2026 and 2025, prepaid expenses and other receivables
were comprised of the following (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z7PSXYzVUWh4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B3_zBTiNLsL1tF3" style="display: none"&gt;Schedule
        of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20260331_z9Ua6NdEC7Q3" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20250331_zQAmhQj4bWBb" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_zIRNVvM77ce7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid clinical research costs&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;192&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentAdvancesToSuppliers_iI_zQv0n1zLtdE5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid insurance&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;595&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;241&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--CurrentPrepaidExpenses_iI_zjZfbtSMhbb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other prepaid expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;567&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;42&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PrepaidInvestorRelations_iI_zRbsssHADf6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid investor relations&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;534&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TaxDeposits_iI_zjx42jxiEREi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;68&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;68&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PrepaidGpuInfrastructureCosts_iI_zUSNVdDOcRWb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid GPU infrastructure costs&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PrepaidGpuLeasesShortterm_iI_zg8pSOSwroF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid GPU leases, short-term&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--OtherCurrentReceivables_iI_zmSrzmJLGY4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;220&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;12&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalPrepaidExpensesAndOtherReceivables_iI_zW8WIRSq50ma" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&#160;Total prepaid expenses and other receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,984&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;555&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As of March 31, 2026, other assets consists of the long-term portion of
the prepaid investor relations contract in the amount of $&lt;span id="xdx_90F_ecustom--OtherAssetsLongTermPortion_iI_pn3n3_dm_c20260331_zURFV8E1uB5f" title="Other assets long term portion"&gt;0.7&lt;/span&gt;
million and security deposits of $&lt;span id="xdx_90D_ecustom--SecurityDeposits_iI_pn3n3_dm_c20260331_zZ5uTCLcU4xg" title="Security deposits"&gt;2.6&lt;/span&gt;
million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;















</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001233">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z7PSXYzVUWh4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B3_zBTiNLsL1tF3" style="display: none"&gt;Schedule
        of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20260331_z9Ua6NdEC7Q3" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20250331_zQAmhQj4bWBb" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_zIRNVvM77ce7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid clinical research costs&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;192&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentAdvancesToSuppliers_iI_zQv0n1zLtdE5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid insurance&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;595&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;241&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--CurrentPrepaidExpenses_iI_zjZfbtSMhbb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other prepaid expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;567&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;42&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PrepaidInvestorRelations_iI_zRbsssHADf6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid investor relations&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;534&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TaxDeposits_iI_zjx42jxiEREi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;68&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;68&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PrepaidGpuInfrastructureCosts_iI_zUSNVdDOcRWb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid GPU infrastructure costs&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PrepaidGpuLeasesShortterm_iI_zg8pSOSwroF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid GPU leases, short-term&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--OtherCurrentReceivables_iI_zmSrzmJLGY4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;220&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;12&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalPrepaidExpensesAndOtherReceivables_iI_zW8WIRSq50ma" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&#160;Total prepaid expenses and other receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: blue; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,984&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;555&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock>
    <ifrs-full:CurrentReceivablesFromSaleOfProperties
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001236"
      unitRef="USD">192000</ifrs-full:CurrentReceivablesFromSaleOfProperties>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001238"
      unitRef="USD">595000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001239"
      unitRef="USD">241000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001241"
      unitRef="USD">567000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001242"
      unitRef="USD">42000</ifrs-full:CurrentPrepaidExpenses>
    <ptgef:PrepaidInvestorRelations
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001244"
      unitRef="USD">534000</ptgef:PrepaidInvestorRelations>
    <ptgef:TaxDeposits
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001247"
      unitRef="USD">68000</ptgef:TaxDeposits>
    <ptgef:TaxDeposits
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001248"
      unitRef="USD">68000</ptgef:TaxDeposits>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001256"
      unitRef="USD">220000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001257"
      unitRef="USD">12000</ifrs-full:OtherCurrentReceivables>
    <ptgef:TotalPrepaidExpensesAndOtherReceivables
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001259"
      unitRef="USD">1984000</ptgef:TotalPrepaidExpensesAndOtherReceivables>
    <ptgef:TotalPrepaidExpensesAndOtherReceivables
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001260"
      unitRef="USD">555000</ptgef:TotalPrepaidExpensesAndOtherReceivables>
    <ptgef:OtherAssetsLongTermPortion
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001262"
      unitRef="USD">700000</ptgef:OtherAssetsLongTermPortion>
    <ptgef:SecurityDeposits
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001264"
      unitRef="USD">2600000</ptgef:SecurityDeposits>
    <ptgef:DisclosureOfStablecoinExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001268">&lt;p id="xdx_80B_ecustom--DisclosureOfStablecoinExplanatory_zwM9XzBhgUe2" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 6. &lt;span id="xdx_823_zVN9tj7Zfm8l"&gt;STABLECOIN
&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;At March 31, 2026 and 2025, the Company&#x2019;s stablecoin holdings were
comprised of the following (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--DisclosureOfStablecoinTableTextBlock_pn3n3_zDroblQh1KVb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BF_z0l09Yg7OyE8" style="display: none"&gt;Schedule of stablecoin&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20260331_zIL509oZDWob" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20250331_zxkMAHWSWtca" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;USDC&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zMbx5Il6jge3" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1272"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zPwhDNdhBP7l" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;USDT&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zOhsY8Mw4WGc" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zql3bii6Mp6" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Stablecoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--Stablecoins_iI_c20250331_z4TOuebvc49" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--Stablecoins_iI_c20260331_zDVgP5X5jJU5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1282"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AE_zCITyjbP5dRj" style="margin: 0pt 0; font-size: 10pt; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The following table summarizes the Company&#x2019;s stablecoin purchases,
contributions, uses in the course of business, and sales for the fiscal year ended March 31, 2026 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfStablecoinPurchasesTableTextBlock_pn3n3_zCPT68n3dJUe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BC_z01UQdLF6AW3" style="display: none"&gt;Schedule of stablecoin purchases&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdcMember_zszXBmIapAeh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdtMember_zTifHJG5VV15" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zkhECywZeAF2" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;For the fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;USDC&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;USDT&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DigitalAssetValueAsOfApril1_zdaHJ180F3W7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Digital asset value as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1286"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ContributionOfStablecoin_zQ1NKlxvcxtj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Contribution of Stablecoin&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,411&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;10&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,421&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ProceedsFromSaleOfDigitalAssets_zWpUAQ0gLn3d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Proceeds from sale of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StablecoinUsedToSettleOperatingCosts_zMMPbm9i27Pg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Stablecoin used to settle operating costs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,413&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(311&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,724&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--StablecoinSold_zYbNqw9JvaN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Stablecoin sold&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProceedsFromExternalDebtDrawdown_zkNJPjYqrzgf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Proceeds from external debt drawdown&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PurchasesOfStablecoin_zzRBfZerqzD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Purchases of stablecoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;311&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;311&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--StablecoinUsedToPurchaseDigitalAssets_zR02CfRYYGVk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Stablecoin used to purchase digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,998&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(10&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(3,008&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--StablecoinValueAsOfMarch31_zeHxYBKMY9vi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Stablecoin value as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1318"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AA_zsS0c3ZQVmC3" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company did not hold or transact stablecoins during
the fiscal year ended March 31, 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s stablecoins are a digital asset intended to maintain
a stable value by tracking the U.S. dollar on a 1:1 basis. Stablecoins are held for use in business operations and not for the purpose
of potential asset appreciation and is therefore classified as a current asset within the consolidated statements of financial position.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ptgef:DisclosureOfStablecoinExplanatory>
    <ptgef:DisclosureOfStablecoinTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001270">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--DisclosureOfStablecoinTableTextBlock_pn3n3_zDroblQh1KVb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BF_z0l09Yg7OyE8" style="display: none"&gt;Schedule of stablecoin&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20260331_zIL509oZDWob" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20250331_zxkMAHWSWtca" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;USDC&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zMbx5Il6jge3" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1272"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDCMember_zPwhDNdhBP7l" style="font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;USDT&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--Stablecoins_iI_c20250331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zOhsY8Mw4WGc" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--Stablecoins_iI_c20260331__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--USDTMember_zql3bii6Mp6" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Stablecoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--Stablecoins_iI_c20250331_z4TOuebvc49" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--Stablecoins_iI_c20260331_zDVgP5X5jJU5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title=" stablecoins"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1282"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:DisclosureOfStablecoinTableTextBlock>
    <ptgef:Stablecoins
      contextRef="AsOf2025-03-31_custom_UsdtMember"
      decimals="-3"
      id="Fact001276"
      unitRef="USD">21000</ptgef:Stablecoins>
    <ptgef:Stablecoins
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001280"
      unitRef="USD">21000</ptgef:Stablecoins>
    <ptgef:DisclosureOfStablecoinPurchasesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001284">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfStablecoinPurchasesTableTextBlock_pn3n3_zCPT68n3dJUe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STABLECOIN (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BC_z01UQdLF6AW3" style="display: none"&gt;Schedule of stablecoin purchases&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdcMember_zszXBmIapAeh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--UsdtMember_zTifHJG5VV15" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zkhECywZeAF2" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;For the fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;USDC&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;USDT&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DigitalAssetValueAsOfApril1_zdaHJ180F3W7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Digital asset value as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1286"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ContributionOfStablecoin_zQ1NKlxvcxtj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Contribution of Stablecoin&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,411&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;10&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,421&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ProceedsFromSaleOfDigitalAssets_zWpUAQ0gLn3d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Proceeds from sale of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StablecoinUsedToSettleOperatingCosts_zMMPbm9i27Pg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Stablecoin used to settle operating costs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,413&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(311&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,724&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--StablecoinSold_zYbNqw9JvaN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Stablecoin sold&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProceedsFromExternalDebtDrawdown_zkNJPjYqrzgf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Proceeds from external debt drawdown&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,100&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PurchasesOfStablecoin_zzRBfZerqzD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Purchases of stablecoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;311&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;311&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--StablecoinUsedToPurchaseDigitalAssets_zR02CfRYYGVk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Stablecoin used to purchase digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,998&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(10&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(3,008&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--StablecoinValueAsOfMarch31_zeHxYBKMY9vi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Stablecoin value as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1318"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:DisclosureOfStablecoinPurchasesTableTextBlock>
    <ptgef:ContributionOfStablecoin
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      decimals="-3"
      id="Fact001290"
      unitRef="USD">5411000</ptgef:ContributionOfStablecoin>
    <ptgef:ContributionOfStablecoin
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      decimals="-3"
      id="Fact001291"
      unitRef="USD">10000</ptgef:ContributionOfStablecoin>
    <ptgef:ContributionOfStablecoin
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001292"
      unitRef="USD">5421000</ptgef:ContributionOfStablecoin>
    <ptgef:ProceedsFromSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      decimals="-3"
      id="Fact001295"
      unitRef="USD">21000</ptgef:ProceedsFromSaleOfDigitalAssets>
    <ptgef:ProceedsFromSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001296"
      unitRef="USD">21000</ptgef:ProceedsFromSaleOfDigitalAssets>
    <ptgef:StablecoinUsedToSettleOperatingCosts
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      decimals="-3"
      id="Fact001298"
      unitRef="USD">-2413000</ptgef:StablecoinUsedToSettleOperatingCosts>
    <ptgef:StablecoinUsedToSettleOperatingCosts
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      decimals="-3"
      id="Fact001299"
      unitRef="USD">-311000</ptgef:StablecoinUsedToSettleOperatingCosts>
    <ptgef:StablecoinUsedToSettleOperatingCosts
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001300"
      unitRef="USD">-2724000</ptgef:StablecoinUsedToSettleOperatingCosts>
    <ptgef:StablecoinSold
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      decimals="-3"
      id="Fact001302"
      unitRef="USD">-2100000</ptgef:StablecoinSold>
    <ptgef:StablecoinSold
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001304"
      unitRef="USD">-2100000</ptgef:StablecoinSold>
    <ptgef:ProceedsFromExternalDebtDrawdown
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      decimals="-3"
      id="Fact001306"
      unitRef="USD">2100000</ptgef:ProceedsFromExternalDebtDrawdown>
    <ptgef:ProceedsFromExternalDebtDrawdown
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001308"
      unitRef="USD">2100000</ptgef:ProceedsFromExternalDebtDrawdown>
    <ptgef:PurchasesOfStablecoin
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      decimals="-3"
      id="Fact001311"
      unitRef="USD">311000</ptgef:PurchasesOfStablecoin>
    <ptgef:PurchasesOfStablecoin
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001312"
      unitRef="USD">311000</ptgef:PurchasesOfStablecoin>
    <ptgef:StablecoinUsedToPurchaseDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_USDCMember"
      decimals="-3"
      id="Fact001314"
      unitRef="USD">-2998000</ptgef:StablecoinUsedToPurchaseDigitalAssets>
    <ptgef:StablecoinUsedToPurchaseDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      decimals="-3"
      id="Fact001315"
      unitRef="USD">-10000</ptgef:StablecoinUsedToPurchaseDigitalAssets>
    <ptgef:StablecoinUsedToPurchaseDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001316"
      unitRef="USD">-3008000</ptgef:StablecoinUsedToPurchaseDigitalAssets>
    <ptgef:StablecoinValueAsOfMarch31
      contextRef="From2025-04-012026-03-31_custom_UsdtMember"
      decimals="-3"
      id="Fact001319"
      unitRef="USD">21000</ptgef:StablecoinValueAsOfMarch31>
    <ptgef:StablecoinValueAsOfMarch31
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001320"
      unitRef="USD">21000</ptgef:StablecoinValueAsOfMarch31>
    <ptgef:DisclosureOfDigitalAssetsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001322">&lt;p id="xdx_801_ecustom--DisclosureOfDigitalAssetsExplanatory_zrqYrphGTdd9" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 7. &lt;span id="xdx_825_zkbTVcyO6Jf"&gt;DIGITAL
ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;At March 31, 2026 and 2025, digital assets were comprised of the
following (in thousands, except for number of tokens held):&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfDigitalAssetsTableTextBlock_pn3n3_z3pEYyiac4Jh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BC_zuVJO3TDndrg" style="display: none"&gt;Schedule of Digital
        assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49B_20260331_zAXsHqW0ntgh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20250331_zxA7HCg3cAi" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ApproximateNumberOfTonTokensHeld_iI_zzFNPsubLrA7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Approximate number of TON Tokens held&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,379,165&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--TonTokensFairValueInThousands_iI_zvYPqCKZZ2f8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;TON Tokens, fair value (in thousands)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1330"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DigitalAssetsFairValueInThousands_iI_zuaZyf59SBQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Digital assets, fair value (in thousands)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AB_z1q1HbI3nHh6" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;At March 31, 2026, digital assets totaling $&lt;span id="xdx_906_ecustom--DigitalAssets_iI_pn3n3_dm_c20260331_zpdsVS7oEZQg" title="Digital assets"&gt;2.5&lt;/span&gt;
million were managed under the Alpha Sigma Capital asset management agreement.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The following table summarizes the Company&#x2019;s digital asset purchases,
contributions, unrealized gains (losses) on digital assets, sales of digital assets, and other movements for the fiscal year ended March
31, 2026:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfDigitalAssetsPurchasesTableTextBlock_pn3n3_zKfnHMmBCzlf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zkP3GrCNTvCi" style="display: none"&gt;Schedule of digital
        assets purchases&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TONMember_zd8TfTnhN7ji" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--BITCOINMember_zM2OwWS2qjU6" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TotalMember_zQOXlnavBZh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;For the fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;TON&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Bitcoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DigitalAssetValueAsOfApril1_zUMU1tikAXeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Digital asset value as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1344"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ContributionOfDigitalAssets_zgXE3BDzJB12" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Contribution of digital assets&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,382&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;420&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,802&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_zTL2wJuiwzLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Unrealized losses on digital assets recognized in Statement of Operations&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,411&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,411&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DigitalAssetsSold_zcpSrncvI5Ki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets sold&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,921&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,921&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PaymentsOnExternalDebtUsingDigitalAssets_zC2H8lfm4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Payments on external debt using digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,825&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,825&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DigitalAssetPurchases_zpNiTxlPdBb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital asset purchases&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,617&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,617&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ReceiptOfDigitalAssetsReceivable_z7DwOCQZ5Xw" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Receipt of digital assets receivable&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;6,667&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;6,667&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--RealizedLossGainOnSaleOfDigitalAssets_zK1izA3o06m3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Realized (loss) gain on sale of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,705&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,700&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--RealizedLossOnNovationOfDigitalAssetsToInvestor_zxXJjlqha4Dj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Realized loss on novation of digital assets to investor&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(676&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(676&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--RevenueReceivedInDigitalAssets_zknQslf53Sja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Revenue received in digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;69&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1380"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;69&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--TokensUsedToSettlePutRights_zgQX1EHZysVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tokens used to settle put rights&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,130&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,130&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DigitalAssetsExchanged_z4PcFalkmFIb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets exchanged&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;425&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(425&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DigitalAssetsTransacted_zqOOtx4zbm52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Digital assets transacted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DigitalAssetValueAsOfMarch31_ztI6Q7YPWhS5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Digital asset value as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1396"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AA_z60UO6ChWQjb" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company did not hold or transact Digital assets during the fiscal year
ended March 31, 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company valued the TON treasury at $&lt;span id="xdx_904_ecustom--TonTokensReceivable_iI_pn3n3_dm_c20260331_zAJSUyfVuhei" title="TON tokens receivable"&gt;1.22&lt;/span&gt;
per liquid token as of March 31, 2026. The Company did not hold digital assets as of March 31, 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company has 2,277,108 TON tokens that are locked under vesting contracts
at March 31, 2026. The following table summarizes the unlocking schedule of TON tokens currently locked as of March 31, 2026:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--SeheduleOfTonTokensTableTextBlock_pn3n3_zaUme3yub7E5" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - DIGITAL ASSETS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20260331_zA4T0ZBkQ7Z8" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CapitalFutureMinimumPaymentsRemainderOfFiscalYear_iI_zcdYkOvwbux" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Fiscal 2027&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,121,493&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CapitalFutureMinimumPaymentsRemainderOfSecondYear_iI_zysjIrexSmR5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Fiscal 2028&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;986,077&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CapitalFutureMinimumPaymentsRemainderOfThirdYear_iI_zwr72ctBdXM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Fiscal 2029&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;169,538&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--CapitalFutureMinimumPaymentsRemainderOfTotalYear_iI_z30jfsuDEpy9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;total&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,277,108&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A4_zz0zQdlPZnEf" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Of the &lt;span id="xdx_90E_ecustom--TonTokensReceivableShares_iI_c20260331_znhLoPheLGtk" title="TON tokens receivable shares"&gt;2,277,108&lt;/span&gt;
locked TON tokens as of March 31, 2026, &lt;span id="xdx_90C_ecustom--TokensArePayable_iI_c20260331_zRNPwJbK48Se" title="Tokens are payable"&gt;336,665&lt;/span&gt;
tokens are payable to investors following the exercise the investors&#x2019; respective put rights.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company valued the TON tokens at $1.04 on average per locked token as
of March 31, 2026. The Company did not hold digital assets as of March 31, 2025. The aggregate fair value of locked tokens is computed
by taking the number of locked tokens and discounting the month-end spot price by an average of 14.8%. The discount used by management
is based on the historical purchases of locked TON management has made on behalf of the Company and Monte Carlo simulation based on estimated
volatility during the lockup period (Level 3 inputs). Management monitors this discount percentage and adjusts when appropriate.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s liquid digital assets are routinely transacted with
in the ordinary course of business and are therefore classified as current assets within the consolidated statements of financial position.
Locked tokens are classified as current or noncurrent assets within the consolidated statements of financial position based on when the
locked tokens vest and become available for use by the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DisclosureOfDigitalAssetsExplanatory>
    <ptgef:ScheduleOfDigitalAssetsTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001324">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfDigitalAssetsTableTextBlock_pn3n3_z3pEYyiac4Jh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BC_zuVJO3TDndrg" style="display: none"&gt;Schedule of Digital
        assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49B_20260331_zAXsHqW0ntgh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20250331_zxA7HCg3cAi" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ApproximateNumberOfTonTokensHeld_iI_zzFNPsubLrA7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Approximate number of TON Tokens held&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,379,165&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--TonTokensFairValueInThousands_iI_zvYPqCKZZ2f8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;TON Tokens, fair value (in thousands)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1330"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DigitalAssetsFairValueInThousands_iI_zuaZyf59SBQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Digital assets, fair value (in thousands)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfDigitalAssetsTableTextBlock>
    <ptgef:ApproximateNumberOfTonTokensHeld
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001326"
      unitRef="USD">2379165000</ptgef:ApproximateNumberOfTonTokensHeld>
    <ptgef:TonTokensFairValueInThousands
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001329"
      unitRef="USD">2492000</ptgef:TonTokensFairValueInThousands>
    <ptgef:DigitalAssetsFairValueInThousands
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001332"
      unitRef="USD">2492000</ptgef:DigitalAssetsFairValueInThousands>
    <ptgef:DigitalAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001335"
      unitRef="USD">2500000</ptgef:DigitalAssets>
    <ptgef:ScheduleOfDigitalAssetsPurchasesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001341">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfDigitalAssetsPurchasesTableTextBlock_pn3n3_zKfnHMmBCzlf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DIGITAL ASSETS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zkP3GrCNTvCi" style="display: none"&gt;Schedule of digital
        assets purchases&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TONMember_zd8TfTnhN7ji" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--BITCOINMember_zM2OwWS2qjU6" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20250401__20260331__ifrs-full--IntangibleAssetsMaterialToEntityAxis__custom--TotalMember_zQOXlnavBZh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;For the fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;TON&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Bitcoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DigitalAssetValueAsOfApril1_zUMU1tikAXeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Digital asset value as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1344"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ContributionOfDigitalAssets_zgXE3BDzJB12" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Contribution of digital assets&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,382&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;420&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,802&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations_zTL2wJuiwzLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Unrealized losses on digital assets recognized in Statement of Operations&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,411&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,411&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DigitalAssetsSold_zcpSrncvI5Ki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets sold&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,921&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,921&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PaymentsOnExternalDebtUsingDigitalAssets_zC2H8lfm4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Payments on external debt using digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,825&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,825&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DigitalAssetPurchases_zpNiTxlPdBb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital asset purchases&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,617&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,617&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ReceiptOfDigitalAssetsReceivable_z7DwOCQZ5Xw" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Receipt of digital assets receivable&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;6,667&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;6,667&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--RealizedLossGainOnSaleOfDigitalAssets_zK1izA3o06m3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Realized (loss) gain on sale of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,705&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,700&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--RealizedLossOnNovationOfDigitalAssetsToInvestor_zxXJjlqha4Dj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Realized loss on novation of digital assets to investor&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(676&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(676&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--RevenueReceivedInDigitalAssets_zknQslf53Sja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Revenue received in digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;69&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1380"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;69&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--TokensUsedToSettlePutRights_zgQX1EHZysVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tokens used to settle put rights&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,130&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,130&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DigitalAssetsExchanged_z4PcFalkmFIb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets exchanged&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;425&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(425&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DigitalAssetsTransacted_zqOOtx4zbm52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Digital assets transacted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DigitalAssetValueAsOfMarch31_ztI6Q7YPWhS5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Digital asset value as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1396"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,492&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfDigitalAssetsPurchasesTableTextBlock>
    <ptgef:ContributionOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001347"
      unitRef="USD">1382000</ptgef:ContributionOfDigitalAssets>
    <ptgef:ContributionOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      decimals="-3"
      id="Fact001348"
      unitRef="USD">420000</ptgef:ContributionOfDigitalAssets>
    <ptgef:ContributionOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001349"
      unitRef="USD">1802000</ptgef:ContributionOfDigitalAssets>
    <ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001351"
      unitRef="USD">-1411000</ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations>
    <ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001353"
      unitRef="USD">-1411000</ptgef:UnrealizedLossesOnDigitalAssetsRecognizedInStatementOfOperations>
    <ptgef:DigitalAssetsSold
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001355"
      unitRef="USD">-2921000</ptgef:DigitalAssetsSold>
    <ptgef:DigitalAssetsSold
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001357"
      unitRef="USD">-2921000</ptgef:DigitalAssetsSold>
    <ptgef:PaymentsOnExternalDebtUsingDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001359"
      unitRef="USD">-1825000</ptgef:PaymentsOnExternalDebtUsingDigitalAssets>
    <ptgef:PaymentsOnExternalDebtUsingDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001361"
      unitRef="USD">-1825000</ptgef:PaymentsOnExternalDebtUsingDigitalAssets>
    <ptgef:DigitalAssetPurchases
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001363"
      unitRef="USD">3617000</ptgef:DigitalAssetPurchases>
    <ptgef:DigitalAssetPurchases
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001365"
      unitRef="USD">3617000</ptgef:DigitalAssetPurchases>
    <ptgef:ReceiptOfDigitalAssetsReceivable
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001367"
      unitRef="USD">6667000</ptgef:ReceiptOfDigitalAssetsReceivable>
    <ptgef:ReceiptOfDigitalAssetsReceivable
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001369"
      unitRef="USD">6667000</ptgef:ReceiptOfDigitalAssetsReceivable>
    <ptgef:RealizedLossGainOnSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001371"
      unitRef="USD">-1705000</ptgef:RealizedLossGainOnSaleOfDigitalAssets>
    <ptgef:RealizedLossGainOnSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      decimals="-3"
      id="Fact001372"
      unitRef="USD">5000</ptgef:RealizedLossGainOnSaleOfDigitalAssets>
    <ptgef:RealizedLossGainOnSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001373"
      unitRef="USD">-1700000</ptgef:RealizedLossGainOnSaleOfDigitalAssets>
    <ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001375"
      unitRef="USD">-676000</ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor>
    <ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001377"
      unitRef="USD">-676000</ptgef:RealizedLossOnNovationOfDigitalAssetsToInvestor>
    <ptgef:RevenueReceivedInDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001379"
      unitRef="USD">69000</ptgef:RevenueReceivedInDigitalAssets>
    <ptgef:RevenueReceivedInDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001381"
      unitRef="USD">69000</ptgef:RevenueReceivedInDigitalAssets>
    <ptgef:TokensUsedToSettlePutRights
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001383"
      unitRef="USD">-1130000</ptgef:TokensUsedToSettlePutRights>
    <ptgef:TokensUsedToSettlePutRights
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001385"
      unitRef="USD">-1130000</ptgef:TokensUsedToSettlePutRights>
    <ptgef:DigitalAssetsExchanged
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001387"
      unitRef="USD">425000</ptgef:DigitalAssetsExchanged>
    <ptgef:DigitalAssetsExchanged
      contextRef="From2025-04-012026-03-31_custom_BITCOINMember"
      decimals="-3"
      id="Fact001388"
      unitRef="USD">-425000</ptgef:DigitalAssetsExchanged>
    <ptgef:DigitalAssetValueAsOfMarch31
      contextRef="From2025-04-012026-03-31_custom_TONMember"
      decimals="-3"
      id="Fact001395"
      unitRef="USD">2492000</ptgef:DigitalAssetValueAsOfMarch31>
    <ptgef:DigitalAssetValueAsOfMarch31
      contextRef="From2025-04-012026-03-31_custom_TotalMember371194906"
      decimals="-3"
      id="Fact001397"
      unitRef="USD">2492000</ptgef:DigitalAssetValueAsOfMarch31>
    <ptgef:TonTokensReceivable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001399"
      unitRef="USD">1220000</ptgef:TonTokensReceivable>
    <ptgef:SeheduleOfTonTokensTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001401">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--SeheduleOfTonTokensTableTextBlock_pn3n3_zaUme3yub7E5" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - DIGITAL ASSETS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20260331_zA4T0ZBkQ7Z8" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CapitalFutureMinimumPaymentsRemainderOfFiscalYear_iI_zcdYkOvwbux" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Fiscal 2027&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,121,493&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CapitalFutureMinimumPaymentsRemainderOfSecondYear_iI_zysjIrexSmR5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Fiscal 2028&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;986,077&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CapitalFutureMinimumPaymentsRemainderOfThirdYear_iI_zwr72ctBdXM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Fiscal 2029&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;169,538&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--CapitalFutureMinimumPaymentsRemainderOfTotalYear_iI_z30jfsuDEpy9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;total&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,277,108&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:SeheduleOfTonTokensTableTextBlock>
    <ptgef:CapitalFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001403"
      unitRef="USD">1121493000</ptgef:CapitalFutureMinimumPaymentsRemainderOfFiscalYear>
    <ptgef:CapitalFutureMinimumPaymentsRemainderOfSecondYear
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001405"
      unitRef="USD">986077000</ptgef:CapitalFutureMinimumPaymentsRemainderOfSecondYear>
    <ptgef:CapitalFutureMinimumPaymentsRemainderOfThirdYear
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001407"
      unitRef="USD">169538000</ptgef:CapitalFutureMinimumPaymentsRemainderOfThirdYear>
    <ptgef:CapitalFutureMinimumPaymentsRemainderOfTotalYear
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001409"
      unitRef="USD">2277108000</ptgef:CapitalFutureMinimumPaymentsRemainderOfTotalYear>
    <ptgef:TonTokensReceivableShares
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001411"
      unitRef="Shares">2277108</ptgef:TonTokensReceivableShares>
    <ptgef:TokensArePayable
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">336665</ptgef:TokensArePayable>
    <ptgef:ScheduleOfReceivablesDigitalAssetsTableXextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001420">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfReceivablesDigitalAssetsTableXextBlock_pn3n3_zcPbiJLjvDeg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RECEIVABLES DIGITAL ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zPxHMxuyE3B" style="display: none"&gt;Schedule of movements
        in Receivables &#x2013; digital assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--USD1Member_zvAQ4nDTUpIi" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LockedTonMember_z6DEuMEBjGO2" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--TotalMember_zdVGRpuUFLv9" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;For the year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;USD1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Locked TON&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DigitalAssetValueAsOfApril1_zyN7eYCb5KJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Digital asset value as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1422"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1423"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1424"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ContributionOfDigitalAssetAndStablecoinReceivables_zRL4hMRNAhBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Contribution of digital asset and stablecoin receivables&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;15,000&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;9,016&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;24,016&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ChangeInFairValueOfDigitalAssetsReceivable_zmi3jzm6lcL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of digital assets receivable&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1430"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,349&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,349&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ReceiptOfDigitalAssetReceivables_zK2cqYByvCn" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Receipt of digital asset receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(6,667&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(6,667&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--TokensUsedToSettlePutRights_zsrqvgIgtnP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Tokens used to settle put rights&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(15,000&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1439"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(15,000&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--StablecoinValueAsOfSeptember30_zMXCskuZKWL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold"&gt;Stablecoin value as of September 30&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1442"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1443"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfReceivablesDigitalAssetsTableXextBlock>
    <ptgef:ContributionOfDigitalAssetAndStablecoinReceivables
      contextRef="From2025-04-012026-03-31_custom_USD1Member"
      decimals="-3"
      id="Fact001426"
      unitRef="USD">15000000</ptgef:ContributionOfDigitalAssetAndStablecoinReceivables>
    <ptgef:ContributionOfDigitalAssetAndStablecoinReceivables
      contextRef="From2025-04-012026-03-31_custom_LockedTonMember"
      decimals="-3"
      id="Fact001427"
      unitRef="USD">9016000</ptgef:ContributionOfDigitalAssetAndStablecoinReceivables>
    <ptgef:ContributionOfDigitalAssetAndStablecoinReceivables
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001428"
      unitRef="USD">24016000</ptgef:ContributionOfDigitalAssetAndStablecoinReceivables>
    <ptgef:ChangeInFairValueOfDigitalAssetsReceivable
      contextRef="From2025-04-012026-03-31_custom_LockedTonMember"
      decimals="-3"
      id="Fact001431"
      unitRef="USD">-2349000</ptgef:ChangeInFairValueOfDigitalAssetsReceivable>
    <ptgef:ChangeInFairValueOfDigitalAssetsReceivable
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001432"
      unitRef="USD">-2349000</ptgef:ChangeInFairValueOfDigitalAssetsReceivable>
    <ptgef:ReceiptOfDigitalAssetReceivables
      contextRef="From2025-04-012026-03-31_custom_LockedTonMember"
      decimals="-3"
      id="Fact001435"
      unitRef="USD">-6667000</ptgef:ReceiptOfDigitalAssetReceivables>
    <ptgef:ReceiptOfDigitalAssetReceivables
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001436"
      unitRef="USD">-6667000</ptgef:ReceiptOfDigitalAssetReceivables>
    <ptgef:TokensUsedToSettlePutRights
      contextRef="From2025-04-012026-03-31_custom_USD1Member"
      decimals="-3"
      id="Fact001438"
      unitRef="USD">-15000000</ptgef:TokensUsedToSettlePutRights>
    <ptgef:TokensUsedToSettlePutRights
      contextRef="From2025-04-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001440"
      unitRef="USD">-15000000</ptgef:TokensUsedToSettlePutRights>
    <ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001446">&lt;p id="xdx_809_ecustom--PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock_z7O8ztP9O2v1" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_826_zBhRRpIPV172"&gt;PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The table below presents the carrying value of property, plant, and equipment,
equipment deposits, and right-of-use assets (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_pn3n3_ztWFvZBQHXNa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BE_zUEvq8NNxXGl" style="display: none"&gt;Schedule of property, plant, and equipment,
        equipment deposits, and right-of-use assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_zpW4srsOHWL1" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zOnbMazTo1Z6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zPP5zmGgsKJ7" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_z0jwmooRmGTl" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;COST&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPUs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPU Deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Right-of-Use Asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20240401__20250331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_zCTFEcOZ6IM" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt"&gt;As of March 31, 2024&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1451"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zg68a3YI6A85" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fixed asset additions&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1455"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1456"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1457"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_zWY57ySxhiGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1460"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_z8Lok5wLuKvi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;As of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1465"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1466"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zPXQ9xd60kh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Fixed asset additions&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,373&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;9,308&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;516&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;11,197&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_ziH7HqU6haxg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1476"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1478"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iE_zEwPtn0uZyJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;As of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,373&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;9,308&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;516&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;11,197&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z3vBMaS9FRxi" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zfy107r1kwd9" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zqFkM2sQsBIl" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_zkDXC4qinAA6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;ACCUMULATED DEPRECIATION&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPUs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPU Deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Right-of-Use Asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20240401__20250331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_z0e0RyH1FQq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt"&gt;As of March 31, 2024&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1485"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1486"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(40&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(40&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FixedAssetDepreciation_zIGD6dCaVfU3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fixed asset depreciation&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FixedAssetDisposals_z0MSpfjD5gR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1496"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_zEzZGIh1qSoe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;As of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1500"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1501"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1502"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1503"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FixedAssetDepreciation_zTXbCosnHwS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Fixed asset depreciation&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(90&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1506"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(103&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(193&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FixedAssetDisposals_zwFuT7n1Ixyg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1510"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1511"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1512"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1513"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43E_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_zGybfrJU1RL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;As of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(90&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1516"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(103&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(193&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z6WN0UwAJsDe" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_znNzd4DstTl9" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zbSlImS7E54" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_ztw4gyvKNWk2" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;CARRYING AMOUNT&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPUs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPU Deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Right-of-Use Asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;As of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_z7Cw7T0yUl3a" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1520"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zhkTwUokACy2" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1522"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zmwSDbI5sjb4" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1524"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zRVR3abWyjxb" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1526"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;As of March 31, 2026&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_zc5BNZvguBda" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;1,283&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zVOZIVXCuQZ6" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;9,308&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zxmNqs7SUpI7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;413&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zEHjO1yjB92k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;11,004&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A0_zfrjX2YHNj1j" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;* Refer to Note 13 for additional information on the Company&#x2019;s office
lease.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ptgef:PropertyPlantAndEquipmentAndRightOfUseAssetsTextBlock>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001448">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_pn3n3_ztWFvZBQHXNa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY, PLANT, AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BE_zUEvq8NNxXGl" style="display: none"&gt;Schedule of property, plant, and equipment,
        equipment deposits, and right-of-use assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_zpW4srsOHWL1" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zOnbMazTo1Z6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zPP5zmGgsKJ7" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_z0jwmooRmGTl" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;COST&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPUs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPU Deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Right-of-Use Asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20240401__20250331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_zCTFEcOZ6IM" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt"&gt;As of March 31, 2024&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1451"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zg68a3YI6A85" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fixed asset additions&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1455"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1456"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1457"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_zWY57ySxhiGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1460"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iS_z8Lok5wLuKvi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;As of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1465"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1466"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--AdditionsToRightofuseAssets_zPXQ9xd60kh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Fixed asset additions&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,373&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;9,308&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;516&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;11,197&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DisposalsPropertyPlantAndEquipment_ziH7HqU6haxg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1476"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1478"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20250401__20260331_eifrs-full--PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_iE_zEwPtn0uZyJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;As of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,373&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;9,308&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;516&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;11,197&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z3vBMaS9FRxi" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_zfy107r1kwd9" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zqFkM2sQsBIl" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_zkDXC4qinAA6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;ACCUMULATED DEPRECIATION&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPUs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPU Deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Right-of-Use Asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20240401__20250331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_z0e0RyH1FQq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt"&gt;As of March 31, 2024&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1485"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1486"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(40&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(40&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FixedAssetDepreciation_zIGD6dCaVfU3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fixed asset depreciation&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FixedAssetDisposals_z0MSpfjD5gR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1496"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_zEzZGIh1qSoe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;As of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1500"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1501"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1502"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1503"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FixedAssetDepreciation_zTXbCosnHwS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Fixed asset depreciation&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(90&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1506"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(103&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(193&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FixedAssetDisposals_zwFuT7n1Ixyg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Fixed asset disposals&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1510"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1511"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1512"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1513"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43E_c20250401__20260331_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_zGybfrJU1RL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;As of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(90&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1516"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(103&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(193&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUsMember_z6WN0UwAJsDe" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--GPUDepositsMember_znNzd4DstTl9" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B9_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RightOfUseAssetMember_zbSlImS7E54" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_4B8_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--TotalMember_ztw4gyvKNWk2" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;CARRYING AMOUNT&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPUs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;GPU Deposits&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Right-of-Use Asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;As of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_z7Cw7T0yUl3a" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1520"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zhkTwUokACy2" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1522"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zmwSDbI5sjb4" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1524"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iI_c20250331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zRVR3abWyjxb" style="font-size: 10pt; text-align: right" title="Property plant equipment carrying amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1526"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;As of March 31, 2026&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUsMember_zc5BNZvguBda" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;1,283&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--GPUDepositsMember_zVOZIVXCuQZ6" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;9,308&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RightOfUseAssetMember_zxmNqs7SUpI7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;413&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iI_c20260331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TotalMember_zEHjO1yjB92k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Property plant equipment carrying amount"&gt;11,004&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2024-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001452"
      unitRef="USD">84000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2024-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001453"
      unitRef="USD">84000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001462"
      unitRef="USD">-84000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001463"
      unitRef="USD">-84000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2025-04-012026-03-31_custom_GPUsMember"
      decimals="-3"
      id="Fact001470"
      unitRef="USD">1373000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2025-04-012026-03-31_custom_GPUDepositsMember"
      decimals="-3"
      id="Fact001471"
      unitRef="USD">9308000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001472"
      unitRef="USD">516000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2025-04-012026-03-31_custom_TotalMember371195968"
      decimals="-3"
      id="Fact001473"
      unitRef="USD">11197000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2026-03-31_custom_GPUsMember"
      decimals="-3"
      id="Fact001480"
      unitRef="USD">1373000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2026-03-31_custom_GPUDepositsMember"
      decimals="-3"
      id="Fact001481"
      unitRef="USD">9308000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2026-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001482"
      unitRef="USD">516000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001483"
      unitRef="USD">11197000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001487"
      unitRef="USD">-40000</ptgef:AccumulatedDepreciationPropertyPlantAndEquipment>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001488"
      unitRef="USD">-40000</ptgef:AccumulatedDepreciationPropertyPlantAndEquipment>
    <ptgef:FixedAssetDepreciation
      contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001492"
      unitRef="USD">-44000</ptgef:FixedAssetDepreciation>
    <ptgef:FixedAssetDepreciation
      contextRef="From2024-04-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001493"
      unitRef="USD">-44000</ptgef:FixedAssetDepreciation>
    <ptgef:FixedAssetDisposals
      contextRef="From2024-04-012025-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001497"
      unitRef="USD">84000</ptgef:FixedAssetDisposals>
    <ptgef:FixedAssetDisposals
      contextRef="From2024-04-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001498"
      unitRef="USD">84000</ptgef:FixedAssetDisposals>
    <ptgef:FixedAssetDepreciation
      contextRef="From2025-04-012026-03-31_custom_GPUsMember"
      decimals="-3"
      id="Fact001505"
      unitRef="USD">-90000</ptgef:FixedAssetDepreciation>
    <ptgef:FixedAssetDepreciation
      contextRef="From2025-04-012026-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001507"
      unitRef="USD">-103000</ptgef:FixedAssetDepreciation>
    <ptgef:FixedAssetDepreciation
      contextRef="From2025-04-012026-03-31_custom_TotalMember371195968"
      decimals="-3"
      id="Fact001508"
      unitRef="USD">-193000</ptgef:FixedAssetDepreciation>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_GPUsMember"
      decimals="-3"
      id="Fact001515"
      unitRef="USD">-90000</ptgef:AccumulatedDepreciationPropertyPlantAndEquipment>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001517"
      unitRef="USD">-103000</ptgef:AccumulatedDepreciationPropertyPlantAndEquipment>
    <ptgef:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001518"
      unitRef="USD">-193000</ptgef:AccumulatedDepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_GPUsMember"
      decimals="-3"
      id="Fact001528"
      unitRef="USD">1283000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_GPUDepositsMember"
      decimals="-3"
      id="Fact001530"
      unitRef="USD">9308000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_RightOfUseAssetMember"
      decimals="-3"
      id="Fact001532"
      unitRef="USD">413000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001534"
      unitRef="USD">11004000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfInvestmentPropertyExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001536">&lt;p id="xdx_80A_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_zZ04UqplP3V7" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 10.
&lt;span id="xdx_82A_zKzSf8mpwIzf"&gt;INVESTMENT IN COMPEDICA&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On June 5, 2025, the Company acquired an equity interest in Compedica, Ltd.
("Compedica"), a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby the Company acquired a 6.0% interest in Compedica, valued at $5.0 million
plus $&lt;span id="xdx_906_eifrs-full--ExpectedReimbursementOtherProvisions_iI_pn3n3_dm_c20250605_zoDQP8rxrp75" title="reimbursement of expenses"&gt;0.1&lt;/span&gt;
million for reimbursement of expenses to Compedica to close the transaction, and Compedica obtained a corresponding 27.4% interest in
the Company and is accounted for under the equity method as it was determined that the Company has significant influence over Compedica
due to the interconnected nature of the ownership of the respective entities. Compedica&#x2019;s interest in the Company was subsequently
diluted to 11.9% as a result of the shares issued under the private placement occurring in September 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company records its share of earnings and losses in Share of losses
from equity method investment within the consolidated statements of operations and other comprehensive income (loss). The Company recorded
a loss of less than $0.1 million for the fiscal year ended March 31, 2026, based on its share of Compedica's losses through the date significant
influence was lost as explained further below. The equity method investment is presented within "Investment in Compedica" on the
consolidated statements of financial position.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On September 25, 2025, in connection with the transition of the Company
to being primarily a digital asset treasury, Alpha Compute lost significant influence over Compedica and discontinued its use of the equity
method to account for its investment. Commencing on the date that significant influence was lost, the Company began accounting for its
investment as a financial instrument within the scope of IFRS 9 with changes in the fair value of its investment reflected as other income
(loss) within the consolidated statements of operations and other comprehensive income (loss). Subsequent to the discontinuing of the
equity method of accounting for Compedica, the fair value of the investment used by management is based on multiples analysis of publicly
traded comparable companies as Compedica is pre-revenue, as well as its holdings in the Company&#x2019;s own ordinary shares (Level 3 inputs).
A loss on impairment of $&lt;span id="xdx_902_eifrs-full--ImpairmentLoss_pn5n6_c20250401__20260331_zcvyWJaYfmxk" title="Loss on impairment"&gt;4.8
&lt;/span&gt;million was recognized as a result of the loss of significant influence.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#x2019;s treasury and the investment being exited. As a result, the Company recognized less than $0.1 million in treasury stock
at the time the return of shares was agreed upon, the fair value of the investment as of February 6, 2026. Following the loss of control
through the exit of the investment, the Company recognized a loss on the change in fair value on the investment in Compedica of $&lt;span id="xdx_90E_ecustom--ChangeInFairValueOnInvestmentInCompedica_iI_pn3n3_dm_c20260206_z0aQaLApZEug" title="Change in fair value on the investment in Compedica"&gt;0.2&lt;/span&gt;
million. The 625,000 shares of the Company were returned to our treasury on May 21, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Movements in the investment balance during the fiscal year ended March 31,
2026 were as follows (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfInvestmentBalanceTableTextBlock_pn3n3_zlJhjYcJHsR4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN COMPEDICA (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BC_zby3KgmHFTqi" style="display: none"&gt;Schedule of investment
        balance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250401__20260331_zlOCaXX9QW9g" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--BalanceAsOfApril1_zzHazQlxorCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Balance as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1549"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--InitialInvestmentInCompedica_zYkc03g0jWq" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Initial investment in Compedica&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,050&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--LossFromEquityMethodInvestment_iN_di_zahSCSUDA4B6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss from equity method investment&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LossOnImpairment_zkQbgSipdHD3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss on impairment&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,804&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfInvestmentInCompedica_z19ccBbFNYO" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of investment in Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(182&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ReturnOfInvestmentInterestToCompedica_zdzWDw93edO" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Return of investment interest to Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(20&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--InvestmentInCompedicaAsOfMarch31_zn3p4WeVfAn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Investment in Compedica as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1561"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A6_zpwusgx72k89" style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ifrs-full:DisclosureOfInvestmentPropertyExplanatory>
    <ifrs-full:ExpectedReimbursementOtherProvisions
      contextRef="AsOf2025-06-05"
      decimals="-3"
      id="Fact001538"
      unitRef="USD">100000</ifrs-full:ExpectedReimbursementOtherProvisions>
    <ifrs-full:ImpairmentLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-5"
      id="Fact001543"
      unitRef="USD">4800000</ifrs-full:ImpairmentLoss>
    <ptgef:ChangeInFairValueOnInvestmentInCompedica
      contextRef="AsOf2026-02-06"
      decimals="-3"
      id="Fact001545"
      unitRef="USD">200000</ptgef:ChangeInFairValueOnInvestmentInCompedica>
    <ptgef:ScheduleOfInvestmentBalanceTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001547">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfInvestmentBalanceTableTextBlock_pn3n3_zlJhjYcJHsR4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN COMPEDICA (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BC_zby3KgmHFTqi" style="display: none"&gt;Schedule of investment
        balance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250401__20260331_zlOCaXX9QW9g" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--BalanceAsOfApril1_zzHazQlxorCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Balance as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1549"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--InitialInvestmentInCompedica_zYkc03g0jWq" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Initial investment in Compedica&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,050&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--LossFromEquityMethodInvestment_iN_di_zahSCSUDA4B6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss from equity method investment&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LossOnImpairment_zkQbgSipdHD3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss on impairment&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,804&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfInvestmentInCompedica_z19ccBbFNYO" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of investment in Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(182&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ReturnOfInvestmentInterestToCompedica_zdzWDw93edO" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Return of investment interest to Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(20&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--InvestmentInCompedicaAsOfMarch31_zn3p4WeVfAn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Investment in Compedica as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1561"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfInvestmentBalanceTableTextBlock>
    <ptgef:InitialInvestmentInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001551"
      unitRef="USD">5050000</ptgef:InitialInvestmentInCompedica>
    <ptgef:LossFromEquityMethodInvestment
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001553"
      unitRef="USD">44000</ptgef:LossFromEquityMethodInvestment>
    <ptgef:LossOnImpairment
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001555"
      unitRef="USD">-4804000</ptgef:LossOnImpairment>
    <ptgef:ChangeInFairValueOfInvestmentInCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001557"
      unitRef="USD">-182000</ptgef:ChangeInFairValueOfInvestmentInCompedica>
    <ptgef:ReturnOfInvestmentInterestToCompedica
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001559"
      unitRef="USD">-20000</ptgef:ReturnOfInvestmentInterestToCompedica>
    <ptgef:DisclosureOfWarrantLiabilityExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001563">&lt;p id="xdx_808_ecustom--DisclosureOfWarrantLiabilityExplanatory_zPnG3vE8Xcj4" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 11. &lt;span id="xdx_82E_zvjKfFiDvhNl"&gt;WARRANT
LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The number of warrants and exercise price information herein have been retroactively
adjusted to reflect the impact of the reverse stock split. See Note 1 &#x201c;Nature of Operations&#x201d; and Note 17, &#x201c;Capital Stock
and Reserves&#x201d; for further discussion on the reverse stock split.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The following table summarizes the changes in the warrant liability
during the fiscal years ended March 31, 2026, 2025, and 2024:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zSJ5yKM1rq49" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;span id="xdx_8B4_zOtX7osxSNha" style="display: none"&gt;Schedule of changes in the warrant
        liability&lt;/span&gt; &lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise
        Price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value
        Balance&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;In 000&#x2019;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;Fair value of warrants at issuance on October 3, 2023:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Class B Warrants&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_z14U3yUSXJNh" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zK7pB4o7jgcf" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_fKDEp_zllTebPXe23f" title="Fair value of warrants amount"&gt;3,537&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Class C Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zZqwBvXW4Ou1" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zF0SOg9UzJKb" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_fKDEp_zfxB5j3Xzxyi" title="Fair value of warrants amount"&gt;4,663&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Placement Agent Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziFZ91lO4No4" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;47.50&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqB6XUDfY1ib" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares"&gt;7,896&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zKQVysaZxH3e" title="Fair value of warrants amount"&gt;232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_zqtHTdLnVvM9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(6,868&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Warrant liability as of April 1, 2024&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20250331_zhCdCZ7VkcPa" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending"&gt;323,686&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20250331_z6bRcsRO5bu1" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending"&gt;1,564&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20250331_zvb4yxb3qUW" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount"&gt;388&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Warrant liability as of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20250401__20260331_zAn9IrmUx4c" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending"&gt;323,686&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20250401__20260331_zXKrm1Z1oqRl" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending"&gt;1,952&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold"&gt;Fair value of warrants at issuance on January 27, 2026:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Placement Agent Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqGukfYAhsNa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;1.25&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zExFn0kJ4wUc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;1,050,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zcGJf8jsozm4" title="Fair value of warrants amount"&gt;1,123&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20250401__20260331_ztiBIMoimCGd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(2,883&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrant liability as of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--WarrantsLiabilityShares_iE_pip0_c20250401__20260331_zP0o7uHf3ANj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending"&gt;1,373,686&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20250401__20260331_zoyisK1hdM8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, fair value at ending"&gt;192&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A0_zYmtGb15ZT0l" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series B Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;A fair value of $&lt;span id="xdx_908_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zdWGdTOdKe33" title="Fair value of warrant per share"&gt;22.40&lt;/span&gt;
per each Series B Warrant was estimated at the issue date of October 3, 2023. A fair value of $&lt;span id="xdx_90C_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zML2kunHQvE4" title="Fair value of warrant per share"&gt;0.00&lt;/span&gt;
and $&lt;span id="xdx_905_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesBWarrantsMember_zLXUTsdR3qqh" title="Fair value of warrant per share"&gt;5.65&lt;/span&gt;
per each warrant has been identified as of March 31, 2026 and 2025, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The inputs associated with calculating the fair value are reflected
below.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zbBkvky6ahpb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B0_z7H6GUTire6" style="display: none"&gt;&#160;Schedule of inputs
        associated with calculating the fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;October 3, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcNWdnKA7t1h" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcMANoGEFI6" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zvyaleOiJoij" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrFeYkgCqag3" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBI4iPKaOJHg" title="Share price"&gt;9.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zOrTS1j4RgTl" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zmUJEZZIZuc" title="Expected life"&gt;3.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zbsUkU7mGR4a" title="Expected life"&gt;1.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zv2etxEPHTLc" title="Expected life"&gt;0.51&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zRNSZr9Bsyke" title="Expected volatility"&gt;90.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBLER54ju4x2" title="Expected volatility"&gt;207.73&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zGmE7X8gkY7h" title="Expected volatility"&gt;85.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zVHBmmT4Tp8h" title="Risk free interest rate"&gt;4.95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zM5h9A2Z0Qd3" title="Risk free interest rate"&gt;3.96&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zFFewYVR6R3a" title="Risk free interest rate"&gt;3.65&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zm1zYIyIC7N4" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1650"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEIaEviJaoxi" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1652"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z0PrTeT67bw9" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1654"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AE_zlDGzZ3JoRZ2" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series C Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;A fair value of $&lt;span id="xdx_90A_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_z5lV7XrevEIc" title="Fair value of warrant per share"&gt;29.60&lt;/span&gt;
per each Series C Warrant was estimated at the issue date of October 3, 2023. A fair value of $&lt;span id="xdx_902_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_zGuWmpHCDq37" title="Fair value of warrant per share"&gt;0.00&lt;/span&gt;
and $&lt;span id="xdx_900_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeiesCWarrantsMember_zw3h8fUfUFC2" title="Fair value of warrant per share"&gt;6.40&lt;/span&gt;
per each warrant has been identified as of March 31, 2026 and 2025, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The inputs associated with calculating the fair value are reflected
below.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_zHEeq0KcG7Nh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BA_zNeBUyzvjDYi" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;October 3, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7CNQyvZbpx1" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7Hzf0fZPJHk" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zjwJkg7CCLv2" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zviTyKgs47jj" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHQ1bHUhjjFh" title="Share price"&gt;9.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zcltZ3A3DHUg" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zS3YhwfRInCc" title="Expected life"&gt;5.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zwfYlASTWvZk" title="Expected life"&gt;3.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zMOMU1FAanz3" title="Expected life"&gt;2.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zmtNXmZHp5Yg" title="Expected volatility"&gt;100.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zVoQrwL8D1wi" title="Expected volatility"&gt;152.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z0oIs26uJvz4" title="Expected volatility"&gt;95.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zh1OWyqxbWui" title="Risk free interest rate"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4scHsvnC34f" title="Risk free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7jZajot0X8f" title="Risk free interest rate"&gt;3.73&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zlJFTptLrip9" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1694"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zztiSm7DHUbh" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1696"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zQlFOIhDXNG1" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1698"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AC_zNvEScPOlZli" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2023 Placement Agent Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;A fair value of $&lt;span id="xdx_907_ecustom--FairValueOfWarrantPerShare_iI_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zp4vbltIl7P" title="Fair value of warrant per share"&gt;29.40&lt;/span&gt;
per each 2023 Placement Agent Warrant was estimated at the issue date of October 3, 2023. A fair value of $&lt;span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zzwBi5irKrEd" title="Fair value of warrant per share"&gt;0.00&lt;/span&gt;
and $&lt;span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7vpi84hlblg" title="Fair value of warrant per share"&gt;6.34&lt;/span&gt;
per each warrant has been identified as of March 31, 2026 and 2025, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The inputs associated with calculating the fair value are reflected
below.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory_z0WMoHkN2ua8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B7_zdxKP3McVBCi" style="display: none"&gt;Schedule of Placement agent warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;October 3, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsGPaZikPNz5" title="Exercise price"&gt;47.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zZIC6pi2wQ0i" title="Exercise price"&gt;47.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcJncvXobtOc" title="Exercise price"&gt;47.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGPqkcKIacvc" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zbKildqYSvU9" title="Share price"&gt;9.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zTZfbXr7F0O8" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKrk0SpAaIth" title="Expected life"&gt;4.99&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zilGNvCPG75l" title="Expected life"&gt;3.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWOGkooFnHW7" title="Expected life"&gt;2.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z3WsBb78muC1" title="Expected volatility"&gt;100.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zUSXXPL9Rkdf" title="Expected volatility"&gt;152.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z1axsY3Lm7h5" title="Expected volatility"&gt;95.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsQkgNMI2bc" title="Risk free interest rate"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zEzRqFTHCrCe" title="Risk free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8OQj2rILoJd" title="Risk free interest rate"&gt;3.73&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zk25m7D81mwh" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zVbfQKyutFzi" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1740"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMWBmMUg5oN9" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1742"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A7_zMovU1XiikA" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2026 Placement Agent Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;A fair value of $&lt;span id="xdx_90E_ecustom--FairValueOfWarrantPerShare_iI_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zrPVyWvLZLn2" title="Fair value of warrant per share"&gt;1.07&lt;/span&gt;
per each 2026 Placement Agent Warrant was estimated at the issue date of January 19, 2026. A fair value of $&lt;span id="xdx_908_ecustom--FairValueOfWarrantPerShare_iI_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrants2026Member_zbAbw8GA52f2" title="Fair value of warrant per share"&gt;0.18&lt;/span&gt;
per each warrant has been identified as of March 31, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The inputs associated with calculating the fair value are reflected
below.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementPlacementAgentExplanatory_z8nF7hZ9QcQ7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_z1jn5tB36Ll8" style="display: none"&gt;Schedule of 2026 placement
        agent warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;January
        19, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ExercisePriceFairValue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw8zpZbvkl1e" title="Exercise price"&gt;1.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zyrEA4PyGcIi" title="Exercise price"&gt;1.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharePriceFairvalue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zCQwB50xVWX8" title="Share price"&gt;1.30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zNeHaoLISPfj" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9hgK6z2usf" title="Expected life"&gt;5.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zoTZ4ibQOFdk" title="Expected life"&gt;4.79&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zq6YJfRZVQy4" title="Expected volatility"&gt;115.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zfwXAkArfdR9" title="Expected volatility"&gt;105.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8O8MSDk6kic" title="Risk free interest rate"&gt;3.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zrNAFmyLNYC7" title="Risk free interest rate"&gt;3.83&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zaPQDYAdUsOk" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1770"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_za1yL1zZIOEk" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AE_zBa8c1qZbeed" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;















</ptgef:DisclosureOfWarrantLiabilityExplanatory>
    <ptgef:ScheduleOfWarrantLiabilityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001565">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zSJ5yKM1rq49" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;span id="xdx_8B4_zOtX7osxSNha" style="display: none"&gt;Schedule of changes in the warrant
        liability&lt;/span&gt; &lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise
        Price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value
        Balance&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;In 000&#x2019;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;Fair value of warrants at issuance on October 3, 2023:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Class B Warrants&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_z14U3yUSXJNh" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zK7pB4o7jgcf" style="width: 12%; font-size: 10pt; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_fKDEp_zllTebPXe23f" title="Fair value of warrants amount"&gt;3,537&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Class C Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zZqwBvXW4Ou1" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zF0SOg9UzJKb" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_fKDEp_zfxB5j3Xzxyi" title="Fair value of warrants amount"&gt;4,663&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Placement Agent Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziFZ91lO4No4" style="font-size: 10pt; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;47.50&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqB6XUDfY1ib" style="font-size: 10pt; text-align: right" title="Fair value of warrants shares"&gt;7,896&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zKQVysaZxH3e" title="Fair value of warrants amount"&gt;232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_zqtHTdLnVvM9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(6,868&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Warrant liability as of April 1, 2024&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20250331_zhCdCZ7VkcPa" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending"&gt;323,686&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20250331_z6bRcsRO5bu1" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending"&gt;1,564&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20250331_zvb4yxb3qUW" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Change in fair value of warrant liability, amount"&gt;388&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Warrant liability as of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20250401__20260331_zAn9IrmUx4c" style="font-size: 10pt; text-align: right" title="Warrants outstanding, shares at ending"&gt;323,686&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20250401__20260331_zXKrm1Z1oqRl" style="font-size: 10pt; text-align: right" title="Warrants outstanding, fair value at ending"&gt;1,952&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold"&gt;Fair value of warrants at issuance on January 27, 2026:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Placement Agent Warrants&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zqGukfYAhsNa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;1.25&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zExFn0kJ4wUc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;1,050,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_fKDEp_zcGJf8jsozm4" title="Fair value of warrants amount"&gt;1,123&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20250401__20260331_ztiBIMoimCGd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(2,883&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrant liability as of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--WarrantsLiabilityShares_iE_pip0_c20250401__20260331_zP0o7uHf3ANj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending"&gt;1,373,686&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20250401__20260331_zoyisK1hdM8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, fair value at ending"&gt;192&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:ScheduleOfWarrantLiabilityTableTextBlock>
    <ptgef:FairValueOfWarrantsAtIssuanceExercisePrice
      contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember"
      decimals="INF"
      id="Fact001567"
      unitRef="USDPShares">45.20</ptgef:FairValueOfWarrantsAtIssuanceExercisePrice>
    <ptgef:FairValueOfWarrantsShares
      contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember"
      decimals="INF"
      id="Fact001569"
      unitRef="Shares">157895</ptgef:FairValueOfWarrantsShares>
    <ptgef:FairValueOfWarrantsAmount
      contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember"
      decimals="-3"
      id="Fact001571"
      unitRef="USD">3537000</ptgef:FairValueOfWarrantsAmount>
    <ptgef:FairValueOfWarrantsAtIssuanceExercisePrice
      contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember"
      decimals="INF"
      id="Fact001573"
      unitRef="USDPShares">45.20</ptgef:FairValueOfWarrantsAtIssuanceExercisePrice>
    <ptgef:FairValueOfWarrantsShares
      contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">157895</ptgef:FairValueOfWarrantsShares>
    <ptgef:FairValueOfWarrantsAmount
      contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember"
      decimals="-3"
      id="Fact001577"
      unitRef="USD">4663000</ptgef:FairValueOfWarrantsAmount>
    <ptgef:FairValueOfWarrantsAtIssuanceExercisePrice
      contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001579"
      unitRef="USDPShares">47.50</ptgef:FairValueOfWarrantsAtIssuanceExercisePrice>
    <ptgef:FairValueOfWarrantsShares
      contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001581"
      unitRef="Shares">7896</ptgef:FairValueOfWarrantsShares>
    <ptgef:FairValueOfWarrantsAmount
      contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember"
      decimals="-3"
      id="Fact001583"
      unitRef="USD">232000</ptgef:FairValueOfWarrantsAmount>
    <ptgef:ChangeInFairValueOfWarrantLiabilityAmount
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001585"
      unitRef="USD">-6868000</ptgef:ChangeInFairValueOfWarrantLiabilityAmount>
    <ptgef:WarrantsLiabilityShares
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001587"
      unitRef="Shares">323686</ptgef:WarrantsLiabilityShares>
    <ptgef:WarrantsLiabilityFairValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001589"
      unitRef="USD">1564000</ptgef:WarrantsLiabilityFairValue>
    <ptgef:ChangeInFairValueOfWarrantLiabilityAmount
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001591"
      unitRef="USD">388000</ptgef:ChangeInFairValueOfWarrantLiabilityAmount>
    <ptgef:WarrantsLiabilityShares
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001593"
      unitRef="Shares">323686</ptgef:WarrantsLiabilityShares>
    <ptgef:WarrantsLiabilityFairValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001595"
      unitRef="USD">1952000</ptgef:WarrantsLiabilityFairValue>
    <ptgef:FairValueOfWarrantsAtIssuanceExercisePrice
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001597"
      unitRef="USDPShares">1.25</ptgef:FairValueOfWarrantsAtIssuanceExercisePrice>
    <ptgef:FairValueOfWarrantsShares
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001599"
      unitRef="Shares">1050000</ptgef:FairValueOfWarrantsShares>
    <ptgef:FairValueOfWarrantsAmount
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="-3"
      id="Fact001601"
      unitRef="USD">1123000</ptgef:FairValueOfWarrantsAmount>
    <ptgef:ChangeInFairValueOfWarrantLiabilityAmount
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001603"
      unitRef="USD">-2883000</ptgef:ChangeInFairValueOfWarrantLiabilityAmount>
    <ptgef:WarrantsLiabilityShares
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001605"
      unitRef="Shares">1373686</ptgef:WarrantsLiabilityShares>
    <ptgef:WarrantsLiabilityFairValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001607"
      unitRef="USD">192000</ptgef:WarrantsLiabilityFairValue>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2023-10-03_custom_SeiesBWarrantsMember"
      decimals="INF"
      id="Fact001609"
      unitRef="USDPShares">22.40</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2026-03-31_custom_SeiesBWarrantsMember"
      decimals="INF"
      id="Fact001611"
      unitRef="USDPShares">0.00</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2025-03-31_custom_SeiesBWarrantsMember"
      decimals="INF"
      id="Fact001613"
      unitRef="USDPShares">5.65</ptgef:FairValueOfWarrantPerShare>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001618">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zbBkvky6ahpb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B0_z7H6GUTire6" style="display: none"&gt;&#160;Schedule of inputs
        associated with calculating the fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;October 3, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcNWdnKA7t1h" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zcMANoGEFI6" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zvyaleOiJoij" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrFeYkgCqag3" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBI4iPKaOJHg" title="Share price"&gt;9.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zOrTS1j4RgTl" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zmUJEZZIZuc" title="Expected life"&gt;3.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zbsUkU7mGR4a" title="Expected life"&gt;1.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zv2etxEPHTLc" title="Expected life"&gt;0.51&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zRNSZr9Bsyke" title="Expected volatility"&gt;90.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zBLER54ju4x2" title="Expected volatility"&gt;207.73&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zGmE7X8gkY7h" title="Expected volatility"&gt;85.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zVHBmmT4Tp8h" title="Risk free interest rate"&gt;4.95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zM5h9A2Z0Qd3" title="Risk free interest rate"&gt;3.96&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zFFewYVR6R3a" title="Risk free interest rate"&gt;3.65&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zm1zYIyIC7N4" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1650"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEIaEviJaoxi" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1652"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z0PrTeT67bw9" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1654"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001620"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2025-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001622"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001624"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001626"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2025-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001628"
      unitRef="USDPShares">9.25</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001630"
      unitRef="USDPShares">0.32</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      id="Fact001632">P3Y3D</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember"
      id="Fact001634">P1Y6M3D</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember"
      id="Fact001636">P0Y6M3D</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001638"
      unitRef="Pure">0.904</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001640"
      unitRef="Pure">2.0773</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001642"
      unitRef="Pure">0.8500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001644"
      unitRef="Pure">0.0495</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001646"
      unitRef="Pure">0.0396</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001648"
      unitRef="Pure">0.0365</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2023-10-03_custom_SeiesCWarrantsMember"
      decimals="INF"
      id="Fact001656"
      unitRef="USDPShares">29.60</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2026-03-31_custom_SeiesCWarrantsMember"
      decimals="INF"
      id="Fact001658"
      unitRef="USDPShares">0.00</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2025-03-31_custom_SeiesCWarrantsMember"
      decimals="INF"
      id="Fact001660"
      unitRef="USDPShares">6.40</ptgef:FairValueOfWarrantPerShare>
    <ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001662">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_zHEeq0KcG7Nh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BA_zNeBUyzvjDYi" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;October 3, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7CNQyvZbpx1" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7Hzf0fZPJHk" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zjwJkg7CCLv2" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zviTyKgs47jj" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHQ1bHUhjjFh" title="Share price"&gt;9.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zcltZ3A3DHUg" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zS3YhwfRInCc" title="Expected life"&gt;5.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zwfYlASTWvZk" title="Expected life"&gt;3.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zMOMU1FAanz3" title="Expected life"&gt;2.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zmtNXmZHp5Yg" title="Expected volatility"&gt;100.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zVoQrwL8D1wi" title="Expected volatility"&gt;152.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z0oIs26uJvz4" title="Expected volatility"&gt;95.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zh1OWyqxbWui" title="Risk free interest rate"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4scHsvnC34f" title="Risk free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7jZajot0X8f" title="Risk free interest rate"&gt;3.73&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zlJFTptLrip9" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1694"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zztiSm7DHUbh" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1696"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zQlFOIhDXNG1" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1698"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001664"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2025-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001666"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2026-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001668"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001670"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2025-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001672"
      unitRef="USDPShares">9.25</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2026-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001674"
      unitRef="USDPShares">0.32</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      id="Fact001676">P5Y</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember"
      id="Fact001678">P3Y6M3D</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember"
      id="Fact001680">P2Y6M3D</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001682"
      unitRef="Pure">1.007</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001684"
      unitRef="Pure">1.5201</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001686"
      unitRef="Pure">0.9500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001688"
      unitRef="Pure">0.0480</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001690"
      unitRef="Pure">0.0391</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001692"
      unitRef="Pure">0.0373</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2024-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001700"
      unitRef="USDPShares">29.40</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001702"
      unitRef="USDPShares">0.00</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001704"
      unitRef="USDPShares">6.34</ptgef:FairValueOfWarrantPerShare>
    <ptgef:DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001706">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory_z0WMoHkN2ua8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B7_zdxKP3McVBCi" style="display: none"&gt;Schedule of Placement agent warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;October 3, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsGPaZikPNz5" title="Exercise price"&gt;47.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExercisePriceFairValue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zZIC6pi2wQ0i" title="Exercise price"&gt;47.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcJncvXobtOc" title="Exercise price"&gt;47.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGPqkcKIacvc" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zbKildqYSvU9" title="Share price"&gt;9.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zTZfbXr7F0O8" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKrk0SpAaIth" title="Expected life"&gt;4.99&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptions_dtY_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zilGNvCPG75l" title="Expected life"&gt;3.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWOGkooFnHW7" title="Expected life"&gt;2.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z3WsBb78muC1" title="Expected volatility"&gt;100.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zUSXXPL9Rkdf" title="Expected volatility"&gt;152.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z1axsY3Lm7h5" title="Expected volatility"&gt;95.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zsQkgNMI2bc" title="Risk free interest rate"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zEzRqFTHCrCe" title="Risk free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8OQj2rILoJd" title="Risk free interest rate"&gt;3.73&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zk25m7D81mwh" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zVbfQKyutFzi" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1740"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMWBmMUg5oN9" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1742"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:DisclosureOfFairValueOfPlacementAgentWarrantsMeasurementExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001708"
      unitRef="USDPShares">47.60</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001710"
      unitRef="USDPShares">47.50</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001712"
      unitRef="USDPShares">47.50</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001714"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001716"
      unitRef="USDPShares">9.25</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001718"
      unitRef="USDPShares">0.32</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      id="Fact001720">P4Y11M26D</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember"
      id="Fact001722">P3Y6M3D</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember"
      id="Fact001724">P2Y6M3D</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001726"
      unitRef="Pure">1.007</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001728"
      unitRef="Pure">1.5201</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001730"
      unitRef="Pure">0.9500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001732"
      unitRef="Pure">0.0480</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001734"
      unitRef="Pure">0.0391</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001736"
      unitRef="Pure">0.0373</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2026-01-19_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001744"
      unitRef="USDPShares">1.07</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2026-03-31_custom_PlacementAgentWarrants2026Member"
      decimals="INF"
      id="Fact001746"
      unitRef="USDPShares">0.18</ptgef:FairValueOfWarrantPerShare>
    <ptgef:DisclosureOfFairValueMeasurementPlacementAgentExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001748">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementPlacementAgentExplanatory_z8nF7hZ9QcQ7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_z1jn5tB36Ll8" style="display: none"&gt;Schedule of 2026 placement
        agent warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;January
        19, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ExercisePriceFairValue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw8zpZbvkl1e" title="Exercise price"&gt;1.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zyrEA4PyGcIi" title="Exercise price"&gt;1.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharePriceFairvalue_iI_pip0_c20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zCQwB50xVWX8" title="Share price"&gt;1.30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zNeHaoLISPfj" title="Share price"&gt;0.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--OptionLifeShareOptions_dtY_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9hgK6z2usf" title="Expected life"&gt;5.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_ecustom--OptionLifeShareOptions_dtY_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zoTZ4ibQOFdk" title="Expected life"&gt;4.79&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zq6YJfRZVQy4" title="Expected volatility"&gt;115.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zfwXAkArfdR9" title="Expected volatility"&gt;105.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z8O8MSDk6kic" title="Risk free interest rate"&gt;3.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentsWarrantsMember_zrNAFmyLNYC7" title="Risk free interest rate"&gt;3.83&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20260102__20260119__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zaPQDYAdUsOk" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1770"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_za1yL1zZIOEk" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:DisclosureOfFairValueMeasurementPlacementAgentExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2026-01-19_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001750"
      unitRef="USDPShares">1.25</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2026-03-31_custom_PlacementAgentsWarrantsMember"
      decimals="INF"
      id="Fact001752"
      unitRef="USDPShares">1.25</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2026-01-19_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001754"
      unitRef="USDPShares">1.30</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2026-03-31_custom_PlacementAgentsWarrantsMember"
      decimals="INF"
      id="Fact001756"
      unitRef="USDPShares">0.32</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember"
      id="Fact001758">P5Y</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember"
      id="Fact001760">P4Y9M14D</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001762"
      unitRef="Pure">1.1500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember"
      decimals="INF"
      id="Fact001764"
      unitRef="Pure">1.0500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2026-01-022026-01-19_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001766"
      unitRef="Pure">0.0368</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_PlacementAgentsWarrantsMember"
      decimals="INF"
      id="Fact001768"
      unitRef="Pure">0.0383</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001776">&lt;p id="xdx_803_ecustom--DisclosureOPutRightLiabilityAndTonPayableExplanatory_z07eYSeNTsjj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
12. &lt;span id="xdx_82A_zuEEucpkJCY2"&gt;PUT RIGHT LIABILITY AND TON PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On September 2, 2025, the Company entered into five Side Letter Agreements
(&#x201c;Side Letters&#x201d;) with certain investors to repurchase its outstanding ordinary shares, as well as pre-funded warrants to purchase
ordinary shares held by these investors at the option of the holders and on August 25, 2025, the Company entered into a Treasury Management
Agreement with DWF MaaS Limited (&#x201c;DWF&#x201d;) whereby DWF is entitled to convert the Ordinary Shares it subscribed for in the September
2025 private placement into an equivalent value of TON from the amount of TON held by DWF on behalf of the Company up to a maximum value
of $15.0 million (collectively, the &#x201c;Contingent Put Options&#x201d;). &lt;span id="xdx_90B_ecustom--TreasuryManagementAgreementDescription_c20250401__20260331_zZ9hVwnMMisa" title="Treasury Management Agreement description"&gt;A
total of 2,266,890 and 265,000 ordinary shares and an additional 745,226 and 2,513,240 pre-funded warrants to purchase ordinary shares
were subject to repurchase as defined within the Side Letters and Treasury Management Agreement, respectively, with various right expiration
dates between March 2026 and September 2026. In the event the holders exercise their Contingent Put Options, the Company is obligated
to settle the contract by transferring the same amount of USDC, Liquid TON, or Locked TON based on the Original Consideration within each
Side Letter or Treasury Management Agreement with no adjustment for value. As of September 30, 2025, a total of 2,531,890 ordinary shares
and an additional 3,258,466 pre-funded warrants to purchase ordinary shares were still subject to repurchase on various settlement dates
through September 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of the put right liability is estimated
using a Black-Scholes model and in certain cases, a Monte Carlo simulation. The weighted average assumptions used to value the Side Letter
put rights at inception and as of March 31, 2026 are as follows:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock_pn3n3_zIddunfGqcRc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zrXKzoyKcZp8" style="display: none"&gt;Schedule of fair value
        of the put right liability estimated using a Black-Scholes model&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;September
        2, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;ALP shares and TON correlation factor&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20250902_zrhsWfzkS2cg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor"&gt;0.60&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20260331_zsboCpXxXzli" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor"&gt;0.10&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20250902_z195kcmK5ewe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price"&gt;6.96&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20260331_zjtJL9O38m4" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price"&gt;0.32&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Remaining term (in years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250829__20250902_zgpKwqXliCyj" title="Remaining term (in years)"&gt;0.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250401__20260331_zr7gRSLEwfG9" title="Remaining term (in years)"&gt;0.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected ALP volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902_zHgZF7d9rVxf" title="Expected ALP volatility"&gt;82.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331_z9MBYxO8IvT1" title="Expected ALP volatility"&gt;85.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250829__20250902_z18yGKKVtm09" title="Risk free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331_zuDUQO9pypXi" title="Risk free interest rate"&gt;3.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;ALP dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250829__20250902_z2bPoYPz0Jyf" title="ALP dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331_z16FwPms4IIg" title="ALP dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;TON token price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--TonTokenPrice_iI_pip0_c20250902_zAN6Q8YbDBn9" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price"&gt;3.11&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TonTokenPrice_iI_pip0_c20260331_z5jWLgPHY1Ma" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price"&gt;1.22&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;TON token volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zc1NOWV4TEr8" title="Expected ALP volatility"&gt;62.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zvd0uikAd9Ji" title="Expected ALP volatility"&gt;53.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Locked TON token discount for lack of marketability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250829__20250902_zCBHvDMCKXYg" title="Locked TON token discount for lack of marketability rate"&gt;19.30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250401__20260331_zEN42IfWuxrj" title="Locked TON token discount for lack of marketability rate"&gt;14.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of the put right liability is most sensitive
to expected share price volatility, the value of the underlying digital assets, expected term and discount rate. An increase in expected
volatility, expected term or underlying digital asset values would result in a higher fair value measurement. An increase in the discount
rate would result in a lower fair value measurement. Management considered the interrelationship of these assumptions when determining
the fair value measurement.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The DWF put right was capped at $&lt;span id="xdx_900_eifrs-full--CurrentInterestReceivable_iI_pn3n3_dm_c20260331_zKAyaNILcu4" title="Fair value of stablecoin receivable"&gt;15.0
&lt;/span&gt;million, the fair value of the stablecoin receivable contributed, which corresponded to the aggregate fair value of the ordinary
shares and pre-funded warrants issued to DWF. Therefore, at inception, the DWF put right was determined to have a fair value of $15.0
million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;At inception, the outstanding Contingent Put Options
were determined to have a fair value of $16.1 million, net of issuance costs of $2.0 million, which was included within Put right liability
within the Company&#x2019;s consolidated balance sheet.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On December 8, 2025 and December 30, 2025, one Side
Letter put right and the DWF put right were exercised, respectively, and on March 24, 2026 and December 30, 2025, the contributed locked
TON tokens receivable in the amount of 1,114,130, with a fair value of $&lt;span id="xdx_902_ecustom--FairValueOfContribution_iI_pn3n3_dm_c20251208_zi9zyN3RICOg" title="Fair value of contribution"&gt;2.5&lt;/span&gt;
at contribution, and $&lt;span id="xdx_90B_ecustom--Usd1Receivable_iI_pn3n3_dm_c20251208_zFn8D3KFL3v3" title="USD1 receivable"&gt;15.0&lt;/span&gt;
million USD1 receivable were returned to the investor and DWF, respectively. In connection with the exercise of the Side Letter put right
on December 8, 2025, the Company recognized a loss on the exercise of $1.1 million, recognized as the difference between the fair value
of the TON contributed by the respective investor at the time of put exercise and the carrying value of the put right. When the locked
TON receivables were returned to the investor on March 24, 2026, the Company recognized a $0.4 million gain from the settlement of a portion
of the TON payable, recognized as the difference between the carrying value of the TON contributed by the respective investors at the
time the TON was returned to the investors and the fair value of the TON payable. As of March 31, 2026, the Company owes the investor
420,434 liquid TON tokens with a fair value of $0.5 million. When the USD1 receivable was returned to DWF on December 30, 2025, no such
gains or losses were recognized as USD1 is pegged to the U.S. dollar. Additionally, the Company terminated its Treasury Management Agreement
with DWF in connection with the return of DWF&#x2019;s initial investment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On January 27, 2026 and March 19, 2026, one Side Letter
put right was partially exercised and a second Side Letter put right was fully exercised, respectively. In connection with the exercises
of the Side Letter put rights, the Company recognized a loss on the exercise of $&lt;span id="xdx_907_ecustom--LossOnExercise_iI_pn3n3_dm_c20260127_znSdY4n71Gdb" title="loss on the exercise"&gt;0.4
&lt;/span&gt;million, recognized as the difference between the fair value of the TON contributed by the respective investor at the time of put
exercise and the carrying value of the put right. The put rights were not settled during the fiscal year ended March 31, 2026 and as of
March 31, 2026, the Company owes the investors 369,278 liquid TON tokens and 453,125 locked Ton tokens receivable with fair values of
$0.5 million and $0.3 million, respectively, which corresponds to the fair value of the liquid and locked tokens to be returned to the
respective investors at March 31, 2026. The outstanding TON balances payable were settled and the TON tokens returned to the respective
investors in separate transfers on April 15, April 24, and April 28, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;As of March 31, 2026, the outstanding Contingent Put
Options were remeasured to fair value of $&lt;span id="xdx_90A_ecustom--OutstandingContingentPutOptionsFairValue_iI_pn3n3_dm_c20260331_zNmujS1Hj00d" title="Outstanding Contingent Put Options fair value"&gt;7.1&lt;/span&gt;
million, with the remeasurement change in fair value of $&lt;span id="xdx_90E_ecustom--RemeasurementChangeInFairValue_iI_pn3n3_dm_c20260331_zwOU7OuzWywk" title="Remeasurement change in fair value"&gt;6.0&lt;/span&gt;
million recorded within other losses in the Consolidated Statements of Operations and Comprehensive Income (Loss).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes the changes in the put
right liability during the fiscal year ended March 31, 2026 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfPutRightLiabilityTableTextBlock_pn3n3_zDV6kJn48r9d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;span id="xdx_8BA_zrd7CcyH9Nqh" style="display: none"&gt;Schedule of put
        right liability&lt;/span&gt; &lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331_zI5dL0OGoDy6" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BalanceOfPutRightLiability_zaWkEXp0qrEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Balance as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_zaoCRQMYme17" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Put right recognition at contract inception&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;18,150&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--GainsLossesOnChangeInFairValueOfDerivatives_zyPmsHzo3NEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of put right liability, net of redemptions&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,959&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--ProceedsFromExerciseOfOptions_zFTV2D5OOMT" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Exercise of side letter put right&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,920&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--SettlementOfDwfMaasLimitedPutRight_zR6kRtNdRtWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Settlement of DWF Maas Limited put right&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(15,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LossOnExerciseOfPutRightLiability_zoxN7NLCVRZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss on exercise of put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;916&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--PutRightLiabilityEndingBalance_zHmCFY1nPVij" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Put right liability as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;7,105&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;








&lt;p id="xdx_8AB_zGtOGLFdxRA7" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes the changes in TON payable
during the fiscal year ended March 31, 2026 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;






&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfTonPayableTableTextBlock_pn3n3_zdAZZDIkciB5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B7_zMjtOO9WIA6c" style="display: none"&gt;Schedule of TON payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331_z5nOEyLqwnp5" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BalanceOfTonPayable_zZXYzpeNQcA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Balance as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1852"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ExerciseOfSideLetterPutRightPayable_zt7S9e2GJCjb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Exercise of side letter put right&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,920&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_iN_di_zn3xJzVG1Lnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(51&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--GainOnSettlementOfTonPayable_iN_di_z0cqKFLVZR3f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Gain on settlement of TON payable&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(336&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SettlementOfPutRightLiabilityUsingDigitalAssets_iN_di_zvFzBjEs7nWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Settlement of put right liability using digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,108&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TonPayableEndingBalanceAsOfMarch31_z5qhLQCmoKBh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;TON payable as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,425&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A9_z6rNMOcoI9K" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;




</ptgef:DisclosureOPutRightLiabilityAndTonPayableExplanatory>
    <ptgef:TreasuryManagementAgreementDescription contextRef="From2025-04-01to2026-03-31" id="Fact001778">A
total of 2,266,890 and 265,000 ordinary shares and an additional 745,226 and 2,513,240 pre-funded warrants to purchase ordinary shares
were subject to repurchase as defined within the Side Letters and Treasury Management Agreement, respectively, with various right expiration
dates between March 2026 and September 2026. In the event the holders exercise their Contingent Put Options, the Company is obligated
to settle the contract by transferring the same amount of USDC, Liquid TON, or Locked TON based on the Original Consideration within each
Side Letter or Treasury Management Agreement with no adjustment for value. As of September 30, 2025, a total of 2,531,890 ordinary shares
and an additional 3,258,466 pre-funded warrants to purchase ordinary shares were still subject to repurchase on various settlement dates
through September 2026.</ptgef:TreasuryManagementAgreementDescription>
    <ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001780">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock_pn3n3_zIddunfGqcRc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zrXKzoyKcZp8" style="display: none"&gt;Schedule of fair value
        of the put right liability estimated using a Black-Scholes model&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;September
        2, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March
        31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;ALP shares and TON correlation factor&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20250902_zrhsWfzkS2cg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor"&gt;0.60&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20260331_zsboCpXxXzli" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Alp shares and ton correlation factor"&gt;0.10&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20250902_z195kcmK5ewe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price"&gt;6.96&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_pip0_c20260331_zjtJL9O38m4" style="font-size: 10pt; font-weight: bold; text-align: right" title="Share price"&gt;0.32&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Remaining term (in years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250829__20250902_zgpKwqXliCyj" title="Remaining term (in years)"&gt;0.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--PutRightLiabilityemainingTermInYears_dtY_c20250401__20260331_zr7gRSLEwfG9" title="Remaining term (in years)"&gt;0.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected ALP volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902_zHgZF7d9rVxf" title="Expected ALP volatility"&gt;82.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331_z9MBYxO8IvT1" title="Expected ALP volatility"&gt;85.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250829__20250902_z18yGKKVtm09" title="Risk free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331_zuDUQO9pypXi" title="Risk free interest rate"&gt;3.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;ALP dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250829__20250902_z2bPoYPz0Jyf" title="ALP dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331_z16FwPms4IIg" title="ALP dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;TON token price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--TonTokenPrice_iI_pip0_c20250902_zAN6Q8YbDBn9" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price"&gt;3.11&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TonTokenPrice_iI_pip0_c20260331_z5jWLgPHY1Ma" style="font-size: 10pt; font-weight: bold; text-align: right" title="TON token price"&gt;1.22&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;TON token volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250829__20250902__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zc1NOWV4TEr8" title="Expected ALP volatility"&gt;62.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--ClassesOfShareCapitalAxis__custom--TonTokenVolatilityMember_zvd0uikAd9Ji" title="Expected ALP volatility"&gt;53.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Locked TON token discount for lack of marketability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250829__20250902_zCBHvDMCKXYg" title="Locked TON token discount for lack of marketability rate"&gt;19.30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--LockedTonTokenDiscountForLackOfMarketabilityRate_pip0_dp_c20250401__20260331_zEN42IfWuxrj" title="Locked TON token discount for lack of marketability rate"&gt;14.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of the put right liability is most sensitive
to expected share price volatility, the value of the underlying digital assets, expected term and discount rate. An increase in expected
volatility, expected term or underlying digital asset values would result in a higher fair value measurement. An increase in the discount
rate would result in a lower fair value measurement. Management considered the interrelationship of these assumptions when determining
the fair value measurement.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The DWF put right was capped at $&lt;span id="xdx_900_eifrs-full--CurrentInterestReceivable_iI_pn3n3_dm_c20260331_zKAyaNILcu4" title="Fair value of stablecoin receivable"&gt;15.0
&lt;/span&gt;million, the fair value of the stablecoin receivable contributed, which corresponded to the aggregate fair value of the ordinary
shares and pre-funded warrants issued to DWF. Therefore, at inception, the DWF put right was determined to have a fair value of $15.0
million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;At inception, the outstanding Contingent Put Options
were determined to have a fair value of $16.1 million, net of issuance costs of $2.0 million, which was included within Put right liability
within the Company&#x2019;s consolidated balance sheet.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On December 8, 2025 and December 30, 2025, one Side
Letter put right and the DWF put right were exercised, respectively, and on March 24, 2026 and December 30, 2025, the contributed locked
TON tokens receivable in the amount of 1,114,130, with a fair value of $&lt;span id="xdx_902_ecustom--FairValueOfContribution_iI_pn3n3_dm_c20251208_zi9zyN3RICOg" title="Fair value of contribution"&gt;2.5&lt;/span&gt;
at contribution, and $&lt;span id="xdx_90B_ecustom--Usd1Receivable_iI_pn3n3_dm_c20251208_zFn8D3KFL3v3" title="USD1 receivable"&gt;15.0&lt;/span&gt;
million USD1 receivable were returned to the investor and DWF, respectively. In connection with the exercise of the Side Letter put right
on December 8, 2025, the Company recognized a loss on the exercise of $1.1 million, recognized as the difference between the fair value
of the TON contributed by the respective investor at the time of put exercise and the carrying value of the put right. When the locked
TON receivables were returned to the investor on March 24, 2026, the Company recognized a $0.4 million gain from the settlement of a portion
of the TON payable, recognized as the difference between the carrying value of the TON contributed by the respective investors at the
time the TON was returned to the investors and the fair value of the TON payable. As of March 31, 2026, the Company owes the investor
420,434 liquid TON tokens with a fair value of $0.5 million. When the USD1 receivable was returned to DWF on December 30, 2025, no such
gains or losses were recognized as USD1 is pegged to the U.S. dollar. Additionally, the Company terminated its Treasury Management Agreement
with DWF in connection with the return of DWF&#x2019;s initial investment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On January 27, 2026 and March 19, 2026, one Side Letter
put right was partially exercised and a second Side Letter put right was fully exercised, respectively. In connection with the exercises
of the Side Letter put rights, the Company recognized a loss on the exercise of $&lt;span id="xdx_907_ecustom--LossOnExercise_iI_pn3n3_dm_c20260127_znSdY4n71Gdb" title="loss on the exercise"&gt;0.4
&lt;/span&gt;million, recognized as the difference between the fair value of the TON contributed by the respective investor at the time of put
exercise and the carrying value of the put right. The put rights were not settled during the fiscal year ended March 31, 2026 and as of
March 31, 2026, the Company owes the investors 369,278 liquid TON tokens and 453,125 locked Ton tokens receivable with fair values of
$0.5 million and $0.3 million, respectively, which corresponds to the fair value of the liquid and locked tokens to be returned to the
respective investors at March 31, 2026. The outstanding TON balances payable were settled and the TON tokens returned to the respective
investors in separate transfers on April 15, April 24, and April 28, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;As of March 31, 2026, the outstanding Contingent Put
Options were remeasured to fair value of $&lt;span id="xdx_90A_ecustom--OutstandingContingentPutOptionsFairValue_iI_pn3n3_dm_c20260331_zNmujS1Hj00d" title="Outstanding Contingent Put Options fair value"&gt;7.1&lt;/span&gt;
million, with the remeasurement change in fair value of $&lt;span id="xdx_90E_ecustom--RemeasurementChangeInFairValue_iI_pn3n3_dm_c20260331_zwOU7OuzWywk" title="Remeasurement change in fair value"&gt;6.0&lt;/span&gt;
million recorded within other losses in the Consolidated Statements of Operations and Comprehensive Income (Loss).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes the changes in the put
right liability during the fiscal year ended March 31, 2026 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfPutRightLiabilityTableTextBlock_pn3n3_zDV6kJn48r9d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;span id="xdx_8BA_zrd7CcyH9Nqh" style="display: none"&gt;Schedule of put
        right liability&lt;/span&gt; &lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331_zI5dL0OGoDy6" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BalanceOfPutRightLiability_zaWkEXp0qrEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Balance as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_zaoCRQMYme17" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Put right recognition at contract inception&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;18,150&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--GainsLossesOnChangeInFairValueOfDerivatives_zyPmsHzo3NEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of put right liability, net of redemptions&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,959&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--ProceedsFromExerciseOfOptions_zFTV2D5OOMT" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Exercise of side letter put right&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,920&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--SettlementOfDwfMaasLimitedPutRight_zR6kRtNdRtWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Settlement of DWF Maas Limited put right&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(15,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LossOnExerciseOfPutRightLiability_zoxN7NLCVRZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss on exercise of put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;916&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--PutRightLiabilityEndingBalance_zHmCFY1nPVij" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Put right liability as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;7,105&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;








</ptgef:ScheduleOfFairValueOfThePutRightLiabilityIsEstimatedUsingBlackScholesModelTableTextBlock>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="AsOf2025-09-02"
      decimals="INF"
      id="Fact001782"
      unitRef="USDPShares">0.60</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001784"
      unitRef="USDPShares">0.10</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2025-09-02"
      decimals="INF"
      id="Fact001786"
      unitRef="USDPShares">6.96</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001788"
      unitRef="USDPShares">0.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ptgef:PutRightLiabilityemainingTermInYears contextRef="From2025-08-292025-09-02" id="Fact001790">P0Y9M</ptgef:PutRightLiabilityemainingTermInYears>
    <ptgef:PutRightLiabilityemainingTermInYears contextRef="From2025-04-01to2026-03-31" id="Fact001792">P0Y3M</ptgef:PutRightLiabilityemainingTermInYears>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-08-292025-09-02"
      decimals="INF"
      id="Fact001794"
      unitRef="Pure">0.8290</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001796"
      unitRef="Pure">0.8500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-08-292025-09-02"
      decimals="INF"
      id="Fact001798"
      unitRef="Pure">0.0391</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001800"
      unitRef="Pure">0.0363</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:TonTokenPrice
      contextRef="AsOf2025-09-02"
      decimals="INF"
      id="Fact001806"
      unitRef="USDPShares">3.11</ptgef:TonTokenPrice>
    <ptgef:TonTokenPrice
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001808"
      unitRef="USDPShares">1.22</ptgef:TonTokenPrice>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-08-292025-09-02_custom_TonTokenVolatilityMember"
      decimals="INF"
      id="Fact001810"
      unitRef="Pure">0.6200</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_TonTokenVolatilityMember"
      decimals="INF"
      id="Fact001812"
      unitRef="Pure">0.5390</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ptgef:LockedTonTokenDiscountForLackOfMarketabilityRate
      contextRef="From2025-08-292025-09-02"
      decimals="INF"
      id="Fact001814"
      unitRef="Pure">0.1930</ptgef:LockedTonTokenDiscountForLackOfMarketabilityRate>
    <ptgef:LockedTonTokenDiscountForLackOfMarketabilityRate
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001816"
      unitRef="Pure">0.1480</ptgef:LockedTonTokenDiscountForLackOfMarketabilityRate>
    <ifrs-full:CurrentInterestReceivable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001818"
      unitRef="USD">15000000.0</ifrs-full:CurrentInterestReceivable>
    <ptgef:FairValueOfContribution
      contextRef="AsOf2025-12-08"
      decimals="-3"
      id="Fact001820"
      unitRef="USD">2500000</ptgef:FairValueOfContribution>
    <ptgef:Usd1Receivable
      contextRef="AsOf2025-12-08"
      decimals="-3"
      id="Fact001822"
      unitRef="USD">15000000.0</ptgef:Usd1Receivable>
    <ptgef:LossOnExercise
      contextRef="AsOf2026-01-27"
      decimals="-3"
      id="Fact001824"
      unitRef="USD">400000</ptgef:LossOnExercise>
    <ptgef:OutstandingContingentPutOptionsFairValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001830"
      unitRef="USD">7100000</ptgef:OutstandingContingentPutOptionsFairValue>
    <ptgef:RemeasurementChangeInFairValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001832"
      unitRef="USD">6000000.0</ptgef:RemeasurementChangeInFairValue>
    <ptgef:ScheduleOfPutRightLiabilityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001834">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfPutRightLiabilityTableTextBlock_pn3n3_zDV6kJn48r9d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;span id="xdx_8BA_zrd7CcyH9Nqh" style="display: none"&gt;Schedule of put
        right liability&lt;/span&gt; &lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331_zI5dL0OGoDy6" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BalanceOfPutRightLiability_zaWkEXp0qrEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Balance as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets_zaoCRQMYme17" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Put right recognition at contract inception&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;18,150&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--GainsLossesOnChangeInFairValueOfDerivatives_zyPmsHzo3NEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of put right liability, net of redemptions&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,959&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--ProceedsFromExerciseOfOptions_zFTV2D5OOMT" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Exercise of side letter put right&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,920&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--SettlementOfDwfMaasLimitedPutRight_zR6kRtNdRtWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Settlement of DWF Maas Limited put right&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(15,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LossOnExerciseOfPutRightLiability_zoxN7NLCVRZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss on exercise of put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;916&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--PutRightLiabilityEndingBalance_zHmCFY1nPVij" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Put right liability as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;7,105&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;








</ptgef:ScheduleOfPutRightLiabilityTableTextBlock>
    <ifrs-full:DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001838"
      unitRef="USD">18150000</ifrs-full:DecreaseThroughRightToConsiderationBecomingUnconditionalContractAssets>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001840"
      unitRef="USD">5959000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001842"
      unitRef="USD">-2920000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ptgef:SettlementOfDwfMaasLimitedPutRight
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001844"
      unitRef="USD">-15000000</ptgef:SettlementOfDwfMaasLimitedPutRight>
    <ptgef:LossOnExerciseOfPutRightLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001846"
      unitRef="USD">916000</ptgef:LossOnExerciseOfPutRightLiability>
    <ptgef:PutRightLiabilityEndingBalance
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001848"
      unitRef="USD">7105000</ptgef:PutRightLiabilityEndingBalance>
    <ptgef:ScheduleOfTonPayableTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001850">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfTonPayableTableTextBlock_pn3n3_zdAZZDIkciB5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PUT RIGHT LIABILITY AND TON PAYABLE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B7_zMjtOO9WIA6c" style="display: none"&gt;Schedule of TON payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331_z5nOEyLqwnp5" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fiscal year ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BalanceOfTonPayable_zZXYzpeNQcA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Balance as of April 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1852"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ExerciseOfSideLetterPutRightPayable_zt7S9e2GJCjb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Exercise of side letter put right&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,920&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_iN_di_zn3xJzVG1Lnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change in fair value of TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(51&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--GainOnSettlementOfTonPayable_iN_di_z0cqKFLVZR3f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Gain on settlement of TON payable&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(336&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SettlementOfPutRightLiabilityUsingDigitalAssets_iN_di_zvFzBjEs7nWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Settlement of put right liability using digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,108&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TonPayableEndingBalanceAsOfMarch31_z5qhLQCmoKBh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;TON payable as of March 31&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,425&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:ScheduleOfTonPayableTableTextBlock>
    <ptgef:ExerciseOfSideLetterPutRightPayable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001854"
      unitRef="USD">2920000</ptgef:ExerciseOfSideLetterPutRightPayable>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001856"
      unitRef="USD">51000</ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001858"
      unitRef="USD">336000</ptgef:GainOnSettlementOfTonPayable>
    <ptgef:SettlementOfPutRightLiabilityUsingDigitalAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001860"
      unitRef="USD">1108000</ptgef:SettlementOfPutRightLiabilityUsingDigitalAssets>
    <ptgef:TonPayableEndingBalanceAsOfMarch31
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001862"
      unitRef="USD">1425000</ptgef:TonPayableEndingBalanceAsOfMarch31>
    <ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001864">&lt;p id="xdx_803_ecustom--AccountsPayableAndAccruedLiabilitiesTextBlock_z59nQYgQ1B6h" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 13.
&lt;span id="xdx_829_ztC318AGAszd"&gt;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;At March 31, 2026 and 2025, accounts payable and accrued liabilities
were comprised of the following (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zuBiDBB0PrP4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B2_zHYRDfycesC8" style="display: none"&gt;Schedule of accounts
        payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20260331_z5S14yhvqA45" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20250331_zrj8TolvXpN6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccountsPayable_iI_zWeTCv2cvwGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,413&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;427&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedOtherProfessionalFees_iI_zokfs4wSvUad" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued other professional fees&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;262&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zjeBhK6CLhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued accounting and auditing fees&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;73&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;155&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_z4sLGMmf6tN4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued bonuses and other payroll-related expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;913&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;89&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedCRO_iI_zHNCOvDYDg2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued CRO&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1880"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;80&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ProfessionalFeesExpenses_iI_zg7p3eGGJla9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued legal fees&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;414&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;60&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedClinicalAndRdServices_iI_zjEWa0vnkMU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued clinical and R&amp;amp;D services&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--CapitalExpenditures_iI_zsLMetrmU6T9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Capital expenditures&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;333&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherAccruedExpenses_iI_zGfBgATblded" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Other&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;13&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_zDwF6E6m6JXd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable and accrued liabilities&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,504&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,100&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A9_zWulB43PTbTa" style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;















</ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock>
    <ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001866">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zuBiDBB0PrP4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B2_zHYRDfycesC8" style="display: none"&gt;Schedule of accounts
        payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20260331_z5S14yhvqA45" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20250331_zrj8TolvXpN6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccountsPayable_iI_zWeTCv2cvwGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,413&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;427&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedOtherProfessionalFees_iI_zokfs4wSvUad" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued other professional fees&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;262&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zjeBhK6CLhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued accounting and auditing fees&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;73&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;155&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_z4sLGMmf6tN4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued bonuses and other payroll-related expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;913&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;89&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedCRO_iI_zHNCOvDYDg2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued CRO&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1880"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;80&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ProfessionalFeesExpenses_iI_zg7p3eGGJla9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued legal fees&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;414&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;60&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedClinicalAndRdServices_iI_zjEWa0vnkMU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued clinical and R&amp;amp;D services&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--CapitalExpenditures_iI_zsLMetrmU6T9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Capital expenditures&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;333&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherAccruedExpenses_iI_zGfBgATblded" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Other&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;13&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_zDwF6E6m6JXd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable and accrued liabilities&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;5,504&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,100&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ptgef:AccountsPayable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001868"
      unitRef="USD">2413000</ptgef:AccountsPayable>
    <ptgef:AccountsPayable
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001869"
      unitRef="USD">427000</ptgef:AccountsPayable>
    <ptgef:AccruedOtherProfessionalFees
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001872"
      unitRef="USD">262000</ptgef:AccruedOtherProfessionalFees>
    <ptgef:AccruedAccountingAndAuditingFees
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001874"
      unitRef="USD">73000</ptgef:AccruedAccountingAndAuditingFees>
    <ptgef:AccruedAccountingAndAuditingFees
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001875"
      unitRef="USD">155000</ptgef:AccruedAccountingAndAuditingFees>
    <ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001877"
      unitRef="USD">913000</ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses>
    <ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001878"
      unitRef="USD">89000</ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses>
    <ptgef:AccruedCRO
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001881"
      unitRef="USD">80000</ptgef:AccruedCRO>
    <ptgef:ProfessionalFeesExpenses
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001883"
      unitRef="USD">414000</ptgef:ProfessionalFeesExpenses>
    <ptgef:ProfessionalFeesExpenses
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001884"
      unitRef="USD">60000</ptgef:ProfessionalFeesExpenses>
    <ptgef:AccruedClinicalAndRdServices
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001887"
      unitRef="USD">14000</ptgef:AccruedClinicalAndRdServices>
    <ptgef:CapitalExpenditures
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001889"
      unitRef="USD">333000</ptgef:CapitalExpenditures>
    <ptgef:CapitalExpenditures
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001890"
      unitRef="USD">0</ptgef:CapitalExpenditures>
    <ptgef:OtherAccruedExpenses
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001893"
      unitRef="USD">13000</ptgef:OtherAccruedExpenses>
    <ptgef:AccountsPayableAndAccruedLiabilityNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001895"
      unitRef="USD">5504000</ptgef:AccountsPayableAndAccruedLiabilityNet>
    <ptgef:AccountsPayableAndAccruedLiabilityNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001896"
      unitRef="USD">1100000</ptgef:AccountsPayableAndAccruedLiabilityNet>
    <ptgef:DisclosureOfLeaseLiabilityExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001900">&lt;p id="xdx_801_ecustom--DisclosureOfLeaseLiabilityExplanatory_z9KmRbVR8QT3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 14. &lt;span id="xdx_829_zvaoSzA5FLWd"&gt;LEASE
LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company entered into a lease of GPU equipment, which commenced on November
30, 2025 (the &#x201c;GPU Lease&#x201d;). The GPU Lease provided for an original term of one year, with the full balance paid at commencement
in the amount of $&lt;span id="xdx_90B_ecustom--Commencement_iI_pn3n3_dm_c20251130_zI01nE8kweZi" title="Commencement"&gt;0.3&lt;/span&gt;
million, with a purchase option exercisable at any point during the lease, with the purchase option being the remaining portion of the
GPU&#x2019;s purchase price of $&lt;span id="xdx_908_ecustom--PurchasePriceLeaseLiability_iI_pn3n3_dm_c20251130_zoACPsApa8Di" title="Purchase price"&gt;0.2&lt;/span&gt;
million. On February 5, 2026, the Company exercised the purchase price for the GPU equipment with a payment of $&lt;span id="xdx_902_ecustom--PurchaseEquipmentPayment_iI_pn3n3_dm_c20260205_zX9w3DdTcVzb" title="Purchase equipment payment"&gt;0.2&lt;/span&gt;
million, however the validity of the purchase option was disputed by the GPU owner and the broker of the lease has not yet been able to
deliver the GPU in question. The Company is pursuing a refund for the purchase option price, and the amount due is included in prepaid
expenses and other receivables within the consolidated balance sheet as of March 31, 2026. As the full balance of the lease was paid at
commencement and the purchase option ultimately disputed, no interest expense was incurred on the lease. As of March 31, 2026, the Company
had no contractual commitments remaining on the GPU lease.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company entered into a lease of office space in Lisbon, Portugal, which
commenced on March 1, 2026 (the &#x201c;Lisbon Lease&#x201d;). The Lisbon Lease provided for an original term of two years with purchase
options at the end of the 12&lt;sup&gt;th&lt;/sup&gt; and 24&lt;sup&gt;th&lt;/sup&gt; months of the lease, with certain rent payments and option payments being
credited towards the purchase price if the option is exercised. The Company calculated the Lisbon Lease liability using its incremental
borrowing rate of 14.75%. The Company prepaid the first twelve months rent in the amount of EUR 84,000.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Lisbon Lease liability is payable as follows (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfLeaseLiabilityTableTextBlock_pn3n3_zyHnYTCitGr9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASE LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BF_ziAyf6haDmHi" style="display: none"&gt;Schedule
        of Lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20260331_zHueMHvmtzS" style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; color: #212529; font-weight: bold"&gt;Fiscal Year ended March 31,&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LeaseLiabilityFutureMinimumPaymentsDue_iI_zTsB5kKZnvr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;2027&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;68&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LeaseLiabilityFutureMinimumPaymentsYearTwoDue_iI_zhc2Ggde5K81" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;92&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LeaseLiabilityFutureMinimumPaymentsYearDue_iI_zZh0HG83xjWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;Total&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;160&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--Interest_iI_zgG0B6A3tiCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Less: Interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;(22&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TotalLeaseLiability_iI_zY5T9jBgSXvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;Total lease liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;138&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LeaseLiabilityCurrent_iI_zzvimpsFkTI5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Lease liability - current&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;65&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LeaseLiabilityNoncurrent_iI_zGLcqpdlDgZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Lease liability - non-current&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;73&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A6_zDMMI7S1wOL" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ptgef:DisclosureOfLeaseLiabilityExplanatory>
    <ptgef:Commencement
      contextRef="AsOf2025-11-30"
      decimals="-3"
      id="Fact001902"
      unitRef="USD">300000</ptgef:Commencement>
    <ptgef:PurchasePriceLeaseLiability
      contextRef="AsOf2025-11-30"
      decimals="-3"
      id="Fact001904"
      unitRef="USD">200000</ptgef:PurchasePriceLeaseLiability>
    <ptgef:PurchaseEquipmentPayment
      contextRef="AsOf2026-02-05"
      decimals="-3"
      id="Fact001906"
      unitRef="USD">200000</ptgef:PurchaseEquipmentPayment>
    <ptgef:ScheduleOfLeaseLiabilityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001908">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfLeaseLiabilityTableTextBlock_pn3n3_zyHnYTCitGr9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASE LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BF_ziAyf6haDmHi" style="display: none"&gt;Schedule
        of Lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20260331_zHueMHvmtzS" style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; color: #212529; font-weight: bold"&gt;Fiscal Year ended March 31,&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LeaseLiabilityFutureMinimumPaymentsDue_iI_zTsB5kKZnvr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;2027&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;68&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LeaseLiabilityFutureMinimumPaymentsYearTwoDue_iI_zhc2Ggde5K81" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;92&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LeaseLiabilityFutureMinimumPaymentsYearDue_iI_zZh0HG83xjWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;Total&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;160&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--Interest_iI_zgG0B6A3tiCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Less: Interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;(22&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TotalLeaseLiability_iI_zY5T9jBgSXvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;Total lease liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;138&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LeaseLiabilityCurrent_iI_zzvimpsFkTI5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Lease liability - current&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;65&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LeaseLiabilityNoncurrent_iI_zGLcqpdlDgZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Lease liability - non-current&lt;/td&gt;
    &lt;td style="font-size: 10pt; color: #212529; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: right"&gt;73&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; color: #212529; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfLeaseLiabilityTableTextBlock>
    <ptgef:LeaseLiabilityFutureMinimumPaymentsDue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001910"
      unitRef="USD">68000</ptgef:LeaseLiabilityFutureMinimumPaymentsDue>
    <ptgef:LeaseLiabilityFutureMinimumPaymentsYearTwoDue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001912"
      unitRef="USD">92000</ptgef:LeaseLiabilityFutureMinimumPaymentsYearTwoDue>
    <ptgef:LeaseLiabilityFutureMinimumPaymentsYearDue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001914"
      unitRef="USD">160000</ptgef:LeaseLiabilityFutureMinimumPaymentsYearDue>
    <ptgef:Interest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001916"
      unitRef="USD">-22000</ptgef:Interest>
    <ptgef:TotalLeaseLiability
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001918"
      unitRef="USD">138000</ptgef:TotalLeaseLiability>
    <ptgef:LeaseLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001920"
      unitRef="USD">65000</ptgef:LeaseLiabilityCurrent>
    <ptgef:LeaseLiabilityNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001922"
      unitRef="USD">73000</ptgef:LeaseLiabilityNoncurrent>
    <ptgef:DisclosureOfBitgoPrimeLoanExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001924">&lt;p id="xdx_80E_ecustom--DisclosureOfBitgoPrimeLoanExplanatory_zGDH3das5ZEl" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 15. &lt;span id="xdx_825_z1fcrPTvlYR5"&gt;BITGO
PRIME LOAN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;span id="xdx_904_ecustom--MasterLoanAgreementDescription_c20250802__20250828_zJgY9dHZTQm2" title="Master Loan Agreement description"&gt;On
August 28, 2025, the Company entered into a master loan agreement (the &#x201c;Master Loan Agreement&#x201d;) with BitGo Prime, LLC (&#x201c;BitGo&#x201d;).
Pursuant to the Master Loan Agreement, the Company may borrow up to $35.0 million at an interest rate of 14.75% per annum with a 2.00%
origination fee paid upfront in the amount of $0.3 million. The Loan shall only be used to purchase liquid TON that will be delivered
to BitGo and such purchased liquid TON will also be pledged as collateral for the Loan. The outstanding loan balance must be repaid within
six months of the origination of the Loan, unless provided for otherwise or amended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;span id="xdx_907_ecustom--MasterLoanAgreementDescription_c20251005__20251007_zn4PWtC6iFC8" title="Master Loan Agreement description"&gt;On
October 7, 2025, the Company received its initial draw on the Master Loan Agreement in the amount of $2.1 million. No further draws have
been made on the loan, and on November 25, 2025 the loan balance was paid down to $1.8 million. On January 9, 2026, the remaining balance
of the loan was paid down and the Master Loan Agreement was exited. In connection with the extinguishment of the Master Loan Agreement,
the Company derecognized $0.1 million of deferred financing, incurred $0.5 million in loan termination fees paid to BitGo, and had $0.8
million in accrued interest forgiven by BitGo for payment of the loan termination fees, resulting in a net gain on debt extinguishment
of $0.3 million being recognized within the Consolidated Statements of Operations and Comprehensive Income (Loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ptgef:DisclosureOfBitgoPrimeLoanExplanatory>
    <ptgef:MasterLoanAgreementDescription contextRef="From2025-08-022025-08-28" id="Fact001926">On
August 28, 2025, the Company entered into a master loan agreement (the &#x201c;Master Loan Agreement&#x201d;) with BitGo Prime, LLC (&#x201c;BitGo&#x201d;).
Pursuant to the Master Loan Agreement, the Company may borrow up to $35.0 million at an interest rate of 14.75% per annum with a 2.00%
origination fee paid upfront in the amount of $0.3 million. The Loan shall only be used to purchase liquid TON that will be delivered
to BitGo and such purchased liquid TON will also be pledged as collateral for the Loan. The outstanding loan balance must be repaid within
six months of the origination of the Loan, unless provided for otherwise or amended.</ptgef:MasterLoanAgreementDescription>
    <ptgef:MasterLoanAgreementDescription contextRef="From2025-10-052025-10-07" id="Fact001928">On
October 7, 2025, the Company received its initial draw on the Master Loan Agreement in the amount of $2.1 million. No further draws have
been made on the loan, and on November 25, 2025 the loan balance was paid down to $1.8 million. On January 9, 2026, the remaining balance
of the loan was paid down and the Master Loan Agreement was exited. In connection with the extinguishment of the Master Loan Agreement,
the Company derecognized $0.1 million of deferred financing, incurred $0.5 million in loan termination fees paid to BitGo, and had $0.8
million in accrued interest forgiven by BitGo for payment of the loan termination fees, resulting in a net gain on debt extinguishment
of $0.3 million being recognized within the Consolidated Statements of Operations and Comprehensive Income (Loss).</ptgef:MasterLoanAgreementDescription>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact001930">&lt;p id="xdx_805_eifrs-full--DisclosureOfIncomeTaxExplanatory_zISa5cJIJr6f" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 16. &lt;span id="xdx_820_z7MKXEC3mKok"&gt;INCOME
TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company is a BVI business company. The
BVI government does not, under existing legislation, impose any income or corporate tax on corporations. PDS is a U.S. corporation and
is subject to U.S. federal, state and local income taxes, as applicable. iOx is subject to U.K. taxes.&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The benefit from income taxes consists of the
following for the years ended March 31, 2026 and 2025 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zINoBiaRScub" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B0_zMmAGq60eaq3" style="display: none"&gt;Schedule
        of income tax benefit&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250401__20260331_zk0uk8CvJz41" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240401__20250331_zhkTLop2mpcb" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Current tax:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CurrentTaxOnProfitsForYear_ztkQYH3yFeJe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;Current tax on profits for the year&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1941"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1942"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AdjustmentsForCurrentTaxOfPriorPeriods_zFIKDWyJbwXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Adjustments for current
        tax of prior periods&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1944"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentTaxExpenseIncome_i01_pn3n3_zZ7mca4NHGn" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total current tax benefit&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1947"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred income tax:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DecreaseIncreaseInDeferredTaxAssets_zmt0QnBzqidh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Decrease (increase) in deferred
        tax assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1953"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ProfitLossFromContinuingOperation_i01_pn3n3_zDKwrJAl1i4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1956"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p id="xdx_8AE_zMohqScrQGC2" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Reconciliation of tax expense (benefit) at statutory tax rate and the income
tax benefit as reported in the Consolidated Statement of Operations and Comprehensive Income (Loss) for the years ended March 31, 2026
and 2026 is as follows (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z0sT7P32qNd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;span id="xdx_8BD_zp1uJytHxqO1" style="display: none"&gt;Schedule of reconciliation
        income tax rates&lt;/span&gt; &lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20250401__20260331_zxB3RRPk4Na8" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240401__20250331_zhn17T8tMIra" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_zYZQnEKeSmKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss before income tax&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(38,627&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(6,781&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--TaxUsingBviTaxRate_pip0_dp_ztfnfs4nFxSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax using BVI tax rate of 0%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1965"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectOfTaxRatesInOtherCountries_zMKOlGVADbk7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Effect of tax rates in other countries&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(273&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(24&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DerecognitionOfDeferredTaxAssets_zpF3OA9h1TWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Derecognition of deferred tax assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(156&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--NondeductibleExpenses_zxYssXEsZbT4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Nondeductible expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1973"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1974"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_zUWhvh4QdqYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Utilization of losses not previously benefitted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1977"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxEffectsRelatedToEquityCompensation_zA30sF2tpoGi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Income tax effects related to equity compensation&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;429&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ForeignCurrencyEffectAndOther_zCrtam5qUHZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Foreign currency effect and other&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1982"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxExpense_zNYBWWsrZ7gh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax in the statement of loss&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1985"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p id="xdx_8A2_zLsNXd7vgLCa" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As of March 31, 2026 and 2025, the Company had $&lt;span id="xdx_90F_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_pn3n3_dm_c20250401__20260331_zHRWbVY9BNo9" title="U.S. federal net operating losses"&gt;1.4&lt;/span&gt;
million and $&lt;span id="xdx_908_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_pn3n3_dm_c20240401__20250331_zHEO2BTTYCa9" title="U.S. federal net operating losses"&gt;0.6&lt;/span&gt;
million of U.S. federal net operating losses, respectively, which carryforward indefinitely but are limited to 80% of taxable income when
utilized. As of March 31, 2026 and 2025, the Company also had $&lt;span id="xdx_908_ecustom--UkLossCarryForwards_pn3n3_dm_c20250401__20260331_z33l5WhHXCga" title="UK Loss carry forwards"&gt;15.9&lt;/span&gt;
million in UK loss carryforwards, which carryforward indefinitely&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As of March 31, 2026 and 2025, the Company&#x2019;s deferred tax assets and
liabilities consisted of the effects of temporary differences attributable to the following (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfDeferredTaxAssetsTableTextBlock_pn3n3_zcwaE4FrkEFa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B3_znCPruTYwnwd" style="display: none"&gt;Schedule
        of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260331_z3hbdug8JZJh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250331_zwWuvRPMVKC9" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsAbstract_iB_zroFL7nzjGM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;The balance comprises temporary differences attributable to:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzNDo_zYYvIBRwiBn5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax loss&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,265&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;3,935&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--StockbasedCompensation_i01_pn3n3_maNDTAzNDo_zg5NkV192sbd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;Share-based compensation&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;11&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;397&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ReservesAndAccruals_i01I_pn3n3_maNDTAzNDo_zpF098fkMhS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Reserves and accruals&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2005"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--NetDeferredTaxAssets_i01TI_pn3n3_mtNDTAzNDo_zFqHYt7xYwP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;4,276&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4,349&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetNotRecognized_i01NI_pn3n3_di_zXXTsip0DILl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax asset not recognized&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,276&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,349&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--NetDeferredTaxAsset_i01TI_pn3n3_zLCqto0u8Gba" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2014"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2015"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AD_zgZf5vpXNZSj" style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company assesses its deferred tax assets for recognition by considering
both positive and negative evidence in order to ascertain whether it is probable that deferred tax assets will be realized. Realization
of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain.
Due to the history of losses the Company has generated in the past, the Company believes that it is not probable that all of the deferred
tax assets in the U.S. and U.K. can be realized as of March 31, 2026; accordingly, the Company has not recognized any of its deferred
tax assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s deferred tax assets not recognized decreased by $&lt;span id="xdx_906_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20260331_zJA8QNH2SAH" title="deferred tax assets"&gt;0.1&lt;/span&gt;
million for the year ended March 31, 2026. The change in the deferred tax assets not recognized was primarily due to the true-up adjustment
for stock compensation.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company has concluded that there are no uncertain tax treatments that
require disclosure or recognition.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On December 20, 2021, the OECD published the Global Anti-Base Erosion Model
Rules (the "GloBE Rules"), also known as Pillar II. The GloBE Rules aim to impose a global minimum tax of 15% on multinational
enterprises with a revenue in excess of &#x20ac;750 million. As the Company&#x2019;s revenue is below this threshold, it is currently outside
the scope of the Pillar II rules.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company continues to monitor developments in jurisdictions where it
operates, including the U.K., U.S., and British Virgin Islands. As of the reporting date, Pillar II is not expected to have a material
impact on the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On July 4th 2025, President Trump signed into law the One Big Beautiful
Bill Act ("OBBBA"). The OBBBA includes changes to U.S. tax law applicable to the Company beginning in 2025. The impact of the
OBBBA on the Company's consolidated financial statements have been reflected in its current and deferred taxes; however, the enactment
did not have a material impact to the Company's consolidated financial statements for the fiscal years ended March 31, 2026 and 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001936">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zINoBiaRScub" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B0_zMmAGq60eaq3" style="display: none"&gt;Schedule
        of income tax benefit&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250401__20260331_zk0uk8CvJz41" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240401__20250331_zhkTLop2mpcb" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Current tax:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CurrentTaxOnProfitsForYear_ztkQYH3yFeJe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;Current tax on profits for the year&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1941"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1942"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AdjustmentsForCurrentTaxOfPriorPeriods_zFIKDWyJbwXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Adjustments for current
        tax of prior periods&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1944"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentTaxExpenseIncome_i01_pn3n3_zZ7mca4NHGn" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total current tax benefit&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1947"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred income tax:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DecreaseIncreaseInDeferredTaxAssets_zmt0QnBzqidh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Decrease (increase) in deferred
        tax assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1953"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ProfitLossFromContinuingOperation_i01_pn3n3_zDKwrJAl1i4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1956"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;



</ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock>
    <ptgef:AdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001945"
      unitRef="USD">-3000</ptgef:AdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001948"
      unitRef="USD">-3000</ifrs-full:CurrentTaxExpenseIncome>
    <ptgef:ProfitLossFromContinuingOperation
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001957"
      unitRef="USD">-3000</ptgef:ProfitLossFromContinuingOperation>
    <ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001959">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z0sT7P32qNd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;span id="xdx_8BD_zp1uJytHxqO1" style="display: none"&gt;Schedule of reconciliation
        income tax rates&lt;/span&gt; &lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20250401__20260331_zxB3RRPk4Na8" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240401__20250331_zhn17T8tMIra" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_zYZQnEKeSmKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss before income tax&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(38,627&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(6,781&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--TaxUsingBviTaxRate_pip0_dp_ztfnfs4nFxSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax using BVI tax rate of 0%&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1965"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectOfTaxRatesInOtherCountries_zMKOlGVADbk7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Effect of tax rates in other countries&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(273&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(24&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DerecognitionOfDeferredTaxAssets_zpF3OA9h1TWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Derecognition of deferred tax assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(156&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--NondeductibleExpenses_zxYssXEsZbT4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Nondeductible expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1973"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1974"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_zUWhvh4QdqYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Utilization of losses not previously benefitted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1977"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxEffectsRelatedToEquityCompensation_zA30sF2tpoGi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Income tax effects related to equity compensation&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;429&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ForeignCurrencyEffectAndOther_zCrtam5qUHZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Foreign currency effect and other&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1982"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxExpense_zNYBWWsrZ7gh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax in the statement of loss&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1985"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;



</ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock>
    <ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001961"
      unitRef="USD">-38627000</ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax>
    <ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001962"
      unitRef="USD">-6781000</ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax>
    <ptgef:EffectOfTaxRatesInOtherCountries
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001967"
      unitRef="USD">-273000</ptgef:EffectOfTaxRatesInOtherCountries>
    <ptgef:EffectOfTaxRatesInOtherCountries
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001968"
      unitRef="USD">-24000</ptgef:EffectOfTaxRatesInOtherCountries>
    <ptgef:DerecognitionOfDeferredTaxAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001970"
      unitRef="USD">-156000</ptgef:DerecognitionOfDeferredTaxAssets>
    <ptgef:DerecognitionOfDeferredTaxAssets
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001971"
      unitRef="USD">23000</ptgef:DerecognitionOfDeferredTaxAssets>
    <ptgef:IncomeTaxEffectsRelatedToEquityCompensation
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001979"
      unitRef="USD">429000</ptgef:IncomeTaxEffectsRelatedToEquityCompensation>
    <ptgef:ForeignCurrencyEffectAndOther
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001983"
      unitRef="USD">-2000</ptgef:ForeignCurrencyEffectAndOther>
    <ptgef:IncomeTaxExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001986"
      unitRef="USD">-3000</ptgef:IncomeTaxExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001988"
      unitRef="USD">1400000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001990"
      unitRef="USD">600000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ptgef:UkLossCarryForwards
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001992"
      unitRef="USD">15900000</ptgef:UkLossCarryForwards>
    <ptgef:ScheduleOfDeferredTaxAssetsTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001994">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfDeferredTaxAssetsTableTextBlock_pn3n3_zcwaE4FrkEFa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B3_znCPruTYwnwd" style="display: none"&gt;Schedule
        of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260331_z3hbdug8JZJh" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250331_zwWuvRPMVKC9" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsAbstract_iB_zroFL7nzjGM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;The balance comprises temporary differences attributable to:&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzNDo_zYYvIBRwiBn5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax loss&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,265&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;3,935&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--StockbasedCompensation_i01_pn3n3_maNDTAzNDo_zg5NkV192sbd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;Share-based compensation&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;11&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;397&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ReservesAndAccruals_i01I_pn3n3_maNDTAzNDo_zpF098fkMhS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Reserves and accruals&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2005"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--NetDeferredTaxAssets_i01TI_pn3n3_mtNDTAzNDo_zFqHYt7xYwP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;4,276&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4,349&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetNotRecognized_i01NI_pn3n3_di_zXXTsip0DILl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax asset not recognized&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,276&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,349&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--NetDeferredTaxAsset_i01TI_pn3n3_zLCqto0u8Gba" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2014"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2015"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfDeferredTaxAssetsTableTextBlock>
    <ptgef:DeferredTaxAssetsNetOperatingLossCarryforward
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001999"
      unitRef="USD">4265000</ptgef:DeferredTaxAssetsNetOperatingLossCarryforward>
    <ptgef:DeferredTaxAssetsNetOperatingLossCarryforward
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact002000"
      unitRef="USD">3935000</ptgef:DeferredTaxAssetsNetOperatingLossCarryforward>
    <ptgef:StockbasedCompensation
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002002"
      unitRef="USD">11000</ptgef:StockbasedCompensation>
    <ptgef:StockbasedCompensation
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact002003"
      unitRef="USD">397000</ptgef:StockbasedCompensation>
    <ptgef:ReservesAndAccruals
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact002006"
      unitRef="USD">17000</ptgef:ReservesAndAccruals>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002008"
      unitRef="USD">4276000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact002009"
      unitRef="USD">4349000</ifrs-full:NetDeferredTaxAssets>
    <ptgef:DeferredTaxAssetNotRecognized
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002011"
      unitRef="USD">4276000</ptgef:DeferredTaxAssetNotRecognized>
    <ptgef:DeferredTaxAssetNotRecognized
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact002012"
      unitRef="USD">4349000</ptgef:DeferredTaxAssetNotRecognized>
    <ifrs-full:DeferredTaxAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002020"
      unitRef="USD">100000</ifrs-full:DeferredTaxAssets>
    <ptgef:CapitalStockAndReservesTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002022">&lt;p id="xdx_809_ecustom--CapitalStockAndReservesTextBlock_zMaTHYdGT5ob" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 17. &lt;span id="xdx_82A_z0M6mbPW7N6h"&gt;CAPITAL
STOCK AND RESERVES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;Authorized ordinary shares&lt;b&gt;:&lt;/b&gt; Unlimited number of Alpha Compute
ordinary shares without par value.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Private Placement Financings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On January 29, 2025, the Company completed the sale of &lt;span id="xdx_90A_ecustom--SaleOfStock_iI_c20250129_zoNQuKM7BNgh" title="Sale of stock"&gt;524,390&lt;/span&gt;
ordinary shares for aggregate proceeds of $&lt;span id="xdx_90D_ecustom--AggregateProceeds_iI_c20250129_zPzgMx1xEox4" title="aggregate proceeds"&gt;2,150,000&lt;/span&gt;,
at a per share price of $4.10, the closing price of a share on Nasdaq on the date preceding the date of the securities purchase agreement.
The shares were sold to two directors of the Company, Messrs. Gregory Bailey and James Mellon. The shares were sold in a private placement
transaction pursuant to Regulation S, and were issued as restricted stock. The proceeds are being used for general corporate purposes
and working capital.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On September 25, 2025, the Company completed the sale of&lt;span id="xdx_90A_ecustom--SaleOfStock_iI_c20250925_zQ64BTqkhxr" title="Sale of stock"&gt;
3,415,780&lt;/span&gt;
ordinary shares at a per share price of $&lt;span id="xdx_901_ecustom--SharesPrice_iI_c20250925_zhw2oogyDLXg" title="Share price"&gt;5.73&lt;/span&gt;,
and pre-funded warrants to purchase &lt;span id="xdx_90D_ecustom--WarrantsToPurchase_iI_c20250925_zvr30dZnfgEh" title="Warrants to purchase"&gt;3,258,466&lt;/span&gt;
ordinary shares at a purchase price of $&lt;span id="xdx_909_ecustom--PurchasePrice_iI_c20250925_zRxnoxvcSlE6" title="Purchase price"&gt;5.73&lt;/span&gt;
per ordinary share (less $0.001 per pre-funded warrant) for gross proceeds of approximately $&lt;span id="xdx_904_ecustom--GrossProceeds_pn3n3_dm_c20250401__20260331_zrNM5Tyj8Etl" title="Gross proceeds"&gt;34.5
&lt;/span&gt;million, consisting of cash of $&lt;span id="xdx_90B_eifrs-full--Cash_iI_pn3n3_dm_c20250925_zNpp85JcpAG7" title="Cash"&gt;3.3&lt;/span&gt;
million and digital assets and stablecoin of $&lt;span id="xdx_904_ecustom--DgitalAssets_iI_pn3n3_dm_c20250925_zGhJyOdnC5s7" title="Dgital assets"&gt;32.9&lt;/span&gt;
million. Each pre-funded warrant is exercisable for one ordinary share at an exercise price of $0.001 per pre-funded warrant, is immediately
exercisable and will expire once exercised in full. The shares and pre-funded warrants were sold in a private placement transaction in
reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated under the Securities Act, and the
proceeds are being used for the establishment of the Company&#x2019;s digital asset treasury. During the fiscal year ended March 31, 2026,
111,295 pre-funded warrants issued under the private placement were exercised and 2,513,240 were forfeited by DWF in connection with the
return of DWF&#x2019;s initial investment. The remaining 633,931 pre-funded warrants outstanding have no expiration date.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;span id="xdx_90B_ecustom--OrdinarySharesIssued_iI_c20250925_zMzEOzVAaOMj" title="Ordinary shares issued"&gt;160,000&lt;/span&gt;
ordinary shares were issued to the Company&#x2019;s third-party asset manager as consideration for continued services to be provided to
the Company pursuant to a Treasury Management Agreement. The shares have a three-year vesting term and are subject to forfeiture in the
event the agreement with the asset manager is terminated under certain circumstances. The shares were sold in a private placement transaction
in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated under the Securities Act, and
were issued as restricted stock.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On December 8, 2025 and December 30, 2025, one Side Letter put right issued
as part of the September 25, 2025 private placement financing and the DWF put right were exercised, respectively, and on March 24, 2026
and December 30, 2025, the contributed locked TON tokens receivable in the amount of 1,114,130, with a fair value of $2.5 million at contribution,
and $15.0 million USD1 receivable were returned to the investor and DWF, respectively. Additionally, the Company terminated its Treasury
Management Agreement with DWF in connection with the return of DWF&#x2019;s initial investment. Upon return of the investor and DWF&#x2019;s
shares to the Company, the Company recognized treasury stock in the amount of 17,452 and 105,000 shares, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Shares Issued Under the ATM Program&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;During the fiscal year ended March 31, 2026, the Company sold &lt;span id="xdx_90D_ecustom--NumberOfSharesSold_c20250401__20260331__ifrs-full--CounterpartiesAxis__custom--ATMMember_zdNaRIiNOalb" title="Number of shares sold"&gt;4,062,632&lt;/span&gt;
ordinary shares under the ATM program, generating net proceeds of approximately $&lt;span id="xdx_908_ecustom--NetProceeds_c20250401__20260331__ifrs-full--CounterpartiesAxis__custom--ATMMember_zDJgS01vnRkk" title="net proceeds"&gt;12.0&lt;/span&gt;
million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Shares Issued for Investment in Compedica&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On June 5, 2025, the Company acquired an equity interest in Compedica, Ltd.
("Compedica"), a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby the Company issued &lt;span id="xdx_909_ecustom--OrdinarySharesIssued_iI_c20250605_z3YHUlvLdZLa" title="Ordinary shares issued"&gt;625,000&lt;/span&gt;
ordinary shares valued at $5,000,000, at a per share price of $8.00, in exchange for a minority equity interest in Compedica.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On February 6, 2026, the Company and Compedica agreed to exchange their
ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being returned to the
Company&#x2019;s treasury and the investment being exited. As a result, the Company recognized less than $&lt;span id="xdx_902_ecustom--TreasuryStock_iI_pn3n3_dm_c20260206_zMSlAAoDUoai" title="Treasury stock"&gt;0.1&lt;/span&gt;
million in treasury stock at the time the shares were returned, the fair value of the investment as of February 6, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Registered Direct Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On January 13, 2026, the Company entered into a securities purchase agreement
with certain purchasers, pursuant to which the Company offered for sale to the Purchasers in a registered direct offering an aggregate
of &lt;span id="xdx_901_ecustom--AggregateOfferingOrdinaryShares_iI_c20260113_zVZTy70PWhb5" title="Aggregate offering ordinary shares"&gt;5,230,000&lt;/span&gt;
ordinary shares and, in lieu thereof, pre-funded warrants to purchase up to &lt;span id="xdx_902_ecustom--Proceedsfromexerciseofwarrant_iI_c20260113_zFPuJ3It08D2" title="ProceedsFromExerciseOfWarrants"&gt;9,770,000&lt;/span&gt;
ordinary shares. The net proceeds from the Offering were approximately $&lt;span id="xdx_902_eifrs-full--ProceedsFromExerciseOfWarrants_pn3n3_dm_c20260101__20260113_zFC7djCYkVFl" title="Net proceeds"&gt;12.7&lt;/span&gt;
million. During the fiscal year ended March 31, 2026,&lt;span id="xdx_90E_eifrs-full--NumberOfSharesIssued_iI_c20260113_znl1rWpAssDl" title="Pre-funded warrants issued"&gt;
9,120,000&lt;/span&gt;
pre-funded warrants issued under the registered direct offering were exercised. The remaining&lt;span id="xdx_909_eifrs-full--IncreaseDecreaseInNumberOfSharesOutstanding_c20260111__20260113_znS3Grajme2c" title="pre-funded warrants outstanding shares"&gt;
650,000&lt;/span&gt;
pre-funded warrants outstanding have no expiration date.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse Share Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The reverse stock split decreased the number of ordinary shares outstanding
as of September 30, 2023, from 17,808,225 to 890,412. All share and per share information included in the consolidated financial statements
and in the Notes to the consolidated financial statements have been retroactively adjusted to reflect the impact of the reverse stock
split unless otherwise noted. The number of ordinary shares authorized remained at an unlimited number of common shares without par value.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Any fractional shares resulting from the reverse stock
split were rounded up to the nearest whole post-split ordinary share. As a result of this round up provision, the Company issued an additional
&lt;span id="xdx_907_ecustom--AdditionalSharesIssued_iI_c20250930_zm6jUddGOn86" title="Additional shares issued"&gt;52,254&lt;/span&gt;
shares.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series A Warrants and Pre-Funded Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On September 29, 2023, we entered into a securities purchase agreement (the
&#x201c;2023 Purchase Agreement&#x201d;) with an institutional and accredited investor in connection with a registered direct offering (the
&#x201c;2023 Registered Direct Offering&#x201d;) and a concurrent private placement (the &#x201c;2023 Private Placement,&#x201d; and together
with the Registered Direct Offering, the &#x201c;2023 Offerings&#x201d;). The 2023 Offerings closed on October 3, 2023.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Pursuant to the 2023 Purchase Agreement, in the 2023 Registered Direct Offering,
the Company sold (i) &lt;span id="xdx_906_ecustom--NumberOfSharesSold_c20220401__20230930_zlx1w6YbxBBc" title="Number of shares sold"&gt;98,500&lt;/span&gt;
shares of the Company&#x2019;s ordinary shares at a purchase price of $38.00 per share and (ii) pre-funded warrants to purchase up to 59,395
ordinary shares, at a purchase price of $37.98 per pre-funded warrant. All pre-funded warrants, which were exercisable for one ordinary
share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;In the 2023 Private Placement, we issued to such institutional and accredited
investor unregistered Series A Warrants to purchase up to &lt;span id="xdx_906_ecustom--WarrantsPurchase_c20230401__20230930_zcahS3lcc5q5" title="Warrants purchase"&gt;157,895&lt;/span&gt;
ordinary shares. Each Series A Warrant was immediately exercisable for one private warrant share at an exercise price of $38.00 per share
but expired on April 3, 2025, 18 months from the date of issuance.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Series A Warrants and the pre-funded warrants are classified as a component
of equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the ordinary
shares with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares,
and permit the holders to receive a fixed number of ordinary shares upon exercise. In addition, the Series A Warrants and the pre-funded
warrants do not provide any guarantee of value or return.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On the October 3, 2023 issue date, the calculated fair value of the Series
A Warrants and the pre-funded warrants was $&lt;span id="xdx_90E_ecustom--WarrantsPerShare_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zLmUN36Qaprd" title="Fair value of warrants"&gt;2.968&lt;/span&gt;
million ($18.80 per such warrant). Because the fair value of the warrants accounted for as liabilities exceeded the net proceeds from
the 2023 Registered Direct Offering, the proceeds allocated to the ordinary shares, the pre-funded warrants and the Series A warrants
was zero. The Series A Warrants expired on April 3, 2025, 18 months from the date of issuance, and all pre-funded warrants were exercised
in full on May 9, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series A Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The inputs associated with calculating the fair value are reflected below.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zJmEF76Kps05" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details )"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BC_zyf6XnpCBDcc" style="display: none"&gt;Schedule of inputs associated with calculating
        the fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;October
        3, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw4EC71or03" title="Exercise price"&gt;38.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharePriceFairvalue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziV5CYcdG7K8" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_903_ecustom--OptionLifeShareOptions_dtY_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zXs0B3wo5NJ9" title="Expected life"&gt;1.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zL9lmSzNwlMb" title="Expected volatility"&gt;96.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHOFaNy6c8ya" title="Risk free interest rate"&gt;5.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQQ7PNDXngPa" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2085"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A1_zre7Mydms1lg" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Nature and Purpose of Reserves&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock Option Reserve&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The stock option reserve reflects the reserve of compensation
expense recognized over the vesting period based upon the grant date fair value of the Company&#x2019;s equity settled grants calculated
in accordance with IFRS 2, &#x201c;Share-based Payment&#x201d;. See Note 18, &#x201c;Stock Option Reserve,&#x201d; below for a further discussion.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:CapitalStockAndReservesTextBlock>
    <ptgef:SaleOfStock
      contextRef="AsOf2025-01-29"
      decimals="INF"
      id="Fact002024"
      unitRef="Shares">524390</ptgef:SaleOfStock>
    <ptgef:AggregateProceeds
      contextRef="AsOf2025-01-29"
      decimals="0"
      id="Fact002026"
      unitRef="USD">2150000</ptgef:AggregateProceeds>
    <ptgef:SaleOfStock
      contextRef="AsOf2025-09-25"
      decimals="INF"
      id="Fact002028"
      unitRef="Shares">3415780</ptgef:SaleOfStock>
    <ptgef:SharesPrice
      contextRef="AsOf2025-09-25"
      decimals="INF"
      id="Fact002030"
      unitRef="USDPShares">5.73</ptgef:SharesPrice>
    <ptgef:WarrantsToPurchase
      contextRef="AsOf2025-09-25"
      decimals="INF"
      id="Fact002032"
      unitRef="Shares">3258466</ptgef:WarrantsToPurchase>
    <ptgef:PurchasePrice
      contextRef="AsOf2025-09-25"
      decimals="INF"
      id="Fact002034"
      unitRef="USDPShares">5.73</ptgef:PurchasePrice>
    <ptgef:GrossProceeds
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002036"
      unitRef="USD">34500000</ptgef:GrossProceeds>
    <ifrs-full:Cash
      contextRef="AsOf2025-09-25"
      decimals="-3"
      id="Fact002038"
      unitRef="USD">3300000</ifrs-full:Cash>
    <ptgef:DgitalAssets
      contextRef="AsOf2025-09-25"
      decimals="-3"
      id="Fact002040"
      unitRef="USD">32900000</ptgef:DgitalAssets>
    <ptgef:OrdinarySharesIssued
      contextRef="AsOf2025-09-25"
      decimals="INF"
      id="Fact002042"
      unitRef="Shares">160000</ptgef:OrdinarySharesIssued>
    <ptgef:NumberOfSharesSold
      contextRef="From2025-04-012026-03-31_custom_ATMMember"
      decimals="INF"
      id="Fact002044"
      unitRef="Shares">4062632</ptgef:NumberOfSharesSold>
    <ptgef:NetProceeds
      contextRef="From2025-04-012026-03-31_custom_ATMMember"
      decimals="0"
      id="Fact002046"
      unitRef="USD">12.0</ptgef:NetProceeds>
    <ptgef:OrdinarySharesIssued
      contextRef="AsOf2025-06-05"
      decimals="INF"
      id="Fact002048"
      unitRef="Shares">625000</ptgef:OrdinarySharesIssued>
    <ptgef:TreasuryStock
      contextRef="AsOf2026-02-06"
      decimals="-3"
      id="Fact002053"
      unitRef="USD">100000</ptgef:TreasuryStock>
    <ptgef:AggregateOfferingOrdinaryShares
      contextRef="AsOf2026-01-13"
      decimals="INF"
      id="Fact002055"
      unitRef="Shares">5230000</ptgef:AggregateOfferingOrdinaryShares>
    <ptgef:Proceedsfromexerciseofwarrant
      contextRef="AsOf2026-01-13"
      decimals="INF"
      id="Fact002057"
      unitRef="Shares">9770000</ptgef:Proceedsfromexerciseofwarrant>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="From2026-01-012026-01-13"
      decimals="-3"
      id="Fact002059"
      unitRef="USD">12700000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-01-13"
      decimals="INF"
      id="Fact002061"
      unitRef="Shares">9120000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="From2026-01-112026-01-13"
      decimals="INF"
      id="Fact002063"
      unitRef="Shares">650000</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <ptgef:AdditionalSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002065"
      unitRef="Shares">52254</ptgef:AdditionalSharesIssued>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-04-012023-09-30"
      decimals="INF"
      id="Fact002067"
      unitRef="Shares">98500</ptgef:NumberOfSharesSold>
    <ptgef:WarrantsPurchase
      contextRef="From2023-04-012023-09-30"
      decimals="INF"
      id="Fact002069"
      unitRef="Shares">157895</ptgef:WarrantsPurchase>
    <ptgef:WarrantsPerShare
      contextRef="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember"
      decimals="INF"
      id="Fact002071"
      unitRef="USDPShares">2.968</ptgef:WarrantsPerShare>
    <ptgef:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002073">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zJmEF76Kps05" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details )"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BC_zyf6XnpCBDcc" style="display: none"&gt;Schedule of inputs associated with calculating
        the fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;October
        3, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ExercisePriceFairValue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw4EC71or03" title="Exercise price"&gt;38.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharePriceFairvalue_iI_pip0_c20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_ziV5CYcdG7K8" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life (years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_903_ecustom--OptionLifeShareOptions_dtY_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zXs0B3wo5NJ9" title="Expected life"&gt;1.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zL9lmSzNwlMb" title="Expected volatility"&gt;96.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHOFaNy6c8ya" title="Risk free interest rate"&gt;5.32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20241001__20241003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQQ7PNDXngPa" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2085"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2024-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002075"
      unitRef="USDPShares">38.00</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2024-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002077"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember"
      id="Fact002079">P1Y6M</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002081"
      unitRef="Pure">0.960</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-10-012024-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002083"
      unitRef="Pure">0.0532</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact002090">&lt;p id="xdx_80F_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_z0sTtvsAGwEl" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
18. &lt;span id="xdx_82B_zJ120GyPr3xe"&gt;STOCK OPTION RESERVE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The share option reserve reflects the reserve of compensation expense recognized
over the vesting period based upon the grant date fair value of the Company&#x2019;s equity settled grants calculated in accordance with
IFRS 2, &#x201c;&lt;i&gt;Share-based Payment&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted
Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The following table provides the activity for the Company&#x2019;s
stock option reserve for the fiscal years ended March 31, 2026 and 2025 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_pn3n3_zQlgUwnMFFc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zg3911QQfmG5" style="display: none"&gt;Schedule of stock option
        reserve&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Balance, beginning of year&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20250401__20260331_zTttwvXdqSWk" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;23,530&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20250331_zHIUt32fJSbd" style="width: 12%; font-size: 10pt; text-align: right"&gt;23,841&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Share-based compensation expense&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20250401__20260331_zD8TjPMADUpa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;1,745&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20240401__20250331_zRWWFpgQGmna" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;321&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Correction of prior period overstated share-based compensation
        expense&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20250401__20260331_zCMB8KtkMoDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Correction of prior period overstated share-based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2100"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20240401__20250331_zqXZzU3nC9h" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Correction of prior period overstated share-based compensation expense"&gt;(632&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Balance, end of year&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20250401__20260331_zQh7X8oL6xu5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"&gt;25,275&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20250331_ztoJWxIq1csi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance"&gt;23,530&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: center"&gt;(1)&lt;/td&gt;
    &lt;td style="width: 86%; font-size: 10pt; text-align: left"&gt;Amount is net of $0.6 million reversal of share-based compensation expense for unvested
        share options forfeited during the fiscal year ended.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;(2)&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Amount represents the correction as of March 31, 2025 for the overstated share-based compensation
        expenses in Fiscal 2022 and Fiscal 2024.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A6_zHajdFlhghO" style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. All share and per share information have been retroactively adjusted to reflect
the impact of the reverse stock split unless otherwise noted. See Note 1 &#x201c;Nature of Operations&#x201d; and Note 17, &#x201c;Capital
Stock and Reserves&#x201d; for further discussion on the reverse stock split.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The 2021 Equity Incentive Plan (the &#x201c;Equity Incentive
Plan&#x201d;), as amended on January 19, 2022, allows for the grant of equity awards up to 248,043 or 15% of shares currently issued and
outstanding, 3,616,999as of March 31, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On March 7, 2025, the Board authorized the grant of
a total of &lt;span id="xdx_90C_ecustom--AuthorizedGrantOptionPurchaseShares_iI_pip0_c20250307_zYUQYky0Uwoe" title=" Authorized grant option purchase shares"&gt;160,000&lt;/span&gt;
options to purchase ordinary shares at a per share exercise price of $4.45, with a term of 10 years. Vesting will accelerate on a change
of control of the Company. The options had a per share fair value of $4.04 and vest as to one-quarter immediately and the balance as to
one-third on each March 7, 2026, 2027 and 2028. The grants were made to certain directors, officers and employees. The options were issued
under the Company&#x2019;s 2021 Equity Incentive Plan.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;In Fiscal 2026, the Board of Directors authorized on March 11, 2026, the
grant of 1,930,396 share options to purchase ordinary shares at a per share rate ranging from $1.30 to $8.26. Once vested, the share options
are exercisable for a period ending 10 years after the date of grant. Vesting will accelerate on a change of control of the Company. The
options had a per share fair value of $0.40 and vest as to one-quarter immediately and the remaining balance as to one-third on each March
11, 2027, 2028, and 2029. The grants were made to certain directors, officers, and advisors. The options were issued as discretionary
options outside the 2021 Equity Incentive Plan, and not part of any regularly constituted compensation plan. These options were awarded
pursuant to contractor agreements and advisory agreements contingent on the Company raising at least $50 million in equity financing via
either private or public share offerings, which was achieved on January 14, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On March 11, 2026 the Board of Directors also authorized the grant of &lt;span id="xdx_90B_ecustom--SharesIssuedGrantedRsu_iI_c20260311_z2gG3aMQcugk" title="Shares issued granted RSU"&gt;1,235,924&lt;/span&gt;
Restricted Stock Units which vested immediately upon the grant date. The grants were made to certain directors, officers, and employees.
The Restricted Stock Units were issued as discretionary awards outside the 2021 Equity Incentive Plan, and not part of any regularly constituted
compensation plan. These options were awarded pursuant to contractor agreements contingent on the Company raising at least $50 million
in equity financing via either private or public share offerings, which was achieved on January 14, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On July 27, 2025 the board authorized the grant of &lt;span id="xdx_907_ecustom--AuthorizedGrantOptionPurchaseShares_iI_c20250727_zRYJavRTRrzg" title=" Authorized grant option purchase shares"&gt;97,739&lt;/span&gt;
share options under the terms of the Company&#x2019;s 2021 Equity Incentive Plan to board members and employees. These options were fully
vested at the time of grant.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;As of March 31, 2026, no shares were reserved for awards
previously granted or available for future awards under the Amended and Restated 2021 Equity Incentive Plan.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 21pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The changes in the number of stock options issued and outstanding
for the fiscal years ended March 31, 2026 and 2025 were as follows:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zgeG60Y8aoWc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B5_zRjZbyHo3iW8" style="display: none"&gt;&#160;Schedule of share options issued
        and outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20250401__20260331_zj7VJGh2zJ32" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance"&gt;225,117&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20250331_z65qTL5i5Q8k" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance"&gt;90,281&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Granted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zUxYnHSiwRqh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;2,028,135&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_zg2B21mMxib6" style="font-size: 10pt; text-align: right" title="Granted"&gt;160,000&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Expired or forfeited&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zidYIcIDQuZ7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;(6,745&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_z585SocDALW5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;(25,164&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zyCIvbmNY4sh" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlJ9nP6aePD6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance"&gt;225,117&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Exercisable, end of period&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zeqUc30cW8W5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zWaEvFNwkmLb" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;102,855&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Available for future awards&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20250401__20260331_z3rVNZ5aGWHi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Available for future awards"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2139"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20240401__20250331_zv0t3DdU9vF" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available for future awards"&gt;17,516&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AA_zm4MJb9ShjZ8" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The table above does not include fully vested restricted
stock units (&#x201c;RSUs&#x201d;) granted to certain executives in January 2021 and January 2022. In January 2024, the Company issued&lt;span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zb8BcihnZoZ6" title="Shares issued"&gt;
308&lt;/span&gt;
shares for the exercise of &lt;span id="xdx_908_ecustom--NumberOfSharesExercise_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zN0yyMBlMf8e" title="Shares issued"&gt;470&lt;/span&gt;
RSUs net of 162 shares withheld to pay for an employee&#x2019;s payroll taxes. In September 2024, the Company issued &lt;span id="xdx_905_eifrs-full--NumberOfSharesIssued_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_ziO9FWvsv2Le" title="Shares issued"&gt;882&lt;/span&gt;
shares for the exercise of &lt;span id="xdx_904_ecustom--NumberOfSharesExercise_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zHwswvtgSAoe" title="Shares issued"&gt;1,152&lt;/span&gt;
RSUs net of &lt;span id="xdx_904_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20250930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zh1BHbPZ8Iaj" title="Shares repurchased into treasury employee payroll taxes"&gt;270&lt;/span&gt;
shares withheld to pay for an employee&#x2019;s payroll taxes. In December 2024, the Company issued &lt;span id="xdx_909_eifrs-full--NumberOfSharesIssued_iI_pip0_c20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_ztKMN6JLex9a" title="Shares issued"&gt;8,173&lt;/span&gt;
shares for the exercise of &lt;span id="xdx_90C_ecustom--NumberOfSharesExercise_iI_pip0_c20260331__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z86xq60VrTzl" title="Shares issued"&gt;11,905&lt;/span&gt;
RSUs net of 3,732 shares withheld to pay for an employee&#x2019;s payroll taxes. As of March 31, 2026, there were 1,241,334 RSUs granted
and outstanding, of which 4,550, 860, and 1,235,924 RSUs expire on January 13, 2031, January 19, 2032, and March 11, 2036, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The weighted-average estimated fair value of share
options granted during the years ended March 31, 2026 and 2025 was $0.40 and $4.04 per share, respectively, using the Black-Scholes option
pricing model with the following weighted-average assumptions:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfWeightedAverageAssumptionsTableTextBlock_zTv9z2f1KcE" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BE_zXqVQ5uzHeb5" style="display: none"&gt;Schedule of weighted-average estimated
        fair value of share options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt"&gt;Grant Price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zBwUR57N7nIi" title="Grant price"&gt;1.30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zqgA2HDH1mYj" title="Grant price"&gt;4.45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected life (in years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zIzdxsHkCVy4" title="Expected life"&gt;10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_ecustom--OptionLifeShareOptionsGranted_dtY_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zRn0b9MkpPXf" title="Expected life"&gt;5.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-free interest rates&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zbm327X5L0R4" title="Risk free interest rate"&gt;3.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zhUY2lomD35l" title="Risk free interest rate"&gt;4.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zpkwI2rP4Ecj" title="Expected volatility"&gt;115.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zGasLKz8m0E5" title="Expected volatility"&gt;135.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvUjY2opY4nb"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2174"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvfRB8UiCMCf"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2175"&gt;&#x2014;&lt;/span&gt;&#160;&lt;/span&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A0_z4sCcna5E4V8" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The following is the weighted average exercise price and the remaining
contractual life for outstanding options as of March 31, 2026 and 2025:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_z3jO5UVi58zc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt; &lt;span id="xdx_8BA_zQerUm64wrF7" style="display: none"&gt;Schedule of weighted average exercise price and the remaining
        contractual life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20250401__20260331_zaU7tofFXeW" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;6.84&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20250331_zrFiK1dgikvb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;62.51&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life (in years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20250401__20260331_zLKzMSH9P2O4" title="Weighted average remaining contractual life (in years)"&gt;9.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20250331_zFFZeaPhjGB3" title="Weighted average remaining contractual life (in years)"&gt;9.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AE_znQ9iA2kaHl2" style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Share options granted and outstanding at the
end of the year have the following expiration dates and exercise prices:&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z7wkIYWaRz39" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8B1_zqijrz5Mknw7" style="display: none"&gt;Schedule of Share options granted and
        outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_488_ecustom--ExpirationDate_zKINvOlmRmS2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_48C_ecustom--ExercisePrice_pip0_zC1MEnqFF5Z7" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_482_ecustom--ShareOptions_zPB6RVYkEeRl" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Share Options as of&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Grant Date&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Expiration Date&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise Price $&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January132021Member_z23nODcb10eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; font-size: 10pt; text-align: left"&gt;January 13, 2021&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; font-size: 10pt; text-align: center"&gt;January
        13, 2031&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; font-size: 10pt; text-align: right"&gt;21,400&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January192022Member_z0QzW6haKfGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;January 19, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;January
        19, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12,475&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--February152022Member_zQ4F2fGDGb19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;February 15, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;February
        15, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;171.80&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2196"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--June82022Member_zu6xZSM5Ptlf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;June 8, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;June
        8, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;220.00&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2199"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272022Member_zVcBTLbtjKcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;July 27, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;July
        27, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;201.20&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March302023Member_ztOORJsba2E9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;March 30, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;March
        30, 2033&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;24,497&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March72025Member_zsxlz6Wud1k9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;March 7, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;March
        7, 2035&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4.45&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;160,000&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272026Member_zZNh6A3YOVMb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;July 27, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;July
        27, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5.73&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;97,739&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March112026Member_zc8GVRMsAJa6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;March 11, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;March
        11, 2036&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,930,396&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20240401__20250331_zEdYJu7BN6y6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;/p&gt;



&lt;p id="xdx_8A8_zisDzzJYdgMb" style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The vested options can be exercised at any
time in accordance with the applicable option agreement. The exercise price was greater than the market price for all options outstanding
as of March 31, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company recorded approximately $&lt;span id="xdx_904_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20250401__20260331_zMaeFDpBLSoj" title="Share based compensation expense"&gt;2.3&lt;/span&gt;
million of share-based compensation expense in the year ended March 31, 2026. During Fiscal 2025, the Company recorded approximately $&lt;span id="xdx_907_ecustom--SharebasedCompensationExpense_pn5n6_c20250401__20260331__ifrs-full--MeasurementAxis__custom--VestedStockOptionMember_zTYsBG74UNJe" title="Share based compensation expense"&gt;0.3&lt;/span&gt;
million of share-based compensation, which reflects an additional $&lt;span id="xdx_90C_ecustom--ReversalOfSharebasedCompensation_pn3n3_dm_c20250401__20260331_zye4ucMdcJF3" title="Reversal of share-based compensation"&gt;0.3&lt;/span&gt;
million in share-based compensation expense for the accelerated vesting of certain employee share options offset by $&lt;span id="xdx_90D_ecustom--ShareBasedCompensationExpenseUnvestedShareOptions_pn3n3_dm_c20250401__20260331_zqJPuDgWjKbh" title="Share based compensation expense unvested share options"&gt;0.6&lt;/span&gt;
million reversal of share-based compensation for unvested share options forfeited during the year. The Company recorded approximately
$&lt;span id="xdx_90E_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20230401__20240331_zQG8kckinny9" title="Share based compensation expense"&gt;2.6
&lt;/span&gt;million of share-based compensation expense in the year ended March 31, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002092">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_pn3n3_zQlgUwnMFFc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zg3911QQfmG5" style="display: none"&gt;Schedule of stock option
        reserve&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Balance, beginning of year&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20250401__20260331_zTttwvXdqSWk" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;23,530&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20250331_zHIUt32fJSbd" style="width: 12%; font-size: 10pt; text-align: right"&gt;23,841&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Share-based compensation expense&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20250401__20260331_zD8TjPMADUpa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;1,745&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20240401__20250331_zRWWFpgQGmna" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;321&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Correction of prior period overstated share-based compensation
        expense&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20250401__20260331_zCMB8KtkMoDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Correction of prior period overstated share-based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2100"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense_pn3n3_c20240401__20250331_zqXZzU3nC9h" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Correction of prior period overstated share-based compensation expense"&gt;(632&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Balance, end of year&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20250401__20260331_zQh7X8oL6xu5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"&gt;25,275&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20250331_ztoJWxIq1csi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance"&gt;23,530&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: center"&gt;(1)&lt;/td&gt;
    &lt;td style="width: 86%; font-size: 10pt; text-align: left"&gt;Amount is net of $0.6 million reversal of share-based compensation expense for unvested
        share options forfeited during the fiscal year ended.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;(2)&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Amount represents the correction as of March 31, 2025 for the overstated share-based compensation
        expenses in Fiscal 2022 and Fiscal 2024.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock>
    <ptgef:StockOptionReserve
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact002093"
      unitRef="USD">23530000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact002094"
      unitRef="USD">23841000</ptgef:StockOptionReserve>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002096"
      unitRef="USD">1745000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002098"
      unitRef="USD">321000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002102"
      unitRef="USD">-632000</ptgef:CorrectionOfPriorPeriodOverstatedSharebasedCompensationsExpense>
    <ptgef:StockOptionReserve
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002104"
      unitRef="USD">25275000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact002106"
      unitRef="USD">23530000</ptgef:StockOptionReserve>
    <ptgef:AuthorizedGrantOptionPurchaseShares
      contextRef="AsOf2025-03-07"
      decimals="INF"
      id="Fact002108"
      unitRef="Shares">160000</ptgef:AuthorizedGrantOptionPurchaseShares>
    <ptgef:SharesIssuedGrantedRsu
      contextRef="AsOf2026-03-11"
      decimals="INF"
      id="Fact002110"
      unitRef="Shares">1235924</ptgef:SharesIssuedGrantedRsu>
    <ptgef:AuthorizedGrantOptionPurchaseShares
      contextRef="AsOf2025-07-27"
      decimals="INF"
      id="Fact002112"
      unitRef="Shares">97739</ptgef:AuthorizedGrantOptionPurchaseShares>
    <ptgef:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002117">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zgeG60Y8aoWc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B5_zRjZbyHo3iW8" style="display: none"&gt;&#160;Schedule of share options issued
        and outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20250401__20260331_zj7VJGh2zJ32" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance"&gt;225,117&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20250331_z65qTL5i5Q8k" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance"&gt;90,281&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Granted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zUxYnHSiwRqh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;2,028,135&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_zg2B21mMxib6" style="font-size: 10pt; text-align: right" title="Granted"&gt;160,000&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Expired or forfeited&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20250401__20260331_zidYIcIDQuZ7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;(6,745&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20250331_z585SocDALW5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;(25,164&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zyCIvbmNY4sh" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlJ9nP6aePD6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance"&gt;225,117&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Exercisable, end of period&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20250401__20260331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zeqUc30cW8W5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20250331__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zWaEvFNwkmLb" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;102,855&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Available for future awards&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20250401__20260331_z3rVNZ5aGWHi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Available for future awards"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2139"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement_pip0_c20240401__20250331_zv0t3DdU9vF" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available for future awards"&gt;17,516&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact002119"
      unitRef="Shares">225117</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact002121"
      unitRef="Shares">90281</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact002123"
      unitRef="Shares">2028135</ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact002125"
      unitRef="Shares">160000</ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact002127"
      unitRef="Shares">-6745</ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact002129"
      unitRef="Shares">-25164</ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2026-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact002131"
      unitRef="Shares">2246507</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2025-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact002133"
      unitRef="Shares">225117</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="From2025-04-012026-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact002135"
      unitRef="Shares">2246507</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="From2024-04-012025-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact002137"
      unitRef="Shares">102855</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact002141"
      unitRef="Shares">17516</ptgef:NumberOfShareOptionsAvailableForFutureAwardsSharebasedPaymentsArrangement>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact002143"
      unitRef="Shares">308</ifrs-full:NumberOfSharesIssued>
    <ptgef:NumberOfSharesExercise
      contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact002145"
      unitRef="Shares">470</ptgef:NumberOfSharesExercise>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact002147"
      unitRef="Shares">882</ifrs-full:NumberOfSharesIssued>
    <ptgef:NumberOfSharesExercise
      contextRef="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact002149"
      unitRef="Shares">1152</ptgef:NumberOfSharesExercise>
    <ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes
      contextRef="AsOf2025-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact002151"
      unitRef="Shares">270</ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact002153"
      unitRef="Shares">8173</ifrs-full:NumberOfSharesIssued>
    <ptgef:NumberOfSharesExercise
      contextRef="AsOf2026-03-31_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact002155"
      unitRef="Shares">11905</ptgef:NumberOfSharesExercise>
    <ptgef:ScheduleOfWeightedAverageAssumptionsTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002157">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfWeightedAverageAssumptionsTableTextBlock_zTv9z2f1KcE" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BE_zXqVQ5uzHeb5" style="display: none"&gt;Schedule of weighted-average estimated
        fair value of share options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt"&gt;Grant Price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zBwUR57N7nIi" title="Grant price"&gt;1.30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--DescriptionOfGrantPriceShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zqgA2HDH1mYj" title="Grant price"&gt;4.45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected life (in years)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zIzdxsHkCVy4" title="Expected life"&gt;10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_ecustom--OptionLifeShareOptionsGranted_dtY_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zRn0b9MkpPXf" title="Expected life"&gt;5.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-free interest rates&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zbm327X5L0R4" title="Risk free interest rate"&gt;3.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zhUY2lomD35l" title="Risk free interest rate"&gt;4.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Volatility&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zpkwI2rP4Ecj" title="Expected volatility"&gt;115.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zGasLKz8m0E5" title="Expected volatility"&gt;135.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20250401__20260331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvUjY2opY4nb"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2174"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20250331__ifrs-full--MeasurementAxis__custom--StockOptionGrantedMember_zvfRB8UiCMCf"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2175"&gt;&#x2014;&lt;/span&gt;&#160;&lt;/span&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfWeightedAverageAssumptionsTableTextBlock>
    <ptgef:DescriptionOfGrantPriceShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember"
      decimals="INF"
      id="Fact002159"
      unitRef="USDPShares">0.0130</ptgef:DescriptionOfGrantPriceShareOptionsGranted>
    <ptgef:DescriptionOfGrantPriceShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember"
      decimals="INF"
      id="Fact002161"
      unitRef="USDPShares">0.0445</ptgef:DescriptionOfGrantPriceShareOptionsGranted>
    <ptgef:OptionLifeShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember"
      id="Fact002163">P10Y</ptgef:OptionLifeShareOptionsGranted>
    <ptgef:OptionLifeShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember"
      id="Fact002165">P5Y9M</ptgef:OptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember"
      decimals="INF"
      id="Fact002167"
      unitRef="Pure">0.0368</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember"
      decimals="INF"
      id="Fact002169"
      unitRef="Pure">0.0414</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_StockOptionGrantedMember"
      decimals="INF"
      id="Fact002171"
      unitRef="Pure">1.150</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_StockOptionGrantedMember"
      decimals="INF"
      id="Fact002173"
      unitRef="Pure">1.358</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact002177">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_z3jO5UVi58zc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt; &lt;span id="xdx_8BA_zQerUm64wrF7" style="display: none"&gt;Schedule of weighted average exercise price and the remaining
        contractual life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20250401__20260331_zaU7tofFXeW" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;6.84&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20250331_zrFiK1dgikvb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;62.51&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life (in years)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20250401__20260331_zLKzMSH9P2O4" title="Weighted average remaining contractual life (in years)"&gt;9.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20250331_zFFZeaPhjGB3" title="Weighted average remaining contractual life (in years)"&gt;9.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact002179"
      unitRef="USDPShares">6.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact002181"
      unitRef="USDPShares">62.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2025-04-01to2026-03-31" id="Fact002183">P9Y10M24D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2024-04-012025-03-31" id="Fact002185">P9Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ptgef:ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002187">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z7wkIYWaRz39" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8B1_zqijrz5Mknw7" style="display: none"&gt;Schedule of Share options granted and
        outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_488_ecustom--ExpirationDate_zKINvOlmRmS2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_48C_ecustom--ExercisePrice_pip0_zC1MEnqFF5Z7" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_482_ecustom--ShareOptions_zPB6RVYkEeRl" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Share Options as of&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Grant Date&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Expiration Date&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise Price $&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January132021Member_z23nODcb10eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; font-size: 10pt; text-align: left"&gt;January 13, 2021&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; font-size: 10pt; text-align: center"&gt;January
        13, 2031&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; font-size: 10pt; text-align: right"&gt;21,400&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--January192022Member_z0QzW6haKfGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;January 19, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;January
        19, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12,475&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--February152022Member_zQ4F2fGDGb19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;February 15, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;February
        15, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;171.80&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2196"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--June82022Member_zu6xZSM5Ptlf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;June 8, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;June
        8, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;220.00&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2199"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272022Member_zVcBTLbtjKcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;July 27, 2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;July
        27, 2032&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;201.20&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March302023Member_ztOORJsba2E9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;March 30, 2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;March
        30, 2033&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;24,497&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March72025Member_zsxlz6Wud1k9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;March 7, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;March
        7, 2035&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4.45&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;160,000&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--July272026Member_zZNh6A3YOVMb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;July 27, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;July
        27, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5.73&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;97,739&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250401__20260331__ifrs-full--InterestRateBenchmarksAxis__custom--March112026Member_zc8GVRMsAJa6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;March 11, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;March
        11, 2036&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,930,396&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20240401__20250331_zEdYJu7BN6y6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;/p&gt;



</ptgef:ScheduleOfShareBasedCompensationStocksOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_January132021Member"
      id="Fact002188">January
        13, 2031</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_January132021Member"
      decimals="INF"
      id="Fact002189"
      unitRef="USDPShares">355.00</ptgef:ExercisePrice>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_January132021Member"
      decimals="-3"
      id="Fact002190"
      unitRef="Shares">21400000</ptgef:ShareOptions>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_January192022Member"
      id="Fact002191">January
        19, 2032</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_January192022Member"
      decimals="INF"
      id="Fact002192"
      unitRef="USDPShares">204.40</ptgef:ExercisePrice>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_January192022Member"
      decimals="-3"
      id="Fact002193"
      unitRef="Shares">12475000</ptgef:ShareOptions>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_February152022Member"
      id="Fact002194">February
        15, 2032</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_February152022Member"
      decimals="INF"
      id="Fact002195"
      unitRef="USDPShares">171.80</ptgef:ExercisePrice>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_June82022Member"
      id="Fact002197">June
        8, 2032</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_June82022Member"
      decimals="INF"
      id="Fact002198"
      unitRef="USDPShares">220.00</ptgef:ExercisePrice>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_July272022Member"
      id="Fact002200">July
        27, 2032</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_July272022Member"
      decimals="INF"
      id="Fact002201"
      unitRef="USDPShares">201.20</ptgef:ExercisePrice>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_March302023Member"
      id="Fact002203">March
        30, 2033</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_March302023Member"
      decimals="INF"
      id="Fact002204"
      unitRef="USDPShares">58.40</ptgef:ExercisePrice>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_March302023Member"
      decimals="-3"
      id="Fact002205"
      unitRef="Shares">24497000</ptgef:ShareOptions>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_March72025Member"
      id="Fact002206">March
        7, 2035</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_March72025Member"
      decimals="INF"
      id="Fact002207"
      unitRef="USDPShares">4.45</ptgef:ExercisePrice>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_March72025Member"
      decimals="-3"
      id="Fact002208"
      unitRef="Shares">160000000</ptgef:ShareOptions>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_July272026Member"
      id="Fact002209">July
        27, 2025</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_July272026Member"
      decimals="INF"
      id="Fact002210"
      unitRef="USDPShares">5.73</ptgef:ExercisePrice>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_July272026Member"
      decimals="-3"
      id="Fact002211"
      unitRef="Shares">97739000</ptgef:ShareOptions>
    <ptgef:ExpirationDate
      contextRef="From2025-04-012026-03-31_custom_March112026Member"
      id="Fact002212">March
        11, 2036</ptgef:ExpirationDate>
    <ptgef:ExercisePrice
      contextRef="From2025-04-012026-03-31_custom_March112026Member"
      decimals="INF"
      id="Fact002213"
      unitRef="USDPShares">1.30</ptgef:ExercisePrice>
    <ptgef:ShareOptions
      contextRef="From2025-04-012026-03-31_custom_March112026Member"
      decimals="-3"
      id="Fact002214"
      unitRef="Shares">1930396000</ptgef:ShareOptions>
    <ptgef:ShareOptions
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002217"
      unitRef="Shares">2246507000</ptgef:ShareOptions>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002222"
      unitRef="USD">2300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ptgef:SharebasedCompensationExpense
      contextRef="From2025-04-012026-03-31_custom_VestedStockOptionMember"
      decimals="-5"
      id="Fact002224"
      unitRef="USD">300000</ptgef:SharebasedCompensationExpense>
    <ptgef:ReversalOfSharebasedCompensation
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002226"
      unitRef="USD">300000</ptgef:ReversalOfSharebasedCompensation>
    <ptgef:ShareBasedCompensationExpenseUnvestedShareOptions
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002228"
      unitRef="USD">600000</ptgef:ShareBasedCompensationExpenseUnvestedShareOptions>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact002230"
      unitRef="USD">2600000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:EarningsPerShareExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact002232">&lt;p id="xdx_80B_eifrs-full--EarningsPerShareExplanatory_zpRwY5iYljT4" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 19. &lt;span id="xdx_820_zDbbmKWLPfc5"&gt;LOSS
PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is calculated
by dividing the net loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Diluted EPS is calculated by dividing the net loss attributable to ordinary
equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted average
number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares. Shares
issuable under pre-funded warrants are considered outstanding for this purpose.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The calculation of Basic and Diluted EPS reflects the
pre-funded warrants as outstanding shares.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The following table reflects the loss and share data used in the
basic and diluted EPS calculations (in thousands, except per share amounts):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zsS4CoeES4S4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span id="xdx_8BA_zvvguM3k50j8" style="display: none"&gt;Schedule
        of loss and share data used in the basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;Numerator&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to owners of the
        Company&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20250401__20260331_zcRKw8gluL3i" title="Weighted average shares outstanding, Diluted"&gt;(38,627&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20240401__20250331_z2CcesYCo3yk" title="Weighted average shares outstanding, Diluted"&gt;(6,767&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20230401__20240331_zt94WqBLzg82" title="Weighted average shares outstanding, Diluted"&gt;(75,339&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Weighted average number of shares &#x2013; Basic and Diluted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20250401__20260331_zgFzVd15Ikal" title="Weighted average shares outstanding, Diluted"&gt;9,248&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240401__20250331_zRBOm79ICEl8" title="Weighted average shares outstanding, Diluted"&gt;1,183&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20240331_z0WLRcgGgh2k" title="Weighted average shares outstanding, Diluted"&gt;968&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per share&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_ecustom--LossPerShareBasic_pip0_c20250401__20260331_zmbXl2cSO4al" title="Loss per share, Basic"&gt;&lt;span id="xdx_90E_ecustom--LossPerShareDiluted_pip0_c20250401__20260331_zZwh5dIZyVJ2" title="Loss per share, Diluted"&gt;(4.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--LossPerShareBasic_pip0_c20240401__20250331_zyMCfFL2LpE1" title="Loss per share, Basic"&gt;&lt;span id="xdx_907_ecustom--LossPerShareDiluted_pip0_c20240401__20250331_zkOoovScaKYj" title="Loss per share, Diluted"&gt;(5.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--LossPerShareBasic_pip0_c20230401__20240331_zShoRiQyeKue" title="Loss per share, Basic"&gt;&lt;span id="xdx_90C_ecustom--LossPerShareDiluted_pip0_c20230401__20240331_zRBuKRaCJxSg" title="Loss per share, Diluted"&gt;(77.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A1_zE1HceF0FEjf" style="margin: 0pt 0; font-size: 10pt; text-align: justify; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The inclusion of the Company&#x2019;s share purchase
warrants (other than pre-funded warrants, as described above), stock options and RSUs in the computation of diluted loss per share would
have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between
basic loss per share and diluted loss per share for the fiscal years ended March 31, 2026, 2025, and 2024. The following table reflects
the Company&#x2019;s outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded
from the calculation.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_zJv9JThhJnb3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B2_z71f9aNcXd96" style="display: none"&gt;Schedule of anti-dilutive
        effect on loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zXFaxJRIrlg5" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,531,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_ztitv7YcRfn3" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zmL6DkL2CZV" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Share options&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zPkX8p87qSch" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zHgwbhDxhbOj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;225,117&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_za9b0O0g2D32" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;90,281&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock units&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_z2Qo9CmrTeW6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,241,334&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zxskHsRj6qbd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;5,410&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zp4ohqFmVDm8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;18,467&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AD_zeDx4wONh7Yj" style="margin: 0pt 0; font-size: 10pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ifrs-full:EarningsPerShareExplanatory>
    <ptgef:ScheduleOfEarningsPerShareTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002234">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zsS4CoeES4S4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span id="xdx_8BA_zvvguM3k50j8" style="display: none"&gt;Schedule
        of loss and share data used in the basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;Numerator&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to owners of the
        Company&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20250401__20260331_zcRKw8gluL3i" title="Weighted average shares outstanding, Diluted"&gt;(38,627&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20240401__20250331_z2CcesYCo3yk" title="Weighted average shares outstanding, Diluted"&gt;(6,767&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_ecustom--WeightedAverageSharesOutstandingDiluted_pn3n3_c20230401__20240331_zt94WqBLzg82" title="Weighted average shares outstanding, Diluted"&gt;(75,339&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Weighted average number of shares &#x2013; Basic and Diluted&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20250401__20260331_zgFzVd15Ikal" title="Weighted average shares outstanding, Diluted"&gt;9,248&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240401__20250331_zRBOm79ICEl8" title="Weighted average shares outstanding, Diluted"&gt;1,183&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20240331_z0WLRcgGgh2k" title="Weighted average shares outstanding, Diluted"&gt;968&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per share&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_ecustom--LossPerShareBasic_pip0_c20250401__20260331_zmbXl2cSO4al" title="Loss per share, Basic"&gt;&lt;span id="xdx_90E_ecustom--LossPerShareDiluted_pip0_c20250401__20260331_zZwh5dIZyVJ2" title="Loss per share, Diluted"&gt;(4.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--LossPerShareBasic_pip0_c20240401__20250331_zyMCfFL2LpE1" title="Loss per share, Basic"&gt;&lt;span id="xdx_907_ecustom--LossPerShareDiluted_pip0_c20240401__20250331_zkOoovScaKYj" title="Loss per share, Diluted"&gt;(5.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--LossPerShareBasic_pip0_c20230401__20240331_zShoRiQyeKue" title="Loss per share, Basic"&gt;&lt;span id="xdx_90C_ecustom--LossPerShareDiluted_pip0_c20230401__20240331_zRBuKRaCJxSg" title="Loss per share, Diluted"&gt;(77.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfEarningsPerShareTableTextBlock>
    <ptgef:WeightedAverageSharesOutstandingDiluted
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002236"
      unitRef="USD">-38627000</ptgef:WeightedAverageSharesOutstandingDiluted>
    <ptgef:WeightedAverageSharesOutstandingDiluted
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002238"
      unitRef="USD">-6767000</ptgef:WeightedAverageSharesOutstandingDiluted>
    <ptgef:WeightedAverageSharesOutstandingDiluted
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact002240"
      unitRef="USD">-75339000</ptgef:WeightedAverageSharesOutstandingDiluted>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002242"
      unitRef="Shares">9248000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002244"
      unitRef="Shares">1183000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact002246"
      unitRef="Shares">968000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:LossPerShareBasic
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact002248"
      unitRef="USDPShares">-4.18</ptgef:LossPerShareBasic>
    <ptgef:LossPerShareDiluted
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact002250"
      unitRef="USDPShares">-4.18</ptgef:LossPerShareDiluted>
    <ptgef:LossPerShareBasic
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact002252"
      unitRef="USDPShares">-5.72</ptgef:LossPerShareBasic>
    <ptgef:LossPerShareDiluted
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact002254"
      unitRef="USDPShares">-5.72</ptgef:LossPerShareDiluted>
    <ptgef:LossPerShareBasic
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact002256"
      unitRef="USDPShares">-77.83</ptgef:LossPerShareBasic>
    <ptgef:LossPerShareDiluted
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact002258"
      unitRef="USDPShares">-77.83</ptgef:LossPerShareDiluted>
    <ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002260">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_zJv9JThhJnb3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B2_z71f9aNcXd96" style="display: none"&gt;Schedule of anti-dilutive
        effect on loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zXFaxJRIrlg5" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,531,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_ztitv7YcRfn3" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zmL6DkL2CZV" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Share options&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zPkX8p87qSch" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;2,246,507&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zHgwbhDxhbOj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;225,117&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_za9b0O0g2D32" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;90,281&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock units&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_z2Qo9CmrTeW6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;1,241,334&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zxskHsRj6qbd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;5,410&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zp4ohqFmVDm8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;18,467&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2026-03-31_ifrs-full_WarrantsMember"
      decimals="INF"
      id="Fact002262"
      unitRef="Shares">1531581</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2025-03-31_ifrs-full_WarrantsMember"
      decimals="INF"
      id="Fact002264"
      unitRef="Shares">481581</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2024-03-31_ifrs-full_WarrantsMember"
      decimals="INF"
      id="Fact002266"
      unitRef="Shares">481581</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2026-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002268"
      unitRef="Shares">2246507</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2025-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002270"
      unitRef="Shares">225117</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2024-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002272"
      unitRef="Shares">90281</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2026-03-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact002274"
      unitRef="Shares">1241334</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2025-03-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact002276"
      unitRef="Shares">5410</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2024-03-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact002278"
      unitRef="Shares">18467</ptgef:AntidilutiveEffectOnLossPerShare>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact002280">&lt;p id="xdx_80B_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zZ9WIfMXZg8c" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
20. &lt;span id="xdx_827_zLVV0F4PNx7j"&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;iOx &#x2013; Parexel Master Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Effective March 15, 2022, iOx, a wholly-owned subsidiary
of the Company, entered into a Master Services Agreement (the &#x201c;MSA&#x201d;) with Parexel under which Parexel agreed to act as a clinical
service provider (&#x201c;CRO&#x201d;) pursuant to a work order (&#x201c;Work Order&#x201d;) effective June 1, 2022. Under such Work Order,
Parexel planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer. The MSA provided
for a five-year term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided
for service fees and pass-through expenses and clinical sites totaling $&lt;span id="xdx_903_ecustom--ServiceFees_iI_pn3n3_dm_c20220315__ifrs-full--CounterpartiesAxis__custom--CROMember_zUwMMp0oBXU6" title="service fees"&gt;11.5&lt;/span&gt;
million. During the year ended March 31, 2023 (&#x201c;Fiscal 2023&#x201d;), the Company executed two change orders resulting in a $&lt;span id="xdx_90B_ecustom--BudgetCosts_pn3n3_dm_c20220401__20230331_zj1yncGY4Ava" title="Budget costs"&gt;0.6&lt;/span&gt;
million increase in the overall estimated budgeted costs. As a result of the Company&#x2019;s decision to discontinue the development with
respect to this program, on December 20, 2023, the Company provided Parexel notice of termination of the contract, with a planned termination
date of April 18, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;As the ongoing CRO services were wound down, the Company
noticed that expenses incurred under the CRO agreement were higher than originally budgeted. Parexel agreed to refund the Company $&lt;span id="xdx_90B_ecustom--GrossProceeds_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_ziyWSMhmr6qj" title="Gross proceeds"&gt;0.552&lt;/span&gt;
million and release the liability for amounts invoiced and unbilled services totaling $&lt;span id="xdx_901_ecustom--UnbilledServices_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_zBD2mmbKfgR3" title="Unbilled services"&gt;1.486
&lt;/span&gt;million, and the Company forfeited advanced payments of $&lt;span id="xdx_90A_ecustom--ForfeitedAdvancedPayments_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_ziugDIR1fpp" title="Forfeited advanced payments"&gt;1.091&lt;/span&gt;
million. As a result, the Company recognized a net gain of $&lt;span id="xdx_903_ecustom--NetGain_pn3n3_dm_c20240901__20240930__ifrs-full--CounterpartiesAxis__custom--CROAgreementMember_zvGcqNBmp0Fb" title="Net gain"&gt;0.946&lt;/span&gt;
million as of September 30, 2024. The Company received the refund from Parexel on October 3, 2024. As of March 31, 2024, the Company reflected
$&lt;span id="xdx_908_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_pn3n3_dm_c20230401__20240331__ifrs-full--CounterpartiesAxis__custom--CROMember_zotmX1mpiIuj" title="Accounts payable and accrued liabilitie"&gt;1.414&lt;/span&gt;
million of payables to Parexel in accounts payable and accrued liabilities and $&lt;span id="xdx_903_ecustom--PrepaidExpensesAndOtherReceivables_pn3n3_dm_c20230401__20240331__ifrs-full--CounterpartiesAxis__custom--CROMember_zbLOmLQIMeTf" title="prepaid expenses and other receivables"&gt;1.277&lt;/span&gt;
million in prepaid expenses and other receivables in the consolidated statement of financial position.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Buzz HPC GPU Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On February 6, 2026 he Company entered into a GPU infrastructure services
agreement with Buzz Performance Cloud Inc. pursuant to which the Company secured rights to access 504 NVIDIA B200 GPUs for a 24-month
term. The arrangement contemplates aggregate contractual payments of approximately $&lt;span id="xdx_901_ecustom--ContractualPayments_iI_pn3n3_dm_c20260206_zDTtexGSiN8i" title="Contractual payments"&gt;29.6&lt;/span&gt;
million over the contract term and requires a security deposit of $&lt;span id="xdx_901_ecustom--SecurityDeposits_iI_pn3n3_dm_c20260206_zTPpUh86TuFg" title="Security deposit"&gt;2.6&lt;/span&gt;
million, which was paid on February 13, 2026. As of March 31, 2026, no liability was yet recorded as the services did not commence until
early June.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;atNorth Colocation Lease Payments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On December 11, 2025 the Company signed an enterprise colocation service
agreement (the &#x201c;Colo Agreement&#x201d;) with atNorth AB (&#x201c;atNorth&#x201d;) to deploy the Company&#x2019;s GPU hardware to atNorth&#x2019;s
data center located in Kista, Sweden. The Colo Agreement consists of two data halls with a Phase I deployment of 1,213 kW of power and
a Phase II of 1,017 kW of power, with Phase II being structured as a Right of First Refusal (the &#x201c;ROFR&#x201d;). The agreement&#x2019;s
commencement date was April 1, 2026, and extends for 60 months after which it automatically extends for successive 12 month periods unless
6 months&#x2019; notice is provided by either party. On April 10, 2026, the Company paid a 982,368 EUR deposit to secure Phase I of the
agreement. As of the date of the issuance of these consolidated financial statements, the ROFR for Phase II of the deployment has expired,
although atNorth is still being considered for a further deployment once ready. The monthly colocation fee for Phase I that has commenced
is 163,728 EUR plus variable electricity costs estimated at 0.126 EUR/kWh.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;GaMee Acquisition Token Buyback&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#x201c;SPA&#x201d;) with Animoca Brands Limited (&#x201c;Animoca Brands&#x201d;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#x201c;GaMee Global&#x201d;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#x201c;GaMee Transaction&#x201d;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. The SPA
contains a post-closing item requiring the Company to, within ninety (90) days after close, acquire from the open market $2 million worth
of GMEE tokens. GMEE is the native utility token of the GaMee gaming platform and ecosystem. The GaMee Transaction closed on May 27, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Tarus &#x2013; Fortrea Clinical Service Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On March 1, 2023, Tarus entered into a clinical service
agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier
of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services
to be provided is approximately $12.1 million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;In March 2025, the Company resumed patient enrollment
into the final cohort arm of TT-10 (PORT-6) as part of the Phase 1a TT-10-101 (ADPORT-601) clinical trial, following a prior pause due
to funding constraints. This decision reflects the favorable safety and preliminary activity signals observed in earlier dose cohorts.
In April 2025, we announced confirmatory preclinical results in mesothelioma with our TT-4 (PORT-7) compound, supporting advancement of
this indication in its first-inhuman trial of TT-4 (PORT-7) which is expected to commence in the quarter ending March 31, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On May 31, 2026, Cyncado and ADDRI executed a definitive
Clinical Trial Research Agreement establishing the terms of the study. The trial is expected to enroll approximately 50 patients across
multiple clinical sites, will be led by A/Prof Steven Kao and Dr. Melvin Chin, and is intended to run in parallel with Cyncado's planned
U.S. mesothelioma activities. Under the agreement, Cyncado will supply TT-4 and provide limited support as part of an international mesothelioma
program. The trial remains subject to customary regulatory and ethics approvals and site activation before enrollment begins.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Nasdaq Notifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On December 10, 2024, the Company received written
notice (the &#x201c;Notice&#x201d;) from The Nasdaq Stock Market, LLC (&#x201c;Nasdaq&#x201d;) indicating that it was not in compliance with
the minimum shareholders&#x2019; equity requirement for continued listing on The Nasdaq Capital Market (the &#x201c;Capital Market&#x201d;)
as set forth in Nasdaq Listing Rule 5550(b)(1) (the &#x201c;Shareholders&#x2019; Equity Requirement&#x201d;), because the shareholders&#x2019;
equity of $695,000 as of September 30, 2024, as reported in the Company&#x2019;s Report on Form 6-K containing unaudited consolidated financial
statements for the three and six months ended September 30, 2024, filed with the United States Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) on December 31, 2024, was below the required minimum of $2.5 million, and because as of the date of the Notice, the
Company did not meet either of the alternative continued listing standards for the Nasdaq Capital Market, relating to market value of
listed securities of at least $35 million or net income from continuing operations of at least $500,000 in the most recently completed
fiscal year or in two of the last three most recently completed fiscal years. The Company submitted a plan on January 24, 2025, to regain
compliance with the shareholders&#x2019; equity requirement or achieve compliance with an alternative continued listing standard for the
Capital Market (the &#x201c;Compliance Plan&#x201d;) and on February 11, 2025, the Company received notification from Nasdaq that Nasdaq
accepted the Compliance Plan and granted the Company an extension to regain compliance with the continued listing standards by June 9,
2025. In keeping with the Compliance Plan, on June 5, 2025, the Company increased its shareholders&#x2019; equity, and submitted documentation
to Nasdaq indicating compliance as of June 9, 2025, with the shareholders&#x2019; equity requirement. The Nasdaq Stock Market, LLC indicated
by letter dated June 24, 2025, that the Company has regained compliance with the continued listing standards of the Nasdaq Capital Market.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On March 2, 2026, the Company received a deficiency
letter from the Nasdaq Listing Qualifications Department (the &#x201c;Staff&#x201d;) notifying the Company that because the closing bid
price for the Company&#x2019;s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet
the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule
5550(a)(2) (the &#x201c;Bid Price Rule&#x201d;). The deficiency letter does not result in the immediate delisting of the Company&#x2019;s
common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial
period of 180 calendar days, or until August 31, 2026 (the &#x201c;Compliance Period&#x201d;), to regain compliance with the Bid Price Rule.
If, at any time during the Compliance Period, the closing bid price per share of the Company&#x2019;s common stock is at least $1.00 for
a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it complies with the Bid Price
Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The Nasdaq
letter also provides that in the event the Company does not regain compliance by August 31, 2026, the Company may be eligible for an additional
180 calendar day period to regain compliance. To qualify, the Company must meet the continued listing requirement for market value of
publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the bid price requirement.
Notwithstanding the terms set forth in the Nasdaq letter, there can be no assurance that the Company will be eligible for an additional
180 calendar day period to regain compliance. If the Company meets the applicable requirements, Nasdaq will inform the Company that it
has been granted an additional 180 calendar days. If, however, it appears to Nasdaq that the Company will not be able to cure the deficiency,
or if the Company is otherwise not eligible, Nasdaq could provide notice that the Company&#x2019;s common stock will become subject to
delisting. In such event, Nasdaq rules would permit the Company to appeal the delisting determination to a Nasdaq Hearings Panel.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Ground Tunnel Consulting Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On July 15, 2025, Alpha Transform Holdings, a related
party of the Company, entered into a consulting service agreement with Ground Tunnel Capital LLC, a third-party advisory and marketing
consultant. This consulting service agreement was assigned to the Company on October 25, 2025. The effective date of the agreement occurred
upon the closing of the subsequent private placement of ordinary shares, which occurred on September 25, 2025, with contractual services
to be provided through July 15, 2028. $1.0 million was paid upon execution of the contract, with subsequent milestone payments of $0.25
million due on each October 15, 2025, January 15, 2026, April 15, 2026 and July 15, 2026. On April 15, 2026, the Company submitted its
third milestone payment in the amount of $0.25 million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Treasury Management Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;At the closing of the Company&#x2019;s financing on
September 25, 2025, the Company entered into a treasury management agreement (the &#x201c;DWF TMA&#x201d;) with DWF MaaS Limited (&#x201c;DWF&#x201d;),
pursuant to which the Company appointed DWF to manage $15.0 million that DWF contributed in the September 2025 financing and implement
the TON treasury strategy for the Company. Under the DWF TMA, DWF is entitled to retain 100% of all profits earned until the balance with
DWF reaches $150.0 million at which point the Company will earn a 3% yield on all DWF-managed TON holdings, and additionally 10% of any
profits from asset management will be shared with the Company. In consideration for the services to be provided, the Company issued 160,000
ordinary shares to DWF, which shares shall vest linearly over a period of three (3) years from the date of issue to DWF. The initial term
of the agreement is 3 years and will commence on the date that the aggregate transfers from the Company to DWF reach $150 million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company has the right to terminate the agreement
with 90 days&#x2019; notice provided that a) the termination notice is submitted more than 18 months following commencement of the contract
term, and b) the Company publicly announces it will cease its strategy of holding TON as a treasury asset. Pursuant to the DWF AMA, DWF
is entitled to convert the Ordinary Shares it subscribed for in the September 2025 private placement into an equivalent value of TON from
the amount of TON held by DWF on behalf of the Company up to a maximum value of $15,000,000. DWF was granted the right to exercise this
conversion option at any time within twelve months from August 25, 2025.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The range of management and trading activities that
DWF is authorized to conduct under the DWF AMA is limited to market-making, buying and selling the TON tokens, and providing liquidity
on decentralized or centralized exchanges. DWF cannot use derivatives as part of their mandate. DWF is mandated to actively manage the
assets under management to provide market liquidity in TON trading pairs and generate a return. DWF is required to hold and secure the
assets using institutional-grade custody solutions, which may include qualified third-party custodians, centralized cryptocurrency exchanges,
multi-party computation (MPC) wallets, and other industry-standard security protocols designed to safeguard digital assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;In addition to the initial $15.0 million that DWF contributed
in the September 2025 financing, the Company is required to make additional transfers of a) $5 million 15 days after the close of the
September 2025 financing, and b) $55.0 million within 3 months of the September 2025 financing, with no less than $20.0 million to be
transferred each month. The Company also agrees to transfer 50% of any subsequent treasury fundraising to DWF for asset management until
the total assets under management total $225.0 million. Through December 30, 2025, there had been no additional transfers to DWF, and
DWF was managing only the $15.0 million of their own funds that they contributed as part of the September 2025 financing.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On December 30, 2025, the Company entered into that
certain Settlement Agreement and Release (the &#x201c;Settlement Agreement&#x201d;), by and between the Company and DWF MaaS Limited (&#x201c;DWF&#x201d;).
The Settlement Agreement resolves certain disputes over the rights and obligations related to that certain Treasury Management Agreement,
dated as of August 25, 2025 (the &#x201c;Treasury Management Agreement&#x201d;), by and between the Company and DWF, pursuant to which the
Company appointed DWF to manage and implement a portion of the Company&#x2019;s TON treasury strategy. On September 25, 2025, DWF subscribed
for (i) 105,000 ordinary shares (the &#x201c;Shares&#x201d;) of the Company, no par value per share (the &#x201c;Ordinary Shares&#x201d;),
and (ii) pre-funded warrants to purchase up to 2,513,240 Ordinary Shares (the &#x201c;Pre-Funded Warrants&#x201d; and together with the
Shares, the &#x201c;Repurchase Securities&#x201d;), in exchange for consideration of USD1 $15,000,000, in each case pursuant to that certain
Securities Purchase Agreement, dated as of September 2, 2025, by and between the Company and certain investors party thereto (including
DWF). Also on September 25, 2025, pursuant to the terms of the Treasury Management Agreement, the Company and DWF entered into that certain
Ordinary Share Issuance Agreement (the &#x201c;Restricted Share Agreement&#x201d;), pursuant to which the Company issued 160,000 Ordinary
Shares (the &#x201c;Restricted Shares&#x201d;) to DWF, with such Restricted Shares vesting linearly over a three (3) year period from the
date of issuance. Pursuant to the Settlement Agreement, the Company agreed to: (i) purchase the Repurchase Securities from DWF for an
aggregate amount of USD1 $15,000,000 (or whatever amount remains in the digital wallet used to fund the initial deposit pursuant to the
Treasury Management Agreement); (ii) remove the vesting restrictions applicable to the Restricted Shares; and (iii) pay DWF USD $35,000.
As part of the Settlement Agreement, the Company and DWF each agreed to a mutual full release of claims. Further, the Treasury Management
Agreement and the Restricted Share Agreement were terminated and no longer enforceable.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Vertical Data Server Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On January 5, 2026, the Company signed an agreement
with Vertical Data Inc. to acquire 72 Dell XE9780-B300 Servers containing a total of 576 GPUs along with associated required networking
equipment, at a total cost of $&lt;span id="xdx_907_ecustom--NetworkingEquipmentCost_iI_pn3n3_dm_c20260105_zCgH8B05Y3d5" title="Networking equipment cost"&gt;40.9&lt;/span&gt;
million. On the same day a deposit of $&lt;span id="xdx_90B_ecustom--Deposit_iI_pn3n3_dm_c20260105_zC8372JhHxyd" title="Deposit"&gt;2.0&lt;/span&gt;
million was made, with additional deposits made in January and February 2026 of $6.0 million for a total of $8.6 million in deposits made
in order to hold the allocation of servers. The remaining cost of the acquisition will be funded via a GPU equipment financing lender.
The anticipated asset-backed loan will be non-recourse to the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;



</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ptgef:ServiceFees
      contextRef="AsOf2022-03-15_custom_CROMember"
      decimals="-3"
      id="Fact002282"
      unitRef="USD">11500000</ptgef:ServiceFees>
    <ptgef:BudgetCosts
      contextRef="From2022-04-012023-03-31"
      decimals="-3"
      id="Fact002284"
      unitRef="USD">600000</ptgef:BudgetCosts>
    <ptgef:GrossProceeds
      contextRef="From2024-09-012024-09-30_custom_CROAgreementMember"
      decimals="-3"
      id="Fact002289"
      unitRef="USD">552000</ptgef:GrossProceeds>
    <ptgef:UnbilledServices
      contextRef="From2024-09-012024-09-30_custom_CROAgreementMember"
      decimals="-3"
      id="Fact002291"
      unitRef="USD">1486000</ptgef:UnbilledServices>
    <ptgef:ForfeitedAdvancedPayments
      contextRef="From2024-09-012024-09-30_custom_CROAgreementMember"
      decimals="-3"
      id="Fact002293"
      unitRef="USD">1091000.000</ptgef:ForfeitedAdvancedPayments>
    <ptgef:NetGain
      contextRef="From2024-09-012024-09-30_custom_CROAgreementMember"
      decimals="-3"
      id="Fact002295"
      unitRef="USD">946000</ptgef:NetGain>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2023-04-012024-03-31_custom_CROMember"
      decimals="-3"
      id="Fact002297"
      unitRef="USD">1414000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ptgef:PrepaidExpensesAndOtherReceivables
      contextRef="From2023-04-012024-03-31_custom_CROMember"
      decimals="-3"
      id="Fact002299"
      unitRef="USD">1277000</ptgef:PrepaidExpensesAndOtherReceivables>
    <ptgef:ContractualPayments
      contextRef="AsOf2026-02-06"
      decimals="-3"
      id="Fact002301"
      unitRef="USD">29600000</ptgef:ContractualPayments>
    <ptgef:SecurityDeposits
      contextRef="AsOf2026-02-06"
      decimals="-3"
      id="Fact002303"
      unitRef="USD">2600000</ptgef:SecurityDeposits>
    <ptgef:NetworkingEquipmentCost
      contextRef="AsOf2026-01-05"
      decimals="-3"
      id="Fact002312"
      unitRef="USD">40900000</ptgef:NetworkingEquipmentCost>
    <ptgef:Deposit
      contextRef="AsOf2026-01-05"
      decimals="-3"
      id="Fact002314"
      unitRef="USD">2000000.0</ptgef:Deposit>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact002316">&lt;p id="xdx_80E_eifrs-full--DisclosureOfRelatedPartyExplanatory_zMNWtSsQYAeg" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 21. &lt;span id="xdx_82D_zH4lT6D4Duwf"&gt;RELATED
PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Private Placement Financing&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On January 29, 2025, the Company completed the sale of&lt;span id="xdx_90C_ecustom--SaleOfStock_iI_c20250129_zniq1FZ66aA3" title="sale of stock"&gt;
524,390&lt;/span&gt;
ordinary shares for aggregate proceeds of $&lt;span id="xdx_901_ecustom--AggregateProceeds_iI_c20250129_z4e7wqaeITZe" title="aggregate proceeds"&gt;2,150,000&lt;/span&gt;,
at a per share price of $4.10, the closing price of a share on Nasdaq on the date preceding the date of the securities purchase agreement.
The shares were sold to two former directors of the Company, Messrs. Gregory Bailey and James Mellon. The shares were sold in a private
placement transaction pursuant to Regulation S, and were issued as restricted stock. The proceeds are being used for general corporate
purposes and working capital.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;SalvaRx Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Two of the Company&#x2019;s former directors, Messrs.
Gregory Bailey and James Mellon, are also directors of SalvaRx Group plc, a company which owned approximately 2.2% of the Company&#x2019;s
issued and outstanding ordinary shares as of March 31, 2025. As of March 31, 2026, SalvaRx Group plc owns no issued and outstanding shares
of the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company has entered into related party transactions
and certain services agreements with certain of its shareholders. Key management personnel of the Company have also entered into related
party transactions with certain of its shareholders. Key management personnel are those people who have the authority and responsibility
for planning, directing and controlling the activities of the Company, including directors and senior management of the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The following subsidiaries and associates are considered related
parties:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in"&gt;(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&lt;b&gt;iOx&lt;/b&gt;. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Alpha Compute director resigned from the iOx board 	leaving
two Alpha Compute insiders as directors. The management team of Alpha Compute comprises the management team of iOx.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-indent: 0in"&gt;(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&lt;b&gt;Saugatuck&lt;/b&gt;. Saugatuck is 70% owned by the Company and is controlled by Alpha Compute.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0.5in; font-size: 10pt; text-indent: 0in"&gt;(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&lt;b&gt;Portage Development Services Inc&lt;/b&gt;. PDS provides human resources and other services to each operating subsidiary of Alpha Compute
		through shared services agreements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Transactions between the parent company and its subsidiaries,
which are related parties, have been eliminated in consolidation and are not disclosed in this note.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Board Resignations and Appointments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On April 25, 2024, Mark Simon resigned all of his positions
on the Board of Directors, and on April 26, 2024, Linda Kozick and Dr. Robert Glassman resigned all of their positions on the Board of
Directors. On April 30, 2024, Dr. Jean -Christophe Renondin and Dr. Justin Stebbing were elected to the Board. On August 3, 2025, Justin
Stebbing, and Jean-Christophe Renondin resigned from the Board of Directors and Brittany Kaiser was appointed to the Board. On September
25, 2025, Gregory Bailey and James Mellon resigned from the Board of Directors and Michael Terpin and Enzo Villani were appointed to the
Board. On December 19, 2025, Alexander Pickett resigned from the board of directors of the Company. On February 6, 2026 Steven Mintz resigned
from the board of directors and was replaced with F. Dan Siciliano.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 20.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Advisory Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On August 20, 2025, the Company entered into an independent
contractor agreement with Ralph Matthew McKibbin (the &#x201c;McKibbin Agreement&#x201d;), pursuant to which Mr. McKibbin will provide development
advisory services to the Company. Mr. McKibbin is entitled to an equity grant in options at a strike price equal to the fair market value
on the date of the grant of 0.25% of the issued and outstanding ordinary shares of the Company after giving effect to the number of issued
and outstanding ordinary shares of the Company as of immediately after the Closing. 50% of the options will vest immediately and the remaining
50% shall vest in equal installments over a 12-month period. Due to the relationship between Ms. Kaiser and Mr. McKibbin, the McKibbin
Agreement is a related party transaction for Ms. Kaiser.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Relationship with DecentraNet&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;DecentraNet is an early-stage venture investment fund and advisory firm.
They invest at the earliest stages (F&amp;amp;F, Pre-Seed, and Seed), and have advisory clients ranging from startups to multi-billion dollar
public companies. In Fiscal 2026 the Company paid DecentraNet a total of $&lt;span id="xdx_903_ecustom--Decentranet_iI_pip0_c20260331_zgVeevC4nwF8" title="DecentraNet"&gt;55,000&lt;/span&gt;
for advisory and fundraising services. Mr. McKibbin is the founder of DecentraNet and a related party to the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Retention Agreements and General Releases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On July 22, 2024, the Company and Portage Development
Services, Inc. entered into a Retention Agreement and General Release (&#x201c;Retention Agreement&#x201d;) with each of Allan Shaw, the
Company&#x2019;s former Chief Financial Officer (&#x201c;Employee&#x201d;) and Joseph Ciavarella, the Company&#x2019;s former controller (&#x201c;Consultant&#x201d;).
Under the terms of each of the Retention Agreements, Employee&#x2019;s current employment agreement and Consultant&#x2019;s current consulting
agreement both terminated on July 22, 2024, except with respect to certain provisions. In return for continuing to provide services to
the Company and its affiliates and completing certain tasks as described in the respective Retention Agreements, the Company paid an aggregate
$0.2 million (the &#x201c;Retention Amount&#x201d;) to Employee and Consultant, in addition to their monthly pay through September 30, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company accrued the Retention Amount, as well as
the monthly pay totaling $0.2 million through September 30, 2024, in the consolidated financial statements for the three months ended
June 30, 2024, as the material terms of the Retention Agreements were known and agreed upon at June 30, 2024. In accordance with the terms
of the Retention Agreements, the Company paid in full the Retention Amount and issued 14,348 ordinary shares to the Employee and Consultant
in lieu of cash bonuses accrued in Fiscal 2023 totaling $0.1 million by September 30, 2024, the date on which the Employee&#x2019;s employment
and the Consultant&#x2019;s consulting relationship with the Company and its affiliates ended.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Relationship with Compedica&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;As discussed in Note 10, the Company acquired an equity
interest in Compedica, a U.K.-based biotechnology company specializing in medical devices for support with complications from diabetes.
The investment was made in a stock-for-stock transaction whereby Compedica obtained a corresponding 27.4% interest in the Company, which
was subsequently diluted in connection with the private financing in September 2025. As of September 30, 2025, Compedica owned 11.9% of
the Company&#x2019;s ordinary shares issued and outstanding. At the time of the Compedica investment, Jim Mellon was a director of both
Compedica and the Company and a greater than 5% owner of the Company.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;On February 6, 2026, the Company and Compedica agreed
to exchange their ownership interests in the counterparty with each other, with the 625,000 shares in the Company held by Compedica being
returned to the Company&#x2019;s treasury and the investment being exited. As of March 31, 2026, the Company no longer has any affiliation
with Compedica, its employees, or directors, excepting the 625,000 Company shares to be returned, which was completed on May 21, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Asset Management Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;At the closing of the Company&#x2019;s financing on
September 25, 2025, the Company entered into an Asset Management Agreement (the &#x201c;Asset Management Agreement&#x201d;) with Alpha Sigma
Capital, LLC (the &#x201c;Asset Manager&#x201d;). Pursuant to the Asset Management Agreement, the Asset Manager shall provide discretionary
investment management services with respect to, among other assets (including without limitation certain subsequently raised funds), certain
of the Company&#x2019;s net proceeds from the Offering (the &#x201c;Account Assets&#x201d;) in accordance with the terms of the Asset Management
Agreement.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Under the Asset Management Agreement, the Company shall
pay the Asset Manager an asset-based fee equal to 1.0% per annum of the Account Assets. The Account Assets managed under the agreement
are held in the name of the Company and remain under Company control. The agreement term is one year, after which it renews automatically
and can be terminated by the Company with 90 days&#x2019; notice, provided that the Company has decided to end the TON digital asset treasury
strategy.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Asset Manager is mandated to invest the Account
Assets principally with a long-only strategy primarily in TON, including staking (and restaking) TON to improve returns. The Asset Manager
is not permitted to invest in any OTC derivatives, futures contracts, or option contracts that would require the Asset Manager to register
as a commodity pool operator or commodity trading advisor.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Mr. Enzo Villani, Chief Investment Officer of the Company,
is the Chief Executive Officer and Chief Investment Officer of the Asset Manager. Alpha Sigma Capital was also an investor in the Company&#x2019;s
September 2025 financing.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Alpha Transform Holdings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Alpha Transform Holdings ("ATH") is a related
party of the Company because it is majority-owned by Enzo Villani, CIO and Chairman, and Michael Terpin, board member. On July 15, 2025,
ATH entered into a consulting service agreement with Ground Tunnel Capital LLC, a third-party advisory and marketing consultant. This
consulting service agreement was assigned to the Company on October 25, 2025, after Company board approval on October 20, 2025. The effective
date of the agreement occurred upon the closing of the subsequent private placement of ordinary shares, which occurred on September 25,
2025, with contractual services to be provided through July 15, 2028. $1.0 million was paid upon execution of the contract, with subsequent
milestone payments of $0.25 million due on each October 15, 2025, January 15, 2026, April 15, 2026 and July 15, 2026. On April 15, 2026,
the Company submitted its third milestone payment in the amount of $0.25 million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Blockchain Wire / Content Syndicate&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Content Syndicate (dba Blockchain Wire) is a press release distribution
service focused on news from blockchain and crypto companies and projects. Their global reach includes distribution to broadcast and online
media outlets, social media sites, trade publications, leading blogs, industry executives, influencers and investors. They offer multiple
distribution options, ease-of-use, broad partnership integrations and a dedicated client services team. In Fiscal 2026 we paid Content
Syndicate a total of $0.2 million for distribution and placement of press releases and media buys. Content Syndicate is a related party
by virtue of being owned by Enzo Villani and Michael Terpin.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensation Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The following table summarizes all compensation paid or payable by the Company
to its directors and senior management for the fiscal years ended March 31, 2026, 2025, and 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfCompensationPayableTableTextBlock_pn3n3_zHXd7Jnzfrck" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BA_zixr8vFgcR02" style="display: none"&gt;Schedule of compensation payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20250401__20260331_zsRoltRPBld9" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20240401__20250331_zsUMlGFMdxLi" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20230401__20240331_z3f7odmy8b53" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Years ended March 31,&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--ShorttermEmployeeBenefitsExpense_z3Z4JOrwThD3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;Short-term employee benefits (salary, bonus, etc.)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;4,052&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;13,787&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;2,127&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--PostemploymentBenefitExpenseInProfitOrLoss_zgWTLhldnN2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Post-employment benefits&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--OtherLongtermBenefits_z3xdmb0zVY02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Other long-term benefits&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TerminationBenefitsExpense_zafHHyIajBx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Termination benefits&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;152&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;49&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--SharebasedPaymentCompensation_zOi8VtKNS8R6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Share-based payment compensation&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,600&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;590&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--KeyManagementPersonnelCompensationPostemploymentBenefits_zCLlzQjclxc6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White; font-size: 10pt"&gt;&#160;Total&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;5,804&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,968&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,176&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A6_ztqJSmixiNEk" style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensation Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The following tables and accompanying notes set forth all compensation paid
or payable by the Company to its directors and senior management for the fiscal years ended March 31, 2026, 2025, and 2024. The share
information is adjusted to give effect to the 1-for-20 reverse share split completed on August 15, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Director Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;




&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_pn3n3_zsSJyhx1c6Hc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B3_zt4kH5O16nzc" style="display: none"&gt;Schedule of Compensation&lt;/span&gt;&lt;b&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Name &amp;amp; Principal Position&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Year&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Fee and&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Salary&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Transaction&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Closing Bonus&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Securities Under&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Options Granted&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Shares
        or Units&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(16)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Other&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total
        Compensation&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Michael Terpin&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNonqqAnuxL6" style="width: 6%; font-size: 10pt; text-align: right" title="Fee and salary"&gt;61,250&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoGAzHJAW9ha" style="width: 6%; font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2365"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBJ5jtH5VJxi" style="width: 6%; font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2367"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXUS9z2RFnKe" style="width: 6%; font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2369"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zo5x151YrI08" style="width: 6%; font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2371"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zeGeIqzBlHHa" style="width: 6%; font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2373"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKAQnKIBVFl" style="width: 6%; font-size: 10pt; text-align: right" title="Total compensation"&gt;61,250&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;F. Daniel Siciliano&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAxjPVuOqAd1" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;17,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0Ds2tWNJgJf" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2379"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zViTOGYOjUTb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2381"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3EDhTZQUYtk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2383"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKfKYHRU4df" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2385"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQAzgB6RPKmk" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2387"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxHSyyvchTo5" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;17,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Gregory H. Bailey, M.D.&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zKA2GK6DRIsb" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zclrmtQoP3W8" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3E62n2WJsch" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2395"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3Laoj6J7x6l" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2397"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zaQPMUPA12H9" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2399"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDEwTQWqSVWl" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2401"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zYYV6QOSnEii" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;55,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zQW0F083ILE8" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzLkgMAohvck" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2407"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9zPiAillZth" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2409"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcxjFC5oiD82" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2411"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdpe9o9DRVRe" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2413"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zJVTE3UPEleg" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2415"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0EPcEey05sf" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zafYIIQiMnc6" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;49,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjHLde5nX3Ka" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2421"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV8qA7QLXBM" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2423"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zq29hiLqruh1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2425"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zidJETtEIj0l" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2427"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zOKkHDjgv5kg" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2429"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr7iC3iWVabk" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;49,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;James Mellon&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zkYEtExNX3L8" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTjiH2TcAZI7" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_znhHbc0cne87" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2437"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zawteqprpt8c" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2439"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHczKE0v7c61" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2441"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCpjNRF2mW7" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2443"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5rHhXnKidG6" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;55,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zWig206U3G18" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfu21gboJ1tk" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2449"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdxYO2zK8eqa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2451"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUcKJJa0bhBf" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2453"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjf6JrncjUyb" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2455"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqKSY5CqTFQe" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2457"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTy5cU7HFV8f" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zw2QCK6ec9pi" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;35,242&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhtuMXozwUg2" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2463"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBDeiB7FkJYf" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2465"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zM1t9ctOZH3i" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2467"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyAu82T1XFni" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2469"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoebWFZWmLZj" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQlZs1WrdtE1" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;35,242&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Steven Mintz&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zK96CTLr4KUh" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;77,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZ3OGprqhqdc" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPEXV0JcrOGk" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2479"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfvaAeHDuLK3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;54,796&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztrvWOcSlcsb" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2483"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z4VfQDhLBvr4" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2485"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhjUsjqSYTi4" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;157,296&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zESRkB16EQy" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbyRiuRbTuIe" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2491"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2Vmxgqk48k8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2493"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMg9yIgKCJBg" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;113,158&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zG3vzCuGNoxi" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2497"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z59r180DH0gd" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2499"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zmGKMJGieq5h" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;143,158&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zVw44CDH5dJ7" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;45,750&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwiyV4Epblrb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2505"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zObscOD9MX7h" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2507"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQYts612ziEc" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2509"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKS6PeaJLfE6" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2511"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlQzVcEdoni3" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2513"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zGWAWnEfDsil" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;45,750&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Jean-Christophe Renondin, M.D.&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zlfHg9RK3Rq4" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCwBzTB6Tehc" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjoDgQ1BiKXi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2521"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqK9q24YXjn5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;54,796&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyUIr0qWbKhk" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2525"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zv9U42HQIach" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2527"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zT9pNoVuuFN2" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;109,796&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zPxvg4vmLqY2" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNNyYB3ivBO1" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2533"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEsWlDotiEAd" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2535"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMJYowivhzb1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;96,992&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zin1LxHAWUNj" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2539"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zVtfsIEfAri6" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2541"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ziu28NvBoHPk" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;126,992&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_z75HluNHcuTe" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2545"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIHqOh38LsRb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2547"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHmEUgDNtzBe" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2549"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCKmV9NTn7w5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2551"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdFx3W0dfNC3" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2553"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zANYBart5atk" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2555"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9sT2Ix8V7l8" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2557"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Justin Stebbing, M.D. PhD&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_z2XVSuy8aLk9" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEqzzTFqvfXb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFDJzVGeF81e" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2563"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIEBADLsTBd9" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;64,760&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlqOVuJSjh34" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2567"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvtSbnsTGWWl" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2569"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zedrsawnoOL4" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;119,760&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zf6HK6RHLWDh" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zA28749keNBk" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2575"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2RqB6D16r43" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2577"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyddtzDsyDzi" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;121,240&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDN79Ubqn1" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2581"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zm2UjAPrRcrf" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2583"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNXemAyLNf1" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;151,240&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zykeYTyHgPE9" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2587"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsWWmglVHGT4" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2589"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgB2nUeblEPa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2591"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcQYHpDiclT3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2593"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqF6sXtREO3h" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2595"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztFzI9yvPxfj" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2597"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQzOCViYiew7" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2599"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Linda Kozick&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zovruTySfId" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2601"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zkjeS6ybUqid" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2603"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWnki9hi25J8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2605"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBOPWIdToL4e" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2607"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxQqGNhqk2ul" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2609"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFUoJqbH15Ze" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2611"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgQvMyONcsPe" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2613"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zYn1MzZ5W86d" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2615"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCWtdzLwNGR2" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2617"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zERocssYs7ia" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2619"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAHFQeeI0HD3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2621"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNVDfucmuhr6" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2623"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV0Wd7pQjWy6" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2625"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z7sbm2QsPH98" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2627"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zvdbgjx5V7W7" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;42,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcGa3Q6kgqsb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2631"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPHe0cUYrxBg" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2633"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z1TiHjTnJaii" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2635"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZa3YuppNtv7" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2637"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsZPQcnLKMsb" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2639"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr9JH4Y9zCf5" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;42,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Mark Simon&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z3o4vt2SH14h" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2643"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zy2icmNOfQ6c" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2645"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSWn5iEL3Pd6" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2647"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zpWBlry94uwk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2649"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAEfHnsSJ9T3" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2651"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEKwVCuNjS2a" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2653"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV6hacfGlro6" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2655"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zPzxiVbd5jvj" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2657"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWu738896MJd" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2659"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUSHpXd20fGl" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2661"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3g5SeQqJbF8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2663"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAV11Afrww21" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2665"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_za0HrOXyFQX3" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2667"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWRzANTguJke" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2669"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z9ajTWyVlY6d" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;55,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2bSz4QeWlel" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2673"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z8cJcD5mYKm3" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2675"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zblyaUGazip8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2677"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj5sjbH4qSDc" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2679"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMX6fWtOk2kd" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2681"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSME3co5fKs4" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;55,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Robert Glassman&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zQySdV047Tic" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2685"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTJWhurMpP02" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2687"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSfs9jdBhhri" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2689"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXFY3pmarW25" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2691"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZXTLYmgUsmc" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2693"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zrxZi6X6OiBl" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2695"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5wbwwQk5Bk6" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2697"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zs32GrJba2ra" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2699"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj6i0XkDl3w2" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2701"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z6C27MJSgYn7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2703"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zF3eb7ynJui7" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2705"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKd32So0gR5f" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2707"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhCzgbRnYmIb" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2709"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbGNoa8KJwNa" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2711"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zgb4SR5eT5K2" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;45,258&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zw9Fd80Mp8H3" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2715"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zg9P2hh7j3l4" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2717"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlsZDtlIXCj6" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2719"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvzYssiMoRwg" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2721"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zU85u4TYgDY5" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2723"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwbCohDoSo3f" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;45,258&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Executive Officer Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="display: none"&gt;Schedule of Executive officer compansation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Name &amp;amp; Principal Position&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Year&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Fee and&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Salary&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Transaction&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Closing Bonus&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Securities Under&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Options Granted&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Shares
        or Units&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(16)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Other&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total
        Compensation&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Executive Officers&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Brittany Kaiser&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt; text-align: left"&gt;Chief Executive Officer and Director&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zsRSL83B4n5d" style="width: 6%; font-size: 10pt; text-align: right" title="Fee and salary"&gt;661,290&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zEPCzIssRzuh" style="width: 6%; font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2733"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_z9WoVYJ9tcVc" style="width: 6%; font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;500,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zBtwdwmLfEhh" style="width: 6%; font-size: 10pt; text-align: right" title="Securities under option granted"&gt;218,219&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_z1m4vflnG5Eb" style="width: 6%; font-size: 10pt; text-align: right" title="Shares ot units"&gt;149,015&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zr1kX8GaJow9" style="width: 6%; font-size: 10pt; text-align: right" title="Other compensation"&gt;187,102&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zypWIDBYVWrf" style="width: 6%; font-size: 10pt; text-align: right" title="Total compensation"&gt;1,715,627&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Enzo Villani&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Investment Officer and Director&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zuBZJQ4UkBle" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;369,355&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zfgD9Ar5QVqf" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2747"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zg4LeBuAFIIe" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;500,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zWanGbKiWGDj" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;218,219&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zO5BLxUIsWd1" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;248,359&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zqTFCmUoSNrk" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2755"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zUJuSOMnWKud" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;1,335,933&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Wes Levitt&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Financial Officer&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zDMGf2sJVGbk" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;219,086&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zxNhK6nhvpDf" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2761"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_z3R8ngyshAf1" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2763"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zKV5oLx0hZUk" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2765"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WesLevittMember_zaFdFsTKgH79" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;219,086&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Yury Mitin&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Business Development Officer&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zlKYXakmAHL6" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;369,355&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zGd8isiJ1sg7" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2771"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z7yuUMs6AoV9" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;500,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z2wfnxTx7kg7" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;218,219&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_z9zucdGqvRy5" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;99,344&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zMuFYiLuL7s6" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2779"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zlzrsBO89wOh" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;1,186,918&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Alexander Pickett&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(10)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Executive Officer and Director&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zoMNnwHrkis7" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;51,250&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zlzP7JEn326k" style="font-size: 10pt; text-align: right" title="Bonus"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zmQX7tKOXXuc" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2787"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zIyXQtfMZB8b" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;234,132&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zmfQD2Fqp8o" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2791"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zxxULj9kjEyb" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;39&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zphngo34IxSi" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;310,422&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z7JQI9mIRBO4" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zri8f7P16vp3" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2799"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z2cIt3P0KVP5" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2801"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z7vwdqupXKGk" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;145,488&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zZ6gqYXgH0y1" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2805"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_z9hQDr1rk7Pb" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2807"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zy7HRIehI78a" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;175,488&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Ian Walters&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(11)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Executive Officer and Chairman of the Board&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z2ntn3Utyoac" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2811"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zWpHmoUEhn4g" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2813"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zILmvAYvfjGd" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2815"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zCuFeibAUeOe" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2817"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zr7KsUmwyex" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2819"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zWnm3M0wFTwj" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;152,383&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zVQy7Vsh067c" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;152,383&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zZP4cl1iLIV8" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;453,186&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zumuaXLbdQc" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2827"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z6ls8nrnoZae" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2829"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zQHEZPMXgYf9" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2831"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z7D5qD7vSuo5" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2833"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zUWMSVTb3bC7" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;54,716&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zKRTAAcMFwcb" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;507,902&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zTzgKDKRCom4" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;642,700&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zaKJJnXEzbIe" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2841"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zts7mxcbz45f" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2843"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_z2xJ4xMUomX4" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2845"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zuAxUZwjGMkl" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2847"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zvkRwFiVuEnj" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;75,185&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanWaltersMember_zfLBZfrTGhFa" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;717,885&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Andrea Park&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(12)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Financial Officer&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zkFIM5fA7jme" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;218,429&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z9mNpC5oEbig" style="font-size: 10pt; text-align: right" title="Bonus"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zlePMuqfP4ba" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2857"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zifOP4lRS4t6" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;39,857&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z7sO66XItMi5" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2861"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zA3W7uVaXwed" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2863"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zSaS1byRA9Ek" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;308,286&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z1jy5LrjM131" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;163,790&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zMpHN4gcxztc" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2869"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_z6rgIlKruOy" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2871"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zKc5sRNqdGc3" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;113,158&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zBGMsDFPQ8d6" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2875"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zoGOCLueFBL3" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;28,659&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaParkMember_zoF3oXg6sq64" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;305,607&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Allan Shaw&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(13)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zgHuSnsumjKf" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2881"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zwy0CgrPuZli" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2883"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zCS6zaIV38eb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2885"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zEX4abnPhO16" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2887"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zhhURZ8lkuF1" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2889"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z3kfJRvUNAt9" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2891"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zP1b00oWqVv7" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2893"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Financial Officer and Secretary&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z6X35sXeNlJd" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;234,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zrRLLPKPECX9" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2897"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z1CPirGeDu62" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2899"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z54qeNf02j9i" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2901"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z5VFfQMkHou8" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2903"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zK8VHsn7BFx2" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2905"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zFwhvvEOIZkg" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;234,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z128A2Qx5r2g" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;469,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zRVtZdvGG0b" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2911"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zO5VyWod8IRi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2913"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zZvYXgeGleDf" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2915"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zcKBy7zxDL68" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2917"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zkgEV3Rsqmmi" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;49,205&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_zhAAJ03Vki78" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;518,205&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Robert Kramer&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Scientific Officer&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zeKbjXkh9SAg" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2923"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zlMWWmBuKCbg" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2925"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zdKEptj4Ttvf" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2927"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zxVDrHOOSkJj" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2929"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zCM0ZLJrDV58" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2931"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zyWlCsnUIaFc" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2933"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zaI15fUmyoJ2" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2935"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zBrpjzORSNtg" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;112,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zvONFNFROw6" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2939"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_z8V1YvePObZ2" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2941"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zLJURtCSGyDk" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2943"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zqWbFcPd9nX3" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2945"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zGSCMGrHVHT2" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;6,750&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zGFjVTSYQkyc" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;119,250&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_z2QfVJVQM7ai" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;168,750&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zIHfSoC5oSB7" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2953"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zkda0TIEZEGi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2955"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zpdX0MBauMFh" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2957"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_ztBrxvJWBszk" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2959"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zMOI2sHHiYQ3" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;17,141&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zlKvAEI42wSc" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;185,891&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Brian Wiley&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(14)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Chief Business Officer&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z6HodCwr8EHb" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2965"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zCjtu4hrtYg2" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2967"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zCl12DUxoWVh" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2969"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zintvgYZfpY2" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2971"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zzbVPpIjLuyf" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2973"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zzbWtG8jsEv1" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2975"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z3NPcwpBXBig" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2977"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zP7mrsMruzlk" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;114,844&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zJD4rK71PVy9" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2981"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zxgXDDrTAOz7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2983"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zOLKndqNBW3c" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2985"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zYw5JAKDM8T2" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2987"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zF1ljkUkl9K" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;8,627&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zlvNGoBPCXNe" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;123,471&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zjhBwpmoheL5" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;153,125&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zNmlvkqiUwSj" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2995"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zKv4L5Ya4Anb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2997"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zZNZFXTdGWbl" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2999"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zArx74zd0d5g" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3001"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zEaYMv5dbTJe" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;2,297&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_z2IpzrN0hMfg" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;155,422&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Justin Fairchild&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(15)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Vice President of Development&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJcX9OX6qix8" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3007"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zxANUsRQQ4Y4" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3009"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zOPIyjs78oJ7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3011"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zvYY00g2HBsa" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3013"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_z8GgjQWtVzt3" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3015"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zUaiROfbpGCi" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3017"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJ7dIehYUuRl" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3019"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zg1aCPOJvQC6" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;20,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zTB1JqzFenLk" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3023"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_ztFNYUEEbQLb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3025"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zDvqGPJR89El" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3027"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zbmVM01TE0Ck" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3029"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zcUWUNrEXErh" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3031"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_ziG576A421Sf" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;20,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zOZ59H7Pa2V3" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;270,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zJ1fGE5mCRKa" style="font-size: 10pt; text-align: right" title="Bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3037"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zSCh88irr74l" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3039"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zXvRYRzgl2dk" style="font-size: 10pt; text-align: right" title="Securities under option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3041"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zvzDFfhxtqB" style="font-size: 10pt; text-align: right" title="Shares ot units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3043"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zsor9CvvkZQ2" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;55,301&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--ExecutiveOfficerCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinFairchildMember_zlXniLHAyag4" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;325,301&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;






























&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Notes&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(1)&lt;/td&gt;
    &lt;td&gt;Represents base salary earned by executive officers in accordance with their respective contractor agreements and director&#x2019;s fees
        earned by directors. For Brittany Kaiser, Enzo Villani, Yury Mitin, and Wes Levitt, their base salary is comprised of equal portions payable
        in USD and TON tokens. The figures in the table represent the sum of both. To date, these executives&#x2019; USD portions of their salaries
        have been paid monthly, while the TON portions have been accrued by the Company.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(2)&lt;/td&gt;
    &lt;td&gt;Dr. Bailey, Mr. Mellon, Mr. Mintz and Ms. Kozick waived their directors&#x2019; fees with respect to the three months ended March 31, 2024.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(3)&lt;/td&gt;
    &lt;td&gt;The contractor agreements for executives Brittany Kaiser, Enzo Villani, and Yury Mitin each provided for bonuses consisting of $250,000
        in cash and $250,000 worth of TON tokens, payable upon the Company raising at least $50 million in equity financing through private or
        public share offerings. This milestone was achieved on January 14, 2026, upon the closing of a $15 million registered direct share offering,
        which, together with prior equity financings, resulted in aggregate equity financing proceeds in excess of $50 million. During Fiscal
        2026, the Company paid the cash portion of the bonus to each executive and accrued the TON token portion of each executive&#x2019;s bonus.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(4)&lt;/td&gt;
    &lt;td&gt;Represents employee benefits paid by the Company.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(5)&lt;/td&gt;
    &lt;td&gt;Represents the aggregate grant date fair value of 14,600 options to purchase ordinary shares granted on March 30, 2023, which vested on
        the first anniversary of the date of grant.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(6)&lt;/td&gt;
    &lt;td&gt;Represents the aggregate grant date fair value of options to purchase ordinary shares granted on March 7, 2025, which one-quarter vested
        immediately, one-quarter vested on March 7, 2026, and the remaining balance to vest in equal parts on March 7, 2027 and March 7, 2028.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(7)&lt;/td&gt;
    &lt;td&gt;Mr. Mellon and Dr. Bailey served as directors of the Company through September 25, 2025.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(8)&lt;/td&gt;
    &lt;td&gt;Dr. Renondin and Dr. Stebbin served as directors of the Company through August 3, 2025.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(9)&lt;/td&gt;
    &lt;td&gt;Mr. Mintz served as a director of the Company through February 6, 2026.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(10)&lt;/td&gt;
    &lt;td&gt;Ms. Kozick and Dr. Glassman served as directors of the Company through April 25, 2024, and Mr. Simon served as a director of the Company
        through April 24, 2024.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(11)&lt;/td&gt;
    &lt;td&gt;Mr. Pickett was appointed as our Chief Executive Officer under a consultancy agreement and joined our Board of Directors on December 15,
        2024. He resigned as Chief Executive Officer on August 2, 2025 and departed the Board of Directors on December 19, 2025.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(12)&lt;/td&gt;
    &lt;td&gt;Dr. Walters served as our Chief Executive Officer and Chairman of our Board of Directors through December 14, 2024. In accordance with
        his employment agreement, all unvested share options at that time vested immediately.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(13)&lt;/td&gt;
    &lt;td&gt;Ms. Park was appointed as our Chief Financial Officer on September 30, 2024 and left the Company in October 2025.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(14)&lt;/td&gt;
    &lt;td&gt;Mr. Shaw served as our Chief Financial Officer and Secretary through September 30, 2024. Other compensation in the amount of $127,250
        represent payments made to Mr. Shaw under a Retention Agreement and General Release (&#x201c;Retention Agreement&#x201d;) dated July 22,
        2024. Additional information concerning the Retention Agreement may be found in Note 14, Related Party Transactions to the consolidated
        financial statements included elsewhere in this Annual Report.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(15)&lt;/td&gt;
    &lt;td&gt;Mr. Wiley served as our Chief Business Officer through November 15, 2024. In accordance with his employment agreement, all unvested share
        options at that time vested immediately.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(16)&lt;/td&gt;
    &lt;td&gt;Mr. Fairchild resigned as our Vice President of Development in January 2024 but continued to provide his services as a consultant through
        May 31, 2024, his resignation date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(17)&lt;/td&gt;
    &lt;td&gt;On March 11, 2026, the Board authorized the grant of 149,015 RSUs to Ms. Kaiser, 99,344 RSUs to Mr. Mitin, and 248,359RSUs to Mr. Villani,
        which were owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private
        or public share offerings. These RSUs were formally granted on April 29, 2026.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"&gt;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Outstanding Equity Awards at Fiscal Year-End&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The following table and related notes provide certain information regarding
all outstanding equity awards for our executive officers as of March 31, 2026, as adjusted to give effect to the 1-for-20 reverse share
split completed on August 15, 2024:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfOutstandingEquityAwardsTableTextBlock_pn3n3_zUddgk7Gcfgb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BC_zds2qVV7hoNg" style="display: none"&gt;Schedule of outstanding equity awards&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_489_ecustom--GrantDate_zv5L3hacsjJi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_482_eifrs-full--AdjustedWeightedAverageShares_zXG6jKTofL26" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_484_ecustom--NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_zdw0j2DqgZS7" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_481_ecustom--ExercisePrices_zDsaBjP2lnfh" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_482_ecustom--OptionExpirationDate_zxMOuc8Am8T5" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_485_ecustom--NumberofShareUnitsofStockThetHaveNotVested_zAWcL9PojHuk" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_481_ecustom--MarketValueNumberofShareUnitsofStockThetHaveNotVested_zVLiL1qWgK3l" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Option
        Awards&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Stock
        Awards&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of Shares or&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Market Value of Shares or&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Securities Underlying&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Option&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Option&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Units of Stock&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Units of Stock&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unexercised
        Options&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Exercise&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;That Have&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;That Have&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Name&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Grant Date&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Exercisable&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unexercisable&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Price&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Not Vested&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Not Vested&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zgOPBxjAs4Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 15%; font-size: 10pt; font-style: normal"&gt;Alexander Pickett&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;3/7/2025&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;36,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3061"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;4.45&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;3/7/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3064"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3065"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettTwoMember_zZvKOqSPCb94" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;45,937&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3068"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5.73&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3071"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3072"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersMember_z6dycgWI0aA1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal; text-align: left"&gt;Ian B. Walters&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;15,085&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3075"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12/14/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3078"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3079"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersTwoMember_zd9ZGUIjKT68" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;6,285&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3082"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12/14/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3085"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3086"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersThreeMember_zJXquc5spit6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2021&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7,550&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3089"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12/14/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3092"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3093"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkMember_zBMSVdDCBMY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal; text-align: left"&gt;Andrea E. Park&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/7/2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;28,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3096"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4.45&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/7/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3099"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3100"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkTwoMember_zlaEd1lAoeMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7,820&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3103"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5.73&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3106"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3107"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z8UjEeWV6QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal"&gt;Allan Shaw&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,761&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3110"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;9/30/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3113"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3114"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawTwoMember_zG4l5SHTmNF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;840&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3117"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;9/30/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3120"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3121"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawThreeMember_z8RpUX7kiZui" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2021&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;6,550&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3124"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;9/30/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3127"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3128"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zNIBveNX6rz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal"&gt;Robert Kramer&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2,771&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3131"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2033&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3134"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3135"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerTwoMember_zAm81wtqiGEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,255&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3138"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2032&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3141"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3142"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerThreeMember_zN2YlmYF5yYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2021&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3,050&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3145"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2031&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3148"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3149"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zDZU33gCl6p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal"&gt;Brian Wiley&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2,386&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3152"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;11/15/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3155"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3156"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyTwoMember_zLLro33yoEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3159"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;11/15/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3162"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3163"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zjRR9pOhLd0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Brittany Kaiser&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/11/2026&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;545,315&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3166"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5/14/2036&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3169"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3170"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zgu2Ii9G1Ngk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Enzo Villani&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/11/2026&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;545,315&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3173"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5/14/2036&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3176"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3177"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zNOIQExz8De1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Yury Mitin&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/11/2026&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;545,315&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3180"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5/14/2036&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3183"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3184"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





























&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Notes&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(1)&lt;/td&gt;
    &lt;td&gt;Except as set forth below, vesting of all options is subject to continued service as an employee, director and/or consultant of Alpha
        Compute or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the
        date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(2)&lt;/td&gt;
    &lt;td&gt;On December 15, 2024, Mr. Pickett was appointed as a director of the Company and our Chief Executive Officer under a consultancy agreement
        and served in such capacities through December 19, 2025, his resignation date. These options were awarded to Mr. Pickett for his services
        as a director. One fourth of the options vested immediately on grant date, and the remaining vest in three equal annual installments thereafter.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(3)&lt;/td&gt;
    &lt;td&gt;Dr. Walters served as our Chief Executive Officer and a director of the Company through December 14, 2024. Pursuant to the terms of his
        employment agreement, all unvested share options immediately vested on such date. Pursuant to the terms of his share option agreements,
        the vested share options are exercisable for two years from this date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(4)&lt;/td&gt;
    &lt;td&gt;On September 30, 2024, Ms. Park was appointed as our Chief Financial Officer and departed the Company in October 2025. One fourth of the
        options vested immediately on the grant date, and the remaining vest in three equal annual installments thereafter.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(5)&lt;/td&gt;
    &lt;td&gt;Mr. Shaw served as our Chief Financial Officer through September 30, 2024. Pursuant to the terms of his share option agreements, the vested
        share options are exercisable for two years from such date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(6)&lt;/td&gt;
    &lt;td&gt;The above table excludes 4,550 RSUs to Mr. Kramer granted on January 13, 2021, with a grant date value of $1,615,250, which vested on
        the grant date but are subject to certain restrictions and 860 RSUs granted on January 19, 2022 with a grant date value of $175,784, which
        vested on the grant date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(7)&lt;/td&gt;
    &lt;td&gt;Mr. Wiley served as our Chief Business Officer through November 15, 2024. Pursuant to the terms of his employment agreement, all unvested
        shares immediately vested on such date. Pursuant to the terms of his share option agreement, the vested share options are exercisable
        for two years from such date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(8)&lt;/td&gt;
    &lt;td&gt;On March 11, 2026, the Board authorized the grant of 545,315 share options each to Ms. Kaiser, Mr. Mitin, and Mr. Villani, which were
        owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private or public
        share offerings. These share options were formally granted on May 14, 2026.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_zE2OMNS89Pl9" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ptgef:SaleOfStock
      contextRef="AsOf2025-01-29"
      decimals="INF"
      id="Fact002318"
      unitRef="Shares">524390</ptgef:SaleOfStock>
    <ptgef:AggregateProceeds
      contextRef="AsOf2025-01-29"
      decimals="0"
      id="Fact002320"
      unitRef="USD">2150000</ptgef:AggregateProceeds>
    <ptgef:Decentranet
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002326"
      unitRef="USD">55000</ptgef:Decentranet>
    <ptgef:ScheduleOfCompensationPayableTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002332">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfCompensationPayableTableTextBlock_pn3n3_zHXd7Jnzfrck" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BA_zixr8vFgcR02" style="display: none"&gt;Schedule of compensation payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20250401__20260331_zsRoltRPBld9" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20240401__20250331_zsUMlGFMdxLi" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20230401__20240331_z3f7odmy8b53" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Years ended March 31,&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--ShorttermEmployeeBenefitsExpense_z3Z4JOrwThD3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;Short-term employee benefits (salary, bonus, etc.)&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;4,052&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;13,787&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;2,127&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--PostemploymentBenefitExpenseInProfitOrLoss_zgWTLhldnN2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Post-employment benefits&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--OtherLongtermBenefits_z3xdmb0zVY02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Other long-term benefits&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TerminationBenefitsExpense_zafHHyIajBx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Termination benefits&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;152&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;49&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--SharebasedPaymentCompensation_zOi8VtKNS8R6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Share-based payment compensation&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,600&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;590&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--KeyManagementPersonnelCompensationPostemploymentBenefits_zCLlzQjclxc6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White; font-size: 10pt"&gt;&#160;Total&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;5,804&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,968&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,176&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</ptgef:ScheduleOfCompensationPayableTableTextBlock>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002334"
      unitRef="USD">4052000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002335"
      unitRef="USD">13787000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact002336"
      unitRef="USD">2127000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002346"
      unitRef="USD">152000</ifrs-full:TerminationBenefitsExpense>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact002348"
      unitRef="USD">49000</ifrs-full:TerminationBenefitsExpense>
    <ptgef:SharebasedPaymentCompensation
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002350"
      unitRef="USD">1600000</ptgef:SharebasedPaymentCompensation>
    <ptgef:SharebasedPaymentCompensation
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002351"
      unitRef="USD">590000</ptgef:SharebasedPaymentCompensation>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact002354"
      unitRef="USD">5804000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact002355"
      unitRef="USD">1968000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact002356"
      unitRef="USD">2176000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact002361">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_pn3n3_zsSJyhx1c6Hc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B3_zt4kH5O16nzc" style="display: none"&gt;Schedule of Compensation&lt;/span&gt;&lt;b&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Name &amp;amp; Principal Position&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Year&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Fee and&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Salary&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Transaction&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Closing Bonus&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Securities Under&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Options Granted&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Shares
        or Units&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(16)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Other&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total
        Compensation&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Michael Terpin&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNonqqAnuxL6" style="width: 6%; font-size: 10pt; text-align: right" title="Fee and salary"&gt;61,250&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoGAzHJAW9ha" style="width: 6%; font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2365"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBJ5jtH5VJxi" style="width: 6%; font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2367"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXUS9z2RFnKe" style="width: 6%; font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2369"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zo5x151YrI08" style="width: 6%; font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2371"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zeGeIqzBlHHa" style="width: 6%; font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2373"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MichaelTerpinMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKAQnKIBVFl" style="width: 6%; font-size: 10pt; text-align: right" title="Total compensation"&gt;61,250&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;F. Daniel Siciliano&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionExpense_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAxjPVuOqAd1" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;17,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionIncome_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0Ds2tWNJgJf" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2379"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zViTOGYOjUTb" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2381"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3EDhTZQUYtk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2383"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzKfKYHRU4df" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2385"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQAzgB6RPKmk" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2387"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--FDanielSicilianoMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxHSyyvchTo5" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;17,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Gregory H. Bailey, M.D.&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zKA2GK6DRIsb" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zclrmtQoP3W8" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3E62n2WJsch" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2395"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3Laoj6J7x6l" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2397"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zaQPMUPA12H9" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2399"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDEwTQWqSVWl" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2401"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zYYV6QOSnEii" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;55,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zQW0F083ILE8" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zzLkgMAohvck" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2407"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9zPiAillZth" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2409"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcxjFC5oiD82" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2411"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdpe9o9DRVRe" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2413"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zJVTE3UPEleg" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2415"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z0EPcEey05sf" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember_zafYIIQiMnc6" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;49,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjHLde5nX3Ka" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2421"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV8qA7QLXBM" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2423"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zq29hiLqruh1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2425"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zidJETtEIj0l" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2427"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zOKkHDjgv5kg" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2429"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--GregoryHBaileyMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr7iC3iWVabk" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;49,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;James Mellon&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zkYEtExNX3L8" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTjiH2TcAZI7" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_znhHbc0cne87" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2437"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zawteqprpt8c" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2439"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHczKE0v7c61" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2441"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCpjNRF2mW7" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2443"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5rHhXnKidG6" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;55,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zWig206U3G18" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfu21gboJ1tk" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2449"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdxYO2zK8eqa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2451"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUcKJJa0bhBf" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2453"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjf6JrncjUyb" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2455"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqKSY5CqTFQe" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2457"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTy5cU7HFV8f" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember_zw2QCK6ec9pi" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;35,242&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhtuMXozwUg2" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2463"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBDeiB7FkJYf" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2465"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zM1t9ctOZH3i" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2467"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyAu82T1XFni" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2469"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zoebWFZWmLZj" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JamesMellonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQlZs1WrdtE1" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;35,242&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Steven Mintz&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zK96CTLr4KUh" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;77,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZ3OGprqhqdc" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPEXV0JcrOGk" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2479"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zfvaAeHDuLK3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;54,796&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztrvWOcSlcsb" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2483"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z4VfQDhLBvr4" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2485"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhjUsjqSYTi4" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;157,296&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zESRkB16EQy" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbyRiuRbTuIe" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2491"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2Vmxgqk48k8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2493"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMg9yIgKCJBg" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;113,158&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zG3vzCuGNoxi" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2497"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z59r180DH0gd" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2499"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zmGKMJGieq5h" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;143,158&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember_zVw44CDH5dJ7" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;45,750&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwiyV4Epblrb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2505"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zObscOD9MX7h" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2507"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQYts612ziEc" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2509"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKS6PeaJLfE6" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2511"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlQzVcEdoni3" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2513"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StevenMintzMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zGWAWnEfDsil" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;45,750&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Jean-Christophe Renondin, M.D.&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zlfHg9RK3Rq4" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCwBzTB6Tehc" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zjoDgQ1BiKXi" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2521"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--SecuritiesUnderOptionsGranted_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqK9q24YXjn5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;54,796&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyUIr0qWbKhk" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2525"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zv9U42HQIach" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2527"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zT9pNoVuuFN2" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;109,796&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_zPxvg4vmLqY2" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNNyYB3ivBO1" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2533"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEsWlDotiEAd" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2535"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMJYowivhzb1" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;96,992&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zin1LxHAWUNj" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2539"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zVtfsIEfAri6" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2541"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ziu28NvBoHPk" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;126,992&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember_z75HluNHcuTe" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2545"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIHqOh38LsRb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2547"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zHmEUgDNtzBe" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2549"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--SecuritiesUnderOptionsGranted_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCKmV9NTn7w5" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2551"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zdFx3W0dfNC3" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2553"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zANYBart5atk" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2555"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JeanChristopheRenondinMDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z9sT2Ix8V7l8" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2557"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Justin Stebbing, M.D. PhD&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_z2XVSuy8aLk9" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEqzzTFqvfXb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;25,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFDJzVGeF81e" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2563"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zIEBADLsTBd9" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;64,760&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlqOVuJSjh34" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2567"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvtSbnsTGWWl" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2569"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zedrsawnoOL4" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;119,760&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zf6HK6RHLWDh" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;30,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zA28749keNBk" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2575"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2RqB6D16r43" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2577"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zyddtzDsyDzi" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;121,240&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;(5)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zDN79Ubqn1" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2581"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zm2UjAPrRcrf" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2583"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNXemAyLNf1" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;151,240&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember_zykeYTyHgPE9" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2587"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsWWmglVHGT4" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2589"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgB2nUeblEPa" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2591"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcQYHpDiclT3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2593"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zqF6sXtREO3h" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2595"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_ztFzI9yvPxfj" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2597"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--JustinStebbingMDPhDMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zQzOCViYiew7" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2599"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Linda Kozick&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zovruTySfId" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2601"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zkjeS6ybUqid" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2603"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWnki9hi25J8" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2605"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zBOPWIdToL4e" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2607"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zxQqGNhqk2ul" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2609"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zFUoJqbH15Ze" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2611"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zgQvMyONcsPe" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2613"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zYn1MzZ5W86d" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2615"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zCWtdzLwNGR2" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2617"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zERocssYs7ia" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2619"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAHFQeeI0HD3" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2621"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zNVDfucmuhr6" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2623"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV0Wd7pQjWy6" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2625"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z7sbm2QsPH98" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2627"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember_zvdbgjx5V7W7" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;42,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zcGa3Q6kgqsb" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2631"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zPHe0cUYrxBg" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2633"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z1TiHjTnJaii" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2635"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZa3YuppNtv7" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2637"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zsZPQcnLKMsb" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2639"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--LindaKozickMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zr9JH4Y9zCf5" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;42,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Mark Simon&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z3o4vt2SH14h" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2643"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zy2icmNOfQ6c" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2645"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSWn5iEL3Pd6" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2647"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zpWBlry94uwk" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2649"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAEfHnsSJ9T3" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2651"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zEKwVCuNjS2a" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2653"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zV6hacfGlro6" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2655"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_zPzxiVbd5jvj" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2657"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWu738896MJd" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2659"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zUSHpXd20fGl" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2661"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z3g5SeQqJbF8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2663"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zAV11Afrww21" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2665"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_za0HrOXyFQX3" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2667"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zWRzANTguJke" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2669"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember_z9ajTWyVlY6d" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;55,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z2bSz4QeWlel" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2673"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z8cJcD5mYKm3" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2675"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zblyaUGazip8" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2677"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj5sjbH4qSDc" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2679"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zMX6fWtOk2kd" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2681"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MarkSimonMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSME3co5fKs4" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;55,500&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal"&gt;Robert Glassman&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zQySdV047Tic" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2685"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--FeeAndCommissionIncome_c20250401__20260331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zTJWhurMpP02" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2687"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--TransactionClosingBonus_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zSfs9jdBhhri" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2689"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zXFY3pmarW25" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2691"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--NumberOfSharesIssued_iI_c20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zZXTLYmgUsmc" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2693"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--OtherCompensation_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zrxZi6X6OiBl" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2695"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z5wbwwQk5Bk6" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2697"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--FeeAndCommissionExpense_c20240401__20250331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zs32GrJba2ra" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2699"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--FeeAndCommissionIncome_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zj6i0XkDl3w2" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2701"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransactionClosingBonus_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_z6C27MJSgYn7" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2703"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zF3eb7ynJui7" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2705"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zKd32So0gR5f" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2707"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--OtherCompensation_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zhCzgbRnYmIb" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2709"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zbGNoa8KJwNa" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2711"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2024&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--FeeAndCommissionExpense_c20230401__20240331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember_zgb4SR5eT5K2" style="font-size: 10pt; text-align: right" title="Fee and salary"&gt;45,258&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--FeeAndCommissionIncome_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zw9Fd80Mp8H3" style="font-size: 10pt; text-align: right" title="Bonus compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2715"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransactionClosingBonus_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zg9P2hh7j3l4" style="font-size: 10pt; text-align: right" title="Transaction closing bonus"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2717"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--SecuritiesUnderOptionsGranted_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zlsZDtlIXCj6" style="font-size: 10pt; text-align: right" title=" Securities Under options Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2719"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--NumberOfSharesIssued_iI_c20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zvzYssiMoRwg" style="font-size: 10pt; text-align: right" title="Shares or units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2721"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OtherCompensation_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zU85u4TYgDY5" style="font-size: 10pt; text-align: right" title="Other compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2723"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertGlassmanMember__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--DirectorCompensationMember_zwbCohDoSo3f" style="font-size: 10pt; text-align: right" title="Total compensation"&gt;45,258&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember"
      decimals="-3"
      id="Fact002363"
      unitRef="USD">61250000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_MichaelTerpinMember_custom_DirectorCompensationMember"
      decimals="-3"
      id="Fact002375"
      unitRef="USD">61250000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember"
      decimals="-3"
      id="Fact002377"
      unitRef="USD">17500000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_FDanielSicilianoMember_custom_DirectorCompensationMember"
      decimals="-3"
      id="Fact002389"
      unitRef="USD">17500000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      decimals="-3"
      id="Fact002391"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      decimals="-3"
      id="Fact002393"
      unitRef="USD">25000000</ifrs-full:FeeAndCommissionIncome>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      decimals="-3"
      id="Fact002403"
      unitRef="USD">55000000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      decimals="-3"
      id="Fact002405"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      decimals="-3"
      id="Fact002417"
      unitRef="USD">30000000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      decimals="-3"
      id="Fact002419"
      unitRef="USD">49500000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_GregoryHBaileyMDMember"
      decimals="-3"
      id="Fact002431"
      unitRef="USD">49500000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      decimals="-3"
      id="Fact002433"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      decimals="-3"
      id="Fact002435"
      unitRef="USD">25000000</ifrs-full:FeeAndCommissionIncome>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      decimals="-3"
      id="Fact002445"
      unitRef="USD">55000000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      decimals="-3"
      id="Fact002447"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      decimals="-3"
      id="Fact002459"
      unitRef="USD">30000000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      decimals="-3"
      id="Fact002461"
      unitRef="USD">35242000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_JamesMellonMember"
      decimals="-3"
      id="Fact002473"
      unitRef="USD">35242000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002475"
      unitRef="USD">77500000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002477"
      unitRef="USD">25000000</ifrs-full:FeeAndCommissionIncome>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002481"
      unitRef="USD">54796000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002487"
      unitRef="USD">157296000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002489"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002495"
      unitRef="USD">113158000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002501"
      unitRef="USD">143158000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002503"
      unitRef="USD">45750000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_StevenMintzMember"
      decimals="-3"
      id="Fact002515"
      unitRef="USD">45750000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      decimals="-3"
      id="Fact002517"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      decimals="-3"
      id="Fact002519"
      unitRef="USD">25000000</ifrs-full:FeeAndCommissionIncome>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      decimals="-3"
      id="Fact002523"
      unitRef="USD">54796000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      decimals="-3"
      id="Fact002529"
      unitRef="USD">109796000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      decimals="-3"
      id="Fact002531"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      decimals="-3"
      id="Fact002537"
      unitRef="USD">96992000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JeanChristopheRenondinMDMember"
      decimals="-3"
      id="Fact002543"
      unitRef="USD">126992000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      decimals="-3"
      id="Fact002559"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      decimals="-3"
      id="Fact002561"
      unitRef="USD">25000000</ifrs-full:FeeAndCommissionIncome>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      decimals="-3"
      id="Fact002565"
      unitRef="USD">64760000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      decimals="-3"
      id="Fact002571"
      unitRef="USD">119760000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      decimals="-3"
      id="Fact002573"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      decimals="-3"
      id="Fact002579"
      unitRef="USD">121240000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_DirectorCompensationMember_custom_JustinStebbingMDPhDMember"
      decimals="-3"
      id="Fact002585"
      unitRef="USD">151240000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      decimals="-3"
      id="Fact002629"
      unitRef="USD">42000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_LindaKozickMember"
      decimals="-3"
      id="Fact002641"
      unitRef="USD">42000000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      decimals="-3"
      id="Fact002671"
      unitRef="USD">55500000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_MarkSimonMember"
      decimals="-3"
      id="Fact002683"
      unitRef="USD">55500000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      decimals="-3"
      id="Fact002713"
      unitRef="USD">45258000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_DirectorCompensationMember_custom_RobertGlassmanMember"
      decimals="-3"
      id="Fact002725"
      unitRef="USD">45258000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_MarkSimonMember"
      decimals="-3"
      id="Fact002731"
      unitRef="USD">661290000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember"
      decimals="-3"
      id="Fact002735"
      unitRef="USD">500000000</ptgef:TransactionClosingBonus>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember"
      decimals="-3"
      id="Fact002737"
      unitRef="USD">218219000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember"
      decimals="-3"
      id="Fact002739"
      unitRef="Shares">149015000</ifrs-full:NumberOfSharesIssued>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember"
      decimals="-3"
      id="Fact002741"
      unitRef="USD">187102000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrittanyKaiserMember"
      decimals="-3"
      id="Fact002743"
      unitRef="USD">1715627000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember"
      decimals="-3"
      id="Fact002745"
      unitRef="USD">369355000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember"
      decimals="-3"
      id="Fact002749"
      unitRef="USD">500000000</ptgef:TransactionClosingBonus>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember"
      decimals="-3"
      id="Fact002751"
      unitRef="USD">218219000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember"
      decimals="-3"
      id="Fact002753"
      unitRef="Shares">248359000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_EnzoVillaniMember"
      decimals="-3"
      id="Fact002757"
      unitRef="USD">1335933000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember"
      decimals="-3"
      id="Fact002759"
      unitRef="USD">219086000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_WesLevittMember"
      decimals="-3"
      id="Fact002767"
      unitRef="USD">219086000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember"
      decimals="-3"
      id="Fact002769"
      unitRef="USD">369355000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:TransactionClosingBonus
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember"
      decimals="-3"
      id="Fact002773"
      unitRef="USD">500000000</ptgef:TransactionClosingBonus>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember"
      decimals="-3"
      id="Fact002775"
      unitRef="USD">218219000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember"
      decimals="-3"
      id="Fact002777"
      unitRef="Shares">99344000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_YuryMitinMember"
      decimals="-3"
      id="Fact002781"
      unitRef="USD">1186918000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002783"
      unitRef="USD">51250000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002785"
      unitRef="USD">25000000</ifrs-full:FeeAndCommissionIncome>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002789"
      unitRef="USD">234132000</ptgef:SecuritiesUnderOptionsGranted>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002793"
      unitRef="USD">39000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002795"
      unitRef="USD">310422000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002797"
      unitRef="USD">30000000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002803"
      unitRef="USD">145488000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact002809"
      unitRef="USD">175488000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ptgef:OtherCompensation
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002821"
      unitRef="USD">152383000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002823"
      unitRef="USD">152383000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002825"
      unitRef="USD">453186000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002835"
      unitRef="USD">54716000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002837"
      unitRef="USD">507902000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002839"
      unitRef="USD">642700000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002849"
      unitRef="USD">75185000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_IanWaltersMember"
      decimals="-3"
      id="Fact002851"
      unitRef="USD">717885000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002853"
      unitRef="USD">218429000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionIncome
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002855"
      unitRef="USD">50000000</ifrs-full:FeeAndCommissionIncome>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002859"
      unitRef="USD">39857000</ptgef:SecuritiesUnderOptionsGranted>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2025-04-012026-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002865"
      unitRef="USD">308286000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002867"
      unitRef="USD">163790000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:SecuritiesUnderOptionsGranted
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002873"
      unitRef="USD">113158000</ptgef:SecuritiesUnderOptionsGranted>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002877"
      unitRef="USD">28659000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AndreaParkMember"
      decimals="-3"
      id="Fact002879"
      unitRef="USD">305607000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      decimals="-3"
      id="Fact002895"
      unitRef="USD">234500000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      decimals="-3"
      id="Fact002907"
      unitRef="USD">234500000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      decimals="-3"
      id="Fact002909"
      unitRef="USD">469000000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      decimals="-3"
      id="Fact002919"
      unitRef="USD">49205000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_AllanShawMember"
      decimals="-3"
      id="Fact002921"
      unitRef="USD">518205000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      decimals="-3"
      id="Fact002937"
      unitRef="USD">112500000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      decimals="-3"
      id="Fact002947"
      unitRef="USD">6750000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      decimals="-3"
      id="Fact002949"
      unitRef="USD">119250000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      decimals="-3"
      id="Fact002951"
      unitRef="USD">168750000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      decimals="-3"
      id="Fact002961"
      unitRef="USD">17141000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_RobertKramerMember"
      decimals="-3"
      id="Fact002963"
      unitRef="USD">185891000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      decimals="-3"
      id="Fact002979"
      unitRef="USD">114844000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      decimals="-3"
      id="Fact002989"
      unitRef="USD">8627000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      decimals="-3"
      id="Fact002991"
      unitRef="USD">123471000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      decimals="-3"
      id="Fact002993"
      unitRef="USD">153125000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      decimals="-3"
      id="Fact003003"
      unitRef="USD">2297000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_BrianWileyMember"
      decimals="-3"
      id="Fact003005"
      unitRef="USD">155422000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      decimals="-3"
      id="Fact003021"
      unitRef="USD">20000000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      decimals="-3"
      id="Fact003033"
      unitRef="USD">20000000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      decimals="-3"
      id="Fact003035"
      unitRef="USD">270000000</ifrs-full:FeeAndCommissionExpense>
    <ptgef:OtherCompensation
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      decimals="-3"
      id="Fact003045"
      unitRef="USD">55301000</ptgef:OtherCompensation>
    <ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31_custom_ExecutiveOfficerCompensationMember_custom_JustinFairchildMember"
      decimals="-3"
      id="Fact003047"
      unitRef="USD">325301000</ifrs-full:CompensationFromThirdPartiesForItemsOfPropertyPlantAndEquipment>
    <ptgef:ScheduleOfOutstandingEquityAwardsTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact003058">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfOutstandingEquityAwardsTableTextBlock_pn3n3_zUddgk7Gcfgb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BC_zds2qVV7hoNg" style="display: none"&gt;Schedule of outstanding equity awards&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_489_ecustom--GrantDate_zv5L3hacsjJi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_482_eifrs-full--AdjustedWeightedAverageShares_zXG6jKTofL26" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_484_ecustom--NumberofSecuritiesUnderlyingUnexercisedOptionsUnExercisable_zdw0j2DqgZS7" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_481_ecustom--ExercisePrices_zDsaBjP2lnfh" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_482_ecustom--OptionExpirationDate_zxMOuc8Am8T5" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_485_ecustom--NumberofShareUnitsofStockThetHaveNotVested_zAWcL9PojHuk" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_481_ecustom--MarketValueNumberofShareUnitsofStockThetHaveNotVested_zVLiL1qWgK3l" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Option
        Awards&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Stock
        Awards&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of Shares or&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Market Value of Shares or&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Securities Underlying&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Option&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Option&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Units of Stock&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Units of Stock&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unexercised
        Options&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Exercise&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;That Have&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;That Have&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Name&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Grant Date&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: normal; text-align: center"&gt;Exercisable&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unexercisable&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Price&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Not Vested&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Not Vested&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettMember_zgOPBxjAs4Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 15%; font-size: 10pt; font-style: normal"&gt;Alexander Pickett&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;3/7/2025&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;36,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3061"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;4.45&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;3/7/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3064"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3065"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AlexanderPickettTwoMember_zZvKOqSPCb94" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;45,937&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3068"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5.73&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3071"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3072"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersMember_z6dycgWI0aA1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal; text-align: left"&gt;Ian B. Walters&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;15,085&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3075"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12/14/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3078"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3079"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersTwoMember_zd9ZGUIjKT68" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;6,285&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3082"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12/14/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3085"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3086"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IanBWaltersThreeMember_zJXquc5spit6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2021&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7,550&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3089"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12/14/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3092"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3093"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkMember_zBMSVdDCBMY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal; text-align: left"&gt;Andrea E. Park&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/7/2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;28,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3096"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4.45&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/7/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3099"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3100"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AndreaEParkTwoMember_zlaEd1lAoeMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7,820&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3103"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5.73&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7/27/2035&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3106"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3107"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawMember_z8UjEeWV6QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal"&gt;Allan Shaw&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,761&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3110"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;9/30/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3113"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3114"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawTwoMember_zG4l5SHTmNF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;840&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3117"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;9/30/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3120"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3121"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AllanShawThreeMember_z8RpUX7kiZui" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2021&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;6,550&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3124"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;9/30/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3127"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3128"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerMember_zNIBveNX6rz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal"&gt;Robert Kramer&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2,771&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3131"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2033&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3134"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3135"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerTwoMember_zAm81wtqiGEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,255&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3138"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2032&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3141"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3142"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RobertKramerThreeMember_zN2YlmYF5yYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2021&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3,050&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3145"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;355.00&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/13/2031&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3148"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3149"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyMember_zDZU33gCl6p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-style: normal"&gt;Brian Wiley&lt;span style="font-size: 10pt; font-style: normal; font-weight: 700"&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/30/2023&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;2,386&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3152"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;58.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;11/15/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3155"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3156"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrianWileyTwoMember_zLLro33yoEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1/19/2022&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3159"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;204.40&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;11/15/2026&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3162"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3163"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--BrittanyKaiserMember_zjRR9pOhLd0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Brittany Kaiser&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/11/2026&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;545,315&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3166"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5/14/2036&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3169"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3170"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--EnzoVillaniMember_zgu2Ii9G1Ngk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Enzo Villani&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/11/2026&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;545,315&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3173"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5/14/2036&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3176"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3177"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41A_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--YuryMitinMember_zNOIQExz8De1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: 400; font-style: normal; text-align: left"&gt;Yury Mitin&lt;span style="font-size: 10pt; font-style: normal; font-weight: 400"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3/11/2026&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;545,315&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3180"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1.30&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5/14/2036&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3183"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3184"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





























&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Notes&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(1)&lt;/td&gt;
    &lt;td&gt;Except as set forth below, vesting of all options is subject to continued service as an employee, director and/or consultant of Alpha
        Compute or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the
        date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.75in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(2)&lt;/td&gt;
    &lt;td&gt;On December 15, 2024, Mr. Pickett was appointed as a director of the Company and our Chief Executive Officer under a consultancy agreement
        and served in such capacities through December 19, 2025, his resignation date. These options were awarded to Mr. Pickett for his services
        as a director. One fourth of the options vested immediately on grant date, and the remaining vest in three equal annual installments thereafter.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(3)&lt;/td&gt;
    &lt;td&gt;Dr. Walters served as our Chief Executive Officer and a director of the Company through December 14, 2024. Pursuant to the terms of his
        employment agreement, all unvested share options immediately vested on such date. Pursuant to the terms of his share option agreements,
        the vested share options are exercisable for two years from this date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(4)&lt;/td&gt;
    &lt;td&gt;On September 30, 2024, Ms. Park was appointed as our Chief Financial Officer and departed the Company in October 2025. One fourth of the
        options vested immediately on the grant date, and the remaining vest in three equal annual installments thereafter.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(5)&lt;/td&gt;
    &lt;td&gt;Mr. Shaw served as our Chief Financial Officer through September 30, 2024. Pursuant to the terms of his share option agreements, the vested
        share options are exercisable for two years from such date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(6)&lt;/td&gt;
    &lt;td&gt;The above table excludes 4,550 RSUs to Mr. Kramer granted on January 13, 2021, with a grant date value of $1,615,250, which vested on
        the grant date but are subject to certain restrictions and 860 RSUs granted on January 19, 2022 with a grant date value of $175,784, which
        vested on the grant date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(7)&lt;/td&gt;
    &lt;td&gt;Mr. Wiley served as our Chief Business Officer through November 15, 2024. Pursuant to the terms of his employment agreement, all unvested
        shares immediately vested on such date. Pursuant to the terms of his share option agreement, the vested share options are exercisable
        for two years from such date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;(8)&lt;/td&gt;
    &lt;td&gt;On March 11, 2026, the Board authorized the grant of 545,315 share options each to Ms. Kaiser, Mr. Mitin, and Mr. Villani, which were
        owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private or public
        share offerings. These share options were formally granted on May 14, 2026.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ptgef:ScheduleOfOutstandingEquityAwardsTableTextBlock>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember"
      id="Fact003059">3/7/2025</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember"
      decimals="-3"
      id="Fact003060"
      unitRef="Shares">36000000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember"
      id="Fact003062">4.45</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettMember"
      id="Fact003063">3/7/2035</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember"
      id="Fact003066">7/27/2025</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember"
      decimals="-3"
      id="Fact003067"
      unitRef="Shares">45937000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember"
      id="Fact003069">5.73</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_AlexanderPickettTwoMember"
      id="Fact003070">7/27/2035</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember"
      id="Fact003073">3/30/2023</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember"
      decimals="-3"
      id="Fact003074"
      unitRef="Shares">15085000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember"
      id="Fact003076">58.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersMember"
      id="Fact003077">12/14/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember"
      id="Fact003080">1/19/2022</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember"
      decimals="-3"
      id="Fact003081"
      unitRef="Shares">6285000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember"
      id="Fact003083">204.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersTwoMember"
      id="Fact003084">12/14/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember"
      id="Fact003087">1/13/2021</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember"
      decimals="-3"
      id="Fact003088"
      unitRef="Shares">7550000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember"
      id="Fact003090">355.00</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_IanBWaltersThreeMember"
      id="Fact003091">12/14/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember"
      id="Fact003094">3/7/2025</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember"
      decimals="-3"
      id="Fact003095"
      unitRef="Shares">28000000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember"
      id="Fact003097">4.45</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkMember"
      id="Fact003098">3/7/2035</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember"
      id="Fact003101">7/27/2025</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember"
      decimals="-3"
      id="Fact003102"
      unitRef="Shares">7820000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember"
      id="Fact003104">5.73</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_AndreaEParkTwoMember"
      id="Fact003105">7/27/2035</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_AllanShawMember"
      id="Fact003108">3/30/2023</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_AllanShawMember"
      decimals="-3"
      id="Fact003109"
      unitRef="Shares">1761000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_AllanShawMember"
      id="Fact003111">58.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_AllanShawMember"
      id="Fact003112">9/30/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember"
      id="Fact003115">1/19/2022</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember"
      decimals="-3"
      id="Fact003116"
      unitRef="Shares">840000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember"
      id="Fact003118">204.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_AllanShawTwoMember"
      id="Fact003119">9/30/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember"
      id="Fact003122">1/13/2021</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember"
      decimals="-3"
      id="Fact003123"
      unitRef="Shares">6550000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember"
      id="Fact003125">355.00</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_AllanShawThreeMember"
      id="Fact003126">9/30/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_RobertKramerMember"
      id="Fact003129">3/30/2023</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_RobertKramerMember"
      decimals="-3"
      id="Fact003130"
      unitRef="Shares">2771000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_RobertKramerMember"
      id="Fact003132">58.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_RobertKramerMember"
      id="Fact003133">3/30/2033</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember"
      id="Fact003136">1/19/2022</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember"
      decimals="-3"
      id="Fact003137"
      unitRef="Shares">1255000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember"
      id="Fact003139">204.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_RobertKramerTwoMember"
      id="Fact003140">1/19/2032</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember"
      id="Fact003143">1/13/2021</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember"
      decimals="-3"
      id="Fact003144"
      unitRef="Shares">3050000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember"
      id="Fact003146">355.00</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_RobertKramerThreeMember"
      id="Fact003147">1/13/2031</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_BrianWileyMember"
      id="Fact003150">3/30/2023</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_BrianWileyMember"
      decimals="-3"
      id="Fact003151"
      unitRef="Shares">2386000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_BrianWileyMember"
      id="Fact003153">58.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_BrianWileyMember"
      id="Fact003154">11/15/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember"
      id="Fact003157">1/19/2022</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember"
      decimals="-3"
      id="Fact003158"
      unitRef="Shares">3000000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember"
      id="Fact003160">204.40</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_BrianWileyTwoMember"
      id="Fact003161">11/15/2026</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember"
      id="Fact003164">3/11/2026</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember"
      decimals="-3"
      id="Fact003165"
      unitRef="Shares">545315000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember"
      id="Fact003167">1.30</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_BrittanyKaiserMember"
      id="Fact003168">5/14/2036</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember"
      id="Fact003171">3/11/2026</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember"
      decimals="-3"
      id="Fact003172"
      unitRef="Shares">545315000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember"
      id="Fact003174">1.30</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_EnzoVillaniMember"
      id="Fact003175">5/14/2036</ptgef:OptionExpirationDate>
    <ptgef:GrantDate
      contextRef="From2025-04-012026-03-31_custom_YuryMitinMember"
      id="Fact003178">3/11/2026</ptgef:GrantDate>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2025-04-012026-03-31_custom_YuryMitinMember"
      decimals="-3"
      id="Fact003179"
      unitRef="Shares">545315000</ifrs-full:AdjustedWeightedAverageShares>
    <ptgef:ExercisePrices
      contextRef="From2025-04-012026-03-31_custom_YuryMitinMember"
      id="Fact003181">1.30</ptgef:ExercisePrices>
    <ptgef:OptionExpirationDate
      contextRef="From2025-04-012026-03-31_custom_YuryMitinMember"
      id="Fact003182">5/14/2036</ptgef:OptionExpirationDate>
    <ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact003192">&lt;p id="xdx_80F_ecustom--DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_z5MIA4iv3GT8" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
22. &lt;span id="xdx_82B_z4CGRHbfWm3g"&gt;FINANCIAL INSTRUMENTS AND RISK MANAGEMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s financial instruments recognized
in the Company&#x2019;s consolidated statements of financial position consist of the following:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Fair value estimates are made at a specific point in
time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties
and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could
significantly affect these estimates.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The following table summarizes the Company&#x2019;s financial instruments
as of March 31, 2026 and 2025 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_pn3n3_zopiDedCWlsj" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zP6ymNiXA3pj" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zrf25agWTCtl" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zqXWYoAPlBYb" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zHT3SIfzSXld" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z67FiqFDONzi" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zMq4F3VxRHq5" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial assets&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;686&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3208"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3209"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;1,670&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3211"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3212"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--Stablecoin_i01I_pn3n3_z4e3MwE56iRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Stablecoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3215"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3216"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3217"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3218"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3219"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3_zhCqM31u9Eg9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,984&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3222"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3223"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;555&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3225"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3226"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 48%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z4sBZhEDAyW7" style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zwLMtx0mT413" style="font-size: 10pt; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zrTGko2d4Dwd" style="font-size: 10pt; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zfFMkwFheHT" style="font-size: 10pt; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Amortized &lt;br/&gt;Cost&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"&gt;&lt;b&gt;FVTPL&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"&gt;&lt;b&gt;FVTPL&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3_zxH3Lyhkpnfd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,146&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3234"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,100&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3236"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TonPayableToSettlePutRightsExercised_i01I_pn3n3_zqvR3mXfUEmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3238"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,425&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3240"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3241"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--PutRightLiability_i01I_pn3n3_zQLRQYSyQa81" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3243"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,105&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3245"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3246"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3248"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;192&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3250"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,952&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--LeaseLiabilityCurrentAndNoncurrent_i01I_pn3n3_zjFhkn48tGci" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Lease liability - current and noncurrent&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3253"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;138&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3255"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3256"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A2_zfMYLKFaEllf" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;*FVTOCI refers to financial assets and liabilities with changes in fair
value recognized within other comprehensive income.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;**FVTPL refers to financial assets and liabilities with changes in fair
value recognized within the statement of operations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;A summary of the Company&#x2019;s risk exposures as it relates to
financial instruments are reflected below.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s financial assets and liabilities are comprised of cash
and cash equivalents, receivables and investments in equities and private entities, current digital assets at fair value, stablecoins,
accounts payable and accrued liabilities, lease liability, and warrant liability.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company classifies the fair value of these transactions according to
the following fair value hierarchy based on the amount of observable inputs used to value the instrument:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 20.65pt"&gt;&lt;/td&gt;
    &lt;td style="width: 16.35pt"&gt;&#xb7;&lt;/td&gt;
    &lt;td&gt;Level 1 &#x2013; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the
        reporting date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 20.65pt"&gt;&lt;/td&gt;
    &lt;td style="width: 16.35pt"&gt;&#xb7;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
        can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
        the reporting date.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 20.65pt"&gt;&lt;/td&gt;
    &lt;td style="width: 16.35pt"&gt;&#xb7;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
        as Level 3 financial instrument.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Assessment of the significance of a particular input to the fair value measurement
requires judgment and may affect the placement within the fair value hierarchy.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;The following methods and assumptions were used to estimate their
fair values:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;b&gt;Investment in Compedica&lt;/b&gt;: The fair value of the investment used by
management is based on multiples analysis of publicly traded comparable companies as the Company is pre-revenue, along with Compedica&#x2019;s
holdings in the Company&#x2019;s ordinary shares (Level 3 inputs) (see Note 10, &#x201c;Investment in Compedica&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;b&gt;Put Option Liability&lt;/b&gt;: The fair value is estimated using a Black-Scholes
model and in certain cases, a Monte Carlo simulation (Level 3) (see Note 12, &#x201c;Put Right Liability and TON Payable&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;b&gt;TON Payable&lt;/b&gt;: The fair value corresponds to the valuation of the TON
owed to the respective investors based on the Level 3 inputs denoted above (see Note 12, &#x201c;Put Right Liability and TON Payable&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 20.75pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&lt;b&gt;Warrant Liability&lt;/b&gt;: The Series B Warrants, the Series C Warrants and
the 2023 and 2026 Placement Agent Warrants include the obligation, in the event of a Fundamental Transaction, as defined in the Series
B Warrants, the Series C Warrants and the 2023 and 2026 Placement Agent Warrants, for the Company or the successor entity to purchase
the warrants from the holder at the discretion of the holder and at the Black-Scholes value, as defined in the warrant agreements. As
a result, management concluded that, in line with IFRS 9 and paragraphs16A and 16B of IAS 32, such warrants will be accounted for as financial
liabilities on the consolidated statement of financial position with the changes in fair value recognized in the consolidated statement
of operations and other comprehensive loss. See Note 11, &#x201c;Warrant Liability&#x201d; for further discussion.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The fair value is estimated using a Black-Scholes model and in certain cases,
a Monte Carlo simulation (Level 3) (see Note 11, &#x201c;Warrant Liability&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The following tables present the Company&#x2019;s assets, including digital
assets accounted for in accordance with IAS 38 &#x201c;&lt;i&gt;Intangible Assets&lt;/i&gt;&#x201d; (Level 1 and Level 3) (see Note 7, &#x201c;Digital
Assets&#x201d;), and financial liabilities that are measured at fair value (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock_pn3n3_zVLrHZkHFJR2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BB_zE0eYMntBHej" style="display: none"&gt;Schedule of liabilities
        measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_z1rLN6TA4HHd" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z2qYM4LPUosi" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zD5X6q9UAmW9" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zBld36kkVgs4" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zoeTRhfaF2J1" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zM5QmpE2t1fb" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial and digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DigitalAssetsAtFairValueTonLiquid_iI_zOUS9oCBMjnk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets at fair value, TON liquid&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;126&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3268"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3269"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3270"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3271"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3272"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DigitalAssetsAtFairValueTonLocked_iI_zOUaVSZgiZeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets at fair value, TON locked&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3274"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3275"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,366&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3277"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3278"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3279"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zVPTI8wLoSN7" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z0j5MCgowog9" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zeKOfFQgFhQi" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zZzGpxmA9f99" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zCicAgyZOiU6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zzktOzhiinp3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TonPayableToSettlePutRightsExercised_iI_zg7mekSAa8u3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left"&gt;TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3281"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3282"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,425&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3284"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3285"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3286"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PutRightLiability_iI_z4Hlvat2BdB1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3288"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3289"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,105&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3291"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3292"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3293"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--WarrantLiability_iI_pn3n3_zteIRtenVdC9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3295"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3296"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;192&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3298"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3299"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,952&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"&gt;&lt;/p&gt;



&lt;p id="xdx_8A4_zLUt3EOmq79e" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Credit Risk, Liquidity Risk, Digital Asset Risk, and Foreign Currency Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21pt; font-size: 10pt; text-indent: 15pt"&gt;Our financial instruments are exposed to certain financial risks:
Credit Risk, Liquidity Risk, Digital Asset Risk, and Foreign Currency Risk.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Credit risk is the risk of loss associated with a counterparty&#x2019;s
inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#x2019;s consolidated statements of financial position.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash and cash equivalents: &lt;/b&gt;Cash and cash equivalents
comprise cash on hand and amounts invested in underlying treasury and money market funds that are readily convertible to a known amount
of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. As of March 31,
2026 and 2025, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. Cash
and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Liquidity risk is the risk that the Company will encounter
difficulty in satisfying financial obligations as they become due. The Company&#x2019;s approach to managing liquidity is to ensure, as
far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&#x2019;s reputation. The Company holds sufficient cash and cash equivalents
to satisfy current obligations under accounts payable and accruals. The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Digital Asset Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company is subject to various risks including market risk, liquidity
risk and other risks related to its concentration in TON and other digital assets. Investing in digital assets is currently highly speculative
and volatile.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The price of our digital assets has been, and will likely continue to be,
highly volatile. Our financial results and the market price of our common stock could be materially adversely affected if the price of
our digital assets decreases substantially, as it has in the past, including as a result of shifts in market sentiment, speculative trading,
macroeconomic trends, technology-related disruptions and regulatory announcements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;









&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;








&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;Our historical financial statements do not reflect the potential variability
in earnings that we may experience in the future from holding or selling digital assets. Accordingly, volatility in our earnings may be
significantly more than what we experienced in prior periods, and it may be difficult to evaluate the Company&#x2019;s business and future
prospects. We also may need to perform an analysis each quarter to identify whether events or changes in circumstances indicate that our
digital assets are impaired.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company will face risks relating to the custody of its digital assets.
Cybersecurity threats, including hacking, phishing and other malicious attacks, could result in the loss, theft or misappropriation of
our digital assets. If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain
access to our private keys, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose
some or all of our digital assets and our financial condition and results of operations could be materially adversely affected.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;There is a risk that some or all of the Company&#x2019;s digital assets could
be lost or stolen. There can be no assurance that our custodians will maintain adequate insurance or that such coverage will cover any
losses with respect to the Company&#x2019;s digital assets. Further, transactions in digital assets are irrevocable. Stolen or incorrectly
transferred digital assets may be irretrievable. As a result, any incorrectly executed transactions of the Company&#x2019;s digital assets
could adversely affect an investment in the Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company&#x2019;s shareholders have no specific rights to any specific
digital assets. In the event of the insolvency of the Company, its assets may be inadequate to satisfy a claim by its shareholders.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The SEC has stated that certain digital assets may be considered securities
under federal securities laws. The test for determining whether a particular digital asset is a security is complex and difficult to apply,
and the outcome is difficult to predict. Future developments could change the legal status of digital assets we hold. If our digital assets
are determined to be securities under federal or state securities laws or in a proceeding in a court of law, or otherwise, it may have
material adverse consequences for our digital assets, making them more difficult to be traded, cleared or custodied compared to other
digital assets that are not considered securities. In addition, if our digital assets are considered securities, the Company could be
considered an unregistered investment company under the Investment Company Act of 1940, which could necessitate the Company&#x2019;s liquidation.
If the Company is required to comply with additional regulatory obligations, it could result in a significant increase in operating expenses
and make it difficult to continue our current operations, which would materially and adversely affect our business, financial condition
and results of operations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;As a company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company. The current uncertainty in global capital markets could have an impact on the Company&#x2019;s future
ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available
to the Company. See Note 17, &#x201c;Capital Stock and Reserves,&#x201d; for a discussion of the Company&#x2019;s share offering and current
funding levels.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;While the Company operates in various jurisdictions,
substantially all of the Company&#x2019;s transactions are denominated in the U.S. Dollar.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



</ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory>
    <ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact003198">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_pn3n3_zopiDedCWlsj" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zP6ymNiXA3pj" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zrf25agWTCtl" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zqXWYoAPlBYb" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zHT3SIfzSXld" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z67FiqFDONzi" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zMq4F3VxRHq5" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial assets&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;686&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3208"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3209"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;1,670&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3211"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3212"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--Stablecoin_i01I_pn3n3_z4e3MwE56iRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Stablecoin&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;21&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3215"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3216"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3217"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3218"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3219"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3_zhCqM31u9Eg9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,984&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3222"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3223"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;555&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3225"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3226"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 48%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z4sBZhEDAyW7" style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20260331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zwLMtx0mT413" style="font-size: 10pt; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zrTGko2d4Dwd" style="font-size: 10pt; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20250331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zfFMkwFheHT" style="font-size: 10pt; text-align: right; width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Amortized &lt;br/&gt;Cost&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"&gt;&lt;b&gt;FVTPL&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: middle; font-size: 10pt; text-align: center"&gt;&lt;b&gt;FVTPL&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3_zxH3Lyhkpnfd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,146&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3234"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,100&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3236"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TonPayableToSettlePutRightsExercised_i01I_pn3n3_zqvR3mXfUEmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3238"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,425&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3240"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3241"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--PutRightLiability_i01I_pn3n3_zQLRQYSyQa81" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3243"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,105&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3245"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3246"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3248"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;192&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3250"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,952&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--LeaseLiabilityCurrentAndNoncurrent_i01I_pn3n3_zjFhkn48tGci" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Lease liability - current and noncurrent&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3253"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;138&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3255"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3256"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact003207"
      unitRef="USD">686000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact003210"
      unitRef="USD">1670000</ifrs-full:CashAndCashEquivalents>
    <ptgef:Stablecoin
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact003214"
      unitRef="USD">21000</ptgef:Stablecoin>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact003221"
      unitRef="USD">1984000</ptgef:PrepaidExpensesAndOtherReceivable>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact003224"
      unitRef="USD">555000</ptgef:PrepaidExpensesAndOtherReceivable>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2026-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact003233"
      unitRef="USD">4146000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2025-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact003235"
      unitRef="USD">1100000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      decimals="-3"
      id="Fact003239"
      unitRef="USD">1425000</ptgef:TonPayableToSettlePutRightsExercised>
    <ptgef:PutRightLiability
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      decimals="-3"
      id="Fact003244"
      unitRef="USD">7105000</ptgef:PutRightLiability>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      decimals="-3"
      id="Fact003249"
      unitRef="USD">192000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2025-03-31_custom_FairValueThroughProfitOrLossMember"
      decimals="-3"
      id="Fact003251"
      unitRef="USD">1952000</ifrs-full:WarrantLiability>
    <ptgef:LeaseLiabilityCurrentAndNoncurrent
      contextRef="AsOf2026-03-31_custom_FairValueThroughProfitOrLossMember"
      decimals="-3"
      id="Fact003254"
      unitRef="USD">138000</ptgef:LeaseLiabilityCurrentAndNoncurrent>
    <ptgef:LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact003265">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock_pn3n3_zVLrHZkHFJR2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BB_zE0eYMntBHej" style="display: none"&gt;Schedule of liabilities
        measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_z1rLN6TA4HHd" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z2qYM4LPUosi" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zD5X6q9UAmW9" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zBld36kkVgs4" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zoeTRhfaF2J1" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zM5QmpE2t1fb" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial and digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DigitalAssetsAtFairValueTonLiquid_iI_zOUS9oCBMjnk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets at fair value, TON liquid&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;126&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3268"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3269"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3270"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3271"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3272"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DigitalAssetsAtFairValueTonLocked_iI_zOUaVSZgiZeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Digital assets at fair value, TON locked&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3274"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3275"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,366&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3277"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3278"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3279"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zVPTI8wLoSN7" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_z0j5MCgowog9" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20260331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zeKOfFQgFhQi" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level1Member_zZzGpxmA9f99" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level2Member_zCicAgyZOiU6" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250331__ifrs-full--ImpairmentOfFinancialAssetsAxis__custom--Level3Member_zzktOzhiinp3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TonPayableToSettlePutRightsExercised_iI_zg7mekSAa8u3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left"&gt;TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3281"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3282"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,425&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3284"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3285"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3286"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PutRightLiability_iI_z4Hlvat2BdB1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3288"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3289"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,105&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3291"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3292"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3293"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--WarrantLiability_iI_pn3n3_zteIRtenVdC9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3295"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3296"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;192&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3298"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3299"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;1,952&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: Red"&gt;&lt;/p&gt;



</ptgef:LiabilitiesMeasuredFairValueRecurringBasisTableTextBlock>
    <ptgef:DigitalAssetsAtFairValueTonLiquid
      contextRef="AsOf2026-03-31_custom_Level1Member"
      decimals="-3"
      id="Fact003267"
      unitRef="USD">126000</ptgef:DigitalAssetsAtFairValueTonLiquid>
    <ptgef:DigitalAssetsAtFairValueTonLocked
      contextRef="AsOf2026-03-31_custom_Level3Member"
      decimals="-3"
      id="Fact003276"
      unitRef="USD">2366000</ptgef:DigitalAssetsAtFairValueTonLocked>
    <ptgef:TonPayableToSettlePutRightsExercised
      contextRef="AsOf2026-03-31_custom_Level3Member"
      decimals="-3"
      id="Fact003283"
      unitRef="USD">1425000</ptgef:TonPayableToSettlePutRightsExercised>
    <ptgef:PutRightLiability
      contextRef="AsOf2026-03-31_custom_Level3Member"
      decimals="-3"
      id="Fact003290"
      unitRef="USD">7105000</ptgef:PutRightLiability>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2026-03-31_custom_Level3Member"
      decimals="-3"
      id="Fact003297"
      unitRef="USD">192000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2025-03-31_custom_Level3Member"
      decimals="-3"
      id="Fact003300"
      unitRef="USD">1952000</ifrs-full:WarrantLiability>
    <ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact003305">&lt;p id="xdx_80B_ecustom--DisclosureOfSegmentReportingExplanatoryTextBlock_zYLhgw8IYnpk" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
23. &lt;span id="xdx_822_z3o7VW2Q9lrg"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;While the Company operates in various jurisdictions,
substantially all of the Company&#x2019;s transactions are denominated in the U.S. Dollar.&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Prior to the fiscal year ended March 31, 2026,
the Company had one operating segment, Immuno-Oncology. In September 2025, in connection with the replacement of the previous leadership
team, the Company made a strategic shift to digital assets and compute processing. While the majority of the Company&#x2019;s operations
following September 2025 are now focused on compute processing and digital assets, certain subsidiaries continue to operate in the immuno-oncology
space.&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Our management reporting system produces reports
that present information about our business activities in a variety of ways. Based on these reports, the Chief Executive Officer, who
is responsible for assessing the performance of our Company and for making resource allocation decisions as our Chief Operating Decision
Maker (&#x201c;CODM&#x201d;), evaluates business activities based on several different results. Operating results are reviewed by operating
segment, comprised of the Company&#x2019;s two operating segments: Digital &amp;amp; Compute and Immuno-Oncology.&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;We use an operating loss indicator to measure
the performance of our operating segments. Information about assets and liabilities is not regularly provided to our CODM.&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

















&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;Results by segment for the fiscal years ended
March 31, 2026, 2025, and 2024 is as follows:&lt;/p&gt;

&lt;p style="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSegmentReportingTableTextBlock_pn3n3_zISlVstkjR3k" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BD_zZgatWOTNhLg" style="display: none"&gt;Schedule of segment reporting&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DigitalComputeMember_zQQi4pef5xyh" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zxYOSbH0llda" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zhorSaE3Ib7b" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zNoGn4xBsSre" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Digital &amp;amp; Compute&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Immuno-Oncology&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Immuno-Oncology&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Immuno-Oncology&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--Revenue_zzcc9PH4Xbo" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment revenues&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;97&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3313"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3314"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3315"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--ProfitLossAbstract_iB_z4pFFDeP9sG6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--ResearchAndDevelopmentExpense_zg3qCDmOqQQ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3322"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,801&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3,129&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12,535&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--GeneralAndAdministrativeExpense_zBljTZEYD6Lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: justify"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;16,344&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,855&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4,254&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5,664&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--DepreciationAndAmortisationExpense_zZweoOSFcnG6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Depreciation and amortization expense&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;193&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3333"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;35&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;54&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--ProfitLossFromOperatingActivities_zYBtJ9OJJg14" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment loss from operations&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(16,440&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(6,656&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(7,418&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(18,253&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--GainsLossesOnChangeInFairValueOfWarrants_z9f3jskqymAl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,097&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,786&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(388&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;6,868&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_zMuQEE6EtH44" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3347"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3348"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3349"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;11,305&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ChangeInFairValueOfPutRightsNetOfRedemptions_z5PYPZjGT4g3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of put rights, net of redemptions&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(5,959&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3353"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3354"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3355"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--LossOnRevaluationOfDigitalAssets_zrVzmHl7BkU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on revaluation of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,411&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3358"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3359"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3360"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--LossOnRevaluationOfDigitalAssetReceivables_zONRYqKAQWV4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on revaluation of digital asset receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,349&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3363"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3364"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3365"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RealizedLossOnSaleOfDigitalAssets_zYMyFjnobtSb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Realized loss on sale of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,700&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3368"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3369"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3370"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--RealizedLossOnNovationOfDigitalAssetReceivables_zjFyq3GlZbCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Realized loss on novation of digital asset receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;676&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3373"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3374"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3375"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--GainOnSettlementWithParexelIoxCro_zlrftFnk0Qda" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on settlement with Parexel - iOx CRO&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3377"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3378"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;946&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3380"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LossOnRegisteredDirectOffering_z3GRGfSxrWIj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on Registered Direct Offering&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3382"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3383"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3384"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(2,432&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--OfferingCosts_zrDU1QCJpZs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Offering costs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3387"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3388"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3389"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(662&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ImpairmentLossIoxIprd_zc4PuDWSybLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - iOx IPR&amp;amp;D&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3392"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3393"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3394"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(57,890&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ImpairmentLossTarusIprd_zSdN1Vd63KFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - Tarus IPR&amp;amp;D&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3397"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3398"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3399"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(23,615&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ImpairmentLossStimunity_zG0sZ3DAYpQk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - Stimunity&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3402"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3403"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3404"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(1,002&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ImpairmentLossSaugatuck_zKChggm43D9j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - Saugatuck&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3407"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3408"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3409"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(178&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--CommitmentFeeUnderCommittedPurchaseAgreement_zR6Fjac30Lp8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Commitment fee under Committed Purchase Agreement&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3412"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3413"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3414"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(839&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--GainOnDissolutionOfInvestmentInAssociate_zFpbZKRPfAK3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on dissolution of investment in associate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3417"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3418"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3419"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;27&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--GainFromSaleOfInvestmentInPublicCompany_zcVdomIRFAg1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain from sale of investment in public company&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3422"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3423"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3424"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;725&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ImpairmentLossInvestmentInCompedica_zSXzRwv8SsX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - investment in Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3427"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,804&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3429"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LossOnRevaluationOfInvestmentInCompedica_zB6DUIoyVn3j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on revaluation of investment in Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(182&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3433"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3434"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3435"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_z2SYs5jPLmgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;51&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3438"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3439"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3440"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--GainOnSettlementOfTonPayable_zWhbQpfNGVn4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on settlement of TON payable&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;336&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3443"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3444"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3445"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LossOnSettlementOfPutRightLiability_zc6tV1Gj9iBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on settlement of put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(916&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3448"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3449"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--NetForeignExchangeGain_iN_di_zCRqQGgWV2Ze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Foreign exchange transaction (loss) gain&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;4&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(5&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(7&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--InterestExpenseIncomeDefinedBenefitPlans_zs5vJnEVBKN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Interest (expense) income, net&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,022&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;86&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;242&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LossOnExtinguishmentOfDebt_z4wcapWYoUf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on extinguishment of debt&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(582&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--GainOnExtinguishmentOfDebt_zxJa9QeFlVa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on forgiveness of loan interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;837&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3469"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ShareOfLossesFromEquityMethodInvestment_zv6RnYQVW1F3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Share of losses from equity method investment&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3474"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(233&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SegmentLossBeforeBenefitForIncomeTaxes_zybOlmQXZrD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment loss before benefit for income taxes&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(28,912&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(9,715&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(6,781&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(85,930&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxBenefit_zH7StBEZswxj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Income tax benefit&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3482"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3483"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;10,548&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--SegmentNetLoss_z7sEEjClSHjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Segment net loss&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(28,912&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(9,715&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(6,778&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(75,382&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8AC_zrgbPX9ps6q" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ptgef:DisclosureOfSegmentReportingExplanatoryTextBlock>
    <ptgef:ScheduleOfSegmentReportingTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact003310">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSegmentReportingTableTextBlock_pn3n3_zISlVstkjR3k" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BD_zZgatWOTNhLg" style="display: none"&gt;Schedule of segment reporting&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DigitalComputeMember_zQQi4pef5xyh" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zxYOSbH0llda" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zhorSaE3Ib7b" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ImmunoOncologyMember_zNoGn4xBsSre" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Digital &amp;amp; Compute&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Immuno-Oncology&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Immuno-Oncology&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Immuno-Oncology&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--Revenue_zzcc9PH4Xbo" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment revenues&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;97&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3313"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3314"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3315"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--ProfitLossAbstract_iB_z4pFFDeP9sG6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--ResearchAndDevelopmentExpense_zg3qCDmOqQQ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3322"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,801&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;3,129&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;12,535&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--GeneralAndAdministrativeExpense_zBljTZEYD6Lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: justify"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;16,344&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,855&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;4,254&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;5,664&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--DepreciationAndAmortisationExpense_zZweoOSFcnG6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Depreciation and amortization expense&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;193&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3333"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;35&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;54&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--ProfitLossFromOperatingActivities_zYBtJ9OJJg14" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment loss from operations&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(16,440&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(6,656&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(7,418&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(18,253&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--GainsLossesOnChangeInFairValueOfWarrants_z9f3jskqymAl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,097&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,786&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(388&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;6,868&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_zMuQEE6EtH44" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of deferred purchase price payable - Tarus and deferred
        obligation - iOx milestone&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3347"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3348"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3349"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;11,305&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ChangeInFairValueOfPutRightsNetOfRedemptions_z5PYPZjGT4g3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of put rights, net of redemptions&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(5,959&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3353"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3354"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3355"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--LossOnRevaluationOfDigitalAssets_zrVzmHl7BkU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on revaluation of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,411&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3358"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3359"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3360"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--LossOnRevaluationOfDigitalAssetReceivables_zONRYqKAQWV4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on revaluation of digital asset receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,349&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3363"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3364"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3365"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RealizedLossOnSaleOfDigitalAssets_zYMyFjnobtSb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Realized loss on sale of digital assets&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,700&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3368"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3369"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3370"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--RealizedLossOnNovationOfDigitalAssetReceivables_zjFyq3GlZbCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Realized loss on novation of digital asset receivables&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;676&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3373"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3374"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3375"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--GainOnSettlementWithParexelIoxCro_zlrftFnk0Qda" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on settlement with Parexel - iOx CRO&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3377"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3378"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;946&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3380"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LossOnRegisteredDirectOffering_z3GRGfSxrWIj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on Registered Direct Offering&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3382"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3383"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3384"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(2,432&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--OfferingCosts_zrDU1QCJpZs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Offering costs&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3387"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3388"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3389"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(662&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ImpairmentLossIoxIprd_zc4PuDWSybLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - iOx IPR&amp;amp;D&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3392"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3393"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3394"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(57,890&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ImpairmentLossTarusIprd_zSdN1Vd63KFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - Tarus IPR&amp;amp;D&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3397"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3398"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3399"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(23,615&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ImpairmentLossStimunity_zG0sZ3DAYpQk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - Stimunity&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3402"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3403"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3404"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(1,002&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ImpairmentLossSaugatuck_zKChggm43D9j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - Saugatuck&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3407"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3408"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3409"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(178&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--CommitmentFeeUnderCommittedPurchaseAgreement_zR6Fjac30Lp8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Commitment fee under Committed Purchase Agreement&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3412"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3413"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3414"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(839&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--GainOnDissolutionOfInvestmentInAssociate_zFpbZKRPfAK3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on dissolution of investment in associate&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3417"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3418"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3419"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;27&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--GainFromSaleOfInvestmentInPublicCompany_zcVdomIRFAg1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain from sale of investment in public company&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3422"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3423"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3424"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;725&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ImpairmentLossInvestmentInCompedica_zSXzRwv8SsX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Impairment loss - investment in Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3427"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,804&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3429"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LossOnRevaluationOfInvestmentInCompedica_zB6DUIoyVn3j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on revaluation of investment in Compedica&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(182&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3433"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3434"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3435"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ChangeInFairValueOfTonPayableToSettlePutRightsExercised_z2SYs5jPLmgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Change in fair value of TON payable to settle put rights exercised&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;51&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3438"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3439"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3440"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--GainOnSettlementOfTonPayable_zWhbQpfNGVn4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on settlement of TON payable&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;336&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3443"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3444"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3445"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LossOnSettlementOfPutRightLiability_zc6tV1Gj9iBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on settlement of put right liability&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(916&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3448"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3449"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--NetForeignExchangeGain_iN_di_zCRqQGgWV2Ze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Foreign exchange transaction (loss) gain&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;4&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(5&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(7&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;7&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--InterestExpenseIncomeDefinedBenefitPlans_zs5vJnEVBKN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Interest (expense) income, net&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,022&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;86&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;242&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LossOnExtinguishmentOfDebt_z4wcapWYoUf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Loss on extinguishment of debt&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(582&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--GainOnExtinguishmentOfDebt_zxJa9QeFlVa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left"&gt;Gain on forgiveness of loan interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;$&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;837&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3469"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ShareOfLossesFromEquityMethodInvestment_zv6RnYQVW1F3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Share of losses from equity method investment&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(44&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3474"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(233&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SegmentLossBeforeBenefitForIncomeTaxes_zybOlmQXZrD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;Segment loss before benefit for income taxes&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(28,912&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(9,715&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(6,781&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;(85,930&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxBenefit_zH7StBEZswxj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Income tax benefit&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3482"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3483"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;10,548&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--SegmentNetLoss_z7sEEjClSHjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Segment net loss&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(28,912&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(9,715&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(6,778&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(75,382&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</ptgef:ScheduleOfSegmentReportingTableTextBlock>
    <ifrs-full:Revenue
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003312"
      unitRef="USD">97000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003323"
      unitRef="USD">2801000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003324"
      unitRef="USD">3129000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003325"
      unitRef="USD">12535000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003327"
      unitRef="USD">16344000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003328"
      unitRef="USD">3855000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003329"
      unitRef="USD">4254000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003330"
      unitRef="USD">5664000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003332"
      unitRef="USD">193000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003334"
      unitRef="USD">35000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003335"
      unitRef="USD">54000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003337"
      unitRef="USD">-16440000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003338"
      unitRef="USD">-6656000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003339"
      unitRef="USD">-7418000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003340"
      unitRef="USD">-18253000</ifrs-full:ProfitLossFromOperatingActivities>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003342"
      unitRef="USD">1097000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003343"
      unitRef="USD">1786000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003344"
      unitRef="USD">-388000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003345"
      unitRef="USD">6868000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003350"
      unitRef="USD">11305000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003352"
      unitRef="USD">-5959000</ptgef:ChangeInFairValueOfPutRightsNetOfRedemptions>
    <ptgef:LossOnRevaluationOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003357"
      unitRef="USD">-1411000</ptgef:LossOnRevaluationOfDigitalAssets>
    <ptgef:LossOnRevaluationOfDigitalAssetReceivables
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003362"
      unitRef="USD">-2349000</ptgef:LossOnRevaluationOfDigitalAssetReceivables>
    <ptgef:RealizedLossOnSaleOfDigitalAssets
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003367"
      unitRef="USD">-1700000</ptgef:RealizedLossOnSaleOfDigitalAssets>
    <ptgef:RealizedLossOnNovationOfDigitalAssetReceivables
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003372"
      unitRef="USD">676000</ptgef:RealizedLossOnNovationOfDigitalAssetReceivables>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003379"
      unitRef="USD">946000</ptgef:GainOnSettlementWithParexelIoxCro>
    <ptgef:LossOnRegisteredDirectOffering
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003385"
      unitRef="USD">-2432000</ptgef:LossOnRegisteredDirectOffering>
    <ptgef:OfferingCosts
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003390"
      unitRef="USD">-662000</ptgef:OfferingCosts>
    <ptgef:ImpairmentLossIoxIprd
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003395"
      unitRef="USD">-57890000</ptgef:ImpairmentLossIoxIprd>
    <ptgef:ImpairmentLossTarusIprd
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003400"
      unitRef="USD">-23615000</ptgef:ImpairmentLossTarusIprd>
    <ptgef:ImpairmentLossStimunity
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003405"
      unitRef="USD">-1002000</ptgef:ImpairmentLossStimunity>
    <ptgef:ImpairmentLossSaugatuck
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003410"
      unitRef="USD">-178000</ptgef:ImpairmentLossSaugatuck>
    <ptgef:CommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003415"
      unitRef="USD">-839000</ptgef:CommitmentFeeUnderCommittedPurchaseAgreement>
    <ptgef:GainOnDissolutionOfInvestmentInAssociate
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003420"
      unitRef="USD">27000</ptgef:GainOnDissolutionOfInvestmentInAssociate>
    <ptgef:GainFromSaleOfInvestmentInPublicCompany
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003425"
      unitRef="USD">725000</ptgef:GainFromSaleOfInvestmentInPublicCompany>
    <ptgef:ImpairmentLossInvestmentInCompedica
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003428"
      unitRef="USD">-4804000</ptgef:ImpairmentLossInvestmentInCompedica>
    <ptgef:LossOnRevaluationOfInvestmentInCompedica
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003432"
      unitRef="USD">-182000</ptgef:LossOnRevaluationOfInvestmentInCompedica>
    <ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003437"
      unitRef="USD">51000</ptgef:ChangeInFairValueOfTonPayableToSettlePutRightsExercised>
    <ptgef:GainOnSettlementOfTonPayable
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003442"
      unitRef="USD">336000</ptgef:GainOnSettlementOfTonPayable>
    <ptgef:LossOnSettlementOfPutRightLiability
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003447"
      unitRef="USD">-916000</ptgef:LossOnSettlementOfPutRightLiability>
    <ifrs-full:NetForeignExchangeGain
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003452"
      unitRef="USD">-4000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003453"
      unitRef="USD">5000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003454"
      unitRef="USD">7000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003455"
      unitRef="USD">-7000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003457"
      unitRef="USD">-1022000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003458"
      unitRef="USD">8000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003459"
      unitRef="USD">86000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003460"
      unitRef="USD">242000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ptgef:LossOnExtinguishmentOfDebt
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003462"
      unitRef="USD">-582000</ptgef:LossOnExtinguishmentOfDebt>
    <ptgef:GainOnExtinguishmentOfDebt
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003467"
      unitRef="USD">837000</ptgef:GainOnExtinguishmentOfDebt>
    <ptgef:ShareOfLossesFromEquityMethodInvestment
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003473"
      unitRef="USD">-44000</ptgef:ShareOfLossesFromEquityMethodInvestment>
    <ptgef:ShareOfLossesFromEquityMethodInvestment
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003475"
      unitRef="USD">-233000</ptgef:ShareOfLossesFromEquityMethodInvestment>
    <ptgef:SegmentLossBeforeBenefitForIncomeTaxes
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003477"
      unitRef="USD">-28912000</ptgef:SegmentLossBeforeBenefitForIncomeTaxes>
    <ptgef:SegmentLossBeforeBenefitForIncomeTaxes
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003478"
      unitRef="USD">-9715000</ptgef:SegmentLossBeforeBenefitForIncomeTaxes>
    <ptgef:SegmentLossBeforeBenefitForIncomeTaxes
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003479"
      unitRef="USD">-6781000</ptgef:SegmentLossBeforeBenefitForIncomeTaxes>
    <ptgef:SegmentLossBeforeBenefitForIncomeTaxes
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003480"
      unitRef="USD">-85930000</ptgef:SegmentLossBeforeBenefitForIncomeTaxes>
    <ptgef:IncomeTaxBenefit
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003484"
      unitRef="USD">3000</ptgef:IncomeTaxBenefit>
    <ptgef:IncomeTaxBenefit
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003485"
      unitRef="USD">10548000</ptgef:IncomeTaxBenefit>
    <ptgef:SegmentNetLoss
      contextRef="From2025-04-012026-03-31_custom_DigitalComputeMember"
      decimals="-3"
      id="Fact003487"
      unitRef="USD">-28912000</ptgef:SegmentNetLoss>
    <ptgef:SegmentNetLoss
      contextRef="From2025-04-012026-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003488"
      unitRef="USD">-9715000</ptgef:SegmentNetLoss>
    <ptgef:SegmentNetLoss
      contextRef="From2024-04-012025-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003489"
      unitRef="USD">-6778000</ptgef:SegmentNetLoss>
    <ptgef:SegmentNetLoss
      contextRef="From2023-04-012024-03-31_custom_ImmunoOncologyMember"
      decimals="-3"
      id="Fact003490"
      unitRef="USD">-75382000</ptgef:SegmentNetLoss>
    <ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact003492">&lt;p id="xdx_80F_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zwQXyHqLpqGk" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
23. &lt;span id="xdx_82F_zNp7jQKCHDr7"&gt;CAPITAL MANAGEMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company considers the items included in shareholders&#x2019;
equity as capital. The Company had accounts payable and accrued liabilities of approximately $&lt;span id="xdx_90C_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20260331_zZBBUNtoLlGj" title="Payables and accrued expenses"&gt;4.1&lt;/span&gt;
million as of March 31, 2026 (accounts payable and accrued liabilities of approximately $&lt;span id="xdx_908_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20250331_zUqGwimzqy85" title="Payables and accrued expenses"&gt;1.1
&lt;/span&gt;million as of March 31, 2025), put right liabilities of approximately $&lt;span id="xdx_902_ecustom--PutRightLiabilities_iI_pn3n3_dm_c20260331_ziAVwt4tP7kg" title="Put right liabilities"&gt;7.1&lt;/span&gt;
million as of March 31, 2026 (nil as of March 31, 2025), and current assets of approximately $&lt;span id="xdx_90B_ecustom--CurrentAsset_iI_pn3n3_dm_c20260331_zOziBbIgo0M3" title="Current assets"&gt;4.0&lt;/span&gt;
million as of March 31, 2026 (approximately $&lt;span id="xdx_900_ecustom--CurrentAsset_iI_pn3n3_dm_c20250331_zgrBYQWg9aie" title="Current assets"&gt;2.2&lt;/span&gt;
million as of March 31, 2025). The Company&#x2019;s objectives when managing capital are to safeguard the Company&#x2019;s ability to continue
as a going concern in order to pursue new business opportunities and to maintain a flexible capital structure while developing the Telegram
ecosystem and managing a strategic reserve of digital assets, which optimizes the costs of capital at an acceptable risk.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company manages the capital structure and makes
adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"&gt;The Company is not subject to any externally imposed
capital requirements and does not presently utilize any quantitative measures to monitor its capital. During fiscal year ended March 31,
2026, the Company shifted its capital management approach to focus primarily developing the Telegram ecosystem, managing a strategic reserve
of digital assets, and acquiring GPUs to generate revenues from compute demand. There were no other changes to the Company&#x2019;s approach
to capital management during the fiscal year ended March 31, 2026.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;















</ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock>
    <ptgef:PayablesAndAccruedExpense
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact003494"
      unitRef="USD">4100000</ptgef:PayablesAndAccruedExpense>
    <ptgef:PayablesAndAccruedExpense
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact003496"
      unitRef="USD">1100000</ptgef:PayablesAndAccruedExpense>
    <ptgef:PutRightLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact003498"
      unitRef="USD">7100000</ptgef:PutRightLiabilities>
    <ptgef:CurrentAsset
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact003500"
      unitRef="USD">4000000.0</ptgef:CurrentAsset>
    <ptgef:CurrentAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact003502"
      unitRef="USD">2200000</ptgef:CurrentAsset>
    <ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact003506">&lt;p id="xdx_80F_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zOQllwliGhTc" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
24. &lt;span id="xdx_82D_z6qOlJGjKTEf"&gt;NON-CONTROLLING INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The table below summarize the Company&#x2019;s non-controlling interest as
of the periods presented (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zasandL9FVq4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_z878ccb405r7" style="display: none"&gt;Schedule of non-controlling
        interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; font-size: 10pt; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Saugatuck&lt;/b&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;and subsidary&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold"&gt;Non-controlling interest as of April 1, 2023&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zKO3eXzggBki" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(650&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztXhWty3KIZk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest"&gt;(43&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Non-controlling interest as of March 31, 2024&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z60iZH9zo4r" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(693&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z94XkukyZVqe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest"&gt;(11&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Non-controlling interest as of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zpONoyrL8okk" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(704&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zUWl0fjhWlAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest"&gt;(1&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Non-controlling interest as of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znWEiQvoQnbk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(705&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;/p&gt;



&lt;p id="xdx_8A3_zejfsfDugYI9" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company held 70% interest in Saugatuck and subsidiary through SalvaRx.
Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



</ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory>
    <ptgef:ScheduleOfNoncontrollingInterestTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact003508">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zasandL9FVq4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_z878ccb405r7" style="display: none"&gt;Schedule of non-controlling
        interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; font-size: 10pt; text-align: center"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Saugatuck&lt;/b&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;and subsidary&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold"&gt;Non-controlling interest as of April 1, 2023&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zKO3eXzggBki" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(650&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztXhWty3KIZk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest"&gt;(43&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Non-controlling interest as of March 31, 2024&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z60iZH9zo4r" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(693&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20250331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z94XkukyZVqe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest"&gt;(11&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Non-controlling interest as of March 31, 2025&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zpONoyrL8okk" style="font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(704&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zUWl0fjhWlAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest"&gt;(1&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Non-controlling interest as of March 31, 2026&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20250401__20260331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znWEiQvoQnbk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(705&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center; color: Red"&gt;&lt;/p&gt;



</ptgef:ScheduleOfNoncontrollingInterestTableTextBlock>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2023-03-31_custom_SaugatuckMember"
      decimals="-3"
      id="Fact003510"
      unitRef="USD">-650000</ifrs-full:NoncontrollingInterests>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2023-04-012024-03-31_custom_SaugatuckMember371226578"
      decimals="-3"
      id="Fact003512"
      unitRef="USD">-43000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2024-03-31_custom_SaugatuckMember"
      decimals="-3"
      id="Fact003514"
      unitRef="USD">-693000</ifrs-full:NoncontrollingInterests>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2024-04-012025-03-31_custom_SaugatuckMember371226609"
      decimals="-3"
      id="Fact003516"
      unitRef="USD">-11000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2025-03-31_custom_SaugatuckMember"
      decimals="-3"
      id="Fact003518"
      unitRef="USD">-704000</ifrs-full:NoncontrollingInterests>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2025-04-012026-03-31_custom_SaugatuckMember371226609"
      decimals="-3"
      id="Fact003520"
      unitRef="USD">-1000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2026-03-31_custom_SaugatuckMember"
      decimals="-3"
      id="Fact003522"
      unitRef="USD">-705000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="From2025-04-01to2026-03-31" id="Fact003524">&lt;p id="xdx_80C_eifrs-full--DisclosureOfEventsAfterReportingPeriodExplanatory_zhFykYXAexX3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE
25. &lt;span id="xdx_82F_zE0GY6Qb2dv"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;The Company has evaluated subsequent events through July 15, 2026 the date
on which the consolidated financial statements were available to be issued.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On April 14, 2026, pursuant to prior approvals by our board of directors,
we filed a Certificate of Change of Name and Amendment to our Memorandum and Articles of Association. The documents changed our corporate
name from AlphaTON Capital Corp to Alpha Compute Corp to better reflect the nature of our expanded current business operations in compute
and AI infrastructure.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On April 21, 2026, our shares of common stock will begin trading under the
new symbol ALP on the Nasdaq Capital Market. The Certificate of Change of Name and Amendment to our Memorandum and Articles of Association
are filed as Exhibit 99.1 and Exhibit 99.2 to this current report and are incorporated herein by reference.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On May 12, 2026, Alpha Compute Corp (the &#x201c;Company&#x201d;) issued a
press release announcing the execution of a compute off-take agreement related to a cluster of 504 NVIDIA B200 GPUs. A copy of the press
release is attached hereto as Exhibit 99.1.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;As previously disclosed, in connection with Alpha Compute Corp&#x2019;s (the
&#x201c;Company&#x201d;) September 2025 private placement financing (the &#x201c;Sept. 2025 Private Placement Financing&#x201d;), the Company
entered into certain Side Letter Agreements (each, a &#x201c;Side Letter&#x201d;) with certain investors in the Sept. 2025 Private Placement
Financing. The Side Letters granted an irrevocable right and option to these investors to require the Company to repurchase all the ordinary
shares of the Company (&#x201c;Ordinary Shares&#x201d;) received by the respective investor in exchange for the consideration initially
provided by the respective investor to the Company (the &#x201c;Put Option&#x201d;). The period in which the Put Option may be exercised
varies from six to twelve months, depending on the investor, after the September 25, 2025 closing of the Sept. 2025 Private Placement
Financing. On June 22, 2026 two of these investors exercised their Put Options, obligating the Company to transfer to the investors a
total of 2,114,583 TON tokens and 5,136,459 USDC tokens (which represents the consideration initially provided by these investors to the
Company), with no adjustment for value, in exchange for the repurchase by the Company of a total of 1,196,295 Ordinary Shares and 633,931
Pre-Funded Warrants received by these investors in the Sept. 2025 Private Placement Financing.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"&gt;On March 19, 2026, the Company entered into a sale and purchase agreement
(the &#x201c;SPA&#x201d;) with Animoca Brands Limited (&#x201c;Animoca Brands&#x201d;) to acquire a 60% controlling equity interest in Ga
Mee Global Limited (&#x201c;GaMee Global&#x201d;), a company incorporated in Hong Kong and wholly owned subsidiary of Animoca Brands, and
certain digital tokens (the &#x201c;GaMee Transaction&#x201d;). GAMEE is a gaming and entertainment platform within Telegram's ecosystem
and provides the Company with additional distribution and customer acquisition opportunities within the decentralized AI space. Animoca
Brands, prior to closing, will conduct a reorganization to transfer 100% of the equity of Gamee Limited, a company incorporated in the
United Kingdom (the &#x201c;UK Company&#x201d;) to GaMee Global. The UK Company owns the entire equity in Gamee Mobile s.r.o., a company
incorporated under the laws of the Czech Republic (the &#x201c;Czech Company&#x201d; and together with GaMee Global and the UK Company,
&#x201c;GaMee&#x201d;). Under the terms of the SPA, at the closing of the GaMee Transaction (&#x201c;Completion&#x201d;), the Company has
agreed to pay total upfront consideration of $3.5 million (the &#x201c;Completion Consideration&#x201d;), comprised of: (i) $1.5 million
in cash, and (ii) $2.0 million in equity consideration in the Company, valued at $1.00 per share. The equity portion of the Completion
Consideration under subparagraph (ii) is structured as a combination of ordinary shares of the Company (&#x201c;Ordinary Shares&#x201d;)
and pre-funded warrants exercisable for Ordinary Shares (&#x201c;Pre-Funded Warrants&#x201d;). Specifically, at Completion, Animoca Brands
will receive: (i) 99,800 Ordinary Shares, and (ii) Pre-Funded Warrants exercisable for 1,900,200 Ordinary Shares, representing the balance
of the equity portion of the Completion Consideration. The GaMee Transaction closed on May 27, 2026.&lt;/p&gt;



</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
